PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Simpson, PJ; Xie, HF; Bolam, DN; Gilbert, HJ; Williamson, MP				Simpson, PJ; Xie, HF; Bolam, DN; Gilbert, HJ; Williamson, MP			The structural basis for the ligand specificity of family 2 carbohydrate-binding modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULOMONAS-FIMI; TRYPTOPHAN RESIDUES; PROTEIN STRUCTURES; DOMAIN; XYLANASE	The interactions of proteins with polysaccharides play a key role in the microbial hydrolysis of cellulose and xylan, the most abundant organic molecules in the biosphere, and are thus pivotal to the recycling of photosynthetically fixed carbon. Enzymes that attack these recalcitrant polymers have a modular structure comprising catalytic modules and non-catalytic carbohydrate-binding modules (CBMs). The largest prokaryotic CBM: family, CBM2, contains members that bind cellulose (CBM2a) and xylan (CEM2b), respectively. A possible explanation for the different ligand specificity of CBM2b is that one of the surface tryptophans involved in the protein-carbohydrate interaction is rotated by 90 degrees compared with its position in CBM2a (thus matching the structure of the binding site to the helical secondary structure of xylan), which may be promoted by a single amino acid difference between the two families. Here we show that by mutation of this single residue (Arg-262-->Gly), a CBM2b xylan-binding module completely loses its affinity for xylan and becomes a cellulose-binding module. The structural effect of the mutation has been revealed using NMR spectroscopy, which confirms that Trp-259 rotates 90 degrees to lie flat against the protein surface. Except for this one residue, the mutation only results in minor changes to the structure. The mutated protein interacts with cellulose using the same residues that the wild-type CBM2b uses to interact with xylan, suggesting that the recognition is of the secondary structure of the polysaccharide rather than any specific recognition of the absence or presence of functional groups.	Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst, Sheffield S10 2TN, S Yorkshire, England; Newcastle Univ, Dept Biol & Nutr Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Sheffield; Newcastle University - UK	Williamson, MP (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	m.williamson@sheffield.ac.uk		Bolam, David/0000-0003-0314-3122; Williamson, Mike/0000-0001-5572-1903				Baxter NJ, 1997, J BIOMOL NMR, V9, P359, DOI 10.1023/A:1018334207887; Black GW, 1996, BIOCHEM J, V319, P515, DOI 10.1042/bj3190515; BLACK GW, 1995, BIOCHEM J, V307, P191, DOI 10.1042/bj3070191; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 1999, ROY SOC CH, P202; Bray MR, 1996, PROTEIN SCI, V5, P2311, DOI 10.1002/pro.5560051117; Brett C., 1990, PHYSL BIOCH PLANT CE; Coutinho PM, 1999, ROY SOC CH, P3; Creagh AL, 1996, P NATL ACAD SCI USA, V93, P12229, DOI 10.1073/pnas.93.22.12229; DIN N, 1994, P NATL ACAD SCI USA, V91, P11383, DOI 10.1073/pnas.91.24.11383; DIN N, 1994, MOL MICROBIOL, V11, P747, DOI 10.1111/j.1365-2958.1994.tb00352.x; Dupont C, 1998, BIOCHEM J, V330, P41, DOI 10.1042/bj3300041; GARDNER KH, 1974, BIOPOLYMERS, V13, P1975, DOI 10.1002/bip.1974.360131005; GILKES NR, 1992, J BIOL CHEM, V267, P6743; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; MILLWARDSADLER SJ, 1994, MOL MICROBIOL, V11, P375, DOI 10.1111/j.1365-2958.1994.tb00317.x; Nagy T, 1998, FEBS LETT, V429, P312, DOI 10.1016/S0014-5793(98)00625-5; NIEDUSZYNSKI IA, 1972, BIOPOLYMERS, V11, P1335, DOI 10.1002/bip.1972.360110703; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; Simpson PJ, 1999, STRUCTURE, V7, P853, DOI 10.1016/S0969-2126(99)80108-7; Southall SM, 1999, FEBS LETT, V447, P58, DOI 10.1016/S0014-5793(99)00263-X; Tomme P, 1996, BIOCHEMISTRY-US, V35, P13885, DOI 10.1021/bi961185i; Tomme P, 1995, Adv Microb Physiol, V37, P1, DOI 10.1016/S0065-2911(08)60143-5; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	29	120	125	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41137	41142		10.1074/jbc.M006948200	http://dx.doi.org/10.1074/jbc.M006948200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10973978	hybrid			2022-12-27	WOS:000166114600065
J	Fridmann, Y; Ulitzur, S; Horovitz, A				Fridmann, Y; Ulitzur, S; Horovitz, A			In vivo and in vitro function of GroEL mutants with impaired allosteric properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOMERIC CHAPERONIN GROEL; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; INTERRING COMMUNICATION; VIBRIO-FISCHERI; ATP HYDROLYSIS; PROTEIN; BINDING; HEAD	Escherichia coli cells that produce only plasmid-encoded wild-type or mutant GroEL were generated by bacteriophage P1 transduction. Effects of mutations that affect the allosteric properties of GroEL were characterized in vivo. Cells containing only GroEL(R197A), which has reduced intra-ring positive cooperativity and inter-ring negative cooperativity in ATP binding, grow poorly upon a temperature shift from 25 to 42 degreesC. This strain supports the growth of phages T4 and T5 but not phage lambda and produces light at 28 degreesC when transformed with a second plasmid containing the lux operon. In contrast, cells containing only GroEL(R13G, A126V) which lacks negative cooperativity between rings but has intact intra-ring positive cooperativity grow normally and support phage growth but do not produce light at 28 degreesC. In vitro refolding of luciferase in the presence of this mutant is found to be less efficient compared with wild-type GroEL or other mutants tested. Our results show that allostery in GroEL is important in vivo in a manner that depends on the physiological conditions and is protein substrate specific.	Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel	Weizmann Institute of Science; Technion Israel Institute of Technology	Horovitz, A (corresponding author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.	Amnon.Horovitz@weizmann.ac.il						ADAR YY, 1993, J BIOLUM CHEMILUM, V8, P261, DOI 10.1002/bio.1170080506; Aharoni A, 1996, J MOL BIOL, V258, P732, DOI 10.1006/jmbi.1996.0282; Aharoni A, 1997, P NATL ACAD SCI USA, V94, P1698, DOI 10.1073/pnas.94.5.1698; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Chatellier J, 1998, P NATL ACAD SCI USA, V95, P9861, DOI 10.1073/pnas.95.17.9861; DOLAN KM, 1992, J BACTERIOL, V174, P5132, DOI 10.1128/JB.174.15.5132-5135.1992; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; Fedorov AN, 1997, J MOL BIOL, V268, P712, DOI 10.1006/jmbi.1997.1007; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HOROVITZ A, 1993, J BIOL CHEM, V268, P9957; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; Horovitz A, 1998, CURR OPIN STRUC BIOL, V8, P93, DOI 10.1016/S0959-440X(98)80015-8; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; Inbar E, 1997, BIOCHEMISTRY-US, V36, P12276, DOI 10.1021/bi9714870; Ivic A, 1997, GENE, V194, P1, DOI 10.1016/S0378-1119(97)00087-5; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; Llorca O, 1997, J BIOL CHEM, V272, P32925, DOI 10.1074/jbc.272.52.32925; MEIGHEN EA, 1971, J BIOL CHEM, V246, P7666; Ranson NA, 1998, BIOCHEM J, V333, P233, DOI 10.1042/bj3330233; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; STERNBERG N, 1973, J MOL BIOL, V76, P25, DOI 10.1016/0022-2836(73)90079-X; ULITZUR S, 1995, PHOTOCHEM PHOTOBIOL, V62, P625, DOI 10.1111/j.1751-1097.1995.tb08709.x; ULITZUR S, 1987, BIOLUMINESCENCE CHEM, P381; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; Wang JD, 1998, P NATL ACAD SCI USA, V95, P12163, DOI 10.1073/pnas.95.21.12163; Weber F, 1998, NAT STRUCT BIOL, V5, P977, DOI 10.1038/2952; WHITE ZW, 1995, J BIOL CHEM, V270, P20404, DOI 10.1074/jbc.270.35.20404; YIFRACH O, 1994, J MOL BIOL, V243, P397, DOI 10.1006/jmbi.1994.1667; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Yifrach O, 2000, P NATL ACAD SCI USA, V97, P1521, DOI 10.1073/pnas.040449997; ZWEIG M, 1973, J MOL BIOL, V80, P505, DOI 10.1016/0022-2836(73)90418-X	40	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37951	37956		10.1074/jbc.M007594200	http://dx.doi.org/10.1074/jbc.M007594200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973985	hybrid			2022-12-27	WOS:000165618700087
J	Hahn, A; Heusinger-Ribeiro, J; Lanz, T; Zenkel, S; Goppelt-Struebe, M				Hahn, A; Heusinger-Ribeiro, J; Lanz, T; Zenkel, S; Goppelt-Struebe, M			Induction of connective tissue growth factor by activation of heptahelical receptors - Modulation by Rho proteins and the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MESANGIAL CELLS; PROSTAGLANDIN G/H SYNTHASE-2; LYSOPHOSPHATIDIC ACID; ENDOTHELIAL-CELLS; FACTOR GENE; EXPRESSION; KINASE; SEROTONIN; FAMILY; IDENTIFICATION	Expression of connective tissue growth factor (CTGF) was induced in renal mesangial cells by activation of heptahelical receptors by serotonin (5-HT) and lysophosphatidic acid (LPA), Induction of CTGF mRNA was transient with maximal expression after I to 2 h, whereas induction of CTGF by transforming growth factor beta (TGF-beta) increased over time, In contrast to the induction of other early response genes (Egr-1 and cyclooxygenase-2), LPA-mediated induction of CTGF was pertussis toxin-insensitive and independent of p42/44 MAP kinase activation. B-HT-mediated CTGF induction was due to activation of 5-HT2A receptors and likewise independent of p42/44 MAP kinase activation. Upon stimulation, enhanced levels of CTGF protein were detected in cellular homogenates, whereas no protein was detectable in cell culture supernatants, Inhibition of proteins of the Rho family by toxin B abrogated basal as well as CTGF expression stimulated by LPA, 5-HT, and TGF-beta. Inhibition of the downstream mediator of RhoA, the Rho kinase by Y-27632 partially reduced induction of CTGF by LPA and TGF-beta. Toxin B not only affected gene expression, but disrupted the actin cytoskeleton similarly as observed after treatment with cytochalasin D, Disassembly of actin stress fibers by cytochalasin D partially reduced basal and stimulated CTGF expression. These data indicate that an intact actin cytoskeleton is critical for the expression of CTGF, Elimination of the input of Rho proteins by toxin B, however, was significantly more effective and their effect on CTGF expression thus goes beyond disruption of the cytoskeleton. These findings thus establish activation of heptahelical receptors coupled to pertussis toxin-insensitive G:proteins as a novel signaling pathway to induce CTGF. Proteins of the Rho family and an intact cytoskeleton were identified as critical determinants of CTGF expression induced by LPA and 5-HT, and also by TGF-beta.	Univ Erlangen Nurnberg, Med Klin 4, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Goppelt-Struebe, M (corresponding author), Univ Erlangen Nurnberg, Med Klin 4, Loschgestr 8, D-91054 Erlangen, Germany.	Goppelt-Struebe@rzmail.uni-erlangen.de						Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Boes M, 1999, ENDOCRINOLOGY, V140, P1575, DOI 10.1210/en.140.4.1575; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Dammeier J, 1998, J BIOL CHEM, V273, P18185, DOI 10.1074/jbc.273.29.18185; Dammeier J, 1998, INT J BIOCHEM CELL B, V30, P909, DOI 10.1016/S1357-2725(98)00046-6; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Essig M, 1998, CIRC RES, V83, P683, DOI 10.1161/01.RES.83.7.683; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Gaits F, 1997, KIDNEY INT, V51, P1022, DOI 10.1038/ki.1997.143; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; GOOPELSTRUEBE M, 2000, BIOCH J 1, V349, P217; Goppelt-Struebe M, 1998, J CELL PHYSIOL, V175, P341, DOI 10.1002/(SICI)1097-4652(199806)175:3<341::AID-JCP12>3.0.CO;2-8; Goppelt-Struebe M, 1999, BIOCHEM J, V339, P329, DOI 10.1042/0264-6021:3390329; GoppeltStruebe M, 1997, N-S ARCH PHARMACOL, V356, P240, DOI 10.1007/PL00005047; GOPPELTSTRUEBE M, 1995, PROSTAG LEUKOTR ESS, V52, P213, DOI 10.1016/0952-3278(95)90039-X; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Hishikawa K, 1999, CIRCULATION, V100, P2108, DOI 10.1161/01.CIR.100.20.2108; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; Inoue CN, 1999, CLIN SCI, V96, P431, DOI 10.1042/CS19980248; INOUE CN, 1995, CIRC RES, V77, P888, DOI 10.1161/01.RES.77.5.888; Inoue CN, 1997, P SOC EXP BIOL MED, V216, P370; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Kasho M, 1998, KIDNEY INT, V54, P1083, DOI 10.1046/j.1523-1755.1998.00114.x; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; LOVETT DH, 1983, J IMMUNOL, V131, P2830; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Mason R.M., 1997, J AM SOC NEPHROL, V8, p642A; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; NEBIGIL CG, 1995, AM J PHYSIOL-RENAL, V268, pF122, DOI 10.1152/ajprenal.1995.268.1.F122; Oemar BS, 1997, CIRCULATION, V95, P831; Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Reiser COA, 1998, BIOCHEM J, V330, P1107; Ricupero DA, 2000, J BIOL CHEM, V275, P12475, DOI 10.1074/jbc.275.17.12475; Riser BL, 2000, J AM SOC NEPHROL, V11, P25, DOI 10.1681/ASN.V11125; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Steffen CL, 1998, GROWTH FACTORS, V15, P199, DOI 10.3109/08977199809002117; STROEBEL M, 1994, J BIOL CHEM, V269, P22952; Verbeke M, 1996, J AM SOC NEPHROL, V7, P621	54	96	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37429	37435		10.1074/jbc.M000976200	http://dx.doi.org/10.1074/jbc.M000976200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10976101	hybrid			2022-12-27	WOS:000165618700018
J	Yu, XQ; Kanost, MR				Yu, XQ; Kanost, MR			Immulectin-2, a lipopolysaccharide specific lectin from an insect, Manduca sexta, is induced in response to gram-negative bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; C-TYPE LECTIN; BETA-1,3-GLUCAN RECOGNITION PROTEIN; PERIPLANETA LECTIN; HYPHANTRIA-CUNEA; CDNA CLONING; COCKROACH; PURIFICATION; HEMOLYMPH; SILKWORM	A lipopolysaccharide-specific lectin, immulectin-2, was isolated from plasma of the tobacco hornworm, Manduca sexta. Immulectin-2 has specificity for xylose, glucose, lipopolysaccharide, and mannan, A cDNA clone encoding immulectin-2 was isolated from an Escherichia coli-induced M. sexta larval fat body cDNA library. The cDNA is 1253 base pairs long, with an open reading frame of 981 base pairs, encoding a 327-residue polypeptide, Immulectin-2 is a member of the C-type lectin superfamily, It consists of two carbohydrate recognition domains, which is similar to the organization of M, sexta immulectin-1, Immulectin-8 was present at a constitutively low level in plasma of control larvae and increased 3-4-fold after injection of Gram negative bacteria or lipopolysaccharide, Immulectin-2 mRNA was detected in fat body of control larvae, and its level increased dramatically after injection of E. coli. The concentration of immulectin-2 in plasma did not change significantly after injection of Gram-positive bacteria or yeast, even though its mRNA level was increased by these treatments. Compared with immulectin-1, immulectin-2 has a more restricted specificity for binding to Gram-negative bacteria. Immulectin-2 at low physiological concentrations agglutinated E, coli in a calcium-dependent manner. It also bound to immobilized lipopolysaccharide from E, coli, Binding of immulectin-2 to lipopolysaccharide stimulated phenol oxidase activation in plasma. The properties of immulectin-2 are consistent with its function as a pattern recognition receptor for detection and defense against Gram-negative bacterial infection in M. sexta.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Kanost, MR (corresponding author), Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA.	kanost@ksu.edu	YU, XIAO-QIANG/AAL-1797-2021; YU, XiaoQiang/GRJ-1077-2022	YU, XIAO-QIANG/0000-0003-1419-9009; Kanost, Michael/0000-0002-6827-0061	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041247, R01GM041247, R29GM041247] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41247, R37 GM041247] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashida Masaaki, 1998, P135; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Chen CL, 1999, COMP BIOCHEM PHYS B, V122, P309, DOI 10.1016/S0305-0491(99)00020-6; CHEN CL, 1993, BIOCHEM J, V294, P181, DOI 10.1042/bj2940181; CHEN CL, 1995, BIOCHEM J, V310, P23, DOI 10.1042/bj3100023; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; DUNN PE, 1983, J INVERTEBR PATHOL, V41, P77, DOI 10.1016/0022-2011(83)90238-0; Epstein J, 1996, CURR OPIN IMMUNOL, V8, P29, DOI 10.1016/S0952-7915(96)80101-4; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; *GEN COMP GROUP, 1991, PROGR MAN GCG PACK V; Haq S, 1996, J BIOL CHEM, V271, P20213, DOI 10.1074/jbc.271.33.20213; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Jiang H, 1996, INSECT MOL BIOL, V5, P31, DOI 10.1111/j.1365-2583.1996.tb00038.x; Jiang HB, 2000, INSECT BIOCHEM MOLEC, V30, P95, DOI 10.1016/S0965-1748(99)00113-7; JOMORI T, 1992, FEBS LETT, V296, P283, DOI 10.1016/0014-5793(92)80305-Z; JOMORI T, 1990, EUR J BIOCHEM, V190, P201, DOI 10.1111/j.1432-1033.1990.tb15565.x; Kawasaki K, 1996, INSECT BIOCHEM MOLEC, V26, P355, DOI 10.1016/0965-1748(95)00101-8; KAWASAKI N, 1989, J BIOCHEM-TOKYO, V106, P483, DOI 10.1093/oxfordjournals.jbchem.a122878; Koizumi N, 1999, FEBS LETT, V443, P139, DOI 10.1016/S0014-5793(98)01701-3; Koizumi N, 1997, EUR J BIOCHEM, V248, P217, DOI 10.1111/j.1432-1033.1997.t01-1-00217.x; KUBO T, 1993, DEV BIOL, V156, P381, DOI 10.1006/dbio.1993.1085; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; Matsushita M, 1996, MICROBIOL IMMUNOL, V40, P887, DOI 10.1111/j.1348-0421.1996.tb01156.x; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shin SW, 1998, INSECT BIOCHEM MOLEC, V28, P827, DOI 10.1016/S0965-1748(98)00077-0; Shin SW, 2000, FEBS LETT, V467, P70, DOI 10.1016/S0014-5793(00)01127-3; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; Vilmos P, 1998, IMMUNOL LETT, V62, P59, DOI 10.1016/S0165-2478(98)00023-6; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wilson R, 1999, J IMMUNOL, V162, P1590; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Yu XQ, 1999, INSECT BIOCHEM MOLEC, V29, P585, DOI 10.1016/S0965-1748(99)00036-3	46	225	242	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37373	37381		10.1074/jbc.M003021200	http://dx.doi.org/10.1074/jbc.M003021200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10954704	hybrid			2022-12-27	WOS:000165618700011
J	Marcu, MG; Chadli, A; Bouhouche, I; Catelli, M; Neckers, LM				Marcu, MG; Chadli, A; Bouhouche, I; Catelli, M; Neckers, LM			The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP90 MOLECULAR CHAPERONE; CELL-FREE SYSTEM; PROGESTERONE-RECEPTOR; DNA GYRASE; IN-VITRO; GELDANAMYCIN; KINASE; SITE; HETEROCOMPLEX; CONFORMATION	Heat shock protein 90 (Hsp90), one of the most abundant chaperones in eukaryotes, participates in folding and stabilization of signal-transducing molecules including steroid hormone receptors and protein kinases, The amino terminus of Hsp90 contains a non-conventional nucleotide-binding site, related to the ATP-binding motif of bacterial DNA gyrase. The anti-tumor agents geldanamycin and radicicol bind specifically at this site and induce destabilization of Hsp90-dependent client proteins. We recently demonstrated that the gyrase inhibitor novobiocin also interacts with Hsp90, altering the affinity of the chaperone for geldanamycin and radicicol and causing in vitro and in vivo depletion of key regulatory Hsp90-dependent kinases including v-Src, Raf-l, and p185(ExbB2). In the present study we used deletion/mutation analysis to identify the site of interaction of novobiocin with Hsp90, and we demonstrate that the novobiocin-binding site resides in the carboxyl terminus of the chaperone. Surprisingly, this motif also recognizes ATP, and ATP and novobiocin efficiently compete with each other for binding to this region of Hsp90. Novobiocin interferes with association of the cochaperones Hsc70 and p23 with Hsp90. These results identify a second site on Hsp90 where the binding of small molecule inhibitors can significantly impact the function of this chaperone, and they support the hypothesis that both amino- and carboxyl-terminal domains of Hsp90 interact to modulate chaperone activity.	NCI, Dept Cell & Canc Biol, Med Branch, NIH, Rockville, MD 20850 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; CNRS, UPR Cochin Port Royal, F-75014 Paris, France	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic; Centre National de la Recherche Scientifique (CNRS)	Neckers, LM (corresponding author), NCI, Dept Cell & Canc Biol, Med Branch, NIH, Rockville, MD 20850 USA.				NATIONAL CANCER INSTITUTE [Z01SC010074, ZIASC010074] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chavany C, 1996, J BIOL CHEM, V271, P4974; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hartson SD, 1999, BIOCHEMISTRY-US, V38, P3837, DOI 10.1021/bi983027s; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; Jibard N, 1999, EXP CELL RES, V247, P461, DOI 10.1006/excr.1998.4375; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; Marcu MG, 2000, JNCI-J NATL CANCER I, V92, P242, DOI 10.1093/jnci/92.3.242; MAXWELL A, 1993, MOL MICROBIOL, V9, P681, DOI 10.1111/j.1365-2958.1993.tb01728.x; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; Scheibel T, 1999, P NATL ACAD SCI USA, V96, P1297, DOI 10.1073/pnas.96.4.1297; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Soti C, 1998, EUR J BIOCHEM, V255, P611, DOI 10.1046/j.1432-1327.1998.2550611.x; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STAUDENBAUER WL, 1981, NUCLEIC ACIDS RES, V9, P3589, DOI 10.1093/nar/9.15.3589; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	37	420	447	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37181	37186		10.1074/jbc.M003701200	http://dx.doi.org/10.1074/jbc.M003701200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10945979	hybrid			2022-12-27	WOS:000165577700099
J	Roduit, R; Morin, J; Masse, F; Segall, L; Roche, E; Newgard, CB; Assimacopoulos-Jeannet, F; Prentki, M				Roduit, R; Morin, J; Masse, F; Segall, L; Roche, E; Newgard, CB; Assimacopoulos-Jeannet, F; Prentki, M			Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-alpha gene in the pancreatic beta-cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PALMITOYLTRANSFERASE-I GENE; OBESE PREDIABETIC RATS; DIABETIC FATTY RATS; INSULIN-SECRETION; LINE INS-1; RESPONSE ELEMENT; MALONYL-COA; ISLET CELLS; C-FOS; ACIDS	To better understand the action of glucose on fatty acid metabolism in the beta -cell and the link between chronically elevated glucose or fatty acids and beta -cell decompensation in adipogenic diabetes, we investigated whether glucose regulates peroxisomal proliferator-activated receptor (PPAR) gene expression in the beta -cell, Islets or INS(832/13) beta -cells exposed to high glucose show a 60-80% reduction in PPAR alpha mRNA expression. Oleate, either in the absence or presence of glucose, has no effect. The action of glucose is dose-dependent in the 6-20 mill range and maximal after 6 h, Glucose also causes quantitatively similar reductions in PPARa! protein and DNA binding activity of this transcription factor. The effect of glucose is blocked by the glucokinase inhibitor mannoheptulose, is partially mimicked by a-deoxyglucose, and is not blocked by the 3-O-methyl or the 6-deoxy analogues of the sugar that are not phosphorylated. Chronic elevated glucose reduces the expression levels of the PPAR target genes, uncoupling protein 2 and acyl-CoA oxidase, which are involved in fat oxidation and lipid detoxification. A 3-day exposure of INS-1 cells to elevated glucose results in a permanent rise in malonyl-CoA, the inhibition of fat oxidation, and the promotion of fatty acid esterification processes and causes elevated insulin secretion at low glucose. The results suggest that a reduction in PPAR alpha gene expression together with a rise in malonyl-CoA plays a role in the coordinated adaptation of beta -cell glucose and lipid metabolism to hyperglycemia and may be implicated in the mechanism of beta -cell "glucolipotoxicity."	Univ Montreal, Mol Nutr Unit, Dept Nutr, Montreal, PQ H2L 4M1, Canada; Ctr Hosp Univ Montreal, Montreal, PQ H2L 4M1, Canada; Inst Canc, Montreal, PQ H2L 4M1, Canada; Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dept Biochem & Int Med, Dallas, TX 75235 USA; Univ Geneva, Ctr Med, Dept Biochem Med, CH-1211 Geneva, Switzerland	Universite de Montreal; Universite de Montreal; Universite de Montreal; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Geneva	Prentki, M (corresponding author), CR CHUM, Pavillon de Seve 4,1560 Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.		Roduit, Raphael/AAC-3890-2021; Roche, Enrique/V-5738-2017	Roduit, Raphael/0000-0001-7440-2799; Roche, Enrique/0000-0001-5128-1672				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Bollheimer LC, 1998, J CLIN INVEST, V101, P1094, DOI 10.1172/JCI420; BONNY C, 1995, MOL ENDOCRINOL, V9, P1413, DOI 10.1210/me.9.10.1413; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Brun T, 1997, DIABETES, V46, P393, DOI 10.2337/diabetes.46.3.393; BRUN T, 1993, J BIOL CHEM, V268, P18905; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cournarie F, 1999, FEBS LETT, V460, P527, DOI 10.1016/S0014-5793(99)01407-6; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; Foufelle F, 1998, Curr Opin Clin Nutr Metab Care, V1, P323, DOI 10.1097/00075197-199807000-00002; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GOTOH M, 1987, TRANSPLANTATION, V43, P725, DOI 10.1097/00007890-198705000-00024; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; Higa M, 1999, P NATL ACAD SCI USA, V96, P11513, DOI 10.1073/pnas.96.20.11513; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; MARIE S, 1993, J BIOL CHEM, V268, P23881; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; McGarry JD, 1999, DIABETOLOGIA, V42, P128, DOI 10.1007/s001250051130; MCGARRY JD, 1976, J LIPID RES, V17, P277; Meyer K, 1999, ARCH TOXICOL, V73, P440, DOI 10.1007/s002040050633; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OHNEDA M, 1995, DIABETOLOGIA, V38, P173, DOI 10.1007/BF00400091; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Rieusset J, 1999, BIOCHEM BIOPH RES CO, V265, P265, DOI 10.1006/bbrc.1999.1657; Roche E, 1999, DIABETES, V48, P2007, DOI 10.2337/diabetes.48.10.2007; Roche E, 1998, DIABETES, V47, P1086, DOI 10.2337/diabetes.47.7.1086; Roche E, 1997, J BIOL CHEM, V272, P3091, DOI 10.1074/jbc.272.5.3091; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; Segall L, 1999, AM J PHYSIOL-ENDOC M, V277, pE521, DOI 10.1152/ajpendo.1999.277.3.E521; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; SHARP GW, 1996, AM J PHYSIOL, V271, pC1731; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimabukuro M, 1997, BIOCHEM BIOPH RES CO, V237, P359, DOI 10.1006/bbrc.1997.7140; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Shimabukuro M, 1998, J BIOL CHEM, V273, P3547, DOI 10.1074/jbc.273.6.3547; Susini S, 2000, FASEB J, V14, P128, DOI 10.1096/fasebj.14.1.128; Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Velho G, 1998, EUR J ENDOCRINOL, V138, P233, DOI 10.1530/eje.0.1380233; WITSELL AL, 1990, BIOTECHNIQUES, V9, P318; Zhou YT, 1998, P NATL ACAD SCI USA, V95, P8898, DOI 10.1073/pnas.95.15.8898	57	141	146	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35799	35806		10.1074/jbc.M006001200	http://dx.doi.org/10.1074/jbc.M006001200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967113	hybrid			2022-12-27	WOS:000165382000024
J	Sakamoto, H; Kitamura, T; Yoshimura, A				Sakamoto, H; Kitamura, T; Yoshimura, A			Mitogen-activated protein kinase plays an essential role in the erythropoietin-dependent proliferation of CTLL-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; JAK-3 JANUS KINASE; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAINS; HEMATOPOIETIC-CELLS; GENE-EXPRESSION; INDUCIBLE GENE; BETA-SUBUNIT; RECEPTOR; STAT5	Erythropoietin (EPO) and its receptor (EPOR) are required for development of erythrocytes. It has been shown that the ectopic expression of EPOR confers EPO-dependent proliferation on an interleukin 3 (IL3)-dependent cell line, Ba/F3, whereas the IL2-dependent T cell line, CTLL-2 expressing the EPOR (T-ER), fails to proliferate in response to EPO. However, the molecular basis of the EPO unresponsiveness in CTLL-8 has not been clarified. We found that the expression level of JAK2 in T-ER cells was much lower than that in Ba/F3 cells. Therefore, we examined the effects of forced expression of JAK2 in T ER cells. In T-ER transformants expressing JAK2 (T-JER), EPO induced tyrosine phosphorylation of the EPOR, JAK2, and STATE, and consequently STAT5-responsive genes including bcl-X and cis1 were normally induced. Furthermore, T-JER cells were resistant to apoptosis until at least 72 h after switching from IL2 to EPO. Although T-JER cells could not continuously proliferate in the presence of EPO, additional expression of JAK2 in T-JER (T-JJER) to a level similar to that in Ba/F3 cells supported long term proliferation in response to EPO. JAK2 was equally coimmunoprecipitated with the EPOR among T-JER, T-JJER, and Ba/F3 cells expressing the EPOR (BF-ER), However, EPO-dependent mitogen-activated protein (MAP) kinase activation was observed in T-JJER and BF-ER cells but not in T-JER cells. EPO dependent long term proliferation of T-JER cells was conferred by expression of the constitutively activated form of MEK1. Our results suggest that MAP kinase activation is, at least in part, an important component for mitotic signal from the EPOR, and CTLL-2 cells probably lack signaling molecule(s) in JAK2 and the Ras-MAP kinase pathway.	Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Univ Tokyo, Inst Med Sci, Dept Hemopoiet Factors, Minato Ku, Tokyo 1088639, Japan	Kurume University; University of Tokyo	Yoshimura, A (corresponding author), Kurume Univ, Inst Life Sci, Aikawa Machi 2432-3, Kurume, Fukuoka 8390861, Japan.	yosimura@lsi.kurume-u.ac.jp	Kitamura, Toshio/AAA-2071-2021; Wilson, Matthew H/K-3193-2013; Yoshimura, Akihiko/K-5515-2013					BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; Chin H, 1998, BLOOD, V91, P3734; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; Gaffen SL, 1999, BLOOD, V94, P74, DOI 10.1182/blood.V94.1.74.413k36_74_86; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Jenkins BJ, 1998, BLOOD, V92, P1989, DOI 10.1182/blood.V92.6.1989; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Kieslinger M, 2000, GENE DEV, V14, P232; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; MIGLIACCIO AR, 1991, P NATL ACAD SCI USA, V88, P11086, DOI 10.1073/pnas.88.24.11086; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, BLOOD, V84, P1501; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; SHOWERS MO, 1992, BLOOD, V80, P3070; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YAMAMURA Y, 1992, EMBO J, V11, P4909, DOI 10.1002/j.1460-2075.1992.tb05597.x; YAMAMURA Y, 1994, P NATL ACAD SCI USA, V91, P8866, DOI 10.1073/pnas.91.19.8866; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	48	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35857	35862		10.1074/jbc.M006317200	http://dx.doi.org/10.1074/jbc.M006317200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10960479	hybrid			2022-12-27	WOS:000165382000032
J	Tcherkasskaya, O; Bychkova, VE; Uversky, VN; Gronenborn, AM				Tcherkasskaya, O; Bychkova, VE; Uversky, VN; Gronenborn, AM			Multisite fluorescence in proteins with multiple tryptophan residues - Apomyoglobin natural variants and site-directed mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREQUENCY-DOMAIN FLUOROMETRY; MOLTEN GLOBULE INTERMEDIATE; SPERM WHALE APOMYOGLOBINS; STRUCTURAL CHARACTERIZATION; CONFORMATIONAL PROPERTIES; FOLDING REACTIONS; ESCHERICHIA-COLI; ENERGY-TRANSFER; MYOGLOBIN; STATE	Time-resolved fluorescence experiments were carried out on a variety of apomyoglobins with one or two tryptophan (Trp) residues located at invariant positions 7 and 14 in the primary sequence. In all cases, the Trp fluorescence kinetics were resolved adequately into two discrete lifetime domains, and decay-associated spectra (DAS) were obtained for each decay component. The DAS resolved for unfolded proteins were indistinguishable by position of the emission maxima and the spectral shapes. The folded proteins revealed noticeable differences in the DAS, which relate to the diverse local environments around the Trp residues in the individual proteins. Furthermore, the DAS of wild-type protein possessing two Trp residues were simulated well by that of one Trp mutants either in the native, molten globule, or unfolded states. Overall, employing Trp fluorescence and site-directed mutagenesis allowed us to highlight the conformational changes induced by the single amino acid replacement and generate novel structural information on equilibrium folding intermediates. Specifically, it was found that conformational fluctuations in the local cluster around the evolutionarily conserved Trp(14) are very similar in the native and molten globule states of apomyoglobins, This result indicates that residues in the E and B helices contributing to this cluster are most likely involved in the stabilization of the overall architecture of the structured molten globule intermediate.	NCI, Lab Expt & Computat Biol, NIH, Bethesda, MD 20892 USA; Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia; Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Russian Academy of Sciences; University of California System; University of California Santa Cruz; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Tcherkasskaya, O (corresponding author), NCI, Lab Expt & Computat Biol, NIH, Bethesda, MD 20892 USA.		Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857; Gronenborn, Angela M/0000-0001-9072-3525	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON S, 1970, BIOCHEMISTRY-US, V9, P4723, DOI 10.1021/bi00826a015; BALESTRIERI C, 1978, COMP BIOCHEM PHYS B, V60, P195, DOI 10.1016/0305-0491(78)90130-X; Ballew RM, 1996, NAT STRUCT BIOL, V3, P923, DOI 10.1038/nsb1196-923; BARRICK D, 1993, BIOCHEMISTRY-US, V32, P3790, DOI 10.1021/bi00065a035; BARRICK D, 1993, PROTEIN SCI, V2, P869, DOI 10.1002/pro.5560020601; BISMUTO E, 1989, BIOCHEMISTRY-US, V28, P1508, DOI 10.1021/bi00430a013; BISMUTO E, 1994, J MOL BIOL, V241, P103, DOI 10.1006/jmbi.1994.1477; BOENS N, 1990, P SPIE C TIME RESOLV, V2, P456; Chang Y, 1997, BIOCHEMISTRY-US, V36, P7652, DOI 10.1021/bi970197g; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; COCCO MJ, 1990, BIOCHEMISTRY-US, V29, P11067, DOI 10.1021/bi00502a008; Demchenko A. P., 1992, TOPICS FLUORESCENCE, V3, P65; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; Eaton WA, 1997, CURR OPIN STRUC BIOL, V7, P10, DOI 10.1016/S0959-440X(97)80003-6; EFTINK MR, 1987, BIOCHEMISTRY-US, V26, P8338, DOI 10.1021/bi00399a047; Eftink MR, 1997, METHOD ENZYMOL, V278, P258; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; EVANS SV, 1990, J MOL BIOL, V213, P885, DOI 10.1016/S0022-2836(05)80270-0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hudson BS, 1999, J PHYS CHEM A, V103, P2227, DOI 10.1021/jp983585g; HUGHSON FM, 1989, BIOCHEMISTRY-US, V28, P4415, DOI 10.1021/bi00436a044; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IRACE G, 1981, BIOCHEMISTRY-US, V20, P792, DOI 10.1021/bi00507a022; JANES SM, 1987, BIOPHYS J, V51, P653, DOI 10.1016/S0006-3495(87)83390-8; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; JOHNSON KA, 1989, J MOL BIOL, V207, P459, DOI 10.1016/0022-2836(89)90269-6; KATAOKA M, 1995, J MOL BIOL, V249, P215, DOI 10.1006/jmbi.1995.0290; Kay MS, 1996, NAT STRUCT BIOL, V3, P439, DOI 10.1038/nsb0596-439; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KNUTSON JR, 1983, CHEM PHYS LETT, V102, P501, DOI 10.1016/0009-2614(83)87454-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ JR, 1999, PRINCIPLES FLUROESCE, P487; LATTMAN EE, 1971, J MOL BIOL, V60, P271, DOI 10.1016/0022-2836(71)90293-2; Lecomte JTJ, 1999, PROTEIN SCI, V8, P1484, DOI 10.1110/ps.8.7.1484; Meagher JL, 1998, J BIOL CHEM, V273, P23283, DOI 10.1074/jbc.273.36.23283; Morawetz H, 1999, J POLYM SCI POL CHEM, V37, P1725, DOI 10.1002/(SICI)1099-0518(19990615)37:12<1725::AID-POLA1>3.0.CO;2-D; Park SH, 1999, NAT STRUCT BIOL, V6, P943, DOI 10.1038/13311; POKALSKY C, 1995, J BIOL CHEM, V270, P3809, DOI 10.1074/jbc.270.8.3809; POSTNIKOVA GB, 1991, EUR J BIOCHEM, V198, P223, DOI 10.1111/j.1432-1033.1991.tb16005.x; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Ptitsyn OB, 1999, J MOL BIOL, V291, P671, DOI 10.1006/jmbi.1999.2920; Rischel C, 1996, J MOL BIOL, V257, P877, DOI 10.1006/jmbi.1996.0208; Sillen A, 1999, PROTEINS, V37, P253, DOI 10.1002/(SICI)1097-0134(19991101)37:2<253::AID-PROT10>3.0.CO;2-J; Sillen A, 2000, PROTEIN SCI, V9, P158; Sirangelo I, 2000, BBA-PROTEIN STRUCT M, V1476, P173, DOI 10.1016/S0167-4838(99)00257-5; Sirangelo I, 1998, EUR BIOPHYS J BIOPHY, V27, P27, DOI 10.1007/s002490050107; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; Tanio M, 1999, BIOPHYS J, V77, P431, DOI 10.1016/S0006-3495(99)76901-8; Tcherkasskaya O, 2000, BIOCHEMISTRY-US, V39, P1879, DOI 10.1021/bi992117+; Tcherkasskaya O, 1999, FEBS LETT, V455, P325, DOI 10.1016/S0014-5793(99)00792-9; Tcherkasskaya O, 1999, PROTEIN ENG, V12, P485, DOI 10.1093/protein/12.6.485; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; Uversky VN, 1998, P NATL ACAD SCI USA, V95, P5480, DOI 10.1073/pnas.95.10.5480; WASYLEWSKI Z, 1988, EUR J BIOCHEM, V172, P719, DOI 10.1111/j.1432-1033.1988.tb13948.x; [No title captured]	55	28	28	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36285	36294		10.1074/jbc.M003008200	http://dx.doi.org/10.1074/jbc.M003008200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10948189	hybrid			2022-12-27	WOS:000165382000091
J	Peirce, M; Metzger, H				Peirce, M; Metzger, H			Detergent-resistant microdomains offer no refuge for proteins phosphorylated by the IgE receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; BASOPHILIC LEUKEMIA-CELLS; HIGH-AFFINITY RECEPTOR; IMMUNOGLOBULIN-E; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MEMBRANE DOMAINS; ACTIVATION; PHOSPHATASES; MECHANISM	When the high affinity receptor for IgE and related receptors become aggregated, they emigrate to specialized microdomains of the plasma membrane that are enriched in certain lipids and lipid-anchored proteins. Among the latter are the kinases that initiate signaling cascade(s) by phosphorylating the receptors. In studying the IgE receptor, we explored whether, in addition to their potential role in enhancing the initiation of signaling by the kinase(s), the microdomains might augment the stimulation by excluding phosphatases. In vitro assessment of phosphatase activity, using either a relevant or irrelevant substrate, suggested that the microdomains were deficient in phosphatase activity, but, in vivo, proteins confined to the microdomains were found to be no less vulnerable to dephosphorylation than those outside such domains. In the course of our experiments, we observed that the procedures routinely used to isolate the detergent-resistant domains dissociated the receptor for IgE, thereby artificially accentuating the observed preferential distribution of phosphorylated subunits in the microdomains.	NIAMS, Arthritis & Rheumatism Branch, Sect Chem Immunol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Metzger, H (corresponding author), NIAMS, Arthritis & Rheumatism Branch, Sect Chem Immunol, NIH, Bldg 10,Rm 9N-228,10 Ctr Dr,MSC-1820, Bethesda, MD 20892 USA.		Peirce, Matthew/ABB-9577-2021	Peirce, Matthew/0000-0003-3648-5639	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18126; ALBER G, 1992, J IMMUNOL, V149, P2428; ALCARAZ G, 1984, J BIOL CHEM, V259, P4922; Amoui M, 1997, EUR J IMMUNOL, V27, P1881, DOI 10.1002/eji.1830270810; Baird B, 1999, BIOPHYS CHEM, V82, P109, DOI 10.1016/S0301-4622(99)00110-6; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; Chen T, 1996, J BIOL CHEM, V271, P25308, DOI 10.1074/jbc.271.41.25308; EISEMAN E, 1992, NATURE, V355, P78; FEWTRELL C, 1980, J IMMUNOL, V125, P701; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Grucza RA, 1999, BIOCHEMISTRY-US, V38, P5024, DOI 10.1021/bi9829938; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; KENT UM, 1994, P NATL ACAD SCI USA, V91, P3087, DOI 10.1073/pnas.91.8.3087; Kimura T, 1997, J IMMUNOL, V159, P4426; KINET JP, 1985, BIOCHEMISTRY-US, V24, P4117, DOI 10.1021/bi00336a046; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; LIU FT, 1980, J IMMUNOL, V124, P2728; Mao SY, 1997, J BIOL CHEM, V272, P14067, DOI 10.1074/jbc.272.22.14067; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; PRIBLUDA VS, 1992, P NATL ACAD SCI USA, V89, P11446, DOI 10.1073/pnas.89.23.11446; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; Pribluda VS, 1997, J BIOL CHEM, V272, P11185; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; RIVNAY B, 1982, J BIOL CHEM, V257, P2800; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stauffer TP, 1997, J CELL BIOL, V139, P1447, DOI 10.1083/jcb.139.6.1447; Stephan V, 1997, CELL SIGNAL, V9, P65, DOI 10.1016/S0898-6568(96)00093-9; Torigoe C, 1998, SCIENCE, V281, P568, DOI 10.1126/science.281.5376.568; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Walchli S, 2000, J BIOL CHEM, V275, P9792, DOI 10.1074/jbc.275.13.9792	42	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34976	34982		10.1074/jbc.M005819200	http://dx.doi.org/10.1074/jbc.M005819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956655	hybrid			2022-12-27	WOS:000165422800022
J	Sedova, M; Blatter, LA				Sedova, M; Blatter, LA			Intracellular sodium modulates mitochondrial calcium signaling in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; NITRIC-OXIDE; OXIDATIVE-PHOSPHORYLATION; INOSITOL TRISPHOSPHATE; LIVER-MITOCHONDRIA; HEART-MITOCHONDRIA; STORE DEPLETION; CA2+; OSCILLATIONS; TRANSPORT	We have investigated the role of extramitochondrial Na+ for the regulation of mitochondrial Ca2+ concentration ([Ca2+](m)) in permeabilized single vascular endothelial cells. [Ca2+], was measured by loading the cells with the membrane-permeant Ca2+ indicator fluo-3/AM: and subsequent removal of cytoplasmic fluo-3 by surface membrane permeabilization with digitonin. An elevation of extramitochondrial Ca2+ resulted in a dose-dependent increase in the rate of Ca2+ accumulation into mitochondria (k(0.5) = 3 muM) via the mitochondrial Ca2+ uniporter. In the presence of 10 mM extramitochondrial Na+ ([Na+](em)), repetitive application of brief pulses of high Ca2' (2-10 muM) to simulate cytoplasmic [Ca2+] oscillations caused transient increases of [Ca2+], characterized by a fast rising phase that was followed by a slow decay. Removal of extramitochondrial Naf or inhibition of mitochondrial Na+/Ca2+ exchange with clonazepam blocked mitochondrial Ca2+ efflux and resulted in a net accumulation of Ca2+ by the mitochondria. Half-maximal activation of mitochondrial Na+/Ca2+ exchange occurred at [Na+](em) = 4.4 mM, which is well within the physiological range of cytoplasmic [Na+]. This study provides evidence that Ca2+ efflux from the mitochondria in vascular endothelial cells occurs solely via Na+/Ca2+ exchange and emphasizes the important role of intracellular Nat for mitochondrial Ca2+ regulation.	Loyola Univ, Stritch Sch Med, Dept Physiol, Maywood, IL 60153 USA	Loyola University Chicago	Blatter, LA (corresponding author), Loyola Univ, Stritch Sch Med, Dept Physiol, 2160 S 1st Ave, Maywood, IL 60153 USA.	LBLATTE@LUMC.EDU	Blatter, Lothar/AAC-8431-2020		NHLBI NIH HHS [HL-62231, HL-51941] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051941, R01HL062231] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Babcock DF, 1998, CURR OPIN NEUROBIOL, V8, P398, DOI 10.1016/S0959-4388(98)80067-6; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BLATTER LA, 1991, J GEN PHYSIOL, V98, P1141, DOI 10.1085/jgp.98.6.1141; BLATTER LA, 1995, AM J PHYSIOL-CELL PH, V268, pC503, DOI 10.1152/ajpcell.1995.268.2.C503; BLATTER LA, 1995, CIRC RES, V76, P922, DOI 10.1161/01.RES.76.5.922; CARTER TD, 1991, BIOCHEM J, V278, P697, DOI 10.1042/bj2780697; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COX DA, 1993, J BIOL CHEM, V268, P938; CROMPTON M, 1977, EUR J BIOCHEM, V79, P549, DOI 10.1111/j.1432-1033.1977.tb11839.x; CROMPTON M, 1976, EUR J BIOCHEM, V69, P453, DOI 10.1111/j.1432-1033.1976.tb10930.x; CROMPTON M, 1978, EUR J BIOCHEM, V82, P25, DOI 10.1111/j.1432-1033.1978.tb11993.x; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Donnadieu E, 1996, CELL CALCIUM, V20, P53, DOI 10.1016/S0143-4160(96)90050-0; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; GRIFFITH TM, 1986, CARDIOVASC RES, V20, P7, DOI 10.1093/cvr/20.1.7; Gunter TE, 1998, BBA-BIOENERGETICS, V1366, P5, DOI 10.1016/S0005-2728(98)00117-0; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hajnoczky G, 1997, EMBO J, V16, P3533, DOI 10.1093/emboj/16.12.3533; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; HAWORTH RA, 1980, FEBS LETT, V110, P216, DOI 10.1016/0014-5793(80)80076-7; HEFFRON JJA, 1981, BIOCHEM J, V194, P925, DOI 10.1042/bj1940925; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; JACOB R, 1991, CELL CALCIUM, V12, P127, DOI 10.1016/0143-4160(91)90014-6; Jornot L, 1999, J CELL SCI, V112, P1013; Jou MJ, 1996, J PHYSIOL-LONDON, V497, P299, DOI 10.1113/jphysiol.1996.sp021769; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; LI WH, 1992, J BIOL CHEM, V267, P17983; LIDOFSKY SD, 1993, J BIOL CHEM, V268, P14632; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Paltauf-Doburzynska J, 2000, J PHYSIOL-LONDON, V524, P701, DOI 10.1111/j.1469-7793.2000.00701.x; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; RIZZUTO R, 1987, BIOCHEM J, V246, P271, DOI 10.1042/bj2460271; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; SAGE SO, 1991, J PHYSIOL-LONDON, V441, P559, DOI 10.1113/jphysiol.1991.sp018767; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Sedova M, 2000, J PHYSIOL-LONDON, V523, P549, DOI 10.1111/j.1469-7793.2000.t01-3-00549.x; Sedova M, 2000, BIOPHYS J, V78, p70A; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Teubl M, 1999, J BIOL CHEM, V274, P29529, DOI 10.1074/jbc.274.41.29529; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; WINGROVE DE, 1986, J BIOL CHEM, V261, P5166	61	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35402	35407		10.1074/jbc.M006058200	http://dx.doi.org/10.1074/jbc.M006058200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10958797	hybrid			2022-12-27	WOS:000165422800076
J	Kasahara, K; Watanabe, K; Takeuchi, K; Kaneko, H; Oohira, A; Yamamoto, T; Sanai, Y				Kasahara, K; Watanabe, K; Takeuchi, K; Kaneko, H; Oohira, A; Yamamoto, T; Sanai, Y			Involvement of gangliosides in glycosylphosphatidylinositol-anchored neuronal cell adhesion molecule TAG-1 signaling in lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; PROTEIN-TYROSINE KINASE; CHONDROITIN SULFATE PROTEOGLYCAN; ENRICHED MEMBRANE SUBDOMAINS; CAVEOLAE-LIKE DOMAINS; MELANOMA B16 CELLS; FC-EPSILON-RI; IMMUNOGLOBULIN SUPERFAMILY; PLASMA-MEMBRANE; NERVOUS-SYSTEM	The association of ganglioside GD3 with TAG-1, a glycosylphosphatidylinositol-anchored neuronal cell adhesion molecule, was examined by coimmunoprecipitation experiments. Previously, we have shown that the anti-ganglioside GD3 antibody (R24) immunoprecipitated the Src family kinase Lyn from the rat cerebellum, and R24 treatment of primary cerebellar cultures induced Lyn activation and rapid tyrosine phosphorylation of an 80-kDa protein (p80), We now report that R24 coimmunoprecipitates a 135-kDa protein (p135) from primary cerebellar cultures. Treatment with phosphatidylinositol-specific phospholipase C revealed that p135 was glycosylphosphatidylinositol-anchored to the membrane. It was identified as TAG-1 by sequential immunoprecipitation with an anti-TAG-1 antibody. Antibody-mediated cross-linking of TAG-1 induced Lyn activation and rapid tyrosine phosphorylation of p80. Selective inhibitor for Src family kinases reduced the tyrosine phosphorylation of p80. Sucrose density gradient analysis revealed that the TAG-1 and tyrosine-phosphorylated p80 in cerebellar cultures were present in the lipid raft fraction. These data show that TAG-1 transduces signals via Lyn to p80 in the lipid rafts of the cerebellum. Furthermore, degradation of cell-surface glycosphingolipids by endoglycoceramidase induced an alteration of TAG-1 distribution on an OptiPrep gradient and reduced the TAG-1-mediated Lyn activation and tyrosine phosphorylation of p80, These observations suggest that glycosphingolipids are involved in TAG-1-mediated signaling in lipid rafts.	Tokyo Metropolitan Org Med Res, Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, Tokyo 1138613, Japan; Tokyo Metropolitan Inst Gerontol, Dept Cell Recognit, Itabashi Ku, Tokyo 1730015, Japan; Inst Dev Res, Dept Perinatol & Neuroglycosci, Kasugai, Aichi 4800392, Japan; Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 1080071, Japan	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Gerontology; University of Tokyo	Kasahara, K (corresponding author), Tokyo Metropolitan Org Med Res, Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, 3-18-22 Honkagome, Tokyo 1138613, Japan.	kasahara@rinshoken.or.jp	Takeuchi, Kosei/AAV-3577-2021	Takeuchi, Kosei/0000-0001-6397-2243; Kasahara, Kohji/0000-0001-7010-8365				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Buttiglione M, 1998, J NEUROSCI, V18, P6853; Chen S, 1996, DEV BRAIN RES, V92, P140, DOI 10.1016/0165-3806(95)00208-1; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; Draberova L, 1996, IMMUNOLOGY, V87, P141; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; FUTERMAN AH, 1995, TRENDS CELL BIOL, V5, P377, DOI 10.1016/S0962-8924(00)89078-9; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; Henke RC, 1997, J NEUROSCI RES, V49, P655, DOI 10.1002/(SICI)1097-4547(19970915)49:6<655::AID-JNR1>3.3.CO;2-0; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Ilangumaran S, 2000, IMMUNOL TODAY, V21, P2, DOI 10.1016/S0167-5699(99)01494-2; Ilangumaran S, 1999, MOL BIOL CELL, V10, P891, DOI 10.1091/mbc.10.4.891; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; ITO M, 1991, J BIOL CHEM, V266, P7919; Ito M, 1996, J BIOL CHEM, V271, P12655, DOI 10.1074/jbc.271.21.12655; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Izu H, 1997, J BIOL CHEM, V272, P19846, DOI 10.1074/jbc.272.32.19846; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Kasahara K, 1999, BIOPHYS CHEM, V82, P121, DOI 10.1016/S0301-4622(99)00111-8; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; Katagiri YU, 1999, J BIOL CHEM, V274, P35278, DOI 10.1074/jbc.274.49.35278; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; KNIEP B, 1994, BIOCHEM BIOPH RES CO, V203, P1069, DOI 10.1006/bbrc.1994.2291; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; KUHAR SG, 1993, DEVELOPMENT, V117, P97; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LEDEEN RW, 1984, J NEUROSCI RES, V12, P147, DOI 10.1002/jnr.490120204; Levi G., 1989, DISSECTION TISSUE CU, P211; MAEDA N, 1992, DEV BIOL, V151, P564, DOI 10.1016/0012-1606(92)90194-L; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; Masserini M, 1999, J NEUROCHEM, V73, P1, DOI 10.1046/j.1471-4159.1999.0730001.x; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; MINOGUCHI K, 1994, J BIOL CHEM, V269, P5249; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OLIVE S, 1995, J NEUROCHEM, V65, P2307; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; PURPURA DP, 1978, NATURE, V276, P520, DOI 10.1038/276520a0; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; ROISEN FJ, 1981, SCIENCE, V214, P577, DOI 10.1126/science.7291999; ROSNER H, 1992, NEUROCHEM INT, V20, P339, DOI 10.1016/0197-0186(92)90048-V; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Sheets ED, 1997, BIOCHEMISTRY-US, V36, P12449, DOI 10.1021/bi9710939; Sheikh KA, 1999, P NATL ACAD SCI USA, V96, P7532, DOI 10.1073/pnas.96.13.7532; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1999, MOL BIOL CELL, V10, P3187, DOI 10.1091/mbc.10.10.3187; SKAPER SD, 1985, DEV BRAIN RES, V23, P19, DOI 10.1016/0165-3806(85)90003-3; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Surviladze Z, 1998, EUR J IMMUNOL, V28, P1847, DOI 10.1002/(SICI)1521-4141(199806)28:06<1847::AID-IMMU1847>3.0.CO;2-O; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; SWAIM WD, 1994, J BIOL CHEM, V269, P19466; TETTAMANTI G, 1994, PROG BRAIN RES, V101, P77; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; TOFFANO G, 1983, BRAIN RES, V261, P163, DOI 10.1016/0006-8993(83)91298-2; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; YAMAKAWA T, 1978, TRENDS BIOCHEM SCI, V3, P128, DOI 10.1016/S0968-0004(78)80031-0; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142; YOSHIHARA Y, 1995, J NEUROBIOL, V28, P51, DOI 10.1002/neu.480280106; ZISCH AH, 1995, MOL CELL NEUROSCI, V6, P263, DOI 10.1006/mcne.1995.1021	77	131	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34701	34709		10.1074/jbc.M003163200	http://dx.doi.org/10.1074/jbc.M003163200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944523	hybrid			2022-12-27	WOS:000165095300094
J	Perrin, RJ; Woods, WS; Clayton, DF; George, JM				Perrin, RJ; Woods, WS; Clayton, DF; George, JM			Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids - Structural analysis using site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-SYSTEM ATROPHY; GLIAL CYTOPLASMIC INCLUSIONS; ALZHEIMERS-DISEASE; LEWY BODIES; SECONDARY STRUCTURE; PRECURSOR PROTEIN; AMPHIPATHIC HELIX; NERVOUS-SYSTEM; VESICLES; MUTATION	alpha -Synuclein has been centrally implicated in neurodegenerative disease, and a normal function in developmental synaptic plasticity has been suggested by studies in songbirds. A variety of observations suggest the protein partitions between membrane and cytosol, a behavior apparently conferred by a conserved structural similarity to the exchangeable apolipoproteins. Here we show that the capacity to bind lipids is broadly distributed across exons 3, 4, and 5 (encoding residues 1-102), Binding to phosphatidylserine-containing vesicles requires the presence of all three exons, while binding to phosphatidic acid can be mediated by any one of the three. Consistent with a "class A2" helical binding mechanism, lipid association is disrupted by introduction of charged residues along the hydrophobic face of the predicted cu-helix and also by biotinylation of conserved lysines (which line the interfacial region). Circular dichroism spectroscopy reveals a general correlation between the amount of lipid-induced alpha -helix content and the degree of binding to PS-containing vesicles. Two point mutations associated with Parkinson's disease have little (A30P) or no (A53T) effect on lipid binding or a-helicity. These results are consistent with the hypothesis that alpha -synuclein's normal functions depend on an ability to undergo a large conformational change in the presence of specific phospholipids.	Univ Illinois, Dept Cell & Struct Biol, Chem & Life Sci Lab B107, Urbana, IL 61801 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	George, JM (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Chem & Life Sci Lab B107, 601 S Goodwin, Urbana, IL 61801 USA.		Clayton, David/B-2190-2008; George, Julia M/B-2169-2008; Woods, Wendy/B-6602-2008	Clayton, David/0000-0002-6395-3488; George, Julia M/0000-0001-6194-6914; 	NIA NIH HHS [1R01 AG13762] Funding Source: Medline; NIGMS NIH HHS [5T32GM07143-20] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013762] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; Dittman JS, 1998, J NEUROSCI, V18, P6147; Gai WP, 1998, LANCET, V352, P547, DOI 10.1016/S0140-6736(05)79256-4; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Gomis A, 1999, J NEUROSCI, V19, P6309; GREEN N. M., 1970, Methods in Enzymology, V18A, P418, DOI 10.1016/0076-6879(71)18342-5; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; HUANG KP, 1993, NEUROCHEM INT, V22, P417, DOI 10.1016/0197-0186(93)90037-6; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Refsgaard HHF, 2000, P NATL ACAD SCI USA, V97, P611, DOI 10.1073/pnas.97.2.611; SALEM N, 1995, MOL MEMBR BIOL, V12, P131, DOI 10.3109/09687689509038508; SASTRY PS, 1985, PROG LIPID RES, V24, P69, DOI 10.1016/0163-7827(85)90011-6; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1992, J LIPID RES, V33, P141; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Stevens CF, 1999, NEURON, V24, P1017, DOI 10.1016/S0896-6273(00)81047-8; Surguchov A, 1999, MOL CELL NEUROSCI, V13, P95, DOI 10.1006/mcne.1999.0735; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8; Wang LY, 1998, NATURE, V394, P384, DOI 10.1038/28645; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6	42	338	343	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34393	34398		10.1074/jbc.M004851200	http://dx.doi.org/10.1074/jbc.M004851200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10952980	hybrid			2022-12-27	WOS:000165095300054
J	Zhang, YL; Yao, ZJ; Sarmiento, M; Wu, L; Burke, TR; Zhang, ZY				Zhang, YL; Yao, ZJ; Sarmiento, M; Wu, L; Burke, TR; Zhang, ZY			Thermodynamic study of ligand binding to protein-tyrosine phosphatase 1B and its substrate-trapping mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTHALPY-ENTROPY COMPENSATION; SOLID-PHASE SYNTHESIS; TITRATION CALORIMETRY; O-PHOSPHOTYROSINE; TRANSITION-STATE; INSULIN-RECEPTOR; CRYSTAL-STRUCTURE; INHIBITOR DESIGN; FOCAL ADHESIONS; SIGNATURE MOTIF	The binding of several phosphonodifluoromethyl phenylalanine (F(2)Pmp)-containing peptides to protein-tyrosine phosphatase 1B (PTP1B) and its substrate-trapping mutants (C215S and D181A) has been studied using isothermal titration calorimetry. The binding of a high affinity ligand, Ac-Asp-Ala-Asp-Glu-F(2)Pmp-Leu-NH2, to PTP1B (K-d = 0.24 muM) is favored by both enthalpic and entropic contributions. Disruption of ionic interactions between the side chain of Arg-47 and the N-terminal acidic residues reduces the binding affinity primarily through the reduction of the T DeltaS term. The role of Arg-47 may be to maximize surface contact between PTP1B and the peptide, which contributes to high affinity binding. The active site Cys-215-->Ser mutant PTP1B binds ligands with the same affinity as the wild-type enzyme. However, unlike wild-type PTP1B, peptide binding to C215S is predominately driven by enthalpy change, which likely results from the elimination of the electrostatic repulsion between the thiolate anion and the phosphonate group. The increased enthalpic contribution is offset by reduction in the binding entropy, which may be the result of increased entropy of the unbound protein caused by this mutation. The general acid-deficient mutant D181A binds the peptide 5-fold tighter than the C215S mutant, consistent with the observation that the Asp to Ala mutant is a better "substrate-trapping" reagent than C215S, The increased binding affinity for D181A as compared with the wildtype PTP1B results primarily from an increase in the DeltaH of binding in the mutant, which may be related to decreased electrostatic repulsion between the phosphate moiety and PTP1B, These results have important implications for the design of high affinity PTP1B inhibitors.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; NCI, Med Chem Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Burke, Terrence R/N-2601-2014	Burke, Terrence/0000-0001-9925-8586	NIGMS NIH HHS [5T32-GM-07491, GM-55242] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491, R01GM055242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Alhambra C, 1998, J AM CHEM SOC, V120, P3858, DOI 10.1021/ja972578n; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; Bradshaw JM, 1998, BIOCHEMISTRY-US, V37, P9083, DOI 10.1021/bi973147k; Burke TR, 1996, BIOCHEMISTRY-US, V35, P15989, DOI 10.1021/bi961256d; BURKE TR, 1994, BIOCHEM BIOPH RES CO, V204, P129, DOI 10.1006/bbrc.1994.2435; BURKE TR, 1993, J ORG CHEM, V58, P1336, DOI 10.1021/jo00058a009; CHEN L, 1995, BIOCHEM BIOPH RES CO, V216, P976, DOI 10.1006/bbrc.1995.2716; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; CONNELLY PR, 1990, BIOCHEMISTRY-US, V29, P6108, DOI 10.1021/bi00477a031; DUNITZ JD, 1995, CHEM BIOL, V2, P709, DOI 10.1016/1074-5521(95)90097-7; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Glover NR, 1999, BIOCHEMISTRY-US, V38, P5256, DOI 10.1021/bi9825450; GORDEEV MF, 1994, TETRAHEDRON LETT, V35, P7585, DOI 10.1016/S0040-4039(00)78349-3; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Hibbert F., 1990, ADV PHYS ORG CHEM, V26, P255, DOI DOI 10.1016/S0065-3160(08)60047-7; HINTZ HJ, 1983, ANNU REV BIOPHYS BIO, V12, P285; Hoff RH, 1999, J AM CHEM SOC, V121, P9514, DOI 10.1021/ja992361o; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JUSZEZAK LJ, 1997, BIOCHEMISTRY-US, V26, P2227; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Peters GH, 1998, BIOCHEMISTRY-US, V37, P5383, DOI 10.1021/bi971187i; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; Sarmiento M, 1998, J BIOL CHEM, V273, P26368, DOI 10.1074/jbc.273.41.26368; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; SIGURSKJOLD BW, 1994, BIOCHEMISTRY-US, V33, P10191, DOI 10.1021/bi00199a048; SMYTH MS, 1994, TETRAHEDRON LETT, V35, P551, DOI 10.1016/S0040-4039(00)75835-7; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Vetter SW, 2000, J BIOL CHEM, V275, P2265, DOI 10.1074/jbc.275.4.2265; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; Wang F, 1998, BIOCHEMISTRY-US, V37, P15289, DOI 10.1021/bi981481q; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wrobel J, 1999, J MED CHEM, V42, P3199, DOI 10.1021/jm990260v; Yang J, 2000, J BIOL CHEM, V275, P4066, DOI 10.1074/jbc.275.6.4066; Zhang YL, 1998, ANAL BIOCHEM, V261, P139, DOI 10.1006/abio.1998.2738; Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16389, DOI 10.1021/bi00050a020; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; Zhang ZY, 1997, BIOCHEMISTRY-US, V36, P1362, DOI 10.1021/bi9624043; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007	63	47	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34205	34212		10.1074/jbc.M004490200	http://dx.doi.org/10.1074/jbc.M004490200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10952978	hybrid			2022-12-27	WOS:000165095300030
J	Kreienkamp, HJ; Zitzer, H; Gundelfinger, ED; Richter, D; Bockers, TM				Kreienkamp, HJ; Zitzer, H; Gundelfinger, ED; Richter, D; Bockers, TM			The calcium-independent receptor for alpha-latrotoxin from human and rodent brains interacts with members of the ProSAP/SSTRIP/Shank family of multidomain proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							90/POSTSYNAPTIC DENSITY-95-ASSOCIATED PROTEIN; POSTSYNAPTIC DENSITY PROTEINS; COUPLED RECEPTORS; BINDING-PROTEIN; DOMAIN; PSD-95; CORTACTIN; EXOCYTOSIS; DEFINES; SHANK	Subtypes of the calcium-independent receptors for alpha -latrotoxin (CIRL1-3) define a distinct subgroup within the large family of the seven-transmembrane region cell surface receptors, The physiological function of CIRLs is unknown because neither extracellular ligands nor intracellular coupling proteins (G-proteins) have been identified. Using yeast two-hybrid screening, we identified a novel interaction between the C termini of CIRL1 and -2 and the PSD-95/discs large/ZO-1 (PDZ) domain of a recently discovered multidomain protein family (ProSAP/SSTRIP/Shank) present in human and rat brain. In vitro, CIRL1 and CIRL2 interacted strongly with the PDZ domain of ProSAP1, The specificity of this interaction has been verified by in vivo experiments using solubilized rat brain membrane fractions and ProSAP1 antibodies; only CIRL1, but not CIRL2, was coimmunoprecipitated with ProSAP1. In situ hybridization revealed that ProSAP1 and CIRL1 are co-expressed in the cortex, hippocampus, and cerebellum. Colocalization was also observed at the subcellular level, as both CIRL1 and ProSAP1 are enriched in the postsynaptic density fraction from rat brain. Expression of all three CIRL isoforms is highly regulated during postnatal brain development, with CIRL3 exhibiting its highest expression levels immediately after birth, followed by CIRL2 and finally CIRL1 in aged rats.	Univ Hamburg, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany; Leibnitz Inst Neurobiol, D-39118 Magdeburg, Germany; Univ Munster, Inst Anat, D-48149 Munster, Germany	University of Hamburg; Leibniz Institut fur Neurobiologie (LIN); University of Munster	Richter, D (corresponding author), Univ Hamburg, Inst Zellbiochem & Klin Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.							Boeckers TM, 1999, BIOCHEM BIOPH RES CO, V264, P247, DOI 10.1006/bbrc.1999.1489; Boeckers TM, 1999, J NEUROSCI, V19, P6506; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hlubek MD, 2000, MOL PHARMACOL, V57, P519, DOI 10.1124/mol.57.3.519; Ichtchenko K, 1999, J BIOL CHEM, V274, P5491, DOI 10.1074/jbc.274.9.5491; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kawabe H, 1999, J BIOL CHEM, V274, P30914, DOI 10.1074/jbc.274.43.30914; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Matsushita H, 1999, FEBS LETT, V443, P348, DOI 10.1016/S0014-5793(99)00005-8; Naisbitt S, 1997, J NEUROSCI, V17, P5687; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Shiratsuchi T, 1997, CYTOGENET CELL GENET, V79, P103, DOI 10.1159/000134693; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; White GRM, 1998, ONCOGENE, V17, P3513, DOI 10.1038/sj.onc.1202487; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463; Zitzer H, 1999, J BIOL CHEM, V274, P18153, DOI 10.1074/jbc.274.26.18153; Zitzer H, 1999, J BIOL CHEM, V274, P32997, DOI 10.1074/jbc.274.46.32997	27	70	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32387	32390		10.1074/jbc.C000490200	http://dx.doi.org/10.1074/jbc.C000490200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10964907	hybrid			2022-12-27	WOS:000090003800003
J	Downey, P; Szabo, I; Ivashikina, N; Negro, A; Guzzo, F; Ache, P; Hedrich, R; Terzi, M; Lo Schiavo, F				Downey, P; Szabo, I; Ivashikina, N; Negro, A; Guzzo, F; Ache, P; Hedrich, R; Terzi, M; Lo Schiavo, F			KDC1, a novel carrot root hair K+ channel - Cloning, characterization, and expression in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; POTASSIUM CHANNEL; APOPLASTIC PH; MEMBRANE; POTATO; GENE; RECTIFIER; MECHANISM; SEQUENCE; SUBUNIT	Potassium is an essential nutrient which plays an important role in many aspects of plant growth and development. Plants have developed a number of highly specific mechanisms to take up potassium from the soil; these include the expression of K+ transporters and potassium channels in root cells. Despite the fact that root epidermal and hair cells are in direct contact with the soil, the role of these tissues in K+ uptake is not well understood. Here we report the molecular cloning and functional characterization of a novel potassium channel KDC1 which forms part of a new subfamily of plant K-in channels. Kdc1 was isolated from carrot root RNA and in situ hybridization experiments show Kdc1 to be highly expressed in root hair cells. Expressing the KDC1 protein in Chinese hamster ovary cells identified it as a voltage and pH-dependent inwardly rectifying potassium channel. An electrophysiological analysis of carrot root hair protoplasts confirmed the biophysical properties of the Kdc1 gene product (KDC1) in the heterologous expression system. KDC1 thus represents a major K+ uptake channel in carrot root hair cells.	Univ Padua, Ctr Biotechnol, Ctr Ric Interdipartimentale Biotechnol Innovat, I-35121 Padua, Italy; Univ Padua, Dipartimento Biol, I-35121 Padua, Italy; Univ Wurzburg, Lehrstuhl Mol Pflanzenphysiol & Biophys, Julius von Sachs Inst Biowissensch, D-97082 Wurzburg, Germany; Univ Verona, Ist Policattedra, I-37134 Verona, Italy	University of Padua; University of Padua; University of Wurzburg; University of Verona	Downey, P (corresponding author), Univ Padua, Ctr Biotechnol, Ctr Ric Interdipartimentale Biotechnol Innovat, Viale G Colombo 3, I-35121 Padua, Italy.	pdowney@civ.bio.unipd.it	Szabo, Ildiko/AAW-5972-2021; Hedrich, Rainer/G-8771-2011; Ache, Peter/AAS-7651-2021; Padova, Ildiko/K-5344-2016	Szabo, Ildiko/0000-0002-3637-3947; Hedrich, Rainer/0000-0003-3224-1362; Ache, Peter/0000-0002-2902-7552; GUZZO, Flavia/0000-0003-2946-1962; NEGRO, ALESSANDRO/0000-0003-3142-7632				Amtmann A, 1999, PLANT PHYSIOL, V120, P331, DOI 10.1104/pp.120.1.331; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Bibikova TN, 1998, DEVELOPMENT, V125, P2925; Bruggemann L, 1999, P NATL ACAD SCI USA, V96, P3298, DOI 10.1073/pnas.96.6.3298; CLARKSON DT, 1980, ANNU REV PLANT PHYS, V31, P239, DOI 10.1146/annurev.pp.31.060180.001323; Connor JX, 1998, J BIOL CHEM, V273, P28906, DOI 10.1074/jbc.273.44.28906; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Czempinski K, 1997, EMBO J, V16, P2565, DOI 10.1093/emboj/16.10.2565; Daram P, 1997, EMBO J, V16, P3455, DOI 10.1093/emboj/16.12.3455; DREWS GN, 1998, ARABIDOPSIS PROTOCOL; Ehrhardt T, 1997, FEBS LETT, V409, P166, DOI 10.1016/S0014-5793(97)00502-4; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Felle HH, 1998, J EXP BOT, V49, P987, DOI 10.1093/jexbot/49.323.987; GASSMANN W, 1994, PLANT PHYSIOL, V105, P1399, DOI 10.1104/pp.105.4.1399; Gaymard F, 1996, J BIOL CHEM, V271, P22863, DOI 10.1074/jbc.271.37.22863; Gaymard F, 1998, CELL, V94, P647, DOI 10.1016/S0092-8674(00)81606-2; GLASS DB, 1986, J BIOL CHEM, V261, P2987; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hartje S, 2000, PLANTA, V210, P723, DOI 10.1007/s004250050673; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Hirsch RE, 1998, SCIENCE, V280, P918, DOI 10.1126/science.280.5365.918; Hoth S, 1997, P NATL ACAD SCI USA, V94, P4806, DOI 10.1073/pnas.94.9.4806; Hoth S, 1999, J BIOL CHEM, V274, P11599, DOI 10.1074/jbc.274.17.11599; Ketchum KA, 1996, FEBS LETT, V378, P19, DOI 10.1016/0014-5793(95)01417-9; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; Lagarde D, 1996, PLANT J, V9, P195, DOI 10.1046/j.1365-313X.1996.09020195.x; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; Marten I, 1999, P NATL ACAD SCI USA, V96, P7581, DOI 10.1073/pnas.96.13.7581; MORAN N, 1988, PLANT PHYSIOL, V88, P643, DOI 10.1104/pp.88.3.643; MULLERROBER B, 1995, EMBO J, V14, P2409, DOI 10.1002/j.1460-2075.1995.tb07238.x; NAKAMURA RL, 1995, PLANT PHYSIOL, V109, P371, DOI 10.1104/pp.109.2.371; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Philippar K, 1999, P NATL ACAD SCI USA, V96, P12186, DOI 10.1073/pnas.96.21.12186; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHROEDER JI, 1984, NATURE, V312, P361, DOI 10.1038/312361a0; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; Taylor DP, 1996, PHYSIOL PLANTARUM, V97, P35, DOI 10.1111/j.1399-3054.1996.tb00475.x; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; Yu SP, 1998, J NEUROSCI RES, V52, P612, DOI 10.1002/(SICI)1097-4547(19980601)52:5<612::AID-JNR13>3.0.CO;2-3; Zimmermann S, 1998, PLANT PHYSIOL, V116, P879, DOI 10.1104/pp.116.3.879	48	40	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39420	39426		10.1074/jbc.M002962200	http://dx.doi.org/10.1074/jbc.M002962200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10970888	hybrid			2022-12-27	WOS:000165953100066
J	Kar, S; Soong, L; Colmenares, M; Goldsmith-Pestana, K; McMahon-Pratt, D				Kar, S; Soong, L; Colmenares, M; Goldsmith-Pestana, K; McMahon-Pratt, D			The immunologically protective P-4 antigen of Leishmania amastigotes - A developmentally regulated single strand-specific nuclease associated with the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; MESSENGER-RNA; CUTANEOUS LEISHMANIASIS; EXCISION-REPAIR; CHAGASI PROMASTIGOTES; TRYPANOSOMA-BRUCEI; MEMBRANE-PROTEINS; GOLGI-APPARATUS; SIGNAL PEPTIDE; L AMAZONENSIS	The purified membrane-associated Leishmania pifanoi amastigote protein P-4 has been shown to induce protective immunity against infection and to elicit preferentially a T helper 1-like response in peripheral blood mononuclear cells of patients with American cutaneous leishmaniasis. As this molecule is potentially important for future vaccine studies, the L. pifanoi gene encoding the P-4 membrane protein was cloned and sequenced. Southern blot analyses indicate the presence of six tandemly arrayed copies of the P-4 gene in L. pifanoi; homologues of the P-4 gene are found in all other species of the genus Leishmania examined. DNA-derived protein sequence data indicated an identity to the Pi zinc-dependent nuclease of Penicillium citrinum (20.8%) and the C-terminal domain of the 3' nucleotidase of Leishmania donovani (33.7%), Consistent with these sequence analyses, purified L. pifanoi P-4 protein possesses single strand nuclease (DNA and RNA) and phosphomonoesterase activity, with a preference for UMP > TMP > AMP >> CMP, Double-labeling immunofluorescence microscopic analyses employing anti-binding protein antibodies revealed that the P-4 protein is localized in the endoplasmic reticulum of the amastigote. Northern blot analyses indicated that the gene is selectively expressed in the intracellular amastigote stage (mammalian host) but not in the promastigote stage (insect) of the parasite. Based upon its subcellular localization and single-stranded specific nuclease activity, possible roles of the P-4 nuclease in the amastigote in RNA stability (gene expression) or DNA repair are discussed.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA	Yale University	McMahon-Pratt, D (corresponding author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, POB 208034,60 Coll St, New Haven, CT 06510 USA.	diane.mcmahon-pratt@yale.edu	Colmenares, Maria Isabel/H-2848-2017	Colmenares, Maria Isabel/0000-0003-4114-277X				Al-Qahtani A, 1998, BIOCHEM J, V331, P521, DOI 10.1042/bj3310521; Bangs JD, 1996, J BIOL CHEM, V271, P18387, DOI 10.1074/jbc.271.31.18387; BANYOPADHYAY R, 1990, MOL CELL BIOL, V10, P2060; Beetham JK, 1997, J BIOL CHEM, V272, P17360, DOI 10.1074/jbc.272.28.17360; BEVERLEY SM, 1988, NUCLEIC ACIDS RES, V16, P925, DOI 10.1093/nar/16.3.925; BISHOP RP, 1990, MOL BIOCHEM PARASIT, V18, P127; BLAINEAU C, 1991, MOL BIOCHEM PARASIT, V46, P293, DOI 10.1016/0166-6851(91)90053-9; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; CAMPOSNETO A, 1995, J EXP MED, V182, P1423, DOI 10.1084/jem.182.5.1423; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; Coutinho SG, 1996, EXP PARASITOL, V84, P144, DOI 10.1006/expr.1996.0100; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; DEBRABANT A, 1995, MOL BIOCHEM PARASIT, V71, P51, DOI 10.1016/0166-6851(95)00035-Y; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; DUBOISE SM, 1994, THESIS YALE U NEW HA; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GLASER TA, 1988, P NATL ACAD SCI USA, V85, P7602, DOI 10.1073/pnas.85.20.7602; Gomord V, 1999, BIOCHIMIE, V81, P607, DOI 10.1016/S0300-9084(99)80118-7; GOTTLIEB M, 1983, MOL BIOCHEM PARASIT, V7, P303, DOI 10.1016/0166-6851(83)90013-0; GRIMALDI G, 1993, CLIN MICROBIOL REV, V6, P230, DOI 10.1128/CMR.6.3.230-250.1993; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; Handman E, 1997, PARASITOL TODAY, V13, P236, DOI 10.1016/S0169-4758(97)01060-0; HART DT, 1982, EXP PARASITOL, V54, P397, DOI 10.1016/0014-4894(82)90049-2; Hodgkinson VH, 1996, EXP PARASITOL, V83, P94, DOI 10.1006/expr.1996.0053; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; Kim PK, 1999, J BIOL CHEM, V274, P36876, DOI 10.1074/jbc.274.52.36876; LANDFORD CK, 1992, EXP PARASITOL, V74, P360; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; McCoy JJ, 1998, MOL BIOCHEM PARASIT, V95, P251, DOI 10.1016/S0166-6851(98)00112-1; MCMAHONPRATT D, 1993, INFECT IMMUN, V61, P3351, DOI 10.1128/IAI.61.8.3351-3359.1993; MODABBER F, 1990, SCAND J INFECT DIS, P72; Mosser David M., 1993, Seminars in Cell Biology, V4, P315, DOI 10.1006/scel.1993.1038; MOUGNEAU E, 1995, SCIENCE, V268, P563, DOI 10.1126/science.7725103; Mziaut H, 1999, J BIOL CHEM, V274, P14122, DOI 10.1074/jbc.274.20.14122; Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; PAN AA, 1988, J IMMUNOL, V140, P2406; Paramchuk WJ, 1997, MOL BIOCHEM PARASIT, V90, P203, DOI 10.1016/S0166-6851(97)00141-2; Parikh SS, 1997, STRUCTURE, V5, P1543, DOI 10.1016/S0969-2126(97)00303-1; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; Peters C, 1997, INFECT IMMUN, V65, P783, DOI 10.1128/IAI.65.2.783-786.1997; PETERSEN EA, 1984, J IMMUNOL, V132, P2603; RAINEY PM, 1991, MOL BIOCHEM PARASIT, V45, P307, DOI 10.1016/0166-6851(91)90099-R; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; RUSSELL DG, 1988, J IMMUNOL, V140, P1274; RUSSELL DG, 1989, IMMUNOL TODAY, V10, P328, DOI 10.1016/0167-5699(89)90188-6; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Shamu CE, 1998, CURR BIOL, V8, pR121, DOI 10.1016/S0960-9822(98)70986-8; SHISHIDO K, 1986, BIOCHIM BIOPHYS ACTA, V884, P215, DOI 10.1016/0304-4165(86)90247-3; SIRAKOVA TD, 1994, INFECT IMMUN, V62, P4208, DOI 10.1128/IAI.62.10.4208-4218.1994; SOONG L, 1995, INFECT IMMUN, V63, P3559, DOI 10.1128/IAI.63.9.3559-3566.1995; STRAUS AH, 1993, J BIOL CHEM, V268, P13723; Straus AH, 1997, BRAZ J MED BIOL RES, V30, P395, DOI 10.1590/S0100-879X1997000300014; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; VOGT VM, 1973, EUR J BIOCHEM, V33, P192, DOI 10.1111/j.1432-1033.1973.tb02669.x; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; YANG DM, 1990, J IMMUNOL, V145, P2281; Zhang WW, 1997, P NATL ACAD SCI USA, V94, P8807, DOI 10.1073/pnas.94.16.8807; ZILBERSTEIN D, 1993, MOL BIOCHEM PARASIT, V61, P197, DOI 10.1016/0166-6851(93)90066-7; ZLOTNICK GW, 1987, COMP BIOCHEM PHYS B, V87, P629, DOI 10.1016/0305-0491(87)90063-0; ZLOTNICK GW, 1986, ANAL BIOCHEM, V153, P121, DOI 10.1016/0003-2697(86)90069-2	65	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37789	37797		10.1074/jbc.M002149200	http://dx.doi.org/10.1074/jbc.M002149200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10969068	hybrid			2022-12-27	WOS:000165618700066
J	Lee, KN; Lee, CS; Tae, WC; Jackson, KW; Christiansen, VJ; McKee, PA				Lee, KN; Lee, CS; Tae, WC; Jackson, KW; Christiansen, VJ; McKee, PA			Cross-linking of wild-type and mutant alpha(2)-antiplasmins to fibrin by activated factor XIII and by a tissue transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE TRANSGLUTAMINASE; PIG LIVER TRANSGLUTAMINASE; COAGULATION FACTOR-XIII; PLASMA FACTOR-XIIIA; ALPHA2-PLASMIN INHIBITOR; STRUCTURAL FEATURES; COLORIMETRIC ASSAY; PURIFICATION; IDENTIFICATION; EXPRESSION	Human alpha (2)-antiplasmin (alpha (2)AP), the main inhibitor of plasmin-mediated fibrinolysis, is a substrate for plasma transglutaminase, also termed activated factor XIII (FXIIIa). Of 452 amino acids in alpha (2)AP, only Gln(2) is believed to be a fibrin-cross-linking (or FXIIIa-reactive) site. Kinetic efficiencies (k(cat)/K-m(app)) of FXIIIa and the guinea pig liver tissue transglutaminase (tTG;) and reactivities of Gin substrate sites were compared for recombinant wild-type alpha (2)AP (WT-alpha (2)AP) and Q2A mutant alpha (2)AP (Q2A-alpha (2)AP), [C-14]Methylamine incorporation showed the k(cat)/K-m(app) of FXIIIa to be 3-fold greater than that of tTG for WT-alpha (2)AP, With FXIIIa or tTG catalysis, [C-14]methylamine was incorporated into Q2A-alpha (2)AP, indicating that WT-alpha (2)AP has more than one Gin cross-linking site. To identify transglutaminase-reactive sites in WT-alpha (2)AP or Q2A-alpha (2)AP, each was labeled with 5-(biotinamido)pentylamine by FXIIIa or tTG catalysis, After each labeled alpha (2)AP was digested by trypsin, sequence and mass analyses of each labeled peptide showed that 4 of 35 Gin residues were labeled with the following reactivities: Gln(2) > Gln(21) > Gln(419) > Gln(447). Q(2)A-alpha (2)AP was also labeled at Gln(21) > Gln(419) > Gln(447), but became cross-linked to fibrin;by FXIIIa or tTG at approximately one-tenth the rate for WT-alpha (2)AP, These results show that alpha (2)AP is a better substrate for FXIIIa than for this particular tTG, but that either enzyme involves the same Gin substrate sites in alpha (2)AP and yields the same order of reactivities.	Univ Oklahoma, Hlth Sci Ctr, William K Warren Med Res Inst, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Lee, KN (corresponding author), Univ Oklahoma, Hlth Sci Ctr, William K Warren Med Res Inst, POB 26901,BSEB 306, Oklahoma City, OK 73190 USA.	kyung-lee@ouhsc.edu						AESCHLIMANN D, 1992, J BIOL CHEM, V267, P11316; BRENNER SC, 1978, BIOCHIM BIOPHYS ACTA, V522, P74, DOI 10.1016/0005-2744(78)90323-6; CARMINES PK, 1983, RENAL PHYSIOL BIOCH, V6, P281; CHUNG SI, 1974, J BIOL CHEM, V249, P940; COLLEN D, 1976, EUR J BIOCHEM, V69, P209, DOI 10.1111/j.1432-1033.1976.tb10875.x; CURTIS CG, 1973, BIOCHEM BIOPH RES CO, V52, P51, DOI 10.1016/0006-291X(73)90952-2; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1966, J BIOL CHEM, V241, P5518; FOLK JE, 1969, J BIOL CHEM, V244, P3707; GORMAN JJ, 1980, J BIOL CHEM, V255, P419; GORMAN JJ, 1981, J BIOL CHEM, V256, P2712; GREENBERG CS, 1987, BLOOD, V70, P702; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Haroon ZA, 1999, FASEB J, V13, P1787, DOI 10.1096/fasebj.13.13.1787; HORTIN G, 1987, J BIOL CHEM, V262, P3082; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; JEON WM, 1989, ANAL BIOCHEM, V182, P170, DOI 10.1016/0003-2697(89)90737-9; KWON KS, 1995, BBA-PROTEIN STRUCT M, V1247, P179, DOI 10.1016/0167-4838(94)00224-5; LEE KN, 1986, PREP BIOCHEM, V16, P321, DOI 10.1080/00327488608068752; LEE KN, 1992, BIOCHIM BIOPHYS ACTA, V1136, P12, DOI 10.1016/0167-4889(92)90078-P; Lee KN, 1998, THROMB HAEMOSTASIS, V80, P637; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; LEE KN, 1988, CLIN CHEM, V34, P906; LEE KN, 1985, J BIOL CHEM, V260, P4689; Lee KN, 1999, BLOOD, V94, P164, DOI 10.1182/blood.V94.1.164.413k16_164_171; Lee SC, 1997, PREP BIOCHEM BIOTECH, V27, P227, DOI 10.1080/10826069708001281; LIJNEN HR, 1987, EUR J BIOCHEM, V166, P565, DOI 10.1111/j.1432-1033.1987.tb13551.x; LIN XL, 1989, J BIOL CHEM, V264, P4482; MIESCHENDAHL M, 1986, BIO-TECHNOL, V4, P802, DOI 10.1038/nbt0986-802; MIMURO J, 1986, J CLIN INVEST, V77, P1006, DOI 10.1172/JCI112352; MOROI M, 1976, J BIOL CHEM, V251, P5956; Rashtchian Ayoub, 1995, Current Opinion in Biotechnology, V6, P30, DOI 10.1016/0958-1669(95)80006-9; Reed GL, 1999, CIRCULATION, V99, P299, DOI 10.1161/01.CIR.99.2.299; RUBIN H, 1990, J BIOL CHEM, V265, P1199; Schaefer BM, 1996, ARCH DERMATOL RES, V288, P122, DOI 10.1007/BF02505820; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; SHAINOFF JR, 1991, J BIOL CHEM, V266, P6429; TAMAKI T, 1981, BIOCHIM BIOPHYS ACTA, V661, P280, DOI 10.1016/0005-2744(81)90016-4; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; VALENZUELA R, 1992, AM J PATHOL, V141, P861; Valnickova Z, 1998, J BIOL CHEM, V273, P27220, DOI 10.1074/jbc.273.42.27220; WEITZ JI, 1993, J CLIN INVEST, V91, P1343, DOI 10.1172/JCI116335; WIMAN B, 1977, EUR J BIOCHEM, V78, P19, DOI 10.1111/j.1432-1033.1977.tb11709.x	43	36	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37382	37389		10.1074/jbc.M003375200	http://dx.doi.org/10.1074/jbc.M003375200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10958788	hybrid			2022-12-27	WOS:000165618700012
J	O'Neill, S; Robinson, A; Deering, A; Ryan, M; Fitzgerald, DJ; Moran, N				O'Neill, S; Robinson, A; Deering, A; Ryan, M; Fitzgerald, DJ; Moran, N			The platelet integrin alpha(IIb)beta(3) has an endogenous thiol isomerase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; BINDING-SITE; CYTOPLASMIC TAIL; CELL-ADHESION; LIGAND; CONFORMATION; AGGREGATION; ACTIVATION; THIOREDOXIN; BETA(1)	Integrins are cysteine-rich heterodimeric cell-surface adhesion molecules that alter their affinity for ligands in response to cellular activation. The molecular mechanisms involved in this activation of integrins are not understood. Treatment with the thiol-reducing agent, dithiothreitol, can induce an activation-like state in many integrins suggesting that cysteine-cysteine dithiol bonds are important for the receptor's tertiary structure and may be involved in activation-induced conformational changes. Here we demonstrate that the platelet-specific integrin, alpha (IIb)beta (3), contains an endogenous thiol isomerase activity, predicted from the presence of the tetrapeptide motif, CXXC, in each of the cysteine-rich repeats of the beta (3) polypeptide. This motif comprises the active site in enzymes involved in disulfide exchange reactions, including protein-disulfide isomerase (EC 5.3.4.1) and thioredoxin. Intrinsic thiol isomerase activity is also observed in the related integrin, alpha (v)beta (3), which shares a common beta -subunit. Thiol isomerase activity within alpha (IIb)beta (3) is time dependent and saturable, and is inhibited by the protein-disulfide isomerase inhibitor, bacitracin. Furthermore, this activity is calcium-sensitive and is regulated in the EDTA-stabilized conformation of the integrin. This novel demonstration of an enzymatic activity associated with an integrin subunit suggests that altered thiol bonding within the integrin or its substrates may be locally modified during alpha (IIb)beta (3) activation.	Royal Coll Surgeons Ireland, Dept Clin Pharmacol, Ctr Cardiovasc Sci, Dublin 2, Ireland	Royal College of Surgeons - Ireland; Trinity College Dublin	Moran, N (corresponding author), Royal Coll Surgeons Ireland, Dept Clin Pharmacol, Ctr Cardiovasc Sci, 123 St Stephens Green, Dublin 2, Ireland.	nmoran@rcsi.ie	Moran, Niamh/F-4188-2012; O'Neill, Sarah/C-8041-2012	Moran, Niamh/0000-0002-8614-3242; 				BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BONIFACE JJ, 1990, SCIENCE, V247, P61, DOI 10.1126/science.2104678; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; Calvete JJ, 1999, P SOC EXP BIOL MED, V222, P29, DOI 10.1111/j.1525-1373.1999.09993.x; CHEN K, 1995, BRIT J HAEMATOL, V90, P425, DOI 10.1111/j.1365-2141.1995.tb05169.x; CHEW CC, 1995, BIOCHEM SOC T, V23, pS394, DOI 10.1042/bst023394s; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; DAVIS GE, 1993, J IMMUNOL, V151, P7138; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; EDWARDS BS, 1995, BLOOD, V86, P2288, DOI 10.1182/blood.V86.6.2288.bloodjournal8662288; Essex DW, 1999, BRIT J HAEMATOL, V104, P448, DOI 10.1046/j.1365-2141.1999.01197.x; ESSEX DW, 1995, BLOOD, V86, P2168, DOI 10.1182/blood.V86.6.2168.bloodjournal8662168; GoferDadosh N, 1997, BIOCHEM BIOPH RES CO, V232, P724, DOI 10.1006/bbrc.1997.6201; GULINO D, 1992, J BIOL CHEM, V267, P1001; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; Huang EM, 1997, BLOOD, V89, P3205, DOI 10.1182/blood.V89.9.3205; KOEDAM JA, 1994, BIOCHEM BIOPH RES CO, V198, P1225, DOI 10.1006/bbrc.1994.1173; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOUNS WC, 1994, BLOOD, V84, P1108; Langenbach KJ, 1999, J BIOL CHEM, V274, P7032, DOI 10.1074/jbc.274.11.7032; Leisner TM, 1999, J BIOL CHEM, V274, P12945, DOI 10.1074/jbc.274.18.12945; Liu CY, 1998, BLOOD, V92, p344A; LUNDSTROMLJUNG J, 1995, FEBS LETT, V357, P305, DOI 10.1016/0014-5793(94)01386-F; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MENDELSOHN ME, 1991, P NATL ACAD SCI USA, V88, P11212, DOI 10.1073/pnas.88.24.11212; Mou YL, 1998, J IMMUNOL, V161, P6323; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Ni HY, 1998, J BIOL CHEM, V273, P7981, DOI 10.1074/jbc.273.14.7981; ONEILL S, 1998, IRISH J MED SCI, V167, P197; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Pariser HP, 1998, DEV BRAIN RES, V111, P1, DOI 10.1016/S0165-3806(98)00113-8; PEERSCHKE EI, 1995, THROMB HAEMOSTASIS, V73, P862; Peter K, 1996, BLOOD COAGUL FIBRIN, V7, P233, DOI 10.1097/00001721-199603000-00031; PHILLIPS DR, 1992, METHOD ENZYMOL, V215, P244; Pierini LM, 2000, BLOOD, V95, P2471; PIGIET VP, 1988, P NATL ACAD SCI U S, V83, P7643; Ruan J, 1999, BRIT J HAEMATOL, V105, P523, DOI 10.1111/j.1365-2141.1999.01376.x; Stephens G, 1998, J BIOL CHEM, V273, P20317, DOI 10.1074/jbc.273.32.20317; Takagi J, 1997, J BIOCHEM, V121, P914; Vinogradova O, 2000, P NATL ACAD SCI USA, V97, P1450, DOI 10.1073/pnas.040548197; Wang RG, 1997, BLOOD, V90, P1718, DOI 10.1182/blood.V90.4.1718.1718_1718_1719; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; Yan B, 2000, J BIOL CHEM, V275, P7249, DOI 10.1074/jbc.275.10.7249; ZUCKER MB, 1984, THROMB HAEMOSTASIS, V51, P119	46	106	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36984	36990		10.1074/jbc.M003279200	http://dx.doi.org/10.1074/jbc.M003279200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10942760	hybrid			2022-12-27	WOS:000165577700075
J	Reyland, ME; Evans, RM; White, EK				Reyland, ME; Evans, RM; White, EK			Lipoproteins regulate expression of the steroidogenic acute regulatory protein (StAR) in mouse adrenocortical cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMITOCHONDRIAL CHOLESTEROL TRANSFER; LIPOID ADRENAL-HYPERPLASIA; PROMOTER ACTIVITY; SCAVENGER RECEPTOR; GENE-TRANSCRIPTION; BINDING PROTEIN; CDNA CLONING; SR-BI; FACTOR-1; GLAND	The steroidogenic acute regulatory protein (StAR) is required for the movement of cholesterol from the outer to the inner mitochondrial membrane, the site of cholesterol side chain cleavage. Here we describe a novel form of regulation of StAR gene expression in steroidogenic cells. Treatment of Y-1 BS1 adrenocortical cells with either low density lipoprotein (LDL) or high density lipoprotein (HDL) increases expression of endogenous StAR mRNA and protein in a dose dependent manner. Induction of StAR mRNA by lipoprotein requires basal cAMP-dependent protein kinase, since the inhibitor, R-p-8-Br-cAMP, inhibited induction of StAR protein by LDL, Likewise, basal StAR expression or LDL induction of StAR protein was not detectable in Y-1 kin-8 cells which are deficient in cAMP-dependent protein kinase, Aminoglutethimide and ketoconazole were used to determine if side chain cleavage of lipoprotein-derived cholesterol is required for induction of StAR mRNA. Treatment with either drug alone induced StAR mRNA expression 1.5-3-fold, while induction of StAR in cells treated with either drug plus LDL, was equal to, or greater than, induction seen with either agent alone, suggesting that lipoprotein does not regulate StAR via generation of an oxysterol intermediate. Both LDL and HDL increased expression of a mouse -966 StAR promoter-reporter construct 1.5-2.5-fold, indicating that regulation occurs at the level of transcription. In contrast, neither lipoprotein was able to induce transcription from a -966 StAR promoter in which the steroidogenic factor-1 site at -135 was abolished, indicating that regulation of StAR transcription by lipoproteins requires steroidogenic factor-1. The regulation of StAR gene expression by lipoproteins may represent a positive feedback circuit which links cholesterol availability with steroidogenic output.	Univ Colorado, Hlth Sci Ctr, Sch Dent, Dept Basic Sci & Oral Res, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pathol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Reyland, ME (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Dent, Dept Basic Sci & Oral Res, 4200 E 9th Ave,Box C286, Denver, CO 80262 USA.				NIDDK NIH HHS [DK050690] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050690] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accad M, 1998, CURR BIOL, V8, pR601, DOI 10.1016/S0960-9822(98)70386-0; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; Cherradi N, 1998, MOL ENDOCRINOL, V12, P962, DOI 10.1210/me.12.7.962; Christenson LK, 1998, J BIOL CHEM, V273, P30729, DOI 10.1074/jbc.273.46.30729; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; Estabrook RW, 1996, P NATL ACAD SCI USA, V93, P13552, DOI 10.1073/pnas.93.24.13552; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JEFCOATE CR, 1986, ENDOCR RES, V12, P315, DOI 10.3109/07435808609035444; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; KOVANEN PT, 1980, J BIOL CHEM, V255, P5591; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316; Miller WL, 1997, J MOL ENDOCRINOL, V19, P227, DOI 10.1677/jme.0.0190227; ORMEJOHNSON NR, 1990, BIOCHIM BIOPHYS ACTA, V1020, P213, DOI 10.1016/0005-2728(90)90151-S; PON LA, 1986, J BIOL CHEM, V261, P3309; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; RAE PA, 1979, P NATL ACAD SCI USA, V76, P1896, DOI 10.1073/pnas.76.4.1896; Reinhart AJ, 1999, MOL ENDOCRINOL, V13, P729, DOI 10.1210/me.13.5.729; Reyland ME, 1998, AM J PHYSIOL-CELL PH, V275, pC780, DOI 10.1152/ajpcell.1998.275.3.C780; REYLAND ME, 1993, MOL ENDOCRINOL, V7, P1021, DOI 10.1210/me.7.8.1021; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Sandhoff TW, 1998, ENDOCRINOLOGY, V139, P4820, DOI 10.1210/en.139.12.4820; Schimmer B P, 1979, Methods Enzymol, V58, P570; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Sugawara T, 1997, BIOCHEMISTRY-US, V36, P7249, DOI 10.1021/bi9628984; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; TAKAGI K, 1989, J BIOL CHEM, V264, P12352; Tamasawa N, 1997, ATHEROSCLEROSIS, V131, P237, DOI 10.1016/S0021-9150(97)00055-5; VANDENBOSSCHE H, 1992, J STEROID BIOCHEM, V43, P1003, DOI 10.1016/0960-0760(92)90328-G; Wang XJ, 1998, ENDOCRINOLOGY, V139, P3903, DOI 10.1210/en.139.9.3903	39	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36637	36644		10.1074/jbc.M006456200	http://dx.doi.org/10.1074/jbc.M006456200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10960482	hybrid			2022-12-27	WOS:000165577700027
J	Saez-Vasquez, J; Pikaard, CS				Saez-Vasquez, J; Pikaard, CS			RNA polymerase I holoenzyme-promoter interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION; GENE-TRANSCRIPTION; YEAST; IDENTIFICATION; PURIFICATION; COMPONENTS; SUBUNITS; MOUSE	In plants and animals, RNA polymerase I (pol I) can be purified in a form that is self-sufficient for accurate rRNA gene promoter-dependent transcription and that has biochemical properties suggestive of a single complex, or holoenzyme, In this study, we examined the promoter binding properties of a highly purified Brassica pol I holoenzyme activity. DNase I footprinting revealed protection of the core promoter region from similar to -30 to +20, in good agreement with the boundaries of the minimal promoter defined by deletion analyses (-33 to +6), Using conventional polyacrylamide electrophoretic mobility shift assays (EMSA), protein-DNA complexes were mostly excluded from the gel. However, agarose EMSA revealed promoter-specific binding activity that co purified with promoter-dependent transcription activity. Titration, time-course, and competition experiments revealed the formation or dissociation of a single protein-DNA complex, This protein-DNA complex could be labeled by incorporation of radioactive ribonucleotides into RNA in the presence of rw-amanitin, suggesting that the polymerase I enzyme is part of the complex. Collectively, these results suggest that transcriptionally competent pol I holoenzymes can associate with rRNA gene promoters in a single DNA binding event.	Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Pikaard, CS (corresponding author), Washington Univ, Dept Biol, Campus Box 1137,1 Brookings Dr, St Louis, MO 63130 USA.	pikaard@biology.wustl.edu	Pikaard, Craig S/K-8772-2012; Saez-Vasquez, Julio/HDO-3375-2022	Pikaard, Craig S/0000-0001-8204-7459; Saez-Vasquez, Julio/0000-0002-2717-7995	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050910] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert AC, 1999, MOL CELL BIOL, V19, P796; BUHLER JM, 1976, J BIOL CHEM, V251, P1712; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; DOELLING JH, 1995, PLANT J, V8, P683, DOI 10.1046/j.1365-313X.1995.08050683.x; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; GUILFOYLE TJ, 1980, BIOCHEMISTRY-US, V19, P5966, DOI 10.1021/bi00567a004; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Hannan Katherine M., 1998, Frontiers in Bioscience, V3, pD376; Hannan RD, 1999, NUCLEIC ACIDS RES, V27, P3720, DOI 10.1093/nar/27.18.3720; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1994, TRANSCRIPTION MECHAN, P107; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kornberg Roger D., 1999, Trends in Cell Biology, V9, pM46, DOI 10.1016/S0962-8924(99)01679-7; Larkin RM, 1996, GENE, V172, P211, DOI 10.1016/0378-1119(96)00030-3; Larkin RM, 1999, GENE, V231, P41, DOI 10.1016/S0378-1119(99)00090-6; LOBO SM, 1994, TRANSCRIPTION MECH R, V3, P127; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; Reeder RH, 1999, PROG NUCLEIC ACID RE, V62, P293; Roeder RG, 1996, METHOD ENZYMOL, V273, P165; SaezVasquez J, 1997, P NATL ACAD SCI USA, V94, P11869, DOI 10.1073/pnas.94.22.11869; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNAPP A, 1991, J BIOL CHEM, V266, P24588; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; Seither P, 1998, J MOL BIOL, V275, P43, DOI 10.1006/jmbi.1997.1434; SERIZAWA H, 1994, RAV S MOL C, V3, P27; SONG CZ, 1994, J BIOL CHEM, V269, P26976; Wang ZX, 1997, GENE DEV, V11, P2371, DOI 10.1101/gad.11.18.2371; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	32	16	17	2	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37173	37180		10.1074/jbc.M006057200	http://dx.doi.org/10.1074/jbc.M006057200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10940310	hybrid			2022-12-27	WOS:000165577700098
J	Shimasaki, NB; Kane, CM				Shimasaki, NB; Kane, CM			Structural basis for the species-specific activity of TFIIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ELONGATION-FACTOR TFIIS; TISSUE-SPECIFIC EXPRESSION; PROMOTE READ-THROUGH; FACTOR-S-II; TRANSCRIPTION ELONGATION; FACTOR-SII; TERMINATION SITES; INTRINSIC BLOCKS; ZINC-FINGER	Many proteins involved in eukaryotic transcription are similar in function and in sequence between organisms. Despite the sequence similarities, there are many factors that do not function across species. For example, transcript elongation factor TFIIS is highly conserved among eukaryotes, and yet the TFIIS protein from Saccharomyces cerevisiae cannot function with mammalian RNA polymerase II and vice versa. To determine the reason for this species specificity, chimeras were constructed linking three structurally independent regions of the TFIIS proteins from yeast and human cells. Two independently folding domains, II and III, have been examined previously using NMR (1-3). Yeast domain II alone is able to bind yeast RNA polymerase II with the same affinity as the full-length TFIIS protein, and this domain was expected to confer the species selectivity. Domain III has previously been shown to be readily exchanged between mammalian and yeast factors. However, the results presented here indicate that domain II is insufficient to confer species selectivity, and a primary determinant lies in a 30-amino acid highly conserved linker region connecting domain II with domain III. These 30 amino acids may physically orient domains II and III to support functional interactions between TFIIS and RNA polymerase II.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Kane, CM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 401 Barker Hall, Berkeley, CA 94720 USA.	kanecm@uclink4.berkeley.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054012] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54012] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; [Anonymous], 1991, Methods Enzymol, V194, P1; Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; Awrey DE, 1998, J BIOL CHEM, V273, P22595, DOI 10.1074/jbc.273.35.22595; Booth V, 2000, J BIOL CHEM, V275, P31266, DOI 10.1074/jbc.M002595200; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; CHRISTIE KR, 1995, THESIS U CALIFORNIA; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; CIPRESPALACIN G, 1995, BIOCHEMISTRY-US, V34, P15375, DOI 10.1021/bi00046a046; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; Ishiguro A, 2000, MOL CELL BIOL, V20, P1263, DOI 10.1128/MCB.20.4.1263-1270.2000; Ito T, 1996, FEBS LETT, V385, P21, DOI 10.1016/0014-5793(96)00340-7; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; JEON CJ, 1994, P NATL ACAD SCI USA, V91, P9106, DOI 10.1073/pnas.91.19.9106; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; KANE CM, 1994, TRANSCRIPTION MECH R, pCH16; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; Koulich D, 1998, J MOL BIOL, V276, P379, DOI 10.1006/jmbi.1997.1545; Koulich D, 1997, J BIOL CHEM, V272, P7201, DOI 10.1074/jbc.272.11.7201; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; Kulish D, 2000, J BIOL CHEM, V275, P12789, DOI 10.1074/jbc.275.17.12789; Loizos N, 1999, J BIOL CHEM, V274, P23378, DOI 10.1074/jbc.274.33.23378; Morin PE, 1996, P NATL ACAD SCI USA, V93, P10604, DOI 10.1073/pnas.93.20.10604; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NOGI Y, 1993, MOL CELL BIOL, V13, P114, DOI 10.1128/MCB.13.1.114; Olmsted VK, 1998, J BIOL CHEM, V273, P22589, DOI 10.1074/jbc.273.35.22589; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; Powell W, 1996, J BIOL CHEM, V271, P22301, DOI 10.1074/jbc.271.37.22301; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1994, TRANSCRIPTION MECH R, pCH15; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAWADOGO M, 1980, BIOCHEM BIOPH RES CO, V96, P258, DOI 10.1016/0006-291X(80)91208-5; Shaw SP, 1996, MOL CELL BIOL, V16, P3651; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; Shimoaraiso M, 1997, J BIOL CHEM, V272, P26550, DOI 10.1074/jbc.272.42.26550; SIKORSKI RS, 1989, GENETICS, V122, P19; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SPENCER CA, 1990, ONCOGENE, V5, P777; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; Taira Y, 1998, GENES CELLS, V3, P289, DOI 10.1046/j.1365-2443.1998.00188.x; Umehara T, 1995, GENE, V167, P297, DOI 10.1016/0378-1119(95)00634-6; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wang B, 1998, STRUCTURE, V6, P555, DOI 10.1016/S0969-2126(98)00058-6; Weaver ZA, 1997, GENOMICS, V46, P516, DOI 10.1006/geno.1997.5073; Williams LA, 1996, YEAST, V12, P227, DOI 10.1002/(SICI)1097-0061(19960315)12:3<227::AID-YEA905>3.3.CO;2-0; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; Wu JS, 1996, P NATL ACAD SCI USA, V93, P11552, DOI 10.1073/pnas.93.21.11552; XU QH, 1994, J BIOL CHEM, V269, P3100; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	58	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36541	36549		10.1074/jbc.M005834200	http://dx.doi.org/10.1074/jbc.M005834200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10940308	hybrid			2022-12-27	WOS:000165577700013
J	Chakravarthy, MV; Abraha, TW; Schwartz, RJ; Fiorotto, ML; Booth, FW				Chakravarthy, MV; Abraha, TW; Schwartz, RJ; Fiorotto, ML; Booth, FW			Insulin-like growth factor-I extends in vitro replicative life span of skeletal muscle satellite cells by enhancing G(1)/S cell cycle progression via the activation of phosphatidylinositol 3 '-kinase/Akt signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA GENE-PRODUCT; HUMAN-DIPLOID FIBROBLASTS; PROTEIN-KINASE; TUMOR SUPPRESSION; MICE LACKING; SENESCENCE; P27(KIP1); 3-KINASE; ACCUMULATION	Interest is growing in methods to extend replicative life span of non-immortalized stem cells. Using the insulin-like growth factor I (IGF-I) transgenic mouse in which the IG;F-I transgene is expressed during skeletal muscle development and maturation prior to isolation and during culture of satellite cells (the myogenic stem cells of mature skeletal muscle fibers) as a model system, we elucidated the underlying molecular mechanisms of IGF-I-mediated enhancement of proliferative potential of these cells. Satellite cells from IGF-I transgenic muscles achieved at least five additional population doublings above the maximum that was attained by wild type satellite cells. This IGF-I-induced increase in proliferative potential was mediated via activation of the phosphatidylinositol 3'-kinase/Akt pathway, independent of mitogen-activated protein kinase activity, facilitating G(1)/S cell cycle progression via a down-regulation of p27(Kip1). Adenovirally mediated ectopic overexpression of p27(Kip1) i, exponentially growing IGF-I transgenic satellite cells reversed the increase in cyclin E-cdk2 kinase activity, pRb phosphorylation, and cyclin A protein abundance, thereby implicating an important role for p27(Kip1) i, promoting satellite cell senescence. These observations provide a more complete dissection of molecular events by which increased local expression of a growth factor in mature skeletal muscle fibers extends replicative life span of primary stem cells than previously known.	Univ Missouri, Dept Vet Biomed Sci, Coll Vet Med, Columbia, MO 65211 USA; Univ Missouri, Dept Physiol, Coll Vet Med, Columbia, MO 65211 USA; Univ Missouri, Dalton Cardiovasc Inst, Coll Vet Med, Columbia, MO 65211 USA; Univ Texas, Sch Med, Dept Integrat Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; USDA, Dept Pediat, Agr Res Stn, Childrens Nutr Res Ctr, Houston, TX 77030 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Texas System; Baylor College of Medicine; United States Department of Agriculture (USDA)	Booth, FW (corresponding author), Univ Missouri, Dept Vet Biomed Sci, Coll Vet Med, E102 Vet Med Bldg,1600 E Rollins Rd, Columbia, MO 65211 USA.		Chakravarthy, Manu/AAD-7553-2021	Chakravarthy, Manu/0000-0002-3699-150X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR019393, R01AR019393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018780] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 19393] Funding Source: Medline; NIA NIH HHS [AG18780] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams GR, 1998, J APPL PHYSIOL, V84, P1716, DOI 10.1152/jappl.1998.84.5.1716; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ANGELLO JC, 1992, MECH AGEING DEV, V62, P1, DOI 10.1016/0047-6374(92)90139-5; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Bischoff R, 1994, MYOLOGY, P97; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Chakravarthy MV, 2000, J APPL PHYSIOL, V89, P1365, DOI 10.1152/jappl.2000.89.4.1365; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; Chen J, 1996, J CLIN INVEST, V97, P1983, DOI 10.1172/JCI118631; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Criswell DS, 1998, AM J PHYSIOL-ENDOC M, V275, pE373; DANTO SI, 1984, J CELL BIOL, V98, P2179, DOI 10.1083/jcb.98.6.2179; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Decary S, 1997, HUM GENE THER, V8, P1429, DOI 10.1089/hum.1997.8.12-1429; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; GOLDSTEIN S, 1993, J CELL PHYSIOL, V156, P294, DOI 10.1002/jcp.1041560211; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Liu JL, 2000, P SOC EXP BIOL MED, V223, P344, DOI 10.1046/j.1525-1373.2000.22349.x; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NEVINS JR, 1992, SCIENCE, V258, P424; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Schulze A, 1996, MOL CELL BIOL, V16, P4632; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH JR, 1980, MECH AGEING DEV, V12, P355, DOI 10.1016/0047-6374(80)90068-8; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STOCKDALE F, 1961, EXP CELL RES, V24, P508, DOI 10.1016/0014-4827(61)90450-5; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tu WW, 1999, BRIT J HAEMATOL, V104, P785, DOI 10.1046/j.1365-2141.1999.01272.x; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9; WRIGHT WE, 1985, EXP CELL RES, V157, P343, DOI 10.1016/0014-4827(85)90119-3	57	177	182	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35942	35952		10.1074/jbc.M005832200	http://dx.doi.org/10.1074/jbc.M005832200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10962000	hybrid			2022-12-27	WOS:000165382000044
J	Delage-Mourroux, R; Martini, PGV; Choi, I; Kraichely, DM; Hoeksema, J; Katzenellenbogen, BS				Delage-Mourroux, R; Martini, PGV; Choi, I; Kraichely, DM; Hoeksema, J; Katzenellenbogen, BS			Analysis of estrogen receptor interaction with a repressor of estrogen receptor activity (REA) and the regulation of estrogen receptor transcriptional activity by REA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; ER-ALPHA; DEPENDENT TRANSCRIPTION; PEPTIDE ANTAGONISTS; COACTIVATOR-1 SRC-1; CO-REPRESSOR; ACTIVATION; BINDING; BETA; ANTIESTROGENS	The transcriptional activity of nuclear hormone receptors is known to be modulated by coregulator proteins. We found that the repressor of estrogen receptor activity (REA), a protein recruited to the hormone-occupied estrogen receptor (ER), decreased the transcriptional activity of ER, both when ER was acting directly through DNA response elements as well as when it was tethered to other transcription factors. Administration of antisense REA resulted in a 2-4-fold increase in ER transactivation, implying that endogenous REA normally dampens the stimulatory response to estradiol, To define the interaction regions between ER and REA, we used glutathione S-transferase pull-down assays. We found that REA bound to the ligand-binding domain (E domain) of ER, but not to other regions of ER, and that REA interaction with ER involved a region in the C-terminal half of REA, REA and the coactivator SRC-1 were involved in a functional competition for regulation of ER transcriptional activity, which we show results from competition between these two coregulators for interaction with ER, REA contains an LXXLL motif near its N terminus, but this motif was not involved in its binding to ER, Rather, this sequence was required for the competitive binding of REA and SRC-1 to ER and thus: for optimal repression of ER activity. Our findings show that the regions of REA required for its interaction with ER and for its repression of ER activity are different.	Univ Illinois, Dept Mol & Integrat Physiol, Coll Med, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Struct Biol, Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Katzenellenbogen, BS (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, Coll Med, Urbana, IL 61801 USA.		DELAGE-MOURROUX, Régis/ABE-1424-2021	DELAGE-MOURROUX, Régis/0000-0002-7145-5948	NCI NIH HHS [5T32 CA09067, CA18119, CA60514] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060514, R01CA018119, T32CA009067, R37CA018119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Carlson KE, 1997, BIOCHEMISTRY-US, V36, P14897, DOI 10.1021/bi971746l; Chang CY, 1999, MOL CELL BIOL, V19, P8226; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; INCE BA, 1995, ENDOCRINOLOGY, V136, P3194, DOI 10.1210/en.136.8.3194; INCE BA, 1993, J BIOL CHEM, V268, P14026; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Katzenellenbogen JA, 1996, CHEM BIOL, V3, P529, DOI 10.1016/S1074-5521(96)90143-X; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; ONATE SA, 1995, SCIENCE, V270, P1354; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Schodin DJ, 1995, J BIOL CHEM, V270, P31163, DOI 10.1074/jbc.270.52.31163; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Sun J, 1999, ENDOCRINOLOGY, V140, P800, DOI 10.1210/en.140.2.800; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222; Zamir I, 1996, MOL CELL BIOL, V16, P5458	48	114	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35848	35856		10.1074/jbc.M001327200	http://dx.doi.org/10.1074/jbc.M001327200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10960470	hybrid			2022-12-27	WOS:000165382000031
J	Giampuzzi, M; Botti, G; Di Duca, M; Arata, L; Ghiggeri, G; Gusmano, R; Ravazzolo, R; Di Donato, A				Giampuzzi, M; Botti, G; Di Duca, M; Arata, L; Ghiggeri, G; Gusmano, R; Ravazzolo, R; Di Donato, A			Lysyl oxidase activates the transcription activity of human collagene III promoter - Possible involvement of Ku antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; DNA-BINDING; CROSS-LINKING; MESSENGER-RNA; UP-REGULATION; BETA-AMINOPROPIONITRILE; ADRIAMYCIN NEPHROPATHY; INTERSTITIAL FIBROSIS; V(D)J RECOMBINATION	Lysyl oxidase is an extracellular enzyme that controls the maturation of collagen and elastin, Lysyl oxidase and collagen III often show similar expression patterns in fibrotic tissues. Therefore, we investigated the influence of lysyl oxidase overexpression on the promoter activity of human COL3A1 gene. Our results showed that when COS-7 cells overexpressed the mature form of lysyl oxidase, the activity of the human COL3A1 promoter was increased up to an average of 12 times when tested by luciferase reporter assay. The effect was specific, because other promoters were not affected. Moreover, lysyl oxidase effect was abolished by beta -aminopropionitrile, a specific inhibitor of its catalytic activity. Electrophoretic mobility shift assay showed a binding activity in the region from -101 to -77 that was significantly increased by lysyl oxidase overexpression, The binding was specifically competed by the cold probe, and the mutagenesis of this region abolished both the binding activity in gel retardation and lysyl oxidase stimulation of COL3A1 promoter in transfection experiments. We identified the binding activity as Ku antigen in its two components: Ku80 and Ku70. This study suggests a new coordinated mechanism by which lysyl oxidase might control the development of fibrosis.	Gaslini Childrens Hosp, Dept Nephrol, Genoa, Italy; Gaslini Childrens Hosp, Fondo Malattie Renali Bambino, Genoa, Italy; Gaslini Childrens Hosp, Mol Genet Lab, Genoa, Italy; Univ Genoa, Dept Oncol Biol & Genet, I-16147 Genoa, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS Istituto Giannina Gaslini; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa	Di Donato, A (corresponding author), Ist Giannina Gaslini, Lab Nephrol, Largo G Gaslini 5, I-16147 Genoa, Italy.		Di Duca, Marco/AAB-4531-2021; Ghiggeri, Gian Marco/N-4712-2015	Di Duca, Marco/0000-0001-8456-7706; Ghiggeri, Gian Marco/0000-0003-3659-9062				Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; BARRESI R, 1994, GENE, V140, P195, DOI 10.1016/0378-1119(94)90544-4; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; BERTANI T, 1986, KIDNEY INT, V30, P488, DOI 10.1038/ki.1986.212; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burgman P, 1997, CANCER RES, V57, P2847; Camara-Clayette V, 1999, NUCLEIC ACIDS RES, V27, P1656, DOI 10.1093/nar/27.7.1656; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; CHANOKI M, 1995, BRIT J DERMATOL, V133, P710; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CRONSHAW AD, 1995, BIOCHEM J, V306, P279, DOI 10.1042/bj3060279; Decitre M, 1998, LAB INVEST, V78, P143; Di Donato A, 1997, FEBS LETT, V419, P63, DOI 10.1016/S0014-5793(97)01420-8; DiDonato A, 1997, NEPHRON, V76, P192, DOI 10.1159/000190168; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; DIMACULANGAN DD, 1994, DIFFERENTIATION, V58, P47, DOI 10.1046/j.1432-0436.1994.5810047.x; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; Gacheru SN, 1997, J CELL BIOCHEM, V65, P395, DOI 10.1002/(SICI)1097-4644(19970601)65:3<395::AID-JCB9>3.0.CO;2-N; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; Giffin W, 1999, MOL CELL BIOL, V19, P4065; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GREEN RS, 1995, LAB INVEST, V73, P476; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; HAJNAL A, 1993, CANCER RES, V53, P4670; HAMALAINEN ER, 1995, J BIOL CHEM, V270, P21590, DOI 10.1074/jbc.270.37.21590; Jeggo P, 1999, CR ACAD SCI III-VIE, V322, P109, DOI 10.1016/S0764-4469(99)80031-6; JEGGO PA, 1994, INT J RADIAT BIOL, V66, P573, DOI 10.1080/09553009414551651; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; JONES CL, 1991, KIDNEY INT, V40, P1012; JOURDANLESAUX C, 1994, BIOCHEM BIOPH RES CO, V199, P587, DOI 10.1006/bbrc.1994.1269; KAGAN HM, 1984, J BIOL CHEM, V259, P1203; KAGAN HM, 1980, J BIOL CHEM, V255, P3656; KAGAN HM, 1991, AM J RESP CELL MOL B, V5, P296; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; Kim YH, 1999, J CELL BIOCHEM, V72, P181, DOI 10.1002/(SICI)1097-4644(19990201)72:2<181::AID-JCB3>3.0.CO;2-D; Koike M, 1999, J CELL SCI, V112, P4031; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; KUIVANIEMI H, 1985, AM J HUM GENET, V37, P798; KUIVANIEMI H, 1986, FEBS LETT, V195, P261, DOI 10.1016/0014-5793(86)80172-7; KUNCIO GS, 1991, KIDNEY INT, V39, P550, DOI 10.1038/ki.1991.63; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langenau DM, 1999, J MOL ENDOCRINOL, V23, P137, DOI 10.1677/jme.0.0230137; LEROMANCER M, 1993, CR ACAD SCI III-VIE, V316, P1283; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; LEVENE CI, 1985, BIOCHEM J, V232, P293, DOI 10.1042/bj2320293; Li WD, 1997, P NATL ACAD SCI USA, V94, P12817, DOI 10.1073/pnas.94.24.12817; MARTIN JE, 1991, VIRCHOWS ARCH A, V419, P403, DOI 10.1007/BF01605074; MURAWAKI Y, 1991, HEPATOLOGY, V14, P1167, DOI 10.1002/hep.1840140635; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; OKUDA S, 1986, KIDNEY INT, V29, P502, DOI 10.1038/ki.1986.28; Oleggini R, 2000, NEPHROL DIAL TRANSPL, V15, P778, DOI 10.1093/ndt/15.6.778; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Petroski MD, 1998, J VIROL, V72, P8181, DOI 10.1128/JVI.72.10.8181-8190.1998; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; QUAGLINO D, 1993, MATRIX, V13, P481, DOI 10.1016/S0934-8832(11)80114-9; REISER K, 1992, FASEB J, V6, P2439, DOI 10.1096/fasebj.6.7.1348714; RILEY DJ, 1982, AM REV RESPIR DIS, V125, P67; Roy R, 1996, J CELL BIOCHEM, V62, P411, DOI 10.1002/(SICI)1097-4644(199609)62:3<411::AID-JCB11>3.0.CO;2-L; ROYCE PM, 1980, BIOCHEM J, V192, P576; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA AK, 1993, KIDNEY INT, V44, P774, DOI 10.1038/ki.1993.312; Sharma R, 1997, BIOSCIENCE REP, V17, P409, DOI 10.1023/A:1027361418200; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; Shieh B, 1997, INT IMMUNOL, V9, P1885, DOI 10.1093/intimm/9.12.1885; SIEGEL RC, 1974, P NATL ACAD SCI USA, V71, P4826, DOI 10.1073/pnas.71.12.4826; SIEGEL RC, 1978, P NATL ACAD SCI USA, V75, P2945, DOI 10.1073/pnas.75.6.2945; SOMMER P, 1993, LAB INVEST, V69, P460; TAMAKI K, 1994, KIDNEY INT, V45, P525, DOI 10.1038/ki.1994.68; Tan RSP, 1996, CANCER RES, V56, P2417; Torrance H, 1998, J BIOL CHEM, V273, P20810, DOI 10.1074/jbc.273.33.20810; Trivedy C, 1999, J ORAL PATHOL MED, V28, P246; VAHERI A, 1965, VIROLOGY, V27, P434, DOI 10.1016/0042-6822(65)90126-1; Warriar N, 1996, J BIOL CHEM, V271, P18662, DOI 10.1074/jbc.271.31.18662; Wheldon TE, 1998, RADIOTHER ONCOL, V48, P5, DOI 10.1016/S0167-8140(98)00022-X; Woudstra EC, 1999, RADIAT RES, V152, P214, DOI 10.2307/3580096	80	104	113	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36341	36349		10.1074/jbc.M003362200	http://dx.doi.org/10.1074/jbc.M003362200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10942761	hybrid			2022-12-27	WOS:000165382000098
J	Krieger-Brauer, HI; Medda, P; Kather, H				Krieger-Brauer, HI; Medda, P; Kather, H			Basic fibroblast growth factor utilizes both types of component subunits of G(s) for dual signaling in human adipocytes - Stimulation of adenylyl cyclase via G alpha(s) and inhibition of NADPH oxidase by G beta gamma(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT H2O2 GENERATION; HETEROTRIMERIC G-PROTEINS; BETA-GAMMA-SUBUNITS; ALPHA-SUBUNIT; H2O2-GENERATING SYSTEM; HYDROGEN-PEROXIDE; PLASMA-MEMBRANES; RECEPTOR KINASE; BINDING; ACTIVATION	Basic fibroblast growth factor (bFGF), a ligand of receptor protein-tyrosine kinases, promoted the dissociation of G(s) and had antagonistic stimulatory and inhibitory effects on adenylyl cyclase and NADPH oxidase in human fat cell plasma membranes. The bFGF-induced activation of adenylyl cyclase was blocked by COOH-terminal anti-Ca,, indicating that it was mediated by Ga,. The inhibitory action of bFGF was mimicked by exogenously supplied G beta gamma -subunits and was reversed by anti-G beta (1/2), or beta ARK-CT, a COOH-terminal beta -adrenergic receptor kinase fragment that specifically binds free G beta gamma, indicating that it was transduced by G beta gamma complexes. The bFGF-induced inhibition of NADPH-dependent H2O2 generation was also reversed by peptide 100-119, an inhibitor of G(s) activation by ligand-occupied beta -adrenergic receptors, indicating that the G beta gamma complexes mediating the inhibitory action of the growth factor are derived from G(s). The findings suggest a direct, non-kinase-dependent, coupling of bFGF receptor(s) to and G(s) provide the first example of a ligand of receptor protein-tyrosine kinases that is capable of utilizing both types of component subunits of a single heterotrimeric G protein for dual signaling in a single cell type.	Univ Heidelberg, Klin Inst Herzinfarktforsch, Med Klin, D-69115 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Krieger-Brauer, HI (corresponding author), Univ Heidelberg, Klin Inst Herzinfarktforsch, Med Klin, Bergheimerstr 58, D-69115 Heidelberg, Germany.							Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bayewitch ML, 1998, J BIOL CHEM, V273, P2273, DOI 10.1074/jbc.273.4.2273; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; BURRUS LW, 1992, MOL CELL BIOL, V12, P5600, DOI 10.1128/MCB.12.12.5600; Degtiar VE, 1997, J PHYSIOL-LONDON, V502, P321, DOI 10.1111/j.1469-7793.1997.321bk.x; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JO H, 1992, ENDOCRINOLOGY, V131, P2855, DOI 10.1210/en.131.6.2855; Kanzaki M, 1997, J BIOL CHEM, V272, P14733, DOI 10.1074/jbc.272.23.14733; KATADA T, 1982, J BIOL CHEM, V257, P3739; KATADA T, 1984, J BIOL CHEM, V259, P3586; KATAOKA R, 1993, J BIOL CHEM, V268, P19851; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Krieger-Brauer HI, 2000, J BIOL CHEM, V275, P2486, DOI 10.1074/jbc.275.4.2486; Krieger-Brauer HI, 1999, J BIOL CHEM, V274, P28308, DOI 10.1074/jbc.274.40.28308; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; MAGNALDO I, 1989, CELL SIGNAL, V1, P507, DOI 10.1016/0898-6568(89)90035-1; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; NAIR BG, 1990, J BIOL CHEM, V265, P21317; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; ORLY J, 1975, P NATL ACAD SCI USA, V72, P3433, DOI 10.1073/pnas.72.9.3433; Pursiheimo JP, 2000, P NATL ACAD SCI USA, V97, P168, DOI 10.1073/pnas.97.1.168; RODBELL M, 1964, J BIOL CHEM, V239, P375; SA G, 1994, J BIOL CHEM, V269, P3219; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; StryjekKaminska D, 1996, BIOCHEM J, V316, P87, DOI 10.1042/bj3160087; Szebenyi G, 1999, INT REV CYTOL, V185, P45; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TEICHERTKULISZEWSKA K, 1992, J CLIN INVEST, V90, P1226, DOI 10.1172/JCI115984; TOYOSHIGE M, 1994, BIOCHEMISTRY-US, V33, P4865, DOI 10.1021/bi00182a014; Toyoshige M, 1996, J BIOL CHEM, V271, P8791, DOI 10.1074/jbc.271.15.8791; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; YAMASHITA H, 1995, CELL GROWTH DIFFER, V6, P1457; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	46	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35920	35925		10.1074/jbc.M002490200	http://dx.doi.org/10.1074/jbc.M002490200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10969069	hybrid			2022-12-27	WOS:000165382000041
J	Osborne, A; Thorneley, RNF; Abell, C; Bornemann, S				Osborne, A; Thorneley, RNF; Abell, C; Bornemann, S			Studies with substrate and cofactor analogues provide evidence for a radical mechanism in the chorismate synthase reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN MONONUCLEOTIDE; NEUROSPORA-CRASSA; INTERMEDIATE; ENZYME; PHOSPHATE; PATHWAY; BINDING; MODEL; ASSAY; ACID	Chorismate synthase catalyzes the conversion of 5-enolpyruvylshikimate 3-phosphate (EPSP) to chorismate. The strict requirement for a reduced FMN cofactor and a trans-1,4-elimination are unusual. (6R)-6-Fluoro-EPSP was shown to be converted to chorismate stoichiometrically with enzyme-active sites in the presence of dithionite. This conversion was associated with the oxidation of FMN to give a stable flavin semiquinone. The IC,, of the fluorinated substrate analogue was 0.5 and 250 muM with the Escherichia coli enzyme, depending on whether it was preincubated with the enzyme or not. The lack of dissociation of the flavin semiquinone and chorismate from the enzyme appears to be the basis of the essentially irreversible inhibition by this analogue. A dithionite-dependent transient formation of flavin semiquinone during turnover of (6S)-6-fluoro-EPSP has been observed. These reactions are best rationalized by radical chemistry that is strongly supportive of a radical mechanism occurring during normal turnover. The lack of activity with 5-deaza-FMN provides additional evidence for the role of flavin in catalysis by the E. coli enzyme.	John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England; Univ Cambridge, Chem Lab, Dept Chem, Cambridge CB2 1EW, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Cambridge	Bornemann, S (corresponding author), John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.		Bornemann, Stephen/K-2938-2012	Bornemann, Stephen/0000-0001-5930-9473				BALASUBRAMANIAN S, 1995, BIOCHEMISTRY-US, V34, P341, DOI 10.1021/bi00001a042; BALASUBRAMANIAN S, 1991, J AM CHEM SOC, V113, P8945, DOI 10.1021/ja00023a051; BARTLETT PA, 1989, BCPC MONOGRAPH, V42, P155; BORNEMANN S, 1995, BIOCHEM J, V305, P707, DOI 10.1042/bj3050707; BORNEMANN S, 1995, J BIOL CHEM, V270, P22811, DOI 10.1074/jbc.270.39.22811; Bornemann S, 1996, BIOCHEMISTRY-US, V35, P9907, DOI 10.1021/bi952958q; Bornemann S, 2000, BIOORG CHEM, V28, P191, DOI 10.1006/bioo.2000.1174; Bornemann S, 1996, BIOCHEM SOC T, V24, P84, DOI 10.1042/bst0240084; COPLEY SD, 1987, J AM CHEM SOC, V109, P5008, DOI 10.1021/ja00250a040; DAVIES GM, 1994, ANTIMICROB AGENTS CH, V38, P403, DOI 10.1128/AAC.38.2.403; FLOSS HG, 1972, J BIOL CHEM, V247, P736; GIBSON F, 1964, BIOCHEM J, V90, P256, DOI 10.1042/bj0900256; GIESE B, 1994, TETRAHEDRON LETT, V35, P1677, DOI 10.1016/0040-4039(94)88317-3; HEMMERICH P, 1977, FEBS LETT, V84, P5, DOI 10.1016/0014-5793(77)81047-8; HILL RK, 1969, J AM CHEM SOC, V91, P5893, DOI 10.1021/ja01049a045; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LAUHON CT, 1994, BIOCHEMISTRY-US, V33, P14100, DOI 10.1021/bi00251a019; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Macheroux P, 1996, BIOCHEMISTRY-US, V35, P1643, DOI 10.1021/bi951705u; Macheroux P, 1999, PLANTA, V207, P325, DOI 10.1007/s004250050489; Macheroux P, 1998, BIOCHEM J, V335, P319, DOI 10.1042/bj3350319; Macheroux P, 1996, J BIOL CHEM, V271, P25850, DOI 10.1074/jbc.271.42.25850; MACHEROUX P, 1997, FLAVINS FLAVOPROTEIN, P113; MORELL H, 1967, J BIOL CHEM, V242, P82; MULLER F, 1972, EUR J BIOCHEM, V25, P573, DOI 10.1111/j.1432-1033.1972.tb01730.x; ONDERKA DK, 1969, J AM CHEM SOC, V91, P5894, DOI 10.1021/ja01049a046; RAMJEE MK, 1994, ANAL BIOCHEM, V220, P137, DOI 10.1006/abio.1994.1309; RAMJEE MN, 1992, J AM CHEM SOC, V114, P3151, DOI 10.1021/ja00034a079; RAMJEE MN, 1991, J AM CHEM SOC, V113, P8566, DOI 10.1021/ja00022a078; SPENCER R, 1976, BIOCHEMISTRY-US, V15, P1043, DOI 10.1021/bi00650a015; SUTHERLAND JK, 1989, J CHEM SOC CHEM COMM, P1386, DOI 10.1039/c39890001386; Theoclitou ME, 1996, BIOORG MED CHEM LETT, V6, P1285, DOI 10.1016/0960-894X(96)00217-X; WELCH GR, 1974, ARCH BIOCHEM BIOPHYS, V165, P505, DOI 10.1016/0003-9861(74)90276-8; WHITE PJ, 1988, BIOCHEM J, V251, P313, DOI 10.1042/bj2510313	34	31	32	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35825	35830		10.1074/jbc.M005796200	http://dx.doi.org/10.1074/jbc.M005796200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10956653	hybrid			2022-12-27	WOS:000165382000028
J	Schmoll, D; Walker, KS; Alessi, DR; Grempler, R; Burchell, A; Guo, SD; Walther, R; Unterman, TG				Schmoll, D; Walker, KS; Alessi, DR; Grempler, R; Burchell, A; Guo, SD; Walther, R; Unterman, TG			Regulation of glucose-6-phosphatase gene expression by protein kinase B alpha and the forkhead transcription factor FKHR - Evidence for insulin response unit-dependent and -independent effects of insulin on promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; PHOSPHATIDYLINOSITOL 3-KINASE; CAENORHABDITIS-ELEGANS; CATALYTIC SUBUNIT; HEPATOMA-CELLS; CAMP INDUCTION; FAMILY MEMBER; BINDING-SITES; ACTIVATION; PHOSPHORYLATION	Glucose-6-phosphatase plays an important role in the regulation of hepatic glucose production, and insulin suppresses glucose-6-phosphatase gene expression. Recent Studies indicate that protein kinase B and Forkhead proteins contribute to insulin-regulated gene expression in the liver. Here, we examined the role of protein kinase B and Forkhead proteins in mediating effects of insulin on glucose-6-phosphatase promoter activity. Transient transfection studies with reporter gene constructs demonstrate that insulin suppresses both basal and dexamethasone/cAMP-induced activity of the glucose-6-phosphatase promoter in H4IIE hepatoma cells. Both effects are partially mimicked by coexpression bf protein kinase B alpha. Coexpression of the Forkhead transcription factor FKHR stimulates the glucose-6-phosphatase promoter activity via interaction with an insulin response unit (IRU), and this activation is suppressed by protein kinase B, Coexpression of a mutated form of FKHR that cannot be phosphorylated by protein kinase B abolishes the regulation of the glucose-6-phosphatase promoter by protein kinase B and disrupts the ability of insulin to regulate the glucose-6-phosphatase promoter via the IRU, Mutation of the insulin response unit of the glucose-6-phosphatase promoter also prevents the regulation of promoter activity by FKHR and protein kinase B but only partially impairs the ability of insulin: to suppress both basal and dexamethasone/cAMP-stimulated promoter function. Taken together, these results indicate that signaling by protein kinase B to Forkhead proteins can account for the ability of insulin to regulate glucose-6-phosphatase promoter activity via the IRU and that other mechanisms that are independent of the IRU, protein kinase B, and Forkhead proteins also are important in mediating effects of in insulin-on glucose-6-phosphatase gene expression.	Univ Greifswald, Klinikum Sauerbruchstr, Dept Biochem, D-17487 Greifswald, Germany; Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland; Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA; Chicago Area Vet Affairs Hlth Care Syst, W Side Div, Chicago, IL 60612 USA	Ernst Moritz Arndt Universitat Greifswald; University of Dundee; University of Dundee; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Schmoll, D (corresponding author), Univ Greifswald, Klinikum Sauerbruchstr, Dept Biochem, D-17487 Greifswald, Germany.		Burchell, Ann/B-7475-2008	Schmoll, Dieter/0000-0003-2578-3366; Alessi, Dario/0000-0002-2140-9185	NIDDK NIH HHS [DK41430] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041430, R29DK041430] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ayala JE, 1999, DIABETES, V48, P1885, DOI 10.2337/diabetes.48.9.1885; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cha JY, 2000, J BIOL CHEM, V275, P18358, DOI 10.1074/jbc.M909536199; Chou JY, 1999, TRENDS ENDOCRIN MET, V10, P104; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Dickens M, 1998, J BIOL CHEM, V273, P20144, DOI 10.1074/jbc.273.32.20144; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nordlie RC, 1999, ANNU REV NUTR, V19, P379, DOI 10.1146/annurev.nutr.19.1.379; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Schmoll D, 1999, BIOCHEM J, V338, P457, DOI 10.1042/0264-6021:3380457; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Streeper RS, 1998, P NATL ACAD SCI USA, V95, P9208, DOI 10.1073/pnas.95.16.9208; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Yeagley D, 2000, J BIOL CHEM, V275, P17814, DOI 10.1074/jbc.M909842199; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743	38	290	299	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36324	36333		10.1074/jbc.M003616200	http://dx.doi.org/10.1074/jbc.M003616200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10960473	hybrid			2022-12-27	WOS:000165382000096
J	Eto, B; Puzon-McLaughlin, W; Sheppard, D; Sehara-Fujisawa, A; Zhang, XP; Takada, Y				Eto, B; Puzon-McLaughlin, W; Sheppard, D; Sehara-Fujisawa, A; Zhang, XP; Takada, Y			RGD-independent binding of integrin alpha(9)beta(1) to the ADAM-12 and-15 disintegrin domains mediates cell-cell interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELTRIN-ALPHA; III REPEAT; IN-VIVO; METALLOPROTEASE; SUBUNIT; METARGIDIN; EXPRESSION; ADHESION; SEQUENCE; PROTEIN	ADAMs (a disintegrin and metalloproteases) mediate several important processes (e.g. tumor necrosis factor-cy:release, fertilization, and myoblast fusion). The ADAM disintegrin domains generally lack RGD motifs, and their receptors are virtually unknown. Here we show that integrin alpha (9)beta (1) specifically interacts with the recombinant ADAMs-12 and -15 disintegrin domains in an RGD-independent manner. We also show that interaction between ADAM-12 or -15 and alpha (9)beta (1) supports cell-cell interaction Interestingly, the cation requirement and integrin activation status required for alpha (9)beta (1)/ADAM-mediated cell adhesion and cell-cell interaction is similar to those required for known integrin-extracellular matrix interaction. These results are quite different from recent reports that ADAM-2/alpha (6)beta (1) interaction during sperm/egg fusion requires an integrin activation status distinct from that for extracellular matrix interaction. These results suggest that alpha (9)beta (1) may be a major receptor for ADAMs that lack RGD motifs, and that, considering a wide distribution of ADAMs and alpha (9)beta (1), this interaction may be of potential biological and pathological significance.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, Ctr Occupat & Environm Hlth,Lung Biol Ctr, San Francisco, CA 94143 USA; Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan	Scripps Research Institute; University of California System; University of California San Francisco; Tokyo Metropolitan Institute of Medical Science	Takada, Y (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd,CAL-10, La Jolla, CA 92037 USA.			takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047175, R01GM049899] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47175, GM49899] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Bigler D, 2000, J BIOL CHEM, V275, P11576, DOI 10.1074/jbc.275.16.11576; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Bohm BB, 1999, ARTHRITIS RHEUM, V42, P1946, DOI 10.1002/1529-0131(199909)42:9<1946::AID-ANR21>3.0.CO;2-E; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EVANS JP, 1995, J CELL SCI, V108, P3267; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Kurisaki T, 1998, MECH DEVELOP, V73, P211, DOI 10.1016/S0925-4773(98)00043-4; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Miller BJ, 2000, J CELL BIOL, V149, P1289, DOI 10.1083/jcb.149.6.1289; Mosser DD, 1997, BIOTECHNIQUES, V22, P150, DOI 10.2144/97221rr02; Nath D, 1999, J CELL SCI, V112, P579; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Takahashi H, 2000, J BIOL CHEM, V275, P23589, DOI 10.1074/jbc.M003526200; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; WANG A, 1995, DEV DYNAM, V204, P421, DOI 10.1002/aja.1002040408; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; Yokosaki Y, 1998, J BIOL CHEM, V273, P11423, DOI 10.1074/jbc.273.19.11423; Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345; Zolkiewska A, 1999, EXP CELL RES, V252, P423, DOI 10.1006/excr.1999.4632	42	183	194	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34922	34930		10.1074/jbc.M001953200	http://dx.doi.org/10.1074/jbc.M001953200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10944520				2022-12-27	WOS:000165422800015
J	McManus, MJ; Boerner, JL; Danielsen, AJ; Wang, Z; Matsumura, F; Maihle, NJ				McManus, MJ; Boerner, JL; Danielsen, AJ; Wang, Z; Matsumura, F; Maihle, NJ			An oncogenic epidermal growth factor receptor signals via a p21-activated kinase-caldesmon-myosin phosphotyrosine complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; RET PROTOONCOGENE; ACTIVATION; TYROSINE; DOMAIN; ACTIN; PHOSPHORYLATION; TRANSFORMATION; MUTATIONS; PROTEINS	Many ligand-independent receptor tyrosine kinases are tumorigenic. The biochemical signals that mediate ligand-independent transformation of cells by these transmembrane receptors are poorly defined. In this report, we demonstrate that a constitutively activated mutant epidermal growth factor receptor (v-ErbB) induces the formation of a transformation-specific signaling module that complexes with myosin II. The components:of this signaling complex include the signal adapter proteins Shc, Grb2, and Nck, and tyrosine-phosphorylated forms of p21-activated kinase (Pak), caldesmon, and myosin light chain kinase. Transformation specific, tyrosine phosphorylation of Pak enhances the catalytic activity of this serine/threonine kinase. Furthermore, the tyrosine phosphorylation of Pak is Rho-, but not Ras-, Rac-, or Cdc42-dependent. These results demonstrate :that a ligand-independent epidermal growth factor receptor mutant can transduce oncogenic signals that are distinct from ligand-dependent, mitogenic signals. In addition, these data provide evidence for-the coupling of oncogenic receptor tyrosine kinases with the actomyosin molecular motor. This myosin-associated signaling module may mediate some of the biochemical changes of myosin found in v-ErbB-transformed fibroblasts, thereby contributing to the regulation of the mechanical forces governing cellular adhesion, cytoskeletal tension, and, hence, anchorage-independent cell growth.	Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Tumor Biol Program, Rochester, MN 55905 USA; Rutgers State Univ, Nelson Labs, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Mayo Clinic; Mayo Clinic; Rutgers State University New Brunswick	Maihle, NJ (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.			Matsumura, Fumio/0000-0002-8204-153X	NATIONAL CANCER INSTITUTE [T32CA075926, R01CA079808, R29CA075238] Funding Source: NIH RePORTER; NCI NIH HHS [CA75238, CA75926, CA79808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Biscardi JS, 1999, ADV CANCER RES, V76, P61; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; Boerner JL, 2000, J CELL SCI, V113, P935; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Cai S, 1998, AM J PHYSIOL-CELL PH, V275, pC1349, DOI 10.1152/ajpcell.1998.275.5.C1349; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Foster DB, 2000, J BIOL CHEM, V275, P1959, DOI 10.1074/jbc.275.3.1959; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; McManus MJ, 1997, P NATL ACAD SCI USA, V94, P11351, DOI 10.1073/pnas.94.21.11351; MCMANUS MJ, 1995, J VIROL, V69, P3631, DOI 10.1128/JVI.69.6.3631-3638.1995; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; POLLARD TD, 1974, ANAL BIOCHEM, V60, P258, DOI 10.1016/0003-2697(74)90152-3; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; TOKUI T, 1995, BIOCHEMISTRY-US, V34, P5173, DOI 10.1021/bi00015a031; Tu H, 1999, MOL CELL BIOL, V19, P602; Wang Z, 1999, J BIOL CHEM, V274, P33807, DOI 10.1074/jbc.274.47.33807; WATTERSON DM, 1995, FEBS LETT, V373, P217; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	40	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35328	35334		10.1074/jbc.M005399200	http://dx.doi.org/10.1074/jbc.M005399200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954714	hybrid			2022-12-27	WOS:000165422800067
J	Safadi, F; Reddy, VS; Reddy, ASN				Safadi, F; Reddy, VS; Reddy, ASN			A pollen-specific novel calmodulin-binding protein with tetratricopeptide repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC-FREE CALCIUM; TUBE GROWTH; PLANT-CELLS; SIGNAL-TRANSDUCTION; TIP GROWTH; ARABIDOPSIS-THALIANA; LILIUM-LONGIFLORUM; EXTRACELLULAR CALMODULIN; GLCNAC TRANSFERASE; ANGIOSPERM POLLEN	Calcium is essential for pollen germination and pollen tube growth. A large body of information has established a link between elevation of cytosolic Ca2+ at the pollen tube tip and its growth. Since the action of Ca2+ is primarily mediated by Ca2+-binding proteins such as calmodulin (CaM), identification of CaM-binding proteins in pollen should provide insights into the mechanisms by which Ca2+ regulates pollen germination and tube growth. In this study, a CaM-binding protein from maize pollen (maize pollen calmodulin-binding protein, MPCBP) was isolated in a protein-protein interaction-based screening using S-35-labeled CaM as a probe, MPCBP has a molecular mass of about 72 kDa and contains three tetratricopeptide repeats (TPR) suggesting that it is a member of the TPR family of proteins. MPCBP protein shares a high sequence identity with two hypothetical TPR-containing proteins from Arabidopsis, Using gel overlay assays and CaM-Sepharose binding, we show that the bacterially expressed MPCBP binds to bovine CaM and three CaM isoforms from Arabidopsis in a Ca2+-dependent manner. To map the CaM-binding domain several truncated versions of the MPCBP were expressed in bacteria and tested for their ability to bind CaM, Based on these studies, the CaM-binding domain was mapped to an 18-amino acid stretch between the first and second TPR regions. Gel and fluorescence shift assays performed with CaM and a CaM-binding synthetic peptide further confirmed MPCBP binding to CaM, Western, Northern, and reverse transcriptase-polymerase chain reaction analysis have shown that MPCBP expression is specific to pollen. MPCBP was detected in both soluble and microsomal proteins. Immunoblots showed the presence of MPCBP in mature and germinating pollen. Pollen-specific expression of MPCBP, its CaM-binding properties, and the presence of TPR motifs suggest a role for this protein in Ca2+-regulated events during pollen germination and growth.	Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Colorado State Univ, Cell & Mol Biol Program, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University	Reddy, ASN (corresponding author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.		Safadi, Fayez/AAU-8699-2021	Reddy, Anireddy/0000-0002-4038-4091				BEDNARSKA E, 1995, FOLIA HISTOCHEM CYTO, V33, P43; Bednarska E., 1989, Sexual Plant Reproduction, V2, P53, DOI 10.1007/BF00190119; Bibikova TN, 1997, PLANTA, V203, P495, DOI 10.1007/s004250050219; Bibikova TN, 1999, PLANT J, V17, P657, DOI 10.1046/j.1365-313X.1999.00415.x; BREWBAKE JL, 1963, AM J BOT, V50, P859, DOI 10.2307/2439772; Broadwater Anne H., 1994, P538; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; Cai G, 1997, TRENDS PLANT SCI, V2, P86, DOI 10.1016/S1360-1385(96)10057-1; Calder GM, 1997, BIOCHEM BIOPH RES CO, V234, P690, DOI 10.1006/bbrc.1997.6514; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; DERKSEN J, 1995, ACTA BOT NEERL, V44, P93; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; Franklin-Tong VE, 1999, PLANT CELL, V11, P727, DOI 10.1105/tpc.11.4.727; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; Harlow E., 1988, ANTIBODIES LAB MANUA; HAUSSER I, 1984, PLANTA, V162, P33, DOI 10.1007/BF00397418; Hepler PK, 1997, TRENDS PLANT SCI, V2, P79, DOI 10.1016/S1360-1385(97)88385-9; HERNANDEZ TJ, 1995, PLANT MOL BIOL, V27, P1221; HERTH W, 1990, TIP GROWTH PLANT FUN, P91; HESLOPHARRISON J, 1989, J CELL SCI, V94, P319; HESLOPHARRISON J, 1987, INT REV CYTOL, V107, P1, DOI 10.1016/S0074-7696(08)61072-4; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HoldawayClarke TL, 1997, PLANT CELL, V9, P1999, DOI 10.1105/tpc.9.11.1999; Jacobsen SE, 1996, P NATL ACAD SCI USA, V93, P9292, DOI 10.1073/pnas.93.17.9292; JAFFE LA, 1975, J CELL BIOL, V67, P488, DOI 10.1083/jcb.67.2.488; Kragler F, 1998, P NATL ACAD SCI USA, V95, P13336, DOI 10.1073/pnas.95.22.13336; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; KUHTREIBER WM, 1990, J CELL BIOL, V110, P1565, DOI 10.1083/jcb.110.5.1565; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lee SH, 1999, BBA-PROTEIN STRUCT M, V1433, P56, DOI 10.1016/S0167-4838(99)00149-1; Liao BR, 1995, METHOD CELL BIOL, V49, P487, DOI 10.1016/S0091-679X(08)61475-2; Lubas WA, 1997, J BIOL CHEM, V272, P9316; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; Ma LG, 1997, PLANTA, V202, P336, DOI 10.1007/s004250050135; Ma LG, 1999, PLANT CELL, V11, P1351, DOI 10.1105/tpc.11.7.1351; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MALENCIK DA, 1984, BIOCHEMISTRY-US, V23, P2420, DOI 10.1021/bi00306a016; MALHO R, 1994, PLANT J, V5, P331, DOI 10.1111/j.1365-313X.1994.00331.x; Malho R, 1996, PLANT CELL, V8, P1935, DOI 10.1105/tpc.8.11.1935; MALHO R, 1995, PLANT CELL, V7, P1173, DOI 10.1105/tpc.7.8.1173; MASCARENHAS JP, 1964, PLANT PHYSIOL, V39, P70, DOI 10.1104/pp.39.1.70; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; Messerli MA, 1999, J CELL SCI, V112, P1497; MILLER DD, 1992, J CELL SCI, V101, P7; Moutinho A, 1998, SEX PLANT REPROD, V11, P131, DOI 10.1007/s004970050130; OBERMEYER G, 1991, EUR J CELL BIOL, V56, P319; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PICTON JM, 1985, PLANTA, V163, P20, DOI 10.1007/BF00395892; PICTON JM, 1983, PROTOPLASMA, V115, P11, DOI 10.1007/BF01293575; PIERSON ES, 1990, J EXP BOT, V41, P1461, DOI 10.1093/jxb/41.11.1461; PIERSON ES, 1992, INT REV CYTOL, V140, P73, DOI 10.1016/S0074-7696(08)61094-3; Pierson ES, 1996, DEV BIOL, V174, P160, DOI 10.1006/dbio.1996.0060; PIERSON ES, 1994, PLANT CELL, V6, P1815, DOI 10.1105/tpc.6.12.1815; POLITO VS, 1983, POLLEN BIOL IMPLICAT, P53; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; RASICALDOGNO F, 1989, PLANT PHYSIOL, V90, P1429, DOI 10.1104/pp.90.4.1429; RATHORE KS, 1991, DEV BIOL, V148, P612, DOI 10.1016/0012-1606(91)90278-B; Reddy ASN, 1996, J BIOL CHEM, V271, P7052, DOI 10.1074/jbc.271.12.7052; REDDY ASN, 1993, PLANT SCI, V94, P109, DOI 10.1016/0168-9452(93)90012-O; REDDY ASN, 2001, IN PRESS INT REV CYT; REDDY ASN, 2000, IN PRESS HDB PLANT C; Reddy VS, 1999, J BIOL CHEM, V274, P31727, DOI 10.1074/jbc.274.44.31727; REISS HD, 1985, PLANTA, V163, P84, DOI 10.1007/BF00395901; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; Robertson M, 1998, PLANT CELL, V10, P995, DOI 10.1105/tpc.10.6.995; Rozwadowski K, 1999, PLANT PHYSIOL, V120, P787, DOI 10.1104/pp.120.3.787; Sambrook J., 2002, MOL CLONING LAB MANU; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Snedden WA, 1998, TRENDS PLANT SCI, V3, P299, DOI 10.1016/S1360-1385(98)01284-9; Song H, 1997, P NATL ACAD SCI USA, V94, P322, DOI 10.1073/pnas.94.1.322; STEER MW, 1989, NEW PHYTOL, V111, P323, DOI 10.1111/j.1469-8137.1989.tb00697.x; Taylor LP, 1997, ANNU REV PLANT PHYS, V48, P461, DOI 10.1146/annurev.arplant.48.1.461; Tirlapur Uday K., 1994, Zygote, V2, P63; TIRLAPUR UK, 1992, ANN BOT-LONDON, V69, P503, DOI 10.1093/oxfordjournals.aob.a088379; TREWAVAS A, 1991, TRENDS GENET, V7, P356, DOI 10.1016/0168-9525(91)90255-O; Trewavas AJ, 1998, CURR OPIN PLANT BIOL, V1, P428, DOI 10.1016/S1369-5266(98)80268-9; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; Venolia L, 1999, CELL MOTIL CYTOSKEL, V42, P163, DOI 10.1002/(SICI)1097-0169(1999)42:3&lt;163::AID-CM1&gt;3.0.CO;2-E; Vucich VA, 1996, MOL GEN GENET, V252, P510, DOI 10.1007/BF02172397; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	87	38	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35457	35470		10.1074/jbc.M002720200	http://dx.doi.org/10.1074/jbc.M002720200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956642	hybrid			2022-12-27	WOS:000165422800083
J	Tabata, H; Matsuoka, T; Endo, F; Nishimura, Y; Matsushita, S				Tabata, H; Matsuoka, T; Endo, F; Nishimura, Y; Matsushita, S			Ligation of HLA-DR molecules on B cells induces enhanced expression of IgM heavy chain genes in association with SyK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; PROTEIN-TYROSINE KINASE; MEDIATED SIGNAL-TRANSDUCTION; SRC FAMILY KINASES; LYMPHOCYTES-B; MONOCLONAL-ANTIBODIES; SELECTIVE INHIBITOR; CYTOPLASMIC DOMAIN; IMMUNOGLOBULIN-M; SECRETING CELLS	Signals transmitted by class II major histocompatibility complex are important regarding cell function related to antigen presentation. We examined effects of DR-mediated signaling on Ig production from B cells. Cross-linking HLA-DR molecules on B cells by solid-phase anti-HLA-DR monoclonal antibodies, led to an increased production of IgM, without proliferation or apoptosis. This event was accompanied by an enhanced expression of both membrane- and secretory-type IgM heavy chain mRNA. When peptide-pulsed B cells were co-incubated with an HLA-DR-restricted T cell clone treated by the protein synthesis inhibitor emetine, peptide-induced de novo expression of lymphokines and cell-surface molecules on T cells can be neglected. CD40-CD154 interaction was not involved in IgM enhancement,: in such a system. The protein-tyrosine kinase inhibitors and the Syk inhibitor piceatannol, but not the Src inhibitor PP2 had a marked inhibitory effect on IgM secretion. Furthermore, ligation of HLA-DR on B cells using the F(ab')B fragment of anti-DR monoclonal antibody, enhanced Syk activity. Our data suggest that HLA-DR on B cells not only present antigenic peptides to T cells, but also up-regulate IgM production, in association with Syk activation and without the involvement of Src kinases, hence the possible physiological relevance of Src-independent Syk activation.	Kumamoto Univ, Grad Sch Med Sci, Dept Neurosci & Immunol, Div Immunogenet, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Pediat, Kumamoto 8600811, Japan	Kumamoto University; Kumamoto University	Matsushita, S (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Neurosci & Immunol, Div Immunogenet, Kumamoto 8600811, Japan.							AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ANDERSSON J, 1977, CELL, V10, P27, DOI 10.1016/0092-8674(77)90136-2; AOKI Y, 1995, J BIOL CHEM, V270, P15658, DOI 10.1074/jbc.270.26.15658; BISHOP GA, 1991, J IMMUNOL, V147, P1107; Boes M, 1998, J EXP MED, V188, P2381, DOI 10.1084/jem.188.12.2381; BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N; CAMBIER JC, 1989, J EXP MED, V170, P877, DOI 10.1084/jem.170.3.877; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Greer SF, 1998, J BIOL CHEM, V273, P11970, DOI 10.1074/jbc.273.19.11970; HAMANO T, 1990, J IMMUNOL, V144, P811; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARTON JA, 1993, J IMMUNOL, V151, P5282; HARTON JA, 1995, IMMUNITY, V3, P349, DOI 10.1016/1074-7613(95)90119-1; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7; KANNER SB, 1995, TISSUE ANTIGENS, V46, P145, DOI 10.1111/j.1399-0039.1995.tb03113.x; KANSAS GS, 1991, J IMMUNOL, V147, P4094; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KONDO N, 1992, CLIN EXP IMMUNOL, V88, P35; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; LANE PJL, 1990, J IMMUNOL, V144, P3684; Latour S, 1997, MOL CELL BIOL, V17, P4434, DOI 10.1128/MCB.17.8.4434; LAW CL, 1994, J BIOL CHEM, V269, P12310; MARKOWITZ JS, 1993, J IMMUNOL, V150, P1223; Matsuoka T, 1999, FASEB J, V13, pA275; Matsuoka T, 1996, J IMMUNOL, V157, P4837; Matsushita S, 1997, J IMMUNOL, V158, P5685; MEHINDATE K, 1995, J EXP MED, V182, P1573, DOI 10.1084/jem.182.5.1573; Miller LA, 1999, EUR J IMMUNOL, V29, P1426, DOI 10.1002/(SICI)1521-4141(199905)29:05<1426::AID-IMMU1426>3.0.CO;2-J; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MOONEY NA, 1990, J IMMUNOL, V145, P2070; MORIO T, 1994, EUR J IMMUNOL, V24, P651, DOI 10.1002/eji.1830240325; MOURAD W, 1989, J EXP MED, V170, P2011, DOI 10.1084/jem.170.6.2011; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; PALACIOS R, 1983, P NATL ACAD SCI-BIOL, V80, P3456, DOI 10.1073/pnas.80.11.3456; Randall TD, 1998, IMMUNITY, V8, P733, DOI 10.1016/S1074-7613(00)80578-6; Rich T, 1997, J IMMUNOL, V159, P3792; ROBBINS PA, 1987, HUM IMMUNOL, V18, P301, DOI 10.1016/0198-8859(87)90077-2; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; SONE T, 1985, J IMMUNOL, V135, P1288; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRUMAN JP, 1994, INT IMMUNOL, V6, P887, DOI 10.1093/intimm/6.6.887; TSOI MS, 1978, J IMMUNOL, V120, P1485; TSUJI K, 1992, HLA 1991 P 11 INT HI, V1; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Wang BH, 1998, PLANTA MED, V64, P195, DOI 10.1055/s-2006-957407; WEAVER CT, 1986, J IMMUNOL, V137, P3868; Xu R, 1999, J IMMUNOL, V163, P1110; Zoller KE, 1997, J IMMUNOL, V158, P1650	60	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34998	35005		10.1074/jbc.M002089200	http://dx.doi.org/10.1074/jbc.M002089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10948188	hybrid			2022-12-27	WOS:000165422800025
J	Willemoes, M; Hove-Jensen, B; Larsen, S				Willemoes, M; Hove-Jensen, B; Larsen, S			Steady state kinetic model for the binding of substrates and allosteric effecters to Escherichia coli phosphoribosyl-diphosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; NUCLEOTIDE BINDING; RAT-LIVER; SYNTHETASE; INHIBITION; MECHANISM; SITE; GENE; PYROPHOSPHATE; PURIFICATION	A steady state kinetic investigation of the P-i activation of 5-phospho-D-ribosyl alpha -1-diphosphate synthase from Escherichia coli suggests that P-i can bind randomly to the enzyme either before or after an ordered addition-of free Mg2+ and substrates. Unsaturation with ribose 5-phosphate increased the apparent cooperativity of P-i activation. At unsaturating P-i concentrations partial substrate inhibition by ribose 5-phosphate was observed. Together these results suggest that saturation of the enzyme with P-i directs the subsequent ordered binding of Mg2+ and substrates via a fast pathway, whereas saturation with ribose B-phosphate leads to the binding of Mg2+ and substrates via a slow pathway where P-i binds to the enzyme last. The random mechanism for P-i binding was further supported by studies with competitive inhibitors of Mg2+, MgATP, and ribose 5-phosphate that all appeared noncompetitive when varying P-i at either saturating or unsaturating ribose B-phosphate concentrations. Furthermore, none of the inhibitors induced inhibition at increasing P-i concentrations. Results from ADP inhibition of P-i activation suggest that these effectors compete for binding to a common regulatory site.	Univ Copenhagen, Dept Chem, Ctr Crystallog Studies, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Inst Mol Biol, Ctr Enzyme Res, DK-1307 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen	Willemoes, M (corresponding author), Univ Copenhagen, Dept Chem, Ctr Crystallog Studies, Univiersitetsparken 5, DK-2100 Copenhagen, Denmark.	martin@xray.ki.ku.dk	Willemoës, Martin/K-4359-2014; Larsen, Sine/A-4487-2017	Willemoës, Martin/0000-0003-1689-2712; Larsen, Sine/0000-0003-3848-1789				ARNVIG K, 1990, EUR J BIOCHEM, V192, P195, DOI 10.1111/j.1432-1033.1990.tb19214.x; BECKER MA, 1995, J CLIN INVEST, V96, P2133, DOI 10.1172/JCI118267; BOWER SG, 1988, J BACTERIOL, V170, P3243, DOI 10.1128/jb.170.7.3243-3248.1988; BOWER SG, 1989, J BIOL CHEM, V264, P10287; Cleland W W, 1979, Methods Enzymol, V63, P500; Eriksen TA, 2000, NAT STRUCT BIOL, V7, P303; FERDINAND W, 1966, BIOCHEM J, V98, P278, DOI 10.1042/bj0980278; FOX IH, 1972, J BIOL CHEM, V247, P2126; FRY DW, 1995, MOL PHARMACOL, V47, P810; GIBSON KJ, 1982, J BIOL CHEM, V257, P2391; HOVEJENSEN B, 1989, MOL MICROBIOL, V3, P1487, DOI 10.1111/j.1365-2958.1989.tb00134.x; HOVEJENSEN B, 1986, J BIOL CHEM, V261, P6765; HOVEJENSEN B, 1988, J BACTERIOL, V170, P1148, DOI 10.1128/jb.170.3.1148-1152.1988; Jensen KF, 1983, METABOLISM NUCLEOTID, P1; KHORANA HG, 1958, J BIOL CHEM, V230, P941; Krath BN, 1999, BBA-PROTEIN STRUCT M, V1430, P403, DOI 10.1016/S0167-4838(99)00022-9; Krath BN, 1999, PLANT PHYSIOL, V119, P497, DOI 10.1104/pp.119.2.497; Lundegaard C, 1999, BIOCHEMISTRY-US, V38, P3327, DOI 10.1021/bi982279q; MILLER GA, 1975, ARCH BIOCHEM BIOPHYS, V171, P732, DOI 10.1016/0003-9861(75)90086-7; Neet K E, 1980, Methods Enzymol, V64, P139; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; Parry RJ, 1996, BIOORGAN MED CHEM, V4, P1077, DOI 10.1016/0968-0896(96)00090-9; ROTH DG, 1974, J BIOL CHEM, V249, P291; Scherman MS, 1996, J BIOL CHEM, V271, P29652, DOI 10.1074/jbc.271.47.29652; SCHUBERT KR, 1975, J BIOL CHEM, V250, P7492; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RM, 1956, J AM CHEM SOC, V78, P2376, DOI 10.1021/ja01592a009; Sonoda T, 1998, BBA-PROTEIN STRUCT M, V1387, P32, DOI 10.1016/S0167-4838(98)00106-X; SWITZER RL, 1973, J BIOL CHEM, V248, P1063; SWITZER RL, 1969, J BIOL CHEM, V244, P2854; SWITZER RL, 1971, J BIOL CHEM, V246, P2447; WELLS BD, 1976, J THEOR BIOL, V60, P209, DOI 10.1016/0022-5193(76)90165-X; White RH, 1996, BIOCHEMISTRY-US, V35, P3447, DOI 10.1021/bi952308m; Willemoes M, 1996, BIOCHEMISTRY-US, V35, P8181, DOI 10.1021/bi9528560; Willemoes M, 1997, BIOCHEMISTRY-US, V36, P5078, DOI 10.1021/bi962610a; Zhang RL, 1996, BIOCHEMISTRY-US, V35, P3038, DOI 10.1021/bi952188i	36	32	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35408	35412		10.1074/jbc.M006346200	http://dx.doi.org/10.1074/jbc.M006346200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954724	hybrid			2022-12-27	WOS:000165422800077
J	Zhang, YJ; Sugiura, R; Lu, YB; Asami, M; Maeda, T; Itoh, T; Takenawa, T; Shuntoh, H; Kuno, T				Zhang, YJ; Sugiura, R; Lu, YB; Asami, M; Maeda, T; Itoh, T; Takenawa, T; Shuntoh, H; Kuno, T			Phosphatidylinositol 4-phosphate 5-kinase its3 and calcineurin Ppb1 coordinately regulate cytokinesis in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; ALPHA-ACTININ; KINASE; 4,5-BISPHOSPHATE; PROTEIN; ORGANIZATION; PHOSPHATASE; EXPRESSION; INTEGRITY	The ppb1(+) gene encodes a fission yeast homologue of the mammalian calcineurin. We have recently shown that Ppb1 is essential for chloride ion homeostasis, and acts antagonistically with Pmk1 mitogen-activated protein kinase pathway. In an attempt to identify genes that share an essential function with calcineurin, we screened for mutations that confer sensitivity to the calcineurin inhibitor FR506 and high temperature, and isolated a mutant, its3-1. its3(+) was shown to be an essential gene encoding a functional homologue of phosphatidylinositol-4-phosphate 5-kinase (PI(4)P5K), The temperature:upshift or addition of FK506 induced marked disorganization of actin patches and dramatic increase in the frequency of septation in the its3-1 mutants but not in: the wild-type cells. Expression of a green fluorescent protein-tagged Its3 and the phospholipase C delta pleckstrin homology domain indicated plasma membrane localization of PI(4)P5K and phosphatidylinositol 4,5-bisphosphate. These green fluorescent protein-tagged proteins were concentrated at the septum of dividing cells, and the mutant Its3 was no longer localized to the plasma membrane. These data suggest that fission yeast PI(4)P5K Its3 functions coordinately with calcineurin and plays a key role in cytokinesis, and that the plasma membrane localization of Its3 is the crucial event in:cytokinesis.	Kobe Univ, Sch Med, Dept Pharmacol, Chuo Ku, Kobe, Hyogo 6500017, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Tokyo 1088639, Japan; Kobe Univ, Sch Med, Fac Hlth Sci, Kobe, Hyogo 6540142, Japan	Kobe University; University of Tokyo; Kobe University	Kuno, T (corresponding author), Kobe Univ, Sch Med, Dept Pharmacol, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	tkuno@kobe-u.ac.jp						Balasubramanian MK, 1997, METHOD ENZYMOL, V283, P494; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; HELM R, 1995, NATURE, V373, P663; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Itoh T, 1998, J BIOL CHEM, V273, P20292, DOI 10.1074/jbc.273.32.20292; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JOCHOVA J, 1991, CELL BIOL INT REP, V15, P607, DOI 10.1016/0309-1651(91)90007-6; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; MARKS J, 1986, J CELL SCI, P229; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; PLOCHOCKAZULINSKA D, 1995, J BIOL CHEM, V270, P24794, DOI 10.1074/jbc.270.42.24794; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Robinson LC, 1999, MOL BIOL CELL, V10, P1077, DOI 10.1091/mbc.10.4.1077; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Sugiura R, 1999, NATURE, V399, P479, DOI 10.1038/20951; Sugiura R, 1998, EMBO J, V17, P140, DOI 10.1093/emboj/17.1.140; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toda T, 1996, MOL CELL BIOL, V16, P6752; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Vancurova I, 1999, J BIOL CHEM, V274, P1147, DOI 10.1074/jbc.274.2.1147; YOSHIDA T, 1994, J CELL SCI, V107, P1725	35	82	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35600	35606		10.1074/jbc.M005575200	http://dx.doi.org/10.1074/jbc.M005575200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10950958	hybrid			2022-12-27	WOS:000165422800101
J	Komatsu, S; Yano, T; Shibata, M; Tuft, RA; Ikebe, M				Komatsu, S; Yano, T; Shibata, M; Tuft, RA; Ikebe, M			Effects of the regulatory light chain phosphorylation of myosin II on mitosis and cytokinesis of mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PROTEIN KINASE-C; MITOTIC SPINDLE; MONOCLONAL-ANTIBODY; CLEAVAGE FURROW; CULTURED-CELLS; SURFACE IG; ACTIN; DICTYOSTELIUM; DISRUPTION	Myosin plays an important role in mitosis, especially during cytokinesis. Although it has been assumed that phosphorylation of regulatory light chain of myosin (RLC) controls motility of mammalian non-muscle cells, the functional significance of RLC phosphorylation remains uninvestigated. To address this problem, we have produced unphosphorylatable RLC (T18A/S19A RLC) and overexpressed it in COS-7 cells and normal rat kidney cells. Overexpression of T18A/S19A RLC but not wild type RLC almost completely abolished concanavalin A-induced receptor cap formation. The results indicate that myosin phosphorylation is critical for concanavalin A-induced gathering of surface receptors, T18A/S19A RLC overexpression resulted in the production of multinucleated cells, suggesting the failure of proper cell division in these cells. Video microscopic observation revealed that cells expressing T18A/S19A RLC showed abnormalities during mitosis in two respects. One is that the cells produced abnormal cleavage furrows, resulting in incomplete cytokinesis, which suggests that myosin phosphorylation is important for the normal recruitment of myosin molecules into the contractile ring structure. The other is that separation of chromosomes from the metaphase plate is disrupted in T18A/S19A RLC expressing cells, thus preventing proper transition hom metaphase to anaphase, These results suggest that, in addition to cytokinesis, myosin and myosin phosphorylation play a role in the karyokinetic process.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Biomed Imaging Grp, Worcester, MA 01655 USA; Med & Biol Labs, Nagano 396, Japan	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA.	mitsuo.ikebe@umassmed.edu			NHLBI NIH HHS [HL60831, HL56218] Funding Source: Medline; NIAMS NIH HHS [AR41653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056218, R01HL060831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; AUBIN JE, 1979, EXP CELL RES, V124, P93, DOI 10.1016/0014-4827(79)90260-X; BENGUR AR, 1987, J BIOL CHEM, V262, P7613; BOURGUIGNON LYW, 1980, CELL BIOL INT REP, V4, P541, DOI 10.1016/0309-1651(80)90019-3; BOURGUIGNON LYW, 1978, J CELL PHYSIOL, V95, P239, DOI 10.1002/jcp.1040950302; BOURGUIGNON LYW, 1977, P NATL ACAD SCI USA, V74, P5031, DOI 10.1073/pnas.74.11.5031; BOURGUIGNON LYW, 1981, J CELL BIOL, V91, P889, DOI 10.1083/jcb.91.3.889; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; CHEN PX, 1994, J CELL BIOL, V127, P1933, DOI 10.1083/jcb.127.6.1933; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; CONDEELIS J, 1979, J CELL BIOL, V80, P751, DOI 10.1083/jcb.80.3.751; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; EDELMAN AM, 1990, MOL CELL BIOCHEM, V97, P87; FISHKIND DJ, 1991, J CELL BIOL, V114, P967, DOI 10.1083/jcb.114.5.967; FLANAGAN J, 1978, NATURE, V273, P278, DOI 10.1038/273278a0; FUJIWARA K, 1976, J CELL BIOL, V71, P848, DOI 10.1083/jcb.71.3.848; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; HIGHASHIHARA M, 1989, J BIOL CHEM, V264, P5218; IKEBE M, 1987, J BIOL CHEM, V262, P9569; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; Jordan P, 1997, J CELL BIOL, V139, P1805, DOI 10.1083/jcb.139.7.1805; KAMISOYAMA H, 1994, BIOCHEMISTRY-US, V33, P840, DOI 10.1021/bi00169a027; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; Komatsu S, 1996, BIOCHEM BIOPH RES CO, V223, P741, DOI 10.1006/bbrc.1996.0966; KORN ED, 1978, P NATL ACAD SCI USA, V75, P588, DOI 10.1073/pnas.75.2.588; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MABUCHI I, 1986, INT REV CYTOL, V101, P175, DOI 10.1016/S0074-7696(08)60249-1; MABUCHI I, 1977, J CELL BIOL, V74, P251, DOI 10.1083/jcb.74.1.251; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; MAUPIN P, 1986, J ULTRA MOL STRUCT R, V94, P92, DOI 10.1016/0889-1605(86)90055-8; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8808; OSTROW BD, 1994, J CELL BIOL, V127, P1945, DOI 10.1083/jcb.127.6.1945; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; POLLARD TD, 1990, ANN NY ACAD SCI, V582, P120; Salmon ED, 1989, CURR OPIN CELL BIOL, V1, P541, DOI 10.1016/0955-0674(89)90018-5; SANGER JM, 1989, CELL MOTIL CYTOSKEL, V14, P201, DOI 10.1002/cm.970140207; SCHREINER GF, 1977, J EXP MED, V145, P1393, DOI 10.1084/jem.145.5.1393; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; Shuster CB, 1999, J CELL BIOL, V146, P981, DOI 10.1083/jcb.146.5.981; Simerly C, 1998, MOL BIOL CELL, V9, P2509, DOI 10.1091/mbc.9.9.2509; Smith JL, 1996, P NATL ACAD SCI USA, V93, P12321, DOI 10.1073/pnas.93.22.12321; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; VALERIUS NH, 1981, CELL, V24, P195, DOI 10.1016/0092-8674(81)90515-8; WILSON AK, 1991, J CELL BIOL, V114, P277, DOI 10.1083/jcb.114.2.277; YAMAKITA Y, 1994, J CELL BIOL, V124, P129, DOI 10.1083/jcb.124.1.129; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016; YANO T, 1991, BIOCHEM BIOPH RES CO, V175, P1144, DOI 10.1016/0006-291X(91)91685-6; ZIGMOND SH, 1972, EXP CELL RES, V73, P383, DOI 10.1016/0014-4827(72)90062-6	54	88	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34512	34520		10.1074/jbc.M003019200	http://dx.doi.org/10.1074/jbc.M003019200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944522	hybrid			2022-12-27	WOS:000165095300070
J	Kusmierczyk, AR; Martin, J				Kusmierczyk, AR; Martin, J			High salt-induced conversion of Escherichia coli GroEL into a fully functional thermophilic chaperonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; CRYSTAL-STRUCTURE; HYDROPHOBIC SURFACES; ATPASE ACTIVITY; CENTRAL CAVITY; ALPHA-LACTALBUMIN; BINDING; HYDROLYSIS; PURIFICATION; INTERMEDIATE	The GroE chaperonin system can adapt to and function at various environmental folding conditions. To examine chaperonin-assisted protein folding at high salt concentrations, we characterized Escherichia coli GroE chaperonin activity in 1.2 M ammonium sulfate, Our data are consistent with GroEL undergoing a conformational change at this salt concentration, characterized by elevated ATPase activity and increased exposure of hydrophobic surface, as indicated by increased binding of the fluorophore bis-(5,5')-8-anilino-1-naphthalene sulfonic acid to the chaperonin, The presence of the salt results in increased substrate stringency and dependence on the full GroE system for release and productive folding of substrate proteins. Surprisingly, GroEL is fully functional as a thermophilic chaperonin in high concentrations of ammonium sulfate and is stable at temperatures up to 75 degreesC, At these extreme conditions, GroEL can suppress aggregation and mediate refolding of non-native proteins.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA	Brown University	Martin, J (corresponding author), Brown Univ, Dept Mol Biol Cell Biol & Biochem, Box G-J2, Providence, RI 02912 USA.			Kusmierczyk, Andrew/0000-0001-6363-7437	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054534] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54534] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andra S, 1998, EUR J BIOCHEM, V255, P93, DOI 10.1046/j.1432-1327.1998.2550093.x; BOHNERT JL, 1982, BIOCHEMISTRY-US, V21, P5570, DOI 10.1021/bi00265a029; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; Brazil BT, 1998, J BIOL CHEM, V273, P3257, DOI 10.1074/jbc.273.6.3257; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; Clark AC, 1998, METHOD ENZYMOL, V290, P100; Cliff MJ, 1999, J MOL BIOL, V293, P667, DOI 10.1006/jmbi.1999.3138; DESCHAMPS JR, 1995, PROTEIN EXPRES PURIF, V6, P555, DOI 10.1006/prep.1995.1073; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FREIFELDER D, 1982, BIOPHYSICAL CHEM APP, pCH15; Furutani M, 1998, J BIOL CHEM, V273, P28399, DOI 10.1074/jbc.273.43.28399; GIBBONS DL, 1995, J BIOL CHEM, V270, P7335, DOI 10.1074/jbc.270.13.7335; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; Gutsche I, 2000, CURR BIOL, V10, P405, DOI 10.1016/S0960-9822(00)00421-8; Gutsche I, 1999, J MOL BIOL, V293, P295, DOI 10.1006/jmbi.1999.3008; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENSEL R, 1988, FEMS MICROBIOL LETT, V49, P75, DOI 10.1111/j.1574-6968.1988.tb02685.x; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LUO GX, 1994, J BIOL CHEM, V269, P32151; Ma JP, 1998, P NATL ACAD SCI USA, V95, P8502, DOI 10.1073/pnas.95.15.8502; Makino Y, 1997, J BIOL CHEM, V272, P12468, DOI 10.1074/jbc.272.19.12468; Martin J, 1998, J BIOL CHEM, V273, P7351, DOI 10.1074/jbc.273.13.7351; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Mendoza JA, 1996, BIOCHEM BIOPH RES CO, V229, P271, DOI 10.1006/bbrc.1996.1791; Minuth T, 1998, EUR J BIOCHEM, V258, P837, DOI 10.1046/j.1432-1327.1998.2580837.x; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Perrett S, 1997, J MOL BIOL, V269, P892, DOI 10.1006/jmbi.1997.1081; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SEALE JW, 1995, BIOCHEMISTRY-US, V34, P7443, DOI 10.1021/bi00022a018; TAKII Y, 1992, APPL MICROBIOL BIOT, V38, P243, DOI 10.1007/BF00174476; TIMASHEFF SN, 1997, PROTEIN STRUCTURE PR, pCH14; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Yifrach O, 2000, P NATL ACAD SCI USA, V97, P1521, DOI 10.1073/pnas.040449997	54	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33504	33511		10.1074/jbc.M006256200	http://dx.doi.org/10.1074/jbc.M006256200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10945996	hybrid, Green Published			2022-12-27	WOS:000090104600046
J	Mizushina, Y; Kamisuki, S; Mizuno, T; Takemura, M; Asahara, H; Linn, S; Yamaguchi, T; Matsukage, A; Hanaoka, F; Yoshida, S; Saneyoshi, M; Sugawara, F; Sakaguchi, K				Mizushina, Y; Kamisuki, S; Mizuno, T; Takemura, M; Asahara, H; Linn, S; Yamaguchi, T; Matsukage, A; Hanaoka, F; Yoshida, S; Saneyoshi, M; Sugawara, F; Sakaguchi, K			Dehydroaltenusin, a mammalian DNA polymerase alpha inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE-THYMINE DIMER; PRIMASE COMPLEX; SELECTIVE-INHIBITION; ESCHERICHIA-COLI; 4 SUBUNITS; MOUSE; CELLS; BETA; PURIFICATION; REPLICATION	Dehydroaltenusin was found to be an inhibitor of mammalian DNA polymerase alpha (pol alpha) in vitro. Surprisingly, among the polymerases and DNA metabolic enzymes tested, dehydroaltenusin inhibited only mammalian pol alpha. Dehydroaltenusin did not influence the activities of the other replicative DNA polymerases, such as delta and epsilon; it also showed no effect even on the pol alpha activity from another vertebrate (fish) or plant species. The inhibitory effect of dehydroaltenusin on mammalian pol alpha was dose-dependent, and 50% inhibition was observed at a concentration of 0.5 muM. Dehydroaltenusin-induced inhibition of mammalian pol alpha activity was competitive with the template-primer and non-competitive with the dNTP substrate. BIAcore analysis demonstrated that dehydroaltenusin bound to the core domain of the largest subunit, p180, of mouse pol alpha, which has catalytic activity, but did not bind to the smallest subunit or the DNA primase p46 of mouse pol alpha. These results suggest that the dehydroaltenusin molecule competes with the template primer molecule on its binding site of the catalytic domain of mammalian pol alpha, binds to the site, and simultaneously disturbs dNTP substrate incorporation into the template-primer.	Sci Univ Tokyo, Dept Appl Biol Sci, Noda, Chiba 2788510, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Nagoya Univ, Sch Med, Res Inst Dis Mechanism & Control, Lab Canc Cell Biol, Nagoya, Aichi 4668550, Japan; Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA; Teikyo Univ Sci & Technol, Dept Biol Sci, Yamanashi 4090193, Japan; Japan Womens Univ, Dept Chem & Biol Sci, Bunkyo Ku, Tokyo 1128681, Japan	Tokyo University of Science; RIKEN; Nagoya University; University of California System; University of California Berkeley; Japan Womens University	Sakaguchi, K (corresponding author), Sci Univ Tokyo, Dept Appl Biol Sci, Noda, Chiba 2788510, Japan.							CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; Chui GSJ, 1995, METHOD ENZYMOL, V262, P93; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; COPELAND WC, 1993, J BIOL CHEM, V268, P26179; DATE T, 1988, BIOCHEMISTRY-US, V27, P2983, DOI 10.1021/bi00408a048; DEPAMPHILIS ML, 1996, DNA REPLICATION EUKA, P461; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KOIZUMI KT, 1997, BIOCHEM MOL BIOL INT, V41, P1179; KORNBERG A, 1992, DNA REPLICATION, P197; LU BC, 1991, J BIOL CHEM, V266, P21060; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; Mizuno T, 1999, MOL CELL BIOL, V19, P7886; Mizuno T, 1996, J CELL SCI, V109, P2627; Mizushina Y, 1999, J BIOL CHEM, V274, P25599, DOI 10.1074/jbc.274.36.25599; Mizushina Y, 1998, BIOCHEM J, V330, P1325, DOI 10.1042/bj3301325; Mizushina Y, 1997, BBA-GEN SUBJECTS, V1336, P509, DOI 10.1016/S0304-4165(97)00067-6; Mizushina Y, 1996, BBA-GENE STRUCT EXPR, V1308, P256, DOI 10.1016/0167-4781(96)00121-2; NAKANISHI S, 1995, BIOSCI BIOTECH BIOCH, V59, P1333, DOI 10.1271/bbb.59.1333; NAKAYAMA C, 1985, J BIOCHEM-TOKYO, V97, P1385, DOI 10.1093/oxfordjournals.jbchem.a135192; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; OGURO M, 1979, EUR J BIOCHEM, V97, P603, DOI 10.1111/j.1432-1033.1979.tb13149.x; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; SAKAGUCHI K, 1980, CELL STRUCT FUNCT, V5, P323, DOI 10.1247/csf.5.323; SHOJIKAWAGUCHI M, 1995, J BIOCHEM-TOKYO, V117, P1095, DOI 10.1093/oxfordjournals.jbchem.a124812; SO AG, 1992, CRIT REV BIOCHEM MOL, V27, P129, DOI 10.3109/10409239209082561; SOLTIS DA, 1982, J BIOL CHEM, V257, P1332; SUZUKI M, 1989, J BIOL CHEM, V264, P10065; TAKADATAKAYAMA R, 1990, BIOCHEM BIOPH RES CO, V170, P589, DOI 10.1016/0006-291X(90)92132-J; TAMAI K, 1988, BIOCHIM BIOPHYS ACTA, V950, P263, DOI 10.1016/0167-4781(88)90122-4; THOMAS R, 1971, J CHEM SOC CHEM COMM, V8, P393; Tomikawa A, 1998, NUCLEOS NUCLEOT NUCL, V17, P487, DOI 10.1080/07328319808005193; Ueno T, 2000, BIOCHEMISTRY-US, V39, P5995, DOI 10.1021/bi992661i	35	58	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33957	33961		10.1074/jbc.M006096200	http://dx.doi.org/10.1074/jbc.M006096200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10942777	hybrid			2022-12-27	WOS:000090104600107
J	Bhakta, S; Bartes, A; Bowman, KG; Kao, WM; Polsky, I; Lee, JK; Cook, BN; Bruehl, RE; Rosen, SD; Bertozzi, CR; Hemmerich, S				Bhakta, S; Bartes, A; Bowman, KG; Kao, WM; Polsky, I; Lee, JK; Cook, BN; Bruehl, RE; Rosen, SD; Bertozzi, CR; Hemmerich, S			Sulfation of N-acetylglucosamine by chondroitin 6-sulfotransferase 2 (GST-5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-SELECTIN LIGAND; SIALYL-LEWIS-X; MOLECULAR-CLONING; CARBOHYDRATE SULFOTRANSFERASES; RESPIRATORY MUCINS; KERATAN SULFATE; EXPRESSION; OLIGOSACCHARIDES; ROLES; IDENTIFICATION	Based on sequence homology with a previously cloned human GlcNAc 6-O-sulfotransferase, we have identified an open reading frame (ORF) encoding a novel member of the Gal/GalNAc/GlcNAc 6-O-sulfotransferase (GST) family termed GST-5 on the human X chromosome (band Xp11). GST-5 has recently been characterized as a novel GalNAc 6-O-sulfotransferase termed chondroitin 6-sulfotransferase-2 (Kitagawa, H., Fujita, M,, Itio, N., and Sugahara K, (2000) J. Biol Chem. 275, 21075-21080), We have coexpressed a human GST-5 cDNA with a GlyCAM-1/IgG fusion protein in COS-7 cells and observed fourfold enhanced [S-35]sulfate incorporation into this mucin acceptor. All mucin-associated [S-35]sulfate was incorporated as GlcNAc-6-sulfate or Gal beta1-->4GlcNAc-6-sulfate. GST-5 was also expressed in soluble epitope-tagged form and found to catalyze 6-O-sulfation of GlcNAc residues in synthetic acceptor structures. In particular, GST-B was found to catalyze 6-O-sulfation of beta -benzyl GlcNAc but not alpha- or beta -benzyl GalNAc, In the mouse genome we have found a homologous ORF that predicts a novel murine GlcNAc 6-O-sulfotransferase with 88% identity to the human enzyme. This gene was mapped to mouse chromosome X at band XA3.1-3.2. GST-5 is the newest member of an emerging family of carbohydrate 6-O-sulfotransferases that includes chondroitin g-sulfotransferase (GST-0), keratan-sulfate galactose 6-O-sulfotransferase (GST-1), the ubiquitously expressed GlcNAc 6-O-sulfotransferase (GST-S), high endothelial cell GlcNAc 6-O-sulfotransferase (GST-3), and intestinal GlcNAc 6-O-sulfotransferase (GST-4),	Roche Biosci, Dept Resp Dis, Palo Alto, CA 94304 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Immunol, San Francisco, CA 94143 USA	Roche Holding; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hemmerich, S (corresponding author), Thios Biotechnol, 828 Clayton St, San Francisco, CA 94117 USA.	stefan@thiosbiotech.com		Bowman, Kendra/0000-0002-0562-589X; Rosen, Steven/0000-0002-6245-701X	NIGMS NIH HHS [R01GM5741, R01GM59907-01, R37GM23547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059907, R37GM023547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Blake JA, 2000, NUCLEIC ACIDS RES, V28, P108, DOI 10.1093/nar/28.1.108; Bowman KG, 1999, CHEM BIOL, V6, pR9, DOI 10.1016/S1074-5521(99)80014-3; Bowman KG, 1998, CHEM BIOL, V5, P447, DOI 10.1016/S1074-5521(98)90161-2; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Carrel L, 1999, P NATL ACAD SCI USA, V96, P14440, DOI 10.1073/pnas.96.25.14440; Cook BN, 2000, J AM CHEM SOC, V122, P8612, DOI 10.1021/ja001224k; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Fukuda M, 1999, J CELL BIOL, V147, P467, DOI 10.1083/jcb.147.3.467; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1998, BBA-GENE STRUCT EXPR, V1399, P57, DOI 10.1016/S0167-4781(98)00089-X; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; Gleeson PA, 1998, HISTOCHEM CELL BIOL, V109, P517, DOI 10.1007/s004180050252; Grabenhorst E, 1999, J BIOL CHEM, V274, P36107, DOI 10.1074/jbc.274.51.36107; Habuchi O, 1996, GLYCOBIOLOGY, V6, P51, DOI 10.1093/glycob/6.1.51; Habuchi O, 1997, GLYCOBIOLOGY, V7, P405, DOI 10.1093/glycob/7.3.405; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hemmerich S, 2000, GLYCOBIOLOGY, V10, P849, DOI 10.1093/glycob/10.9.849; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Hooper LV, 1996, FASEB J, V10, P1137, DOI 10.1096/fasebj.10.10.8751716; IOANNOU PA, 1999, CURRENT PROTOCOLS HU; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; Kitagawa H, 2000, J BIOL CHEM, V275, P21075, DOI 10.1074/jbc.M002101200; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; Li XA, 1999, GENOMICS, V55, P345, DOI 10.1006/geno.1998.5653; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; LoGuidice JM, 1997, GLYCOCONJUGATE J, V14, P113, DOI 10.1023/A:1018525318185; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Nelson RM, 1995, ANNU REV CELL DEV BI, V11, P601, DOI 10.1146/annurev.cellbio.11.1.601; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; ROSEN SD, 1999, OLIGOSACCHARIDES CHE, V2, P245; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Spiro RG, 1996, BIOCHEM J, V319, P209, DOI 10.1042/bj3190209; Uchimura K, 2000, BIOCHEM BIOPH RES CO, V274, P291, DOI 10.1006/bbrc.2000.3141; Uchimura K, 1998, GLYCOBIOLOGY, V8, P489, DOI 10.1093/glycob/8.5.489; Uchimura K, 1998, J BIOCHEM-TOKYO, V124, P670, DOI 10.1093/oxfordjournals.jbchem.a022164; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181	43	31	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40226	40234		10.1074/jbc.M006414200	http://dx.doi.org/10.1074/jbc.M006414200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10956661	hybrid			2022-12-27	WOS:000166039500060
J	Fowler, SJ; Jose, S; Zhang, XM; Deutzmann, R; Sarras, MP; Boot-Handford, RP				Fowler, SJ; Jose, S; Zhang, XM; Deutzmann, R; Sarras, MP; Boot-Handford, RP			Characterization of hydra type IV collagen - Type IV collagen is essential for head regeneration and its expression is up-regulated upon exposure to glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; EXTRACELLULAR-MATRIX MESOGLEA; AMINO-ACID SEQUENCE; STRUCTURAL ORGANIZATION; CAENORHABDITIS-ELEGANS; ALPHA-2(IV) COLLAGEN; CHAIN; GENE; LAMININ; IDENTIFICATION	Hydra vulgaris mesoglea is a primitive basement membrane that also exhibits some features of an interstitial matrix. We have characterized cDNAs that encode the full-length hydra alpha1(IV) chain. The 5169-base pair transcript encodes a protein of 1723 amino acids, including an interrupted 1455-residue collagenous domain and a 228-residue C-terminal noncollagenous domain. N-terminal sequence analyses of collagen IV peptides suggest the molecule is homotrimeric. Denatured hydra type IV collagen protein occurs as dimers and higher order aggregates held together by nonreducible cross-links. Hydra collagen TV exhibits no functional evidence for the presence of a 7 S domain. Type TV collagen is expressed by the ectoderm along the entire longitudinal axis of the animal but is most intense at the base of the tentacles at the site of battery cell transdifferentiation. Antisense studies show that inhibition of collagen IV translation causes a blockage in head regeneration, indicating its importance in normal hydra development. Exposure of adult hydra to 15 mm glucose resulted in up-regulation of type IV collagen mRNA levels within 48 h and significant thickening of the mesoglea within 14 days, suggesting that basement membrane thickening seen in diabetes may be, in evolutionary terms, an ancient glucose-mediated response.	Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; Univ Regensburg, Inst Biochem 1, D-8400 Regensburg, Germany; SW Missouri State Univ, Dept Biomed Sci, Springfield, MO 65804 USA	University of Manchester; University of Kansas; University of Kansas Medical Center; University of Regensburg; Missouri State University	Boot-Handford, RP (corresponding author), Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Sch Biol Sci, 2-205 Stopford, Manchester M13 9PT, Lancs, England.			Boot-Handford, Raymond/0000-0002-6167-8419	NIDDK NIH HHS [DK47840] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047840] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGOSTI CG, 1991, CELL MOTIL CYTOSKEL, V20, P215, DOI 10.1002/cm.970200305; BARZANSKY B, 1974, AM ZOOL, V14, P575; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; BOOTHANDFORD RP, 1987, J BIOL CHEM, V262, P12475; Boute N, 1996, BIOL CELL, V88, P37, DOI 10.1016/S0248-4900(97)86829-3; BRAZEL D, 1987, EUR J BIOCHEM, V168, P529, DOI 10.1111/j.1432-1033.1987.tb13450.x; BURNETT AL, 1969, J EXP ZOOL, V171, P15, DOI 10.1002/jez.1401710104; DAY RM, 1981, SCIENCE, V211, P291, DOI 10.1126/science.7444468; Deutzmann R, 2000, DEVELOPMENT, V127, P4669; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; EXPOSITO JY, 1993, J BIOL CHEM, V268, P5249; EXPOSITO JY, 1994, J BIOL CHEM, V269, P13167; FAWCETT DW, 1961, BIOL HYDRA SOME OTHE, P65; Flanagan WM, 1996, NUCLEIC ACIDS RES, V24, P2936, DOI 10.1093/nar/24.15.2936; Graham PL, 1997, J CELL BIOL, V137, P1171, DOI 10.1083/jcb.137.5.1171; Grens A, 1999, DEVELOPMENT, V126, P517; Grens A, 1995, DEVELOPMENT, V121, P4027; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; HAUSMAN RE, 1971, J EXP ZOOL, V177, P435, DOI 10.1002/jez.1401770405; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; JOHANSSON C, 1992, J BIOL CHEM, V267, P24533; KUHN K, 1994, MATRIX BIOL, V14, P439; LEINONEN A, 1994, J BIOL CHEM, V269, P26172; Leontovich AA, 2000, DEVELOPMENT, V127, P907; NOELKEN ME, 1986, J BIOL CHEM, V261, P4706; OBERBAUMER I, 1985, EUR J BIOCHEM, V147, P217, DOI 10.1111/j.1432-1033.1985.tb08739.x; PETTITT J, 1991, J BIOL CHEM, V266, P16149; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; SARRAS MP, 1991, DEV BIOL, V148, P495, DOI 10.1016/0012-1606(91)90267-7; SARRAS MP, 1991, DEV BIOL, V148, P481, DOI 10.1016/0012-1606(91)90266-6; SARRAS MP, 1994, DEV BIOL, V164, P312, DOI 10.1006/dbio.1994.1201; SHOSTAK S, 1965, DEV BIOL, V12, P434, DOI 10.1016/0012-1606(65)90008-4; SIBLEY MH, 1993, J CELL BIOL, V123, P255, DOI 10.1083/jcb.123.1.255; SIMONASSMANN P, 1995, EXPERIENTIA, V51, P883, DOI 10.1007/BF01921739; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAGNER RW, 1995, NAT MED, V1, P1116, DOI 10.1038/nm1195-1116; Yan L, 2000, DEV BIOL, V219, P115, DOI 10.1006/dbio.1999.9568; Yan L, 2000, DEVELOPMENT, V127, P129; YURCHENCO PD, 1990, ANN NY ACAD SCI, V580, P195, DOI 10.1111/j.1749-6632.1990.tb17929.x; ZHANG X, 1990, DIABETOLOGIA, V33, P704, DOI 10.1007/BF00400573; ZHANG XM, 1994, DEVELOPMENT, V120, P425	41	53	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39589	39599		10.1074/jbc.M005871200	http://dx.doi.org/10.1074/jbc.M005871200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10956657	hybrid			2022-12-27	WOS:000165953100085
J	Dutta, R; Yoshida, T; Inouye, M				Dutta, R; Yoshida, T; Inouye, M			The critical role of the conserved Thr(247) residue in the functioning of the osmosensor EnvZ, a histidine kinase/phosphatase, in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 REGULATORY PROTEINS; PORIN GENE-EXPRESSION; SIGNAL-TRANSDUCTION; PHOSPHATASE-ACTIVITIES; OMPC GENES; OSMOREGULATORY EXPRESSION; TRANSCRIPTIONAL ACTIVATOR; TRANSMEMBRANE RECEPTOR; BACTERIAL CHEMOTAXIS; PHOSPHORYLATION	The histidine kinase/phosphatase EnvZ helps Escherichia coli adapt to osmotic-shock by controlling the phosphorylation state of the transcription factor OmpR, which regulates the levels of the outer membrane porin proteins OmpF and OmpC. We examined the effects of mutating the highly conserved Thr(247) residue in EnvZ, Using purified C-terminal domains of wild-type and mutant EnvZ proteins, we demonstrate that Thr(247) plays a vital role in EnvZ function, variously affecting its autokinase and phosphotransferase activities, but mostly its function as a phosphatase, The cytoplasmic domain of EnvZ (EnvZc) is composed of three segments: the Linker domain (residues 180-222), domain A (residues 223-289), and domain B (residues 290-450), It has been shown that the isolated domain A itself can dephosphorylate phosphorylated OmpR. Here we show that mutating Thr247 to Arg in domain A abolishes its phosphatase activity. Furthermore, using an in vivo beta -galactosidase activity assay of Taz1-1 (hybrid of the aspartate receptor Tar and EnvZ) constructs of the Thr(247) mutants in RU1012 cells expressing ompC-lacZ, we demonstrate that the external signal primarily down-regulates the phosphatase activity of EnvZ, Of the nine EnvZc(T247X) mutants (X = Ser, Ale, Cys, Lys, Asn, Glu, Gin, Tyr, or Arg) analyzed, only Ser functionally substituted for Thr at this position, whereas all the others displayed constitutive expression of beta -galactosidase.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.			Yoshida, Takeshi/0000-0003-0133-5067	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019043, R01GM019043] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19043] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOL CHEM, V264, P14090; AIBA H, 1989, J BIOL CHEM, V264, P8563; Arnez JG, 1998, PROTEINS, V32, P362; DELGADO J, 1993, MOL MICROBIOL, V10, P1037, DOI 10.1111/j.1365-2958.1993.tb00974.x; Dutta R, 1996, J BIOL CHEM, V271, P1424, DOI 10.1074/jbc.271.3.1424; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Dutta R, 1999, MOL MICROBIOL, V34, P633, DOI 10.1046/j.1365-2958.1999.01646.x; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; FERSHT A, 1999, STRUCTURE EMCH PROTE, P84; FORST S, 1988, J BACTERIOL, V170, P5080, DOI 10.1128/jb.170.11.5080-5085.1988; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; FORST SA, 1994, RES MICROBIOL, V145, P363, DOI 10.1016/0923-2508(94)90083-3; Grebe TW, 1999, ADV MICROB PHYSIOL, V41, P139, DOI 10.1016/S0065-2911(08)60167-8; HALL MN, 1981, J MOL BIOL, V151, P1, DOI 10.1016/0022-2836(81)90218-7; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Hsing WH, 1998, J BACTERIOL, V180, P4538, DOI 10.1128/JB.180.17.4538-4546.1998; IGO MM, 1988, J BACTERIOL, V170, P5971, DOI 10.1128/jb.170.12.5971-5973.1988; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; Jiang P, 2000, BIOCHEMISTRY-US, V39, P5057, DOI 10.1021/bi992921w; JIN T, 1993, J MOL BIOL, V232, P484, DOI 10.1006/jmbi.1993.1404; Kramer G, 1999, P NATL ACAD SCI USA, V96, P604, DOI 10.1073/pnas.96.2.604; Loomis WF, 1998, CURR OPIN MICROBIOL, V1, P643, DOI 10.1016/S1369-5274(98)80109-4; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MATSUYAMA SI, 1986, J BACTERIOL, V168, P1309, DOI 10.1128/jb.168.3.1309-1314.1986; MILLER F, 1972, IMMUNOCHEMISTRY, V9, P217, DOI 10.1016/0019-2791(72)90087-0; MIZUNO T, 1987, J BIOCHEM-TOKYO, V101, P387, DOI 10.1093/oxfordjournals.jbchem.a121923; Park H, 1997, J BACTERIOL, V179, P4382, DOI 10.1128/jb.179.13.4382-4390.1997; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Pratt L., 1995, 2 COMPONENT SIGNAL T, P105; RAMPERSAUD A, 1991, J BIOL CHEM, V266, P7633; ROBERTS DL, 1994, J BIOL CHEM, V269, P8728; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; SARMA V, 1977, J BACTERIOL, V132, P23, DOI 10.1128/JB.132.1.23-27.1977; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Skarphol K, 1997, J BACTERIOL, V179, P1413, DOI 10.1128/jb.179.4.1413-1416.1997; SLAUCH JM, 1989, J MOL BIOL, V210, P281, DOI 10.1016/0022-2836(89)90330-6; STOCK A, 1988, P NATL ACAD SCI USA, V85, P1403, DOI 10.1073/pnas.85.5.1403; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; WANDERSMAN C, 1980, J BACTERIOL, V143, P1374, DOI 10.1128/JB.143.3.1374-1383.1980; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057; Zhu Y, 2000, P NATL ACAD SCI USA, V97, P7808, DOI 10.1073/pnas.97.14.7808	52	58	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38645	38653		10.1074/jbc.M005872200	http://dx.doi.org/10.1074/jbc.M005872200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10973966	hybrid			2022-12-27	WOS:000165739800069
J	Harada, A; Furuta, B; Takeuchi, K; Itakura, M; Takahashi, M; Umeda, M				Harada, A; Furuta, B; Takeuchi, K; Itakura, M; Takahashi, M; Umeda, M			Nadrin, a novel neuron-specific GTPase-activating protein involved in regulated exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILIZED MAST-CELLS; CHROMAFFIN CELLS; BINDING PROTEINS; PC12 CELLS; CA2+-DEPENDENT EXOCYTOSIS; ACTIN CYTOSKELETON; SYNAPTIC VESICLES; RHO-GDI; ORGANIZATION; DOMAIN	It has been proposed that the cortical actin filament networks act as a cortical barrier that must be reorganized to enable docking and fusion of the synaptic vesicles with the plasma membranes, We identified a novel neuron-associated developmentally regulated protein, designated as Nadrin, Expression of Nadrin is restricted to neurons and correlates well with the differentiation of neurons, Nadrin has a unique structure; it contains a GTPase-activating protein (GAP) domain for Rho family GTPases, a potential coiled-coil domain, and a succession of 29 glutamines, In vitro the GAP domain activates RhoA, Rac1, and Cdc42 GTPases, Expression of Nadrin in NIH3T3 cells markedly reduced the number of the actin stress fibers and the formation of the ruffled membranes, suggesting that Nadrin regulates actin filament reorganization. In PC12 cells, Nadrin colocalized with synaptotagmin in the neurite termini and also with cortical actin filaments in the subplasmalemmal regions, Expression of Nadrin or its mutant composed of the coiled-coil and GAP domain enhanced Ca2+-dependent exocytosis of PC12 cells, but a mutant lacking the GAP domain inhibited exocytosis, These results suggest that Nadrin plays a role in regulating Ca2+-dependent exocytosis, most likely by catalyzing GTPase activity of Rho family proteins and by inducing the reorganization of the cortical actin filaments.	Tokyo Metropolitan Inst Med Sci, Dept Mol Biodynam, Bunkyo Ku, Tokyo 1138613, Japan; Ochanomizu Univ, Fac Sci, Dept Biol, Bunkyo Ku, Tokyo 1128610, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan	Tokyo Metropolitan Institute of Medical Science; Ochanomizu University	Umeda, M (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Mol Biodynam, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P40; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Bernstein BW, 1998, MOL BRAIN RES, V53, P236, DOI 10.1016/S0169-328X(97)00319-7; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Brown AM, 1998, MOL BIOL CELL, V9, P1053, DOI 10.1091/mbc.9.5.1053; BURGOYNE RD, 1982, PROC R SOC SER B-BIO, V216, P111, DOI 10.1098/rspb.1982.0064; Calakos N, 1996, PHYSIOL REV, V76, P1; CASTICAS S, 1991, P NATL ACAD SCI U S, V88, P785; Chasserot-Golaz S, 1998, J NEUROCHEM, V70, P2347; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; Daly C, 1997, J NEUROSCI, V17, P2365; Emoto K, 1996, P NATL ACAD SCI USA, V93, P12867, DOI 10.1073/pnas.93.23.12867; Fernandez-Chacon R, 1999, ANNU REV PHYSIOL, V61, P753, DOI 10.1146/annurev.physiol.61.1.753; Gasman S, 1997, J BIOL CHEM, V272, P20564, DOI 10.1074/jbc.272.33.20564; Gasman S, 1998, J BIOL CHEM, V273, P16913, DOI 10.1074/jbc.273.27.16913; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harada A, 1999, J BIOCHEM, V125, P443, DOI 10.1093/oxfordjournals.jbchem.a022306; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Ikonomov OC, 1998, J NEUROSCI, V18, P6331; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Itakura M, 1999, BIOCHEM BIOPH RES CO, V265, P691, DOI 10.1006/bbrc.1999.1756; Kaneda M, 1997, J BIOCHEM-TOKYO, V122, P1233; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; Kozma R, 1996, MOL CELL BIOL, V16, P5069; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; LEE RWH, 1981, NEUROSCIENCE, V6, P2087, DOI 10.1016/0306-4522(81)90048-8; LEUNG T, 1993, J BIOL CHEM, V268, P3813; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LOU XJ, 1995, MOL CELL NEUROSCI, V6, P252, DOI 10.1006/mcne.1995.1020; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MIYAMOTO S, 1995, BIOCHIM BIOPHYS ACTA, V11, P85; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Muller RT, 1997, MOL BIOL CELL, V8, P2039, DOI 10.1091/mbc.8.10.2039; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; OSullivan AJ, 1996, MOL BIOL CELL, V7, P397, DOI 10.1091/mbc.7.3.397; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Seastone DJ, 1998, MOL BIOL CELL, V9, P2891, DOI 10.1091/mbc.9.10.2891; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; TAKAHASHI M, 1991, BRAIN RES, V551, P279, DOI 10.1016/0006-8993(91)90942-O; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tatsis N, 1998, J BIOL CHEM, V273, P34631, DOI 10.1074/jbc.273.51.34631; Trifaro JM, 1997, NEUROCHEM RES, V22, P831, DOI 10.1023/A:1022087910902; TRIFARO JM, 1993, TRENDS NEUROSCI, V16, P466, DOI 10.1016/0166-2236(93)90079-2; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; WICK PF, 1993, J BIOL CHEM, V268, P10983; Zhang L, 1996, NEURON, V17, P287, DOI 10.1016/S0896-6273(00)80160-9; ZHENG Y, 1993, J BIOL CHEM, V268, P24629	60	51	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36885	36891		10.1074/jbc.M004069200	http://dx.doi.org/10.1074/jbc.M004069200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967100	hybrid			2022-12-27	WOS:000165577700063
J	Reddy, MA; Prasadarao, NV; Wass, CA; Kim, KS				Reddy, MA; Prasadarao, NV; Wass, CA; Kim, KS			Phosphatidylinositol 3-kinase activation and interaction with focal adhesion kinase in Escherichia coli K1 invasion of human brain microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PROTEIN-A; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; LISTERIA-MONOCYTOGENES; INDUCED APOPTOSIS; COMMON THEMES; GENE LOCUS; CONTRIBUTES; OVEREXPRESSION; IDENTIFICATION	Invasion of brain microvascular endothelial cells (BMEC) is a prerequisite for successful crossing of the blood-brain barrier by Escherichia coli K1. We have previously demonstrated the requirement of cytoskeletal rearrangements and activation of focal adhesion kinase (FAK) in E. coli K1 invasion of human BMEC (HBMEC), The current study investigated the role of phosphatidylinositol S-kinase (PI3K) activation and PI3K interaction with FAR in E. coli invasion of HBMEC. PI3K inhibitor LY294002 blocked E. coli K1 invasion of HBMEC in a dose-dependent manner, whereas an inactive analogue LYS03511 had no such effect. In HBMEC, E, coli K1 increased phosphorylation of Akt, a downstream effector of PI3K, which was completely blocked by LY294002. In contrast, non-invasive E. coli failed to activate PI3K Overexpression of PI3K mutants Delta p85 and catalytically inactive p110 in HBMEC significantly inhibited both PI3K/Akt activation and E. coli gl invasion of HBMEC, Stimulation of HBMEC with E. coli K1 increased PI3K association with FAK. Furthermore, PI3K/Akt activation was blocked in HBMEC-overexpressing FAK dominant-negative mutants (FRNK and Phe397FAK). These results demonstrated the involvement of PI3K signaling in E. coli K1 invasion of HBMEC and identified a novel role for PI3K interaction with FAR in the pathogenesis off. coli meningitis.	Childrens Hosp Los Angeles, Div Infect Dis, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Pediat, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; University of Southern California	Kim, KS (corresponding author), Johns Hopkins Univ, Sch Med, Ped Infect Dis Div, 600 N Wolfe St,Pk 256, Baltimore, MD 21287 USA.			Reddy, Marpadga A/0000-0001-9259-7243	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026310] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-61951] Funding Source: Medline; NIAID NIH HHS [AI-47225] Funding Source: Medline; NINDS NIH HHS [R01-NS-26310] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Badger JL, 1999, INFECT IMMUN, V67, P4208, DOI 10.1128/IAI.67.8.4208-4215.1999; BRIGITTE MJ, 1995, ANNU REV CELL DEV BI, V11, P379; Carpenter CL, 1997, ADV ENZYME REGUL, V37, P377, DOI 10.1016/S0065-2571(96)00005-2; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Greiffenberg L, 1998, INFECT IMMUN, V66, P5260, DOI 10.1128/IAI.66.11.5260-5267.1998; Guan JL, 1996, INT REV CYTOL, V168, P81, DOI 10.1016/S0074-7696(08)60883-9; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HUANG SH, 1995, INFECT IMMUN, V63, P4470, DOI 10.1128/IAI.63.11.4470-4475.1995; Huang SH, 1999, INFECT IMMUN, V67, P2103, DOI 10.1128/IAI.67.5.2103-2109.1999; Ireton K, 1999, J BIOL CHEM, V274, P17025, DOI 10.1074/jbc.274.24.17025; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Kim K S, 2000, Subcell Biochem, V33, P47; Leib SL, 1999, INFECT DIS CLIN N AM, V13, P527, DOI 10.1016/S0891-5520(05)70093-3; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Martinez JJ, 2000, EMBO J, V19, P2803, DOI 10.1093/emboj/19.12.2803; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Nizet V, 1997, INFECT IMMUN, V65, P5074, DOI 10.1128/IAI.65.12.5074-5081.1997; Prasadarao NV, 1999, INFECT IMMUN, V67, P5775, DOI 10.1128/IAI.67.11.5775-5783.1999; Prasadarao NV, 1999, INFECT IMMUN, V67, P1131, DOI 10.1128/IAI.67.3.1131-1138.1999; Prasadarao NV, 1996, INFECT IMMUN, V64, P154, DOI 10.1128/IAI.64.1.154-160.1996; Prasadarao NV, 1996, INFECT IMMUN, V64, P146, DOI 10.1128/IAI.64.1.146-153.1996; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reddy MA, 2000, INFECT IMMUN, V68, P6423, DOI 10.1128/IAI.68.11.6423-6430.2000; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Stins MF, 1997, J NEUROIMMUNOL, V76, P81, DOI 10.1016/S0165-5728(97)00036-2; Wang Y, 1999, INFECT IMMUN, V67, P4751, DOI 10.1128/IAI.67.9.4751-4756.1999; WANG Y, 2000, 100 AM SOC MICR GEN, P65; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413	42	88	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36769	36774		10.1074/jbc.M007382200	http://dx.doi.org/10.1074/jbc.M007382200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973983	hybrid			2022-12-27	WOS:000165577700047
J	White, JR; Lee, JM; Dede, K; Imburgia, CS; Jurewicz, AJ; Chan, G; Fornwald, JA; Dhanak, D; Christmann, LT; Darcy, MG; Widdowson, KL; Foley, JJ; Schmidt, DB; Sarau, HM				White, JR; Lee, JM; Dede, K; Imburgia, CS; Jurewicz, AJ; Chan, G; Fornwald, JA; Dhanak, D; Christmann, LT; Darcy, MG; Widdowson, KL; Foley, JJ; Schmidt, DB; Sarau, HM			Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLERGIC INFLAMMATION; MOLECULAR-CLONING; GUINEA-PIG; FUNCTIONAL-CHARACTERIZATION; CHEMOATTRACTANT CYTOKINE; BIOLOGICAL-ACTIVITY; C5A RECEPTOR; EXPRESSION; RANTES; MCP-4	Eosinophils have been implicated in the pathogenesis of asthma and other allergic diseases. Several CC chemokines including eotaxin (CCL-11), eotaxin-2 (CCL-24), RANTES (CCL-5), and monocyte chemotactic protein-3 (MCP-3, CCL-7) and 4 (MCP-4 CCL-13) are potent eosinophil chemotactic and activating peptides acting through CC chemokine receptor-3 (CCR3). Thus, antagonism of CCR3 could have a therapeutic role in asthma and other eosinophil-mediated diseases. A high throughput, cellular functional screen was configured using RBL-2H3 cells stably expressing CCR3 (RBL-2H3-CCR3) to identify non-peptide receptor antagonists. A small molecule CCR3 antagonist was identified, SK&F 45523, and chemical optimization led to the generation of a number of highly potent, selective CCR3 antagonists including SB-297006 and SB-328437, These compounds were further characterized in vitro and demonstrated high affinity, competitive inhibition of I-125-eotaxin and I-125-MCP-4 binding to human eosinophils. The compounds were potent inhibitors of eotaxin- and MCP-P induced Ca2+ mobilization in RBL-2H3-CCR3 cells and eosinophils. Additionally, SB-328437 inhibited eosinophil chemotaxis induced by three ligands that activate CCR3 with similar potencies. Selectivity was affirmed using a panel of 10 seven-transmembrane receptors. This is the first description of a non-peptide CCR3 antagonist, which should be useful in further elucidating the pathophysioiogical role of CCR3 in allergic inflammatory diseases.	SmithKline Beecham Pharmaceut, Dept Biomol Discovery, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Pulm Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Med Chem, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	White, JR (corresponding author), SmithKline Beecham Pharmaceut, Dept Immunol, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.			White, John R/0000-0003-2998-1626				Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Baggiolini M, 1996, J CLIN INVEST, V97, P587, DOI 10.1172/JCI118451; BAGGIOLINI M, 1994, CHEST, V105, P95; BARLUENGA J, 1990, J ORG CHEM, V55, P3104, DOI 10.1021/jo00297a027; Berkhout TA, 1997, J BIOL CHEM, V272, P16404, DOI 10.1074/jbc.272.26.16404; Bischoff SC, 1999, AM J GASTROENTEROL, V94, P3521, DOI 10.1111/j.1572-0241.1999.01641.x; BROOKS DP, 1991, PHARMACOLOGY, V43, P90, DOI 10.1159/000138833; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Durham SR, 1998, CLIN EXP ALLERGY, V28, P20; Elsner J, 1997, EUR J IMMUNOL, V27, P2892, DOI 10.1002/eji.1830271122; EMONDSALT X, 1992, LIFE SCI, V50, pPL101, DOI 10.1016/0024-3205(92)90352-P; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HAY DWP, 1991, PULM PHARMACOL THER, V4, P177, DOI 10.1016/0952-0600(91)90009-R; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687; Howard AD, 2000, NATURE, V406, P70, DOI 10.1038/35017610; JOSE PJ, 1994, BIOCHEM BIOPH RES CO, V205, P788, DOI 10.1006/bbrc.1994.2734; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kita H, 1996, J EXP MED, V183, P2421, DOI 10.1084/jem.183.6.2421; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; KROEGEL C, 1994, J ALLERGY CLIN IMMUN, V93, P725, DOI 10.1016/0091-6749(94)90252-6; LANZA TJ, 1992, J MED CHEM, V35, P252, DOI 10.1021/jm00080a008; Leung DYM, 1999, J ALLERGY CLIN IMMUN, V104, pS99, DOI 10.1016/S0091-6749(99)70051-5; Mackay CR, 1997, CURR BIOL, V7, pR384, DOI 10.1016/S0960-9822(06)00181-3; Mackay CR, 1996, J EXP MED, V184, P799, DOI 10.1084/jem.184.3.799; Macphee CH, 1998, J IMMUNOL, V161, P6273; Martin U, 1997, J EXP MED, V186, P199, DOI 10.1084/jem.186.2.199; Medhurst AD, 1999, BRIT J PHARMACOL, V128, P627, DOI 10.1038/sj.bjp.0702854; Nibbs RJB, 2000, J IMMUNOL, V164, P1488, DOI 10.4049/jimmunol.164.3.1488; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Proudfoot AEI, 1999, J BIOL CHEM, V274, P32478, DOI 10.1074/jbc.274.45.32478; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; PROUDFOOT AEI, 1995, FEBS LETT, V376, P19, DOI 10.1016/0014-5793(95)01235-X; ROLLINS TE, 1988, J BIOL CHEM, V263, P520; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; SCHALL TJ, 1994, CYTOKINE HDB, P419; Smart D, 1999, BRIT J PHARMACOL, V128, P1, DOI 10.1038/sj.bjp.0702780; Stellato C, 1999, J IMMUNOL, V163, P5624; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; Sullivan E, 1999, METH MOL B, V114, P125; White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095; White JR, 1997, J LEUKOCYTE BIOL, V62, P667, DOI 10.1002/jlb.62.5.667; Yang Y, 1998, BLOOD, V92, P3912, DOI 10.1182/blood.V92.10.3912.422k23_3912_3923; Ying S, 1999, J IMMUNOL, V163, P6321	55	97	109	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36626	36631		10.1074/jbc.M006613200	http://dx.doi.org/10.1074/jbc.M006613200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10969084	hybrid			2022-12-27	WOS:000165577700025
J	Yang, Q; Manicone, A; Coursen, JD; Linke, SP; Nagashima, M; Forgues, M; Wang, XW				Yang, Q; Manicone, A; Coursen, JD; Linke, SP; Nagashima, M; Forgues, M; Wang, XW			Identification of a functional domain in a GADD45-mediated G(2)/M checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-REGULATED PROTEIN GADD45; CELL-CYCLE CHECKPOINTS; DNA-DAMAGING AGENTS; GROWTH ARREST; RAN/TC4 GTPASE; P53; INDUCTION; MITOSIS; YEAST; GENES	Cell cycle checkpoints are essential for the maintenance of genomic stability in response to DNA damage. We demonstrated recently that GADD45, a DNA damage-inducible protein, activates a G(2)/M checkpoint induced by either UV radiation or alkylating agents. GADD45 can interact in vivo with the G(2) cell cycle-specific kinase, Cdc2, proliferating cell nuclear antigen (PCNA), and the cell cycle kinase inhibitor p21(waf1). The ability of GADD45 to induce a G2/M arrest may be caused in part by the inhibition of Cdc2 kinase activity. Here, we report the identification of a region of GADD45 that is involved in this G(2)/M checkpoint. Mutants of GADD45 that lacked either the first 35 or the last 80 residues still retained an ability to induce G(2)/M arrest. A mutant with a deletion of the central region (residues 50-76), which is conserved in the family members GADD45 beta and GADD45 gamma, lacked such activity. This mutant also lacked an ability to bind to Cdc2, PCNA, and p21(waf1) in vivo. Consistently, either GADD45 beta or GADD45 gamma bind to Cdc2 in vivo. However, unlike GADD45, neither GADD45 beta nor GADD45 gamma inhibited the Cdc2 kinase or induced G2/M arrest. The unique effect of GADD45 may be caused by the presence of a region containing DEDDDR residues. Alanine substitutions in the region abolished GADD45 induction of a G(2)/M arrest and its inactivation of the Cdc2 kinase but not its binding to Cdc2, PCNA, or p21(waf1). Therefore, the binding of GADD45 to Cdc2 was insufficient to induce a G2/M arrest, and additional activity contributed by the DEDDDR residues may be necessary to regulate the G(2)/M checkpoint.	NCI, Human Carcinogenesis Lab, DBS, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, XW (corresponding author), NCI, Human Carcinogenesis Lab, DBS, NIH, 37 Convent Dr,MSC 4255,Bldg 37,Rm 2C08, Bethesda, MD 20892 USA.		Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X; Linke, Steven/0000-0001-8584-4947	DIVISION OF BASIC SCIENCES - NCI [Z01BC010421] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHEN IT, 1995, ONCOGENE, V11, P1931; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; O'Connor P M, 1996, Prog Cell Cycle Res, V2, P165; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; POWELL SN, 1995, CANCER RES, V55, P1643; REN MD, 1994, MOL CELL BIOL, V14, P4216, DOI 10.1128/MCB.14.6.4216; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEWART N, 1995, ONCOGENE, V10, P109; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	35	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36892	36898		10.1074/jbc.M005319200	http://dx.doi.org/10.1074/jbc.M005319200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973963	hybrid			2022-12-27	WOS:000165577700064
J	Adler, CE; Miyoshi-Akiyama, TS; Aleman, LM; Tanaka, M; Smith, JM; Mayer, BJ				Adler, CE; Miyoshi-Akiyama, TS; Aleman, LM; Tanaka, M; Smith, JM; Mayer, BJ			Abl family kinases and Cbl cooperate with the Nck adaptor to modulate Xenopus development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE KINASE; SRC HOMOLOGY-3 DOMAINS; C-ABL; SIGNAL-TRANSDUCTION; SH3 DOMAINS; RING FINGER; ACTIVATION; PROTOONCOGENE; LOCALIZATION	We previously showed that overexpression of the Nck Src homology (SH) 2/SH3 adaptor in Xenopus embryos induced developmental defects including anterior truncation and mesoderm ventralization. Mutagenic analysis indicated that this was due to relocalization of endogenous proteins that bind the first two SH3 domains of Nck. We therefore screened a Xenopus expression library with Nck SH3 domains to identify Nck-interacting proteins, and evaluated candidate binding proteins for a potential,role in Nck-induced anterior truncation/ventralization. Of 39 binding proteins analyzed, only the Abl-related kinase Arg and the Cbl proto-oncogene product bound preferentially to the first two SH3 domains in tandem:compared with the individual domains, consistent with a role in the developmental phenotype, High level overexpression of c-Abl or Arg alone induced anterior truncation, as did lower levels of an activated form of Abl; Cbl alone had no effect. In a sensitized system where subthreshold amounts of a ventralizing Nck mutant were expressed, co-expression of the combination of Abl:or Arg and Cbl at modest levels strongly potentiated anterior truncation, while Arg, Abl, or Cbl alone were without effect. These results suggest a role for both Cbl and Abl family kinases in patterning the Xenopus embryo.	Harvard Univ, Childrens Hosp, Sch Med, Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Mayer, BJ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.	bmayer@neuron.uchc.edu			NATIONAL CANCER INSTITUTE [R01CA082258] Funding Source: NIH RePORTER; NCI NIH HHS [CA82258] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAYA E, 1993, DEVELOPMENT, V118, P477; ATALIOTIS P, 1995, DEVELOPMENT, V121, P3099; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Gupta RW, 1998, ONCOGENE, V17, P2155, DOI 10.1038/sj.onc.1202158; Heasman J, 1997, DEVELOPMENT, V124, P4179; Isaacs HV, 1997, CELL MOL LIFE SCI, V53, P350, DOI 10.1007/PL00000611; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Mysliwiec T, 1996, ONCOGENE, V12, P631; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Raitano AB, 1997, BBA-REV CANCER, V1333, pF201, DOI 10.1016/S0304-419X(97)00023-1; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Ryan PJ, 1998, BIOCHEM BIOPH RES CO, V244, P763, DOI 10.1006/bbrc.1998.8326; Slack JMW, 1996, BIOCHEM SOC SYMP, P1; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; Symes K, 1996, P NATL ACAD SCI USA, V93, P9641, DOI 10.1073/pnas.93.18.9641; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Wang BL, 1996, ONCOGENE, V13, P193; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Wunderlich L, 1999, CELL SIGNAL, V11, P253, DOI 10.1016/S0898-6568(98)00054-0; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	43	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36472	36478		10.1074/jbc.M005424200	http://dx.doi.org/10.1074/jbc.M005424200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967110	hybrid			2022-12-27	WOS:000165382000115
J	Lancaster, MK; Dibb, KM; Quinn, CC; Leach, R; Lee, JK; Findlay, JBC; Boyett, MR				Lancaster, MK; Dibb, KM; Quinn, CC; Leach, R; Lee, JK; Findlay, JBC; Boyett, MR			Residues and mechanisms for slow activation and Ba2+ block of the cardiac muscarinic K+ channel, Kir3.1/Kir3.4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER POTASSIUM CHANNELS; NEGATIVELY CHARGED RESIDUE; INWARD-RECTIFIER; XENOPUS OOCYTES; I-KACH; GATING PROPERTIES; RECTIFICATION; KIR2.1; MEMBRANE; SPERMINE	Mechanisms and residues responsible for slow activation and Ba2+ block of the cardiac muscarinic K+ channel, Kir3.1/Kir3.4, were investigated using site-directed mutagenesis. Mutagenesis of negatively charged residues located throughout the pore of the channel (in H5, M2, and proximal C terminus) reduced or abolished slow activation. The strongest effects resulted from mutagenesis of residues in H5 close to the selectivity filter; mutagenesis of residues in M2 and proximal C terminus equivalent to those identified as important determinants of the activation kinetics of Kir2.1 was less effective. In giant patches, slow activation was present in cell-attached patches, lost on excision of the patch, and restored on perfusion with polyamine, Mutagenesis of residues in H5 and M2 close to the selectivity filter also decreased Ba2+ block of the channel. A critical residue for Ba2+ block was identified in Kir3.4. Mutagenesis of the equivalent residue in Kir3.1 failed to have as pronounced an effect on Ba2+ block, suggesting an asymmetry of the channel pore. It is concluded that slow activation is principally the result of unbinding of polyamines from negatively charged residues close to the selectivity filter of the channel and not an intrinsic gating mechanism. Ba2+ block involves an interaction with the same residues.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Nagoya Univ, Environm Med Res Inst, Nagoya, Aichi 46401, Japan	University of Leeds; Nagoya University	Lancaster, MK (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England.		Lancaster, Matthew/L-2396-2013; Dibb, Katharine/G-8764-2015	Lancaster, Matthew/0000-0002-3976-736X; Dibb, Katharine/0000-0002-9309-3853; Boyett, Mark/0000-0003-3931-2020				COHEN IS, 1989, BIOPHYS J, V55, P197, DOI 10.1016/S0006-3495(89)82792-4; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; DASCAL N, 1995, P NATL ACAD SCI USA, V92, P6758, DOI 10.1073/pnas.92.15.6758; Dibb KM, 2000, PFLUG ARCH EUR J PHY, V440, P740, DOI 10.1007/s004240000344; DOUPNIK CA, 1995, J GEN PHYSIOL, V106, P1, DOI 10.1085/jgp.106.1.1; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Hilgemann DW, 1998, METHOD ENZYMOL, V293, P267; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; Jiang YX, 2000, J GEN PHYSIOL, V115, P269, DOI 10.1085/jgp.115.3.269; Kofuji P, 1996, J PHYSIOL-LONDON, V490, P633, DOI 10.1113/jphysiol.1996.sp021173; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; Lee JK, 1999, J GEN PHYSIOL, V113, P555, DOI 10.1085/jgp.113.4.555; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; Lopatin AN, 1996, J GEN PHYSIOL, V108, P105, DOI 10.1085/jgp.108.2.105; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; Luchian T, 1997, J PHYSIOL-LONDON, V505, P13, DOI 10.1111/j.1469-7793.1997.013bc.x; Owen JM, 1999, EXP PHYSIOL, V84, P471, DOI 10.1017/S0958067099018060; PESSIA M, 1995, NEURON, V14, P1039, DOI 10.1016/0896-6273(95)90342-9; Reuveny E, 1996, BIOPHYS J, V70, P754, DOI 10.1016/S0006-3495(96)79615-7; Shieh RC, 1998, BIOPHYS J, V75, P2313, DOI 10.1016/S0006-3495(98)77675-1; Shyng SL, 1996, P NATL ACAD SCI USA, V93, P12014, DOI 10.1073/pnas.93.21.12014; SIMMONS MA, 1987, PFLUG ARCH EUR J PHY, V409, P454, DOI 10.1007/BF00583801; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; Wischmeyer E, 1997, MOL CELL NEUROSCI, V9, P194, DOI 10.1006/mcne.1997.0614; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; YAMADA M, 1995, J BIOL CHEM, V270, P9289, DOI 10.1074/jbc.270.16.9289; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; Yang J, 1997, P NATL ACAD SCI USA, V94, P1568, DOI 10.1073/pnas.94.4.1568; ZANG WJ, 1995, PFLUG ARCH EUR J PHY, V430, P348, DOI 10.1007/BF00373909; Zhou H, 1996, AM J PHYSIOL-CELL PH, V271, pC1949, DOI 10.1152/ajpcell.1996.271.6.C1949	35	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35831	35839		10.1074/jbc.M006565200	http://dx.doi.org/10.1074/jbc.M006565200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10956662	hybrid			2022-12-27	WOS:000165382000029
J	Vignal, E; De Toledo, M; Comunale, F; Ladopoulou, A; Gauthier-Rouviere, C; Blangy, A; Fort, P				Vignal, E; De Toledo, M; Comunale, F; Ladopoulou, A; Gauthier-Rouviere, C; Blangy, A; Fort, P			Characterization of TCL, a new GTPase of the Rho family related to TC10 and Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; RAS; CELLS; MORPHOLOGY; PROTEINS; PATHWAY; GROWTH; RAC1	GTPases of the Rho family control a wide variety of cellular processes such as cell morphology, motility, proliferation, differentiation, and apoptosis, We report here the characterization of a new Rho member, which shares 85% and 78% amino acid similarity to TC10 and Cdc42, respectively. This GTPase, termed as TC10-like (TCL) is encoded by an unexpectedly large locus, made of five exons spanning over 85 kilobases on human chromosome 14, TCL mRNA is 2.5 kilobases long and is mainly expressed in heart. In vitro, TCL shows rapid GDP/GTP exchange and displays higher GTP dissociation and hydolysis rates than TC10, Using the yeast two-hybrid system and GST pull-down assays, we show that GTP-bound but not GDP-bound TCL protein directly interacts with Cdc42/Rac interacting binding domains, such as those found in PAK and WASP. Despite its overall similarity to TC10 and Cdc42, the constitutively active TCL mutant displays distinct morphogenic activity in REF-52 fibroblasts, producing large and dynamic F-actin-rich ruffles on the dorsal cell membrane. Interestingly, TCL morphogenic activity is blocked by dominant negative Rad and Cdc42 mutants, suggesting a crosstalk between these three Rho GTPases.	Ctr Rech Biochim Macromol, CNRS UPR 1086, F-34293 Montpellier 5, France; Demokritos Natl Ctr Sci Res, Inst Radioisotopes & Radiodiagnost Prod, Mol Diagnost Lab, Athens 15310, Greece	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; National Centre of Scientific Research "Demokritos"	Fort, P (corresponding author), Ctr Rech Biochim Macromol, CNRS UPR 1086, 1919 Route Mende, F-34293 Montpellier 5, France.	fort@crbm.cnrs-mop.fr	Fort, Philippe/M-9498-2015; Vignal, Emmanuel/B-6985-2009	Fort, Philippe/0000-0001-5997-8722; Comunale, Franck/0000-0001-8838-2151; GAUTHIER-ROUVIERE, Cecile/0000-0002-8364-3882; Vignal, Emmanuel/0000-0002-2585-119X; BLANGY, Anne/0000-0001-7043-0784				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Blangy A, 2000, J CELL SCI, V113, P729; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRUNK U, 1981, J MICROSC-OXFORD, V123, P121, DOI 10.1111/j.1365-2818.1981.tb01288.x; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Courjal F, 1997, GENOMICS, V44, P242, DOI 10.1006/geno.1997.4871; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Fort P, 1999, Prog Mol Subcell Biol, V22, P159; Gallo G, 1998, CURR BIOL, V8, pR80, DOI 10.1016/S0960-9822(98)70051-X; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Gomez J, 1998, IMMUNOL CELL BIOL, V76, P125, DOI 10.1046/j.1440-1711.1998.00723.x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; LeGallic L, 1997, GENOMICS, V42, P157; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Reif K, 1998, IMMUNITY, V8, P395, DOI 10.1016/S1074-7613(00)80545-2; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Stam J C, 1999, Prog Mol Subcell Biol, V22, P51; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van der Voort H. T. M., 1993, Bioimaging, V1, P20, DOI 10.1002/1361-6374(199303)1:1<20::AID-BIO5>3.3.CO;2-U; VANDERVOORT HTM, 1995, J MICROSC-OXFORD, V178, P165, DOI 10.1111/j.1365-2818.1995.tb03593.x	35	95	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36457	36464		10.1074/jbc.M003487200	http://dx.doi.org/10.1074/jbc.M003487200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967094	Green Published, hybrid			2022-12-27	WOS:000165382000113
J	Geva, A; Lassere, TB; Lichtarge, O; Pollitt, SK; Baranski, TJ				Geva, A; Lassere, TB; Lichtarge, O; Pollitt, SK; Baranski, TJ			Genetic mapping of the human C5a receptor - Identification of transmembrane amino acids critical for receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PHEROMONE RESPONSE PATHWAY; NEUROKININ-1 RECEPTOR; PLASMA-MEMBRANE; BINDING-SITE; RHODOPSIN; ACTIVATION; YEAST; SELECTIVITY; HELICES	Many hormones and sensory stimuli signal through a superfamily of seven transmembrane-spanning receptors to activate heterotrimeric G proteins, How the seven transmembrane segments of the receptors (a molecular architecture of bundled cu-helices conserved from yeast to man) work as "on/off' switches remains unknown. Previously, we used random saturation mutagenesis coupled with a genetic selection in yeast to determine the relative importance of amino acids in four of the seven transmembrane segments of the human C5a receptor (Baranski, T, J., Herzmark, P,, Lichtarge, O,, Gerber, B, O,, Trueheart, J,, Meng, E, C,, Iiri, T., Sheikh, S, P., and Bourne, H, R, (1999) J, Bioh Chen, 274, 15757-15765). In this study, we evaluate helices I, II, and TV,thereby furnishing a complete mutational map of the seven transmembrane helices of the human C5a receptor. Our analysis identified 19 amino acid positions resistant to non-conservative substitutions. When combined with the 25 essential residues previously identified in helices III and V-VII, they delineate two distinct components of the receptor switch: a ligand-binding surface at or near the extracellular surface of the helix bundle and a core cluster in the cytoplasmic half of the bundle. In addition, we found critical amino acids in the first and second helices that are predicted to face the lipid membrane. These residues form an extended surface that might mediate interactions with lipids and other membrane proteins or function as an oligomerization domain with other receptors.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	Washington University (WUSTL); Washington University (WUSTL); Baylor College of Medicine; University of California System; University of California San Francisco	Baranski, TJ (corresponding author), Washington Univ, Sch Med, Dept Med, POB 8103,660 S Euclid Ave, St Louis, MO 63110 USA.							AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7945, DOI 10.1021/bi990014l; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; DAYHOFF MO, 1979, ATLAS PROTEIN SEQ S3, V5, P353; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; Elling CE, 1996, EMBO J, V15, P6213, DOI 10.1002/j.1460-2075.1996.tb01011.x; Erickson JP, 1998, J BIOL CHEM, V273, P1506, DOI 10.1074/jbc.273.3.1506; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FONG TM, 1992, J BIOL CHEM, V267, P25668; FONG TM, 1994, J BIOL CHEM, V269, P14957; GERARD C, 1985, J BIOL CHEM, V260, P2613; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; GU WX, 1995, ENDOCRINOLOGY, V136, P3146, DOI 10.1210/en.136.7.3146; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Javitch JA, 1999, BIOCHEMISTRY-US, V38, P7961, DOI 10.1021/bi9905314; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Klein C, 1998, NAT BIOTECHNOL, V16, P1334, DOI 10.1038/4310; KOLAKOWSKI LF, 1995, J BIOL CHEM, V270, P18077, DOI 10.1074/jbc.270.30.18077; Krebs A, 1998, J MOL BIOL, V282, P991, DOI 10.1006/jmbi.1998.2070; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MERY L, 1994, J BIOL CHEM, V269, P3457; MIN KC, 1993, J BIOL CHEM, V268, P9400; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Price LA, 1996, MOL PHARMACOL, V50, P829; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WONG SKF, 1990, J BIOL CHEM, V265, P6219	54	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35393	35401		10.1074/jbc.M005602200	http://dx.doi.org/10.1074/jbc.M005602200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952985	hybrid			2022-12-27	WOS:000165422800075
J	Feschenko, MS; Stevenson, E; Sweadner, KJ				Feschenko, MS; Stevenson, E; Sweadner, KJ			Interaction of protein kinase C and cAMP-dependent pathways in the phosphorylation of the Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; ALPHA-SUBUNIT; INTACT-CELLS; CATALYTIC SUBUNIT; EPITHELIAL-CELLS; STRUCTURAL BASIS; PLASMA-MEMBRANE; XENOPUS OOCYTES; CHOROID-PLEXUS; NA+,K+-ATPASE	To test the hypothesis that there is cross-talk between the protein kinase C (PKC) and protein kinase A (PKA) pathways in the regulation of the Na,K-ATPase, we measured its phosphorylation in mammalian cell cultures. Phosphorylation of the PKC site, Ser-18, appeared to be due to the activation of the a isoform of the kinase. In NRK-52E and L6 cells, this phosphorylation was reduced by prior activation of a cAMP-dependent signaling pathway with forskolin. In principle this would be consistent with direct interaction between the two phosphorylation sites, but further investigation suggested a more indirect mechanism. First, phosphorylation of Ser-938, the PKA site, could not be detected despite the presence of active PKA. Second, there was a major reduction in the phosphorylation of unrelated phosphoproteins as a consequence of elevation of cAMP, suggesting generalized reduction of kinase activity or activation of phosphatase activity. In NRK-52E and L6, phosphorylation of the Na,K-ATPase at Ser-18 paralleled this global change. In C6 cells, in contrast, there was no cAMP effect on Na,K-ATPase phosphorylation at Ser-18 and no global cAMP effect on other phosphoproteins. The cross-talk is evidently mediated by events occurring at the cellular level.	Massachusetts Gen Hosp, Lab Membrane Biol, Ctr Neurosci, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Sweadner, KJ (corresponding author), Massachusetts Gen Hosp, Lab Membrane Biol, Ctr Neurosci, Charlestown, MA 02129 USA.	sweadner@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027653] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS27653] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; Arystarkhova E, 1996, J BIOL CHEM, V271, P23407, DOI 10.1074/jbc.271.38.23407; Arystarkhova E, 1997, J BIOL CHEM, V272, P22405, DOI 10.1074/jbc.272.36.22405; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; Beguin P, 1996, AM J PHYSIOL-CELL PH, V270, pC131, DOI 10.1152/ajpcell.1996.270.1.C131; Begum N, 1996, J BIOL CHEM, V271, P31166, DOI 10.1074/jbc.271.49.31166; Belusa R, 1997, J BIOL CHEM, V272, P20179, DOI 10.1074/jbc.272.32.20179; Beron J, 1997, MOL BIOL CELL, V8, P387, DOI 10.1091/mbc.8.3.387; BERTORELLO A, 1990, AM J PHYSIOL, V259, pF924, DOI 10.1152/ajprenal.1990.259.6.F924; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; Bertorello AM, 1999, AM J PHYSIOL-LUNG C, V276, pL20, DOI 10.1152/ajplung.1999.276.1.L20; BORGHINI I, 1994, P NATL ACAD SCI USA, V91, P6211, DOI 10.1073/pnas.91.13.6211; Canfield VA, 1996, BIOCHEMISTRY-US, V35, P14165, DOI 10.1021/bi961851f; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; Carranza ML, 1996, FEBS LETT, V396, P309, DOI 10.1016/0014-5793(96)01121-0; Carranza ML, 1998, J PHYSIOL-LONDON, V511, P235, DOI 10.1111/j.1469-7793.1998.235bi.x; Cheng SXJ, 1999, J PHYSIOL-LONDON, V518, P37, DOI 10.1111/j.1469-7793.1999.0037r.x; Cheng XJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1981, DOI 10.1152/ajpcell.1997.273.6.C1981; Cheng XJ, 1997, AM J PHYSIOL-CELL PH, V273, pC893, DOI 10.1152/ajpcell.1997.273.3.C893; Chibalin AV, 1998, J BIOL CHEM, V273, P8814, DOI 10.1074/jbc.273.15.8814; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; COHEN P, 1989, J BIOL CHEM, V264, P21435; Cornelius F, 1996, FEBS LETT, V380, P277, DOI 10.1016/0014-5793(96)00032-4; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; Efendiev R, 1999, FEBS LETT, V456, P45, DOI 10.1016/S0014-5793(99)00925-4; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; Feraille E, 2000, MOL BIOL CELL, V11, P39, DOI 10.1091/mbc.11.1.39; Feschenko MS, 1997, ANN NY ACAD SCI, V834, P479, DOI 10.1111/j.1749-6632.1997.tb52306.x; FESCHENKO MS, 1994, J BIOL CHEM, V269, P30436; Feschenko MS, 1997, J BIOL CHEM, V272, P17726, DOI 10.1074/jbc.272.28.17726; FESCHENKO MS, 1995, J BIOL CHEM, V270, P14072, DOI 10.1074/jbc.270.23.14072; Fisone G, 1998, MOL MED, V4, P258, DOI 10.1007/BF03401922; FISONE G, 1994, J BIOL CHEM, V269, P9368; FISONE G, 1995, J BIOL CHEM, V270, P2427, DOI 10.1074/jbc.270.6.2427; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; Kiroytcheva M, 1999, KIDNEY INT, V55, P1819, DOI 10.1046/j.1523-1755.1999.00414.x; Li DL, 1998, AM J PHYSIOL-RENAL, V275, pF863, DOI 10.1152/ajprenal.1998.275.6.F863; Li DL, 1999, AM J PHYSIOL-HEART C, V276, pH2109, DOI 10.1152/ajpheart.1999.276.6.H2109; Liang MY, 1999, AM J PHYSIOL-RENAL, V277, pF859, DOI 10.1152/ajprenal.1999.277.6.F859; Logvinenko NS, 1996, P NATL ACAD SCI USA, V93, P9132, DOI 10.1073/pnas.93.17.9132; MIDDLETON JP, 1993, J BIOL CHEM, V268, P15958; Muscella A, 2000, J NEUROCHEM, V74, P1325; Nestor NB, 1997, ANN NY ACAD SCI, V834, P579, DOI 10.1111/j.1749-6632.1997.tb52324.x; Nishi A, 1999, J NEUROCHEM, V73, P1492, DOI 10.1046/j.1471-4159.1999.0731492.x; Nowicki S, 1997, J CLIN INVEST, V99, P1224, DOI 10.1172/JCI119279; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; ROBINSON JD, 1980, BIOCHIM BIOPHYS ACTA, V598, P543, DOI 10.1016/0005-2736(80)90034-6; SATOH T, 1993, J CLIN INVEST, V91, P409, DOI 10.1172/JCI116215; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; Sweeney G, 1998, DIABETOLOGIA, V41, P1199, DOI 10.1007/s001250051052; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; TRIA E, 1974, BIOCHIM BIOPHYS ACTA, V343, P297, DOI 10.1016/0304-4165(74)90094-4; Vasilets LA, 1997, CELL PHYSIOL BIOCHEM, V7, P1, DOI 10.1159/000154847; YOON KL, 1994, J BIOL CHEM, V269, P28249; Zaheer A, 1997, J BIOL CHEM, V272, P5183, DOI 10.1074/jbc.272.8.5183	58	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34693	34700		10.1074/jbc.M005869200	http://dx.doi.org/10.1074/jbc.M005869200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10940309	hybrid			2022-12-27	WOS:000165095300093
J	Zhang, J; Tamilarasu, N; Hwang, SW; Garber, ME; Huq, I; Jones, KA; Rana, TM				Zhang, J; Tamilarasu, N; Hwang, SW; Garber, ME; Huq, I; Jones, KA; Rana, TM			HIV-1 TAR RNA enhances the interaction between Tat and cyclin T1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; PHOTO-CROSS-LINKING; FACTOR P-TEFB; TRANSCRIPTIONAL ACTIVATION; BINDING DOMAIN; PHAGE-LAMBDA; DNA-BINDING; IN-VITRO; PROTEIN; COMPLEX	Human immunodeficiency virus, type 1 (HIV-1), Tat activates elongation of RNA polymerase II transcription at the HIV-1 promoter through interaction with the cyclin T1 (CycT1) subunit of the positive transcription elongation factor complex, P-TEFb, Binding of Tat to CycT1 induces cooperative binding of the beta -TEFb complex onto nascent HIV-1 TAR RNA. Here the specific interaction between Tat protein, human cyclin T1, and HIV-1 TAR RNA was analyzed by fluorescence resonance energy transfer, using fluorescein-labeled TAR RNA and a rhodamine-labeled Tat protein synthesized through solid-phase chemistry. We find that CycT1 remodels the structure of Tat to enhance its affinity for TAR RNA and that TAR RNA further enhances the interaction between Tat and CycT1, We conclude that TAR RNA nucleates the formation of the Tat.beta -TEFb complex through an induced fit mechanism.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Salk Inst Biol Studies, Regulatory Biol Lab, La Jolla, CA 92037 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Salk Institute	Rana, TM (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Ln, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041404, R56AI041404] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 41404] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; Frankel AD, 1998, CELL, V92, P149, DOI 10.1016/S0092-8674(00)80908-3; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garber ME, 1998, COLD SPRING HARB SYM, V63, P371, DOI 10.1101/sqb.1998.63.371; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ivanov D, 1999, J MOL BIOL, V288, P41, DOI 10.1006/jmbi.1999.2663; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Keen NJ, 1997, EMBO J, V16, P5260, DOI 10.1093/emboj/16.17.5260; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P303; Legault P, 1998, CELL, V93, P289, DOI 10.1016/S0092-8674(00)81579-2; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Mogridge J, 1998, MOL CELL, V1, P265, DOI 10.1016/S1097-2765(00)80027-1; NEENHOLD HR, 1995, BIOCHEMISTRY-US, V34, P6303, DOI 10.1021/bi00019a007; Ping YH, 1997, RNA, V3, P850; Shah K, 1996, BIOCONJUGATE CHEM, V7, P283, DOI 10.1021/bc960023w; SHAH K, 1994, BIOCONJUGATE CHEM, V5, P508, DOI 10.1021/bc00030a005; Su LL, 1997, GENE DEV, V11, P2214, DOI 10.1101/gad.11.17.2214; VanGilst MR, 1997, BIOCHEMISTRY-US, V36, P1514, DOI 10.1021/bi961920q; Wang ZY, 1996, BIOCHEMISTRY-US, V35, P6491, DOI 10.1021/bi960037p; WEBER G, 1957, T FARADAY SOC, V53, P646, DOI 10.1039/tf9575300646; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589; Yang MS, 1997, METHOD ENZYMOL, V278, P417; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	35	57	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34314	34319		10.1074/jbc.M006804200	http://dx.doi.org/10.1074/jbc.M006804200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944537	hybrid			2022-12-27	WOS:000165095300044
J	Zhou, WL; Carpenter, G				Zhou, WL; Carpenter, G			Heregulin-dependent trafficking and cleavage of ErbB-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; AMYLOID PRECURSOR PROTEIN; FACTOR RECEPTOR ACTIVATION; ALPHA-SECRETASE CLEAVAGE; MEMBRANE DOMAINS; SIGNALING NETWORK; CARDIAC MYOCYTES; BREAST-CANCER; MESSENGER-RNA; MAMMARY-GLAND	Heregulin was shown to promote the proteolytic cleavage of its receptor, ErbB-4, in several cell lines. The growth factor also rapidly promoted the transient translocation of ErbB-4 to a detergent-insoluble fraction, in which the receptor was hyper-tyrosine-phosphorylated compared with the receptor present in the detergent-soluble pool. However, an 80-kDa proteolytic fragment of ErbB-4 was found in the detergent soluble fraction, but not in the detergent-insoluble fraction. Although the heregulin-induced cleavage of ErbB-4 produced a fragment of ErbB-4 very similar to that induced by 12-O-tetradecanoylphorbol-13-acetate or pervanadate teach of which is blocked by metalloprotease inhibitors), the growth factor-induced cleavage was not sensitive to these inhibitors under the same conditions. The heregulin-induced cleavage of ErbB-4 could be blocked by conditions that prevent clathrin-coated pit formation, suggesting that heregulin-mediated ErbB-4 cleavage occurs subsequent to internalization. When reagents that prevent acidification of endosomes were employed, heregulin-induced ErbB-4 cleavage was sensitive to metalloprotease inhibitors. The results imply that during ligand-dependent receptor trafficking, activated ErbB-4 receptors are subject to proteolytic cleavage involving an intracellular metalloprotease.	Vanderbilt Univ, Med Ctr, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Biochem, 647 Light Hall,23rd Ave S Pierce, Nashville, TN 37232 USA.				NCI NIH HHS [CA24071] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Baulida J, 1996, J BIOL CHEM, V271, P5251; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Codony-Servat J, 1999, CANCER RES, V59, P1196; DELCARPIO JB, 1991, CIRC RES, V69, P1591, DOI 10.1161/01.RES.69.6.1591; Drose S., 1996, J EXP BIOL, V200, P1; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Golding JP, 2000, NAT CELL BIOL, V2, P103, DOI 10.1038/35000058; Graber HU, 1999, INT J CANCER, V84, P24, DOI 10.1002/(SICI)1097-0215(19990219)84:1<24::AID-IJC5>3.0.CO;2-2; Harlow E., 1988, ANTIBODIES LAB MANUA; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Huang C, 1999, J BIOL CHEM, V274, P36707, DOI 10.1074/jbc.274.51.36707; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; Leupin O, 2000, CURR BIOL, V10, P277, DOI 10.1016/S0960-9822(00)00362-6; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P17146; QUINTART J, 1979, J CELL BIOL, V82, P644, DOI 10.1083/jcb.82.3.644; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Solomon KA, 1997, J IMMUNOL, V159, P4524; Sorkin Alexander, 1998, Frontiers in Bioscience, V3, pD729; SRIHAVASAN R, 1998, J PATHOL, V185, P126; STEINHELPER ME, 1990, AM J PHYSIOL, V259, pH1826, DOI 10.1152/ajpheart.1990.259.6.H1826; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; Vaskovsky A, 2000, J NEUROCHEM, V74, P979, DOI 10.1046/j.1471-4159.2000.0740979.x; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Vogt U, 1998, GENE, V223, P375, DOI 10.1016/S0378-1119(98)00454-5; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; YABBOWITZ R, 1997, BLOOD, V90, P706; YANG T, 1994, CIRC RES, V75, P870, DOI 10.1161/01.RES.75.5.870; Zhao YY, 1999, CIRC RES, V84, P1380	59	80	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34737	34743		10.1074/jbc.M003756200	http://dx.doi.org/10.1074/jbc.M003756200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944525	hybrid			2022-12-27	WOS:000165095300098
J	Huang, XY; Raushel, FM				Huang, XY; Raushel, FM			Restricted passage of reaction intermediates through the ammonia tunnel of carbamoyl phosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRYPTOPHAN SYNTHASE; GLUTAMINE; SUBSTRATE; SITE	The x-ray crystal structure of the heterodimeric carbamoyl phosphate synthetase from Escherichia coli has identified an intermolecular tunnel that connects the glutamine binding site within the small amidotransferase subunit to the two phosphorylation sites within the large synthetase subunit, The tunneling of the ammonia intermediate through the interior of the protein has been proposed as a mechanism for the delivery of the ammonia from the small subunit to the large subunit. A series of mutants created within the ammonia tunnel were prepared by the placement of a constriction via site-directed mutagenesis. The degree of constriction within the ammonia tunnel of these enzymes was found to correlate to the extent of the uncoupling of the partial reactions, the diminution of carbamoyl phosphate formation, and the percentage of the internally derived ammonia that is channeled through the ammonia tunnel. NMR spectroscopy and a radiolabeled probe were used to detect and identify the enzymatic synthesis of N-amino carbamoyl phosphate and N-hydroxy carbamoyl phosphate from hydroxylamine and hydrazine, The kinetic results indicate that hydroxylamine, derived from the hydrolysis of gamma-glutamyl hydroxamate, is channeled through the ammonia tunnel to the large subunit. Discrimination between the passage of ammonia and hydroxylamine was observed among some of these tunnel-impaired enzymes. The overall results provide biochemical evidence for the tunneling of ammonia within the native carbamoyl phosphate synthetase.	Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Raushel, FM (corresponding author), Texas A&M Univ, Dept Chem, POB 30012, College Stn, TX 77843 USA.		Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NIDDK NIH HHS [DK 30343] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK030343, R01DK030343] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN CM, 1966, CURRENT ASPECTS BIOC, P401; ANDERSON KS, 1995, J BIOL CHEM, V270, P29936; Anderson KS, 1999, METHOD ENZYMOL, V308, P111; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3164, DOI 10.1021/bi00874a013; Cleland W. W, 1970, ENZYMES, V2, P1; COHEN NS, 1985, BIOCHEM J, V229, P205, DOI 10.1042/bj2290205; FASMAN GD, 1975, HDB BIOCH MOL BIOL, P307; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holden HM, 1998, CURR OPIN STRUC BIOL, V8, P679, DOI 10.1016/S0959-440X(98)80086-9; Huang XY, 2000, BIOCHEMISTRY-US, V39, P3240, DOI 10.1021/bi9926173; LICHTER RL, 1970, J AM CHEM SOC, V93, P5218; MAREYA SM, 1994, BIOCHEMISTRY-US, V33, P2945, DOI 10.1021/bi00176a026; MATTHEWS SL, 1972, BIOCHEMISTRY-US, V11, P1176, DOI 10.1021/bi00757a010; MCKINLEY S, 1967, J BIOL CHEM, V242, P3381; Miles BW, 2000, BIOCHEMISTRY-US, V39, P5051, DOI 10.1021/bi992772h; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; Mullins LS, 1999, J AM CHEM SOC, V121, P3803, DOI 10.1021/ja990063l; OVADI J, 1991, J THEOR BIOL, V152, P1, DOI 10.1016/S0022-5193(05)80500-4; Raushel FM, 1999, BIOCHEMISTRY-US, V38, P7891, DOI 10.1021/bi990871p; Raushel FM, 1998, BIOCHEMISTRY-US, V37, P10272, DOI 10.1021/bi980753m; Raushel FM, 1998, CURR OPIN CHEM BIOL, V2, P624, DOI 10.1016/S1367-5931(98)80094-X; RAUSHEL FM, 1980, BIOCHEMISTRY-US, V19, P3170, DOI 10.1021/bi00555a009; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; SCHLICHTING I, 1994, J BIOL CHEM, V269, P26591; SNODGRASS PJ, 1969, J LAB CLIN MED, V73, P940; Stapleton MA, 1996, BIOCHEMISTRY-US, V35, P14352, DOI 10.1021/bi961183y; Thoden JB, 1999, ACTA CRYSTALLOGR D, V55, P8, DOI 10.1107/S0907444998006234; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; WANG TT, 1972, J BIOL CHEM, V247, P4437; WELLNER VP, 1973, BIOCHEMISTRY-US, V12, P2061, DOI 10.1021/bi00735a006; WIMMER MJ, 1979, J BIOL CHEM, V254, P1854	34	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26233	26240		10.1074/jbc.275.34.26233	http://dx.doi.org/10.1074/jbc.275.34.26233			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10950966	hybrid			2022-12-27	WOS:000088999700049
J	Bauer, CB; Holden, HM; Thoden, JB; Smith, R; Rayment, I				Bauer, CB; Holden, HM; Thoden, JB; Smith, R; Rayment, I			X-ray structures of the apo and MgATP-bound states of Dictyostelium discoideum myosin motor domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN; MUSCLE-CONTRACTION; CRYSTAL-STRUCTURE; ACTIVE-SITE; COMPLEX; SUBFRAGMENT-1; MGADP; CONFORMATION; HYDROLYSIS; RESOLUTION	Myosin is the most comprehensively studied molecular motor that converts energy from the hydrolysis of MgATP into directed movement. Its motile cycle consists of a sequential series of interactions between myosin, actin, MgATP, and the products of hydrolysis, where the affinity of myosin for actin is modulated by the nature of the nucleotide bound in the active site. The first step in the contractile cycle occurs when ATP binds to actomyosin and releases myosin from the complex. We report here the structure of the motor domain of Dictyostelium discoideum myosin II both in its nucleotide-free state and complexed with MgATP. The structure with MgATP was obtained by soaking the crystals in substrate. These structures reveal that both the apo form and the MgATP complex are very similar to those previously seen with MgATP gammaS and MgAMP-PNP. Moreover, these structures are similar to that of chicken skeletal myosin subfragment-l, The crystallized protein is enzymatically active in solution, indicating that the conformation of myosin observed in chicken skeletal myosin subfragment-l is unable to hydrolyze ATP and most likely represents the pre-hydrolysis structure for the myosin head that occurs after release from actin.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Rayment, I (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.		rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035186] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35186] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker JE, 1998, P NATL ACAD SCI USA, V95, P2944, DOI 10.1073/pnas.95.6.2944; Bauer CB, 1997, J MOL BIOL, V274, P394, DOI 10.1006/jmbi.1997.1325; Brust-Mascher I, 1999, BIOCHEMISTRY-US, V38, P12607, DOI 10.1021/bi9905967; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; DANTZIG JA, 1985, J GEN PHYSIOL, V86, P305, DOI 10.1085/jgp.86.3.305; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GOODY RS, 1975, PROTEIN LIGAND INTER, P109; GREENE LE, 1980, J BIOL CHEM, V255, P543; Gulick AM, 2000, J BIOL CHEM, V275, P398, DOI 10.1074/jbc.275.1.398; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; HENRY GD, 1993, BIOCHEMISTRY-US, V32, P10451, DOI 10.1021/bi00090a022; HOLMES KC, 1997, CURR BIOL, V7, P112; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park S, 1997, BIOCHEMISTRY-US, V36, P3368, DOI 10.1021/bi9624999; Phan BC, 1996, BIOPHYS CHEM, V59, P341, DOI 10.1016/0301-4622(95)00127-1; PONOMAREV MA, 1995, FEBS LETT, V371, P261, DOI 10.1016/0014-5793(95)00898-J; Ramachandran S, 1999, BIOCHEMISTRY-US, V38, P9097, DOI 10.1021/bi9902945; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Resetar AM, 1995, BIOCHEMISTRY-US, V34, P16039, DOI 10.1021/bi00049a018; Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2; Rostkova EV, 1999, BIOCHEMISTRY-MOSCOW+, V64, P875; Roussel A., 1991, SILICON GRAPHICS GEO, V86; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4	37	104	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38494	38499		10.1074/jbc.M005585200	http://dx.doi.org/10.1074/jbc.M005585200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10954715	hybrid			2022-12-27	WOS:000165739800049
J	Ives, EB; Nichols, J; Wente, SR; York, JD				Ives, EB; Nichols, J; Wente, SR; York, JD			Biochemical and functional characterization of inositol 1,3,4,5,6-pentakisphosphate 2-kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; ASSEMBLY PROTEIN AP-2; SACCHAROMYCES-CEREVISIAE; RNA-EXPORT; ARGININE METABOLISM; ACTIN CYTOSKELETON; YEAST-CELLS; SH3 DOMAIN; AMPHIPHYSIN; BINDING	Synthesis of inositol 1,2,3,4,5,6-hexakisphosphate (IP6), also known as phytate, is integral to cellular function in all eukaryotes. Production of IP6 predominately occurs through phosphorylation of inositol 1,3,4,5,6-pentakisphosphate (IP5) by a 2-kinase. Recent cloning of the gene encoding this kinase from Saccharomyces cerevisiae, designated scIpk1, has identified a cellular role for IP6 production in the regulation of mRNA export from the nucleus. In this report, we characterize the biochemical and functional parameters of recombinant scIpk1. Purified recombinant scIpk1 kinase activity is highly selective for IP5 substrate and exhibits apparent Ii, values of 644 nM and 62.8 muM for IP5 and ATP, respectively. The observed apparent catalytic efficiency (k(cat)/ K-m) of scIpk1 is 31,610 s(-1) M-1. A sequence similarity search was used to identify an IP5 2-kinase from the fission yeast Schizosaccharomyces pombe. Recombinant spIpk1 has similar substrate selectivity and catalytic efficiency to its budding yeast counterpart, despite sharing only 24% sequence identity. Cells lacking scIPk1 are deficient in IP6 production and exhibit lethality in combination with a gle1 mutant allele. Both of these phenotypes are complemented by expression of the spIPK1 gene in the sc-ipk1 cells. Analysis of several inactive mutants and multiple sequence alignment of scIpk1, spIpk1, and a putative Candida albicans Ipk1 have identified residues involved in catalysis. This includes two conserved motifs: E(i/l/m)KPKWL(t/y) and LXMTLRDV(t/g) (l/c)(f/y)I. Our data suggest that the mechanism for IP6 production is conserved across species.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Washington University (WUSTL); Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Wente, SR (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051219, R37GM051219] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55672] Funding Source: Medline; NIGMS NIH HHS [GM51219] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Balguerie A, 1999, J CELL SCI, V112, P2529; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; BECK KA, 1991, J BIOL CHEM, V266, P4442; Biswas S, 1996, Subcell Biochem, V26, P287; Colwill K, 1999, GENETICS, V152, P881; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DESFARGES L, 1993, YEAST, V9, P267, DOI 10.1002/yea.320090306; DROBAK BK, 1992, BIOCHEM J, V288, P697, DOI 10.1042/bj2880697; DUBOIS E, 1994, MOL GEN GENET, V243, P315, DOI 10.1007/BF00301067; Gadd GM, 1997, MICROBIOL-SGM, V143, P437, DOI 10.1099/00221287-143-2-437; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HUANG XQ, 1994, COMPUT APPL BIOSCI, V10, P227; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Lee J, 1998, CURR BIOL, V8, P1310, DOI 10.1016/S0960-9822(07)00561-1; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MESSENGUY F, 1993, MOL CELL BIOL, V13, P2586, DOI 10.1128/MCB.13.4.2586; Mizutani A, 1997, BIOCHEM BIOPH RES CO, V240, P128, DOI 10.1006/bbrc.1997.7578; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Navarro P, 1997, BBA-PROTEIN STRUCT M, V1343, P187, DOI 10.1016/S0167-4838(97)00108-8; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Ongusaha PP, 1998, BIOCHEM J, V335, P671, DOI 10.1042/bj3350671; PHILLIPPY BQ, 1994, J BIOL CHEM, V269, P28393; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Sambrook J., 2002, MOL CLONING LAB MANU; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P8976, DOI 10.1073/pnas.89.19.8976; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Watkins JL, 1998, P NATL ACAD SCI USA, V95, P6779, DOI 10.1073/pnas.95.12.6779; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96	49	64	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36575	36583		10.1074/jbc.M007586200	http://dx.doi.org/10.1074/jbc.M007586200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10960485	hybrid			2022-12-27	WOS:000165577700018
J	Kunz, J; Schneider, U; Howald, I; Schmidt, A; Hall, MN				Kunz, J; Schneider, U; Howald, I; Schmidt, A; Hall, MN			HEAT repeats mediate plasma membrane localization of Tor2p in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL KINASE HOMOLOG; GTP-BINDING PROTEIN; EXCHANGE FACTOR ROM2; P70 S6 KINASE; SACCHAROMYCES-CEREVISIAE; SIGNALING PATHWAY; CELL-GROWTH; AMINO-ACID; ACTIN CYTOSKELETON; SERINE RESIDUE	The subcellular distribution of Tor1p and Tor2p, two phosphatidylinositol kinase homologs and targets of the immunosuppressive drug rapamycin in Saccharomyces cerevisiae, was analyzed. We found that Tor protein is peripherally associated with membranes. Subcellular fractionation and immunofluorescence studies showed that Tor1p and Tor2p associate with the plasma membrane and a second fraction that is distinct from Golgi, vacuoles, mitochondria, and nucleus and may represent vesicular structures. Pulse-chase experiments showed that association of Tor protein with plasma membrane and the second compartment is fast, does not appear to involve components of endocytic, secretory, or Golgi to vacuole transport pathways, and is not affected by the immunosuppressive drag rapamycin. Deletion analysis reveals that two domains within Tor2p independently mediate localization to both compartments. These domains are composed of HEAT repeats that are thought to act as protein-protein interaction surfaces. Our studies therefore place Tor proteins at the site of action of their known downstream effecters and suggest that they may be part of a multiprotein complex.	Univ Basel, Biozentrum, Dept Biochem, CH-4056 Basel, Switzerland	University of Basel	Hall, MN (corresponding author), Univ Basel, Biozentrum, Dept Biochem, Klingelbergstr 70, CH-4056 Basel, Switzerland.			Hall, Michael N/0000-0002-2998-0757				Alarcon CM, 1999, MOL BIOL CELL, V10, P2531, DOI 10.1091/mbc.10.8.2531; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Fiorentino DF, 1997, MOL BIOL CELL, V8, P2519, DOI 10.1091/mbc.8.12.2519; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Gusella JF, 1998, CURR OPIN NEUROBIOL, V8, P425, DOI 10.1016/S0959-4388(98)80071-8; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Helliwell SB, 1998, GENETICS, V148, P99; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; Manning BD, 1997, MOL BIOL CELL, V8, P1829, DOI 10.1091/mbc.8.10.1829; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MCCAFFREY M, 1991, J CELL BIOL, V115, P309, DOI 10.1083/jcb.115.2.309; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHERMAN F, 1991, P3; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; STAN R, 1994, J BIOL CHEM, V269, P32027; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	53	106	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37011	37020		10.1074/jbc.M007296200	http://dx.doi.org/10.1074/jbc.M007296200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973982	Green Accepted, hybrid			2022-12-27	WOS:000165577700079
J	Morii, H; Nishihara, M; Koga, Y				Morii, H; Nishihara, M; Koga, Y			CTP : 2,3-di-O-geranylgeranyl-sn-glycero-1-phosphate cytidyltransferase in the methanogenic archaeon Methanothermobacter thermoautotrophicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENANTIOMERIC GLYCEROPHOSPHATE BACKBONE; METHANOBACTERIUM-THERMOAUTOTROPHICUM; SN-GLYCEROL-1-PHOSPHATE DEHYDROGENASE; ARCHAEBACTERIAL MEMBRANES; ETHER LIPIDS; BIOSYNTHESIS; PURIFICATION; ENZYME; ACID; PHOSPHOLIPIDS	CDP-S, 3-di-O-geranylgeranyl-sn-glycerol synthase (CDP-archaeol synthase) activity was discovered in the membrane fraction of the methanoarchaeon Methano-thennobacter thermoautotrophicus cells. It catalyzed the formation of CDP-2,3-di-O-geranylgeranyl-sn-glycerol from CTP and 2,3-di-O-geranylgeranyl-sn-glycero-1-phosphate (unsaturated archaetidic acid). The identity of the reaction product was confirmed by thin layer chromatography, fast atom bombardment-mass spectroscopy, chemical analysis, and by UV spectroscopy. One mole of the product was formed hom approximately 1 mol of each of the reactants. The enzyme showed maximal. activity at pH 8.5 and 55 degreesC in the presence of Mg2+ and K+ ions. By in vivo pulse labeling of phospholipids with P-32(i), CDP-archaeol was found to be an intracellular intermediate. A cell-free homogenate of Bf. thermoautotrophicus, when incubated with L-serine, converted the product of CDP-archaeol synthase reaction to a product with the same chromatographic mobility as archaetidylserine. It was concluded from these results that both CDP-archaeol and CDP-archaeol synthase were involved in cellular phospholipid biosynthesis. Among various synthetic substrate analogs, both enantiomers of unsaturated archaetidic acid possessing geranylgeranyl chains showed similar levels of activity, while archaetidic acid with saturated or monounsaturated isoprenoid or straight chains was a poor substrate, despite having the same stereostructure as the fully active substrate. The ester analogs with geranylgeranioyl chains showed significant activities. These results suggest that the enzyme dose not recognize ether or ester bonds between glycerophosphate and hydrocarbon chains nor the stereostructure of the glycerophosphate backbone but mainly targets substrates with geranylgeranyl chains.	Univ Occupat & Environm Hlth, Sch Med, Dept Chem, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Hlth Sci, Dept Environm Management, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Koga, Y (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Chem, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.							BAER E, 1951, J BIOL CHEM, V189, P235; BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BITTMAN R, 1984, CHEM PHYS LIPIDS, V34, P201, DOI 10.1016/0009-3084(84)90044-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARTER JR, 1968, J LIPID RES, V9, P748; CHEN AJ, 1993, J BIOL CHEM, V268, P21701; Dowhan W, 1997, BBA-LIPID LIPID MET, V1348, P157, DOI 10.1016/S0005-2760(97)00111-2; ISOBE M, 1987, TETRAHEDRON, V43, P4767, DOI 10.1016/S0040-4020(01)86918-0; KATES M, 1971, CAN J BIOCHEM CELL B, V49, P275, DOI 10.1139/o71-040; KATES M, 1978, Progress in the Chemistry of Fats and Other Lipids, V15, P301; KATES M, 1972, TECHNIQUES LIPIDOLOG, P558; MENGER FM, 1993, J AM CHEM SOC, V115, P6600, DOI 10.1021/ja00068a017; NISHIHARA M, 1995, J BIOCHEM-TOKYO, V117, P933, DOI 10.1093/oxfordjournals.jbchem.a124822; NISHIHARA M, 1990, BIOCHEM CELL BIOL, V68, P91, DOI 10.1139/o90-011; Nishihara M, 1997, J BIOCHEM-TOKYO, V122, P572; NISHIHARA M, 1989, BIOCHEMISTRY-US, V28, P95, DOI 10.1021/bi00427a014; NISHIHARA M, 1987, J BIOCHEM-TOKYO, V101, P1007, DOI 10.1093/oxfordjournals.jbchem.a121942; POULTER CD, 1988, J AM CHEM SOC, V110, P2620, DOI 10.1021/ja00216a041; Rosenthal A F, 1975, Methods Enzymol, V35, P429, DOI 10.1016/0076-6879(75)35179-3; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPARROW CP, 1992, METHOD ENZYMOL, V209, P237; SPARROW CP, 1985, J BIOL CHEM, V260, P2084; Wasserfallen A, 2000, INT J SYST EVOL MICR, V50, P43, DOI 10.1099/00207713-50-1-43; ZHANG DL, 1990, J AM CHEM SOC, V112, P1264, DOI 10.1021/ja00159a067; ZHANG DL, 1993, J AM CHEM SOC, V115, P1270, DOI 10.1021/ja00057a008	27	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36568	36574		10.1074/jbc.M005925200	http://dx.doi.org/10.1074/jbc.M005925200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10960477	hybrid			2022-12-27	WOS:000165577700017
J	Perugini, MA; Schuck, P; Howlett, GJ				Perugini, MA; Schuck, P; Howlett, GJ			Self-association of human apolipoprotein E3 and E4 in the presence and absence of phospholipid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; LOW-DENSITY LIPOPROTEINS; RECEPTOR-BINDING DOMAIN; AMINO-ACID-SEQUENCE; E ISOFORMS; ALZHEIMERS-DISEASE; AQUEOUS-SOLUTIONS; NMR-SPECTROSCOPY; LAMM EQUATION; SEDIMENTATION	Human apolipoprotein E (apoE) exists as three main isoforms, differing by single amino acid substitutions, with the apoE4 isoform strongly linked to the incidence of late onset Alzheimer's disease. We have expressed and purified apoE3 and apoE4 from Escherichia coli and compared their hydrodynamic properties by gel permeation liquid chromatography, capillary electrophoresis, circular dichroism, and sedimentation methods. Sedimentation velocity experiments, employing a new method for determining the size distribution of polydisperse macromolecules in solution (Schuck, P. (2000) Biophys. J. 78, 1606-1619), provide direct evidence for the heterogeneous solution structures of apoE3 and apoE4. In a lipid-free environment, apoE3 and apoE4 exist as a slow equilibrium mixture of monomer, tetramer, octamer, and a small proportion of higher oligomers. Both sedimentation velocity and equilibrium experiments indicate that apoE4 has a greater propensity to self-associate. We also demonstrate that apoE3 and apoE4 oligomers dissociate significantly in the presence of dihexanoylphosphatidylcholine micelles (20 mM) and to a lesser extent at submicellar concentrations (4 mM). The ct-helical content for both isoforms was almost identical (50%) in the presence and absence of dihexanoylphosphatidylcholine. These results reveal that apoE oligomers undergo phospholipid-induced dissociation to folded monomers, suggesting the monomeric form prevails on the lipoprotein surface in vivo.	Univ Melbourne, Russel Grimwade Sch Biochem & Mol biol, Parkville, Vic 3052, Australia; NIH, Div Bioengn & Phys Sci, Off Res Serv, Bethesda, MD 20892 USA	University of Melbourne; National Institutes of Health (NIH) - USA	Howlett, GJ (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia.	g.howlett@biochemistry.unimelb.edu.au	Schuck, Peter/AAA-6888-2020	Schuck, Peter/0000-0002-8859-6966; Perugini, Matthew/0000-0001-8052-5584	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD010485] Funding Source: NIH RePORTER	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Buchko GW, 1998, BBA-LIPID LIPID MET, V1392, P101, DOI 10.1016/S0005-2760(98)00028-9; BURNS RA, 1980, BIOCHEMISTRY-US, V19, P3100, DOI 10.1021/bi00554a041; Chan W, 1996, BIOCHEMISTRY-US, V35, P7123, DOI 10.1021/bi952852v; CLAVERIE JM, 1976, BIOPOLYMERS, V15, P843, DOI 10.1002/bip.1976.360150504; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; COX DJ, 1969, ARCH BIOCHEM BIOPHYS, V129, P106, DOI 10.1016/0003-9861(69)90157-X; DERGUNOV AD, 1992, BIOL CHEM H-S, V373, P323, DOI 10.1515/bchm3.1992.373.1.323; DONG LM, 1994, J BIOL CHEM, V269, P22358; EISENBERG S, 1984, J LIPID RES, V25, P1017; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Forstner M, 1999, PROTEIN EXPRES PURIF, V17, P267, DOI 10.1006/prep.1999.1144; Golabek AA, 1996, J BIOL CHEM, V271, P10602, DOI 10.1074/jbc.271.18.10602; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Lamm O., 1929, ARK MAT ASTR FYS, V21B, P1; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; MacPhee CE, 1997, FEBS LETT, V416, P265, DOI 10.1016/S0014-5793(97)01224-6; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Minton AP, 1997, CURR OPIN BIOTECH, V8, P65, DOI 10.1016/S0958-1669(97)80159-0; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P375; RALL SC, 1982, J BIOL CHEM, V257, P4171; ROZEK A, 1995, BIOCHEMISTRY-US, V34, P7401, DOI 10.1021/bi00022a013; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SHORE VG, 1973, BIOCHEMISTRY-US, V12, P502, DOI 10.1021/bi00727a022; SPARROW JT, 1992, BIOCHEMISTRY-US, V31, P1065, DOI 10.1021/bi00119a015; TAUSK RJM, 1974, BIOPHYS CHEM, V2, P175, DOI 10.1016/0301-4622(74)80004-9; UTERMANN G, 1975, FEBS LETT, V56, P352, DOI 10.1016/0014-5793(75)81125-2; Wang GS, 1996, BIOCHEMISTRY-US, V35, P10358, DOI 10.1021/bi960934t; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; Wood SJ, 1996, BIOCHEMISTRY-US, V35, P12623, DOI 10.1021/bi961074j; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375; ZANNIS VI, 1982, J LIPID RES, V23, P911; ZIMMERMAN SB, 1993, BIOCHIM BIOPHYS ACTA, V1216, P175, DOI 10.1016/0167-4781(93)90142-Z	40	101	102	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36758	36765		10.1074/jbc.M005565200	http://dx.doi.org/10.1074/jbc.M005565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10970893	hybrid			2022-12-27	WOS:000165577700045
J	Tullai, JW; Cummins, PM; Pabon, A; Roberts, JL; Lopingeo, MC; Shrimpton, CN; Smith, AI; Martignetti, JA; Ferro, ES; Glucksman, MJ				Tullai, JW; Cummins, PM; Pabon, A; Roberts, JL; Lopingeo, MC; Shrimpton, CN; Smith, AI; Martignetti, JA; Ferro, ES; Glucksman, MJ			The neuropeptide processing enzyme EC 3.4.24.15 is modulated by protein kinase A phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENKEPHALIN-CONTAINING PEPTIDES; HORMONE-RELEASING HORMONE; ENDOPEPTIDASE 24.15; LUTEINIZING-HORMONE; METALLOENDOPEPTIDASE EC-3.4.24.15; SECRETORY GRANULES; GROWTH-FACTOR; RAT TESTES; CELLS; INHIBITION	The metalloendopeptidase EC 3.4.24.15 (EP24.15) is a neuropeptide-metabolizing enzyme expressed predominantly in brain, pituitary, and testis, and is implicated in several physiological processes and diseases. Multiple putative phosphorylation sites in the primary sequence led us to investigate whether phosphorylation effects the specificity and/or the kinetics of substrate cleavage. Only protein kinase A (PICA) treatment resulted in serine phosphorylation with a stoichiometry of 1.11 +/- 0.12 mol of phosphate/mol of recombinant rat EP24.15. Mutation analysis of each putative PICA site, in vitro phosphorylation, and phosphopeptide mapping indicated serine 644 as the phosphorylation site. Phosphorylation effects on catalytic activity were assessed using physiological (GnRH, GnRH(1-9) bradykinin, and neurotensin) and fluorimetric (MCA-PLGPDL-Dnp and orthoaminobenzoyl-GGFLRRV-Dnp-edn) substrates. The most dramatic change upon PICA phosphorylation was a substrate-specific, 7-fold increase in both K-m and k(cat) for GnRH. In both rat PC12 and mouse AtT-20 cells, EP24.15 was serine-phosphorylated, and EP24.15 phosphate incorporation was enhanced by forskolin treatment, and attenuated by H89, consistent with PICA-mediated phosphorylation. Cloning of the full-length mouse EP24.15 cDNA revealed 96.7% amino acid identity to the rat sequence, and conservation at serine 644, consistent with its putative functional role. Therefore, PICA phosphorylation is suggested to play a regulatory role in EP24.15 enzyme activity.	CUNY Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, Struct Neurol & Proteom Lab, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Baker Med Res Inst, Peptide Biol Lab, Melbourne, Vic 8008, Australia	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Baker Heart and Diabetes Institute	Glucksman, MJ (corresponding author), CUNY Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, Struct Neurol & Proteom Lab, Box 1065,1425 Madison Ave, New York, NY 10029 USA.	glux@msvax.mssm.edu	Ferro, Emer S/D-3908-2012	Ferro, Emer S/0000-0003-1651-9192; Smith, Ian/0000-0002-4143-2892	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007135] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD28822] Funding Source: Medline; NIDA NIH HHS [2T32-DA7135-16] Funding Source: Medline; NIDDK NIH HHS [T32-DK07645] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asara JM, 1999, J AM SOC MASS SPECTR, V10, P35, DOI 10.1016/S1044-0305(98)00129-9; CACACE AM, 1993, ONCOGENE, V8, P2095; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHU TG, 1985, ENDOCRINOLOGY, V116, P1418, DOI 10.1210/endo-116-4-1418; Crack PJ, 1999, BRAIN RES, V835, P113, DOI 10.1016/S0006-8993(99)01494-8; Cummins PM, 1999, J BIOL CHEM, V274, P16003, DOI 10.1074/jbc.274.23.16003; DAHMS P, 1992, EUR J BIOCHEM, V208, P145, DOI 10.1111/j.1432-1033.1992.tb17168.x; DIXON M, 1959, BIOCHEM J, V55, P170; FERRO ES, 1995, J CELL BIOCHEM, V57, P311, DOI 10.1002/jcb.240570215; Ferro ES, 1999, DNA CELL BIOL, V18, P781, DOI 10.1089/104454999314926; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Ganju RK, 1996, BLOOD, V88, P4159; GARVEY EP, 1989, BIOCHEMISTRY-US, V28, P2083, DOI 10.1021/bi00431a018; GLUCKSMAN MJ, 1992, BIOPHYS J, V62, P119, DOI 10.1016/S0006-3495(92)81798-8; GLUCKSMAN MJ, 1995, METH NEUROSCI, V23, P296; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HARDIE DG, 1992, BIOCH MESSENGERS HOR; HEALY DP, 1992, BRAIN RES, V571, P121, DOI 10.1016/0006-8993(92)90517-D; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; JULIANO L, 1990, BIOCHEM BIOPH RES CO, V173, P647, DOI 10.1016/S0006-291X(05)80084-1; KAMTEKAR S, 1995, FASEB J, V9, P1013, DOI 10.1096/fasebj.9.11.7649401; KEST B, 1992, PSYCHOPHARMACOLOGY, V106, P408, DOI 10.1007/BF02245427; KRAUSS RS, 1992, MOL CELL BIOL, V12, P3117, DOI 10.1128/MCB.12.7.3117; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASDUN A, 1989, J PHARMACOL EXP THER, V251, P439; LASDUN A, 1990, J PHARMACOL EXP THER, V253, P1265; LEVINE JE, 1999, ENCY REPROD, V2, P478; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MAINS RE, 1987, ANN NY ACAD SCI, V493, P278, DOI 10.1111/j.1749-6632.1987.tb27213.x; Martins LM, 1998, BLOOD, V92, P3042, DOI 10.1182/blood.V92.9.3042.421k55_3042_3049; Mason GGF, 1996, EUR J BIOCHEM, V238, P453, DOI 10.1111/j.1432-1033.1996.0453z.x; Montiel JL, 1997, J NEUROCHEM, V68, P354; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NESTLER EJ, 1983, NATURE, V305, P583, DOI 10.1038/305583a0; NEUFELD E, 1989, ANAL BIOCHEM, V177, P138, DOI 10.1016/0003-2697(89)90028-6; NIEDBALSKI JS, 1986, ANAL BIOCHEM, V158, P138, DOI 10.1016/0003-2697(86)90601-9; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; ORLOWSKI M, 1988, BIOCHEMISTRY-US, V27, P597, DOI 10.1021/bi00402a015; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Shrimpton CN, 1997, J BIOL CHEM, V272, P17395, DOI 10.1074/jbc.272.28.17395; Smith B J, 1994, Methods Mol Biol, V32, P297; VANDERGEER P, 1993, PROTEIN PHOSPHORYLAT, P32; Vincent B, 1997, EUR J PHARMACOL, V334, P49, DOI 10.1016/S0014-2999(97)01209-0; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; WILKINS MR, 1998, 2 D PROTEOME ANAL PR, P531; Wu TJ, 1997, J NEUROENDOCRINOL, V9, P813, DOI 10.1046/j.1365-2826.1997.00637.x; Yamin R, 1999, J BIOL CHEM, V274, P18777, DOI 10.1074/jbc.274.26.18777	52	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36514	36522		10.1074/jbc.M001843200	http://dx.doi.org/10.1074/jbc.M001843200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10969067	hybrid			2022-12-27	WOS:000165577700010
J	Bertram, PG; Choi, JH; Carvalho, J; Ai, WD; Zeng, CB; Chan, TF; Zheng, XFS				Bertram, PG; Choi, JH; Carvalho, J; Ai, WD; Zeng, CB; Chan, TF; Zheng, XFS			Tripartite regulation of Gln3p by TOR, Ure2p, and phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SIGNALING PATHWAY; RAPAMYCIN; YEAST; PROTEINS; DOMAIN; IDENTIFICATION; TRANSCRIPTION; GENE; SEQUENCE	Gln3p is a GATA-type transcription factor responsive to different nitrogen nutrients and starvation in yeast Saccharomyces cerevisiae, Recent evidence has linked TOR signaling to Gln3p. Rapamycin causes dephosphorylation and nuclear translocation of Gln3p, thereby activating nitrogen catabolite repressible-sensitive genes. However, a detailed mechanistic understanding of this process is lacking, In this study, we show that Tor1p physically interacts with Gln3p, An intact TOR kinase domain is essential for the phosphorylation of Gln3p, inhibition of Gln3p nude ar entry and repression of Gln3p-dependent transcription. In contrast, at least two distinct protein phosphatases, Pph3p and the Tap42p-dependent phosphatases, are involved in the activation of Gln3p. The yeast pro-prion protein Ure2p binds to both hyper- and hypo-phosphorylated Gln3p. In contrast to the free Gln3p, the Ure2p-bound Gln3p is significantly resistant to dephosphorylation, Taken together, these results reveal. a tripartite regulatory mechanism by which the phosphorylation of Gln3p is regulated.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Mol Genet Program, St Louis, MO 63110 USA; Washington Univ, Sch Med, Mol Cell Biol Program, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Zheng, XFS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8069,660 S Euclid Ave, St Louis, MO 63110 USA.		Chan, TingFung/A-6161-2013	Chan, TingFung/0000-0002-0489-3884				ADAMS A, 1997, METHODS YEAST GENETI, P137; Alarcon CM, 1999, MOL BIOL CELL, V10, P2531, DOI 10.1091/mbc.10.8.2531; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 1998, CURR BIOL, V8, P1259, DOI 10.1016/S0960-9822(07)00535-0; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; Brachmann CB, 1998, YEAST, V14, P115; CAFFERKEY R, 1994, GENE, V141, P133, DOI 10.1016/0378-1119(94)90141-4; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; Coffman JA, 1997, J BACTERIOL, V179, P3416, DOI 10.1128/jb.179.11.3416-3429.1997; COORNAERT D, 1991, GENE, V97, P163, DOI 10.1016/0378-1119(91)90048-G; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Edskes HK, 2000, P NATL ACAD SCI USA, V97, P6625, DOI 10.1073/pnas.120168697; Edskes HK, 1999, GENETICS, V153, P585; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; James P, 1996, GENETICS, V144, P1425; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KURNUVILLA F, 1999, CHEM BIOL, V6, pR129; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; MAHAJAN PB, 1994, INT J IMMUNOPHARMACO, V16, P711, DOI 10.1016/0192-0561(94)90091-4; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	35	182	189	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35727	35733		10.1074/jbc.M004235200	http://dx.doi.org/10.1074/jbc.M004235200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10940301	hybrid			2022-12-27	WOS:000165382000014
J	Pan, Z; Zhou, LM; Hetherington, CJ; Zhang, DE				Pan, Z; Zhou, LM; Hetherington, CJ; Zhang, DE			Hepatocytes contribute to soluble CD14 production, and CDP4 expression is differentially regulated in hepatocytes and monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE-BINDING-PROTEIN; BACTERIAL LIPOPOLYSACCHARIDE; ENDOTHELIAL-CELLS; INNATE IMMUNITY; DEFICIENT MICE; SEPTIC SHOCK; IN-VIVO; GENE; RECEPTOR; LPS	CD14 presents as a glycosylphosphatidylinositol-linked membrane protein on the surface of monocytes/macrophages and as a soluble protein in the serum. Our previous studies have shown that an 80-kilobase pair (kb) genomic DNA fragment containing the human CD14 gene is Sufficient to direct CD14 expression in a monocyte-specific manner in transgenic mice. In addition, we discovered that human CD14 is highly expressed in hepatocytes, Here, we report the generation of transgenic mice with either a 24- or 33-kb human CD14 genomic DNA fragment. Data from multiple transgenic lines show that neither the 24- nor the 33-kb transgenic mice express human CD14 in monocytes/macrophages. However, human CD14 is highly expressed in the liver of the 33-kb transgenic mice. These results demonstrate that human CD14 expression is regulated differently in monocytes and hepatocytes, Furthermore, we identified an upstream regulatory element beyond the 24-kb region, but within the 33-kb region of the human CD14 gene,which is critical for CD14 expression in hepatocytes, but not in monocytes/macrophages. Most importantly, the data demonstrate that the liver is one of the major organs for the production of soluble CD14. These transgenic mice provide an excellent system to further explore the functions of soluble CD14.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Zhang, DE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-L51,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA/AI59589] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA059589] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; BAZIL V, 1989, MOL IMMUNOL, V26, P657, DOI 10.1016/0161-5890(89)90048-5; BEEKHUIZEN H, 1991, J IMMUNOL, V147, P3761; Blondin C, 1997, EUR J IMMUNOL, V27, P3303, DOI 10.1002/eji.1830271229; Cauwels A, 1999, J IMMUNOL, V162, P4762; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; FEARNS C, 1995, J EXP MED, V181, P857, DOI 10.1084/jem.181.3.857; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; GRIFFIN JD, 1981, J CLIN INVEST, V68, P932, DOI 10.1172/JCI110348; HAZIOT A, 1993, J IMMUNOL, V151, P1500; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Heidenreich S, 1997, J IMMUNOL, V159, P3178; Hetherington CJ, 1999, J IMMUNOL, V162, P503; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Jack RS, 1997, NATURE, V389, P742, DOI 10.1038/39622; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Liu SB, 1998, INFECT IMMUN, V66, P5089, DOI 10.1128/IAI.66.11.5089-5098.1998; LUE KH, 1991, J IMMUNOL, V147, P1134; Nanbo A, 1999, EUR J BIOCHEM, V260, P183, DOI 10.1046/j.1432-1327.1999.00141.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Pan Z, 1999, J BIOL CHEM, V274, P23242, DOI 10.1074/jbc.274.33.23242; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Radomska HS, 1998, GENE, V222, P305, DOI 10.1016/S0378-1119(98)00491-0; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Schletter J, 1995, ARCH MICROBIOL, V164, P383, DOI 10.1007/BF02529735; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SCOTT LM, 1992, BLOOD, V80, P1725; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; SIMMONS DL, 1989, BLOOD, V73, P284; STONE R, 1994, SCIENCE, V264, P365, DOI 10.1126/science.8153620; Su GL, 1999, J HEPATOL, V31, P435, DOI 10.1016/S0168-8278(99)80034-8; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; VOLPES R, 1991, LANCET, V337, P60, DOI 10.1016/0140-6736(91)93387-O; Wang PY, 1998, J BIOL CHEM, V273, P24309, DOI 10.1074/jbc.273.38.24309; Wright SD, 1999, J EXP MED, V189, P605, DOI 10.1084/jem.189.4.605; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wurfel MM, 1997, J EXP MED, V186, P2051, DOI 10.1084/jem.186.12.2051; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160; ZHANG DE, 1990, J BIOL CHEM, V265, P3382; ZHANG DE, 1994, J IMMUNOL, V153, P3276; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZIEGLERHEITBROCK HWL, 1993, IMMUNOL TODAY, V14, P121, DOI 10.1016/0167-5699(93)90212-4; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	51	62	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36430	36435		10.1074/jbc.M003192200	http://dx.doi.org/10.1074/jbc.M003192200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10960472	hybrid			2022-12-27	WOS:000165382000109
J	Bourbon, NA; Yun, J; Kester, M				Bourbon, NA; Yun, J; Kester, M			Ceramide directly activates protein kinase C zeta to regulate a stress-activated protein kinase signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ARACHIDONIC-ACID; MESANGIAL CELLS; INDUCED TRANSLOCATION; INDUCED APOPTOSIS; PKC-ZETA; PATHWAY; BINDING; DIFFERENTIATION; TRANSDUCTION	We have previously shown that interleukin 1 (IL-1)receptor-generated ceramide induces growth arrest in smooth muscle pericytes by activating an upstream kinase in the stress-activated protein kinase (SAPK) cascade. We now report the mechanism by which ceramide activates the SAPK signaling pathway in human embryonic kidney cells (HEK-293). We demonstrate that ceramide activation of protein kinase C zeta (PKC zeta) mediates SAPK signal complex formation and subsequent growth suppression. Ceramide directly activates both immunoprecipitated and recombinant human PKC zeta in vitro. Additionally, ceramide activates SAPK activity, which is blocked with a dominant-negative mutant of PKC zeta Coimmunoprecipitation studies reveal that ceramide induces the association of SAPK with PKC zeta, but not with PKC epsilon. In addition, ceramide treatment induces PKC zeta association with phosphorylated SEK and MEKK1, elements of the SAPK signaling complex. The biological role of ceramide to induce cell cycle arrest is mimicked by overexpression of a constitutively active PKC zeta. Together, these studies demonstrate that ceramide induces cell cycle arrest by enhancing the ability of PKC zeta to form a signaling complex with MEKK1, SEK, and SAPK.	Penn State Univ, Milton S Hershey Med Ctr, Dept Pharmacol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Kester, M (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Dept Pharmacol, Coll Med, POB 850, Hershey, PA 17033 USA.				NIDDK NIH HHS [DK53715] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053715] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Bieberich E, 2000, J BIOL CHEM, V275, P177, DOI 10.1074/jbc.275.1.177; BISWAS P, 1995, FEBS LETT, V373, P146, DOI 10.1016/0014-5793(95)01025-A; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Cacace AM, 1996, ONCOGENE, V13, P2517; Carpio LC, 1999, PROSTAG LEUKOTR ESS, V61, P267, DOI 10.1054/plef.1999.0100; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Coroneos E, 1996, BIOCHEM J, V316, P13, DOI 10.1042/bj3160013; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; GalveRoperh I, 1997, FEBS LETT, V415, P271, DOI 10.1016/S0014-5793(97)00985-X; Hurley JH, 1997, PROTEIN SCI, V6, P477; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kieser A, 1996, GENE DEV, V10, P1455, DOI 10.1101/gad.10.12.1455; KIM MY, 1991, J BIOL CHEM, V266, P484; Liu Q, 1998, J IMMUNOL, V160, P1393; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Mandal A, 1997, J BIOL CHEM, V272, P20306, DOI 10.1074/jbc.272.32.20306; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MONTANER S, 1995, ONCOGENE, V10, P2213; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; MUSIAL A, 1995, J BIOL CHEM, V270, P21632, DOI 10.1074/jbc.270.37.21632; Sawai H, 1997, J BIOL CHEM, V272, P2452; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shin EA, 1999, FEBS LETT, V452, P355, DOI 10.1016/S0014-5793(99)00657-2; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; SOZERI O, 1992, ONCOGENE, V7, P2259; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; van Blitterswijk WJ, 1998, BIOCHEM J, V331, P679; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671	42	188	192	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35617	35623		10.1074/jbc.M007346200	http://dx.doi.org/10.1074/jbc.M007346200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10962008	hybrid			2022-12-27	WOS:000165422800104
J	Pearlstone, JR; Chandra, M; Sorenson, MM; Smillie, LB				Pearlstone, JR; Chandra, M; Sorenson, MM; Smillie, LB			Biological function and site IICa2+-induced opening of the regulatory domain of skeletal troponin C are impaired by invariant site I or II Glu mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING SITES; MYOFIBRILLAR ADENOSINE-TRIPHOSPHATASE; CARDIAC TROPONIN; CA2+ BINDING; ANGSTROM RESOLUTION; N-DOMAIN; MUSCLE-CONTRACTION; CIRCULAR-DICHROISM; STRUCTURAL-CHANGES; PROMOTER PLASMIDS	To investigate the roles of site I and II invariant Glu residues 41 and 77 in the functional properties and calcium-induced structural opening of skeletal muscle troponin C (TnC) regulatory domain, we have replaced them by Ala in intact F29W TnC and in wild-type and F29W N domains (TnC residues 1-90). Reconstitution of intact E41A/F29W and E77A/F29W mutants into TnC-depleted muscle skinned fibers showed that Ca2+-induced tension is greatly reduced compared with the F29W control. Circular dichroism measurements of wild-type N domain as a function of pCa (= -log[Ca2+]) demonstrated that similar to 90% of the total change in molar ellipticity at 222 nm ([theta](222 nm)) could be assigned to site II Ca2+ binding. With E41A, E77A, and cardiac TnC N domains this [theta](222 nm) change attributable to site II was reduced to less than or equal to 40% of that seen with wild type, consistent with their structures remaining closed in +Ca2+. Furthermore, the Ca2+-induced changes in fluorescence, near UV CD, and UV difference spectra observed with intact F29W are largely abolished with E41A/F29W and E77A/F29W TnCs. Taken together, the data indicate that the major structural change in N domain, including the closed to open transition, is triggered by site II Ca2+ binding, all interpretation relevant to the energetics of the skeletal muscle TnC and cardiac TnC systems.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Fed Rio de Janeiro, ICB, Dept Bioquim Med, CCS, BR-21941590 Rio De Janeiro, Brazil	University of Alberta; Universidade Federal do Rio de Janeiro	Smillie, LB (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.							BABU A, 1992, J BIOL CHEM, V267, P15469; BECKINGHAM K, 1991, J BIOL CHEM, V266, P6027; CARLSTROM G, 1993, J MOL BIOL, V231, P415, DOI 10.1006/jmbi.1993.1291; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CHANDRA M, 1994, J BIOL CHEM, V269, P14988; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; Dong WJ, 1999, J BIOL CHEM, V274, P31382, DOI 10.1074/jbc.274.44.31382; EASTWOOD AB, 1979, TISSUE CELL, V11, P553, DOI 10.1016/0040-8166(79)90062-4; Evenas J, 1997, BIOCHEMISTRY-US, V36, P3448, DOI 10.1021/bi9628275; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Filatov VL, 1999, BIOCHEMISTRY-MOSCOW+, V64, P969; Foguel D, 1996, P NATL ACAD SCI USA, V93, P10642, DOI 10.1073/pnas.93.20.10642; Gagne SM, 1998, BIOCHEM CELL BIOL, V76, P302, DOI 10.1139/bcb-76-2-3-302; Gagne SM, 1997, BIOCHEMISTRY-US, V36, P4386, DOI 10.1021/bi963076+; Gagne SM, 1998, J MOL BIOL, V278, P667, DOI 10.1006/jmbi.1998.1723; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P777; GAHLMANN R, 1988, J MOL BIOL, V201, P379, DOI 10.1016/0022-2836(88)90145-3; GOLOSINSKA K, 1991, J BIOL CHEM, V266, P15797; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; HAIECH J, 1991, J BIOL CHEM, V266, P3427; HANNON JD, 1992, CIRC RES, V71, P984, DOI 10.1161/01.RES.71.4.984; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; IIDA S, 1988, J BIOCHEM-TOKYO, V103, P482, DOI 10.1093/oxfordjournals.jbchem.a122296; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; JOHNSON JD, 1994, J BIOL CHEM, V269, P8919; JOHNSON JD, 1978, J BIOL CHEM, V253, P3775; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Li MX, 1997, BIOCHEMISTRY-US, V36, P12519, DOI 10.1021/bi971222l; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; LI MX, 1995, BIOCHEMISTRY-US, V34, P8330, DOI 10.1021/bi00026a014; LI MX, 1994, BIOCHEMISTRY-US, V33, P917, DOI 10.1021/bi00170a010; MANNING MC, 1989, J PHARMACEUT BIOMED, V7, P1103, DOI 10.1016/0731-7085(89)80049-4; MAUNE JF, 1992, J BIOL CHEM, V267, P2586; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; McKay RT, 1999, BIOCHEMISTRY-US, V38, P5478; MCKAY RT, 1999, THESIS U ALBERTA, P148; MEAD DA, 1985, NUCLEIC ACIDS RES, V13, P1103, DOI 10.1093/nar/13.4.1103; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; Paakkonen K, 1998, J BIOL CHEM, V273, P15633, DOI 10.1074/jbc.273.25.15633; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; Perry SV, 1999, MOL CELL BIOCHEM, V190, P9, DOI 10.1023/A:1006939307715; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; PUTKEY JA, 1991, J BIOL CHEM, V266, P14881; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATYSHUR KA, 1994, ACTA CRYSTALLOGR D, V50, P40, DOI 10.1107/S090744499300798X; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; SORENSON MM, 1995, J BIOL CHEM, V270, P9770, DOI 10.1074/jbc.270.17.9770; Spyracopoulos L, 1998, BIOCHEMISTRY-US, V37, P18032, DOI 10.1021/bi9816960; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P9538, DOI 10.1073/pnas.87.24.9538; SZCYESNA D, 1996, J BIOL CHEM, V271, P8381; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Yu A, 1999, BBA-PROTEIN STRUCT M, V1431, P53, DOI 10.1016/S0167-4838(99)00043-6; Yu A, 1999, NATO ADV SCI I E-APP, V358, P515; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	72	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35106	35115		10.1074/jbc.M001000200	http://dx.doi.org/10.1074/jbc.M001000200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952969	hybrid			2022-12-27	WOS:000165422800039
J	Samuel, D; Kumar, TKS; Srimathi, T; Hsieh, H; Yu, C				Samuel, D; Kumar, TKS; Srimathi, T; Hsieh, H; Yu, C			Identification and characterization of an equilibrium intermediate in the unfolding pathway of an all beta-barrel protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; MOLTEN GLOBULE STATE; BINDING; BOVINE	The guanidinium hydrochloride (GdnHCl)-induced unfolding of an all beta -sheet protein, the human acidic fibroblast growth factor (hFGF-1), is studied using a variety of biophysical techniques including multidimensional NMR. spectroscopy. The unfolding of hFGF-1 in GdnHCl is shown to involve the formation of a stable equilibrium intermediate. Size exclusion chromotagraphy using fast protein liquid chromatography shows that the intermediate accumulates maximally at 0.96 hz GdnHCl, 1-Anilinonapthalene 8-sulfonate binding, one-dimensional H-1 NMR, and limited proteolytic digestion experiments suggest that the intermediate has characteristics resembling a molten globule state. Chemical shift: perturbation and hydrogen-deuterium exchange monitored by H-1-N-15 heteronuclear single quantum coherence spectra reveal that profound structural changes in the intermediate state (in 0.96 M GdnHCl) occur in the C-terminal, heparin binding region of the protein molecule, Additionally, results of the stopped flow fluorescence experiments suggest that the kinetic refolding of hFGF-1 proceeds through the accumulation of an intermediate at low concentrations of the denaturant. To our knowledge, the present study is the first report wherein an equilibrium intermediate is characterized in detail in an all beta -barrel protein.	Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan	National Tsing Hua University	Yu, C (corresponding author), Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan.	cyu@mx.nthu.edu.tw	Kumar, Dr Suresh/HHZ-2615-2022; Kumar, Suresh Thallapuranam/R-5606-2016; KUMAR, P. SURESH/AAT-8951-2020	Kumar, Dr Suresh/0000-0002-2539-6553; Kumar, Suresh Thallapuranam/0000-0001-7262-1373; KUMAR, P. SURESH/0000-0003-3222-2604				Arai M, 2000, ADV PROTEIN CHEM, V53, P209; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; BHUYAN AK, 1997, BIOCHEMISTRY-US, V38, P9158; Buchanan SK, 1999, CURR OPIN STRUC BIOL, V9, P455, DOI 10.1016/S0959-440X(99)80064-5; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; CARLSSON U, 1995, CURR OPIN STRUC BIOL, V5, P482, DOI 10.1016/0959-440X(95)80032-8; DABORA JM, 1996, J MOL BIOL, V285, P279; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; ELLISON D, 1995, PROTEIN SCI, V4, P1337, DOI 10.1002/pro.5560040709; Ferguson N, 1999, J MOL BIOL, V286, P1597, DOI 10.1006/jmbi.1998.2548; Jones S, 2000, BIOCHEMISTRY-US, V39, P5672, DOI 10.1021/bi9923959; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KUMAR TKS, 1995, BIOCHEM BIOPH RES CO, V207, P536, DOI 10.1006/bbrc.1995.1221; KUMAR TKS, 1994, J BIOL CHEM, V269, P12620; LIU ZP, 1994, BIOCHEMISTRY-US, V33, P134, DOI 10.1021/bi00167a017; Lozano RM, 2000, BIOCHEMISTRY-US, V39, P4982, DOI 10.1021/bi992544n; MACH H, 1995, BIOCHEMISTRY-US, V34, P9913, DOI 10.1021/bi00031a013; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MIERLO CPM, 2000, PROTEIN SCI, V9, P145; Mizuguchi M, 2000, J MOL BIOL, V298, P985, DOI 10.1006/jmbi.2000.3705; Ogura K, 1999, J BIOMOL NMR, V13, P11, DOI 10.1023/A:1008330622467; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; Park SH, 1997, BIOCHEMISTRY-US, V36, P14277, DOI 10.1021/bi971914+; Parker MJ, 1999, J MOL BIOL, V293, P1195, DOI 10.1006/jmbi.1999.3204; PinedaLucena A, 1996, J MOL BIOL, V264, P162, DOI 10.1006/jmbi.1996.0631; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; Ptitsyn Oleg B., 1992, P243; Sanz JM, 1997, EUR J BIOCHEM, V246, P328, DOI 10.1111/j.1432-1033.1997.00328.x; Schonbrunner N, 1997, BIOCHEMISTRY-US, V36, P9057, DOI 10.1021/bi970594r; Schulman BA, 1997, NAT STRUCT BIOL, V4, P630, DOI 10.1038/nsb0897-630; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; Sivaraman T, 1997, BIOCHEM J, V321, P457, DOI 10.1042/bj3210457; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; UVERSKY VN, 1992, FEBS LETT, V314, P89, DOI 10.1016/0014-5793(92)81468-2; WANG L, 1998, PROTEIN SCI, V7, P2360; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	38	42	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34968	34975		10.1074/jbc.M005147200	http://dx.doi.org/10.1074/jbc.M005147200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10950956	hybrid			2022-12-27	WOS:000165422800021
J	Buxton, DB; Adelstein, RS				Buxton, DB; Adelstein, RS			Calcium-dependent threonine phosphorylation of nonmuscle myosin in stimulated RBL-2H3 mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; II HEAVY-CHAIN; BASOPHILIC LEUKEMIA-CELLS; SPHINGOSINE KINASE; HISTAMINE-RELEASE; ANTIGEN; EXOCYTOSIS; SECRETION; RECEPTOR; MTS1	Stimulation of RBL-2H3 mi mast cells through the IgE receptor with antigen, or through a G protein-coupled receptor with carbachol, leads to the rapid appearance of phosphothreonine in nonmuscle myosin heavy chain ZI-A (NMHC-IIA). We demonstrate that this results from phosphorylation of Thr-1940 by calcium/calmodulin-dependent protein kinase II (CaM kinase II), activated by increased intracellular calcium. The phosphorylation site in rodent NMHC-IIA was localized to the carboxyl terminus of NMHC-IIA distal to the coiled-coil region, and,identified as Thr-1940 by site-directed mutagenesis. A fusion protein containing the NMHC-IIA carboxyl terminus was phosphorylated by GaM kinase II in vitro, while mutation of Thr-1940 to Ala eliminated phosphorylation. In contrast to rodents, in humans Thr-1940 is replaced by Ala, and human NMHC-IIA fusion protein was not phosphorylated by CaM kinase II unless Ala-->1940 was mutated to Thr, Similarly, co-transfected Ala-->Thr-1940 human NMHC-IIA was phosphorylated by activated CaM: kinase II in HeLa cells, while wild type was not. In RBL-2H3 mi cells, inhibition of CaM kinase II decreased Thr-1940 phosphorylation, and inhibited release of the secretory granule marker hexosaminidase in response to carbachol but not to antigen. These data indicate a role for CaM kinase stimulation and resultant threonine phosphorylation of NMHC-IIA in RBL-2H3 mi cell activation.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Buxton, DB (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202,10 Ctr Dr, Bethesda, MD 20892 USA.			Buxton, Denis/0000-0003-3077-6435; Adelstein, Robert/0000-0002-8683-2144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004230, Z01HL004230] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An J, 1999, AM J PHYSIOL-ENDOC M, V277, pE862, DOI 10.1152/ajpendo.1999.277.5.E862; BEAVEN MA, 1987, J CELL BIOL, V105, P1129, DOI 10.1083/jcb.105.3.1129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; BURGOYNE RD, 1987, BIOSCIENCE REP, V7, P281, DOI 10.1007/BF01121449; Choi OH, 1996, J MUSCLE RES CELL M, V17, P69, DOI 10.1007/BF00140325; CHOI OH, 1993, J IMMUNOL, V151, P5586; Choi OH, 1996, NATURE, V380, P634; CROSS RA, 1986, FEBS LETT, V200, P355, DOI 10.1016/0014-5793(86)81168-1; Easom RA, 1999, DIABETES, V48, P675, DOI 10.2337/diabetes.48.4.675; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Ford HL, 1997, BIOCHEMISTRY-US, V36, P16321, DOI 10.1021/bi971182l; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GRIGORIAN M, 1994, ELECTROPHORESIS, V15, P463, DOI 10.1002/elps.1150150163; Heist EK, 1998, CELL CALCIUM, V23, P103; HODGE TP, 1992, J CELL BIOL, V118, P1085, DOI 10.1083/jcb.118.5.1085; IKEBE M, 1991, J BIOL CHEM, V266, P7030; JONES SVP, 1991, FEBS LETT, V289, P47, DOI 10.1016/0014-5793(91)80905-I; KATAKAMI Y, 1984, BIOCHEM BIOPH RES CO, V121, P573, DOI 10.1016/0006-291X(84)90220-1; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; Miralem T, 1998, BIOCHEM J, V330, P651, DOI 10.1042/bj3300651; Murakami N, 1998, BIOCHEMISTRY-US, V37, P1989, DOI 10.1021/bi971959a; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Patel R, 1999, J BIOL CHEM, V274, P7958, DOI 10.1074/jbc.274.12.7958; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; SAGIEISENBERG R, 1985, NATURE, V313, P59, DOI 10.1038/313059a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; SPUDICH A, 1994, CELL MOTIL CYTOSKEL, V29, P345, DOI 10.1002/cm.970290407; Sullivan R, 1999, J BIOL CHEM, V274, P38140, DOI 10.1074/jbc.274.53.38140; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; SUN P, 1994, GENE DEV, V8, P227; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Waters WW, 1998, NEUROENDOCRINOLOGY, V67, P145, DOI 10.1159/000054309; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Wilson JR, 1999, DIABETES, V48, P2383, DOI 10.2337/diabetes.48.12.2383	40	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34772	34779		10.1074/jbc.M004996200	http://dx.doi.org/10.1074/jbc.M004996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10945986	hybrid			2022-12-27	WOS:000165095300103
J	Gatti, D; Mitra, B; Rosen, BP				Gatti, D; Mitra, B; Rosen, BP			Escherichia coli soft metal ion-translocating ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							P-TYPE ATPASES; NUCLEOTIDE-BINDING SITE; HELICOBACTER-PYLORI; CADMIUM RESISTANCE; CATALYTIC SUBUNIT; MEMBRANE TOPOLOGY; ARSA ATPASE; ANION PUMP; ZNTA GENE; PROTEIN		Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.	brosen@med.wayne.edu		Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM055425, R01GM054102, R01GM055425] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43918] Funding Source: Medline; NIGMS NIH HHS [GM54102, GM55425] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bayle D, 1998, J BACTERIOL, V180, P317, DOI 10.1128/JB.180.2.317-329.1998; Beard SJ, 1997, MOL MICROBIOL, V25, P883, DOI 10.1111/j.1365-2958.1997.mmi518.x; BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; BHATTACHARJEE H, 2000, IN PRESS BIOMETALS; Camakaris J, 1999, BIOCHEM BIOPH RES CO, V261, P225, DOI 10.1006/bbrc.1999.1073; CHEN CM, 1986, J BIOL CHEM, V261, P5030; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; Gupta A, 1999, NAT MED, V5, P183, DOI 10.1038/5545; HSU CM, 1989, J BIOL CHEM, V264, P17349; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAUR P, 1992, J BIOL CHEM, V267, P19272; Kaur P, 1999, J BIOL CHEM, V274, P25849, DOI 10.1074/jbc.274.36.25849; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Outten FW, 2000, J BIOL CHEM, V275, P31024, DOI 10.1074/jbc.M006508200; Patzer SI, 1998, MOL MICROBIOL, V28, P1199, DOI 10.1046/j.1365-2958.1998.00883.x; Rapisarda VA, 1999, ARCH BIOCHEM BIOPHYS, V370, P143, DOI 10.1006/abbi.1999.1398; Rasmussen B, 2000, NATURE, V405, P676, DOI 10.1038/35015063; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Rensing C, 1998, J BIOL CHEM, V273, P32614, DOI 10.1074/jbc.273.49.32614; Rensing C, 1999, J BACTERIOL, V181, P5891, DOI 10.1128/JB.181.19.5891-5897.1999; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Rutherford JC, 1999, J BIOL CHEM, V274, P25827, DOI 10.1074/jbc.274.36.25827; Sanders OI, 1997, J BACTERIOL, V179, P3365, DOI 10.1128/jb.179.10.3365-3367.1997; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Sharma R, 2000, J BIOL CHEM, V275, P3873, DOI 10.1074/jbc.275.6.3873; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; SURIN BP, 1985, J BACTERIOL, V161, P189, DOI 10.1128/JB.161.1.189-198.1985; TSAI KJ, 1992, J BACTERIOL, V174, P116, DOI 10.1128/jb.174.1.116-121.1992; Walmsley AR, 1999, J BIOL CHEM, V274, P16153, DOI 10.1074/jbc.274.23.16153; WU JH, 1992, J BIOL CHEM, V267, P12570; WylerDuda P, 1996, FEBS LETT, V399, P143, DOI 10.1016/S0014-5793(96)01306-3; Zhou TQ, 2000, EMBO J, V19, P4838, DOI 10.1093/emboj/19.17.4838; Zhou TQ, 1997, J BIOL CHEM, V272, P19731, DOI 10.1074/jbc.272.32.19731	38	64	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34009	34012		10.1074/jbc.R000012200	http://dx.doi.org/10.1074/jbc.R000012200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10964935	hybrid			2022-12-27	WOS:000165095300001
J	Grewal, SS; Fass, DM; Yao, H; Ellig, CL; Goodman, RH; Stork, PJS				Grewal, SS; Fass, DM; Yao, H; Ellig, CL; Goodman, RH; Stork, PJS			Calcium and cAMP signals differentially regulate cAMP-responsive element-binding protein function via a Rap1-extracellular signal-regulated kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; NERVE GROWTH-FACTOR; MAP KINASE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; FACTOR CREB; CYCLIC-AMP; B-RAF; CBP; NUCLEAR	Two major intracellular signals that regulate neuronal function are calcium and cAMP, In many cases, the actions of these two second messengers involve long term changes in gene expression. One well studied target of both calcium and cAMP signaling is the transcription factor cAMP-responsive element-binding protein (CREB), Multiple signaling pathways have been shown to contribute to the regulation of CREB-dependent transcription, including both protein kinase A (PKA)- and mitogen-activated protein (MAP) kinase/extracellular signal-regulated kinase (ERK)-dependent kinase cascades. We have previously described a mechanism by which cAMP and calcium influx may stimulate ERKs in neuronal cells, This pathway involves the PKA-dependent activation of the Ras-related small G-protein, Rap1, and subsequent stimulation of the neuronal Raf isoform, B-Raf, In this study, we examined the contribution of the Rap1-ERK pathway to the control of gene transcription by calcium influx and cAMP, Using the PC12 cell model system, we found that both calcium influx and cAMP stimulated CREB-dependent transcription via a Rap1-ERK pathway, but this regulation occurred through distinct mechanisms. Calcium-mediated phosphorylation of CREB through the PKA-Rap1-ERK pathway. In contrast, cAMP phosphorylated CREB via PKA directly but required a Rap1-ERK pathway to activate a component downstream of CREB phosphorylation and CREB-binding protein recruitment, These data suggest that the Rap 1/B-Raf signaling pathway may have an important role in the regulation of CREB-dependent gene expression.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Stork, PJS (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, L474,SW Sam Jackson Pk Rd, Portland, OR 97201 USA.							Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Grewal SS, 2000, J BIOL CHEM, V275, P3722, DOI 10.1074/jbc.275.5.3722; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Liu YZ, 1999, NEUROREPORT, V10, P1239, DOI 10.1097/00001756-199904260-00016; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Roberson ED, 1999, J NEUROSCI, V19, P4337; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P1031; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zanger K, 1999, MOL ENDOCRINOL, V13, P268, DOI 10.1210/me.13.2.268	58	120	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34433	34441		10.1074/jbc.M004728200	http://dx.doi.org/10.1074/jbc.M004728200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10950954	hybrid			2022-12-27	WOS:000165095300059
J	Li, XJ; Marians, KJ				Li, XJ; Marians, KJ			Two distinct triggers for cycling of the lagging strand polymerase at the replication fork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COORDINATED LEADING-STRAND; OKAZAKI FRAGMENT SIZE; ESCHERICHIA-COLI; DNA-POLYMERASE; III HOLOENZYME; SLIDING CLAMPS; PRIMASE; HELICASE; TEMPLATE; PROTEIN	There are two modes of DNA synthesis at a replication fork. The leading strand is synthesized in a continuous fashion in lengths that in Escherichia coli can be in excess of 2 megabases. On the other hand, the lagging strand is synthesized in relatively short stretches of 2 kilobases. Nevertheless, identical assemblies of the DNA polymerase In: core tethered to the beta sliding clamp account for both modes of DNA synthesis. Yet the same lagging strand polymerase accounts for the synthesis of all Okazaki fragments at a replication fork, cycling repeatedly every 1 or 2 s from the S'-end of the just-completed fragment to the 3'-end of the new primer. Several models have been invoked to account for the rapid cycling of a polymerase complex that can remain bound to the template for upward of 40 min. By using isolated replication protein-DNA template complexes, we have tested these models and show here that cycling of the lagging strand polymerase can be triggered by either the action of primase binding to the replisome and synthesizing a primer or by collision of the lagging strand polymerase with the 5' end of the previous Okazaki fragment.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Li, XJ (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM034557, GM34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; ARAI K, 1981, J BIOL CHEM, V256, P5267; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; HACKER KJ, 1994, J BIOL CHEM, V269, P24209; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P16644; ODONNELL ME, 1985, J BIOL CHEM, V260, P2875; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; SELICK HE, 1987, DNA REPLICATION RECO, V47, P183; SINHA NK, 1980, J BIOL CHEM, V255, P4290; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; SWART JR, 1993, J BIOL CHEM, V268, P12970; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	35	52	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34757	34765		10.1074/jbc.M006556200	http://dx.doi.org/10.1074/jbc.M006556200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10948202	hybrid			2022-12-27	WOS:000165095300101
J	Lagane, B; Gaibelet, G; Meilhoc, E; Masson, JM; Cezanne, L; Lopez, A				Lagane, B; Gaibelet, G; Meilhoc, E; Masson, JM; Cezanne, L; Lopez, A			Role of sterols in modulating the human mu-opioid receptor function in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; RESPONSE PATHWAY; BINDING-SITES; CHOLESTEROL; MEMBRANES; GENE; MODEL	This study provides evidence that the differences in membrane composition found from one cell type to another can represent a limiting factor to recovering the functionality of transmembrane proteins when expressed in heterologous systems. Restoring the properties of the human mu -opioid receptor in yeast (Saccharomyces cerevisiae), similar to those observed in native cells, was achieved by replacing ergosterol from yeast by cholesterol, which is normally found in mammalian plasma membranes. The results suggest that these two sterols have opposite effects with respect to the ligand binding function of the receptor. Ergosterol was found to constrain the Cr-opioid receptor in an inactive state in yeast plasma membranes and cannot replace cholesterol in activating it. These data differ from previous works dealing with the function of related G-protein-coupled receptors (GPCR) in ergosterol-enriched membranes. This suggests that structural requirements of GPCR with respect to their modulation by lipid components differ from one protein to another. As a consequence, we assume that the presence of appropriate lipids around transmembrane proteins determines their function. This highlights the functional significance of lateral heterogeneities of membrane components within biological membranes.	Inst Natl Sci Appl, CNRS, UMR 5089, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National des Sciences Appliquees de Toulouse	Lopez, A (corresponding author), Inst Natl Sci Appl, CNRS, UMR 5089, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.		meilhoc, eliane/AAG-4396-2020; Lagane, Bernard/K-8446-2016; Lagane, Bernard/AAA-2205-2019	Lagane, Bernard/0000-0002-3459-7867				[Anonymous], 1993, CHOLESTEROL MEMBRANE; Baenziger JE, 2000, J BIOL CHEM, V275, P777, DOI 10.1074/jbc.275.2.777; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; Bogdanov M, 1999, J BIOL CHEM, V274, P36827, DOI 10.1074/jbc.274.52.36827; Bogdanov M, 1999, J BIOL CHEM, V274, P12339, DOI 10.1074/jbc.274.18.12339; Brown AJ, 2000, YEAST, V16, P11, DOI 10.1002/(SICI)1097-0061(20000115)16:1<11::AID-YEA502>3.0.CO;2-K; Christian AE, 1997, J LIPID RES, V38, P2264; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Dumas F, 1999, FEBS LETT, V458, P271, DOI 10.1016/S0014-5793(99)01148-5; Emmerson PJ, 1999, J NEUROCHEM, V73, P289, DOI 10.1046/j.1471-4159.1999.0730289.x; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Gaibelet G, 1999, EUR J BIOCHEM, V261, P517, DOI 10.1046/j.1432-1327.1999.00301.x; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; JONES OT, 1988, BIOCHEMISTRY-US, V27, P2364, DOI 10.1021/bi00407a018; LITMAN BJ, 1996, LIPIDS S, V31, P193; LONDON E, 1981, BIOCHEMISTRY-US, V20, P1939, DOI 10.1021/bi00510a033; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Schroeder F, 1996, P SOC EXP BIOL MED, V213, P150, DOI 10.3181/00379727-213-44047; SCHULER I, 1990, BIOCHIM BIOPHYS ACTA, V1028, P82, DOI 10.1016/0005-2736(90)90268-S; SIMMONDS AC, 1982, BIOCHIM BIOPHYS ACTA, V693, P398, DOI 10.1016/0005-2736(82)90447-3; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stanasila L, 1998, BIOCHIMIE, V80, P563, DOI 10.1016/S0300-9084(00)80021-8; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G; Yun CW, 1998, BIOCHEM BIOPH RES CO, V252, P29, DOI 10.1006/bbrc.1998.9600; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993	31	83	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33197	33200		10.1074/jbc.C000576200	http://dx.doi.org/10.1074/jbc.C000576200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10973945	hybrid			2022-12-27	WOS:000090104600004
J	Lan, KL; Zhong, HL; Nanamori, M; Neubig, RR				Lan, KL; Zhong, HL; Nanamori, M; Neubig, RR			Rapid kinetics of regulator of G-protein signaling (RGS)-mediated G alpha(i) and G alpha(o) deactivation - G alpha specificity of RGS4 and RGS7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; HETEROTRIMERIC G-PROTEINS; SACCHAROMYCES-CEREVISIAE; INTRINSIC FLUORESCENCE; TRANSITION-STATE; BINDING; SUBUNITS; FAMILY; TRANSDUCIN; HYDROLYSIS	Regulator of G-protein signaling (RGS) proteins accelerate GTP hydrolysis by G alpha subunits speeding deactivation. Ga deactivation kinetics mediated by RGS are too fast to be directly studied using conventional radiochemical methods. We describe a stopped-flow spectroscopic approach to visualize these rapid kinetics by measuring the intrinsic tryptophan fluorescence decrease of G alpha accompanying GTP hydrolysis and G alpha deactivation on the millisecond time scale. Basal k(cat) values for G alpha (o), G alpha (i1), and G alpha (i2) at 20 degreesC were similar (0.025-0.033 s(-1)). Glutathione S-transferase fusion proteins containing RGS4 and an RGS7 box domain (amino acids 305-453) enhanced the rate of G alpha deactivation in a manner Linear with RGS concentration. RGS4 stimulated rates could be measured up to 5 s(-1) at 3 muM, giving a catalytic efficiency of 1.7-2.8 x 10(6) M-1 s(-1) for all three Ga subunits. In contrast, RGS7 showed catalytic efficiencies of 0.44, 0.10, and 0.02 x 10(6) M-1 s(-1) toward G alpha (o), G alpha (i2), and G alpha (i1), respectively. Thus RGS7 is a weaker GTPase activating protein than RGS4 toward all Ga subunits tested, but it is specific for G alpha (o) over G alpha (i1) or G alpha (i2) Furthermore, the specificity of RGS7 for G alpha (o) does not depend on N- or C-terminal extensions or a G beta (5) subunit but resides in the RGS domain itself.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med Hypertens, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Neubig, RR (corresponding author), Univ Michigan, Dept Pharmacol, 1301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	RNeubig@umich.edu		Neubig, Richard/0000-0003-0501-0008	NIGMS NIH HHS [GM-39561] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Jeong SW, 2000, J NEUROSCI, V20, P4489, DOI 10.1523/JNEUROSCI.20-12-04489.2000; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Lan KL, 1998, BIOCHEMISTRY-US, V37, P837, DOI 10.1021/bi972122i; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Natochin M, 1997, FEBS LETT, V411, P179, DOI 10.1016/S0014-5793(97)00687-X; Natochin M, 1998, J BIOL CHEM, V273, P6731, DOI 10.1074/jbc.273.12.6731; Natochin M, 1998, J BIOL CHEM, V273, P4300, DOI 10.1074/jbc.273.8.4300; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; REMMERS AE, 1994, J BIOL CHEM, V269, P13771; Saitoh O, 1999, J BIOL CHEM, V274, P9899, DOI 10.1074/jbc.274.14.9899; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; SZABO G, 1989, TRENDS PHARMACOL SCI, P46; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wieland T, 1999, N-S ARCH PHARMACOL, V360, P14, DOI 10.1007/s002109900031; Zerangue N, 1998, CURR BIOL, V8, pR313, DOI 10.1016/S0960-9822(98)70196-4; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000	46	82	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33497	33503		10.1074/jbc.M005785200	http://dx.doi.org/10.1074/jbc.M005785200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10942773	hybrid			2022-12-27	WOS:000090104600045
J	Ransamy, TA; Neville, TAM; Chauhan, BM; Aggarwal, D; Sparks, DL				Ransamy, TA; Neville, TAM; Chauhan, BM; Aggarwal, D; Sparks, DL			Apolipoprotein A-I regulates lipid hydrolysis by hepatic lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; HEPARAN-SULFATE PROTEOGLYCANS; TRIGLYCERIDE LIPASES; POSTPRANDIAL LIPEMIA; PLASMA-LIPOPROTEINS; MOLECULAR-BIOLOGY; DIETARY-FAT; LPA-I; LIPOLYSIS	Association of hepatic Lipase (HL) with pure heparan sulfate proteoglycans (HSPG) has little effect on hydrolysis of high density lipoprotein (HDL) particles, but significantly inhibits (>80%) the hydrolysis of low (LDL) and very low density lipoproteins (VLDL). Lipolytic inhibition is associated with a differential ability of the lipoproteins to remove HL from the HSPG. LDL and VLDL are unable to displace HL, whereas HDL readily displaces HL from the HSPG, These data show that HSPG-bound HL is inactive. Purified apolipoprotein (apo) A-I is more efficient than HDL at liberating HL from HSPG, and HL displacement is associated with the direct binding of apoA-I to HSPG. However, displacement of HL by apoA-I does not enhance hydrolysis of VLDL particles. This appears due to the direct inhibition of HL by apoA-I, Both apoA-I and HDL are able to inhibit VLDL lipid hydrolysis by up to 60%. Inhibition of VLDL hydrolysis is associated with the binding of apoA-I to the surface of the VLDL particle and a concomitant decreased affinity for HL. These data show that apoA-I can regulate lipid hydrolysis by HL by liberating! activating the enzyme from cell surface proteoglycans and by directly modulating lipoprotein binding and hydrolysis.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Dept Pathol & Lab Med, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4W7, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute	Sparks, DL (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.							ASSMANN G, 1973, J BIOL CHEM, V248, P7184; Bensadoun A, 1996, CURR OPIN LIPIDOL, V7, P77, DOI 10.1097/00041433-199604000-00005; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; CAMEJO G, 1988, ARTERIOSCLEROSIS, V8, P368, DOI 10.1161/01.ATV.8.4.368; CARDIN AD, 1989, INT J BIOL MACROMOL, V11, P59, DOI 10.1016/0141-8130(89)90042-1; CASTRO GR, 1984, J LIPID RES, V25, P58; CHEVREUIL O, 1993, ARTERIOSCLER THROMB, V13, P1391, DOI 10.1161/01.ATV.13.10.1391; CHOI SSY, 1994, J LIPID RES, V35, P848; CLARK AB, 1985, J BIOL CHEM, V260, P4778; Coffill CR, 1997, J LIPID RES, V38, P2224; de Man FHAF, 1997, J LIPID RES, V38, P2465; Ehnholm C, 1986, Methods Enzymol, V129, P716; EHNHOLM C, 1975, J BIOL CHEM, V250, P6756; EISENBERG S, 1979, J LIPID RES, V20, P614; GRESSNER AM, 1991, EUR J CLIN CHEM CLIN, V29, P293; HAFFNER SM, 1985, ARTERIOSCLEROSIS, V5, P169, DOI 10.1161/01.ATV.5.2.169; Hahn PF, 1943, SCIENCE, V98, P19, DOI 10.1126/science.98.2531.19; HAMILTON RL, 1991, J LIPID RES, V32, P529; Hime NJ, 1998, J BIOL CHEM, V273, P27191, DOI 10.1074/jbc.273.42.27191; HOROWITZ BS, 1993, J CLIN INVEST, V91, P1743, DOI 10.1172/JCI116384; JANSEN H, 1974, H-S Z PHYSIOL CHEM, V355, P1212; JI ZS, 1994, J BIOL CHEM, V269, P13429; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; KIRCHMAIR R, 1995, BAILLIERE CLIN ENDOC, V9, P705, DOI 10.1016/S0950-351X(95)80081-6; Komaromy M, 1996, J BIOL CHEM, V271, P16906, DOI 10.1074/jbc.271.28.16906; KUUSI T, 1979, FEBS LETT, V104, P384, DOI 10.1016/0014-5793(79)80858-3; MAHLEY RW, 1982, MED CLIN N AM, V66, P375, DOI 10.1016/S0025-7125(16)31426-2; Millar JS, 1998, CURR OPIN LIPIDOL, V9, P197, DOI 10.1097/00041433-199806000-00003; MUSLINER TA, 1979, BIOCHIM BIOPHYS ACTA, V575, P277, DOI 10.1016/0005-2760(79)90029-8; MUSLINER TA, 1988, J LIPID RES, V29, P349; MUSLINER TA, 1991, J LIPID RES, V32, P917; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; PHILLIPS MC, 1992, INTERACTIONS APOLIPO, P185; PITAS RE, 1987, J BIOL CHEM, V262, P14352; Plump AS, 1997, J LIPID RES, V38, P1033; POSNER I, 1983, ARCH BIOCHEM BIOPHYS, V226, P306, DOI 10.1016/0003-9861(83)90297-7; REA TJ, 1993, J LIPID RES, V34, P1901; RITTER MC, 1977, J BIOL CHEM, V252, P1208; Sanan DA, 1997, J LIPID RES, V38, P1002; SCHAEFER EJ, 1978, J LIPID RES, V19, P667; Sparks DL, 1998, BBA-LIPID LIPID MET, V1390, P160, DOI 10.1016/S0005-2760(97)00172-0; Sparks DL, 1999, BIOCHEMISTRY-US, V38, P1727, DOI 10.1021/bi981945k; SULTAN F, 1990, BIOCHIM BIOPHYS ACTA, V1042, P150, DOI 10.1016/0005-2760(90)90071-5; Swift LL, 1996, J BIOL CHEM, V271, P31491; WAITE M, 1978, BIOCHIM BIOPHYS ACTA, V530, P292, DOI 10.1016/0005-2760(78)90014-0; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; WEINTRAUB MS, 1987, J CLIN INVEST, V80, P1571, DOI 10.1172/JCI113243; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253	49	25	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33480	33486		10.1074/jbc.M005436200	http://dx.doi.org/10.1074/jbc.M005436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10944531	hybrid			2022-12-27	WOS:000090104600043
J	Weiss, RH; Joo, A; Randour, C				Weiss, RH; Joo, A; Randour, C			P21(Waf1/Cip1) is an assembly factor required for platelet-derived growth factor-induced vascular smooth muscle cell proliferation (vol 275, pg 10285, 2000)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction																		Weiss RH, 2000, J BIOL CHEM, V275, P10285, DOI 10.1074/jbc.275.14.10285	1	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28340	28340						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10970905				2022-12-27	WOS:000089197100108
J	Szekeres, CK; Tang, KQ; Trikha, M; Honn, KV				Szekeres, CK; Tang, KQ; Trikha, M; Honn, KV			Eicosanoid activation of extracellular signal-regulated kinase 1/2 in human epidermoid carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; LIPOXIN A(4) RECEPTOR; SMOOTH-MUSCLE CELLS; 12(S)-HYDROXYEICOSATETRAENOIC ACID; TYROSINE-KINASE; MELANOMA-CELLS; LIPOXYGENASE METABOLITE; PHOSPHOLIPASE-C; ANGIOTENSIN-II; CANCER METASTASIS	12(S)-Hydroxyeicosatetraenoic acid (12(S)-HETE), a 12-lipoxygenase metabolite of arachidonic acid, has multiple effects on tumor and endothelial cells, including stimulation of invasion and angiogenesis. However, the signaling mechanisms controlling these physiological processes are poorly understood. In a human epidermoid carcinoma cell fine (i.e. A431), 12(S)-HETE activates extracellular signal-regulated kinases 1/2 (ERK1/2), which is mediated by upstream kinases MEK and Raf. 12(S)-HETE stimulates phosphorylation of phospholipase C gamma1 and activity of protein kinase C alpha (PKC alpha). In addition, independent of PKC 12(S)-HETE increases tyrosine phosphorylation of Shc, and Grb2, stimulates association between Shc and Src, and increases the activity of Ras, via Src family kinases. Furthermore, at low (10-100 nM) concentrations 12(S)-HETE counteracts epidermal growth factor-stimulated activation of ERK1/2 via stimulating protein tyrosine phosphatases. We also present evidence that 12(S)-HETE stimulates ERK1/2 via G proteins and that A431 cells have multiple binding sites for 12(S)-HETE. Finally, inhibition of 12-lipoxygenase induced apoptosis of A431 cells, which was reversed by addition of exogenous 12(S)-HETE. Collectively we demonstrate that the activation of ERK1/2 by 12(S)-HETE may be regulated by multiple receptors triggering PKC-dependent and PKC-independent pathways in A431 cells.	Wayne State Univ, Dept Radiat Oncol, Detroit, MI 48202 USA; Wayne State Univ, Dept Pathol, Detroit, MI 48202 USA; Wayne State Univ, Dept Chem, Detroit, MI 48202 USA; Karmanos Canc Inst, Detroit, MI 48202 USA	Wayne State University; Wayne State University; Wayne State University; Barbara Ann Karmanos Cancer Institute	Honn, KV (corresponding author), Wayne State Univ, Dept Radiat Oncol, 431 Chem Bldg, Detroit, MI 48202 USA.				NATIONAL CANCER INSTITUTE [R01CA029997] Funding Source: NIH RePORTER; NCI NIH HHS [CA29997] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beindl W, 1996, MOL PHARMACOL, V50, P415; Bleich D, 1997, BIOCHEM BIOPH RES CO, V230, P448, DOI 10.1006/bbrc.1996.5981; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592; CHEN YQ, 1994, CANCER RES, V54, P1574; CHOPRA H, 1991, INT J CANCER, V49, P774, DOI 10.1002/ijc.2910490524; COSTELLO PB, 1991, INFLAMMATION, V15, P269, DOI 10.1007/BF00917312; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; GAO X, 1995, UROLOGY, V46, P227, DOI 10.1016/S0090-4295(99)80198-8; GOPALAKRISHNA R, 1988, P NATL ACAD SCI USA, V85, P612, DOI 10.1073/pnas.85.2.612; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Gronroos E, 1996, BIOCHEM J, V316, P239; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hagmann W, 1996, EXP CELL RES, V228, P197, DOI 10.1006/excr.1996.0317; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Herbertsson H, 1998, J LIPID RES, V39, P237; HONN KV, 1994, CANCER METAST REV, V13, P365, DOI 10.1007/BF00666105; HONN KV, 1994, EXP CELL RES, V214, P120, DOI 10.1006/excr.1994.1240; HONN KV, 1994, CANCER RES, V54, P565; HONN KV, 1992, CANCER METAST REV, V11, P325, DOI 10.1007/BF01307186; Katan M, 1996, CANCER SURV, V27, P199; KEVIN R, 1999, NATURE, V399, P789; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Kurahashi Y, 2000, P NATL ACAD SCI USA, V97, P5779, DOI 10.1073/pnas.97.11.5779; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; LEVITZKI A, 1990, BIOCHEM PHARMACOL, V40, P913, DOI 10.1016/0006-2952(90)90474-Y; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Lindsay MA, 1998, J LEUKOCYTE BIOL, V64, P555, DOI 10.1002/jlb.64.4.555; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LIU B, 1991, CELL REGUL, V2, P1045, DOI 10.1091/mbc.2.12.1045; LIU B, 1995, P NATL ACAD SCI USA, V92, P9323, DOI 10.1073/pnas.92.20.9323; LIU B, 1994, LAB INVEST, V70, P314; Liu XH, 1996, CLIN EXP METASTAS, V14, P145, DOI 10.1007/BF00121211; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Maddox JF, 1997, J BIOL CHEM, V272, P6972, DOI 10.1074/jbc.272.11.6972; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MONG S, 1990, MOL PHARMACOL, V37, P60; Nie D, 1998, CANCER RES, V58, P4047; PERKINS RS, 1995, BIOCHEM J, V310, P795, DOI 10.1042/bj3100795; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Rice RL, 1998, INT J CANCER, V77, P271, DOI 10.1002/(SICI)1097-0215(19980717)77:2<271::AID-IJC17>3.0.CO;2-E; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SILLETTI S, 1994, CANCER RES, V54, P5752; SJOLANDER A, 1994, ANN NY ACAD SCI, V744, P155, DOI 10.1111/j.1749-6632.1994.tb52732.x; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; SUGDEN PH, 1999, CELL SIGNAL, V5, P337; TANG DG, 1995, J CELL PHYSIOL, V165, P291, DOI 10.1002/jcp.1041650210; Tang DG, 1997, ADV EXP MED BIOL, V400, P349; TANG DG, 1995, J CELL SCI, V108, P2629; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; Tang KQ, 2000, BIOCHEMISTRY-US, V39, P3185, DOI 10.1021/bi992664v; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TIMAR J, 1992, INT J CANCER, V52, P594, DOI 10.1002/ijc.2910520418; TIMAR J, 1993, INT J CANCER, V55, P1; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zakaroff-Girard A, 1999, LIFE SCI, V64, P2135, DOI 10.1016/S0024-3205(99)00164-2	65	51	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38831	38841		10.1074/jbc.M002673200	http://dx.doi.org/10.1074/jbc.M002673200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10952974	hybrid			2022-12-27	WOS:000165739800094
J	Liapakis, G; Ballesteros, JA; Papachristou, S; Chan, WC; Chen, X; Javitch, JA				Liapakis, G; Ballesteros, JA; Papachristou, S; Chan, WC; Chen, X; Javitch, JA			The forgotten serine - A critical role for Ser-203(5.42) in ligand binding to and activation of the beta(2)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2) ADRENERGIC-RECEPTOR; SITE-DIRECTED MUTAGENESIS; CONSTITUTIVE ACTIVATION; DOPAMINE-RECEPTOR; AGONIST BINDING; AMINO-ACIDS; RESIDUES; IDENTIFICATION; MECHANISM; SEGMENT	Previous work in the beta (2)-adrenergic receptor demonstrated critical interactions between Ser-204 and Ser-207 in the fifth membrane-spanning segment and the meta-OH and para-Os, respectively, of catecholamine agonists (Strader, C. D., Candelore, M, R., Hill, W. S., Sigal, I. S., and Dixon, R, A. (1989) J. Biol. Chem. 264, 13572-13578). Using the substituted cysteine accessibility method in the beta (2)-adrenergic receptor, we have found that in addition to Ser-204 and Ser-207, Ser-203 is also accessible on the surface of the binding-site crevice and is occluded by bound agonist. Mutation of Ser-203 to Ala, Val, or Cys reduced the binding affinity and adenylyl cyclase-activating potency of agonists containing a meta-OH, whereas their affinities and potencies were largely preserved by mutation of Ser-203 to Thr, which maintained an OH at this position. Thus both Ser-203 and Ser-204 appear to interact with the meta-OH of catecholamines, perhaps through a bifurcated H bond. Furthermore, the removal of the OH at position 203 led to a significant loss of affinity of antagonists with nitrogen in their heterocyclic ring structure. The greatest effect was seen with pindolol, a partial agonist, suggesting that a H bond between the heterocyclic ring and Ser-203 may play a role in partial agonism. In contrast, the affinities of antagonists such as propranolol or alprenolol, which have cyclic structures without H-bonding capability, were unaltered after mutation of Ser-203.	Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, New York, NY 10032 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Columbia University; Columbia University; Columbia University; New York State Psychiatry Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Javitch, JA (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, 630 W 168th St,P&S 11-401, New York, NY 10032 USA.	jaj2@columbia.edu		Javitch, Jonathan/0000-0001-7395-2967	NIMH NIH HHS [MH57324, MH54137] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054137] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Ambrosio C, 2000, MOL PHARMACOL, V57, P198; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BALLESTEROS JA, 2000, IN PRESS BIOPHYS J; BELLEAU B, 1969, BIOCHEM PHARMACOL, V18, P1039, DOI 10.1016/0006-2952(69)90107-5; Cavalli A, 1996, FEBS LETT, V399, P9, DOI 10.1016/S0014-5793(96)01286-0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; COX BA, 1992, J NEUROCHEM, V59, P627, DOI 10.1111/j.1471-4159.1992.tb09416.x; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HO BY, 1992, FEBS LETT, V312, P259, DOI 10.1016/0014-5793(92)80948-G; Hwa J, 1996, J BIOL CHEM, V271, P6322, DOI 10.1074/jbc.271.11.6322; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Javitch JA, 1995, BIOCHEMISTRY-US, V34, P16433, DOI 10.1021/bi00050a026; JAVITCH JA, 1999, REC BIOCH M, P21; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; NEVE KA, 1986, MOL PHARMACOL, V30, P104; NORDSTEDT C, 1990, ANAL BIOCHEM, V189, P231, DOI 10.1016/0003-2697(90)90113-N; POLLOCK NJ, 1992, J BIOL CHEM, V267, P17780; PREISSNER R, 1991, FEBS LETT, V288, P192, DOI 10.1016/0014-5793(91)81032-4; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Rees S, 1996, BIOTECHNIQUES, V20, P102; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Rudling JE, 1999, BRIT J PHARMACOL, V127, P877, DOI 10.1038/sj.bjp.0702614; Sartania N, 1999, J NEUROCHEM, V72, P2621, DOI 10.1046/j.1471-4159.1999.0722621.x; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WANG CD, 1991, MOL PHARMACOL, V40, P168; Watts VJ, 1998, J NEUROSCI, V18, P8692; Wiens BL, 1998, MOL PHARMACOL, V54, P435, DOI 10.1124/mol.54.2.435; Woodward R, 1996, J NEUROCHEM, V66, P394, DOI 10.1046/j.1471-4159.1996.66010394.x	34	161	165	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37779	37788		10.1074/jbc.M002092200	http://dx.doi.org/10.1074/jbc.M002092200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10964911	hybrid			2022-12-27	WOS:000165618700065
J	Meyer, RK; Lustig, A; Oesch, B; Fatzer, R; Zurbriggen, A; Vandevelde, M				Meyer, RK; Lustig, A; Oesch, B; Fatzer, R; Zurbriggen, A; Vandevelde, M			A monomer-dimer equilibrium of a cellular prion protein (PrPC) not observed with recombinant PrP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; SCRAPIE PRION; N-TERMINUS; FORM; BINDING; ISOFORM; GENE; PURIFICATION; INFECTIVITY; PROPAGATION	Both the purified normal (protease-sensitive) isoform of the prion protein (PrPC) (Pergami, P., Jaffe, Il., and Safar, J. (1996) Anal. Biochem. 236, 63-73) and recombinant prion protein (PrP) have been found to be in monomeric form (Mehlhorn, I., Groth, D., Stockel, J., Moffat, B., Reilly, D., Yansura, D., Willet, W. S., Baldwin, Ri., Fletterick, R., Cohen, F. E., Vandlen, R., Henner, D., and Prusiner, S. B. (1996) Biochemistry 35, 5528-5537; and this paper), and therefore PrPC-PrPC interactions were previously unknown. In this report we confirm recombinant PrP to be a monomer by analytical ultracentrifugation. However, by three lines of evidence (enzyme-linked immunosorbent assay (ELISA), cross-linking experiments, and size exclusion chromatography) we could also demonstrate that, under native conditions, at least part of the native bovine PrPC exists as a monomer-dimer equilibrium. A bovine PrPC-specific immunosandwich ELISA was developed and calibrated with recombinant PrP (Meyer, R. It., Oesch, B., Fatter, R., Zurbriggen, A., and Vandevelde, M. (1999) J. Virol. 73, 9386-9392). By this ELISA we identified a distinct PrPC fraction and partially purified this protein. When serial dilutions of brain homogenate or partially purified PrPC were measured, using the peptide antibody C15S, a nonlinear dose-response curve was obtained. This nonlinearity was shown not to be due to an artifact of the procedure but to a monomer-dimer equilibrium of PrPC with preferential binding of the antibody to the dimer. From the curvature we could deduce the association constant (3.9 x 10(8) M-1 at 37 degreesC). Accordingly, DeltaG degrees of the reaction was calculated (-48.6 kJ M-1), and DeltaH degrees (9.5 kJ M-1) as well as DeltaS degrees (0.2 kJ K-1 M-1) were extrapolated from the van't Hoff plot. When serial dilutions of monomeric recombinant PrP were tested, only a straight line was obtained, supporting our hypothesis. Additional evidence of dimer formation was revealed by Western blotting of partially purified PrPC cross-linked by the homobifunctional cross-linker BS3. Finally, size exclusion chromatography of partially purified PrPC fractions revealed an additional shoulder not observed with recombinant PrP. The difference in respect of dimer formation between native PrPC and recombinant PrP could be explained by the lack of glycosylation of the latter.	Univ Bern, Inst Anim Neurol, TSE Reference Ctr, CH-3012 Bern, Switzerland; Univ Basel, Bioctr, CH-4056 Basel, Switzerland; Univ Zurich, Prionics Ltd, CH-8057 Zurich, Switzerland	University of Bern; University of Basel; University of Zurich	Meyer, RK (corresponding author), Univ Bern, Inst Anim Neurol, TSE Reference Ctr, Bremgartenstr 109A, CH-3012 Bern, Switzerland.							Aguzzi A, 1997, NATURE, V389, P795, DOI 10.1038/39758; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BOLTON DC, 1985, J VIROL, V53, P596, DOI 10.1128/JVI.53.2.596-606.1985; BORCHELT DR, 1993, GLYCOBIOLOGY, V3, P319, DOI 10.1093/glycob/3.4.319; BORCHELT DR, 1990, J CELL BIOL, V110, P754; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; BROWN P, 1982, J INFECT DIS, V145, P683, DOI 10.1093/infdis/145.2.683; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; GABIZON R, 1993, AM J HUM GENET, V53, P828; GOLDMANN W, 1991, J GEN VIROL, V72, P201, DOI 10.1099/0022-1317-72-1-201; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HAY B, 1987, BIOCHEMISTRY-US, V26, P8110, DOI 10.1021/bi00399a014; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; KANEKO K, 1995, P NATL ACAD SCI USA, V92, P11160, DOI 10.1073/pnas.92.24.11160; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; LUGARESI E, 1986, NEW ENGL J MED, V315, P997, DOI 10.1056/NEJM198610163151605; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; Meyer RK, 1999, J VIROL, V73, P9386, DOI 10.1128/JVI.73.11.9386-9392.1999; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Pergami P, 1996, ANAL BIOCHEM, V236, P63, DOI 10.1006/abio.1996.0132; PRIOLA SA, 1995, J BIOL CHEM, V270, P3299, DOI 10.1074/jbc.270.7.3299; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, BRAIN PATHOL, V8, P499; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TAGLIAVINI F, 1992, BIOCHEM BIOPH RES CO, V184, P1398, DOI 10.1016/S0006-291X(05)80038-5; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042	43	78	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38081	38087		10.1074/jbc.M007114200	http://dx.doi.org/10.1074/jbc.M007114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10967124	hybrid			2022-12-27	WOS:000165618700103
J	Pulvermuller, A; Schroder, K; Fischer, T; Hofmann, KP				Pulvermuller, A; Schroder, K; Fischer, T; Hofmann, KP			Interactions of metarhodopsin II - Arrestin peptides compete with arrestin and transducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; VISUAL ARRESTIN; G-PROTEIN; PHOSPHORYLATED RHODOPSIN; CRYSTAL-STRUCTURE; BINDING-PROTEIN; 48-KDA PROTEIN; KINETICS; COMPLEX; REGENERATION	Arrestin blocks the interaction of rhodopsin with the G protein transducin (G(t)). To characterize the sites of arrestin that interact with rhodopsin, we have utilized a spectrophotometric peptide competition assay. It is based on the stabilization of the active intermediates metarhodopsin II (MII) and phosphorylated MII by G(t) and arrestin, respectively (extra MII monitor). The protocol involves native disc membranes and three sets of peptides 10-30 amino acids in length spanning the arrestin sequence, In the absence of arrestin, not one of the peptides by itself had an effect on the amount of MII formed. However, inhibition of arrestin-dependent extra MII was found for the peptides at residues 11-30 and 51-70 (IC50 < 100 <mu>M) and residues 231-260 (IC50 < 200 <mu>M) A similar pattern of inhibition by arrestin peptides was seen when arrestin was replaced by G(t) or the farnesylated G(t)gamma C-terminal peptide. Only arrestin-(11-30) inhibited MII.G(t) less (IC50 = 300 muM) than phosphorylated MII.arrestin. We interpreted the data by competition of the arrestin peptides for interaction sites at rhodopsin, exposed in the MPI conformation and specific for both arrestin and G(t). The arrestin sites are located in both the C- and N-terminal domains of the arrestin structure.	Humboldt Univ, Klinikum Charite, Inst Med Phys & Biophys, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Pulvermuller, A (corresponding author), Humboldt Univ, Klinikum Charite, Inst Med Phys & Biophys, Schumannstr 20-21, D-10098 Berlin, Germany.							BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Bartl F, 2000, FEBS LETT, V473, P259, DOI 10.1016/S0014-5793(00)01544-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAFT CM, 1995, FEBS LETT, V362, P247, DOI 10.1016/0014-5793(95)00213-S; Ernst OP, 2000, METHOD ENZYMOL, V315, P471; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Gibson SK, 2000, BIOCHEMISTRY-US, V39, P5738, DOI 10.1021/bi991857f; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Heck M, 2000, METHOD ENZYMOL, V315, P329; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; HOFMANN LP, 1985, BIOCHIM BIOPHYS ACTA, V810, P278; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; KUHN H, 1982, METHOD ENZYMOL, V81, P556; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P314; PALCZEWSKI K, 1992, BIOCHEMISTRY-US, V31, P3902, DOI 10.1021/bi00131a003; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; Palczewski K, 1997, EUR J BIOCHEM, V248, P261, DOI 10.1111/j.1432-1033.1997.00261.x; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Parkes JH, 1999, BIOCHEMISTRY-US, V38, P6862, DOI 10.1021/bi9827666; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; PULVERMULLER A, 1993, BIOCHEMISTRY-US, V32, P14082, DOI 10.1021/bi00214a002; Pulvermuller A, 1997, BIOCHEMISTRY-US, V36, P9253, DOI 10.1021/bi970772g; Sachs K, 2000, METHOD ENZYMOL, V315, P238; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Smith WC, 1999, BIOCHEMISTRY-US, V38, P2752, DOI 10.1021/bi982643l; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; Wilson CJ, 1997, J PROTEIN CHEM, V16, P755, DOI 10.1023/A:1026311832660; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068	46	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37679	37685		10.1074/jbc.M006776200	http://dx.doi.org/10.1074/jbc.M006776200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10969086	hybrid			2022-12-27	WOS:000165618700052
J	Shirakawa, H; Herrera, JE; Bustin, M; Postnikov, Y				Shirakawa, H; Herrera, JE; Bustin, M; Postnikov, Y			Targeting of high mobility group-14/-17 proteins in chromatin is independent of DNA sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP CHROMOSOMAL-PROTEINS; NUCLEOSOME CORES; HMG-17; HISTONE-H1; NUCLEUS; BINDING; GENE	Chromosomal proteins high mobility group (HMG)-14 and HMG-17 are nucleosomal-binding proteins that unfold the chromatin fiber and enhance transcription from chromatin templates. Their intracellular organization is dynamic and related to both cell cycle and transcription. Here we examine possible mechanisms for targeting HMG-14/-17 to specific regions in chromatin. Chromatin immunoprecipitation assays indicate that HMG-17 protein is not preferentially associated with chromatin regions containing transcriptionally active genes, or any type of specific DNA. We used a modification of the random amplified polymorphic DNA method to analyze DNA in various HMG-14/-17 nucleosome complexes. We found that although HMG-14 or HMG-17 proteins preferentially associate with core particles in which the DNA has a low frequency of CG dinucleotides, the genome does not contain consensus sequences that serve as specific targeting sites for the binding of either HMG-14 or HMG-17 proteins to nucleosomes. We used size exclusion and ion exchange chromatography to demonstrate that nuclei contain a large portion of HMG-17 associated with other proteins in a multiprotein complex. We suggest that these complexes regulate the dynamic organization of HMG-14/-17 in the nucleus and serve to target the proteins to specific sites in chromatin.	NCI, Prot Sect, Div Basic Sci, Nihon Univ, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Postnikov, Y (corresponding author), NCI, Prot Sect, Div Basic Sci, Nihon Univ, Bldg 37,Rm 3D-20,9000 Rockville Pike, Bethesda, MD 20892 USA.	yupo@helix.nih.gov	Shirakawa, Hitoshi/D-1406-2009; Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242; SHIRAKAWA, HITOSHI/0000-0002-4828-5274				AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; Dimitrov SI, 1997, METHODS, V12, P57, DOI 10.1006/meth.1997.0447; DRUCKMANN S, 1986, EXP CELL RES, V166, P486, DOI 10.1016/0014-4827(86)90493-3; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; Hock R, 1998, EMBO J, V17, P6992, DOI 10.1093/emboj/17.23.6992; Hock R, 1998, J CELL BIOL, V143, P1427, DOI 10.1083/jcb.143.6.1427; JONES EW, 1982, HMG CHROMOSOMAL PROT; Karlin S, 1997, P NATL ACAD SCI USA, V94, P10227, DOI 10.1073/pnas.94.19.10227; Munteanu MG, 1998, TRENDS BIOCHEM SCI, V23, P341, DOI 10.1016/S0968-0004(98)01265-1; NIGHTINGALE K, 1995, J BIOL CHEM, V270, P4197, DOI 10.1074/jbc.270.9.4197; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; POSTNIKOV YV, 1995, J MOL BIOL, V252, P423, DOI 10.1006/jmbi.1995.0508; POSTNIKOV YV, 1994, NUCLEIC ACIDS RES, V22, P4520, DOI 10.1093/nar/22.21.4520; POSTNIKOV YV, 1991, NUCLEIC ACIDS RES, V19, P717, DOI 10.1093/nar/19.4.717; Postnikov YV, 1997, J MOL BIOL, V274, P454, DOI 10.1006/jmbi.1997.1391; SANDEEN G, 1980, NUCLEIC ACIDS RES, V8, P3757, DOI 10.1093/nar/8.17.3757; Ulyanov NB, 1995, METHOD ENZYMOL, V261, P90; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531; YOUNG PR, 1982, NUCLEIC ACIDS RES, V10, P3099, DOI 10.1093/nar/10.10.3099	24	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37937	37944		10.1074/jbc.M000989200	http://dx.doi.org/10.1074/jbc.M000989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973947	hybrid			2022-12-27	WOS:000165618700085
J	Wower, J; Kirillov, SV; Wower, IK; Guven, S; Hixson, SS; Zimmermann, RA				Wower, J; Kirillov, SV; Wower, IK; Guven, S; Hixson, SS; Zimmermann, RA			Transit of tRNA through the Escherichia coli ribosome - Cross-linking of the 3 ' end of tRNA to specific nucleotides of the 23 S ribosomal RNA at the A, P, and E sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL TRANSFERASE CENTER; CODON-ANTICODON INTERACTION; DEACYLATED TRANSFER-RNA; A-SITE; ELONGATION CYCLE; PEPTIDYLTRANSFERASE CENTER; CRYOELECTRON MICROSCOPY; BINDING-SITES; SUBUNITS; LOOP	When bound to Escherichia coli ribosomes and irradiated with near-UV light, various derivatives of yeast tRNA(Phe) containing 2-azidoadenosine at the 3' terminus form cross-links to 23 S rRNA and 50 S subunit proteins in a site-dependent manner. A and P site-bound tRNAs, whose 3' termini reside in the peptidyl transferase center, label primarily nucleotides U2506 and U2585 and protein L27. In contrast, E site-bound tRNA labels nucleotide C2422 and protein L33. The cross-linking patterns confirm the topographical separation of the peptidyl transferase center from the E site domain. The relative amounts of label incorporated into the universally conserved residues U2506 and U2585 depend on the occupancy of the A and P sites by different tRNA ligands and indicates that these nucleotides play a pivotal role in peptide transfer. In particular, the S'-adenosine of the peptidyl-tRNA analogue, AcPhe-tRNA(Phe), remains,in close contact with U2506 regardless of whether its anticodon is located in the A site or P site. Our findings, therefore, modify and extend the hybrid state model of tRNA-ribosome interaction. We show that the S'-end of the deacylated tRNA that is formed after transpeptidation does not immediately progress to the E site but remains temporarily in the peptidyl transferase center. In addition, we demonstrate that the E site, defined by the labeling of nucleotide C2422 and protein L33, represents an intermediate state of binding that precedes the entry of deacylated tRNA into the F (final) site from which it dissociates into the cytoplasm.	Auburn Univ, Dept Anim & Dairy Sci, Program Cell & Mol Biosci, Auburn, AL 36849 USA; Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA; Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA; Russian Acad Sci, Petersburg Nucl Phys Inst, Gatchina 188350, Leningrad Reg, Russia	Auburn University System; Auburn University; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; National Research Centre - Kurchatov Institute; Petersburg Nuclear Physics Institute; Russian Academy of Sciences	Wower, J (corresponding author), Auburn Univ, Dept Anim & Dairy Sci, Program Cell & Mol Biosci, Auburn, AL 36849 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058267, R01GM022807] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22807, GM58267] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 1999, J BIOL CHEM, V274, P8723, DOI 10.1074/jbc.274.13.8723; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; BEAUCLERK AAD, 1988, EMBO J, V7, P3589, DOI 10.1002/j.1460-2075.1988.tb03236.x; BOCCHETTA M, 2000, IN PRESS RNA; BOON K, 1992, EUR J BIOCHEM, V210, P177, DOI 10.1111/j.1432-1033.1992.tb17406.x; BRIMACOMBE R, 1990, RIBOSOMES PROTEIN SY, P131; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CHRISTIANSEN J, 1990, RIBOSOMES PROTEIN SY, P229; DONTSOVA O, 1994, P NATL ACAD SCI USA, V91, P4125, DOI 10.1073/pnas.91.10.4125; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; Frank J, 1998, J STRUCT BIOL, V124, P142, DOI 10.1006/jsbi.1998.4071; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; Green R, 1997, J MOL BIOL, V266, P40, DOI 10.1006/jmbi.1996.0780; Green R, 1998, SCIENCE, V280, P286, DOI 10.1126/science.280.5361.286; KIRILLOV SV, 1978, EUR J BIOCHEM, V89, P297, DOI 10.1111/j.1432-1033.1978.tb20927.x; KIRILLOV SV, 1982, FEBS LETT, V148, P235, DOI 10.1016/0014-5793(82)80814-4; Kirillov SV, 1999, RNA, V5, P1003, DOI 10.1017/S1355838299990568; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; LAKE JA, 1977, P NATL ACAD SCI USA, V74, P1903, DOI 10.1073/pnas.74.5.1903; LILL R, 1987, J MOL BIOL, V196, P137, DOI 10.1016/0022-2836(87)90516-X; LILL R, 1984, BIOCHEMISTRY-US, V23, P6710, DOI 10.1021/bi00321a066; MAKHNO VI, 1988, MOL BIOL+, V22, P528; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; Muth GW, 2000, SCIENCE, V289, P947, DOI 10.1126/science.289.5481.947; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; NISSEN P, 1995, BIOCHIMIE PARIS, V78, P921; NOLLER HF, 1990, RIBOSOME, P73; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; OSSWALD M, 1990, NUCLEIC ACIDS RES, V18, P6755; Porse BT, 1996, J MOL BIOL, V264, P472, DOI 10.1006/jmbi.1996.0655; PORSE BT, 1995, J MOL BIOL, V249, P1, DOI 10.1006/jmbi.1995.0276; Puglisi EV, 1997, NAT STRUCT BIOL, V4, P775; Rappoport S, 1974, Methods Enzymol, V29, P685; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; ROBERTSON JM, 1981, J MOL BIOL, V151, P57, DOI 10.1016/0022-2836(81)90221-7; RODRIGUEZFONSECA C, 1995, J MOL BIOL, V247, P224, DOI 10.1006/jmbi.1994.0135; ROSEN KV, 1993, BIOCHEMISTRY-US, V32, P12802, DOI 10.1021/bi00210a032; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SEMENKOV Y, 1992, FEBS LETT, V296, P207, DOI 10.1016/0014-5793(92)80380-Y; SEMENKOV YP, 1985, BIOPOLYM KLETKA KIEV, V1, P183; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; STIEGE W, 1983, NUCLEIC ACIDS RES, V11, P1687, DOI 10.1093/nar/11.6.1687; SYLVERS LA, 1993, BIOCONJUGATE CHEM, V4, P411, DOI 10.1021/bc00024a001; SYLVERS LA, 1989, FEBS LETT, V245, P9, DOI 10.1016/0014-5793(89)80180-2; TAMURA K, 1994, FEBS LETT, V353, P173, DOI 10.1016/0014-5793(94)01038-2; WOWER J, 1988, BIOCHEMISTRY-US, V27, P8114, DOI 10.1021/bi00421a021; WOWER J, 1991, BIOCHIMIE, V73, P961, DOI 10.1016/0300-9084(91)90137-P; Wower J, 1995, BIOCHEM CELL BIOL, V73, P1041, DOI 10.1139/o95-111; WOWER J, 1993, EMBO J, V12, P617, DOI 10.1002/j.1460-2075.1993.tb05694.x; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232; WOWER J, 1999, NUCL ACIDS S, V41, P187; Yarus Michael, 1995, P443; Zimmermann R. A., 1980, RIBOSOMES STRUCTURE, P135	54	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37887	37894		10.1074/jbc.M005031200	http://dx.doi.org/10.1074/jbc.M005031200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10961994	hybrid			2022-12-27	WOS:000165618700078
J	Munagala, N; Sarver, AE; Wang, CC				Munagala, N; Sarver, AE; Wang, CC			Converting the guanine phosphoribosyltransferase from Giardia lamblia to a hypoxanthine-guanine phosphoribosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; XANTHINE PHOSPHORIBOSYLTRANSFERASE; TRITRICHOMONAS-FETUS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; OROTATE PHOSPHORIBOSYLTRANSFERASE; POINT MUTATIONS; FLEXIBLE LOOP; BINDING; SPECIFICITY	Guanine phosphoribosyltransferase from Giardia lamblia a key enzyme in the purine salvage pathway, is a potential target for anti-giardiasis chemotherapy. Recent structural determination of GPRTase (Shi, W., Munagala, N. R., Wang, C. C., Li, C. M, Tyler, P. C,, Furneaux, R I., Grubmeyer, C., Schramm, V. L., and Alno, S. C. (2000) Biochemistry 39, 6781-6790) showed distinctive features, which could be responsible for its singular guanine specificity. Through characterizing specifically designed site-specific mutants of GPRTase, we identified essential moieties in the active site for substrate binding. Mutating the unusual Tyr-127 of GPRTase to the highly conserved De results in B-fold lower K-m for guanine, A L186F mutation in GPRTase increased the affinity toward guanine by 3.3-fold, whereas the corresponding human HGPRTase mutant L192F showed a 33-fold increase in K-m for guanine. A double mutant (Y127I/K152R) of GPRTase retained the improved binding of guanine and also enabled the enzyme to utilize hypoxanthine as a substrate with a K-m, of 54 +/- 15.5 muM A triple mutant (Y127I/K152/L186F) resulted in further increased binding affinity with both guanine and hypoxanthine with the latter showing a lowered K-m of 29.8 +/- 4.1 muM. Dissociation constants measured by fluorescence quenching showed 6-fold tighter binding of GMP with the triple mutant compared with wild type. Thus, by increasing the binding affinity of 6-oxopurine, we were able to convert the GPRTase to a HGPRTase.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 513 Parnassus, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019391] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-19391] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CRAIG SP, 1991, P NATL ACAD SCI USA, V88, P2500, DOI 10.1073/pnas.88.6.2500; EADS JC, 1994, CELL, V78, P325, DOI 10.1016/0092-8674(94)90301-8; Henriksen A, 1996, BIOCHEMISTRY-US, V35, P3803, DOI 10.1021/bi952226y; Heroux A, 1999, BIOCHEMISTRY-US, V38, P14485, DOI 10.1021/bi990507q; JOCHIMSEN B, 1975, MOL GEN GENET, V143, P85, DOI 10.1007/BF00269424; KANNAANEH J, 1994, EUR J BIOCHEM, V223, P595; Lee CC, 1998, BIOCHEMISTRY-US, V37, P3491, DOI 10.1021/bi9720179; Munagala NR, 1998, BIOCHEMISTRY-US, V37, P4045, DOI 10.1021/bi972515h; Munagala NR, 1998, BIOCHEMISTRY-US, V37, P16612, DOI 10.1021/bi9818974; Page JP, 1999, EUR J BIOCHEM, V259, P565, DOI 10.1046/j.1432-1327.1999.00020.x; SCAPIN G, 1995, BIOCHEMISTRY-US, V34, P10744, DOI 10.1021/bi00034a006; Schumacher MA, 1996, NAT STRUCT BIOL, V3, P881, DOI 10.1038/nsb1096-881; Shi WX, 2000, BIOCHEMISTRY-US, V39, P6781, DOI 10.1021/bi000128t; Shi WX, 1999, BIOCHEMISTRY-US, V38, P9872, DOI 10.1021/bi990664p; Sommer JM, 1996, MOL BIOCHEM PARASIT, V78, P185, DOI 10.1016/S0166-6851(96)02623-0; Somoza JR, 1996, BIOCHEMISTRY-US, V35, P7032, DOI 10.1021/bi953072p; WANG CC, 1983, J EXP MED, V158, P1703, DOI 10.1084/jem.158.5.1703; WANG CC, 1984, J MED CHEM, V27, P1, DOI 10.1021/jm00367a001; Wang CC, 1997, PARASITOLOGY, V114, pS31; YU Y, 1997, BIOCHEMISTRY-US, V36, P3700; YUAN L, 1992, BIOCHEMISTRY-US, V31, P806, DOI 10.1021/bi00118a024	23	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37072	37077		10.1074/jbc.M007239200	http://dx.doi.org/10.1074/jbc.M007239200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10976110	hybrid			2022-12-27	WOS:000165577700086
J	Ryabova, LA; Pooggin, MM; Dominguez, DI; Hohn, T				Ryabova, LA; Pooggin, MM; Dominguez, DI; Hohn, T			Continuous and discontinuous ribosome scanning on the cauliflower mosaic virus 35 S RNA leader is controlled by short open reading frames	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCISTRONIC MESSENGER-RNA; EUKARYOTIC RIBOSOMES; TRANSLATIONAL REGULATION; SECONDARY STRUCTURE; STABLE HAIRPIN; INITIATION; PROTEIN; PHOSPHORYLATION; REINITIATION; EFFICIENCY	The pathways of scanning ribosome migration controlled by the cauliflower mosaic virus 35 S RNA leader were investigated in vitro and in vivo. This long (600 nucleotides) leader contains several short open reading frames (sORFs) and folds into an extended hairpin structure with three main stable stem sections. Translation initiation downstream of the leader is cap-dependent and occurs via ribosomal shunt under the control of two cis elements, a short open reading frame A (sORF A) followed by stem section 1. Here we show that a second similar configuration comprising sORF B followed by stem section 2 also allows shunting. The efficiency of the secondary shunt was greatly increased when stem section 1 was destabilized. In addition, we present evidence that a significant fi action of reinitiation-competent ribosomes that escape both shunt events migrate linearly via the structured central region but are intercepted by internal AUG start codons. Thus, expression downstream of the 35 S RNA leader is largely controlled by its multiple sORFs.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hohn, T (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	Hohn@fmi.ch		Pooggin, Mikhail/0000-0003-2308-393X; Ryabova, Lyubov/0000-0003-1989-203X				Belsham GJ, 2000, COLD SPRING HARBOR M, V39, P869; BONNEVILLE JM, 1989, CELL, V59, P1135, DOI 10.1016/0092-8674(89)90769-1; CURRAN J, 1988, EMBO J, V7, P2869, DOI 10.1002/j.1460-2075.1988.tb03143.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Dominguez DI, 1998, J BIOL CHEM, V273, P3669, DOI 10.1074/jbc.273.6.3669; FRANCK A, 1980, CELL, V21, P285, DOI 10.1016/0092-8674(80)90136-1; FUTTERER J, 1990, EMBO J, V9, P1697, DOI 10.1002/j.1460-2075.1990.tb08293.x; FUTTERER J, 1992, NUCLEIC ACIDS RES, V20, P3851, DOI 10.1093/nar/20.15.3851; FUTTERER J, 1991, EMBO J, V10, P3887, DOI 10.1002/j.1460-2075.1991.tb04958.x; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; Futterer J, 1996, J VIROL, V70, P2999; Guerra-Peraza O, 2000, J VIROL, V74, P2067, DOI 10.1128/JVI.74.5.2067-2072.2000; Gurevich VV, 1996, METHOD ENZYMOL, V275, P382; Hemmings-Mieszczak M, 1999, RNA, V5, P1149, DOI 10.1017/S1355838299990325; Hemmings-Mieszczak M, 1998, RNA, V4, P101; HemmingsMieszczak M, 1997, J MOL BIOL, V267, P1075, DOI 10.1006/jmbi.1997.0929; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Hohn T, 1998, LOOK BEYOND TRANSCRIPTION, P84; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; LUUKKONEN BGM, 1995, J VIROL, V69, P4086, DOI 10.1128/JVI.69.7.4086-4094.1995; MERRICK WC, 1990, ENZYME, V44, P7, DOI 10.1159/000468743; Paraskeva E, 1999, MOL CELL BIOL, V19, P807; Pestova TV, 1999, TRENDS BIOCHEM SCI, V24, P85, DOI 10.1016/S0968-0004(99)01356-0; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Pooggin MM, 2000, J BIOL CHEM, V275, P17288, DOI 10.1074/jbc.M001143200; Pooggin MM, 1998, J VIROL, V72, P4157, DOI 10.1128/JVI.72.5.4157-4169.1998; RAMAIAH KVA, 1992, P NATL ACAD SCI USA, V89, P12063, DOI 10.1073/pnas.89.24.12063; Remm M, 1999, J VIROL, V73, P3062, DOI 10.1128/JVI.73.4.3062-3070.1999; ROBERTS BE, 1973, P NATL ACAD SCI USA, V70, P2330, DOI 10.1073/pnas.70.8.2330; Ryabova LA, 2000, GENE DEV, V14, P817; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SchmidtPuchta W, 1997, NUCLEIC ACIDS RES, V25, P2854, DOI 10.1093/nar/25.14.2854; Yueh A, 2000, GENE DEV, V14, P414; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	40	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37278	37284		10.1074/jbc.M004909200	http://dx.doi.org/10.1074/jbc.M004909200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973961	hybrid			2022-12-27	WOS:000165577700113
J	Xia, RH; Stangler, T; Abramson, JJ				Xia, RH; Stangler, T; Abramson, JJ			Skeletal muscle ryanodine receptor is a redox sensor with a well defined redox potential that is sensitive to channel modulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CALCIUM RELEASE; SARCOPLASMIC-RETICULUM; CA2+ RELEASE; SULFHYDRYL OXIDATION; GLUTATHIONE; DISULFIDE; REAGENTS; PURIFICATION; BINDING	Hyperreactive sulfhydryl groups associated with the Ca2+ release protein from sarcoplasmic reticulum are shown to have a well defined reduction potential that is sensitive to the cellular environment. Ca2+ channel activators lower the redox potential of the ryanodine receptor, which favors the oxidation of thiols and the opening of the Ca2+ release protein. In contrast, channel inhibitors increase the redox potential, which favors the reduction of disulfides and the closure of the release protein. Modulation of redox potential of reactive thiols may be a general control mechanism by which sarcoplasmic/endoplasmic reticulum, ryanodine receptors/IP3 receptors, control cytoplasmic Ca2+ concentrations.	Portland State Univ, Dept Phys, Portland, OR 97207 USA	Portland State University	Abramson, JJ (corresponding author), Portland State Univ, Dept Phys, POB 751, Portland, OR 97207 USA.							ABRAMSON JJ, 1993, ARCH BIOCHEM BIOPHYS, V301, P396, DOI 10.1006/abbi.1993.1162; ABRAMSON JJ, 1988, MOL CELL BIOCHEM, V82, P81; ABRAMSON JJ, 1988, J BIOL CHEM, V263, P18750; Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; Anzai K, 1998, BIOCHEM BIOPH RES CO, V249, P938, DOI 10.1006/bbrc.1998.9244; Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Dulhunty A, 2000, ANTIOXID REDOX SIGN, V2, P27, DOI 10.1089/ars.2000.2.1-27; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; Feng W, 2000, BIOPHYS J, V78, p123A; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; INUI M, 1987, J BIOL CHEM, V262, P1740; KAPLIN AI, 1994, J BIOL CHEM, V269, P28972; LIU GH, 1994, MOL PHARMACOL, V45, P189; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; Morad M, 2000, ANTIOXID REDOX SIGN, V2, P1, DOI 10.1089/ars.2000.2.1-1; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; REID MB, 1993, J APPL PHYSIOL, V75, P1081, DOI 10.1152/jappl.1993.75.3.1081; RENARDROONEY DC, 1995, BIOCHEM J, V310, P185, DOI 10.1042/bj3100185; SALAMA G, 1992, J PHYSIOL-LONDON, V454, P389, DOI 10.1113/jphysiol.1992.sp019270; Stoyanovsky D, 1997, CELL CALCIUM, V21, P19, DOI 10.1016/S0143-4160(97)90093-2; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; TRIMM JL, 1986, J BIOL CHEM, V261, P6092; Zable AC, 1997, J BIOL CHEM, V272, P7069, DOI 10.1074/jbc.272.11.7069; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	27	112	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36556	36561		10.1074/jbc.M007613200	http://dx.doi.org/10.1074/jbc.M007613200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10952995	hybrid			2022-12-27	WOS:000165577700015
J	Agani, FH; Pichiule, P; Chavez, JC; LaManna, JC				Agani, FH; Pichiule, P; Chavez, JC; LaManna, JC			The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 1-ALPHA; XENOMITOCHONDRIAL CYBRIDS; ERYTHROPOIETIN GENE; OXIDATIVE STRESS; PROTEIN; BINDING; TRANSCRIPTION; CELLS; MPTP; STABILIZATION	Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factor that regulates transcriptional activation of several genes responsive to the lack of oxygen, including erythropoietin, vascular endothelial growth factor, glycolytic enzymes, and glucose transporters. Because the involvement of mitochondria in the regulation of HIF-1 has been postulated, we tested the effects of mitochondrial electron transport chain deficiency on HIF-1 protein expression and DNA binding in hypoxic cells. The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) inhibits electron transport chain at the level of complex I. MPTP is first converted to a pharmacologically active metabolite 1-methyl-4-phenylpyridinum (MPP+). MPP+ effectively inhibited both complex I activity and hypoxic accumulation of HIF-1 alpha protein in dopaminergic cell lines PC12 and CATH.a, In C57BL/6 mice, a single dose of MPTP (15 mg/kg, intraperitoneal) inhibited complex I activity and HIF-1 alpha protein accumulation in the striatum in response to a subsequent hypoxic challenge (8% O-2, 4 h). In a genetic model system, 40% complex I-inhibited human-ape xe-nomitochondrial cybrids, hypoxic induction of HIF-1 alpha was severely reduced, and HIF-1 DNA binding was diminished. However, succinate, the mitochondrial complex II substrate, restored the hypoxic response in cybrid cells, suggesting that electron transport chain activity is required for activation of HIF-1. A partial complex I deficiency and a mild reduction in intact cell oxygen consumption effectively prevented hypoxic induction of HIF-1 alpha protein.	Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA	Case Western Reserve University	LaManna, JC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Anat, 10900 Euclid Ave, Cleveland, OH 44106 USA.		LaManna, Joseph/D-3860-2013; LaManna, Joseph C/C-3347-2012	LaManna, Joseph/0000-0002-0159-4512; LaManna, Joseph C/0000-0002-0159-4512	NHLBI NIH HHS [HL 56470] Funding Source: Medline; NINDS NIH HHS [NS37111, NS 38632] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037111, R01NS038632] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; de la Torre JC, 1999, ACTA NEUROPATHOL, V98, P1, DOI 10.1007/s004010051044; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; Feldser D, 1999, CANCER RES, V59, P3915; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Kenyon L, 1997, P NATL ACAD SCI USA, V94, P9131, DOI 10.1073/pnas.94.17.9131; MARONGIU ME, 1988, NEUROSCI LETT, V94, P349, DOI 10.1016/0304-3940(88)90043-2; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MILLER WG, 1999, TRENDS NEUROSCI, V10, P424; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Przedborski S, 1998, MOVEMENT DISORD, V13, P35; RAMSAY RR, 1991, J NEUROCHEM, V56, P1184, DOI 10.1111/j.1471-4159.1991.tb11409.x; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schapira AHV, 1998, BBA-BIOENERGETICS, V1366, P225, DOI 10.1016/S0005-2728(98)00115-7; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Spooren WPJM, 1998, NEUROSCIENCE, V85, P649; Sriram K, 1997, BRAIN RES, V749, P44, DOI 10.1016/S0006-8993(96)01271-1; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zaman K, 1999, J NEUROSCI, V19, P9821; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	32	155	163	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35863	35867		10.1074/jbc.M005643200	http://dx.doi.org/10.1074/jbc.M005643200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10961998	hybrid			2022-12-27	WOS:000165382000033
J	Boschi-Muller, S; Azza, S; Sanglier-Cianferani, S; Talfournier, F; Van Dorsselear, A; Branlant, G				Boschi-Muller, S; Azza, S; Sanglier-Cianferani, S; Talfournier, F; Van Dorsselear, A; Branlant, G			A sulfenic acid enzyme intermediate is involved in the catalytic mechanism of peptide methionine sulfoxide reductase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; GLUTATHIONE-PEROXIDASE; THIOREDOXIN REDUCTASE; IN-VIVO; EXPRESSION; PROTEINS; RESIDUES; GENE; RESOLUTION; KINETICS	Methionine oxidation into methionine sulfoxide is known to be involved in many pathologies and to exert regulatory effects on proteins. This oxidation can be reversed by a ubiquitous monomeric enzyme, the peptide methionine sulfoxide reductase (MsrA), whose activity in vivo requires the thioredoxin-regenerating system. The proposed chemical mechanism of Escherichia coli MsrA involves three Cys residues (positions 51, 198, and 206), A fourth Cys (position 86) is not important for catalysis, In the absence of a reducing system, 2 mol of methionine are formed per mole of enzyme for wild type and Cys->86 Ser mutant MsrA, whereas only 1 mol is formed for mutants in which either Cys-198 or Cys-206 is mutated, Reduction of methionine sulfoxide is shown to proceed through the formation of a sulfenic acid intermediate, This intermediate has been characterized by chemical probes and mass spectrometry analyses. Together, the results support a three-step chemical mechanism in vivo: 1) Cys-51 attacks the sulfur atom of the sulfoxide substrate leading, via a rearrangement, to the formation of a sulfenic acid intermediate on Cys-BI and release of 1 mol of methionine/mol of enzyme; 2) the sulfenic acid is then reduced via a double displacement mechanism involving formation of a disulfide bond between Cys-51 and Cys-198, followed by formation of a disulfide bond between Cys-198 and Cys-206, which liberates Cys-51, and 3) the disulfide bond between Cys-198 and Cys-206 is reduced by thioredoxin-dependent recycling system process.	Fac Sci, UMR CNRS UHP 7567, F-54506 Vandoeuvre Les Nancy, France; Univ Strasbourg, UMR CNRS ULP 7509, Lab Spectrometrie Masse Bioorgan, F-67087 Strasbourg, France	Universite de Lorraine; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Branlant, G (corresponding author), Fac Sci, UMR CNRS UHP 7567, Bld des Aiguillettes,BP 239, F-54506 Vandoeuvre Les Nancy, France.	Guy.Branlant@maem.uhp-nancy.fr		Cianferani, Sarah/0000-0003-4013-4129; Boschi, Sandrine/0000-0001-8962-4749				ABRAMS WR, 1981, P NATL ACAD SCI-BIOL, V78, P7483, DOI 10.1073/pnas.78.12.7483; ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; BENITEZ LV, 1974, J BIOL CHEM, V249, P6234; Carsol MA, 1997, EUR J BIOCHEM, V247, P248, DOI 10.1111/j.1432-1033.1997.00248.x; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Crane EJ, 1997, BIOCHEMISTRY-US, V36, P8611, DOI 10.1021/bi9707990; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; JACQUOT JP, 1994, J MOL BIOL, V235, P1357, DOI 10.1006/jmbi.1994.1091; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Lin TY, 1999, BIOCHEMISTRY-US, V38, P15508, DOI 10.1021/bi9907678; Lowther WT, 2000, P NATL ACAD SCI USA, V97, P6463, DOI 10.1073/pnas.97.12.6463; Moskovitz J, 1997, P NATL ACAD SCI USA, V94, P9585, DOI 10.1073/pnas.94.18.9585; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; Moskovitz J, 2000, J BIOL CHEM, V275, P14167, DOI 10.1074/jbc.275.19.14167; MOSKOVITZ J, 1995, J BACTERIOL, V177, P502, DOI 10.1128/jb.177.3.502-507.1995; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P3205, DOI 10.1073/pnas.93.8.3205; Mossner E, 1999, J BIOL CHEM, V274, P25254, DOI 10.1074/jbc.274.36.25254; RAHMAN MA, 1992, J BIOL CHEM, V267, P15549; Ren B, 1997, J MOL BIOL, V268, P869, DOI 10.1006/jmbi.1997.1005; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; Silver M, 1979, Methods Enzymol, V62, P135, DOI 10.1016/0076-6879(79)62208-5; STEIN M, 1995, PLANT MOL BIOL, V28, P487, DOI 10.1007/BF00020396; Sun HY, 1999, BIOCHEMISTRY-US, V38, P105, DOI 10.1021/bi981295k; Tete-Favier F, 2000, ACTA CRYSTALLOGR D, V56, P1194, DOI 10.1107/S0907444900009483; URSINI F, 1995, METHOD ENZYMOL, V252, P38; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; WALLACE TJ, 1964, J AM CHEM SOC, V86, P4099, DOI 10.1021/ja01073a039; WALLACE TJ, 1965, J ORG CHEM, V30, P1502, DOI 10.1021/jo01016a039	32	158	166	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35908	35913		10.1074/jbc.M006137200	http://dx.doi.org/10.1074/jbc.M006137200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964927	hybrid, Green Published			2022-12-27	WOS:000165382000039
J	Christmann, M; Kaina, B				Christmann, M; Kaina, B			Nuclear translocation of mismatch repair proteins MSH2 and MSH6 as a response of cells to alkylating agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPOLYPOSIS COLON-CANCER; DNA-DAMAGE TOLERANCE; MAMMALIAN-CELLS; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; CHROMOSOMAL INSTABILITY; METHYLATING AGENTS; ESCHERICHIA-COLI; GENOTOXIC AGENTS; BINDING-ACTIVITY; GENE-EXPRESSION	Mammalian:mismatch repair has been implicated in mismatch correction, the prevention of mutagenesis and cancer, and the induction of genotoxicity and apoptosis.:sere, we show that treatment of cells specifically with agents inducing O(6)-methylguanine in DNA, such as N-methyl-N'-nitro-N-nitrosoguanidine and N-methyl-N-nitrosourea, elevates the level of MSH2 and MSH6 and increases GT mismatch binding activity in the nucleus. This inducible response occurs immediately after alkylation, is long-lasting and dose-dependent, and results from translocation of the preformed MutS alpha complex (composed of MSHS and MSH6) from the cytoplasm into the nucleus. It is not caused by an increase in MSH2 gene activity. Cells expressing the DNA repair protein O(6)-methylguanine-DNA methyltransferase (MG:MT), thus having the ability to repair O(6)-methylguanine, showed no translocation of MutSa, whereas inhibition of MGMT by O(6)-benzylguanine provoked the translocation. The results demonstrate that O(6)-methylguanine lesions are,involved in triggering nuclear accumulation of MSH2 and MSH6. The finding that treatment of cells with O(6)-methylguanine-generating mutagens results in an increase of MutS alpha and GT binding activity in the nucleus:indicates a novel type of genotoxic stress response.	Johannes Gutenberg Univ Mainz, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Kaina, B (corresponding author), Johannes Gutenberg Univ Mainz, Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher 67, D-55131 Mainz, Germany.	Kaina@mail.uni-mainz.de						AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Belloni M, 1999, J NEUROCHEM, V72, P974, DOI 10.1046/j.1471-4159.1999.0720974.x; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRANCH P, 1995, CANCER RES, V55, P2304; BRENNAND J, 1986, CARCINOGENESIS, V7, P185, DOI 10.1093/carcin/7.1.185; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DOLAN ME, 1991, CARCINOGENESIS, V12, P2305, DOI 10.1093/carcin/12.12.2305; Dosch J, 1996, ONCOGENE, V13, P1927; Dosch J, 1998, CARCINOGENESIS, V19, P567, DOI 10.1093/carcin/19.4.567; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; Herrlich P, 1997, BIOL CHEM, V378, P1217; KAINA B, 1991, CARCINOGENESIS, V12, P1857; Kaina B, 1997, MUTAT RES-FUND MOL M, V381, P227, DOI 10.1016/S0027-5107(97)00187-5; Kaina B, 1999, NATO ASI 2, V55, P289; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Korabiowska M, 1999, ONCOL REP, V6, P921; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Littman SJ, 1999, J BIOL CHEM, V274, P7474, DOI 10.1074/jbc.274.11.7474; LOVELESS A, 1969, NATURE, V223, P206, DOI 10.1038/223206a0; Marra G, 1996, ONCOGENE, V13, P2189; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PEGG AE, 1993, BIOCHEMISTRY-US, V32, P11998, DOI 10.1021/bi00096a009; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SEDGWICK B, 1983, MOL GEN GENET, V191, P466, DOI 10.1007/BF00425764; Tsuzuki T, 1996, CARCINOGENESIS, V17, P1215, DOI 10.1093/carcin/17.6.1215; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491	49	85	86	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36256	36262		10.1074/jbc.M005377200	http://dx.doi.org/10.1074/jbc.M005377200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10954713	hybrid			2022-12-27	WOS:000165382000087
J	Dupont, J; Karas, M; LeRoith, D				Dupont, J; Karas, M; LeRoith, D			The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; IGF-BINDING-PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; RETINOBLASTOMA PROTEIN; RECEPTOR SUBSTRATE-1; SIGNALING PATHWAYS; DEPENDENT KINASES; RIBONUCLEIC-ACID; CDK INHIBITORS; EXPRESSION	To gain insight into the mechanisms involved in the cross-talk between IGF-1 receptor (IGF-1R) and estrogen receptor signaling pathways, we used MCF-7-derived cells (SX13), which exhibit a 50% reduction in IGF-1R expression. Growth of NEO cells (control MCF-7 cells) was stimulated by both IGF-1 and estradiol (E2), and the addition of both mitogens resulted in a synergistic response. Estrogen enhanced IGF-1R signaling in NEO cells, but this effect was markedly diminished in SX13 cells. Estrogen was also able to potentiate the IGF-1 effect on the expression of cyclin D1 and cyclin E and on the phosphorylation of retinoblastoma protein in control but not in SX13 cells. IGF-1 increased the protein level of p21 and the luciferase activity of the p21 promoter, whereas it only reduced the protein level of p27 without affecting p27 promoter activity. Estrogen did not affect the p21 inhibitor, but it decreased the protein level of p27 and the p27 promoter luciferase activity. These effects of both mitogens were also observed at the level of association of both cyclin-dependent kinase inhibitors with CDK2 suggesting that IGF-1 and E2 affect the activity of both p21 and p27. Taken together, these data suggest that in MCF-7 cells, estrogen potentiates the IGF-1 effect on IGF-1R signaling as well as on the cell cycle components. Moreover, IGF-I and E2 regulate the expression of p21 and p27 and their association with CDK2 differently.	NIDDK, Sect Cellular & Mol Physiol, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	LeRoith, D (corresponding author), NIDDK, Sect Cellular & Mol Physiol, Clin Endocrinol Branch, NIH, Rm 8D12,Bldg 10, Bethesda, MD 20892 USA.							Ahmad S, 1999, BIOCHEM PHARMACOL, V58, P425, DOI 10.1016/S0006-2952(99)00125-2; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dupont J, 1998, BIOCHEM J, V335, P293, DOI 10.1042/bj3350293; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; Huynh H, 1996, CLIN CANCER RES, V2, P2037; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Johannessen LE, 1999, BIOCHEM J, V337, P599, DOI 10.1042/0264-6021:3370599; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; Kleinman D, 1996, ENDOCRINOLOGY, V137, P1089, DOI 10.1210/en.137.3.1089; KLEINMAN D, 1995, ENDOCRINOLOGY, V136, P2531, DOI 10.1210/en.136.6.2531; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lalli E, 1996, EMBO J, V15, P528, DOI 10.1002/j.1460-2075.1996.tb00385.x; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lee AV, 1995, BIOMED PHARMACOTHER, V49, P415, DOI 10.1016/0753-3322(96)82678-3; Liu Y, 1996, CANCER RES, V56, P31; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Moro A, 2000, BIOCHEM BIOPH RES CO, V269, P31, DOI 10.1006/bbrc.2000.2256; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Richards RG, 1998, J BIOL CHEM, V273, P11962, DOI 10.1074/jbc.273.19.11962; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; RUAN WF, 1995, ENDOCRINOLOGY, V136, P1296, DOI 10.1210/en.136.3.1296; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; Stoica A, 2000, J CELL BIOCHEM, V76, P605, DOI 10.1002/(SICI)1097-4644(20000315)76:4<605::AID-JCB9>3.0.CO;2-T; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Teruel T, 1996, BIOCHEM J, V319, P627, DOI 10.1042/bj3190627; Valverde AM, 1997, MOL ENDOCRINOL, V11, P595, DOI 10.1210/me.11.5.595; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White MF, 1998, CURR TOP MICROBIOL, V228, P179; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	48	126	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35893	35901		10.1074/jbc.M006741200	http://dx.doi.org/10.1074/jbc.M006741200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967123	hybrid, Green Submitted			2022-12-27	WOS:000165382000037
J	Persons, DL; Yazlovitskaya, EM; Pelling, JC				Persons, DL; Yazlovitskaya, EM; Pelling, JC			Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DAMAGE-INDUCED PHOSPHORYLATION; DNA-DAMAGE; SERINE 15; RADIOSENSITIZING AGENT; INHIBITOR; TRANSDUCTION; EXPRESSION; CELLS; ATM	The p53 tumor suppressor protein is a transcription factor that plays a major role in the DNA damage response. After DNA damage, p53 levels increase due primarily to stabilization of the protein. The molecular mechanisms leading to stabilization of p53 after DNA damage have not been completely elucidated. Recently we reported that cisplatin treatment activated extracellular signal-regulated kinase 1 and 2 (ERK1/2) and that inhibition of ERK1/2 resulted in enhanced sensitivity to cisplatin. In the present study, we examined the potential role of ERK1/2 activation in regulation of the p53 response to cisplatin. In the ovarian carcinoma cell line A2780, inhibition of ERK1/2 activation with the mitogen-activated protein kinase/ERK kinase 1 (MEK1) inhibitor PD98059 resulted in decreased p53 protein half-life and diminished accumulation of p53 protein during exposure to cisplatin. We also demonstrated that p53 protein co-immunoprecipitated with ERK1/2 protein and was phosphorylated by activated recombinant murine ERK2 in vitro. Furthermore, PD98059 decreased the phosphorylation of p53 at serine 15 during cisplatin exposure, suggesting that ERK1/2 mediates in part phosphorylation of p53 during the cisplatin DNA response. These results strongly suggest that cisplatin-induced ERK activation is an up-stream regulator of the p53 response to DNA damage caused by cisplatin.	Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Clin Lab 1213, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Persons, DL (corresponding author), Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Clin Lab 1213, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	dpersons@kumc.edu			NCI NIH HHS [CA72987] Funding Source: Medline; NCRR NIH HHS [P20RR11825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072987] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chernikova SB, 1999, RADIAT RES, V151, P159, DOI 10.2307/3579766; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Delmastro DA, 1997, CANCER CHEMOTH PHARM, V39, P245; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; EASTMAN A, 1995, SEMIN CANCER BIOL, V6, P45, DOI 10.1006/scbi.1995.0006; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Harlow E, 1988, ANTIBODIES LABORATOR, P521; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Keller D, 1999, BIOCHEM BIOPH RES CO, V261, P464, DOI 10.1006/bbrc.1999.1023; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mayo LD, 1997, CANCER RES, V57, P5013; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Prives C, 1999, J PATHOL, V187, P112; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	57	231	235	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35778	35785		10.1074/jbc.M004267200	http://dx.doi.org/10.1074/jbc.M004267200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10958792	hybrid			2022-12-27	WOS:000165382000021
J	Tran, TT; Dai, WX; Sarkar, HK				Tran, TT; Dai, WX; Sarkar, HK			Cyclosporin A inhibits creatine uptake by altering surface expression of the creatine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; SKELETAL-MUSCLE; NERVOUS-SYSTEM; MOLECULAR CHARACTERIZATION; IMMUNOSUPPRESSANT FK506; FUNCTIONAL EXPRESSION; DOWN-REGULATION; IN-SITU; IMMUNOPHILINS; LOCALIZATION	The immunosuppressive drug cyclosporin A (CsA) inhibited the hCRT-1 cDNA-induced creatine uptake in Xenopus oocytes and the endogenous creatine uptake in cultured C2C12 muscle cells in a dose- and time-dependent manner, FK506, another potent immunosuppressant, was unable to mimic the effect of CsA suggesting that the inhibitory effect of CsA was specific. To delineate the mechanism underlying, we investigated the effect of CsA on the K-m and V-max of creatine transport and also on the cell surface distribution of the creatine transporter, Although CsA treatment did not affect the K-m (20-24 muM) for creatine, it significantly decreased the V-max of creatine uptake in both oocytes and muscle cells. CsA treatment reduced the cell surface expression level of the creatine transporter in the muscle cells by similar to 60% without significantly altering its total expression level, and the reduction in the cell surface expression paralleled the decrease in creatine uptake, Taken together, our results suggest that CsA inhibited creatine uptake by altering the surface abundance of the creatine transporter. We propose that CsA impairs the targeting of the creatine transporter by inhibiting the function of an associated cyclophilin, resulting in an apparent loss in surface expression of the creatine transporter. Our results also suggest that prolonged exposure to CsA may result in chronically creatine-depleted muscle, which may be a cause for the development of CsA-associated clinical myopathies in organ transplant patients.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	Baylor College of Medicine	Sarkar, HK (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza, Houston, TX 77030 USA.	hsarkar@bcm.tmc.edu						Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; ARELLANO F, 1991, LANCET, V337, P915, DOI 10.1016/0140-6736(91)90245-K; BEIS I, 1975, BIOCHEM J, V152, P23, DOI 10.1042/bj1520023; BENNETT WM, 1994, MINER ELECTROL METAB, V20, P214; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; Biring MS, 1998, J APPL PHYSIOL, V84, P1967, DOI 10.1152/jappl.1998.84.6.1967; BOREL JF, 1989, PHARMACOL REV, V41, P259; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Budak-Alpdogan T, 1998, BONE MARROW TRANSPL, V22, P115, DOI 10.1038/sj.bmt.1701285; Dai WX, 1999, ARCH BIOCHEM BIOPHYS, V361, P75, DOI 10.1006/abbi.1998.0959; DALY MM, 1980, ARCH BIOCHEM BIOPHYS, V203, P317, DOI 10.1016/0003-9861(80)90182-4; Daniels GM, 1998, METHOD ENZYMOL, V296, P307; FERNANDEZSOLA J, 1990, LANCET, V335, P362; FITCH CD, 1974, J BIOL CHEM, V249, P1060; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GARCIAESCRIG M, 1994, CLIN NEUROPHARMACOL, V17, P298, DOI 10.1097/00002826-199406000-00010; GOY JJ, 1989, LANCET, V1, P1446; Guerrero-Ontiveros ML, 1998, MOL CELL BIOCHEM, V184, P427, DOI 10.1023/A:1006895414925; GUIMBAL C, 1993, J BIOL CHEM, V268, P8418; HARDIMAN O, 1993, NEUROLOGY, V43, P1432, DOI 10.1212/WNL.43.7.1432; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HELEKAR SA, 1994, NEURON, V12, P179, DOI 10.1016/0896-6273(94)90162-7; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; Hoyer P F, 1995, Contrib Nephrol, V114, P111; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LODISH HF, 1991, J BIOL CHEM, V266, P14835; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; MAYSER W, 1992, FEBS LETT, V305, P31, DOI 10.1016/0014-5793(92)80649-2; MEKHFI H, 1990, AM J PHYSIOL, V258, pH1151, DOI 10.1152/ajpheart.1990.258.4.H1151; NASH SR, 1994, RECEPTOR CHANNEL, V2, P165; Neubauer S, 1999, CIRCULATION, V100, P1847, DOI 10.1161/01.CIR.100.18.1847; OCHIAI T, 1987, TRANSPLANT P, V19, P1284; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RAMAMOORTHY S, 1992, PEDIATR RES, V32, P125, DOI 10.1203/00006450-199207000-00024; RUIZ M, 1994, INVEST OPHTH VIS SCI, V35, P4039; Saltarelli MD, 1996, DEV NEUROSCI-BASEL, V18, P524, DOI 10.1159/000111450; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHAW LM, 1990, CLIN CHEM, V36, P1841; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; SORA I, 1994, BIOCHEM BIOPH RES CO, V204, P419, DOI 10.1006/bbrc.1994.2475; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; TEGZESS AM, 1988, TRANSPLANT P, V20, P530; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vinnakota S, 1997, J NEUROCHEM, V69, P2238; Walker J B, 1979, Adv Enzymol Relat Areas Mol Biol, V50, P177; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WYSS M, 1994, MOL CELL BIOCHEM, V133, P51, DOI 10.1007/BF01267947	49	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35708	35714		10.1074/jbc.M005636200	http://dx.doi.org/10.1074/jbc.M005636200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964923	hybrid			2022-12-27	WOS:000165382000011
J	Yamage, M; Debrabant, A; Dwyer, DM				Yamage, M; Debrabant, A; Dwyer, DM			Molecular characterization of a hyperinducible, surface membrane-anchored, class I nuclease of a trypanosomatid parasite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-DONOVANI PROMASTIGOTES; AMINO-ACID-SEQUENCE; 3'-NUCLEOTIDASE NUCLEASE; CRITHIDIA-LUCILIAE; PENICILLIUM-CITRINUM; ASPERGILLUS-ORYZAE; PURINE STARVATION; MESSENGER-RNAS; GENE; PROTEIN	The 3'-nucleotidase/nuclease (5'-NT/NU) is a surface enzyme unique to trypanosomatid parasites. These organisms lack the pathway for de novo purine biosynthesis and thus are entirely dependent upon their hosts to supply this nutrient for their survival, growth, and multiplication. The 3'-NT/NU is involved in the salvage of preformed purines via the hydrolysis of either 3'-nucleotides or nucleic acids. In Crithidia luciliae, this enzyme is highly inducible. For example, in these organisms purine starvation triggers an similar to 1000-fold up-expression of 3'-NT/NU activity. In the present study, we cloned and characterized a gene encoding this intriguing enzyme from C. luciliae (Cl). Sequence analysis showed that the Cl 3'-NT/NU deduced protein possessed five regions, which we defined here as being characteristic of members of the class I nuclease family. Further, we demonstrated that the Cl 3'-NT/NU-expressed protein possessed both 3'-nucleotidase and nuclease activities. Moreover, we showed that the dramatic up-expression of 5'-NT/NU activity in response to purine starvation of C. luciliae was concomitant with the similar to 100-fold elevation in steady-state mRNA specific for this gene. Finally, results of our nuclear run-on analyses demonstrated that such up-regulation in 3'-NT/NU enzyme activity was mediated at the posttranscriptional level.	NIAID, Div Intramural Res, Parasit Dis Lab, Cell Biol Sect,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Dwyer, DM (corresponding author), NIAID, Div Intramural Res, Parasit Dis Lab, Cell Biol Sect,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000745, Z01AI000745, Z01AI000162] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Alleman MM, 1995, EXP PARASITOL, V81, P519, DOI 10.1006/expr.1995.1145; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aoyagi S, 1998, FEBS LETT, V429, P134, DOI 10.1016/S0014-5793(98)00563-8; Bates P.A., 1991, P537; BATES PA, 1987, MOL BIOCHEM PARASIT, V26, P289, DOI 10.1016/0166-6851(87)90081-8; BATES PA, 1993, FEMS MICROBIOL LETT, V107, P53, DOI 10.1111/j.1574-6968.1993.tb06003.x; BATES PA, 1990, MOL BIOCHEM PARASIT, V39, P247, DOI 10.1016/0166-6851(90)90063-R; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BRYANT C, 1989, BIOCH ADAPTATION PAR, P71; Burchmore RJS, 1998, J BIOL CHEM, V273, P29118, DOI 10.1074/jbc.273.44.29118; CAMPBELL TA, 1991, MOL BIOCHEM PARASIT, V47, P109, DOI 10.1016/0166-6851(91)90153-W; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CHAREST H, 1994, MOL CELL BIOL, V14, P2975, DOI 10.1128/MCB.14.5.2975; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; Croan D, 1996, MOL BIOCHEM PARASIT, V79, P97, DOI 10.1016/0166-6851(96)02629-1; DEBRABANT A, 1995, MOL BIOCHEM PARASIT, V71, P51, DOI 10.1016/0166-6851(95)00035-Y; DESCOTEAUX A, 1994, METH MOL G, V3, P22; DOYLE PS, 1993, EXP PARASITOL, V77, P435, DOI 10.1006/expr.1993.1103; FONG D, 1988, MOL BIOCHEM PARASIT, V31, P97, DOI 10.1016/0166-6851(88)90149-1; FRASER MJ, 1993, NUCLEASES, P171; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOTTLIEB M, 1989, PARASITOL TODAY, V5, P257, DOI 10.1016/0169-4758(89)90259-7; GOTTLIEB M, 1985, SCIENCE, V227, P72, DOI 10.1126/science.2981117; GOTTLIEB M, 1988, EXP PARASITOL, V66, P108, DOI 10.1016/0014-4894(88)90055-0; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; HASSAN HF, 1987, MOL BIOCHEM PARASIT, V23, P285, DOI 10.1016/0166-6851(87)90035-1; IWAMATSU A, 1991, J BIOCHEM-TOKYO, V110, P151, DOI 10.1093/oxfordjournals.jbchem.a123534; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JOSHI M, 1993, MOL BIOCHEM PARASIT, V58, P345, DOI 10.1016/0166-6851(93)90057-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee BR, 1995, APPL MICROBIOL BIOT, V44, P425; Lewin B., 2000, GENES; MAEKAWA K, 1991, EUR J BIOCHEM, V200, P651, DOI 10.1111/j.1432-1033.1991.tb16228.x; Mahmood R, 1998, J BIOL CHEM, V273, P23729, DOI 10.1074/jbc.273.37.23729; MCCARTHYBURKE C, 1991, EXP PARASITOL, V73, P385, DOI 10.1016/0014-4894(91)90112-A; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NEUBERT TA, 1990, J BIOL CHEM, V265, P7236; Pogue GP, 1996, MOL BIOCHEM PARASIT, V81, P27, DOI 10.1016/0166-6851(96)02697-7; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHNEIDER A, 1993, J BIOL CHEM, V268, P21868; Shishido K, 1982, NUCLEASES, P155; Stiles JK, 1999, ANN TROP MED PARASIT, V93, P781, DOI 10.1080/00034989957781; Sullivan JT, 1998, P NATL ACAD SCI USA, V95, P5145, DOI 10.1073/pnas.95.9.5145; SUNO M, 1973, J BIOCHEM-TOKYO, V73, P1291, DOI 10.1093/oxfordjournals.jbchem.a130203; TABATA N, 1991, AGR BIOL CHEM TOKYO, V55, P461, DOI 10.1080/00021369.1991.10870590; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; *UNDP WHO WORLD BA, 1997, TROP RES PROGR 1995; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; Zhang WW, 1996, MOL BIOCHEM PARASIT, V78, P79, DOI 10.1016/S0166-6851(96)02612-6; ZLOTNICK GW, 1987, COMP BIOCHEM PHYS B, V87, P629, DOI 10.1016/0305-0491(87)90063-0	53	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36369	36379		10.1074/jbc.M004036200	http://dx.doi.org/10.1074/jbc.M004036200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10945983	hybrid			2022-12-27	WOS:000165382000101
J	Yamamura, Y; Hua, XX; Bergelson, S; Lodish, HF				Yamamura, Y; Hua, XX; Bergelson, S; Lodish, HF			Critical role of Smads and AP-1 complex in transforming growth factor-beta-dependent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAD-RELATED PROTEIN; TGF-BETA; C-JUN; TRANSCRIPTION FACTORS; LEUKEMIA CELLS; FAS LIGAND; B-CELLS; ACTIVATION; INDUCTION; RECEPTOR	Transforming growth factor-beta1 (TGF-beta1) induces not only cell growth inhibition but also apoptosis in hepatocytes, myeloid cells, and epithelial cells. Although Smad proteins are identified as key signal transducers in TGF-beta1 dependent growth inhibition, their roles in the induction of apoptosis are unclear. We show here that both Smad proteins and AP-1 complex are involved in TGF-beta1 signaling for apoptosis. Overexpression of a dominant-negative Smad3 mutant or Smad7, both of which impair Smad-mediated signal transduction, inhibits TGF-beta1-dependent apoptosis. Only the JunD-FosB form of the AP-1 complex is markedly activated during TGF-beta1-dependent apoptosis, FosB substantially enhances Smad3.Smad4-dependent transcription, and dominant-negative FosB blocks TGF-beta1-dependent apoptosis but not growth inhibition. Expression of JunD.FosB enhances induction of apoptosis by TGF-beta1. Moreover, JunD.FosB binds to the 12-O-tetradecanoyl-13-acetate-responsive gene promoter element and recruits Smad3.Smad4 to form a multicomponent complex. These results suggest that Smad proteins and AP-1 complex synergize to mediate TGF-beta1-dependent apoptosis.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Tokyo Med & Dent Univ, Dept Retroviral Regulat, Div Med Res, Tokyo 1138519, Japan	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Tokyo Medical & Dental University (TMDU)	Yamamura, Y (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.							ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Altieri P, 1998, J CELL PHYSIOL, V177, P214, DOI 10.1002/(SICI)1097-4652(199811)177:2<214::AID-JCP3>3.3.CO;2-Y; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Bergelson S, 1998, J BIOL CHEM, V273, P2396, DOI 10.1074/jbc.273.4.2396; Brodin G, 1999, CANCER RES, V59, P2731; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KIM SJ, 1990, MOL CELL BIOL, V12, P5015; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LIN JK, 1992, CANCER RES, V52, P385; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Takiya S, 1995, J CLIN PATHOL, V48, P1093, DOI 10.1136/jcp.48.12.1093; Tang WL, 1998, J BIOL CHEM, V273, P5506, DOI 10.1074/jbc.273.10.5506; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	39	162	175	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36295	36302		10.1074/jbc.M006023200	http://dx.doi.org/10.1074/jbc.M006023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10942775	hybrid			2022-12-27	WOS:000165382000092
J	Korsisaari, N; Makela, TP				Korsisaari, N; Makela, TP			Interactions of Cdk7 and Kin28 with Hint/PKCI-1 and Hnt1 histidine triad proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXY-TERMINAL DOMAIN; ACTIVATING KINASE CAK; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVITY; FACTOR TFIIH; BINDING; CLONING; CYCLIN; YEAST	Cyclin-dependent kinase 7 (Cdk7) forms a trimeric complex with cyclin H and Mat1 to form the mammalian Cdk-activating kinase, CAK, as well as a part of the basal transcription factor TFIIH, where Cdk7 phosphorylates the C-terminal domain (CTD) of the large subunit of RNA polymerase II. Here, we report a novel interaction between Cdk7 and a histidine triad (HIT) family protein, Hint/PKCI-1. This interaction was initially observed in a yeast two hybrid study and subsequently verified by co-immunoprecipitation and subcellular localization studies, where overexpression of Cdk7 leads to partial relocalization of Hint to the nucleus. The physical association is independent of cyclin H binding or Cdk7 kinase activity and is conserved between the related Sacharomyces cerevisiae CTD kinase Kin28 and the HIT protein Hnt1. Furthermore, combination of a disruption of HNT1 and a KIN28 temperature-sensitive allele in S. cerevisae led to highly elongated cell morphology and reduced colony formation, indicating a genetic interaction between KIN28 and HNT1. The physical and genetic interactions of Hint and Hnt1 with Cdk7 and Kin28 suggest a role for this class of histidine triad proteins in the regulation of Cdk7 and Kin28 functions.	Univ Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Biocentrum Helsinki, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Diagnost Lab, Helsinki 00029, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Makela, TP (corresponding author), Univ Helsinki, Haartman Inst, POB 21, FIN-00014 Helsinki, Finland.	tomi.makela@helsinki.fi	makela, tomi/B-3734-2009	makela, tomi/0000-0002-4869-8044				Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; BREVET A, 1991, J BACTERIOL, V173, P5275, DOI 10.1128/jb.173.17.5275-5279.1991; Brzoska PM, 1996, GENOMICS, V36, P151, DOI 10.1006/geno.1996.0435; BRZOSKA PM, 1995, P NATL ACAD SCI USA, V92, P7824, DOI 10.1073/pnas.92.17.7824; Busso D, 2000, J BIOL CHEM, V275, P22815, DOI 10.1074/jbc.M002578200; Chen J, 1998, J BACTERIOL, V180, P2345, DOI 10.1128/JB.180.9.2345-2349.1998; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Damagnez V, 1995, EMBO J, V14, P6164, DOI 10.1002/j.1460-2075.1995.tb00307.x; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; FRASER ED, 1991, FEBS LETT, V294, P285, DOI 10.1016/0014-5793(91)81450-M; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Fusco C, 1998, GENOMICS, V51, P351, DOI 10.1006/geno.1998.5368; Gilmour J, 1997, BIOCHEM J, V326, P471, DOI 10.1042/bj3260471; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Huang Y, 1995, BIOCHEM J, V312, P925, DOI 10.1042/bj3120925; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Klein MG, 1998, EXP CELL RES, V244, P26, DOI 10.1006/excr.1998.4153; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PEARSON JD, 1990, J BIOL CHEM, V265, P4583; Razin E, 1999, J BIOL CHEM, V274, P34272, DOI 10.1074/jbc.274.48.34272; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Sambrook J, 1989, MOL CLONING; Stanhill A, 1999, MOL CELL BIOL, V19, P7529; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587	40	55	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34837	34840		10.1074/jbc.C000505200	http://dx.doi.org/10.1074/jbc.C000505200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10958787	hybrid			2022-12-27	WOS:000165422800002
J	Kronfeld, I; Kazimirsky, G; Lorenzo, PS; Garfield, SH; Blumberg, PM; Brodie, C				Kronfeld, I; Kazimirsky, G; Lorenzo, PS; Garfield, SH; Blumberg, PM; Brodie, C			Phosphorylation of protein kinase C delta on distinct tyrosine residues regulates specific cellular functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; PHORBOL ESTER; PKC-DELTA; SIGNAL-TRANSDUCTION; GLUTAMINE-SYNTHETASE; GLIAL-CELLS; ACTIVATION; EXPRESSION; DOMAINS; SRC	Protein kinase C delta (PKC delta) inhibits proliferation and decreases expression of the differentiation marker glutamine synthetase (GS) in C6 glioma cells. Here, we report that distinct, specific tyrosine residues on PKC delta are involved in these two responses. Transfection of cells with PKC delta mutated at tyrosine 155 to phenylalanine caused enhanced proliferation in response to 12-phorbol la-myristate 13-acetate, whereas GS expression resembled that for the PKC delta wild-type transfectant. Conversely, transfection with PKC delta mutated at tyrosine 187 to phenylalanine resulted in increased expression of GS, whereas the rate of proliferation resembled that of the PKC delta wild-type transfectant. The tyrosine phosphorylation of PKC delta and the decrease in GS expression induced by platelet-derived growth factor (PDGF) were abolished by the Src kinase inhibitors PP1 and PP2. In response to PDGF, Fyn associated with PKC delta via tyrosine 187. Finally, overexpression of dominant negative Fyn abrogated the decrease in GS expression and reduced the tyrosine phosphorylation of PKC delta induced by PDGF. We conclude that the tyrosine phosphorylation of PKC delta and its association with tyrosine kinases may be an important point of divergence in PKC signaling.	Bar Ilan Univ, Fac Life Sci, Gonda Goldschmied Med Diag Res Ctr, IL-52900 Ramat Gan, Israel; NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; NCI, Expt Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	Bar Ilan University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brodie, C (corresponding author), Bar Ilan Univ, Fac Life Sci, Gonda Goldschmied Med Diag Res Ctr, IL-52900 Ramat Gan, Israel.	chaya@mail.biu.ac.il						Acs P, 1997, J BIOL CHEM, V272, P28793, DOI 10.1074/jbc.272.45.28793; Acs P, 1997, J BIOL CHEM, V272, P22148, DOI 10.1074/jbc.272.35.22148; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Brodie C, 1998, J BIOL CHEM, V273, P30713, DOI 10.1074/jbc.273.46.30713; Brodie C, 1998, MOL BRAIN RES, V56, P108, DOI 10.1016/S0169-328X(98)00035-7; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Kiley SC, 1999, CANCER RES, V59, P3230; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mochly-Rosen D, 1998, FASEB J, V12, P35; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; Ron D, 1999, J BIOL CHEM, V274, P19003, DOI 10.1074/jbc.274.27.19003; Shanmugam M, 1998, ONCOGENE, V16, P1649, DOI 10.1038/sj.onc.1201684; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wang WJ, 1997, J BIOL CHEM, V272, P76; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	43	96	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35491	35498		10.1074/jbc.M005991200	http://dx.doi.org/10.1074/jbc.M005991200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10945993	hybrid			2022-12-27	WOS:000165422800087
J	Tolkunova, E; Park, H; Xia, J; King, MP; Davidson, E				Tolkunova, E; Park, H; Xia, J; King, MP; Davidson, E			The human lysyl-tRNA synthetase gene encodes both the cytoplasmic and mitochondrial enzymes by means of an unusual alternative splicing of the primary transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIES-SPECIFIC AMINOACYLATION; ESCHERICHIA-COLI; IN-VITRO; IDENTIFICATION; TRANSLATION; NUCLEOTIDE; EXPRESSION; TRNA(LYS); CLONING; INITIATION	Two cDNAs encoding human lysyl-tRNA synthetase have been identified. One encodes the cytoplasmic form of the enzyme identified previously. The second cDNA contains the same sequence but with a 180-bp insertion at the 5'-end of the mRNA. This results in a predicted protein whose carboxyl 576 amino acids are identical to those of the cytoplasmic enzyme but with a different amino terminus of 49 amino acids that contains a putative mitochondrial targeting sequence. Expression of the two lysyl-tRNA synthetase-green fluorescent protein gene fusions in a human cell line confirmed that the cytoplasmic form was targeted to the cytoplasm and the mitochondrial form to mitochondria, The genomic lysyl-tRNA synthetase gene consisted of 15 exons. The two isoforms were created by alternative splicing of the first three exons of the gene. The cytoplasmic form was created by splicing exon 1 to exon 3, The inclusion of exon 2 between exons 1 and 3 produced an mRNA encoding the mitochondrial isoform with an additional upstream small open reading frame, consisting mainly of a portion of the 5' coding region of the cytoplasmic isoform, This is the first example of mitochondrial targeting sequence being encoded on the second exon of a gene. Ribonuclease protection analysis showed that the mRNA encoding the cytoplasmic isoform makes up approximately 70%, and the mitochondrial isoform approximately 30%, of the mature transcripts from the lysyl-tRNA synthetase gene. The mitochondrial form of the enzyme, purified after expression in Escherichia coli, aminoacylated in vitro transcripts corresponding to both the cytoplasmic and mitochondrial tRNA(Lys), despite the difference in the discriminator base sequence in the acceptor stems of these tRNAs.	Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA	Jefferson University	King, MP (corresponding author), Thomas Jefferson Univ, Dept Biochem & Mol Biol, 233 S 10th St, Philadelphia, PA 19107 USA.	Michael.King@mail.tju.edu	Tolkunova, Elena/U-7174-2017	Tolkunova, Elena/0000-0003-1254-2619				Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Bullard JN, 1999, J MOL BIOL, V288, P567, DOI 10.1006/jmbi.1999.2708; CHATTON B, 1988, J BIOL CHEM, V263, P52; CLAROS MG, 1995, COMPUT APPL BIOSCI, V11, P441; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; DANPURE C, 1997, TRENDS CELL BIOL, V5, P230; Davidson E, 1997, TRENDS CARDIOVAS MED, V7, P16, DOI 10.1016/S1050-1738(96)00122-3; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FROLOVA LY, 1991, GENE, V109, P291, DOI 10.1016/0378-1119(91)90624-K; GATTI DL, 1991, J MOL BIOL, V218, P557, DOI 10.1016/0022-2836(91)90701-7; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Helm M, 1998, NUCLEIC ACIDS RES, V26, P1636, DOI 10.1093/nar/26.7.1636; HIPPS D, 1995, P NATL ACAD SCI USA, V92, P5550, DOI 10.1073/pnas.92.12.5550; Jorgensen R, 2000, J BIOL CHEM, V275, P16820, DOI 10.1074/jbc.275.22.16820; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Ladner RD, 1997, J BIOL CHEM, V272, P19072, DOI 10.1074/jbc.272.30.19072; LEE CP, 1993, P NATL ACAD SCI USA, V90, P7149, DOI 10.1073/pnas.90.15.7149; Leehey MA, 1995, BIOCHEMISTRY-US, V34, P16235, DOI 10.1021/bi00050a001; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; MARTIN NC, 1994, BIOCHIMIE, V76, P1161, DOI 10.1016/0300-9084(94)90045-0; MASUCCI JP, 1995, MOL CELL BIOL, V15, P2872; MIRANDE M, 1986, BIOCHIMIE, V68, P1001, DOI 10.1016/S0300-9084(86)80043-8; Mudge SJ, 1998, GENE, V209, P45, DOI 10.1016/S0378-1119(98)00007-9; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; Nichols RC, 1996, GENOMICS, V36, P210, DOI 10.1006/geno.1996.0449; OHANLON TP, 1995, BIOCHEM BIOPH RES CO, V210, P556, DOI 10.1006/bbrc.1995.1696; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128; Rodova M, 1999, BIOCHEM BIOPH RES CO, V255, P765, DOI 10.1006/bbrc.1999.0141; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SHIBA K, 1994, J BIOL CHEM, V269, P30049; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; Small I, 1998, PLANT MOL BIOL, V38, P265, DOI 10.1023/A:1006081903354; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142	39	101	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35063	35069		10.1074/jbc.M006265200	http://dx.doi.org/10.1074/jbc.M006265200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952987	hybrid			2022-12-27	WOS:000165422800033
J	Kim, S; Harris, M; Varner, JA				Kim, S; Harris, M; Varner, JA			Regulation of integrin alpha(v)beta(3)-mediated endothelial cell migration and angiogenesis by integrin alpha(5)beta(1) and protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN RECEPTOR; MESODERMAL DEFECTS; BLOOD-VESSELS; HUMAN SKIN; ADHESION; RHO; ACTIVATION; EMBRYOS; GROWTH; PHOSPHORYLATION	Recent studies indicate that angiogenesis depends, in part, on ligation of integrin alpha (5)beta (1) by fibronectin. Evidence is now provided that integrin alpha (5)beta (1) regulates the function of integrin alpha (v)beta (3) on endothelial cells during their migration in vitro or angiogenesis in vivo. Secretion of fibronectin by endothelial cells leads to the ligation of integrin alpha (5)beta (1), which potentiates alpha (v)beta (3)-mediated migration on vitronectin without influencing alpha (v)beta (3)-mediated cell adhesion. Endothelial cell attachment to vitronectin suppresses protein kinase A (PKA) activity, while addition of soluble anti-alpha (5)beta (1) restores this activity. Moreover, agents that activate intracellular PKA, such as forskolin, dibutyryl cAMP or alpha (5)beta (1) antagonists, suppress endothelial cell migration on vitronectin in vitro or angiogenesis in vivo. In contrast, inhibitors of PRA reverse the anti-migratory or anti-angiogenic effects mediated by alpha (5)beta (1) antagonists. Therefore, alpha (v)beta (3)-mediated endothelial cell. migration and angiogenesis can be regulated by PRA activity, which depends on the ligation state of integrin alpha (5)beta (1).	Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Varner, JA (corresponding author), Univ Calif San Diego, Ctr Canc, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Varner, Judith/0000-0002-9251-0600; Kim, Semi/0000-0001-8043-1465				Blystone SD, 1999, J CELL BIOL, V145, P889, DOI 10.1083/jcb.145.4.889; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Breier G, 1996, TRENDS CELL BIOL, V6, P454, DOI 10.1016/0962-8924(96)84935-X; Breier G, 1997, THROMB HAEMOSTASIS, V78, P678; BRODSKY FM, 1982, J IMMUNOL, V128, P129; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; Brooks PC, 1999, METH MOL B, V129, P257; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Carron CP, 1998, CANCER RES, V58, P1930; CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; ChristofidouSolomidou M, 1997, AM J PATHOL, V151, P975; CLARK RAF, 1982, J INVEST DERMATOL, V79, P269, DOI 10.1111/1523-1747.ep12500076; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; DRAKE CJ, 1995, J CELL SCI, V108, P2655; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Goh KL, 1997, DEVELOPMENT, V124, P4309; Imhof BA, 1997, EUR J IMMUNOL, V27, P3242, DOI 10.1002/eji.1830271223; KACZMAREK J, 1994, INT J CANCER, V58, P11; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; Neri D, 1997, NAT BIOTECHNOL, V15, P1271, DOI 10.1038/nbt1197-1271; NEWMAN PJ, 1985, BLOOD, V65, P227; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; PACIFICI R, 1994, J IMMUNOL, V153, P2222; Padmanabhan J, 1999, J NEUROBIOL, V39, P407, DOI 10.1002/(SICI)1097-4695(19990605)39:3<407::AID-NEU7>3.0.CO;2-S; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Simon KO, 1997, J BIOL CHEM, V272, P29380, DOI 10.1074/jbc.272.46.29380; Stromblad S, 1996, CHEM BIOL, V3, P881, DOI 10.1016/S1074-5521(96)90176-3; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Varner J A, 1997, EXS, V79, P361; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; YANG JT, 1993, DEVELOPMENT, V119, P1093	42	191	208	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33920	33928		10.1074/jbc.M003668200	http://dx.doi.org/10.1074/jbc.M003668200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10944524	hybrid			2022-12-27	WOS:000090104600102
J	Silva, PI; Daffre, S; Bulet, P				Silva, PI; Daffre, S; Bulet, P			Isolation and characterization of gomesin, an 18-residue cysteine-rich defense peptide from the spider Acanthoscurria gomesiana hemocytes with sequence similarities to horseshoe crab antimicrobial peptides of the tachyplesin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-DONOVANI PROMASTIGOTES; INDUCIBLE ANTIBACTERIAL PEPTIDE; INSECT IMMUNITY; COLORIMETRIC ASSAY; DISULFIDE BONDS; BROAD-SPECTRUM; PROTEGRIN-1; CONFORMATION; TRIDENTATUS	We have purified a small size antimicrobial peptide, named gomesin, from the hemocytes of the unchallenged tarantula spider Acanthoscurria gomesiana, Gomesin has a molecular mass of 2270.4 Ha, with 18 amino acids, including a pyroglutamic acid as the N terminus, a C-terminal arginine Lu-amide, and four cysteine residues forming two disulfide bridges, This peptide shows marked sequence similarities to antimicrobial peptides from other arthropods such as tachyplesin and polyphemusin from horseshoe crabs and androctonin from scorpions, Interestingly, it also shows sequence similarities to protegrins, antimicrobial peptides from porcine leukocytes, Gomesin strongly affects bacterial growth, as well as the development of filamentous fungi and yeast. In addition, we showed that gomesin affects the viability of the parasite Leishmania amazonensis.	Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, BR-05508900 Sao Paulo, Brazil; Inst Butantan, Lab Artropodes, BR-05503900 Sao Paulo, Brazil; Inst Biol Mol & Cellulaire, CNRS, UPR Reponse Immunitaire & Dev Insectes 9022, F-67084 Strasbourg, France	Universidade de Sao Paulo; Instituto Butantan; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Daffre, S (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Ave Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, Brazil.	sidaffre@icb.usp.br	Silva Junior, Pedro Ismael/E-1437-2011; Daffre, Sirlei/M-4233-2013; BULET, Philippe/C-8557-2014	Silva Junior, Pedro Ismael/0000-0001-6619-6489; Daffre, Sirlei/0000-0002-9966-0433; BULET, Philippe/0000-0001-9016-265X				Aitken Alastair, 1996, P339, DOI 10.1007/978-1-60327-259-9_51; Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Aumelas A, 1996, EUR J BIOCHEM, V237, P575, DOI 10.1111/j.1432-1033.1996.0575p.x; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BULET P, 1991, J BIOL CHEM, V266, P24520; Bulet P, 1999, DEV COMP IMMUNOL, V23, P329, DOI 10.1016/S0145-305X(99)00015-4; BULET P, 1992, EUR J BIOCHEM, V209, P977, DOI 10.1111/j.1432-1033.1992.tb17371.x; BULET P, 1993, J BIOL CHEM, V268, P14893; COCIANCICH S, 1994, BIOCHEM J, V300, P567, DOI 10.1042/bj3000567; COCIANCICH S, 1993, BIOCHEM BIOPH RES CO, V194, P17, DOI 10.1006/bbrc.1993.1778; Destoumieux D, 1997, J BIOL CHEM, V272, P28398, DOI 10.1074/jbc.272.45.28398; Diaz-Achirica P, 1998, BIOCHEM J, V330, P453, DOI 10.1042/bj3300453; Dimarcq JL, 1998, BIOPOLYMERS, V47, P465, DOI 10.1002/(SICI)1097-0282(1998)47:6<465::AID-BIP5>3.0.CO;2-#; EhretSabatier L, 1996, J BIOL CHEM, V271, P29537, DOI 10.1074/jbc.271.47.29537; Fahrner RL, 1996, CHEM BIOL, V3, P543, DOI 10.1016/S1074-5521(96)90145-3; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; Fogaca AC, 1999, J BIOL CHEM, V274, P25330, DOI 10.1074/jbc.274.36.25330; Ganz T, 1999, MOL MED TODAY, V5, P292, DOI 10.1016/S1357-4310(99)01490-2; Harwig SSL, 1996, EUR J BIOCHEM, V240, P352, DOI 10.1111/j.1432-1033.1996.0352h.x; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hwang PM, 1998, BIOCHEM CELL BIOL, V76, P235, DOI 10.1139/bcb-76-2-3-235; Iwanaga S, 1998, J BIOCHEM, V123, P1; KATSU T, 1993, BIOL PHARM BULL, V16, P178; KAWANO K, 1990, J BIOL CHEM, V265, P15365; KIDERLEN AF, 1990, J IMMUNOL METHODS, V127, P11, DOI 10.1016/0022-1759(90)90334-R; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; Lamberty M, 1999, J BIOL CHEM, V274, P9320, DOI 10.1074/jbc.274.14.9320; Mandard N, 1999, J BIOMOL STRUCT DYN, V17, P367, DOI 10.1080/07391102.1999.10508368; Mitta G, 1999, J CELL SCI, V112, P4233; MIYATA T, 1989, J BIOCHEM, V106, P663, DOI 10.1093/oxfordjournals.jbchem.a122913; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; Rao AG, 1999, ARCH BIOCHEM BIOPHYS, V361, P127, DOI 10.1006/abbi.1998.0962; SODERHALL K, 1983, DEV COMP IMMUNOL, V7, P229, DOI 10.1016/0145-305X(83)90004-6; Steinberg DA, 1997, ANTIMICROB AGENTS CH, V41, P1738, DOI 10.1128/AAC.41.8.1738; Tam JP, 2000, BIOCHEM BIOPH RES CO, V267, P783, DOI 10.1006/bbrc.1999.2035; TAMAMURA H, 1993, CHEM PHARM BULL, V41, P978; TAMAMURA H, 1993, BIOCHIM BIOPHYS ACTA, V1163, P209, DOI 10.1016/0167-4838(93)90183-R; UttenweilerJoseph S, 1997, ANAL BIOCHEM, V247, P366, DOI 10.1006/abio.1997.2083; WASSEF MK, 1985, LIPIDS, V20, P108, DOI 10.1007/BF02534216; Yans LZ, 1998, J BIOL CHEM, V273, P2059, DOI 10.1074/jbc.273.4.2059	41	200	207	3	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33464	33470		10.1074/jbc.M001491200	http://dx.doi.org/10.1074/jbc.M001491200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10942757	hybrid			2022-12-27	WOS:000090104600041
J	Wharton, W; Savell, J; Cress, WD; Seto, E; Pledger, WJ				Wharton, W; Savell, J; Cress, WD; Seto, E; Pledger, WJ			Inhibition of mitogenesis in Balb/c-3T3 cells by trichostatin A - Multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; GROWTH-FACTOR; E2F ACTIVITY; 3T3 CELLS; S-PHASE; YEAST; EXPRESSION; P27(KIP1); REGULATOR	Trichostatin A (TSA), a global repressor of histone deacetylase activity, inhibits the proliferation of a number of cell types. However, the identification of the mechanisms underlying TSA-mediated growth arrests has remained elusive. In order to resolve in more detail the cellular process modulated during the growth inhibition induced by TSA, me studied the effect of the drug on G(0)/G(1) traverse in mitogen-stimulated quiescent Balb/c-3T3 cells. Cyclin D1 and retinoblastoma proteins were induced following the mitogenic stimulation of both control and TSA-treated cells, and cyclin D1 formed complexes with CDK4 under both conditions. However, cyclin D1-associated kinase was not increased in growth-arrested cells. The lack of cyclin D-associated kinase was paralleled by an accumulation of RE in a hypophosphorylated form, as would be expected. In contrast, p130 became partially phosphorylated, accompanied by a marked increase in p130-dependent E2F DNA binding activity and a partial release of free E2F-4, Despite the presence of E2F complexes not bound to pocket proteins, late G(1) EaF-dependent gene expression was not observed, The lack of cyclin D1-associated kinase in TSA-treated cultures was potentially due to high levels of the cyclin-dependent inhibitor p27(kip1). However, the modulation of p27(kip1) levels by the deacetylase inhibitor cannot be responsible for the induction of the cell cycle arrest, since the growth of murine embryo fibroblasts deficient in both p27(kip1) and p21(cip1) was also inhibited by TSA, These data support a model in which TSA inhibits very early cell cycle traverse, which, in turn, leads to a decrease in cyclin D1-associated kinase activation and a repression of late cell cycle-dependent events. Alterations in early G(0)/G(1) gene expression accompany the TSA-mediated growth arrest.	Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol Immunol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Wharton, W (corresponding author), Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Coll Med, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [CA727694] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Allfrey V G, 1966, Proc Can Cancer Conf, V6, P313; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Ausubel FM, 1998, CURRENT PROTOCOLS MO; DeRubertis F, 1996, NATURE, V384, P589; Dong F, 1998, MOL BIOL CELL, V9, P2081, DOI 10.1091/mbc.9.8.2081; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Elend M, 1999, CURR BIOL, V9, pR936, DOI 10.1016/S0960-9822(00)80109-8; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Iavarone A, 1999, MOL CELL BIOL, V19, P916; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MAYOL X, 1995, ONCOGENE, V11, P801; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pelengaris S, 2000, CURR OPIN GENET DEV, V10, P100, DOI 10.1016/S0959-437X(99)00046-5; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Siavoshian S, 1997, BIOCHEM BIOPH RES CO, V232, P169, DOI 10.1006/bbrc.1997.6255; Stiegler P, 1998, CANCER RES, V58, P5049; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Vaziri C, 1998, CELL GROWTH DIFFER, V9, P465; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wang AH, 1999, MOL CELL BIOL, V19, P7816; WHARTON W, 1979, IN VITRO CELL DEV B, V15, P861; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001	39	53	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33981	33987		10.1074/jbc.M005600200	http://dx.doi.org/10.1074/jbc.M005600200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10945992	hybrid			2022-12-27	WOS:000090104600111
J	Mills, JS; Miettinen, HM; Cummings, D; Jesaitis, AJ				Mills, JS; Miettinen, HM; Cummings, D; Jesaitis, AJ			Characterization of the binding site on the formyl peptide receptor using three receptor mutants and analogs of Met-Leu-Phe and Met-Met-Trp-Leu-Leu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-FORMYLPEPTIDE RECEPTOR; G-PROTEIN; SIGNAL-TRANSDUCTION; IDENTIFICATION; LIGAND; ACTIVATION; CDNA; RHODOPSIN; MODEL; CHEMOATTRACTANTS	The formyl peptide receptor (FPR) is a chemotactic G protein-coupled receptor found on the surface of phagocytes. We have previously shown that the formyl peptide binding site maps to the membrane-spanning region (Miettinen, H. R., Mills, J. S., Gripentrog, J. M., Dratz, E. A., Granger, E. L., and Jesaitis, A. J. (1997) J. Immunol, 159, 4045-4054). Recent reports have indicated that nonformylated peptides, such as MMWLL can also activate this receptor (Chen, J., Bernstein, H. S., Chen, M.,Wang, L., Ishi, M., Turck, C. W., and Coughlin, S. R. (1995) J, Biol. Chem. 270, 23398-23401.) Here we show that the selectivity for the binding of different NH2-terminal analogs of MMWLL or MLF can be markedly altered by mutating Asp-106 to asparagine or Arg-201 to alanine. Both D106N and R201A produced a similar change in ligand specificity, including an enhanced ability to bind the HIV-I peptide DP178. In contrast, the mutation R205A exhibited altered specificity at the COOH terminus of fMLF, with R205A binding fMLF-O-butyl > fMLF-O-methyl > fiMLF, whereas wt FPR bound fMLF > fMLF-O-methyl similar to fMLF-O-butyl. These data, taken together with our previous finding that the leucine side chain of fMLF is probably bound to FPR near FPR (VRK95)-V-93 (Mills, J. S., Miettinen, H. M., Barnidge, D., Vlases, M. J., Wimer-Mackin, S., Dratz, E. A., and Jesaitis, A. J. (1998) J. Biol. Chem. 273, 10428-10435.), indicate that the most Likely positioning of fMLF in the binding pocket of EPR is approximately parallel to the fifth transmembrane helix with the formamide group of fMLF hydrogen-bonded to both Asp-106 and Arg-201, the leucine side chain pointing toward the second transmembrane region, and the COOH-terminal carboxyl group of fMLF ion-paired with Arg-205.	Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA	Montana State University System; Montana State University Bozeman	Mills, JS (corresponding author), Montana State Univ, Dept Microbiol, 109 Lewis Hall, Bozeman, MT 59717 USA.	umbmj@mantana.edu		Jesaitis, Algirdas/0000-0001-9001-5617	PHS HHS [2RO1A40108-4] Funding Source: Medline; SAMHSA HHS [2ROAI22735-14] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); SAMHSA HHS		Alvarez V, 1996, IMMUNOGENETICS, V44, P446, DOI 10.1007/BF02602806; Beck M, 1998, BIOCHEMISTRY-US, V37, P7630, DOI 10.1021/bi9801560; BELLEAU B, 1989, INT J IMMUNOPHARMACO, V11, P467, DOI 10.1016/0192-0561(89)90175-6; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BROOM MF, 1989, EXPERIENTIA, V45, P1097, DOI 10.1007/BF01950167; CHEN J, 1995, J BIOL CHEM, V270, P23398, DOI 10.1074/jbc.270.40.23398; Dahlgren C, 2000, BLOOD, V95, P1810, DOI 10.1182/blood.V95.5.1810.005k06_1810_1818; DEMARTINO JA, 1995, J BIOL CHEM, V270, P15966, DOI 10.1074/jbc.270.27.15966; Derian CK, 1996, BIOCHEMISTRY-US, V35, P1265, DOI 10.1021/bi952087k; Eilers M, 1999, P NATL ACAD SCI USA, V96, P487, DOI 10.1073/pnas.96.2.487; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; FREER RJ, 1982, BIOCHEMISTRY-US, V21, P257, DOI 10.1021/bi00531a009; FREER RJ, 1980, BIOCHEMISTRY-US, V19, P2404, DOI 10.1021/bi00552a019; GAO JL, 1994, J EXP MED, V180, P2191, DOI 10.1084/jem.180.6.2191; GAO JL, 1993, J BIOL CHEM, V268, P25395; Gao JL, 1998, GENOMICS, V51, P270, DOI 10.1006/geno.1998.5376; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; GIERSCHIK P, 1989, EUR J PHARM-MOLEC PH, V172, P481, DOI 10.1016/0922-4106(89)90031-X; HAN BM, 1995, BIOCHEMISTRY-US, V34, P13412, DOI 10.1021/bi00041a019; HEDNER J, 1983, ACTA PHYSIOL SCAND, V117, P427, DOI 10.1111/j.1748-1716.1983.tb00017.x; Higgins JD, 1996, J MED CHEM, V39, P1013, DOI 10.1021/jm950908d; Klein C, 1998, NAT BIOTECHNOL, V16, P1334, DOI 10.1038/4310; Laakkonen LJ, 1996, BIOCHEMISTRY-US, V35, P7651, DOI 10.1021/bi952203j; Le YY, 1999, J IMMUNOL, V163, P6777; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; Miettinen HM, 1998, J CELL SCI, V111, P1921; Miettinen HM, 1997, J IMMUNOL, V159, P4045; Mills JS, 1999, CURR INFLAMMAT RES, P215; Mills JS, 1998, J BIOL CHEM, V273, P10428, DOI 10.1074/jbc.273.17.10428; MURPHY PM, 1992, J BIOL CHEM, V267, P7637; NODA K, 1995, J BIOL CHEM, V270, P2284, DOI 10.1074/jbc.270.5.2284; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PERLMAN JH, 1994, J BIOL CHEM, V269, P1610; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; Su SB, 1999, BLOOD, V93, P3885, DOI 10.1182/blood.V93.11.3885.411k19_3885_3892; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Su SB, 1999, J IMMUNOL, V162, P5924; WEITZ CJ, 1993, BIOCHEMISTRY-US, V32, P14176, DOI 10.1021/bi00214a016; Wenzel-Seifert K, 1998, J BIOL CHEM, V273, P24181, DOI 10.1074/jbc.273.37.24181; YE RD, 1992, BIOCHEM BIOPH RES CO, V184, P582, DOI 10.1016/0006-291X(92)90629-Y; YE RD, 1993, J IMMUNOL, V150, P1383	41	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39012	39017		10.1074/jbc.M003081200	http://dx.doi.org/10.1074/jbc.M003081200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10960471	hybrid			2022-12-27	WOS:000165953100011
J	Wrisch, A; Grissmer, S				Wrisch, A; Grissmer, S			Structural differences of bacterial and mammalian K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; CHARYBDOTOXIN BLOCK; BINDING-SITES; MUTANT CYCLES; KALIOTOXIN; VESTIBULE; INHIBITOR; KV1.3; PORE; SELECTIVITY	Using a peptide toxin, kaliotoxin (KTX), we gained new insight into the topology of the pore region of a voltage-gated potassium channel, mKv1.1. In order to find new interactions between mHv1.1 and KTX, we investigated the pH dependence of KTX block which was stronger at pH, 6.2 compared with pH(o) 7.4. Using site-directed mutagenesis on the channel and the toxin, we found that protonation of His(34) in KTX caused the pH(o) dependence of KTX block. Glu(350) and Glu(353) in mKv1.1, which interact with His(34) in KTX, were calculated to be 4 and 7 Angstrom away from His(34)/KTX, respectively. Docking of KTX into a homology model of mHv1.1 based on the KcsA crystal structure using this and other known interactions as constraints showed structural differences between mKv1.1 and KcsA within the turret (amino acids 348-357). To satisfy our data, we would have to modify the KcsA crystal structure for the mKv1.1 channel orienting Glu(350) 7 Angstrom and Glu(353) 4 Angstrom more toward the center of the pore compared with KcsA. This would place Glu(350) 15 Angstrom and Glu(353) 11 Angstrom away from the center of the pore instead of the distances for the equivalent KcsA residues with 22 Angstrom for Gly(53) and 15 Angstrom for Gly(56), respectively. Bacterial and mammalian potassium channels may have structural differences regarding the turret of the outer pore vestibule. This topological difference between both channel types may have substantial influence on structure-guided development of new drugs for mammalian potassium channels by rational drug design.	Univ Ulm, Dept Appl Physiol, D-89081 Ulm, Germany	Ulm University	Grissmer, S (corresponding author), Univ Ulm, Dept Appl Physiol, Albert Einstein Allee 11, D-89081 Ulm, Germany.							AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; Aiyar J, 1996, J BIOL CHEM, V271, P31013, DOI 10.1074/jbc.271.49.31013; Bretschneider F, 1999, BIOPHYS J, V76, P2351, DOI 10.1016/S0006-3495(99)77392-3; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CREST M, 1992, J BIOL CHEM, V267, P1640; DEUTSCH C, 1991, J BIOL CHEM, V266, P3668; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dudlak CS, 2000, BIOPHYS J, V78, p97A; ECCLESTON E, 1973, NATURE-NEW BIOL, V244, P73, DOI 10.1038/newbio244073b0; Gairi M, 1997, J PEPT SCI, V3, P314, DOI 10.1002/(SICI)1099-1387(199707)3:4<314::AID-PSC117>3.0.CO;2-E; Garcia M L, 1999, Methods Enzymol, V294, P624; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GRISSMER S, 1984, PFLUG ARCH EUR J PHY, V402, P353, DOI 10.1007/BF00583935; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Hille B., 1992, IONIC CHANNELS EXCIT; Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697; Legros C, 2000, J BIOL CHEM, V275, P16918, DOI 10.1074/jbc.275.22.16918; LOEWENTHAL R, 1992, J MOL BIOL, V224, P759, DOI 10.1016/0022-2836(92)90560-7; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Mourre C, 1999, J PHARMACOL EXP THER, V291, P943; Perez-Cornejo P, 1998, J GEN PHYSIOL, V111, P441, DOI 10.1085/jgp.111.3.441; Rauer H, 2000, J BIOL CHEM, V275, P1201, DOI 10.1074/jbc.275.2.1201; Rauer H, 1996, MOL PHARMACOL, V50, P1625; Rehwald M, 1999, FEBS LETT, V443, P357, DOI 10.1016/S0014-5793(99)00007-1; Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P7401, DOI 10.1021/bi00444a038; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509; ULBRICHT W, 1975, PHILOS T ROY SOC B, V270, P353, DOI 10.1098/rstb.1975.0015	35	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39345	39353		10.1074/jbc.M006827200	http://dx.doi.org/10.1074/jbc.M006827200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10962004	hybrid			2022-12-27	WOS:000165953100057
J	Galbiati, F; Volonte, D; Minetti, C; Bregman, DB; Lisanti, MP				Galbiati, F; Volonte, D; Minetti, C; Bregman, DB; Lisanti, MP			Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation - Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutants and rescues wild-type caveolin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANE DOMAINS; NITRIC-OXIDE SYNTHASE; ROUS-SARCOMA VIRUS; RNA-POLYMERASE-II; PLASMA-MEMBRANE; GENE FAMILY; SMOOTH-MUSCLE; SUBCELLULAR-DISTRIBUTION; INTEGRAL COMPONENT; TRANSPORT VESICLES	Caveolin-3 is the principal structural protein of caveolae in striated muscle. Autosomal dominant limb-girdle muscular dystrophy (LGMD-1C) in humans is due to mutations (Delta TFT and Pro --> Leu) within the CAV3 gene. We have shown that LGMD-1C mutations lead to formation of unstable aggregates of caveolin-3 that are retained intracellularly and are rapidly degraded. The mechanism by which LGMD-1C mutants of caveolin-3 are degraded remains unknown. Here, we show that LGMD-1C mutants of caveolin-3 undergo ubiquitination-proteasomal degradation. Treatment with proteasomal inhibitors (MG-132, MG-115, lactacystin, or proteasome inhibitor I), but not lysosomal inhibitors, prevented degradation of LGMD-1C caveolin-3 mutants. In the presence of MG-132, LGMD-1C caveolin-3 mutants accumulated within the endoplasmic reticulum and did not reach the plasma membrane. LGMD-1C mutants of caveolin-3 behave in a dominant negative fashion, causing intracellular retention and degradation of wild-type caveolin-3, Interestingly, in cells co-expressing wildtype and mutant forms of caveolin-3, MG-132 treatment rescued wild-type caveolin-3; wild-type caveolin-3 was not degraded and reached the plasma membrane. These results may have clinical implications for treatment of patients with LGMD-1C.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Univ Genoa, Ist Giannina Gaslini, Serv Malattie Neuro Muscolari, I-16147 Genoa, Italy; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Genoa; IRCCS Istituto Giannina Gaslini; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Minetti, Carlo/K-4666-2018; Lisanti, Michael/B-6131-2018; Galbiati, Ferruccio/AAF-3527-2020; Lisanti, Michael P/C-6866-2013	Minetti, Carlo/0000-0002-0640-1804; Lisanti, Michael/0000-0003-2034-1382; 	Telethon [1111] Funding Source: Medline	Telethon(Fondazione Telethon)		Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BONILLA E, 1981, AM J PATHOL, V104, P167; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CORLEYMASTICK C, 1995, J CELL BIOL, V129, P1523; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Crosbie RH, 1998, FEBS LETT, V427, P279, DOI 10.1016/S0014-5793(98)00442-6; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Galbiati F, 1999, J BIOL CHEM, V274, P25632, DOI 10.1074/jbc.274.36.25632; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; Herrmann JM, 1999, TRENDS CELL BIOL, V9, P5, DOI 10.1016/S0962-8924(98)01414-7; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Kagan A, 2000, J BIOL CHEM, V275, P11241, DOI 10.1074/jbc.275.15.11241; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MOLDOVAN NI, 1995, EXP CELL RES, V219, P309, DOI 10.1006/excr.1995.1233; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NORTH AJ, 1993, J CELL BIOL, V120, P1159, DOI 10.1083/jcb.120.5.1159; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Razani B, 2000, J CELL SCI, V113, P2103; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SEVERS NJ, 1988, J CELL SCI, V90, P341; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SIFERS RN, 1995, NAT STRUCT BIOL, V2, P355, DOI 10.1038/nsb0595-355; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tang ZL, 1997, J BIOL CHEM, V272, P2437, DOI 10.1074/jbc.272.4.2437; THOMAS PJ, 1992, FEBS LETT, V312, P7, DOI 10.1016/0014-5793(92)81399-7; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Volonte D, 1999, FEBS LETT, V445, P431, DOI 10.1016/S0014-5793(99)00164-7; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Welihinda AA, 1999, GENE EXPRESSION, V7, P293	65	81	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37702	37711		10.1074/jbc.M006657200	http://dx.doi.org/10.1074/jbc.M006657200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973975	hybrid			2022-12-27	WOS:000165618700055
J	Schumacher, A; Koetsier, PA; Hertz, J; Doerfler, W				Schumacher, A; Koetsier, PA; Hertz, J; Doerfler, W			Epigenetic and genotype-specific effects on the stability of de Novo imposed methylation patterns in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL GENE-EXPRESSION; DNA METHYLATION; DENOVO METHYLATION; FOREIGN DNA; DETERMINES METHYLATION; CELLULAR MOSAICISM; HAMSTER-CELLS; MOUSE EMBRYO; SEQUENCES; EMBRYOGENESIS	The chloramphenicol acetyltransferase gene under the control of the late E2A promoter of adenovirus type 2 (Ad2) was introduced as transgene into the B6D2F1 mouse strain with mixed genetic background and became extensively de novo methylated. The methylation of this pAd2E2AL-CAT (7-1A) transgene was regulated in a strain-specific manner apparently depending on the site of integration. Transmission of the 7-1A transgene into an inbred DBA/2, 129/sv, or FVB/N genetic background led to a significant loss of methylation in the transgene, whereas C57BL/6, CB20, and Balb/c backgrounds favored the de novo methylation in very specific patterns. The newly established patterns of de novo methylation were transmitted to the offspring and remained stable for many generations, regardless of the heterozygosity of strain-specific DNA sequences present in these mouse strains. Segregation analyses showed a non-mendelian transmission of methylation phenotypes and suggested the involvement of dominant modifiers of methylation. The genotype-specific modifications of the transgene were followed for 11 backcross generations. These observations reflect an evolutionarily conserved mechanism directed against foreign, e.g. viral or bacterial, DNA at least in the chromosomal location of the 7-1A transgene, In seven additional mouse lines carrying the same transgene in different chromosomal locations, strain-specific alterations of methylation patterns were not observed.	Univ Cologne, Inst Genet, D-50931 Cologne, Germany	University of Cologne	Doerfler, W (corresponding author), Univ Cologne, Inst Genet, Weyertal 121, D-50931 Cologne, Germany.	doerfler@scan.genetik.uni-koeln.de	Schumacher, Axel/C-6612-2008					Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; Beck JA, 2000, NAT GENET, V24, P23, DOI 10.1038/71641; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; CHAILLET JR, 1995, GENE DEV, V9, P1177, DOI 10.1101/gad.9.10.1177; DELOIA JA, 1990, DEVELOPMENT, P73; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; DOERFLER W, 1999, FOREIGN DNA MAMMALIA; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; Engler P, 1998, P NATL ACAD SCI USA, V95, P10763, DOI 10.1073/pnas.95.18.10763; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; HELLER H, 1995, P NATL ACAD SCI USA, V92, P5515, DOI 10.1073/pnas.92.12.5515; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; Ivanova AV, 1998, NAT GENET, V19, P192, DOI 10.1038/566; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KAKUTANI T, 1995, NUCLEIC ACIDS RES, V23, P130, DOI 10.1093/nar/23.1.130; KOETSIER PA, 1993, BIOTECHNIQUES, V15, P260; Koetsier PA, 1996, TRANSGENIC RES, V5, P235, DOI 10.1007/BF01972877; LACY E, 1983, CELL, V34, P343, DOI 10.1016/0092-8674(83)90369-0; LATHAM KE, 1991, DEVELOPMENT, V113, P561; Latham KE, 1995, DIFFERENTIATION, V59, P269; LETTMANN C, 1991, NUCLEIC ACIDS RES, V19, P7131, DOI 10.1093/nar/19.25.7131; MARTIN CC, 1995, GENET RES, V65, P21, DOI 10.1017/S0016672300032973; MCGOWAN R, 1989, GENE DEV, V3, P1669, DOI 10.1101/gad.3.11.1669; MONK M, 1990, TRENDS GENET, V6, P110, DOI 10.1016/0168-9525(90)90124-O; MONK M, 1987, DEVELOPMENT, V99, P371; MULLER U, 1987, J VIROL, V61, P3710; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; Reik W, 1998, CURR OPIN GENET DEV, V8, P154, DOI 10.1016/S0959-437X(98)80136-6; REIK W, 1990, DEVELOPMENT, P99; Remus R, 1999, J VIROL, V73, P1010, DOI 10.1128/JVI.73.2.1010-1022.1999; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SAPIENZA C, 1990, DEVELOPMENT, P107; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SASAKI H, 1991, DEVELOPMENT, V111, P573; Schweizer J, 1998, DNA CELL BIOL, V17, P427, DOI 10.1089/dna.1998.17.427; Solter D, 1998, INT J DEV BIOL, V42, P951; SURANI MA, 1990, DEVELOPMENT, P89; SUTTER D, 1979, COLD SPRING HARB SYM, V44, P565, DOI 10.1101/SQB.1980.044.01.058; SUTTER D, 1980, P NATL ACAD SCI-BIOL, V77, P253, DOI 10.1073/pnas.77.1.253; SUTTER D, 1978, CELL, V14, P569, DOI 10.1016/0092-8674(78)90243-X; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; TOTH M, 1989, P NATL ACAD SCI USA, V86, P3728, DOI 10.1073/pnas.86.10.3728; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; VARDIMON L, 1980, NUCLEIC ACIDS RES, V8, P2461, DOI 10.1093/nar/8.11.2461; Weichman K, 1997, MOL CELL BIOL, V17, P5269, DOI 10.1128/MCB.17.9.5269; WU X, 1992, MECH EUKARYOTIC DNA, P69; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	51	36	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37915	37921		10.1074/jbc.M004839200	http://dx.doi.org/10.1074/jbc.M004839200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10954710	hybrid			2022-12-27	WOS:000165618700082
J	Gorman, L; Mercatante, DR; Kole, R				Gorman, L; Mercatante, DR; Kole, R			Restoration of correct splicing of thalassemic beta-globin pre-mRNA by modified U1 snRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SMALL NUCLEAR RNAS; ICAM-1 ANTISENSE OLIGONUCLEOTIDE; SITE-SPECIFIC MUTAGENESIS; EXTERNAL GUIDE SEQUENCES; MESSENGER-RNA; MAMMALIAN-CELLS; PREMESSENGER RNA; IN-VIVO; GENE-EXPRESSION	The T-->G mutation at nucleotide 705 in the second intron of the p-globin gene creates an aberrant 5' splice site and activates a 3' cryptic splice site upstream from the mutation. As a result, the IVS2-705 pre-mRNA is spliced via the aberrant splice sites leading to a deficiency of P-globin mRNA and protein and to the genetic blood disorder thalassemia. We have shown previously that in cell culture models of thalassemia, aberrant splicing of P-thalassemic IVS2-705 pre-mRNA was permanently corrected by a modified murine U7 snRNA that incorporated sequences antisense to the splice sites activated by the mutation. To explore the possibility of using other snRNAs as vectors for antisense sequences, U1 snRNA was modified in a similar manner. Replacement of the U1 9-nucleotide 5' splice site recognition sequence with nucleotides complementary to the aberrant 5' splice site failed to correct splicing of IVS2-705 pre-mRNA In contrast, U1 snRNA targeted to the cryptic 3' splice site was effective. A hybrid with a modified U7 snRNA gene under the control of the U1 promoter and terminator sequences resulted in the highest levels of correction (up to 70%) in transiently and stably transfected target cells.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Kole, R (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.	kole@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051940] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-51940] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baserga S., 1993, RNA WORLD, P359; Bennett CF, 1997, J PHARMACOL EXP THER, V280, P988; BENZ EJ, 1996, T AM CLIN CLIMAT ASS, V108, P78; Bertrand E, 1997, RNA, V3, P75; Biasolo MA, 1996, J VIROL, V70, P2154, DOI 10.1128/JVI.70.4.2154-2161.1996; BOND UM, 1991, GENE DEV, V5, P1709, DOI 10.1101/gad.5.9.1709; BRINGMANN P, 1984, EMBO J, V3, P1357, DOI 10.1002/j.1460-2075.1984.tb01977.x; Cantor GH, 1996, ANTISENSE NUCLEIC A, V6, P301, DOI 10.1089/oli.1.1996.6.301; CHEN IT, 1993, MOL CELL BIOL, V13, P289, DOI 10.1128/MCB.13.1.289; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; COHEN JB, 1993, MOL CELL BIOL, V13, P2666, DOI 10.1128/MCB.13.5.2666; COHEN JB, 1994, P NATL ACAD SCI USA, V91, P10470, DOI 10.1073/pnas.91.22.10470; Crooke ST, 1998, ANTISENSE NUCLEIC A, V8, P133, DOI 10.1089/oli.1.1998.8.133; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Friedman KJ, 1999, J BIOL CHEM, V274, P36193, DOI 10.1074/jbc.274.51.36193; Good PD, 1997, GENE THER, V4, P45, DOI 10.1038/sj.gt.3300354; Gorman L, 1998, P NATL ACAD SCI USA, V95, P4929, DOI 10.1073/pnas.95.9.4929; GRIMM C, 1993, EMBO J, V12, P1229, DOI 10.1002/j.1460-2075.1993.tb05764.x; GRUBER A, 1991, BIOCHIM BIOPHYS ACTA, V1088, P151, DOI 10.1016/0167-4781(91)90167-K; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HASHIMOTO C, 1984, NUCLEIC ACIDS RES, V12, P3283, DOI 10.1093/nar/12.7.3283; Hashiramoto A, 1999, ARTHRITIS RHEUM, V42, P954, DOI 10.1002/1529-0131(199905)42:5<954::AID-ANR14>3.0.CO;2-J; He JK, 1997, CANCER RES, V57, P3993; He YK, 1998, JNCI-J NATL CANCER I, V90, P1080, DOI 10.1093/jnci/90.14.1080; JACOB A, 1993, EUR J BIOCHEM, V216, P19, DOI 10.1111/j.1432-1033.1993.tb18111.x; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; JONES DH, 1991, BIOTECHNIQUES, V10, P62; JONES DH, 1992, BIOTECHNIQUES, V12, P528; KEAN JM, 1995, BIOCHEMISTRY-US, V34, P14617, DOI 10.1021/bi00045a001; Kenney JL, 1998, BLOOD, V92, P1721, DOI 10.1182/blood.V92.5.1721.417a08_1721_1727; KRAWCZAK M, 1992, HUM GENET, V90, P41; Li B, 1997, NEUROCHEM INT, V31, P393, DOI 10.1016/S0197-0186(96)00109-X; Liu DK, 1997, J VIROL, V71, P4079, DOI 10.1128/JVI.71.5.4079-4085.1997; Ma MYX, 1998, ANTISENSE NUCLEIC A, V8, P415; Michienzi A, 1998, HUM GENE THER, V9, P621, DOI 10.1089/hum.1998.9.5-621; Michienzi A, 1996, P NATL ACAD SCI USA, V93, P7219, DOI 10.1073/pnas.93.14.7219; Mirochnitchenko O, 1993, Antisense Res Dev, V3, P171; Montgomery RA, 1997, HUM MOL GENET, V6, P519, DOI 10.1093/hmg/6.4.519; Moore M., 1993, RNA WORLD, P303; NOONBERG SB, 1994, NUCLEIC ACIDS RES, V22, P2830, DOI 10.1093/nar/22.14.2830; Offensperger WB, 1998, MOL BIOTECHNOL, V9, P161, DOI 10.1007/BF02760817; Perez-Ruiz M, 1999, ANTISENSE NUCLEIC A, V9, P33, DOI 10.1089/oli.1.1999.9.33; RINKE J, 1985, J MOL BIOL, V185, P721, DOI 10.1016/0022-2836(85)90057-9; Roh H, 1998, J SURG RES, V77, P85, DOI 10.1006/jsre.1998.5353; Rubenstein M, 1998, METHOD FIND EXP CLIN, V20, P825, DOI 10.1358/mf.1998.20.10.487534; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAUFELE F, 1986, NATURE, V323, P777, DOI 10.1038/323777a0; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Schmajuk G, 1999, J BIOL CHEM, V274, P21783, DOI 10.1074/jbc.274.31.21783; SCHWARTZ E, 1991, HEMATOLOGY BASIC PRI, P586; Sierakowska H, 1999, RNA, V5, P369, DOI 10.1017/S135583829998130X; Sierakowska H, 1997, NUCLEOS NUCLEOT NUCL, V16, P1173, DOI 10.1080/07328319708006154; Sierakowska H, 1996, P NATL ACAD SCI USA, V93, P12840, DOI 10.1073/pnas.93.23.12840; SMITH CC, 1986, P NATL ACAD SCI USA, V83, P2787, DOI 10.1073/pnas.83.9.2787; SPYCHER C, 1994, NUCLEIC ACIDS RES, V22, P4023, DOI 10.1093/nar/22.20.4023; STRUB K, 1984, EMBO J, V3, P2801, DOI 10.1002/j.1460-2075.1984.tb02212.x; Suter D, 1999, HUM MOL GENET, V8, P2415, DOI 10.1093/hmg/8.13.2415; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Werner M, 1998, RNA, V4, P847, DOI 10.1017/S1355838298980323; Werner M, 1999, ANTISENSE NUCLEIC A, V9, P81, DOI 10.1089/oli.1.1999.9.81; Wilton SD, 1999, NEUROMUSCULAR DISORD, V9, P330, DOI 10.1016/S0960-8966(99)00010-3; Yacyshyn BR, 1998, GASTROENTEROLOGY, V114, P1133, DOI 10.1016/S0016-5085(98)70418-4; Zhang H, 1999, ANTIMICROB AGENTS CH, V43, P347, DOI 10.1128/AAC.43.2.347; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	66	27	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35914	35919		10.1074/jbc.M006259200	http://dx.doi.org/10.1074/jbc.M006259200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10969081	hybrid, Green Published			2022-12-27	WOS:000165382000040
J	King, TR; Fang, Y; Mahon, ES; Anderson, DH				King, TR; Fang, Y; Mahon, ES; Anderson, DH			Using a phage display library to identify basic residues in A-Raf required to mediate binding to the Src homology 2 domains of the p85 subunit of phosphatidylinositol 3 '-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL SH2 DOMAIN; PHOSPHOTYROSINE-DEPENDENT MANNER; GROWTH-FACTOR RECEPTORS; HIGH-AFFINITY; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; P85-ALPHA SUBUNIT; PEPTIDE LIGANDS; BETA RECEPTOR; ABL ONCOGENE	Src homology 2 (SH2) domains are found in a variety of cytoplasmic proteins involved in mediating signals from cell surface receptors to various intracellular pathways. They fold as modular units and are capable of recognizing and binding to short linear peptide sequences containing a phosphorylated tyrosine residue. Here we show that each of the SH2 domains of the p85 subunit of phosphatidylinositol 3-kinase selects phage displayed peptide sequences containing the core (L/I)-A-(R/K)-I-R. The serine/threonine kinase A-Raf, containing the sequence LQRIRS, is associated with the p85 protein in both quiescent and growth factor stimulated cells. This suggests:that p85 and A-Raf exist in a protein complex in cells and that complex formation does not require growth factor stimulation. We also show that p85 and A-Raf can bind directly to each other in vitro and that this interaction is mediated in part by the p85 SH2 domains. Further, the p85 SH2 domains require at least one df four distinct basic-X-basic sequence motifs within A-Raf for binding. This is the first description of a phosphotyrosine-independent SH2 domain interaction that requires basic residues on the SH2 ligand.	Saskatchewan Canc Agcy, Hlth Res Div, Dept Oncol, Saskatoon, SK S7N 4H4, Canada; Saskatchewan Canc Agcy, Hlth Res Div, Canc Res Unit, Saskatoon, SK S7N 4H4, Canada; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Anderson, DH (corresponding author), Saskatchewan Canc Agcy, Hlth Res Div, Dept Oncol, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.	danderson@scf.sk.ca						ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Anderson DH, 1998, ONCOGENE, V16, P2321, DOI 10.1038/sj.onc.1201780; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; Breeze AL, 1996, EMBO J, V15, P3579, DOI 10.1002/j.1460-2075.1996.tb00727.x; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Dutartre H, 1998, VIROLOGY, V247, P200, DOI 10.1006/viro.1998.9244; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; LETWIN K, 1988, ONCOGENE, V3, P621; Li SC, 1999, CURR BIOL, V9, P1355, DOI 10.1016/S0960-9822(00)80080-9; MALEK SN, 1994, J BIOL CHEM, V269, P33009; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Raffel GD, 1996, J BIOL CHEM, V271, P4640; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Schmandt R, 1999, ONCOGENE, V18, P1867, DOI 10.1038/sj.onc.1202507; SCOTT JK, 1992, TRENDS BIOCHEM SCI, V17, P241, DOI 10.1016/0968-0004(92)90401-T; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Siegal G, 1998, J MOL BIOL, V276, P461, DOI 10.1006/jmbi.1997.1562; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JYJ, 1985, J BIOL CHEM, V260, P64; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Yuryev A, 2000, MOL CELL BIOL, V20, P4870, DOI 10.1128/MCB.20.13.4870-4878.2000; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36450	36456		10.1074/jbc.M004720200	http://dx.doi.org/10.1074/jbc.M004720200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967104	hybrid			2022-12-27	WOS:000165382000112
J	Lambrechts, A; Kwiatkowski, AV; Lanier, LM; Bear, JE; Vandekerckhove, J; Ampe, C; Gertler, FB				Lambrechts, A; Kwiatkowski, AV; Lanier, LM; Bear, JE; Vandekerckhove, J; Ampe, C; Gertler, FB			cAMP-dependent protein kinase phosphorylation of EVL, a mena/VASP relative, regulates its interaction with actin and SH3 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; PROLINE-RICH SEQUENCES; ABL TYROSINE KINASE; HUMAN PLATELETS; FOCAL ADHESION; LISTERIA-MONOCYTOGENES; MONOCLONAL-ANTIBODY; BINDING PROPERTIES; ENA/VASP FAMILY; EVH1 DOMAIN	Proteins of the Ena/VASP family are implicated in processes that require dynamic actin remodeling such as axon guidance and platelet activation. In this work, we explored some of the pathways that likely regulate actin dynamics in part via EVL (Ena/VASP-like protein). Two isoforms, EVL and EVL-I, were highly expressed in hematopoietic cells of thymus and spleen. In CDS-activated T-cells, EVL was found in F-actin-rich patches and at the distal tips of the microspikes that formed on the activated side of the T-cells. Like the other family members, EVL localized to focal adhesions and the leading edge of lamellipodia when expressed in fibroblasts. EVL was a substrate for the cAMP-dependent protein kinase, and this phosphorylation regulated several of the interactions between EVL and its ligands. Unlike VASP, EVL nucleated actin polymerization under physiological conditions, whereas phosphorylation of both EVL and VASP decreased their nucleating activity. EVL bound directly to the Abl, Lyn, and nSrc SH3 domains; the FE65 WW domain; and profilin, likely via its proline-rich core. Binding of Abl and nSrc SH3 domains, but not profilin or other SH3 domains, was abolished by cAMP-dependent protein kinase phosphorylation of EVL. We show strong cooperative binding of two profilin dimers on the polyproline sequence of EVL, Additionally, profilin competed with the SH3 domains for binding to partially overlapping binding sites. These data suggest that the function of EVL could be modulated in a complex manner by its interactions with multiple ligands and through phosphorylation by cyclic nucleotide dependent kinases.	MIT, Dept Biol, Cambridge, MA 02139 USA; State Univ Ghent VIB, Fac Med, Dept Med Prot Chem, B-9000 Ghent, Belgium	Massachusetts Institute of Technology (MIT); Flanders Institute for Biotechnology (VIB); Ghent University	Gertler, FB (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave,68-270, Cambridge, MA 02139 USA.	fgertler@mit.edu	Ampe, Christophe/B-5534-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058801] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58801] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahern-Djamali SM, 1998, MOL BIOL CELL, V9, P2157, DOI 10.1091/mbc.9.8.2157; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; BRENNER SL, 1983, J BIOL CHEM, V258, P5013; BUTT E, 1994, J BIOL CHEM, V269, P14509; Carl UD, 1999, CURR BIOL, V9, P715, DOI 10.1016/S0960-9822(99)80315-7; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Comer AR, 1998, MOL CELL BIOL, V18, P152, DOI 10.1128/MCB.18.1.152; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fedorov AA, 1999, NAT STRUCT BIOL, V6, P661, DOI 10.1038/10717; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Geese M, 2000, J CELL SCI, V113, P1415; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Jonckheere V, 1999, FEBS LETT, V447, P257, DOI 10.1016/S0014-5793(99)00293-8; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; LAMBRECHTS A, 1995, EUR J BIOCHEM, V230, P281, DOI 10.1111/j.1432-1033.1995.0281i.x; Lambrechts A, 1997, EMBO J, V16, P484, DOI 10.1093/emboj/16.3.484; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; NIEBUHR K, 1997, IMMUNOLOGY METHODS M, P798; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Pawson T, 2000, GENE DEV, V14, P1027; Pigino G, 1997, J CELL SCI, V110, P257; Reinhard M, 1996, FEBS LETT, V399, P103, DOI 10.1016/S0014-5793(96)01295-1; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; RKAUSE M, 2000, J CELL BIOL, V149, P181; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SELLIAH N, 1995, J NEUROIMMUNOL, V56, P107, DOI 10.1016/0165-5728(94)00142-B; Sharma P, 1998, BIOCHEMISTRY-US, V37, P4759, DOI 10.1021/bi972746o; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; SIESS W, 1990, BIOCHEM J, V271, P815, DOI 10.1042/bj2710815; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wills Z, 1999, NEURON, V22, P291, DOI 10.1016/S0896-6273(00)81090-9; Zhang J, 1998, J IMMUNOL, V161, P2930	61	142	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36143	36151		10.1074/jbc.M006274200	http://dx.doi.org/10.1074/jbc.M006274200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10945997	hybrid			2022-12-27	WOS:000165382000071
J	Minty, A; Dumont, X; Kaghad, M; Caput, D				Minty, A; Dumont, X; Kaghad, M; Caput, D			Covalent modification of p73 alpha by SUMO-1 - Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; NUCLEAR-BODIES; CONJUGATING ENZYME; ANDROGEN RECEPTOR; S-PHASE; P53; PML; KINASE; FAMILY; DEATH	Two-hybrid screening in yeast with p73 alpha isolated SUMO-1 (small ubiquitin-like modifier (1) over bar), the enzyme responsible for its conjugation, Ubc-9, and a number of novel SUMO-l-interacting proteins, including thymine DNA glycosylase, PM-Sc175, PIASx, PKY, and CHD3/ZFH, A subset: of these proteins contain a common motif, hhX-SXS/Taaa, where h is a hydrophobic amino acid and a is an acidic amino acid, that is shown to interact with SUMO-1 in the two-hybrid system. We show here that p73 alpha, but not p73 beta, can be covalently modified by SUMO-I, The major SUMO-l-modified residue in p73 alpha is the C-terminal lysine (Lys(627)). The sequence surrounding this lysine:conforms to a consensus SUMO-1 modification:site b(X)XXhKXE, where b is a basic amino acid. SUMO-l-modified p73 is more rapidly degraded by the proteasme than unmodified p73, although SUMO-1 modification:is not required for p73 degradation. SUMO-I modification does not affect the transcriptional activity of p73 alpha on an RGC-luciferase reporter gene in SK-N-AS cells. Instead, SUMO-1 modification may alter the subcellular localization of p73, because SUMO-1-modified p73 is preferentially found in detergent-insoluble fractions, Alternatively, it may modulate the interaction of p73 with other proteins that are substrates for SUMO-1 modification or which interact with SUMO-1, such as those identified here.	Sanofi Synthelabo Rech, Mol & Funct Genom Dept, F-31676 Labege, France	Sanofi-Aventis; Sanofi France	Minty, A (corresponding author), Sanofi Synthelabo Rech, Mol & Funct Genom Dept, F-31676 Labege, France.	adrian.minty@sanofi-synthelabo.com						ALDERUCCIO F, 1991, J EXP MED, V173, P941, DOI 10.1084/jem.173.4.941; Aubry F, 1998, EUR J BIOCHEM, V254, P558, DOI 10.1046/j.1432-1327.1998.2540558.x; Begley DA, 1997, GENE, V200, P35, DOI 10.1016/S0378-1119(97)00350-8; BRODY MN, 1996, ONCOGENE, V13, P971; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hofmann H, 2000, J VIROL, V74, P2510, DOI 10.1128/JVI.74.6.2510-2524.2000; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Lehembre F, 2000, MOL CELL BIOL, V20, P1072, DOI 10.1128/MCB.20.3.1072-1082.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liou ML, 1999, J BIOL CHEM, V274, P10145, DOI 10.1074/jbc.274.15.10145; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; Million K, 1999, J CELL SCI, V112, P4357; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Okura T, 1996, J IMMUNOL, V157, P4277; Ozaki T, 1999, CANCER RES, V59, P5902; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; SUGIMOTO T, 1984, J NATL CANCER I, V73, P51; SUSUKI T, 1999, J BIOL CHEM, V274, P31181; Tanaka K, 1999, MOL CELL BIOL, V19, P8660; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Trost M, 2000, J BIOL CHEM, V275, P7373, DOI 10.1074/jbc.275.10.7373; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Um S, 1998, J BIOL CHEM, V273, P20728, DOI 10.1074/jbc.273.33.20728; Vikhanskaya F, 2000, NUCLEIC ACIDS RES, V28, P513, DOI 10.1093/nar/28.2.513; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	80	325	335	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36316	36323		10.1074/jbc.M004293200	http://dx.doi.org/10.1074/jbc.M004293200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10961991	hybrid			2022-12-27	WOS:000165382000095
J	Drugan, JK; Rogers-Graham, K; Gilmer, T; Campbell, S; Clark, GJ				Drugan, JK; Rogers-Graham, K; Gilmer, T; Campbell, S; Clark, GJ			The Ras/p120 GTPase-activating protein (GAP) interaction is regulated by the p120 GAP pleckstrin homology domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; BRUTON TYROSINE KINASE; HIGH-AFFINITY BINDING; RAS-GTPASE; PHOSPHOINOSITIDE BINDING; PH DOMAIN; TRANSFORMATION; IDENTIFICATION; SPECIFICITY; GENE	Pleckstrin homology domains are structurally conserved functional domains that can undergo both protein/protein and protein/lipid interactions. Pleckstrin homology domains can mediate inter- and intra-molecular binding events to regulate enzyme activity. They occur in numerous proteins including many that interact with Pas superfamily members, such as p120 GAP, The pleckstrin homology domain of p120 GAP is located in the NH2-terminal, noncatalytic region of p120 GAP. Overexpression of the noncatalytic domains of p120 GAP may modulate Pas signal transduction pathways. Here, we demonstrate that expression of the isolated pleckstrin homology domain of p120 GAP specifically inhibits Pas-mediated signaling and transformation but not normal cellular growth. Furthermore, we show that the pleckstrin homology domain binds the catalytic domain of p120 GAP and interferes with the Ras/GAP interaction. Thus, we suggest that the pleckstrin homology domain of p120 GAP may specifically regulate the interaction of Pas with p120 GAP via competitive intramolecular binding.	NCI, Dept Cell & Canc Biol, NIH, Rockville, MD 20850 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Glaxo Wellcome Inc, Dept Cell Biol, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Dept Biochem, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline; University of North Carolina; University of North Carolina Chapel Hill	Clark, GJ (corresponding author), NCI, Dept Cell & Canc Biol, NIH, 9610 Med Ctr Dr, Rockville, MD 20850 USA.			campbell, sharon/0000-0003-0311-409X	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010279] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA070308, R29CA072644, R29CA064569] Funding Source: NIH RePORTER; NCI NIH HHS [CA72644-10, CA70308, CA64569] Funding Source: Medline	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLLAG G, 1992, CANCER BIOL, V3, P199; CAMPBELLBURK SL, 1995, METHOD ENZYMOL, V255, P3; CARLIER MF, 1987, BIOCHEMISTRY-US, V26, P4428, DOI 10.1021/bi00388a036; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Chidiac P, 1999, J BIOL CHEM, V274, P19639, DOI 10.1074/jbc.274.28.19639; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Graham SM, 1996, MOL CELL BIOL, V16, P6132; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kojima T, 1997, BIOCHEM BIOPH RES CO, V236, P333, DOI 10.1006/bbrc.1997.6947; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Li TJ, 1997, ONCOGENE, V15, P1375, DOI 10.1038/sj.onc.1201308; Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; RUGGIERI R, 1994, MOL BIOL CELL, V5, P173, DOI 10.1091/mbc.5.2.173; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Srinivasan N, 1996, BIOCHEM BIOPH RES CO, V220, P697, DOI 10.1006/bbrc.1996.0467; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752	42	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35021	35027		10.1074/jbc.M004386200	http://dx.doi.org/10.1074/jbc.M004386200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954709	hybrid			2022-12-27	WOS:000165422800028
J	Nakatsu, Y; Asahina, H; Citterio, E; Rademakers, S; Vermeulen, W; Kamiuchi, S; Yeo, JP; Khaw, MC; Saijo, M; Kodo, N; Matsuda, T; Hoeijmakers, JHJ; Tanaka, K				Nakatsu, Y; Asahina, H; Citterio, E; Rademakers, S; Vermeulen, W; Kamiuchi, S; Yeo, JP; Khaw, MC; Saijo, M; Kodo, N; Matsuda, T; Hoeijmakers, JHJ; Tanaka, K			XAB2, a novel tetratricopeptide repeat protein involved in transcription-coupled DNA repair and transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; GROUP-C FIBROBLASTS; XERODERMA-PIGMENTOSUM; COCKAYNE-SYNDROME; ACTIVE GENES; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; ELONGATION COMPLEXES	Nucleotide excision repair is a highly versatile DNA repair system responsible for elimination of a wide variety of lesions from the genome. It is comprised of two subpathways: transcription-coupled repair that accomplishes efficient removal of damage blocking transcription and global genome repair, Recently, the basic mechanism of global genome repair has emerged from biochemical studies. However, little is known about transcription-coupled repair in eukaryotes, Here we report the identification of a novel protein designated XAB2 (XPA-binding protein 2) that was identified by virtue of its ability to interact with XPA, a factor central to both nucleotide excision repair subpathways, The XAB2 protein of 855 amino acids consists mainly of 15 tetratricopeptide repeats. In addition to interacting with XPA, immunoprecipitation experiments demonstrated that a fraction of XAB2 is able to interact with the transcription-coupled repair-specific proteins CSA and CSB as well as RNA polymerase II. Furthermore, antibodies against XAB2 inhibited both transcription-coupled repair and transcription in vivo but not global genome repair when microinjected into living fibroblasts. These results indicate that XAB2 is a novel component involved in transcription-coupled repair and transcription.	Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan; Erasmus Univ, Ctr Biomed Genet, Dept Cell Biol & Genet, MGC, NL-3000 DR Rotterdam, Netherlands	Osaka University; Japan Science & Technology Agency (JST); Erasmus University Rotterdam	Tanaka, K (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.	ktanaka@imcb.osaka-u.ac.jp	Hoeijmakers, Jan/AAX-6972-2021; Vermeulen, Wim/W-8708-2019	Vermeulen, Wim/0000-0003-3616-734X; Nakatsu, Yoshimichi/0000-0001-7408-7071; Citterio, Elisabetta/0000-0003-2347-3495				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Araujo SJ, 1999, MUTAT RES-DNA REPAIR, V435, P23, DOI 10.1016/S0921-8777(99)00042-7; Araujo SJ, 2000, GENE DEV, V14, P349; BAUREN G, 1994, CELL, V76, P183, DOI 10.1016/0092-8674(94)90182-1; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; CARREAU M, 1992, MUTAT RES, V274, P57, DOI 10.1016/0921-8777(92)90043-3; Citterio E, 1998, J BIOL CHEM, V273, P11844, DOI 10.1074/jbc.273.19.11844; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DECOCK JGR, 1992, MUTAT RES, V274, P85, DOI 10.1016/0921-8777(92)90055-8; Dix I, 1999, RNA, V5, P360, DOI 10.1017/S1355838299981396; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Hanawalt PC, 1999, NATO ADV SCI I A-LIF, V302, P169; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI L, 1995, MOL CELL BIOL, V15, P5396; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MAYNE LV, 1982, CANCER RES, V42, P1473; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McDonald WH, 1999, MOL CELL BIOL, V19, P5352; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NAGAI A, 1995, BIOCHEM BIOPH RES CO, V211, P960, DOI 10.1006/bbrc.1995.1905; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SIKORSKI RS, 1991, COLD SH Q B, V56, P663; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Tantin D, 1998, J BIOL CHEM, V273, P27794, DOI 10.1074/jbc.273.43.27794; Tantin D, 1997, MOL CELL BIOL, V17, P6803, DOI 10.1128/MCB.17.12.6803; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	51	107	116	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34931	34937		10.1074/jbc.M004936200	http://dx.doi.org/10.1074/jbc.M004936200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10944529	Green Published, hybrid			2022-12-27	WOS:000165422800016
J	Sher, I; Lang, T; Lubinsky-Mink, S; Kuhn, J; Adir, N; Chatterjee, S; Schomburg, D; Ron, D				Sher, I; Lang, T; Lubinsky-Mink, S; Kuhn, J; Adir, N; Chatterjee, S; Schomburg, D; Ron, D			Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; HEPARAN-SULFATE; EXPRESSION; MOLECULES; DOMAINS; COMMON; REGIONS; CLONING; PROTEIN; FAMILY	Fibroblast growth factors (FGFs) mediate a multitude of physiological and pathological processes by activating a family of tyrosine kinase receptors (FGFRs), Each FGFR binds to a unique subset of FGFs and ligand binding specificity is essential in regulating FGF activity, FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR, Previously, mutations in FGF-2 identified a set of residues that are important for high affinity receptor binding, known as the primary receptor-binding site. FGF-7 contains this primary site as well as a region that restricts interaction with FGFR1. The sequences that confer on FGF-7 its specific binding to KGFR have not been identified. By utilizing domain swapping and site-directed mutagenesis we have found that the loop connecting the beta4-beta5 strands of FGF-7 contributes to high affinity receptor binding and is critical for KGFR recognition. Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of FGF-7 for KGFR and its biological potency but did not result in the ability to bind FGFR1. Point mutations in residues comprising this loop of FGF-7 reduced both binding affinity and biological potency. The reciprocal loop replacement mutant (FGF2-L4/7) retained FGF-2 like affinity for FGFR1 and for KGFR, Our results show that topologically similar regions in these two FGFs have different roles in regulating receptor binding specificity and suggest that specificity may require the concerted action of distinct regions of an FGF.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel; Univ Koeln, Inst Biochem, D-50674 Koeln, Germany	Technion Israel Institute of Technology; Technion Israel Institute of Technology; University of Cologne	Ron, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.		Adir, Noam/ABE-6990-2020	Schomburg, Dietmar/0000-0002-3354-822X				AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Berman B, 1999, J BIOL CHEM, V274, P36132, DOI 10.1074/jbc.274.51.36132; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; Chang DZ, 1996, J BIOL CHEM, V271, P13349, DOI 10.1074/jbc.271.23.13349; Chellaiah A, 1999, J BIOL CHEM, V274, P34785, DOI 10.1074/jbc.274.49.34785; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; GRAY TE, 1995, BIOCHEMISTRY-US, V34, P10325, DOI 10.1021/bi00033a002; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; JOHNSON WC, 1990, PROTEINS STRUCT FUNC, V205; Luo YD, 1998, BIOCHEMISTRY-US, V37, P16506, DOI 10.1021/bi9816599; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; Osslund TD, 1998, PROTEIN SCI, V7, P1681, DOI 10.1002/pro.5560070803; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; REICHSLOTKY R, 1995, J BIOL CHEM, V270, P29813; RON D, 1993, J BIOL CHEM, V268, P2984; RON D, 1993, J BIOL CHEM, V268, P5388; Rubin J. S., 1995, V74, P191; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SHAOUL E, 1995, ONCOGENE, V10, P1553; Sher I, 1999, J BIOL CHEM, V274, P35016, DOI 10.1074/jbc.274.49.35016; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; Wang F, 1999, BIOCHEMISTRY-US, V38, P160, DOI 10.1021/bi981758m; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	41	12	13	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34881	34886		10.1074/jbc.M003293200	http://dx.doi.org/10.1074/jbc.M003293200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10950949	hybrid			2022-12-27	WOS:000165422800010
J	Steinberg, SJ; Morgenthaler, J; Heinzer, AK; Smith, KD; Watkins, PA				Steinberg, SJ; Morgenthaler, J; Heinzer, AK; Smith, KD; Watkins, PA			Very long-chain acyl-CoA synthetases - Human "bubblegum" represents a new family of proteins capable of activating very long-chain fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; ALPHA-OXIDATION; PHYTANIC ACID; RAT-LIVER; GENE; EXPRESSION; CLONING; CELLS; HYPERTENSION; PREDICTION	Activation by thioesterification to coenzyme A is a prerequisite for most reactions involving fatty acids. Enzymes catalyzing activation, acyl-CoA synthetases, have been classified by their chain length specificities, The most recently identified family is the very long-chain acyl-CoA synthetases (VLCS), Although several members of this group are capable of activating very long-chain fatty acids (VLCFA), one is a bile acid-CoA synthetase,and others have been characterized as fatty acid transport proteins, It was reported that the Drosophila melanogaster mutant bubblegum (BGM) had elevated VLCFA and that the product of the defective gene had sequence homology to acyl-CoA synthetases. Therefore, we cloned full-length cDNA for a human homolog of BGM, and we investigated the properties of its protein product, hsBG, to determine whether it had VLCS activity. Northern blot analysis showed that hsBG is expressed primarily in brain, Compared with vector-transfected cells, COS-l cells expressing hsBG; had increased acyl-CoA synthetase activity with either long-chain fatty acid (2.4-fold) or VLCFA (2.6-fold) substrates, Despite this increased VLCFA activation, hsBG-expressing cells did not have increased rates of VLCFA degradation, Confocal microscopy showed that hsBG had a cytoplasmic localization in some COS-1 cells expressing the protein, whereas it appeared to associate with plasma:membrane in others, Fractionation of these cells revealed that most of the hsBG-dependent acyl-CoA synthetase activity was soluble and not membrane-bound. Immunoaffinity-purified hsBG from transfected COS-1 cells was enzymatically active, hsBG and hsVLCS are only 15% identical, and comparison with sequences of two: conserved motifs from all known families of acyl-CoA synthetases revealed that hsBG along with the D, melanogaster and murine homologs comprise a new family of acyl-CoA synthetases, Thus, two protein families: are now known that contain enzymes capable of activating VLCFA. Because hsBG is expressed in brain but previously described VLCSs were not highly expressed in this organ, hsBG may play a central role in brain VLCFA metabolism and myelinogenesis.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Watkins, PA (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.			Watkins, Paul A./0000-0002-3246-1405	NICHD NIH HHS [HD10981] Funding Source: Medline; NINDS NIH HHS [NS 37355, NS10533] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037355] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; Choi JY, 1999, J BIOL CHEM, V274, P4671, DOI 10.1074/jbc.274.8.4671; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; IWAI N, 1994, HYPERTENSION, V23, P375, DOI 10.1161/01.HYP.23.3.375; Kang MJ, 1997, P NATL ACAD SCI USA, V94, P2880, DOI 10.1073/pnas.94.7.2880; Lovry O.H., 1951, J BIOL CHEM, V193, P265; Min KT, 1999, SCIENCE, V284, P1985, DOI 10.1126/science.284.5422.1985; Moser HW, 1995, METABOLIC MOL BASES, V7h, P2325; MURALIDHARAN VB, 1984, J BIOL CHEM, V259, P3021; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; POULOS A, 1995, LIPIDS, V30, P1, DOI 10.1007/BF02537036; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SAMANI NJ, 1995, J HUM HYPERTENS, V9, P501; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; Smith KD, 1999, NEUROCHEM RES, V24, P521, DOI 10.1023/A:1022535930009; Steinberg SJ, 1999, MOL GENET METAB, V68, P32, DOI 10.1006/mgme.1999.2883; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; SVENNERHOLM L, 1968, J LIPID RES, V9, P215; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; Watkins PA, 1997, PROG LIPID RES, V36, P55, DOI 10.1016/S0163-7827(97)00004-0; Watkins PA, 1999, PROSTAG LEUKOTR ESS, V60, P323, DOI 10.1016/S0952-3278(99)80007-6; WATKINS PA, 1995, AM J HUM GENET, V57, P292; WATKINS PA, 1994, BBA-LIPID LIPID MET, V1214, P288, DOI 10.1016/0005-2760(94)90075-2; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210	33	101	110	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35162	35169		10.1074/jbc.M006403200	http://dx.doi.org/10.1074/jbc.M006403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954726	hybrid			2022-12-27	WOS:000165422800046
J	Haskell, CA; Cleary, MD; Charo, IF				Haskell, CA; Cleary, MD; Charo, IF			Unique role of the chemokine domain of fractalkine in cell capture - Kinetics of receptor dissociation correlate with cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOATTRACTANT PROTEIN-1 RECEPTOR; HUMAN CC CHEMOKINE; CX3C CHEMOKINE; FUNCTIONAL-CHARACTERIZATION; SIGNAL-TRANSDUCTION; PHYSIOLOGICAL FLOW; DISTINCT ROLES; L-SELECTIN; RESPONSES; CX(3)CR1	The chemokine fractalkine (FR) has two structural features that make it unique in the chemokine family: a CX3C motif and an extended carboxyl terminus that anchors it to the cell surface. This mucin-like stalk or an equivalent spacer is required for FK to mediate the adhesion of cells expressing its receptor, CX(3)CR1, To determine whether the ability of FK to act as a cell adhesion molecule is due to the unique presentation of a chemokine domain on a stalk or to properties of the chemokine domain itself, we created a series of chimeras in which other soluble chemokines (RANTES (regulated on activation normal T cell expressed), monocyte chemoattractant protein 1, macrophage inflammatory protein 1 beta, secondary lymphoid tissue chemokine, and interleukin 8) were fused to the mucin stalk. When tested in a static-cell adhesion assay, many of these chemokine chimeras demonstrated activity equivalent to that of FK, In flow assays, however, none of the chimeras captured cells as efficiently as FK, Interestingly, FK captured cells expressing either CX(3)CR1 or the viral receptor US28. Cells bound to FK without rolling or detaching, whereas the interleukin 8 and monocyte chemoattractant protein 1 chimeras induced primarily cell rolling and detaching, respectively. In binding studies, FK has a significantly slower off-rate from its receptors than any of the other chemokine chimeras had for their cognate receptors, We conclude that presentation of a chemokine atop a mucin-like stalk is not, in and of itself, sufficient to capture cells. The unique ability of FK to mediate adhesion under flow may be a function of its slow receptor off-rate.	Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Charo, IF (corresponding author), Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063894, R01HL052773] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-63894, HL-52773] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Arai H, 1997, J BIOL CHEM, V272, P25037, DOI 10.1074/jbc.272.40.25037; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Berkhout TA, 1997, J BIOL CHEM, V272, P16404, DOI 10.1074/jbc.272.26.16404; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Fong AM, 2000, J BIOL CHEM, V275, P3781, DOI 10.1074/jbc.275.6.3781; Franci C, 1996, J IMMUNOL, V157, P5606; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; Goda S, 2000, J IMMUNOL, V164, P4313, DOI 10.4049/jimmunol.164.8.4313; Gosling J, 2000, J IMMUNOL, V164, P2851, DOI 10.4049/jimmunol.164.6.2851; Harrison JK, 1999, J LEUKOCYTE BIOL, V66, P937, DOI 10.1002/jlb.66.6.937; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; ISHII K, 1993, J BIOL CHEM, V268, P9780; Jarnagin K, 1999, BIOCHEMISTRY-US, V38, P16167, DOI 10.1021/bi9912239; Kitayama J, 1997, J IMMUNOL, V159, P3929; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; LEE J, 1992, J BIOL CHEM, V267, P16283; Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614; Muehlhoefer A, 2000, J IMMUNOL, V164, P3368, DOI 10.4049/jimmunol.164.6.3368; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; Pachynski RK, 1998, J IMMUNOL, V161, P952; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158	39	111	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34183	34189		10.1074/jbc.M005731200	http://dx.doi.org/10.1074/jbc.M005731200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10940307	hybrid			2022-12-27	WOS:000165095300027
J	Izawa, I; Nishizawa, M; Ohtakara, K; Ohtsuka, K; Inada, H; Inagaki, M				Izawa, I; Nishizawa, M; Ohtakara, K; Ohtsuka, K; Inada, H; Inagaki, M			Identification of Mrj, a DnaJ/Hsp40 family protein, as a keratin 8/18 filament regulatory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRISEOFULVIN-TREATED MICE; RHO-ASSOCIATED KINASE; ALPHA-B-CRYSTALLIN; INTERMEDIATE FILAMENTS; MOLECULAR CHAPERONES; DYNAMIC PROPERTY; MALLORY BODIES; PHOSPHORYLATION; DISEASE; HSP70	To elucidate the function of keratins 8 and 18 (K8/18), major components of the intermediate filaments of simple epithelia, we searched for K8/18-binding proteins by screening a yeast two-hybrid library. We report here that human Mrj, a DnaJ/Hsp40 family protein, directly binds to K18. Among the interactions between DnaJ/Hsp40 family proteins and various intermediate filament proteins that we tested using two-hybrid methods, Mrj specifically interacted with K18, Immunostaining with anti-Mrj antibody showed that Mrj colocalized with K8/18 filaments in HeLa cells. Mrj was immunoprecipitated not only with K18, but also with the stress-induced and constitutively expressed heat shock protein Hsp/c70. Mrj bound to K18 through its C terminus and interacted with Hsp/c70 via its N terminus, which contains the J domain. Microinjection of anti-Mrj antibody resulted in the disorganization of K8/18 filaments, without effects on the organization of actin filaments and microtubules, Taken together, these results suggest that Mrj may play an important role in the regulation of K8/18 filament organization as a K18-specific co-chaperone working together with Hsp/c70.	Aichi Canc Ctr, Inst Res, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Inst Res, Cell Stress Biol Res Grp, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Mie Univ, Sch Med, Dept Neurosurg, Tsu, Mie 5148507, Japan	Aichi Cancer Center; Aichi Cancer Center; Mie University	Inagaki, M (corresponding author), Aichi Canc Ctr, Inst Res, Div Biochem, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Inagaki, Masaki/B-9920-2016					BARIBAULT H, 1994, GENE DEV, V8, P2964, DOI 10.1101/gad.8.24.2964; BARIBAULT H, 1993, GENE DEV, V7, P1191, DOI 10.1101/gad.7.7a.1191; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHOU CF, 1994, BIOCHEM J, V298, P457, DOI 10.1042/bj2980457; COULOMBE PA, 1991, J CELL BIOL, V115, P1661, DOI 10.1083/jcb.115.6.1661; Coulombe PA, 1993, CURR OPIN CELL BIOL, V5, P17, DOI 10.1016/S0955-0674(05)80004-3; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DENK H, 1975, LAB INVEST, V32, P773; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FRANKE WW, 1979, LAB INVEST, V40, P207; FRANKE WW, 1987, CELL, V48, P3, DOI 10.1016/0092-8674(87)90345-X; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hunter PJ, 1999, DEVELOPMENT, V126, P1247; Hutton E, 1998, J CELL BIOL, V143, P487, DOI 10.1083/jcb.143.2.487; Inada H, 1998, BIOCHEM BIOPH RES CO, V253, P21, DOI 10.1006/bbrc.1998.9732; Inada H, 1999, J BIOL CHEM, V274, P34932, DOI 10.1074/jbc.274.49.34932; INAGAKI M, 1994, BRAIN PATHOL, V4, P239, DOI 10.1111/j.1750-3639.1994.tb00839.x; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; JENSEN K, 1994, HEPATOLOGY, V20, P1330, DOI 10.1016/0270-9139(94)90776-5; JENSEN K, 1994, HEPATOLOGY, V20, P1061, DOI 10.1002/hep.1840200440; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Ku NO, 1997, J CLIN INVEST, V99, P19, DOI 10.1172/JCI119127; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; Liang P, 1997, J CELL SCI, V110, P1431; LIAO J, 1995, J BIOL CHEM, V270, P915, DOI 10.1074/jbc.270.2.915; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Liao JA, 1997, FEBS LETT, V417, P316, DOI 10.1016/S0014-5793(97)01315-X; LLOYD C, 1995, J CELL BIOL, V129, P1329, DOI 10.1083/jcb.129.5.1329; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; Magin TM, 1998, J CELL BIOL, V140, P1441, DOI 10.1083/jcb.140.6.1441; Michels AA, 1999, J BIOL CHEM, V274, P36757, DOI 10.1074/jbc.274.51.36757; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Naishiro Y, 1999, ONCOGENE, V18, P3244, DOI 10.1038/sj.onc.1202661; NAPOLITANO EW, 1985, J CELL BIOL, V101, P1323, DOI 10.1083/jcb.101.4.1323; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; Ohtsuka K, 2000, CELL STRESS CHAPERON, V5, P98, DOI 10.1379/1466-1268(2000)005<0098:MHDHCO>2.0.CO;2; Oka M, 1998, J BIOL CHEM, V273, P29727, DOI 10.1074/jbc.273.45.29727; OMARY MB, 1992, J CELL BIOL, V117, P583, DOI 10.1083/jcb.117.3.583; Omary MB, 1997, HEPATOLOGY, V25, P1043, DOI 10.1002/hep.510250537; Perng MD, 1999, J CELL SCI, V112, P2099; Sambrook J., 2002, MOL CLONING LAB MANU; Seki N, 1999, J HUM GENET, V44, P185, DOI 10.1007/s100380050139; SKALLI O, 1991, CELL MOTIL CYTOSKEL, V19, P67, DOI 10.1002/cm.970190202; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534; Takahashi K, 1996, P NATL ACAD SCI USA, V93, P14776, DOI 10.1073/pnas.93.25.14776; Toivola DM, 1997, J CELL SCI, V110, P23; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; YANO T, 1991, EUR J BIOCHEM, V197, P281, DOI 10.1111/j.1432-1033.1991.tb15909.x; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	58	75	88	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34521	34527		10.1074/jbc.M003492200	http://dx.doi.org/10.1074/jbc.M003492200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10954706	hybrid			2022-12-27	WOS:000165095300071
J	Villani, G; Le Gac, NT				Villani, G; Le Gac, NT			Interactions of DNA helicases with damaged DNA: Possible biological consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							STRAND-SEPARATING ACTIVITY; WERNER-SYNDROME PROTEIN; BENZO<A>PYRENE-DNA ADDUCTS INHIBIT; NUCLEOTIDE EXCISION-REPAIR; SIMPLEX VIRUS-DNA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; BINDING PROTEIN; RECA PROTEIN; ATPASE ACTIVITIES		CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Miami	Villani, G (corresponding author), CNRS, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.	villani@ipbs.fr			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062643] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62643] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Araujo SJ, 2000, GENE DEV, V14, P349; BACHUR NR, 1993, MOL PHARMACOL, V44, P1064; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BANVILLE DL, 1990, BIOCHEMISTRY-US, V29, P9294, DOI 10.1021/bi00491a027; Batty DP, 2000, GENE, V241, P193, DOI 10.1016/S0378-1119(99)00489-8; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; BIANCHI M, 1985, EMBO J, V4, P3025, DOI 10.1002/j.1460-2075.1985.tb04039.x; Bianco PR, 2000, NATURE, V405, P368, DOI 10.1038/35012652; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; BOEHMER PE, 1992, J BIOL CHEM, V267, P4981; Boehmer PE, 1998, J BIOL CHEM, V273, P2676, DOI 10.1074/jbc.273.5.2676; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; Brosh RM, 2000, NUCLEIC ACIDS RES, V28, P2420, DOI 10.1093/nar/28.12.2420; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; BROWN WC, 1989, J BIOL CHEM, V264, P6748; CALSOU P, 1994, NUCLEIC ACIDS RES, V22, P4937, DOI 10.1093/nar/22.23.4937; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Cooper MP, 2000, GENE DEV, V14, P907; COUGH G, 1989, MUTAT RES, V227, P193; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; Cox MM, 2000, PROG NUCLEIC ACID RE, V63, P311, DOI 10.1016/S0079-6603(08)60726-6; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; Egelman E, 2000, TRENDS BIOCHEM SCI, V25, P183, DOI 10.1016/S0968-0004(00)01570-X; Egelman EH, 1998, J STRUCT BIOL, V124, P123, DOI 10.1006/jsbi.1998.4050; Eisen A, 1998, BIOESSAYS, V20, P634, DOI 10.1002/(SICI)1521-1878(199808)20:8<634::AID-BIES6>3.0.CO;2-I; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Friedberg E. C., 1995, DNA REPAIR MUTAGENES, P1; GEORGE JW, 1992, J BIOL CHEM, V267, P10683; Goodman MF, 2000, TRENDS BIOCHEM SCI, V25, P189, DOI 10.1016/S0968-0004(00)01564-4; Gordienko I, 1997, EMBO J, V16, P889, DOI 10.1093/emboj/16.4.889; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; HUANG L, 1993, J BIOL CHEM, V268, P26731; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; KARU AE, 1972, P NATL ACAD SCI USA, V69, P2855, DOI 10.1073/pnas.69.10.2855; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KIM YT, 1992, J BIOL CHEM, V267, P15032; KORNBERG A, 1992, DNA REPLICATION, P355; Le Gac NT, 1998, J BIOL CHEM, V273, P13801, DOI 10.1074/jbc.273.22.13801; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lehman IR, 1999, J BIOL CHEM, V274, P28059, DOI 10.1074/jbc.274.40.28059; Liu QQ, 2000, J BIOL CHEM, V275, P1615, DOI 10.1074/jbc.275.3.1615; LIVNEH Z, 1982, P NATL ACAD SCI-BIOL, V79, P3171, DOI 10.1073/pnas.79.10.3171; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; NAEGELI H, 1992, J BIOL CHEM, V267, P392; NAEGELI H, 1993, J BIOL CHEM, V268, P10386; NAEGELI H, 1995, FASEB J, V9, P1043, DOI 10.1096/fasebj.9.11.7649403; OH EY, 1989, J BIOL CHEM, V264, P1336; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Patrick SM, 1997, BBA-GENE STRUCT EXPR, V1354, P279, DOI 10.1016/S0167-4781(97)00136-X; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Shiratori A, 1999, YEAST, V15, P219, DOI 10.1002/(SICI)1097-0061(199902)15:3<219::AID-YEA349>3.3.CO;2-V; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; TURCHI JJ, 1992, NUCLEIC ACIDS RES, V20, P6075, DOI 10.1093/nar/20.22.6075; Tuteja N, 1997, BIOCHEM BIOPH RES CO, V236, P636, DOI 10.1006/bbrc.1997.7021; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; Veaute X, 2000, MUTAT RES-DNA REPAIR, V459, P19, DOI 10.1016/S0921-8777(99)00052-X; VILLANI G, 1994, J BIOL CHEM, V269, P21676; VILLANI G, 1993, FEBS LETT, V333, P89, DOI 10.1016/0014-5793(93)80380-D; Winkler GS, 2000, J BIOL CHEM, V275, P4258, DOI 10.1074/jbc.275.6.4258; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yong YQ, 1996, CHEM RES TOXICOL, V9, P179, DOI 10.1021/tx950112h; You ZY, 1999, MOL CELL BIOL, V19, P8003; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+	78	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33185	33188		10.1074/jbc.R000011200	http://dx.doi.org/10.1074/jbc.R000011200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10954729	hybrid			2022-12-27	WOS:000090104600001
J	Zhang, YB; Swietnicki, W; Zagorski, MG; Surewicz, WK; Sonnichsen, FD				Zhang, YB; Swietnicki, W; Zagorski, MG; Surewicz, WK; Sonnichsen, FD			Solution structure of the E200K variant of human prion protein - Implications for the mechanism of pathogenesis in familial prion diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRP 27-30; SCRAPIE; NMR; CONVERSION; RESISTANT; STABILITY; SYSTEM; DOMAIN	Prion propagation in transmissible spongiform encephalopathies involves the conversion of cellular prion protein, PrPC, into a pathogenic conformer, PrPSc. Hereditary forms of the disease are Linked to specific mutations in the gene coding for the prion protein. To gain insight into the molecular basis of these disorders, the solution structure of the familial Creutzfeldt-Jakob disease-related E200K variant of human prion protein was determined by multi-dimensional nuclear magnetic resonance spectroscopy, Remarkably, apart from minor differences in flexible regions, the backbone tertiary structure of the E200K variant is nearly identical to that reported for the wild-type human prion protein, The only major consequence of the mutation is the perturbation of surface electrostatic potential. The present structural data strongly suggest that protein surface defects leading to abnormalities in the interaction of prion protein with auxiliary proteins/chaperones or cellular membranes should be considered key determinants of a spontaneous PrPC --> PrPSc conversion in the E200K form of hereditary prion disease.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Surewicz, WK (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	wks3@po.cwru.edu	Swietnicki, Wieslaw/AAL-2452-2021; Swietnicki, Wieslaw/GOP-2576-2022; Sönnichsen, Frank D/D-8408-2011; Swietnicki, Wieslaw/AAU-1536-2020	Sönnichsen, Frank D/0000-0002-4539-3755; Swietnicki, Wieslaw/0000-0002-9354-8184	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055362, R01GM055362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038604] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014363] Funding Source: NIH RePORTER; NIA NIH HHS [AG14363] Funding Source: Medline; NIGMS NIH HHS [GM55362] Funding Source: Medline; NINDS NIH HHS [NS38604] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHAPMAN J, 1994, NEUROLOGY, V44, P1683, DOI 10.1212/WNL.44.9.1683; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Horiuchi M, 1999, STRUCTURE, V7, pR231, DOI 10.1016/S0969-2126(00)80049-0; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Liu H, 1999, BIOCHEMISTRY-US, V38, P5362, DOI 10.1021/bi982878x; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1994, P NATL ACAD SCI USA, V91, P4611, DOI 10.1073/pnas.91.11.4611; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zimmerman DE, 1997, J MOL BIOL, V269, P592, DOI 10.1006/jmbi.1997.1052	34	106	110	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33650	33654		10.1074/jbc.C000483200	http://dx.doi.org/10.1074/jbc.C000483200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10954699	hybrid			2022-12-27	WOS:000090104600066
J	Thomas, M; Langley, B; Berry, C; Sharma, M; Kirk, S; Bass, J; Kambadur, R				Thomas, M; Langley, B; Berry, C; Sharma, M; Kirk, S; Bass, J; Kambadur, R			Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; BETA SUPERFAMILY MEMBER; TGF-BETA; CDK INHIBITORS; MYOGENIC LINEAGE; SKELETAL-MUSCLE; GENE MYF-5; MICE; DIFFERENTIATION; PROGRESSION	Myostatin, a member of the transforming growth factor-beta (TGF-beta) superfamily, has been shown to be a negative regulator of myogenesis. Here we show that myostatin functions by controlling the proliferation of muscle precursor cells. When C2C12 myoblasts were incubated with myostatin, proliferation of myoblasts decreased with increasing levels of myostatin. Fluorescence-activated cell sorting analysis revealed that myostatin prevented the progression of myoblasts from the G(1)- to S-phase of the cell cycle. Western analysis indicated that myostatin specifically up-regulated p21(Waf1,Cip1).a cyclin-dependent kinase inhibitor, and decreased the levels and activity of Cdk2 protein in myoblasts, Furthermore, we also observed that in myoblasts treated with myostatin protein, Rb was predominately present in the hypophosphorylated form. These results suggests that, in response to myostatin signaling, there is an increase in p21 expression and a decrease in Cdk2 protein and activity thus resulting in an accumulation of hypophosphorylated Rb protein. This, in turn, leads to the arrest of myoblasts in G(1)-phase of cell cycle, Thus, we propose that the generalized muscular hyperplasia phenotype observed in animals that lack functional myostatin could be as a result of deregulated myoblast proliferation.	AgRes, Anim Genom, Hamilton 2001, New Zealand	AgResearch - New Zealand	Kambadur, R (corresponding author), AgRes, Anim Genom, Private Bag 3123, Hamilton 2001, New Zealand.		Oliffe, John Lindsay/F-3436-2011; Langley, Brett C/P-7207-2017	Oliffe, John Lindsay/0000-0001-9029-4003; Langley, Brett C/0000-0003-4009-2109				BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Gonzalez-Cadavid NF, 1998, P NATL ACAD SCI USA, V95, P14938, DOI 10.1073/pnas.95.25.14938; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Ji SQ, 1998, AM J PHYSIOL-REG I, V275, pR1265, DOI 10.1152/ajpregu.1998.275.4.R1265; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; McPherron AC., 1996, GROWTH FACTORS CYTOK, P357, DOI [10.1016/s1874-5687(96)80016-4, DOI 10.1016/S1874-5687(96)80016-4]; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; O'Malley J. P., 1996, Methods in Cell Science, V18, P19, DOI 10.1007/BF00123519; OLIVER MH, 1989, J CELL SCI, V92, P513; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; QUINN LS, 1983, DIFFERENTIATION, V24, P111, DOI 10.1111/j.1432-0436.1983.tb01310.x; Rawls A, 1998, DEVELOPMENT, V125, P2349; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Saltis J, 1996, MOL CELL ENDOCRINOL, V116, P227, DOI 10.1016/0303-7207(95)03721-7; Sharma M, 1999, J CELL PHYSIOL, V180, P1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	35	701	803	2	79	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40235	40243		10.1074/jbc.M004356200	http://dx.doi.org/10.1074/jbc.M004356200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10976104	hybrid			2022-12-27	WOS:000166039500061
J	Yang, TB; Poovaiah, BW				Yang, TB; Poovaiah, BW			An early ethylene up-regulated gene encoding a calmodulin-binding protein involved in plant senescence and death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; SIGNAL-TRANSDUCTION; RESPONSE PATHWAY; CALCIUM; EXPRESSION; POLLINATION; PERCEPTION; MECHANISM; APOPTOSIS; TARGETS	S-35-Labeled calmodulin (CaM) was used to screen a tobacco anther cDNA library. A positive clone (NtER1) with high homology to an early ethylene-up-regulated gene (ER66) in tomato, and an Arabidopsis homolog was isolated and characterized. Based on the helical wheel projection, a 25-mer peptide corresponding to the predicted CaM-binding region of NtER1 (amino acids 796-820) was synthesized. The gel-mobility shift assay showed that the peptide formed a stable complex with CaM only in the presence of Ca2+. CaM binds to NtER1 with high affinity (K-d similar to 12 nM) in a calcium-dependent manner. Tobacco flowers at different stages of development were treated with ethylene or with 1-methylcyclopropene for 2 h before treating with ethylene. Northern analysis showed that the NtER1 was rapidly induced after 15 min of exposure to ethylene. However, the 2-h 1-methylcyclopropene treatment totally blocked NtER1 expression in flowers at all stages of development, suggesting that NtER1 is an early ethylene-up-regulated gene. The senescing leaves and petals had significantly increased NtER1 induction as compared with young leaves and petals, implying that NtER1 is developmentally regulated and acts as a trigger for senescence and death. This is the first documented evidence for the involvement of Ca2+/CaM-mediated signaling in ethylene action.	Washington State Univ, Lab Plant Mol Biol & Physiol, Dept Hort, Pullman, WA 99164 USA	Washington State University	Poovaiah, BW (corresponding author), Washington State Univ, Lab Plant Mol Biol & Physiol, Dept Hort, Pullman, WA 99164 USA.	poovaiah@wsu.edu						Abeles F, 1992, ETHYLENE PLANT BIOL; [Anonymous], SENESCENCE AGEING PL; ARAZI T, 1995, PLANT PHYSIOL, V108, P551, DOI 10.1104/pp.108.2.551; Bleecker AB, 1996, PLANT PHYSIOL, V111, P653, DOI 10.1104/pp.111.3.653; BOLLER T, 1983, PLANTA, V157, P22, DOI 10.1007/BF00394536; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROGLIE KE, 1986, P NATL ACAD SCI USA, V83, P6820, DOI 10.1073/pnas.83.18.6820; Chang C, 1999, CURR OPIN PLANT BIOL, V2, P352, DOI 10.1016/S1369-5266(99)00004-7; CLORE GM, 1993, CURR OPIN STRUC BIOL, V3, P838, DOI 10.1016/0959-440X(93)90146-C; Deikman J, 1997, PHYSIOL PLANTARUM, V100, P561, DOI 10.1034/j.1399-3054.1997.1000318.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; Gallardo M, 1999, PHYTOCHEMISTRY, V50, P373, DOI 10.1016/S0031-9422(98)00591-3; GILROY S, 1992, P NATL ACAD SCI USA, V89, P3591, DOI 10.1073/pnas.89.8.3591; Groover A, 1999, PLANT PHYSIOL, V119, P375, DOI 10.1104/pp.119.2.375; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; Kieber JJ, 1997, ANNU REV PLANT PHYS, V48, P277, DOI 10.1146/annurev.arplant.48.1.277; Kuo AL, 1996, PLANT CELL, V8, P259, DOI 10.1105/tpc.8.2.259; KUSHAD MM, 1984, PLANT PHYSIOL, V76, P293, DOI 10.1104/pp.76.2.293; Kwak SH, 1997, PLANT CELL PHYSIOL, V38, P1142, DOI 10.1093/oxfordjournals.pcp.a029099; LESHEM YY, 1987, PHYSIOL PLANTARUM, V69, P551, DOI 10.1111/j.1399-3054.1987.tb09239.x; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; LICOLN JE, 1987, P NATL ACAD SCI USA, V84, P2793; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MATTOO AK, 1988, SENESCENCE AGING PLA, P242; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; MEYER RC, 1991, PLANT MOL BIOL, V17, P277, DOI 10.1007/BF00039505; NICOTERA P, 1994, MOL CELL BIOCHEM, V135, P89, DOI 10.1007/BF00925964; NOODEN LD, 1988, SENESCENCE AGING PLA, P2; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; POOVAIAH BW, 1973, PLANT PHYSIOL, V52, P236, DOI 10.1104/pp.52.3.236; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; POOVAIAH BW, 1987, CRC CR REV PLANT SCI, V6, P47, DOI 10.1080/07352688709382247; PORAT R, 1995, PHYSIOL PLANTARUM, V93, P778, DOI 10.1111/j.1399-3054.1995.tb05131.x; RAZ V, 1992, PLANT CELL, V4, P1123, DOI 10.1105/tpc.4.9.1123; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; SEREK M, 1995, PLANT GROWTH REGUL, V16, P93, DOI 10.1007/BF00040512; Snedden WA, 1998, TRENDS PLANT SCI, V3, P299, DOI 10.1016/S1360-1385(98)01284-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Takezawa D, 1996, J BIOL CHEM, V271, P8126, DOI 10.1074/jbc.271.14.8126; TREWAVAS A, 1999, PLANT PHYSIOL, V120, P428; Trewavas AJ, 1997, PLANT CELL, V9, P1181, DOI 10.1105/tpc.9.7.1181; Wang H, 1996, PLANT CELL, V8, P375, DOI 10.1105/tpc.8.3.375; Xu HX, 1998, PLANT CELL, V10, P585, DOI 10.1105/tpc.10.4.585; Xu Y, 2000, PLANT PHYSIOL, V122, P1323, DOI 10.1104/pp.122.4.1323; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; Yang T, 1998, PLANT MOL BIOL, V37, P109, DOI 10.1023/A:1005902905512; Yang TB, 2000, J BIOL CHEM, V275, P3137, DOI 10.1074/jbc.275.5.3137; Yang TB, 1996, MOL GEN GENET, V252, P684, DOI 10.1007/BF02173974; Zegzouti H, 1999, PLANT J, V18, P589, DOI 10.1046/j.1365-313x.1999.00483.x; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	53	106	121	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38467	38473		10.1074/jbc.M003566200	http://dx.doi.org/10.1074/jbc.M003566200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10952977	hybrid			2022-12-27	WOS:000165739800045
J	Adam, PJ; Regan, CP; Hautmann, MB; Owens, GK				Adam, PJ; Regan, CP; Hautmann, MB; Owens, GK			Positive- and negative-acting Kruppel-like transcription factors bind a transforming growth factor beta control element required for expression of the smooth muscle cell differentiation marker SM22 alpha in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; TGF-BETA; TRANSGENIC MICE; CACCC ELEMENT; CARG ELEMENTS; DNA-SEQUENCE; GENE; PROMOTER; GROWTH-FACTOR-BETA-1; IDENTIFICATION	Transforming growth factor beta (TGF-beta) is implicated in the regulation of smooth muscle cell (SMC) differentiation. We previously identified a novel TGF-beta control element (TCE) in the promoters of SMC differentiation marker genes, including alpha -smooth muscle actin and SM22 alpha. In this study, the importance of the TCE in regulation of SM22 alpha gene expression in vivo was investigated by mutating it within the context of a mouse SM22 alpha promoter-lacZ transgenic construct. Mutation of the TCE completely abolished SM22 alpha promoter activity in arterial SMCs as well as in developing heart and skeletal muscle. To identify the transcription factor(s) binding to the TCE, we performed yeast one-hybrid cloning analysis and identified gut-enriched Kruppel-like factor (GKLF), However, cotransfection studies in cultured cells showed that GKLF repressed the TGF-beta -dependent increases in SM22 alpha and alpha -smooth muscle actin promoter activities. Furthermore, GKLF was not highly expressed in differentiated SMCs in vivo, and TGF-beta down-regulated GKLF expression in dedifferentiated cultured SMCs. In contrast, overexpression of a related factor (BTEB2) transactivated SM22 alpha promoter activity. Thus, our findings suggest a reciprocal role for related Kruppel-like transcription factors in the regulation of SMC differentiation through a TCE-dependent mechanism.	Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	University of Virginia	Owens, GK (corresponding author), Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, POB 449 Hlth Sci Ctr, Charlottesville, VA 22908 USA.			Regan, Chris/0000-0002-3201-5878	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038854, T32HL007284, P01HL019242] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32HL07284, R01HL38854, P01HL19242] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Asano H, 1999, MOL CELL BIOL, V19, P3571; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLANK RS, 1992, J BIOL CHEM, V267, P984; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUBAND JL, 1993, DIFFERENTIATION, V55, P1, DOI 10.1111/j.1432-0436.1993.tb00027.x; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GORDON JW, 1981, SCIENCE, V214, P1244, DOI 10.1126/science.6272397; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; Hautmann MB, 1999, ARTERIOSCL THROM VAS, V19, P2049, DOI 10.1161/01.ATV.19.9.2049; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1998, CIRC RES, V82, P908; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; Martin KM, 2000, BIOCHEM J, V345, P529, DOI 10.1042/0264-6021:3450529; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Moessler H, 1996, DEVELOPMENT, V122, P2415; NIKOL S, 1992, J CLIN INVEST, V90, P1582, DOI 10.1172/JCI116027; OWENS GK, 1995, PHYSIOL REV, V75, P487; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; VERBEEK MM, 1994, AM J PATHOL, V144, P372; VERNET M, 1993, METHOD ENZYMOL, V225, P434; Watanabe N, 1999, CIRC RES, V85, P182, DOI 10.1161/01.RES.85.2.182; Yang X, 1999, DEVELOPMENT, V126, P1571; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	48	199	208	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37798	37806		10.1074/jbc.M006323200	http://dx.doi.org/10.1074/jbc.M006323200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10954723	hybrid			2022-12-27	WOS:000165618700067
J	Guth, S; Valcarcel, J				Guth, S; Valcarcel, J			Kinetic role for mammalian SF1/BBP in spliceosome assembly and function after polypyrimidine tract recognition by U2AF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SPLICING FACTOR SF1; BRANCHPOINT SEQUENCE; EXON SEQUENCES; SITE SELECTION; PROTEIN; BINDING; SNRNP; REGION; DOMAIN	Two sequences important for pre-mRNA splicing precede the 3' end of introns in higher eukaryotes, the branch point (BP) and the polypyrimidine (Py) tract. Initial recognition of these signals involves cooperative binding of the splicing factor SF1/mammalian branch point binding protein (mBBP) to the BP and of U2AF(65) to the By tract. Both factors are required for recruitment of the U2 small nuclear ribonucleoprotein particle (U2 snRNP) to the BP in reactions reconstituted from purified components. In contrast, extensive depletion of ST1/BBP in Saccharomyces cerevisiae does not compromise spliceosome assembly or splicing significantly. As BP sequences are less conserved in mammals, these discrepancies could reflect more stringent requirements for SF1/BBP in this system. We report here that extensive depletion of SF1/mBBP from nuclear extracts of HeLa cells results in only modest reduction of their activity in spliceosome assembly and splicing. Some of these effects reflect differences in the kinetics of U2 snRNP binding. Although U2AF(65) binding was reduced in the depleted extracts, the defects caused by SF1/mBBP depletion could not be fully restored by an increase in occupancy of the Py tract by exogenously added U2AF65, arguing for a role of SF1/mBBP in U2 snRNP recruitment distinct from promoting U2AF65 binding.	European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Valcarcel, J (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Valcarcel, Juan/O-9814-2014	Valcarcel, Juan/0000-0001-5398-3571; Guth-Gundel, Sabine/0000-0001-9115-1397				Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Arning S, 1996, RNA, V2, P794; BEHRENS SE, 1993, MOL CELL BIOL, V13, P307, DOI 10.1128/MCB.13.1.307; Berglund JA, 1998, RNA, V4, P998, DOI 10.1017/S1355838298980499; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; Burge CB, 1999, RNA WORLD, P525; Chiara MD, 1996, MOL CELL BIOL, V16, P3317; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; GamaCarvalho M, 1997, J CELL BIOL, V137, P975, DOI 10.1083/jcb.137.5.975; GAUR RK, 1995, RNA, V1, P407; Gozani O, 1998, MOL CELL BIOL, V18, P4752, DOI 10.1128/MCB.18.8.4752; Guth S, 1999, MOL CELL BIOL, V19, P8263; HARLOW E, 1988, ANTIBODIES LABORATOR, P78; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HODGES PE, 1994, CURR BIOL, V4, P264, DOI 10.1016/S0960-9822(00)00061-0; Kambach C, 1999, CURR OPIN STRUC BIOL, V9, P222, DOI 10.1016/S0959-440X(99)80032-3; KRAMER A, 1991, EMBO J, V10, P1503, DOI 10.1002/j.1460-2075.1991.tb07670.x; Kramer A, 1998, GENE, V211, P29, DOI 10.1016/S0378-1119(98)00058-4; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KRAMER A, 1992, MOL CELL BIOL, V12, P4545; LEE CG, 1993, J BIOL CHEM, V268, P13472; MACMILLAN AM, 1994, GENE DEV, V8, P3008, DOI 10.1101/gad.8.24.3008; Mazroui R, 1999, RNA, V5, P1615, DOI 10.1017/S1355838299991872; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NELSON KK, 1989, GENE DEV, V3, P1562, DOI 10.1101/gad.3.10.1562; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; Rain JC, 1998, RNA, V4, P551, DOI 10.1017/S1355838298980335; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; Rutz B, 1999, RNA, V5, P819, DOI 10.1017/S1355838299982286; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; Wang X, 1999, EMBO J, V18, P4549, DOI 10.1093/emboj/18.16.4549; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WILL CL, 1993, MOL BIOL REP, V18, P121, DOI 10.1007/BF00986766; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZAPP ML, 1989, NUCLEIC ACIDS RES, V17, P2655, DOI 10.1093/nar/17.7.2655; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597	46	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38059	38066		10.1074/jbc.M001483200	http://dx.doi.org/10.1074/jbc.M001483200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10954700	hybrid			2022-12-27	WOS:000165618700100
J	Knauer, DJ; Majumdar, D; Fong, PC; Knauer, MF				Knauer, DJ; Majumdar, D; Fong, PC; Knauer, MF			SERPIN regulation of factor XIa - The novel observation that protease nexin 1 in the presence of heparin is a more potent inhibitor of factor XIa than C1 inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; RECEPTOR-RELATED PROTEIN; PLASMA THROMBOPLASTIN ANTECEDENT; BLOOD-COAGULATION FACTOR; ACTIVATED HAGEMAN-FACTOR; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; ALPHA(2)-MACROGLOBULIN RECEPTOR; APOLIPOPROTEIN-E; MECHANISM	In the present studies we have made the novel observation that protease nexin 1 (PN1), a member of the serine protease inhibitor (SERPIN) superfamily, is a potent inhibitor of the blood coagulation Factor Ma (FXIa). The inhibitory complexes formed between PN1 and FXIa are stable when subjected to reducing agents, SDS, and boiling, a characteristic of the acyl linkage formed between SERPINs and their cognate proteases. Using a sensitive fluorescence-quenched peptide substrate, the K-assoc of PN1 for FXIa was determined to be 7.9 x 10(4) M-1 s(-1) in the absence of heparin. In the presence of heparin, this rate was accelerated to 1.7 x 10(6), M-1 s(-1), making PN1 a far better inhibitor of FXIa than C1 inhibitor, which is the only other SERPIN known to significantly inhibit FXIa. FXIa-PN1 complexes are shown to be internalized and degraded by human fibroblasts, most likely via the low density lipoprotein receptor-related protein (LRP), since degradation was strongly inhibited by the LRP agonist, receptor associated protein. Since FXIa proteolytically modifies the amyloid precursor protein, this observation may suggest an accessory role for PN1 in the pathobiogenesis of Alzheimer's disease.	Univ Calif Irvine, Sch Biol Sci, Dept Dev & Cell Biol, Irvine, CA 92627 USA	University of California System; University of California Irvine	Knauer, MF (corresponding author), Univ Calif Irvine, Sch Biol Sci, Dept Dev & Cell Biol, Irvine, CA 92627 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034001] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM34001-12] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200; BOUMA BN, 1983, BLOOD, V62, P1123; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; CONESE M, 1994, J BIOL CHEM, V269, P17886; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DONOVAN FM, 1994, J BIOL CHEM, V269, P17199; FORBES CD, 1970, J LAB CLIN MED, V76, P809; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GRONKE RS, 1989, BLOOD, V73, P472; GRONKE RS, 1987, J BIOL CHEM, V262, P3030; HECK LW, 1974, J EXP MED, V140, P1615, DOI 10.1084/jem.140.6.1615; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOWARD EW, 1986, J BIOL CHEM, V261, P684; HOWARD EW, 1987, J CELL PHYSIOL, V131, P276, DOI 10.1002/jcp.1041310219; KITCHENS CS, 1991, SEMIN THROMB HEMOST, V17, P55, DOI 10.1055/s-2007-1002590; Knauer MF, 1999, J BIOL CHEM, V274, P275, DOI 10.1074/jbc.274.1.275; Knauer MF, 1997, J BIOL CHEM, V272, P29039, DOI 10.1074/jbc.272.46.29039; KOMIYAMA Y, 1988, THROMB RES, V50, P329, DOI 10.1016/0049-3848(88)90234-4; Kridel SJ, 1996, J BIOL CHEM, V271, P20935, DOI 10.1074/jbc.271.34.20935; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; SAITO H, 1977, BLOOD, V50, P377; SAITO H, 1979, P NATL ACAD SCI USA, V76, P2013, DOI 10.1073/pnas.76.4.2013; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SAPORITOIRWIN SM, 1995, J BIOL CHEM, V270, P26265, DOI 10.1074/jbc.270.44.26265; SCHUBERT D, 1989, BIOCHEM BIOPH RES CO, V162, P83, DOI 10.1016/0006-291X(89)91965-7; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SMALL DH, 1994, J NEUROSCI, V14, P2117; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Van Uden E, 1999, MOL CELL NEUROSCI, V14, P129, DOI 10.1006/mcne.1999.0772; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; VANNOSTRAND WE, 1995, THROMB RES, V78, P43, DOI 10.1016/0049-3848(95)00033-X; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; Wuillemin WA, 1996, J BIOL CHEM, V271, P12913, DOI 10.1074/jbc.271.22.12913; YANG AJ, 1995, J BIOL CHEM, V270, P14786, DOI 10.1074/jbc.270.24.14786; Zhang Y, 1997, J BIOL CHEM, V272, P26139, DOI 10.1074/jbc.272.42.26139	41	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37340	37346		10.1074/jbc.M003909200	http://dx.doi.org/10.1074/jbc.M003909200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973954	hybrid			2022-12-27	WOS:000165618700007
J	Phippen, TM; Sweigart, AL; Moniwa, M; Krumm, A; Davie, JR; Parkhurst, SM				Phippen, TM; Sweigart, AL; Moniwa, M; Krumm, A; Davie, JR; Parkhurst, SM			Drosophila C-terminal binding protein functions as a context-dependent transcriptional co-factor and interferes with both Mad and Groucho transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; ADENOVIRUS E1A; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; COREPRESSOR GROUCHO; DOMAIN; INTERACTS; HAIRY; CTBP; EMBRYO	Drosophila C-terminal binding protein (dCtBP) and Groucho have been identified as Hairy-interacting proteins required for embryonic segmentation and Hairy-mediated transcriptional repression. While both dCtBP and Groucho are required for proper Hairy function, their properties are very different. As would be expected for a co-repressor, reduced Groucho activity enhances the hairy mutant phenotype, In contrast, reduced dCtBP activity suppresses it. We show here that dCtBP can function as either a co-activator or co-repressor of transcription in a context-dependent manner. The regions of dCtBP required for activation and repression are separable. We find that mSin3A-histone deacetylase complexes are altered in the presence of dCtBP and that dCtBP interferes with both Groucho and Mad transcriptional repression. Similar to CtBP's role in attenuating E1A's oncogenicity, we propose that dCtBP can interfere with corepressor-histone deacetylase complexes, thereby attenuating transcriptional repression. Hairy defines a new class of proteins that requires both CtBP and Groucho co-factors for proper function.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Program Dev Biol, Seattle, WA 98109 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Parkhurst, SM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, A1-162,1100 Fairview Ave N, Seattle, WA 98109 USA.			Davie, James/0000-0002-0420-6888	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM047852, R01GM047852] Funding Source: NIH RePORTER; NICHD NIH HHS [5T32HD07183] Funding Source: Medline; NIGMS NIH HHS [GM47852] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V2; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Berg A, 1998, EUR J BIOCHEM, V252, P45, DOI 10.1046/j.1432-1327.1998.2520045.x; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Brannon M, 1999, DEVELOPMENT, V126, P3159; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Cai HN, 1996, P NATL ACAD SCI USA, V93, P9309, DOI 10.1073/pnas.93.18.9309; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Goodman RH, 1998, CURR OPIN NEUROBIOL, V8, P413, DOI 10.1016/S0959-4388(98)80069-X; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; INGHAM PW, 1985, GENETICS, V111, P463; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Kiermaier A, 1997, CURR BIOL, V7, pR505, DOI 10.1016/S0960-9822(06)00249-1; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Mannervik M, 1999, P NATL ACAD SCI USA, V96, P6797, DOI 10.1073/pnas.96.12.6797; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Mymryk JS, 1996, ONCOGENE, V13, P1581; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; Parkhurst SM, 1998, TRENDS GENET, V14, P130, DOI 10.1016/S0168-9525(98)01407-3; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; ROTH SY, 1995, CURR OPIN GENET DEV, V5, P168, DOI 10.1016/0959-437X(95)80004-2; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Wieschaus E., 1986, P199; Zhang HL, 1999, P NATL ACAD SCI USA, V96, P535, DOI 10.1073/pnas.96.2.535	62	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37628	37637		10.1074/jbc.M004234200	http://dx.doi.org/10.1074/jbc.M004234200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973955	hybrid			2022-12-27	WOS:000165618700045
J	Suzuki, T; Suzuki, J; Mitome, N; Ueno, H; Yoshida, M				Suzuki, T; Suzuki, J; Mitome, N; Ueno, H; Yoshida, M			Second stalk of ATP synthase - Cross-linking of gamma subunit in F-1 to truncated F(o)b subunit prevents ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1F0-ATPASE; DELTA-SUBUNIT; B-SUBUNIT; 2ND STALK; DOMAIN; ROTATION; F1-ATPASE; EPSILON; COMPLEX; PARTS	ATP synthase consists of two portions, F-1 and F-o, connected by two stalks: a central rotor stalk containing gamma and epsilon subunits and a peripheral, second stalk formed by delta and two copies of F(o)b subunits. The second stalk is expected to keep the stator subunits from spinning along with the rotor. We isolated a TF1-b'(2) complex (alpha (3)beta (3)gamma delta epsilonb'(2)) of a thermophilic Bacillus PS3, in which b' was a truncated cytoplasmic fragment of F(o)b subunit, and introduced a cysteine at its N terminus (bc'). Association of b'(2) or bc'(2) with TF1 did not have significant effect on ATPase activity. A disulfide bond between the introduced cysteine of bc' and cysteine 109 of gamma subunit was readily formed, and this cross-link caused inactivation of ATPase. This implies that F(o)b subunit bound to stator subunits of F-1 with enough strength to resist rotation of gamma subunit and to prevent catalysis. Contrary to this apparent tight binding, some detergents such as lauryldodecylamine oxide tend to cause release of b'(2) from TF1.	Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Nagatsuta 4259, Yokohama, Kanagawa 2268503, Japan.							Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Bottcher B, 2000, J MOL BIOL, V296, P449, DOI 10.1006/jmbi.1999.3435; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Fillingame RH, 2000, J EXP BIOL, V203, P9; Garcia JJ, 1998, J BIOL CHEM, V273, P15940, DOI 10.1074/jbc.273.26.15940; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; McLachlin DT, 2000, BIOCHEMISTRY-US, V39, P3486, DOI 10.1021/bi992586b; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sambrook J., 2002, MOL CLONING LAB MANU; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Sorgen PL, 1999, J BIOL CHEM, V274, P36261, DOI 10.1074/jbc.274.51.36261; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381; Wilkens S, 1998, BBA-BIOENERGETICS, V1365, P93, DOI 10.1016/S0005-2728(98)00048-6; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; YOSHIDA M, 1984, H PLUS ATPASE ATP SY, P147	34	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37902	37906		10.1074/jbc.M007075200	http://dx.doi.org/10.1074/jbc.M007075200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10970900	hybrid			2022-12-27	WOS:000165618700080
J	Wilson, KF; Wu, WJ; Cerione, RA				Wilson, KF; Wu, WJ; Cerione, RA			Cdc42 stimulates RNA splicing via the S6 kinase and a novel S6 kinase target, the nuclear cap-binding complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNALING PATHWAY; MAMMALIAN TARGET; LOCALIZATION; TRANSLATION; RAPAMYCIN; EXPORT; RAC1	Cdc42 is a low molecular weight GTP-binding protein that plays a key regulatory role in a variety of cellular activities. The importance of the coordination of different cell functions by Cdc42 is underscored by the fact that a constitutively active Cdc42 mutant induces cellular transformation. In this study, we describe a novel function for Cdc42: its ability to stimulate pre-messenger RNA splicing. This activity is dependent on cysteine 37 in the effector loop of Cdc42 but is not dependent on cell growth. A likely candidate protein for mediating the Cdc42 effects on pre-mRNA splicing is the nuclear RNA cap-binding complex (CBC), which plays a key role in an early step of cap dependent RNA splicing. Activation of the CBC by Cdc42 can be inhibited by rapamycin, Additionally, phosphatidylinositol 3-kinase and the Cdc42 effector, pp70 Se kinase, stimulate the RNA cap-binding activity of the CBC, S6 kinase may directly target the CBC in vivo as it can phosphorylate the 80-kDa subunit of the CBC, CBP80, at residues that are subject to a growth factor-dependent and rapamycin-sensitive phosphorylation in vivo. Together these data suggest the involvement of a Cdc42-S6 kinase pathway in the regulation of RNA splicing, mediated by an increase in capped RNA binding by the CBC, as well as raise the possibility that the effects of Cdc42 on cell growth may be due in part to its regulation of RNA processing.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; COFFER PJ, 1994, BIOCHEM BIOPH RES CO, V198, P780, DOI 10.1006/bbrc.1994.1112; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; HARA K, 1997, J BIOL CHEM, V272, P26547; Izaurralde E, 1995, COLD SPRING HARB SYM, V60, P669, DOI 10.1101/SQB.1995.060.01.072; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; Lewis JD, 1996, NUCLEIC ACIDS RES, V24, P3332, DOI 10.1093/nar/24.17.3332; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; OLSON ME, 1995, SCIENCE, V269, P53; Peterson RT, 1998, CURR BIOL, V8, pR248, DOI 10.1016/S0960-9822(98)70152-6; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Tang T, 1996, J NEUROCHEM, V66, P1198; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; VAN AL, 1997, GENE DEV, V11, P2295; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; Wilson KF, 1999, J BIOL CHEM, V274, P4166, DOI 10.1074/jbc.274.7.4166; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	32	59	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37307	37310		10.1074/jbc.C000482200	http://dx.doi.org/10.1074/jbc.C000482200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973943	hybrid			2022-12-27	WOS:000165618700002
J	Edwards, TK; Saleem, A; Shaman, JA; Dennis, T; Gerigk, C; Oliveros, E; Gartenberg, MR; Rubin, EH				Edwards, TK; Saleem, A; Shaman, JA; Dennis, T; Gerigk, C; Oliveros, E; Gartenberg, MR; Rubin, EH			Role for nucleolin/Nsr1 in the cellular localization of topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; ANTITUMOR DRUG CAMPTOTHECIN; YEAST NSR1 PROTEIN; RNA-POLYMERASE-I; RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; DNA TOPOISOMERASES; NUCLEOLAR PROTEIN; MESSENGER-RNA; CLEAVABLE COMPLEXES	Nucleolin functions in ribosome biogenesis and contains an acidic N terminus that binds nuclear localization sequences. In previous work we showed that human nucleolin associates with the N-terminal region of human topoisomerase I (Top1), We have now mapped the topoisomerase I interaction domain of nucleolin to the N-terminal 225 amino acids. We also show that the Saccharomyces cerevisiae nucleolin ortholog, Nsr1p, physically interacts with yeast topoisomerase I, yTop1p. Studies of isogenic NSR1(+) and Delta nsr1 strains indicate that NSR1 is important in determining the cellular localization of yTop1p. Moreover, deletion of NSR1 reduces sensitivity to camptothecin, an antineoplastic topoisomerase I inhibitor. By contrast, Delta nsr1 cells are hypersensitive to the topoisomerase II-targeting drug amsacrine. These findings indicate that nucleolin/Nsr1 is involved in the cellular localization of Top1 and that this localization may be important in determining sensitivity to drugs that target topoisomerases.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst NEw JErsey, Dept Med, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst NEw JErsey, Dept Pharmacol, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Rubin, EH (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst NEw JErsey, Dept Med, New Brunswick, NJ 08901 USA.			Gartenberg, Marc/0000-0003-0713-7993; Shaman, Jeffrey/0000-0001-7397-5755	NATIONAL CANCER INSTITUTE [R29CA070981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051402, R55GM051402, R01GM059170] Funding Source: NIH RePORTER; NCI NIH HHS [CA70981] Funding Source: Medline; NIGMS NIH HHS [GM59170, GM51402] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELSON HT, 1972, NATURE-NEW BIOL, V237, P144, DOI 10.1038/newbio237144a0; Albor A, 1998, CANCER RES, V58, P2091; ALSNER J, 1992, J BIOL CHEM, V267, P12408; Beidler DR, 1996, CANCER RES, V56, P345; BEIDLER DR, 1995, MOL PHARMACOL, V47, P907; BENDIXEN C, 1990, BIOCHEMISTRY-US, V29, P5613, DOI 10.1021/bi00475a028; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; Buckwalter CA, 1996, CANCER RES, V56, P1674; BUGLER B, 1987, J BIOL CHEM, V262, P10922; CHANG JY, 1992, BIOCHEM PHARMACOL, V43, P2443, DOI 10.1016/0006-2952(92)90325-D; CHEN A, 1994, ANN REV PHARM TOXICO, V84, P191; Cheng TH, 1998, P NATL ACAD SCI USA, V95, P5521, DOI 10.1073/pnas.95.10.5521; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; Daniely Y, 2000, J CELL BIOL, V149, P799, DOI 10.1083/jcb.149.4.799; Danks MK, 1996, CANCER RES, V56, P1664; David-Pfeuty T, 1999, ONCOGENE, V18, P7409, DOI 10.1038/sj.onc.1203103; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Duguet M, 1997, J CELL SCI, V110, P1345; EGYHAZI E, 1987, MOL CELL BIOL, V7, P4308, DOI 10.1128/MCB.7.12.4308; ENG WK, 1988, MOL PHARMACOL, V34, P755; Fan Y, 1998, J MED CHEM, V41, P2216, DOI 10.1021/jm9605445; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; FELDHOFF PW, 1994, CANCER RES, V54, P756; Gadal O, 1997, MOL CELL BIOL, V17, P1787, DOI 10.1128/MCB.17.4.1787; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GARTENBERG MR, 1992, P NATL ACAD SCI USA, V89, P11461, DOI 10.1073/pnas.89.23.11461; Ginisty H, 1999, J CELL SCI, V112, P761; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; GOLDWASSER F, 1995, CANCER RES, V55, P2116; Haluska P, 1998, NUCLEIC ACIDS RES, V26, P1841, DOI 10.1093/nar/26.7.1841; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Hanakahi LA, 1999, J BIOL CHEM, V274, P15908, DOI 10.1074/jbc.274.22.15908; HARKER WG, 1995, CANCER RES, V55, P4962; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; HSIANG YH, 1989, CANCER RES, V49, P5077; JAVAHERIAN K, 1983, NUCLEIC ACIDS RES, V11, P461, DOI 10.1093/nar/11.2.461; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KONDO K, 1992, J BIOL CHEM, V267, P16259; KONDO K, 1992, J BIOL CHEM, V267, P16252; KORDIYAK GJ, 1994, BIOCHEMISTRY-US, V33, P13484, DOI 10.1021/bi00249a037; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; Mirabella A, 1997, EMBO J, V16, P523, DOI 10.1093/emboj/16.3.523; MIRSKI SEL, 1995, CANCER RES, V55, P2129; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Mo YY, 2000, EXP CELL RES, V256, P480, DOI 10.1006/excr.2000.4864; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; OHTAKE Y, 1995, MOL CELL BIOL, V15, P2772; Pantazis P, 1995, ANTICANCER RES, V15, P1873; Park H, 1999, YEAST, V15, P35, DOI 10.1002/(SICI)1097-0061(19990115)15:1<35::AID-YEA340>3.0.CO;2-R; Pommier Y, 1998, BIOCHEMISTRY-US, V37, P3818, DOI 10.1021/bi972067d; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Reid RJD, 1998, BBA-GENE STRUCT EXPR, V1400, P289, DOI 10.1016/S0167-4781(98)00142-0; Reid RJD, 1997, J BIOL CHEM, V272, P12091, DOI 10.1074/jbc.272.18.12091; ROSE KM, 1988, CHROMOSOMA, V96, P411, DOI 10.1007/BF00303034; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; RUBIN E, 1994, J BIOL CHEM, V269, P2433; SANTIAGO TC, 1986, NUCLEIC ACIDS RES, V14, P8347, DOI 10.1093/nar/14.21.8347; SAPP M, 1989, EUR J BIOCHEM, V179, P541, DOI 10.1111/j.1432-1033.1989.tb14581.x; SCHULTZ MC, 1992, GENE DEV, V6, P1332, DOI 10.1101/gad.6.7.1332; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Simmons DT, 1996, VIROLOGY, V222, P365, DOI 10.1006/viro.1996.0433; Sorensen M, 1998, BRIT J CANCER, V77, P2152, DOI 10.1038/bjc.1998.360; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; Straub T, 1998, J BIOL CHEM, V273, P26261, DOI 10.1074/jbc.273.41.26261; THRASH C, 1985, P NATL ACAD SCI USA, V82, P4374, DOI 10.1073/pnas.82.13.4374; Tsalik EL, 1998, YEAST, V14, P847, DOI 10.1002/(SICI)1097-0061(19980630)14:9<847::AID-YEA285>3.0.CO;2-9; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; Wadkins RM, 1998, EXP CELL RES, V241, P332, DOI 10.1006/excr.1998.4033; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Wessel I, 1997, CANCER RES, V57, P4451; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wu JX, 1997, NUCLEIC ACIDS RES, V25, P4181, DOI 10.1093/nar/25.21.4181; WU RS, 1971, P NATL ACAD SCI USA, V68, P3009, DOI 10.1073/pnas.68.12.3009; Xue Zhixiong, 1994, Trends in Cell Biology, V4, P414, DOI 10.1016/0962-8924(94)90095-7; XUE ZX, 1993, EUR J CELL BIOL, V62, P13; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060	87	42	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36181	36188		10.1074/jbc.M006628200	http://dx.doi.org/10.1074/jbc.M006628200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967121	hybrid			2022-12-27	WOS:000165382000076
J	Davani, B; Khan, A; Hult, M; Martensson, E; Okret, SE; Efendic, S; Jornvall, H; Oppermann, UCT				Davani, B; Khan, A; Hult, M; Martensson, E; Okret, SE; Efendic, S; Jornvall, H; Oppermann, UCT			Type 1 11 beta-hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELLS; GLUCAGON-SECRETION; RAT; INHIBITION; REDUCTASE; CORTICOSTERONE; LOCALIZATION; SENSITIVITY; EXPRESSION; STEROIDS	Metabolic transformation of glucocorticoid hormones constitutes a determinant of their cell-specific effects. The most important reaction for this class of steroids is the reversible C11 keto/beta -hydroxyl conversion between receptor-binding 11 beta -OH steroids and the nonbinding 11-oxo compounds, carried out by 11 beta -hydroxysteroid dehydrogenases (11 beta -HSDs). In this study, we determined the role of glucocorticoid conversion by 11 beta -HSD in pancreatic islets and its function in the regulation of insulin release. Pancreatic islets isolated from ob/ob mice display type 1 11 beta -hydroxysteroid dehydrogenase activity, i.e. in intact cells the reductive reaction prevails, leading from dehydrocorticosterone to corticosterone. Expression of type 1 11 beta -HSD mRNA was detected by reverse transcriptase-polymerase chain reaction in islets isolated from ob/ob mice and also from human tissue. Incubation of beta -cells in the presence of 11-dehydrocorticosterone leads to a dose-dependent inhibition of insulin release, indicating cellular activation of 11-dehydrocorticosterone to the receptor ligand, further confirmed by reporter gene assays. Inhibition of 11 beta -HSD activity by carbenoxolone reverses inhibition of insulin release. The presence of 11 beta -HSD in islets supports the concept that reactivation of inert circulating hormone precursors in a cell-specific manner plays a major role in glucocorticoid physiology in rodents and man.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Huddinge Univ Hosp, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden; Karolinska Hosp, Dept Mol Med, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Oppermann, UCT (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.							AGARWAL AK, 1995, GENOMICS, V29, P195, DOI 10.1006/geno.1995.1231; Barnes PJ, 1995, BIOCHEM SOC T, V23, P940, DOI 10.1042/bst0230940; BARSEGHIAN G, 1980, ENDOCRINOLOGY, V106, P547, DOI 10.1210/endo-106-2-547; BARSEGHIAN G, 1982, ENDOCRINOLOGY, V111, P1648, DOI 10.1210/endo-111-5-1648; BILLAUDEL B, 1979, HORM METAB RES, V11, P555, DOI 10.1055/s-0028-1092779; Bujalska IJ, 1997, LANCET, V349, P1210, DOI 10.1016/S0140-6736(96)11222-8; Delaunay F, 1997, J CLIN INVEST, V100, P2094, DOI 10.1172/JCI119743; Delaunay F, 1996, EUR J BIOCHEM, V242, P839, DOI 10.1111/j.1432-1033.1996.0839r.x; DINNEEN S, 1993, J CLIN INVEST, V92, P2283, DOI 10.1172/JCI116832; Gremlich S, 1997, J BIOL CHEM, V272, P3216, DOI 10.1074/jbc.272.6.3216; Hult M, 1998, FEBS LETT, V441, P25, DOI 10.1016/S0014-5793(98)01515-4; KHAN A, 1992, AM J PHYSIOL, V263, pE663, DOI 10.1152/ajpendo.1992.263.4.E663; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; Krozowski Z, 1995, J STEROID BIOCHEM, V55, P457, DOI 10.1016/0960-0760(95)00194-8; LAKSHMI V, 1988, ENDOCRINOLOGY, V123, P2390, DOI 10.1210/endo-123-5-2390; Lambillotte C, 1997, J CLIN INVEST, V99, P414, DOI 10.1172/JCI119175; Leckie CM, 1998, J ENDOCRINOL, V159, P233, DOI 10.1677/joe.0.1590233; LENZEN S, 1984, ENDOCR REV, V5, P411, DOI 10.1210/edrv-5-3-411; Ling ZC, 1998, DIABETOLOGIA, V41, P634, DOI 10.1007/s001250050961; LOW SC, 1994, J MOL ENDOCRINOL, V13, P167, DOI 10.1677/jme.0.0130167; Lowe WL, 1998, PRINCIPLES MOL MED, P433; MARANDICI A, 1993, STEROIDS, V58, P153, DOI 10.1016/0039-128X(93)90062-R; MCMAHON M, 1988, DIABETES METAB REV, V4, P17, DOI 10.1002/dmr.5610040105; Michael AE, 1997, MOL CELL ENDOCRINOL, V132, P43, DOI 10.1016/S0303-7207(97)00118-4; MONDER C, 1993, VITAM HORM, V47, P187, DOI 10.1016/S0083-6729(08)60447-1; MUNE T, 1995, NAT GENET, V10, P394, DOI 10.1038/ng0895-394; Napolitano A, 1998, J STEROID BIOCHEM, V64, P251, DOI 10.1016/S0960-0760(97)00200-8; OPPERMANN UCT, 1995, EUR J BIOCHEM, V227, P202, DOI 10.1111/j.1432-1033.1995.tb20377.x; Oppermann UCT, 1997, EUR J BIOCHEM, V249, P355, DOI 10.1111/j.1432-1033.1997.t01-1-00355.x; Plat L, 1996, AM J PHYSIOL-ENDOC M, V270, pE36, DOI 10.1152/ajpendo.1996.270.1.E36; Reichardt HM, 2000, ADV PHARMACOL, V47, P1; Ricketts ML, 1998, J ENDOCRINOL, V156, P159, DOI 10.1677/joe.0.1560159; Stewart PM, 1999, VITAM HORM, V57, P249; SURWIT RS, 1992, DIABETES CARE, V15, P1413, DOI 10.2337/diacare.15.10.1413; vanderBurg B, 1997, TRENDS ENDOCRIN MET, V8, P152, DOI 10.1016/S1043-2760(97)00006-4; Voice MW, 1996, BIOCHEM J, V317, P621, DOI 10.1042/bj3170621; WALKER BR, 1995, J CLIN ENDOCR METAB, V80, P3155, DOI 10.1210/jc.80.11.3155	37	95	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34841	34844		10.1074/jbc.C000600200	http://dx.doi.org/10.1074/jbc.C000600200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10973946	hybrid			2022-12-27	WOS:000165422800003
J	Goldfinger, LE; Jiang, LH; Hopkinson, SB; Stack, MS; Jones, JCR				Goldfinger, LE; Jiang, LH; Hopkinson, SB; Stack, MS; Jones, JCR			Spatial regulation and activity modulation of plasmin by high affinity binding to the G domain of the alpha(3) subunit of laminin-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; ENDOTHELIAL-CELL RECEPTOR; ANNEXIN-II TETRAMER; HEPARIN-BINDING; A-CHAIN; T-PA; ACTIVATOR; EXPRESSION; CLONING; ADHESION	Cells in complex tissues contact extracellular matrix that interacts with integrin receptors to influence gene expression, proliferation, apoptosis, adhesion, and motility, During development, tissue remodeling, and tumorigenesis, matrix components are modified by enzymatic digestion with subsequent effects on integrin binding and signaling. We are interested in understanding the mechanisms by which broad spectrum proteinases such as plasmin are targeted to their extracellular matrix protein substrates, We have utilized plasmin-mediated cleavage of the epithelial basement membrane glycoprotein laminin-5 as a model to evaluate molecular events that direct plasmin activity to specific structural domains. We report that plasminogen and tissue plasminogen activator (tPA) exhibit high affinity, specific binding to the G(1) subdomain of the N terminus of the laminin-5 alpha (3) subunit, with equilibrium dissociation constants of 50 nM for plasminogen and 80 nM for tPA, No high affinity binding to the G(2), G(3), and G(4) subdomains was observed. As a result of binding to the G(1) subdomain, the catalytic efficiency of tPA-catalyzed plasminogen activation is enhanced 32-fold, leading to increased matrix-associated plasmin that is positioned favorably for cleavage within the G(4) subdomain as we have reported previously (Goldfinger, L. E,, Stack, M. S,, and Jones, J, C, R, (1998) J, Cell Biol, 141, 255-265), Thus, physical constraints dictated by interaction of proteinase and matrix macromolecule control not only enzymatic activity but may regulate substrate targeting of proteinases.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA	Northwestern University; Northwestern University	Jones, JCR (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Morton 4-616,303 E Chicago Ave, Chicago, IL 60611 USA.		Jones, Jonathan C R/T-9467-2017	Jones, Jonathan C R/0000-0002-1496-4922	NCI NIH HHS [T32 CA09560] Funding Source: Medline; NIDCR NIH HHS [P01 DE12328] Funding Source: Medline; NIGMS NIH HHS [R01 GM38470] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038470] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; Ashkenas J, 1996, DEV BIOL, V180, P433, DOI 10.1006/dbio.1996.0317; Baker SE, 1996, J CELL SCI, V109, P2509; BLASCHKE RJ, 1994, METHOD ENZYMOL, V245, P535; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTELLINO FJ, 1981, CHEM REV, V81, P431, DOI 10.1021/cr00045a001; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; Frieser M, 1997, EUR J BIOCHEM, V246, P727, DOI 10.1111/j.1432-1033.1997.t01-1-00727.x; Gase K, 1996, EUR J BIOCHEM, V239, P42, DOI 10.1111/j.1432-1033.1996.0042u.x; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Hajjar KA, 1998, J BIOL CHEM, V273, P9987, DOI 10.1074/jbc.273.16.9987; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HIGHSMITH RF, 1981, J BIOL CHEM, V256, P6788; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; Jonsson U., 1992, ADV BIOSENSOR, P291; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; MOSER TL, 1993, J BIOL CHEM, V268, P18917; OSSOWSKI L, 1978, BIOL MARKERS NEOPLAS, P473; REICH E, 1978, BIOL MARKERS NEOPLAS, P506; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RYAN MC, 1994, J BIOL CHEM, V269, P22779; SASAKI M, 1988, J BIOL CHEM, V263, P16536; STACK MS, 1995, MOL BASIS THROMBOSIS, P479; STACK MS, 1990, BIOCHEMISTRY-US, V30, P2073; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; Sung U, 1997, EUR J BIOCHEM, V250, P138, DOI 10.1111/j.1432-1033.1997.00138.x; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; YAMAGUCHI H, 1995, AMYLOID, V2, P7, DOI 10.3109/13506129509031882; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280	40	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34887	34893		10.1074/jbc.M006652200	http://dx.doi.org/10.1074/jbc.M006652200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956663	hybrid			2022-12-27	WOS:000165422800011
J	Hayes, DS; Peng, ZY; Setlow, P				Hayes, DS; Peng, ZY; Setlow, P			Equilibrium and kinetic binding interactions between DNA and a group of novel, nonspecific DNA-binding proteins from spores of Bacillus and Clostridium species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA/BETA-TYPE SMALL; SINGLE-STRANDED-DNA; ACID-SOLUBLE PROTEINS; ESCHERICHIA-COLI; SUBTILIS SPORES; IN-VITRO; NONCOOPERATIVE BINDING; MUTANT SMALL; MEGATERIUM; VIVO	Binding of alpha/beta -type small acid-soluble spore proteins (SASP) is the major determinant of DNA resistance to damage caused by UV radiation, heat, and oxidizing agents in spores of Bacillus and Clostridium species. Analysis of several alpha/beta -type SASP showed that these proteins have essentially no secondary structure in the absence of DNA, but become significantly cu-helical upon binding to double-stranded DNAs or oligonucleotides. Folding of alpha/beta -type SASP induced by a variety of DNAs and :oligonucleotides was measured by CD spectroscopy, and this allowed determination of a DNA binding site size of 4 base pairs as well as equilibrium binding parameters of the alpha/beta -type SASP-DNA interaction, Analysis of the equilibrium binding data further allowed determination of both intrinsic binding constants (LC) and cooperativity factors (omega), as the alpha/beta -type SASP-DNA interaction was significantly cooperative, with the degree of cooperativity depending on both the bound DNA and the salt concentration, Kinetic analysis of the interaction of one alpha/beta -type SASP, SspC(Tyr), With DNA indicated that each binding event involves the dimerization of SspC(Tyr) monomers at a DNA binding site. The implications of these findings for the structure of the alpha/beta -type SASP.DNA complex and the physiology of alpha/beta -type SASP degradation during spore germination are discussed.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA	University of Connecticut	Setlow, P (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, MC-3305,263 Farmington Ave, Farmington, CT 06030 USA.	setlow@sun.uchc.edu			NIGMS NIH HHS [GM19698, GM54533] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019698, R29GM054533, R37GM019698] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ando RA, 1998, J MOL BIOL, V283, P785, DOI 10.1006/jmbi.1998.2124; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BUJALOWSKI W, 1987, BIOCHEMISTRY-US, V26, P3099, DOI 10.1021/bi00385a023; CABRERAMARTINEZ RM, 1989, FEMS MICROBIOL LETT, V61, P139, DOI 10.1111/j.1574-6968.1989.tb03567.x; Cantor CR, 1980, BIOPHYSICAL CHEM BEH; DEJONG EAM, 1987, BIOCHEMISTRY-US, V26, P2039, DOI 10.1021/bi00381a037; Driks A, 2000, PROKARYOTIC DEVELOPMENT, P191; Frankel AD, 1998, CELL, V92, P149, DOI 10.1016/S0092-8674(00)80908-3; Gazit E, 1999, J BIOL CHEM, V274, P2652, DOI 10.1074/jbc.274.5.2652; GERHARDT P, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P43; GRIFFITH J, 1994, P NATL ACAD SCI USA, V91, P8224, DOI 10.1073/pnas.91.17.8224; GROCH N, 1992, EUR J BIOCHEM, V207, P677, DOI 10.1111/j.1432-1033.1992.tb17095.x; Hayes CS, 1998, J BIOL CHEM, V273, P17326, DOI 10.1074/jbc.273.28.17326; Hayes CS, 1998, J BACTERIOL, V180, P2694, DOI 10.1128/JB.180.10.2694-2700.1998; Hayes CS, 1997, J BACTERIOL, V179, P6020, DOI 10.1128/jb.179.19.6020-6027.1997; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KUIL ME, 1989, BIOCHEMISTRY-US, V28, P9795, DOI 10.1021/bi00451a038; LOHMAN TM, 1986, CRIT REV BIOCHEM MOL, V19, P191, DOI 10.3109/10409238609084656; LOSHON CA, 1986, J BACTERIOL, V167, P168, DOI 10.1128/jb.167.1.168-173.1986; MARQUIS RE, 1994, J APPL BACTERIOL, V76, pS40, DOI 10.1111/j.1365-2672.1994.tb04356.x; MASON JM, 1986, J BACTERIOL, V167, P174, DOI 10.1128/jb.167.1.174-178.1986; McAfee JG, 1996, BIOCHEMISTRY-US, V35, P4034, DOI 10.1021/bi952555q; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MOHR SC, 1991, P NATL ACAD SCI USA, V88, P77, DOI 10.1073/pnas.88.1.77; NICHOLSON WL, 1990, J BACTERIOL, V172, P6900, DOI 10.1128/jb.172.12.6900-6906.1990; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; SANCHEZSALAS JL, 1992, J BACTERIOL, V174, P807, DOI 10.1128/jb.174.3.807-814.1992; SANCHEZSALAS JL, 1992, BIOCHIMIE, V74, P651, DOI 10.1016/0300-9084(92)90137-4; SETLOW B, 1991, J BACTERIOL, V173, P1642, DOI 10.1128/jb.173.5.1642-1653.1991; SETLOW B, 1995, J BACTERIOL, V177, P4149, DOI 10.1128/jb.177.14.4149-4151.1995; SETLOW B, 1992, J BACTERIOL, V174, P2312, DOI 10.1128/JB.174.7.2312-2322.1992; SETLOW B, 1993, APPL ENVIRON MICROB, V59, P3418, DOI 10.1128/AEM.59.10.3418-3423.1993; SETLOW B, 1995, APPL ENVIRON MICROB, V61, P2787, DOI 10.1128/AEM.61.7.2787-2790.1995; SETLOW P, 1975, J BIOL CHEM, V250, P8159; SETLOW P, 1975, J BIOL CHEM, V250, P8168; SETLOW P, 1995, ANNU REV MICROBIOL, V49, P29, DOI 10.1146/annurev.mi.49.100195.000333; SETLOW P, 1994, J APPL BACTERIOL, V76, pS49, DOI 10.1111/j.1365-2672.1994.tb04357.x; SETLOW P, 1988, ANNU REV MICROBIOL, V42, P319, DOI 10.1146/annurev.mi.42.100188.001535; Setlow P., 1981, SPORULATION GERMINAT, P13; Sober H. A., 1970, HDB BIOCH SELECTED D; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SWERDLOW BM, 1981, J BACTERIOL, V148, P20, DOI 10.1128/JB.148.1.20-29.1981; TOVARROJO F, 1991, J BACTERIOL, V173, P4827, DOI 10.1128/jb.173.15.4827-4835.1991; URBANKE C, 1990, BIOCHEMISTRY-US, V29, P1744, DOI 10.1021/bi00459a012; VanGilst MR, 1997, BIOCHEMISTRY-US, V36, P1514, DOI 10.1021/bi961920q; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532	53	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35040	35050		10.1074/jbc.M005669200	http://dx.doi.org/10.1074/jbc.M005669200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954716	hybrid			2022-12-27	WOS:000165422800031
J	Kawashima, H; Hirose, M; Hirose, J; Nagakubo, D; Plaas, AHK; Miyasaka, M				Kawashima, H; Hirose, M; Hirose, J; Nagakubo, D; Plaas, AHK; Miyasaka, M			Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH ENDOTHELIAL VENULES; HYALURONAN-BINDING; MONOCLONAL-ANTIBODIES; HEPARAN-SULFATE; CELL-ADHESION; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; AMINO-TERMINUS; LIGAND; DOMAIN	Here:we show that a large chondroitin sulfate proteoglycan, versican, derived from a renal adenocarcinoma cell line ACHN, binds L-selectin, P-selectin, and CD44. The binding was mediated by the interaction of the chondroitin:sulfate (CS) chain of versican with the carbohydrate-binding domain of L- and P-selectin and CD44. The binding of versican to L- and P-selectin was inhibited by CS B, CS E, and heparan sulfate (HS) but not by: any other glycosaminoglycans tested. On the other hand, the binding to CD44 was inhibited by hyaluronic acid, chondroitin (CH), CS A, CS B, CS C, CS D, and CS E but not by HS or keratan sulfate. A cross-blocking study indicated that L- and P-selectin recognize: close or overlapping sites on versican, whereas CD44 recognizes separate sites. We also show that soluble L- and P-selectin directly bind to immobilized CS B, CS E, and HS and that soluble CD44 directly binds to immobilized hyaluronic acid, CH, and all the CS chains examined. Consistent with these results, structural analysis showed that versican is modified with at least CS B and CB C. Thus, proteoglycans sufficiently modified with the appropriate glycosaminoglycans should be able: to bind L-selectin, P-selectin, and/or CD44.	Osaka Univ, Grad Sch Med, Ctr Biomed Res, Dept Bioregulat, Suita, Osaka 5650871, Japan; Shriners Hosp Children, Cell Biol Lab, Tampa, FL 33612 USA	Osaka University	Miyasaka, M (corresponding author), Osaka Univ, Grad Sch Med, Ctr Biomed Res, Dept Bioregulat, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		まゆみ, 廣瀬/AAK-5735-2020; Nagakubo, Daisuke/AAW-3621-2021	Nagakubo, Daisuke/0000-0003-1213-1246				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; AVNUR Z, 1984, CELL, V38, P811, DOI 10.1016/0092-8674(84)90276-9; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; COUCHMAN JR, 1984, NATURE, V307, P650, DOI 10.1038/307650a0; CROVELLO CS, 1995, CELL, V82, P279, DOI 10.1016/0092-8674(95)90315-1; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Goda K, 1999, EUR J IMMUNOL, V29, P1551, DOI 10.1002/(SICI)1521-4141(199905)29:05<1551::AID-IMMU1551>3.0.CO;2-0; Hamai A, 1997, J BIOL CHEM, V272, P9123; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; Hwang ST, 1996, J EXP MED, V184, P1343, DOI 10.1084/jem.184.4.1343; IMAI Y, 1993, NATURE, V361, P555; JANDIK KA, 1994, GLYCOBIOLOGY, V4, P289, DOI 10.1093/glycob/4.3.289; Kawashima H, 1999, INT IMMUNOL, V11, P393, DOI 10.1093/intimm/11.3.393; Kinoshita A, 1997, J BIOL CHEM, V272, P19656, DOI 10.1074/jbc.272.32.19656; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Li RH, 1998, EUR J IMMUNOL, V28, P1745, DOI 10.1002/(SICI)1521-4141(199806)28:06<1745::AID-IMMU1745>3.0.CO;2-5; LIAO HX, 1995, J IMMUNOL, V155, P3938; LINDAHL U, 1979, P NATL ACAD SCI USA, V76, P3198, DOI 10.1073/pnas.76.7.3198; Mikhailov D, 1999, J BIOL CHEM, V274, P25317, DOI 10.1074/jbc.274.36.25317; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; NELSON RM, 1993, BLOOD, V82, P3253; Petersen F, 1999, J BIOL CHEM, V274, P12376, DOI 10.1074/jbc.274.18.12376; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; SCHLOSSMAN SF, 1995, LEUCOCYTE TYPING, V5, P1713; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; SORRELL JM, 1988, J IMMUNOL, V140, P4263; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TOYAMASORIMACHI N, 1994, INT IMMUNOL, V6, P655, DOI 10.1093/intimm/6.4.655; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Watanabe N, 1999, J BIOCHEM-TOKYO, V125, P826, DOI 10.1093/oxfordjournals.jbchem.a022355; Wolff EA, 1999, J BIOL CHEM, V274, P2518, DOI 10.1074/jbc.274.4.2518; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; ZHENG Z, 1995, J CELL BIOL, V130, P485, DOI 10.1083/jcb.130.2.485; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	61	207	213	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35448	35456		10.1074/jbc.M003387200	http://dx.doi.org/10.1074/jbc.M003387200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10950950	hybrid			2022-12-27	WOS:000165422800082
J	Martins, A; Shuman, S				Martins, A; Shuman, S			Mechanism of phosphoanhydride cleavage by baculovirus phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CAPPING ENZYME BINDS; MESSENGER-RNA; CRYSTAL-STRUCTURE; NUCLEOSIDE TRIPHOSPHATASE; CATALYTIC MECHANISM; TERMINAL DOMAIN; POLYMERASE; GUANYLYLTRANSFERASE; 5'-TRIPHOSPHATASE	Baculovirus phosphatase (BVP) is a member of the metazoan RNA triphosphatase enzyme family that includes the RNA triphosphatase component of the mRNA capping apparatus, BVP and other metazoan RNA triphosphatases belong to a superfamily of phosphatases that act via the formation and hydrolysis of a covalent cysteinyl-phosphate intermediate. Here we demonstrate the formation of a BVP phosphoenzyme upon reaction with [gamma-P-32]ATP and identify the linkage as a thiophosphate based on its chemical lability, We surmise:that the phosphate is linked to Cys(119) of BVP because replacement of Cys(119) by alanine or serine abrogates phosphoenzyme formation and phosphohydrolase activity. The catalytic cysteine is situated within a conserved phosphate-binding loop ((118)HCTHGINRTGY(128)). We show that all of the non-aliphatic side chains of the phosphate-binding loop are functionally important, insofar as mutants H118A, H121A, N124A, R125A, T126A, and Y128A were inactive in gamma phosphate hydrolysis and the T120A mutant was 7% as active as wild-type BVP, Structure-activity relationships at the essential positions: of the phosphate-binding loop were elucidated by conservative substitutions. A conserved aspartic acid (Asp(60)) invoked as a candidate general acid catalyst was dispensable for phosphohydrolase activity and phosphoenzyme formation by BVP, We propose that the low pK(a) of the bridging oxygen of the beta phosphate leaving group circumvents a requirement for expulsion by a proton donor during attack by cysteine on the gamma phosphorus. in contrast, a conserved aspartic acid is essential for the phosphomonoesterase reactions catalyzed by protein phosphatases, where the serine or tyrosine leaving groups have a much higher pK(a) than does ADP.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Martins, Alexandra/J-9592-2013	Martins, Alexandra/0000-0003-4322-8497				DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Deshpande T, 1999, J BIOL CHEM, V274, P16590, DOI 10.1074/jbc.274.23.16590; Evans B, 1996, BIOCHEMISTRY-US, V35, P13609, DOI 10.1021/bi9605651; Fjeld CC, 2000, J BIOL CHEM, V275, P6749, DOI 10.1074/jbc.275.10.6749; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Gross CH, 1998, J VIROL, V72, P7057, DOI 10.1128/JVI.72.9.7057-7063.1998; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HERR EB, 1957, BIOCHIM BIOPHYS ACTA, V25, P219, DOI 10.1016/0006-3002(57)90456-0; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Pei Y, 2000, NUCLEIC ACIDS RES, V28, P1885, DOI 10.1093/nar/28.9.1885; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; Rodriguez CR, 1999, NUCLEIC ACIDS RES, V27, P2181, DOI 10.1093/nar/27.10.2181; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Takagi T, 1998, P NATL ACAD SCI USA, V95, P9808, DOI 10.1073/pnas.95.17.9808; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V243, P101, DOI 10.1006/bbrc.1997.8038; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Yamada-Okabe T, 1998, NUCLEIC ACIDS RES, V26, P1700, DOI 10.1093/nar/26.7.1700; Yokoska J, 2000, BIOCHEM BIOPH RES CO, V268, P617, DOI 10.1006/bbrc.2000.2188; Yu L, 1997, J VIROL, V71, P9837, DOI 10.1128/JVI.71.12.9837-9843.1997; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	39	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35070	35076		10.1074/jbc.M005748200	http://dx.doi.org/10.1074/jbc.M005748200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954717	hybrid			2022-12-27	WOS:000165422800034
J	Baggio, L; Adatia, F; Bock, T; Brubaker, PL; Drucker, DJ				Baggio, L; Adatia, F; Bock, T; Brubaker, PL; Drucker, DJ			Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAGON-LIKE PEPTIDE-1; DEPENDENT INSULINOTROPIC POLYPEPTIDE; PROGLUCAGON GENE-TRANSCRIPTION; DIABETIC-PATIENTS; BODY-WEIGHT; FASTING HYPERGLYCEMIA; BIOLOGICAL-ACTIVITY; PROMOTES SATIETY; FUSION GENE; DB/DB MICE	Activation of glucagon-like peptide (GLP)-1 receptor signaling promotes glucose lowering via multiple mechanisms, including regulation of food intake, glucose-dependent insulin secretion, and stimulation of beta -cell mass. As GLP-1 exhibits a short t(1/2) in vivo, the biological consequences of prolonged GLP-1 receptor signaling remains unclear. To address this question, we have now generated metallothionein promoter-prepro exendin (MT-Ex) transgenic mice. MT-Ex mice process preproexendin correctly, as is made evident by detection of circulating plasma exendin-4 immunoreactivity using high pressure liquid chromatography and an exendin-4-specific radioimmunoassay, Despite elevated levels of exendin-4, fasting plasma glucose and glucose clearance following oral and intraperitoneal glucose tolerance tests are normal in MT-Ex mice. Induction of transgene expression significantly reduced glycemic excursion during both oral and intraperitoneal glucose tolerance tests (p < 0.05) and increased levels of glucose-stimulated insulin following oral glucose administration (p < 0.05), Despite evidence that exendin-4 may induce beta -cell proliferation, beta -cell mass and islet histology were normal in MT-Ex mice. MT-Ex mice exhibited no differences in basal food intake or body weight; however, induction of exendin-4 expression was associated with reduced short term food ingestion (p < 0.05), In contrast, short term water intake was significantly reduced in the absence of zinc in fluid-restricted MT-Ex mice (p < 0.05), These findings illustrate that sustained elevation of circulating exendin-4 is not invariably associated with changes in glucose homeostasis, increased beta -cell mass, or reduction in food intake in mice in vivo.	Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Med, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Lab Med & Pathobiol, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Physiol, Toronto, ON M5G 2C4, Canada; Kobenhavns Kommunehosp, Bartholin Inst, Copenhagen, Denmark	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Drucker, DJ (corresponding author), Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Med, 101 Coll St,CCRW3-845, Toronto, ON M5G 2C4, Canada.	d.drucker@utoronto.ca	Drucker, Daniel J/A-4092-2010					Bhavsar S, 1998, DIABETES, V47, pA192; BRUBAKER PL, 1992, J BIOL CHEM, V267, P20728; Burcelin R, 1999, ANN NY ACAD SCI, V875, P277, DOI 10.1111/j.1749-6632.1999.tb08510.x; Chen YQE, 1997, J BIOL CHEM, V272, P4108, DOI 10.1074/jbc.272.7.4108; Creutzfeldt WOC, 1996, DIABETES CARE, V19, P580, DOI 10.2337/diacare.19.6.580; DAlessio DA, 1996, J CLIN INVEST, V97, P133, DOI 10.1172/JCI118380; Deacon CF, 1998, DIABETOLOGIA, V41, P271, DOI 10.1007/s001250050903; DEACON CF, 1995, DIABETES, V44, P1126, DOI 10.2337/diabetes.44.9.1126; DEACON CF, 1995, J CLIN ENDOCR METAB, V80, P952, DOI 10.1210/jc.80.3.952; Dhanvantari S, 1996, MOL ENDOCRINOL, V10, P342, DOI 10.1210/me.10.4.342; Donahey JCK, 1998, BRAIN RES, V779, P75, DOI 10.1016/S0006-8993(97)01057-3; DRUCKER DJ, 1994, MOL ENDOCRINOL, V8, P1646, DOI 10.1210/me.8.12.1646; DRUCKER DJ, 1986, J BIOL CHEM, V261, P9637; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Edvell A, 1999, ENDOCRINOLOGY, V140, P778, DOI 10.1210/en.140.2.778; EHRLICH P, 1994, AM J PHYSIOL-ENDOC M, V267, pE662, DOI 10.1152/ajpendo.1994.267.5.E662; ENG J, 1992, J BIOL CHEM, V267, P7402; FEHMANN HC, 1991, ENDOCRINOLOGY, V128, P2880, DOI 10.1210/endo-128-6-2880; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; Flint A, 1998, J CLIN INVEST, V101, P515, DOI 10.1172/JCI990; Greig NH, 1999, DIABETOLOGIA, V42, P45, DOI 10.1007/s001250051111; Gromada J, 1996, BRIT J PHARMACOL, V118, P769, DOI 10.1111/j.1476-5381.1996.tb15466.x; Gutzwiller JP, 1999, AM J PHYSIOL-REG I, V276, pR1541, DOI 10.1152/ajpregu.1999.276.5.R1541; HENDRICK GK, 1993, METABOLISM, V42, P1, DOI 10.1016/0026-0495(93)90163-I; Hill ME, 1999, MOL ENDOCRINOL, V13, P1474, DOI 10.1210/me.13.9.1474; Holst JJ, 1998, DIABETES, V47, P1663, DOI 10.2337/diabetes.47.11.1663; JONES IR, 1987, DIABETOLOGIA, V30, P707, DOI 10.1007/BF00296993; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; Knudsen LB, 2000, J MED CHEM, V43, P1664, DOI 10.1021/jm9909645; KOLLIGS F, 1995, DIABETES, V44, P16, DOI 10.2337/diabetes.44.1.16; LOW MJ, 1985, CELL, V41, P211, DOI 10.1016/0092-8674(85)90075-3; Meeran K, 1999, ENDOCRINOLOGY, V140, P244, DOI 10.1210/en.140.1.244; Nauck MA, 1998, DIABETES CARE, V21, P1925, DOI 10.2337/diacare.21.11.1925; NAUCK MA, 1993, DIABETOLOGIA, V36, P741, DOI 10.1007/BF00401145; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; Pohl M, 1998, J BIOL CHEM, V273, P9778, DOI 10.1074/jbc.273.16.9778; Rachman J, 1996, DIABETES, V45, P1524, DOI 10.2337/diabetes.45.11.1524; Raufman JP, 1996, REGUL PEPTIDES, V61, P1, DOI 10.1016/0167-0115(96)00135-8; SCHEPP W, 1994, EUR J PHARM-MOLEC PH, V269, P183, DOI 10.1016/0922-4106(94)90085-X; Schirra J, 1998, J CLIN INVEST, V101, P1421, DOI 10.1172/JCI1349; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038/nm1196-1254; Scrocchi LA, 1998, ENDOCRINOLOGY, V139, P3127, DOI 10.1210/en.139.7.3127; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; Seeley RJ, 2000, ENDOCRINOLOGY, V141, P473, DOI 10.1210/en.141.2.473; Siegel EG, 1999, REGUL PEPTIDES, V79, P93, DOI 10.1016/S0167-0115(98)00155-4; Stoffers DA, 2000, DIABETES, V49, P741, DOI 10.2337/diabetes.49.5.741; Szayna M, 2000, ENDOCRINOLOGY, V141, P1936, DOI 10.1210/en.141.6.1936; TangChristensen M, 1996, AM J PHYSIOL-REG I, V271, pR848, DOI 10.1152/ajpregu.1996.271.4.R848; Todd JF, 1997, EUR J CLIN INVEST, V27, P533, DOI 10.1046/j.1365-2362.1997.1490691.x; Tseng CC, 1996, AM J PHYSIOL-ENDOC M, V270, pE661, DOI 10.1152/ajpendo.1996.270.4.E661; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; Wang YH, 1997, J CLIN INVEST, V99, P2883, DOI 10.1172/JCI119482; White SA, 1999, HORM METAB RES, V31, P519, DOI 10.1055/s-2007-978787; Widmann C, 1996, MOL ENDOCRINOL, V10, P62, DOI 10.1210/me.10.1.62; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270; Young AA, 1999, DIABETES, V48, P1026, DOI 10.2337/diabetes.48.5.1026; Zhou J, 1999, DIABETES, V48, P2358, DOI 10.2337/diabetes.48.12.2358	58	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34471	34477		10.1074/jbc.M005119200	http://dx.doi.org/10.1074/jbc.M005119200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10952981	hybrid			2022-12-27	WOS:000165095300064
J	Liou, JS; Chen, CY; Chen, JS; Faller, DV				Liou, JS; Chen, CY; Chen, JS; Faller, DV			Oncogenic Ras mediates apoptosis in response to protein kinase C inhibition through the generation of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; NF-KAPPA-B; ALKYL-PHOSPHOLIPID ANALOGS; GROWTH-FACTOR; HUMAN FIBROBLASTS; NADPH OXIDASE; PC12 CELLS; P53-INDEPENDENT APOPTOSIS; SIGNAL-TRANSDUCTION; CYTO-TOXICITY	Ras is a well established modulator of apoptosis. Suppression of protein kinase C (PKC) activity can selectively induce apoptosis in cells expressing a constitutively activated Ras protein. We wished to determine whether reactive oxygen species serve as an effector of Ras-mediated apoptosis. Ras-transformed NIH/3T3 cells contained higher basal levels of intracellular H2O2 compared with normal NIH/3T3 cells, and PKC inhibition up-regulated ROS to 5-fold greater levels in Ras-transformed cells than in normal cells. Treatment with N-acetyl-L-cysteine reduced both the basal and inducible levels of intracellular H2O2 in NIH/3T3-Ras cells and antagonized the induction of apoptosis by PKC inhibition. Culturing NIH/3T3-Ras cells in low oxygen conditions, which prevents ROS generation, also inhibited the apoptotic response to PKC inhibition. These results suggest that reactive oxygen species are necessary as downstream effecters of the Ras-mediated apoptotic response to PKC inhibition. However, the generation of ROS alone is not sufficient to induce apoptosis in Ras-transformed cells because inhibition of cell cycle progression prevented the induction of apoptosis in NIH/3T3-Ras cells without inhibiting the generation of intracellular H2O2 observed after PKC inhibition. These findings suggest that continued cell cycle progression of Ras-transformed cells during PKC inhibition is also necessary for the induction of apoptosis.	Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA	Boston University	Faller, DV (corresponding author), Boston Univ, Sch Med, Canc Res Ctr, 715 Albany St,Rm K-701, Boston, MA 02118 USA.				NCPDCID CDC HHS [NCI 50459] Funding Source: Medline	NCPDCID CDC HHS		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Anderson KM, 1999, MED HYPOTHESES, V52, P451, DOI 10.1054/mehy.1997.0521; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chen CY, 1998, CELL DEATH DIFFER, V5, P984, DOI 10.1038/sj.cdd.4400448; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Coopersmith CM, 1997, J CELL BIOL, V138, P167, DOI 10.1083/jcb.138.1.167; DANIEL LW, 1987, LIPIDS, V22, P851, DOI 10.1007/BF02535543; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; Foo SY, 1999, TRENDS GENET, V15, P229; FRENKEL K, 1987, CARCINOGENESIS, V8, P455, DOI 10.1093/carcin/8.3.455; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOFFMAN DR, 1986, CANCER RES, V46, P5803; HOFFMAN DR, 1984, BLOOD, V63, P545; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JANSSEN JWG, 1985, CANCER RES, V45, P3262; JANSSEN YMW, 1993, LAB INVEST, V69, P261; JONES SA, 1994, FEBS LETT, V355, P178, DOI 10.1016/0014-5793(94)01201-6; Joneson T, 1999, MOL CELL BIOL, V19, P5892; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King KL, 1998, ANNU REV PHYSIOL, V60, P601, DOI 10.1146/annurev.physiol.60.1.601; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; KRAMER IM, 1989, J BIOL CHEM, V264, P5876; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; LU Y, 1994, J IMMUNOL, V153, P1495; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Mills EM, 1998, J BIOL CHEM, V273, P22165, DOI 10.1074/jbc.273.35.22165; MOLLINEDO F, 1993, BIOCHEM BIOPH RES CO, V192, P603, DOI 10.1006/bbrc.1993.1458; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ohmori M, 1997, CANCER RES, V57, P4714; Parrizas M, 1997, BIOCHEM BIOPH RES CO, V234, P616, DOI 10.1006/bbrc.1997.6641; Parrizas M, 1997, J BIOL CHEM, V272, P154; PERRINE SP, 1994, BRIT J HAEMATOL, V88, P555, DOI 10.1111/j.1365-2141.1994.tb05073.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TIDWELL T, 1981, BLOOD, V57, P794; VANBLITTERSWIJK WJ, 1987, LIPIDS, V22, P820, DOI 10.1007/BF02535537; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANBLITTERSWIJK WJ, 1987, LIPIDS, V22, P842, DOI 10.1007/BF02535541; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Wagner BA, 1998, CANCER RES, V58, P2809; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	72	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39001	39011		10.1074/jbc.M007154200	http://dx.doi.org/10.1074/jbc.M007154200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10967125	hybrid			2022-12-27	WOS:000165953100010
J	Brehm, K; Jensen, K; Frosch, M				Brehm, K; Jensen, K; Frosch, M			mRNA trans-splicing in the human parasitic cestode Echinococcus multilocularis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; SCHISTOSOMA-MANSONI; LEADER RNA; CAENORHABDITIS-ELEGANS; SL-RNA; GENES; CDNA; SEQUENCES; IDENTIFICATION; PROTEIN	An identical 36-nucleotide exon was identified at the 5' termini of different mRNAs from the cestode Echinococcus multilocularis. We provide evidence that this exon constitutes a new spliced leader (SL) that is obviously trans-spliced to echinococcal pre-mRNAs, donated by a non-polyadenylated, trimethylguanosine-capped SL-RNA of 104 nucleotides. Sequence comparisons indicated that cestode and trematode SLs are likely to be derived from a common ancestor gene. No conservation was, however, observed concerning the spectrum of mRNAs that is trans-spliced in cestodes and trematodes, indicating that trans-splicing of a particular flatworm mRNA is not correlated with the function of the encoded protein. We also show that the echinococcal gene elp, encoding a member of the ezrin/radixin/moesin protein family, is expressed via two alternative transcripts, spliced either cis or trans at an identical splice acceptor site. This was accompanied by the formation of different elp primary transcripts, harboring a complete or a truncated upstream intron, which supports the hypothesis that alternative cis/trans-splicing depends on the presence or absence of an upstream splice donor site. A putative SL gene was also identified on chromosomal DNA of Echinococcus granulosus, indicating widespread utilization of trans-splicing in the genus.	Univ Wurzburg, Inst Hyg & Mikrobiol, D-97080 Wurzburg, Germany	University of Wurzburg	Brehm, K (corresponding author), Univ Wurzburg, Inst Hyg & Mikrobiol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.		Frosch, Matthias/H-2411-2013					ADAMS DS, 1987, GENE, V54, P93, DOI 10.1016/0378-1119(87)90351-9; ADAMS DS, 1985, BIOCHEMISTRY-US, V24, P117, DOI 10.1021/bi00322a017; AKSOY S, 1992, GENE, V113, P239, DOI 10.1016/0378-1119(92)90401-A; Blaxter M, 1996, INT J PARASITOL, V26, P1025, DOI 10.1016/S0020-7519(96)00060-4; Blaxter ML, 1996, MOL BIOCHEM PARASIT, V77, P77, DOI 10.1016/0166-6851(96)02571-6; BLUMENTHAL T, 1995, TRENDS GENET, V11, P132, DOI 10.1016/S0168-9525(00)89026-5; Brehm K, 1999, MOL BIOCHEM PARASIT, V100, P147, DOI 10.1016/S0166-6851(99)00051-1; Brehm K, 2000, MOL BIOCHEM PARASIT, V107, P297, DOI 10.1016/S0166-6851(00)00178-X; Carranza S, 1997, MOL BIOL EVOL, V14, P485, DOI 10.1093/oxfordjournals.molbev.a025785; CONRAD R, 1993, EMBO J, V12, P1249, DOI 10.1002/j.1460-2075.1993.tb05766.x; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; Davis RE, 1997, MOL BIOCHEM PARASIT, V89, P25, DOI 10.1016/S0166-6851(97)00097-2; DAVIS RE, 1995, J BIOL CHEM, V270, P21813, DOI 10.1074/jbc.270.37.21813; Davis RE, 1997, MOL BIOCHEM PARASIT, V87, P29, DOI 10.1016/S0166-6851(97)00040-6; Davis RE, 1996, PARASITOL TODAY, V12, P33, DOI 10.1016/0169-4758(96)80643-0; DAVIS RE, 1994, J BIOL CHEM, V269, P20026; DIVIACCO S, 1992, GENE, V122, P313, DOI 10.1016/0378-1119(92)90220-J; DONELSON JE, 1990, PARASITOL TODAY, V6, P327, DOI 10.1016/0169-4758(90)90177-6; El-Dabaa E, 1998, J PARASITOL, V84, P954, DOI 10.2307/3284627; ELSAYED NMA, 1995, MOL BIOCHEM PARASIT, V73, P75, DOI 10.1016/0166-6851(95)00098-L; FROSCH PM, 1994, PARASITOL RES, V80, P703, DOI 10.1007/BF00932958; Hamdan FF, 1998, PARASITOL RES, V84, P839, DOI 10.1007/s004360050497; HEMMINGS L, 1991, MOL BIOCHEM PARASIT, V44, P53, DOI 10.1016/0166-6851(91)90220-Z; HENKLEDUHRSEN K, 1995, BIOCHEM J, V308, P441, DOI 10.1042/bj3080441; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hubert K, 1999, CELL MOTIL CYTOSKEL, V42, P178, DOI 10.1002/(SICI)1097-0169(1999)42:3<178::AID-CM2>3.3.CO;2-V; Jura H, 1996, INFECT IMMUN, V64, P3484, DOI 10.1128/IAI.64.9.3484-3490.1996; Keiper BD, 2000, J BIOL CHEM, V275, P10590, DOI 10.1074/jbc.275.14.10590; KELLER M, 1992, NUCLEIC ACIDS RES, V20, P1711, DOI 10.1093/nar/20.7.1711; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kurtis JD, 1997, INFECT IMMUN, V65, P344, DOI 10.1128/IAI.65.1.344-347.1997; Levick MP, 1996, MOL BIOCHEM PARASIT, V76, P345, DOI 10.1016/0166-6851(95)02569-3; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; MARONEY PA, 1995, RNA, V1, P714; MARTIN SAM, 1995, MOL BIOCHEM PARASIT, V70, P241, DOI 10.1016/0166-6851(95)00032-V; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MCMANUS DP, 1985, MOL BIOCHEM PARASIT, V16, P251, DOI 10.1016/0166-6851(85)90068-4; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; NILSEN TW, 1995, MOL BIOCHEM PARASIT, V73, P1, DOI 10.1016/0166-6851(94)00107-X; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; Rausch Robert L., 1995, P89; Reddy NRJ, 1996, BIOTECHNIQUES, V21, P868; ROSS LH, 1995, J BIOL CHEM, V270, P22066, DOI 10.1074/jbc.270.37.22066; SHIWAKU K, 1995, BIOCHEM BIOPH RES CO, V211, P49, DOI 10.1006/bbrc.1995.1776; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; VANDOREN K, 1990, MOL CELL BIOL, V10, P1796	47	72	90	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38311	38318		10.1074/jbc.M006091200	http://dx.doi.org/10.1074/jbc.M006091200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10973970	hybrid			2022-12-27	WOS:000165739800026
J	Stanhope-Baker, P; Williams, BRG				Stanhope-Baker, P; Williams, BRG			Identification of connective tissue growth factor as a target of WT1 transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSOR WT1; DENYS-DRASH SYNDROME; FACTOR BINDING-PROTEINS; IMMEDIATE-EARLY GENE; I RECEPTOR GENE; WILMS-TUMOR; DNA-BINDING; OLIGONUCLEOTIDE ARRAYS; NOV PROTOONCOGENE; SELF-ASSOCIATION	The Wilms tumor suppressor WT1 has transcription-activating and -suppressing capabilities. WT1-responsive promoters have been described; however, in large part, it remains unclear which potential downstream genes are physiologically relevant and mediate the function of WT1 in tumorigenesis and development. To identify genes regulated by WT1 in vivo, we used a dominant-negative version of WT1 to modulate WT1 activity in a Wilms tumor cell line. Screening oligonucleotide arrays with RNA from these cells uncovered a number of genes whose expression was altered by abrogation of WT1 function. Several of the genes encode members of the CCN family of growth regulators. The promoter of one of these genes, connective tissue growth factor (CTGF), is suppressed by WT1 both in its endogenous location and in reporter constructs. WT1 regulation of CTGF expression is not mediated by previously identified WT1 recognition elements and may therefore involve a novel mechanism. Our results indicate that CTGF is a bona fide target of WT1 transcriptional suppression and likely plays a role in Wilms tumorigenesis and associated disease syndromes.	Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Williams, BRG (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Mail Code NB40,9500 Euclid Ave, Cleveland, OH 44195 USA.	williab@ccf.org	Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				Babic AM, 1999, MOL CELL BIOL, V19, P2958; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; Borel F, 1996, BIOCHEMISTRY-US, V35, P12070, DOI 10.1021/bi960758o; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; COPPES MJ, 1995, WILMS TUMOR CLIN MOL; DEPLAEN E, 1994, IMMUNOGENETICS, V40, P360, DOI 10.1007/BF01246677; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DROP SLS, 1992, GROWTH REGULAT, V2, P69; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Duarte A, 1998, BRIT J CANCER, V77, P253, DOI 10.1038/bjc.1998.41; Englert C, 1998, TRENDS BIOCHEM SCI, V23, P389, DOI 10.1016/S0968-0004(98)01277-8; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hastie Nicholas D., 1992, Human Molecular Genetics, V1, P293; Holmes G, 1997, BIOCHEM BIOPH RES CO, V233, P723, DOI 10.1006/bbrc.1997.6545; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kato MV, 1996, ONCOGENE, V12, P1361; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; LITTLE M, 1995, HUM MOL GENET, V4, P351, DOI 10.1093/hmg/4.3.351; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Martinerie C, 1996, ONCOGENE, V12, P1479; MARTINERIE C, 1994, ONCOGENE, V9, P2729; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOFFETT P, 1995, P NATL ACAD SCI USA, V92, P11105, DOI 10.1073/pnas.92.24.11105; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; *PE APPL BIOS, 1997, ABI PRISM 7700 SEQ D; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; Sakamoto Y, 1997, ONCOGENE, V15, P2001, DOI 10.1038/sj.onc.1201391; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yamanaka Y, 1997, J BIOL CHEM, V272, P30729, DOI 10.1074/jbc.272.49.30729; Ye Y, 1996, EMBO J, V15, P5606, DOI 10.1002/j.1460-2075.1996.tb00945.x	57	33	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38139	38150		10.1074/jbc.M004901200	http://dx.doi.org/10.1074/jbc.M004901200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10973960	hybrid			2022-12-27	WOS:000165739800004
J	Bohme, CC; Arscott, LD; Becker, K; Schirmer, RH; Williams, CH				Bohme, CC; Arscott, LD; Becker, K; Schirmer, RH; Williams, CH			Kinetic characterization of glutathione reductase from the malarial parasite Plasmodium falciparum - Comparison with the human enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DEFICIENT ERYTHROCYTES; OXIDATIVE STRESS; PYRIDINE; DEHYDROGENASE; YEAST; SITE; 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA; DISULFIDE; MECHANISM	The homodimeric flavoenzyme glutathione reductase (GR) maintains high intracellular concentrations of the antioxidant glutathione (GSSG + NADPH + H+ <----> 2 GSH + NADP(+)), Due to its central function in cellular redox metabolism, inhibition of GR from the malarial parasite Plasmodium falciparum represents an important approach to antimalarial drug development; therefore, the catalytic mechanism of GR from P. falciparum has been analyzed and compared with the human host enzyme. The reductive half-reaction is similar to the analogous reaction with GR from other species. The oxidative half-reaction is biphasic, reflecting formation and breakdown of a mixed disulfide between the interchange thiol and GSH, The equilibrium between the E-ox-EH2 and GSSG-GSH couples has been modeled showing that the Michaelis complex, mixed disulfide-GSH, is the predominant enzyme form as the oxidative half-reaction progresses; rate constants used in modeling allow calculation of an K-eq from the Haldane relationship, 0.075, very similar to the K-eq of the same reaction for the yeast enzyme (0.085) (Arscott, L. D., Veine, D, M., and Williams, C. H., Jr. (2000) Biochemistry 39, 4711-4721). Enzyme-monitored turnover indicates that E(FADH(-))(S-S).NADP(+) and E(FAD)(SH)(2).NADPH are dominant enzyme species in turnover. Since the individual forms of the enzyme differ in their susceptibility to inhibitors, the prevailing states of GR in the cell are of practical relevance.	Vet Affairs Med Ctr, Res Serv 151, Ann Arbor, MI 48105 USA; Heidelberg Univ, Ctr Biochem, D-69120 Heidelberg, Germany; Univ Wurzburg, Res Ctr Infect Dis, D-97070 Wurzburg, Germany; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Ruprecht Karls University Heidelberg; University of Wurzburg; University of Michigan System; University of Michigan	Williams, CH (corresponding author), Vet Affairs Med Ctr, Res Serv 151, 2215 Fuller Rd, Ann Arbor, MI 48105 USA.	chaswill@umich.edu			NIGMS NIH HHS [GM21444] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arscott LD, 2000, BIOCHEMISTRY-US, V39, P4711, DOI 10.1021/bi9926431; ARSCOTT LD, 1981, BIOCHEMISTRY-US, V20, P1513, DOI 10.1021/bi00509a016; AUKRUST P, 1995, BLOOD, V86, P1383, DOI 10.1182/blood.V86.4.1383.bloodjournal8641383; BECKER K, 1995, METHOD ENZYMOL, V251, P173, DOI 10.1016/0076-6879(95)51120-2; BECKER K, 1994, HISTOCHEMISTRY, V102, P389, DOI 10.1007/BF00268910; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; Beutler E, 1984, RED CELL METABOLISM, P68; CALDINI R, 1992, J CELL PHYSIOL, V151, P172, DOI 10.1002/jcp.1041510122; CANEPA L, 1991, BIOCHIM BIOPHYS ACTA, V1074, P101, DOI 10.1016/0304-4165(91)90046-J; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; DAVIS RE, 1960, J AM CHEM SOC, V82, P5949, DOI 10.1021/ja01507a039; ENGEL PC, 1967, BIOCHEM J, V105, P691, DOI 10.1042/bj1050691; Farber PM, 1998, FEBS LETT, V422, P311, DOI 10.1016/S0014-5793(98)00031-3; Farber PM, 1996, EUR J BIOCHEM, V239, P655, DOI 10.1111/j.1432-1033.1996.0655u.x; Gilberger TW, 2000, MOL BIOCHEM PARASIT, V107, P169, DOI 10.1016/S0166-6851(00)00188-2; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Golden MHN, 1998, BRIT MED BULL, V54, P433, DOI 10.1093/oxfordjournals.bmb.a011699; Guttmann P., 1891, BERLIN KLIN WOCH, P953; HOPKINS N, 1995, BIOCHEMISTRY-US, V34, P11766, DOI 10.1021/bi00037a014; HUBER PW, 1980, BIOCHEMISTRY-US, V19, P4568, DOI 10.1021/bi00561a005; HUNT NH, 1990, BLOOD CELLS, V16, P499; Jocelyn P. C., 1972, BIOCH SH GROUP, P10; KARPLUS PA, 1988, EUR J BIOCHEM, V171, P193, DOI 10.1111/j.1432-1033.1988.tb13775.x; KARPLUS PA, 1989, EUR J BIOCHEM, V178, P693, DOI 10.1111/j.1432-1033.1989.tb14500.x; Krauth-Siegel RL, 1998, BIOCHEMISTRY-US, V37, P13968, DOI 10.1021/bi980637j; KrauthSiegel RL, 1996, EUR J BIOCHEM, V235, P345, DOI 10.1111/j.1432-1033.1996.00345.x; Lennon BW, 1997, BIOCHEMISTRY-US, V36, P9464, DOI 10.1021/bi970307j; MARQUARDT DW, 1963, J MOL BIOL, V95, P701; MASSEY V, 1965, J BIOL CHEM, V240, P4470; MILLER H, 1991, J BIOL CHEM, V266, P19342; PAI EF, 1983, J BIOL CHEM, V258, P1752; RIETVELD P, 1994, BIOCHEMISTRY-US, V33, P13888, DOI 10.1021/bi00250a043; Schirmer M, 1999, FLAVINS FLAVOPROTEIN, P857; SCHIRMER M, 1908, FLAVINS FLAVOPROTEIN; SCHIRMER RH, 1988, COENZYMES COFACTORS, P553; SCHIRMER RH, 1987, COENZYMES COFACTORS, P333; Veine DM, 1998, BIOCHEMISTRY-US, V37, P15575, DOI 10.1021/bi9811314; VENNERSTROM JL, 1995, ANTIMICROB AGENTS CH, V39, P2671, DOI 10.1128/AAC.39.12.2671; Williams C H Jr, 1979, Methods Enzymol, V62, P185; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; WONG KK, 1988, BIOCHEMISTRY-US, V27, P7091, DOI 10.1021/bi00418a063; ZHANG Y, 1988, BIOCHEM PHARMACOL, V37, P861, DOI 10.1016/0006-2952(88)90173-6	42	52	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37317	37323		10.1074/jbc.M007695200	http://dx.doi.org/10.1074/jbc.M007695200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10969088	hybrid			2022-12-27	WOS:000165618700004
J	Casolaro, V; Keane-Myers, AM; Swendeman, SL; Steindler, C; Zhong, FM; Sheffery, M; Georas, SN; Ono, SJ				Casolaro, V; Keane-Myers, AM; Swendeman, SL; Steindler, C; Zhong, FM; Sheffery, M; Georas, SN; Ono, SJ			Identification and characterization of a critical CP2-binding element in the human interleukin-4 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CP2; HELPER CELL SUBSETS; STAGE SELECTOR PROTEIN; IL-4 GENE-EXPRESSION; SIMPLEX VIRUS TYPE-1; LONG TERMINAL REPEAT; ACTIVATED T-CELLS; DNA-BINDING; NUCLEAR FACTOR; IN-VITRO	Expression of cytokine genes in T cells is thought to result from a complex network of antigen- and mitogen-activated transcriptional regulators. CP2, a factor homologous to Drosophila Elf-1 and previously found to be a critical regulator of several viral and cellular genes in response to developmental signals, is rapidly activated in T helper (Th) cells in response to mitogenic stimulation. Here we show that overexpression of CP2 enhances interleukin (IL)-4 promoter-driven chloramphenicol acetyltransferase expression, while repressing IL-2 promoter activity, in transiently transfected Jurkat cells. A CP2-protected element, partially overlapping the nuclear factor of activated T cell-binding P2 sequence, was required for IL-4 promoter activation in CPS-overexpressing Jurkat cells. This CPS-response element is the site of a cooperative interaction between CP2 and an inducible heteromeric co-factor(s). Mutation of conserved nucleotide contacts within the CPa-response element prevented CP2 binding and significantly reduced constitutive and induced IL-4 promoter activity. Expression of a CP2 mutant lacking the Elf-l-homology region of the DNA-binding domain inhibited IL-4 promoter activity in a dominant negative fashion in transiently transfected Jurkat cells. Moreover, overexpressed CP2 markedly enhanced, while its dominant negative mutant consistently suppressed, expression of the endogenous IL-4 gene in the murine Th2 cell line DIG. Taken together, these findings point to CP2 as a critical IL-4 transactivator in Th cells.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21224 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Comm Immunol, Boston, MA 02114 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02114 USA; Cornell Univ, Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Mem Sloan Kettering Canc Ctr, Grad Sch Med Sci, New York, NY 10021 USA	Johns Hopkins University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Schepens Eye Research Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Casolaro, V (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21224 USA.	casolaro@mail.jhmi.edu	Casolaro, Vincenzo/E-9144-2010	Casolaro, Vincenzo/0000-0001-9810-0488	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI001152, R29AI041463, Z01AI000888, R01AI041463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049661] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41463, AI01152] Funding Source: Medline; NIGMS NIH HHS [GM49661] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI N, 1989, J IMMUNOL, V142, P274; Belichon S, 1996, ACTA OECOL, V17, P503; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; CASOLARO V, 1995, P NATL ACAD SCI USA, V92, P11623, DOI 10.1073/pnas.92.25.11623; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; Cron RQ, 1999, J IMMUNOL, V162, P860; CUNNINGHAM JM, 1995, GENOMICS, V30, P398; Cunningham JM, 1995, BLOOD, V86, P4; DABROWSKI CE, 1994, MOL CELL BIOL, V14, P2545, DOI 10.1128/MCB.14.4.2545; FITCH FW, 1993, ANNU REV IMMUNOL, V11, P29, DOI 10.1146/annurev.immunol.11.1.29; Georas S, 2000, LEUKEMIA, V14, P629, DOI 10.1038/sj.leu.2401712; Georas SN, 1998, BLOOD, V92, P4529, DOI 10.1182/blood.V92.12.4529.424k39_4529_4538; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Ikuta T, 1998, ANN NY ACAD SCI, V850, P87, DOI 10.1111/j.1749-6632.1998.tb10466.x; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; KIM CG, 1990, MOL CELL BIOL, V10, P5958, DOI 10.1128/MCB.10.11.5958; KleinHessling S, 1996, P NATL ACAD SCI USA, V93, P15311, DOI 10.1073/pnas.93.26.15311; LEDERER JA, 1994, J IMMUNOL, V152, P77; Lederer JA, 1996, J EXP MED, V184, P397, DOI 10.1084/jem.184.2.397; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883; LIM LC, 1993, J BIOL CHEM, V268, P18008; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; LIWEBER M, 1994, J IMMUNOL, V153, P4122; MIN LW, 1992, J IMMUNOL, V148, P1913; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; PARADA CA, 1995, J BIOL CHEM, V270, P2274, DOI 10.1074/jbc.270.5.2274; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHIRRA MK, 1994, MOL CELL BIOL, V14, P5076, DOI 10.1128/MCB.14.8.5076; Shirra MK, 1998, J BIOL CHEM, V273, P19260, DOI 10.1074/jbc.273.30.19260; SIGMAN DS, 1990, BIOCHEMISTRY-US, V29, P9097, DOI 10.1021/bi00491a001; SONG ZM, 1994, J EXP MED, V180, P1763, DOI 10.1084/jem.180.5.1763; SUEYOSHI T, 1995, MOL CELL BIOL, V15, P4158; Takemoto N, 1997, INT IMMUNOL, V9, P1329, DOI 10.1093/intimm/9.9.1329; UV AE, 1994, MOL CELL BIOL, V14, P4020, DOI 10.1128/MCB.14.6.4020; Volker JL, 1997, GENE DEV, V11, P1435, DOI 10.1101/gad.11.11.1435; WEINBERG AD, 1990, J IMMUNOL, V144, P1800; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; ZHONG FM, 1994, J BIOL CHEM, V269, P21269	41	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36605	36611		10.1074/jbc.M007086200	http://dx.doi.org/10.1074/jbc.M007086200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973979	hybrid			2022-12-27	WOS:000165577700022
J	Bahr, C; Rohwer, A; Stempka, L; Rincke, G; Marks, F; Gschwendt, M				Bahr, C; Rohwer, A; Stempka, L; Rincke, G; Marks, F; Gschwendt, M			DIK, a novel protein kinase that interacts with protein kinase C delta - Cloning, characterization, and gene analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; PKC-DELTA; PROTEOLYTIC ACTIVATION; TUMOR PROMOTION; PHORBOL ESTER; CELLS; EXPRESSION; APOPTOSIS; KERATINOCYTES	A novel serine/threonine kinase, termed DIK, was cloned-using the yeast two-hybrid system to screen a cDNA library from the human keratinocyte cell line Ha-CaT with the catalytic domain of rat protein kinase C6 (PKC delta (cat)) CDNA as bait. The predicted 784-amino acid polypeptide with a calculated molecular mass of 86 kDa contains a-catalytic kinase domain and a putative regulatory domain with ankyrin-like repeats and a nuclear localization signal. Expression of DIK at the mRNA and protein level could be demonstrated in several cell lines. The dik gene is located on chromosome 21q22.3 and possesses 8 exons and 7 introns, DIK was synthesized in an in vitro transcription/translation system and expressed:as recombinant protein in bacteria, HEK, COS-7, and baculovirus-infected insect cells. In the in vitro system and in cells, but not in bacteria, various post-translationally modified forms of DIK were produced. DM was shown to exhibit protein kinase activity toward autophosphorylation and substrate phosphorylation. The interaction of PKC delta (cat) and PKC delta with DIK was confirmed by coimmunoprecipitation of the proteins from HEK cells transiently transfected with PRC delta (cat) or PKC gamma and DIK expression constructs.	German Canc Res Ctr, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Gschwendt, M (corresponding author), German Canc Res Ctr, D-69120 Heidelberg, Germany.	m.gschwendt@dkfz.de						Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Blobe GC, 1996, CANCER SURV, V27, P213; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CUTLER RE, 1994, ENDOCRINOLOGY, V135, P1669, DOI 10.1210/en.135.4.1669; Dekker LV, 1997, J BIOL CHEM, V272, P12747, DOI 10.1074/jbc.272.19.12747; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Ettinger SL, 1996, J BIOL CHEM, V271, P14514, DOI 10.1074/jbc.271.24.14514; FUJISE A, 1994, J BIOL CHEM, V269, P31642; GEIGES D, 1995, EXP CELL RES, V219, P299, DOI 10.1006/excr.1995.1231; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; GSCHWENDT M, 1994, FEBS LETT, V338, P85, DOI 10.1016/0014-5793(94)80121-5; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Izumi Y, 1997, J BIOL CHEM, V272, P7381, DOI 10.1074/jbc.272.11.7381; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; LAPORTA CAM, 1995, CARCINOGENESIS, V16, P1233; Li LW, 1999, MOL CELL BIOL, V19, P8547; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LIAO L, 1994, CELL GROWTH DIFFER, V5, P1185; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Marks Friedrich, 1996, P81, DOI 10.1002/9783527615032.ch3; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Raveh T, 2000, P NATL ACAD SCI USA, V97, P1572, DOI 10.1073/pnas.020519497; Reddig PJ, 1999, CANCER RES, V59, P5710; Schullery DS, 1999, J BIOL CHEM, V274, P15101, DOI 10.1074/jbc.274.21.15101; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Shanmugam M, 1999, MOL CELL ENDOCRINOL, V148, P109, DOI 10.1016/S0303-7207(98)00229-9; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; ZANG R, 1994, BIOCHEM J, V304, P641, DOI 10.1042/bj3040641	47	45	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36350	36357		10.1074/jbc.M004771200	http://dx.doi.org/10.1074/jbc.M004771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10948194	hybrid			2022-12-27	WOS:000165382000099
J	Bang, S; Jeong, EJ; Kim, IK; Jung, YK; Kim, KS				Bang, S; Jeong, EJ; Kim, IK; Jung, YK; Kim, KS			Fas- and tumor necrosis factor-mediated apoptosis uses the same binding surface of FADD to trigger signal transduction - A typical model for convergent signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-ASSOCIATED PROTEIN TRADD; DEATH DOMAIN; CELL-DEATH; TNF RECEPTOR; MUTATIONAL ANALYSIS; CD95 FAS/APO-1; COMPLEX; PATHWAYS; ANTIGEN	FADD is known to function as a common signaling conduit in Fas- and tumor necrosis factor (TNF)-mediated apoptosis, The convergent death signals from the Fas receptor and TNF receptor 1 are transferred to FADD by death domain interactions triggering the same cellular event, caspase-8 activation. In this work, we investigated whether the same binding surface of FADD is used for both signaling pathways by using FADD death domain mutants. Mutations in helices alpha2 and alpha3 of the FADD death domain, the interacting surface with the Fas death domain, affected TNF-mediated apoptosis to various extents. This indicated that TNF-mediated apoptosis uses the same binding surface of the FADD death domain as Fas-mediated apoptosis. The binding specificity is not the same, however. Some mutations affected the binding affinity of the Fas death domain for the FADD death domain, but did not influence TNF-mediated apoptosis and vice versa, Interestingly, all mutants tested that affected TNF-mediated apoptosis have structural perturbations, implying that the structural integrity, involving helices alpha2 and alpha3 in particular, is critical in TNF-mediated apoptosis. Our results suggest that different signaling molecules use a similar structural interaction to trigger the same cellular event, such as caspase-8 recruitment, which could be typical in convergent signal transduction.	Korea Inst Sci & Technol, Struct Biol Ctr, Seoul 130650, South Korea; Kwangju Inst Sci & Technol, Dept Life Sci, Puk Gu, Kwangju 500712, South Korea	Korea Institute of Science & Technology (KIST); Gwangju Institute of Science & Technology (GIST)	Kim, KS (corresponding author), Korea Inst Sci & Technol, Struct Biol Ctr, Cheongryang Box 131, Seoul 130650, South Korea.			Jung, Yong-Keun/0000-0002-9686-3120				Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; ITOH N, 1993, J BIOL CHEM, V268, P10932; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Martinez O M, 1999, Int Rev Immunol, V18, P527, DOI 10.3109/08830189909088497; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Park A, 1996, J BIOL CHEM, V271, P9858, DOI 10.1074/jbc.271.16.9858; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wallach D, 1996, Behring Inst Mitt, P144; WONG GHW, 1994, J IMMUNOL, V152, P1751; Xiao T, 1999, CELL, V99, P545, DOI 10.1016/S0092-8674(00)81542-1; Zhang J, 1996, MOL CELL BIOL, V16, P2756	26	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36217	36222		10.1074/jbc.M006620200	http://dx.doi.org/10.1074/jbc.M006620200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10952991	hybrid			2022-12-27	WOS:000165382000081
J	Roshak, AK; Capper, EA; Stevenson, C; Eichman, C; Marshall, LA				Roshak, AK; Capper, EA; Stevenson, C; Eichman, C; Marshall, LA			Human calcium-independent phospholipase A(2) mediates lymphocyte proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID MOBILIZATION; CYTOSOLIC PHOSPHOLIPASE-A2; RECOMBINANT EXPRESSION; P388D(1) MACROPHAGES; ANTISENSE INHIBITION; BROMOENOL LACTONE; GENE-EXPRESSION; SYNOVIAL-FLUID; CELL-CYCLE; METABOLISM	Activation of lymphocytes induces blastogenesis and cell division which is accompanied by membrane lipid metabolism such as increased fatty acid turnover. To date little is known about the enzymatic mechanism(s) regulating this process. Release of fatty acids such as arachidonic acid requires sn-2-deacylation catalyzed by a class of enzymes known as phospholipases A, (PLA,, EC 3.1.1.4), Herein, we confirm that human peripheral blood B or T lymphocytes (PBL) do not possess measurable levels of 85-kDa PLA(2) as assessed by Western immunoblot, Low levels of 14-kDa PLA(2) protein and activity were detectable in the particulate fraction of PBL and Jurkat cells. Western immunoblot analysis indicates that PBLs possess the calcium-independent PLA, (iPLA(2)) protein. Calcium-independent sn-2-acylhydrolytic activity was measurable in PBL cytosols and could be inhibited by the selective iPLA(2) inhibitor bromoenol lactone, Mitogen activation of PBLs resulted in maintenance of activity levels which remained constant over 72 h suggesting an important role for iPLA(2) in this proliferative process. Indeed, evaluation of iPLA(2) activity in cell cycle-arrested Jurkat T cell fractions revealed the highest iPLA(2) levels occurring at the G(2)/M phase. Addition of the iPLA(2) inhibitors, bromoenol lactone, or arachidonyl trifluoromethyl ketone (AAOCF(3)), inhibited both mitogen-induced PBL as well as Jurkat T cell proliferation. Moreover, specific depletion of iPLA(2) protein by antisense treatment also resulted in marked suppression of cell division. Inhibition of Jurkat cell proliferation was not associated with arrest at a particular phase of the cell cycle nor was it associated with apoptosis as assessed by flow cytometry, These findings provide the first evidence that iPLA(2) plays a key role in the lymphocyte proliferative response.	SmithKline Beecham Pharmaceut, Dept Immunol, King Of Prussia, PA 19406 USA	GlaxoSmithKline	Roshak, AK (corresponding author), SmithKline Beecham Pharmaceut, Dept Immunol, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.			Spudich, Elizabeth/0000-0002-6223-8271				ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Akiba S, 1998, FEBS LETT, V437, P225, DOI 10.1016/S0014-5793(98)01236-8; Anderson KM, 1997, J BIOL CHEM, V272, P30504, DOI 10.1074/jbc.272.48.30504; Balboa MA, 1998, J BIOL CHEM, V273, P7684, DOI 10.1074/jbc.273.13.7684; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8531; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BROOKS R, 1993, CELL CYCLE PRACTICAL, P1; CHEN J, 1994, J BIOL CHEM, V269, P2365; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CROWL RM, 1991, J BIOL CHEM, V266, P2647; Gilbert JJ, 1996, J IMMUNOL, V156, P2054; GOPPELT M, 1985, BIOCHIM BIOPHYS ACTA, V833, P463, DOI 10.1016/0005-2760(85)90104-3; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; KANDA A, 1989, BIOCHEM BIOPH RES CO, V163, P42, DOI 10.1016/0006-291X(89)92096-2; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LAI CY, 1988, BIOCHEM BIOPH RES CO, V157, P488, DOI 10.1016/S0006-291X(88)80275-4; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; MARSHALL LA, 1994, J PHARMACOL EXP THER, V268, P709; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; Marshall LA, 1997, J BIOL CHEM, V272, P759, DOI 10.1074/jbc.272.2.759; MARSHALL LA, 1993, BIOCHEM CELL BIOL, V71, P331, DOI 10.1139/o93-050; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; OKA S, 1991, J BIOL CHEM, V266, P9956; PONTUS KA, 1998, FEBS LETT, V434, P295; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; RESCH K, 1981, EUR J BIOCHEM, V115, P247, DOI 10.1111/j.1432-1033.1981.tb05230.x; RESCH K, 1972, EUR J BIOCHEM, V27, P153, DOI 10.1111/j.1432-1033.1972.tb01821.x; RODE HN, 1982, BIOCHIM BIOPHYS ACTA, V688, P66, DOI 10.1016/0005-2736(82)90579-X; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Roshak A, 1996, J RHEUMATOL, V23, P420; Roshak AK, 1999, J LEUKOCYTE BIOL, V65, P43, DOI 10.1002/jlb.65.1.43; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V248, P1; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; TRAMPOSCH KM, 1994, J PHARMACOL EXP THER, V271, P852	45	79	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35692	35698		10.1074/jbc.M002273200	http://dx.doi.org/10.1074/jbc.M002273200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964913	hybrid			2022-12-27	WOS:000165382000009
J	Wang, HY; Maechler, P; Antinozzi, PA; Hagenfeldt, KA; Wollheim, CB				Wang, HY; Maechler, P; Antinozzi, PA; Hagenfeldt, KA; Wollheim, CB			Hepatocyte nuclear factor 4 alpha regulates the expression of pancreatic beta-cell genes implicated in glucose metabolism and nutrient-induced insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; HNF-4 GENE; FACTOR-I; MUTATION; ACTIVATION; YOUNG; ARGININE	Mutations in the HNF4 alpha gene are associated with the subtype 1 of maturity-onset diabetes of the young (MODY1), which is characterized by impaired insulin secretory response to glucose in pancreatic beta -cells. Hepatocyte nuclear factor 4 alpha (HNF4 alpha) is a transcription factor critical for liver development and hepatocyte-specific gene expression. However, the role of HNF4 alpha in the regulation of pancreatic beta -cell gene expression and its correlation with metabolism secretion coupling have not been previously investigated. The tetracycline-inducible system was employed to achieve tightly controlled expression of both wild type (WT) and dominant-negative mutant (DN) of HNF4 alpha in INS-1 cells. The induction of WT-HNF4 alpha resulted in a left shift in glucose-stimulated insulin secretion, whereas DN-HNPF4 alpha selectively impaired nutrient-stimulated insulin release, Induction of DN-HNF4 alpha also caused defective mitochondrial function substantiated by reduced [C-14]pyruvate oxidation, attenuated substrate-evoked mitochondrial membrane hyperpolarization, and blunted nutrient-generated cellular ATP production. Quantitative evaluation of HNF4 alpha -regulated pancreatic p-cell gene expression revealed altered mRNA levels of insulin, glucose transporter-2, L-pyruvate kinase, aldolase B, 2-oxoglutarate dehydrogenase El subunit, and mitochondrial uncoupling protein-2, The patterns of HNF4a-regulated gene expression are strikingly similar to that of its downstream transcription factor HNF1 alpha, Indeed, HNF4a changed the HNF1 alpha mRNA levels and HNF1 alpha promoter luciferase activity through altered HNF4 alpha binding. These results demonstrate the importance of HNF4 alpha in beta -cell metabolism-secretion coupling.	Ctr Med Univ Geneva, Div Biochim Clin, Dept Med Interne, CH-1211 Geneva 4, Switzerland	University of Geneva	Wollheim, CB (corresponding author), Ctr Med Univ Geneva, Div Biochim Clin, Dept Med Interne, CH-1211 Geneva 4, Switzerland.	Claes.Wollheim@medicine.unige.ch		Maechler, Pierre/0000-0002-2005-1433				Antinozzi PA, 1998, J BIOL CHEM, V273, P16146, DOI 10.1074/jbc.273.26.16146; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BYNE MM, 1995, DIABETES, V44, P699; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Fraser JD, 1997, J BIOL CHEM, V272, P13892, DOI 10.1074/jbc.272.21.13892; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gragnoli C, 1997, DIABETES, V46, P1648, DOI 10.2337/diabetes.46.10.1648; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hani E, 1998, J CLIN INVEST, V101, P521, DOI 10.1172/JCI1403; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Herman WH, 1997, DIABETES, V46, P1749, DOI 10.2337/diabetes.46.11.1749; Ilag LL, 2000, DIABETES, V49, P961, DOI 10.2337/diabetes.49.6.961; Kennedy ED, 1998, DIABETES METAB, V24, P15; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Lausen J, 2000, NUCLEIC ACIDS RES, V28, P430, DOI 10.1093/nar/28.2.430; Lehto M, 1999, DIABETES, V48, P423, DOI 10.2337/diabetes.48.2.423; Li JX, 2000, GENE DEV, V14, P464; Lindner T, 1997, J CLIN INVEST, V100, P1400, DOI 10.1172/JCI119660; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; MUIRA N, 1993, NUCLEIC ACIDS RES, V21, P3731; Noel RJ, 1997, J BIOL CHEM, V272, P18621, DOI 10.1074/jbc.272.30.18621; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; Ware TL, 2000, EMBO J, V19, P3119, DOI 10.1093/emboj/19.12.3119; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	37	167	170	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35953	35959		10.1074/jbc.M006612200	http://dx.doi.org/10.1074/jbc.M006612200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967120	hybrid, Green Published			2022-12-27	WOS:000165382000045
J	Wilkening, G; Linke, T; Uhlhorn-Dierks, G; Sandhoff, K				Wilkening, G; Linke, T; Uhlhorn-Dierks, G; Sandhoff, K			Degradation of membrane-bound ganglioside GM1 - Stimulation by bis(monoacylglycero)phosphate and the activator proteins SAP-B and GM2-AP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL DEGRADATION; SULFATIDE ACTIVATOR; SPHINGOLIPIDS; LOCALIZATION; SPECIFICITY; TOPOLOGY; STORAGE; ENZYME; LIVER; FORMS	According to our hypothesis (Furst, W,, and Sandhoff, K, (1992) Biochim, Biophys. Acta 1126, 1-16) glycosphingolipids of the plasma membrane are digested after endocytosis as components of intraendosomal and intralysosomal vesicles and membrane structures. The lysosomal degradation of glycosphingolipids with short oligosaccharide chains by acid exohydrolases requires small, non-enzymatic cofactors, called sphingolipid activator proteins (SAPs), A total of five activator proteins have been identified as follows: namely the saposins SAP-A, -B, -C, and -D, which are derived from the single chain SAP-precursor protein (prosaposin), and the GM2 activator protein. A deficiency of prosaposin results in the storage of ceramide and sphingolipids with short oligosaccharide head groups. The loss of the GM2 activator protein blocks the degradation of the ganglioside GM2. The enzymatic hydrolysis of the ganglioside GM1 is catalyzed by beta -galactosidase, a water-soluble acid exohydrolase, The lack of ganglioside GM1 accumulation in patients suffering from either prosaposin or GM2 activator protein deficiency has led to the hypothesis that SAPs are not needed for the hydrolysis of the ganglioside GM1 in vivo, In this study we demonstrate that an activator protein is required for the enzymatic degradation of membrane-bound ganglioside GM1 and that both SAP-B and the GM2 activator protein significantly enhance the degradation of the ganglioside GM1 by acid beta -galactosidase in a liposomal, detergent-free assay system. These findings offer a possible explanation for the observation that no storage of the ganglioside GM1 has been observed in patients with either isolated prosaposin or isolated GM2 activator deficiency. We also demonstrate that anionic phospholipids such as bis(monoacylglycero)phosphate and phosphatidylinositol, which specifically occur in inner membranes of endosomes and in lysosomes, are essential for the activator-stimulated hydrolysis of the ganglioside GM1. Assays utilizing surface:plasmon resonance spectroscopy showed that bis(monoacylglycero)phosphate increases the binding of both beta -galactosidase and activator proteins to substrate-carrying membranes.	Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	University of Bonn	Sandhoff, K (corresponding author), Kekule Inst Organ Chem & Biochem, Gerhard Domagk Str 1, D-53121 Bonn, Germany.							BLEISTEIN J, 1980, H-S Z PHYSIOL CHEM, V361, P595; BRADOVA V, 1993, HUM GENET, V92, P143, DOI 10.1007/BF00219682; CONZELMANN E, 1982, EUR J BIOCHEM, V123, P455, DOI 10.1111/j.1432-1033.1982.tb19789.x; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; Giehl A, 1999, EUR J BIOCHEM, V261, P650, DOI 10.1046/j.1432-1327.1999.00302.x; HUBBES M, 1992, BIOCHEM J, V285, P827, DOI 10.1042/bj2850827; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kolter T, 1999, ANGEW CHEM INT EDIT, V38, P1532, DOI 10.1002/(SICI)1521-3773(19990601)38:11<1532::AID-ANIE1532>3.0.CO;2-U; LINKE T, 2000, IN PRESS BIOL CHEM; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; NAOI M, 1988, CHROMATOGRAPHIA, V426, P75; Sandhoff K, 1996, TRENDS CELL BIOL, V6, P98, DOI 10.1016/0962-8924(96)80999-8; Schutte CG, 1998, PROTEIN SCI, V7, P1039; STREMMEL W, 1976, H-S Z PHYSIOL CHEM, V357, P803, DOI 10.1515/bchm2.1976.357.1.803; SUZUKI Y, 1972, J LIPID RES, V13, P687; SWALLOW DM, 1993, ANN HUM GENET, V57, P187, DOI 10.1111/j.1469-1809.1993.tb01594.x; VOGEL A, 1991, EUR J BIOCHEM, V200, P591, DOI 10.1111/j.1432-1033.1991.tb16222.x; VOGEL A, 1987, ARCH BIOCHEM BIOPHYS, V259, P627, DOI 10.1016/0003-9861(87)90529-7; WHERRETT JR, 1972, J BIOL CHEM, V247, P4114; WIEGANDT H, 1965, Z NATURFORSCH PT B, VB 20, P164; Wilkening G, 1998, J BIOL CHEM, V273, P30271, DOI 10.1074/jbc.273.46.30271; WU YY, 1994, J BIOL CHEM, V269, P16276	25	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35814	35819		10.1074/jbc.M006568200	http://dx.doi.org/10.1074/jbc.M006568200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10942779	hybrid			2022-12-27	WOS:000165382000026
J	Egawa, T; Shimada, H; Ishimura, Y				Egawa, T; Shimada, H; Ishimura, Y			Formation of compound I in the reaction of native myoglobins with hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; SPERM WHALE MYOGLOBIN; HORSERADISH-PEROXIDASE; EPOXIDATION; CATALYSIS; MUTANTS; ROLES; INTERMEDIATE; PEROXYGENASE; REPLACEMENT	Reaction of ferric native myoglobin (Mb) with hydrogen peroxide (H2O2) was studied by the aid of stopped-flow rapid-scan spectrophotometry. In contrast to the results in previous studies where compound I was reported to be undetectable, both sperm whale and horse heart: metmyoglobins (metMbs) formed a significant quantity of compound I, an oxoferryl porphyrin pi -cation radical(Por(+)-Fe-IV(0)), during their reactions with H2O2. With both kinds of Mbs, formation of compound I was,more clearly observed in D2O than in H2O. The compound thus formed was capable of performing monooxygenation of thioanisole to methyl phenyl sulfoxide and a 2-electron oxidation of H2O2 giving O-2 and H2O as products. It was also converted into ferryl myoglobin (Por-Fe-IV(0)-globin(+)) spontaneously. Rate constants for these reactions and that for a direct conversion of metMb to ferryl Mb through the homolysis of H2O2 were determined. These results established unambiguously that native metMb can form both compound I and ferryl Mb upon reaction with H2O2 and that these high valent iron compounds serve as essential intermediates in Mb-assisted peroxidative reactions. The observed deuterium effect on the apparent stability of compound I was attributable to that effect on the hydrogen abstraction step in the 2-electron oxidation of H2O2 by compound I.	Keio Univ, Sch Med, Dept Biochem, Shinjuku Ku, Tokyo 1608582, Japan	Keio University	Ishimura, Y (corresponding author), Keio Univ, Sch Med, Dept Biochem, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.							ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; BAEK HK, 1989, BIOCHEMISTRY-US, V28, P5714, DOI 10.1021/bi00440a003; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; Fenwick CW, 1996, J AM CHEM SOC, V118, P12236, DOI 10.1021/ja962764d; GALARIS D, 1990, ARCH BIOCHEM BIOPHYS, V281, P163, DOI 10.1016/0003-9861(90)90427-Z; GEORGE P, 1952, BIOCHEM J, V52, P511, DOI 10.1042/bj0520511; GIBSON JF, 1958, NATURE, V181, P1398, DOI 10.1038/1811398a0; Golub G., 1965, SIAM J NUMER ANAL, V2, P205, DOI DOI 10.1137/0702016; GRISHAM M B, 1985, Journal of Free Radicals in Biology and Medicine, V1, P227, DOI 10.1016/0748-5514(85)90122-9; HARAMI T, 1977, J CHEM PHYS, V67, P1164, DOI 10.1063/1.434969; HEWSON WD, 1979, PORPHYRINS, V7, P295; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; HUG SJ, 1990, BIOCHEMISTRY-US, V29, P1475, DOI 10.1021/bi00458a019; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; Matsui T, 1999, J AM CHEM SOC, V121, P9952, DOI 10.1021/ja9914846; Matsui T, 1997, J BIOL CHEM, V272, P32735, DOI 10.1074/jbc.272.52.32735; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P345; MORISHIMA I, 1978, BIOCHEMISTRY-US, V17, P4384, DOI 10.1021/bi00614a005; NEWMYER SL, 1995, J BIOL CHEM, V270, P19430, DOI 10.1074/jbc.270.33.19430; Ozaki S, 1997, J AM CHEM SOC, V119, P6666, DOI 10.1021/ja970453c; Ozaki S, 1996, J AM CHEM SOC, V118, P9784, DOI 10.1021/ja961223l; PEISACH J, 1968, J BIOL CHEM, V243, P1871; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; POULOS TL, 1980, J BIOL CHEM, V255, P8199; RAO SI, 1993, J BIOL CHEM, V268, P803; RodriguezLopez JN, 1996, J BIOL CHEM, V271, P4023; SALOMAA P, 1964, J AM CHEM SOC, V86, P1, DOI 10.1021/ja01055a001; Schonbaum G. R., 1976, ENZYMES, V13, P363, DOI [10.1016/S1874-6047(08)60245-0, DOI 10.1016/S1874-6047(08)60245-0]; Schowen R. L., 1977, ISOTOPE EFFECTS ENZY, P64; SITTER AJ, 1985, BIOCHIM BIOPHYS ACTA, V828, P229, DOI 10.1016/0167-4838(85)90301-2; SZABO ZG, 1969, COMPREHENSIVE CHEM K, V2, P31; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; WILKS A, 1992, J BIOL CHEM, V267, P8827; YONETANI T, 1967, J BIOL CHEM, V242, P1974	37	108	110	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34858	34866		10.1074/jbc.M004026200	http://dx.doi.org/10.1074/jbc.M004026200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10945982	hybrid			2022-12-27	WOS:000165422800007
J	Recheis, B; Osanger, A; Haubenwallner, S; Schneider, WJ; Nimpf, J				Recheis, B; Osanger, A; Haubenwallner, S; Schneider, WJ; Nimpf, J			Chicken coagulation factor XIIIA is produced by the theca externa and stabilizes the ovarian follicular wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULOSA-CELLS; TISSUE TRANSGLUTAMINASE; CROSS-LINKING; OOCYTE GROWTH; DOMESTIC-FOWL; RECEPTOR; IDENTIFICATION; BINDING; CHONDROCYTES; FIBRONECTIN	Development of the follicle in egg-laying species such as the chicken is regulated by systemic factors as well as by-the highly orchestrated interplay of differentially expressed genes within this organ. Differential mRNA display analysis of defined phases of follicle development resulted in the characterization of coagulation factor XIIIA. It is expressed and produced by cells of the theca externa in a highly regulated manner during distinct growth phases of the follicle. Transcripts for factor XIIIA are already detectable at the beginning of follicle development,and peak at the end of phase 2. Protein levels, however, still increase during phase 3, peak shortly after ovulation, and persist until the postovulatory tissue is completely resorbed. Factor XIIIA is secreted asa monomer into the extracellular matrix of the theca-externa and is not associated with factor XIIIB as is the case in plasma. Our data suggest that, due to its transglutaminase activity, factor XIIIA stabilizes the follicular wall by cross-linking matrix components. Thus, coagulation factor XIIIA might play a key role in coping with-the massive mechanical stress exerted by the large amount of yolk accumulating during the rapid growth phase of the oocyte.	Inst Med Biochem, Dept Mol Genet, Bioctr, A-1030 Vienna, Austria; Univ Vienna, A-1030 Vienna, Austria	University of Vienna	Nimpf, J (corresponding author), Inst Med Biochem, Dept Mol Genet, Bioctr, Dr Bohrgasse 9-2, A-1030 Vienna, Austria.	JNIMPF@mol.univie.ac.at		Nimpf, Johannes/0000-0002-9273-3492				AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; ASEM EK, 1994, J REPROD FERTIL, V101, P375, DOI 10.1530/jrf.0.1010375; Bausek N, 2000, J BIOL CHEM, V275, P28866, DOI 10.1074/jbc.275.37.28866; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CERIO R, 1990, AM J DERMATOPATH, V12, P221, DOI 10.1097/00000372-199006000-00002; Chapeau C, 1996, POULTRY SCI, V75, P1536, DOI 10.3382/ps.0751536; DAHL E, 1970, Z ZELLFORSCH MIK ANA, V109, P195, DOI 10.1007/BF00365241; GRUNDMANN U, 1986, P NATL ACAD SCI USA, V83, P8024, DOI 10.1073/pnas.83.21.8024; HENRIKSSON P, 1985, J CLIN INVEST, V76, P528, DOI 10.1172/JCI112002; Hermann M, 1998, FASEB J, V12, P897, DOI 10.1096/fasebj.12.10.897; HERZ J, 1991, J BIOL CHEM, V266, P21232; JOHNSON A L, 1990, Critical Reviews in Poultry Biology, V2, P319; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEUTZ A, 1988, J BIOL CHEM, V263, P3905; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LOPACIUK S, 1976, THROMB RES, V8, P453, DOI 10.1016/0049-3848(76)90223-1; Monsonego A, 1998, FASEB J, V12, P1163, DOI 10.1096/fasebj.12.12.1163; MOSHER DF, 1991, ANN NY ACAD SCI, V614, P167; Muszbek L, 1996, CRIT REV CL LAB SCI, V33, P357, DOI 10.3109/10408369609084691; Nimpf J, 1998, ATHEROSCLEROSIS, V141, P191, DOI 10.1016/S0021-9150(98)00172-5; NIMPF J, 1988, J LIPID RES, V29, P657; Nurminskaya M, 1998, J CELL BIOL, V142, P1135, DOI 10.1083/jcb.142.4.1135; Nurminskaya M, 1996, DEV DYNAM, V206, P260, DOI 10.1002/(SICI)1097-0177(199607)206:3<260::AID-AJA4>3.0.CO;2-G; PERRY MM, 1978, J ANAT, V125, P481; PORTER TE, 1989, ENDOCRINOLOGY, V125, P109, DOI 10.1210/endo-125-1-109; Raghunath M, 1996, J CLIN INVEST, V98, P1174, DOI 10.1172/JCI118901; Rubartelli A., 1997, UNUSUAL SECRETORY PA, P87, DOI [10.1007/978-3-662-22581-3_3, DOI 10.1007/978-3-662-22581-3_3]; Schneider WJ, 1998, BIOL CHEM, V379, P965; Ueki S, 1996, J CELL SCI, V109, P2727; VIEIRA PM, 1995, J LIPID RES, V36, P601; Waclawek M, 1998, BIOL REPROD, V59, P1230, DOI 10.1095/biolreprod59.5.1230; YOSHIMURA Y, 1985, Japanese Poultry Science, V22, P274	33	10	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35320	35327		10.1074/jbc.M005025200	http://dx.doi.org/10.1074/jbc.M005025200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10948196	hybrid			2022-12-27	WOS:000165422800066
J	Thome, KC; Dhar, SK; Quintana, DG; Delmolino, L; Shahsafaei, A; Dutta, A				Thome, KC; Dhar, SK; Quintana, DG; Delmolino, L; Shahsafaei, A; Dutta, A			Subsets of human origin recognition complex (ORC) subunits are expressed in non-proliferating cells and associate with non-ORC proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; DROSOPHILA HOMOLOG; XENOPUS; GENE; CDK; IDENTIFICATION; LATHEO; PHOSPHORYLATION; LOCALIZATION; EUKARYOTES	The origin recognition complex (ORC) in yeast is a complex of six tightly associated subunits essential for the initiation of DNA replication. Human ORC subunits are nuclear in proliferating cells and in proliferative tissues like the testis, consistent with a role of human ORC in DNA replication. Orc2, Orc3, and Orc5 also are detected in non-proliferating cells like cardiac myocytes, adrenal cortical cells, and neurons, suggesting an additional role of these proteins in non-proliferating cells. Although Orc2-5 co-immunoprecipitate with each other under mild extraction conditions, a hole complex of the subunits is difficult to detect. When extracted under more stringent extraction conditions, several of the subunits eo-immunoprecipitate with stoichiometric amounts of other unidentified proteins but not with any of the known ORC subunits, The variation in abundance of individual ORC subunits (relative to each other) in several tissues, expression of some subunits in non-proliferating tissues, and the absence of a stoichiometric complex of all the subunits in cell extracts indicate that subunits of human ORC in somatic cells might have activities independent of their role as a six subunit complex involved in replication initiation. Finally, all ORC subunits remain consistently nuclear, and Orc2 is consistently phosphorylated through all stages of the cell cycle, whereas Orc1 is selectively phosphorylated in mitosis.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Mol Oncol,Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dutta, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Mol Oncol,Dept Pathol, Boston, MA 02115 USA.		Dutta, Anindya/P-3203-2016; Quintana, David G/M-5628-2018	Dutta, Anindya/0000-0002-4319-0073; Quintana, David G./0000-0002-4909-6686	NCI NIH HHS [CA60499] Funding Source: Medline; NHLBI NIH HHS [T32 HL07627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007627] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Austin RJ, 1999, GENE DEV, V13, P2639, DOI 10.1101/gad.13.20.2639; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BOYNTON S, 1992, GENETICS, V131, P655; Carpenter PB, 1998, J BIOL CHEM, V273, P24891, DOI 10.1074/jbc.273.38.24891; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Chesnokov I, 1999, GENE DEV, V13, P1289, DOI 10.1101/gad.13.10.1289; Dorfman DM, 1997, MODERN PATHOL, V10, P859; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Ishiai M, 1997, GENOMICS, V46, P294, DOI 10.1006/geno.1997.5003; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; Lee DG, 1997, MOL CELL BIOL, V17, P7159, DOI 10.1128/MCB.17.12.7159; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LOO S, 1995, MOL CELL BIOL, V16, P741; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; Moon KY, 1999, P NATL ACAD SCI USA, V96, P12367, DOI 10.1073/pnas.96.22.12367; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Natale DA, 2000, EMBO J, V19, P2728, DOI 10.1093/emboj/19.11.2728; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; Rohrbough J, 1999, NEURON, V23, P55, DOI 10.1016/S0896-6273(00)80753-9; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tatsumi Y, 2000, J BIOL CHEM, V275, P5904, DOI 10.1074/jbc.275.8.5904; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421	37	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35233	35241		10.1074/jbc.M005765200	http://dx.doi.org/10.1074/jbc.M005765200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954718	hybrid			2022-12-27	WOS:000165422800055
J	Wu, K; Jiang, SW; Thangaraju, M; Wu, G; Couch, FJ				Wu, K; Jiang, SW; Thangaraju, M; Wu, G; Couch, FJ			Induction of the BRCA2 promoter by nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER SUSCEPTIBILITY GENE; TRANSCRIPTION FACTOR USF; SPORADIC BREAST-TUMORS; OVARIAN CANCERS; DNA-REPAIR; TATA BOX; RAD51; MUTATIONS; INVOLVEMENT; EXPRESSION	BRCA2 is a tumor suppressor gene that has been implicated in response to DNA damage, cell cycle control, and transcription. BRCA2 has been found to be overexpressed in-many breast tumors, suggesting that altered expression of the BRCA2 gene may contribute to breast tumbrigenesis.( To determine how BRCA2 is overexpressed in tumors, we investigated the transcriptional regulation of the BRCA2 promoter, Deletion mapping of the BRCA2 promoter identified three regions associated with 3-fold activation or repression and one upstream stimulatory factor binding site associated with 20-fold activation Gel shift and cotransfection studies verified the role of USF in regulation of BRCA2 transcription, Analysis df the:-144 to -59 region associated with 3-fold activation identified a putative NF kappaB binding site. Cotransfection of the p65 and p50 subunits of NF kappaB upregulated the BRCA2 promoter 16-fold in a luciferase reporter assay, whereas mutations in the binding site ablated:the effect. Gel shift and supershift assays with anti-p65 and -p50 antibodies demonstrated that NF kappaB binds specifically to the NF kappaB site. In addition, ectopic expression of NF kappaB resulted in increased levels of endogeneous BRCA2 expression. Thus, NF kappaB and USF regulate BRCA2 expression through the BRCA2 promoter.	Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Endocrinol Res Unit, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Couch, FJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, 200 1st St SW,1001 Guggenheim Bldg, Rochester, MN 55905 USA.							Bertwistle D, 1997, CANCER RES, V57, P5485; Bieche I, 1999, ONCOGENE, V18, P5232, DOI 10.1038/sj.onc.1202903; Bieche I, 1997, BRIT J CANCER, V76, P1416, DOI 10.1038/bjc.1997.572; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Couch FJ, 1996, GENOMICS, V36, P86, DOI 10.1006/geno.1996.0428; Davis PL, 1999, ONCOGENE, V18, P6000, DOI 10.1038/sj.onc.1202990; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Easton D, 1997, NAT GENET, V16, P210, DOI 10.1038/ng0797-210; Gretarsdottir S, 1998, CANCER RES, V58, P859; Hamann U, 1996, CANCER RES, V56, P1988; Ismail PM, 1999, ONCOGENE, V18, P5582, DOI 10.1038/sj.onc.1202932; KERANGUEVEN F, 1995, GENE CHROMOSOME CANC, V13, P291, DOI 10.1002/gcc.2870130410; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Luo X, 1996, MOL CELL BIOL, V16, P1367; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Scholtz B, 1996, J BIOL CHEM, V271, P32375, DOI 10.1074/jbc.271.50.32375; Sharan C, 1999, BIOCHEM BIOPH RES CO, V265, P285, DOI 10.1006/bbrc.1999.1652; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Siddique H, 1998, ONCOGENE, V16, P2283, DOI 10.1038/sj.onc.1202003; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Spillman MA, 1996, ONCOGENE, V13, P1639; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; Thorlacius S, 1998, LANCET, V352, P1337, DOI 10.1016/S0140-6736(98)03300-5; Vaughn JP, 1996, CANCER RES, V56, P4590; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yuan SSF, 1999, CANCER RES, V59, P3547	42	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35548	35556		10.1074/jbc.M004390200	http://dx.doi.org/10.1074/jbc.M004390200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10961992	hybrid			2022-12-27	WOS:000165422800094
J	Jiang, LH; Rassendren, F; Surprenant, A; North, RA				Jiang, LH; Rassendren, F; Surprenant, A; North, RA			Identification of amino acid residues contributing to the ATP-binding site of a purinergic P2X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION SELECTIVITY; CHANNELS; PURINOCEPTORS; PROTEINS; SUBUNIT; MOTIFS; PORE	P2X receptor subunits have intracellular N and C termini, two membrane-spanning domains, and an extracellular loop of about 280 amino acids. We expressed the rat P2X(2), receptor in human embryonic kidney cells, and used alanine-scanning mutagenesis on 30 residues with polar side chains conserved among the seven rat P2X receptor subunits. This identified a region proximal to the first transmembrane domain which contained 2 lysine residues that were critical for the action of ATP (Lys(69) and Lys(71)). We substituted cysteines in this region (Asp(57) to Asp(71)) and found that for S65C and I67C ATP-evoked currents were inhibited by methanethiosulfonates. At I67C, the inhibition by negatively charged ethylsulfonate and pentylsulfonate derivatives could be overcome by increasing the ATP concentration, consistent with a reduced affinity of ATP binding. The inhibitory action of the methanethiosulfonates was prevented by pre-exposure to ATP, suggesting occlusion of the binding site. Finally, introduction of negative charges into the receptor by mutagenesis at this position (I67E and I67D) also gave receptors in which the ATP concentration-response curve was right-shifted. The results suggest that residues close to IIe(67) contribute to the ATP-binding site.	Univ Sheffield, Inst Mol Physiol, Sheffield S10 2TN, S Yorkshire, England; CNRS, UPR 1142, Inst Genet Humaine, F-34396 Montpellier, France	University of Sheffield; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	North, RA (corresponding author), Univ Sheffield, Inst Mol Physiol, Alfred Denny Bldg, Sheffield S10 2TN, S Yorkshire, England.		Jiang, Lin-Hua/D-2030-2010; Jiang, Lin-Hua/AAU-1078-2020; North, Richard/GQA-6156-2022; Rassendren, Francois/AAA-6190-2021	Jiang, Lin-Hua/0000-0001-6398-0411; Jiang, Lin-Hua/0000-0001-6398-0411; Rassendren, Francois/0000-0003-3320-2461				Anson LC, 1998, J NEUROSCI, V18, P581; Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Ding SH, 1999, J GEN PHYSIOL, V113, P695, DOI 10.1085/jgp.113.5.695; Egan TM, 1998, J NEUROSCI, V18, P2350; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; Evans RJ, 1996, J PHYSIOL-LONDON, V497, P413, DOI 10.1113/jphysiol.1996.sp021777; Freist W, 1998, FEBS LETT, V434, P61, DOI 10.1016/S0014-5793(98)00958-2; GarciaGuzman M, 1997, MOL PHARMACOL, V51, P109, DOI 10.1124/mol.51.1.109; Hille B., 1992, IONIC CHANNELS EXCIT; IMOTO K, 1993, FEBS LETT, V325, P100, DOI 10.1016/0014-5793(93)81422-V; KABSCH W, 1995, FASEB J, V9, P167, DOI 10.1096/fasebj.9.2.7781919; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Stoop R, 1999, MOL PHARMACOL, V56, P973, DOI 10.1124/mol.56.5.973; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; Zimmermann H, 1999, PROG BRAIN RES, V120, P371	25	179	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34190	34196		10.1074/jbc.M005481200	http://dx.doi.org/10.1074/jbc.M005481200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10940304	hybrid			2022-12-27	WOS:000165095300028
J	Asazuma, N; Wilde, JI; Berlanga, O; Leduc, M; Leo, A; Schweighoffer, E; Tybulewicz, V; Bon, C; Liu, SK; McGlade, CJ; Schraven, B; Watson, SP				Asazuma, N; Wilde, JI; Berlanga, O; Leduc, M; Leo, A; Schweighoffer, E; Tybulewicz, V; Bon, C; Liu, SK; McGlade, CJ; Schraven, B; Watson, SP			Interaction of linker for activation of T cells with multiple adapter proteins in platelets activated by the glycoprotein VI-selective ligand, convulxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-GAMMA-CHAIN; COLLAGEN-RELATED PEPTIDE; TYROSINE KINASE SYK; PHOSPHOLIPASE C-GAMMA-2; INTEGRIN ALPHA(2)BETA(1); MOLECULAR-CLONING; NUCLEAR FACTOR; SLP-76; LAT; PHOSPHORYLATION	The snake venom toxin convulxin activates platelets through the collagen receptor glycoprotein VI (GPVI)/Fc receptor gamma -chain (FcR gamma -chain) complex leading to tyrosine phosphorylation and activation of the tyrosine Syk and phospholipase C gamma2 (PLC gamma2), In the present study, we demonstrate that convulxin is a considerably more powerful agonist than collagen or the GPVI-selective collagen-related peptide (CRP), Confirmation that the response to convulxin is mediated solely via Syk was provided by studies on Syk-deficient platelets. The increase in phosphorylation of the FcR gamma -chain is associated with marked increases in tyrosine phosphorylation of downstream proteins including Syk, linker for activation of T cells (LAT), SLP-76, and PLC gamma2, The transmembrane adapter LAT coprecipitates with SLP-76 and PLC gamma2, as well as with a number of other adapter proteins, some of which have not been previously described in platelets, including Cbl, Grb2, Gads, and SKAP-HOM. Cads is constitutively associated with SLP-76 and is probably the protein bridging its association with LAT, There was no detectable association between Grb2 and SLP-76 in control or stimulated cells, suggesting that the interaction of LAT with Grb2 is present in a separate complex to that of LAT Gads SLP-76. These results show that the trimeric convulxin stimulates a much greater phosphorylation of the FcR gamma -chain and subsequent downstream responses relative to CRP and collagen, presumably because of its ability to cause a greater degree of cross-linking of GPVI, The adapter LAT appears to play a critical role in recruiting a number of other adapter proteins to the surface membrane in response to activation of GPVI, presumably at sites of glycolipid-enriched microdomains, enabling an organized signaling cascade that leads to platelet activation.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Heidelberg Univ, Inst Immunol, D-69120 Heidelberg, Germany; Inst Pasteur, Unite Venens, F-75724 Paris 15, France; Univ Toronto, Hosp Sick Children, Res Inst, Dept Med Biophys, Toronto, ON M5G 1X8, Canada; Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England	University of Oxford; Ruprecht Karls University Heidelberg; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); MRC National Institute for Medical Research	Watson, SP (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	steve.watson@pharm.ox.ac.uk	Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423; Liu, Stanley/0000-0001-6851-0857				Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Asselin J, 1999, BIOCHEM J, V339, P413, DOI 10.1042/0264-6021:3390413; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Fang N, 1999, J BIOL CHEM, V274, P16206, DOI 10.1074/jbc.274.23.16206; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1998, J BIOL CHEM, V273, P34437, DOI 10.1074/jbc.273.51.34437; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Gross BS, 1999, EUR J BIOCHEM, V263, P612, DOI 10.1046/j.1432-1327.1999.00560.x; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; IVO MBF, 1997, TOXICON, V35, P1217; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Lindholm CK, 1999, J BIOL CHEM, V274, P28050, DOI 10.1074/jbc.274.39.28050; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; LUI J, 1998, P NATL ACAD SCI USA, V95, P8779; Marie-Cardine A, 1999, EUR J IMMUNOL, V29, P1175, DOI 10.1002/(SICI)1521-4141(199904)29:04<1175::AID-IMMU1175>3.0.CO;2-Z; Marie-Cardine A, 1998, FEBS LETT, V435, P55, DOI 10.1016/S0014-5793(98)01040-0; Marie-Cardine A, 1998, J BIOL CHEM, V273, P25789, DOI 10.1074/jbc.273.40.25789; Melford SK, 1997, J BIOL CHEM, V272, P27539, DOI 10.1074/jbc.272.44.27539; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Mountford JC, 1999, THROMB HAEMOSTASIS, V82, P1153; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Watson SP, 1999, THROMB HAEMOSTASIS, V82, P365; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	40	80	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33427	33434		10.1074/jbc.M001439200	http://dx.doi.org/10.1074/jbc.M001439200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10942756	hybrid			2022-12-27	WOS:000090104600036
J	Hill, KL; Hutchings, NR; Grandgenett, PM; Donelson, JE				Hill, KL; Hutchings, NR; Grandgenett, PM; Donelson, JE			T lymphocyte-triggering factor of African trypanosomes is associated with the flagellar fraction of the cytoskeleton and represents a new family of proteins that are present in several divergent eukaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; BRUCEI-BRUCEI; MOLECULAR-CLONING; PARAFLAGELLAR ROD; ALPHA-TUBULIN; CELL-DIVISION; POCKET; GENE; LOCALIZATION; CLIP-170	The trypanosome cytoskeleton consists almost entirely of microtubule-based structures. Although alpha- and beta -tubulin from Trypanosoma brucei have been well characterized, much less is known about other cytoskeleton-associated proteins in trypanosomes. Using biochemical fractionation, we demonstrate here that T lymphocyte-triggering factor (TLTF) from T, brucei is a component of the detergent-resistant and Ca2+-resistant fraction of the parasite cytoskeleton. This fraction contains the flagellar apparatus and a subset of cytoskeletal protein complexes that together function in cell motility,cytokinesis, and organelle inheritance. We also show that TLTF-related genes are present in several highly divergent eukaryotic organisms. Although the function of the corresponding proteins is not known, the mammalian TLTF-like gene (GAS11; growth arrest-specific gene 11) is up-regulated in growth-arrested cells and is a candidate tumor suppressor (Whitmore, S. A, Settasatian, C., Crawford, J., Lower, K. M., McCallum, B., Seshadri, R., Cornelisse, C. J., Moerland, E. W., Cleton-Jansen, A. M., Tipping; A. J., Mathew, C. G., Savnio, M., Savoia, A, Verlander, P., Auerbach, A. D., Van Berkel, C., Pronk, J. C., Doggett, N. A, and Callen, D. F. (1998) Genomics 52, 325-331), suggestive of a role in coordinating cytoskeleton activities. Consistent with this possibility, we show that the human GAS11 protein contains a 144-amino acid domain that co-localizes with microtubules when fused to the green fluorescent protein and expressed in mammalian cells. These findings suggest that TLTF represents a newly defined protein family, whose members contribute to cytoskeleton function in species as diverse as protozoa and mammals.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Interdept Genet PhD Program, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Hill, KL (corresponding author), Univ Calif Los Angeles, Dept Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	kenthill@mednet.ucla.edu	Donelson, John E/F-5795-2010		NIAID NIH HHS [AI07511, AI40591] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BALABAN N, 1989, CELL MOTIL CYTOSKEL, V14, P393, DOI 10.1002/cm.970140309; BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; BANGS JD, 1993, J CELL SCI, V105, P1101; Bangs JD, 1996, J BIOL CHEM, V271, P18387, DOI 10.1074/jbc.271.31.18387; Bastin P, 1996, PARASITOL TODAY, V12, P302, DOI 10.1016/0169-4758(96)10031-4; Bastin P, 1998, NATURE, V391, P548, DOI 10.1038/35300; Biebinger S, 1996, NUCLEIC ACIDS RES, V24, P1202, DOI 10.1093/nar/24.7.1202; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHU DTW, 1989, DEV BIOL, V136, P104, DOI 10.1016/0012-1606(89)90134-6; COLIGAN JE, 1995, CURRENT PROTOCOLS IM, V2; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; Diamantopoulos GS, 1999, J CELL BIOL, V144, P99, DOI 10.1083/jcb.144.1.99; Dilbeck V, 1999, J CELL SCI, V112, P4687; Gull K, 1999, ANNU REV MICROBIOL, V53, P629, DOI 10.1146/annurev.micro.53.1.629; HEMPHILL A, 1991, J PARASITOL, V77, P603, DOI 10.2307/3283167; Hill KL, 1999, J CELL SCI, V112, P3091; HILL KL, 1991, J BIOL CHEM, V266, P15060; Hill KL, 1996, J CELL BIOL, V135, P1535, DOI 10.1083/jcb.135.6.1535; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Kim KS, 1997, J BIOL CHEM, V272, P24637, DOI 10.1074/jbc.272.39.24637; Kohl L, 1998, MOL BIOCHEM PARASIT, V93, P1, DOI 10.1016/S0166-6851(98)00014-0; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; LEE MGS, 1990, MOL CELL BIOL, V10, P4506, DOI 10.1128/MCB.10.9.4506; Ludin B, 1996, GENE, V173, P107, DOI 10.1016/0378-1119(95)00899-3; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACRAE TH, 1990, BIOCHEM J, V265, P87, DOI 10.1042/bj2650087; McDowell MA, 1998, BIOCHEM J, V335, P681, DOI 10.1042/bj3350681; MULLER N, 1993, PARASITOLOGY, V107, P411, DOI 10.1017/S0031182000067767; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; OLSSON T, 1993, CELL, V72, P715, DOI 10.1016/0092-8674(93)90400-K; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; ROBINSON D, 1991, METHOD ENZYMOL, V196, P285; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; Roggy JL, 1999, MOL BIOCHEM PARASIT, V98, P1, DOI 10.1016/S0166-6851(98)00114-5; Schneider A, 1997, J CELL SCI, V110, P431; SCHNEIDER A, 1987, J CELL BIOL, V104, P431, DOI 10.1083/jcb.104.3.431; SCHNEIDER A, 1988, SCIENCE, V241, P459, DOI 10.1126/science.3393912; Scott V, 1997, J CELL SCI, V110, P157; SEEBECK T, 1990, PARASITOL TODAY, V6, P49, DOI 10.1016/0169-4758(90)90069-G; SHERWIN T, 1989, PHILOS T R SOC B, V323, P573, DOI 10.1098/rstb.1989.0037; Tellam JT, 1997, J BIOL CHEM, V272, P6187, DOI 10.1074/jbc.272.10.6187; Vaidya T, 1997, J EXP MED, V186, P433, DOI 10.1084/jem.186.3.433; Vickerman K, 1976, BIOL KINETOPLASTIDA, P35; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; Whitmore SA, 1998, GENOMICS, V52, P325, DOI 10.1006/geno.1998.5457; WOODS A, 1989, J CELL SCI, V93, P491	51	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39369	39378		10.1074/jbc.M006907200	http://dx.doi.org/10.1074/jbc.M006907200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10969087	hybrid			2022-12-27	WOS:000165953100060
J	Verzijl, N; DeGroot, J; Thorpe, SR; Bank, RA; Shaw, JN; Lyons, TJ; Bijlsma, JWJ; Lafeber, FPJG; Baynes, JW; TeKoppele, JM				Verzijl, N; DeGroot, J; Thorpe, SR; Bank, RA; Shaw, JN; Lyons, TJ; Bijlsma, JWJ; Lafeber, FPJG; Baynes, JW; TeKoppele, JM			Effect of collagen turnover on the accumulation of advanced glycation end products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTIC-ACID RACEMIZATION; HUMAN ARTICULAR-CARTILAGE; PERFORMANCE LIQUID-CHROMATOGRAPHY; AGE-DEPENDENT ACCUMULATION; HUMAN SKIN COLLAGEN; AMINO-ACID; NONENZYMATIC GLYCATION; EXTRACELLULAR-MATRIX; DIABETES-MELLITUS; LENS PROTEINS	Collagen molecules in articular cartilage have an exceptionally long lifetime, which makes them susceptible to the accumulation of advanced glycation end products (AGEs). In fact, in comparison to other collagen-rich tissues, articular cartilage contains relatively high amounts of the AGE pentosidine. To test the hypothesis that this higher AGE accumulation is primarily the result of the slow turnover of cartilage collagen, AGE levels in cartilage and skin collagen were compared with the degree of racemization of aspartic acid (% D-Asp, a measure of the residence time of a protein). AGE (N-epsilon-(carboxymethyl)lysine, N-epsilon-(carboxyethyl)lysine, and pentosidine) and % D-Asp concentrations increased linearly with age in both cartilage and skin collagen (p < 0.0001), The rate of increase in AGEs was greater in cartilage collagen than in skin collagen (p < 0.0001). % D-Asp was also higher in cartilage collagen than in skin collagen (p < 0.0001), indicating that cartilage collagen has a longer residence time in the tissue, and thus a slower turnover, than skin collagen. In both types of collagen, AGE concentrations increased linearly with % D-Asp (p < 0.0005). Interestingly, the slopes of the curves of AGEs versus % D-Asp, i.e. the rates of accumulation of AGEs corrected for turnover, were identical for cartilage and skin collagen. The present study thus provides the first experimental evidence that protein turnover is a major determinant in AGE accumulation in different collagen types. From the age-related increases in % D-Asp the half-life of cartilage collagen was calculated to be 117 years and that of skin collagen 15 years, thereby providing the first reasonable estimates of the half-lives of these collagens.	TNO, Prevent & Hlth, Gaubius Lab, NL-2301 CE Leiden, Netherlands; Univ Utrecht, Med Ctr, Dept Rheumatol & Clin Immunol, NL-3508 GA Utrecht, Netherlands; Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA	Netherlands Organization Applied Science Research; Utrecht University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Medical University of South Carolina	TeKoppele, JM (corresponding author), TNO, Prevent & Hlth, Gaubius Lab, POB 2215, NL-2301 CE Leiden, Netherlands.	JM.teKoppele@pg.tno.nl	YAMAMOTO, MASAHIRO/F-9094-2011; DeGroot, Jeroen/C-4585-2012	YAMAMOTO, MASAHIRO/0000-0003-3859-0125; Lyons, Timothy/0000-0003-2106-1622	NATIONAL EYE INSTITUTE [R29EY010697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019971, R37DK019971] Funding Source: NIH RePORTER; NEI NIH HHS [EY 10697] Funding Source: Medline; NIDDK NIH HHS [DK 19971] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; Arrhenius S., 1889, Z PHYS CHEM, V4U, P226, DOI [10.1515/zpch-1889-0416, DOI 10.1515/ZPCH-1889-0416]; ASWAD DW, 1984, ANAL BIOCHEM, V137, P405, DOI 10.1016/0003-2697(84)90106-4; BADA JL, 1973, P NATL ACAD SCI USA, V70, P1331, DOI 10.1073/pnas.70.5.1331; Bank RA, 1997, J CHROMATOGR B, V703, P37, DOI 10.1016/S0378-4347(97)00391-5; Bank RA, 1998, BIOCHEM J, V330, P345, DOI 10.1042/bj3300345; Bank RA, 1996, ANAL BIOCHEM, V240, P167, DOI 10.1006/abio.1996.0346; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; Choi JK, 1997, INT J BIOMETEOROL, V41, P68, DOI 10.1007/s004840050056; Cloos PAC, 2000, BIOCHEM J, V345, P473, DOI 10.1042/0264-6021:3450473; DeGroot J, 1999, ARTHRITIS RHEUM, V42, P1003, DOI 10.1002/1529-0131(199905)42:5<1003::AID-ANR20>3.0.CO;2-K; DUNN JA, 1989, BIOCHEMISTRY-US, V28, P9464, DOI 10.1021/bi00450a033; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DYER DG, 1991, J BIOL CHEM, V266, P11654; EYRE DR, 1980, BIOCHEM J, V188, P823, DOI 10.1042/bj1880823; Freeman MAR, 1999, J ORTHOP RES, V17, P3, DOI 10.1002/jor.1100170103; Gineyts E, 2000, BIOCHEM J, V345, P481, DOI 10.1042/0264-6021:3450481; Haimovici N, 1982, Prog Clin Biol Res, V107, P453; HELFMAN PM, 1976, NATURE, V262, P279, DOI 10.1038/262279b0; HELFMAN PM, 1975, P NATL ACAD SCI USA, V72, P2891, DOI 10.1073/pnas.72.8.2891; HORVATH SM, 1949, J CLIN INVEST, V28, P469, DOI 10.1172/JCI102092; KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003-2697(88)90532-5; LIBBY WF, 1964, SCIENCE, V146, P1171; LYONS TJ, 1991, J CLIN INVEST, V87, P1910, DOI 10.1172/JCI115216; MAN EH, 1983, SCIENCE, V220, P1407, DOI 10.1126/science.6857259; Maroudas A, 1998, ARCH BIOCHEM BIOPHYS, V350, P61, DOI 10.1006/abbi.1997.0492; MAROUDAS A, 1992, CONNECT TISSUE RES, V28, P161, DOI 10.3109/03008209209015033; MAROUDAS A, 1980, STUDIES JOINT DISEAS, V1, P59; MASTERS PM, 1977, NATURE, V268, P71, DOI 10.1038/268071a0; MONNIER VM, 1992, DIABETES, V41, P36, DOI 10.2337/diab.41.2.S36; OHTANI S, 1991, J FORENSIC SCI, V36, P792; Ohtani S, 1998, J FORENSIC SCI, V43, P949; Ohtani S, 1996, GROWTH DEVELOP AGING, V60, P1; Ohtani S, 1998, AM J FOREN MED PATH, V19, P284, DOI 10.1097/00000433-199809000-00017; PFEIFFER H, 1995, INT J LEGAL MED, V108, P19, DOI 10.1007/BF01845611; PFEIFFER H, 1995, INT J LEGAL MED, V108, P24, DOI 10.1007/BF01845612; RITZ S, 1993, J FORENSIC SCI, V38, P633; SCHMIDT MB, 1990, J ORTHOPAED RES, V8, P353, DOI 10.1002/jor.1100080307; SELL DR, 1989, J BIOL CHEM, V264, P21597; SMITH GG, 1978, J ORG CHEM, V43, P1, DOI 10.1021/jo00395a001; UCHIYAMA A, 1991, J BIOCHEM, V110, P714, DOI 10.1093/oxfordjournals.jbchem.a123646; VANBOEKEL MAM, 1991, MOL BIOL REP, V15, P57, DOI 10.1007/BF00364840; Verzijl N, 2000, BIOCHEM J, V350, P381, DOI 10.1042/0264-6021:3500381; WellsKnecht MC, 1997, J CLIN INVEST, V100, P839, DOI 10.1172/JCI119599	44	602	616	3	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39027	39031		10.1074/jbc.M006700200	http://dx.doi.org/10.1074/jbc.M006700200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10976109	hybrid, Green Published			2022-12-27	WOS:000165953100013
J	Brasaemle, DL; Rubin, B; Harten, IA; Gruia-Gray, J; Kimmel, AR; Londos, C				Brasaemle, DL; Rubin, B; Harten, IA; Gruia-Gray, J; Kimmel, AR; Londos, C			Perilipin A increases triacylglycerol storage by decreasing the rate of triacylglycerol hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; CHOLESTERYL ESTER HYDROLASE; DEPENDENT PROTEIN-KINASE; ACYL-COA SYNTHETASE; LEYDIG TUMOR-CELLS; SACCHAROMYCES-CEREVISIAE; LIPID PARTICLES; ENDOPLASMIC-RETICULUM; MEMBRANE-FRACTION; MAMMALIAN-CELLS	The perilipins are the most abundant proteins at the surfaces of lipid droplets in adipocytes and are also found in steroidogenic cells. To investigate perilipin function, perilipin A, the predominant isoform, was ectopically expressed in fibroblastic 3T3-L1 pre-adipocytes that normally lack the perilipins. In control cells, fluorescent staining of neutral lipids with Bodipy 493/503 showed a few minute and widely dispersed lipid droplets, while in cells stably expressing perilipin A, the lipid droplets were more numerous and tightly clustered in one or two regions of the cytoplasm. Immunofluorescence microscopy revealed that the ectopic perilipin A localized to the surfaces of the tiny clustered lipid droplets; subcellular fractionation of the cells using sucrose gradients confirmed that the perilipin A localized exclusively to lipid droplets. Cells expressing perilipin A stored 6-30-fold more triacylglycerol than control cells due to reduced lipolysis of triacylglycerol stores. The lipolysis of stored triacylglycerol was 5 times slower in lipid-loaded cells expressing perilipin A than in lipid-loaded control cells, when triacylglycerol synthesis was blocked with 6 muM triacsin C. This stabilization of triacylglycerol was not due to the suppression of triacylglycerol lipase activity by the expression of perilipin A. We conclude that perilipin A increases the triacylglycerol content of cells by forming a barrier that reduces the access of soluble lipases to stored lipids, thus inhibiting triacylglycerol hydrolysis. These studies suggest that perilipin A plays a major role in the regulation of triacylglycerol storage and lipolysis in adipocytes.	Rutgers State Univ, Dept Nutrit Sci, New Brunswick, NJ 08901 USA; Med Coll Penn & Hahnemann Univ, Dept Biochem, Philadelphia, PA 19129 USA; NIDDK, Mol Mechanisms Dev Sect, NIH, Bethesda, MD 20892 USA; NIDDK, Membrane Regulat Sect, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	Rutgers State University New Brunswick; Drexel University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Brasaemle, DL (corresponding author), Rutgers State Univ, Dept Nutrit Sci, 96 Lipman Dr, New Brunswick, NJ 08901 USA.			Brasaemle, Dawn/0000-0002-8553-8285	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015503, ZIADK015505, Z01DK015505] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1987, FUNCTIONAL HISTOLOGY; Athenstaedt K, 1997, J BACTERIOL, V179, P7611, DOI 10.1128/jb.179.24.7611-7616.1997; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; BELFRAGE P, 1969, J LIPID RES, V10, P341; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLEMAN R, 1976, J BIOL CHEM, V251, P4537; CUI Z, 1993, J BIOL CHEM, V268, P16655; DELALLERA M, 1979, BIOCHIM BIOPHYS ACTA, V574, P414, DOI 10.1016/0005-2760(79)90237-6; DELAMATRE JG, 1993, J CELL PHYSIOL, V157, P164, DOI 10.1002/jcp.1041570121; EGAN JJ, 1990, J BIOL CHEM, V265, P18769; GOCZE PM, 1992, ENDOCRINOLOGY, V131, P2972, DOI 10.1210/en.131.6.2972; GOCZE PM, 1994, CYTOMETRY, V17, P151, DOI 10.1002/cyto.990170207; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Gros J, 1999, J CELL SCI, V112, P3791; Hammersen F., 1985, HISTOLOGY COLOR ATLA; HARRISON EH, 1990, J LIPID RES, V31, P2187; HILAIRE N, 1995, J BIOL CHEM, V270, P27027, DOI 10.1074/jbc.270.45.27027; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; HOLST LS, 1994, FEBS LETT, V355, P125, DOI 10.1016/0014-5793(94)01185-0; KAWAMURA M, 1981, P NATL ACAD SCI-BIOL, V78, P732, DOI 10.1073/pnas.78.2.732; Khelef N, 1998, J BIOL CHEM, V273, P11218, DOI 10.1074/jbc.273.18.11218; Khoo J C, 1975, Methods Enzymol, V35, P181, DOI 10.1016/0076-6879(75)35154-9; KHOO JC, 1993, J LIPID RES, V34, P1969; Leber R, 1998, MOL BIOL CELL, V9, P375, DOI 10.1091/mbc.9.2.375; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Lehner R, 1999, BIOCHEM J, V338, P761, DOI 10.1042/0264-6021:3380761; Lehner R, 1997, BIOCHEMISTRY-US, V36, P1861, DOI 10.1021/bi962186d; Londos C, 1996, INT J OBESITY, V20, pS97; LONDOS C, 1995, BIOCHEM SOC T, V23, P611, DOI 10.1042/bst0230611; MOREAU H, 1991, BIOCHEMISTRY-US, V30, P1037, DOI 10.1021/bi00218a022; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; REINHART MP, 1987, J BIOL CHEM, V262, P9649; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; SCOW RO, 1980, FED PROC, V39, P2610; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Spector A A, 1980, Prog Lipid Res, V19, P155; TOMODA H, 1991, J BIOL CHEM, V266, P4214; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; Weiss L., 1983, HISTOLOGY CELL TISSU; YEAMAN SJ, 1994, ADV ENZYME REGUL, V34, P355, DOI 10.1016/0065-2571(94)90022-1	50	357	380	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38486	38493		10.1074/jbc.M007322200	http://dx.doi.org/10.1074/jbc.M007322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10948207	hybrid			2022-12-27	WOS:000165739800048
J	Cameron, A; Appel, J; Houghten, RA; Lindberg, I				Cameron, A; Appel, J; Houghten, RA; Lindberg, I			Polyarginines are potent furin inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUENCHED FLUOROGENIC SUBSTRATE; SUBTILISIN-LIKE ENDOPROTEASE; PROHORMONE CONVERTASES; PROPROTEIN CONVERTASES; ALPHA-1-ANTITRYPSIN PORTLAND; PROCESSING ENDOPROTEASE; COMBINATORIAL LIBRARIES; MOLECULAR MECHANISMS; IN-VITRO; SPECIFICITY	The ubiquitous serine endoprotease furin has been implicated in the activation of bacterial toxins and viral glycoproteins as well as in the metastatic progression of certain tumors, Although high molecular mass bioengineered serpin inhibitors have been well characterized, no small nontoxic nanomolar inhibitors have been reported to date. Here we describe the identification of such inhibitors using positional scanning amidated and acetylated synthetic L- and D hexapeptide combinatorial libraries, The results indicated that L-Arg or L-Lys in all positions generated the most potent inhibitors. However, further investigation revealed that the peptide terminating groups hindered inhibition. Consequently, a series of non-amidated and acetylated polyarginines was synthesized. The most potent inhibitor identified, nona-L-arginine, had a K-i for furin of 40 nM. The K-i, values for the related convertases PACE4 and prohormone con vertase-1 (PC1) were 110 nM and 2.5 muM respectively. Although nona-L-arginine was cleaved by furin, the major products after a 6-h incubation at 37 degreesC were hexa-and hepta-L-arginines, both of which retained the great majority of their potency and specificity against furin, Hexa-D-arginine was as potent and specific a furin inhibitor as hexa-L-arginine (K-i values of hexa-D-arginine: 106 nM, 580 nM, and 13.2 muM for furin, PACE4, and PC1, respectively). PC2 was not inhibited by any polyarginine tested; indeed, PC2 showed an increase in activity of up to 140% of the control in the presence of L-polyarginines, Data are also presented that show extended subsite recognition by furin and PC2, Whereas N-terminal acetylation was found to reduce the inhibitory potency of the L-hexapeptide LLRVKR against furin 8-fold, C-terminal amidation reduced the potency <2-fold. Conversely, N-terminal acetylation increased the potency against PC2 nearly 8-fold, whereas C-terminal amidation of the same peptide increased the potency by a factor of 1,6, Our data indicate that non-acetylated, poly-D-arginine-derived molecules may represent excellent lead compounds for the development of therapeutically useful furin inhibitors.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Torrey Pines Institute for Molecular Studies, California	Lindberg, I (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.		Lindberg, Iris/Q-3825-2019		NIDA NIH HHS [DA05084, R56 DA005084, R01 DA005084] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005084, R56DA005084] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; ANGLIKER H, 1995, ANAL BIOCHEM, V224, P409, DOI 10.1006/abio.1995.1058; ANGLIKER H, 1995, J MED CHEM, V38, P4014, DOI 10.1021/jm00020a016; ANGLIKER H, 1993, BIOCHEM J, V293, P75, DOI 10.1042/bj2930075; Apletalina E, 1998, J BIOL CHEM, V273, P26589, DOI 10.1074/jbc.273.41.26589; BASAK A, 1994, INT J PEPT PROT RES, V44, P253; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Berman Y, 1999, J NEUROCHEM, V72, P2120, DOI 10.1046/j.1471-4159.1999.0722120.x; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; Cameron A, 2000, FEBS LETT, V473, P135, DOI 10.1016/S0014-5793(00)01511-8; Cieplik M, 1998, BIOL CHEM, V379, P1433, DOI 10.1515/bchm.1998.379.12.1433; COYLE AJ, 1994, AM J RESP CRIT CARE, V150, pS63, DOI 10.1164/ajrccm/150.5_Pt_2.S63; Dahlen JR, 1998, J BIOL CHEM, V273, P1851, DOI 10.1074/jbc.273.4.1851; Dufour EK, 1998, FEBS LETT, V426, P41, DOI 10.1016/S0014-5793(98)00307-X; Frenette G, 1997, BBA-GEN SUBJECTS, V1334, P109, DOI 10.1016/S0304-4165(96)00080-3; Fricker LD, 2000, J NEUROSCI, V20, P639, DOI 10.1523/JNEUROSCI.20-02-00639.2000; FRIGAS E, 1981, MAYO CLIN P, V56, P245; Fujisawa T, 1999, INT ARCH ALLERGY IMM, V120, P65, DOI 10.1159/000053598; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; Houghten RA, 1999, J MED CHEM, V42, P3743, DOI 10.1021/jm990174v; Jean F, 2000, P NATL ACAD SCI USA, V97, P2864, DOI 10.1073/pnas.050504297; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Khan AR, 1998, PROTEIN SCI, V7, P815; KO KH, 1999, AM J PHYSIOL, V277, P6811; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; Lazure C, 1998, J BIOL CHEM, V273, P8572, DOI 10.1074/jbc.273.15.8572; Lindberg I., 1995, METH NEUROSCI, V23, P94; LU WY, 1993, J BIOL CHEM, V268, P14583; Mains RE, 1997, BIOCHEM J, V321, P587, DOI 10.1042/bj3210587; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Oliva AA, 2000, BBA-PROTEIN STRUCT M, V1477, P338, DOI 10.1016/S0167-4838(99)00283-6; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; Santavicca M, 1996, BIOCHEM J, V315, P953, DOI 10.1042/bj3150953; Schwingshackl A, 1999, J ALLERGY CLIN IMMUN, V104, P983, DOI 10.1016/S0091-6749(99)70079-5; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Shinde U, 2000, SEMIN CELL DEV BIOL, V11, P35, DOI 10.1006/scdb.1999.0349; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Stroh A, 1999, EUR J CELL BIOL, V78, P151, DOI 10.1016/S0171-9335(99)80094-6; Teuchert M, 1999, J BIOL CHEM, V274, P8199, DOI 10.1074/jbc.274.12.8199; Teuchert M, 1999, J BIOL CHEM, V274, P36781, DOI 10.1074/jbc.274.51.36781; Tsuji A, 1999, J BIOCHEM, V126, P591, DOI 10.1093/oxfordjournals.jbchem.a022491; VanRompaey L, 1997, BIOCHEM J, V326, P507; Vepa S, 1997, AM J PHYSIOL-LUNG C, V272, pL608, DOI 10.1152/ajplung.1997.272.4.L608; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509	57	162	182	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36741	36749		10.1074/jbc.M003848200	http://dx.doi.org/10.1074/jbc.M003848200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10958789	hybrid, Green Submitted			2022-12-27	WOS:000165577700043
J	Jung, YS; Bonagura, CA; Tilley, GJ; Gao-Sheridan, HS; Armstrong, FA; Stout, CD; Burgess, BK				Jung, YS; Bonagura, CA; Tilley, GJ; Gao-Sheridan, HS; Armstrong, FA; Stout, CD; Burgess, BK			Structure of C42D Azotobacter vinelandii FdI - A Cys-X-X-Asp-X-X-Cys motif ligates an air-stable [4Fe-4S](2+/+) cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; PYROCOCCUS-FURIOSUS FERREDOXIN; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; DESULFOVIBRIO-AFRICANUS FERREDOXIN; PUTIDA 7-IRON FERREDOXINS; LIGAND 4FE-4S CLUSTER; F-A; SPECTROSCOPIC CHARACTERIZATION; CLOSTRIDIUM-PASTEURIANUM	All naturally occurring ferredoxins that have Cys-XX-Asp-X-X-Cys motifs contain [4Fe-4S]2(+/+) clusters that can be easily and reversibly converted to [3Fe-4S](+/0) clusters. In contrast, ferredoxins with unmodified Cys-X-X-Cyss-X-X-Cys motifs assemble [4Fe-4S]2(+/+) clusters that cannot be easily interconverted with [3Fe-4S](+/0) clusters. In this study we changed the central cysteine of the Cys(39)-X-X-Cys(42)-X-X-Cys(45) of Azotobacter vinelandii FdI, which coordinates its [4Fe-4S]2(+/+) cluster, into an aspartate. UV-visible, EPR, and CD spectroscopies, metal analysis, and x-ray crystallography show that, Like native FdI, aerobically purified C42D FdI is a seven-iron protein retaining its [4Fe-4S]2(+/+) cluster with monodentate aspartate ligation to one iron. Unlike known clusters of this type the reduced [4Fe-4S](+) cluster of C42D FdI exhibits only an S = 1/2 EPR with no higher spin signals detected. The cluster shows only a minor change in reduction potential relative to the native protein. All attempts to convert the cluster to a 3Fe cluster using conventional methods of oxygen or ferricyanide oxidation or thiol exchange were not successful. The cluster conversion was ultimately accomplished using a new electrochemical method. Hydrophobic and electrostatic interaction and the lack of Gly residues adjacent to the Asp Ligand explain the remarkable stability of this cluster.	Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Oxford, Dept Chem, Oxford OX1 3QR, England	University of California System; University of California Irvine; Scripps Research Institute; University of Oxford	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036325, R01GM045209] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45209, GM-36325] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; Aono S, 1996, J BIOL INORG CHEM, V1, P523, DOI 10.1007/s007750050087; Aono S, 1998, BIOCHEMISTRY-US, V37, P9812, DOI 10.1021/bi972818b; AONO S, 1989, J BACTERIOL, V171, P3433, DOI 10.1128/jb.171.6.3433-3439.1989; ARMSTRONG FA, 1993, METHOD ENZYMOL, V227, P479, DOI 10.1016/0076-6879(93)27020-H; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BELL SH, 1982, FEBS LETT, V142, P143, DOI 10.1016/0014-5793(82)80238-X; BERTINI I, 1993, FEBS LETT, V332, P268, DOI 10.1016/0014-5793(93)80647-D; Bian SM, 1998, J AM CHEM SOC, V120, P3532, DOI 10.1021/ja974296t; Boll M, 2000, BIOCHEMISTRY-US, V39, P4929, DOI 10.1021/bi9927890; BOVIERLAPIERRE G, 1987, BIOCHIM BIOPHYS ACTA, V913, P20, DOI 10.1016/0167-4838(87)90227-5; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; Busch JLH, 2000, BIOCHEM J, V346, P375, DOI 10.1042/0264-6021:3460375; Busch JLH, 1996, BIOCHEM J, V314, P63, DOI 10.1042/bj3140063; Busch JLH, 1997, BIOCHEM J, V323, P95, DOI 10.1042/bj3230095; BUTT JN, 1991, J AM CHEM SOC, V113, P6663, DOI 10.1021/ja00017a045; BUTT JN, 1993, J AM CHEM SOC, V115, P1413, DOI 10.1021/ja00057a026; Calzolai L, 1996, J AM CHEM SOC, V118, P2513, DOI 10.1021/ja953744z; CALZOLAI L, 1995, BIOCHEMISTRY-US, V34, P11373, DOI 10.1021/bi00036a010; Camba R, 2000, BIOCHEMISTRY-US, V39, P10587, DOI 10.1021/bi000832+; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CARNEY MJ, 1988, J AM CHEM SOC, V110, P6084, DOI 10.1021/ja00226a025; CHENG H, 1990, J BIOL CHEM, V265, P12388; CHENG H, 1992, J BIOL CHEM, V267, P8073; Coldren CD, 1997, P NATL ACAD SCI USA, V94, P6635, DOI 10.1073/pnas.94.13.6635; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; Duderstadt RE, 1999, FEBS LETT, V454, P21, DOI 10.1016/S0014-5793(99)00766-8; Duff JLC, 1996, J AM CHEM SOC, V118, P8593, DOI 10.1021/ja961465l; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; Fawcett SEJ, 1998, BIOCHEM J, V335, P357, DOI 10.1042/bj3350357; FLINT DH, 1993, J BIOL CHEM, V268, P14732; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P5514, DOI 10.1074/jbc.273.10.5514; GAOSHERIDAN HS, 1998, THESIS U CALIFORNIA; GEORGE SJ, 1989, BIOCHEM J, V264, P275, DOI 10.1042/bj2640275; GIBNEY BR, 1996, P NATL ACAD SCI U S, V93, P1541; GORST CM, 1995, BIOCHEMISTRY-US, V34, P600, DOI 10.1021/bi00002a027; GRAVES MC, 1985, P NATL ACAD SCI USA, V82, P1653, DOI 10.1073/pnas.82.6.1653; HAGEN WR, 1985, FEBS LETT, V189, P250, DOI 10.1016/0014-5793(85)81033-4; HERRING HA, 1998, J AM CHEM SOC, V120, P11628; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; ISAS JM, 1994, J BIOL CHEM, V269, P19404; ISAS JM, 1995, J BIOL CHEM, V270, P21258, DOI 10.1074/jbc.270.36.21258; JOHNSON MK, 1994, ENCY INORGANIC CHEM, V4, P1896; Jordan PA, 1997, FEBS LETT, V416, P349, DOI 10.1016/S0014-5793(97)01219-2; Jung YS, 1997, J BIOL INORG CHEM, V2, P209, DOI 10.1007/s007750050126; Jung YS, 1999, J BIOL CHEM, V274, P2978, DOI 10.1074/jbc.274.5.2978; Jung YS, 1999, J BIOL CHEM, V274, P32402, DOI 10.1074/jbc.274.45.32402; Jung YS, 1996, J BIOL CHEM, V271, P31135, DOI 10.1074/jbc.271.49.31135; Jung YS, 1997, J BIOL CHEM, V272, P8040, DOI 10.1074/jbc.272.12.8040; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; KENT TA, 1985, J BIOL CHEM, V260, P6871; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KISSINGER CR, 1991, J MOL BIOL, V219, P693, DOI 10.1016/0022-2836(91)90665-S; LINDAHL PA, 1990, J CLUST SCI, V1, P29; MANDORI A, 1992, BIOCHEMISTRY-US, V31, P2703; MARTIN AE, 1989, J BACTERIOL, V171, P3162, DOI 10.1128/jb.171.6.3162-3167.1989; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MINAMI Y, 1985, J BIOCHEM-TOKYO, V97, P745, DOI 10.1093/oxfordjournals.jbchem.a135114; MORGAN TV, 1985, FEBS LETT, V183, P206, DOI 10.1016/0014-5793(85)80777-8; MORGAN TV, 1984, P NATL ACAD SCI-BIOL, V81, P1931, DOI 10.1073/pnas.81.7.1931; MORGAN TV, 1988, J BIOL CHEM, V263, P1370; MOURA JJG, 1984, EUR J BIOCHEM, V141, P319, DOI 10.1111/j.1432-1033.1984.tb08194.x; MOURA JJG, 1982, J BIOL CHEM, V257, P6259; OKAWARA N, 1988, J BIOCHEM-TOKYO, V104, P196, DOI 10.1093/oxfordjournals.jbchem.a122441; ONATE YA, 1989, J BIOL CHEM, V264, P18386; REGSTROM K, 1999, P NATL ACAD SCI U S, V96, P12389; Reyntjens B, 1997, J BIOL INORG CHEM, V2, P595, DOI 10.1007/s007750050174; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; ROTH EKH, 1992, INORG CHEM, V31, P240, DOI 10.1021/ic00028a022; SHEN B, 1995, P NATL ACAD SCI USA, V92, P10064, DOI 10.1073/pnas.92.22.10064; SHEN BH, 1994, J BIOL CHEM, V269, P8564; SHEN BH, 1993, J BIOL CHEM, V268, P25928; Sridhar V, 1998, J BIOL INORG CHEM, V3, P140; STOUT CD, 1988, J BIOL CHEM, V263, P9256; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; THOMSON AJ, 1981, BIOCHIM BIOPHYS ACTA, V637, P423, DOI 10.1016/0005-2728(81)90047-5; THOMSON AJ, 1992, J INORG BIOCHEM, V47, P197, DOI 10.1016/0162-0134(92)84065-U; TONG JJ, 1994, J BIOL CHEM, V269, P24920; VAZQUEZ A, 1994, PROTEIN EXPRES PURIF, V5, P96, DOI 10.1006/prep.1994.1014; WAKABAYASHI S, 1983, FEBS LETT, V162, P21, DOI 10.1016/0014-5793(83)81041-2; Wakagi T, 1996, BIOCHEM BIOPH RES CO, V225, P489, DOI 10.1006/bbrc.1996.1200; WEIGEL JA, 1991, J AM CHEM SOC, V113, P4184, DOI 10.1021/ja00011a020; Yannone SM, 1998, J BIOL INORG CHEM, V3, P253, DOI 10.1007/s007750050229; Yannone SM, 1997, J BIOL CHEM, V272, P14454, DOI 10.1074/jbc.272.22.14454; YU L, 1995, BIOCHEMISTRY-US, V34, P7861, DOI 10.1021/bi00024a010; YU LA, 1995, J BIOL CHEM, V270, P28118; Zhou J, 1996, J AM CHEM SOC, V118, P1966, DOI 10.1021/ja9537843; Zhou ZH, 1997, BIOCHEMISTRY-US, V36, P10892, DOI 10.1021/bi9708141	98	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36974	36983		10.1074/jbc.M004947200	http://dx.doi.org/10.1074/jbc.M004947200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10961993	hybrid			2022-12-27	WOS:000165577700074
J	Underwood, MC; Zhong, DG; Mathur, A; Heyduk, T; Bajaj, SP				Underwood, MC; Zhong, DG; Mathur, A; Heyduk, T; Bajaj, SP			Thermodynamic linkage between the S1 site, the Na+ site, and the Ca2+ site in the protease domain of human coagulation factor Xa - Studies on catalytic efficiency and inhibitor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONO-VALENT CATIONS; FACTOR-VA; RESIDUE 225; FACTOR-IX; ACTIVATION; STIMULATION; PROTHROMBIN; THROMBIN; CLEAVAGE; AMIDASE	The serine protease domain of factor Xa (FXa) contains a sodium as well as a calcium-binding site. Here, we investigated the functional significance of these two cation-binding sites and their thermodynamic links to the S1 site. Kinetic data reveal that Na+ binds to the substrate bound FXa with K-d similar to 39 mM in the absence and similar to9.5 mM in the presence of Ca2+. Sodium-bound FXa (sodium-Xa) has similar to 18-fold increased catalytic efficiency (similar to4.5-fold decrease in K-m and similar to4-fold increase in k(cat)) in hydrolyzing S-2222 (benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide), and Ca2+ further increases this k(cat) similar to1.4-fold. Ca2+ binds to the protease domain of substrate bound FXa with K-d similar to 705 par in the absence and similar to 175 muM in the presence of Na+. Ca2+ binding to the protease domain of FXa (Xa-calcium) has no effect on the K-m but increases the k(cat) similar to4-fold in hydrolyzing S-2222, and Na+ further increases this k(cat) similar to1.4-fold. In agreement with the K-m data, sodium-Xa has similar to5-fold increased affinity in its interaction with p-aminobenzamidine (S1 site probe) and similar to4-fold increased rate in binding to the two-domain tissue factor pathway inhibitor; Ca2+ (+/-Na+) has no effect on these interactions. Antithrombin binds to Xa-calcium with a similar to4-fold faster rate, to sodium-Xa with a similar to 24-fold faster rate and to sodium-Xa-calcium with a similar to 28-fold faster rate. Thus, Ca2+ and Na+ together increase the catalytic efficiency of FXa similar to 28-fold. Na+ enhances Ca2+ binding, and Ca2+ enhances Na+ binding. Further, Na+ enhances S1 site occupancy, and S1 site occupancy enhances Na+ binding. Therefore, Na+ site is thermodynamically linked to the S1 site as well as to the protease domain Ca2+ site, whereas Ca2+ site is only linked to the Na+ site. The significance of these findings is that during physiologic coagulation, most of the FXa formed will exist as sodium-Xa-calcium, which has maximum biologic activity.	St Louis Univ, Sch Med, Hlth Sci Ctr, Dept Biochem & Mol Biol,Div Hematol & Oncol, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Saint Louis University; Saint Louis University; Saint Louis University	Bajaj, SP (corresponding author), St Louis Univ, Sch Med, Hlth Sci Ctr, Dept Biochem & Mol Biol,Div Hematol & Oncol, 3635 Vista Ave,POB 15250, St Louis, MO 63110 USA.	BajajPS@slu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036365, R55HL036365, R56HL036365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM050514, R01GM050514] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36365] Funding Source: Medline; NIGMS NIH HHS [GM50514] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; Bajaj SP, 1999, SEMIN THROMB HEMOST, V25, P407, DOI 10.1055/s-2007-994943; BAJAJ SP, 1990, J BIOL CHEM, V265, P2956; Bajaj SP, 1999, THROMB HAEMOSTASIS, V82, P218; Betz A, 1997, BIOCHEMISTRY-US, V36, P181, DOI 10.1021/bi962060g; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P225; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; FERSHT A, 1998, STRUCTURE MECH PROTE, P125; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; He XH, 1999, J BIOL CHEM, V274, P4970, DOI 10.1074/jbc.274.8.4970; HILL KAW, 1986, J BIOL CHEM, V261, P4991; HILL KAW, 1987, J BIOL CHEM, V262, P140; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JESTY J, 1990, J BIOL CHEM, V265, P17539; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P52; LEACH RD, 1991, THROMB RES, V62, P635, DOI 10.1016/0049-3848(91)90368-7; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; MANN KG, 1990, BLOOD, V76, P1; MARQUART M, 1983, ACTA CRYSTALLOGR B, V39, P480, DOI 10.1107/S010876818300275X; Mathur A, 1997, J BIOL CHEM, V272, P23418, DOI 10.1074/jbc.272.37.23418; Mathur A, 1998, BLOOD, V92, p40A; MONROE DM, 1988, ANAL BIOCHEM, V172, P427, DOI 10.1016/0003-2697(88)90465-4; MORITA T, 1986, J BIOL CHEM, V261, P4015; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; ORTHNER CL, 1978, ARCH BIOCHEM BIOPHYS, V185, P400, DOI 10.1016/0003-9861(78)90182-0; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERSSON E, 1993, J BIOL CHEM, V268, P22531; PETERSEN JGL, 1993, J BIOL CHEM, V268, P13344; Pryzdial ELG, 1996, J BIOL CHEM, V271, P16614, DOI 10.1074/jbc.271.28.16614; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P1817, DOI 10.1021/bi992006a; Rezaie AR, 1999, THROMB HAEMOSTASIS, P36; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; ROBERTS PS, 1974, THROMB DIATH HAEMOST, V31, P309, DOI 10.1055/s-0038-1649165; Rosenberg I.M., 1996, PROTEIN ANAL PURIFIC, V1996, P153; Rudolph AE, 2000, BIOCHEMISTRY-US, V39, P2861, DOI 10.1021/bi992379b; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; STEINER SA, 1980, BIOCHEM BIOPH RES CO, V94, P340, DOI 10.1016/S0006-291X(80)80226-9; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	47	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36876	36884		10.1074/jbc.M001386200	http://dx.doi.org/10.1074/jbc.M001386200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973949	hybrid			2022-12-27	WOS:000165577700062
J	Wu, G; MacKenzie, R; Durda, PJ; Tsang, P				Wu, G; MacKenzie, R; Durda, PJ; Tsang, P			The binding of a glycoprotein 120 V3 loop peptide to HIV-1 neutralizing antibodies - Structural implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PANCREATIC TRYPSIN-INHIBITOR; NUCLEAR-MAGNETIC-RESONANCE; 2-DIMENSIONAL NMR-SPECTROSCOPY; SURFACE-PLASMON RESONANCE; C-13 RELAXATION-TIMES; SOLUTION CONFORMATIONS; SYNTHETIC PEPTIDES; ENVELOPE PROTEIN; MONOCLONAL-ANTIBODIES	The structural and antigenic properties of a peptide ("CRK") derived from the V3 loop of HIV-1 gp120 protein were studied using NMR and SPR techniques. The sequence of CRK corresponds to the central portion of the V3 loop containing the highly conserved ''GPGR'' residue sequence. Although the biological significance of this conserved sequence is unknown, the adoption of conserved secondary structure (type II beta -turn) in this region has been proposed. The tendency of CRK (while free or conjugated to protein), to adopt such structure and the influence of such structure upon CRK antigenicity were investigated by NMR and SPR, respectively. Regardless of conjugation, CRK is conformationally averaged in solution but a weak tendency of the CRK "GPGR'' residues to adopt a beta -turn conformation was observed after conjugation. The influence of GPGR structure upon CRK antigenicity was investigated by measuring the affinities of two cognate antibodies: "5023A" and "5025A," for CRK, protein-conjugated CRK and gp120 protein. Each antibody bound to all the antigens with nearly the same affinity. From these data, it appears that: (a) antibody binding most likely involves an induced fit of the peptide and (b) the gp120 V3 loop is probably conformationally heterogeneous. Since 5023A and 5025A are HIV-1 neutralizing antibodies, neutralization in these cases appears to be independent of adopted GPGR beta -turn structure.	Univ Cincinnati, Dept Chem, Cincinnati, OH 45221 USA; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA	University System of Ohio; University of Cincinnati; National Research Council Canada; Harvard University; Massachusetts General Hospital	Tsang, P (corresponding author), Univ Cincinnati, Dept Chem, Cincinnati, OH 45221 USA.	pearl.tsang@uc.edu			NIGMS NIH HHS [GM-47013] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALASUBRAMANIAN S, 1994, J MAGN RESON SER B, V104, P240, DOI 10.1006/jmrb.1994.1081; Beeser SA, 1998, J MOL BIOL, V284, P1581, DOI 10.1006/jmbi.1998.2240; BERNDT KD, 1992, J MOL BIOL, V227, P757, DOI 10.1016/0022-2836(92)90222-6; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROWN LR, 1978, EUR J BIOCHEM, V88, P87, DOI 10.1111/j.1432-1033.1978.tb12425.x; CATASTI P, 1995, J BIOL CHEM, V270, P2224, DOI 10.1074/jbc.270.5.2224; Catasti P, 1996, J BIOL CHEM, V271, P8236, DOI 10.1074/jbc.271.14.8236; CHANDRASEKHAR K, 1991, BIOCHEMISTRY-US, V30, P9187, DOI 10.1021/bi00102a009; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; DELORIMIER R, 1994, BIOCHEMISTRY-US, V33, P2055, DOI 10.1021/bi00174a011; DETTIN M, 1993, BIOCHEM BIOPH RES CO, V191, P364, DOI 10.1006/bbrc.1993.1226; DURDA PJ, 1990, AIDS RES HUM RETROV, V6, P1115, DOI 10.1089/aid.1990.6.1115; DYSON HJ, 1985, NATURE, V318, P480; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; DYSON HJ, 1995, IMMUNOLOGICAL RECOGN, P133; EBINA S, 1989, J BIOL CHEM, V264, P7882; Ghiara JB, 1997, J MOL BIOL, V266, P31, DOI 10.1006/jmbi.1996.0768; GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; GUPTA G, 1993, J BIOMOL STRUCT DYN, V11, P345, DOI 10.1080/07391102.1993.10508731; Hansen JE, 1996, PROTEINS, V25, P1, DOI 10.1002/(SICI)1097-0134(199605)25:1<1::AID-PROT1>3.0.CO;2-N; Harlow E., 1988, ANTIBODIES LABORATOR, P628; HATTORI T, 1989, FEBS LETT, V248, P48, DOI 10.1016/0014-5793(89)80429-6; Huang XL, 1997, BIOCHEMISTRY-US, V36, P10846, DOI 10.1021/bi9703655; Huang XL, 1996, FEBS LETT, V393, P280, DOI 10.1016/0014-5793(96)00912-X; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jelinek R, 1997, J MAGN RESON, V125, P185, DOI 10.1006/jmre.1996.1099; Jelinek R, 1997, J MOL BIOL, V266, P649, DOI 10.1006/jmbi.1996.0821; JEMMERSON R, 1987, P NATL ACAD SCI USA, V84, P9180, DOI 10.1073/pnas.84.24.9180; Jemmerson R., 1995, IMMUNOLOGICAL RECOGN, P213; JOHNSON ME, 1994, FEBS LETT, V337, P4, DOI 10.1016/0014-5793(94)80618-7; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KIM PS, 1988, BIOPHYS CHEM, V31, P107, DOI 10.1016/0301-4622(88)80014-0; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LANGEDIJK JPM, 1991, J GEN VIROL, V72, P2519, DOI 10.1099/0022-1317-72-10-2519; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Markert RLM, 1996, EUR J BIOCHEM, V237, P188, DOI 10.1111/j.1432-1033.1996.0188n.x; NIRMALA NR, 1988, J AM CHEM SOC, V110, P7557, DOI 10.1021/ja00230a057; Niwa Y, 1996, EUR J BIOCHEM, V237, P64, DOI 10.1111/j.1432-1033.1996.0064n.x; OTTING G, 1986, J MAGN RESON, V66, P187, DOI 10.1016/0022-2364(86)90122-8; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PORTER R, 1986, CIB FDN S, V119, P70; RANCE M, 1989, METHOD ENZYMOL, V176, P114; RANCE M, 1986, J MAGN RESON, V66, P372, DOI 10.1016/0022-2364(86)90043-0; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SCHWAB C, 1993, PROTEIN SCI, V2, P175; SPANGLER BD, 1991, J IMMUNOL, V146, P1591; Speck RF, 1997, J VIROL, V71, P7136, DOI 10.1128/JVI.71.9.7136-7139.1997; Stanfield RL, 1999, STRUCTURE, V7, P131, DOI 10.1016/S0969-2126(99)80020-3; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Tsang P, 1997, J MOL RECOGNIT, V10, P256; Tugarinov V, 1999, NAT STRUCT BIOL, V6, P331; Ugolini S, 1997, J EXP MED, V186, P1287, DOI 10.1084/jem.186.8.1287; VANGEET AL, 1970, ANAL CHEM, V42, P679, DOI 10.1021/ac60288a022; Vranken WF, 1996, EUR J BIOCHEM, V236, P100, DOI 10.1111/j.1432-1033.1996.00100.x; Vu HM, 1996, BIOCHEMISTRY-US, V35, P5158, DOI 10.1021/bi952665x; Vu HM, 1999, J VIROL, V73, P746, DOI 10.1128/JVI.73.1.746-750.1999; WAGNER G, 1982, J MOL BIOL, V155, P347, DOI 10.1016/0022-2836(82)90009-2; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; Weliky DP, 1999, NAT STRUCT BIOL, V6, P141; WLODAWER A, 1987, J MOL BIOL, V198, P469, DOI 10.1016/0022-2836(87)90294-4; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WUTHRICH K, 1986, NMR PROTEINS NUUCL A; ZVI A, 1992, BIOCHEMISTRY-US, V31, P6972, DOI 10.1021/bi00145a015	68	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36645	36652		10.1074/jbc.M005369200	http://dx.doi.org/10.1074/jbc.M005369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967109	hybrid			2022-12-27	WOS:000165577700028
J	Goicoechea, S; Orr, AW; Pallero, MA; Eggleton, P; Murphy-Ullrich, JE				Goicoechea, S; Orr, AW; Pallero, MA; Eggleton, P; Murphy-Ullrich, JE			Thrombospondin mediates focal adhesion disassembly through interactions with cell surface calreticulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; RECEPTOR-RELATED PROTEIN; CALCIUM-BINDING PROTEIN; RO/SS-A-ANTIGEN; ENDOTHELIAL-CELLS; EXTRACELLULAR-MATRIX; HEAT-SHOCK; NG108-15 CELLS; UP-REGULATION; EXPRESSION	Thrombospondin induces reorganization of the actin cytoskeleton and restructuring of focal adhesions. This activity is localized to amino acids 17-35 in the N-terminal heparin-binding domain of thrombospondin and can be replicated by a peptide (hep I) with this sequence. Thrombospondin/hep I stimulate focal adhesion disassembly through a mechanism involving phosphoinositide 3-kinase, activation. However, the receptor for this thrombospondin sequence is unknown. We now report that calreticulin on the cell surface mediates focal adhesion disassembly by thrombospondin/hep I. A 60-kDa protein from endothelial cell detergent extracts has homology and-immunoreactivity to calreticulin, binds a hep I affinity column, and neutralizes thrombospondin/hep I-mediated focal adhesion disassembly, Calreticulin on the cell Surface was confirmed by biotinylation, confocal microscopy, and by fluorescence-activated cell sorting analyses, Thrombospondin and calreticulin potentially bind through the hep I sequence, since thrombospondin-calreticulin complex formation can be blocked specifically by hep I peptide. Antibodies to calreticulin and preincubation of thrombospondin/hep I with glutathione S-transferase-calreticulin block thrombospondin/hep I-mediated focal adhesion disassembly and :phosphoinositide 3-kinase activation, suggesting that calreticulin is a component of the thrombospondin-induced signaling cascade that regulates cytoskeletal organization. These data identify both a novel receptor for the N terminus of thrombospondin and a distinct role for cell surface calreticulin in cell adhesion.	Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Cell Adhes & Matrix Res Ctr, Birmingham, AL 35294 USA; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3RE, England	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Oxford	Murphy-Ullrich, JE (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, G038 Volker Hall,1670 Univ Blvd, Birmingham, AL 35294 USA.	murphy@uab.edu	Orr, Anthony/P-8927-2015	Orr, Anthony/0000-0002-2377-213X; Eggleton, Paul/0000-0001-8244-2125; Goicoechea, Silvia/0000-0003-1107-389X	NHLBI NIH HHS [HL44575] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044575] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams J. C., 1995, THROMBOSPONDIN GENE; Arosa FA, 1999, J BIOL CHEM, V274, P16917, DOI 10.1074/jbc.274.24.16917; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; Cho JH, 1999, EUR J BIOCHEM, V266, P878, DOI 10.1046/j.1432-1327.1999.00920.x; Chung CY, 1996, MOL BIOL CELL, V7, P883, DOI 10.1091/mbc.7.6.883; CONWAY EM, 1995, J BIOL CHEM, V270, P17011, DOI 10.1074/jbc.270.28.17011; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; Coppolino MG, 2000, INT J BIOCHEM CELL B, V32, P171, DOI 10.1016/S1357-2725(99)00043-6; Coppolino MG, 1999, BIOCHEM J, V340, P41, DOI 10.1042/0264-6021:3400041; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; Denning GM, 1997, BLOOD, V90, P372; DiPietro LA, 1996, AM J PATHOL, V148, P1851; EGGLETON P, 1994, CLIN IMMUNOL IMMUNOP, V72, P405, DOI 10.1006/clin.1994.1160; Fadel MP, 1999, J BIOL CHEM, V274, P15085, DOI 10.1074/jbc.274.21.15085; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; GRAY AJ, 1995, J BIOL CHEM, V270, P26602, DOI 10.1074/jbc.270.44.26602; Greenwood JA, 1998, J BIOL CHEM, V273, P1755, DOI 10.1074/jbc.273.3.1755; Greenwood JA, 1998, MICROSC RES TECHNIQ, V43, P420, DOI 10.1002/(SICI)1097-0029(19981201)43:5<420::AID-JEMT8>3.0.CO;2-B; Guo WX, 1999, J LAB CLIN MED, V133, P541, DOI 10.1016/S0022-2143(99)90183-X; HOWE SR, 1995, AM J PATHOL, V146, P1568; KAWASHIMA T, 1994, LUPUS, V3, P493, DOI 10.1177/096120339400300612; KETIS NV, 1990, J CELL SCI, V96, P263; Kishore U, 1997, BIOCHEM J, V322, P543, DOI 10.1042/bj3220543; Krutzsch HC, 1999, J BIOL CHEM, V274, P24080, DOI 10.1074/jbc.274.34.24080; KUWABARA K, 1995, J BIOL CHEM, V270, P8179, DOI 10.1074/jbc.270.14.8179; Kwon MS, 2000, MOL BIOL CELL, V11, P1433, DOI 10.1091/mbc.11.4.1433; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; LIEU TS, 1988, J CLIN INVEST, V82, P96, DOI 10.1172/JCI113607; McDonnell JM, 1996, J BIOL CHEM, V271, P7891, DOI 10.1074/jbc.271.14.7891; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MILNER RE, 1991, J BIOL CHEM, V266, P7155; MurphyUllrich JE, 1996, J CELL SCI, V109, P2499; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; MURPHYULLRICH JE, 1995, TRENDS GLYCOSCI GLYC, V7, P89; Nguyen TQ, 1996, MOL IMMUNOL, V33, P379, DOI 10.1016/0161-5890(95)00149-2; Opas M, 1996, J CELL BIOL, V135, P1913, DOI 10.1083/jcb.135.6.1913; PEERSCHKE EIB, 1993, J LEUKOCYTE BIOL, V53, P179, DOI 10.1002/jlb.53.2.179; Phelan MW, 1998, J LAB CLIN MED, V132, P519, DOI 10.1016/S0022-2143(98)90131-7; Pike SE, 1999, BLOOD, V94, P2461, DOI 10.1182/blood.V94.7.2461.419a26_2461_2468; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; RAUGI GJ, 1987, J INVEST DERMATOL, V89, P551, DOI 10.1111/1523-1747.ep12461198; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SUN XJ, 1989, J BIOL CHEM, V264, P11288; Szewczenko-Pawlikowski M, 1997, MOL CELL BIOCHEM, V177, P145, DOI 10.1023/A:1006874019070; van den Berg RH, 1998, J IMMUNOL, V161, P6924; VANDENBERG RH, 1995, EUR J IMMUNOL, V25, P2206, DOI 10.1002/eji.1830250814; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; Xiao GQ, 1999, MOL BRAIN RES, V72, P121, DOI 10.1016/S0169-328X(99)00188-6; Xiao GQ, 1999, J NEUROSCI RES, V58, P652, DOI 10.1002/(SICI)1097-4547(19991201)58:5<652::AID-JNR6>3.0.CO;2-H; Zhu J, 1996, CLIN EXP IMMUNOL, V103, P47, DOI 10.1046/j.1365-2249.1996.00912.x; Zhu Q, 1997, BIOCHEM BIOPH RES CO, V232, P354, DOI 10.1006/bbrc.1997.6195	64	131	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36358	36368		10.1074/jbc.M005951200	http://dx.doi.org/10.1074/jbc.M005951200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964924	hybrid			2022-12-27	WOS:000165382000100
J	Kamashev, DE; Balandina, AV; Karpov, VL				Kamashev, DE; Balandina, AV; Karpov, VL			Tramtrack protein-DNA interactions - A cross-linking study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PEPTIDE; CRYSTAL-STRUCTURE; BINDING DOMAIN; YEAST ADR1; SEQUENCE; RECOGNITION; REGION; ORIENTATION; EXPRESSION; EXTENSION	Interaction of the Tramtrack protein from Drosophila melanogaster with DNA was analyzed by a cross-linking method. Tramtrack, residues cross-linkable to the partially, depurinated DNA were identified by direct sequencing. The N-terminal alpha -amino group of the protein DNA-binding domain was found to be the major product of cross-linking. The location of the N terminus on the DNA was determined by identification of the DNA bases that were cross-linked to the protein cy-amino group. We conclude that accessory N-terminal peptide preceding the first zinc finger of Tramtrack directly interacts with DNA, both in specific and nonspecific DNA-protein complexes. Our finding explains the role in the protein binding of the DNA bases outside of the direct interaction with the zinc fingers.	Russian Acad Sci, W Engelhardt Inst Mol Biol, Lab Chromatin Struct & Funct, Moscow 117984, Russia	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Kamashev, DE (corresponding author), Russian Acad Sci, W Engelhardt Inst Mol Biol, Lab Chromatin Struct & Funct, 32 Vavilov Str, Moscow 117984, Russia.	kamashev@imb.imb.ac.ru	Karpov, Vadim/G-7932-2014; Kamashev, Dmitri/K-6560-2017	Kamashev, Dmitri/0000-0003-4158-5300				BROWN JL, 1991, EMBO J, V10, P665, DOI 10.1002/j.1460-2075.1991.tb07995.x; Dutnall RN, 1996, STRUCTURE, V4, P599, DOI 10.1016/S0969-2126(96)00064-0; EBRALIDSE KK, 1988, NATURE, V331, P365, DOI 10.1038/331365a0; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; Hyre DE, 1998, J MOL BIOL, V279, P929, DOI 10.1006/jmbi.1998.1811; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; KAMASHEV DE, 1995, FEBS LETT, V375, P27, DOI 10.1016/0014-5793(95)01153-6; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MIRZABEKOV AD, 1989, METHOD ENZYMOL, V170, P386; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; NAKASEKO Y, 1992, J MOL BIOL, V228, P619, DOI 10.1016/0022-2836(92)90845-B; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Schmiedeskamp M, 1997, BIOCHEMISTRY-US, V36, P14003, DOI 10.1021/bi971364f; THUKRAL SK, 1991, MOL CELL BIOL, V11, P1566, DOI 10.1128/MCB.11.3.1566; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291	17	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36056	36061		10.1074/jbc.M001691200	http://dx.doi.org/10.1074/jbc.M001691200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964908	hybrid			2022-12-27	WOS:000165382000059
J	Lai, CF; Feng, X; Nishimura, R; Teitelbaum, SL; Avioli, LV; Ross, FP; Cheng, SL				Lai, CF; Feng, X; Nishimura, R; Teitelbaum, SL; Avioli, LV; Ross, FP; Cheng, SL			Transforming growth factor-beta up-regulates the beta(5) integrin subunit expression via Sp1 and Smad signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-LIKE CELLS; TGF-BETA; VITRONECTIN RECEPTOR; ALPHA-V; CHEMOTACTIC RESPONSE; FUNCTIONAL-ANALYSIS; BONE SIALOPROTEIN; GENE-EXPRESSION; DIFFERENTIATION; PROMOTER	Integrin-mediated cell-matrix interactions play important:roles in regulating cell function. Since transforming growth factor-beta (TGF-beta) modulates many osteoblast activities, we hypothesized that the growth factor acts in part by modulating integrin expression. TGF-beta increased cell adhesion to vitronectin and up-regulated the surface level of alpha (v)beta (5) via increasing beta (5) protein synthesis,by a transcriptional mechanism. Promoter activity analysis demonstrated that a TGF-beta -responsive element resides between nucleotides -63 and -44. Electrophoretic mobility shift assay and immunoprecipitation/Western studies indicated that the nuclear complex formed using the -66/-42 oligonucleotide contained both Sp1/Sp3 and Smad proteins. Since nuclear Sp1/Sp3 levels were not altered, whereas Smad levels were increased by TGF-beta, we investigated the roles of Smad proteins in the up-regulation of beta (5) gene activation. Co-transfection of cells with beta (5) promoter reporter construct and expression vectors for Smad3, Smad4, and Spl increased the stimulatory effect of TGF-beta. Furthermore, expression of dominant negative Smad3 or Smad4 in cells decreased or abolished the stimulation of beta (5) promoter activity by TGF-beta. Smad4 mutant also inhibited the up-regulation of surface beta (5) level by TGF-beta. Thus, TGF-beta increases expression of the integrin beta (5) gene by mechanisms involving Sp1/Sp3 and Smad transcription factors.	Washington Univ, Sch Med, Dept Internal Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Osaka Univ, Fac Dent, Dept Biochem, Suita, Osaka 565, Japan	Washington University (WUSTL); Washington University (WUSTL); Osaka University	Cheng, SL (corresponding author), Washington Univ, Barnes Jewish Hosp, Sch Med, Div Bone & Mineral Dis, 216 S Kingshighway Blvd, St Louis, MO 63110 USA.	scheng@imgate.wustl.edu		Teitelbaum, Steven/0000-0002-4054-6679; Nishimura, Riko/0000-0001-7279-8363	NIAMS NIH HHS [AR32087, AR07033, AR42404] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087, T32AR007033, R01AR042404] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; AMARNANI S, 1993, J BONE MINER RES, V8, P157; Bostrom MPG, 1998, CLIN ORTHOP RELAT R, pS124, DOI 10.1097/00003086-199810001-00014; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Cheng SL, 2000, J CELL BIOCHEM, V77, P265, DOI 10.1002/(SICI)1097-4644(20000501)77:2<265::AID-JCB9>3.0.CO;2-6; Choi JY, 1996, J CELL BIOCHEM, V61, P609, DOI 10.1002/(SICI)1097-4644(19960616)61:4<609::AID-JCB15>3.3.CO;2-Q; CLOVER J, 1992, J CELL SCI, V103, P267; Cohen MM, 1997, J BONE MINER RES, V12, P322, DOI 10.1359/jbmr.1997.12.3.322; CONFORTI G, 1994, CELL ADHES COMMUN, V1, P279, DOI 10.3109/15419069409097260; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; De Deyne PG, 1998, J CELL SCI, V111, P2729; Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903; Feng X, 1999, J BIOL CHEM, V274, P1366, DOI 10.1074/jbc.274.3.1366; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; GRONOWICZ GA, 1995, ENDOCRINOLOGY, V136, P598, DOI 10.1210/en.136.2.598; Gronthos S, 1997, J BONE MINER RES, V12, P1189, DOI 10.1359/jbmr.1997.12.8.1189; GRZESIK WJ, 1994, J BONE MINER RES, V9, P487, DOI 10.1002/jbmr.5650090408; HEINO J, 1989, J BIOL CHEM, V264, P21806; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; Hu PPC, 1998, ENDOCR REV, V19, P349, DOI 10.1210/er.19.3.349; HUGHES DE, 1993, J BONE MINER RES, V8, P527; HUGHES FJ, 1992, BONE MINER, V19, P63, DOI 10.1016/0169-6009(92)90844-4; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNOTZ RA, 1989, J BIOL CHEM, V264, P389; Jikko A, 1999, J BONE MINER RES, V14, P1075, DOI 10.1359/jbmr.1999.14.7.1075; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KIM JP, 1994, J BIOL CHEM, V269, P26926; Kim LT, 1997, P SOC EXP BIOL MED, V214, P123; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LIND M, 1995, APMIS, V103, P140, DOI 10.1111/j.1699-0463.1995.tb01089.x; Liu YK, 1997, FEBS LETT, V420, P112, DOI 10.1016/S0014-5793(97)01498-1; LUCAS PA, 1989, BONE, V10, P459, DOI 10.1016/8756-3282(89)90079-3; MARCELLI C, 1990, J BONE MINER RES, V5, P1087; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McCann TJ, 1997, MATRIX BIOL, V16, P273, DOI 10.1016/S0945-053X(97)90015-9; Memmo LM, 1998, J CELL SCI, V111, P425; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Moursi AM, 1997, J CELL SCI, V110, P2187; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; Opperman LA, 1997, J BONE MINER RES, V12, P301, DOI 10.1359/jbmr.1997.12.3.301; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; OURSLER MJ, 1994, J BONE MINER RES, V9, P443; Padgett RW, 1998, PHARMACOL THERAPEUT, V78, P47, DOI 10.1016/S0163-7258(97)00166-6; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P825; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; QU Q, 1998, BONE NY, V23, pS529; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; ROSIER RN, 1998, CLIN ORTHOP S, V335, pS294; Roth DA, 1997, J BONE MINER RES, V12, P311, DOI 10.1359/jbmr.1997.12.3.311; SAITO T, 1994, J ORTHOP RES, V12, P384, DOI 10.1002/jor.1100120311; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SMITH JW, 1990, J BIOL CHEM, V265, P11008; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; Sung V, 1998, J CELL PHYSIOL, V176, P482, DOI 10.1002/(SICI)1097-4652(199809)176:3<482::AID-JCP5>3.0.CO;2-K; TAKAHASHI T, 1986, CELL TISSUE RES, V245, P9; TAKAHASHI T, 1986, ARCH ORAL BIOL, V31, P703, DOI 10.1016/0003-9969(86)90101-9; WERGEDAL JE, 1990, J BONE MINER RES, V5, P179, DOI 10.1002/jbmr.5650050212; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853; ZHOU HY, 1995, CALCIFIED TISSUE INT, V56, P403, DOI 10.1007/BF00301610	72	87	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36400	36406		10.1074/jbc.M002131200	http://dx.doi.org/10.1074/jbc.M002131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964912	hybrid			2022-12-27	WOS:000165382000105
J	Chen, H; Hu, B; Allegretto, EA; Adams, JS				Chen, H; Hu, B; Allegretto, EA; Adams, JS			The vitamin D response element-binding protein - A novel dominant-negative regulator of vitamin D-directed transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WORLD PRIMATE CELLS; DNA-BINDING; SQUIRREL-MONKEY; HNRNP PROTEINS; MESSENGER-RNA; RECEPTOR; RESISTANCE; CLONING; ESTROGEN; GENE	Vitamin D resistance in certain primate genera is associated with the constitutive overexpression of a non-vitamin D receptor (VDR)-related, vitamin D response element-binding protein (VDRE-BP) and squelching of vitamin D-directed transactivation. We used DNA affinity chromatography to purify proteins associated with non-VDR-VDRE binding activity from vitamin D-resistant New World primate cells. In electrophoretic mobility shift assays, these proteins bound specifically to either single-strand or double-strand oligonucleotides harboring the VDRE, Amino acid sequencing of tryptic peptides from a 34-kDa (VDRE-BP1) and 38-kDa species (VDRE-BP-2) possessed sequence homology with human heterogeneous nuclear ribonucleoprotein (hnRNP) A1 and hnRNPA2, respectively. cDNAs bearing the open reading frame for both VDRE-BPs were cloned and used to transfect wild-type, hormone-responsive primate cells, Transient and stable overexpression of the VDREBP2 cDNA, but not the VDRE-BP1 cDNA, in wild-type cells with a VDRE-luciferase reporter resulted in significant reduction in reporter activity. These data suggest that the hnRNPA2-related VDRE-BP2 is a dominant-negative regulator of vitamin D action.	Univ Calif Los Angeles, Div Endocrinol Diabet & Metab, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Burns & Allen Res Inst, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Dept Pathol, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA; Ligand Pharmaceut Inc, San Diego, CA 92121 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Ligand Pharmaceuticals	Adams, JS (corresponding author), Univ Calif Los Angeles, Div Endocrinol Diabet & Metab, Cedars Sinai Med Ctr, Sch Med, 8700 Beverly Blvd,Rm B-131, Los Angeles, CA 90048 USA.		Adams, John S/I-3365-2013	Adams, John S/0000-0001-9607-5020	NIAMS NIH HHS [AR37399] Funding Source: Medline; NIDDK NIH HHS [DK07682] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037399] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS JS, 1985, AM J PRIMATOL, V9, P219, DOI 10.1002/ajp.1350090307; ALLEGRETTO EA, 1995, J BIOL CHEM, V270, P23906, DOI 10.1074/jbc.270.41.23906; Arbelle JE, 1996, ENDOCRINOLOGY, V137, P786, DOI 10.1210/en.137.2.786; BIAMONTI G, 1989, NUCLEIC ACIDS RES, V16, P3751; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; BRANDON DD, 1989, CANCER RES, V49, pS2203; BROWN GM, 1970, ENDOCRINOLOGY, V86, P519, DOI 10.1210/endo-86-3-519; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Chen H, 1997, J CLIN INVEST, V99, P669, DOI 10.1172/JCI119210; Chen H, 1998, J BIOL CHEM, V273, P31352, DOI 10.1074/jbc.273.47.31352; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; CHROUSOS GP, 1984, J CLIN ENDOCR METAB, V58, P516, DOI 10.1210/jcem-58-3-516; CHROUSOS GP, 1984, ENDOCRINOLOGY, V115, P25, DOI 10.1210/endo-115-1-25; CHROUSOS GP, 1982, P NATL ACAD SCI-BIOL, V79, P2036, DOI 10.1073/pnas.79.6.2036; COOKE NE, 1989, ENDOCR REV, V10, P294, DOI 10.1210/edrv-10-3-294; Dreyfuss G, 1996, CELL, V85, P963, DOI 10.1016/S0092-8674(00)81298-2; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; Fu GK, 1997, MOL ENDOCRINOL, V11, P1961, DOI 10.1210/me.11.13.1961; Gacad MA, 1997, J BIOL CHEM, V272, P8433, DOI 10.1074/jbc.272.13.8433; GACAD MA, 1992, AM J PRIMATOL, V28, P263, DOI 10.1002/ajp.1350280404; GACAD MA, 1991, J CLIN INVEST, V87, P996, DOI 10.1172/JCI115108; GACAD MA, 1992, ENDOCRINOLOGY, V131, P2581, DOI 10.1210/en.131.6.2581; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; HAHN S, 1992, Current Biology, V2, P152, DOI 10.1016/0960-9822(92)90268-F; HEWISON M, 1993, CLIN ENDOCRINOL, V39, P663, DOI 10.1111/j.1365-2265.1993.tb02424.x; HOLICK MF, 1987, FASEB J, V46, P1876; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; JIANPING YE, 1996, MOL CELL BIOL, V16, P4744; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Kitanaka S, 1998, NEW ENGL J MED, V338, P653, DOI 10.1056/NEJM199803053381004; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LAHIRI DK, 1986, NUCLEIC ACIDS RES, V14, P4077, DOI 10.1093/nar/14.10.4077; Lipsett M.B., 1985, Recent Progress in Hormone Research, V41, P199; Malloy PJ, 1999, AM J MED, V106, P355, DOI 10.1016/S0002-9343(98)00419-7; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; Ohmori M, 1996, MOL ENDOCRINOL, V10, P1407, DOI 10.1210/me.10.11.1407; PIKE JW, 1987, J BIOL CHEM, V262, P1305; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; Safadi FF, 1999, J CLIN INVEST, V103, P239, DOI 10.1172/JCI5244; SHARP ZD, 1990, BIOCHIM BIOPHYS ACTA, V1048, P306, DOI 10.1016/0167-4781(90)90073-B; Staal A, 1996, MOL ENDOCRINOL, V10, P1444, DOI 10.1210/me.10.11.1444; Subauste JS, 1998, MOL ENDOCRINOL, V12, P1380, DOI 10.1210/me.12.9.1380; TAKAHASHI N, 1985, BIOCHEM J, V227, P555, DOI 10.1042/bj2270555; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; ZERIVITZ K, 1989, GENE ANAL TECH, V6, P101, DOI 10.1016/0735-0651(89)90016-2; Zou AH, 1997, J BIOL CHEM, V272, P19027, DOI 10.1074/jbc.272.30.19027	55	49	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35557	35564		10.1074/jbc.M007117200	http://dx.doi.org/10.1074/jbc.M007117200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10948206	hybrid			2022-12-27	WOS:000165422800095
J	Vincent, B; Paitel, E; Frobert, Y; Lehmann, S; Grassi, J; Checler, F				Vincent, B; Paitel, E; Frobert, Y; Lehmann, S; Grassi, J; Checler, F			Phorbol ester-regulated cleavage of normal prion protein in HEK293 human cells and murine neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-APP MATURATION; ALZHEIMERS-DISEASE; MONOCLONAL-ANTIBODIES; NORMAL BRAIN; PRP0/0 MICE; PEPTIDE; NEUROTOXICITY; SEQUENCE; RELEASE	Cellular prion protein (PrPc) undergoes a proteolytic attach at the 110/111 down arrow 112 peptide bond, whereas the PrP isoform (PrPres) that accumulates in the brain tissue in Creutzfeldt-Jakob disease reveals an alternate cleavage site at about residue 90. Interestingly, the normal processing of PrP occurs inside the 106-126 amino acid region thought to be responsible for the neurotoxicity of the pathogenic prions, whereas PrPres cleavage preserves this potentially toxic domain, Therefore, any molecular mechanisms leading to enhanced cleavage at the 110/111 down arrow 112 peptide bond Could be of potential interest, We set up TSM1 neurons and HEK293 stable transfectants overexpressing the wild-type or 3F4-tagged murine PrPc, respectively, Both mock-transfected and PrPc-expressing cell Lines produced an 11-12-kDa PrP fragment (referred to as N1), the immunological: characterization of which strongly suggests that it corresponds to the N-terminal PrPc fragment derived hom normal processing. We have established that the recovery of secreted N1 is increased by the protein kinase C agonists PDBu and PMA in a time- and dose-dependent manner in both cell lines. In contrast, secretion of N1 remains unaffected by the inactive PDBu analog alpha PDD and by the protein kinase A effecters dibutyryl cAMP and forskolin. Overall, our data indicate that the normal processing of PrPc is up-regulated by protein kinase C but not protein kinase A in human cells and murine neurons.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France; CEA Saclay, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France; CNRS, UPR 1142, Inst Genet Humaine, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Checler, F (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.	checler@ipmc.cnrs.fr	Checler, Frederic/C-1241-2009; Lehmann, Sylvain/P-1301-2017	Checler, Frederic/0000-0003-2098-1750; Lehmann, Sylvain/0000-0001-6117-562X; Vincent, Bruno/0000-0003-3876-2118				Ancolio K, 1999, P NATL ACAD SCI USA, V96, P4119, DOI 10.1073/pnas.96.7.4119; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; Brown DR, 1999, J NEUROCHEM, V73, P1105, DOI 10.1046/j.1471-4159.1999.0731105.x; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CHECLER F, 1995, J NEUROCHEM, V65, P1431; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; Demart S, 1999, BIOCHEM BIOPH RES CO, V265, P652, DOI 10.1006/bbrc.1999.1730; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Ghetti B, 1996, BRAIN PATHOL, V6, P127, DOI 10.1111/j.1750-3639.1996.tb00796.x; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; JACOBSEN JS, 1994, J BIOL CHEM, V269, P8376; Jimenez-Huete A, 1998, AM J PATHOL, V153, P1561, DOI 10.1016/S0002-9440(10)65744-6; Jobling MF, 1999, J NEUROCHEM, V73, P1557, DOI 10.1046/j.1471-4159.1999.0731557.x; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Krasemann S, 1996, J IMMUNOL METHODS, V199, P109, DOI 10.1016/S0022-1759(96)00165-2; Krasemann S, 1996, MOL MED, V2, P725, DOI 10.1007/BF03401656; Kretzschmar HA, 1997, J NEURAL TRANSM-SUPP, P191; Marambaud P, 1999, BRIT J PHARMACOL, V126, P1186, DOI 10.1038/sj.bjp.0702406; Marambaud P, 1998, MOL MED, V4, P715, DOI 10.1007/BF03401766; Negro A, 2000, BIOCHEM BIOPH RES CO, V271, P337, DOI 10.1006/bbrc.2000.2628; Prusiner SB, 1996, TRENDS BIOCHEM SCI, V21, P482, DOI 10.1016/S0968-0004(96)10063-3; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028	29	97	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35612	35616		10.1074/jbc.M004628200	http://dx.doi.org/10.1074/jbc.M004628200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952979	hybrid			2022-12-27	WOS:000165422800103
J	Cunningham, SA; Arrate, MP; Rodriguez, JM; Bjercke, RJ; Vanderslice, P; Morris, AP; Brock, TA				Cunningham, SA; Arrate, MP; Rodriguez, JM; Bjercke, RJ; Vanderslice, P; Morris, AP; Brock, TA			A novel protein with homology to the junctional adhesion molecule - Characterization of leukocyte interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; DOWN-SYNDROME; IMMUNOGLOBULIN SUPERFAMILY; PDZ DOMAINS; PECAM-1; LIGAND; ALPHA(V)BETA(3); ORGANIZATION; CD31/PECAM-1; RECOGNITION	We have cloned a novel cDNA belonging to the Ig superfamily that shows 44% similarity to the junctional adhesion molecule (JAM) and maps to chromosome 21q21.2. The open reading frame of JAM2 predicts a 34-kDa type I integral membrane protein that features two Ig-Like folds and three N-linked glycosylation sites in the extracellular domain. A single protein kinase C phosphorylation consensus site and a PDZ-binding motif are present in the short intracellular tail. Heterologous expression of JAM2 in Chinese hamster ovary cells defined a 48-kDa protein that localizes predominantly to the intercellular borders. Northern blot analysis showed that JAM2 is preferentially expressed in the heart. JAM2 homotypic interactions were demonstrated by the ability of JAM2-Fc to capture JAM2-expressing Chinese hamster ovary cells. We further showed that JAM2, but not JAM1, is capable of adhering to the HSB and HPB-ALL lymphocyte cell lines. Neutralizing mouse anti-JAM2 polyclonal antibodies provided evidence against homotypic interactions in this assay. Biotinylation of HSB cell membranes revealed a 43-kDa counter receptor that precipitates specifically with JAM2-Fc. These characteristics of JAM2 led us to hypothesize a role for this novel protein in adhesion events associated with cardiac inflammatory conditions.	Texas Biotechnol Corp, Dept Pharmacol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System	Cunningham, SA (corresponding author), Texas Biotechnol Corp, Dept Pharmacol, 7000 Fannin,Suite 1920, Houston, TX 77030 USA.	scunningham@tbc.com						ATHERTON A, 1972, J PHYSIOL-LONDON, V222, P447, DOI 10.1113/jphysiol.1972.sp009808; AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Buckley CD, 1996, J CELL SCI, V109, P437; Cunningham SA, 1999, J BIOL CHEM, V274, P18421, DOI 10.1074/jbc.274.26.18421; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Hartwell DW, 1999, THROMB HAEMOSTASIS, V82, P850, DOI 10.1055/s-0037-1615922; KOBAYASHI T, 1994, CLIN EXP IMMUNOL, V96, P110; KORENBERG JR, 1992, AM J HUM GENET, V50, P294; Liu Y, 2000, J CELL SCI, V113, P2363; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Newman PJ, 1997, J CLIN INVEST, V100, pS25; Ozaki H, 1999, J IMMUNOL, V163, P553; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Ruef J, 1999, THROMB HAEMOSTASIS, V82, P109, DOI 10.1055/s-0037-1614638; Sheibani N, 1999, DEV DYNAM, V214, P44, DOI 10.1002/(SICI)1097-0177(199901)214:1<44::AID-DVDY5>3.0.CO;2-L; SIMIONESCU M, 1976, J CELL BIOL, V68, P705, DOI 10.1083/jcb.68.3.705; SIMMONS DL, 1999, ADV MOL CEL, V28, P113; SINET PM, 1994, BIOMED PHARMACOTHER, V48, P247, DOI 10.1016/0753-3322(94)90140-6; Sobocka MB, 2000, BLOOD, V95, P2600; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Takashima S, 1997, CURR OPIN NEUROL, V10, P148, DOI 10.1097/00019052-199704000-00013; TODDERUD G, 1992, J LEUKOCYTE BIOL, V52, P85, DOI 10.1002/jlb.52.1.85; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Williams LA, 1999, MOL IMMUNOL, V36, P1175, DOI 10.1016/S0161-5890(99)00122-4	36	124	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34750	34756		10.1074/jbc.M002718200	http://dx.doi.org/10.1074/jbc.M002718200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10945976	hybrid			2022-12-27	WOS:000165095300100
J	Takaku, K; Sonoshita, M; Sasaki, N; Uozumi, N; Doi, Y; Shimizu, T; Taketo, MM				Takaku, K; Sonoshita, M; Sasaki, N; Uozumi, N; Doi, Y; Shimizu, T; Taketo, MM			Suppression of intestinal polyposis in Apc(Delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; MAST-CELLS; GROUP-II; PROSTAGLANDIN PRODUCTION; P388D(1) MACROPHAGES; DEPENDENT INCREASE; MAJOR MODIFIER; COLON-CANCER; CYCLOOXYGENASE-2; GENERATION	Arachidonic acid is a precursor for biosynthesis of eicosanoids, including prostaglandins, thromboxanes, leukotrienes, and lipoxins. Cytosolic phospholipase A, (cPLA(2)) plays a key role in the release of arachidonic acid as the substrate of cyclooxygenase-l (COX-1) or COX-2. We found that the level of cPLA(2) mRNA was markedly elevated in the polyps and correlated with the polyp size in the small intestine of the Apc(Delta 716) knockout mouse, a model for human familial adenomatous polyposis. To determine the role of cPLA(2) in intestinal tumorigenesis, we then introduced a cPLA(2) gene mutation into Apc(Delta 716) mice. In the compound mutant mice, the size of the small intestinal polyps was reduced significantly, although the numbers remained unchanged. These results provide direct genetic evidence that cPLA(2) plays a key role in the expansion of polyps in the small intestine rather than in the initiation process. In contrast, colonic polyps were not affected in either size or number. Interestingly, group X sPLA(2) was constitutively expressed in the colon at much higher levels than in the small intestine. These results suggest that in the colon, group X sPLA(2) supplies arachidonic acid in both the normal epithelium and the polyps even in the absence of cPLA(2).	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Biomed Genet, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Taketo, MM (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Biomed Genet, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		SONOSHITA, MASAHIRO/Q-1571-2019; Sasaki, Nobuya/F-6579-2012; Sonoshita, Masahiro/AAE-5516-2019; Uozumi, Nobuyuki/AAG-3252-2019	SONOSHITA, MASAHIRO/0000-0003-2890-336X; 				Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952; Dennis EA, 2000, AM J RESP CRIT CARE, V161, pS32, DOI 10.1164/ajrccm.161.supplement_1.ltta-7; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dimberg J, 1998, ANTICANCER RES, V18, P3283; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Fujita T, 1998, CANCER RES, V58, P4823; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gould KA, 1996, GENETICS, V144, P1769; HOLTZMAN MJ, 1991, AM REV RESPIR DIS, V143, P188, DOI 10.1164/ajrccm/143.1.188; Hull MA, 1999, BRIT J CANCER, V79, P1399, DOI 10.1038/sj.bjc.6690224; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Sawada H, 1999, EUR J BIOCHEM, V263, P826, DOI 10.1046/j.1432-1327.1999.00565.x; Shattuck-Brandt RL, 2000, GASTROENTEROLOGY, V118, P337, DOI 10.1016/S0016-5085(00)70216-2; Shindou H, 2000, BIOCHEM BIOPH RES CO, V271, P812, DOI 10.1006/bbrc.2000.2723; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Soydan AS, 1997, EUR J CANCER, V33, P1508, DOI 10.1016/S0959-8049(97)00168-8; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Taketo MM, 1998, CLINICAL SIGNIFICANCE AND POTENTIAL OF SELECTIVE COX-2 INHIBITORS, P129; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Yang VW, 1998, CANCER RES, V58, P1750	41	124	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34013	34016		10.1074/jbc.C000586200	http://dx.doi.org/10.1074/jbc.C000586200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10969066	hybrid			2022-12-27	WOS:000165095300002
J	Babenko, AP; Gonzalez, GC; Bryan, J				Babenko, AP; Gonzalez, GC; Bryan, J			Accelerated publication - Hetero-concatemeric K(IR)6.X-4/SUR1(4) channels display distinct conductivities but uniform ATP inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNELS; SULFONYLUREA RECEPTOR; SUBUNIT STOICHIOMETRY; UNITARY CONDUCTANCE; ION CHANNELS; TERMINUS; KIR6.1; CELLS; SELECTIVITY; ACTIVATION	K(IR)6.1 and K(IR)6.2 are the pore-forming subunits of K-NDP, the nucleotide-diphosphate-activated K-ATP channels, and classical K-ATP channels, respectively. "Hybrid" channels, in which the structure is predetermined by concatemerizing K(IR)6.1 and K(IR)6.2, exhibit distinct conductivities specified by subunit number and position. Inclusion of one K(IR)6.2 is sufficient to open K(IR)6.X-X-X-X/SUR1(4) in the absence of nucleotide stimulation through sulfonylurea receptor-1 (SUR1). ATP inhibited the spontaneous bursting of hybrid channels with an IC50(ATP) similar to 10(-5) M, similar to that of K(IR)6.2(4)-containing channels. These findings and a transient increase in K-NDP channel activity following rapid wash-out of MgATP suggested that K(IR)6.1 is not ATP-insensitive as previously believed. We propose that SUR-dependent, inhibitory ATP-enhanced interactions of the cytoplasmic domains of both K(IR)6.1 and K(IR)6.2 stabilize a closed form of the M2 bundle in the gating apparatus.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Babenko, AP (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.							Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; Ammala C, 1996, J PHYSIOL-LONDON, V494, P709, DOI 10.1113/jphysiol.1996.sp021526; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Babenko AP, 1999, J BIOL CHEM, V274, P11587, DOI 10.1074/jbc.274.17.11587; Babenko AP, 1999, FEBS LETT, V445, P131, DOI 10.1016/S0014-5793(99)00102-7; Babenko AP, 1998, CIRC RES, V83, P1132, DOI 10.1161/01.RES.83.11.1132; Babenko AP, 1999, BIOCHEM BIOPH RES CO, V255, P231, DOI 10.1006/bbrc.1999.0172; Babenko AP, 2000, J BIOL CHEM, V275, P717, DOI 10.1074/jbc.275.2.717; Babenko AP, 1999, FEBS LETT, V459, P367, DOI 10.1016/S0014-5793(99)01215-6; BEECH DJ, 1993, BRIT J PHARMACOL, V110, P573, DOI 10.1111/j.1476-5381.1993.tb13849.x; Berneche S, 2000, BIOPHYS J, V78, P2900, DOI 10.1016/S0006-3495(00)76831-7; Capener CE, 2000, BIOPHYS J, V78, P2929, DOI 10.1016/S0006-3495(00)76833-0; Crank J., 1975, MATH DIFFUSION; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; FURUKAWA T, 1994, J PHYSIOL-LONDON, V479, P95, DOI 10.1113/jphysiol.1994.sp020280; Kondo C, 1998, RECEPTOR CHANNEL, V6, P129; Li L, 1999, BIOPHYS J, V76, pA77; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Repunte VP, 1999, EMBO J, V18, P3317, DOI 10.1093/emboj/18.12.3317; Seharaseyon J, 2000, J BIOL CHEM, V275, P17561, DOI 10.1074/jbc.275.23.17561; Silverman SK, 1998, BIOPHYS J, V75, P1330, DOI 10.1016/S0006-3495(98)74051-2; Takano M, 1998, J PHYSIOL-LONDON, V512, P395, DOI 10.1111/j.1469-7793.1998.395be.x; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zheng J, 1998, J GEN PHYSIOL, V112, P457, DOI 10.1085/jgp.112.4.457	31	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31563	31566		10.1074/jbc.C000553200	http://dx.doi.org/10.1074/jbc.C000553200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10956638	hybrid			2022-12-27	WOS:000089858900003
J	Pece, S; Gutkind, JS				Pece, S; Gutkind, JS			Signaling from E-cadherins to the MAPK pathway by the recruitment and activation of epidermal growth factor receptors upon cell-cell contact formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATENIN COMPLEX; PROTEIN INTERACTIONS; ADHESION; JUNCTIONS; INTEGRINS; SURVIVAL; LINE	E-cadherins are well characterized cell surface molecules expressed in epithelial cells, which play a major role in cell adhesion through the establishment of calcium-dependent hemophilic interactions at sites of cell-cell contacts. They are also integral components of morphogenetic programs controlling the maintenance of the structural and functional integrity of epithelia, Accumulated evidence indicates that the E-cadherin-mediated cell adhesion system is highly regulated from inside the cells by a number of intracellular signaling pathways. Recently available information suggests that E-cadherins may also play a role in the transduction of signals from the outside of the cell to the cytoplasm. However, the nature of the biochemical routes regulated by E-cadherins is still largely unknown. In this study, we set out to explore the possibility that E-cadherins may regulate the activity of MAPK, a key signaling pathway involved in cell fate decisions, upon the formation of cell-cell contacts among neighboring cells. By using an immortalized non-tumorigenic keratinocyte cell line, HaCat, as a model system, we provide evidence that the assembly of calcium-dependent adherens junctions leads to a rapid and remarkable increase in the state of activation of MAPK and that this event is mediated by E-cadherins. Furthermore, we found that E-cadherins stimulate the MAPK pathway through the ligand-independent activation of epidermal growth factor receptors and the consequent activation of a biochemical route leading to the stimulation of MAPKs. These findings suggest that E-cadherins can initiate outside-in signal transducing pathways through the engagement of tyrosine kinase receptors for epidermal growth factor, thus providing a novel molecular mechanism whereby these cell adhesion molecules may ultimately control the fate of normal and transformed epithelial cells.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bldg 30,Rm 211,9000 Rockville Pike, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Pece, Salvatore/B-9609-2013; Gutkind, J. Silvio/J-1201-2016	Pece, Salvatore/0000-0003-1764-3929; Gutkind, J. Silvio/0000-0002-5150-4482	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551, Z01DE000558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Braga VMM, 1999, J CLIN PATHOL-MOL PA, V52, P197, DOI 10.1136/mp.52.4.197; Breitkreutz D, 1998, EUR J CELL BIOL, V75, P273, DOI 10.1016/S0171-9335(98)80123-4; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kinch M S, 1997, Cell Adhes Commun, V4, P425, DOI 10.3109/15419069709004459; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIOZAKI H, 1995, BRIT J CANCER, V71, P250, DOI 10.1038/bjc.1995.52; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	26	277	290	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41227	41233		10.1074/jbc.M006578200	http://dx.doi.org/10.1074/jbc.M006578200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10969083	hybrid			2022-12-27	WOS:000166114600076
J	Yap, CL; Hughan, SC; Cranmer, SL; Nesbitt, WS; Rooney, MM; Giuliano, S; Kulkarni, S; Dopheide, SM; Yuan, YP; Salem, HH; Jackson, SP				Yap, CL; Hughan, SC; Cranmer, SL; Nesbitt, WS; Rooney, MM; Giuliano, S; Kulkarni, S; Dopheide, SM; Yuan, YP; Salem, HH; Jackson, SP			Synergistic adhesive interactions and signaling mechanisms operating between platelet glycoprotein Ib/IX and integrin alpha(IIB)beta(3) - Studies in human platelets and transfected Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; VONWILLEBRAND-FACTOR-BINDING; IIB-IIIA; SHEAR-STRESS; TYROSINE PHOSPHORYLATION; THROMBUS FORMATION; IIB/IIIA COMPLEX; FLOW CONDITIONS; MOLECULAR-BASIS; DISTINCT ROLES	This study investigates three aspects of the adhesive interaction operating between platelet glycoprotein Ib/IX and integrin alpha (IIb)beta (3). These include the following: 1) examining the sufficiency of GPIb/IX and integrin alpha (IIb)beta (3) to mediate irreversible cell adhesion on immobilized von Willebrand factor (vWf) under flow; 2) the ability of the vWf-GPIb interaction to induce integrin alpha (IIb)beta (3) activation independent of endogenous platelet stimuli; and 3) the identification of key second messengers linking the vWf-GPIb/IX interaction to integrin alpha (IIb)beta (3) activation. By using Chinese hamster ovary cells transfected with GPIb/IX and integrin alpha (IIb)beta (3), we demonstrate that these receptors are both necessary and sufficient to mediate irreversible cell adhesion under flow, wherein GPIb/M mediates cell tethering and rolling on immobilized vWf, and integrin alpha (IIb)beta (3) mediates cell arrest, Moreover, we demonstrate direct signaling between GPIb/M and integrin alpha (IIb)beta (3). Studies on human platelets demonstrated that vWf binding to GPIb/M is able to induce integrin alpha (IIb)beta (3) activation independent of endogenous platelet stimuli under both static and physiological flow conditions (150-1800 s(-1)). Analysis of the key second messengers linking the vWf-GPIb interaction to integrin alpha (IIb)beta (3) activation demonstrated that the first step in the activation process involves calcium release from internal stores, whereas transmembrane calcium influx is a secondary event potentiating integrin alpha (IIb)beta (3) activation.	Box HIll Hosp, Monash Med Sch, Dept Med, Australian Ctr Blood Dis, Box Hill, Vic 3128, Australia	Box Hill Hospital; Monash University	Jackson, SP (corresponding author), Box HIll Hosp, Monash Med Sch, Dept Med, Australian Ctr Blood Dis, Arnold St, Box Hill, Vic 3128, Australia.	Shaun.Jackson@med.monash.edu.au		Jackson, Shaun/0000-0002-4750-1991; Nesbitt, Warwick/0000-0001-5644-7053				Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; CHOW TW, 1992, BLOOD, V80, P113; COOKE BM, 1993, MICROVASC RES, V45, P33, DOI 10.1006/mvre.1993.1004; Cranmer SL, 1999, J BIOL CHEM, V274, P6097, DOI 10.1074/jbc.274.10.6097; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; FRANCESCONI M, 1995, BIOCHEM BIOPH RES CO, V214, P102, DOI 10.1006/bbrc.1995.2262; FRANCESCONI MA, 1993, THROMB HAEMOSTASIS, V70, P697; Gachet C, 1997, THROMB HAEMOSTASIS, V78, P271; GRALNICK HR, 1985, J CLIN INVEST, V75, P19; Gu MY, 1999, J CELL BIOL, V147, P1085, DOI 10.1083/jcb.147.5.1085; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HANDA M, 1986, J BIOL CHEM, V261, P2579; Hechler B, 1998, BLOOD, V92, P152, DOI 10.1182/blood.V92.1.152.413k27_152_159; Heraud JM, 1998, J BIOL CHEM, V273, P17817, DOI 10.1074/jbc.273.28.17817; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IKEDA Y, 1993, THROMB HAEMOSTASIS, V69, P496; Ingall AH, 1999, J MED CHEM, V42, P213, DOI 10.1021/jm981072s; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; Kermode JC, 1996, BLOOD CELL MOL DIS, V22, P238, DOI 10.1006/bcmd.1996.0104; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; Kulkarni S, 2000, J CLIN INVEST, V105, P783, DOI 10.1172/JCI7569; Kuwahara M, 1999, BLOOD, V94, P1149, DOI 10.1182/blood.V94.4.1149.416k18_1149_1155; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEY K, 1991, BLOOD, V77, P2553; MacKenzie AB, 1996, J BIOL CHEM, V271, P2879, DOI 10.1074/jbc.271.6.2879; MOAKE JL, 1988, BLOOD, V71, P1366; MOLNAR J, 1961, ARCH BIOCHEM BIOPHYS, V93, P353, DOI 10.1016/0003-9861(61)90278-8; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; MORITZ MW, 1983, J LAB CLIN MED, V101, P537; NIIYA K, 1987, BLOOD, V70, P475; ODA A, 1995, THROMB HAEMOSTASIS, V74, P736; Ruggeri ZM, 1993, CURR OPIN CELL BIOL, V5, P898, DOI 10.1016/0955-0674(93)90041-N; RUGGERI ZM, 1985, SEMIN HEMATOL, V22, P203; Ruggeri ZM, 1999, BLOOD, V94, P172, DOI 10.1182/blood.V94.1.172.413k17_172_178; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAGE SO, 1987, J BIOL CHEM, V262, P16364; SAKARIASSEN KS, 1986, BRIT J HAEMATOL, V63, P681, DOI 10.1111/j.1365-2141.1986.tb07552.x; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; Shattil SJ, 1999, THROMB HAEMOSTASIS, V82, P318; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WEISS HJ, 1991, ANN NY ACAD SCI, V614, P125, DOI 10.1111/j.1749-6632.1991.tb43698.x; WEISS HJ, 1986, BLOOD, V67, P322; WEISS HJ, 1971, NEW ENGL J MED, V285, P369, DOI 10.1056/NEJM197108122850703; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847; Yuan YP, 1999, J BIOL CHEM, V274, P36241, DOI 10.1074/jbc.274.51.36241; Zaffran Y, 2000, J BIOL CHEM, V275, P16779, DOI 10.1074/jbc.275.22.16779	55	91	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41377	41388		10.1074/jbc.M005590200	http://dx.doi.org/10.1074/jbc.M005590200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10967111	hybrid			2022-12-27	WOS:000166114600095
J	Dupraz, P; Cottet, S; Hamburger, F; Dolci, W; Felley-Bosco, E; Thorens, B				Dupraz, P; Cottet, S; Hamburger, F; Dolci, W; Felley-Bosco, E; Thorens, B			Dominant negative MyD88 proteins inhibit interleukin-1 beta/interferon-gamma-mediated induction of nuclear factor kappa B-dependent nitrite production and apoptosis in beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIVO GENE DELIVERY; OXIDE SYNTHASE; INSULIN-SECRETION; DIABETES-MELLITUS; FATTY-ACIDS; EXPRESSION; CYTOKINES; INTERLEUKIN-1; DESTRUCTION; MEDIATORS	Insulin-dependent diabetes mellitus is an autoimmune disease in which pancreatic islet beta cells are destroyed by a combination of immunological and inflammatory mechanisms. In particular, cytokine-induced production of nitric oxide has been shown to correlate with beta cell apoptosis and/or inhibition of insulin secretion. In the present study, we investigated whether the interleukin (IL)-1 beta intracellular signal transduction pathway could be blocked by overexpression of dominant negative forms of the IL-1 receptor interacting protein MyD88, We show that overexpression of the Toll domain or the 1pr mutant of MyD88 in beta Tc-Tet cells decreased nuclear factor kappaB (NF-kappaB) activation upon IL-1 beta and IL-1 beta /interferon (IFN)-gamma stimulation, Inducible nitric oxide synthase mRNA accumulation and nitrite production, which required the simultaneous presence of IL-1 beta and IFN-gamma, were also suppressed by similar to 70%, and these cells were more resistant to cytokine-induced apoptosis as compared with parental cells. The decrease in glucose-stimulated insulin secretion induced by IL-1 beta and IFN-gamma was however not prevented. This was because these dysfunctions were induced by IFN-gamma alone, which decreased cellular insulin content and stimulated insulin exocytosis, These results demonstrate that IL-1 beta is involved in inducible nitric oxide synthase gene expression and induction of apoptosis in mouse beta cells but does not contribute to impaired glucose stimulated insulin secretion. Furthermore, our data show that IL-1 beta cellular actions can be blocked by expression of MyD88 dominant negative proteins and, finally, that cytokine-induced beta cell secretory dysfunctions are due to the action of IFN-gamma.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Thorens, B (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, 27 Rue Bugnon, CH-1005 Lausanne, Switzerland.		Felley-Bosco, Emanuela/E-7484-2017	Felley-Bosco, Emanuela/0000-0002-3408-0294				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Benoist C, 1997, CELL, V89, P1, DOI 10.1016/S0092-8674(00)80174-9; Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; CHARNEAU P, 1994, J MOL BIOL, V241, P561; Darville MI, 1998, DIABETOLOGIA, V41, P1101, DOI 10.1007/s001250051036; Delaney CA, 1997, ENDOCRINOLOGY, V138, P2610, DOI 10.1210/en.138.6.2610; Dupraz P, 1999, GENE THER, V6, P1160, DOI 10.1038/sj.gt.3300922; Efrat S, 1998, EUR J ENDOCRINOL, V138, P129, DOI 10.1530/eje.0.1380129; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; EIZIRIK DL, 1994, J CLIN INVEST, V93, P1968, DOI 10.1172/JCI117188; Eizirik DL, 1996, DIABETOLOGIA, V39, P875; Eizirik DL, 1997, DIABETES METAB REV, V13, P293, DOI 10.1002/(SICI)1099-0895(199712)13:4<293::AID-DMR195>3.0.CO;2-4; Fleischer N, 1998, DIABETES, V47, P1419, DOI 10.2337/diabetes.47.9.1419; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gremlich S, 1997, J BIOL CHEM, V272, P3216, DOI 10.1074/jbc.272.6.3216; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; Ling ZD, 2000, DIABETES, V49, P340, DOI 10.2337/diabetes.49.3.340; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Pakala SV, 1999, J EXP MED, V189, P1053, DOI 10.1084/jem.189.7.1053; Pavlovic D, 1999, EUR CYTOKINE NETW, V10, P403; RABINOVITCH A, 1994, J CLIN ENDOCR METAB, V79, P1058, DOI 10.1210/jc.79.4.1058; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; RAGO R, 1990, ANAL BIOCHEM, V191, P31; SUAREZPINZON WL, 1994, ENDOCRINOLOGY, V134, P1006, DOI 10.1210/en.134.3.1006; Takamura T, 1998, J BIOL CHEM, V273, P2493, DOI 10.1074/jbc.273.5.2493; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999; Zumsteg U, 2000, DIABETES, V49, P39, DOI 10.2337/diabetes.49.1.39	43	66	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37672	37678		10.1074/jbc.M005150200	http://dx.doi.org/10.1074/jbc.M005150200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10967106	hybrid			2022-12-27	WOS:000165618700051
J	Liszewski, MK; Leung, M; Cui, WY; Subramanian, VB; Parkinson, J; Barlow, PN; Manchester, M; Atkinson, JP				Liszewski, MK; Leung, M; Cui, WY; Subramanian, VB; Parkinson, J; Barlow, PN; Manchester, M; Atkinson, JP			Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEASLES-VIRUS RECEPTOR; CRYSTAL-STRUCTURE; FACTOR-H; COMPONENT C3; MONOCLONAL-ANTIBODY; SECONDARY STRUCTURE; MULTIPLE ISOFORMS; N-GLYCANS; BINDING; MODULES	Membrane cofactor protein (MCP; CD46), a widely distributed regulator of complement activation, is a cofactor for the factor I-mediated degradation of C3b and C4b deposited on host cells. MCP possesses four extracellular, contiguous complement control protein modules (CCPs) important for this inhibitory activity. The goal of the present study was to delineate functional sites within these modules. We employed multiple approaches including mutagenesis, epitope mapping, and comparisons to primate MCP to make the following observations. First, functional sites were located to each of the four CCPs. Second, some residues were important for both C3b and C4b interactions while others were specific for one or the other. Third, while a reduction in ligand binding was invariably accompanied by a parallel reduction in cofactor activity (CA), other mutants lost or had reduced CA but retained ligand binding. Fourth, two C4b-regulatory domains overlapped measles virus interactive regions, indicating that the hemagglutinin docks to a site important for complement inhibition. Fifth, several MCP regulatory areas corresponded to functionally critical, homologous positions in other CCP-bearing C3b/C4b-binding proteins. Based on these data and the recently derived crystal structure of repeats one and two, computer modeling was employed to predict MCP structure and examine active sites.	Washington Univ, Sch Med, Div Rheumatol, Dept Med, St Louis, MO 63110 USA; Scripps Res Inst, Dept Neuropharmacol, Div Virol, La Jolla, CA 92037 USA; Edinburgh Ctr Prot Technol, Edinburgh EH9 3JJ, Midlothian, Scotland	Washington University (WUSTL); Scripps Research Institute; University of Edinburgh	Atkinson, JP (corresponding author), Washington Univ, Sch Med, Div Rheumatol, Dept Med, 660 S Euclid Ave,Box 8045, St Louis, MO 63110 USA.		Barlow, Paul N/G-2853-2011; Parkinson, John/A-4424-2008	Parkinson, John/0000-0001-9815-1189; Atkinson, John/0000-0002-2514-3441; Manchester, Marianne/0000-0002-7143-5744	NIAID NIH HHS [R01AI37618] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037618] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Accardo P, 1996, J IMMUNOL, V157, P4935; ADAMS EM, 1991, J IMMUNOL, V147, P3005; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON DJ, 1989, BIOL REPROD, V41, P285, DOI 10.1095/biolreprod41.2.285; ANDERSON DJ, 1993, P NATL ACAD SCI USA, V90, P10051, DOI 10.1073/pnas.90.21.10051; ANDREWS PW, 1985, ANN HUM GENET, V49, P31, DOI 10.1111/j.1469-1809.1985.tb01673.x; BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; BARLOW PN, 1991, BIOCHEMISTRY-US, V30, P997, DOI 10.1021/bi00218a016; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; Bouma B, 1999, EMBO J, V18, P5166, DOI 10.1093/emboj/18.19.5166; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Buchholz CJ, 1997, J BIOL CHEM, V272, P22072, DOI 10.1074/jbc.272.35.22072; Casasnovas JM, 1999, EMBO J, V18, P2911, DOI 10.1093/emboj/18.11.2911; CERVONI F, 1992, J IMMUNOL, V148, P1431; COLE JL, 1985, P NATL ACAD SCI USA, V82, P859, DOI 10.1073/pnas.82.3.859; COYNE KE, 1992, J IMMUNOL, V149, P2906; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; DYKMAN TR, 1983, P NATL ACAD SCI-BIOL, V80, P1698, DOI 10.1073/pnas.80.6.1698; Higgins PJ, 1997, J IMMUNOL, V158, P2872; Howard J, 1998, J LEUKOCYTE BIOL, V64, P68, DOI 10.1002/jlb.64.1.68; HSI BL, 1988, AM J REPROD IMMUNOL, V18, P21; Hsu EC, 1999, VIROLOGY, V258, P314, DOI 10.1006/viro.1999.9712; Hsu EC, 1997, J VIROL, V71, P6144, DOI 10.1128/JVI.71.8.6144-6154.1997; IWATA K, 1995, J BIOL CHEM, V270, P15148, DOI 10.1074/jbc.270.25.15148; Kallstrom H, 1997, MOL MICROBIOL, V25, P639, DOI 10.1046/j.1365-2958.1997.4841857.x; Kirkitadze MD, 1999, BIOCHEMISTRY-US, V38, P7019, DOI 10.1021/bi982453a; Kirkitadze MD, 1999, BIOCHEM J, V344, P167, DOI 10.1042/0264-6021:3440167; Kirkitadze MD, 1999, FEBS LETT, V459, P133, DOI 10.1016/S0014-5793(99)01205-3; Kirkitadze MD, 1999, PROG COLL POL SCI S, V113, P164; Kitamura M, 1997, J REPROD IMMUNOL, V33, P83, DOI 10.1016/S0165-0378(97)01017-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; Krych-Goldberg M, 1999, J BIOL CHEM, V274, P31160, DOI 10.1074/jbc.274.44.31160; Lambris JD, 1996, J IMMUNOL, V156, P4821; Liszewski MK, 1996, ADV IMMUNOL, V61, P201; Liszewski MK, 1998, J IMMUNOL, V161, P3711; Liszewski MK, 1996, J IMMUNOL, V156, P4415; LISZEWSKI MK, 1998, COMPLEMENT SYSTEM, P146; Lozahic S, 2000, EUR J IMMUNOL, V30, P900, DOI 10.1002/1521-4141(200003)30:3<900::AID-IMMU900>3.0.CO;2-X; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Maisner A, 1996, J VIROL, V70, P4973, DOI 10.1128/JVI.70.8.4973-4977.1996; MAISNER A, 1995, VIROLOGY, V210, P479, DOI 10.1006/viro.1995.1365; MAISNER A, 1994, J VIROL, V68, P6299, DOI 10.1128/JVI.68.10.6299-6304.1994; Manchester M, 1997, VIROLOGY, V233, P174, DOI 10.1006/viro.1997.8581; MANCHESTER M, 1995, P NATL ACAD SCI USA, V92, P2303, DOI 10.1073/pnas.92.6.2303; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; Mumenthaler C, 1997, PROTEIN SCI, V6, P588; Nagar B, 1998, SCIENCE, V280, P1277, DOI 10.1126/science.280.5367.1277; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; NICKELLS MW, 1990, J IMMUNOL, V144, P4262; NICKELLS MW, 1995, J IMMUNOL, V154, P2829; Ogata RT, 1998, J IMMUNOL, V161, P4785; OKADA N, 1995, P NATL ACAD SCI USA, V92, P2489, DOI 10.1073/pnas.92.7.2489; Oran AE, 1999, J BIOL CHEM, V274, P5120, DOI 10.1074/jbc.274.8.5120; PERKINS SJ, 1988, BIOCHEMISTRY-US, V27, P4004, DOI 10.1021/bi00411a017; POST TW, 1991, J EXP MED, V174, P93, DOI 10.1084/jem.174.1.93; ROONEY IA, 1993, XENOBIOTICA, V1, P29; RUSSELL SM, 1992, EUR J IMMUNOL, V22, P1513, DOI 10.1002/eji.1830220625; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Santoro F, 1999, CELL, V99, P817, DOI 10.1016/S0092-8674(00)81678-5; Schwarzenbacher R, 1999, EMBO J, V18, P6228, DOI 10.1093/emboj/18.22.6228; SEYA T, 1993, EUR J IMMUNOL, V23, P1322, DOI 10.1002/eji.1830230620; TANIGUCHISIDLE A, 1994, J IMMUNOL, V153, P5285; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; Xu CG, 2000, SCIENCE, V287, P498, DOI 10.1126/science.287.5452.498	67	117	122	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37692	37701		10.1074/jbc.M004650200	http://dx.doi.org/10.1074/jbc.M004650200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10960475	hybrid			2022-12-27	WOS:000165618700054
J	Asoh, S; Ohtsu, T; Ohta, S				Asoh, S; Ohtsu, T; Ohta, S			The super anti-apoptotic factor Bcl-xFNK constructed by disturbing intramolecular polar interactions in rat Bcl-x(L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C ACCUMULATION; CELL-DEATH; HYDROGEN-PEROXIDE; PROTEIN; MITOCHONDRIA; CHANNEL; RELEASE; INVOLVEMENT; INHIBITORS; DEPENDENCE	A powerful artificial anti-apoptotic factor will be useful for medical applications of the future therapies for many diseases by prolonging survival of sick cells. For constructing it, we designed the super anti-apoptotic factor by disturbing three intramolecular polar interactions among alpha -helix structures of Ecl-x,. The resultant mutant Bcl-x(L), named Bcl-xFNK was expected to make the pore-forming domain more mobile and flexible than the wild-type, When overexpressed in Jurkat cells, Bcl-xFNK was markedly more potent in prolonging survival following apoptosis-inducing treatment with a kind of cell death cytokines (anti-Fas), a protein kinase inhibitor (staurosporine), cell cycle inhibitors (TN-16, camptothecin, hydroxyurea, and trichostatin A), or oxidative stress (hydrogen peroxide and paraquat) than wild-type Bcl-x(L), Furthermore, the transfectants of bcl-xFNK became more resistant against a calcium ionophore and even a heat treatment than wild-type Bcl-x(L). In addition, Bcl-xFNK showed marked anti-apoptotic activity in Chinese hamster ovary and Jurkat cells deprived of serum. Thus, Bcl-xFNK may be the first mutant generated by site-directed mutagenesis of Bcl-x(L) with a gain-of-function phenotype, Interestingly, Bcl-xFNK was found to allow interleukin-3-dependent FDC-P1 to grow without interleukin-3, but not BaF/3. In Bcl-xFNK transfectants of FDC-P1 and Jurkat, the p42/p44 mitogen-activated protein kinase was activated by 2 to 5 times, but not in those of BaF/3 and Chinese hamster ovary. Bcl-xFNK might gain a new function to activate the mitogen-activated protein kinase in a cell-type specific manner. The findings of this study suggest that the central alpha5-alpha6 pore-forming region of anti-apoptotic factor Bcl-x(L) has a pivotal role in suppressing apoptosis.	Nippon Med Sch, Inst Gerontol, Dept Biochem & Cell Biol, Nakahara Ku, Kawasaki, Kanagawa 2118533, Japan	Nippon Medical School	Ohta, S (corresponding author), Nippon Med Sch, Inst Gerontol, Dept Biochem & Cell Biol, Nakahara Ku, 1-396 Kosuhicho, Kawasaki, Kanagawa 2118533, Japan.							Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; Asoh S, 1999, NEUROSCI LETT, V272, P62, DOI 10.1016/S0304-3940(99)00485-1; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Ishibashi Y, 1998, BIOCHEM BIOPH RES CO, V243, P609, DOI 10.1006/bbrc.1998.8145; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Marzo I, 1998, BIOMED PHARMACOTHER, V52, P248, DOI 10.1016/S0753-3322(98)80009-7; Mastrangelo AJ, 2000, BIOTECHNOL BIOENG, V67, P555, DOI 10.1002/(SICI)1097-0290(20000305)67:5<555::AID-BIT6>3.0.CO;2-T; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; Medina V, 1997, CANCER RES, V57, P3697; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Samali A, 1999, FEBS LETT, V461, P306, DOI 10.1016/S0014-5793(99)01486-6; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu T, 1997, LEUKEMIA, V11, P1238, DOI 10.1038/sj.leu.2400734; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Takadera T, 1997, EUR J BIOCHEM, V249, P8, DOI 10.1111/j.1432-1033.1997.00008.x; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; Tey BT, 2000, BIOTECHNOL BIOENG, V68, P31, DOI 10.1002/(SICI)1097-0290(20000405)68:1<31::AID-BIT4>3.0.CO;2-L; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	33	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37240	37245		10.1074/jbc.M005841200	http://dx.doi.org/10.1074/jbc.M005841200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10970895	hybrid			2022-12-27	WOS:000165577700107
J	Hsieh, CM; Fukumoto, S; Layne, MD; Maemura, K; Charles, H; Patel, A; Perrella, MA; Lee, ME				Hsieh, CM; Fukumoto, S; Layne, MD; Maemura, K; Charles, H; Patel, A; Perrella, MA; Lee, ME			Striated muscle preferentially expressed genes alpha and beta are two serine/threonine protein kinases derived from the same gene as the aortic preferentially expressed gene-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; CONSERVED FEATURES; RAT HEARTS; SMOOTH; TELOKIN; FAMILY; IDENTIFICATION; ISOFORMS; DATABASE; DOMAIN	Aortic preferentially expressed gene (APEG)-1 is a 1.4-kilobase pair (kb) mRNA expressed in vascular smooth muscle cells and is down-regulated by vascular injury. An APEG-1 5'-end cDNA probe identified three additional isoforms. The 9-kb striated preferentially expressed gene (SPEG)alpha and the 11-kb SPEG beta were found in skeletal muscle and heart. The 4-kb brain preferentially expressed gene was detected in the brain and aorta. We report here cloning of the Il-kb SPEG beta cDNA SPEG beta encodes a 355-kDa protein that contains two serine/threonine kinase domains and is homologous to proteins of the myosin light chain kinase family. At least one Kinase domain is active and capable of autophosphorylation. In the genome, all four isoforms share the middle three of the five exons of APEG-1, and they differ from each other by using different 5'- and S'-ends and alternative splicing. We show that the expression of SPEG alpha and SPEG beta is developmentally regulated in the striated muscle during C2C12 myoblast to myotube differentiation in vitro and cardiomyocyte maturation in vivo. This developmental regulation suggests that both SPEG alpha and SPEG beta can serve as sensitive markers for striated muscle differentiation and that they may be important for adult striated muscle function.	Brigham & Womens Hosp, Div Cardiovasc, Program Dev Cardiovasc Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Pulm & Crit Care Div, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Perrella, MA (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Program Dev Cardiovasc Biol, 75 Francis St, Boston, MA 02115 USA.	mperrella@rics.bwh.harvard.edu		Layne, Matthew/0000-0003-0007-4870	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788, F32HL010113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60788, HL10113] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PAW, 1995, CIRC RES, V76, P681, DOI 10.1161/01.RES.76.4.681; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; Chin MT, 1999, J MOL CELL CARDIOL, V31, P2199, DOI 10.1006/jmcc.1999.1054; CLAYCOMB WC, 1992, TRENDS CARDIOVAS MED, V2, P231, DOI 10.1016/1050-1738(92)90030-V; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; EPSTEIN HF, 1991, SCIENCE, V251, P1039, DOI 10.1126/science.1998120; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; Gittenberger-de Groot AC, 1999, ARTERIOSCL THROM VAS, V19, P1589; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; Hsieh CM, 1999, J BIOL CHEM, V274, P14344, DOI 10.1074/jbc.274.20.14344; Hsieh CM, 1996, J BIOL CHEM, V271, P17354, DOI 10.1074/jbc.271.29.17354; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KEMP BE, 1994, PROTEIN KINASES, P30; Maruyama K, 1997, FASEB J, V11, P341, DOI 10.1096/fasebj.11.5.9141500; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; NAUMANN K, 1994, DIFFERENTIATION, V55, P203, DOI 10.1046/j.1432-0436.1994.5530203.x; Nieznanski K, 1997, BIOCHEM J, V322, P65, DOI 10.1042/bj3220065; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; OWENS GK, 1995, PHYSIOL REV, V75, P487; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; Rumyantsev P P, 1977, Int Rev Cytol, V51, P186; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918	37	47	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36966	36973		10.1074/jbc.M006028200	http://dx.doi.org/10.1074/jbc.M006028200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973969	hybrid			2022-12-27	WOS:000165577700073
J	Llano, E; Pendas, AM; Aza-Blanc, P; Kornberg, TB; Lopez-Otin, C				Llano, E; Pendas, AM; Aza-Blanc, P; Kornberg, TB; Lopez-Otin, C			RETRACTED: Dm1-MMP, a matrix metalloproteinase from Drosophila with a potential role in extracellular matrix remodeling during neural development (Retracted article. See vol. 294, pg. 1428, 2019)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							CELL-MIGRATION; IMMUNOGLOBULIN SUPERFAMILY; TISSUE INHIBITORS; GENETIC-ANALYSIS; GROWTH; EXPRESSION; MELANOGASTER; DOMAIN; MEMBER; COLLAGENASE	We have cloned and characterized a cDNA encoding Dm1-MMP, the first matrix metalloproteinase (MMP) identified in Drosophila melanogaster. The isolated cDNA encodes a protein of 541 residues that has a domain organization identical to that of most vertebrate MMPs including a signal sequence, a prodomain with the activation locus, a catalytic domain with a zinc-binding site, and a COOH-terminal hemopexin domain, Northern blot analysis of Dm1-MMP expression in embryonic and larval adult tissues revealed a strong expression level in the developing embryo at 10-22 h, declining thereafter and being undetectable in adults. Western blot analysis confirmed the presence of pro-and active forms of Dm1-MMP in vivo during larval development. In situ hybridization experiments demonstrated that Dm1-MMP is expressed in a segmented pattern in cell clusters at the midline during embryonic stage 12-13, when neurons of the central nervous system start to arise. Recombinant Dm1-MMP produced in Escherichia coli exhibits a potent proteolytic activity against synthetic peptides used for analysis of vertebrate MMPs. This activity is inhibited by tissue inhibitors of metalloproteinases and by synthetic MMP inhibitors such as BB-94. Furthermore, Dm1-MMP is able to degrade the extracellular matrix and basement membrane proteins fibronectin and type TV collagen. On the basis of these data, together with the predominant expression of Dm1-MMP in embryonic neural cells, we propose that this enzyme may be involved in the extracellular matrix remodeling taking place during the development of the central nervous system in Drosophila.	Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, Inst Univ Oncol, E-33006 Oviedo, Spain; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of Oviedo; Instituto Universitario de Oncologia de Asturias; University of California System; University of California San Francisco	Lopez-Otin, C (corresponding author), Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, Inst Univ Oncol, E-33006 Oviedo, Spain.	CLO@correo.uniovi.es	Pendas, Alberto M/L-1017-2014	Pendas, Alberto M/0000-0001-9264-3721				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Butler SJ, 1997, DEVELOPMENT, V124, P781; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CECCHINI JP, 1987, EUR J BIOCHEM, V165, P587, DOI 10.1111/j.1432-1033.1987.tb11480.x; CHIANG C, 1994, DEVELOPMENT, V120, P3581; Couet J, 1996, J BIOL CHEM, V271, P4545; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; FESSLER JH, 1989, ANNU REV CELL BIOL, V5, P309, DOI 10.1146/annurev.cb.05.110189.001521; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; GRATECOS D, 1988, EMBO J, V7, P215, DOI 10.1002/j.1460-2075.1988.tb02802.x; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GROSS J, 1965, P NATL ACAD SCI USA, V54, P1197, DOI 10.1073/pnas.54.4.1197; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; KINOSHITA T, 1992, P NATL ACAD SCI USA, V89, P4693, DOI 10.1073/pnas.89.10.4693; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Konttinen YT, 1999, ANN RHEUM DIS, V58, P691, DOI 10.1136/ard.58.11.691; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; Leontovich AA, 2000, DEVELOPMENT, V127, P907; LEPAGE T, 1990, EMBO J, V9, P3003, DOI 10.1002/j.1460-2075.1990.tb07493.x; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; Maidment JM, 1999, J BIOL CHEM, V274, P34706, DOI 10.1074/jbc.274.49.34706; Maniatis T., 1982, MOL CLONING; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Menne TV, 1997, DEVELOPMENT, V124, P4949; MUIR D, 1994, EXP CELL RES, V210, P243, DOI 10.1006/excr.1994.1036; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Noordermeer JN, 1998, NEURON, V21, P991, DOI 10.1016/S0896-6273(00)80618-2; NORDSTROM LA, 1995, MOL CELL NEUROSCI, V6, P56, DOI 10.1006/mcne.1995.1006; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Park HI, 2000, J BIOL CHEM, V275, P20540, DOI 10.1074/jbc.M002349200; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pohar N, 1999, GENOMICS, V57, P293, DOI 10.1006/geno.1999.5776; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; ROEBROEK AJM, 1992, J BIOL CHEM, V267, P17208; ROEBROEK AJM, 1993, EMBO J, V12, P1853, DOI 10.1002/j.1460-2075.1993.tb05834.x; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; SIDENKIAMOS I, 1990, NUCLEIC ACIDS RES, V18, P6261, DOI 10.1093/nar/18.21.6261; Sotillos S, 1997, DEVELOPMENT, V124, P4769; SPANA EP, 1995, DEVELOPMENT, V121, P3489; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; Stracke JO, 2000, J BIOL CHEM, V275, P14809, DOI 10.1074/jbc.275.20.14809; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Uria JA, 2000, CANCER RES, V60, P4745; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; Wada K, 1998, GENE, V211, P57, DOI 10.1016/S0378-1119(98)00076-6; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Yang MZ, 1997, J BIOL CHEM, V272, P13527, DOI 10.1074/jbc.272.21.13527; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Yu Q, 2000, GENE DEV, V14, P163	60	98	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35978	35985		10.1074/jbc.M006045200	http://dx.doi.org/10.1074/jbc.M006045200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964925	hybrid			2022-12-27	WOS:000165382000048
J	Nillni, EA; Vaslet, C; Harris, M; Hollenberg, A; Bjorbaek, C; Flier, JS				Nillni, EA; Vaslet, C; Harris, M; Hollenberg, A; Bjorbaek, C; Flier, JS			Leptin regulates prothyrotropin-releasing hormone biosynthesis - Evidence for direct and indirect pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; AGOUTI-RELATED PROTEIN; MESSENGER-RIBONUCLEIC-ACID; OBESE GENE-PRODUCT; NEUROPEPTIDE-Y; OB/OB MICE; FRAMESHIFT MUTATION; INDUCED SUPPRESSION; RESPONSE ELEMENTS; THYROID-FUNCTION	The hypothalamic-pituitary-thyroid axis is down-regulated during starvation, and falling levels of leptin are a critical signal for this adaptation, acting to suppress preprothyrbtropin-releasing hormone (prepro-TRH) mRNA expression in the paraventricular nucleus of the hypothalamus, This study addresses the mechanism for this regulation, using primary cultures of fetal rat hypothalamic neurons as a model system. Leptin dose-dependently stimulated a 10-fold increase in pro-TRH biosynthesis, with a maximum response at 10 nM, TRH release was quantified using immunoprecipitation, followed by isoelectric focusing gel electrophoresis and specific TRH, radioimmunoassay, Leptin stimulated TRH release by 7-fold. Immunocytochemistry revealed that a substantial population of cells expressed TRH or leptin receptors and that 8-13% of those expressing leptin receptors coexpressed TRH. Leptin produced a 5-fold induction of luciferase activity in CV-1 cells transfected with a TRH promoter and the long form of the leptin receptor cDNA, Although the above data are consistent with a direct ability of leptin to promote TRH biosynthesis through actions on TRH neurons, addition of alpha -melanocyte-stimulating hormone produced a 3.5-fold increase in TRH biosynthesis and release, whereas neuropeptide Y treatment suppressed pro-TRH biosynthesis similar to3-fold. Furthermore, the melanocortin-4 receptor antagonist SHU9119 partially inhibited leptin-stimulated TRH release from the neuronal culture, Consequently, our data suggest that leptin regulates the TRH neurons through both direct and indirect pathways.	Brown Univ, Rhode Isl Hosp, Sch Med, Div Endocrinol, Providence, RI 02903 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol, Boston, MA 02215 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Nillni, EA (corresponding author), Brown Univ, Rhode Isl Hosp, Sch Med, Div Endocrinol, 55 Claverick St, Providence, RI 02903 USA.	Eduardo_Nillni@Brown.edu	Bjorbaek, Christian/S-4727-2019; Harris, Mark/A-5858-2011; Flier, jeffrey/AAG-6223-2019	Harris, Mark/0000-0003-2461-6603; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058148] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 RO1 DK58148-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 1999, ENDOCRINOLOGY, V140, P4923, DOI 10.1210/en.140.11.4923; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 1998, ENDOCRINOLOGY, V139, P3485, DOI 10.1210/en.139.8.3485; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; BLAKE NG, 1991, ENDOCRINOLOGY, V129, P2714, DOI 10.1210/endo-129-5-2714; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cohen RN, 1998, MOL ENDOCRINOL, V12, P1567, DOI 10.1210/me.12.10.1567; Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0; Elmquist JK, 1998, J COMP NEUROL, V395, P535; Fekete C, 2000, J NEUROSCI, V20, P1550; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; FREAKE HC, 1995, ANNU REV NUTR, V15, P263, DOI 10.1146/annurev.nu.15.070195.001403; GANTZ I, 1993, J BIOL CHEM, V268, P15174; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hileman SM, 2000, ENDOCRINOLOGY, V141, P1955, DOI 10.1210/en.141.6.1955; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kask A, 1999, NEUROREPORT, V10, P707, DOI 10.1097/00001756-199903170-00009; Kim MS, 2000, J CLIN INVEST, V105, P1005, DOI 10.1172/JCI8857; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Legradi G, 1999, ENDOCRINOLOGY, V140, P3643, DOI 10.1210/en.140.8.3643; Legradi G, 1997, ENDOCRINOLOGY, V138, P2569, DOI 10.1210/en.138.6.2569; Legradi G, 1998, ENDOCRINOLOGY, V139, P3262, DOI 10.1210/en.139.7.3262; Legradi G, 1998, NEUROENDOCRINOLOGY, V68, P89, DOI 10.1159/000054354; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MUENZER J, 1979, J BIOL CHEM, V254, P5623; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1260, DOI 10.1210/en.132.3.1260; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1271, DOI 10.1210/en.132.3.1271; Nillni EA, 1999, ENDOCRINE, V10, P185, DOI 10.1007/BF02738618; Nillni EA, 1999, ENDOCR REV, V20, P599, DOI 10.1210/er.20.5.599; NILLNI EA, 1995, J NEUROCHEM, V65, P2462; Nillni EA, 1996, ENDOCRINOLOGY, V137, P5651, DOI 10.1210/en.137.12.5651; NILLNI EA, 1991, METHODS NEUROSCIENCE, V6, P51; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RONDEEL JMM, 1992, NEUROENDOCRINOLOGY, V56, P348, DOI 10.1159/000126248; Rosenfeld RD, 1998, BIOCHEMISTRY-US, V37, P16041, DOI 10.1021/bi981027m; SASAKI S, 1982, J DENT RES, V61, P1479; Schaner P, 1997, J BIOL CHEM, V272, P19958, DOI 10.1074/jbc.272.32.19958; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; TONI R, 1993, J ENDOCRINOL INVEST, V16, P715, DOI 10.1007/BF03348918; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	53	174	179	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36124	36133		10.1074/jbc.M003549200	http://dx.doi.org/10.1074/jbc.M003549200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967095	hybrid			2022-12-27	WOS:000165382000069
J	Vadlamudi, RK; Adam, L; Wang, RA; Mandal, M; Nguyen, D; Sahin, A; Chernoff, J; Hung, MC; Kumar, R				Vadlamudi, RK; Adam, L; Wang, RA; Mandal, M; Nguyen, D; Sahin, A; Chernoff, J; Hung, MC; Kumar, R			Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAS TRANSFORMATION; RAT-1 FIBROBLASTS; PAK KINASES; CDC42; RAC1; PAXILLIN; PHOSPHORYLATION; LOCALIZATION; INHIBITION	Stimulation of growth factor signaling has been implicated;in the development of invasive phenotypes and the activation of pal-activated kinase (Pak1) in human breast; cancer cells (Adam, L., Vadlamudi, R., Kondapaka, S. B., Chernoff, J., Mendelsohn, J,, and Kumar, Ri (1998) J. Biol. Chem. 273, 28238-28246; Adam, L., Vadlamudi, R,, Mandal, M,, Chernoff, J., and Kumar, R. (2000) J. Biol. Chem. 275, 12041-12050). To study the role of: Pak1 in the regulation of motility and growth of breast:epithelial cells, we developed human epithelial MCF-7 clones that overexpressed the kinase-active T423E Pak1 mutant under an inducible tetracycline promoter or that stably expressed the kinase-active H83L,H86L Pak1 mutant, which is deficient in small GTPase binding sites, The expression of both T423E and H83L,H86L Pak1 mutants in breast epithelial cells was accompanied:by increased cell motility without any apparent effect On the growth rate of cells, The T423E Pak1 mutant was primarily localized to filopodia, and the H83L,H86L Pak1 mutant was primarily localized to ruffles. Cells expressing T423E Pak1 exhibited a regulatable stimulation of mitogen-activated protein kinase and Jun N-terminal kinase activities. The expression of kinase-active Pak1 mutants significantly stimulated anchorage-independent growth of cells in soft agar in a preferential mitogen-activated protein kinase-sensitive manner.: In addition, regulatable expression of kinase-active Pak1-resulted in an abnormal organization of mitotic spindles characterized by appearance of multiple spindle orientations. We also provide evidence to suggest a close correlation between the status of Pak1 kinase activity and base-line invasiveness of human breast cancer cells and breast tumor grades. This study is the first demonstration of Pak1 regulation of anchorage-independent growth, potential Pak1 regulation of invasiveness, and abnormal organization of mitotic spindles of human epithelial breast cancer cells.	Univ Texas, MD Anderson Canc Ctr 108, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Fox Chase Canc Ctr, Philadelphia, PA 19100 USA	University of Texas System; UTMD Anderson Cancer Center; Fox Chase Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr 108, Dept Mol & Cellular Oncol, 1515 Holcomble Blvd, Houston, TX 77030 USA.	rkumar@notes.mdacc.tmc.edu	Hung, Mien-Chie/ABD-5911-2021; Mandal, Mahitosh/GMW-6195-2022; Wang, Brian/HGA-9535-2022; Chernoff, Jonathan/I-7631-2014	Hung, Mien-Chie/0000-0003-4317-4740; Mandal, Mahitosh/0000-0003-3861-3323; Chernoff, Jonathan/0000-0002-4803-7836	NATIONAL CANCER INSTITUTE [U01CA065746, P30CA016672, R01CA065746] Funding Source: NIH RePORTER; NCI NIH HHS [CA 80066, CA65746, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; ALI IU, 1988, SCIENCE, V240, P1795, DOI 10.1126/science.3289120; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COX AD, 1994, METHOD ENZYMOL, V238, P277; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Kozma R, 1996, MOL CELL BIOL, V16, P5069; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; QIU A, 1992, P NATL ACAD SCI USA, V92, P11781; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Tang CK, 1996, CANCER RES, V56, P3350; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Vadlamudi R, 1999, CANCER RES, V59, P2843; Vadlamudi R, 1999, ONCOGENE, V18, P7253, DOI 10.1038/sj.onc.1203163; Wu C, 1997, J BIOL CHEM, V272, P30623, DOI 10.1074/jbc.272.49.30623; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	29	215	227	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36238	36244		10.1074/jbc.M002138200	http://dx.doi.org/10.1074/jbc.M002138200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10945974	hybrid			2022-12-27	WOS:000165382000084
J	Wang, HY; Doronin, S; Malbon, CC				Wang, HY; Doronin, S; Malbon, CC			Insulin activation of mitogen-activated protein kinases Erk1,2 is amplified via beta-adrenergic receptor expression and requires the integrity of the Tyr(350) of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; TYROSINE KINASE; LINKED RECEPTORS; PHOSPHATIDYLINOSITOL 3-KINASE; BETA(2)-ADRENERGIC RECEPTORS; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; CROSS-TALK; PHOSPHORYLATION; CELLS	Insulin activates a complex set of intracellular responses, including the activation of mitogen-activated protein kinases Erk1,2. The counterregulatory actions of insulin on:catecholamine action are well known and include phosphorylation of the beta (2)-adrenergic receptor on Tyr(350), Tyr(354), and Tyr(364) in the C-terminal cytoplasmic domain, as well as enhanced sequestration of the beta (2)-adrenergicreceptor. Both beta -adrenerse agonists and insulin provoke sequestration of beta (2)-adrenerac receptors in a synergistic manner. In the current work, crosstalk between insulin action and beta (2)-adrenergic receptors revealed that insulin activation of Erk1,2 was amplified via beta (2)-adrenerse receptors. In Chinese hamster ovary cells, expression of beta (2)-adrenerse receptors enhanced 5-10-fold the activation of Erk1,2 by insulin and prolonged the activation, the greatest enhancement occurring at 5 min post-insulin. The potentiation of insulin signaling on Erk1,2 was proportional to the level of expression of beta (2)-adrenerse receptor. The potentiation of insulin signaling requires the integrity of Tyr350 Of the beta (2)-adrenergic receptor, a residue phosphorylated in response to insulin. beta (2)-adrenergic receptors with a Y350F mutation failed to potentiate insulin activation of Erk1,2. Expression of the C-terminal domain of the beta (2)-adrenerse receptor (pro(323)-Leu(418)) in cells expressing the intact: beta (2)-adrenergic receptor acts as a dominant negative,:blocking the potentiation of insulin activation of Erk1,2 via the beta (2)-adrenergic receptor. Blockade of beta (2)-adrenergic receptor sequestration does not alter the ability of the beta (2)-adrenergic receptor to potentiate insulin action On Erk1,2, We propose a new paradigm in which a G-protein-linked receptor, such as the beta (2)-adrenergic receptor, itself acts as a receptor-based scaffold via its binding site for Src homology 2 domains, facilitating signaling of the mitogen-activated protein kinase pathway by insulin.	SUNY Stony Brook, Hlth Sci Ctr, Med Ctr, Dept Mol Pharmacol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Malbon, CC (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Med Ctr, Dept Mol Pharmacol, Stony Brook, NY 11794 USA.	craig@pharm.som.sunysb.edu	malbon, craig/ABF-3604-2020					Baltensperger K, 1996, J BIOL CHEM, V271, P1061, DOI 10.1074/jbc.271.2.1061; BOUVIER M, 1995, METHOD ENZYMOL, V250, P300; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0; GEAHLEN RL, 1989, PEPTIDES PROTEIN PHO, P239; GEORGE ST, 1988, BIOCHEM BIOPH RES CO, V150, P665, DOI 10.1016/0006-291X(88)90443-3; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Karoor V, 1998, Adv Pharmacol, V42, P425; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; Karoor V, 1996, J BIOL CHEM, V271, P29347, DOI 10.1074/jbc.271.46.29347; Karoor V, 1998, J BIOL CHEM, V273, P33035, DOI 10.1074/jbc.273.49.33035; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Malbon CC, 1998, CELL SIGNAL, V10, P523, DOI 10.1016/S0898-6568(97)00194-0; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; QUON MJ, 1994, TRENDS ENDOCRIN MET, V5, P369, DOI 10.1016/1043-2760(94)90104-X; ROCCA GJD, 1997, J BIOL CHEM, V272, P19125; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shih ML, 1998, CELL SIGNAL, V10, P575, DOI 10.1016/S0898-6568(97)00195-2; Shih ML, 1996, J BIOL CHEM, V271, P21478, DOI 10.1074/jbc.271.35.21478; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1994, J BIOL CHEM, V269, P1; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36086	36093		10.1074/jbc.M004404200	http://dx.doi.org/10.1074/jbc.M004404200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10940302	hybrid			2022-12-27	WOS:000165382000064
J	Li, SH; Chow, LH; Pickering, JG				Li, SH; Chow, LH; Pickering, JG			Cell surface-bound collagenase-1 and focal substrate degradation stimulate the rear release of motile vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HUMAN ATHEROSCLEROTIC PLAQUE; I COLLAGEN; MATRIX METALLOPROTEINASES; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR; CATHEPSIN-K; MIGRATION; INTEGRIN; EXPRESSION	TO migrate in the vessel wall, smooth muscle cells (SMCs) must contend with abundant type I collagen. We investigated: the mechanisms used by human SMCs to efficiently migrate on type I collagen, following stimulation with fibroblast growth factor-2 (FGF-2). FGF-a-stimulated migration was inhibited by a hydroxamic acid inhibitor of matrix metalloproteinases and by a neutralizing anti-collagenase-1 antibody. Moreover, migration speed of SMCs plated on mutant collagenase-resistant type I collagen was not increased by FGF-S. Time-lapse video analysis of unstimulated SMCs migrating on collagen revealed discrete phases of leading edge membrane extension and rear retraction, the latter often after rupture of an elongated tail. FGF-2 stimulation yielded a more synchronous, gliding motion with a collagenase-1-mediated decrease in tail ripping. Surface labeling of SMCs with biotin followed by immunoprecipitation revealed that a proportion of active collagenase-1, expressed in response to FGF-2, was bound to the plasma membrane. Pericellular collagen substrate cleavage-was verified by immunostaining for neoepitopes generated by collagenase-1 action and was localized to discrete zones beneath the cell tail and the leading edge. These results identify a novel mechanism by which SMC migration on collagen is enhanced, whereby rear release from the substrate is orchestrated by the localized actions of membrane-bound collagenase-1.	Univ Western Ontario, London Hlth Sci Ctr, John P Robarts Res Inst,Vasc Biol Grp, Dept Med Cardiol, London, ON N6A 5A5, Canada; Univ Western Ontario, London Hlth Sci Ctr, John P Robarts Res Inst,Vasc Biol Grp, Dept Med Biophys, London, ON N6A 5A5, Canada; Univ Western Ontario, London Hlth Sci Ctr, John P Robarts Res Inst,Vasc Biol Grp, Dept Biochem, London, ON N6A 5A5, Canada	London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario)	Pickering, JG (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, John P Robarts Res Inst,Vasc Biol Grp, Dept Med Cardiol, 339 Winderemere Rd, London, ON N6A 5A5, Canada.	gpickering@rri.on.ca	Pickering, J. Geoffrey/G-3341-2011	Pickering, J. Geoffrey/0000-0001-6474-3274				BARD JBL, 1975, J CELL BIOL, V67, P400, DOI 10.1083/jcb.67.2.400; BARNES MJ, 1985, COLLAGEN REL RES, V5, P65; Bendeck MP, 1996, CIRC RES, V78, P38, DOI 10.1161/01.RES.78.1.38; BILATO C, 1995, J CLIN INVEST, V96, P1905, DOI 10.1172/JCI118236; Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; BIRKEDALHANSEN B, 1988, BIOCHEMISTRY-US, V27, P6751, DOI 10.1021/bi00418a016; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; CHEN WT, 1981, J CELL BIOL, V90, P187, DOI 10.1083/jcb.90.1.187; Cheng L, 1998, CIRCULATION, V98, P2195, DOI 10.1161/01.CIR.98.20.2195; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; JACKSON CL, 1993, AM J PATHOL, V143, P1024; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; Li SH, 1999, CIRC RES, V85, P338, DOI 10.1161/01.RES.85.4.338; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Messent AJ, 1998, J CELL SCI, V111, P1127; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Nikkari ST, 1996, AM J PATHOL, V148, P777; NIKKARI ST, 1995, CIRCULATION, V92, P1393, DOI 10.1161/01.CIR.92.6.1393; Palecek SP, 1996, J CELL SCI, V109, P941; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pickering JG, 1996, AM J CARDIOL, V78, P633, DOI 10.1016/S0002-9149(96)00384-0; Pickering JG, 1997, ARTERIOSCL THROM VAS, V17, P475, DOI 10.1161/01.ATV.17.3.475; PICKERING JG, 1993, J CLIN INVEST, V91, P724, DOI 10.1172/JCI116254; Pickering JG, 1997, CIRC RES, V80, P627, DOI 10.1161/01.RES.80.5.627; PICKERING JG, 1992, J AM COLL CARDIOL, V20, P1430, DOI 10.1016/0735-1097(92)90259-P; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; Strauss BH, 1996, CIRC RES, V79, P541, DOI 10.1161/01.RES.79.3.541; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503; Sukhova GK, 1998, J CLIN INVEST, V102, P576, DOI 10.1172/JCI181; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35	45	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35384	35392		10.1074/jbc.M005139200	http://dx.doi.org/10.1074/jbc.M005139200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10948197	hybrid			2022-12-27	WOS:000165422800074
J	Thorne, RF; Marshall, JF; Shafren, DR; Gibson, PG; Hart, IR; Burns, GF				Thorne, RF; Marshall, JF; Shafren, DR; Gibson, PG; Hart, IR; Burns, GF			The integrins alpha(3)beta(1) and alpha(6)beta(1) physically and functionally associate with CD36 in human melanoma cells - Requirement for the extracellular domain of CD36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GLYCOPROTEIN-IV CD36; PROTEIN-TYROSINE KINASES; ROD OUTER SEGMENTS; SIGNAL-TRANSDUCTION; VITRONECTIN RECEPTOR; ADHESION MOLECULES; RESTING PLATELETS; MONOCLONAL-ANTIBODIES; MEMBRANE MICRODOMAINS; UROKINASE RECEPTOR	Lateral association between different transmembrane glycoproteins Can serve to modulate integrin function. Here we characterize a physical association between the integrins alpha (3)beta (1) and alpha (6)beta (1) and CD36 on the surface of melanoma cells and show that ectopic expression of CD36 by CD36-negative MV3 melanoma cells increases their haptotactic migration on extracellular matrix components. The association was demonstrated by co-immunoprecipitation, reimmunoprecipitation, and immunoblotting of surface-labeled cells lysed in Brij 96 detergent. Confocal microscopy illustrated the co-association of alpha (3) and CD36 in cell membrane projections and ruffles. A requirement for the extracellular domain of CD36 in this association was shown by co-immunoprecipitation experiments using surface-labeled MV3 melanoma or COS-7 cells:that had been transiently transfected with chimeric constructs between CD36 and intercellular adhesion molecule 1 (ICAM-1) or with a truncation mutant of CD36. CD36 is known to engage in signal transduction and to localize to membrane microdomains or rafts in several-cell types. Toward a mechanistic explanation for the functional effects of CD36 expression, we demonstrate that in fractionated Triton X-100 lysates of the MV3 cells stably transfected with CD36, CD36 was greatly enriched with the detergent-insoluble fractions that represent plasma membrane rafts. Significantly, when these fractionated lysates were reprobed for endogenous beta (1) integrin, it was found that a 4-fold increase in the proportion of the mature protein was contained within the detergent-insoluble fractions when extracted from the CD36-transfected cells compared with MV3 cells transfected with vector only. These results suggest that in melanoma cells CD36 expression may induce the sequestration:of certain integrins into membrane microdomains and promote cell migration.	Univ Newcastle, Fac Med & Hlth Sci, Canc Res Unit, Newcastle, NSW 2300, Australia; Univ Newcastle, Fac Med & Hlth Sci, Dept Microbiol, Newcastle, NSW 2308, Australia; John Hunter Hosp, Dept Resp Med, Newcastle, NSW 2305, Australia; St Thomas Hosp, Rayne Inst, Imperial Canc Res Fund, Richard Dimbleby Dept Canc Res, London SE1 7EH, England	University of Newcastle; University of Newcastle; John Hunter Hospital; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Thorne, RF (corresponding author), Univ Newcastle, Fac Med & Hlth Sci, Canc Res Unit, Level 5,David Maddison Clin Sci Bldg,Cnr King & W, Newcastle, NSW 2300, Australia.		gibson, peter/G-6194-2014	gibson, peter/0000-0001-5865-489X; Marshall, John/0000-0002-0494-2295				Abitorabi MA, 1997, J CELL BIOL, V139, P563, DOI 10.1083/jcb.139.2.563; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Adams JC, 1997, INT J BIOCHEM CELL B, V29, P861, DOI 10.1016/S1357-2725(96)00171-9; AIKEN ML, 1990, BLOOD, V76, P2501; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Ardini E, 1997, J BIOL CHEM, V272, P2342; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BERGER G, 1993, BLOOD, V82, P3034; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; BULL HA, 1994, FEBS LETT, V351, P41, DOI 10.1016/0014-5793(94)00814-0; BURNS GF, 1988, J CELL BIOL, V107, P1225, DOI 10.1083/jcb.107.3.1225; CHAN KFJ, 1988, J BIOL CHEM, V263, P568; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; Coopman PJ, 1996, MOL BIOL CELL, V7, P1789, DOI 10.1091/mbc.7.11.1789; DANEN EHJ, 1993, INT J CANCER, V54, P315, DOI 10.1002/ijc.2910540225; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DEDHAR S, 1995, CANCER METAST REV, V14, P165, DOI 10.1007/BF00690289; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DIAZRICART M, 1993, BLOOD, V82, P491; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; Dorahy DJ, 1998, BIOCHEM J, V333, P373, DOI 10.1042/bj3330373; Dorahy DJ, 1997, J BIOL CHEM, V272, P1323, DOI 10.1074/jbc.272.2.1323; Dorahy DJ, 1996, BIOCHEM BIOPH RES CO, V218, P575, DOI 10.1006/bbrc.1996.0102; Erwig LP, 1999, BLOOD, V93, P1406, DOI 10.1182/blood.V93.4.1406.404k10_1406_1412; Fadok VA, 1998, J IMMUNOL, V161, P6250; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; FRA AM, 1994, J BIOL CHEM, V269, P30745; Franc NC, 1999, SCIENCE, V284, P1991, DOI 10.1126/science.284.5422.1991; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; GREENWALT DE, 1992, BLOOD, V80, P1105; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Jones PH, 1996, CELL ADHES COMMUN, V4, P297, DOI 10.3109/15419069609010773; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Ko YG, 1999, J IMMUNOL, V162, P7217; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kronenberg A, 1998, THROMB HAEMOSTASIS, V79, P1021; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; LISANTI MP, 1994, J CELL BIOL, V126, P11; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Mannion BA, 1996, J IMMUNOL, V157, P2039; Mazurov A V, 1992, Platelets, V3, P181, DOI 10.3109/09537109209013181; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MonierGavelle F, 1997, J CELL BIOL, V137, P1663, DOI 10.1083/jcb.137.7.1663; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PEARCE SFA, 1994, BLOOD, V84, P384; Porter JC, 1997, J CELL BIOL, V138, P1437, DOI 10.1083/jcb.138.6.1437; Radford KJ, 1996, BIOCHEM BIOPH RES CO, V222, P13, DOI 10.1006/bbrc.1996.0690; Radford KJ, 1997, J IMMUNOL, V158, P3353; Rainger GE, 1997, CURR BIOL, V7, P316, DOI 10.1016/S0960-9822(06)00155-2; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; RUBENSTEIN E, 1994, EUROPEAN J IMMUNOLOG, V24, P3005; Ryeom SW, 1996, J CELL SCI, V109, P387; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; SI ZY, 1994, PATHOLOGY, V26, P6, DOI 10.1080/00313029400169011; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SLUPSKY JR, 1989, J BIOL CHEM, V264, P12289; Stern M, 1996, AM J PATHOL, V149, P911; STOMSKI FC, 1992, EXP CELL RES, V198, P85, DOI 10.1016/0014-4827(92)90152-X; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANDON NN, 1991, BLOOD, V78, P2809; Tao NB, 1996, J BIOL CHEM, V271, P22315, DOI 10.1074/jbc.271.37.22315; Thorne RF, 1997, BIOCHEM BIOPH RES CO, V240, P812, DOI 10.1006/bbrc.1997.7755; THORNE RF, 2000, THROMBOSIS VESSEL WA, P149; VANMUIJEN GNP, 1991, INT J CANCER, V48, P85; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865; Warren AP, 2000, IMMUNOLOGY, V99, P62, DOI 10.1046/j.1365-2567.2000.00953.x; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; WONG JEL, 1989, BLOOD S1, V74, P638; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165	107	78	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35264	35275		10.1074/jbc.M003969200	http://dx.doi.org/10.1074/jbc.M003969200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956645	hybrid			2022-12-27	WOS:000165422800059
J	Mayr, C; Richter, K; Lilie, H; Buchner, J				Mayr, C; Richter, K; Lilie, H; Buchner, J			Cpr6 and Cpr7, two closely related Hsp90-associated immunophilins from Saccharomyces cerevisiae, differ in their functional properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; PROLYL CIS/TRANS ISOMERASES; STEROID-RECEPTOR COMPLEXES; CIS-TRANS-ISOMERIZATION; GLUCOCORTICOID RECEPTOR; CHAPERONE FUNCTION; CITRATE SYNTHASE; TRIGGER FACTOR; FK506-BINDING IMMUNOPHILIN; MOLECULAR CHAPERONES	Hsp90 is an abundant cytosolic molecular chaperone. It controls the folding of target proteins including steroid hormone receptors and kinases in complex with several partner proteins. Prominent members of this protein family are large peptidyl prolyl cis/trans isomerases (PPIases), which catalyze the cis/trans isomerization of prolyl peptide bonds in proteins and possess chaperone activity. In Saccharomyces cerevisiae, two closely related large Hsp90-associated PPIases, Cpr6 and Cpr7, exist. We show here that these homologous proteins bind with comparable affinity to Hsp90 but exhibit significant structural and functional differences. Cpr6 is more stable than Cpr7 against thermal denaturation and displays an up to 100-fold higher PPIase activity. In contrast, the chaperone activity of Cpr6 is much lower than that of Cpr7. Based on these results we suggest that the two immunophilins pet-form overlapping but not identical tasks in the Hsp90 chaperone cycle.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Univ Halle Wittenberg, Inst Biotechnol, D-06114 Halle, Germany	Technical University of Munich; Martin Luther University Halle Wittenberg	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany.		Buchner, Johannes/A-2651-2010; Richter, Klaus/A-2673-2010	Richter, Klaus/0000-0002-8952-9642; Buchner, Johannes/0000-0003-1282-7737				Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; Buchner J, 1998, METHOD ENZYMOL, V290, P409, DOI 10.1016/S0076-6879(98)90034-9; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Caamano CA, 1998, J BIOL CHEM, V273, P20473, DOI 10.1074/jbc.273.32.20473; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; Dolinski KJ, 1998, MOL CELL BIOL, V18, P7344, DOI 10.1128/MCB.18.12.7344; Duina AA, 1996, YEAST, V12, P943, DOI 10.1002/(SICI)1097-0061(199608)12:10<943::AID-YEA997>3.0.CO;2-3; Duina AA, 1998, J BIOL CHEM, V273, P10819, DOI 10.1074/jbc.273.18.10819; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; GALAT A, 1992, BIOCHEMISTRY-US, V31, P21607; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Grallert H, 1998, J BIOL CHEM, V273, P33305, DOI 10.1074/jbc.273.50.33305; HARDING MW, 1989, NATURE, V341, P761; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Janowski B, 1997, ANAL BIOCHEM, V252, P299, DOI 10.1006/abio.1997.2330; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; KIM PS, 1982, AN REV BIOCH, V51, P247; KONFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Marsh JA, 1998, MOL CELL BIOL, V18, P7353, DOI 10.1128/MCB.18.12.7353; Mayr C, 2000, J CHROMATOGR B, V737, P295, DOI 10.1016/S0378-4347(99)00393-X; Mayr LM, 1996, BIOCHEMISTRY-US, V35, P5550, DOI 10.1021/bi953035y; MUCKE M, 1994, J MOL BIOL, V239, P713, DOI 10.1006/jmbi.1994.1408; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; Scheibel T, 1999, P NATL ACAD SCI USA, V96, P1297, DOI 10.1073/pnas.96.4.1297; Schmid FX, 1996, BIOL CHEM, V377, P417; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SCHMID FX, 1993, ADV PROTEIN CHEM, V44, P25, DOI 10.1016/S0065-3233(08)60563-X; Scholz C, 1997, J MOL BIOL, V273, P752, DOI 10.1006/jmbi.1997.1301; Scholz C, 1997, FEBS LETT, V414, P69, DOI 10.1016/S0014-5793(97)00979-4; Scholz C, 1998, J MOL BIOL, V277, P723, DOI 10.1006/jmbi.1997.1604; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1995, SCI MED, V2, P38; STEIN RL, 1993, ADV PROTEIN CHEM, V44, P1, DOI 10.1016/S0065-3233(08)60562-8; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Warth R, 1997, BIOL CHEM, V378, P381, DOI 10.1515/bchm.1997.378.5.381; Weikl T, 1999, J MOL BIOL, V293, P685, DOI 10.1006/jmbi.1999.3172; WIELAND O., 1964, BIOCHEM Z, V339, P501; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	59	89	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34140	34146		10.1074/jbc.M005251200	http://dx.doi.org/10.1074/jbc.M005251200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942767	hybrid			2022-12-27	WOS:000165095300022
J	Valet, P; Grujic, D; Wade, J; Ito, M; Zingaretti, MC; Soloveva, V; Ross, SR; Graves, RA; Cinti, S; Lafontan, M; Lowell, BB				Valet, P; Grujic, D; Wade, J; Ito, M; Zingaretti, MC; Soloveva, V; Ross, SR; Graves, RA; Cinti, S; Lafontan, M; Lowell, BB			Expression of human alpha 2-adrenergic receptors in adipose tissue of beta 3-adrenergic receptor-deficient mice promotes diet-induced obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-CELL FUNCTION; REGIONAL VARIATION; ADIPOCYTES; LIPOLYSIS; WOMEN; WHITE; GENE; ADRENOCEPTORS; DISRUPTION; BINDING	Catecholamines play an important role in controlling white adipose tissue function and development. beta- and alpha2-adrenergic receptors (ARs) couple positively and negatively, respectively, to adenylyl cyclase and are coexpressed in human adipocytes. Previous studies have demonstrated increased adipocyte alpha2/beta -AR balance in obesity, and it has been proposed that increased alpha2-ARs in adipose tissue with or without decreased beta -ARs may contribute mechanistically to the development of increased fat mass. To critically test this hypothesis, adipocyte alpha2/beta -AR balance was genetically manipulated in mice. Human alpha 2A-ARs were transgenically expressed in the adipose tissue of mice that were either homozygous (-/-) or heterozygous (+/-) for a disrupted beta3-AR allele. Mice expressing alpha2-ARs in fat, in the absence of beta3-ARs (beta3-AR (-/-) background), developed high fat diet-induced obesity. Strikingly, this effect was due entirely to adipocyte hyperplasia and required the presence of alpha2-ARs, the absence of beta3-ARs, and a high fat diet. Of note, obese alpha2-transgenic, beta3 (-/-) mice failed to develop insulin resistance, which may reflect the fact that expanded fat mass was due to adipocyte hyperplasia and not adipocyte hypertrophy. In summary, we have demonstrated that increased alpha2/beta -AR balance in adipocytes promotes obesity by stimulating adipocyte hyperplasia. This study also demonstrates one way in which two genes (alpha2 and beta3-AR) and diet interact to influence fat mass.	Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Toulouse 3, CHR Rangueil, Inst Louis Bugnard, INSERM U317, F-31403 Toulouse, France; Univ Ancona, Inst Normal Human Morphol, I-60020 Ancona, Italy; Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Univ Chicago, Dept Med, Gastroenterol Sect, Chicago, IL 60637 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Marche Polytechnic University; University of Pennsylvania; University of Pennsylvania; University of Chicago	Lowell, BB (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrinol, RN-325,330 Brookline Ave, Boston, MA 02215 USA.		Valet, Philippe/N-7472-2017	Valet, Philippe/0000-0001-6520-7393; CINTI, Saverio/0000-0003-0362-5017				ARNER P, 1992, AM J CLIN NUTR, V55, P228; BERLAN M, 1985, EUR J CLIN INVEST, V15, P341, DOI 10.1111/j.1365-2362.1985.tb00282.x; Berman DM, 1998, METABOLISM, V47, P467, DOI 10.1016/S0026-0495(98)90061-0; BJORNTORP P, 1991, INT J OBESITY, V15, P67; CARPENE C, 1990, J LIPID RES, V31, P811; CARPENE C, 1976, J LIPID RES, P24; CASTAN I, 1994, AM J PHYSIOL, V266, pR1141, DOI 10.1152/ajpregu.1994.266.4.R1141; Cinti S, 1998, DIABETOLOGIA, V41, P171, DOI 10.1007/s001250050886; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; GALITZKY J, 1990, J PHARMACOL EXP THER, V252, P312; Hallakou S, 1997, DIABETES, V46, P1393, DOI 10.2337/diabetes.46.9.1393; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; HIRSCH J, 1968, J LIPID RES, V9, P110; JOHNSON PR, 1972, J LIPID RES, V13, P2; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LACASA D, 1986, J LIPID RES, V27, P368; LAFONTAN M, 1993, J LIPID RES, V34, P1057; LAFONTAN M, 1995, ENDOCR REV, V16, P716, DOI 10.1210/er.16.6.716; MAURIEGE P, 1995, J LIPID RES, V36, P672; MAURIEGE P, 1995, AM J PHYSIOL-ENDOC M, V269, pE341, DOI 10.1152/ajpendo.1995.269.2.E341; MAURIEGE P, 1991, J LIPID RES, V32, P1625; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Revelli JP, 1997, J CLIN INVEST, V100, P1098, DOI 10.1172/JCI119620; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SALMON DMW, 1985, INT J OBESITY, V9, P443; SCHNEIDER BS, 1981, AM J PHYSIOL, V240, pE358, DOI 10.1152/ajpendo.1981.240.4.E358; SJOSTROM L, 1971, J LIPID RES, V12, P521; SOLOVEVA V, 1994, J CELL BIOCHEM, V18, P172; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; Thomas SA, 1997, NATURE, V387, P94, DOI 10.1038/387094a0; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; Van Harmelen V, 1998, DIABETES, V47, P913, DOI 10.2337/diabetes.47.6.913	33	75	78	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34797	34802		10.1074/jbc.M005210200	http://dx.doi.org/10.1074/jbc.M005210200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10948198	Green Published, hybrid			2022-12-27	WOS:000165095300106
J	Peterson, YK; Bernard, ML; Ma, HZ; Hazard, S; Graber, SG; Lanier, SM				Peterson, YK; Bernard, ML; Ma, HZ; Hazard, S; Graber, SG; Lanier, SM			Stabilization of the GDP-bound conformation of Gi alpha by a peptide derived from the G-protein regulatory motif of AGS3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; BETA; MEMBRANES; SUBUNITS; BINDING	The G-protein regulatory (GPR) motif in AGS3 was recently identified as a region for protein binding to heterotrimeric G-protein alpha subunits. To define the properties of this similar to 20-amino acid motif, we designed a GPR consensus peptide and determined its influence on the activation state of G-protein and receptor coupling to G-protein. The GPR peptide sequence (28 amino acids) encompassed the consensus sequence defined by the four GPR motifs conserved in the family of AGS3 proteins. The GPR consensus peptide effectively prevented the binding of AGS3 to Gi alpha1,2 in protein interaction assays, inhibited guanosine 5'-O-(3-thiotriphosphate) binding to Gi alpha, and stabilized the GDP-bound conformation of Gi alpha, The GPR peptide had little effect on nucleotide binding to Go alpha and brain G-protein indicating selective regulation of Gia. Thus, the GPR peptide functions as a guanine nucleotide dissociation inhibitor for Gi alpha. The GPR consensus peptide also blocked receptor coupling to Gi alpha beta gamma indicating that although the AGS3-GPR peptide stabilized the GDP-bound conformation of Gi alpha, this conformation of Gi alpha (GDP) was not recognized by a G-protein coupled receptor. The AGS3-GPR motif presents an opportunity for selective control of Gi alpha- and G beta gamma -regulated effector systems, and the GPR motif allows for alternative modes of signal input to G-protein signaling systems.	Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29403 USA; Med Univ S Carolina, Dept Lib & Informat, Charleston, SC 29403 USA; W Virginia Univ, Sch Med, Dept Pharmacol & Toxicol, Morgantown, WV 26506 USA	Medical University of South Carolina; Medical University of South Carolina; West Virginia University	Lanier, SM (corresponding author), Med Univ S Carolina, Dept Pharmacol, 173 Ashley Ave, Charleston, SC 29403 USA.		Bernard, Michael/AAW-3944-2021	Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024821, R01NS024821] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM08716] Funding Source: Medline; NIMH NIH HHS [MH5993] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; Clawges HM, 1997, BIOCHEMISTRY-US, V36, P12930, DOI 10.1021/bi970112b; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; Hildebrandt JD, 1997, BIOCHEM PHARMACOL, V54, P325, DOI 10.1016/S0006-2952(97)00269-4; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Nanoff C, 1997, PHYSIOL RES, V46, P79; Richardson M, 1999, J BIOL CHEM, V274, P13525, DOI 10.1074/jbc.274.19.13525; ROSS EM, 1994, METHOD ENZYMOL, V237, P26; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5	21	114	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33193	33196		10.1074/jbc.C000509200	http://dx.doi.org/10.1074/jbc.C000509200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10969064	hybrid			2022-12-27	WOS:000090104600003
J	Lebrun, P; Baron, V; Hauck, CR; Schlaepfer, DD; Van Obberghen, E				Lebrun, P; Baron, V; Hauck, CR; Schlaepfer, DD; Van Obberghen, E			Cell adhesion and focal adhesion kinase regulate insulin receptor substrate-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; MUSCLE CELLS; C-JUN; INTEGRIN; BINDING; GROWTH; ACTIVATION	Integrins are transmembrane receptors involved in interactions between cells and extracellular matrix proteins. Here we show that cell adhesion regulates insulin receptor substrate-1 (IRS-1) mRNA synthesis, When fibroblasts are held in suspension, lower levels of IRS-1 mRNA, but not of IRS-2 mRNA, are detected, and this effect is due to the negative regulation of IRS-1 transcription rather than to decreased mRNA stability. Upon fibronectin- or vitronectin-mediated integrin stimulation, the level of IRS-1 mRNA was restored within 4 h, The focal adhesion kinase (FAK) is known to be activated upon integrin stimulation, and we found that IRS-1 was not expressed in FAK(-/-) cells. Stable re-expression of epitope-tagged FAK in FAK(-/-) fibroblasts (DA2 cells) restored normal levels of IRS-1 expression, confirming that IRS-1 mRNA expression is regulated by FAK, It is known that integrins activate the JNK pathway. However, in adherent FAK(-/-) cells, we failed to detect activation of JNK, whereas JNK was stimulated in DA2 cells, This confirms the role of FAK in integrin-induced JNK stimulation. FAR-independent stimulation of JNK with anisomycin treatment both in FAK(-/-) cells and in suspended FAK(-/-) cells confirmed that IRS-1 mRNA transcription can be partially regulated by JNK, We suggest that integrins can modulate insulin and insulin-like growth factor-1 signaling pathways by regulating the levels of IRS-1 in cells and that FAR-mediated signaling to JNK is one pathway involved in this process.	INSERM, U145, Inst Federatif Rech, F-06107 Nice 2, France; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Scripps Research Institute	Baron, V (corresponding author), INSERM, U145, Inst Federatif Rech, 50 Ave Valombrose, F-06107 Nice 2, France.		LEBRUN, Patricia/O-5765-2016					Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; ARAKI E, 1995, MOL ENDOCRINOL, V9, P1367, DOI 10.1210/me.9.10.1367; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Echtermeyer F, 1996, J BIOL CHEM, V271, P2071, DOI 10.1074/jbc.271.4.2071; Edwards GM, 1998, J BIOL CHEM, V273, P9495, DOI 10.1074/jbc.273.16.9495; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAHN R, 1997, INT TXB DIABETES MEL, P437; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Matsuda K, 1997, DIABETES, V46, P354, DOI 10.2337/diabetes.46.3.354; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miele C, 1999, J BIOL CHEM, V274, P3094, DOI 10.1074/jbc.274.5.3094; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Pabla R, 1999, J CELL BIOL, V144, P175, DOI 10.1083/jcb.144.1.175; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; SHAW RJ, 1990, J CELL BIOL, V111, P2139, DOI 10.1083/jcb.111.5.2139; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Walzog B, 1999, FASEB J, V13, P1855, DOI 10.1096/fasebj.13.13.1855; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xu JH, 1996, J CELL BIOL, V132, P239, DOI 10.1083/jcb.132.1.239; Zheng B, 1998, J BIOL CHEM, V273, P8994, DOI 10.1074/jbc.273.15.8994; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	51	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38371	38377		10.1074/jbc.M006162200	http://dx.doi.org/10.1074/jbc.M006162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10967115	hybrid, Green Published			2022-12-27	WOS:000165739800033
J	Millard, EE; Srivastava, K; Traub, LM; Schaffer, JE; Ory, DS				Millard, EE; Srivastava, K; Traub, LM; Schaffer, JE; Ory, DS			Niemann-Pick type C1 (NPC1) overexpression alters cellular cholesterol homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; HAMSTER OVARY CELLS; HUMAN FIBROBLASTS; PROTEIN; TRANSPORT; DISEASE; TRAFFICKING; METABOLISM; MEMBRANE; MUTATION	The Niemann-Pick type C1 (NPC1) protein is a key participant in intracellular trafficking of low density lipoprotein cholesterol, but its role in regulation of sterol homeostasis is not well understood. To characterize further the function of NPC1, we generated stable Chinese hamster ovary (CHO) cell lines overexpressing the human NPC1 protein (CHO/NPC1). NPC1 overexpression increases the rate of trafficking of low density lipoprotein cholesterol to the endoplasmic reticulum and the rate of delivery of endosomal cholesterol to the plasma membrane (PM). CHO/NPC1 cells exhibit a 1.5-fold increase in total cellular cholesterol and up to a 2.9-fold increase in PM cholesterol. This increase in PM cholesterol is closely paralleled by a 3-fold increase in de novo cholesterol synthesis. Inhibition of cholesterol synthesis results in marked redistribution of PM cholesterol to intracellular sites, suggesting an unsuspected role for NPC1 in internalization of PM cholesterol, Despite elevated total cellular cholesterol, CHO/NPC1 cells exhibit increased cholesterol synthesis, which may be attributable to both resistance to oxysterol suppression of sterol-regulated gene expression and to reduced endoplasmic reticulum cholesterol levels under basal conditions. Taken together, these studies provide important new insights into the role of NPC1 in the determination of the levels and distribution of cellular cholesterol.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Washington University (WUSTL); Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ory, DS (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.	dory@imgate.wustl.edu		Traub, Linton/0000-0002-1303-0298				BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BROWN MS, 1973, P NATL ACAD SCI USA, V70, P2162, DOI 10.1073/pnas.70.7.2162; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Davies JP, 2000, J BIOL CHEM, V275, P24367, DOI 10.1074/jbc.M002184200; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; KRIEGER M, 1978, J BIOL CHEM, V253, P4093; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Patel SC, 1999, P NATL ACAD SCI USA, V96, P1657, DOI 10.1073/pnas.96.4.1657; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; Watari H, 1999, P NATL ACAD SCI USA, V96, P805, DOI 10.1073/pnas.96.3.805; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Yang T, 2000, J BIOL CHEM, V275, P29881, DOI 10.1074/jbc.M005439200	27	94	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38445	38451		10.1074/jbc.M003180200	http://dx.doi.org/10.1074/jbc.M003180200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10964915	hybrid			2022-12-27	WOS:000165739800042
J	Han, X; Sterling, H; Chen, YM; Saginario, C; Brown, EJ; Frazier, WA; Lindberg, FP; Vignery, A				Han, X; Sterling, H; Chen, YM; Saginario, C; Brown, EJ; Frazier, WA; Lindberg, FP; Vignery, A			CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; NEURAL ADHESION MOLECULE; MEMBRANE-PROTEIN; EXPRESSION; ANTIGEN; FAMILY; CELLS; OVEREXPRESSION; GLYCOPROTEIN; RETROVIRUS	The macrophage fusion receptor (MFR), also called P84/BIT/SIRP alpha /SHPS-1, is a transmembrane glycoprotein that belongs to the superfamily of immunoglobulins. Previously, we showed that MFR expression is highly induced at the onset of fusion in macrophages, and that MFR appears to play a role in macrophage-macrophage adhesion/fusion leading to multinucleation. The recent finding that I4P/CD47 acts as a ligand for MFR led us to hypothesize that it interacts with CD47 at the onset of cell-cell fusion. CD47 is a transmembrane glycoprotein, which, like MFR, belongs to the superfamily of immunoglobulins. We show that macrophages express the hemopoietic form of CD47, the expression of which is induced at the onset of fusion, but to a lower level than MFR. A glutathione S-transferase CD47 fusion protein engineered to contain the extracellular domain of CD47, binds macrophages, associates with MFR, and prevents multinucleation. CD47 and MFR associate via their amino-terminal immunoglobulin variable domain. Of the nine monoclonal antibodies raised against the extracellular domain of CD47, three block fusion, as well as MFR-CD47 interaction, whereas the others have no effect. Together, these data suggest that CD47 is involved in macrophage multinucleation by virtue of interacting with MFR during adhesion/fusion.	Yale Univ, Sch Med, Dept Orthopaed & Rehabil, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Washington Univ, Sch Med, Div Infect Dis, St Louis, MO 63110 USA; Univ Calif San Francisco, Ctr Host Pathogen Interact, San Francisco, CA 94143 USA; Washington Univ, Sch Med, Dept Biochem, St Louis, MO 63110 USA	Yale University; Yale University; Washington University (WUSTL); University of California System; University of California San Francisco; Washington University (WUSTL)	Vignery, A (corresponding author), Yale Univ, Sch Med, Dept Orthopaed & Rehabil, 333 Cedar St, New Haven, CT 06510 USA.	agnes.vignery@yale.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057573] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12110] Funding Source: Medline; NIGMS NIH HHS [GM57573-01] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babic I, 2000, J IMMUNOL, V164, P3652, DOI 10.4049/jimmunol.164.7.3652; Baron R, 1995, ACTA ORTHOP SCAND, V66, P66, DOI 10.3109/17453679509157650; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CHUANG W, 1990, DEV BIOL, V137, P219, DOI 10.1016/0012-1606(90)90249-I; Comu S, 1997, J NEUROSCI, V17, P8702; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kirby JE, 1998, MOL MICROBIOL, V27, P323, DOI 10.1046/j.1365-2958.1998.00680.x; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; MAWBY WJ, 1994, BIOCHEM J, V304, P525, DOI 10.1042/bj3040525; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Nishiyama Y, 1997, JPN J CANCER RES, V88, P120, DOI 10.1111/j.1349-7006.1997.tb00356.x; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; PARKINSON JE, 1995, VIROLOGY, V214, P177, DOI 10.1006/viro.1995.9942; REINHOLD MI, 1995, J CELL SCI, V108, P3419; Saginario C, 1995, P NATL ACAD SCI USA, V92, P12210, DOI 10.1073/pnas.92.26.12210; Saginario C, 1998, MOL CELL BIOL, V18, P6213, DOI 10.1128/MCB.18.11.6213; Sanderson CM, 1996, J VIROL, V70, P905, DOI 10.1128/JVI.70.2.905-914.1996; Sano S, 1999, BIOCHEM J, V344, P667, DOI 10.1042/0264-6021:3440667; Sano S, 1997, FEBS LETT, V411, P327, DOI 10.1016/S0014-5793(97)00724-2; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Sterling H, 1998, J CELL BIOL, V143, P837, DOI 10.1083/jcb.143.3.837; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; VIGNERY A, 1989, AM J PATHOL, V135, P565; VIGNERY A, 1989, J HISTOCHEM CYTOCHEM, V37, P1265, DOI 10.1177/37.8.2546991; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	36	168	184	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37984	37992		10.1074/jbc.M002334200	http://dx.doi.org/10.1074/jbc.M002334200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10964914	hybrid			2022-12-27	WOS:000165618700091
J	Low, BC; Seow, KT; Guy, GR				Low, BC; Seow, KT; Guy, GR			The BNIP-2 and Cdc42GAP homology domain of BNIP-2 mediates its homophilic association and heterophilic interaction with Cdc42GAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; RHO FAMILY; RAS; COMPLEX; GAPS; EFFECTORS; SEQUENCE; CASCADE; BINDING	We recently showed that BNIP-2 is a putative substrate of the fibroblast growth factor receptor tyrosine kinase and it possesses GTPase-activating activity toward the small GTPase, Cdc42. The carboxyl terminus of BNIP-2 shares high homology to the non-catalytic do main of Cdc42GAP, termed BCH (for BNIP-2 and Cdc42GAP homology) domain. Despite the lack of obvious homology to any known catalytic domains of GTPase-activating proteins (GAPs), the BCH domain of BNIP-2 bound Cdc42 and stimulated the GTPase activity via a novel arginine-patch motif similar to that employed by one contributing partner in a Cdc42 homodimer, In contrast, the BCH domain of Cdc42GAP, although it can bind Cdc42, is catalytically inactive, This raises the possibility that these domains might have other roles in the cell. Using glutathione S-transferase recombinant proteins, immunoprecipitation studies, and yeast two-hybrid assays, it was found that BNIP-2 and Cdc42GAP could form homo and hetero complexes via their conserved BCH domains. Molecular modeling of the BNIP-2 BCH homodimer complex and subsequent deletion mutagenesis helped to identify the region (RRKMP221)-R-217 as the major BCH interaction site within BMP-S. In comparison, deletion of either the arginine-patch (RRLRK239)-R-235 (necessary for GAP activity) or region (EYV290)-E-288 (a Cdc42 binding sequence) had no effect on BCH-BCH interaction. Extensive data base searches showed that the BCH domain is highly conserved across species. The results suggest that BCH domains of BNIP-2 and Cdc42GAP represent a novel protein-protein interaction domain that could potentially determine and/or modify the physiological roles of these molecules.	Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Guy, GR (corresponding author), Inst Mol & Cell Biol, Signal Transduct Lab, 30 Med Dr, Singapore 117609, Singapore.	mcbgg@imcb.nus.edu.sg	Low, Boon Chuan/AAU-7685-2021; Low, Boon Chuan/H-8049-2012	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X				Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1999, CURR BIOL, V9, pR195, DOI 10.1016/S0960-9822(99)80127-4; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Bax B, 1998, NATURE, V392, P447, DOI 10.1038/33040; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Calmels TPG, 1998, FEBS LETT, V426, P205, DOI 10.1016/S0014-5793(98)00331-7; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall A, 1999, BRIT J CANCER, V80, P25; Harpur AG, 1999, J BIOL CHEM, V274, P12323, DOI 10.1074/jbc.274.18.12323; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Low BC, 1999, J BIOL CHEM, V274, P33123, DOI 10.1074/jbc.274.46.33123; Low BC, 2000, J BIOL CHEM, V275, P14415, DOI 10.1074/jbc.275.19.14415; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Rittinger K, 1998, NATURE, V392, P448, DOI 10.1038/33043; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; SAMBROOK J, 1989, MOL CLONING LABORATO, V1, P53; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Sprang SR, 1997, CURR OPIN STRUC BIOL, V7, P849, DOI 10.1016/S0959-440X(97)80157-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728; Zhang BL, 1999, J BIOL CHEM, V274, P2609, DOI 10.1074/jbc.274.5.2609	46	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37742	37751		10.1074/jbc.M004897200	http://dx.doi.org/10.1074/jbc.M004897200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10954711	hybrid			2022-12-27	WOS:000165618700060
J	Chou, CL; Yip, KP; Michea, L; Kador, K; Ferraris, JD; Wade, JB; Knepper, MA				Chou, CL; Yip, KP; Michea, L; Kador, K; Ferraris, JD; Wade, JB; Knepper, MA			Regulation of aquaporin-2 trafficking by vasopressin in the renal collecting duct - Roles of ryanodine-sensitive Ca2+ stores and calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; WATER PERMEABILITY; INTRACELLULAR CA2+; RAT; ACTIVATION; RECEPTOR; CALCIUM; EXPRESSION; CHANNELS; HORMONE	In the renal collecting duct, vasopressin increases osmotic water permeability (P-f) by triggering trafficking of aquaporin-2 vesicles to the apical plasma membrane. We investigated the role of vasopressin-induced intracellular Ca2+ mobilization in this process. In isolated inner medullary collecting ducts (IMCDs), vasopressin (0.1 nM) and 8-(4-chlorophenylthio)-cAMP (0.1 mM) elicited marked increases in [Ca2+](i) (fluo-4), Vasopressin-induced Ca2+ mobilization was completely blocked by preloading with the Ca2+ chelator BAPTA, In parallel experiments, BAPTA completely blocked the vasopressin-induced increase in P-f without affecting adenosine 3',5'-cyclic monophosphate (cAMP) production. Previously, we demonstrated the lack of activation of the phosphoinositide-signaIing pathway by vasopressin in IMCD, suggesting an inositol 1,4,5-trisphosphate-independent mechanism of Ca2+ release. Evidence for expression of the type I ryanodine receptor (RyR1) in IMCD was obtained by immunofluorescence, immunoblotting, and reverse transcription-polymerase chain reaction, Ryanodine (100 muM), a ryanodine receptor antagonist, blocked the arginine vasopressin-mediated increase in P-f and blocked vasopressin-stimulated redistribution of aquaporin-2 to the plasma membrane domain in primary cultures of IMCD cells, as assessed by immunofluorescence immunocytochemistry. Calmodulin inhibitors (W7 and trifluoperazine) blocked the P-f response to vasopressin and the vasopressin-stimulated redistribution of aquaporin-2. The results suggest that Ca2+ release from ryanodine-sensitive stores plays an essential role in vasopressin-mediated aquaporin-2 trafficking via a calmodulin-dependent mechanism.	NHLBI, Kidney & Electrolyte Metab Lab, NIH, Bethesda, MD 20892 USA; Univ S Florida, Coll Med, Dept Physiol & Biophys, Tampa, FL 33612 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); State University System of Florida; University of South Florida; University System of Maryland; University of Maryland Baltimore	Knepper, MA (corresponding author), NHLBI, Kidney & Electrolyte Metab Lab, NIH, 10 Ctr Dr,MSC 1603,Bldg 10,Rm 6N260, Bethesda, MD 20892 USA.		Yip, Kay-Pong D/H-4639-2012; Knepper, Mark/AAF-8412-2020	Yip, Kay-Pong D/0000-0003-4364-6701; 	Intramural NIH HHS [Z01 HL001285-21, Z99 HL999999] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL001285] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; ALZAHID G, 1977, J MEMBRANE BIOL, V31, P103, DOI 10.1007/BF01869401; BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; Brown D, 1998, AM J PHYSIOL-RENAL, V275, pF328, DOI 10.1152/ajprenal.1998.275.3.F328; BURG M, 1966, AM J PHYSIOL, V210, P1293, DOI 10.1152/ajplegacy.1966.210.6.1293; Burgoyne RD, 1998, CELL CALCIUM, V24, P367, DOI 10.1016/S0143-4160(98)90060-4; BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; Chabardes D, 1996, J BIOL CHEM, V271, P19264, DOI 10.1074/jbc.271.32.19264; CHAMPIGNEULLE A, 1993, AM J PHYSIOL, V265, pF35, DOI 10.1152/ajprenal.1993.265.1.F35; Cheng H, 1996, CELL CALCIUM, V20, P129, DOI 10.1016/S0143-4160(96)90102-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU CL, 1995, AM J PHYSIOL-RENAL, V269, pF78, DOI 10.1152/ajprenal.1995.269.1.F78; Chou CL, 1998, AM J PHYSIOL-RENAL, V274, pF564, DOI 10.1152/ajprenal.1998.274.3.F564; DIGIOVANNI SR, 1994, P NATL ACAD SCI USA, V91, P8984, DOI 10.1073/pnas.91.19.8984; DILLINGHAM MA, 1986, J PHYSIOL-LONDON, V372, P41, DOI 10.1113/jphysiol.1986.sp015995; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V270, pF623, DOI 10.1152/ajprenal.1996.270.4.F623; GROMADA J, 1995, FEBS LETT, V373, P182, DOI 10.1016/0014-5793(95)01070-U; Gustafson CE, 2000, AM J PHYSIOL-RENAL, V278, pF317, DOI 10.1152/ajprenal.2000.278.2.F317; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; Jaggar JH, 2000, AM J PHYSIOL-CELL PH, V278, pC235, DOI 10.1152/ajpcell.2000.278.2.C235; Katsura T, 1997, Am J Physiol, V272, pF817; Knepper MA, 1997, AM J PHYSIOL-RENAL, V272, pF3, DOI 10.1152/ajprenal.1997.272.1.F3; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEVINE SD, 1981, J CLIN INVEST, V67, P662, DOI 10.1172/JCI110081; MAEDA Y, 1993, AM J PHYSIOL, V265, pF15, DOI 10.1152/ajprenal.1993.265.1.F15; MAEDA Y, 1992, AM J PHYSIOL, V263, pF319, DOI 10.1152/ajprenal.1992.263.2.F319; NEYLON CB, 1995, BIOCHEM BIOPH RES CO, V215, P814, DOI 10.1006/bbrc.1995.2536; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Ozawa T, 1998, BIOCHEM BIOPH RES CO, V246, P422, DOI 10.1006/bbrc.1998.8636; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Querfurth HW, 1998, BIOCHEM J, V334, P79, DOI 10.1042/bj3340079; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; STAR RA, 1988, J CLIN INVEST, V81, P1879, DOI 10.1172/JCI113534; Terris J, 1996, AM J PHYSIOL-RENAL, V271, pF414, DOI 10.1152/ajprenal.1996.271.2.F414; Tunwell REA, 1996, J BIOL CHEM, V271, P29583, DOI 10.1074/jbc.271.47.29583; Wade JB, 2000, AM J PHYSIOL-RENAL, V278, pF52, DOI 10.1152/ajprenal.2000.278.1.F52; WALL SM, 1992, AM J PHYSIOL, V262, pF989, DOI 10.1152/ajprenal.1992.262.6.F989; Yip KP, 1996, AM J PHYSIOL-RENAL, V271, pF1004, DOI 10.1152/ajprenal.1996.271.5.F1004; Zhang MJ, 1998, BIOCHEM CELL BIOL, V76, P313, DOI 10.1139/bcb-76-2-3-313	41	170	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36839	36846		10.1074/jbc.M005552200	http://dx.doi.org/10.1074/jbc.M005552200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973964	hybrid			2022-12-27	WOS:000165577700057
J	Lindsay, H; Beaumont, E; Richards, SD; Kelly, SM; Sanderson, SJ; Price, NC; Lindsay, JG				Lindsay, H; Beaumont, E; Richards, SD; Kelly, SM; Sanderson, SJ; Price, NC; Lindsay, JG			FAD insertion is essential for attaining the assembly competence of the dihydrolipoamide dehydrogenase (E3) monomer from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFINED CRYSTAL-STRUCTURE; LIPOAMIDE DEHYDROGENASE; LIPOYL DOMAIN; 3-DIMENSIONAL STRUCTURE; NUCLEOTIDE-SEQUENCE; AZOTOBACTER-VINELANDII; MULTIENZYME COMPLEX; BINDING DOMAIN; ACID; RESOLUTION	Dihydrolipoamide dehydrogenase (E3) from Escherichia coli, an FAD-linked homodimer, can be fully reconstituted in. vitro following denaturation in 6 M guanidinium chloride. Complete restoration of activity occurs within 1-2 h in the presence of FAD, dithiothreitol, and bovine serum albumin. In the absence of FAD, the dihydrolipoamide dehydrogenase monomer forms a stable folding intermediate, which is incapable of dimerization, This intermediate displays a similar tryptic resistance to the native enzyme but is less heat-stable, because its ability to form native E3 is lost after incubation at 65 degreesC for 15 min, The presence of FAD promotes slow, additional conformational rearrangements of the E3 subunit as observed by cofactor-dependent decreases in intrinsic tryptophan fluorescence. However, after 2 h, the tryptophan fluorescence spectrum and far UV CD spectrum of E3, refolded in the absence of FAD, are similar to that of the native enzyme, and full activity can still be recovered on addition of FAD, Cross-linking studies show that FAD insertion is necessary for the monomeric folding intermediate to attain an assembly competent state leading to dimerization. Thus cofactor insertion represents a key step in the assembly of this enzyme, although its initial presence appears not to be required to promote the correct folding pathway.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Univ Stirling, Dept Biol Sci, Stirling FK9 4LA, Scotland	University of Glasgow; University of Stirling	Lindsay, JG (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	G.Lindsay@bio.gla.ac.uk	Kelly, Sharon/K-4611-2013	Kelly, Sharon/0000-0002-3516-1387				Berg A, 1997, EUR J BIOCHEM, V244, P352, DOI 10.1111/j.1432-1033.1997.00352.x; DANSON MJ, 1987, BIOCHEM J, V243, P661, DOI 10.1042/bj2430661; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; delaSierra IL, 1997, J MOL BIOL, V269, P129, DOI 10.1006/jmbi.1997.1009; ELSE AJ, 1994, MOL BIOCHEM PARASIT, V64, P233, DOI 10.1016/0166-6851(93)00016-3; Engels A, 1997, BBA-PROTEIN STRUCT M, V1340, P33, DOI 10.1016/S0167-4838(97)00025-3; Harris RA, 1997, ADV ENZYME REGUL, V37, P271, DOI 10.1016/S0065-2571(96)00009-X; HOPKINS N, 1995, BIOCHEMISTRY-US, V34, P11757, DOI 10.1021/bi00037a013; JACKMAN SA, 1990, EUR J BIOCHEM, V193, P91, DOI 10.1111/j.1432-1033.1990.tb19308.x; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KALIA YN, 1993, J MOL BIOL, V230, P323, DOI 10.1006/jmbi.1993.1145; KALSE JF, 1968, BIOCHIM BIOPHYS ACTA, V159, P244, DOI 10.1016/0005-2744(68)90073-9; KOCHI H, 1976, ARCH BIOCHEM BIOPHYS, V173, P71, DOI 10.1016/0003-9861(76)90236-8; Mande SS, 1996, STRUCTURE, V4, P277, DOI 10.1016/S0969-2126(96)00032-9; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; MATTEVI A, 1991, J MOL BIOL, V220, P975, DOI 10.1016/0022-2836(91)90367-F; MATTEVI A, 1992, PROTEINS, V13, P336, DOI 10.1002/prot.340130406; MATTEVI A, 1993, J MOL BIOL, V230, P1183, DOI 10.1006/jmbi.1993.1235; MATTEVI A, 1993, J MOL BIOL, V230, P1200, DOI 10.1006/jmbi.1993.1236; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; McCartney RG, 1997, BIOCHEMISTRY-US, V36, P6819, DOI 10.1021/bi9630016; PATEL MS, 1995, FASEB J, V9, P1164, DOI 10.1096/fasebj.9.12.7672509; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; RUSSELL GC, 1992, BIOCHEM J, V1076, P225; SAIJO T, 1995, BIOCHEM J, V261, P189; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P155, DOI 10.1111/j.1432-1033.1983.tb07441.x; STEPHENS PE, 1983, EUR J BIOCHEM, V135, P519, DOI 10.1111/j.1432-1033.1983.tb07683.x; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P481, DOI 10.1111/j.1432-1033.1983.tb07490.x; THORPE C, 1974, BIOCHEMISTRY-US, V13, P3263, DOI 10.1021/bi00713a013; Toyoda T, 1998, J BIOCHEM-TOKYO, V123, P668; VISSER J, 1968, BIOCHIM BIOPHYS ACTA, V159, P257, DOI 10.1016/0005-2744(68)90074-0; Wallis NG, 1996, J MOL BIOL, V263, P463, DOI 10.1006/jmbi.1996.0589; WALLIS NG, 1994, J MOL BIOL, V236, P209, DOI 10.1006/jmbi.1994.1130; WEST SM, 1995, BIOCHEM J, V308, P1025, DOI 10.1042/bj3081025; WEST SM, 1989, BIOCHEM J, V171, P609; WHITE MF, 1993, BIOCHEM J, V291, P479, DOI 10.1042/bj2910479; Williams Jr C.H., 1989, ANN N Y ACAD SCI, V573, P55	37	16	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36665	36670		10.1074/jbc.M004777200	http://dx.doi.org/10.1074/jbc.M004777200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10970889	hybrid			2022-12-27	WOS:000165577700031
J	Narouz-Ott, L; Maurer, P; Nitsche, DP; Smyth, N; Paulsson, M				Narouz-Ott, L; Maurer, P; Nitsche, DP; Smyth, N; Paulsson, M			Thrombospondin-4 binds specifically to both collagenous and non-collagenous extracellular matrix proteins via its C-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; NERVOUS-SYSTEM; GENE FAMILY; CARTILAGE; COMP; EXPRESSION; TISSUES; FIBRONECTIN; LAMININ; TENDON	Full-length and truncated forms of rat thrombospondin-4 (TSP-4) were expressed recombinantly in a mammalian cell line and purified to homogeneity. Biochemical analysis revealed a limited proteolytic processing, which detaches the N-terminal heparin-binding domain from the rest of the molecule and confirmed the importance of the heptad-repeat domain for pentamerization. In electron microscopy the uncleaved TSP-4 was seen as a large central particle to which five smaller globules are attached by elongated Linker regions. Binding of TSP-4 to collagens and to non-collagenous proteins could be detected in enzyme-linked immunosorbent assay-style ligand binding assays, by surface plasmon resonance spectroscopy, and in rotary shadowing electron microscopy. Although the binding of TSP-4 to solid-phase collagens was enhanced by Zn2+, that to non-collagenous proteins was not. The interactions of TSP-4 with both classes of proteins are mediated by C-terminal domains of the TSP-4 subunits but do not require an oligomeric structure. Major binding sites for TSP-4 are located in or close to the N- and C-terminal telopeptides in collagen I, but additional sites are detected in more central regions of the molecule.	Univ Cologne, Fac Med, Inst Biochem, D-50931 Cologne, Germany	University of Cologne	Paulsson, M (corresponding author), Univ Cologne, Fac Med, Inst Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.			Smyth, Neil/0000-0002-3734-2149				Adams JC, 1997, INT J BIOCHEM CELL B, V29, P861, DOI 10.1016/S1357-2725(96)00171-9; ARBER S, 1995, J CELL BIOL, V131, P1083, DOI 10.1083/jcb.131.4.1083; BAENZIGE.NL, 1971, P NATL ACAD SCI USA, V68, P240, DOI 10.1073/pnas.68.1.240; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; GALVIN NJ, 1987, J CELL BIOL, V104, P1413, DOI 10.1083/jcb.104.5.1413; HAUSER N, 1995, FEBS LETT, V368, P307, DOI 10.1016/0014-5793(95)00675-Y; Hecht JT, 1998, MATRIX BIOL, V17, P269, DOI 10.1016/S0945-053X(98)90080-4; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; Kyriakides TR, 1998, J HISTOCHEM CYTOCHEM, V46, P1007, DOI 10.1177/002215549804600904; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLER J, 1993, J CELL BIOL, V120, P1059, DOI 10.1083/jcb.120.4.1059; LAWLER J, 1995, J BIOL CHEM, V270, P2809, DOI 10.1074/jbc.270.6.2809; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; LAWLER J, 1992, BIOCHEMISTRY-US, V31, P1173, DOI 10.1021/bi00119a029; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; PAULSSON M, 1988, J BIOL CHEM, V263, P5425; Piecha D, 1999, J BIOL CHEM, V274, P13353, DOI 10.1074/jbc.274.19.13353; QABAR AN, 1994, J BIOL CHEM, V269, P1262; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; TUCKER RP, 1995, DEV DYNAM, V203, P477, DOI 10.1002/aja.1002030410; Urry LA, 1998, DEV DYNAM, V211, P390, DOI 10.1002/(SICI)1097-0177(199804)211:4<390::AID-AJA10>3.0.CO;2-8; VOS HL, 1992, J BIOL CHEM, V267, P12192	32	80	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37110	37117		10.1074/jbc.M007223200	http://dx.doi.org/10.1074/jbc.M007223200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10956668	hybrid			2022-12-27	WOS:000165577700091
J	Spencer, NY; Zeng, H; Patel, RP; Hogg, N				Spencer, NY; Zeng, H; Patel, RP; Hogg, N			Reaction of S-nitrosoglutathione with the heme group of deoxyhemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIOPLEGIC ISCHEMIC ARREST; NITRIC-OXIDE; BIOCHEMICAL-CHARACTERIZATION; OXYGEN-BINDING; NITROSOHEMOGLOBIN; HEMOGLOBIN; TRANSNITROSATION; GLUTATHIONE; HEART; NO	The mechanism of interaction between S-nitrosoglutathione (GSNO) and hemoglobin is a crucial component of hypotheses concerning the role played by S-nitrosohemoglobin in vivo. We previously demonstrated (Patel, R. P,, Hogg, N, Spencer, N, Y,, Kalyanaraman, B,, Matalon, S,, and Darley-Usmar, V, Me (1999) J, Biol. Chem 274, 15487-15492) that transnitrosation between oxygenated hemoglobin and GSNO is a slow, reversible process, and that the reaction between GSNO and deoxygenated hemoglobin (deoxyHb) did not conform to second order reversible kinetics. In this study we have reinvestigated this reaction and show that GSNO reacts with deoxyHb to form glutathione, nitric oxide, and ferric hemoglobin. Nitric oxide formed hom this reaction is immediately autocaptured to form nitrosylated hemoglobin. GSNO reduction by deoxyHb is essentially irreversible, The kinetics of this reaction depended upon the conformation of the protein, with more rapid kinetics occurring in the high oxygen affinity state (i.e. modification of the Cys beta -93) than in the low oxygen affinity state (i.e. treatment with inositol hexaphosphate), A more rapid reaction occurred when deoxymyoglobin was used, further supporting the observation that the kinetics of reduction are directly proportional to oxygen affinity. This observation provides a mechanism for how deoxygenation of hemoglobin/myoglobin could facilitate nitric oxide release hom S-nitrosothiols and represents a potential physiological mechanism of S-nitrosothiol metabolism.	Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Free Rad Biol, Birmingham, AL 35294 USA	Medical College of Wisconsin; Medical College of Wisconsin; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Hogg, N (corresponding author), Med Coll Wisconsin, Biophys Res Inst, 8701 Watertown Plank Rd,POB 26509, Milwaukee, WI 53226 USA.		Spencer, Netanya/AAS-7999-2020	Spencer, Netanya/0000-0003-1010-5458; Patel, Rakesh/0000-0002-1526-4303	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055792, R01GM055792] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 01008] Funding Source: Medline; NIGMS NIH HHS [GM 55792] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Bonaventura C, 1999, J BIOL CHEM, V274, P24742, DOI 10.1074/jbc.274.35.24742; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HILLE R, 1979, J BIOL CHEM, V254, P2110; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Konorev EA, 1996, BRIT J PHARMACOL, V119, P511, DOI 10.1111/j.1476-5381.1996.tb15701.x; KONOREV EA, 1995, J PHARMACOL EXP THER, V274, P200; Konorev EA, 1996, FEBS LETT, V378, P111, DOI 10.1016/0014-5793(95)01429-2; Liao JC, 1999, P NATL ACAD SCI USA, V96, P8757, DOI 10.1073/pnas.96.15.8757; McMahon TJ, 2000, J BIOL CHEM, V275, P16738, DOI 10.1074/jbc.M000532200; Patel RP, 1999, J BIOL CHEM, V274, P15487, DOI 10.1074/jbc.274.22.15487; RIGGS A, 1961, J BIOL CHEM, V236, P1948; Rossi R, 1997, ANAL BIOCHEM, V254, P215, DOI 10.1006/abio.1997.2424; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; Tsikas D, 1999, ANAL BIOCHEM, V273, P32, DOI 10.1006/abio.1999.4209; Wolzt M, 1999, J BIOL CHEM, V274, P28983, DOI 10.1074/jbc.274.41.28983	20	57	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36562	36567		10.1074/jbc.M005347200	http://dx.doi.org/10.1074/jbc.M005347200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10945989	hybrid			2022-12-27	WOS:000165577700016
J	MacRae, IJ; Hanna, E; Ho, JD; Fisher, AJ; Segel, IH				MacRae, IJ; Hanna, E; Ho, JD; Fisher, AJ; Segel, IH			Induction of positive cooperativity by amino acid replacements within the C-terminal domain of Penicillium chrysogenum ATP sulfurylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 5'-PHOSPHOSULFATE KINASE; SULFATE-ACTIVATING ENZYMES; SITE-DIRECTED MUTAGENESIS; KINETIC CHARACTERIZATION; FILAMENTOUS FUNGI; SULFHYDRYL-GROUP; HIGHER-PLANTS; RAT-LIVER; PURIFICATION; INHIBITION	ATP sulfurylase from Penicillium chrysogenum is an allosteric enzyme in which Cys-509 is critical for maintaining the R state. Cys-509 is located in a C-terminal domain that is 42% identical to the conserved core of adenosine 5'-phosphosulfate (adenylylsulfate) (APS) kinase, This domain is believed to provide the binding site for the allosteric effector, 3'-phosphoadenosine 5'-phosphosulfate (PAPS), Replacement of Cys-509 with either Tyr or Ser destabilizes the R state, resulting in an enzyme that is intrinsically cooperative at pH 8 in the absence of PAPS. The kinetics of C509Y resemble those of the wild type enzyme in which Cys-509 has been covalently modified. The kinetics of C509S resemble those of the wild type enzyme in the presence of PAPS. It is likely that the negative charge on the Cys-509 side chain helps to stabilize the R state. Treatment of the enzyme with a low level of trypsin results in cleavage at Lys-527, a residue that lies in a region analogous to a PAPS motif-containing mobile loop of true APS kinase, Both mutant enzymes were cleaved more rapidly than the wild type enzyme, suggesting that movement of the mobile loop occurs during the R to T transition.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Segel, IH (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.		Hanna, Ehab Y/B-1593-2017	Hanna, Ehab Y/0000-0003-3241-2440; Fisher, Andrew/0000-0003-3488-6594; Ho, Joseph/0000-0002-9636-5527				BALLIO A, 1959, SSPISS, V2, P343; Deyrup AT, 1999, J BIOL CHEM, V274, P28929, DOI 10.1074/jbc.274.41.28929; FOSTER BA, 1994, J BIOL CHEM, V269, P19777; HANSON AD, 1991, PLANT PHYSIOL, V97, P1199, DOI 10.1104/pp.97.3.1199; ITAHASHI M, 1961, J BIOCHEM, V50, P52, DOI 10.1093/oxfordjournals.jbchem.a127408; MacRae I, 1997, ARCH BIOCHEM BIOPHYS, V337, P17, DOI 10.1006/abbi.1996.9751; MacRae IJ, 1998, J BIOL CHEM, V273, P28583, DOI 10.1074/jbc.273.44.28583; MacRae IJ, 2000, BIOCHEMISTRY-US, V39, P1613, DOI 10.1021/bi9924157; MARTIN RL, 1989, J BIOL CHEM, V264, P11768; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OSSLUND T, 1982, PLANT PHYSIOL, V70, P39, DOI 10.1104/pp.70.1.39; PETTIGREW DW, 1977, J BIOL CHEM, V252, P4546; RENOSTO F, 1985, J BIOL CHEM, V260, P1535; RENOSTO F, 1987, J BIOL CHEM, V262, P16279; RENOSTO F, 1977, ARCH BIOCHEM BIOPHYS, V180, P416, DOI 10.1016/0003-9861(77)90056-X; RENOSTO F, 1985, J BACTERIOL, V164, P674, DOI 10.1128/JB.164.2.674-683.1985; RENOSTO F, 1991, ARCH BIOCHEM BIOPHYS, V290, P66, DOI 10.1016/0003-9861(91)90592-7; RENOSTO F, 1990, J BIOL CHEM, V265, P10300; RENOSTO F, 1984, J BIOL CHEM, V259, P2113; RENOSTO F, 1993, ARCH BIOCHEM BIOPHYS, V307, P272, DOI 10.1006/abbi.1993.1590; RUBIN MM, 1966, J MOL BIOL, V21, P265, DOI 10.1016/0022-2836(66)90097-0; RYAN LD, 1974, ARCH BIOCHEM BIOPHYS, V160, P279, DOI 10.1016/S0003-9861(74)80035-4; SATISHCHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P11684, DOI 10.1021/bi00162a003; SEGEL IH, 1987, METHOD ENZYMOL, V143, P334; SEGEL IH, 1993, ENZYME KINETICS BEHA, P421; SEUBERT PA, 1983, ARCH BIOCHEM BIOPHYS, V225, P679, DOI 10.1016/0003-9861(83)90079-6; STORER AC, 1976, BIOCHEM J, V159, P1; TWEEDIE JW, 1971, PREP BIOCHEM, V1, P91, DOI 10.1080/00327487108081932; Venkatachalam KV, 1999, J BIOL CHEM, V274, P2601, DOI 10.1074/jbc.274.5.2601; WOOD HG, 1966, J BIOL CHEM, V241, P5692; YU M, 1989, ARCH BIOCHEM BIOPHYS, V269, P156, DOI 10.1016/0003-9861(89)90096-9	31	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36303	36310		10.1074/jbc.M005992200	http://dx.doi.org/10.1074/jbc.M005992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10956658	hybrid			2022-12-27	WOS:000165382000093
J	Pastorcic, M; Das, HK				Pastorcic, M; Das, HK			Regulation of transcription of the human presenilin-1 gene by Ets transcription factors and the p53 protooncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; GAMMA-SECRETASE; BINDING-PROTEIN; MISSENSE MUTATIONS; CELL-GROWTH; C-FOS; ACTIVATION; EXPRESSION; APOPTOSIS; PROTEOLYSIS	The expression of the human presenilin-1 cellular gene is suppressed by the p53 protooncogene. The rapid kinetic of the down-regulation has suggested that it may result from a primary mechanism. We show here that p53 also suppresses the transcription of a presenilin-1 promoter-chloramphenicol acetyltransferase reporter synthetic gene in transient infection assays in neuroblastoma (SK-N-SH) and hepatoma (HepG2) cell lines. Only:a minimum promoter including sequences from -35 td + 6 from the transcription initiation is sufficient to confer down-regulation. We have previously defined a crucial DNA element controlling 90% of the expression of the gene:within the same short area, and the identification of the transcription factors involved should also provide insights into the regulation of PSI by p53. This region,contains an Ets transcription factor binding motif, and a a-base pair alteration within the core sequence (GGAA to TTAA) of the Ets consensus also reduced transcription by more than 90%. We now show that Ets1 and Ets2: indeed transactivate a PSI promoter-chloramphenicol acetyltransferase reporter including the (-35 to +6):fragment. Furthermore, in vitro translated Ets2 binds specifically to the -10 Ets motif in electrophoretic mobility shift assays. Therefore, Ets1/2 factors bind specifically to the -10 Ets element and activate PS1 transcription. We also show that the coactivator p300 enhances the activation by Ets1 and Ets2 as well as the repression by p53. p300 is known to interact with p53 as well as with Ets1 and Ets2. We show that p53 does not bind directly to the PSI promoter. Hence the repression of PS1:transcription by p53 is likely to be mediated through protein-protein interactions.	Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA; Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center	Pastorcic, M (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA.	mpastor@hsc.unt.edu						Abraham J, 2000, J MOL BIOL, V295, P853, DOI 10.1006/jmbi.1999.3415; Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Baumeister R, 1997, Genes Funct, V1, P149; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chan YM, 1999, NEURON, V23, P201, DOI 10.1016/S0896-6273(00)80771-0; Davis JA, 1998, NEURON, V20, P603, DOI 10.1016/S0896-6273(00)80998-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hong CS, 1999, J NEUROSCI, V19, P637; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; KAGDAD M, 1997, CELL, V90, P809; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIM K, 1989, BIOTECHNIQUES, V7, P576; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; Pastorcic M, 1999, J BIOL CHEM, V274, P24297, DOI 10.1074/jbc.274.34.24297; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000	47	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34938	34945		10.1074/jbc.M005411200	http://dx.doi.org/10.1074/jbc.M005411200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10942770	hybrid			2022-12-27	WOS:000165422800017
J	Yusta, B; Boushey, RP; Drucker, DJ				Yusta, B; Boushey, RP; Drucker, DJ			The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGEN-ACTIVATED PROTEIN; ADULT-RAT HEPATOCYTES; GENE-EXPRESSION; GROWTH-FACTOR; PROLIFERATION; INDUCTION; SEVERITY; MYOCYTES; CELLS	Glucagon and the glucagon-like peptides regulate metabolic functions via signaling through a glucagon receptor subfamily of G protein-coupled receptors, Activation of glucagon-like peptide-2 receptor (GLP-2R) signaling maintains the integrity of the intestinal epithelial mucose via regulation of crypt cell proliferation. Because GLP-2 decreases mortality and reduces intestinal apoptosis in rodents after experimental injury, we examined whether GLP-2R signaling directly modifies the cellular response to external injury. We show here that activation of GLP-2R signaling inhibits cycloheximide-induced apoptosis in baby hamster kidney fibroblasts expressing a transfected GLP-2 receptor. GLP-2 reduced DNA fragmentation and improved cell survival, in association with reduced activation of caspase-3 and decreased poly(ADP-ribose) polymerase cleavage and reduced caspase-8 and caspase-9-like activities. Both GLP-2 and forskolin reduced mitochondrial cytochrome c release and decreased the cycloheximide-induced cleavage of caspase-3 in the presence or absence of the PKA inhibitor H-89, Similarly, GLP-2 increased cell survival following cycloheximide in the presence of the kinase inhibitors PD98054 and LY294002. These findings provide evidence that signaling through G; protein-coupled receptors of the glucagon superfamily is directly linked to regulation of apoptosis and suggest the existence of a cAMP-dependent protein kinase-, phosphatidylinositol 3-kinase-, and mitogen-activated protein kinase-independent pathway coupling GLP-2R signaling to caspase inhibition and cell survival.	Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Med, Toronto, ON M5G 1L7, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Drucker, DJ (corresponding author), Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Dept Med, 101 Coll St,CCRW3-838, Toronto, ON M5G 1L7, Canada.		Drucker, Daniel J/A-4092-2010					Boushey RP, 1999, AM J PHYSIOL-ENDOC M, V277, pE937, DOI 10.1152/ajpendo.1999.277.5.E937; Bucher N L, 1975, Adv Enzyme Regul, V13, P281; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; Chance WT, 1997, AM J PHYSIOL-GASTR L, V273, pG559, DOI 10.1152/ajpgi.1997.273.2.G559; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; Drucker DJ, 1999, TRENDS ENDOCRIN MET, V10, P153, DOI 10.1016/S1043-2760(98)00136-2; Drucker DJ, 1999, AM J PHYSIOL-GASTR L, V276, pG79, DOI 10.1152/ajpgi.1999.276.1.G79; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Drucker DJ, 1997, NAT BIOTECHNOL, V15, P673, DOI 10.1038/nbt0797-673; Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073/pnas.93.15.7911; Edvell A, 1999, ENDOCRINOLOGY, V140, P778, DOI 10.1210/en.140.2.778; Gu CH, 2000, J BIOL CHEM, V275, P20726, DOI 10.1074/jbc.M000152200; Iwai-Kanai E, 1999, CIRCULATION, V100, P305, DOI 10.1161/01.CIR.100.3.305; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; Kimura M, 1997, EUR J PHARMACOL, V324, P267, DOI 10.1016/S0014-2999(97)00078-2; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Mabrouk GM, 1998, BIOCHEM J, V330, P759; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; Montrose-Rafizadeh C, 1999, ENDOCRINOLOGY, V140, P1132, DOI 10.1210/en.140.3.1132; Munroe DG, 1999, P NATL ACAD SCI USA, V96, P1569, DOI 10.1073/pnas.96.4.1569; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Prasad R, 2000, J PEDIATR SURG, V35, P357, DOI 10.1016/S0022-3468(00)90040-X; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Scott RB, 1998, AM J PHYSIOL-GASTR L, V275, pG911, DOI 10.1152/ajpgi.1998.275.5.G911; Sharma K, 1999, MOL ENDOCRINOL, V13, P82, DOI 10.1210/me.13.1.82; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; Stoffers DA, 2000, DIABETES, V49, P741, DOI 10.2337/diabetes.49.5.741; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Thangaraju M, 1999, CANCER RES, V59, P1649; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsai CH, 1997, AM J PHYSIOL-ENDOC M, V273, pE77, DOI 10.1152/ajpendo.1997.273.1.E77; Turner PR, 2000, MOL ENDOCRINOL, V14, P241, DOI 10.1210/me.14.2.241; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yusta B, 1999, J BIOL CHEM, V274, P30459, DOI 10.1074/jbc.274.43.30459	43	88	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35345	35352		10.1074/jbc.M005510200	http://dx.doi.org/10.1074/jbc.M005510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10940305	Green Published, hybrid			2022-12-27	WOS:000165422800069
J	Gu, YC; Publicover, SJ				Gu, YC; Publicover, SJ			Expression of functional metabotropic glutamate receptors primary cultured rat osteoblasts - Cross-talk with N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CEREBELLAR GRANULE CELLS; NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR-BETA; BONE-CELLS; NMDA CURRENTS; IN-VITRO; PATHWAYS; CA2+; ACTIVATION	Osteoblasts and osteoclasts express functional N-methyl-D-aspartate (NMDA) receptors, which participate in regulation of bone matrix. In rat femoral osteoblasts held in whole cell clamp there is a robust NMDA current but little if any response to L-glutamate, We have investigated expression of metabotropic glutamate receptors (mGluRs) in these cells. By reverse transcription polymerase chain reaction, we have detected expression of mGluR1b (but not mGluR1a, 2, 3, 4, 5, or 6), Blockade of mGluRs with (+/-)-alpha -methyl-carboxyphenyl-glycine resulted in an enlarged L-glutamate-induced current that resembled the response to NMDA. Conversely, prior stimulation of mGluRs with trans-(+/-)-1-amino-1,3-cyclopentanedicarboxylic acid (1S,3R-ACPD; mGluR agonist) reduced the NMDA-induced current by 77%. Monitoring of [Ca2+](i) showed that NMDA induced a sustained elevation of [Ca2+](i). which was dependent upon [Ca2+](o). Treatment with 1S,3R-ACPD generated an initial transient that was independent of [Ca2+](o), followed by a sustained, [Ca2+](o)-dependent phase, a response consistent with phospholipase C-mediated mobilization of stored Ca2+, Investigations of the interaction between the two receptors confirmed inhibitory modulation of the NMDA receptor-induced rise in [Ca2+](i) by mGluRs. Parathyroid hormone, which also activates phospholipase C in osteoblasts, had a similar inhibitory effect on the NMDA receptor-induced [Ca2+](i) response. Elevation of [Ca2+](i) mediated by mGluR activation was reduced by subsequent stimulation of NMDA receptors, This is the first description of mGluRs in bone and shows that complex glutamatergic signaling can occur in this tissue.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Publicover, SJ (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	s.j.publicover@bham.ac.uk	Publicover, Steve J/E-7970-2018	gu, yuchun/0000-0002-7558-0447				Ahmed MAAS, 2000, J CELL PHYSIOL, V183, P163; Ajubi NE, 1999, AM J PHYSIOL-ENDOC M, V276, pE171, DOI 10.1152/ajpendo.1999.276.1.E171; Akaike N, 1997, J PHYSIOL-LONDON, V504, P665, DOI 10.1111/j.1469-7793.1997.665bd.x; AKATSU T, 1991, J BONE MINER RES, V6, P183; Birch MA, 1997, J BONE MINER RES, V12, pO10; BLEAKMAN D, 1992, MOL PHARMACOL, V42, P192; CHALLISS RAJ, 1994, NEUROPHARMACOLOGY, V33, P15, DOI 10.1016/0028-3908(94)90092-2; Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756-3282(97)00295-0; CIVITELLI R, 1988, AM J PHYSIOL, V255, pE660, DOI 10.1152/ajpendo.1988.255.5.E660; COLLWELL CS, 1994, NEUROSCIENCE, V17, P441; Contractor A, 1998, P NATL ACAD SCI USA, V95, P8969, DOI 10.1073/pnas.95.15.8969; COURTNEY MJ, 1992, J NEUROCHEM, V59, P983, DOI 10.1111/j.1471-4159.1992.tb08339.x; Espinosa L, 1999, J PHYSIOL-LONDON, V518, P47, DOI 10.1111/j.1469-7793.1999.0047r.x; Genever P. G., 1999, Calcified Tissue International, V64, pS41; Genever PG, 1999, BLOOD, V93, P2876; Ghosh PK, 1997, DEV BRAIN RES, V102, P1, DOI 10.1016/S0165-3806(97)00066-7; Golshani P, 1998, J NEUROPHYSIOL, V80, P143, DOI 10.1152/jn.1998.80.1.143; Gu Y, 2000, J PHYSIOL-LONDON, V523, p155P; Guyton A.C., 2011, HALL TXB MED PHYSL; HARVEY J, 1993, BRIT J PHARMACOL, V109, P1085, DOI 10.1111/j.1476-5381.1993.tb13733.x; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; JOLY C, 1995, J NEUROSCI, V15, P3970; JONES DB, 1991, CELL MATER, V1, P329; Kane MD, 1998, NEUROSCI LETT, V252, P1, DOI 10.1016/S0304-3940(98)00484-4; Kanematsu M, 1997, J BONE MINER RES, V12, P1789, DOI 10.1359/jbmr.1997.12.11.1789; KAPLAN AD, 1995, ENDOCRINOLOGY, V136, P1674, DOI 10.1210/en.136.4.1674; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; KELSO SR, 1992, J PHYSIOL-LONDON, V449, P705, DOI 10.1113/jphysiol.1992.sp019110; Laketic-Ljubojevic I, 1999, BONE, V25, P631, DOI 10.1016/S8756-3282(99)00224-0; MARUSIC A, 1991, J IMMUNOL, V146, P2633; Mason DJ, 1997, BONE, V20, P199, DOI 10.1016/S8756-3282(96)00386-9; MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo-128-6-2895; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOORE EDW, 1990, CELL CALCIUM, V11, P157, DOI 10.1016/0143-4160(90)90068-6; MORRISETT RA, 1990, J NEUROCHEM, V54, P1517, DOI 10.1111/j.1471-4159.1990.tb01199.x; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756-3282(98)00061-1; Peet NM, 1999, FASEB J, V13, P2179, DOI 10.1096/fasebj.13.15.2179; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; Pizzi M, 1999, EUR J NEUROSCI, V11, P2489, DOI 10.1046/j.1460-9568.1999.00669.x; Pizzi M, 1996, MOL PHARMACOL, V49, P586; RALSTON SH, 1994, ENDOCRINOLOGY, V135, P330, DOI 10.1210/en.135.1.330; SANTI MR, 1994, J NEUROCHEM, V63, P1207; Schwindinger WF, 1998, ENDOCRINE, V8, P201, DOI 10.1385/ENDO:8:2:201; Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756-3282(99)00215-X; Shimegi S, 1996, CALCIFIED TISSUE INT, V58, P109, DOI 10.1007/BF02529732; Skerry TM, 1999, J BONE MINER METAB, V17, P66, DOI 10.1007/s007740050067; Tam VK, 1998, AM J PHYSIOL-CELL PH, V274, pC1686, DOI 10.1152/ajpcell.1998.274.6.C1686; TATAKIS DN, 1992, BONE MINER, V18, P1, DOI 10.1016/0169-6009(92)90795-F; Tokuda H, 1999, PROSTAG LEUKOTR ESS, V61, P189, DOI 10.1054/plef.1999.0089; Tsai JA, 1999, BIOCHEM BIOPH RES CO, V263, P206, DOI 10.1006/bbrc.1999.1339; Valerio A, 1997, NEUROREPORT, V8, P2695, DOI 10.1097/00001756-199708180-00012; Walker LM, 2000, J CELL BIOCHEM, V79, P648, DOI 10.1002/1097-4644(20001215)79:4<648::AID-JCB130>3.0.CO;2-Q; Wiemann M, 1999, CALCIFIED TISSUE INT, V65, P479, DOI 10.1007/s002239900736; Wiemann M, 1998, CALCIFIED TISSUE INT, V63, P154, DOI 10.1007/s002239900507; YAMAGUCHI DT, 1988, J BIOL CHEM, V263, P10745; Yu SP, 1997, J PHYSIOL-LONDON, V499, P721, DOI 10.1113/jphysiol.1997.sp021964	58	74	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34252	34259		10.1074/jbc.M004520200	http://dx.doi.org/10.1074/jbc.M004520200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10950953	hybrid			2022-12-27	WOS:000165095300036
J	Mao, QC; Deeley, RG; Cole, SPC				Mao, QC; Deeley, RG; Cole, SPC			Functional reconstitution of substrate transport by purified multidrug resistance protein MRP1 (ABCC1) in phospholipid vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATE EXPORT PUMP; ORGANIC ANION TRANSPORTER; CANCER CELL-LINE; P-GLYCOPROTEIN; ATPASE ACTIVITY; LEUKOTRIENE C-4; MONOCLONAL-ANTIBODIES; VINCRISTINE TRANSPORT; DEPENDENT TRANSPORT; CYSTIC-FIBROSIS	The 190-kDa multidrug resistance protein MRP1 (ABCC1) is a polytopic transmembrane protein belonging to the ATP-binding cassette transporter superfamily,In addition to conferring resistance to various antineoplastic agents, MRP1 is a transporter of conjugated organic anions, including the cysteinyl leukotriene C-4 (LTC4). We previously characterized the ATPase activity of reconstituted immunoaffinity-purified native MRP1 and showed it could be stimulated by its organic anion substrates (Mao, Q., Leslie, E, M., Deeley, R. G., and Cole, S. P. C. (1999) Biochim. Biophys. Acta 1461, 69-82). Here we show that purified reconstituted MRP1 is also capable of active transport of its substrates. Thus LTC4 uptake by MRP1 proteoliposomes was osmotically sensitive and could be inhibited by two MRP1-specific monoclonal antibodies. LTC4 uptake was also markedly reduced by the competitive inhibitor, S-decyl-glutathione, as well as by the MRP1 substrates 17 beta -estradiol 17-beta-(D-glucuronide), oxidized glutathione, and vincristine in the presence of reduced glutathione. The K-m for ATP and LTC4 were 357 +/- 184 muM and 366 +/- 38 nM, respectively, and 2.14 +/- 0.75 muM for 17 beta -estradiol 17-beta-(D-glucuronide). Transport of vincristine required the presence of both ATP and GSH. Conversely, GSH transport was stimulated by vincristine and verapamil. Our data represent the first reconstitution of transport competent purified native MRP1 and confirm that MRP1 is an efflux pump, which can transport conjugated organic anions and co-transport vincristine together with GSH.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Cole, SPC (corresponding author), Queens Univ, Canc Res Labs, Rm 328,Botterell Hall, Kingston, ON K7L 3N6, Canada.		Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017	Cole, Susan P.C./0000-0001-6571-6884				Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Bryan J, 1997, CURR OPIN CELL BIOL, V9, P553, DOI 10.1016/S0955-0674(97)80033-6; BUCHLER M, 1994, EUR J BIOCHEM, V224, P345, DOI 10.1111/j.1432-1033.1994.00345.x; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Cladera J, 1997, EUR J BIOCHEM, V243, P798, DOI 10.1111/j.1432-1033.1997.00798.x; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Dekkers DWC, 1998, BIOCHEMISTRY-US, V37, P14833, DOI 10.1021/bi981011w; Ding GY, 1999, ANTICANCER RES, V19, P3243; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; Hagmann W, 1999, EUR J BIOCHEM, V265, P281, DOI 10.1046/j.1432-1327.1999.00735.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Jedlitschky G, 1996, CANCER RES, V56, P988; Kamp D, 1998, BBA-BIOMEMBRANES, V1372, P91, DOI 10.1016/S0005-2736(98)00049-2; Keppler D, 1997, BIOL CHEM, V378, P787; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Lee AG, 1998, BBA-REV BIOMEMBRANES, V1376, P381, DOI 10.1016/S0304-4157(98)00010-0; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Madon J, 2000, MOL PHARMACOL, V57, P634, DOI 10.1124/mol.57.3.634; MAO QC, 1995, J BIOL CHEM, V270, P5258, DOI 10.1074/jbc.270.10.5258; Mao QC, 1999, BBA-BIOMEMBRANES, V1461, P69, DOI 10.1016/S0005-2736(99)00150-9; McAleer MA, 1999, J BIOL CHEM, V274, P23541, DOI 10.1074/jbc.274.33.23541; MIRSKI SEL, 1987, CANCER RES, V47, P2594; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Romsicki Y, 1999, BIOCHEMISTRY-US, V38, P6887, DOI 10.1021/bi990064q; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; Sharom FJ, 1997, BIOCHEM SOC T, V25, P1088, DOI 10.1042/bst0251088; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Zeng H, 1999, CANCER RES, V59, P5964; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	59	95	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34166	34172		10.1074/jbc.M004584200	http://dx.doi.org/10.1074/jbc.M004584200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942765	hybrid			2022-12-27	WOS:000165095300025
J	Attmane-Elakeb, A; Sibella, V; Vernimmen, C; Belenfant, X; Hebert, SC; Bichara, M				Attmane-Elakeb, A; Sibella, V; Vernimmen, C; Belenfant, X; Hebert, SC; Bichara, M			Regulation by glucocorticoids of expression and activity of rBSC1, the Na+-K+ (NH4+)-2Cl(-) cotransporter of medullary thick ascending limb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLIC-ACIDOSIS; CL COTRANSPORTER; MEMBRANE-VESICLES; RAT-KIDNEY; VASOPRESSIN	To assess whether glucocorticoids regulate rBSC1, the apical Na+-K+(NH4+)-2Cl(-) cotransporter of kidney medullary thick ascending limb (MTAL), studies were performed in normal rats, adrenalectomized (ADX) rats, and ADX rats infused with dexamethasone for 6 days. The effects of dexamethasone on rBSC1 were also studied in vitro using isolated rat MTAL segments. Cotransport activity was estimated by intracellular pH measurements; rBSC1 protein was quantified in MTAL crude membranes by immunoblotting analysis, and mRNA was quantified by quantitative reverse transcription-polymerase chain reaction. The abundance of rBSC1 protein and mRNA increased in ADX rats infused with dexamethasone compared with ADX rats (p < 0.04), In addition, application of dexamethasone for 1-3 h to MTALs caused rBSC1 protein and mRNA abundance and cotransport activity to significantly increase in a hyperosmotic medium (450 mosmol/kg of H2O) containing 0.7 nM arginine vasopressin, which is an in vitro experimental condition that resembles the in vivo MTAL environment. Results obtained in various media and with 8-bromo-cAMP indicated that stimulation of rBSC1 expression by glucocorticoids required interactions between glucocorticoid receptor- and cAMP-dependent factors. Up to 100 nar d-aldosterone had no effect on cotransport activity in vitro. Thus glucocorticoids directly stimulate MTAL rBSC1 expression and activity, which contributes to glucocorticoid-dependent effects on the renal regulation of acid-base balance and urinary concentrating ability.	Univ Paris 07, Fac Med Xavier Bichat, INSERM U426, Inst Federat Reg Xavier Bichat, F-75870 Paris 18, France; Hop Andre Gregoire, Serv Nephrol, F-93100 Montreuil, France; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Yale University	Bichara, M (corresponding author), Univ Paris 07, Fac Med Xavier Bichat, INSERM U426, Inst Federat Reg Xavier Bichat, 16 Rue Henri Huchard, F-75870 Paris 18, France.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036803] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36803] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amlal H, 1998, J CLIN INVEST, V101, P1045, DOI 10.1172/JCI686; Amlal H, 1996, AM J PHYSIOL-CELL PH, V271, pC455, DOI 10.1152/ajpcell.1996.271.2.C455; Attmane-Elakeb A, 1998, J BIOL CHEM, V273, P33681, DOI 10.1074/jbc.273.50.33681; Attmane-Elakeb A, 1998, KIDNEY INT, V53, P439, DOI 10.1046/j.1523-1755.1998.00760.x; AttmaneElakeb A, 1997, J BIOL CHEM, V272, P25668, DOI 10.1074/jbc.272.41.25668; BOYKIN J, 1978, J CLIN INVEST, V62, P738, DOI 10.1172/JCI109184; COOKE RC, 1973, J LAB CLIN MED, V82, P784; DOUCET A, 1986, AM J PHYSIOL, V251, pF851, DOI 10.1152/ajprenal.1986.251.5.F851; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V271, pF619, DOI 10.1152/ajprenal.1996.271.3.F619; FARMAN N, 1983, AM J PHYSIOL, V244, pF325, DOI 10.1152/ajprenal.1983.244.3.F325; FARMAN N, 1991, AM J PHYSIOL, V260, pC226, DOI 10.1152/ajpcell.1991.260.2.C226; GAMBA G, 1994, J BIOL CHEM, V269, P17713; IGARASHI P, 1995, AM J PHYSIOL-RENAL, V269, pF405, DOI 10.1152/ajprenal.1995.269.3.F405; Kaplan MR, 1996, KIDNEY INT, V49, P40, DOI 10.1038/ki.1996.6; Kim GH, 1999, AM J PHYSIOL-RENAL, V276, pF96, DOI 10.1152/ajprenal.1999.276.1.F96; KINSELLA J, 1984, P NATL ACAD SCI-BIOL, V81, P630, DOI 10.1073/pnas.81.2.630; KNEPPER M, 1983, AM J PHYSIOL, V244, pF579, DOI 10.1152/ajprenal.1983.244.6.F579; KNEPPER MA, 1989, PHYSIOL REV, V69, P179, DOI 10.1152/physrev.1989.69.1.179; LEE SM, 1983, AM J PHYSIOL, V244, pF504, DOI 10.1152/ajprenal.1983.244.5.F504; Marumo R, 1998, KIDNEY INT, V54, P877, DOI 10.1046/j.1523-1755.1998.00051.x; MAY RC, 1986, J CLIN INVEST, V77, P614, DOI 10.1172/JCI112344; MCDONALD KM, 1976, KIDNEY INT, V10, P38, DOI 10.1038/ki.1976.77; MOREL F, 1982, KIDNEY INT, V21, P55; Mount DB, 1999, AM J PHYSIOL-RENAL, V276, pF347, DOI 10.1152/ajprenal.1999.276.3.F347; Nielsen S, 1998, AM J PHYSIOL-RENAL, V275, pF885, DOI 10.1152/ajprenal.1998.275.6.F885; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PEREZ GO, 1979, HORM RES, V11, P12, DOI 10.1159/000179033; RAYSON BM, 1984, AM J PHYSIOL, V246, pF656, DOI 10.1152/ajprenal.1984.246.5.F656; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; TODDTURLA KM, 1993, AM J PHYSIOL, V264, pF781, DOI 10.1152/ajprenal.1993.264.5.F781; WELBOURNE TC, 1988, AM J PHYSIOL, V254, pF134, DOI 10.1152/ajprenal.1988.254.1.F134; WELBOURNE TC, 1976, ENDOCRINOLOGY, V99, P762	33	27	27	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33548	33553		10.1074/jbc.M006591200	http://dx.doi.org/10.1074/jbc.M006591200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10942780	hybrid			2022-12-27	WOS:000090104600053
J	Kodera, Y; Takeyama, K; Murayama, A; Suzawa, M; Masuhiro, Y; Kato, S				Kodera, Y; Takeyama, K; Murayama, A; Suzawa, M; Masuhiro, Y; Kato, S			Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; NUCLEAR RECEPTORS; DIFFERENTIATION; COMPLEX; REQUIRES; BINDING	The nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma) is a member of the nuclear receptor superfamily and acts as a ligand-dependent transcription factor mediating adipocyte differentiation, cell proliferation and inflammatory processes, and modulation of insulin sensitivity. Members of the 160-kDa protein (SRC-1/TIF2/AIB-1) family of coactivators, CBP/p300 and TRAP220/DRIP205, are shown to interact directly with PPAR gamma and potentiate nuclear receptor transactivation function in a ligand-dependent fashion. Because PPAR gamma ligands exert partially overlapping but distinct subsets of biological action through PPAR gamma binding, we wished to examine whether interactions between PPAR gamma and known coactivators were induced to the same extent by different classes of PPAR gamma ligand. The natural ligand 15-deoxy-Delta 12,14-prostaglandin J(2) induced PPAR gamma interactions with all coactivators tested (SRC-1, TIF2, AIB-1, p300, TRAP220/DRIP205) in yeast and mammalian two-hybrid assays, as well as in a glutathione S-transferase pull-down assay. However, under the same conditions troglitazone, a synthetic PPAR gamma ligand that acts as an antidiabetic agent, did not induce PPAR gamma interactions with any of the coactivators. Our findings suggest that ligand binding may alter PPAR gamma structure in a ligand type-specific way, resulting in distinct PPAR gamma -coactivator interactions.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Kato, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130032, Japan.							Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Castillo G, 1999, EMBO J, V18, P3676, DOI 10.1093/emboj/18.13.3676; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Day C, 1999, DIABETIC MED, V16, P179, DOI 10.1046/j.1464-5491.1999.00023.x; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Glass CK, 2000, GENE DEV, V14, P121; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, MOL CELL BIOL, V15, P5858; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; ONATE SA, 1995, SCIENCE, V270, P1354; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; Takeyama KI, 1999, MOL CELL BIOL, V19, P1049; Yanagi Y, 2000, BIOCHEM BIOPH RES CO, V269, P410, DOI 10.1006/bbrc.2000.2304; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yanase T, 1997, BIOCHEM BIOPH RES CO, V233, P320, DOI 10.1006/bbrc.1997.6446; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	32	178	183	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33201	33204		10.1074/jbc.C000517200	http://dx.doi.org/10.1074/jbc.C000517200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10944516	hybrid			2022-12-27	WOS:000090104600005
J	Ouellette, AJ; Satchell, DP; Hsieh, MM; Hagen, SJ; Selsted, ME				Ouellette, AJ; Satchell, DP; Hsieh, MM; Hagen, SJ; Selsted, ME			Characterization of luminal paneth cell alpha-defensins in mouse small intestine - Attenuated antimicrobial activities of peptides with truncated amino termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-DEFENSE; SALMONELLA VIRULENCE; PHOSPHOLIPASE A(2); MESSENGER-RNA; RABBIT NP-2; HUMAN HNP-1; SECRETION; CRYPTDIN; PROTEIN; GENE	Paneth cells at the base of small intestinal crypts secrete apical granules that contain antimicrobial peptides including alpha -defensins, termed cryptdins, Using an antibody specific for mouse cryptdin-1, -2, -3, and -6, immunogold-localization studies demonstrated that cryptdins are constituents of mouse Paneth cell secretory granules. Several cryptdin peptides have been purified from rinses of adult mouse small. intestine by gel filtration and reverse-phase high performance liquid chromatography. Their primary structures were determined by peptide sequencing, and their antimicrobial activities were compared with those of the corresponding tissue forms. The isolated luminal cryptdins included peptides identical to the tissue forms of cryptdin-2, -4, and -6 as well as variants of cryptdin-1, -4, and -6 that have N termini truncated by one or two residues. In assays of antimicrobial activity against Staphylococcus aureus, Escherichia coli, and the defensin-sensitive Salmonella typhimurium phoP(-) mutant, full-length cryptdins had the same in vitro antibacterial activities whether isolated from tissue or from the lumen. In contrast, the N-terminal-truncated (des-Leu), (des-Leu-Arg)-cryptdin-6, and (des-Gly)-cryptdin-4 peptides mere markedly less active. The microbicidal activities of recombinant cryptdin-4 and (des-Gly)-cryptdin-4 peptides against E. coli, and S. typhimurium showed that the N-terminal Gly residue or the length of the cryptdin-4 N terminus are determinants of microbicidal activity. Innate immunity in the crypt lumen may be modulated by aminopeptidase modification of alpha -defensins after peptide secretion.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; Harvard University; Beth Israel Deaconess Medical Center	Ouellette, AJ (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA.	aouellet@UCI.EDU			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015681, R37DK015681, R55DK044632, P01DK033506, R01DK044632] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44632, DK 15681, DK33506] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACH AC, 1987, BIOCHEMISTRY-US, V26, P4389, DOI 10.1021/bi00388a030; Bals R, 1999, INFECT IMMUN, V67, P3542, DOI 10.1128/IAI.67.7.3542-3547.1999; Bals R, 1998, INFECT IMMUN, V66, P1225, DOI 10.1128/IAI.66.3.1225-1232.1998; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; BOMAN HG, 1994, CIBA F SYMP, V186, P1; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; DECKX RJ, 1967, BIOCHIM BIOPHYS ACTA, V139, P204, DOI 10.1016/0005-2744(67)90136-2; Elsbach P, 1997, PROG SURG, V24, P17, DOI 10.1159/000075479; GANZ T, 1995, PHARMACOL THERAPEUT, V66, P191, DOI 10.1016/0163-7258(94)00076-F; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; GHOOS Y, 1971, Histochemical Journal, V3, P175, DOI 10.1007/BF01002560; GROISMAN EA, 1992, P NATL ACAD SCI USA, V89, P11939, DOI 10.1073/pnas.89.24.11939; HAGEN SJ, 1990, J ELECTRON MICR TECH, V16, P37, DOI 10.1002/jemt.1060160106; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; KAGAN BL, 1994, TOXICOLOGY, V87, P131, DOI 10.1016/0300-483X(94)90158-9; LEHRER RI, 1988, J CLIN INVEST, V81, P1829, DOI 10.1172/JCI113527; MILLER SI, 1991, MOL MICROBIOL, V5, P2073, DOI 10.1111/j.1365-2958.1991.tb02135.x; MOORE KS, 1992, J HISTOCHEM CYTOCHEM, V40, P367, DOI 10.1177/40.3.1552176; Ouellette AJ, 1999, INFECT IMMUN, V67, P6643; OUELLETTE AJ, 1992, FEBS LETT, V304, P146, DOI 10.1016/0014-5793(92)80606-H; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; PARDI A, 1992, BIOCHEMISTRY-US, V31, P11357, DOI 10.1021/bi00161a013; PEETERS T, 1975, GUT, V16, P553, DOI 10.1136/gut.16.7.553; Porter EM, 1997, INFECT IMMUN, V65, P2389, DOI 10.1128/IAI.65.6.2389-2395.1997; Porter EM, 1997, INFECT IMMUN, V65, P2396, DOI 10.1128/IAI.65.6.2396-2401.1997; Qu XD, 1996, INFECT IMMUN, V64, P5161, DOI 10.1128/IAI.64.12.5161-5165.1996; Quayle AJ, 1998, AM J PATHOL, V152, P1247; REILLY DS, 1994, DEV BIOL, V162, P123, DOI 10.1006/dbio.1994.1072; SATOH Y, 1989, ANAT REC, V225, P124, DOI 10.1002/ar.1092250207; SATOH Y, 1995, GASTROENTEROLOGY, V108, P1345, DOI 10.1016/0016-5085(95)90681-9; SATOH Y, 1992, CELL TISSUE RES, V269, P213, DOI 10.1007/BF00319611; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Selsted M E, 1993, Genet Eng (N Y), V15, P131; SELSTED ME, 1986, ANAL BIOCHEM, V155, P270, DOI 10.1016/0003-2697(86)90436-7; SELSTED ME, 1995, TRENDS CELL BIOL, V5, P114, DOI 10.1016/S0962-8924(00)88961-8; SELSTED ME, 1987, INFECT IMMUN, V55, P2281, DOI 10.1128/IAI.55.9.2281-2286.1987; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; ZHANG XL, 1992, BIOCHEMISTRY-US, V31, P11348, DOI 10.1021/bi00161a012	48	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33969	33973		10.1074/jbc.M004062200	http://dx.doi.org/10.1074/jbc.M004062200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10942762	hybrid			2022-12-27	WOS:000090104600109
J	Rodriguez-Manzaneque, JC; Milchanowski, AB; Dufour, EK; Leduc, R; Iruela-Arispe, ML				Rodriguez-Manzaneque, JC; Milchanowski, AB; Dufour, EK; Leduc, R; Iruela-Arispe, ML			Characterization of METH-1/ADAMTS1 processing reveals two distinct active forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE ACTIVITY; FIBROBLAST GROWTH-FACTOR; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; FURIN CONVERTASE; ADAMTS FAMILY; CLONING; ANGIOGENESIS; PROTEIN; MOTIFS	METH-1/ADAMTS1 is a member of a newly described family of genes that contain metalloprotease, disintegrin, and thrombospondin-like motifs. We have recently shown that METH-1 protein is a potent inhibitor of angiogenesis, Here, we demonstrate that secreted human pro-METH-1 is processed in two consecutive steps to release both p87 and p65 active forms. The p87 form lacks the N-terminal prodomain and p65 results from an additional processing event in the C-terminal end. Generation of p87 was blocked with specific inhibitors of furin, and incubation of pro-METH-1 with purified furin released the p87 fragment but not p65, Generation of p65 required preformation of p87 and was suppressed by inhibitors of matrix metalloproteases. We demonstrate that matrix metalloproteases 2, 8, and 15 were able to release p65 when p87 was used as substrate. This second processing step removes two thrombospondin repeats from the carboxyl-terminal end of p87-METH-1 and alters the affinity of the protein to heparin and endothelial cultures. Furthermore, this deletion was associated with a reduced activity upon suppression of endothelial cell proliferation, We hypothesize that METH-1 processing is relevant for the modulation of the anti-angiogenic properties displayed by the protein.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Sherbrooke	Iruela-Arispe, ML (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Rm 559,611 Charles E Young Dr, Los Angeles, CA 90095 USA.		Iruela-Arispe, M. Luisa/AAJ-1297-2020; Rodriguez-Manzaneque, Juan Carlos/F-3899-2012	Iruela-Arispe, M. Luisa/0000-0002-3050-4168; Rodriguez-Manzaneque, Juan Carlos/0000-0001-5951-7029	NCI NIH HHS [CA 63356-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Carrell RW, 1999, SCIENCE, V285, P1861, DOI 10.1126/science.285.5435.1861; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; DENAULT JB, 1995, FEBS LETT, V362, P276, DOI 10.1016/0014-5793(95)00249-9; Dufour EK, 1998, FEBS LETT, V426, P41, DOI 10.1016/S0014-5793(98)00307-X; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GREENWALD RA, 1992, J RHEUMATOL, V19, P927; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HORNEBECK W, 1994, PATHOL RES PRACT, V190, P895; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; IRUELAARISPE ML, 1993, J CELL BIOCHEM, V52, P414, DOI 10.1002/jcb.240520406; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Kinsella MG, 1997, J BIOL CHEM, V272, P318; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; MATSUO C, 1988, J CELL PHYSIOL, V134, P253, DOI 10.1002/jcp.1041340211; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; O'Reilly MS, 1999, J BIOL CHEM, V274, P29568, DOI 10.1074/jbc.274.41.29568; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Smith GN, 1999, ARTHRITIS RHEUM, V42, P1140, DOI 10.1002/1529-0131(199906)42:6<1140::AID-ANR10>3.0.CO;2-7; SPENCE MJ, 1995, SOMAT CELL MOLEC GEN, V21, P1, DOI 10.1007/BF02255818; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; VANDERSTAPPEN JWJ, 1992, INT J BIOCHEM, V24, P725, DOI 10.1016/0020-711X(92)90006-M; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342	43	127	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33471	33479		10.1074/jbc.M002599200	http://dx.doi.org/10.1074/jbc.M002599200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10944521	hybrid			2022-12-27	WOS:000090104600042
J	Liu, TM; Guo, ZW; Yang, QL; Sad, S; Jennings, HJ				Liu, TM; Guo, ZW; Yang, QL; Sad, S; Jennings, HJ			Biochemical engineering of surface alpha 2-8 polysialic acid for immunotargeting tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B NEISSERIA-MENINGITIDIS; ESCHERICHIA-COLI K1; SIALIC-ACID; ADHESION MOLECULE; EPITOPE; GLYCOPROTEINS; MENINGOCOCCI; ANTIBODIES; RECEPTOR; ANALOGS	To target tumor cells for immunotherapy, we evaluated the feasibility of altering the epitopes on the surface polysialic acid of tumor cells. A precursor (N-propionylmannosamine), when incubated with leukemic cells, RBL-2H3 and RMA, resulted in substitution of the N-acetyl groups of surface alpha2-8 polysialic acid with N-propionyl groups. Expression of the altered alpha2-8 N-propionylpolysialic acid on the surface of tumor cells induced their susceptibility to cell death mediated by monoclonal antibody 13D9 (mAb 13D9), which specifically recognizes alpha2-8 N-propionylated polysialic acid. The expression of alpha2-8 N-propionylated polysialic acid and the lysis of tumor cells by antibody-dependent cytotoxicity depended on the time and dose of incorporation of N-propionylated mannosamine, In vivo, mAb 13D9 effectively controlled metastasis of leukemic cells RIMA when mice were administered the precursor N-propionylated mannosamine.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Jennings, HJ (corresponding author), Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada.		Guo, Zhong-wu/C-7322-2011	Sad, Subash/0000-0002-2462-7137				BAUMANN H, 1993, BIOCHEMISTRY-US, V32, P4007, DOI 10.1021/bi00066a022; FINNE J, 1987, J IMMUNOL, V138, P4402; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; Fusco PC, 1997, J INFECT DIS, V175, P364, DOI 10.1093/infdis/175.2.364; Herrmann M, 1997, J VIROL, V71, P5922, DOI 10.1128/JVI.71.8.5922-5931.1997; JARVIS GA, 1987, INFECT IMMUN, V55, P174, DOI 10.1128/IAI.55.1.174-180.1987; JENNINGS HJ, 1989, J IMMUNOL, V142, P3585; JENNINGS HJ, 1986, J IMMUNOL, V137, P1708; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KAYSER H, 1992, J BIOL CHEM, V267, P16934; KEPPLER OT, 1995, J BIOL CHEM, V270, P1308, DOI 10.1074/jbc.270.3.1308; KOSA RE, 1993, BIOCHEM BIOPH RES CO, V190, P914, DOI 10.1006/bbrc.1993.1136; LIN CH, 1992, J AM CHEM SOC, V114, P10138, DOI 10.1021/ja00052a008; Mahal LK, 1997, SCIENCE, V276, P1125, DOI 10.1126/science.276.5315.1125; Martersteck CM, 1996, GLYCOBIOLOGY, V6, P289, DOI 10.1093/glycob/6.3.289; Pon RA, 1997, J EXP MED, V185, P1929, DOI 10.1084/jem.185.11.1929; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; Rosenberg Abraham, 1976, BIOL ROLES SIALIC AC; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; ROTH J, 1993, POLYSIALIC ACID MICR, P335; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; SHAMES S L, 1991, Glycobiology, V1, P187, DOI 10.1093/glycob/1.2.187; Slovin SF, 1999, SEMIN ONCOL, V26, P448; SPARKS MA, 1993, TETRAHEDRON, V49, P1, DOI 10.1016/S0040-4020(01)80502-0; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VIRAG L, 1995, J IMMUNOL METHODS, V185, P199, DOI 10.1016/0022-1759(95)00115-Q	26	86	95	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32832	32836		10.1074/jbc.C000573200	http://dx.doi.org/10.1074/jbc.C000573200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10976100	hybrid			2022-12-27	WOS:000090003800063
J	Young, KW; Bootman, MD; Channing, DR; Lipp, P; Maycox, PR; Meakin, J; Challiss, RAJ; Nahorski, SR				Young, KW; Bootman, MD; Channing, DR; Lipp, P; Maycox, PR; Meakin, J; Challiss, RAJ; Nahorski, SR			Lysophosphatidic acid-induced Ca2+ mobilization requires intracellular sphingosine 1-phosphate production - Potential involvement of endogenous Edg-4 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; MOLECULAR-CLONING; P115 RHOGEF; KINASE; ACTIVATION; CELLS; SPHINGOSINE-1-PHOSPHATE; RELEASE; GROWTH; TRISPHOSPHATE	Lysophosphatidic acid (LPA)-mediated Ca2+ mobilization in human SH-SY5Y neuroblastoma cells does not involve either inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3)- or ryanodine-receptor pathways, but is sensitive to inhibitors of sphingosine kinase. This present study identifies Edg-4 as the receptor subtype involved and investigates the presence of a Ca2+ signaling cascade based upon the lipid second messenger molecule, sphingosine I-phosphate. Both LPA and direct G-protein activation increase [H-3]sphingosine l-phosphate levels in SH-SY5Y cells. Measurements of Ca-45(2+) release in premeabilized SH-SY5Y cells indicates that sphingosine I-phosphate, sphingosine, and sphingosylphosphorylcholine, but not N-acetylsphingosine are capable of mobilizing intracellular Ca2+. Furthermore, the effect of sphingosine was attenuated by the sphingosine kinase inhibitor dimethylsphingosine, or removal of ATP. Confocal microscopy demonstrated that LPA stimulated intracellular Ca2+ "puffs," which resulted from an interaction between the sphingolipid Ca2+ release pathway and Ins(1,4,5)P-3 receptors. Down-regulation of Ins(1,4,5)P-3 receptors uncovered a Ca2+ response to LPA, which was manifest as a progressive increase in global cellular Ca2+ with no discernible foci. We suggest that activation of an LPA-sensitive Edg-4 receptor solely utilizes the production of intracellular sphingosine l-phosphate to stimulate Ca2+ mobilization in SB-SY5Y cells. Unlike traditional Ca2+ release processes, this novel pathway does not require the progressive recruitment of elementary Ca2+ events.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England; SmithKline Beecham Pharmaceut, Harlow CM19 5AW, Essex, England	University of Leicester; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; GlaxoSmithKline	Young, KW (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.	kwy1@le.ac.uk	Bootman, Martin/AAB-3330-2019; Challiss, R.A. John/A-9412-2008	Bootman, Martin/0000-0002-6447-3451; Challiss, John/0000-0001-5506-2848				Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994; An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; An SZ, 1999, MOL PHARMACOL, V55, P787; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; Burford NT, 1998, EUR J PHARMACOL, V342, P123, DOI 10.1016/S0014-2999(97)01556-2; Choi OH, 1996, NATURE, V380, P634; EHLRICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Heringdorf DM, 1999, FEBS LETT, V461, P217, DOI 10.1016/S0014-5793(99)01463-5; KIM S, 1995, J BIOL CHEM, V270, P5266, DOI 10.1074/jbc.270.10.5266; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee ZW, 1998, J BIOL CHEM, V273, P12710, DOI 10.1074/jbc.273.21.12710; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; Lynch KR, 1999, TRENDS PHARMACOL SCI, V20, P473, DOI 10.1016/S0165-6147(99)01401-7; Martin AK, 1999, BRIT J PHARMACOL, V126, P1559, DOI 10.1038/sj.bjp.0702464; Melendez A, 1998, CURR BIOL, V8, P210, DOI 10.1016/S0960-9822(98)70085-5; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, FASEB J, V13, P1593, DOI 10.1096/fasebj.13.12.1593; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; WILLARS GB, 1995, BRIT J PHARMACOL, V114, P1133, DOI 10.1111/j.1476-5381.1995.tb13325.x; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; Young KW, 1999, BIOCHEM J, V343, P45, DOI 10.1042/0264-6021:3430045; Young KW, 1998, CELL CALCIUM, V24, P59, DOI 10.1016/S0143-4160(98)90089-6; ZUHERINGDORF DM, 1998, EMBO J, V17, P2830	38	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38532	38539		10.1074/jbc.M006631200	http://dx.doi.org/10.1074/jbc.M006631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10954727	hybrid			2022-12-27	WOS:000165739800054
J	Carruthers, LM; Hansen, JC				Carruthers, LM; Hansen, JC			The core histone N termini function independently of linker histones during chromatin condensation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGAROSE-GEL ELECTROPHORESIS; SCANNING FORCE MICROSCOPY; HIGHER-ORDER STRUCTURE; TRANSCRIPTION IN-VIVO; RIBOSOMAL-RNA GENE; GLOBULAR DOMAIN; NUCLEOSOMAL ARRAYS; SELF-ASSOCIATION; MOLECULAR-MODEL; TAIL DOMAINS	The relationships between the core histone N termini and linker histones during chromatin assembly and salt-dependent chromatin condensation were investigated using defined chromatin model systems reconstituted from tandemly repeated 5 S rDNA, histone H5, and either native "intact" core histone octamers or "tailless" histone octamers lacking their N-terminal domains. Nuclease digestion and sedimentation studies indicate that H5 binding and the resulting constraint of entering and exiting nucleosomal DNA occur to the same extent in both tailless and intact chromatin arrays. However, despite possessing a normal chromatosomal structure, tailless chromatin arrays can neither condense into extensively folded structures nor cooperatively oligomerize in MgCl2. Tailless nucleosomal arrays lacking linker histones also are unable to either fold extensively or oligomerize, demonstrating that the core histone N termini perform the same functions during salt-dependent condensation regardless of whether linker histones are components of the array. Our results further indicate that disruption of core histone N termini function in vitro allows a linker histone-containing chromatin fiber to exist in a decondensed state under conditions that normally would promote extensive fiber condensation. These findings have key implications for both the mechanism of chromatin condensation, and the regulation of genomic function by chromatin.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Hansen, JC (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	hansen@biochem.uthscsa.edu			NIGMS NIH HHS [GM45916] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045916, R29GM045916] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1981, J CELL BIOL, V90, P279, DOI 10.1083/jcb.90.2.279; ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; An WJ, 1999, BIOCHIMIE, V81, P727, DOI 10.1016/S0300-9084(99)80130-8; ANNUNZIATO AT, 1988, CHROMOSOMA, V96, P132, DOI 10.1007/BF00331045; BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; Brown DT, 1996, NUCLEIC ACIDS RES, V24, P486, DOI 10.1093/nar/24.3.486; Brown DT, 1997, NUCLEIC ACIDS RES, V25, P5003, DOI 10.1093/nar/25.24.5003; Carruthers LM, 1999, METHOD ENZYMOL, V304, P19; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; Carruthers LM, 2000, METHOD ENZYMOL, V321, P66; Carter GJ, 1998, BIOCHEMISTRY-US, V37, P12477, DOI 10.1021/bi980716v; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; DIMITROV S, 1986, FEBS LETT, V197, P217, DOI 10.1016/0014-5793(86)80329-5; FLETCHER TM, 1994, BIOCHEMISTRY-US, V33, P10859, DOI 10.1021/bi00202a002; FLETCHER TM, 1994, BIOCHEMISTRY-US, V33, P2226, DOI 10.1021/bi00174a032; FLETCHER TM, 1995, J BIOL CHEM, V270, P25359, DOI 10.1074/jbc.270.43.25359; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; GARCIA-RAMIREZ M, 1990, Protein Expression and Purification, V1, P40, DOI 10.1016/1046-5928(90)90043-X; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; GEORGEL P, 1993, J BIOL CHEM, V268, P1947; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; GRIESS GA, 1989, BIOPOLYMERS, V28, P1475, DOI 10.1002/bip.360280811; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; HACQUES MF, 1990, J BIOMOL STRUCT DYN, V8, P619, DOI 10.1080/07391102.1990.10507832; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HANSEN JC, 1993, J BIOL CHEM, V268, P5840; Hansen JC, 1997, METHODS, V12, P62, DOI 10.1006/meth.1997.0448; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; HANSEN JC, 1997, METHOD MOL BIOL, V119, P113; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Herrera JE, 2000, MOL CELL BIOL, V20, P523, DOI 10.1128/MCB.20.2.523-529.2000; Howe L, 1998, J BIOL CHEM, V273, P20693, DOI 10.1074/jbc.273.33.20693; KANDOLF H, 1994, P NATL ACAD SCI USA, V91, P7257, DOI 10.1073/pnas.91.15.7257; KRIEG PA, 1983, NUCLEIC ACIDS RES, V11, P619, DOI 10.1093/nar/11.3.619; Leuba SH, 1998, BIOPHYS J, V74, P2830, DOI 10.1016/S0006-3495(98)77990-1; Leuba SH, 1998, BIOPHYS J, V74, P2823, DOI 10.1016/S0006-3495(98)77989-5; MAMAN JD, 1994, BIOCHEMISTRY-US, V33, P1300, DOI 10.1021/bi00172a003; MCGHEE JD, 1983, NUCLEIC ACIDS RES, V11, P4065, DOI 10.1093/nar/11.12.4065; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; Moore SC, 1997, BIOCHEM BIOPH RES CO, V230, P136, DOI 10.1006/bbrc.1996.5903; Ramakrishnan V, 1997, CRIT REV EUKAR GENE, V7, P215, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.20; ROSE GD, 1994, PROTEINS, V19, P1, DOI 10.1002/prot.340190102; ROTH SY, 1995, CURR OPIN GENET DEV, V5, P168, DOI 10.1016/0959-437X(95)80004-2; Schwarz PM, 1996, BIOCHEMISTRY-US, V35, P4009, DOI 10.1021/bi9525684; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; SEGERS A, 1991, J BIOL CHEM, V266, P1502; SHAW OJ, 1969, ELECTROPHORESIS, P5; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; Shibahara K, 2000, P NATL ACAD SCI USA, V97, P7766, DOI 10.1073/pnas.97.14.7766; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Trieschmann L, 1998, P NATL ACAD SCI USA, V95, P5468, DOI 10.1073/pnas.95.10.5468; Tse C, 1997, BIOCHEMISTRY-US, V36, P11381, DOI 10.1021/bi970801n; Tse C, 1998, P NATL ACAD SCI USA, V95, P12169, DOI 10.1073/pnas.95.21.12169; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; URA K, 1994, J BIOL CHEM, V269, P27171; van Holde K.E., 1988, CHROMATIN; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; Wolffe A., 1998, CHROMATIN STRUCTURE; WOLFFE AP, 1989, EMBO J, V8, P527, DOI 10.1002/j.1460-2075.1989.tb03407.x; Zlatanova J, 1998, BIOPHYS J, V74, P2554, DOI 10.1016/S0006-3495(98)77963-9	69	95	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37285	37290		10.1074/jbc.M006801200	http://dx.doi.org/10.1074/jbc.M006801200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10970897	hybrid			2022-12-27	WOS:000165577700114
J	Ghanshani, S; Wulff, H; Miller, MJ; Rohm, H; Neben, A; Gutman, GA; Cahalan, MD; Chandy, KG				Ghanshani, S; Wulff, H; Miller, MJ; Rohm, H; Neben, A; Gutman, GA; Cahalan, MD; Chandy, KG			Up-regulation of the IKCa1 potassium channel during T-cell activation - Molecular mechanism and functional consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CA CHANNEL; KEY SIGNALING ENZYME; HUMAN LYMPHOCYTE-T; ION CHANNELS; CALCIUM; CONDUCTANCE; GENE; EXPRESSION; KV1.3; TRANSCRIPTION	We used whole cell recording to evaluate functional expression of the intermediate conductance Ca2+-activated KC channel, IKCa1, in response to various mitogenic stimuli. One to two days following engagement of T-cell receptors to trigger both PKC- and Ca2+-dependent events, IKCa1 expression increased from an average of 8 to 300-800 channels/cell. Selective stimulation of the PKC pathway resulted in equivalent up-regulation, whereas a calcium ionophore was relatively ineffective. Enhancement in IKCa1 mRNA levels paralleled the increased channel number. The genomic organization of IKCa1, SKCa2, and SRCa3 were defined, and IKCa and SKCa genes were found to have a remarkably similar intron-exon structure, Mitogens enhanced IKCa1 promoter activity proportional to the increase in IKCa1 mRNA suggesting that transcriptional mechanisms underlie channel up-regulation. Mutation of motifs for AP1 and Ikaros-2 in the promoter abolished this induction. Selective Kv1.3 inhibitors ShK-Dap(22), margatoxin, and correolide suppressed mitogenesis of resting T-cells but not preactivated T-cells with up-regulated IKCa1 channel expression. Selectively blocking IKCa1 channels with clotrimazole or TRAM-34 suppressed mitogenesis of preactivated lymphocytes, whereas resting T-cells were less sensitive. Thus, Kv1.3 channels are essential for activation of quiescent cells, but signaling through the PKC pathway enhances expression of IKCa1 channels that are required for continued proliferation.	Univ Calif Irvine, Sch Med, Dept Phys & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Wulff, H (corresponding author), Univ Calif Irvine, Sch Med, Dept Phys & Biophys, Rm 291,Joan Irvine Smith Hall, Irvine, CA 92697 USA.	hwulff@uci.edu	wulff, Heike/Z-2056-2019	Miller, Mark/0000-0001-5676-389X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014609, R37NS014609] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54221] Funding Source: Medline; NINDS NIH HHS [NS14609] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKASHI M, 1994, BLOOD, V83, P3182; Alizadeh AA, 2000, CURR OPIN IMMUNOL, V12, P219, DOI 10.1016/S0952-7915(99)00078-3; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; Avitahl N, 1999, IMMUNITY, V10, P333, DOI 10.1016/S1074-7613(00)80033-3; Cahalan MD, 1997, CURR OPIN BIOTECH, V8, P749, DOI 10.1016/S0958-1669(97)80130-9; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; CHANDY KG, 1984, J EXP MED, V160, P369, DOI 10.1084/jem.160.2.369; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; COLOMER J, 1993, CELL CALCIUM, V14, P609, DOI 10.1016/0143-4160(93)90061-A; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Cron RQ, 1997, J IMMUNOL METHODS, V205, P145, DOI 10.1016/S0022-1759(97)00065-3; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; DECOURSEY TE, 1987, J GEN PHYSIOL, V89, P405, DOI 10.1085/jgp.89.3.405; DEUTSCH C, 1986, J PHYSIOL-LONDON, V372, P405, DOI 10.1113/jphysiol.1986.sp016016; Dror V, 1999, MOL PSYCHIATR, V4, P254, DOI 10.1038/sj.mp.4000508; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Fanger CM, 2000, J IMMUNOL, V164, P1153, DOI 10.4049/jimmunol.164.3.1153; Fomina AF, 2000, J CELL BIOL, V150, P1435, DOI 10.1083/jcb.150.6.1435; Gan L, 1996, J BIOL CHEM, V271, P5859, DOI 10.1074/jbc.271.10.5859; Ghanshani S, 1998, GENOMICS, V51, P160, DOI 10.1006/geno.1998.5333; GRISSMER S, 1993, J GEN PHYSIOL, V102, P601, DOI 10.1085/jgp.102.4.601; Hanson DC, 1999, BRIT J PHARMACOL, V126, P1707, DOI 10.1038/sj.bjp.0702480; HUANG Y, 1994, J BIOL CHEM, V269, P31183; HUGHES CCW, 1993, J IMMUNOL, V150, P3148; Hughes CCW, 1996, J BIOL CHEM, V271, P5369, DOI 10.1074/jbc.271.10.5369; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jager H, 2000, FEBS LETT, V469, P196, DOI 10.1016/S0014-5793(00)01236-9; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; Jensen BS, 1999, P NATL ACAD SCI USA, V96, P10917, DOI 10.1073/pnas.96.19.10917; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Koo GC, 1997, J IMMUNOL, V158, P5120; Koo GC, 1999, CELL IMMUNOL, V197, P99, DOI 10.1006/cimm.1999.1569; Litt M, 1999, CYTOGENET CELL GENET, V86, P70, DOI 10.1159/000015415; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; Nguyen A, 1996, MOL PHARMACOL, V50, P1672; PARTISETI M, 1993, J IMMUNOL, V151, P2462; PARTISETI M, 1992, J IMMUNOL, V148, P3361; Pena TL, 1999, J MEMBRANE BIOL, V172, P249, DOI 10.1007/s002329900601; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; Rauer H, 2000, J BIOL CHEM, V275, P1201, DOI 10.1074/jbc.275.2.1201; Rauer H, 2000, BIOPHYS J, V78, p73A; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Simon M, 1997, CELL PHYSIOL BIOCHEM, V7, P243, DOI 10.1159/000154879; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; VERHEUGEN JAH, 1995, J GEN PHYSIOL, V105, P765, DOI 10.1085/jgp.105.6.765; VERHEUGEN JAH, 1995, CELL CALCIUM, V17, P287, DOI 10.1016/0143-4160(95)90075-6; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151; Wymore RS, 1996, J BIOL CHEM, V271, P15629, DOI 10.1074/jbc.271.26.15629	53	336	355	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37137	37149		10.1074/jbc.M003941200	http://dx.doi.org/10.1074/jbc.M003941200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10961988	hybrid			2022-12-27	WOS:000165577700094
J	Ha, TU; Segev, DL; Barbie, D; Masiakos, PT; Tran, TT; Dombkowski, D; Glander, M; Clarke, TR; Lorenzo, HK; Donahue, PK; Maheswaran, S				Ha, TU; Segev, DL; Barbie, D; Masiakos, PT; Tran, TT; Dombkowski, D; Glander, M; Clarke, TR; Lorenzo, HK; Donahue, PK; Maheswaran, S			Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F-1; U343 ASTROCYTOMA-CELLS; D-DEPENDENT KINASES; RETINOBLASTOMA PROTEIN; CYCLE ARREST; II RECEPTOR; P16 GENE; RECOMBINANT ADENOVIRUS; SEXUAL DEVELOPMENT; TGF-BETA	Mullerian inhibiting substance (MIS), a transforming growth factor-beta family member, causes regression of the Mullerian duct in male embryos. MIS overexpression in transgenic mice ablates the ovary, and MIS inhibits the growth of ovarian cancer cell lines in vitro, suggesting a key role for this hormone in postnatal development of the ovary. This report describes a mechanism for MIS-mediated growth inhibition in both a human epithelial ovarian cancer cell line and a cell line derived from normal ovarian surface epithelium, which is the origin of human epithelial ovarian cancers, MIS-treated cells accumulated in the G(1) phase of the cell cycle and subsequently underwent apoptosis. MIS up-regulated the cyclin-dependent kinase inhibitor pie through an MIS type II receptor-mediated mechanism and inhibited growth in the absence of detectable or inactive Rb protein, Prolonged treatment with MIS down-regulated the Rb-related protein p130 and increased the Rb family-regulated transcription factor E2F1, overexpression of which inhibited growth. These findings demonstrate that pig is required for MIS-mediated growth inhibition in ovarian epithelial cells and tumor cells and suggest that up-regulation of E2F1 also plays a role in this process.	Massachusetts Gen Hosp, Pediat Surg Res Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Maheswaran, S (corresponding author), Massachusetts Gen Hosp, Pediat Surg Res Lab, WRN 1024,55 Fruit St, Boston, MA 02114 USA.	maheswaran@helix.mgh.harvard.edu	Lorenzo, Hans-Kristian/GLR-5785-2022	Lorenzo, Hans Kristian/0000-0002-7921-177X	NCI NIH HHS [CA17393, T32-CA-71345] Funding Source: Medline; NICHD NIH HHS [HD32112] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032112] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA017393, T32CA071345] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAARENDS WM, 1994, DEVELOPMENT, V120, P189; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; Catlin EA, 1997, ENDOCRINOLOGY, V138, P790, DOI 10.1210/en.138.2.790; CHIN TW, 1991, CANCER RES, V51, P2101; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; DIETL J, 1993, GYNECOL OBSTET INVES, V35, P129, DOI 10.1159/000292682; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Dirks PB, 1997, ONCOGENE, V15, P2037, DOI 10.1038/sj.onc.1201392; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; FULLER AF, 1985, GYNECOL ONCOL, V22, P135, DOI 10.1016/0090-8258(85)90019-8; Furukawa Y, 1999, ONCOGENE, V18, P2003, DOI 10.1038/sj.onc.1202500; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hama S, 1998, INT J CANCER, V77, P47, DOI 10.1002/(SICI)1097-0215(19980703)77:1<47::AID-IJC9>3.3.CO;2-E; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harvat BL, 1998, J CELL SCI, V111, P1185; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HUDSON PL, 1990, J CLIN ENDOCR METAB, V70, P16, DOI 10.1210/jcem-70-1-16; Hunt KK, 1997, CANCER RES, V57, P4722; Imbeaud S, 1996, HUM MOL GENET, V5, P1269, DOI 10.1093/hmg/5.9.1269; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kanuma T, 1997, MOL CARCINOGEN, V18, P134, DOI 10.1002/(SICI)1098-2744(199703)18:3<134::AID-MC2>3.0.CO;2-F; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Lee MM, 1996, J CLIN ENDOCR METAB, V81, P571, DOI 10.1210/jc.81.2.571; Marchini S, 1997, BRIT J CANCER, V76, P146, DOI 10.1038/bjc.1997.355; Masiakos PT, 1999, CLIN CANCER RES, V5, P3488; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; Milde-Langosch K, 1998, INT J CANCER, V79, P61, DOI 10.1002/(SICI)1097-0215(19980220)79:1<61::AID-IJC12>3.0.CO;2-K; Naruse I, 1998, ANTICANCER RES, V18, P4275; OKUDA T, 1995, GENOMICS, V29, P623, DOI 10.1006/geno.1995.9957; Pedram A, 1998, J BIOL CHEM, V273, P13966, DOI 10.1074/jbc.273.22.13966; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; QUELLE DE, 1995, CELL, V83, P993; RAGIN RC, 1992, PROTEIN EXPRES PURIF, V3, P236, DOI 10.1016/1046-5928(92)90020-W; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Scully R E, 1970, Hum Pathol, V1, P73, DOI 10.1016/S0046-8177(70)80005-3; Scully RE, 1995, J CELL BIOCHEM, P208; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; TAKAHASHI M, 1986, BIOL REPROD, V35, P447, DOI 10.1095/biolreprod35.2.447; Teixeira J, 1996, ENDOCRINOLOGY, V137, P160, DOI 10.1210/en.137.1.160; Teixeira J, 1996, J ANDROL, V17, P336; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; UENO S, 1988, ENDOCRINOLOGY, V123, P1652, DOI 10.1210/endo-123-3-1652; Urashima M, 1997, BLOOD, V90, P4106, DOI 10.1182/blood.V90.10.4106; Wolf JK, 1999, GYNECOL ONCOL, V73, P27, DOI 10.1006/gyno.1998.5259; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	63	76	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37101	37109		10.1074/jbc.M005701200	http://dx.doi.org/10.1074/jbc.M005701200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10958795	hybrid			2022-12-27	WOS:000165577700090
J	Chen, J; Shpall, RL; Meyerdierks, A; Hagemeier, M; Bottger, EC; Naumovski, L				Chen, J; Shpall, RL; Meyerdierks, A; Hagemeier, M; Bottger, EC; Naumovski, L			Interferon-inducible Myc/STAT-interacting protein Nmi associates with IFP 35 into a high molecular mass complex and inhibits proteasome-mediated degradation of IFP 35	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; LOCALIZATION; PHOSPHATASE; PATHWAY; GROWTH; TARGET; GENES	Nmi is an interferon (IFN)-inducible protein homologous to IFN-inducible protein IFP 35. The homology consists of a novel Nmi/IFP 35 domain (NID) of 90-92 amino acids that is repeated in tandem in each protein and mediates Nmi-Nmi protein interactions and subcellular localization. In a yeast two-hybrid screen with a fragment of Nmi protein containing both NIDs, we identified an interaction:between Nmi and IFP 35. Deletion derivatives of the proteins indicate that both NIDs are required for the interaction between Nmi and IFP 35. In mammalian cells, Nmi and IFP 35 co-immunoprecipitate and co-localize in large cytoplasmic speckles. Nmi and IFP 35 proteins associate into a high molecular mass complex of 300-400 kDa as determined by native gel electrophoresis and gel filtration. The association of Nmi and IFP 5 into a complex can be demonstrated in multiple cell::lines and is not dependent on treatment with IFN. Short term and long term cultures of transfected HEK293 cells suggest that Nmi and DFP 35 proteins stabilize: each other through complex formation. IFP 35 appears to be more labile because Nmi was stable in the absence of IFP 35, whereas LFP 35 was degraded in the absence of Nmi. A deletion analysis revealed that Nmi must interact with IFP 35 to prevent its degradation and that the amino terminus of Nmi is required, but not sufficient, for this function. Inhibition of the proteasome, but-not other proteases, led to increased levels of IFP 35. Thus, we have shown that Nmi and LFP 35 associate into a protein complex, that IFP 35 is degraded in a proteasome-mediated process, and that a novel function of Nmi is to prevent IFP 35 degradation. The stabilization of IFP 35 by Nmi may serve to amplify the physiologic effects of IFNs.	Stanford Med Ctr, Div Hematol Oncol, Dept Pediat, Stanford, CA 94305 USA; Med Hsch Hannover, Inst Med Mikrobiol, D-30625 Hannover, Germany	Stanford University; Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf	Naumovski, L (corresponding author), Stanford Med Ctr, Div Hematol Oncol, Dept Pediat, 300 Pasteur Dr,H314, Stanford, CA 94305 USA.		Böttger, Erik C./F-6175-2011					BANGE FC, 1994, J BIOL CHEM, V269, P1091; Bao JX, 1996, ONCOGENE, V12, P2171; Bies J, 2000, ONCOGENE, V19, P2846, DOI 10.1038/sj.onc.1203613; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DIANZANI F, 1997, MECH ACTION INTERFER; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Ku NO, 2000, J CELL BIOL, V149, P547, DOI 10.1083/jcb.149.3.547; Lebrun SJ, 1998, J INTERF CYTOK RES, V18, P767, DOI 10.1089/jir.1998.18.767; Lee ND, 1999, J INTERF CYTOK RES, V19, P1245, DOI 10.1089/107999099312902; Meyerdierks A, 1999, J HISTOCHEM CYTOCHEM, V47, P169, DOI 10.1177/002215549904700206; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Wang XY, 1996, BIOCHEM BIOPH RES CO, V229, P316, DOI 10.1006/bbrc.1996.1799; Wong C, 1997, ANAL BIOCHEM, V252, P33, DOI 10.1006/abio.1997.2284; Zhou XJ, 2000, J BIOL CHEM, V275, P21364, DOI 10.1074/jbc.M003177200; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	24	48	52	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36278	36284		10.1074/jbc.M006975200	http://dx.doi.org/10.1074/jbc.M006975200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10950963	hybrid			2022-12-27	WOS:000165382000090
J	Brasher, BB; Van Etten, RA				Brasher, BB; Van Etten, RA			c-Ab1 has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TRANSFORMING ACTIVITY; C-ABL; PROTEIN-BINDING; IN-VIVO; INTERMOLECULAR AUTOPHOSPHORYLATION; CRYSTAL-STRUCTURE; GENE-PRODUCT; CELL-CYCLE; V-ABL; ACTIVATION	Using the specific Abl tyrosine kinase inhibitor STI 571, we purified unphosphorylated murine type IV c-Abl and measured the kinetic parameters of c-Abl tyrosine kinase activity in a solution with a peptide-based assay. Unphosphorylated c-Abl exhibited substantial peptide kinase activity with K-m of 204 muM and V-max of 33 pmol min(-1). Contrary to previous observations using immune complex kinase assays, we found that a transforming c-Abl mutant with a Src homology 3 domain point mutation (P131L) had significantly (about 6-fold) higher intrinsic kinase activity than wild-type c-Abl (K-m = 91 muM, V-max = 112 pmol min(-1)). Autophosphorylation stimulated the activity of wild-type c-Abl about 18-fold and c-Abl P131L about 3.6-fold, resulting in highly active kinases with similar catalytic rates, The autophosphorylation rate was dependent on Abl protein concentration consistent with an intermolecular reaction, A tyrosine to phenylalanine mutation (Y412F) at the c-Abl residue homologous to the c-Src catalytic domain autophosphorylation site impaired the activation of wildtype c-Abl by 90% but reduced activation of c-Abl P131L by only 45%. Mutation of a tyrosine (Tyr-245) in the linker region between the Src homology 2 and catalytic domains that is conserved among the Abl family inhibited the autophosphorylation-induced activation of wild-type c-Abl by 50%, whereas the c-Abl Y245F/Y412F double mutant was minimally activated by autophosphorylation, These results support a model where c-Abl is inhibited in part through an intramolecular Src homology 3-linker interaction and stimulated to full catalytic activity by sequential phosphorylation at Tyr-412 and Tyr-245.	Harvard Univ, Sch Med, Ctr Blood Res, Dept Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Van Etten, RA (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA072465] Funding Source: NIH RePORTER; NCI NIH HHS [CA72465] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1998, ONCOGENE, V16, P1779, DOI 10.1038/sj.onc.1201708; Allen PB, 1996, J BIOL CHEM, V271, P19585, DOI 10.1074/jbc.271.32.19585; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; Buchdunger E, 1996, CANCER RES, V56, P100; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dorey K, 1999, BIOL CHEM, V380, P223; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Gonfloni S, 1999, NAT STRUCT BIOL, V6, P760; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PIWINICAWORMS H, 1987, CELL, V49, P75; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; REYNOLDS FH, 1982, J VIROL, V44, P1097, DOI 10.1128/JVI.44.3.1097-1101.1982; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1995, ONCOGENE, V10, P1977; Walkenhorst J, 1996, ONCOGENE, V12, P1513; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zhu JY, 1996, MOL CELL BIOL, V16, P7054	46	219	233	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35631	35637		10.1074/jbc.M005401200	http://dx.doi.org/10.1074/jbc.M005401200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10964922	Green Published, hybrid			2022-12-27	WOS:000165422800106
J	Hoskins, JR; Kim, SY; Wickner, S				Hoskins, JR; Kim, SY; Wickner, S			Substrate recognition by the ClpA chaperone component of ClpAP protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASES; HEAT-SHOCK PROTEINS; N-END RULE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MU-TRANSPOSASE; REGULATORY SUBUNITS; MOLECULAR CHAPERONE; DNA-REPLICATION; QUALITY-CONTROL	ClpA, a member of the Clp/Hsp100 ATPase family, is a molecular chaperone and regulatory component of Clp-AP protease, We explored the mechanism of protein recognition by ClpA using a high affinity substrate, RepA, which is activated for DNA binding by ClpA and degraded by ClpAP, By characterizing RepA derivatives with N- or C-terminal deletions, we found that the N-terminal portion of RepA is required for recognition. More precisely, RepA derivatives lacking the N-terminal 5 or 10 amino acids are degraded by ClpAP at a rate similar to full-length RepA, whereas RepA derivatives lacking 15 or 20 amino acids are degraded much more slowly. Thus, ClpA recognizes an N-terminal signal in RepA beginning in the vicinity of amino acids 10-15, Moreover, peptides corresponding to RepA amino acids 4-13 and 1-15 inhibit interactions between ClpA and RepA We constructed fusions of RepA and green fluorescent protein, a protein not recognized by ClpA, and found that the N-terminal 15 amino acids of RepA are sufficient to target the fusion protein for degradation by ClpAP. However, fusion proteins containing 46 or 70 N-terminal amino acids of RepA are degraded more efficiently in vitro and are noticeably stabilized in vivo in clpA Delta and clpP Delta strains compared with wild type.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wickner, S (corresponding author), NCI, Mol Biol Lab, NIH, Bldg 37,Rm 2D19,37 Convent Dr,MSC37-4255, Bethesda, MD 20892 USA.	suewick@helix.nih.gov						Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; Chamberlin M J, 1992, Harvey Lect, V88, P1; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Frank EG, 1996, P NATL ACAD SCI USA, V93, P10291, DOI 10.1073/pnas.93.19.10291; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Gonciarz-Swiatek M, 1999, J BIOL CHEM, V274, P13999, DOI 10.1074/jbc.274.20.13999; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Konieczny I, 1997, P NATL ACAD SCI USA, V94, P14378, DOI 10.1073/pnas.94.26.14378; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; Laachouch JE, 1996, EMBO J, V15, P437, DOI 10.1002/j.1460-2075.1996.tb00374.x; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; Roche ED, 1999, EMBO J, V18, P4579, DOI 10.1093/emboj/18.16.4579; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schmidt M, 1999, CURR OPIN CHEM BIOL, V3, P584, DOI 10.1016/S1367-5931(99)00013-7; SHRADER TE, 1993, J BACTERIOL, V175, P4364, DOI 10.1128/JB.175.14.4364-4374.1993; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; Wang LY, 1999, J BACTERIOL, V181, P1211, DOI 10.1128/JB.181.4.1211-1219.1999; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	53	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35361	35367		10.1074/jbc.M006288200	http://dx.doi.org/10.1074/jbc.M006288200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952988	hybrid			2022-12-27	WOS:000165422800071
J	Musil, LS; Le, ACN; VanSlyke, JK; Roberts, LM				Musil, LS; Le, ACN; VanSlyke, JK; Roberts, LM			Regulation of connexin degradation as a mechanism to increase gap junction assembly and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRAJUNCTIONAL ACETYLCHOLINE RECEPTORS; INTERCELLULAR COMMUNICATION; HALF-LIFE; ORNITHINE DECARBOXYLASE; PROTEASOME PATHWAY; ESTROGEN-RECEPTOR; CELL-LINES; PROTEIN; UBIQUITIN; TURNOVER	Connexins, the integral membrane protein constituents of gap junctions, are degraded at a rate (t(1/2) = 1.5-5 h) much faster than most other cell surface proteins. Although the turnover of connexins has been shown to be sensitive to inhibitors of either the lysosome or of the proteasome, how connexins are targeted for degradation and whether this process can be regulated to affect intercellular communication is unknown. We show here that reducing connexin degradation with inhibitors of the proteasome (but not with lysosomal blockers) is associated with a striking increase in gap junction assembly and intercellular dye transfer in cells inefficient in both processes under basal conditions. The effect of proteasome inhibitors on wild-type connexin stability, assembly, and function was mimicked by treatment of assembly-inefficient cells with inhibitors of protein synthesis such as cycloheximide. Sensitivity of connexin degradation to cycloheximide, but not to proteasome inhibitors, was abolished when connexins were rendered structurally abnormal by perturbation of essential disulfide bonds or by mutation. Our findings provide the first evidence that intercellular communication can be up-regulated at the level of connexin turnover and that a short-lived protein may be required for conformationally mature connexins to become substrates of proteasomal degradation.	Oregon Hlth Sci Univ, Vollum Inst Adv Biomed Res L474, Portland, OR 97201 USA	Oregon Health & Science University	Musil, LS (corresponding author), Oregon Hlth Sci Univ, Vollum Inst Adv Biomed Res L474, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.			Le, Anh-Chi/0000-0003-1619-2281				Beardslee MA, 1998, CIRC RES, V83, P629, DOI 10.1161/01.RES.83.6.629; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Borras M, 1996, J STEROID BIOCHEM, V57, P203, DOI 10.1016/0960-0760(95)00272-3; Boundy VA, 1998, J PHARMACOL EXP THER, V286, P1058; Castro C, 1999, J NEUROSCI, V19, P3752; CHANG CC, 1975, NATURE, V253, P643, DOI 10.1038/253643a0; Ciechanover A, 1995, COLD SPRING HARB SYM, V60, P491, DOI 10.1101/SQB.1995.060.01.053; Deschenes SM, 1997, J NEUROSCI, V17, P9077; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; EPSTEIN ML, 1977, EXP CELL RES, V104, P25, DOI 10.1016/0014-4827(77)90064-7; FALLON RF, 1981, J CELL BIOL, V90, P521, DOI 10.1083/jcb.90.2.521; FLAGGNEWTON JL, 1981, J MEMBRANE BIOL, V63, P105, DOI 10.1007/BF01969452; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; FRITSCH JE, 1988, EXP CELL RES, V175, P277, DOI 10.1016/0014-4827(88)90192-9; GLASS JR, 1987, J CELL PHYSIOL, V130, P133, DOI 10.1002/jcp.1041300119; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HARE JF, 1991, P NATL ACAD SCI USA, V88, P5902, DOI 10.1073/pnas.88.13.5902; HENDRIX EM, 1992, MOL REPROD DEV, V33, P27, DOI 10.1002/mrd.1080330105; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KRUTOVSKIKH V, 1994, INT J CANCER, V56, P87; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; LARSEN WJ, 1978, TISSUE CELL, V10, P585, DOI 10.1016/S0040-8166(16)30351-2; Le ACN, 1998, DEV BIOL, V204, P80, DOI 10.1006/dbio.1998.9030; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; McMasters RA, 1998, HUM GENE THER, V9, P2253, DOI 10.1089/hum.1998.9.15-2253; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; Murakami Y, 1996, BIOCHEM J, V317, P77, DOI 10.1042/bj3170077; Musil Linda S., 1994, P173; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; Nagy JI, 1997, EXP CELL RES, V236, P127, DOI 10.1006/excr.1997.3716; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; PENN EJ, 1987, J CELL BIOL, V105, P2327, DOI 10.1083/jcb.105.5.2327; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROOK MB, 1990, J MEMBRANE BIOL, V118, P179, DOI 10.1007/BF01868475; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; STEINBACH JH, 1979, P NATL ACAD SCI USA, V76, P3547, DOI 10.1073/pnas.76.7.3547; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; TRAUB O, 1989, J CELL BIOL, V108, P1039, DOI 10.1083/jcb.108.3.1039; VALDIMARSSON G, 1991, MOL REPROD DEV, V30, P18, DOI 10.1002/mrd.1080300103; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; VanSlyke JK, 2000, METHODS, V20, P156, DOI 10.1006/meth.1999.0933; VENANCE L, 1995, NATURE, V376, P590, DOI 10.1038/376590a0; WILEMAN T, 1990, CELL REGUL, V1, P907, DOI 10.1091/mbc.1.12.907; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852; ZIEMIECKI A, 1982, MOL CELL BIOL, V2, P355, DOI 10.1128/MCB.2.4.355	57	196	209	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25207	25215		10.1074/jbc.275.33.25207	http://dx.doi.org/10.1074/jbc.275.33.25207			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10940315	hybrid			2022-12-27	WOS:000088849400024
J	Brown, MD; Trounce, IA; Jun, AS; Allen, JC; Wallace, DC				Brown, MD; Trounce, IA; Jun, AS; Allen, JC; Wallace, DC			Functional analysis of lymphoblast and cybrid mitochondria containing the 3460, 11778, or 14484 Leber's hereditary optic neuropathy mitochondrial DNA mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX-I; NUCLEOTIDE PAIR-14459; PHYLOGENETIC ANALYSIS; POINT MUTATION; CELL-LINES; PEDIGREES; DYSTONIA; NADH; 11778-MUTATION; DEFICIENCY	Leber's hereditary optic neuropathy (LHON) is a form of blindness caused by mitochondrial DNA (mtDNA) mutations in complex I genes. We report an extensive biochemical analysis of the mitochondrial defects in lymphoblasts and transmitochondrial cybrids harboring the three most common LHON mutations: 3460A, 11778A, and 14484C. Respiration studies revealed that the 3460A mutation reduced the maximal respiration rate 20-28%, the 11778A mutation 30-36%, and the 14484C mutation 10-15%. The respiration defects of the 3460A and 11778A mutations transferred in cybrid experiments linking these defects to the mtDNA. Complex I enzymatic assays revealed that the 3460A mutation resulted in a 79% reduction in specific activity and the 11778A mutation resulted in a 20% reduction, while the 14484C mutation did not affect the complex I activity. The enzyme defect of the 3460A mutation transferred with the mtDNA in cybrids. Overall, these data support the conclusion that the 3460A and 11778A mutants result in complex I defects and that the 14484C mutation causes a much milder biochemical defect. These studies represent the first direct comparison of oxidative phosphorylation defects among all of the primary LHON mtDNA mutations, thus permitting insight into the underlying pathophysiological mechanism of the disease.	Emory Univ, Sch Med, Ctr Mol Med, Atlanta, GA 30322 USA; St Vincents Hosp, Mutat Res Ctr, Fitzroy, Vic 3065, Australia	Emory University; St Vincent's Hospital Melbourne	Brown, MD (corresponding author), Emory Univ, Sch Med, Ctr Mol Med, 1462 Clifton Rd,Rm 420, Atlanta, GA 30322 USA.		Trounce, Ian A/F-8338-2010	Trounce, Ian A/0000-0002-1070-8892; Allen, Jeffrey/0000-0001-9957-6664	NATIONAL EYE INSTITUTE [R29EY011305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER; NEI NIH HHS [EY11305] Funding Source: Medline; NINDS NIH HHS [NS21328] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BROWN MD, 1994, CLIN NEUROSCI, V2, P138; Brown MD, 1997, AM J HUM GENET, V60, P381; BROWN MD, 1995, HUM MUTAT, V6, P311, DOI 10.1002/humu.1380060405; Carelli V, 1999, ANN NEUROL, V45, P320, DOI 10.1002/1531-8249(199903)45:3<320::AID-ANA7>3.0.CO;2-L; Carelli V, 1997, NEUROLOGY, V48, P1623, DOI 10.1212/WNL.48.6.1623; Cock HR, 1999, J NEUROL SCI, V165, P10, DOI 10.1016/S0022-510X(99)00088-X; COCK HR, 1995, AM J HUM GENET, V57, P1501; ESPOSTI MD, 1994, FEBS LETT, V352, P375, DOI 10.1016/0014-5793(94)00971-6; Hofhaus G, 1996, J BIOL CHEM, V271, P13155, DOI 10.1074/jbc.271.22.13155; Howell N, 1997, VISION RES, V37, P3495, DOI 10.1016/S0042-6989(96)00167-8; HOWELL N, 1995, GENETICS, V140, P285; HOWELL N, 1991, AM J HUM GENET, V49, P939; JOHNS DR, 1993, ARCH OPHTHALMOL-CHIC, V111, P495, DOI 10.1001/archopht.1993.01090040087038; Jun AS, 1996, MOL CELL BIOL, V16, P771; JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206; LARSSON NG, 1991, ANN NEUROL, V30, P701, DOI 10.1002/ana.410300511; Majander A, 1996, EUR J BIOCHEM, V239, P201, DOI 10.1111/j.1432-1033.1996.0201u.x; MAJANDER A, 1991, FEBS LETT, V292, P289, DOI 10.1016/0014-5793(91)80886-8; NEWMAN NJ, 1991, AM J OPHTHALMOL, V111, P750, DOI 10.1016/S0002-9394(14)76784-4; OOSTRA RJ, 1995, BIOCHEM BIOPH RES CO, V215, P1001, DOI 10.1006/bbrc.1995.2563; RIORDANEVA P, 1995, BRAIN, V118, P319, DOI 10.1093/brain/118.2.319; SHOFFNER JM, 1995, ANN NEUROL, V38, P163, DOI 10.1002/ana.410380207; SMITH PR, 1994, J NEUROL SCI, V122, P80, DOI 10.1016/0022-510X(94)90055-8; Torroni A, 1997, AM J HUM GENET, V60, P1107; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; VERGANI L, 1995, BIOCHEM BIOPH RES CO, V210, P880, DOI 10.1006/bbrc.1995.1740; WALLACE DC, 1996, EMERY RIMOINS PRINCI, V1, P277	27	198	215	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39831	39836		10.1074/jbc.M006476200	http://dx.doi.org/10.1074/jbc.M006476200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10976107	hybrid			2022-12-27	WOS:000166039500008
J	Masure, S; Cik, M; Hoefnagel, E; Nosrat, CA; Van der Linden, I; Scott, R; Van Gompel, P; Lesage, ASJ; Verhasselt, P; Ibanez, CF; Gordon, RD				Masure, S; Cik, M; Hoefnagel, E; Nosrat, CA; Van der Linden, I; Scott, R; Van Gompel, P; Lesage, ASJ; Verhasselt, P; Ibanez, CF; Gordon, RD			Mammalian GFR alpha-4, a divergent member of the GFR alpha family of coreceptors for glial cell line-derived neurotrophic factor family ligands, is a receptor for the neurotrophic factor persephin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-RET PROTOONCOGENE; TYROSINE KINASE; GDNF FAMILY; FUNCTIONAL RECEPTOR; NEURTURIN; ACTIVATION; EXPRESSION; COMPLEX; MECHANISMS; NEURONS	Four members of the glial cell line-derived neurotrophic factor family have been identified (GDNF, neurturin, persephin, and enovin/artemin). They bind to a specific membrane-anchored GDNF family receptor as follows: GFR alpha -1 for GDNF, GFR alpha -2 for neurturin, GFR alpha -3 for enovin/artemin, and (chicken) GFR alpha -4 for persephin. Subsequent signaling occurs through activation of a common transmembrane tyrosine kinase, cRET. GFR alpha -4, the coreceptor for persephin, was previously identified in chicken only. We describe the cloning and characterization of a mammalian persephin receptor GFR alpha -4 The novel GFR alpha receptor is substantially different in sequence from all known GFR alphas, including chicken GFR alpha -4, and lacks the first cysteine-rich domain present in all previously characterized GFR alphas. At least two different GFR alpha -4 splice variants exist in rat tissues, differing at their respective COOH termini. GFR alpha -4 mRNA is expressed at low levels in different brain areas in the adult as well as in some peripheral tissues including testis and heart. Recombinant rat GFR alpha -4 variants were expressed in mammalian cells and shown to be at least partially secreted from the cells. Persephin binds specifically and with high affinity (K-D = 6 nm) to the rat GFR alpha -4 receptor, but no cRET activation could be demonstrated. Although the newly characterized mammalian GFR alpha -4 receptor is structurally divergent from previously characterized GFR alpha family members, we suggest that it is a mammalian orthologue of the chicken persephin receptor. This discovery will allow a more detailed investigation of the biological targets of persephin action and its potential involvement in diseases of the nervous system.	Janssen Res Fdn, Dept Biotechnol, B-2340 Beerse, Belgium; Janssen Res Fdn, Dept High Throughput Screening, B-2340 Beerse, Belgium; Janssen Res Fdn, Dept Biochem Pharmacol, B-2340 Beerse, Belgium; Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden	Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Karolinska Institutet	Masure, S (corresponding author), Janssen Res Fdn, Dept Biotechnol, Turnhoutseweg 30, B-2340 Beerse, Belgium.	smasure@janbe.jnj.com	Scott, Rizaldy/AAC-5264-2020	Scott, Rizaldy/0000-0002-0288-8862				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Angrist M, 1998, GENOMICS, V48, P354, DOI 10.1006/geno.1997.5191; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; Cik M, 2000, J BIOL CHEM, V275, P27505; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; Davies AM, 1997, NEURON, V19, P485; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; Enokido Y, 1998, CURR BIOL, V8, P1019, DOI 10.1016/S0960-9822(07)00422-8; GERBER LD, 1992, J BIOL CHEM, V267, P12168; Gunn TM, 1999, NATURE, V398, P152, DOI 10.1038/18217; Helou K, 1998, IMMUNOGENETICS, V47, P166, DOI 10.1007/s002510050342; Ibanez CF, 1998, TRENDS NEUROSCI, V21, P438, DOI 10.1016/S0166-2236(98)01266-1; ISLAM MQ, 1987, HEREDITAS, V107, P127, DOI 10.1111/j.1601-5223.1987.tb00277.x; Jaszai J, 1998, J NEUROSCI RES, V53, P494, DOI 10.1002/(SICI)1097-4547(19980815)53:4<494::AID-JNR12>3.0.CO;2-2; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Lindahl M, 2000, MOL CELL NEUROSCI, V15, P522, DOI 10.1006/mcne.2000.0845; Masure S, 1999, EUR J BIOCHEM, V266, P892, DOI 10.1046/j.1432-1327.1999.00925.x; Masure S, 1998, EUR J BIOCHEM, V251, P622, DOI 10.1046/j.1432-1327.1998.2510622.x; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Naveilhan P, 1998, P NATL ACAD SCI USA, V95, P1295, DOI 10.1073/pnas.95.3.1295; Nishino J, 1999, NEURON, V23, P725, DOI 10.1016/S0896-6273(01)80031-3; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; Rosenthal A, 1999, NEURON, V22, P201, DOI 10.1016/S0896-6273(00)81077-6; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Thompson J, 1998, MOL CELL NEUROSCI, V11, P117, DOI 10.1006/mcne.1998.0682; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Trupp M, 1997, J NEUROSCI, V17, P3554; Worby CA, 1998, J BIOL CHEM, V273, P3502, DOI 10.1074/jbc.273.6.3502; Yu T, 1998, J NEUROSCI, V18, P4684	43	45	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39427	39434		10.1074/jbc.M003867200	http://dx.doi.org/10.1074/jbc.M003867200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10958791	hybrid			2022-12-27	WOS:000165953100067
J	Jackson, VN; Zammit, VA; Price, NT				Jackson, VN; Zammit, VA; Price, NT			Identification of positive and negative determinants of malonyl-CoA sensitivity and carnitine affinity within the amino termini of rat liver- and muscle-type carnitine palmitoyltransferase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; EXPRESSION; TOPOLOGY; BINDING; ACYLTRANSFERASE; INHIBITION; RESIDUES; SYSTEM	The extreme amino terminus and, in particular, residue Glu-3 in rat liver (L) carnitine palmitoyltransferase I (CPT I) have previously been shown to be essential for the sensitivity of the enzyme to inhibition by malonyl-CoA. Using the Pichia pastoris expression system, we now observe that, although mutants E3A (GIu-3 --> Ala) or Delta (3-18) of L-CPT I have markedly lowered sensitivity to malonyl-CoA compared with the wild-type protein, the mutant Delta (1-82) generated an enzyme that had regained much of the sensitivity of wild-type CPT I. This suggests that a region antagonistic to malonyl-CoA sensitivity is present within residues 19-82 of the enzyme. This was confirmed in the construct Delta (19-30), which was found to be 50-fold more sensitive than wild-type L-CPT I, Indeed, this mutant was >4-fold more sensitive than even the native muscle (M)-CPT I isoform expressed and assayed under identical conditions. This behavior was dependent on the presence of Glu-3, with the mutant E3A-Delta (19-30) having kinetic characteristics similar to those of the E3A mutant. The increase in the sensitivity of the L-CPT I-Delta (19-30) mutant was not due to a change in the mechanism of inhibition with respect to palmitoyl-CoA, nor to any marked change of the K-0.5 for this substrate. Conversely, for M-CPT I, a decrease in malonyl-CoA sensitivity was invariably observed with increasing deletions from Delta (3-18) to Delta (1-80). However, deletion of residues 3-18 hom M-CPT I affected the II;, for carnitine of this isoform, but not of L-CPT I, These observations (i) provide the first evidence for negative determinants of malonyl-CoA sensitivity within the amino-terminal segment of L-CPT I and (ii) suggest a mechanism for the inverse relationship between affinity for malonyl-CoA and for carnitine of the two isoforms of the enzyme.	Hannah Res Inst, Dept Cell Biochem, Ayr KA6 5HL, Scotland		Zammit, VA (corresponding author), Hannah Res Inst, Dept Cell Biochem, Ayr KA6 5HL, Scotland.							Broadway NM, 1997, BIOCHEM J, V322, P435, DOI 10.1042/bj3220435; CORNISHBOWDEN A, 1995, FUNDAMENTALS ENZYME, P115; DECLERCQ PE, 1987, J BIOL CHEM, V262, P9812; deVries Y, 1997, BIOCHEMISTRY-US, V36, P5285, DOI 10.1021/bi962875p; ESSER V, 1993, J BIOL CHEM, V268, P5817; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Fraser F, 1998, BIOCHEM J, V329, P225, DOI 10.1042/bj3290225; Jackson VN, 1999, BIOCHEM J, V341, P483, DOI 10.1042/0264-6021:3410483; Jackson VN, 2000, J BIOL CHEM, V275, P19560, DOI 10.1074/jbc.M002177200; KOLODZIEJ MP, 1990, BIOCHEM J, V267, P85, DOI 10.1042/bj2670085; KOLODZIEJ MP, 1993, FEBS LETT, V327, P294, DOI 10.1016/0014-5793(93)81007-M; KOLODZIEJ MP, 1990, BIOCHEM J, V272, P421, DOI 10.1042/bj2720421; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; LLOYD AC, 1986, BIOCHEM J, V237, P289, DOI 10.1042/bj2370289; McGarry JD, 2000, BIOCHEM J, V349, P179, DOI 10.1042/0264-6021:3490179; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MURTHY MSR, 1987, P NATL ACAD SCI USA, V84, P378, DOI 10.1073/pnas.84.2.378; MYNATT RL, 1992, BIOCHIM BIOPHYS ACTA, V1128, P105, DOI 10.1016/0005-2760(92)90263-U; MYNATT RL, 1994, BIOCHEM J, V248, P727; SAGGERSON ED, 1982, BIOCHEM J, V202, P397, DOI 10.1042/bj2020397; Shi JY, 2000, BIOCHEMISTRY-US, V39, P712, DOI 10.1021/bi9918700; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; Swanson ST, 1998, BIOCHEM J, V335, P513, DOI 10.1042/bj3350513; Zammit VA, 1999, PROG LIPID RES, V38, P199, DOI 10.1016/S0163-7827(99)00002-8; Zammit VA, 1998, LIPIDS, V33, P371, DOI 10.1007/s11745-998-0217-7; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505; Zammit VA, 1997, ADV ENZYME REGUL, V37, P295, DOI 10.1016/S0065-2571(96)00015-5; Zammit VA, 1996, BIOCHEM J, V314, P1, DOI 10.1042/bj3140001; Zhu HF, 1997, BIOCHEM BIOPH RES CO, V239, P498, DOI 10.1006/bbrc.1997.7494; Zhu HF, 1997, ARCH BIOCHEM BIOPHYS, V347, P53, DOI 10.1006/abbi.1997.0314	31	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38410	38416		10.1074/jbc.M007722200	http://dx.doi.org/10.1074/jbc.M007722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10969089	hybrid			2022-12-27	WOS:000165739800038
J	Shi, LX; Lorkovic, ZJ; Oelmuller, R; Schroder, WP				Shi, LX; Lorkovic, ZJ; Oelmuller, R; Schroder, WP			The low molecular mass PsbW protein is involved in the stabilization of the dimeric photosystem II complex in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; CORE COMPLEX; SUBUNIT; SPINACH; GENE; CRYSTALLOGRAPHY; ORGANIZATION; MEMBRANE; MUTANTS; PLANTS	Arabidopsis thaliana plants have been transformed with an antisense gene to the psbW of photosystem II (PSII). Eight transgenic lines containing low levels of psbW mRNA have been obtained. Transgenic seedlings with low contents of PsbW protein (more than 96% reduced) were selected by Western blotting and used for photosynthetic functional studies. There were no distinct differences in phenotype between the antisense and wild type plants during vegetative period under normal growth light intensities. However, a sucrose gradient separation of briefly solubilized thylakoid membranes revealed that no dimeric PSII supracomplex could be detected in the transgenic plants lacking the PsbW protein. Furthermore, analysis of isolated thylakoids demonstrated that the oxygen-evolving rate in antisense plants decreased by 50% compared with the wild type, This was found to be due to up to 40% of D1 and D2 reaction center proteins of PSII disappearing in the transgenic plants. The absence of the PsbW protein also altered the contents of other PSII proteins to differing extents. These results show that in the absence of the PsbW protein, the stability of the dimeric PSII is diminished and consequently the total number of PSII complexes is greatly reduced. Thus the nuclear encoded PsbW protein may play a crucial role in the biogenesis and regulation of the photosynthetic apparatus.	Univ Stockholm, Arrhenius Labs Nat Sci, Dept Biochem, SE-10691 Stockholm, Sweden; Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Univ Jena, Lehrstuhl Pflanzenphysiol, Inst Allgemeine Bot, D-07743 Jena, Germany; Sodertorns Hogskola, Univ Coll, Bipontus, SE-14104 Huddinge, Sweden	Stockholm University; Friedrich Miescher Institute for Biomedical Research; Friedrich Schiller University of Jena; Sodertorn University	Schroder, WP (corresponding author), Univ Stockholm, Arrhenius Labs Nat Sci, Dept Biochem, SE-10691 Stockholm, Sweden.		Schröder, Wolfgang/A-8799-2008	Schroder, Wolfgang/0000-0001-9831-1533; Lorkovic, Zdravko/0000-0002-3074-7258				ANBUDURAI PR, 1993, Z NATURFORSCH C, V48, P267; ANDERSSON B, 1992, MOL MECHANISMS BIOEN, P121; Baena-Gonzalez E, 1999, PLANTA, V208, P196, DOI 10.1007/s004250050550; Barber J, 1999, CURR OPIN STRUC BIOL, V9, P469, DOI 10.1016/S0959-440X(99)80066-9; Barber J, 1999, TRENDS BIOCHEM SCI, V24, P43, DOI 10.1016/S0968-0004(98)01348-6; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Bianchetti M, 1998, J BIOL CHEM, V273, P16128, DOI 10.1074/jbc.273.26.16128; Eshaghi S, 1999, FEBS LETT, V446, P23, DOI 10.1016/S0014-5793(99)00149-0; FUNK C, 1995, PHOTOSYNTHESIS LIGHT, V3, P329; Hagman A, 1997, BIOCHEMISTRY-US, V36, P12666, DOI 10.1021/bi970685o; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; Hankamer B, 1999, NAT STRUCT BIOL, V6, P560, DOI 10.1038/9341; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; IKEUCHI M, 1991, J BIOL CHEM, V266, P11111; IRRGANG KD, 1995, J BIOL CHEM, V270, P17588, DOI 10.1074/jbc.270.29.17588; KITAMURA K, 1994, FEBS LETT, V354, P113, DOI 10.1016/0014-5793(94)01089-7; KOMENDA J, 1995, BIOCHEMISTRY-US, V34, P9625, DOI 10.1021/bi00029a040; Kruse O, 2000, J BIOL CHEM, V275, P6509, DOI 10.1074/jbc.275.9.6509; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; LORKOVIC ZJ, 1995, PHOTOSYNTHESIS LIGHT, V3, P743; MAYES SR, 1993, BIOCHEMISTRY-US, V32, P1454, DOI 10.1021/bi00057a008; Morris EP, 1997, STRUCTURE, V5, P837, DOI 10.1016/S0969-2126(97)00237-2; Muller B, 1999, PLANT CELL, V11, P2365, DOI 10.1105/tpc.11.12.2365; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Noren H, 1999, BIOSCIENCE REP, V19, P499, DOI 10.1023/A:1020280710067; Pakrasi HB, 1995, ANNU REV GENET, V29, P755; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Rhee KH, 1997, NATURE, V389, P522, DOI 10.1038/39103; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHRODER WP, 1986, BIOCHIM BIOPHYS ACTA, V848, P359, DOI 10.1016/0005-2728(86)90211-2; Shi LX, 1997, PHOTOSYNTH RES, V53, P45, DOI 10.1023/A:1005830405809; Summer EJ, 1997, PLANT PHYSIOL, V113, P1359, DOI 10.1104/pp.113.4.1359; TAKAHASHI Y, 1994, PLANT MOL BIOL, V24, P779, DOI 10.1007/BF00029859; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Zheleva D, 1998, J BIOL CHEM, V273, P16122, DOI 10.1074/jbc.273.26.16122	37	44	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37945	37950		10.1074/jbc.M006300200	http://dx.doi.org/10.1074/jbc.M006300200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10950961	hybrid			2022-12-27	WOS:000165618700086
J	Bakin, AV; Tomlinson, AK; Bhowmick, NA; Moses, HL; Arteaga, CL				Bakin, AV; Tomlinson, AK; Bhowmick, NA; Moses, HL; Arteaga, CL			Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; PHOSPHOINOSITIDE 3-KINASE; ACTIVATION; PROTEIN; RHO; TRANSCRIPTION; INVASIVENESS; RECEPTOR; BINDING; INSULIN	We have studied the role of phosphatidylinositol 3-OH kinase (PI3K)-Akt signaling in transforming growth factor beta (TGF beta)-mediated epithelial to mesenchymal transition (EMT). In NMuMG mammary epithelial cells, exogenous TGF beta1 induced phosphorylation of Akt at Ser-473 and Akt in vitro kinase activity against GrSK-3 beta within 30 min. These responses were temporally correlated with delocalization of E-cadherin, ZO-1, and integrin beta (1) from cell junctions and the acquisition of spindle cell morphology. LY294002, an inhibitor of the p110 catalytic subunit of PI3K, and a dominant-negative mutant of Akt blocked the delocalization of ZO-1 induced by TGF beta1, whereas transfection of constitutively active p110 induced loss of ZO-1 from tight junctions. In addition, LY294002 blocked TGF beta -mediated C-terminal phosphorylation of Smad2. Consistent with these data, TGF beta -induced p3TP-Lux and p(CAGA)(12). Lux reporter activities were inhibited by LY294002 and transiently expressed dominant-negative p85 and Akt mutants in NMuMG and 4T1 cells. Dominant-negative RhoA inhibited TGF beta -induced phosphorylation of Akt at Ser-473, whereas constitutively active RhoA increased the basal phosphorylation of Akt, suggesting that RhoA in involved in TGF beta -induced EMT. Finally, LY294002 and neutralizing TGF beta1 antibodies inhibited ligand-independent constitutively active Akt as well as basal and TGF beta -stimulated migration in 4T1 and EMT6 breast tumor cells. Taken together, these data suggest that PI3K-Akt signaling is required for TGF beta -induced transcriptional responses, EMT, and cell migration.	Vanderbilt Univ, Sch Med, Div Hematol Oncol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA; Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University	Arteaga, CL (corresponding author), Vanderbilt Univ, Sch Med, Div Hematol Oncol, Dept Med, 22nd Ave S,1956 TVC, Nashville, TN 37232 USA.	carlos.arteaga@mcmail.vanderbilt.edu	Bhowmick, Neil/AAA-7302-2019	Bhowmick, Neil/0000-0001-8747-5989; Bakin, Andrei/0000-0002-7728-1969	NCI NIH HHS [R35 CA42572, CA09592, R01 CA62212] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062212, T32CA009592, R35CA042572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; Barbieri MA, 1998, J BIOL CHEM, V273, P19367, DOI 10.1074/jbc.273.31.19367; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fruman DA, 1999, CELL, V97, P817, DOI 10.1016/S0092-8674(00)80792-8; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; GUNDERSEN GG, 1994, J CELL SCI, V107, P645; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Higaki M, 1999, ARTERIOSCL THROM VAS, V19, P2127, DOI 10.1161/01.ATV.19.9.2127; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Krymskaya VP, 1997, AM J PHYSIOL-LUNG C, V273, pL1220, DOI 10.1152/ajplung.1997.273.6.L1220; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LUCAS C, 1990, J IMMUNOL, V145, P1415; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; NOBES CD, 1995, J CELL SCI, V108, P225; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Piek E, 1999, J CELL SCI, V112, P4557; POSTLETHWAITE AE, 1987, J EXP MED, V165, P251, DOI 10.1084/jem.165.1.251; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Tang WL, 1998, J BIOL CHEM, V273, P5506, DOI 10.1074/jbc.273.10.5506; Thelen M, 1995, BIOCHEM BIOPH RES CO, V217, P1255, DOI 10.1006/bbrc.1995.2903; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	50	799	839	3	59	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36803	36810		10.1074/jbc.M005912200	http://dx.doi.org/10.1074/jbc.M005912200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10969078	hybrid			2022-12-27	WOS:000165577700052
J	Morimura, T; Goitsuka, R; Zhang, Y; Saito, I; Reth, M; Kitamura, D				Morimura, T; Goitsuka, R; Zhang, Y; Saito, I; Reth, M; Kitamura, D			Cell cycle arrest and apoptosis induced by Notch1 in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; ANKYRIN REPEATS; HUMAN HOMOLOG; NEURONAL DIFFERENTIATION; IMMUNOGLOBULIN GENES; EMBRYONIC LETHALITY; DROSOPHILA HOMOLOG; TYROSINE KINASE; CRE RECOMBINASE; CHICKEN BURSA	Notch receptors play various roles for cell fate decisions in developing organs, although their functions at the cell level are poorly understood. Recently, we found that Notch1 and its ligand are each expressed in juxta-posed cell compartments in the follicles of the bursa of Fabricius, the central organ for chicken B cell development. To examine the function of Notch1 in B cells, a constitutively active form of chicken Notch1 was expressed in a chicken B cell line, DT40, by a Cre/loxP-mediated inducible expression system. Remarkably, the active Notch1 caused growth suppression of the cells, accompanied by a cell cycle inhibition at the G(1) phase and apoptosis. The expression of Hairy1, a gene product up-regulated by the Notch1 signaling, also induced the apoptosis, but no cell cycle inhibition. Thus, Notch1 signaling induces apoptosis of the B cells through Hairy1, and the G(1) cell cycle arrest through other pathways. This novel function of Notch1 may account for the recent observations indicating the selective inhibition of early B cell development in mice by Notch1.	Tokyo Univ Sci, Biosci Res Inst, Div Mol Biol, Noda, Chiba 2780022, Japan; Japan Sci & Technol Corp, PRESTO, Noda, Chiba 2780022, Japan; Univ Freiburg, Dept Mol Immunol, D-79108 Freiburg, Germany; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany; Univ Tokyo, Inst Med Sci, Genet Mol Lab, Minato Ku, Tokyo 1088639, Japan	Tokyo University of Science; Japan Science & Technology Agency (JST); University of Freiburg; Max Planck Society; University of Tokyo	Kitamura, D (corresponding author), Tokyo Univ Sci, Biosci Res Inst, Div Mol Biol, Noda, Chiba 2780022, Japan.	kitamura@rs.noda.sut.ac.jp						ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; Choi JK, 1996, EMBO J, V15, P5014, DOI 10.1002/j.1460-2075.1996.tb00881.x; Christensen S, 1996, DEVELOPMENT, V122, P1373; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FUKUDA T, 1995, P NATL ACAD SCI USA, V92, P7302, DOI 10.1073/pnas.92.16.7302; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; Goitsuka R, 1997, J IMMUNOL, V159, P3126; Hamada T, 1998, BRIT J HAEMATOL, V102, P691; Hamada Y, 1999, DEVELOPMENT, V126, P3415; Hasserjian RP, 1996, BLOOD, V88, P970, DOI 10.1182/blood.V88.3.970.bloodjournal883970; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; HOUSSAINT E, 1983, EUR J IMMUNOL, V13, P590, DOI 10.1002/eji.1830130715; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jehn BM, 1999, J IMMUNOL, V162, P635; Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Katsuta H, 1998, J IMMUNOL, V160, P1547; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; LASSILA O, 1989, EUR J IMMUNOL, V19, P955, DOI 10.1002/eji.1830190527; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Masteller E L, 1997, Int Rev Immunol, V15, P185, DOI 10.3109/08830189709068176; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; MILNER LA, 1994, BLOOD, V83, P2057; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORIMURA T, 1995, J GEN VIROL, V76, P2979, DOI 10.1099/0022-1317-76-12-2979; Morrison AM, 1998, BLOOD, V92, P3865, DOI 10.1182/blood.V92.10.3865.422k01_3865_3878; MOTYKA B, 1991, EUR J IMMUNOL, V21, P1951, DOI 10.1002/eji.1830210825; Nakamura Y, 2000, J NEUROSCI, V20, P283, DOI 10.1523/JNEUROSCI.20-01-00283.2000; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Nutt SL, 1997, IMMUNOBIOLOGY, V198, P227, DOI 10.1016/S0171-2985(97)80043-5; O'Riordan M, 1999, IMMUNITY, V11, P21, DOI 10.1016/S1074-7613(00)80078-3; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; PINK JRL, 1985, EUR J IMMUNOL, V15, P617, DOI 10.1002/eji.1830150616; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; RATCLIFFE MJH, 1986, EUR J IMMUNOL, V16, P129, DOI 10.1002/eji.1830160204; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Sakai K, 1995, BIOCHEM BIOPH RES CO, V217, P393, DOI 10.1006/bbrc.1995.2789; Schroeder T, 2000, EMBO J, V19, P2558, DOI 10.1093/emboj/19.11.2558; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; WEILL JC, 1986, P NATL ACAD SCI USA, V83, P3336, DOI 10.1073/pnas.83.10.3336; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Zhang Y, 1996, NUCLEIC ACIDS RES, V24, P543, DOI 10.1093/nar/24.4.543; Zhang Y, 1998, EMBO J, V17, P7304, DOI 10.1093/emboj/17.24.7304	74	118	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36523	36531		10.1074/jbc.M006415200	http://dx.doi.org/10.1074/jbc.M006415200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967117	hybrid			2022-12-27	WOS:000165577700011
J	Ward, RA; Nakamura, M; McLeish, KR				Ward, RA; Nakamura, M; McLeish, KR			Priming of the neutrophil respiratory burst involves p38 mitogen-activated protein kinase-dependent exocytosis of flavocytochrome b(558)-containing granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; CHRONIC GRANULOMATOUS-DISEASE; SIGNAL-TRANSDUCTION PATHWAYS; SUPEROXIDE ANION GENERATION; CELL-SURFACE; FACTOR-ALPHA; TNF-ALPHA; SUBCELLULAR-LOCALIZATION; TYROSINE PHOSPHORYLATION	The respiratory burst of human neutrophils is primed by a number of pro-inflammatory stimuli, including tumor necrosis factor-alpha (TNF alpha) and lipopolysaccharide (LPS); however, the mechanism of priming remains unknown. LPS has been shown previously to increase membrane expression of flavocytochrome b(558), a component of the NADPH oxidase. This study shows that TNF alpha also increases membrane expression of flavocytochrome b(558). Mitogen-activated protein kinase (MAPK) modules have been implicated in the action of priming agents. Pharmacologic inhibitors of MAPKs, SB203580 and PD098059, revealed that priming of the respiratory burst and up-regulation of flavocytochrome b(558) are dependent on p38 MAPK but not on extracellular-signal regulated kinase (ERK). TNF alpha and LPS primed respiratory burst activity and increased membrane expression of CD35 and CD66b, specific markers of secretory vesicles and specific granules that contain flavocytochrome b(558) with similar time courses and concentration dependences. These processes also required p38 MAPK but were independent of ERK. TNF alpha failed to prime respiratory burst activity or to increase membrane CD35 expression in enucleated neutrophil cytoplasts. These data suggest that one mechanism by which TNF alpha and LPS prime neutrophil respiratory burst activity is by increasing membrane expression of flavocytochrome b(558) through exocytosis of intracellular granules in a process regulated by p38 MAPK.	Univ Louisville, Dept Med, Mol Signaling Grp, Louisville, KY 40202 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Nagasaki Univ, Inst Trop Med, Dept Host Def Biochem, Nagasaki 8528523, Japan; Vet Affairs Med Ctr, Louisville, KY 40204 USA	University of Louisville; University of Louisville; Nagasaki University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ward, RA (corresponding author), Univ Louisville, Dept Med, Mol Signaling Grp, 615 S Preston St, Louisville, KY 40202 USA.	richard.ward@louisville.edu	McLeish, Kenneth R./B-9819-2013	McLeish, Kenneth R./0000-0002-7816-3286				Absolom D R, 1986, Methods Enzymol, V132, P95; ATKINSON YH, 1988, J CLIN INVEST, V81, P759, DOI 10.1172/JCI113381; Avdi NJ, 1996, J BIOL CHEM, V271, P33598, DOI 10.1074/jbc.271.52.33598; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BAJAJ MS, 1992, INFLAMMATION, V16, P241, DOI 10.1007/BF00918813; BASS DA, 1986, J IMMUNOL, V136, P860; BORREGAARD N, 1994, J LEUKOCYTE BIOL, V56, P80, DOI 10.1002/jlb.56.1.80; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; Coxon PY, 2000, J IMMUNOL, V164, P6530, DOI 10.4049/jimmunol.164.12.6530; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; Detmers PA, 1998, J IMMUNOL, V161, P1921; Downey GP, 1998, J IMMUNOL, V160, P434; DURSTIN M, 1993, BIOCHEM J, V292, P183, DOI 10.1042/bj2920183; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; ENGLISH D, 1986, BLOOD, V67, P1314; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Hale KK, 1999, J IMMUNOL, V162, P4246; HASLETT C, 1985, AM J PATHOL, V119, P101; JOHNSTON RB, 1975, J CLIN INVEST, V55, P1357, DOI 10.1172/JCI108055; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; KLEIN JB, 1990, INFLAMMATION, V14, P599, DOI 10.1007/BF00914279; KLEIN JB, 1995, J LEUKOCYTE BIOL, V57, P500, DOI 10.1002/jlb.57.3.500; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; LINAS SL, 1992, KIDNEY INT, V42, P610, DOI 10.1038/ki.1992.325; Mansfield PJ, 2000, BLOOD, V95, P2407, DOI 10.1182/blood.V95.7.2407.007k02_2407_2412; MCCOLL SR, 1990, J IMMUNOL, V145, P3047; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P835, DOI 10.1002/jlb.64.6.835; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; MEGE JL, 1989, J LEUKOCYTE BIOL, V46, P161, DOI 10.1002/jlb.46.2.161; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; NAKAMURA M, 1987, BLOOD, V69, P1404; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Nick JA, 1996, J IMMUNOL, V156, P4867; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; OZAKI Y, 1988, INFLAMMATION, V12, P297, DOI 10.1007/BF00915767; PETREQUIN PR, 1986, BLOOD, V67, P1119; Pugin J, 1999, AM J RESP CELL MOL, V20, P458, DOI 10.1165/ajrcmb.20.3.3311; Rane MJ, 1997, J IMMUNOL, V159, P5070; REED D, 1988, ARCH SURG-CHICAGO, V123, P1333; ROOS D, 1983, J CELL BIOL, V97, P368, DOI 10.1083/jcb.97.2.368; Smolen JE, 2000, J BIOL CHEM, V275, P15876, DOI 10.1074/jbc.M906232199; Tandon R, 2000, BIOCHEM BIOPH RES CO, V270, P858, DOI 10.1006/bbrc.2000.2540; TRINKLE LS, 1987, DIAGN CLIN IMMUNOL, V5, P62; VOSBECK K, 1990, J LEUKOCYTE BIOL, V47, P97, DOI 10.1002/jlb.47.2.97; WARD RA, 1995, J AM SOC NEPHROL, V5, P1697; WATERMAN WH, 1995, BIOCHEM J, V307, P39, DOI 10.1042/bj3070039; WEISBART RH, 1987, BLOOD, V69, P18; WEISBART RH, 1986, J IMMUNOL, V137, P3584; WEWERS MD, 1990, AM J PHYSIOL, V259, pL276, DOI 10.1152/ajplung.1990.259.4.L276; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WORTHEN GS, 1987, AM REV RESPIR DIS, V136, P19, DOI 10.1164/ajrccm/136.1.19; YASUI K, 1992, BIOCHEM BIOPH RES CO, V183, P1280, DOI 10.1016/S0006-291X(05)80329-8; YOU A, 1997, BIOCHEM BIOPH RES CO, V235, P42; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zu YL, 1998, J IMMUNOL, V160, P1982	63	130	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36713	36719		10.1074/jbc.M003017200	http://dx.doi.org/10.1074/jbc.M003017200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10976103	hybrid			2022-12-27	WOS:000165577700039
J	Yancey, PG; de la Llera-Moya, M; Swarnakar, S; Monzo, P; Klein, SM; Connelly, MA; Johnson, WJ; Williams, DL; Rothblat, GH				Yancey, PG; de la Llera-Moya, M; Swarnakar, S; Monzo, P; Klein, SM; Connelly, MA; Johnson, WJ; Williams, DL; Rothblat, GH			High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR-BI; SELECTIVE UPTAKE; HUMAN-SERUM; FU5AH CELLS; EFFLUX; HDL; MECHANISM; TRANSPORT; MEMBRANE; PROMOTES	The role of high density lipoprotein (HDL) phospholipid in scavenger receptor BI (SR-BI)-mediated free cholesterol flux was examined by manipulating HDL, phosphatidylcholine and sphingomyelin content. Both phosphatidylcholine and sphingomyelin enrichment of HDL enhanced the net efflux of cholesterol from SR-BI-expressing COS-7 cells but by two different mechanisms. Phosphatidylcholine enrichment of HDL increased efflux, whereas sphingomyelin enrichment decreased influx of HDL cholesterol. Although similar trends were observed in control (vector-transfected) COS-7 cells, SR-BI overexpression amplified the effects of phosphatidylcholine and sphingomyelin enrichment of HDL 25-and 2.8-fold, respectively. By using both phosphatidylcholine-enriched and phospholipase A(2)-treated HDL to obtain HDL with a graded phosphatidylcholine content, we showed that SR-BI-mediated cholesterol efflux was highly correlated (r(2) = 0.985) with HDL phosphatidylcholine content. The effects of varying HDL phospholipid composition on SR-BI-mediated free cholesterol flux were not correlated with changes in either the K-d or B-max values for high affinity binding to SR-BI. We conclude that SR-BI-mediated free cholesterol flux is highly sensitive to HDL phospholipid composition. Thus, factors that regulate cellular SR-BI expression and the local modification of HDL phospholipid composition will have a large impact on reverse cholesterol transport.	SUNY Stony Brook, Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Childrens Hosp Philadelphia, Dept Pediat, Div Gastroenterol & Nutr, Philadelphia, PA 19104 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Williams, DL (corresponding author), SUNY Stony Brook, Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.		Eckhardt, Erik/G-1567-2010; Yancey, Patricia/ABB-5856-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063768, R01HL058012, P01HL022633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22633, HL58012, HL63768] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atger V, 1995, J CLIN INVEST, V96, P2613, DOI 10.1172/JCI118326; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BAMBERGER M, 1985, BIOCHEMISTRY-US, V24, P3693, DOI 10.1021/bi00335a044; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Calvo D, 1998, J LIPID RES, V39, P777; Chen WG, 2000, J BIOL CHEM, V275, P30794, DOI 10.1074/jbc.M004552200; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; DAVIDSON WS, 1994, J BIOL CHEM, V269, P22975; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; DAVIDSON WS, 1995, J BIOL CHEM, V270, P5882, DOI 10.1074/jbc.270.11.5882; Davit-Spraul A, 1999, J LIPID RES, V40, P328; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; EISENBERG S, 1984, J LIPID RES, V25, P1017; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING CJ, 1991, CURR OPIN LIPIDOL, V2, P376; Fournier N, 1996, J LIPID RES, V37, P1704; Fournier N, 1997, ARTERIOSCL THROM VAS, V17, P2685, DOI 10.1161/01.ATV.17.11.2685; FRANCESCHINI G, 1991, ATHEROSCLEROSIS, V88, P99, DOI 10.1016/0021-9150(91)90073-C; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; GLOMSET JA, 1964, BIOCHIM BIOPHYS ACTA, V89, P266, DOI 10.1016/0926-6569(64)90215-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; Hatch F T, 1968, Adv Lipid Res, V6, P1; Haynes MP, 2000, BIOCHEMISTRY-US, V39, P4508, DOI 10.1021/bi992125q; Hirano K, 1999, CIRC RES, V85, P108; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Jian B, 1997, J LIPID RES, V38, P734; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; KLANSEK JJ, 1995, J LIPID RES, V36, P2261; Krieger M, 1999, CURR OPIN LIPIDOL, V10, P491, DOI 10.1097/00041433-199912000-00003; KUNZ F, 1994, ARTERIOSCLER THROMB, V14, P1146, DOI 10.1161/01.ATV.14.7.1146; LAGROST L, 1995, J BIOL CHEM, V270, P13004, DOI 10.1074/jbc.270.22.13004; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; PATTNAIK NM, 1976, J BIOL CHEM, V251, P1984; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; Pilon A, 2000, ARTERIOSCL THROM VAS, V20, P1074, DOI 10.1161/01.ATV.20.4.1074; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; Rothblat GH, 1999, J LIPID RES, V40, P781; Schroeder F, 1996, P SOC EXP BIOL MED, V213, P150, DOI 10.3181/00379727-213-44047; Slotte JP, 1999, CHEM PHYS LIPIDS, V102, P13, DOI 10.1016/S0009-3084(99)00071-7; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; Tabas I, 1999, CHEM PHYS LIPIDS, V102, P123, DOI 10.1016/S0009-3084(99)00080-8; TALL AR, 1992, J INTERN MED, V231, P661, DOI 10.1111/j.1365-2796.1992.tb01255.x; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; Williams DL, 1999, CURR OPIN LIPIDOL, V10, P329, DOI 10.1097/00041433-199908000-00007	58	252	264	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36596	36604		10.1074/jbc.M006924200	http://dx.doi.org/10.1074/jbc.M006924200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10964930	hybrid			2022-12-27	WOS:000165577700021
J	Petersen, S; de Graaf, AA; Eggeling, L; Mollney, M; Wiechert, W; Sahm, H				Petersen, S; de Graaf, AA; Eggeling, L; Mollney, M; Wiechert, W; Sahm, H			In vivo quantification of parallel and bidirectional fluxes in the anaplerosis of Corynebacterium glutamicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CITRIC-ACID CYCLE; CENTRAL METABOLIC PATHWAYS; PERFUSED RAT HEARTS; INTERMEDIARY METABOLISM; ESCHERICHIA-COLI; PHOSPHOENOLPYRUVATE CARBOXYLASE; REACTION STEPS; CARBON-FLUX; QUANTITATIVE-ANALYSIS	The C-3-C-4 metabolite interconversion at the anaplerotic node in many microorganisms involves a complex set of reactions. C-3, carboxylation to oxaloacetate can originate from phosphoenolpyruvate and pyruvate, and at the Same time multiple C-4-decarboxylating enzymes may be present. The functions of such parallel reactions are not yet fully understood. Using a C-13 NMR-based strategy, we here quantify the individual fluxes at the anaplerotic node of Corynebacterium glutamicum, which is an example of a bacterium possessing multiple carboxylation and decarboxylation reactions. C. glutamicum was grown with a C-13-labeled glucose isotopomer mixture as the main carbon source and 13C-labeled lactate as a cosubstrate. 58 isotopomers as well as 15 positional labels of biomass compounds were quantified. Applying a generally applicable mathematical model to include metabolite mass and carbon labeling balances, it is shown that pyruvate carboxylase contributed 91 +/- 7% to C-3 carboxylation. The total in vivo carboxylation rate of 1.28 +/- 0.14 mmol/g dry weight/h exceeds the demand of carboxylated metabolites for biosyntheses 3-fold. Excess oxaloacetate was recycled to phosphoenolpyruvate by phosphoenolpyruvate carboxykinase. This shows that the reactions at the anaplerotic node might serve additional purposes other than only providing C-4 metabolites for biosynthesis.	Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany; Univ Siegen, Inst Mech & Regelungstech, D-57068 Siegen, Germany	Helmholtz Association; Research Center Julich; Universitat Siegen	de Graaf, AA (corresponding author), Forschungszentrum Julich, Inst Biotechnol 1, Postfach 1913, D-52425 Julich, Germany.	a.de.graaf@fz-juelich.de		Wiechert, Wolfgang/0000-0001-8501-0694				BARANYAI JM, 1989, BIOCHEM J, V258, P121, DOI 10.1042/bj2580121; CHAMBOST JP, 1980, J BIOL CHEM, V255, P2867; CHAO YP, 1994, J BIOL CHEM, V269, P5122; CHAO YP, 1993, APPL ENVIRON MICROB, V59, P4261, DOI 10.1128/AEM.59.12.4261-4265.1993; CocaignBousquet M, 1996, APPL ENVIRON MICROB, V62, P429, DOI 10.1128/AEM.62.2.429-436.1996; COCAIGNBOUSQUET M, 1995, ENZYME MICROB TECH, V17, P260, DOI 10.1016/0141-0229(94)00023-K; Comte B, 1997, J BIOL CHEM, V272, P26125, DOI 10.1074/jbc.272.42.26125; Comte B, 1997, J BIOL CHEM, V272, P26117, DOI 10.1074/jbc.272.42.26117; DALDAL F, 1983, J BACTERIOL, V153, P390, DOI 10.1128/JB.153.1.390-394.1983; DESROSIERS C, 1994, J BIOL CHEM, V269, P27179; DIESTERHAFT MD, 1973, J BIOL CHEM, V248, P6062; Dominguez H, 1998, EUR J BIOCHEM, V254, P96, DOI 10.1046/j.1432-1327.1998.2540096.x; EIKMANNS BJ, 1989, MOL GEN GENET, V218, P330, DOI 10.1007/BF00331286; EIKMANNS BJ, 1995, J BACTERIOL, V177, P774, DOI 10.1128/jb.177.3.774-782.1995; HELMSTETTER CE, 1996, ESCHERICHIA COLI SAL, V2; JEFFREY FMH, 1991, TRENDS BIOCHEM SCI, V16, P5, DOI 10.1016/0968-0004(91)90004-F; JETTEN MSM, 1993, FEMS MICROBIOL LETT, V111, P183; JETTEN MSM, 1995, ANTON LEEUW INT J G, V67, P221, DOI 10.1007/BF00871217; Jucker BM, 1998, J BIOL CHEM, V273, P12187, DOI 10.1074/jbc.273.20.12187; KATZ J, 1993, J BIOL CHEM, V268, P25509; KORNBERG HL, 1966, ESSAYS BIOCH, V2; Kramer R, 1996, J BIOTECHNOL, V45, P1, DOI 10.1016/0168-1656(95)00146-8; London RE, 1999, J BACTERIOL, V181, P3562, DOI 10.1128/JB.181.11.3562-3570.1999; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; MANDELSTAM J, 1973, BIOCH BACTERIAL GROW; Marx A, 1997, BIOTECHNOL BIOENG, V56, P168, DOI 10.1002/(SICI)1097-0290(19971020)56:2<168::AID-BIT6>3.0.CO;2-N; Marx A, 1996, BIOTECHNOL BIOENG, V49, P111, DOI 10.1002/(SICI)1097-0290(19960120)49:2<111::AID-BIT1>3.0.CO;2-T; Marx A, 1999, METAB ENG, V1, P35, DOI 10.1006/mben.1998.0106; MILRADDEFORCHETTI SR, 1976, J GEN MICROBIOL, V93, P75, DOI 10.1099/00221287-93-1-75; Mollney M, 1999, BIOTECHNOL BIOENG, V66, P86, DOI 10.1002/(SICI)1097-0290(1999)66:2<86::AID-BIT2>3.0.CO;2-A; MORI M, 1985, J BIOCHEM-TOKYO, V98, P1621, DOI 10.1093/oxfordjournals.jbchem.a135432; OBRIEN RW, 1977, J BIOL CHEM, V252, P1257; Park SM, 1997, APPL MICROBIOL BIOT, V47, P430, DOI 10.1007/s002530050952; PETERSWENDISCH PG, 1993, FEMS MICROBIOL LETT, V112, P269, DOI 10.1016/0378-1097(93)90611-5; PetersWendisch PG, 1997, MICROBIOL-SGM, V143, P1095, DOI 10.1099/00221287-143-4-1095; PETERSWENDISCH PG, 1996, THESIS U DUSSELDORF; RABKIN M, 1985, BIOCHEM J, V225, P761, DOI 10.1042/bj2250761; RAUGI GJ, 1975, J BIOL CHEM, V250, P5866; Rognstad R, 1996, BIOCHEM ARCH, V12, P71; Sauer U, 1997, NAT BIOTECHNOL, V15, P448, DOI 10.1038/nbt0597-448; SCHRUMPF B, 1992, APPL MICROBIOL BIOT, V37, P566; SCHRUMPF B, 1991, J BACTERIOL, V173, P4510, DOI 10.1128/JB.173.14.4510-4516.1991; SCRUTTON MC, 1972, ENZYMES, V6; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SHIIO I, 1978, J BIOCHEM-TOKYO, V84, P647, DOI 10.1093/oxfordjournals.jbchem.a132170; SONNTAG K, 1993, EUR J BIOCHEM, V213, P1325, DOI 10.1111/j.1432-1033.1993.tb17884.x; Stryer L., 1988, BIOCHEMISTRY-US; SUNDQVIST KE, 1989, BIOCHEM J, V257, P913, DOI 10.1042/bj2570913; SZYPERSKI T, 1995, EUR J BIOCHEM, V232, P433, DOI 10.1111/j.1432-1033.1995.433zz.x; VALLINO JJ, 1993, BIOTECHNOL BIOENG, V41, P633, DOI 10.1002/bit.260410606; WALKER TE, 1982, J BIOL CHEM, V257, P1189; Wendisch VF, 1997, ARCH MICROBIOL, V168, P262, DOI 10.1007/s002030050497; WeusterBotz D, 1997, BIOTECHNOL PROGR, V13, P387, DOI 10.1021/bp970034j; Wiechert W, 1999, BIOTECHNOL BIOENG, V66, P69; Wiechert W, 1997, BIOTECHNOL BIOENG, V55, P118, DOI 10.1002/(SICI)1097-0290(19970705)55:1<118::AID-BIT13>3.0.CO;2-I; Wiechert W, 1997, BIOTECHNOL BIOENG, V55, P101, DOI 10.1002/(SICI)1097-0290(19970705)55:1<101::AID-BIT12>3.0.CO;2-P; WIECHERT W, 1996, ADV BIOCH ENG BIOTEC, V54	57	152	167	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35932	35941		10.1074/jbc.M908728199	http://dx.doi.org/10.1074/jbc.M908728199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10946002	hybrid, Green Published			2022-12-27	WOS:000165382000043
J	Xu, JY; Tseng, Y; Wirtz, D				Xu, JY; Tseng, Y; Wirtz, D			Strain hardening of actin filament networks - Regulation by the dynamic cross-linking protein alpha-actinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFUSING WAVE SPECTROSCOPY; MECHANICAL-PROPERTIES; F-ACTIN; THERMAL FLUCTUATIONS; ENDOTHELIAL-CELLS; BINDING PROTEINS; GELS; VISCOELASTICITY; CYTOSKELETON; FIBROBLASTS	Mechanical stresses applied to the plasma membrane of an adherent cell induces strain hardening of the cytoskeleton, i.e. the elasticity of the cytoskeleton increases with its deformation. Strain hardening is thought to mediate the transduction of mechanical signals across the plasma membrane through the cytoskeleton. Here, we describe the strain dependence of a model system consisting of actin filaments (F-actin), a major component of the cytoskeleton, and the F-actin cross-linking protein cu-actinin, which localizes along contractile stress fibers and at focal adhesions. We show that the amplitude and rate of shear deformations regulate the resilience of F-actin networks. At low temperatures; for which the lifetime of binding of a-actinin to F-actin is long, F-actin/alpha -actinin networks exhibit strong strain hardening at short time scales and soften at long time scales. For F-actin networks in the absence of alpha -actinin or for F-actin/alpha -actinin networks at high temperatures, strain hardening appears only at very short time scales. We propose a model of strain hardening for F-actin networks, based on both the intrinsic rigidity of F-actin and dynamic topological constraints formed by the cross-linkers located at filaments entanglements. This model offers an explanation for the origin of strain hardening observed when shear stresses are applied against the cellular membrane.	Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Interdept Program Mol Biophys, Baltimore, MD 21218 USA; USDA ARS, Natl Ctr Agr Utilizat Res, Peoria, IL 61604 USA	Johns Hopkins University; Johns Hopkins University; United States Department of Agriculture (USDA)	Wirtz, D (corresponding author), Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA.		Wirtz, Denis/A-3257-2010					ALMO S, 1994, ANN REV CELL BIOL, V10, P207; [Anonymous], 1980, VISCOELASTIC PROPERT; Apgar J, 2000, BIOPHYS J, V79, P1095, DOI 10.1016/S0006-3495(00)76363-6; Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; Bausch AR, 1999, BIOPHYS J, V76, P573, DOI 10.1016/S0006-3495(99)77225-5; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; CONDEELIS J, 1992, CELL MOTIL CYTOSKEL, V22, P1, DOI 10.1002/cm.970220102; Coulombe PA, 2000, TRENDS CELL BIOL, V10, P420, DOI 10.1016/S0962-8924(00)01828-6; CRAIG SW, 1982, METHOD ENZYMOL, V85, P316; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; CRAMER LP, 1994, CURR OPIN CELL BIOL, V6, P62; Critchley David R., 1993, P22; Doi M., 1989, THEORY POLYM DYNAMIC; GIRARD PR, 1995, J CELL PHYSIOL, V163, P179, DOI 10.1002/jcp.1041630121; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Gittes F, 1998, PHYS REV E, V58, pR1241, DOI 10.1103/PhysRevE.58.R1241; GRAZI E, 1993, BIOCHEMISTRY-US, V32, P8896, DOI 10.1021/bi00085a022; GRINNELL F, 1986, EXP CELL RES, V162, P449, DOI 10.1016/0014-4827(86)90349-6; Heidemann SR, 1999, J CELL BIOL, V145, P109, DOI 10.1083/jcb.145.1.109; Hinner B, 1998, PHYS REV LETT, V81, P2614, DOI 10.1103/PhysRevLett.81.2614; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; ISAMBERT H, 1995, J BIOL CHEM, V270, P11437, DOI 10.1074/jbc.270.19.11437; Isambert H, 1996, MACROMOLECULES, V29, P1036, DOI 10.1021/ma946418x; JANMEY PA, 1994, J BIOL CHEM, V269, P32503; JANMEY PA, 1990, NATURE, V345, P89, DOI 10.1038/345089a0; Kano Y, 1996, CIRC RES, V79, P1000, DOI 10.1161/01.RES.79.5.1000; Konstantopoulos K, 1996, J CLIN INVEST, V98, P2661, DOI 10.1172/JCI119088; KUHLMAN PA, 1994, FEBS LETT, V339, P297, DOI 10.1016/0014-5793(94)80434-6; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leinweber B, 1999, BIOPHYS J, V77, P3208, DOI 10.1016/S0006-3495(99)77151-1; Leterrier JF, 1996, J BIOL CHEM, V271, P15687, DOI 10.1074/jbc.271.26.15687; LUM B, 1994, AM J PHYSIOL, V267, pL223; Ma LL, 1999, J BIOL CHEM, V274, P19145, DOI 10.1074/jbc.274.27.19145; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; Mason TG, 1998, MACROMOLECULES, V31, P3600, DOI 10.1021/ma970564w; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Miyata H, 1996, BBA-GEN SUBJECTS, V1290, P83, DOI 10.1016/0304-4165(96)00003-7; Morse DC, 1998, PHYS REV E, V58, pR1237, DOI 10.1103/PhysRevE.58.R1237; Palmer A, 1998, RHEOL ACTA, V37, P97, DOI 10.1007/s003970050095; Palmer A, 1999, BIOPHYS J, V76, P1063, DOI 10.1016/S0006-3495(99)77271-1; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Rivero F, 1996, J CELL SCI, V109, P2679; SATO M, 1987, NATURE, V325, P828, DOI 10.1038/325828a0; Schnurr B, 1997, MACROMOLECULES, V30, P7781, DOI 10.1021/ma970555n; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tang JX, 1999, BIOPHYS J, V76, P2208, DOI 10.1016/S0006-3495(99)77376-5; Thoumine O, 1997, J CELL SCI, V110, P2109; THOUMINE O, 1995, EXP CELL RES, V219, P427, DOI 10.1006/excr.1995.1249; WACHSSTOCK DH, 1994, BIOPHYS J, V66, P801, DOI 10.1016/S0006-3495(94)80856-2; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Xu JY, 1998, BIOPHYS J, V74, P2731, DOI 10.1016/S0006-3495(98)77979-2; Xu JY, 1998, MACROMOLECULES, V31, P6486, DOI 10.1021/ma9717754; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yamada S, 2000, BIOPHYS J, V78, P1736, DOI 10.1016/S0006-3495(00)76725-7	58	187	187	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35886	35892		10.1074/jbc.M002377200	http://dx.doi.org/10.1074/jbc.M002377200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10954703	hybrid			2022-12-27	WOS:000165382000036
J	Kumaraswamy, E; Malykh, A; Korotkov, KV; Kozyavkin, S; Hu, Y; Kwon, SY; Moustafa, ME; Carlson, BA; Berry, MJ; Lee, BJ; Hatfield, DL; Diamond, AM; Gladyshev, VN				Kumaraswamy, E; Malykh, A; Korotkov, KV; Kozyavkin, S; Hu, Y; Kwon, SY; Moustafa, ME; Carlson, BA; Berry, MJ; Lee, BJ; Hatfield, DL; Diamond, AM; Gladyshev, VN			Structure-expression relationships of the 15-kDa selenoprotein gene - Possible role of the protein in cancer etiology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC-ACID HYDROXYLASE; SELENOCYSTEINE-CONTAINING PROTEINS; CLOSTRIDIUM-BARKERI; GLUTATHIONE-PEROXIDASE; MAMMALIAN-CELLS; MESSENGER-RNA; SELENIUM; SEQUENCE; MOUSE; DEIODINASE	Selenium has been implicated in cancer prevention, but the mechanism and possible involvement of seleno-proteins in this process are not understood. To elucidate whether the 15-kDa selenoprotein may play a role in cancer etiology, the complete sequence of the human 15-kDa protein gene was determined, and various characteristics associated with expression of the protein were examined in normal and malignant cells and tissues. The 51-kilobase pair gene for the 15-kDa selenoprotein consisted of five exons and four introns and was localized on chromosome 1p31, a genetic locus commonly mutated or deleted in human cancers. Two stem-loop structures resembling selenocysteine insertion sequence elements were identified in the 3'-untranslated region of the gene, and only one of these was functional. Two alleles in the human 15-kDa protein gene were identified that differed by two single nucleotide polymorphic sites that occurred within the selenocysteine insertion sequence-like structures. These S'-untranslated region polymorphisms resulted in changes in selenocysteine incorporation into protein and responded differently to selenium supplementation. Human and mouse 15-kDa selenoprotein genes manifested the highest level of expression in prostate, liver, kidney, testis, and brain, and the level of the selenoprotein was reduced substantially in a malignant prostate cell line and in hepatocarcinoma. The expression pattern of the 15-kDa protein in normal and malignant tissues, the occurrence of polymorphisms associated with protein expression, the role of selenium in differential regulation of polymorphisms, and the chromosomal location of the gene may be relevant to a role of this protein in cancer.	Univ Nebraska, Dept Biochem, Beadle Ctr, Lincoln, NE 68588 USA; NCI, Sect Mol Biol Selenium, Basic Res Lab, NIH, Bethesda, MD 20892 USA; Fidel Syst Inc, Gaithersburg, MD 20879 USA; Univ Illinois, Chicago, IL 60612 USA; Seoul Natl Univ, IMBG, Genet Mol Lab, Seoul 151742, South Korea; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA	University of Nebraska System; University of Nebraska Lincoln; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Seoul National University (SNU); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, Beadle Ctr, Lincoln, NE 68588 USA.		Gladyshev, Vadim N/A-9894-2013; Moustafa, Mohamed E/E-9002-2018; Moustafa, Mohamed/AAM-2211-2021; Lee, Bong-Jin/AAQ-1609-2020; Kwon, So Yeon/M-5625-2014; Gladyshev, Vadim N/J-6187-2013	Lee, Bong-Jin/0000-0001-7896-2961; Kwon, So Yeon/0000-0002-8490-9101; Kozyavkin, Sergei/0000-0001-5605-5113; Gladyshev, Vadim/0000-0002-0372-7016; Moustafa, Mohamed/0000-0003-1308-6221; Korotkov, Konstantin/0000-0002-2182-6843	NATIONAL CANCER INSTITUTE [Z01BC005317, ZIABC005317] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; Burk RF, 1999, BIOESSAYS, V21, P231, DOI 10.1002/(SICI)1521-1878(199903)21:3<231::AID-BIES7>3.3.CO;2-4; Cheung TH, 1999, CANCER-AM CANCER SOC, V86, P1294, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1294::AID-CNCR26>3.3.CO;2-F; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; DILWORTH GL, 1982, ARCH BIOCHEM BIOPHYS, V219, P30, DOI 10.1016/0003-9861(82)90130-8; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P232, DOI 10.1073/pnas.91.1.232; Gladyshev VN, 1996, BIOCHEMISTRY-US, V35, P212, DOI 10.1021/bi951793i; Gladyshev VN, 1998, BIOCHEM BIOPH RES CO, V251, P488, DOI 10.1006/bbrc.1998.9495; Gladyshev VN, 1999, J BIOMED SCI, V6, P151, DOI 10.1007/BF02255899; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hatfield D, 1999, COMPREHENSIVE NATURA, P353; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Jorcyk CL, 1998, PROSTATE, V34, P10; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; Knekt P, 1998, AM J EPIDEMIOL, V148, P975, DOI 10.1093/oxfordjournals.aje.a009574; Kollmus H, 1996, NUCLEIC ACIDS RES, V24, P1195, DOI 10.1093/nar/24.7.1195; Kryukov GV, 1999, J BIOL CHEM, V274, P33888, DOI 10.1074/jbc.274.48.33888; Leist P, 1996, FREE RADICAL BIO MED, V21, P297, DOI 10.1016/0891-5849(96)00045-7; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Madden TL, 1996, METHOD ENZYMOL, V266, P131; Martin GW, 1996, RNA, V2, P171; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; NAGAI H, 1995, CANCER RES, V55, P1752; Sambrook J., 2002, MOL CLONING LAB MANU; SantoniRugiu E, 1996, AM J PATHOL, V149, P407; SLESAREV AI, 2000, IN PRESS METHODS ENZ; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Thompson KM, 1998, J NUTR, V128, P1289, DOI 10.1093/jn/128.8.1289; Yoshizawa K, 1998, JNCI-J NATL CANCER I, V90, P1219, DOI 10.1093/jnci/90.16.1219	33	120	131	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35540	35547		10.1074/jbc.M004014200	http://dx.doi.org/10.1074/jbc.M004014200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10945981	hybrid, Green Submitted			2022-12-27	WOS:000165422800093
J	Crowder, RJ; Freeman, RS				Crowder, RJ; Freeman, RS			Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PC12 PHEOCHROMOCYTOMA CELLS; NGF-DEPENDENT SURVIVAL; TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-B; SYMPATHETIC NEURONS; BETA-CATENIN; TRANSCRIPTION FACTOR; NEUROTROPHIC FACTOR; INDUCED APOPTOSIS	Numerous studies reveal that phosphatidylinositol (PI) 3-kinase and Akt protein kinase are important mediators of cell survival, However, the survival-promoting mechanisms downstream of these enzymes remain uncharacterized, Glycogen synthase kinase-3 beta (GSR-3 beta), which is inhibited upon phosphorylation by Akt, was recently shown to function during cell death induced by PI 3-kinase inhibitors. In this study, we tested whether GSK-3 beta is critical for the death of sympathetic neurons caused by the withdrawal of their physiological survival factor, the nerve growth factor (NGF). Stimulation with NGF resulted in PI 3-kinase-dependent phosphorylation of GSK-3 beta and inhibition of its protein kinase activity, indicating that GSK-3 beta is targeted by PI 3-kinase/Akt in these neurons. Expression of the GSK-3 beta inhibitor Frat1, but not a mutant Frat1 protein that does not bind GSK-3 beta, rescued neurons from death caused by inhibiting PI 3-kinase. Similarly, expression of Frat1 or kinase-deficient GSK-3 beta reduced death caused by inhibiting Akt, In NGF-maintained neurons, overexpression of GSK-3 gamma caused a small but significant decrease in survival. However, expression of neither Frat1, kinase-deficient GSH-3 beta, nor GSK-3-binding protein inhibited NGF withdrawal-induced death. Thus, although GSK-3 beta function is required for death caused by inactivation of PT 3-kinase and Akt, neuronal death caused by NGF withdrawal can proceed through GSK-3 beta -independent pathways.	Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	University of Rochester	Freeman, RS (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, 601 Elmwood Ave, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034400, R56NS034400] Funding Source: NIH RePORTER; NIA NIH HHS [AG00107] Funding Source: Medline; NINDS NIH HHS [R01 NS034400, NS34400] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; Bartlett SE, 1997, BRAIN RES, V761, P257, DOI 10.1016/S0006-8993(97)00329-6; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARTER AN, 1992, J BIOL CHEM, V267, P14563; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Crowder RJ, 1998, J NEUROSCI, V18, P2933; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deshmukh M, 1997, MOL PHARMACOL, V51, P897, DOI 10.1124/mol.51.6.897; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Easton RM, 1997, J NEUROSCI, V17, P9656; Eilers A, 1998, J NEUROSCI, V18, P1713; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hetman M, 2000, J NEUROSCI, V20, P2567; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Mazzoni IE, 1999, J NEUROSCI, V19, P9716; Miller TM, 1997, J BIOL CHEM, V272, P9847; Neame SJ, 1998, J CELL BIOL, V142, P1583, DOI 10.1083/jcb.142.6.1583; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; Virdee K, 1997, J NEUROCHEM, V69, P550; Virdee K, 1999, BRAIN RES, V837, P127, DOI 10.1016/S0006-8993(99)01643-1; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; WOOD JN, 1995, NEUROSCI LETT, V192, P41, DOI 10.1016/0304-3940(95)11603-T; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	57	145	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34266	34271		10.1074/jbc.M006160200	http://dx.doi.org/10.1074/jbc.M006160200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10954722	hybrid			2022-12-27	WOS:000165095300038
J	Blostein, MD; Rigby, AC; Jacobs, M; Furie, B; Furie, BC				Blostein, MD; Rigby, AC; Jacobs, M; Furie, B; Furie, BC			The Gla domain of human prothrombin has a binding site for factor Va	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; CONFORMATION-SPECIFIC ANTIBODIES; ACTIVATED PROTEIN-C; BLOOD-COAGULATION; MEMBRANE-BINDING; FACTOR VIIA; FACTOR-X; PHOSPHOLIPID-VESICLES; BOVINE PROTHROMBIN; KRINGLE DOMAIN	The role of the Gla domain of human prothrombin in interaction with the prothrombinase complex was studied using a peptide with the sequence of the first 46 residues of human prothrombin, PT-(1-46). Intrinsic fluorescence measurements showed that PT-(1-46) undergoes a conformational alteration upon binding calcium; this conclusion is supported by one-dimensional H-1 NMR spectroscopy, which identifies a change in the chemical environment of tryptophan 41. PT-(1-46) binds phospholipid membranes in a calcium dependent manner with a K-d Of 0.5 muM and inhibits thrombin generation by the prothrombinase complex with a K-i of 0.8 muM. In the absence of phospholipid membranes, PT-(1-46) inhibits thrombin generation by factor Xa in the presence but not absence of factor Va, suggesting that PT-(1-46) inhibits prothrombin-factor Va binding. The addition of factor Va to PT-(1-46) labeled with the fluorophore sulfosuccinimidyl-7-amino-4-methylcoumarin-3-acetic acid (PT-(1-46)AMCA) caused a concentration-dependent quenching of AMCA fluorescence, providing direct evidence of a PT-(1-46)-factor Va interaction. The K-d for this interaction was 1.3 muM. These results indicate that the N-terminal Gla domain of human prothrombin is a functional unit that has a binding site for factor Va. The prothrombin Gla domain is important for interaction of the substrate with the prothrombinase complex.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Ctr Hemostasis & Thrombosis Res, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Furie, BC (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Ctr Hemostasis & Thrombosis Res, Res E Rm 319,POB 15732, Boston, MA 02215 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL018834, P01HL042443, R01HL018834] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18834, HL42443] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BOROWSKI M, 1985, J BIOL CHEM, V260, P9258; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; COLPITTS TL, 1994, BIOCHEMISTRY-US, V33, P3501, DOI 10.1021/bi00178a006; Croce K, 1998, BIOCHEMISTRY-US, V37, P16472, DOI 10.1021/bi981341g; Deguchi H, 1997, BIOCHEM J, V321, P729, DOI 10.1042/bj3210729; Dixon M., 1964, ENZYMES, V2nd; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; FURIE B, 1979, J BIOL CHEM, V254, P9766; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1992, NEW ENGL J MED, V326, P800; GILBERT GE, 1990, J BIOL CHEM, V265, P815; Hof M, 1996, PROTEINS, V24, P485, DOI 10.1002/(SICI)1097-0134(199604)24:4<485::AID-PROT7>3.0.CO;2-D; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; JACOBS M, 1994, J BIOL CHEM, V269, P25494; KOTKOW KJ, 1993, J BIOL CHEM, V268, P15633; KOTKOW KJ, 1995, J BIOL CHEM, V270, P4551, DOI 10.1074/jbc.270.9.4551; Larson PJ, 1996, J BIOL CHEM, V271, P3869; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MARTIN DMA, 1993, BIOCHEMISTRY-US, V32, P13949, DOI 10.1021/bi00213a026; NELSESTUEN GL, 1975, BIOCHEM BIOPH RES CO, V65, P233, DOI 10.1016/S0006-291X(75)80084-2; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; RATCLIFFE JV, 1993, J BIOL CHEM, V268, P24339; ROSING J, 1980, J BIOL CHEM, V255, P274; Ruf W, 1999, BIOCHEMISTRY-US, V38, P1957, DOI 10.1021/bi982254r; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; SESHADRI TP, 1991, J MOL BIOL, V220, P481, DOI 10.1016/0022-2836(91)90025-2; Smirnov MD, 1998, J BIOL CHEM, V273, P9031, DOI 10.1074/jbc.273.15.9031; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; Sunnerhagen M, 1996, HAEMOSTASIS, V26, P45; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P4939, DOI 10.1021/bi00413a052; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yegneswaran S, 1999, J BIOL CHEM, V274, P5462, DOI 10.1074/jbc.274.9.5462	40	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38120	38126		10.1074/jbc.M007174200	http://dx.doi.org/10.1074/jbc.M007174200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973980	hybrid			2022-12-27	WOS:000165618700108
J	Bittel, DC; Smirnova, IV; Andrews, GK				Bittel, DC; Smirnova, IV; Andrews, GK			Functional heterogeneity in the zinc fingers of metalloregulatory protein metal response element-binding transcription factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOTHIONEIN-II GENES; FACTOR MTF-1; DNA-BINDING; OXIDATIVE STRESS; TRANSGENIC MICE; IN-VIVO; MOUSE; EXPRESSION; PROMOTER; DOMAINS	Metal response element-binding transcription factor-1 (MTF-I) is a unique, zinc-inducible transcription factor that binds to metal response elements in the metallothionein promoter and activates transcription in response to metals and oxidative stress. MTF-1 contains six zinc fingers of the Cys(2)-His(2) type. It was previously shown that MTF-I is reversibly activated to bind DNA in response to changes in zinc status, unlike other zinc finger transcription factors, which do not appear to be reversibly activated by zinc in the cellular environment. Here we show that zinc fingers 2-4 constitute the core DNA-binding domain, whereas fingers 5 and 6 appear to be unnecessary for DNA binding in vitro. Deletion of finger I resulted in a protein that bound DNA constitutively in vitro. Furthermore, transfer of MTF-1 finger 1 to a position immediately preceding the three zinc fingers of Spl resulted in a chimeric protein that required exogenous zinc to activate DNA binding in vitro, unlike native Spl, which binds DNA constitutively. Transient transfection experiments demonstrated that intact MTF-I activated a reporter 2.5-4-fold above basal levels after metal treatment in mouse MTF-1 knockout cells, Drosophila SL2 cells, and yeast. However, the metal response was lost in all three systems when finger 1 was deleted, but was unaffected by deletion of fingers 5 and 6, These data suggest that finger 1 of MTF-1 constitutes a unique metal-sensing domain that, in cooperation with the transactivation domains, produces a zinc-sensing metalloregulatory transcription factor.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Andrews, GK (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	gandrews@kumc.edu			NIEHS NIH HHS [ES05704] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andrews GK, 1999, J NUTR, V129, P1643, DOI 10.1093/jn/129.9.1643; ANDREWS GK, 1990, PROG FOOD NUTR SCI, V14, P193; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; Chen XH, 1999, BIOCHEMISTRY-US, V38, P12915, DOI 10.1021/bi9913000; Chen XH, 1998, BIOCHEMISTRY-US, V37, P11152, DOI 10.1021/bi980843r; Chu WA, 1999, J BIOL CHEM, V274, P5279, DOI 10.1074/jbc.274.9.5279; Dalton T, 1996, J NUTR, V126, P825, DOI 10.1093/jn/126.4.825; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; Dalton TP, 1997, MOL CELL BIOL, V17, P2781, DOI 10.1128/MCB.17.5.2781; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; DONAHUE TF, 1988, MOL CELL BIOL, V8, P2955, DOI 10.1128/MCB.8.7.2955; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; Koizumi S, 1999, EUR J BIOCHEM, V259, P635, DOI 10.1046/j.1432-1327.1999.00069.x; KRIZEK BA, 1993, PROTEIN SCI, V2, P1313, DOI 10.1002/pro.5560020814; Labbe S, 1999, METHOD ENZYMOL, V306, P145; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laity JH, 2000, J MOL BIOL, V295, P719, DOI 10.1006/jmbi.1999.3406; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; LUNDBLAD V, 1997, CURRENT PROTOCOLS MO; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; Maur AAD, 1999, BIOL CHEM, V380, P175, DOI 10.1515/BC.1999.026; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; Muller HP, 1995, SOMAT CELL MOLEC GEN, V21, P289, DOI 10.1007/BF02257464; OTSUKA F, 1994, J BIOL CHEM, V269, P23700; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; Rebar EJ, 1996, METHOD ENZYMOL, V267, P129; Sapin V, 1997, DEV DYNAM, V208, P199, DOI 10.1002/(SICI)1097-0177(199702)208:2<199::AID-AJA7>3.0.CO;2-D; Smirnova IV, 2000, J BIOL CHEM, V275, P9377, DOI 10.1074/jbc.275.13.9377; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; Tsai RYL, 1998, MOL CELL BIOL, V18, P6447, DOI 10.1128/MCB.18.11.6447; WELSH N, 1994, MOL CELL ENDOCRINOL, V103, P109, DOI 10.1016/0303-7207(94)90076-0; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	39	62	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37194	37201		10.1074/jbc.M003863200	http://dx.doi.org/10.1074/jbc.M003863200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10958790	hybrid			2022-12-27	WOS:000165577700101
J	Fujimura, T; Esteban, R				Fujimura, T; Esteban, R			Recognition of RNA encapsidation signal by the yeast L-A doublelstranded RNA virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; POL FUSION PROTEIN; RIBOSOMAL FRAMESHIFTING EFFICIENCY; SACCHAROMYCES-CEREVISIAE; BINDING; REPLICATION; PARTICLES; SITES; COMPLEX; CAPSIDS	The encapsidation signal of the yeast L-A virus contains a 24-nucleotide stem-loop structure with a B-nucleotide loop and an A bulged at the 5' side of the stem. The Pol part of the Gag-Pol fusion protein is responsible for encapsidation of viral RNA. Opened empty viral particles containing Gag-Pol specifically bind to this encapsidation signal in vitro. We found that binding to empty particles protected the bulged A and the flanking-two nucleotides from cleavage by Fe(II)-EDTA-generated hydroxyl radicals. The five nucleotides of the loop sequence ((4190)GAUCC(4194)) were not protected. However, T1 RNase protection and in vitro mutagenesis experiments indicated that G(4190) is essential for binding. Although the sequence of the other four nucleotides of the loop is not essential, data from RNase protection and chemical modification experiments suggested that C-4194 was also directly involved in binding to empty particles rather than indirectly through its potential base pairing with G(4190). These results suggest that the Pol domain of Gag-Pol contacts the encapsidation signal at two sites: one, the bulged A, and the other, G and C bases at the opening of the loop. These two sites are conserved in the encapsidation signal of M1, a satellite RNA of the L-A virus.	Univ Salamanca, CSIC, Inst Microbiol Bioquim, Dept Genet & Microbiol, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Fujimura, T (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim, Dept Genet & Microbiol, Avda Campo Charro S-N, Salamanca 37007, Spain.		Esteban, Rosa/K-4356-2014; Fujimura, Tsutomu/K-5807-2014	Esteban, Rosa/0000-0001-6804-7209; Fujimura, Tsutomu/0000-0002-9457-6769				ARNI R, 1988, J BIOL CHEM, V263, P15358; BALASUNDARAM D, 1994, P NATL ACAD SCI USA, V91, P172, DOI 10.1073/pnas.91.1.172; BASHKIN JS, 1993, FOOTPRINTING NUCLEIC, P75; BORER PN, 1995, BIOCHEMISTRY-US, V34, P6488, DOI 10.1021/bi00019a030; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CHENG RH, 1994, J MOL BIOL, V244, P255, DOI 10.1006/jmbi.1994.1726; DINMAN JD, 1992, J VIROL, V66, P3669, DOI 10.1128/JVI.66.6.3669-3676.1992; DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174; DINMAN JD, 1994, GENETICS, V136, P75; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; ESTEBAN R, 1988, J VIROL, V62, P1278, DOI 10.1128/JVI.62.4.1278-1285.1988; ESTEBAN R, 1988, P NATL ACAD SCI USA, V85, P4411, DOI 10.1073/pnas.85.12.4411; FUJIMURA T, 1992, J BIOL CHEM, V267, P2708; FUJIMURA T, 1992, NATURE, V359, P746, DOI 10.1038/359746a0; FUJIMURA T, 1988, CELL, V55, P663, DOI 10.1016/0092-8674(88)90225-5; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; FUJIMURA T, 1988, J BIOL CHEM, V263, P454; FUJIMURA T, 1989, J BIOL CHEM, V264, P10872; ICHO T, 1989, J BIOL CHEM, V264, P6716; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; Moine H, 1997, RNA STRUCTURE FUNCTI, P77; POWERS T, 1995, RNA, V1, P194; Ribas JC, 1998, J BIOL CHEM, V273, P9306, DOI 10.1074/jbc.273.15.9306; RIBAS JC, 1994, J BIOL CHEM, V269, P28420; RODRIGUEZCOUSINO N, 1992, NUCLEIC ACIDS RES, V20, P2761, DOI 10.1093/nar/20.11.2761; SHEN YQ, 1993, VIROLOGY, V195, P481, DOI 10.1006/viro.1993.1399; Steitz TA, 1999, RNA WORLD, P427; TZENG TH, 1992, J VIROL, V66, P999, DOI 10.1128/JVI.66.2.999-1006.1992; Valegard K, 1997, J MOL BIOL, V270, P724, DOI 10.1006/jmbi.1997.1144; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996; Yao WS, 1997, J VIROL, V71, P2157, DOI 10.1128/JVI.71.3.2157-2162.1997; YAO WS, 1995, J VIROL, V69, P1917, DOI 10.1128/JVI.69.3.1917-1919.1995	36	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37118	37126		10.1074/jbc.M005245200	http://dx.doi.org/10.1074/jbc.M005245200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10954712	hybrid			2022-12-27	WOS:000165577700092
J	Warshaw, DM; Guilford, WH; Freyzon, Y; Krementsova, E; Palmiter, KA; Tyska, MJ; Baker, JE; Trybus, KM				Warshaw, DM; Guilford, WH; Freyzon, Y; Krementsova, E; Palmiter, KA; Tyska, MJ; Baker, JE; Trybus, KM			The light chain binding domain of expressed smooth muscle heavy meromyosin acts as a mechanical lever	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN MOTOR DOMAIN; CONFORMATIONAL STATES; LASER TRAP; CONTRACTION; KINETICS; FORCE; COMPLEX; FILAMENTS; MOVEMENT; SYSTEMS	Structural data led to the proposal that the molecular motor myosin moves actin by a swinging of the light chain binding domain, or "neck" To test the hypothesis that the neck functions as a mechanical lever, smooth muscle heavy meromyosin (HMM) mutants were expressed with shorter or longer necks by either deleting or adding light chain binding sites. The mutant HMMs were characterized kinetically and mechanically, with emphasis on measurements of unitary displacements and forces in the laser trap assay, Two shorter necked constructs had smaller unitary step sizes and moved actin more slowly than WT HMM in the motility assay. A longer necked construct that contained an additional essential light chain binding site exhibited a 1.4-fold increase in the unitary step size compared with its control. Kinetic changes were also observed with several of the constructs, The mutant lacking a neck produced force at a somewhat reduced level, while the force exerted by the giraffe construct was higher than control. The single molecule displacement and force data support the hypothesis that the neck functions as a rigid lever, with the fulcrum for movement and force located at a point within the motor domain.	Univ Vermont, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA	University of Vermont	Trybus, KM (corresponding author), Univ Vermont, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA.			Guilford, William/0000-0002-6543-5713	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anson M, 1996, EMBO J, V15, P6069, DOI 10.1002/j.1460-2075.1996.tb00995.x; Block SM, 1996, CELL, V87, P151, DOI 10.1016/S0092-8674(00)81332-X; Chaudoir BM, 1999, J CELL SCI, V112, P1611; CRAIG R, 1980, J MOL BIOL, V140, P35, DOI 10.1016/0022-2836(80)90355-1; Diffee GM, 1996, BIOPHYS J, V71, P341, DOI 10.1016/S0006-3495(96)79231-7; Dobbie I, 1998, NATURE, V396, P383, DOI 10.1038/24647; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Dupuis DE, 1997, J MUSCLE RES CELL M, V18, P17, DOI 10.1023/A:1018672631256; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FISHER AJ, 1995, BIOPHYS J, V68, pS19; Guilford WH, 1997, BIOPHYS J, V72, P1006, DOI 10.1016/S0006-3495(97)78753-8; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; Kitamura K, 1999, NATURE, V397, P129, DOI 10.1038/16403; Lauzon AM, 1998, J MUSCLE RES CELL M, V19, P825, DOI 10.1023/A:1005489501357; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; PATLAK JB, 1993, BIOPHYS J, V65, P29, DOI 10.1016/S0006-3495(93)81041-5; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; Tanaka H, 2000, BIOPHYS J, V78, p3A; TRYBUS KM, 1989, J CELL BIOL, V109, P2879, DOI 10.1083/jcb.109.6.2879; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; Tyska MJ, 1999, P NATL ACAD SCI USA, V96, P4402, DOI 10.1073/pnas.96.8.4402; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; VANBUREN P, 1994, P NATL ACAD SCI USA, V91, P12403, DOI 10.1073/pnas.91.26.12403; WALLER GS, 1995, J BIOL CHEM, V270, P15348, DOI 10.1074/jbc.270.25.15348; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; WORK SS, 1992, ANAL BIOCHEM, V202, P275, DOI 10.1016/0003-2697(92)90106-H	33	78	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37167	37172		10.1074/jbc.M006438200	http://dx.doi.org/10.1074/jbc.M006438200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10945998	hybrid			2022-12-27	WOS:000165577700097
J	Xu, Q; Wu, ZG				Xu, Q; Wu, ZG			The insulin-like growth factor-phosphatidylinositol 3-kinase-Akt signaling pathway regulates myogenin expression in normal myogenic cells but not in Rhabdomyosarcoma-derived RD cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; PROTEIN-KINASE-B; GENE-EXPRESSION; IGF-I; TRANSCRIPTIONAL ACTIVATION; FACTOR MEF-2; MYOD; SITE; EMBRYOGENESIS; DEFICIENCY	Insulin-like growth factors (IGFs) can stimulate skeletal muscle differentiation. One of the molecular mechanisms underlying IGF-stimulated myogenesis is transcriptional induction of myogenin. The current work is aimed to elucidate the signaling pathways mediating the IGF effect on myogenin promoter in mouse C2C12 myogenic cells. We show that phosphatidylinositol 3-kinase (PI3K)/Akt and p70(S6K) are crucial signaling molecules mediating the stimulatory effect of IGFs on myogenin expression. We have identified three cis-elements, namely the E box, MEF2, and MEF3 sites, within the 133-base pair mouse proximal myogenin promoter that are under the control of the IGF/PI3K/Akt pathway. Simultaneous mutation of all three elements completely abolishes activation of the myogenin promoter by PI3K/ Akt. We demonstrate that PI3K/Akt can increase both the MyoD and the MEF2-dependent reporter activity by enhancing the transcriptional activity of MyoD and MEF2. Interestingly, IGF1 does not enhance myogenin expression in Rhabdomyosarcoma-derived RD cells. Consistently, the constitutively active PI3K/Akt fail to activate the myogenic reporters, suggesting the IGF/ PI3K/Akt pathway is defective in RD cells and the defect(s) is downstream to PI3K/Akt. This is the first time that a defect in the IGF/PI3K/Akt pathway has been revealed in RD cells which provides another clue to future therapeutic treatment of Rhabdomyosarcoma.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Wu, ZG (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.		Wu, Zhenguo/B-8144-2013	Wu, Zhenguo/0000-0003-3049-8324				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Anderson J, 1999, GENE CHROMOSOME CANC, V26, P275, DOI 10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3; Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Black BL, 1998, MOL CELL BIOL, V18, P69, DOI 10.1128/MCB.18.1.69; BOUCHE M, 1993, EXP CELL RES, V208, P209, DOI 10.1006/excr.1993.1239; BUCHBERGER A, 1994, J BIOL CHEM, V269, P17289; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Heanue TA, 1999, GENE DEV, V13, P3231, DOI 10.1101/gad.13.24.3231; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Johanson M, 1999, BIOCHEM BIOPH RES CO, V265, P222, DOI 10.1006/bbrc.1999.1390; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; MALIK S, 1995, EUR J BIOCHEM, V230, P88, DOI 10.1111/j.1432-1033.1995.tb20537.x; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Ohto H, 1999, MOL CELL BIOL, V19, P6815; Ornatsky OI, 1996, J BIOL CHEM, V271, P24927, DOI 10.1074/jbc.271.40.24927; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; Puri PL, 2000, GENE DEV, V14, P574; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Relaix F, 1999, GENE DEV, V13, P3171, DOI 10.1101/gad.13.24.3171; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; ROSENTHAL SM, 1995, P NATL ACAD SCI USA, V92, P10307, DOI 10.1073/pnas.92.22.10307; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Spitz F, 1998, P NATL ACAD SCI USA, V95, P14220, DOI 10.1073/pnas.95.24.14220; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	48	139	146	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36750	36757		10.1074/jbc.M005030200	http://dx.doi.org/10.1074/jbc.M005030200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973962	hybrid			2022-12-27	WOS:000165577700044
J	Cabrele, C; Langer, M; Bader, R; Wieland, HA; Doods, HN; Zerbe, O; Beck-Sickinger, AG				Cabrele, C; Langer, M; Bader, R; Wieland, HA; Doods, HN; Zerbe, O; Beck-Sickinger, AG			The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEPTIN RECEPTOR; ANTISENSE OLIGODEOXYNUCLEOTIDES; PANCREATIC-POLYPEPTIDE; CIRCULAR-DICHROISM; FEEDING-BEHAVIOR; Y1 RECEPTOR; PEPTIDE-YY; OBESITY; NPY; MICE	The first Y-5 receptor-selective analog of neuropeptide Y (NPY), [Ala(31),Aib(32)]NPY, has been developed and biologically characterized. Using competition binding assays on cell lines that express different Y receptors, we determined the affinity of this analog to be 6 nM at the human Y-5 receptor, >500 nM at the Y-1 and Y-2 receptors, and >1000 nM at the Y-4 receptor. Activity studies performed in vitro using a cAMP enzyme immunoassay, and in vivo using food intake studies in rats, showed that the peptide acted as an agonist. Further peptides obtained by the combination of the Ala(31)-Aib(32) motif with chimeric peptides containing segments of NPY and pancreatic polypeptide displayed the same selectivity and even higher affinity (up to 0.2 nM) for the Y-5 receptor. In vivo administration of the new Y-5 receptor-selective agonists significantly stimulated feeding in rats. The NMR solution structures of NPY and [Ala(31),Aib(32)]NPY showed a different conformation in the C-terminal region, where the or-helix of NPY was substituted by a more flexible, 3(10)-helical turn structure.	Swiss Fed Inst Technol, Dept Appl Biosci, CH-8057 Zurich, Switzerland; Boehringer Ingelheim Pharma KG, Div Preclin Res, D-88397 Biberach, Germany; Univ Leipzig, Inst Biochem, D-04103 Leipzig, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Boehringer Ingelheim; Leipzig University	Beck-Sickinger, AG (corresponding author), Swiss Fed Inst Technol, Dept Appl Biosci, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Cabrele, Chiara/B-8790-2015	Cabrele, Chiara/0000-0002-7550-6896				BALASUBRAMANIAM A, 1994, J MED CHEM, V37, P811, DOI 10.1021/jm00032a015; Beck Werner, 1994, Letters in Peptide Science, V1, P31, DOI 10.1007/BF00132760; Bischoff A, 1999, TRENDS PHARMACOL SCI, V20, P104, DOI 10.1016/S0165-6147(99)01319-X; CABRELE C, 2000, IN PRESS PEPTIDES; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; COWLEY DJ, 1992, EUR J BIOCHEM, V205, P1099, DOI 10.1111/j.1432-1033.1992.tb16878.x; Criscione L, 1998, J CLIN INVEST, V102, P2136, DOI 10.1172/JCI4188; Dallongeville J, 1998, J MED CHEM, V41, P5337, DOI 10.1021/jm9802867; ECKERD CP, 2000, IN PRESS MOLECULES; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; GERALD C, Patent No. 16542; GERALD C, Patent No. 15646; GRUNDEMAR L, 1997, NEUROPEPTIDE Y DRUG, P1; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hipskind PA, 1997, J MED CHEM, V40, P3712, DOI 10.1021/jm970512x; Ingenhoven N, 1997, J RECEPT SIGNAL TR R, V17, P407, DOI 10.3109/10799899709036617; Inui A, 1999, TRENDS PHARMACOL SCI, V20, P43, DOI 10.1016/S0165-6147(99)01303-6; Kanatani A, 1996, ENDOCRINOLOGY, V137, P3177, DOI 10.1210/en.137.8.3177; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kordik CP, 1999, J MED CHEM, V42, P181, DOI 10.1021/jm980521l; Kushi A, 1998, P NATL ACAD SCI USA, V95, P15659, DOI 10.1073/pnas.95.26.15659; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LEVINE AS, 1984, PEPTIDES, V5, P1025, DOI 10.1016/0196-9781(84)90165-7; LopezValpuesta FJ, 1996, P ROY SOC B-BIOL SCI, V263, P881, DOI 10.1098/rspb.1996.0130; Marsh DJ, 1998, NAT MED, V4, P718, DOI 10.1038/nm0698-718; Michel MC, 1998, PHARMACOL REV, V50, P143; Mohle K, 1997, J COMPUT CHEM, V18, P1415, DOI 10.1002/(SICI)1096-987X(199708)18:11<1415::AID-JCC8>3.0.CO;2-O; Monks SA, 1996, J BIOMOL NMR, V8, P379; PAXINOS G, 1985, J NEUROSCI METH, V13, P139, DOI 10.1016/0165-0270(85)90026-3; Pedrazzini T, 1998, NAT MED, V4, P722, DOI 10.1038/nm0698-722; Rist B, 1998, J MED CHEM, V41, P117, DOI 10.1021/jm970533r; Schaffhauser AO, 1997, DIABETES, V46, P1792, DOI 10.2337/diabetes.46.11.1792; Small CJ, 1997, P NATL ACAD SCI USA, V94, P11686, DOI 10.1073/pnas.94.21.11686; STANLEY BG, 1985, P NATL ACAD SCI USA, V82, P3940, DOI 10.1073/pnas.82.11.3940; Strader CD, 1998, DRUG DISCOV TODAY, V3, P250, DOI 10.1016/S1359-6446(98)01189-1; SZYPERSKI T, 1992, J MAGN RESON, V99, P552, DOI 10.1016/0022-2364(92)90209-P; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; Thiele TE, 1998, NATURE, V396, P366, DOI 10.1038/24614; Toniolo C, 1996, J AM CHEM SOC, V118, P2744, DOI 10.1021/ja9537383; WAHLESTEDT C, 1993, SCIENCE, V259, P528, DOI 10.1126/science.8380941; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; WIELAND HA, 1995, PEPTIDES, V16, P1389, DOI 10.1016/0196-9781(95)02028-4; Wieland HA, 1998, BRIT J PHARMACOL, V125, P549, DOI 10.1038/sj.bjp.0702084; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	50	156	162	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36043	36048		10.1074/jbc.M000626200	http://dx.doi.org/10.1074/jbc.M000626200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10944518	hybrid			2022-12-27	WOS:000165382000057
J	Carreno, S; Gouze, ME; Schaak, S; Emorine, LJ; Maridonneau-Parini, I				Carreno, S; Gouze, ME; Schaak, S; Emorine, LJ; Maridonneau-Parini, I			Lack of palmitoylation redirects p59(Hck) from the plasma membrane to p61(Hck)-positive lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SRC FAMILY KINASES; HUMAN NEUTROPHILS; SUBCELLULAR-LOCALIZATION; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; GENE HCK; ASSOCIATION; RECEPTOR; ACTIVATION	Hck, a protein-tyrosine kinase of phagocytes, is the unique member of the Src family expressed under two alternatively translated isoforms differing in their N-terminal site of acylation: p61(Hck) has an additional 21-amino acid sequence comprising a single myristoylation motif, whereas p59(Hck) N terminus has myristoylation and palmitoylation sites. To identify the molecular determinants involved in the targeting of each isoform, they were fused to GFP and expressed in HeLa and CHO cells. p61(Hck) was associated with lysosomal vesicles, whereas p59(Hck) was found at the plasma membrane and to a low extent associated with lysosomes. Their unique N-terminal domains were sufficient to target GFP to the corresponding intracellular compartments. Mutation of the palmitoylation site of p59(Hck) redirected this isoform to lysosomes, indicating that the palmitoylation state governs the association of p59(Hck) with the plasma membrane or with lysosomes. In addition, both isoforms and the nonpalmitoylated p59(Hck) mutant were found on the Golgi apparatus, suggesting a role of this organelle in the subcellular sorting of Hck isoforms. Regarding their subcellular localizations, we propose that bi-acylated p59(Hck) might transduce plasma membrane receptor signals, whereas p61(Hck) and the nonpalmitoylated p59(Hck) might control the biogenesis of phagolysosomes, two functions yet proposed for Hck in phagocytes.	CNRS, IPBS, Unite Mixte Rech 5089, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Maridonneau-Parini, I (corresponding author), CNRS, IPBS, Unite Mixte Rech 5089, 205 Route Narbonne, F-31077 Toulouse, France.		Maridonneau-Parini, Isabelle/F-1985-2011	Maridonneau-Parini, Isabelle/0000-0003-0189-0976; Carreno, Sebastien/0000-0002-5839-2102				AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247; Astarie-Dequeker C, 2000, INFECT IMMUN, V68, P4827, DOI 10.1128/IAI.68.8.4827-4830.2000; Astarie-Dequeker C, 1999, INFECT IMMUN, V67, P469, DOI 10.1128/IAI.67.2.469-477.1999; Bijlmakers MJJE, 1997, J CELL BIOL, V137, P1029, DOI 10.1083/jcb.137.5.1029; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chiaradonna F, 1999, EMBO J, V18, P3013, DOI 10.1093/emboj/18.11.3013; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; JASMIN BJ, 1989, P NATL ACAD SCI USA, V86, P7218, DOI 10.1073/pnas.86.18.7218; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JS, 1979, J BIOL CHEM, V254, P8015; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; Liu SH, 1998, J CELL BIOL, V140, P1023, DOI 10.1083/jcb.140.5.1023; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; Mocsai A, 1999, J IMMUNOL, V162, P1120; MOHN H, 1995, BIOCHEM J, V309, P657; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; Murray EW, 1998, J BIOL CHEM, V273, P25279, DOI 10.1074/jbc.273.39.25279; N'Diaye EN, 1998, J IMMUNOL, V161, P4983; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1999, BIOCHIM BIOPHYS ACTA, V12, P1; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; Skubitz KM, 1998, FEBS LETT, V439, P97, DOI 10.1016/S0014-5793(98)01347-7; Skubitz KM, 1998, J LEUKOCYTE BIOL, V64, P800, DOI 10.1002/jlb.64.6.800; Suen PW, 1999, J CELL SCI, V112, P4067; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Ward AC, 1998, BIOCHEM BIOPH RES CO, V251, P117, DOI 10.1006/bbrc.1998.9441; Welch H, 1997, J BIOL CHEM, V272, P102; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276; Zlatkine P, 1997, J CELL SCI, V110, P673	50	55	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36223	36229		10.1074/jbc.M003901200	http://dx.doi.org/10.1074/jbc.M003901200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967098	hybrid			2022-12-27	WOS:000165382000082
J	Kupriyanova, TA; Kandror, KV				Kupriyanova, TA; Kandror, KV			Cellugyrin is a marker for a distinct population of intracellular Glut4-containing vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; GLUT4 GLUCOSE-TRANSPORTER; 3T3-L1 ADIPOCYTES; SUBCELLULAR TRAFFICKING; GLUT4-ENRICHED VESICLES; MAJOR PROTEIN; INSULIN; TRANSLOCATION; SYNAPTOGYRIN; COMPARTMENT	Although Glut4 traffic is routinely described as translocation from an "intracellular storage pool" to the plasma membrane, it has been long realized that Glut4 travels through at least two functionally distinct intracellular membrane compartments on the way to and from the cell surface. Biochemical separation and systematic studies of the individual Glut4-containing compartments have been limited by the lack of appropriate reagents. We have prepared a monoclonal antibody against a novel component protein of Glut4 vesicles and have identified this protein as cellugyrin, a ubiquitously expressed homologue of a major synaptic vesicle protein, synaptogyrin. By means of sucrose gradient centrifugation, immunoadsorption, and confocal microscopy, we have shown that virtually all cellugyrin is colocalized with Glut4 in the same vesicles. However, unlike Glut4, cellugyrin is not re-distributed to the plasma membrane in response to insulin stimulation, and at least 40-50% of the total population of Glut4 vesicles do not contain this protein. We suggest that cellugyrin represents a specific marker of a functionally distinct population of Glut4 vesicles that permanently maintains its intracellular localization and is not recruited to the plasma membrane by insulin.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Kandror, KV (corresponding author), Boston Univ, Sch Med, Dept Biochem, K121 715 Albany St, Boston, MA 02118 USA.			Kandror, Konstantin/0000-0002-8601-9313	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200, R01DK052057, R01DK056736, R56DK052057] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52057, DK56736, P30 DK46200] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDINI G, 1991, J BIOL CHEM, V266, P4037; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; Bogan JS, 1999, J CELL BIOL, V146, P609, DOI 10.1083/jcb.146.3.609; CZECH MP, 1993, J BIOL CHEM, V268, P9187; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Fleischer S, 1974, Methods Enzymol, V31, P3; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; Janz R, 1999, NEURON, V24, P687, DOI 10.1016/S0896-6273(00)81122-8; Janz R, 1998, J BIOL CHEM, V273, P2851, DOI 10.1074/jbc.273.5.2851; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kandror KV, 1998, BIOCHEM J, V331, P829, DOI 10.1042/bj3310829; Kedra D, 1998, HUM GENET, V103, P131, DOI 10.1007/s004390050795; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee W, 1999, J BIOL CHEM, V274, P37755, DOI 10.1074/jbc.274.53.37755; Lin BZ, 1997, J BIOL CHEM, V272, P24145, DOI 10.1074/jbc.272.39.24145; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Malide D, 1997, J HISTOCHEM CYTOCHEM, V45, P1083, DOI 10.1177/002215549704500806; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; MARTIN S, 1994, BIOCHEM J, V300, P743, DOI 10.1042/bj3000743; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Randhawa VK, 2000, MOL BIOL CELL, V11, P2403, DOI 10.1091/mbc.11.7.2403; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; SATOH S, 1993, J BIOL CHEM, V268, P17820; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Stenius K, 1995, J CELL BIOL, V131, P1801, DOI 10.1083/jcb.131.6.1801; Sugita S, 1999, J BIOL CHEM, V274, P18893, DOI 10.1074/jbc.274.27.18893; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233	41	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36263	36268		10.1074/jbc.M002797200	http://dx.doi.org/10.1074/jbc.M002797200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967091	hybrid			2022-12-27	WOS:000165382000088
J	Ravid, T; Doolman, R; Avner, R; Harats, D; Roitelman, J				Ravid, T; Doolman, R; Avner, R; Harats, D; Roitelman, J			The ubiquitin-proteasome pathway mediates the regulated degradation of mammalian 3-hydroxy-3-methylglutaryl-coenzyme A reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; HMG-COA REDUCTASE; RETICULUM MEMBRANE-PROTEIN; MEVALONATE-DERIVED PRODUCT; LOW-DENSITY LIPOPROTEIN; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; RAT-LIVER; IN-VIVO; TRANSLATIONAL CONTROL	3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), the key regulatory enzyme in the mevalonate (MVA) pathway, is rapidly degraded in mammalian cells supplemented with sterols or MVA This accelerated turnover was blocked by N-acetyl-leucyl-leucyl-nor-leucinal (ALLN), MG-132, and lactacystin, and to a lesser extent by N-acetyl-leucyl-leucyl-methional (ALLM), indicating the involvement of the 26 S proteasome. Proteasome inhibition led to enhanced accumulation of high:molecular weight polyubiquitin conjugates of HMGR and of HMGal, a chimera between the membrane domain of HMGR and beta -galactosidase. Importantly, increased amounts of polyubiquitinated HMGR and HMGal were observed upon treating cells with sterols or MVA. Cycloheximide inhibited the sterol-stimulated degradation of HMGR concomitantly with a marked reduction in polyubiquitination of the enzyme, Inhibition of squalene synthase with zaragozic acid blocked the MVA- but not sterol-stimulated ubiquitination and degradation of HMGR, Thus, similar to yeast, the ubiquitin-proteasome pathway is involved in the metabolically regulated turnover of mammalian HMGR, Yet, the data indicate divergence between yeast and mammals and suggest distinct roles for sterol and nonsterol metabolic signals in the regulated ubiquitination and degradation of mammalian HMGR.	Chaim Sheba Med Ctr, Inst Lipid & Atherosclerosis Res, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Roitelman, J (corresponding author), Chaim Sheba Med Ctr, Inst Lipid & Atherosclerosis Res, IL-52621 Tel Hashomer, Israel.							BASSON ME, 1988, MOL CELL BIOL, V8, P3797, DOI 10.1128/MCB.8.9.3797; Bordallo J, 1999, FEBS LETT, V448, P244, DOI 10.1016/S0014-5793(99)00362-2; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; BRADFUTE DL, 1994, J BIOL CHEM, V269, P6645; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P7704, DOI 10.1073/pnas.79.24.7704; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHOI JW, 1993, BIOCHEM J, V296, P859, DOI 10.1042/bj2960859; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHUN KT, 1992, J BIOL CHEM, V267, P4236; CLARKE CF, 1985, J BIOL CHEM, V260, P4363; CORRELL CC, 1994, J BIOL CHEM, V269, P633; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; Du EZ, 1999, J BIOL CHEM, V274, P1856, DOI 10.1074/jbc.274.3.1856; EDWARDS PA, 1983, J BIOL CHEM, V258, P219; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; Gardner R, 1998, MOL BIOL CELL, V9, P2611, DOI 10.1091/mbc.9.9.2611; Gardner RG, 1999, EMBO J, V18, P5994, DOI 10.1093/emboj/18.21.5994; Gardner RG, 1999, J BIOL CHEM, V274, P31671, DOI 10.1074/jbc.274.44.31671; GAYEN AK, 1995, ARCH BIOCHEM BIOPHYS, V322, P475, DOI 10.1006/abbi.1995.1491; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hampton RY, 1998, CURR OPIN LIPIDOL, V9, P93, DOI 10.1097/00041433-199804000-00003; Hampton RY, 1996, P NATL ACAD SCI USA, V93, P828, DOI 10.1073/pnas.93.2.828; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1991, J BIOL CHEM, V266, P13311; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; LISCUM L, 1985, J BIOL CHEM, V260, P522; LISCUM L, 1983, J BIOL CHEM, V258, P8450; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; Meigs TE, 1997, ARCH BIOCHEM BIOPHYS, V345, P1, DOI 10.1006/abbi.1997.0200; Meigs TE, 1996, J BIOL CHEM, V271, P7916, DOI 10.1074/jbc.271.14.7916; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; PEFFLEY DM, 1995, SOMAT CELL MOLEC GEN, V21, P189, DOI 10.1007/BF02254770; Plemper RK, 1999, J CELL SCI, V112, P4123; PLEMPER RK, 1999, MOL BIOL REP, V26; Ravid T, 1999, J BIOL CHEM, V274, P29341, DOI 10.1074/jbc.274.41.29341; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; TANAKA RD, 1986, J LIPID RES, V27, P261; Wigley WC, 1999, J CELL BIOL, V145, P481	53	119	123	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35840	35847		10.1074/jbc.M004793200	http://dx.doi.org/10.1074/jbc.M004793200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964918	hybrid			2022-12-27	WOS:000165382000030
J	Xiang, H; Tschirret-Guth, RA; de Montellano, PRO				Xiang, H; Tschirret-Guth, RA; de Montellano, PRO			An A245T mutation conveys on cytochrome P450(eryF) the ability to oxidize alternative substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSPORT COMPONENTS; SITE-DIRECTED MUTAGENESIS; SACCHAROPOLYSPORA-ERYTHRAEA; 6-DEOXYERYTHRONOLIDE-B HYDROXYLASE; OXYGEN ACTIVATION; AMINO-ACID; ERYTHROMYCIN BIOSYNTHESIS; CATALYTIC FUNCTION; ESCHERICHIA-COLI; CYP3A ISOFORMS	Cytochrome P450(eryF) (CYP107A1), which hydroxylates deoxyerythronolide B in erythromycin biosynthesis, lacks the otherwise highly conserved threonine that is thought to promote O-O bond scission. The role of this threonine is satisfied in P450(eryF) by a substrate hydroxyl group, making deoxyerythronolide B the only acceptable substrate. As shown here, replacement of Ala(245) by,threonine enables the oxidation of alternative substrates using either H2O2 or O-2/spinach ferredoxin/ferredoxin reductase as the source of oxidizing equivalents. Testosterone is oxidized to 1-, 11 alpha-, 12-, and 16 alpha -hydroxytestosterone. A kinetic solvent isotope effect of 2.2 indicates that the A245T mutation facilitates dioxygen bond cleavage. This gain-of-function evidence confirms the role of the conserved threonine in P450 catalysis, Furthermore, a Hill coefficient of 1.3 and dependence of the product distribution on the testosterone concentration suggest that two testosterone molecules bind in the active site, in accord with a published structure of the P450(eryF)-androstenedione complex. P450(eryF) is thus a structurally defined model for the P450 catalytic turnover of multiply bound substrates proposed to occur with CYP3A4, In view of its large active site and defined structure, catalytically active P450(eryF) mutants are also attractive templates for the engineering of novel P450 activities.	Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, S-926, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025515, R01GM025515] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25515] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIKENS J, 1994, J AM CHEM SOC, V116, P1143, DOI 10.1021/ja00082a051; ALIVERTI A, 1994, FEBS LETT, V343, P247, DOI 10.1016/0014-5793(94)80565-2; ALIVERTI A, 1990, EUR J BIOCHEM, V191, P551, DOI 10.1111/j.1432-1033.1990.tb19156.x; ANDERSEN JF, 1993, BIOCHEMISTRY-US, V32, P1905, DOI 10.1021/bi00059a004; ANDERSEN JF, 1992, J BACTERIOL, V174, P725, DOI 10.1128/jb.174.3.725-735.1992; ANDERSSON T, 1994, BRIT J CLIN PHARMACO, V38, P131, DOI 10.1111/j.1365-2125.1994.tb04336.x; APLEY EC, 1985, ANAL BIOCHEM, V150, P145, DOI 10.1016/0003-2697(85)90453-1; Betlach MC, 1998, BIOCHEMISTRY-US, V37, P14937, DOI 10.1021/bi981699c; Cupp-Vickery J, 2000, P NATL ACAD SCI USA, V97, P3050, DOI 10.1073/pnas.050406897; CuppVickery JR, 1996, NAT STRUCT BIOL, V3, P632, DOI 10.1038/nsb0796-632; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; de Montellano P. R. O., 1995, CYTCOCHROME P450 STR, P245; Domanski TL, 2000, J PHARMACOL EXP THER, V293, P585; Edholm O, 2000, BIOCHEM BIOPH RES CO, V268, P683, DOI 10.1006/bbrc.2000.2201; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HANIOKA N, 1992, J STEROID BIOCHEM, V43, P1037, DOI 10.1016/0960-0760(92)90331-C; HIROYA K, 1992, FASEB J, V6, P749, DOI 10.1096/fasebj.6.2.1347023; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; IMAI Y, 1989, BIOCHEM BIOPH RES CO, V158, P717, DOI 10.1016/0006-291X(89)92780-0; ISHIGOOKA M, 1992, BIOCHEMISTRY-US, V31, P1528, DOI 10.1021/bi00120a033; Jacobsen JR, 1997, SCIENCE, V277, P367, DOI 10.1126/science.277.5324.367; KIMATA Y, 1995, BIOCHEM BIOPH RES CO, V208, P96, DOI 10.1006/bbrc.1995.1310; Korzekwa KR, 1998, BIOCHEMISTRY-US, V37, P4137, DOI 10.1021/bi9715627; Lee H, 1999, BIOCHEMISTRY-US, V38, P10808, DOI 10.1021/bi990463l; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; Mueller Ernest J., 1995, P83; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; SCHMIDER J, 1995, J PHARMACOL EXP THER, V275, P592; SCHWAB GE, 1988, MOL PHARMACOL, V33, P493; SHAFIEE A, 1987, BIOCHEMISTRY-US, V26, P6204, DOI 10.1021/bi00393a037; SHAFIEE A, 1988, J BACTERIOL, V170, P1548, DOI 10.1128/jb.170.4.1548-1553.1988; SMITH SJ, 1992, DRUG METAB DISPOS, V20, P566; Szklarz GD, 1997, J COMPUT AID MOL DES, V11, P265, DOI 10.1023/A:1007956612081; *TRIN SOFTW, 1993, ENZ KIN VERS 1 4; Truan G, 1998, ARCH BIOCHEM BIOPHYS, V349, P53, DOI 10.1006/abbi.1997.0400; Ueng YF, 1997, BIOCHEMISTRY-US, V36, P370, DOI 10.1021/bi962359z; Vidakovic M, 1998, BIOCHEMISTRY-US, V37, P9211, DOI 10.1021/bi980189f; WAXMAN DJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P160, DOI 10.1016/0003-9861(91)90602-F; WEBER JM, 1991, SCIENCE, V252, P114, DOI 10.1126/science.2011746; YEOM H, 1995, BIOCHEMISTRY-US, V34, P14733, DOI 10.1021/bi00045a014; ZOTCHEV SB, 1995, GENE, V156, P101, DOI 10.1016/0378-1119(95)00012-U	43	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35999	36006		10.1074/jbc.M005811200	http://dx.doi.org/10.1074/jbc.M005811200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10956654	hybrid			2022-12-27	WOS:000165382000051
J	Chen, B; Zhou, GF; Kim, MY; Chishti, Y; Hussey, RE; Ely, B; Skehel, JJ; Reinherz, EL; Harrison, SC; Wiley, DC				Chen, B; Zhou, GF; Kim, MY; Chishti, Y; Hussey, RE; Ely, B; Skehel, JJ; Reinherz, EL; Harrison, SC; Wiley, DC			Expression, purification, and characterization of gp160e, the soluble trimeric ectodomain of the simian immunodeficiency virus envelope glycoprotein, gp160	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; INFLUENZA-VIRUS; MEMBRANE-FUSION; HIV-1 GP41; OLIGOMERIC STRUCTURE; CD4 BINDING; SIV GP41; RECEPTOR; TYPE-1; GP120	The envelope glycoprotein, gp160, of simian immunodeficiency virus (SIV) shares similar to 25% sequence identity with gp160 from the human immunodeficiency virus, type I,, indicating a close structural similarity. As a result of binding to cell surface CD4 and co-receptor (e.g. CCR5 and CXCR4), both SIV and human immunodeficiency virus gp160 mediate viral entry by membrane fusion. We report here the characterization of gp160e, the soluble ectodomain of SIV gp160. The ectodomain has been expressed in both insect cells and Chinese hamster ovary (CHO)-Lec3.2.8.1 cells, deficient in enzymes necessary for synthesizing complex oligosaccharides. Both the primary and a secondary proteolytic cleavage sites between the gp120 and gp41 subunits of gp160 were mutated to prevent cleavage and shedding of gp120. The purified, soluble glycoprotein is shown to be trimeric by chemical cross-linking, gel filtration chromatography, and analytical ultracentrifugation. It forms soluble, tight complexes with soluble CD4 and a number of Fab fragments from neutralizing monoclonal antibodies. Soluble complexes were also produced of enzymatically deglycosylated gp160e and of gp160e variants with deletions in the variable segments.	Childrens Hosp, Howard Hughes Med Inst, Mol Med Lab, Boston, MA 02215 USA; Dana Farber Canc Inst, Boston, MA 02215 USA; Natl Inst Med Res, London NW7 1AA, England	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; MRC National Institute for Medical Research	Wiley, DC (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Mol Med Lab, 320 Longwood Ave,Enders 673, Boston, MA 02215 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI043649, R01AI143649] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43649] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; BACHELDER RE, 1995, J VIROL, V69, P5734, DOI 10.1128/JVI.69.9.5734-5742.1995; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Center RJ, 1998, PROTEIN SCI, V7, P1612, DOI 10.1002/pro.5560070715; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DOMS RW, 1991, ADV EXP MED BIOL, V300, P203; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; Farzan M, 1998, J VIROL, V72, P7620, DOI 10.1128/JVI.72.9.7620-7625.1998; Fass D, 1995, CURR BIOL, V5, P1377, DOI 10.1016/S0960-9822(95)00275-2; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GABUZDA D, 1991, J ACQ IMMUN DEF SYND, V4, P34; GABUZDA DH, 1992, J VIROL, V66, P3306, DOI 10.1128/JVI.66.6.3306-3315.1992; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; Joshi SB, 1998, VIROLOGY, V248, P20, DOI 10.1006/viro.1998.9242; KENT KA, 1992, AIDS RES HUM RETROV, V8, P1147, DOI 10.1089/aid.1992.8.1147; KENT KA, 1991, AIDS, V5, P829, DOI 10.1097/00002030-199107000-00006; KINGSTON RE, 1992, SHORT PROTOCOLS MOL, P55; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Liu J, 1996, J BIOL CHEM, V271, P33639, DOI 10.1074/jbc.271.52.33639; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995; POLLARD SR, 1992, EMBO J, V11, P585, DOI 10.1002/j.1460-2075.1992.tb05090.x; RHODES AD, 1994, J GEN VIROL, V75, P207, DOI 10.1099/0022-1317-75-1-207; RUD EW, 1992, VACCINES 92 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P229; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; SCHAWALLER M, 1989, VIROLOGY, V172, P367, DOI 10.1016/0042-6822(89)90142-6; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; STANLEY P, 1981, MOL CELL BIOL, V1, P687, DOI 10.1128/MCB.1.8.687; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; WEISS CD, 1990, J VIROL, V64, P5674, DOI 10.1128/JVI.64.11.5674-5677.1990; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; Weissenhorn W, 1997, P NATL ACAD SCI USA, V94, P6065, DOI 10.1073/pnas.94.12.6065; WILEY DC, 1977, VIROLOGY, V79, P446, DOI 10.1016/0042-6822(77)90371-3; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; Yang XZ, 2000, J VIROL, V74, P4746, DOI 10.1128/JVI.74.10.4746-4754.2000; Yang ZN, 1999, J STRUCT BIOL, V126, P131, DOI 10.1006/jsbi.1999.4116	56	32	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34946	34953		10.1074/jbc.M004905200	http://dx.doi.org/10.1074/jbc.M004905200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10944528	hybrid			2022-12-27	WOS:000165422800018
J	Gabriel, SE; Makhlina, M; Martsen, E; Thomas, EJ; Lethem, MI; Boucher, RC				Gabriel, SE; Makhlina, M; Martsen, E; Thomas, EJ; Lethem, MI; Boucher, RC			Permeabilization via the P2X(7) purinoreceptor reveals the presence of a Ca2+-activated Cl- conductance in the apical membrane of murine tracheal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING ANION CHANNEL; HUMAN AIRWAY EPITHELIA; HUMAN NASAL EPITHELIUM; CYSTIC-FIBROSIS; INTRACELLULAR CALCIUM; CHLORIDE CHANNEL; ION-TRANSPORT; EXTRACELLULAR NUCLEOTIDES; NEUROTRANSMITTER RELEASE; ACTIVATION	Calcium-activated Cl- secretion is an important modulator of regulated ion transport in murine airway epithelium and is mediated by an unidentified Ca2+-stimulated Cl- channel. We have transfected immortalized murine tracheal epithelial cells with the cDNA encoding the permeabilizing P2X(7) purinoreceptor (P2X(7)-R) to selectively permeabilize the basolateral membrane and thereby isolate the apical membrane Ca2+-activated Cl- current. In P2X(7)-R-permeabilized cells, we have demonstrated that UTP stimulates a Cl- current across the apical membrane of CF and normal murine tracheal epithelial cells. The magnitude of the UTP-stimulated current was significantly greater in CF than in normal cells. Ion substitution studies demonstrated that the current exhibited a permselectivity sequence of Cl- > I- > Br- > gluconate(-). We have also determined a rank order of potency for putative Cl- channel blockers: niflumic acid greater than or equal to 5-nitro-2-(3-phenylpropylamino)benzoic acid > 4,4'-diisothiocyanostilbene-2,2'-disulfonate > glybenclamide much greater than diphenlyamine-2-carboxylate, tamoxifen, and p-tetra-sulfonato-tetra-methoxy-calix[4]arene. Complete characterization of this current and the corresponding single channel properties could lead to the development of a new therapy to correct the defective airway surface liquid in cystic fibrosis patients.	Univ N Carolina, CFPRT Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Cyst Fibrosis Pulm Res & Clin Treatment Ctr, Chapel Hill, NC 27599 USA; Univ Brighton, Sch Pharm & Biomol Sci, Brighton BN2 4GJ, E Sussex, England	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Brighton	Gabriel, SE (corresponding author), Univ N Carolina, CFPRT Ctr, Chapel Hill, NC 27599 USA.	sgabriel@med.unc.edu			NHLBI NIH HHS [HL62564] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062564] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER EM, 1991, J NEUROSCI, V11, P1496; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; CLARKE LL, 1992, AM J PHYSIOL, V262, pC644, DOI 10.1152/ajpcell.1992.262.3.C644; CLARKE LL, 1992, AM J PHYSIOL, V263, pC1190, DOI 10.1152/ajpcell.1992.263.6.C1190; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DEVOR DC, AM J PHYSL, V276, pC827; DUSZYK M, 1992, BIOPHYS J, V61, P583, DOI 10.1016/S0006-3495(92)81861-1; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; GABRIEL SE, 1993, PEDIATR PULM, V9, P223; GABRIEL SE, 1999, IN PRESS AM J PHYSL; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; HANRAHAN JW, 1989, ANN NY ACAD SCI, V574, P30; HANRAHAN JW, 1990, J MEMBRANE BIOL, V116, P65, DOI 10.1007/BF01871673; Humphreys BD, 1998, MOL PHARMACOL, V54, P22, DOI 10.1124/mol.54.1.22; Hwang TH, 1996, AM J PHYSIOL-CELL PH, V270, pC1611, DOI 10.1152/ajpcell.1996.270.6.C1611; Illek B, 1999, PFLUG ARCH EUR J PHY, V437, P812, DOI 10.1007/s004240050850; ISHIKAWA T, 1993, J MEMBRANE BIOL, V135, P261; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KUNZELMANN K, 1992, PFLUG ARCH EUR J PHY, V421, P238, DOI 10.1007/BF00374833; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; MCCANN JD, 1989, AM J PHYSIOL, V257, pL116, DOI 10.1152/ajplung.1989.257.2.L116; MORRIS AP, 1993, AM J PHYSIOL, V264, pC968, DOI 10.1152/ajpcell.1993.264.4.C968; Nichols RA, 1996, NEUROSCI LETT, V211, P135, DOI 10.1016/0304-3940(96)12728-2; NOAH TL, 1991, AM J RESP CELL MOL, V5, P484, DOI 10.1165/ajrcmb/5.5.484; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Romio L, 1999, GENE, V228, P181, DOI 10.1016/S0378-1119(98)00620-9; Schultz BD, 1996, AM J PHYSIOL-LUNG C, V271, pL192, DOI 10.1152/ajplung.1996.271.2.L192; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; SINGH AK, 1995, KIDNEY INT, V48, P985, DOI 10.1038/ki.1995.380; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STUTTS MJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1442, DOI 10.1152/ajpcell.1994.267.5.C1442; TABCHARANI JA, 1989, J MEMBRANE BIOL, V112, P109, DOI 10.1007/BF01871272; TABCHARANI JA, 1991, AM J PHYSIOL, V261, pG992, DOI 10.1152/ajpgi.1991.261.6.G992; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC226, DOI 10.1152/ajpcell.1989.256.2.C226; ZegarraMoran O, 1997, J MEMBRANE BIOL, V156, P297, DOI 10.1007/s002329900209	45	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35028	35033		10.1074/jbc.M004953200	http://dx.doi.org/10.1074/jbc.M004953200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10944530	Green Published, hybrid			2022-12-27	WOS:000165422800029
J	Kawasaki, H; Nose, T; Muta, T; Iwanaga, S; Shimohigashi, Y; Kawabata, S				Kawasaki, H; Nose, T; Muta, T; Iwanaga, S; Shimohigashi, Y; Kawabata, S			Head-to-tail polymerization of coagulin, a clottable protein of the horseshoe crab	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR COAGULATION INHIBITOR; LIMULUS HEMOCYTE TRANSGLUTAMINASE; AMINO-ACID-SEQUENCE; CDNA CLONING; TISSUE LOCALIZATION; INNATE IMMUNITY; PROCLOTTING ENZYME; PURIFICATION; FIBRINOGEN; ACTIVATION	A clottable protein coagulogen of the horseshoe crab Tachypleus tridentatus is proteolytically converted into an insoluble coagulin gel through non-covalent self-polymerization, Here we identified binding sites for the polymerization, A tryptic fragment, derived from the coagulin polymer chemically cross-linked by a bifunctional cross-linker, was isolated. Amino acid sequence analysis indicated that the fragment consists of two peptides cross-linked between Lys(85) and Lys(156) The two lysine residues are oppositely located at the head and tail regions of the elongated molecule separated by a much greater distance than the length of the crosslinker, which suggests that the cross-linking occurs intermolecularly. Based on the x-ray structural analysis, exposure of a hydrophobic cove on the head in response to the release of peptide C has been postulated (Bergner, A., Oganessyan, V,, Muta, T,, Iwanaga, S., Typke, D., Huber, R,, and Bode, W, (1996) EMBO J. 15, 6789-6797), An octapeptide containing Tyr(136), which occupies the tail end of coagulin, was found to inhibit the polymerization, Replacement of Tyr(136) Of the peptide with Ala resulted in loss of the inhibitory activity. These results indicated that the polymerization of coagulin proceeds through the interaction between the newly exposed hydrophobic cove on the head and the wedge-shaped hydrophobic tail.	Kyushu Univ, Grad Sch Sci, Dept Biol, Fukuoka 8128581, Japan; Kyushu Univ, Grad Sch Sci, Dept Chem, Fukuoka 8128581, Japan	Kyushu University; Kyushu University	Kawabata, S (corresponding author), Kyushu Univ, Grad Sch Sci, Dept Biol, Fukuoka 8128581, Japan.			Nose, Takeru/0000-0001-9771-7267				Agarwala KL, 1996, J BIOL CHEM, V271, P23768, DOI 10.1074/jbc.271.39.23768; Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bergner A, 1997, BIOL CHEM, V378, P283, DOI 10.1515/bchm.1997.378.3-4.283; Bergner A, 1996, EMBO J, V15, P6789, DOI 10.1002/j.1460-2075.1996.tb01070.x; BUKU A, 1992, J PROTEIN CHEM, V11, P275, DOI 10.1007/BF01024866; Gokudan S, 1999, P NATL ACAD SCI USA, V96, P10086, DOI 10.1073/pnas.96.18.10086; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; IWANAGA S, 1994, CIBA F SYMP, V186, P160; Iwanaga S, 1998, J BIOCHEM, V123, P1; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; Kawabata Shun-ichiro, 1996, P255; KING DS, 1990, INT J PEPT PROT RES, V36, P255; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATALLO ZS, 1962, AM J PHYSIOL, V202, P675, DOI 10.1152/ajplegacy.1962.202.4.675; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LAUDANO AP, 1983, ANN NY ACAD SCI, V408, P315, DOI 10.1111/j.1749-6632.1983.tb23254.x; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LORAND L, 1981, METHOD ENZYMOL, V80, P333; MIURA Y, 1995, J BIOL CHEM, V270, P558, DOI 10.1074/jbc.270.2.558; MIURA Y, 1994, J BIOL CHEM, V269, P542; Mizuguchi K, 1998, TRENDS BIOCHEM SCI, V23, P239, DOI 10.1016/S0968-0004(98)01216-X; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; NAKAMURA S, 1976, J BIOCHEM, V80, P1011, DOI 10.1093/oxfordjournals.jbchem.a131357; NAKAMURA S, 1976, BIOCHEM BIOPH RES CO, V72, P902, DOI 10.1016/S0006-291X(76)80217-3; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; Pratt KP, 1997, P NATL ACAD SCI USA, V94, P7176, DOI 10.1073/pnas.94.14.7176; ROBERTSON JD, 1970, BIOL BULL-US, V138, P157, DOI 10.2307/1540199; SMITH CL, 1994, NATURE, V368, P548, DOI 10.1038/368548a0; SMITH CL, 1992, PROTEIN SCI, V1, P1225, DOI 10.1002/pro.5560010915; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; TAE HJ, 1983, METHOD ENZYMOL, V91, P580; TAKAGI T, 1984, J BIOCHEM-TOKYO, V95, P1445, DOI 10.1093/oxfordjournals.jbchem.a134752; TOKUNAGA F, 1993, J BIOL CHEM, V268, P252; TOKUNAGA F, 1993, J BIOL CHEM, V268, P262; YEE VC, 1997, STRUCTURE LOND, V15, P125	37	32	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35297	35301		10.1074/jbc.M006856200	http://dx.doi.org/10.1074/jbc.M006856200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10948203	hybrid			2022-12-27	WOS:000165422800063
J	Liu, Y; Lightning, LK; Huang, HW; Moenne-Loccoz, P; Schuller, DJ; Poulos, TL; Loehr, TM; de Montellano, PRO				Liu, Y; Lightning, LK; Huang, HW; Moenne-Loccoz, P; Schuller, DJ; Poulos, TL; Loehr, TM; de Montellano, PRO			Replacement of the distal glycine 139 transforms human heme oxygenase-1 into a peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE IRON LIGAND; RESONANCE RAMAN; CARBON-MONOXIDE; CATALYTIC SITE; HYPERBILIRUBINEMIA; EXPRESSION; OXIDATION; MESSENGER; REVERSAL; COMPLEX	The human heme oxygenase-l crystal structure suggests that Gly-139 and Gly-143 interact directly with iron-bound ligands, We have mutated Gly-139 to an alanine, leucine, phenylalanine, tryptophan, histidine, or aspartate, and Gly-143 to a leucine, lysine, histidine, or aspartate, All of these mutants bind heme, but absorption and resonance Raman spectroscopy indicate that the water coordinated to the iron atom is lost in several of the Gly-139 mutants, giving rise to mixtures of hexacoordinate and pentacoordinate ligation states. The active site perturbation is greatest when large amino acid side chains are introduced. Of the Gly-139 mutants investigated, only G139A catalyzes the NADPH-cytochrome P450 reductase-dependent oxidation of heme to biliverdin, but most of them exhibit a new H2O2-dependent guaiacol peroxidation activity. The Gly-143 mutants, all of which have lost the water ligand, have no heme oxygenase or peroxidase activity, The results establish the importance of Gly-139 and Gly-143 in maintaining the appropriate environment for the heme oxygenase reaction and show that Gly-139 mutations disrupt this environment, probably by displacing the distal helix, converting heme oxygenase into a peroxidase. The principal role of the heme oxygenase active site may be to suppress the ferryl species formation responsible for peroxidase activity.	Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA; Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA	University of California System; University of California San Francisco; University of California System; University of California Irvine; University of California System; University of California Irvine	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.			MOENNE-LOCCOZ, PIERRE/0000-0002-7684-7617	NIDDK NIH HHS [DK30297] Funding Source: Medline; NIGMS NIH HHS [GM34468, GM32688] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034468] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burnett AL, 1998, NAT MED, V4, P84, DOI 10.1038/nm0198-084; Dierks EA, 1998, BIOCHEMISTRY-US, V37, P1839, DOI 10.1021/bi972458s; Dolphin, 1979, PORPHYRINS, VVI, P257; DRUMMOND GS, 1981, P NATL ACAD SCI-BIOL, V78, P6466, DOI 10.1073/pnas.78.10.6466; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; KAPPAS A, 1988, PEDIATRICS, V81, P485; Liu Y, 2000, J BIOL CHEM, V275, P5297, DOI 10.1074/jbc.275.8.5297; Liu Y, 1999, BIOCHEMISTRY-US, V38, P3733, DOI 10.1021/bi982707s; LOEHR TM, 1993, METHOD ENZYMOL, V226, P431; MAINES MD, 1992, BIOCHIM BIOPHYS ACTA, V1131, P166, DOI 10.1016/0167-4781(92)90072-8; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1986, J BIOL CHEM, V261, P411; MAINES MD, 1992, HEME OXYGENASE CLIN, P109; MAINES MD, 1992, HEME OXYGENASE CLIN, P203; MCCOUBREY WK, 1993, ARCH BIOCHEM BIOPHYS, V302, P402, DOI 10.1006/abbi.1993.1231; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; RAMETTES RW, 1965, J AM CHEM SOC, V82, P5001; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFER WH, 1985, BIOCHEMISTRY-US, V24, P3254, DOI 10.1021/bi00334a027; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; Suttner DM, 1999, FASEB J, V13, P1800, DOI 10.1096/fasebj.13.13.1800; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; WILKS A, 1995, J AM CHEM SOC, V117, P2925, DOI 10.1021/ja00115a027; WILKS A, 1993, J BIOL CHEM, V268, P22357; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; Zakhary R, 1997, P NATL ACAD SCI USA, V94, P14848, DOI 10.1073/pnas.94.26.14848; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	37	50	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34501	34507		10.1074/jbc.M004245200	http://dx.doi.org/10.1074/jbc.M004245200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942763	hybrid			2022-12-27	WOS:000165095300068
J	Nakai, A; Ishikawa, T				Nakai, A; Ishikawa, T			A nuclear localization signal is essential for stress-induced dimer-to-trimer transition of heat shock transcription factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; COILED-COIL; FACTOR TRIMERIZATION; IN-VIVO; ACTIVATION; HSF3; OLIGOMERIZATION; SEQUENCE; DOMAIN; THERMOTOLERANCE	Expression of heat shock genes is regulated mainly at the level of transcription by heat shock transcription factors (HSFs). In avian, HSF1 and HSF3 are maintained in a cryptic monomer and dimer form, respectively, in the cytoplasm in the absence of stress. Upon heat stress, they undergo conformational change associated with the formation of a trimer and nuclear translocation. In this study, we identified regions that are necessary for the dimer-to-trimer transition of chicken HSF3 (cHSF3) upon stress conditions. One of these regions coincides with a functional nuclear localization signal (NLS) of cHSF3 that was recognized by a nuclear transport receptor importin alpha. Point mutations of basic amino acids in the NLS inhibit both nuclear translocation and trimer formation of cHSF3. These results demonstrate that the NLS acts positively on the trimer formation of cHSF3 upon stress conditions.	Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cell Biol, Sakyo Ku, Kyoto 6068397, Japan	Kyoto University	Nakai, A (corresponding author), Yamaguchi Univ, Sch Med, Dept Biochem & Mol Biol, Minami Kogushi 1-1-1, Ube, Yamaguchi 7558505, Japan.							Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Bharadwaj S, 1999, MOL CELL BIOL, V19, P8033; Chan CK, 1999, FEBS LETT, V462, P221, DOI 10.1016/S0014-5793(99)01515-X; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; Farkas T, 1998, MOL CELL BIOL, V18, P906, DOI 10.1128/MCB.18.2.906; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; Kawazoe Y, 1999, EUR J BIOCHEM, V265, P688, DOI 10.1046/j.1432-1327.1999.00762.x; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Liu PCC, 1999, J BIOL CHEM, V274, P17219, DOI 10.1074/jbc.274.24.17219; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; Nakai A, 1999, CELL STRESS CHAPERON, V4, P86, DOI 10.1054/csac.1998.0002; Nakai A, 2000, EMBO J, V19, P1545, DOI 10.1093/emboj/19.7.1545; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NAKAI A, 1995, MOL CELL BIOL, V15, P5268; Orosz A, 1996, MOL CELL BIOL, V16, P7018; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SATLSMAN K, 1998, YEAST, V15, P733; SHELDON LA, 1993, GENE DEV, V7, P1549, DOI 10.1101/gad.7.8.1549; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; Tanabe M, 1998, EMBO J, V17, P1750, DOI 10.1093/emboj/17.6.1750; Tanabe M, 1999, J BIOL CHEM, V274, P27845, DOI 10.1074/jbc.274.39.27845; Tanabe M, 1997, J BIOL CHEM, V272, P15389, DOI 10.1074/jbc.272.24.15389; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Zandi E, 1997, GENE DEV, V11, P1299, DOI 10.1101/gad.11.10.1299; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	39	22	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34665	34671		10.1074/jbc.M005302200	http://dx.doi.org/10.1074/jbc.M005302200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942768	hybrid			2022-12-27	WOS:000165095300090
J	Taylor, KR; Holzer, AK; Bazan, JF; Walsh, CA; Gleeson, JG				Taylor, KR; Holzer, AK; Bazan, JF; Walsh, CA; Gleeson, JG			Patient mutations in doublecortin define a repeated tubulin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; DOMINANT RETINITIS-PIGMENTOSA; SUBCORTICAL LAMINAR HETEROTOPIA; DOUBLE CORTEX SYNDROME; NEURONAL MIGRATION; RAS-BINDING; HEAVY-CHAIN; GENE; TAU; IDENTIFICATION	Doublecortin (DCX) missense mutations are found in two clusters in patients with defective cortical neuronal migration. Although DCX can function as a microtubule-associated protein (MAP), the potential relationship between its MAP activity and neuronal migration is not understood. Here we show that the two clusters of patient mutations precisely define an internal tandem repeat. Each repeat alone binds tubulin, whereas neither repeat is sufficient for co-assembly with microtubules, The two tandem repeats are sufficient to mediate microtubule polymerization, and representative patient missense mutations lead to impaired polymerization both in vitro and in vivo as well as impaired microtubule stabilization. Furthermore, each repeat is predicted to have the secondary structure of a beta -grasp superfold motif, a motif not found in other MAPs. The patient mutations are predicted to disrupt the structure of the motif, suggesting that the motif may be critical for the DCX-tubulin interaction. These data provide both genetic and biochemical evidence that the interaction of DCX with microtubules is dependent upon this novel repeated tubulin-binding motif.	Univ Calif San Diego, Dept Neurosci, Biomed Sci Grad Program, Div Pediat Neurol, La Jolla, CA 92093 USA; DNAX Res Inst Mol & Cellular Biol Inc, Dept Mol Biol, Prot Machine Grp, Palo Alto, CA 94304 USA; Harvard Univ, Sch Med, Div Neurogenet, Dept Neurol,Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	University of California System; University of California San Diego; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Gleeson, JG (corresponding author), MTF 324,9500 Gilman Dr, La Jolla, CA 92093 USA.	jogleeson@ucsd.edu	Bazan, J. Fernando/B-4562-2010		NINDS NIH HHS [P01 NS39404, 5K12NS01701-05, R01 NS 38097] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K12NS001701, R01NS038097, P01NS039404] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTH PG, 1987, CAN J NEUROL SCI, V14, P1; Bowne SJ, 1999, HUM MOL GENET, V8, P2121, DOI 10.1093/hmg/8.11.2121; BRODTKORB E, 1992, ACTA NEUROL SCAND, V86, P24, DOI 10.1111/j.1600-0404.1992.tb08049.x; Cainarca S, 1999, HUM MOL GENET, V8, P1387, DOI 10.1093/hmg/8.8.1387; COFFEY RL, 1994, BIOCHEMISTRY-US, V33, P13199, DOI 10.1021/bi00249a006; CRAVCHIK A, 1994, J CELL SCI, V107, P661; des Portes V, 1998, HUM MOL GENET, V7, P1063, DOI 10.1093/hmg/7.7.1063; des Portes V, 1998, CELL, V92, P51; DeTure M, 2000, BRAIN RES, V853, P5, DOI 10.1016/S0006-8993(99)02124-1; DOLL T, 1993, J CELL SCI, V106, P633; EMERSON SD, 1995, BIOCHEMISTRY-US, V34, P6911, DOI 10.1021/bi00021a001; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; FRANKEL FR, 1976, P NATL ACAD SCI USA, V73, P2798, DOI 10.1073/pnas.73.8.2798; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; Geyer M, 1997, NAT STRUCT BIOL, V4, P694, DOI 10.1038/nsb0997-694; Gleeson JG, 1999, ANN NEUROL, V45, P146, DOI 10.1002/1531-8249(199902)45:2<146::AID-ANA3>3.0.CO;2-N; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GOTTLIEB RA, 1985, J CELL BIOL, V101, P1782, DOI 10.1083/jcb.101.5.1782; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Horesh D, 1999, HUM MOL GENET, V8, P1599, DOI 10.1093/hmg/8.9.1599; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Koonce MP, 1997, J BIOL CHEM, V272, P19714, DOI 10.1074/jbc.272.32.19714; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; Pierce EA, 1999, NAT GENET, V22, P248, DOI 10.1038/10305; Pilz DT, 1998, HUM MOL GENET, V7, P2029, DOI 10.1093/hmg/7.13.2029; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Sapir T, 2000, HUM MOL GENET, V9, P703, DOI 10.1093/hmg/9.5.703; Sullivan LS, 1999, NAT GENET, V22, P255, DOI 10.1038/10314; Xu HM, 1997, BRAIN RES, V759, P149, DOI 10.1016/S0006-8993(97)00328-4; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	38	126	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34442	34450		10.1074/jbc.M007078200	http://dx.doi.org/10.1074/jbc.M007078200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10946000	hybrid			2022-12-27	WOS:000165095300060
J	Rettinger, J; Aschrafi, A; Schmalzing, G				Rettinger, J; Aschrafi, A; Schmalzing, G			Roles of individual N-glycans for ATP potency and expression of the rat P2X(1) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; NICOTINIC ACETYLCHOLINE-RECEPTOR; BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; ENDOPLASMIC-RETICULUM; LINKED GLYCOSYLATION; EXTRACELLULAR ATP; P-2X RECEPTOR; STRUCTURAL MOTIF; SUBUNITS	P2X(1) receptor subunits assemble in the ER of Xenopus oocytes to homotrimers that appear as ATP-gated cation channels at the cell surface. Here we address the extent to which N-glycosylation contributes to assembly, surface appearance, and ligand recognition of P2X(1) receptors, SDS-polyacrylamide gel electrophoresis (PAGE) analysis of glycan minus mutants carrying Gln instead of Asn at five individual NXT/S sequons reveals that Asn(284) remains unused because of a proline in the +4 position. The four other sites (Asn(153), Asn(184), Asn(210), and Asn(300)) carry N-glycans, but solely Asn(300) located only eight residues upstream of the predicted reentry loop of P2X(1) acquires complex-type carbohydrates, Like parent P2X(1), glycan minus mutants migrate as homotrimers when resolved by blue native PAGE. Recording of ATP-gated currents reveals that elimination of Asn(153) or Asn(210) diminishes or increases functional expression levels, respectively. In addition, elimination of Asn(210) causes a 3-fold reduction of the potency for ATP, If three or all four N-glycosylation sites are simultaneously eliminated, formation of P2X(1) receptors is severely impaired or abolished, respectively. We conclude that at least one N-glycan per subunit of either position is absolutely required for the formation of P2X(1) receptors and that individual N-glycans possess marked positional effects on expression levels (Asn(154), Asn(210)) and ATP potency (Asn(210)).	Univ Frankfurt, Dept Pharmacol, Bioctr N 260, D-60439 Frankfurt, Germany; Univ Freiburg, Dept Pharmacol & Toxicol, D-79104 Freiburg, Germany	Goethe University Frankfurt; University of Freiburg	Schmalzing, G (corresponding author), Inst Expt & Klin Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.		Aschrafi, Armaz/E-2202-2012	Aschrafi, Armaz/0000-0003-4089-0960				ASANO T, 1993, FEBS LETT, V324, P258, DOI 10.1016/0014-5793(93)80129-I; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Burnstock G, 1999, PROG BRAIN RES, V120, P3; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Collo G, 1996, J NEUROSCI, V16, P2495; Ding SH, 1999, J GEN PHYSIOL, V113, P695, DOI 10.1085/jgp.113.5.695; Ding SH, 2000, J PHYSIOL-LONDON, V522, P199, DOI 10.1111/j.1469-7793.2000.t01-1-00199.x; DWEK RA, 1995, BIOCHEM SOC T, V23, P1; Ennion S, 2000, J BIOL CHEM, V275, P29361, DOI 10.1074/jbc.M003637200; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LECONTE I, 1992, J BIOL CHEM, V267, P17415; MacKenzie AB, 1999, ANN NY ACAD SCI, V868, P716, DOI 10.1111/j.1749-6632.1999.tb11351.x; Melikian HE, 1996, MOL PHARMACOL, V50, P266; Mulryan K, 2000, NATURE, V403, P86, DOI 10.1038/47495; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Nicke A, 1999, PROG BRAIN RES, V120, P61; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Nicke A, 1999, J RECEPT SIGNAL TR R, V19, P493, DOI 10.3109/10799899909036667; NILSSON I, 1993, J BIOL CHEM, V268, P5798; North RA, 1996, SEMIN NEUROSCI, V8, P187; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHMALZING G, 1991, BIOCHEM J, V279, P329, DOI 10.1042/bj2790329; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Soto F, 1997, J MEMBRANE BIOL, V160, P91, DOI 10.1007/s002329900298; Stoop R, 1999, MOL PHARMACOL, V56, P973, DOI 10.1124/mol.56.5.973; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; TATE CG, 1994, J BIOL CHEM, V269, P26303; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; Torres GE, 1998, BIOCHEMISTRY-US, V37, P14845, DOI 10.1021/bi981209g; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; WU JSR, 1994, BBA-BIOMEMBRANES, V1192, P289, DOI 10.1016/0005-2736(94)90131-7; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493	52	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33542	33547		10.1074/jbc.M002918200	http://dx.doi.org/10.1074/jbc.M002918200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10942758	hybrid, Green Published			2022-12-27	WOS:000090104600052
J	Zhang, WY; Ishii, I; Kruth, HS				Zhang, WY; Ishii, I; Kruth, HS			Plasmin-mediated macrophage reversal of low density lipoprotein aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; SURFACE-CONNECTED COMPARTMENTS; SMOOTH-MUSCLE CELLS; LIPID-RICH CORE; MONOCYTE-DERIVED MACROPHAGES; ACTIVATOR EXPRESSION; ELECTRON-MICROSCOPY; CORONARY-ARTERIES; GENE-EXPRESSION; DEFICIENT MICE	Evidence suggests that aggregated low density lipoprotein (AgLDL) accumulates in atherosclerotic lesions. Previously, we showed that AgLDL induces and enters surface-connected compartments (SCC) in human monocyte-derived macrophages by a process we have named patocytosis, Most AgLDL taken up by these macrophages in the absence of serum is stored in SCC and remains undegraded, We now show that macrophages released AgLDL (prepared by vortexing or treatment with phospholipase C or sphingomyelinase) from their SCC when exposed to 10% human lipoprotein-deficient serum (LPDS), Macrophages also took up AgLDL in the presence of LPDS, but subsequently released it. In both cases, the released AgLDL was disaggregated, Although the AgLDL that macrophages took up could not pass through a 0.45-mum filter, >60% of AgLDL could pass this filter after release from the macrophages. Disaggregation of AgLDL was verified by gel-filtration chromatography and electron microscopy that also showed particles larger than LDL, reflecting fusion of LDL that aggregates. The factor in serum that mediated AgLDL release and disaggregation was plasmin generated from plasminogen by macrophage urokinase plasminogen activator. AgLDL release was decreased >90% by inhibitors of plasmin (E-amino caproic acid and antiplasminogen mAb), and also by inhibitors of urokinase plasminogen activator (plasminogen activator inhibitor-1 and anti-urokinase plasminogen activator mAb), Moreover, plasminogen could substitute for LPDS and produce similar macrophage release and disaggregation of AgLDL. Because only plasmin bound to the macrophage surface is protected from serum plasmin inhibitors, interaction of AgLDL with macrophages was necessary for reversal of its aggregation by LPDS. The released disaggregated LDL particles were competent to stimulate LDL receptor-mediated endocytosis in cultured fibroblasts, Macrophage-mediated disaggregation of aggregated and fused LDL is a mechanism for transforming LDL into lipoprotein structures size-consistent with lipid particles found in atherosclerotic lesions.	NHLBI, Sect Expt Atherosclerosis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kruth, HS (corresponding author), NHLBI, Sect Expt Atherosclerosis, NIH, Bldg 10,Rm 5N-113,10 Ctr Dr,MSC 1422, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002832, Z01HL002832] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOCAN TMA, 1986, AM J PATHOL, V123, P413; Buton X, 1999, J BIOL CHEM, V274, P32112, DOI 10.1074/jbc.274.45.32112; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; CHAO FF, 1994, J LIPID RES, V35, P71; CHAO FF, 1990, AM J PATHOL, V136, P169; COETZEE GA, 1980, ARTERY, V7, P1; FALCONE DJ, 1988, J CELL PHYSIOL, V135, P387, DOI 10.1002/jcp.1041350305; Falkenberg M, 1996, THROMB HAEMOSTASIS, V75, P933; FOGELMAN AM, 1981, J LIPID RES, V22, P1131; FRANK JS, 1989, J LIPID RES, V30, P967; Ganne F, 1999, THROMB HAEMOSTASIS, V81, P594; GERRITY RG, 1981, AM J PATHOL, V103, P191; GUYTON JR, 1991, J LIPID RES, V32, P953; GUYTON JR, 1989, AM J PATHOL, V134, P705; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; Hakala JK, 1999, ARTERIOSCL THROM VAS, V19, P1276, DOI 10.1161/01.ATV.19.5.1276; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; KAWABE Y, 1994, ARCH BIOCHEM BIOPHYS, V310, P489, DOI 10.1006/abbi.1994.1197; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; Kienast J, 1998, THROMB HAEMOSTASIS, V79, P579; Kruth H S, 1997, Subcell Biochem, V28, P319; KRUTH HS, 1984, ATHEROSCLEROSIS, V51, P281, DOI 10.1016/0021-9150(84)90175-8; Kruth HS, 1999, J BIOL CHEM, V274, P7495, DOI 10.1074/jbc.274.11.7495; Kruth HS, 1999, EUR J CELL BIOL, V78, P91, DOI 10.1016/S0171-9335(99)80010-7; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; KRUTH HS, 1994, J BIOL CHEM, V269, P24511; LIU H, 1993, FEBS LETT, V316, P27, DOI 10.1016/0014-5793(93)81730-N; Loscalzo Joseph, 1996, Seminars in Thrombosis and Hemostasis, V22, P503, DOI 10.1055/s-2007-999051; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; LUPU F, 1995, ARTERIOSCL THROM VAS, V15, P1444, DOI 10.1161/01.ATV.15.9.1444; MAEBA R, 1994, BBA-LIPID LIPID MET, V1215, P79, DOI 10.1016/0005-2760(94)90094-9; Maor I, 1997, ARTERIOSCL THROM VAS, V17, P2995, DOI 10.1161/01.ATV.17.11.2995; NARUSZEWICZ M, 1994, NUTR METAB CARDIOVAS, V4, P70; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; NORDESTGAARD BG, 1995, ARTERIOSCL THROM VAS, V15, P534, DOI 10.1161/01.ATV.15.4.534; Oorni K, 1998, J BIOL CHEM, V273, P29127, DOI 10.1074/jbc.273.44.29127; PAANANEN K, 1994, J BIOL CHEM, V269, P2023; Padro T, 1997, CARDIOVASC RES, V36, P28, DOI 10.1016/S0008-6363(97)00144-2; PADRO T, 1995, ARTERIOSCL THROM VAS, V15, P893, DOI 10.1161/01.ATV.15.7.893; RAGHUNATH PN, 1995, ARTERIOSCL THROM VAS, V15, P1432, DOI 10.1161/01.ATV.15.9.1432; Rhainds D, 1999, INT J BIOCHEM CELL B, V31, P915, DOI 10.1016/S1357-2725(99)00046-1; Robbie LA, 1996, ARTERIOSCL THROM VAS, V16, P539, DOI 10.1161/01.ATV.16.4.539; Schneider DJ, 1997, ARTERIOSCL THROM VAS, V17, P3294, DOI 10.1161/01.ATV.17.11.3294; SCHNEIDERMAN J, 1992, P NATL ACAD SCI USA, V89, P6998, DOI 10.1073/pnas.89.15.6998; SMITH EB, 1976, ATHEROSCLEROSIS, V25, P71, DOI 10.1016/0021-9150(76)90049-6; STEELE JCH, 1979, THROMB RES, V15, P573, DOI 10.1016/0049-3848(79)90165-8; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1993, J BIOL CHEM, V268, P20419; Tamminen M, 1999, ARTERIOSCL THROM VAS, V19, P847, DOI 10.1161/01.ATV.19.4.847; TERTOV VV, 1992, EUR J CLIN CHEM CLIN, V30, P171; TIPPING PG, 1993, AM J PATHOL, V143, P875; Vassalli J D, 1992, Curr Top Microbiol Immunol, V181, P65; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; XU XX, 1991, J BIOL CHEM, V266, P24849; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; Zhang WY, 1997, J BIOL CHEM, V272, P31700, DOI 10.1074/jbc.272.50.31700	56	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33176	33183		10.1074/jbc.M908714199	http://dx.doi.org/10.1074/jbc.M908714199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10942782	hybrid			2022-12-27	WOS:000090003800107
J	Dinchuk, JE; Henderson, NL; Burn, TC; Huber, R; Ho, SP; Link, J; O'Neil, KT; Focht, RJ; Scully, MS; Hollis, JM; Hollis, GF; Friedman, PA				Dinchuk, JE; Henderson, NL; Burn, TC; Huber, R; Ho, SP; Link, J; O'Neil, KT; Focht, RJ; Scully, MS; Hollis, JM; Hollis, GF; Friedman, PA			Aspartyl beta-hydroxylase (Asph) and an evolutionarily conserved isoform of Asph missing the catalytic domain share exons with junctin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE MODULES; SARCOPLASMIC-RETICULUM; CALCIUM-BINDING; SPLICE VARIANT; FACTOR-IX; GROWTH; RECEPTOR; PROTEIN; IDENTIFICATION; CLONING	The mouse aspartyl beta -hydroxylase gene (Asph, BAH) has been cloned and characterized, The mouse BAH gene spans 200 kilobase pairs of genomic DNA and contains 24 exons. Of three major BAH-related transcripts, the two largest (6,629 and 4,419 base pairs) encode full-length protein and differ only in the use of alternative polyadenylation signals. The smallest BAH-related transcript (2,789 base pairs) uses an alternative 3' terminal exon, resulting in a protein lacking a catalytic domain. Evolutionary conservation of this noncatalytic isoform of BAH (humbug) is demonstrated in mouse, man, and Drosophila, Monoclonal antibody reagents were generated, epitope-mapped, and used to definitively correlate RNA bands on Northern blots with protein species on Western blots, The gene for mouse junctin, a calsequestrin-binding protein, was cloned and characterized and shown to be encoded from the same locus, When expressed in heart tissue, BAH/humbug; preferably use the first exon and often the fourth exon of junctin while preserving the reading frame. Thus, three individual genes share common exons and open reading frames and use separate promoters to achieve differential expression, splicing, and function in a variety of tissues, This unusual form of exon sharing suggests that the functions of junctin, BAH, and humbug may be linked.	Dupont Merck Pharmaceut Co, Expt Stn, Dept Appl Biotechnol, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Expt Stn, Dept Cent Nervous Syst Dis Res, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Expt Stn, DuPont Pharmaceut Res Labs, Wilmington, DE 19880 USA	DuPont; DuPont; DuPont	Dinchuk, JE (corresponding author), Dupont Merck Pharmaceut Co, Expt Stn, Dept Appl Biotechnol, E400-5446, Wilmington, DE 19880 USA.	joseph.e.dinchuk@dupontpharma.com		Burn, Timothy/0000-0001-6648-4333				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; DAVIS C G, 1990, New Biologist, V2, P410; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Goruppi S, 1997, FEBS LETT, V415, P59, DOI 10.1016/S0014-5793(97)01093-4; Harlow E., 1988, ANTIBODIES LAB MANUA; Ho SP, 1996, NUCLEIC ACIDS RES, V24, P1901, DOI 10.1093/nar/24.10.1901; Ince N, 2000, CANCER RES, V60, P1261; JIA S, 1994, P NATL ACAD SCI USA, V91, P7227, DOI 10.1073/pnas.91.15.7227; JIA S, 1992, J BIOL CHEM, V267, P14322; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; KORIOTH F, 1994, GENE, V150, P395, DOI 10.1016/0378-1119(94)90460-X; Lavaissiere L, 1996, J CLIN INVEST, V98, P1313, DOI 10.1172/JCI118918; McGinnis K, 1996, BIOCHEMISTRY-US, V35, P3957, DOI 10.1021/bi951520n; MONKOVIC DD, 1992, BIOCHEM BIOPH RES CO, V189, P233, DOI 10.1016/0006-291X(92)91549-6; Nagano K, 1999, J BIOL CHEM, V274, P2872, DOI 10.1074/jbc.274.5.2872; Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; POVINELLI CM, 1993, ANAL BIOCHEM, V210, P16, DOI 10.1006/abio.1993.1144; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; Ross RJM, 1997, MOL ENDOCRINOL, V11, P265, DOI 10.1210/me.11.3.265; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; STENFLO J, 1991, BLOOD, V78, P1637; Sun BS, 1998, HEPATOLOGY, V27, P228, DOI 10.1002/hep.510270135; SUNNERHAGEN MS, 1993, J BIOL CHEM, V268, P23339; WANG QP, 1991, J BIOL CHEM, V266, P14004; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	31	80	92	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39543	39554		10.1074/jbc.M006753200	http://dx.doi.org/10.1074/jbc.M006753200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10956665	hybrid			2022-12-27	WOS:000165953100081
J	Barrantes, FJ; Antollini, SS; Blanton, MP; Prieto, M				Barrantes, FJ; Antollini, SS; Blanton, MP; Prieto, M			Topography of nicotinic acetylcholine receptor membrane-embedded domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARMORATA ELECTRIC ORGAN; ACYL CHAIN-LENGTH; ALPHA-SUBUNIT; TORPEDO-MARMORATA; TRANSMEMBRANE SEGMENT; TRANSVERSE LOCATION; SPATIAL STRUCTURE; LIPID BILAYERS; FLUORESCENCE; PROTEIN	The topography of nicotinic acetylcholine receptor (AChR) membrane-embedded domains and the relative affinity of lipids for these protein regions were studied using fluorescence methods. Intact Torpedo californica AChR protein and transmembrane peptides were derivatized with N-(1-pyrenyl)maleimide (PM), purified, and reconstituted into asolectin liposomes, Fluorescence mapped to proteolytic fragments consistent with PM labeling of cysteine residues in alpha M1, alpha M4, gamma M1, and gamma M4. The topography of the pyrene-labeled Cys residues with respect to the membrane and the apparent affinity for representative lipids were determined by differential fluorescence quenching with spin-labeled derivatives of fatty acids, phosphatidylcholine, and the steroids cholestane and androstane, Different spin label lipid analogs exhibit different selectivity for the whole AChR protein and its transmembrane domains. In all cases labeled residues were found to lie in a shallow position, For M4 segments, this is compatible with a linear alpha -helical structure, but not so for M1, for which "classical" models locate Cys residues at the center of the hydrophobic stretch. The transmembrane topography of MI can be rationalized on the basis of the presence of a substantial amount of non-helical structure, and/or of kinks attributable to the occurrence of the evolutionarily conserved proline residues. The latter is a striking feature of M1 in the AChR and all members of the rapid ligand-gated ion channel superfamily.	Inst Invest Bioquim Bahia Blanca, RA-8000 Bahia Blanca, Buenos Aires, Argentina; Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol, Lubbock, TX 79430 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Anesthesiol, Lubbock, TX 79430 USA; Ctr Quim Fis Mol, P-1049001 Lisbon, Portugal	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Universidade de Lisboa	Barrantes, FJ (corresponding author), Inst Invest Bioquim Bahia Blanca, CC 857, RA-8000 Bahia Blanca, Buenos Aires, Argentina.	rtfjb1@criba.edu.ar	Prieto, Manuel/N-4448-2013; Barrantes, Francisco J./HCH-0258-2022	Prieto, Manuel/0000-0003-3012-6598; Barrantes, Francisco J./0000-0002-4745-681X	FOGARTY INTERNATIONAL CENTER [R03TW001225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035786] Funding Source: NIH RePORTER; FIC NIH HHS [1RO3-TW01225-01] Funding Source: Medline; NINDS NIH HHS [R29NS35786] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5322, DOI 10.1021/bi00138a011; AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; ARIAS HR, 1990, BIOCHIM BIOPHYS ACTA, V1027, P287, DOI 10.1016/0005-2736(90)90320-N; BAENZIGER JE, 1995, J BIOL CHEM, V270, P29129, DOI 10.1074/jbc.270.49.29129; BARANTES FJ, 1998, NICOTINIC ACETYLCHOL; BARRANTES FJ, 1975, P NATL ACAD SCI USA, V72, P3097, DOI 10.1073/pnas.72.8.3097; BARRANTES FJ, 1978, J MOL BIOL, V124, P1, DOI 10.1016/0022-2836(78)90144-4; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; Blanton MP, 2000, J BIOL CHEM, V275, P3469, DOI 10.1074/jbc.275.5.3469; BLANTON MP, 1991, BIOCHIM BIOPHYS ACTA, V1067, P1, DOI 10.1016/0005-2736(91)90019-5; Blanton MP, 1998, BIOCHEMISTRY-US, V37, P14545, DOI 10.1021/bi981435q; BLATT E, 1984, PHOTOCHEM PHOTOBIOL, V39, P477; Castanho M, 1996, BBA-BIOMEMBRANES, V1279, P164, DOI 10.1016/0005-2736(95)00251-0; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Chattopadhyay A., 1992, BIOMEMBRANE STRUCTUR, P153; CHAVEZ RA, 1992, J CELL BIOL, V116, P385, DOI 10.1083/jcb.116.2.385; Corbin J, 1998, J BIOL CHEM, V273, P771, DOI 10.1074/jbc.273.2.771; CORNELL BA, 1983, BIOCHIM BIOPHYS ACTA, V733, P189, DOI 10.1016/0005-2736(83)90106-2; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; ELLENA JF, 1983, BIOCHEMISTRY-US, V22, P5523, DOI 10.1021/bi00293a012; Grant MA, 1999, BIOCHEMISTRY-US, V38, P10730, DOI 10.1021/bi983007q; GREEN SA, 1990, J AM CHEM SOC, V112, P7337, DOI 10.1021/ja00176a038; JACKSON MB, 1995, ANNU REV PHYSIOL, V57, P447; Kim J, 1998, BIOCHEMISTRY-US, V37, P4680, DOI 10.1021/bi972666k; KUHSE J, 1995, CURR OPIN NEUROBIOL, V5, P318, DOI 10.1016/0959-4388(95)80044-1; Ladokhin AS, 1999, BIOPHYS J, V76, P946, DOI 10.1016/S0006-3495(99)77258-9; Le Novere N, 1999, BIOPHYS J, V76, P2329, DOI 10.1016/S0006-3495(99)77390-X; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; Lugovskoy AA, 1998, EUR J BIOCHEM, V255, P455, DOI 10.1046/j.1432-1327.1998.2550455.x; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MARQUEZ J, 1989, BIOCHEMISTRY-US, V28, P7433, DOI 10.1021/bi00444a042; MARSH D, 1978, P NATL ACAD SCI USA, V75, P4329, DOI 10.1073/pnas.75.9.4329; NARAYANASWAMI V, 1993, BIOCHEMISTRY-US, V32, P12413, DOI 10.1021/bi00097a020; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; Opella SJ, 1999, NAT STRUCT BIOL, V6, P374, DOI 10.1038/7610; Ortells MO, 1996, PROTEIN ENG, V9, P51, DOI 10.1093/protein/9.1.51; ORTELLS MO, 1998, NICOTINIC ACETYLCHOL, P85; Pashkov VS, 1999, FEBS LETT, V457, P117, DOI 10.1016/S0014-5793(99)01023-6; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHREIERMUCCILLO S, 1976, ARCH BIOCHEM BIOPHYS, V172, P1, DOI 10.1016/0003-9861(76)90041-2; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; SOBEL A, 1977, EUR J BIOCHEM, V80, P215, DOI 10.1111/j.1432-1033.1977.tb11874.x; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; WHITE BH, 1991, J BIOL CHEM, V266, P21595; Williamson PTF, 2000, BIOPHYS J, V78, p147A	52	59	59	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37333	37339		10.1074/jbc.M005246200	http://dx.doi.org/10.1074/jbc.M005246200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10967108	Green Published, hybrid			2022-12-27	WOS:000165618700006
J	Gong, QM; Brown, LJ; MacDonald, MJ				Gong, QM; Brown, LJ; MacDonald, MJ			Functional analysis of two promoters for the human mitochondrial glycerol phosphate dehydrogenase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT-IV GENE; LINKED GLYCEROPHOSPHATE DEHYDROGENASE; BINDING-PROTEIN-ALPHA; PANCREATIC-ISLETS; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; PYRUVATE-CARBOXYLASE; TRANSCRIPTION FACTOR; BETA-CELLS; MULTIPLE TRANSCRIPTS; 5'-END HETEROGENEITY	Mitochondrial glycerol phosphate dehydrogenase (mGPD) is abundant in the normal pancreatic insulin cell, but its level is lowered 50% by diabetes. To evaluate mGPD expression, we cloned and characterized the 5'-flanking region of the human mGPD gene. The gene has two alternative first exons and two promoters. The downstream promoter (B) is 10 times more active than the upstream promoter (A) in insulin secreting cells (INS-1) and HeLa cells. Promoter B has higher activity in INS-1 than in non-beta cells. Deletion and mutation analysis suggested that a NRF-2 binding site at -94 to -101 and an E2F binding site at -208 to -215 are important regulatory cis elements in promoter B, Gel mobility shift assays indicated that the -94 to -101 region binds the NRF-2 protein. When INS-1 cells were maintained in the presence of high glucose (25 mM) for 7 days, mGPD was the only 1 of 6 enzyme activities lowered (53%), mGPD promoter B activity was reduced by 60% in INS-1 cells by the high glucose, but in HepG2 cells and HeLa cells, promoter B activity was unchanged or slightly increased. Deletion analysis indicated the glucose responsiveness was distributed across the region from -340 to -260 in promoter B. The results indicate that mGPD gene transcription in the beta cell is regulated differently from other cells and that decreased mGPD promoter B transcription is at least in part the cause of the decreased beta cell mGPD levels in diabetes.	Univ Wisconsin, Childrens Diabet Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	MacDonald, MJ (corresponding author), Univ Wisconsin, Sch Med, Rm 3459,1300 Univ Ave, Madison, WI 53706 USA.				NIDDK NIH HHS [DK28348] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK028348, R01DK028348] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; AZHAR S, 1983, METABOLISM, V32, P1019, DOI 10.1016/0026-0495(83)90070-7; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BASU A, 1993, J BIOL CHEM, V268, P4188; BROWN LJ, 1994, J BIOL CHEM, V269, P14363; Brown LJ, 1996, GENE, V172, P309, DOI 10.1016/0378-1119(96)00019-4; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; Chinenov Y, 1998, J BIOL CHEM, V273, P6203, DOI 10.1074/jbc.273.11.6203; FERNANDEZALVAREZ J, 1994, DIABETOLOGIA, V37, P177, DOI 10.1007/s001250050090; Ferrer J, 1996, DIABETES, V45, P262, DOI 10.2337/diabetes.45.2.262; GIROIX MH, 1991, DIABETES, V40, P227, DOI 10.2337/diabetes.40.2.227; GIROIX MH, 1993, BIOCHEM MED METAB B, V50, P301, DOI 10.1006/bmmb.1993.1072; Gong DW, 1998, DNA CELL BIOL, V17, P301, DOI 10.1089/dna.1998.17.301; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; Jitrapakdee S, 1997, J BIOL CHEM, V272, P20522, DOI 10.1074/jbc.272.33.20522; Jitrapakdee S, 1998, J BIOL CHEM, V273, P34422, DOI 10.1074/jbc.273.51.34422; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; Koza RA, 1996, ARCH BIOCHEM BIOPHYS, V336, P97, DOI 10.1006/abbi.1996.0536; LEE YP, 1965, J BIOL CHEM, V240, P1427; LEHN DA, 1994, GENE, V150, P417, DOI 10.1016/0378-1119(94)90469-3; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MacDonald MJ, 1996, DIABETES, V45, P1626, DOI 10.2337/diabetes.45.11.1626; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; MacDonald MJ, 1996, DIABETES, V45, P886, DOI 10.2337/diabetes.45.7.886; MACDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MACDONALD MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P305, DOI 10.1006/abbi.1995.1297; MACDONALD MJ, 1990, CANCER RES, V50, P7203; MACDONALD MJ, 1983, J CLIN ENDOCR METAB, V57, P662, DOI 10.1210/jcem-57-3-662; Martin ME, 1996, J BIOL CHEM, V271, P25617, DOI 10.1074/jbc.271.41.25617; MEGLASSON MD, 1989, AM J PHYSIOL, V256, pE173, DOI 10.1152/ajpendo.1989.256.1.E173; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; OHNEDA M, 1995, DIABETOLOGIA, V38, P173, DOI 10.1007/BF00400091; OHNEDA M, 1994, AM J PHYSIOL-ENDOC M, V267, pE968, DOI 10.1152/ajpendo.1994.267.6.E968; OHNEDA M, 1993, DIABETES, V42, P1065, DOI 10.2337/diabetes.42.7.1065; OSTENSON CG, 1993, DIABETOLOGIA, V36, P722, DOI 10.1007/BF00401142; Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412; RASSCHAERT J, 1994, MOL CELL BIOCHEM, V135, P137, DOI 10.1007/BF00926516; RUTTER GA, 1992, BIOCHIM BIOPHYS ACTA, V1175, P107, DOI 10.1016/0167-4889(92)90016-5; SCHENKMAN JB, 1965, ENDOCRINOLOGY, V76, P1055, DOI 10.1210/endo-76-6-1055; SENER A, 1993, FEBS LETT, V316, P224, DOI 10.1016/0014-5793(93)81297-D; SENER A, 1993, BIOCHEM MOL BIOL INT, V30, P397; SMALE ST, 1989, CELL, V57, P13; STRAHLE U, 1992, P NATL ACAD SCI USA, V89, P6731, DOI 10.1073/pnas.89.15.6731; Suzuki F, 1998, J BIOL CHEM, V273, P29302, DOI 10.1074/jbc.273.45.29302; SUZUKI H, 1995, J BIOL CHEM, V270, P9676, DOI 10.1074/jbc.270.16.9676; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; Weir GC, 1997, ACTA DIABETOL, V34, P177, DOI 10.1007/s005920050071; WEN LP, 1990, P NATL ACAD SCI USA, V87, P8545, DOI 10.1073/pnas.87.21.8545; Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	57	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38012	38021		10.1074/jbc.M004078200	http://dx.doi.org/10.1074/jbc.M004078200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10954707	hybrid			2022-12-27	WOS:000165618700095
J	Qureshi, SA; Ding, V; Li, ZH; Szalkowski, D; Biazzo-Ashnault, DE; Xie, D; Saperstein, R; Brady, E; Huskey, S; Shen, XL; Liu, K; Xu, LB; Salituro, GM; Heck, JV; Moller, DE; Jones, AB; Zhang, BB				Qureshi, SA; Ding, V; Li, ZH; Szalkowski, D; Biazzo-Ashnault, DE; Xie, D; Saperstein, R; Brady, E; Huskey, S; Shen, XL; Liu, K; Xu, LB; Salituro, GM; Heck, JV; Moller, DE; Jones, AB; Zhang, BB			Activation of insulin signal transduction pathway and anti-diabetic activity of small molecule insulin receptor activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; KINASE-ACTIVITY; TYROSINE KINASE; PROTEIN-KINASE; OBESE SUBJECTS; PHOSPHOINOSITIDE 3-KINASE; 3T3-L1 ADIPOCYTES; CRYSTAL-STRUCTURE; PHOSPHORYLATION; RESISTANCE	We recently described the identification of a non-peptidyl fungal metabolite (L-783,281, compound I), which induced activation of human insulin receptor (Ht) tyrosine kinase and mediated insulin-like effects in cells, as well as decreased blood glucose levels in murine models of Type 2 diabetes (Zhang, B., Salituro, G., Szalkowski, D., Li, Z., Zhang, Y., Royo, I., Vilella, D., Diet, M T., Pelaez, F., Ruby, C., Kendall, R. L., Mao, X., Griffin, P., Calaycay, J., Zierath, J. R., Heck, J. V., Smith, R, G. & Moller, D. E. (1999) Science 284, 974-977). Here we report the characterization of an active analog (compound 2) with enhanced IR kinase activation potency and selectivity over related receptors (insulin-Like growth factor I receptor, epidermal growth factor receptor, and platelet-derived growth factor receptor). The IR activators stimulated tyrosine kinase activity of partially purified native IR and recombinant IR tyrosine kinase domain. Administration of the IR activators to mice was associated with increased IR tyrosine kinase activity in liver. In vivo oral treatment with compound 2 resulted in significant glucose lowering in several rodent models of diabetes. In db/db mice, oral administration of compound 2 elicited significant correction of hyperglycemia, In a streptozotocin-induced diabetic mouse model, compound 2 potentiated the glucose-lowering effect of insulin. In normal rats, compound 2 improved oral glucose tolerance with significant reduction in insulin release following glucose challenge. A structurally related inactive analog (compound 3) was not effective on insulin receptor activation or glucose lowering in db/db mice. Thus, small molecule IR activators exert insulin mimetic and sensitizing effects in cells and in animal models of diabetes. These results have implications for the future development of new therapies for diabetes mellitus.	Merck Res Labs, Dept Mol Endocrinol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Pharmacol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Drug Metab, Rahway, NJ 07065 USA; Merck Res Labs, Dept Comparat Med, Rahway, NJ 07065 USA; Merck Res Labs, Dept Nat Prod Drug Discovery, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company	Zhang, BB (corresponding author), Merck Res Labs, Dept Mol Endocrinol, R80W250,POB 2000,126 E Lincoln Ave, Rahway, NJ 07065 USA.							Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; BLONDEL O, 1989, DIABETES METAB, V15, P382; BLONDEL O, 1989, DIABETOLOGIA, V32, P185, DOI 10.1007/BF00265092; BLONDEL O, 1990, AM J PHYSIOL, V258, pE459, DOI 10.1152/ajpendo.1990.258.3.E459; BONINI JA, 1995, BIOCHEM BIOPH RES CO, V212, P933, DOI 10.1006/bbrc.1995.2059; CARO JF, 1986, J CLIN INVEST, V78, P249, DOI 10.1172/JCI112558; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; FREIDENBERG GR, 1987, J CLIN INVEST, V79, P240, DOI 10.1172/JCI112789; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; KADOWAKI T, 1984, J BIOL CHEM, V259, P4208; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOLB H, 1987, DIABETES METAB REV, V3, P751, DOI 10.1002/dmr.5610030308; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; Liu K, 2000, J MED CHEM, V43, P3487, DOI 10.1021/jm000285q; Luo RZT, 1999, SCIENCE, V285, P1077, DOI 10.1126/science.285.5430.1077; OLEFSKY JM, 1976, J CLIN INVEST, V57, P1165, DOI 10.1172/JCI108384; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROSEN OM, 1989, DIABETES, V38, P1508, DOI 10.2337/diabetes.38.12.1508; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SINHA MK, 1987, DIABETES, V36, P620, DOI 10.2337/diabetes.36.5.620; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; WHITE MF, 1994, J BIOL CHEM, V269, P1; White MF, 1998, CURR TOP MICROBIOL, V228, P179; WHITE MF, 1988, J BIOL CHEM, V263, P2969; YU KT, 1984, J BIOL CHEM, V259, P5277; Zhang B, 1999, SCIENCE, V284, P974, DOI 10.1126/science.284.5416.974; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594; ZICK Y, 1983, J BIOL CHEM, V258, P75	40	58	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36590	36595		10.1074/jbc.M006287200	http://dx.doi.org/10.1074/jbc.M006287200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967116	hybrid			2022-12-27	WOS:000165577700020
J	Stocco, CO; Zhong, LP; Sugimoto, Y; Ichikawa, A; Lau, LF; Gibori, G				Stocco, CO; Zhong, LP; Sugimoto, Y; Ichikawa, A; Lau, LF; Gibori, G			Prostaglandin F-2 alpha-induced expression of 20 alpha-hydroxysteroid dehydrogenase involves the transcription factor NUR77	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; RAT CORPUS-LUTEUM; RIBONUCLEIC-ACID EXPRESSION; ORPHAN STEROID-RECEPTOR; SERUM GROWTH-FACTORS; NGFI-B NUR77; NUCLEAR RECEPTOR; CORPORA-LUTEA; GENE NUR77; LUTEINIZING-HORMONE	Prostaglandin F(2)alpha (PGF(2)alpha) binding to its receptor on the rat corpus luteum triggers various signal transduction pathways that lead to the activation of a steroidogenic enzyme, 20 alpha -hydroxysteroid dehydrogenase (20 alpha -HSD), which in turn catabolizes progesterone. The molecular mechanism underlying PGF(2)alpha -induced 20 alpha -HSD) enzyme activity has not yet been explored. In this report we show, using mice lacking PGF(2)alpha receptor and pregnant rats, that PGF(2)alpha is responsible for the rapid and massive expression of the 20 alpha -HSD gene at the end of pregnancy leading to a decrease in progesterone secretion. We also present evidence that PGF(2)alpha enhances 20 alpha -HSD promoter activity. We have determined a region upstream of the -1590 position in the 20 alpha -HSD promoter that confers regulation by PGF(2)alpha in ovarian primary cells. This region encompasses a unique transcription factor-binding site with a sequence of a NUR77 response element. Deletion of this motif or overexpression of a NUR77 dominant negative protein caused a complete loss of 20 alpha -HSD promoter activation by PGF(2)alpha. NUR77 also transactivated the 20a-HSD promoter in transient transfection experiments in corpus luteum-derived cells (GG-CL), This induction required the NUR77-transactivating domain. We also show that PGF(2)alpha induces a very rapid expression of NUR77 that binds to a distal response element located at -1599/ -1606 but does not interact with another proximal putative NUR77 response element located downstream in the promoter. A rapid increase in NUR77 mRNA was observed in mice corpora lutea just before parturition at a time when 20 alpha -HSD becomes expressed. This increase in the expression of both genes was not seen in PGF(2)alpha receptor knockout mice. By using cyclosporin A and PGF(2)alpha treatment, we established that inhibition of NUR77 DNA binding in vivo prevents PGF(2)alpha induction of the 20 alpha -HSD gene in the corpus luteum. Taken together, our results demonstrate, for the first time, that PGF(2)alpha induces in the corpus luteum the expression of the nuclear orphan receptor and transcription factor, NUR77, which in turn leads to the transcriptional stimulation of 20 alpha -HSD, triggering the decrease in serum progesterone essential for parturition.	Univ Illinois, Coll Med, Dept Physiol & Biophys MC 901, Chicago, IL 60612 USA; Kyoto Univ, Fac Pharmaceut Sci, Dept Physiol Chem, Kyoto 6068501, Japan; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Kyoto University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gibori, G (corresponding author), Univ Illinois, Coll Med, Dept Physiol & Biophys MC 901, 835 S Wolcott Ave, Chicago, IL 60612 USA.		Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X; Lau, Lester/0000-0002-4364-2914	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD011119, R01HD011119, R01HD012356] Funding Source: NIH RePORTER; NICHD NIH HHS [HD12356, HD11119] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBARRACIN CT, 1994, ENDOCRINOLOGY, V134, P2453, DOI 10.1210/en.134.6.2453; ALBARRACIN CT, 1991, ENDOCRINOLOGY, V129, P1821, DOI 10.1210/endo-129-4-1821; BAST JD, 1972, ENDOCRINOLOGY, V91, P1499, DOI 10.1210/endo-91-6-1499; Bertrand JE, 1996, ENDOCRINE, V4, P165, DOI 10.1007/BF02782761; BUSSMANN LE, 1979, J STEROID BIOCHEM, V11, P1485, DOI 10.1016/0022-4731(79)90125-0; CHANG SF, 1995, MOL ENDOCRINOL, V9, P1330, DOI 10.1210/me.9.10.1330; CHIN R, 1988, CELL, V54, P541; CRAWFORD PA, 1995, MOL CELL BIOL, V15, P4331; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; DAVIS IJ, 1991, MOL ENDOCRINOL, V5, P854, DOI 10.1210/mend-5-6-854; DEIS RP, 1971, NATURE, V229, P568, DOI 10.1038/229568a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAHMER TJ, 1990, MOL CELL BIOL, V10, P6454; Fiedler EP, 1999, BIOL REPROD, V61, P643, DOI 10.1095/biolreprod61.3.643; FONG HW, 1996, BIOL REPROD S1, V54, P169; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FUCHS AR, 1974, BIOL REPROD, V10, P24, DOI 10.1095/biolreprod10.1.24; Gibori G., 1993, OVARY, P261; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HASHIMOTO I, 1969, ENDOCRINOLOGY, V84, P886, DOI 10.1210/endo-84-4-886; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; Ishida Maho, 1999, Journal of Reproduction and Development, V45, P321, DOI 10.1262/jrd.45.321; Juengel JL, 1996, BIOL REPROD, V54, P1096, DOI 10.1095/biolreprod54.5.1096; JUENGEL JL, 1993, ENDOCRINOLOGY, V132, P249, DOI 10.1210/en.132.1.249; LEE SL, 1995, SCIENCE, V269, P532, DOI 10.1126/science.7624775; LEUNG PCK, 1992, ENDOCR REV, V13, P476, DOI 10.1210/er.13.3.476; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Mao JF, 1997, ENDOCRINOLOGY, V138, P182, DOI 10.1210/en.138.1.182; MARUYAMA K, 1995, CANCER LETT, V96, P117, DOI 10.1016/0304-3835(95)03921-I; MCLEAN MP, 1995, ENDOCRINOLOGY, V136, P4963, DOI 10.1210/en.136.11.4963; Meinke G, 1999, NAT STRUCT BIOL, V6, P471; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MIURA R, 1994, BIOCHEM J, V299, P561, DOI 10.1042/bj2990561; MORISHIG.WK, 1973, ENDOCRINOLOGY, V92, P1527, DOI 10.1210/endo-92-5-1527; MURDOCH WJ, 1995, J ANIM SCI, V73, P1789; Narko K, 1997, ENDOCRINOLOGY, V138, P3638, DOI 10.1210/en.138.9.3638; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Niswender Gordon D., 1994, P781; Okabe T, 1998, J ENDOCRINOL, V156, P169, DOI 10.1677/joe.0.1560169; Okabe T, 1998, Nihon Rinsho, V56, P1734; OLOFSSON J, 1990, BIOL REPROD, V42, P792, DOI 10.1095/biolreprod42.5.792; OLOFSSON J, 1992, PROSTAG LEUKOTR ESS, V46, P151, DOI 10.1016/0952-3278(92)90222-5; Olofsson JI, 1996, MOL CELL ENDOCRINOL, V123, P45, DOI 10.1016/0303-7207(96)03894-4; PARMER TG, 1994, BIOL REPROD S1, V51, P142; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PHARRISS BB, 1969, P SOC EXP BIOL MED, V130, P92; Sandhoff TW, 1999, ENDOCRINE, V10, P83, DOI 10.1385/ENDO:10:1:83; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; Spencer WE, 1999, BIOTECHNIQUES, V27, P1044, DOI 10.2144/99275rr04; STRAUSS JF, 1974, PROSTAG OTH LIPID M, V5, P73, DOI 10.1016/S0090-6980(74)80134-6; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Sugino N, 1998, ENDOCRINOLOGY, V139, P1936, DOI 10.1210/en.139.4.1936; Telleria CM, 1999, STEROIDS, V64, P760, DOI 10.1016/S0039-128X(99)00061-6; Telleria CM, 1997, ENDOCRINOLOGY, V138, P4812, DOI 10.1210/en.138.11.4812; WIEST WG, 1968, ENDOCRINOLOGY, V82, P844, DOI 10.1210/endo-82-4-844; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YAZDANBAKHSH K, 1995, P NATL ACAD SCI USA, V92, P437, DOI 10.1073/pnas.92.2.437; YOON JK, 1994, MOL CELL BIOL, V14, P7731, DOI 10.1128/MCB.14.12.7731; Zhong L, 1998, BIOCHEM BIOPH RES CO, V249, P797, DOI 10.1006/bbrc.1998.9229; Zhong L, 1997, BIOCHEM BIOPH RES CO, V235, P587, DOI 10.1006/bbrc.1997.6833	65	113	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37202	37211		10.1074/jbc.M006016200	http://dx.doi.org/10.1074/jbc.M006016200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973968	hybrid			2022-12-27	WOS:000165577700102
J	Lumb, MJ; Danpure, CJ				Lumb, MJ; Danpure, CJ			Functional synergism between the most common polymorphism in human alanine : glyoxylate aminotransferase and four of the most common disease-causing mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY HYPEROXALURIA TYPE-1; PEROXISOMAL L-ALANINE; HUMAN-LIVER; POINT MUTATION; PYRUVATE AMINOTRANSFERASE; HEPATIC ALANINE; GENE; MITOCHONDRIAL; SERINE; DIAGNOSIS	The autosomal recessive disorder primary hyperoxaluria type 1 (PN1) is caused by a deficiency of the liver-specific pyridoxal-phosphate-dependent enzyme alanine:glyoxylate aminotransferase (AGT), Numerous mutations and polymorphisms in the gene encoding AGT have been identified, but in only a few cases has the causal relationship between genotype and phenotype actually been demonstrated. In this study, we have determined the effects of the most common naturally occurring amino acid substitutions (both normal polymorphisms and disease-causing mutations) on the properties, especially specific catalytic activity, of purified recombinant AGT. The results presented in this paper show the following: 1) normal human His-tagged AGT can be expressed at high levels in Escherichia coli and purified in a correctly folded, dimerized and catalytically active state; 2) presence of the common P11L polymorphism decreases the specific activity of purified recombinant AGT by a factor of three; 3) AGTs containing four of the most common PH1-specific mutations (G41R, F152I, G170R, and I244T) are all soluble and catalytically active in the absence of the P11L polymorphism, but in its presence all lead to protein destabilization and aggregation into inclusion bodies; 4) naturally occurring;and artificial amino acid substitutions that lead to peroxisome-to-mitochondrion AGT mistargeting in mammalian cells also lead to destabilization and aggregation in E. coli; and 5) the PH1-specific G82E mutation abolishes AGT catalytic activity by interfering with cofactor binding, as does the artificial K209R mutation at the putative site of cofactor Shiff base formation. These results are discussed in the light of the high allelic frequency (similar to 20%) of the P11L polymorphism and its importance ill determining the phenotypic manifestations of mutations in PH1.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Biol, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Danpure, CJ (corresponding author), UCL, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	c.danpure@ucl.ac.uk						ALLSOP J, 1987, CLIN CHIM ACTA, V170, P187, DOI 10.1016/0009-8981(87)90127-6; BARRATT TM, 1999, PEDIAT NEPHROLOGY, P609; COOPER PJ, 1988, J HISTOCHEM CYTOCHEM, V36, P1285, DOI 10.1177/36.10.3418107; Danpure CJ, 1997, BIOESSAYS, V19, P317, DOI 10.1002/bies.950190409; DANPURE CJ, 1994, J INHERIT METAB DIS, V17, P487, DOI 10.1007/BF00711363; Danpure CJ, 1996, PRENATAL DIAG, V16, P587; DANPURE CJ, 1994, HUM GENET, V94, P55, DOI 10.1007/BF02272842; DANPURE CJ, 1993, AM J HUM GENET, V53, P417; DANPURE CJ, 1988, CLIN SCI, V75, P315, DOI 10.1042/cs0750315; DANPURE CJ, 1986, FEBS LETT, V201, P20, DOI 10.1016/0014-5793(86)80563-4; DANPURE CJ, 1989, J CELL BIOL, V108, P1345, DOI 10.1083/jcb.108.4.1345; Danpure CJ., 1995, CALCIUM OXALATE BIOL, P189; Danpure CJ, 1996, KIDNEY STONES MED SU, P859; DANPURE CJ, 1995, METABOLIC MOL BASES, P2385; Fancy DA, 1999, P NATL ACAD SCI USA, V96, P6020, DOI 10.1073/pnas.96.11.6020; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; Holbrook JD, 2000, MOL BIOL EVOL, V17, P387, DOI 10.1093/oxfordjournals.molbev.a026318; Horvath VAP, 1995, CLIN CHIM ACTA, V243, P105, DOI 10.1016/0009-8981(95)06149-5; Ishikawa K, 1996, J BIOCHEM, V119, P970; KAMODA N, 1980, BIOCHEM MED METAB B, V23, P25, DOI 10.1016/0006-2944(80)90051-4; Ledent P, 1997, FEBS LETT, V413, P194, DOI 10.1016/S0014-5793(97)00908-3; Leiper JM, 1996, J CELL BIOL, V135, P939, DOI 10.1083/jcb.135.4.939; MOTLEY A, 1995, J CELL BIOL, V131, P95, DOI 10.1083/jcb.131.1.95; NISHIYAMA K, 1991, BIOCHEM BIOPH RES CO, V176, P1093, DOI 10.1016/0006-291X(91)90396-O; NISHIYAMA K, 1993, J CELL BIOL, V123, P1237, DOI 10.1083/jcb.123.5.1237; NOGUCHI T, 1979, ARCH BIOCHEM BIOPHYS, V196, P645, DOI 10.1016/0003-9861(79)90319-9; ODA T, 1987, EUR J BIOCHEM, V168, P537, DOI 10.1111/j.1432-1033.1987.tb13451.x; Pirulli D, 1999, HUM GENET, V104, P523, DOI 10.1007/s004390050998; PURDUE PE, 1991, HUM GENET, V87, P394; PURDUE PE, 1991, P NATL ACAD SCI USA, V88, P10900, DOI 10.1073/pnas.88.23.10900; PURDUE PE, 1992, GENOMICS, V13, P215, DOI 10.1016/0888-7543(92)90225-H; PURDUE PE, 1990, J CELL BIOL, V111, P2341, DOI 10.1083/jcb.111.6.2341; PURDUE PE, 1992, EUR J BIOCHEM, V207, P757, DOI 10.1111/j.1432-1033.1992.tb17106.x; ROBERTSON WG, 1980, NEPHRON, V26, P105, DOI 10.1159/000181963; Rumsby G, 1997, ANN CLIN BIOCHEM, V34, P400, DOI 10.1177/000456329703400411; TAKADA Y, 1990, BIOCHEM J, V268, P517, DOI 10.1042/bj2680517; TAKADA Y, 1982, COMP BIOCHEM PHYS B, V72, P597, DOI 10.1016/0305-0491(82)90512-0; Tarn AC, 1997, J INHERIT METAB DIS, V20, P689, DOI 10.1023/A:1005326510239; THOMPSON JS, 1966, ARCH BIOCHEM BIOPHYS, V117, P599, DOI 10.1016/0003-9861(66)90101-9; THOMPSON JS, 1967, J BIOL CHEM, V242, P3614; VANSCHNAKENBURG C, 1998, THESIS U LONDON LOND; vonSchnakenburg C, 1997, J MED GENET, V34, P489, DOI 10.1136/jmg.34.6.489; WANDERS RJA, 1990, CLIN CHIM ACTA, V189, P139, DOI 10.1016/0009-8981(90)90084-6; Xue HH, 1999, J BIOL CHEM, V274, P16028, DOI 10.1074/jbc.274.23.16028; Yendt E R, 1988, Md Med J, V37, P857	45	122	126	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36415	36422		10.1074/jbc.M006693200	http://dx.doi.org/10.1074/jbc.M006693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10960483	hybrid			2022-12-27	WOS:000165382000107
J	Thrower, EC; Mobasheri, H; Dargan, S; Marius, P; Lea, EJA; Dawson, AP				Thrower, EC; Mobasheri, H; Dargan, S; Marius, P; Lea, EJA; Dawson, AP			Interaction of luminal calcium and cytosolic ATP in the control of type 1 inositol (1,4,5)-trisphosphate receptor channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,4,5-TRISPHOSPHATE-INDUCED CA2+ RELEASE; TRISPHOSPHATE-SENSITIVE STORES; ENDOPLASMIC-RETICULUM; CEREBELLAR MICROSOMES; CELLS; ACTIVATION; BINDING; ENTRY; HETEROGENEITY; MOBILIZATION	Ca2+ within intracellular stores (luminal Ca2+) is believed to play a role in regulating Ca2+ release into the cytosol via the inositol (1,4,5)-trisphosphate (Ins(1,4,5)P-3)-gated Ca2+ channel (or Ins(1,4,5)P-3 receptor). To investigate this, we incorporated purified Type 1 Ins(1,4,5)-P-3 receptor from rat cerebellum into planar lipid bilayers and monitored effects at altered luminal [Ca2+] using K+ as the current carrier. At a high luminal [Ca2+] and in the presence of optimal [Ins(1,4,5)P-3] and cytosolic [Ca2+], a short burst of Ins(1,4,5)P-3 receptor channel activity was followed by complete inactivation. Lowering the luminal [Ca2+] caused the channel to reactivate indefinitely. At luminal [Ca2+], reflecting a partially empty store, channel activity did not inactivate. The addition of cytosolic ATP to a channel inactivated by high luminal [Ca2+] caused reactivation. We provide evidence that luminal Ca2+ is exerting its effects via a direct interaction with the luminal face of the receptor. Activation of the receptor by ATP may act as a device by which cytosolic Ca2+ overload is prevented when the energy state of the cell is compromised.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Dawson, AP (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	a.dawson@uea.ac.uk	Mobasheri, Hamid/AAX-7520-2020; Mobasheri, Hamid/GYD-7401-2022	Amici-Dargan, Sheila/0000-0001-7563-5041				BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRCHMACHIN MA, 1986, BIOCHIM BIOPHYS ACTA, V855, P277, DOI 10.1016/0005-2736(86)90175-6; Bultynck G, 2000, J PHYSIOL-LONDON, V525, P681, DOI 10.1111/j.1469-7793.2000.t01-1-00681.x; Bygrave FL, 1996, CELL CALCIUM, V19, P547, DOI 10.1016/S0143-4160(96)90064-0; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; COMBETTES L, 1994, J BIOL CHEM, V269, P17561; Combettes L, 1996, EMBO J, V15, P2086, DOI 10.1002/j.1460-2075.1996.tb00562.x; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; COMBETTES L, 1992, FEBS LETT, V301, P287, DOI 10.1016/0014-5793(92)80258-I; Dawson AP, 1997, CURR BIOL, V7, pR544, DOI 10.1016/S0960-9822(06)00277-6; DEMPSTER J, 1995, STRATHCLYDE ELECTROP; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HANNAERTMERAH Z, 1995, CELL CALCIUM, V18, P390, DOI 10.1016/0143-4160(95)90054-3; HIROSE K, 1994, NATURE, V372, P791; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; HORNE JH, 1995, BIOCHEMISTRY-US, V34, P12738, DOI 10.1021/bi00039a033; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; Mak DOD, 1998, P NATL ACAD SCI USA, V95, P15821, DOI 10.1073/pnas.95.26.15821; Marchant JS, 1997, CURR BIOL, V7, P510, DOI 10.1016/S0960-9822(06)00222-3; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MARSHALL ICB, 1994, BIOCHEM J, V301, P591, DOI 10.1042/bj3010591; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; Missiaen L, 1997, BIOCHEM J, V325, P661, DOI 10.1042/bj3250661; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; Missiaen L, 1996, CELL CALCIUM, V19, P91, DOI 10.1016/S0143-4160(96)90016-0; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1993, BIOCHEM J, V292, P631, DOI 10.1042/bj2920631; ONDIAS K, 1998, ANN NY ACAD SCI, V853, P149; PARYS JB, 1993, J BIOL CHEM, V268, P25206; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; SCHINDLER H, 1980, FEBS LETT, V122, P77, DOI 10.1016/0014-5793(80)80405-4; SHUTTLEWORTH TJ, 1995, CELL CALCIUM, V17, P393, DOI 10.1016/0143-4160(95)90085-3; SHUTTLEWORTH TJ, 1992, J BIOL CHEM, V267, P3573; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005; SUAREZISLA BA, 1991, J PHYSIOL-LONDON, V441, P575, DOI 10.1113/jphysiol.1991.sp018768; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Tanimura A, 1996, J CELL BIOL, V132, P607, DOI 10.1083/jcb.132.4.607; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; Thrower E., 1997, Biophysical Journal, V72, pA294; Thrower EC, 1998, BIOCHEM J, V330, P559; VANDEPUT FHMM, 1994, J BIOL CHEM, V269, P12438; WORLEY PF, 1987, NATURE, V325, P159, DOI 10.1038/325159a0; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; YAO Y, 1993, J PHYSIOL-LONDON, V468, P275, DOI 10.1113/jphysiol.1993.sp019771; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; ZHANG BX, 1993, J BIOL CHEM, V268, P10997	54	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36049	36055		10.1074/jbc.M000970200	http://dx.doi.org/10.1074/jbc.M000970200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10956640	hybrid			2022-12-27	WOS:000165382000058
J	Casanovas, O; Miro, B; Estanyol, JM; Itarte, E; Agell, N; Bachs, O				Casanovas, O; Miro, B; Estanyol, JM; Itarte, E; Agell, N; Bachs, O			Osmotic stress regulates the stability of cyclin D1 in a p38(SAPK2)-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; P38 MAP KINASE; RETINOBLASTOMA PROTEIN; GROWTH-FACTOR; ANTIPROLIFERATIVE AGENTS; KINETIC MECHANISM; CELLULAR-RESPONSE; DEPENDENT KINASES; KIDNEY-CELLS; HEAT-SHOCK	We report here that different cell stresses regulate the stability of cyclin D1 protein. Exposition of Granta 519 cells to osmotic shock, oxidative stress, and arsenite induced the post-transcriptional down-regulation of cyclin D1. In the case of osmotic shock, this effect was completely reversed by the addition of p38(SAPK2)-specific inhibitors (SB203580 or SB220025), indicating that this effect is dependent on p38(SAPK2) activity. Moreover, the use of proteasome inhibitors prevented this down-regulation. Thus, osmotic shock induces proteasomal degradation of cyclin D1 protein by a p38(SAPK2)-dependent pathway. The effect of p38(SAPK2) On cyclin D1 stability might be mediated by direct phosphorylation at specific sites. We found that p38(SAPK2) phosphorylates cyclin D1 in vitro at Thr(286) and that this phosphorylation triggers the ubiquitination of cyclin D1. These results link for the first time a stress-induced MAP kinase pathway to cyclin D1 protein stability, and they will help to understand the molecular mechanisms by which stress transduction pathways regulate the cell cycle machinery and take control over cell proliferation.	Univ Barcelona, Fac Med, Dept Biol Cellular & Anat Patol, Inst Invest Biomed August Pi Sunyer, Barcelona 08036, Spain; Univ Autonoma Barcelona, Fac Ciencies, Dept Bioquim & Biol Mol, Bellaterra, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Autonomous University of Barcelona	Bachs, O (corresponding author), Univ Barcelona, Fac Med, Dept Cellular Biol, Casanova 143, Barcelona 08036, Spain.	bachs@medicina.ub.es	Agell, Neus/E-9640-2016; Itarte, Emilio/K-5275-2014; Miro-Mur, Francesc A./AAT-3013-2020; Itarte, Emilio/Q-6246-2019; Estanyol, Josep M/I-1039-2015; Casanovas, Oriol/L-5210-2014	Agell, Neus/0000-0002-1205-6074; Itarte, Emilio/0000-0002-9366-5807; Miro-Mur, Francesc A./0000-0003-3936-2693; Estanyol, Josep M/0000-0001-8621-0057; Casanovas, Oriol/0000-0002-4298-3995				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BATES S, 1994, ONCOGENE, V9, P1633; Chen GJ, 2000, BIOCHEMISTRY-US, V39, P2079, DOI 10.1021/bi9919495; COCKS BG, 1992, J BIOL CHEM, V267, P12307; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; Fox T, 1999, FEBS LETT, V461, P323, DOI 10.1016/S0014-5793(99)01488-X; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Jackson JR, 1998, J PHARMACOL EXP THER, V284, P687; Jadayel DM, 1997, LEUKEMIA, V11, P64, DOI 10.1038/sj.leu.2400555; Kultz D, 1997, J BIOL CHEM, V272, P13165, DOI 10.1074/jbc.272.20.13165; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; LoGrasso PV, 1997, BIOCHEMISTRY-US, V36, P10422, DOI 10.1021/bi9706778; MATSUSHIME H, 1991, COLD SPRING HARB SYM, V56, P69; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; MAYOL X, 1995, ONCOGENE, V11, P801; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NEET K, 1995, MOL CELL BIOL, V15, P4908; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ronchetti D, 1999, BLOOD, V93, P1330, DOI 10.1182/blood.V93.4.1330.404k04_1330_1337; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; SHERR CJ, 1994, STEM CELLS, V12, P47; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Vadiveloo PK, 1998, J BIOL CHEM, V273, P23104, DOI 10.1074/jbc.273.36.23104; Vadiveloo PK, 1996, ONCOGENE, V13, P599; VAIRO G, 1991, J IMMUNOL, V146, P3469; Villalonga P, 2000, ONCOGENE, V19, P690, DOI 10.1038/sj.onc.1203341; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Winston JT, 1996, ONCOGENE, V12, P127; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	56	124	127	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35091	35097		10.1074/jbc.M006324200	http://dx.doi.org/10.1074/jbc.M006324200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952989	hybrid			2022-12-27	WOS:000165422800037
J	Pollock, VV; Barber, MJ				Pollock, VV; Barber, MJ			Serine 121 is an essential amino acid for biotin sulfoxide reductase functionality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDOPTERIN GUANINE DINUCLEOTIDE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; FORMATE DEHYDROGENASE; MOLYBDENUM-COFACTOR; DIMETHYLSULFOXIDE REDUCTASE; METHIONINE SULFOXIDE; NITRATE REDUCTASE; STRUCTURAL GENE; OPERON	Rhodobacter sphaeroides f. sp. denitrificans biotin sulfoxide reductase (BSOR) catalyzes the reduction of d-biotin d-sulfoxide (BSO) to biotin, an important step in oxidized vitamin salvaging, In addition to BSO, the enzyme also catalyzes the reduction of a variety of other substrates, including methionine sulfoxide, with decreased efficiencies, suggesting a potential role as a general cell protector against oxidative damage. Recombinant BSOR, expressed as a glutathione S-transferase fusion protein, contains the molybdopterin guanine dinucleotide cofactor (MGD) as its sole prosthetic group, which is required for the reduction of BSO by either NADPH or reduced methyl viologen, Comparison of the amino acid sequences of BSOR and the closely related MGD-containing enzyme, dimethyl sulfoxide reductase, has indicated a number of conserved residues, including an active site serine residue, serine 121, which has been potentially identified as the fifth coordinating ligand of Mo in BSOR. Site-directed mutagenesis has been used to replace serine 121 with cysteine, threonine, or alanine residues in the BSOR sequence to asses the role of this residue in catalysis and/or Mo coordination. All three BSOR mutant proteins were expressed, purified to homogeneity, and demonstrated to contain both MGD by fluorescence spectroscopy and Mo by inductively coupled plasma mass spectrometry, similar to wild-type enzyme. However, all three mutant proteins were devoid of BSOR activity using either NADPH or reduced methyl viologen as the electron donor. These results strongly suggest that serine 121 in BSOR is essential for catalysis but is not essential for either Mo coordination or MGD binding.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Barber, MJ (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA.	mbarber@com1.med.usf.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032696] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32696] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXLEY MJ, 1991, P NATL ACAD SCI USA, V88, P8450, DOI 10.1073/pnas.88.19.8450; BERG BL, 1991, J BIOL CHEM, V266, P22380; BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; BLASCO F, 1989, MOL GEN GENET, V218, P249, DOI 10.1007/BF00331275; BLASCO F, 1990, MOL GEN GENET, V222, P104, DOI 10.1007/BF00283030; BROT N, 1981, P NATL ACAD SCI-BIOL, V78, P2155, DOI 10.1073/pnas.78.4.2155; Campbell ADC, 1996, J MOL EVOL, V42, P85, DOI 10.1007/BF02198832; CLEARY PP, 1974, BIOCH CELL BIOL, V56, P69; del Campillo-Campbell A, 1979, Methods Enzymol, V62, P379; EJIRI SI, 1980, ANAL BIOCHEM, V102, P393, DOI 10.1016/0003-2697(80)90173-6; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; Garton SD, 2000, J BIOL CHEM, V275, P6798, DOI 10.1074/jbc.275.10.6798; George GN, 1999, J AM CHEM SOC, V121, P1256, DOI 10.1021/ja982843k; Hilton JC, 1999, J BIOL CHEM, V274, P8428, DOI 10.1074/jbc.274.13.8428; HILTON JC, 1294, BIOCHIM BIOPHYS ACTA, P111; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; PIERSON DE, 1990, J BACTERIOL, V172, P2194, DOI 10.1128/jb.172.4.2194-2198.1990; POLLOCK VV, 1995, ARCH BIOCHEM BIOPHYS, V318, P322, DOI 10.1006/abbi.1995.1236; Pollock VV, 1997, J BIOL CHEM, V272, P3355, DOI 10.1074/jbc.272.6.3355; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Shaw AL, 1996, BBA-BIOENERGETICS, V1276, P176, DOI 10.1016/0005-2728(96)00092-8; Temple CA, 2000, BIOCHEMISTRY-US, V39, P4046, DOI 10.1021/bi9921541; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Trieber CA, 1996, J BIOL CHEM, V271, P27339, DOI 10.1074/jbc.271.44.27339; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	31	11	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35086	35090		10.1074/jbc.M006872200	http://dx.doi.org/10.1074/jbc.M006872200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10948204	hybrid			2022-12-27	WOS:000165422800036
J	Bhakat, KK; Mitra, S				Bhakat, KK; Mitra, S			Regulation of the human O-6-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITOR; DNA-REPAIR PROTEIN; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; CHROMATIN STRUCTURE; TRICHOSTATIN-A; CELL-LINES; EXPRESSION; E1A; CBP; ACETYLATION	O-6-Methylguanine-DNA methyltransferase (MGMT)(1), a ubiquitous DNA repair protein, removes O-6-alkylguanine from DNA, including cytotoxic O-6-chloroethylguanine induced by chemotherapeutic N-alkyl N-nitrosourea-type drugs, e.g. 1,3-bis(2-chloroethyl)-1-nitrosourea. Treating the pancreatic carcinoma cell line MIA PaCa-2 with trichostatin A (TSA), a specific inhibitor of histone deacetylase, increased MGMT mRNA and protein levels by 2-3-fold. Surprisingly, TSA treatment increased MGMT promoter-dependent luciferase activity by some 40-fold in a transient reporter expression assay. Deletion and point mutation analysis showed that two AP-1 binding sites in the MGMT promoter are involved in activation by TSA Ectopic expression of the transcriptional coactivators cAMP response element-binding protein-binding protein (CBP) and p300, which have intrinsic histone acetyltransferase activity, enhanced luciferase expression. Overexpression of adenovirus E1A, which binds CBP/p300, strongly inhibited both basal and TSA-inducible MGMT promoter activity, while a mutant E1A, defective in binding CBP/p300, did not. Chromatin immunoprecipitation assays revealed that TSA treatment increased histone acetylation in the endogenous MGMT promoter region, which also showed association with CBP/p300. Taken together, our results indicate that targeted histone acetylation results in the remodeling of chromatin by recruitment of the coactivator CBP/p300, and constitutes an important step in regulating MGMT expression.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Mitra, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-136 Med Res Bldg,Rt 1079, Galveston, TX 77555 USA.		Bhakat, Kishor/C-8072-2012		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007572] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES 07572] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Biswas T, 1999, ONCOGENE, V18, P525, DOI 10.1038/sj.onc.1202320; Boldogh I, 1998, CANCER RES, V58, P3950; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; CITRON M, 1991, CANCER RES, V51, P4131; COSTELLO JF, 1994, MOL CELL BIOL, V14, P6515, DOI 10.1128/MCB.14.10.6515; COUSENS LS, 1979, J BIOL CHEM, V254, P1716; DADEY MV, 1996, EMBO J, V15, P2508; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FOOTE RS, 1980, BIOCHEM BIOPH RES CO, V97, P654, DOI 10.1016/0006-291X(80)90314-9; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; HARRIS LC, 1992, CANCER RES, V52, P6404; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kim TK, 1998, P NATL ACAD SCI USA, V95, P12191, DOI 10.1073/pnas.95.21.12191; Kokkinakis DM, 1997, CANCER RES, V57, P5360; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LUDLUM DB, 1990, MUTAT RES, V233, P117, DOI 10.1016/0027-5107(90)90156-X; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; MYES CA, 1998, MOL CELL BIOL, V18, P2184; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; NAKATSU Y, 1993, MUTAT RES, V293, P119, DOI 10.1016/0921-8777(93)90063-M; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PEGG AE, 1992, FASEB J, V6, P2302, DOI 10.1096/fasebj.6.6.1544541; Qian XLC, 1997, CANCER RES, V57, P3672; Sambrook J., 2002, MOL CLONING LAB MANU; Silber JR, 1996, P NATL ACAD SCI USA, V93, P6941, DOI 10.1073/pnas.93.14.6941; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TANO K, 1990, P NATL ACAD SCI USA, V87, P686, DOI 10.1073/pnas.87.2.686; VanLint C, 1996, GENE EXPRESSION, V5, P245; VONWRONSKI MA, 1992, ONCOL RES, V4, P167; WASHINGTON WJ, 1989, MECH AGEING DEV, V48, P43, DOI 10.1016/0047-6374(89)90024-9; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	45	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34197	34204		10.1074/jbc.M005447200	http://dx.doi.org/10.1074/jbc.M005447200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942771	hybrid			2022-12-27	WOS:000165095300029
J	von Lindern, M; Parren-van Amelsvoort, M; van Dijk, T; Deiner, E; van den Akker, E; van Emst-de Vries, S; Willems, P; Beug, H; Lowenberg, B				von Lindern, M; Parren-van Amelsvoort, M; van Dijk, T; Deiner, E; van den Akker, E; van Emst-de Vries, S; Willems, P; Beug, H; Lowenberg, B			Protein kinase C alpha controls erythropoietin receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID PROGENITOR CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; PHOSPHOINOSITIDE 3-KINASE; TERMINAL DIFFERENTIATION; DNA-SYNTHESIS; MAST-CELLS; IN-VITRO; ACTIVATION; ASSOCIATION	Protein kinase C (PKC) is implied in the activation of multiple targets of erythropoietin (Epo) signaling, but its exact role in Epo receptor (EpoR) signal transduction and in the regulation of erythroid proliferation and differentiation remained elusive. We analyzed the effect of PKC inhibitors with distinct modes of action on EpoR signaling in primary human erythroblasts and in a recently established murine erythroid cell line. Active PKC appeared essential for Epo-induced phosphorylation of the Epo receptor itself, STAT5, Gab1, Erk1/2, AKT, and other downstream targets. Under the same conditions, stem cell factor-induced signal transduction was not impaired. LY294002, a specific inhibitor of phosphoinositol 3-kinase, also suppressed Epo-induced signal transduction, which could be partially relieved by activators of PKC. PKC inhibitors or LY294002 did not affect membrane expression of the EpoR, the association of JAK2 with the EpoR, or the in vitro kinase activity of JAK2. The data suggest that PKC controls EpoR signaling instead of being a downstream effector. PKC and phosphoinositol 3-kinase may act in concert to regulate association of the EpoR complex such that it is responsive to ligand stimulation. Reduced PKC-activity inhibited Epo-dependent differentiation, although it did not effect Epo-dependent "renewal divisions" induced in the presence of Epo, stem cell factor, and dexamethasone.	Erasmus Univ, Inst Hematol, NL-3000 DR Rotterdam, Netherlands; Inst Mol Pathol, A-1030 Vienna, Austria; Catholic Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands	Erasmus University Rotterdam; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Radboud University Nijmegen	von Lindern, M (corresponding author), Erasmus Univ, Inst Hematol, POB 1738, NL-3000 DR Rotterdam, Netherlands.	vonlindern@hema.fgg.eur.nl	Willems, P.H.G.M./L-4759-2015; von Lindern, Marieke/AAH-2350-2020	Willems, P.H.G.M./0000-0002-0915-1599; 				Berridge MJ, 1997, CRIT REV IMMUNOL, V17, P155, DOI 10.1615/CritRevImmunol.v17.i2.30; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; Blobe GC, 1996, CANCER SURV, V27, P213; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; Chin H, 1998, BLOOD, V91, P3734; Damen JE, 1996, EXP HEMATOL, V24, P1455; DAMEN JE, 1993, BLOOD, V82, P2296; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DeJong MO, 1997, STEM CELLS, V15, P275, DOI 10.1002/stem.150275; Devemy E, 1997, CELL SIGNAL, V9, P41, DOI 10.1016/S0898-6568(96)00095-2; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Dubyak GR, 1997, ARCH BIOCHEM BIOPHYS, V341, P129, DOI 10.1006/abbi.1997.9946; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Haslauer M, 1999, BLOOD, V94, P114, DOI 10.1182/blood.V94.1.114.413k21_114_126; HE TC, 1993, BLOOD, V82, P3530; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HESS AD, 1988, J IMMUNOL, V141, P3263; Hoefsloot LH, 1997, BLOOD, V89, P1690, DOI 10.1182/blood.V89.5.1690.1690_1690_1700; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Irvine R, 1998, CURR BIOL, V8, pR557, DOI 10.1016/S0960-9822(07)00360-0; JENIS DM, 1989, INT J CELL CLONING, V7, P190, DOI 10.1002/stem.5530070306; Kawakami Y, 1996, IMMUNOL LETT, V54, P113, DOI 10.1016/S0165-2478(96)02659-4; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lee SK, 1998, J BIOL CHEM, V273, P19829, DOI 10.1074/jbc.273.31.19829; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; Li YK, 1996, J BIOL CHEM, V271, P27025, DOI 10.1074/jbc.271.43.27025; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1994, J BIOL CHEM, V269, P614; MUTA K, 1995, BLOOD, V86, P572, DOI 10.1182/blood.V86.2.572.bloodjournal862572; Myklebust JH, 2000, BLOOD, V95, P510, DOI 10.1182/blood.V95.2.510; PATEL HR, 1995, EXP HEMATOL, V23, P619; Porzig H, 1995, N-S ARCH PHARMACOL, V353, P11; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Rey-Ladino JA, 1999, J IMMUNOL, V162, P5792; Sheng M, 2000, J CELL SCI, V113, P1851; SPIVAK JL, 1992, EXP HEMATOL, V20, P500; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Teng JMC, 1996, J IMMUNOL, V156, P3222; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Tsushima H, 1997, CELL GROWTH DIFFER, V8, P1317; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; Ward AC, 1999, BLOOD, V93, P113, DOI 10.1182/blood.V93.1.113.401k33_113_124; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOGNUM AW, 1990, BLOOD, V76, P697; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yamashita Y, 1998, BLOOD, V91, P1496, DOI 10.1182/blood.V91.5.1496.1496_1496_1507; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; Zauner W, 1998, ADV DRUG DELIVER REV, V30, P97, DOI 10.1016/S0169-409X(97)00110-5	68	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34719	34727		10.1074/jbc.M007042200	http://dx.doi.org/10.1074/jbc.M007042200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10940312	hybrid			2022-12-27	WOS:000165095300096
J	Adak, S; Wang, Q; Stuehr, DJ				Adak, S; Wang, Q; Stuehr, DJ			Arginine conversion to nitroxide by tetrahydrobiopterin-free neuronal nitric-oxide synthase - Implications for mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXY-L-ARGININE; NO SYNTHASE; ELECTRON-TRANSFER; PTERIN; SUBSTRATE; DOMAIN; CATALYSIS; COMPLEX; CALMODULIN; OXIDATION	We studied catalysis by tetrahydrobiopterin (H4B)-free neuronal nitric oxide synthase (nNOS) to understand how heme and H4B participate in nitric oxide (NO) synthesis. H4B-free nNOS catalyzed Arg oxidation to N-omega-hydroxy-L-Arg (NOHA) and citrulline in both NADPH- and H2O2-driven reactions. Citrulline formation was time- and enzyme concentration-dependent but was uncoupled relative to NADPH oxidation, and generated nitrite and nitrate without forming NO. Similar results mere observed when NOHA served as substrate. Steady-state and stopped-Bow spectroscopy with the H4B-free enzyme revealed that a ferrous heme-NO complex built up after initiating catalysis in both NADPH- and H2O2-driven reactions, consistent with formation of nitroxyl as an immediate product. This differed from the H4B-replete enzyme, which formed a ferric heme-NO complex as an immediate product that could then release NO. We make the following conclusions. 1) H4B is not essential for Arg oxidation by nNOS, although it helps couple NADPH oxidation to product formation in both steps of NO synthesis. Thus, the NADPH- or H2O2-driven reactions form common heme-oxy species that can react with substrate in the presence or absence of H4B. 2) The sole essential role of H4B is to enable nNOS to generate NO instead of nitroxyl, On this basis we propose a new unified model for heme-dependent oxygen activation and H4B function in both steps of NO synthesis.	Cleveland Clin, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stuehr, DJ (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave,Immunol NB-3, Cleveland, OH 44195 USA.				NIGMS NIH HHS [GM51491] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; Adak S, 2000, J BIOL CHEM, V275, P17434, DOI 10.1074/jbc.M000846200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Adhikari S, 2000, FEBS LETT, V475, P35, DOI 10.1016/S0014-5793(00)01616-1; BAZYLINSKI DA, 1985, J AM CHEM SOC, V107, P7982, DOI 10.1021/ja00312a031; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; Bommel HM, 1998, J BIOL CHEM, V273, P33142, DOI 10.1074/jbc.273.50.33142; Clague MJ, 1997, BIOCHEMISTRY-US, V36, P14465, DOI 10.1021/bi971024u; Crane BR, 2000, BIOCHEMISTRY-US, V39, P4608, DOI 10.1021/bi992409a; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FUKUTO JM, 1993, J MED CHEM, V36, P2666, DOI 10.1021/jm00070a010; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Groves JT, 1999, CURR OPIN CHEM BIOL, V3, P226, DOI 10.1016/S1367-5931(99)80036-2; Huang LX, 1999, BIOCHEMISTRY-US, V38, P1912, DOI 10.1021/bi981954t; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; KAPPOCK TJ, 1996, CHEM REV, V96, P1659; KAUFMAN S, 1993, ADV ENZYMOL RAMB, V67, P77; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KLATT P, 1993, J BIOL CHEM, V268, P14781; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mansuy Daniel, 1995, P537; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MICHEL T, 1997, J CLIN INVEST, V100, P2417; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; WINK DA, 1996, METHODS NITRIC OXIDE, P403	44	210	211	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33554	33561		10.1074/jbc.M004337200	http://dx.doi.org/10.1074/jbc.M004337200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10945985	hybrid			2022-12-27	WOS:000090104600054
J	Haque, SJ; Harbor, PC; Williams, BRG				Haque, SJ; Harbor, PC; Williams, BRG			Identification of critical residues required for suppressor of cytokine signaling-specific regulation of interleukin-4 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELL PHOSPHATASE; PROTEIN-TYROSINE-PHOSPHATASE; INDUCED STAT INHIBITOR; SOCS-BOX MOTIF; ERYTHROPOIETIN RECEPTOR; JAK/STAT PATHWAY; GENE-EXPRESSION; SH2 DOMAIN; TRANSDUCTION; CLONING	Suppressor of cytokine signaling (SOCS) family proteins were originally identified as cytokine-induced negative regulators of cytokine signaling. We show that SOCS-1 and SOCS-3 inhibit interleukin (IL)-4-dependent signal transducer and activator of transcription 6 (Stat6) activation of and subsequent gene induction. By contrast, SOCS-2 and cytokine-inducible Src homology domain 2 (SH2)-containing protein up-regulate these processes. IL-4 initiates transmembrane signaling through two types of receptor complexes comprising the IL-4R alpha subunit and the associated Janus kinase 1 (Jak1) as common essential components. We demonstrate that both SOCS-1- and SOCS-3-mediated down-regulation of IL-4 signaling is due to an inhibition of the receptor associated Jak1 activity. The SOCS proteins contain an amino-terminal region of variable length and primary structure, a central SH2 domain, and a carboxyl-terminal conserved motif termed SOCS-box. We show that the SH2 domains of SOCS-2, SOCS-3, and cytokine-inducible SH2-containing protein are functionally redundant in regulating the IL-4-dependent Jak-Stat signaling. The Pre-SH2 domains of SOCS-2 and SOCS-3 confer the specificity of their regulatory function. Importantly, the Pre-SH2 domain of SOCS-3 alone can inhibit IL-4 signaling. The SH2-proximal 25 amino acids of SOCS-3 are sufficient for this inhibition, and the Thr residue at position 24 and the Phe residue at position 25 are individually indispensable for its inhibitory function. Thus, the Thr-Phe motif in the Pre-SH2 domain plays a critical role in SOCS 3-mediated inhibition of the IL-4-dependent Jak-Stat signaling, likely by regulating the mode of SOCS-Jak interaction.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Haque, SJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, NB4-0,9500 Euclid Ave, Cleveland, OH 44195 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NCI NIH HHS [P01-CA62220] Funding Source: Medline; NIGMS NIH HHS [R01-GM60533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; AMAN MJ, 1997, CURR BIOL, V7, P784; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Brenner SE, 1998, P NATL ACAD SCI USA, V95, P6073, DOI 10.1073/pnas.95.11.6073; Callard RE, 1996, IMMUNOL TODAY, V17, P108, DOI 10.1016/0167-5699(96)80600-1; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; Haque SJ, 1998, SEMIN ONCOL, V25, P14; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Losman JA, 1999, J IMMUNOL, V162, P3770; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; OShea JJ, 1997, J CLIN IMMUNOL, V17, P431, DOI 10.1023/A:1027388508570; PAUL WE, 1991, BLOOD, V77, P1859; PRASHER DC, 1995, TRENDS GENET, V11, P320, DOI 10.1016/S0168-9525(00)89090-3; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YIN TG, 1994, J BIOL CHEM, V269, P26614; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	53	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26500	26506		10.1074/jbc.275.34.26500	http://dx.doi.org/10.1074/jbc.275.34.26500			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10950967	hybrid			2022-12-27	WOS:000088999700085
J	Kvaratskhelia, M; Wardleworth, BN; Norman, DG; White, MF				Kvaratskhelia, M; Wardleworth, BN; Norman, DG; White, MF			A conserved nuclease domain in the archaeal Holliday junction resolving enzyme Hjc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORV RESTRICTION-ENDONUCLEASE; 4-WAY DNA JUNCTION; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; EVOLUTIONARY RELATIONSHIPS; SACCHAROMYCES-CEREVISIAE; CATALYTIC CENTER; RUVC RESOLVASE; MG2+ BINDING; ACTIVE-SITE	Holliday junction resolving enzymes are ubiquitous proteins that function in the pathway of homologous recombination, catalyzing the rearrangement and repair of DNA. They are metal ion-dependent endonucleases with strong structural specificity for branched DNA species. Whereas the eukaryotic nuclear enzyme remains unknown, an archaeal Holliday junction resolving enzyme, Hjc, has recently been identified. We demonstrate that Hjc manipulates the global structure of the Holliday junction into a 2-fold symmetric X shape, with local disruption of base pairing around the point of cleavage that occurs in a region of duplex DNA 3' to the point of strand exchange. Primary and secondary structural analysis reveals the presence of a conserved catalytic metal ion binding domain in Hjc that has been identified previously in several restriction enzymes. The roles of catalytic residues conserved within this domain have been confirmed by site-directed mutagenesis, This is the first example of this domain in an archaeal enzyme of known function as well as the first in a Holliday junction resolving enzyme.	Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland	University of Dundee	White, MF (corresponding author), Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland.		White, Malcolm F/A-6055-2010	White, Malcolm F/0000-0003-1543-9342				ANDERSON JE, 1993, CURR OPIN STRUC BIOL, V3, P24, DOI 10.1016/0959-440X(93)90197-S; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; Davies GP, 1999, J MOL BIOL, V290, P565, DOI 10.1006/jmbi.1999.2908; DEMASSY B, 1987, J MOL BIOL, V193, P359, DOI 10.1016/0022-2836(87)90224-5; DICKIE P, 1987, J BIOL CHEM, V262, P14826; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; Groll DH, 1997, BIOCHEMISTRY-US, V36, P11389, DOI 10.1021/bi9705826; HYDE H, 1994, J BIOL CHEM, V269, P5202; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; JELTSCH A, 1995, BIOCHEMISTRY-US, V34, P6239, DOI 10.1021/bi00018a028; KEELING PJ, 1995, P NATL ACAD SCI USA, V92, P5761, DOI 10.1073/pnas.92.13.5761; KLEFF S, 1992, EMBO J, V11, P699, DOI 10.1002/j.1460-2075.1992.tb05102.x; Komori K, 1999, P NATL ACAD SCI USA, V96, P8873, DOI 10.1073/pnas.96.16.8873; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; Kovall RA, 1999, CURR OPIN CHEM BIOL, V3, P578, DOI 10.1016/S1367-5931(99)00012-5; Kovall RA, 1998, P NATL ACAD SCI USA, V95, P7893, DOI 10.1073/pnas.95.14.7893; Kvaratskhelia M, 2000, J MOL BIOL, V295, P193, DOI 10.1006/jmbi.1999.3363; Kvaratskhelia M, 2000, J MOL BIOL, V297, P923, DOI 10.1006/jmbi.2000.3624; Lilley DMJ, 1999, NAT STRUCT BIOL, V6, P897, DOI 10.1038/13255; Lilley DMJ, 1997, P NATL ACAD SCI USA, V94, P9513, DOI 10.1073/pnas.94.18.9513; Mahdi AA, 1996, J MOL BIOL, V257, P561, DOI 10.1006/jmbi.1996.0185; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MURCHIE AIH, 1991, EMBO J, V10, P713, DOI 10.1002/j.1460-2075.1991.tb08001.x; Newman M, 1998, EMBO J, V17, P5466, DOI 10.1093/emboj/17.18.5466; Ortiz-Lombardia M, 1999, NAT STRUCT BIOL, V6, P913; Pohler JRG, 1996, J MOL BIOL, V260, P678; Raaijmakers H, 1999, EMBO J, V18, P1447, DOI 10.1093/emboj/18.6.1447; SAITO A, 1995, P NATL ACAD SCI USA, V92, P7470, DOI 10.1073/pnas.92.16.7470; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schofield MJ, 1998, BIOCHEMISTRY-US, V37, P7733, DOI 10.1021/bi980399s; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; Stanford NP, 1999, J MOL BIOL, V288, P105, DOI 10.1006/jmbi.1999.2673; VENCLOVAS C, 1995, NAT STRUCT BIOL, V2, P838, DOI 10.1038/nsb1095-838; VENCLOVAS C, 1994, PROTEINS, V20, P279, DOI 10.1002/prot.340200308; Vipond IB, 1996, BIOCHEMISTRY-US, V35, P1701, DOI 10.1021/bi952391d; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; WEST SC, 1987, J BIOL CHEM, V262, P12752; White MF, 1997, J MOL BIOL, V269, P647, DOI 10.1006/jmbi.1997.1097; White MF, 1996, J MOL BIOL, V257, P330, DOI 10.1006/jmbi.1996.0166; White MF, 1997, MOL CELL BIOL, V17, P6465, DOI 10.1128/MCB.17.11.6465; White MF, 1997, J MOL BIOL, V266, P122, DOI 10.1006/jmbi.1996.0795; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x	49	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25540	25546		10.1074/jbc.M003420200	http://dx.doi.org/10.1074/jbc.M003420200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10940317	hybrid			2022-12-27	WOS:000088849400066
J	Loukas, A; Hintz, M; Linder, D; Mullin, NP; Parkinson, J; Tetteh, KKA; Maizels, RM				Loukas, A; Hintz, M; Linder, D; Mullin, NP; Parkinson, J; Tetteh, KKA; Maizels, RM			A family of secreted mucins from the parasitic nematode Toxocara canis bears diverse mucin domains but shares similar flanking six-cysteine repeat motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SUBMAXILLARY MUCIN; INFECTIVE LARVAE; TRYPANOSOMA-CRUZI; CAENORHABDITIS-ELEGANS; CARBOHYDRATE EPITOPES; BRUGIA-MALAYI; ANTIGENS; SURFACE; PROTEIN; GENES	Infective larvae of the parasitic nematode Toxocara canis secrete a family of mucin-Like glycoproteins, which are implicated in parasite immune evasion. Analysis of T. canis expressed sequence tags identified a family of four mRNAs encoding distinct apomucins (Tc-muc-1-4), one of which had been previously identified in the TES-120 family of glycoproteins secreted by this parasite. The protein products of all four cDNAs contain signal peptides, a repetitive serine/threonine-rich tract, and varying numbers of 36-amino acid six-cysteine (SXC) domains. SXC domains are found in many nematode proteins and show similarity to cnidarian (sea anemone) toxins. Antibodies to the SXC domains of TcMUG-1 and Tc-MUC-3 recognize differently migrating members of TES-120. TES-120 proteins separated by chromatographic methods showed distinct amino acid composition, mass, and sequence information by both Edman degradation and matrix-assisted laser desorption ionization/time of flight mass spectrometry on peptide fragments. Tc-MUC-1, -2, and -3 were shown to be secreted mucins with real masses of 39.7, 47.8, and 45.0 kDa in contrast to their predicted peptide masses of 15.7, 16.2, and 26.0 kDa, respectively. The presence of SXC domains in all mucin products supports the suggestion that the SXC motif is required for mucin assembly or export. Homology modeling indicates that the six-cysteine domains of the T. canis mucins adopt a similar fold to the sea anemone potassium channel-blocking toxin BgK, forming three disulfide bonds within each subunit.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Edinburgh, Dept Chem, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Giessen Klinikum, Inst Biochem, D-35392 Giessen, Germany	University of Edinburgh; University of Edinburgh; University Hospital of Giessen & Marburg	Maizels, RM (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.		Parkinson, John/A-4424-2008; Loukas, Alex/B-7355-2014	Parkinson, John/0000-0001-9815-1189; Loukas, Alex/0000-0002-0896-8441; Mullin, Nicholas/0000-0003-4802-440X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BADLEY JE, 1987, J PARASITOL, V73, P593, DOI 10.2307/3282142; BADLEY JE, 1987, PARASITE IMMUNOL, V9, P133, DOI 10.1111/j.1365-3024.1987.tb00494.x; BANSIL R, 1995, ANNU REV PHYSIOL, V57, P635, DOI 10.1146/annurev.ph.57.030195.003223; Blaxter M, 1996, INT J PARASITOL, V26, P1025, DOI 10.1016/S0020-7519(96)00060-4; Blaxter M, 1998, SCIENCE, V282, P2041, DOI 10.1126/science.282.5396.2041; BRESALIER RS, 1991, J CLIN INVEST, V87, P1037, DOI 10.1172/JCI115063; Daub J, 2000, PARASITOLOGY, V120, P171, DOI 10.1017/S0031182099005375; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; de Diego J, 1997, J IMMUNOL, V159, P4983; Dell A, 1999, BBA-MOL BASIS DIS, V1455, P353, DOI 10.1016/S0925-4439(99)00064-2; DEVINE PL, 1992, BIOESSAYS, V14, P619, DOI 10.1002/bies.950140909; Di Noia JM, 1998, J BIOL CHEM, V273, P10843, DOI 10.1074/jbc.273.18.10843; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; FATTAH DI, 1986, EXP PARASITOL, V61, P421, DOI 10.1016/0014-4894(86)90198-0; Freitas-Junior LHG, 1998, MOL BIOCHEM PARASIT, V93, P101, DOI 10.1016/S0166-6851(98)00025-5; GEMS D, 1995, J BIOL CHEM, V270, P18517, DOI 10.1074/jbc.270.31.18517; Gems D, 1996, P NATL ACAD SCI USA, V93, P1665, DOI 10.1073/pnas.93.4.1665; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gimmi CD, 1996, NAT MED, V2, P1367, DOI 10.1038/nm1296-1367; GLICKMAN LT, 1993, TOXOCARA AND TOXOCARIASIS, P3; Gomez-Escobar N, 1998, EXP PARASITOL, V88, P200, DOI 10.1006/expr.1998.4248; Gum JR, 1997, J BIOL CHEM, V272, P26678, DOI 10.1074/jbc.272.42.26678; HAYES DF, 1990, J IMMUNOL, V145, P962; JONES SJM, 1995, MOL GEN GENET, V248, P719, DOI 10.1007/BF02191712; KHOO K-H, 1991, Glycobiology, V1, P163, DOI 10.1093/glycob/1.2.163; Kim YS, 1996, GLYCOCONJUGATE J, V13, P693, DOI 10.1007/BF00702333; Komatsu M, 1999, CANCER RES, V59, P2229; Loukas A, 1999, CURR BIOL, V9, P825, DOI 10.1016/S0960-9822(99)80366-2; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; MAIZELS RM, 1987, J IMMUNOL, V139, P207; MAIZELS RM, 1984, PARASITE IMMUNOL, V6, P23, DOI 10.1111/j.1365-3024.1984.tb00779.x; Maizels RM, 2000, INT J PARASITOL, V30, P495, DOI 10.1016/S0020-7519(00)00022-9; MARIN MS, 1992, MOL BIOCHEM PARASIT, V55, P155, DOI 10.1016/0166-6851(92)90136-8; MEGHJI M, 1986, MOL BIOCHEM PARASIT, V18, P155, DOI 10.1016/0166-6851(86)90035-6; PAGE AP, 1992, EXP PARASITOL, V75, P56, DOI 10.1016/0014-4894(92)90122-Q; PAGE AP, 1992, PARASITOLOGY, V105, P297, DOI 10.1017/S0031182000074229; PAGE AP, 1992, EXP PARASITOL, V75, P72, DOI 10.1016/0014-4894(92)90123-R; PAGE AP, 1991, PARASITOLOGY, V103, P451, DOI 10.1017/S0031182000059977; Pan TL, 1998, DEV GENES EVOL, V208, P259, DOI 10.1007/s004270050180; Pastrana DV, 1998, INFECT IMMUN, V66, P5955, DOI 10.1128/IAI.66.12.5955-5963.1998; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Perez-Vilar J, 1998, J BIOL CHEM, V273, P14442, DOI 10.1074/jbc.273.23.14442; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SEED B, 1992, Current Biology, V2, P457, DOI 10.1016/0960-9822(92)90647-S; SMITH HV, 1981, MOL BIOCHEM PARASIT, V4, P183, DOI 10.1016/0166-6851(81)90017-7; Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1; Tetteh KKA, 1999, INFECT IMMUN, V67, P4771, DOI 10.1128/IAI.67.9.4771-4779.1999; Tudor JE, 1996, NAT STRUCT BIOL, V3, P317, DOI 10.1038/nsb0496-317; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Zang XX, 1999, BLOOD, V94, P1418, DOI 10.1182/blood.V94.4.1418.416k03_1418_1428	53	73	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39600	39607		10.1074/jbc.M005632200	http://dx.doi.org/10.1074/jbc.M005632200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10950959	hybrid			2022-12-27	WOS:000165953100086
J	Creemers, JWM; van de Loo, JWHP; Plets, E; Hendershot, LM; Van de Ven, WJM				Creemers, JWM; van de Loo, JWHP; Plets, E; Hendershot, LM; Van de Ven, WJM			Binding of BiP to the processing enzyme lymphoma proprotein convertase prevents aggregation, but slows down maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; MOLECULAR CHAPERONE BIP; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; IN-VITRO; PROHORMONE CONVERTASES; SERINE PROTEASES; QUALITY-CONTROL; ER MEMBRANE; FURIN	Lymphoma proprotein convertase (LPC) is a subtilisin-like serine protease of the mammalian proprotein convertase family. It is synthesized as an inactive precursor protein, and propeptide cleavage occurs via intramolecular cleavage in the endoplasmic reticulum. In contrast to other convertases like furin and proprotein convertase-1, propeptide cleavage occurs slowly, Also, both a glycosylated and an unglycosylated precursor are detected. Here we demonstrate that the unglycosylated precursor form of LPC is localized in the cytosol due to the absence of a signal peptide. Using a reducible cross-linker, we found that glycosylated pro-LPC is associated with the molecular chaperone BiP. In addition, we show that pro-LPC is prone to aggregation and forms large complexes linked via interchain disulfide bonds. BiP is associated mainly with non-aggregated pro-LPC and pro-LPC dimers and trimers, suggesting that BiP prevents aggregation. Overexpression of wild-type Dip or a dominant-negative BiP ATPase mutant resulted in reduced processing of pro-LPC. Taken together, these results suggest that binding of BiP to pro-LPC prevents aggregation, but results in slower maturation.	Katholieke Univ Leuven, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA	KU Leuven; St Jude Children's Research Hospital	Creemers, JWM (corresponding author), Katholieke Univ Leuven, Ctr Human Genet, Mol Oncol Lab, Herestr 49, B-3000 Louvain, Belgium.	john.creemers@med.kuleuven.ac.be	Hendershot, Linda/N-8124-2018	Hendershot, Linda/0000-0002-5473-0274; Plets, Evelyn/0000-0001-7312-8804				Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAUT JR, 1993, J BIOL CHEM, V268, P7248; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GOODMAN LJ, 1994, BIOCHEM BIOPH RES CO, V201, P795, DOI 10.1006/bbrc.1994.1771; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hellman R, 1999, J CELL BIOL, V144, P21, DOI 10.1083/jcb.144.1.21; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lamango NS, 1999, ARCH BIOCHEM BIOPHYS, V362, P275, DOI 10.1006/abbi.1998.1033; LEDUC R, 1992, J BIOL CHEM, V267, P14304; Mains RE, 1997, BIOCHEM J, V321, P587, DOI 10.1042/bj3210587; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; Meerabux J, 1996, CANCER RES, V56, P448; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Muller L, 1997, J CELL BIOL, V139, P625, DOI 10.1083/jcb.139.3.625; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; Muresan Z, 1998, MOL ENDOCRINOL, V12, P458, DOI 10.1210/me.12.3.458; Nagahama M, 1998, FEBS LETT, V434, P155, DOI 10.1016/S0014-5793(98)00970-3; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Taylor NA, 1998, J MOL ENDOCRINOL, V21, P209, DOI 10.1677/jme.0.0210209; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wouters S, 1998, BIOCHEM J, V336, P311, DOI 10.1042/bj3360311; YI Z, 1993, J BIOL CHEM, V268, P5615; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509	55	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38842	38847		10.1074/jbc.M006758200	http://dx.doi.org/10.1074/jbc.M006758200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10964928	hybrid			2022-12-27	WOS:000165739800095
J	Shiffman, D; Mikita, T; Tai, JTN; Wade, DP; Porter, JG; Seilhamer, JJ; Somogyi, R; Liang, SD; Lawn, RM				Shiffman, D; Mikita, T; Tai, JTN; Wade, DP; Porter, JG; Seilhamer, JJ; Somogyi, R; Liang, SD; Lawn, RM			Large scale gene expression analysis of cholesterol-loaded macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; DIFFERENTIATION-RELATED PROTEIN; ACTIVATED RECEPTOR-GAMMA; SMOOTH-MUSCLE CELLS; PPAR-GAMMA; ATHEROSCLEROTIC LESIONS; MESSENGER-RNA; OXIDIZED LDL; SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS	We conducted large scale gene expression analysis of the response of macrophages to exposure to oxidized low density lipoprotein (Ox-LDL), Much of the vessel wall lesion of atherosclerosis is composed of macrophages that have become engorged with cholesterol. These resulting "foam cells" contribute to the progression of vascular disease through several pathways. As a potential model of foam cell formation, we treated THP-1 cells with 12-O-tetradecanoylphorbol 13-acetate to differentiate them into a macrophage-like phenotype and subsequently treated them with oxidized low density lipoprotein for various time periods. RNA from Ox-LDL treated and time-matched control untreated cells was hybridized to microarrays containing 9808 human genes. 268 genes were found to be at least 2-fold regulated at one or more time points. These regulation patterns were classified into seven clusters of expression profiles. The data is discussed in terms of the overall pattern of gene expression, the thematic classification of the responding genes, and the clustering of functional groups in distinct expression patterns. The magnitude and the temporal patterns of gene expression identified known and novel molecular components of the cellular response that are implicated in the growth, survival, migratory, inflammatory, and matrix remodeling activity of vessel wall macrophages. In particular, the role of nuclear receptors in mediating the gene expression modulation by Ox-LDL is highlighted.	CV Therapeut Inc, Palo Alto, CA 94304 USA; Incyte Genomics Inc, Palo Alto, CA 94304 USA	CV Therapeutics, Inc.; Incyte	Lawn, RM (corresponding author), CV Therapeut Inc, 3172 Porter Dr, Palo Alto, CA 94304 USA.	lawn@cvt.com						ACTON SL, 1994, J BIOL CHEM, V269, P21003; Arvilommi AM, 1997, EUR J IMMUNOL, V27, P248, DOI 10.1002/eji.1830270137; AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244; Brand K, 1997, ARTERIOSCL THROM VAS, V17, P1901, DOI 10.1161/01.ATV.17.10.1901; Brasaemle DL, 1997, J LIPID RES, V38, P2249; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1983, ANNU REV BIOCHEM, V362, P801; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Costet P, 2000, J BIOL CHEM, V275, P28240; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DHAESELEER P, 2000, IN PRESS BIOINFORMAT; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eligini S, 1999, ARTERIOSCL THROM VAS, V19, P1719, DOI 10.1161/01.ATV.19.7.1719; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; FONG LG, 1991, J LIPID RES, V32, P1899; FRESHNEY IR, 1994, CULTURE ANIMAL CELLS, P277; Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825; Green DR, 2000, NATURE, V405, P28, DOI 10.1038/35011175; Grey ST, 1996, J IMMUNOL, V156, P2256; HAMMER A, 1995, ARTERIOSCL THROM VAS, V15, P704, DOI 10.1161/01.ATV.15.5.704; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; Kataoka H, 1999, CIRCULATION, V99, P3110, DOI 10.1161/01.CIR.99.24.3110; KELLEY JL, 1987, EXP MOL PATHOL, V46, P266, DOI 10.1016/0014-4800(87)90049-9; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; MATIKAINEN S, 1994, INT J CANCER, V57, P98, DOI 10.1002/ijc.2910570118; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; NODAHEINY H, 1995, ARTERIOSCL THROM VAS, V15, P37, DOI 10.1161/01.ATV.15.1.37; PATAKI M, 1992, ARTERIOSCLER THROMB, V12, P936, DOI 10.1161/01.ATV.12.8.936; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSENFELD ME, 1992, AM J PATHOL, V140, P291; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; TSUCHIYA S, 1982, CANCER RES, V42, P1530; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837; Wang XK, 1999, FEBS LETT, V462, P145, DOI 10.1016/S0014-5793(99)01521-5; Wen XL, 1998, P NATL ACAD SCI USA, V95, P334, DOI 10.1073/pnas.95.1.334; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0; Xie B, 1998, J BIOL CHEM, V273, P11576, DOI 10.1074/jbc.273.19.11576; Yamashita Y, 1998, EUR J IMMUNOL, V28, P2981, DOI 10.1002/(SICI)1521-4141(199810)28:10<2981::AID-IMMU2981>3.0.CO;2-D; Yoshida H, 1998, ARTERIOSCL THROM VAS, V18, P794, DOI 10.1161/01.ATV.18.5.794	61	112	127	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37324	37332		10.1074/jbc.M004732200	http://dx.doi.org/10.1074/jbc.M004732200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973959	hybrid			2022-12-27	WOS:000165618700005
J	Atshaves, BP; Starodub, O; McIntosh, A; Petrescu, A; Roths, JB; Kier, AB; Schroeder, F				Atshaves, BP; Starodub, O; McIntosh, A; Petrescu, A; Roths, JB; Kier, AB; Schroeder, F			Sterol carrier protein-2 alters high density lipoprotein-mediated cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-CELL FIBROBLASTS; INTRACELLULAR-TRANSPORT; PLASMA-MEMBRANE; LIPID DROPLETS; IN-VIVO; BINDING; EXPRESSION; LIVER; OVEREXPRESSION; ESTERIFICATION	Although sterol carrier protein-2 (SCP-2) participates in the uptake and intracellular trafficking of cholesterol, its effect on "reverse cholesterol transport" has not been explored. As shown herein, SCP-2 expression inhibited high density lipoprotein (HDL)-mediated efflux of [H-3]cholesterol and fluorescent 22-(N-(7-nitro-benz-oxa-1,3-diazol-4-yl)amino) -23,24-bisnor-5-cholen-3b-ol (NBD-cholesterol) up to 61 and 157%, respectively. Confocal microscopy of living cells allowed kinetic analysis of two intracellular pools of HDL-mediated NBD-cholesterol efflux: the highly fluorescent lipid droplet pool and the less fluorescent pool outside the lipid droplets, designated the cytoplasmic compartment, Both the whole cell and the cytoplasmic compartment exhibited two similar kinetic pools, the half-times of which were consistent with protein (t(1/2)(b) near 1 min) and vesicular (t(1/2)(d) = 10-20 min) mediated sterol transfer. Although SCP-2 expression did not alter cytoplasmic sterol pool sizes, the rapid t(1/2)(b) decreased 36%, while the slower t(1/2)(d) increased 113%. Lipid droplets also exhibited two kinetic pools of NBD-cholesterol efflux but with half-times over 200% shorter than those of the cytoplasmic compartment. The lipid droplet slower effluxing pool size and t(1/2)(d), were increased 48% and 115%, respectively, in SCP-a-expressing cells. Concomitantly, the level of the lipid droplet-specific adipose differentiation-related protein decreased 70%. Overall, HDL-mediated sterol efflux from L-cell fibroblasts reflected that of the cytoplasmic rather than lipid droplet compartment, SCP-2 differentially modulated sterol efflux from the two cytoplasmic pools. However, net efflux was determined primarily by inhibition of the slowly effluxing pool rather than by acceleration of the rapid protein-mediated pool. Finally, SCP-2 expression also inhibited sterol efflux from lipid droplets, an effect related to decreased adipose differentiation-related protein, a lipid droplet surface protein that binds cholesterol with high affinity.	Texas A&M Univ, Texas Vet Med Ctr, Dept Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Pathobiol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Schroeder, F (corresponding author), Texas A&M Univ, Texas Vet Med Ctr, Dept Physiol & Pharmacol, College Stn, TX 77843 USA.	Fschroeder@cvm.tamu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031651] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31651] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Atshaves BP, 1999, J LIPID RES, V40, P610; Atshaves BP, 1998, AM J PHYSIOL-CELL PH, V274, pC633, DOI 10.1152/ajpcell.1998.274.3.C633; Avdulov NA, 1999, BBA-MOL CELL BIOL L, V1437, P37, DOI 10.1016/S0005-2760(98)00178-7; AVIRAM M, 1989, J LIPID RES, V30, P65; BAN T, 1991, ARTERY, V18, P54; Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; BISGAIER CL, 1985, J STEROID BIOCHEM, V23, P967, DOI 10.1016/0022-4731(85)90054-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BRASAEMLE DL, 1988, J LIPID RES, V29, P481; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; Chanderbhan RF, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P197; DICK JPR, 1993, J ROY SOC MED, V86, P171; DIETSCHY JM, 1970, NEW ENGL J MED, V282, P1128, DOI 10.1056/NEJM197005142822005; Fielding CJ, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P273; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 1997, J LIPID RES, V38, P1503; Frolov A, 2000, J BIOL CHEM, V275, P12769, DOI 10.1074/jbc.275.17.12769; Fuchs M, 1997, FASEB J, V11, pA1060; Fuchs M, 1998, BIOCHEM J, V336, P33, DOI 10.1042/bj3360033; GAVEY KL, 1981, J BIOL CHEM, V256, P2993; Igbavboa U, 1996, J NEUROCHEM, V66, P1717; Ito T, 1996, GASTROENTEROLOGY, V110, P1619, DOI 10.1053/gast.1996.v110.pm8613070; KAWATA S, 1991, CLIN CHIM ACTA, V197, P201, DOI 10.1016/0009-8981(91)90140-8; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; McArthur MJ, 1999, J LIPID RES, V40, P1371; Moncecchi D, 1996, BBA-LIPID LIPID MET, V1302, P110, DOI 10.1016/0005-2760(96)00044-6; Moncecchi DM, 1991, PHYSL BIOCH STEROLS, P1; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG244, DOI 10.1152/ajpgi.1998.275.2.G244; Murphy EJ, 1997, BBA-LIPID LIPID MET, V1345, P283, DOI 10.1016/S0005-2760(97)00003-9; MyersPayne SC, 1996, J NEUROCHEM, V66, P313; Neufeld EB, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P93; ORAM JF, 1983, ARTERIOSCLEROSIS, V3, P420, DOI 10.1161/01.ATV.3.5.420; PFEIFER SM, 1993, J STEROID BIOCHEM, V47, P167, DOI 10.1016/0960-0760(93)90071-4; POORTHUIS BJHM, 1982, BIOCHIM BIOPHYS ACTA, V710, P99, DOI 10.1016/0005-2760(82)90195-3; Puglielli L, 1996, BIOCHEM J, V317, P681, DOI 10.1042/bj3170681; PUGLIELLI L, 1995, J BIOL CHEM, V270, P18723, DOI 10.1074/jbc.270.32.18723; Reaven E, 1996, J BIOL CHEM, V271, P16208, DOI 10.1074/jbc.271.27.16208; SCALLEN TJ, 1985, J BIOL CHEM, V260, P4733; SCHROEDER F, 1990, J BIOL CHEM, V265, P151; SCHROEDER F, 1981, FEBS LETT, V135, P127, DOI 10.1016/0014-5793(81)80959-3; Schroeder F, 1996, P SOC EXP BIOL MED, V213, P150, DOI 10.3181/00379727-213-44047; Schroeder F, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P213; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SCHROEDER F, 1976, J BIOL CHEM, V251, P5015; SCHROEDER F, 1990, ADV CHOLESTEROL RES, P47; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; Smart EJ, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P253; Sparrow CP, 1999, J LIPID RES, V40, P1747; STECK TL, 1988, J BIOL CHEM, V263, P13023; Stolowich N, 1999, J BIOL CHEM, V274, P35425, DOI 10.1074/jbc.274.50.35425; TRZASKOS JM, 1983, BIOCHIM BIOPHYS ACTA, V751, P52, DOI 10.1016/0005-2760(83)90256-4; Weisiger RA, 1996, COMP BIOCHEM PHYS B, V115, P319, DOI 10.1016/S0305-0491(96)00179-4; Weisiger RA, 1996, HEPATOLOGY, V24, P1288	62	69	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36852	36861		10.1074/jbc.M003434200	http://dx.doi.org/10.1074/jbc.M003434200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10954705	hybrid			2022-12-27	WOS:000165577700059
J	Fujiwara, C; Imamura, A; Hashiguchi, N; Shimozawa, N; Suzuki, Y; Kondo, N; Imanaka, T; Tsukamoto, T; Osumi, T				Fujiwara, C; Imamura, A; Hashiguchi, N; Shimozawa, N; Suzuki, Y; Kondo, N; Imanaka, T; Tsukamoto, T; Osumi, T			Catalase-less peroxisomes - Implication in the milder forms of peroxisome biogenesis disorder	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENT ZELLWEGER-SYNDROME; OVARY CELL MUTANTS; COMPLEMENTATION GROUP; FUNCTIONAL COMPLEMENTATION; MEMBRANE-PROTEIN; IN-VIVO; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; COMMON-CAUSE; HUMAN PEX1	We established a Chinese hamster ovary cell line having a temperature-sensitive phenotype in peroxisome biogenesis. This mutant (65TS) was produced by transforming a PEX2-defective mutant, Z65, with a mutant PEX2 gene, pEX2(E55K), derived from a patient with infantile Refsum disease, a milder form of peroxisome biogenesis disorder. In 65TS, catalase was found in the cytosol at a nonpermissive temperature (39 degreesC), but upon the shift to a permissive temperature (33 degreesC), catalase gradually localized to the structures containing a 70-kDa peroxisomal membrane protein, PMP70. In contrast to catalase, other matrix proteins containing typical peroxisome targeting signals, acyl-CoA oxidase and peroxisomal 3-ketoacyl-CoA thiolase, were co-localized with PMP70 in most cells, even at 39 degreesC. We found that these structures are partially functional peroxisomes and named them "catalase-less peroxisomes.'' Catalase-less peroxisomes were also observed in human fibroblasts from patients with milder forms of peroxisome biogenesis disorder, including the one from which the mutant PEX2 gene was derived. We suggest that these structures are the causes of the milder phenotypes of the patients. Temperature-dependent restoration of the peroxisomes in 65TS occurred even in the presence of cycloheximide, a protein synthesis inhibitor. Thus, we conclude that in 65TS, catalase-less peroxisomes are the direct precursors of peroxisomes.	Himeji Inst Technol, Fac Sci, Dept Life Sci, Kamigori, Hyogo 6781297, Japan; Gifu Univ, Sch Med, Dept Pediat, Gifu 5008076, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, Toyama 9300194, Japan	University of Hyogo; Gifu University; University of Toyama	Osumi, T (corresponding author), Himeji Inst Technol, Fac Sci, Dept Life Sci, 3-2-1 Koto, Kamigori, Hyogo 6781297, Japan.	osumi@sci.himeji-tech.ac.jp		Shimozawa, Nobuyuki/0000-0003-3040-5458; Imanaka, Tsuneo/0000-0003-4677-1356				Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; Faber KN, 1998, MOL CELL BIOL, V18, P936, DOI 10.1128/MCB.18.2.936; Fiering S, 2000, BIOESSAYS, V22, P381, DOI 10.1002/(SICI)1521-1878(200004)22:4<381::AID-BIES8>3.0.CO;2-E; Fukuda S, 1996, AM J HUM GENET, V59, P1210; Geisbrecht BV, 1998, P NATL ACAD SCI USA, V95, P8630, DOI 10.1073/pnas.95.15.8630; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Imamura A, 1998, HUM MOL GENET, V7, P2089, DOI 10.1093/hmg/7.13.2089; Imamura A, 1998, AM J HUM GENET, V62, P1539, DOI 10.1086/301881; Imamura A, 2000, BRAIN DEV-JPN, V22, P8, DOI 10.1016/S0387-7604(99)00072-8; Imanaka T, 1996, J BIOL CHEM, V271, P3706; Kinoshita N, 1998, J BIOL CHEM, V273, P24122, DOI 10.1074/jbc.273.37.24122; Kunau WH, 1998, CURR BIOL, V8, pR299, DOI 10.1016/S0960-9822(98)70191-5; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; LAZAROW PB, 1982, ANN NY ACAD SCI, V386, P285, DOI 10.1111/j.1749-6632.1982.tb21423.x; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; PATARCA R, 1992, FEBS LETT, V312, P1, DOI 10.1016/0014-5793(92)81397-5; Portsteffen H, 1997, NAT GENET, V17, P449, DOI 10.1038/ng1297-449; Purdue PE, 1996, J CELL BIOL, V134, P849, DOI 10.1083/jcb.134.4.849; Reuber BE, 1997, NAT GENET, V17, P445, DOI 10.1038/ng1297-445; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; Setoyama C, 1995, BIOCHEM BIOPH RES CO, V217, P482, DOI 10.1006/bbrc.1995.2801; Shimozawa N, 1999, HUM MOL GENET, V8, P1077, DOI 10.1093/hmg/8.6.1077; Shimozawa N, 1999, J MED GENET, V36, P779, DOI 10.1136/jmg.36.10.779; Shimozawa N, 1998, AM J HUM GENET, V63, P1898, DOI 10.1086/302142; SHIMOZAWA N, 1988, PEDIATR RES, V24, P723, DOI 10.1203/00006450-198812000-00015; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; SUZUKI Y, 1991, BIOCHEM PHARMACOL, V41, P453, DOI 10.1016/0006-2952(91)90544-F; TAHAK HF, 1999, TRENDS CELL BIOL, V9, P447; Tamura S, 1998, BIOCHEM BIOPH RES CO, V245, P883, DOI 10.1006/bbrc.1998.8522; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; Titorenko VI, 2000, J CELL BIOL, V148, P29, DOI 10.1083/jcb.148.1.29; Titorenko VI, 1998, MOL CELL BIOL, V18, P2789, DOI 10.1128/MCB.18.5.2789; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1995, NAT GENET, V11, P395, DOI 10.1038/ng1295-395; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x; Yamasaki M, 1999, J BIOL CHEM, V274, P35293, DOI 10.1074/jbc.274.50.35293; Yamasaki M., 1998, BIOIMAGES, V6, P1	46	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37271	37277		10.1074/jbc.M006347200	http://dx.doi.org/10.1074/jbc.M006347200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10960480	hybrid			2022-12-27	WOS:000165577700112
J	Janulczyk, R; Iannelli, F; Sjoholm, AG; Pozzi, G; Bjorck, L				Janulczyk, R; Iannelli, F; Sjoholm, AG; Pozzi, G; Bjorck, L			Hic, a novel surface protein of Streptococcus pneumoniae that interferes with complement function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-H; NEISSERIA-GONORRHOEAE; SERUM RESISTANCE; BINDING; VIRULENCE; DEGRADATION; SEQUENCE; REGION; TRANSFORMATION; OPSONIZATION	The important human pathogen Streptococcus pneumoniae was found to absorb factor H, an inhibitor of complement, from human plasma. We identified the gene encoding a novel surface protein, factor H-binding inhibitor of complement (Hic), in the pspC locus of type 3 pneumococci, Unlike PspC proteins in other serotypes, Hic is anchored to the cell wall by means of an LPXTG motif, and the overall sequence homology to various PspC proteins is low. However, the NH2-terminal region showed significant homology to the NH2-terminal region of several PspC proteins. A fragment of Hic, covering this homologous region, was expressed as a glutathione S-transferase (GST) fusion protein. GST:Hic(39-261) bound radiolabeled factor H and inhibited binding of factor H to pneumococci of different serotypes. Interaction kinetics between GST:Hic(39-261) and factor H were studied with surface plasmon resonance and showed a high affinity binding (K-A = 5 x 10(7), K-D = 2.3 x 10(-8)). Mutant pneumococci lacking Hic showed no absorption of factor H in human plasma and no binding of radiolabeled factor H, suggesting that Hic is responsible for factor H-binding in type 3 pneumococci, Factor H-dependent inhibition of the alternative pathway was not diminished by the presence of GST:Hic(39-261). I, addition, an intrinsic inhibitory effect of Hic is suggested.	Univ Lund, Sect Mol Pathogenesis, Dept Cell & Mol Biol, S-22100 Lund, Sweden; Univ Lund, Dept Lab Med, Sect MIG, S-22100 Lund, Sweden; Univ Siena, Dept Mol Biol, I-53100 Siena, Italy	Lund University; Lund University; University of Siena	Janulczyk, R (corresponding author), Univ Lund, Sect Mol Pathogenesis, Dept Cell & Mol Biol, Solvegatan 39, S-22100 Lund, Sweden.		Pozzi, Gianni/Q-2713-2018; Iannelli, Francesco/R-1170-2018	Pozzi, Gianni/0000-0002-9557-4714; Iannelli, Francesco/0000-0001-5064-1496				AKESSON P, 1990, MOL IMMUNOL, V27, P523, DOI 10.1016/0161-5890(90)90071-7; ALONSODEVELASCO E, 1995, MICROBIOL REV, V59, P591, DOI 10.1128/MMBR.59.4.591-603.1995; ANGEL CS, 1994, J INFECT DIS, V170, P600, DOI 10.1093/infdis/170.3.600; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; Berry AM, 1996, INFECT IMMUN, V64, P5255, DOI 10.1128/IAI.64.12.5255-5262.1996; BERRY AM, 1989, INFECT IMMUN, V57, P2037, DOI 10.1128/IAI.57.7.2037-2042.1989; Brooks-Walter A, 1999, INFECT IMMUN, V67, P6533; BROWN EJ, 1985, CURR TOP MICROBIOL, V121, P159; BRUYN GAW, 1992, CLIN INFECT DIS, V14, P251, DOI 10.1093/clinids/14.1.251; CHINA B, 1993, INFECT IMMUN, V61, P3129, DOI 10.1128/IAI.61.8.3129-3136.1993; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOMI H, 1990, J IMMUNOL, V144, P4046; GORDON DL, 1988, J INFECT DIS, V157, P697, DOI 10.1093/infdis/157.4.697; Hammerschmidt S, 1997, MOL MICROBIOL, V25, P1113, DOI 10.1046/j.1365-2958.1997.5391899.x; HARBAUGH MP, 1993, MOL MICROBIOL, V8, P981, DOI 10.1111/j.1365-2958.1993.tb01642.x; HOLLINGSHEAD SK, 1986, J BIOL CHEM, V261, P1677; HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657; HORTON RM, 1995, MOL BIOTECHNOL, V3, P93, DOI 10.1007/BF02789105; HOSTETTER MK, 1986, J INFECT DIS, V153, P682, DOI 10.1093/infdis/153.4.682; Iannelli F, 1999, J BACTERIOL, V181, P2652, DOI 10.1128/JB.181.8.2652-2654.1999; Johnsson E, 1998, J IMMUNOL, V161, P4894; Johnsson E, 1996, J IMMUNOL, V157, P3021; KELLY T, 1994, INFECT IMMUN, V62, P1813, DOI 10.1128/IAI.62.5.1813-1819.1994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCDANIEL LS, 1987, J EXP MED, V165, P381, DOI 10.1084/jem.165.2.381; Morgan BP, 1999, COMPLEMENT REGULATOR, p[59, 121]; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; Neeleman C, 1999, INFECT IMMUN, V67, P4517, DOI 10.1128/IAI.67.9.4517-4524.1999; NESBITT SA, 1992, ANAL BIOCHEM, V206, P267, DOI 10.1016/0003-2697(92)90365-E; NYDEGGER UE, 1978, J IMMUNOL, V120, P1404; Pozzi G, 1996, J BACTERIOL, V178, P6087, DOI 10.1128/jb.178.20.6087-6090.1996; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; Ram S, 1998, J EXP MED, V188, P671, DOI 10.1084/jem.188.4.671; Rosenow C, 1997, MOL MICROBIOL, V25, P819, DOI 10.1111/j.1365-2958.1997.mmi494.x; SHOEMAKER NB, 1974, MOL GEN GENET, V128, P283, DOI 10.1007/BF00268516; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUEDSSON L, 1993, J IMMUNOL, V151, P5856; Tu AHT, 1999, INFECT IMMUN, V67, P4720, DOI 10.1128/IAI.67.9.4720-4724.1999; Wurzner R, 1999, MOL IMMUNOL, V36, P249, DOI 10.1016/S0161-5890(99)00049-8; Zipfel PF, 1999, MOL IMMUNOL, V36, P241, DOI 10.1016/S0161-5890(99)00038-3	41	171	180	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37257	37263		10.1074/jbc.M004572200	http://dx.doi.org/10.1074/jbc.M004572200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967103	hybrid, Green Published			2022-12-27	WOS:000165577700110
J	Kim, SH; Li, ZG; Sacks, DB				Kim, SH; Li, ZG; Sacks, DB			E-cadherin-mediated cell-cell attachment activates Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH SYNDROME PROTEIN; RHO-FAMILY GTPASES; PHOSPHATIDYLINOSITOL 3-KINASE; ADHESION COMPLEX; BINDING PROTEIN; EXCHANGE FACTOR; MDCK CELLS; KINASE-B; DOMAIN; IQGAP1	E-cadherin is a transmembrane protein that mediates Ca2+-dependent cell-cell adhesion. Cdc42, a member of the Rho family of small GTPases, participates in cytoskeletal rearrangement and cell cycle progression. Recent evidence reveals that members of the Rho family modulate E-cadherin function. To further examine the role of Cdc42 in E-cadherin-mediated cell-cell adhesion, we developed an assay for active Cdc42 using the GTPase-binding domain of the Wiskott-Aldrich syndrome protein. Initiation of E cadherin-mediated cell-cell attachment significantly increased in a time-dependent manner the amount of active Cdc42 in MCF-7 epithelial cell lysates. By contrast, Cdc42 activity was not increased under identical conditions in MCF-7 cells incubated with anti-E-cadherin antibodies nor in MDA-MB-231 (E-cadherin negative) epithelial cells. By fusing the Wiskott-Aldrich syndrome protein/GTPase-binding domain to a green fluorescent protein, activation of endogenous Cdc42 by E-cadherin was demonstrated in live cells. These data indicate that E-cadherin activates Cdc42, demonstrating bi-directional interactions between the Rho- and E-cadherin signaling pathways.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sacks, DB (corresponding author), Brigham & Womens Hosp, Dept Pathol, Thorn 530,75 Francis St, Boston, MA 02115 USA.	dsacks@rics.bwh.harvard.edu		Sacks, David/0000-0003-3100-0735	NATIONAL CANCER INSTITUTE [R55CA075205, R01CA075205] Funding Source: NIH RePORTER; NCI NIH HHS [CA75205] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Braga VMM, 1999, J CLIN PATHOL-MOL PA, V52, P197, DOI 10.1136/mp.52.4.197; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Gay B, 1999, J BIOL CHEM, V274, P23311, DOI 10.1074/jbc.274.33.23311; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Jiang WG, 1996, BRIT J SURG, V83, P437, DOI 10.1002/bjs.1800830404; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Nagata K, 1998, J BIOL CHEM, V273, P15453, DOI 10.1074/jbc.273.25.15453; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	48	181	183	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36999	37005		10.1074/jbc.M003430200	http://dx.doi.org/10.1074/jbc.M003430200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10950951	hybrid			2022-12-27	WOS:000165577700077
J	Whisstock, JC; Romero, S; Gurung, R; Nandurkar, H; Ooms, LM; Bottomley, SP; Mitchell, CA				Whisstock, JC; Romero, S; Gurung, R; Nandurkar, H; Ooms, LM; Bottomley, SP; Mitchell, CA			The inositol polyphosphate 5-phosphatases and the apurinic/apyrimidinic base excision repair endonucleases share a common mechanism for catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APURINIC ENDONUCLEASE; SITE-DIRECTED MUTAGENESIS; HUMAN-PLATELETS; DNASE-I; IDENTIFICATION; RESIDUES; MEMBRANE; BINDING; 1,4,5-TRISPHOSPHATE; PHOSPHOINOSITIDES	Inositol polyphosphate 5-phosphatases (5-phosphatase) hydrolyze the 5-position phosphate from the inositol ring of phosphatidylinositol-derived signaling molecules; however; the mechanism of catalysis is only partially characterized. These enzymes play critical roles in regulating cell growth, apoptosis, intracellular calcium oscillations, and post-synaptic vesicular trafficking. The UCLA fold recognition server (threader) predicted that the conserved 300-amino acid catalytic domain, common to all 5-phosphatases, adopts the fold of the apurinic/apyrimidinic (AP) base excision repair endonucleases. PSI-BLAST searches of GENPEPT, using the amino acid sequence of AP endonuclease exonuclease III, identified all members of the B-phosphatase family with highly significant scores. A sequence alignment between exonuclease III and all known 5-phosphatases revealed six highly conserved motifs containing residues that corresponded to the catalytic residues in the AP endonucleases. Mutation of each of these residues to alanine in the mammalian 43-kDa, or yeast Inp52p 5-phosphatase, resulted in complete loss of enzyme activity. We predict the 5-phosphatase enzymes share a similar mechanism of catalysis to the AP endonucleases, consistent with other common functional similarities such as an absolute requirement for magnesium for activity. Based on this analysis, functional roles have been assigned to conserved residues in all B-phosphatase enzymes.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Monash University	Mitchell, CA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.		Nandurkar, Harshal/AAO-7443-2020; Ooms, Lisa/AGZ-7420-2022	Mitchell, Christina A/0000-0001-9372-3192; Nandurkar, Harshal/0000-0002-8767-116X; Ooms, Lisa Michelle/0000-0002-8918-9932; Whisstock, James/0000-0003-4200-5611				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BARZILAY G, 1995, NAT STRUCT BIOL, V2, P561, DOI 10.1038/nsb0795-561; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Communi D, 1996, J BIOL CHEM, V271, P11676, DOI 10.1074/jbc.271.20.11676; Communi D, 1996, BIOCHEM J, V320, P181, DOI 10.1042/bj3200181; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dlakic M, 2000, TRENDS BIOCHEM SCI, V25, P272, DOI 10.1016/S0968-0004(00)01582-6; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Fischer D, 1996, PROTEIN SCI, V5, P947; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Janne PA, 1998, J CLIN INVEST, V101, P2042, DOI 10.1172/JCI2414; Jefferson AB, 1996, BIOCHEMISTRY-US, V35, P7890, DOI 10.1021/bi9602627; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; Jones SJ, 1996, J MOL BIOL, V264, P1154, DOI 10.1006/jmbi.1996.0703; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; Martin TFJ, 1997, CURR OPIN NEUROBIOL, V7, P331, DOI 10.1016/S0959-4388(97)80060-8; Matsuo Y, 1996, PROTEIN SCI, V5, P2459, DOI 10.1002/pro.5560051208; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; Mitchell CA, 1996, BIOCHEM SOC T, V24, P994, DOI 10.1042/bst0240994; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Park J, 1998, J MOL BIOL, V284, P1201, DOI 10.1006/jmbi.1998.2221; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Speed CJ, 1999, J CELL SCI, V112, P669; Speed CJ, 1996, EMBO J, V15, P4852, DOI 10.1002/j.1460-2075.1996.tb00866.x; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; Zhang XL, 1998, SEMIN CELL DEV BIOL, V9, P153, DOI 10.1006/scdb.1997.0220	38	59	60	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37055	37061		10.1074/jbc.M006244200	http://dx.doi.org/10.1074/jbc.M006244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10962003	hybrid			2022-12-27	WOS:000165577700084
J	Xu, W; Longo, FJ; Wintermantel, MR; Jiang, XY; Clark, RA; DeLisle, S				Xu, W; Longo, FJ; Wintermantel, MR; Jiang, XY; Clark, RA; DeLisle, S			Calreticulin modulates capacitative Ca2+ influx by controlling the extent of inositol 1,4,5-trisphosphate-induced Ca2+ store depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; INTRACELLULAR CALCIUM; GENE-EXPRESSION; BINDING PROTEIN; RECEPTOR; TRISPHOSPHATE; ACTIVATION; OVEREXPRESSION; MESSENGER; CURRENTS	Calreticulin (CRT) is a highly conserved Ca2+-binding protein that resides in the lumen of the endoplasmic reticulum (ER). We overexpressed CRT in Xenopus oocytes to determine how it could modulate inositol 1,4-5-trisphosphate (InsP(3))-induced Ca2+ influx. Under conditions where it did not affect the spatially complex elevations in free cytosolic Ca2+ concentration ([Ca2+](i)) due to InsP(3)-induced Ca2+ release, overexpressed CRT decreased by 46% the Ca2+-gated Cl- current due to Ca2+ influx. Deletion mutants revealed that CRT requires its high capacity Ca2+-binding domain to reduce the elevations of [Ca2+](i), due to Ca2+ influx. This functional domain was also required for CRT to attenuate the InsP(3)-induced decline in the free Ca2+ concentration within the ER lumen ([Ca2+](ER)), as monitored with a "chameleon" indicator. Our data suggest that by buffering [Ca2+](ER) near resting levels, CRT may prevent InsP(3) from depleting the intracellular stores sufficiently to activate Ca2+ influx.	Univ Maryland, Sch Med, Vet Affairs Med Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Iowa, Coll Med, Dept Anat, Iowa City, IA 52242 USA; S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX 78230 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78230 USA	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio	DeLisle, S (corresponding author), Univ Maryland, Dept Med, Vet Affairs Med Ctr 3B185, 10 N Greene St, Baltimore, MD 21201 USA.		Clark, Robert/Q-6764-2019	Clark, Robert/0000-0002-4892-3619				BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; DeLisle S, 1996, AM J PHYSIOL-CELL PH, V270, pC1255; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DeLisle S, 1997, J BIOL CHEM, V272, P9956; DELISLE S, 1990, J BIOL CHEM, V265, P11726; Denning GM, 1997, BLOOD, V90, P372; Fadel MP, 1999, J BIOL CHEM, V274, P15085, DOI 10.1074/jbc.274.21.15085; Fasolato C, 1998, MOL BIOL CELL, V9, P1513, DOI 10.1091/mbc.9.6.1513; FUJINO I, 1995, CELL TISSUE RES, V280, P201, DOI 10.1007/s004410050345; GILLO B, 1987, J PHYSIOL-LONDON, V392, P349, DOI 10.1113/jphysiol.1987.sp016784; HAN JK, 1990, J CELL BIOL, V110, P1103, DOI 10.1083/jcb.110.4.1103; Hartzell HC, 1996, J GEN PHYSIOL, V108, P157, DOI 10.1085/jgp.108.3.157; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; LIPP P, 1993, CELL CALCIUM, V14, P359, DOI 10.1016/0143-4160(93)90040-D; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 1996, J BIOL CHEM, V271, P29436, DOI 10.1074/jbc.271.46.29436; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILEDI R, 1989, J PHYSIOL-LONDON, V415, P189, DOI 10.1113/jphysiol.1989.sp017718; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MOREAU M, 1980, DEV BIOL, V78, P201, DOI 10.1016/0012-1606(80)90329-2; Nauseef WM, 1998, J BIOL CHEM, V273, P7107, DOI 10.1074/jbc.273.12.7107; OPAS M, 1996, J CELL BIOL, V135, P1, DOI DOI 10.1083/JCB.135.6.1913; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARKER I, 1986, PROC R SOC SER B-BIO, V228, P307, DOI 10.1098/rspb.1986.0057; PARKER I, 1987, PROC R SOC SER B-BIO, V231, P27, DOI 10.1098/rspb.1987.0033; PARYS JB, 1994, DEV BIOL, V161, P466, DOI 10.1006/dbio.1994.1045; PARYS JB, 1992, J BIOL CHEM, V267, P18776; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Perrone L, 1999, J BIOL CHEM, V274, P4640, DOI 10.1074/jbc.274.8.4640; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PICARD A, 1990, SCIENCE, V247, P327, DOI 10.1126/science.2153316; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; ROBINSON KR, 1985, DEV BIOL, V109, P504, DOI 10.1016/0012-1606(85)90475-0; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; TAKAHASHI T, 1987, P NATL ACAD SCI USA, V84, P5063, DOI 10.1073/pnas.84.14.5063; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943	55	46	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36676	36682		10.1074/jbc.M002041200	http://dx.doi.org/10.1074/jbc.M002041200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973951	hybrid			2022-12-27	WOS:000165577700033
J	Esterbauer, H; Oberkofler, H; Krempler, F; Strosberg, AD; Patsch, W				Esterbauer, H; Oberkofler, H; Krempler, F; Strosberg, AD; Patsch, W			The uncoupling protein-3 gene is transcribed from tissue-specific promoters in humans but not in rodents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKELETAL-MUSCLE; BROWN ADIPOSE-TISSUE; ENERGY-EXPENDITURE; CHROMOSOMAL LOCALIZATION; GENOMIC ORGANIZATION; METABOLIC-RATE; MESSENGER-RNA; EXPRESSION; OBESITY; SEQUENCES	Uncoupling protein-3 (UCP3), a mitochondrial membrane transporter, is a candidate effector of thermogenesis, Even though mice with targeted disruption of the UCP3 gene are not obese, indirect evidence suggests that this protein contributes to the control of energy expenditure in humans, We therefore characterized the human UCP3 gene and compared it with its rodent homologues with respect to tissue-specific expression and regulatory regions, Like rodent UCP3, human UCP3 was expressed in skeletal muscle and brown adipose tissue (BAT). The short mRNA isoform, UCP3(S), which is absent in rodents, was relatively more abundant in human skeletal muscle in comparison to human BAT. Two tissue-specific transcription start sites for each skeletal muscle and BAT were delineated for human UCP3. Tissue-specific transcript initiation was maintained in both tissues and cultured-cells over a wide range of expression levels. In contrast, rodent transcripts were initiated at the same site in BAT and muscle tissue, Comparison of human and rodent promoters indicated a rapid phylogenetic evolution suggesting functional diversification. The transcription from tissue-specific promoters in humans is a novel finding that may provide the basis for therapeutic interventions aimed at regulating energy expenditure in a tissue-specific fashion.	Landeskliniken Salzburg, Dept Lab Med, A-5020 Salzburg, Austria; Krankenhaus Hallein, Dept Internal Med, A-5400 Hallein, Austria; Inst Cochin Genet Mol, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Patsch, W (corresponding author), Landeskliniken Salzburg, Dept Lab Med, A-5020 Salzburg, Austria.			Esterbauer, Harald/0000-0001-7343-7455				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Bao S, 1998, DIABETES, V47, P1935, DOI 10.2337/diabetes.47.12.1935; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Bouchard C, 1997, HUM MOL GENET, V6, P1887, DOI 10.1093/hmg/6.11.1887; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung WK, 1999, DIABETES, V48, P1890, DOI 10.2337/diabetes.48.9.1890; Esterbauer H, 1999, GENOMICS, V62, P98, DOI 10.1006/geno.1999.5977; Esterbauer H, 1999, DIABETOLOGIA, V42, P302, DOI 10.1007/s001250051155; Fisher MH, 1998, J CLIN INVEST, V101, P2387, DOI 10.1172/JCI2496; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1999, BIOCHEM BIOPH RES CO, V256, P27, DOI 10.1006/bbrc.1999.0239; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; HAM RG, 1988, IN VITRO CELL DEV B, V24, P833; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; HENRY RR, 1995, DIABETES, V44, P936, DOI 10.2337/diabetes.44.8.936; Hinz W, 1999, FEBS LETT, V448, P57, DOI 10.1016/S0014-5793(99)00331-2; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; Jurka J, 1996, COMPUT CHEM, V20, P119, DOI 10.1016/S0097-8485(96)80013-1; JURKA J, 1995, NUCLEIC ACIDS RES, V23, P170, DOI 10.1093/nar/23.1.170; Khalfallah Y, 2000, DIABETES, V49, P25, DOI 10.2337/diabetes.49.1.25; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Krook A, 1998, DIABETES, V47, P1528, DOI 10.2337/diabetes.47.9.1528; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Luo DF, 1996, HUM MOL GENET, V5, P693, DOI 10.1093/hmg/5.5.693; Mantzoros CS, 1998, DIABETES, V47, P230, DOI 10.2337/diabetes.47.2.230; Nakagawa Y, 1998, AM J HUM GENET, V63, P547, DOI 10.1086/301974; Oberkofler H, 1997, J LIPID RES, V38, P2125; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pavlath G. K, 1996, HUMAN CELL CULTURE P, P307; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schrauwen P, 1999, DIABETES, V48, P146, DOI 10.2337/diabetes.48.1.146; SIMONSEN L, 1992, AM J PHYSIOL, V263, pE850, DOI 10.1152/ajpendo.1992.263.5.E850; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; Solanes G, 1997, J BIOL CHEM, V272, P25433, DOI 10.1074/jbc.272.41.25433; Stefl B, 1998, AM J PHYSIOL-ENDOC M, V274, pE527, DOI 10.1152/ajpendo.1998.274.3.E527; Taylor BA, 1996, GENOMICS, V34, P389, DOI 10.1006/geno.1996.0302; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vidal H, 1999, AM J PHYSIOL-ENDOC M, V277, pE830, DOI 10.1152/ajpendo.1999.277.5.E830; Vidal-Puig A, 1999, OBES RES, V7, P133, DOI 10.1002/j.1550-8528.1999.tb00694.x; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WARDEN CH, 1995, J CLIN INVEST, V95, P1545, DOI 10.1172/JCI117827; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X; Zilberfarb V, 1997, J CELL SCI, V110, P801; ZURLO F, 1990, J CLIN INVEST, V86, P1423, DOI 10.1172/JCI114857	54	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36394	36399		10.1074/jbc.M005713200	http://dx.doi.org/10.1074/jbc.M005713200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10958796	hybrid			2022-12-27	WOS:000165382000104
J	Medley, QG; Serra-Pages, C; Iannotti, E; Seipel, K; Tang, M; O'Brien, SP; Streuli, M				Medley, QG; Serra-Pages, C; Iannotti, E; Seipel, K; Tang, M; O'Brien, SP; Streuli, M			The Trio guanine nucleotide exchange factor is a RhoA target - Binding of RhoA to the Trio immunoglobulin-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; LIGHT-CHAIN KINASE; CELL-SHAPE CHANGES; FAMILY G-PROTEINS; ACTIN CYTOSKELETON; SIGNALING PATHWAYS; C-ELEGANS; GTPASES; VAV; ACTIVATION	Trio isa complex protein containing two guanine nucleotide exchange factor domains each with associated pleckstrin homology domains, a serine/threonine kinase domain, two SH3 domains, an immunoglobulin-like domain, and spectrin-like repeats. Trio was originally identified as a LAR tyrosine phosphatase-binding protein and is involved in actin remodeling, cell migration, and cell growth. Herein we provide evidence that Trio not only activates RhoA but is also a RhoA target. The RhoA-binding site was mapped to the Trio immunoglobulin-like domain. RhoA isoprenylation is necessary for the RhoA-Trio interaction, because mutation of the RhoA carboxyl-terminal cysteine residue blocked binding, The:existence of an intramolecular functional link between RhoA activation and RhoA binding is suggested by the finding that Trio exchange activity enhanced RhoA binding to Trio. Furthermore, immunofluorescence studies of HeLa cells showed that although ectopically:expressed Trio was evenly distributed within the cell, co-expression of Trio with RhoA resulted in relocalization of Trio into punctate structures. Relocalization was not observed with Trio constructs lacking the immunoglobulin-like domain, indicating that RhoA acts to regulate,Trio localization via binding to the immunoglobulin-like domain. We propose that Trio-mediated RhoA: activation and subsequent RhoA-mediated relocalization of Trio functions to modulate and coordinate Trio signaling.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Streuli, M (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.			Seipel, Katja/0000-0003-3128-1573	NCI NIH HHS [CA75091, CA55547] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075091, R01CA055547] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Awasaki T, 2000, NEURON, V26, P119, DOI 10.1016/S0896-6273(00)81143-5; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Bateman J, 2000, NEURON, V26, P93, DOI 10.1016/S0896-6273(00)81141-1; Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; Blangy A, 2000, J CELL SCI, V113, P729; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; Davis CR, 1998, J BIOL CHEM, V273, P849, DOI 10.1074/jbc.273.2.849; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Johnson RC, 2000, J BIOL CHEM, V275, P19324, DOI 10.1074/jbc.M000676200; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Kawai T, 1999, GENE, V227, P249, DOI 10.1016/S0378-1119(98)00605-2; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Liebl EC, 2000, NEURON, V26, P107, DOI 10.1016/S0896-6273(00)81142-3; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; MOERMAN DG, 1988, GENE DEV, V2, P93, DOI 10.1101/gad.2.1.93; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PASTERIS NG, 1994, CELL, V79, P669; Penzes P, 2000, J BIOL CHEM, V275, P6395, DOI 10.1074/jbc.275.9.6395; POTIER MC, 1995, GENOMICS, V29, P562, DOI 10.1006/geno.1995.9965; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Seipel K, 1999, J CELL SCI, V112, P1825; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; VAN AL, 1997, GENE DEV, V11, P2295; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035; Yron I, 1999, CELL ADHES COMMUN, V7, P1, DOI 10.3109/15419069909034388; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; ZMUIDZINAS A, 1995, EMBO J, V14, P1; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	53	28	30	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36116	36123		10.1074/jbc.M003775200	http://dx.doi.org/10.1074/jbc.M003775200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10948190	hybrid			2022-12-27	WOS:000165382000068
J	Steinberger, P; Sutton, JK; Rader, C; Elia, M; Barbas, CF				Steinberger, P; Sutton, JK; Rader, C; Elia, M; Barbas, CF			Generation and characterization of a recombinant human CCR5-specific antibody - A phage display approach for rabbit antibody humanization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MONOCLONAL-ANTIBODY; HIV-1 INFECTION; CHEMOKINE RECEPTORS; T-CELLS; CORECEPTOR; THERAPY; GENE; PROGRESSION; LIBRARIES	We describe the isolation of a CCR5-specific antibody, ST6, from an antibody phage display library generated from an immune rabbit. ST6 was previously shown to efficiently prevent; the surface expression of CCR5 when expressed intracellularly (Steinberger, P., Andris-Widhopf, J., Buhler, B., Torbett, B. E., and Barbas, C. F., III (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 805-810). Because ST6 has therapeutic potential in human immunodeficiency virus, type 1 disease, its humanization was desired to minimize the potential for immunogenicity, ST6 was humanized using a phage display-based approach. Like the parental rabbit clone, the humanized version ST6/34 efficiently prevented the surface expression of CCR5. The conserved linear peptide epitope bound by these antibodies was mapped using phage display. Both ST6 as well as the humanized anti-CCR5 antibody ST6/34 were produced as complete IgG antibodies and shown to bind to cell surface CCR5.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Barbas, CF (corresponding author), 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Rader, Christoph/0000-0001-9955-3454; Steinberger, Peter/0000-0001-6848-4097	PHS HHS [A141944] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baca M, 1997, J BIOL CHEM, V272, P10678; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Jung S, 1999, CURR OPIN IMMUNOL, V11, P319, DOI 10.1016/S0952-7915(99)80051-X; Karlstrom A, 2000, P NATL ACAD SCI USA, V97, P3878, DOI 10.1073/pnas.97.8.3878; Koenig S, 1996, NAT MED, V2, P165, DOI 10.1038/nm0296-165; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; Presta LG, 1997, CANCER RES, V57, P4593; Rader C, 2000, J BIOL CHEM, V275, P13668, DOI 10.1074/jbc.275.18.13668; Rader C, 1997, CURR OPIN BIOTECH, V8, P503, DOI 10.1016/S0958-1669(97)80075-4; Rader C, 1998, P NATL ACAD SCI USA, V95, P8910, DOI 10.1073/pnas.95.15.8910; RIDDER R, 1995, BIO-TECHNOL, V13, P255, DOI 10.1038/nbt0395-255; Steinberger P, 2000, P NATL ACAD SCI USA, V97, P805, DOI 10.1073/pnas.97.2.805; Tang Y, 1999, J BIOL CHEM, V274, P27371, DOI 10.1074/jbc.274.39.27371; YAMADA O, 1994, GENE THER, V1, P38; Yang AG, 1997, P NATL ACAD SCI USA, V94, P11567, DOI 10.1073/pnas.94.21.11567; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	22	52	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36073	36078		10.1074/jbc.M002765200	http://dx.doi.org/10.1074/jbc.M002765200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10969070	hybrid			2022-12-27	WOS:000165382000062
J	Stros, M; Muselikova, E				Stros, M; Muselikova, E			A role of basic residues and the putative intercalating phenylalanine of the HMG-1 box B in DNA supercoiling and binding to four-way DNA junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICANCER DRUG CISPLATIN; CHROMOSOMAL PROTEIN HMG1; DETERMINING FACTOR SRY; TRANSCRIPTION FACTOR; HISTONE H1; HIGH-MOBILITY-GROUP-1 PROTEIN; NUCLEOPROTEIN STRUCTURES; SEQUENCE SPECIFICITY; DAMAGED DNA; A-DOMAIN	HMG thigh mobility group) 1 is a chromosomal protein with two homologous DNA-binding domains, the HMG boxes A and B. HMG-1, like its individual HMG boxes, can recognize structural distortion of DNA, such as four-way DNA junctions (4WJs), that are very likely to have features common to their natural, yet unknown, cellular binding targets. HMG-1 can also bend/loop DNA and introduce negative supercoils in the presence of topoisomerase I in topologically closed DNAs, Results of our gel shift: assays demonstrate that mutation of Arg(97) within the extended N-terminal strand of the B domain significantly (>50-fold) decreases affinity of the HMG box for 4WJs and alters the mode of binding without changing the structural specificity for 4WJs. Several basic amino acids of the extended N-terminal strand (Lys(96)/Arg(97)) and helix I (Arg(110)/Lys(114)) Of the B domain participate in DNA binding and supercoiling, The putative intercalating hydrophobic Phe(103) of helix I is important for DNA supercoiling but dispensable for binding to supercoiled DNA and 4WJs. We conclude that the B domain of HMG-1 can tolerate substitutions of a number of amino acid residues without abolishing the structure-specific recognition of 4WJs, whereas mutations of most of these residues severely impair the topoisomerase I-mediated DNA supercoiling and change the sign of supercoiling from negative to positive,	Acad Sci Czech Republ, Inst Biophys, CZ-61265 Brno, Czech Republic	Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences	Stros, M (corresponding author), Acad Sci Czech Republ, Inst Biophys, Kralovopolska 135, CZ-61265 Brno, Czech Republic.							Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Allain FHT, 1999, EMBO J, V18, P2563, DOI 10.1093/emboj/18.9.2563; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1019, DOI 10.1093/nar/23.6.1019; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BILLINGS PC, 1992, BIOCHEM BIOPH RES CO, V188, P1286, DOI 10.1016/0006-291X(92)91371-V; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Cryer JE, 1996, CANCER CHEMOTH PHARM, V38, P163, DOI 10.1007/s002800050465; FALCIOLA L, 1994, NUCLEIC ACIDS RES, V22, P285, DOI 10.1093/nar/22.3.285; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Hardman CH, 1995, BIOCHEMISTRY-US, V34, P16596, DOI 10.1021/bi00051a007; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; Hill DA, 1999, NUCLEIC ACIDS RES, V27, P2135, DOI 10.1093/nar/27.10.2135; Hill DA, 1997, NUCLEIC ACIDS RES, V25, P3523, DOI 10.1093/nar/25.17.3523; HU CH, 1994, MOL CELL BIOL, V14, P2871, DOI 10.1128/MCB.14.5.2871; Ivanchenko M, 1997, BIOPHYS J, V72, P1388, DOI 10.1016/S0006-3495(97)78785-X; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; LILLEY DMJ, 1993, ANNU REV BIOPH BIOM, V22, P299, DOI 10.1146/annurev.bb.22.060193.001503; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Murphy FV, 1999, EMBO J, V18, P6610, DOI 10.1093/emboj/18.23.6610; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Palecek E, 1997, ONCOGENE, V15, P2201, DOI 10.1038/sj.onc.1201398; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Pohler JRG, 1998, EMBO J, V17, P817, DOI 10.1093/emboj/17.3.817; Ramstein J, 1999, EUR J BIOCHEM, V260, P692, DOI 10.1046/j.1432-1327.1999.00185.x; Read C., 1995, NUCL ACIDS MOL BIOL, P222; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; Saito K, 1999, PROTEIN ENG, V12, P235, DOI 10.1093/protein/12.3.235; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELVIN PR, 1992, SCIENCE, V255, P82, DOI 10.1126/science.1553534; SHEFLIN LG, 1993, BIOCHEMISTRY-US, V32, P3238, DOI 10.1021/bi00064a005; SHEFLIN LG, 1989, BIOCHEMISTRY-US, V28, P5658, DOI 10.1021/bi00439a048; Stros M, 1998, EUR J BIOCHEM, V251, P427, DOI 10.1046/j.1432-1327.1998.2510427.x; Stros M, 1998, J BIOL CHEM, V273, P10355; STROS M, 1994, FEBS LETT, V344, P201, DOI 10.1016/0014-5793(94)00364-5; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; STROS M, 1994, EUR J BIOCHEM, V225, P581, DOI 10.1111/j.1432-1033.1994.00581.x; Stros M, 2000, EUR J BIOCHEM, V267, P4088, DOI 10.1046/j.1432-1327.2000.01450.x; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; TEO SH, 1995, EMBO J, V14, P3844, DOI 10.1002/j.1460-2075.1995.tb00054.x; Webb M, 1999, J MOL BIOL, V294, P373, DOI 10.1006/jmbi.1999.3150; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WERNER MH, 1995, BIOCHEMISTRY-US, V34, P11998, DOI 10.1021/bi00037a042; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P29261; Yen YM, 1998, J BIOL CHEM, V273, P4424, DOI 10.1074/jbc.273.8.4424; Zlatanova J, 1998, FASEB J, V12, P791, DOI 10.1096/fasebj.12.10.791; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	54	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35699	35707		10.1074/jbc.M007167200	http://dx.doi.org/10.1074/jbc.M007167200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10962007	hybrid			2022-12-27	WOS:000165382000010
J	Davaille, J; Gallois, C; Habib, A; Li, LY; Mallat, A; Tao, JC; Levade, T; Lotersztajn, S				Davaille, J; Gallois, C; Habib, A; Li, LY; Mallat, A; Tao, JC; Levade, T; Lotersztajn, S			Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts - A cyclooxygenase-2 mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; NECROSIS-FACTOR-ALPHA; STELLATE CELLS; GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; RECEPTOR EDG-1; SPHINGOSINE-1-PHOSPHATE; PROLIFERATION	Proliferation of hepatic myofibroblasts (hMF) is central for the development of fibrosis during liver injury, and factors that may limit their growth are potential antifibrotic agents. Sphingosine I-phosphate (S1P) is a bioactive sphingolipid with growth-regulating properties, either via Edg receptors or through intracellular actions. In this study, we examined the effects of S1P on the proliferation of human hMF. Human hMF expressed mRNAs for the S1P receptors Edg1, Edg3, and Edg5. These receptors were functional at nanomolar concentrations and coupled to pertussis toxin-sensitive and -insensitive G proteins, as demonstrated in guanosine 5'-3-O-(thio)triphosphate binding assays. S1P potently inhibited hMF growth (IC50 = 1 muM), in a pertussis toxin-insensitive manner. Analysis of the mechanisms involved in growth inhibition revealed that SIP rapidly increased prostaglandin E-2 production and in turn cAMP, two growth inhibitory messengers for hMF; C-2-ceramide and sphingosine, which inhibited hMF proliferation, did not affect cAMP levels. Production of cAMP by S1P was abolished by NS-398, a selective inhibitor of COX-2. Also, S1P potently induced COX-2 protein expression. Blocking COX-2 by NS-398 blunted the antiproliferative effect of SIP. We conclude that SIP inhibits proliferation of hMF, probably via an intracellular mechanism, through early COX-2-dependent release of prostaglandin E-2 and cAMP, and delayed COX-2 induction. Our results shed light on a novel role for S1P as a growth inhibitory mediator and point out its potential involvement in the negative regulation of liver fibrogenesis.	Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France; Hop Lariboisiere, INSERM, U348, F-75010 Paris, France; CHU Rangueil, INSERM, U466, F-31403 Toulouse, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Lotersztajn, S (corresponding author), Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France.		Habib, Aida/H-8647-2019; Lotersztajn, Sophie/K-9160-2017; Levade, Thierry/O-8948-2014	Habib, Aida/0000-0001-6027-0043; lotersztajn, Sophie/0000-0002-0053-7807				Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994; Auge N, 1999, J BIOL CHEM, V274, P21533, DOI 10.1074/jbc.274.31.21533; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Gallois C, 2000, ANN NY ACAD SCI, V905, P311; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Im DS, 1997, AM J PHYSIOL-GASTR L, V272, pG1091, DOI 10.1152/ajpgi.1997.272.5.G1091; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Knittel T, 1999, HISTOCHEM CELL BIOL, V112, P387, DOI 10.1007/s004180050421; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Liu CH, 1997, GENOMICS, V43, P15, DOI 10.1006/geno.1997.4759; Lynch KR, 1999, TRENDS PHARMACOL SCI, V20, P473, DOI 10.1016/S0165-6147(99)01401-7; Mallat A, 1998, J BIOL CHEM, V273, P27300, DOI 10.1074/jbc.273.42.27300; Mallat A, 1996, J CLIN INVEST, V98, P2771, DOI 10.1172/JCI119103; Olaso E, 1998, J HEPATOL, V29, P836, DOI 10.1016/S0168-8278(98)80269-9; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Sato K, 1999, MOL PHARMACOL, V55, P126, DOI 10.1124/mol.55.1.126; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Tao JC, 1999, J BIOL CHEM, V274, P23761, DOI 10.1074/jbc.274.34.23761; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; WIN KM, 1993, HEPATOLOGY, V18, P137, DOI 10.1002/hep.1840180121; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193	36	111	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34628	34633		10.1074/jbc.M006393200	http://dx.doi.org/10.1074/jbc.M006393200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942778	hybrid			2022-12-27	WOS:000165095300085
J	Langmade, SJ; Ravindra, R; Daniels, PJ; Andrews, GK				Langmade, SJ; Ravindra, R; Daniels, PJ; Andrews, GK			The transcription factor MTF-1 mediates metal regulation of the mouse ZnT1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOTHIONEIN-I GENE; DIETARY ZINC-DEFICIENCY; MESSENGER-RNA; RESPONSE ELEMENT; TRANSGENIC MICE; CONFERS RESISTANCE; SYNAPTIC VESICLES; BINDING-ACTIVITY; DNA-BINDING; EXPRESSION	Metal regulation of the mouse zinc transporter (ZnT)-1 gene was examined in cultured cells and in the developing conceptus. Zinc or cadmium treatment of cell lines rapidly (3 h) and dramatically (about la-fold) induced ZnT1 mRNA levels. In cells incubated in medium supplemented with Chelex-treated fetal bovine serum, to remove metal ions, levels of ZnT1 mRNA were reduced, and induction of this message in response to zinc or cadmium was accentuated (up to 31-fold induction). Changes in ZnT1 gene expression in these experiments paralleled those of metallothionein I (MT-I), Inhibition of RNA synthesis blocked metal induction of ZnT1 and MT-1 mRNAs, whereas inhibition of protein synthesis did not. Metal response element-binding transcription factor (MTF)-1 mediates metal regulation of the metallothionein I gene. In vitro DNA-binding assays demonstrated that mouse MTF-1 can bind avidly to the two metal-response element sequences found in the ZnT1 promoter. Using mouse embryo fibroblasts with homozygous deletions of the MTF-1 gene, it was shown that this transcription factor is essential for basal as well as metal (zinc and cadmium) regulation of the ZnT1 gene in these cells. In vivo, ZnT1 mRNA was abundant in the midgestation visceral yolk sac and placenta. Dietary zinc deficiency during pregnancy down-regulated ZnT1 and MT-I mRNA levels (4-5-fold and >20-fold, respectively) in the visceral yolk sac, but had little effect on these mRNAs in the placenta. Homozygous knockout of the MTF-1 gene in transgenic mice also led to a 4-6-fold reduction in ZnT1 mRNA levels and a loss of MT-I mRNA in the visceral yolk sac, These results suggest that MTF-1 mediates the response to metal ions of both the ZnT1 and the MT-I genes the visceral yolk sac, Overall, these studies suggest that MTF-1 directly coordinates the regulation of genes involved in zinc homeostasis and protection against metal toxicity.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Andrews, GK (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	gandrews@kumc.edu			NCI NIH HHS [CA 61262] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061262] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS GK, 1987, DEVELOPMENT, V100, P463; Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; ANDREWS GK, 1991, DEV BIOL, V145, P13, DOI 10.1016/0012-1606(91)90209-L; Andrews GK, 1999, J NUTR, V129, P1643, DOI 10.1093/jn/129.9.1643; ANDREWS GK, 1987, EUR J BIOCHEM, V166, P527, DOI 10.1111/j.1432-1033.1987.tb13545.x; ANDREWS GK, 1993, METALLOTHIONEIN, V3, P351; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; Dalton T, 1996, J NUTR, V126, P825, DOI 10.1093/jn/126.4.825; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; Dalton TP, 1997, MOL CELL BIOL, V17, P2781, DOI 10.1128/MCB.17.5.2781; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; Davis SR, 1998, J NUTR, V128, P825, DOI 10.1093/jn/128.5.825; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; KARASAWA M, 1991, J INVEST DERMATOL, V97, P97, DOI 10.1111/1523-1747.ep12478393; Koizumi S, 1999, EUR J BIOCHEM, V259, P635, DOI 10.1046/j.1432-1327.1999.00069.x; Li QW, 1998, NUCLEIC ACIDS RES, V26, P5182, DOI 10.1093/nar/26.22.5182; Liang LC, 1996, MOL REPROD DEV, V43, P25, DOI 10.1002/(SICI)1098-2795(199601)43:1&lt;25::AID-MRD4&gt;3.0.CO;2-W; Lichtlen P, 1999, BIOL CHEM, V380, P711, DOI 10.1515/BC.1999.089; Liu YP, 1995, TOXICOL APPL PHARM, V135, P222, DOI 10.1006/taap.1995.1227; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MAYO KE, 1981, J BIOL CHEM, V256, P2621; MCCLAIN CJ, 1990, J LAB CLIN MED, V116, P275; MCCORMICK CC, 1991, BIOCHEM J, V273, P185, DOI 10.1042/bj2730185; McMahon RJ, 1998, P NATL ACAD SCI USA, V95, P4841, DOI 10.1073/pnas.95.9.4841; McMahon RJ, 1998, J NUTR, V128, P667, DOI 10.1093/jn/128.4.667; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; NOLL M, 2000, BIOCHEM MOL BIOL INT, V49, P297; OESTREICHER P, 1989, J NUTR, V119, P639, DOI 10.1093/jn/119.4.639; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; Swerdlow H, 1997, ANAL CHEM, V69, P848, DOI 10.1021/ac961104o; Tsuda M, 1997, J NEUROSCI, V17, P6678; WALSH CT, 1994, ENVIRON HEALTH PERSP, V102, P5, DOI 10.2307/3431820; Wenzel HJ, 1997, P NATL ACAD SCI USA, V94, P12676, DOI 10.1073/pnas.94.23.12676	43	309	320	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34803	34809		10.1074/jbc.M007339200	http://dx.doi.org/10.1074/jbc.M007339200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10952993	hybrid			2022-12-27	WOS:000165095300107
J	Grewal, T; Heeren, J; Mewawala, D; Schnitgerhans, T; Wendt, D; Salomon, G; Enrich, C; Beisiegel, U; Jackle, S				Grewal, T; Heeren, J; Mewawala, D; Schnitgerhans, T; Wendt, D; Salomon, G; Enrich, C; Beisiegel, U; Jackle, S			Annexin VI stimulates endocytosis and is involved in the trafficking of low density lipoprotein to the prelysosomal compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; SUBCELLULAR-DISTRIBUTION; BINDING PROTEINS; TYROSINE KINASE; MEMBRANE; CELLS; ENDOSOMES; RECEPTOR; FUSION; TRANSFERRIN	Annexins are calcium-binding proteins with a wide distribution in most polarized and nonpolarized cells that participate in a variety of membrane-membrane interactions. At the cell surface, annexin VI is thought to remodel the spectrin cytoskeleton to facilitate budding of coated pits. However, annexin VI is also found in late endocytic compartments in a number of cell types, indicating an additional important role at later stages of the endocytic pathway. Therefore overexpression of annexin VI in Chinese hamster ovary cells was used to investigate its possible role in endocytosis and intracellular trafficking of low density Lipoprotein (LDL) and transferrin, While overexpression of annexin VI alone did not alter endocytosis and degradation of LDL, coexpression of annexin VI and LDL receptor resulted in an increase in LDL uptake with a concomitant increase of its degradation. Whereas annexin VI showed a wide intracellular distribution in resting Chinese hamster ovary cells, it was mainly found in the endocytic compartment and remained associated with LDE-containing vesicles even at later stages of the endocytic pathway. Thus, data presented in this study suggest that after stimulating endocytosis at the cell surface, annexin VI remains hound to endocytic vesicles to regulate entry of ligands into the prelysosomal compartment.	Univ Hamburg, Hosp Eppendorf, Med Kernklin & Poliklin, D-20246 Hamburg, Germany; Univ Barcelona, Fac Med, Inst Invest Biomed August Pi I Sunyer, Dept Biol Celular, Barcelona 08036, Spain	University of Hamburg; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Grewal, T (corresponding author), Univ Hamburg, Hosp Eppendorf, Med Kernklin & Poliklin, Martinistr 52, D-20246 Hamburg, Germany.	grewal@uke.uni-hamburg.de		Grewal, Thomas/0000-0002-7937-8887; Enrich, Carlos/0000-0003-0382-2993				Babiychuk EB, 1999, J BIOL CHEM, V274, P35191, DOI 10.1074/jbc.274.49.35191; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; Donato R., 1999, Cell Calcium, V26, P85, DOI 10.1054/ceca.1999.0079; DONELLY SR, 1997, CELL MOL LIFE SCI, V53, P533; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAN H, 1995, EUR J BIOCHEM, V230, P741, DOI 10.1111/j.1432-1033.1995.0741h.x; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; FISCHER HD, 1980, J BIOL CHEM, V255, P9608; Fleet A, 1999, BIOCHEM BIOPH RES CO, V260, P540, DOI 10.1006/bbrc.1999.0915; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; GERKE V, 1985, J BIOL CHEM, V260, P1688; GERKE V, 1997, BIOCHIM BIOPHYS ACTA, V1357, P1229; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JACKLE S, 1994, J BIOL CHEM, V269, P1026; Kamal A, 1998, J CELL BIOL, V142, P937, DOI 10.1083/jcb.142.4.937; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; KIM MJ, 1994, ATHEROSCLEROSIS, V108, P5; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafont F, 1998, J CELL BIOL, V142, P1413, DOI 10.1083/jcb.142.6.1413; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Massey-Harroche D, 1998, J CELL SCI, V111, P3007; MAYORGA LS, 1994, J BIOL CHEM, V269, P30927; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; Morgan RO, 1997, CELL MOL LIFE SCI, V53, P508, DOI 10.1007/s000180050064; Ortega D, 1998, J CELL SCI, V111, P261; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; Pons M, 2000, EXP CELL RES, V257, P33, DOI 10.1006/excr.2000.4861; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; Sambrook J., 1989, MOL CLONING, pA1; SMYTHE E, 1994, J CELL BIOL, V124, P301, DOI 10.1083/jcb.124.3.301; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; TAGOE CE, 1994, BBA-BIOMEMBRANES, V1192, P272, DOI 10.1016/0005-2736(94)90128-7; THIEL C, 1992, J CELL SCI, V103, P733; Turpin E, 1998, BBA-MOL CELL RES, V1402, P115, DOI 10.1016/S0167-4889(97)00151-1; WATANABE T, 1994, J BIOL CHEM, V269, P17656	47	85	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33806	33813		10.1074/jbc.M002662200	http://dx.doi.org/10.1074/jbc.M002662200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10940299	hybrid			2022-12-27	WOS:000090104600087
J	Pitson, SM; Moretti, PAB; Zebol, JR; Xia, P; Gamble, JR; Vadas, MA; D'Andrea, RJ; Wattenberg, BW				Pitson, SM; Moretti, PAB; Zebol, JR; Xia, P; Gamble, JR; Vadas, MA; D'Andrea, RJ; Wattenberg, BW			Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation - A dominant-negative sphingosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SIGNALING PATHWAYS; PROTEIN-COUPLED RECEPTORS; DIACYLGLYCEROL KINASE; MOLECULAR-CLONING; CALCIUM MOBILIZATION; PHOSPHOLIPASE-C; 3T3 FIBROBLASTS; 2ND MESSENGER; CELL-GROWTH; SPHINGOSINE-1-PHOSPHATE	Sphingosine kinase (SK) catalyzes the formation of sphingosine 1-phosphate (S1P), a lipid messenger that plays an important role in a variety of mammalian cell processes, including inhibition of apoptosis and stimulation of cell proliferation. Basal levels of SIP in cells are generally low but can increase rapidly when cells are exposed to various agonists through rapid and transient activation of SK activity. To date, elucidation of the exact signaling pathways affected by these elevated S1P levels has relied on the use of SK inhibitors that are known to have direct effects on other enzymes in the cell. Furthermore, these inhibitors block basal SK activity, which is thought to have a housekeeping function in the cell. To produce a specific inhibitor of SK activation we sought to generate a catalytically inactive, dominant-negative SK. This was accomplished by site-directed mutagenesis of Gly(82) to Asp of the human SK, a residue identified through sequence similarity to the putative catalytic domain of diacylglycerol kinase. This mutant had no detectable SK activity when expressed at high levels in HEK293T cells. Activation of endogenous SK activity by tumor necrosis factor-alpha (TNF alpha), interleukin-lp, and phorbol esters in HEK293T cells was blocked by expression of this inactive sphingosine kinase (hSK(G82D)), Basal SK activity was unaffected by expression of hSR(G82D). Expression of hSK(G82D) had no effect on TNF alpha -induced activation of protein kinase C and sphingomyelinase activities. Thus, hSK(G82D) acts as a specific dominant-negative SK to block SK activation. This discovery provides a powerful tool for the elucidation of the exact signaling pathways affected by elevated S1P levels following SK activation. To this end we have employed the dominant-negative SK to demonstrate that TNF alpha activation of extracellular signal-regulated kinases 1 and 2 (ERK1,2) is dependent on SK activation.	Univ Adelaide, Inst Med & Vet Sci, Div Human Immunol, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia; University of Adelaide; University of Adelaide	Wattenberg, BW (corresponding author), Univ Adelaide, Inst Med & Vet Sci, Div Human Immunol, Hanson Ctr Canc Res, Frome Rd, Adelaide, SA 5000, Australia.	brian.wattenberg@imvs.sa.gov.au	Pitson, Stuart/B-9342-2009; Vadas, Mathew/R-1378-2019; Xia, Pu/G-3090-2010	Pitson, Stuart/0000-0002-9527-2740; Xia, Pu/0000-0003-4705-8878; Gamble, Jennifer/0000-0002-0179-9964				An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; BENNER SA, 1991, ADV ENZYME REGUL, V31, P121, DOI 10.1016/0065-2571(91)90012-B; BEUHRER BM, 1996, BIOCHIM BIOPHYS ACTA, V1303, P233; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Burow ME, 2000, J BIOL CHEM, V275, P9628, DOI 10.1074/jbc.275.13.9628; Choi OH, 1996, NATURE, V380, P634; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DESAI NN, 1992, J BIOL CHEM, V267, P23122; Edsall LC, 1997, J NEUROSCI, V17, P6952; Funaki M, 1999, J BIOL CHEM, V274, P22019, DOI 10.1074/jbc.274.31.22019; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Guan ZH, 1999, J BIOL CHEM, V274, P36200, DOI 10.1074/jbc.274.51.36200; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kozawa O, 1997, J BIOL CHEM, V272, P25099, DOI 10.1074/jbc.272.40.25099; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawler JF, 1998, J BIOL CHEM, V273, P5053, DOI 10.1074/jbc.273.9.5053; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; MCDONALD OB, 1991, J BIOL CHEM, V266, P21773; MEGIDISH T, 1995, BIOCHEM BIOPH RES CO, V216, P739, DOI 10.1006/bbrc.1995.2684; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Melendez AJ, 2000, GENE, V251, P19, DOI 10.1016/S0378-1119(00)00205-5; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; OKOSHI H, 1991, CANCER RES, V51, P6019; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Ponting CP, 1999, NUCLEIC ACIDS RES, V27, P229, DOI 10.1093/nar/27.1.229; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; SU Y, 1994, J BIOL CHEM, V269, P16512; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Xu J, 2000, ANN NY ACAD SCI, V905, P81	60	170	180	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33945	33950		10.1074/jbc.M006176200	http://dx.doi.org/10.1074/jbc.M006176200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10944534	hybrid			2022-12-27	WOS:000090104600105
J	Arcondeguy, T; Lawson, D; Merrick, M				Arcondeguy, T; Lawson, D; Merrick, M			Two residues in the T-loop of GlnK determine NifL-dependent nitrogen control of nif gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PROTEIN; ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE; P-II; AZOTOBACTER-VINELANDII; GLUTAMINE-SYNTHETASE; ENTERIC BACTERIA; WILD-TYPE; URIDYLYLTRANSFERASE; INHIBITION	X-ray crystallographic analysis of the Escherichia coli P-II protein paralogues GInB and GlnK has shown that they share a superimposable structural core but can differ in conformation of the T-loop, a region of the protein (residues 37-54) that has been shown to be important for interaction with other proteins. In Klebsiella pneumoniae GlnK has been shown to have a clearly defined function in regulating NifL-mediated inhibition of NifA activity in response to the nitrogen status, and GlnB, when expressed from the chromosome, does not substitute for GlnB Because the T-loops of K. pneumoniae and E. coli GlnB and GlnK differ at just three residues, 43, 52, and 54, we have used a previously constructed heterologous system, in which a pneumoniae nifLA. is expressed in E. coli, to investigate the importance of GlnK residues 43, 52, and 54 for regulation of the NifLA interaction. By site-directed mutagenesis of glnB we have shown that residue 54 is the single most important amino acid in the T-loop in the context of the regulation of NifA activity. Furthermore, a combination of just two changes, in residues 54 and 43, allows GlnB to function as GlnK and completely relieve NifL inhibition of NifA activity.	John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England; John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Merrick, M (corresponding author), John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Coloney Lane, Norwich NR4 7UH, Norfolk, England.	mike.merrick@bbsrc.ac.uk	Lawson, David M/D-1810-2009					Arcondeguy T, 1999, FEMS MICROBIOL LETT, V180, P263, DOI 10.1016/S0378-1097(99)00497-8; Atkinson MR, 1998, MOL MICROBIOL, V29, P431, DOI 10.1046/j.1365-2958.1998.00932.x; Atkinson MR, 1999, MOL MICROBIOL, V32, P301, DOI 10.1046/j.1365-2958.1999.01349.x; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; CHEN YM, 1982, J BACTERIOL, V150, P214, DOI 10.1128/JB.150.1.214-220.1982; CONTRERAS A, 1991, GENE, V103, P83, DOI 10.1016/0378-1119(91)90395-R; CONTRERAS A, 1991, J BACTERIOL, V173, P7741, DOI 10.1128/jb.173.24.7741-7749.1991; EDWARDS R, 1995, MOL GEN GENET, V247, P189, DOI 10.1007/BF00705649; Forchhammer K, 1999, MOL MICROBIOL, V33, P338, DOI 10.1046/j.1365-2958.1999.01477.x; He LH, 1998, J BACTERIOL, V180, P6661, DOI 10.1128/JB.180.24.6661-6667.1998; HOLTEL A, 1988, MOL GEN GENET, V215, P134, DOI 10.1007/BF00331314; Jack R, 1999, J BACTERIOL, V181, P1156, DOI 10.1128/JB.181.4.1156-1162.1999; Jaggi R, 1996, FEBS LETT, V391, P223, DOI 10.1016/0014-5793(96)00737-5; Jiang P, 1997, J BACTERIOL, V179, P4342, DOI 10.1128/jb.179.13.4342-4353.1997; Jiang P, 1997, J BACTERIOL, V179, P4354, DOI 10.1128/jb.179.13.4354-4360.1997; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12782, DOI 10.1021/bi980667m; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Meletzus D, 1998, J BACTERIOL, V180, P3260, DOI 10.1128/JB.180.12.3260-3264.1998; MERRICK MJ, 1995, MICROBIOL REV, V59, P604, DOI 10.1128/MMBR.59.4.604-622.1995; Miller J. H, 1972, EXPT MOL GENETICS; Ninfa AJ, 2000, TRENDS MICROBIOL, V8, P172, DOI 10.1016/S0966-842X(00)01709-1; REYESRAMIREZ F, 2000, NITROGEN FIXATION MO, P97; Thomas G, 2000, TRENDS GENET, V16, P11, DOI 10.1016/S0168-9525(99)01887-9; van Heeswijk WC, 2000, P NATL ACAD SCI USA, V97, P3942, DOI 10.1073/pnas.97.8.3942; VANHEESWIJK WC, 1995, FEMS MICROBIOL LETT, V132, P153, DOI 10.1016/0378-1097(95)00302-L; vanHeeswijk WC, 1996, MOL MICROBIOL, V21, P133, DOI 10.1046/j.1365-2958.1996.6281349.x; Xu YB, 1998, J MOL BIOL, V282, P149, DOI 10.1006/jmbi.1998.1979	27	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38452	38456		10.1074/jbc.M001935200	http://dx.doi.org/10.1074/jbc.M001935200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10952972	hybrid			2022-12-27	WOS:000165739800043
J	Lotharius, J; O'Malley, KL				Lotharius, J; O'Malley, KL			The Parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation - A novel mechanism of toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; CEREBELLAR GRANULE CELLS; MOUSE STRIATAL MEMBRANES; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; NEUROTOXIN 1-METHYL-4-PHENYLPYRIDINIUM; BRAIN MITOCHONDRIA; NADH DEHYDROGENASE; AMPHETAMINE ACTION; HYDROGEN-PEROXIDE; SUPEROXIDE ANION	Uptake of the Parkinsonism-inducing toxin, 1-methyl-4-phenylpyridinium (MPP+), into dopaminergic terminals is thought to block Complex I activity leading to ATP loss and overproduction of reactive oxygen species (ROS). The present study indicates that MPP+-induced ROS formation is not mitochondrial in origin but results from intracellular dopamine (DA) oxidation. Although a mean lethal dose of MPP+ led to ROS production in identified dopaminergic neurons, toxic doses of the Complex I inhibitor rotenone did not. Concurrent with ROS formation, MPP+ redistributed vesicular DA to the cytoplasm prior to its extrusion from the cell by reverse transport via the DA transporter. MPP+-induced DA redistribution was also associated with cell death. Depleting cells of newly synthesized and/or stored DA significantly attenuated both superorxide production and cell death, whereas enhancing intracellular DA content exacerbated dopaminergic sensitivity to MPP+. Lastly, depleting cells of DA in the presence of succinate completely abolished MPP+-induced cell death. Thus, MPP+ neurotoxicity is a multi-component process involving both mitochondrial dysfunction and ROS generated by vesicular DA displacement. These results suggest that in the presence of a Complex I defect, misregulation of DA storage could lead to the loss of nigrostriatal neurons in Parkinson's disease.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	O'Malley, KL (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, Box 8108,660 S Euclid Ave, St Louis, MO 63110 USA.	omalleyk@pcg.wustl.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS039084, R01NS039084] Funding Source: NIH RePORTER; NIMH NIH HHS [MH45330] Funding Source: Medline; NINDS NIH HHS [NS39084] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKANEYA Y, 1995, NEUROSCI LETT, V193, P53, DOI 10.1016/0304-3940(95)11668-M; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BOWLING AC, 1995, LIFE SCI, V56, P1151, DOI 10.1016/0024-3205(95)00055-B; Budd SL, 1996, J NEUROCHEM, V67, P2282; Budd SL, 1997, FEBS LETT, V415, P21, DOI 10.1016/S0014-5793(97)01088-0; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; CHAN P, 1991, J NEUROCHEM, V57, P348, DOI 10.1111/j.1471-4159.1991.tb02134.x; CHANG GD, 1986, BRAIN RES, V368, P134, DOI 10.1016/0006-8993(86)91050-4; Chinopoulos C, 1999, J NEUROCHEM, V73, P220, DOI 10.1046/j.1471-4159.1999.0730220.x; CLARKE PBS, 1995, BRIT J PHARMACOL, V114, P315, DOI 10.1111/j.1476-5381.1995.tb13229.x; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DANIELS AJ, 1988, J BIOL CHEM, V263, P5034; DELZOMPO M, 1991, EUR J PHARMACOL, V202, P293, DOI 10.1016/0014-2999(91)90309-E; DELZOMPO M, 1992, BRAIN RES, V571, P354, DOI 10.1016/0006-8993(92)90677-2; DELZOMPO M, 1993, BRIT J PHARMACOL, V109, P411; DENTON T, 1987, J NEUROCHEM, V49, P622, DOI 10.1111/j.1471-4159.1987.tb02909.x; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434; DUGAN LL, 1995, J NEUROSCI, V15, P6377; FILLOUX F, 1993, EXP NEUROL, V119, P79, DOI 10.1006/exnr.1993.1008; FISCHER JF, 1979, J PHARMACOL EXP THER, V208, P203; Fon EA, 1997, NEURON, V19, P1271, DOI 10.1016/S0896-6273(00)80418-3; FORNSTEDT B, 1990, ACTA NEUROL SCAND, V82, P12; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gainetdinov RR, 1998, J NEUROCHEM, V70, P1973; Gerlach M, 1996, J NEURAL TRANSM, V103, P987, DOI 10.1007/BF01291788; GLUCK MR, 1994, J BIOL CHEM, V269, P3167; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; HEIKKILA RE, 1973, SCIENCE, V181, P456, DOI 10.1126/science.181.4098.456; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Jones SR, 1999, J NEUROCHEM, V73, P2406, DOI 10.1046/j.1471-4159.1999.0732406.x; Jones SR, 1998, J NEUROSCI, V18, P1979; Klivenyi P, 1998, NEUROBIOL DIS, V5, P253, DOI 10.1006/nbdi.1998.0191; Kristal BS, 1997, J NEUROCHEM, V69, P524; KRUEGER MJ, 1990, BIOCHEM BIOPH RES CO, V169, P123, DOI 10.1016/0006-291X(90)91442-U; Li H, 1997, J NEUROCHEM, V69, P1530; LIANG NY, 1982, BIOCHEM PHARMACOL, V31, P983, DOI 10.1016/0006-2952(82)90332-X; LIU Y, 1992, P NATL ACAD SCI USA, V89, P9074, DOI 10.1073/pnas.89.19.9074; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Lotharius J, 1999, J NEUROSCI, V19, P1284; MAKER HS, 1981, J NEUROCHEM, V36, P589, DOI 10.1111/j.1471-4159.1981.tb01631.x; MARKSTEIN R, 1984, EUR J PHARMACOL, V106, P301, DOI 10.1016/0014-2999(84)90717-9; MICHEL PP, 1990, J NEUROSCI RES, V26, P428, DOI 10.1002/jnr.490260405; MOKHOVA EN, 1986, J BIOENERG BIOMEMBR, V18, P265, DOI 10.1007/BF00743047; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; Obata T, 1999, BRAIN RES, V828, P68, DOI 10.1016/S0006-8993(99)01329-3; OBATA T, 1992, J NEURAL TRANSM-GEN, V89, P139, DOI 10.1007/BF01245361; OWENS GC, 1991, J NEUROCHEM, V56, P1030, DOI 10.1111/j.1471-4159.1991.tb02025.x; Packer MA, 1996, BIOCHEM PHARMACOL, V51, P267, DOI 10.1016/0006-2952(95)02165-5; PETER D, 1994, J BIOL CHEM, V269, P7231; PILEBLAD E, 1985, NEUROPHARMACOLOGY, V24, P689, DOI 10.1016/0028-3908(85)90114-5; PILEBLAD E, 1984, J NEURAL TRANSM, V60, P199, DOI 10.1007/BF01249093; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Przedborski S, 1998, MOVEMENT DISORD, V13, P35; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; RAMSAY RR, 1986, BIOCHEM BIOPH RES CO, V134, P743, DOI 10.1016/S0006-291X(86)80483-1; RAMSAY RR, 1991, J NEUROCHEM, V56, P1184, DOI 10.1111/j.1471-4159.1991.tb11409.x; REINHARD JF, 1990, J NEUROCHEM, V55, P311, DOI 10.1111/j.1471-4159.1990.tb08853.x; REINHARD JF, 1987, P NATL ACAD SCI USA, V84, P8160, DOI 10.1073/pnas.84.22.8160; Reynolds IJ, 1999, ANN NY ACAD SCI, V893, P33, DOI 10.1111/j.1749-6632.1999.tb07816.x; RICAURTE GA, 1985, NEUROSCI LETT, V59, P259, DOI 10.1016/0304-3940(85)90141-7; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; ROLLEMA H, 1986, EUR J PHARMACOL, V126, P345, DOI 10.1016/0014-2999(86)90071-3; Rottenberg H, 1998, BBA-MOL CELL RES, V1404, P393, DOI 10.1016/S0167-4889(98)00088-3; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SANCHEZRAMOS J, 1986, NEUROSCI LETT, V72, P215, DOI 10.1016/0304-3940(86)90083-2; SCHMIDT CJ, 1984, EUR J PHARMACOL, V103, P255, DOI 10.1016/0014-2999(84)90485-0; SCOTT ID, 1980, BIOCHEM J, V186, P21, DOI 10.1042/bj1860021; Shen XM, 1997, CHEM RES TOXICOL, V10, P147, DOI 10.1021/tx960145c; Simbula G, 1997, AM J PHYSIOL-CELL PH, V273, pC479, DOI 10.1152/ajpcell.1997.273.2.C479; SINGER TP, 1990, FEBS LETT, V274, P1, DOI 10.1016/0014-5793(90)81315-F; SIRINATHSINGHJI DJS, 1988, BRAIN RES, V443, P101, DOI 10.1016/0006-8993(88)91603-4; Sonders MS, 1997, J NEUROSCI, V17, P960; SULZER D, 1995, J NEUROSCI, V15, P4102; Takahashi N, 1997, P NATL ACAD SCI USA, V94, P9938, DOI 10.1073/pnas.94.18.9938; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; TANG L, 1994, J PHARMACOL EXP THER, V270, P475; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5	86	263	270	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38581	38588		10.1074/jbc.M005385200	http://dx.doi.org/10.1074/jbc.M005385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10969076	hybrid			2022-12-27	WOS:000165739800060
J	Andley, UP; Song, Z; Wawrousek, EF; Fleming, TP; Bassnett, S				Andley, UP; Song, Z; Wawrousek, EF; Fleming, TP; Bassnett, S			Differential protective activity of alpha A- and alpha B-crystallin in lens epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CHAPERONE ACTIVITY; HUMAN HSP27; TNF-ALPHA; EXPRESSION; GENE; RESISTANCE; REGULATORS; STABILITY; APOPTOSIS	alphaA- and alphaB-crystallins are molecular chaperones expressed at low levels in lens epithelial cells, and their expression increases dramatically during differentiation to lens fibers. However, the functions of alphaA- and alphaB-crystallins in lens epithelial cells have not been studied in detail. In this study, the relative ability of alphaA- and alphaB-crystallin, in protecting lens epithelial cells from apoptotic cell death was determined, The introduction of alphaA-crystallin in the transformed human lens epithelial (HLE) B-3 lens epithelial cell line (which expresses low endogenous levels of alphaB-crystallin) led to a nearly complete protection of cell death induced by staurosporine, Fas monoclonal antibody, or the cytokine tumor necrosis factor cu. To further study the relative protective activities of alphaA- and alphaB-crystallins, we created a cell line derived from alphaA-/-alphaB-/- double knockout mouse lens epithelia by infecting primary cells with Ad12-SV40 hybrid virus. The transformed cell line alpha AYBKO1 derived from alphaA/alphaB double knockout cells was transfected with alphaA- or alphaB-crystallin cDNA contained in pCIneo mammalian expression vector. Cells expressing different amounts of either alphaA-crystallin or alphaB-crystallin were isolated. The ability of alphaA- or aB-crystallin to confer protection from apoptotic cell death was determined by annexin labeling and flow cytometry of staurosporine- or UVA- treated cells. The results indicate that the anti-apoptotic activity of alphaA-crystallin was two to threefold higher than that of alphaB-crystallin, Our work suggests that comparing the in vitro annexin labeling of lens epithelial cells is an effective way to measure the protective activity of alphaA- and alphaB-crystallin. Since the expression of alphaA-crystallin is largely restricted to the lens, its greater protective effect against apoptosis suggests that it may play a significant role in protecting lens epithelial cells from stress.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; NEI, NIH, Bethesda, MD 20892 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Andley, UP (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Campus Box 8096, St Louis, MO 63110 USA.	andley@vision.wustl.edu	Wawrousek, Eric/A-4547-2008	Andley, Usha/0000-0001-7049-7591; Bassnett, Steven/0000-0002-8337-2760	NEI NIH HHS [EY02687, P30 EY002687, R01-EY05681, EY09852] Funding Source: Medline; NATIONAL EYE INSTITUTE [Z01EY000286, R01EY009852, P30EY002687, R01EY005681] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1998, J BIOL CHEM, V273, P31252, DOI 10.1074/jbc.273.47.31252; ANDLEY UP, 1994, INVEST OPHTH VIS SCI, V35, P3094; ANDLEY UP, 2000, IN PRESS FASEB J; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; Bhat SP, 1999, EUR J CELL BIOL, V78, P143, DOI 10.1016/S0171-9335(99)80016-8; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Cobb BA, 2000, J BIOL CHEM, V275, P6664, DOI 10.1074/jbc.275.9.6664; Datta SA, 1999, J BIOL CHEM, V274, P34773, DOI 10.1074/jbc.274.49.34773; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; Fleming TP, 1998, INVEST OPHTH VIS SCI, V39, P1387; GaleaLauri J, 1996, J IMMUNOL, V157, P4109; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 1999, EYE, V13, P403, DOI 10.1038/eye.1999.114; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Iwaki A, 1997, GENOMICS, V45, P386, DOI 10.1006/geno.1997.4956; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Muchowski PJ, 1999, INVEST OPHTH VIS SCI, V40, P951; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; Robinson ML, 1996, INVEST OPHTH VIS SCI, V37, P2276; Samali A, 1998, CELL STRESS CHAPERON, V3, P228, DOI 10.1379/1466-1268(1998)003<0228:HSPROS>2.3.CO;2; SAX CM, 1993, ADV ENZYMOL RAMB, V69, P155; Sun TX, 1999, J BIOL CHEM, V274, P34067, DOI 10.1074/jbc.274.48.34067; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; van Boekel MAM, 1999, BBA-PROTEIN STRUCT M, V1434, P114, DOI 10.1016/S0167-4838(99)00178-8; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; VERMORKEN AJM, 1978, J CELL BIOL, V76, P175, DOI 10.1083/jcb.76.1.175; Wawrousek E. F., 1998, IOVS, V39, pS523	37	135	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36823	36831		10.1074/jbc.M004233200	http://dx.doi.org/10.1074/jbc.M004233200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967101	hybrid			2022-12-27	WOS:000165577700055
J	Kurland, IJ; Alcivar, A; Bassilian, S; Lee, WNP				Kurland, IJ; Alcivar, A; Bassilian, S; Lee, WNP			Loss of [C-13]glycerol carbon via the pentose cycle - Implications for gluconeogenesis measurement by mass isotoper distribution analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE; HEPATOMA-CELLS; MESSENGER-RNA; GLUCOSE; HEPATOCYTES; LIMITATIONS; EXPRESSION; INSULIN; FLUX; RATS	Whereas many reports substantiated the suitability of using [2-C-13]glycerol and Mass Isotoper Distribution Analysis for gluconeogenesis, the use of [C-13]glycerol had been shown to give lower estimates of gluconeogenesis (GNG). The reason for the underestimation has been attributed to asymmetric isotope incorporation during gluconeogenesis as well as zonation of gluconeogenic enzymes and a [C-13]glycerol gradient across the liver. Since the cycling of glycerol carbons through the pentose cycle pathways can introduce asymmetry in glucose labeling pattern and tracer dilution, we present here a study of the role of the pentose cycle in gluconeogenesis in Fao cells. The metabolic regulation of glucose release and gluconeogenesis by insulin was also studied. Serum-starved cells were incubated for 24 h in Dulbecco's modified Eagle's media containing 1.5 mM [U-C-13]glycerol. Mass isotopomers of whole glucose from medium or glycogen and those of the C-1-C-4 fragment were highly asymmetrical, typical of that resulting from the cycling of glucose carbon through the pentose cycle. Substantial exchange of tracer between hexose and pentose intermediates was observed. Our results offer an alternative mechanism for the asymmetrical labeling of glucose carbon from triose phosphate, The scrambling of C-13 in hexose phosphate via the pentose phosphate cycle prior to glucose release into the medium is indistinguishable from dilution of labeled glucose by glycogen using MIDA and probably accounts for the underestimation of GNG using C-13 tracer methods.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Med, Div Endocrinol, Diabet Metab Signaling Lab, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Pediat, Torrance, CA 90502 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Kurland, IJ (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA.	ikurland@mednet.ucla.edu						ARGAUD D, 1995, J BIOL CHEM, V270, P24229, DOI 10.1074/jbc.270.41.24229; Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAWFORD JM, 1983, BIOCHEM J, V212, P595, DOI 10.1042/bj2120585; CRETTAZ M, 1983, ENDOCRINOLOGY, V113, P1201, DOI 10.1210/endo-113-4-1201; ESPINET C, 1993, BIOCHEM J, V293, P173, DOI 10.1042/bj2930173; Hellerstein MK, 1999, AM J PHYSIOL-ENDOC M, V276, pE1146, DOI 10.1152/ajpendo.1999.276.6.E1146; KAHN CR, 1989, MOL ENDOCRINOL, V3, P840, DOI 10.1210/mend-3-5-840; KATZ J, 1967, BIOCHEMISTRY-US, V6, P2227, DOI 10.1021/bi00859a046; KATZ J, 1989, J BIOL CHEM, V264, P12994; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; Lee WNP, 1998, AM J PHYSIOL-ENDOC M, V274, pE843, DOI 10.1152/ajpendo.1998.274.5.E843; MOORE EE, 1982, J CELL PHYSIOL, V111, P1, DOI 10.1002/jcp.1041110102; NEESE RA, 1995, J BIOL CHEM, V270, P14452, DOI 10.1074/jbc.270.24.14452; PERONI O, 1995, AM J PHYSIOL-ENDOC M, V269, pE516, DOI 10.1152/ajpendo.1995.269.3.E516; Previs SF, 1998, J BIOL CHEM, V273, P16853, DOI 10.1074/jbc.273.27.16853; PREVIS SF, 1995, J BIOL CHEM, V270, P19806, DOI 10.1074/jbc.270.34.19806; SZAFRANECK J, 1974, CARBOHYD RES, V38, P97, DOI 10.1016/S0008-6215(00)82341-1; TSERNG KY, 1984, ANAL CHEM, V56, P517, DOI 10.1021/ac00267a049	20	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36787	36793		10.1074/jbc.M004739200	http://dx.doi.org/10.1074/jbc.M004739200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10960476	hybrid			2022-12-27	WOS:000165577700050
J	Ruffle, SV; Mustafa, AO; Kitmitto, A; Holzenburg, A; Ford, RC				Ruffle, SV; Mustafa, AO; Kitmitto, A; Holzenburg, A; Ford, RC			The location of the mobile electron carrier ferredoxin in vascular plant photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CROSS-LINKING; FLASH ABSORPTION-SPECTROSCOPY; SYNECHOCYSTIS SP PCC-6803; 3-DIMENSIONAL STRUCTURE; THYLAKOID MEMBRANES; ANGSTROM RESOLUTION; SOLUBLE FERREDOXIN; LINKED COMPLEX; BINDING-SITES; REDUCTION	In this study, we present the location of the ferredoxin-binding site in photosystem I from spinach. Image analysis of negatively stained two-dimensional crystals indicates that the addition of ferredoxin and chemical cross-linkers do not significantly alter the unit cell, parameters (for untreated photosystem I, a = 26.4 nm, b = 27.6 nm, and gamma = 90 degrees, space group p22(1)2(1) and for ferredoxin cross-linked photosystem I, a = 26.2 nm, b = 27.2 nm, and gamma = 90 degrees, space group p22(1)2(1)), Fourier difference analysis reveals that ferredoxin is bound on top of the stromal ridge principally interacting with the extrinsic subunits PsaC and PsaE, This location would be accessible to the stroma, thereby promoting efficient electron transfer away from photosystem I. This observation is significantly different from that of the ferredoxin binding site proposed for cyanobacteria, A model for the binding of ferredoxin in vascular plants is proposed and is discussed-relative to observations in cyanobacteria.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Manchester; University of Leeds	Ford, RC (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England.			Ford, Robert/0000-0002-0958-1505				AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; ANDERSEN B, 1992, PHYSIOL PLANTARUM, V84, P154, DOI 10.1111/j.1399-3054.1992.tb08778.x; ANDERSSON B, 1980, BIOCHIM BIOPHYS ACTA, V593, P427, DOI 10.1016/0005-2728(80)90078-X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Binda C, 1998, ACTA CRYSTALLOGR D, V54, P1353, DOI 10.1107/S0907444998005137; CHITNIS PR, 1989, J BIOL CHEM, V264, P18381; DEPASCALIS AR, 1994, FEBS LETT, V337, P217, DOI 10.1016/0014-5793(94)80194-0; Fischer N, 1999, J BIOL CHEM, V274, P23333, DOI 10.1074/jbc.274.33.23333; FORD RC, 1995, MICRON, V26, P133, DOI 10.1016/0968-4328(95)00005-O; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; FROMME P, 1994, BBA-BIOENERGETICS, V1187, P99, DOI 10.1016/0005-2728(94)90092-2; GOLBECK JH, 1993, P NATL ACAD SCI USA, V90, P1642, DOI 10.1073/pnas.90.5.1642; HOVMOLLER S, 1992, ULTRAMICROSCOPY, V36, P275; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Kitmitto A, 1998, J BIOL CHEM, V273, P29592, DOI 10.1074/jbc.273.45.29592; Kitmitto A, 1997, J BIOL CHEM, V272, P19497, DOI 10.1074/jbc.272.31.19497; Klukas O, 1999, J BIOL CHEM, V274, P7351, DOI 10.1074/jbc.274.11.7351; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; LELONG C, 1994, J BIOL CHEM, V269, P10034; Lelong C, 1996, EMBO J, V15, P2160, DOI 10.1002/j.1460-2075.1996.tb00569.x; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; MERATI G, 1987, FEBS LETT, V215, P37, DOI 10.1016/0014-5793(87)80109-6; Muhlenhoff U, 1996, EMBO J, V15, P488, DOI 10.1002/j.1460-2075.1996.tb00381.x; Mullineaux CW, 1999, AUST J PLANT PHYSIOL, V26, P671, DOI 10.1071/PP99027; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; SETIF PQY, 1994, BIOCHEMISTRY-US, V33, P8495, DOI 10.1021/bi00194a014; SETIF PQY, 1995, BIOCHEMISTRY-US, V34, P9059, DOI 10.1021/bi00028a015; Shin M, 1971, METHOD ENZYMOL, V23, P440; TAGAWA K, 1968, BIOCHIM BIOPHYS ACTA, V153, P602, DOI 10.1016/0005-2728(68)90188-6; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x	34	15	18	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36250	36255		10.1074/jbc.M006549200	http://dx.doi.org/10.1074/jbc.M006549200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10948201	hybrid			2022-12-27	WOS:000165382000086
J	Schepens, I; Ruelland, E; Miginiac-Maslow, M; Le Marechal, P; Decottignies, P				Schepens, I; Ruelland, E; Miginiac-Maslow, M; Le Marechal, P; Decottignies, P			The role of active site arginines of sorghum NADP-malate dehydrogenase in thioredoxin-dependent activation and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; SUBSTRATE-SPECIFICITY; CHLOROPLAST ENZYME; ARGINYL RESIDUES; REGULATORY SITE; AUTOINHIBITION; REDUCTION; PROTEINS; RELIEF	The activation of sorghum NADP-malate dehydrogenase is initiated by thiol/disulfide interchanges with reduced thioredoxin followed by the release of the C-terminal autoinhibitory extension and a structural modification shaping the active site into a high efficiency and high affinity for oxaloacetate conformation. In the present study, the role of the active site arginines in the activation and catalysis was investigated by site-directed mutagenesis and arginyl-specific chemical derivatization using butanedione, Sequence and mass spectrometry analysis were used to identify the chemically modified groups. Taken together, our data reveal the involvement of Arg-134 and Arg-204 in oxaloacetate coordination, suggest an indirect role for Arg-140 in substrate binding and catalysis, and clearly confirm that Arg-87 is implicated in cofactor binding. In contrast with NAD-malate dehydrogenase, no lactate dehydrogenase activity could be promoted by the R134Q mutation. The decreased susceptibility of the activation of the R204K mutant to NADP and its increased sensitivity to the histidine-specific reagent diethylpyrocarbonate indicated that Arg-204 is involved in the locking of the active site. These results are discussed in relation with the,recently published NADP-MDH three-dimensional structures and the previously established three-dimensional structures of NAD-malate dehydrogenase and lactate dehydrogenase.	Univ Paris Sud, Inst Biotechnol Plantes, UMR 8618 CNRS, Orsay, France; Univ Paris Sud, Inst Biochim & Biol Mol & Cellulaire, UMR 8619, Orsay, France	UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Miginiac-Maslow, M (corresponding author), Univ Paris Sud, Inst Biotechnol Plantes, UMR 8618 CNRS, Batiment 630, Orsay, France.		Ruelland, Eric/D-4863-2012	Schepens, Isabelle/0000-0002-6718-9608				BOERNKE WE, 1995, ARCH BIOCHEM BIOPHYS, V322, P43, DOI 10.1006/abbi.1995.1434; Carr PD, 1999, STRUCTURE, V7, P461, DOI 10.1016/S0969-2126(99)80058-6; CRETIN C, 1990, EUR J BIOCHEM, V192, P299, DOI 10.1111/j.1432-1033.1990.tb19227.x; DECOTTIGNIES P, 1988, J BIOL CHEM, V263, P11780; GOWARD CR, 1994, PROTEIN SCI, V3, P1883, DOI 10.1002/pro.5560031027; HALL MD, 1992, J MOL BIOL, V226, P867, DOI 10.1016/0022-2836(92)90637-Y; ISSAKIDIS E, 1994, J BIOL CHEM, V269, P3511; Issakidis E, 1996, FEBS LETT, V392, P121, DOI 10.1016/0014-5793(96)00801-0; ISSAKIDIS E, 1992, J BIOL CHEM, V267, P21577; Johansson K, 1999, BIOCHEMISTRY-US, V38, P4319, DOI 10.1021/bi982876c; KITZ R, 1962, J BIOL CHEM, V237, P3245; Krimm I, 1999, J BIOL CHEM, V274, P34539, DOI 10.1074/jbc.274.49.34539; LEMAIRE M, 1994, J BIOL CHEM, V269, P27291; NICHOLLS DJ, 1992, BIOCHEM BIOPH RES CO, V189, P1057, DOI 10.1016/0006-291X(92)92311-K; RIORDAN JF, 1979, MOL CELL BIOCHEM, V26, P71; RIORDAN JF, 1973, BIOCHEMISTRY-US, V12, P3915, DOI 10.1021/bi00744a020; Ruelland E, 1998, J BIOL CHEM, V273, P33482, DOI 10.1074/jbc.273.50.33482; Ruelland E, 1999, TRENDS PLANT SCI, V4, P136, DOI 10.1016/S1360-1385(99)01391-6; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schepens I, 2000, J BIOL CHEM, V275, P20996, DOI 10.1074/jbc.M002066200; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242	22	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35792	35798		10.1074/jbc.M006526200	http://dx.doi.org/10.1074/jbc.M006526200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10958800	hybrid			2022-12-27	WOS:000165382000023
J	Tobaben, S; Sudhof, TC; Stahl, B				Tobaben, S; Sudhof, TC; Stahl, B			The G protein-coupled receptor CL1 interacts directly with proteins of the Shank family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-EFFICIENCY TRANSFORMATION; POSTSYNAPTIC DENSITY PROTEINS; ALPHA-LATROTOXIN RECEPTOR; SYNAPTIC PROTEINS; ESCHERICHIA-COLI; BINDING-PROTEIN; PDZ DOMAINS; BRAIN; PURIFICATION; EXOCYTOSIS	PDZ domains play a pivotal role in the synaptic localization of ion channels, receptors, signaling enzymes, and cell adhesion molecules. These domains mediate protein-protein interactions via the recognition of a conserved sequence motif at the extreme C terminus of their: target proteins. By means of a yeast two-hybrid screen using the C terminus of the G protein-coupled Lu-latrotoxin receptor CL1 as bait, three PDZ domain proteins of the Shank family were identified. These proteins belong to a single protein family characterized by a common domain organization. The PDZ domain is highly conserved among the family members, significantly different from other known PDZ domains, and specifically binds to the C terminus of CL1. Shank1 and CL1:are expressed primarily in brain, and both proteins co-enrich in the postsynaptic density. Furthermore, Shank1 induces a clustering of CL1 in transfected cells, strongly supporting an interaction of both proteins in vivo.	Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	Max Planck Society; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Stahl, B (corresponding author), Max Planck Inst Expt Med, Hermann Rein Str 3, D-37075 Gottingen, Germany.							Boeckers TM, 1999, BIOCHEM BIOPH RES CO, V264, P247, DOI 10.1006/bbrc.1999.1489; Boeckers TM, 1999, J NEUROSCI, V19, P6506; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; GRASSO A, 1993, NEUROSCIENCE, V54, P595, DOI 10.1016/0306-4522(93)90231-4; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hata Y, 1996, J NEUROSCI, V16, P2488; Ichtchenko K, 1998, EMBO J, V17, P6188, DOI 10.1093/emboj/17.21.6188; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Rose MD., 1990, METHODS YEAST GENETI; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHNITTLER HJ, 1993, AM J PHYSIOL, V265, P289; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463; Zitzer H, 1999, J BIOL CHEM, V274, P32997, DOI 10.1074/jbc.274.46.32997	41	53	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36204	36210		10.1074/jbc.M006448200	http://dx.doi.org/10.1074/jbc.M006448200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10958799	hybrid			2022-12-27	WOS:000165382000079
J	Whitman, SC; Daugherty, A; Post, SR				Whitman, SC; Daugherty, A; Post, SR			Macrophage colony-stimulating factor rapidly enhances beta-migrating very low density lipoprotein metabolism in macrophages through activation of a G(i/o) protein signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR EXPRESSION; GTP-BINDING PROTEIN; GROWTH-FACTOR; PERTUSSIS TOXIN; HUMAN-MONOCYTES; FACTOR CSF-1; PHOSPHATIDYLINOSITOL 3-KINASE; CHOLESTEROL-METABOLISM; ADP-RIBOSYLATION; MEMBRANE-PROTEIN	Previous studies have examined lipoprotein metabolism by macrophages following prolonged exposure (>24 h) to macrophage colony-stimulating factor (M-CSF). Because M-CSF activates several, signaling pathways that could rapidly affect lipoprotein metabolism, we examined whether acute exposure of macrophages to M-CSF alters the metabolism of either native or modified lipoproteins, Acute incubation of cultured J774 macrophages and resident mouse peritoneal macrophages with M-CSF markedly enhanced low density lipoproteins (LDL) and beta -migrating very low density lipoproteins (beta -VLDL) stimulated cholesteryl [H-3]oleate deposition. In parallel, M-CSF treatment increased the association and degradation of I-125-labeled LDL or beta -VLDL without altering the amount of lipoprotein bound to the cell surface. The increase in LDL and beta -VLDL metabolism did not reflect a generalized effect on lipoprotein endocytosis and metabolism because M-CSF did not alter cholesterol deposition during incubation with acetylated LDL, Moreover, M-CSF did not augment beta -VLDL cholesterol deposition in macrophages from LDL receptor (-/-) mice, indicating that the effect of M-CSF was mediated by the LDL receptor. Incubation of macrophages with pertussis toxin, a specific inhibitor of G(i/o) protein signaling, had no effect on cholesterol deposition during incubation with beta -VLDL alone, but completely blocked the augmented response promoted by M-CSF. In addition, incubation of macrophages with the direct G(i/o) protein activator, mastoparan, mimicked the effect of M-CSF by enhancing cholesterol deposition in cells incubated with beta -VLDL, but not acetylated LDL, In summary, M-CSF rapidly enhances LDL receptor-mediated metabolism of native lipoproteins by macrophages through activation of a G(i/o), protein signaling pathway. Together, these findings describe a novel pathway for regulating lipoprotein metabolism.	Univ Kentucky, Med Ctr, Dept Pharmacol, Atherosclerosis Res Grp,Linda & Jack Gill Heart I, Lexington, KY 40536 USA; Univ Kentucky, Div Cardiovasc Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Post, SR (corresponding author), Univ Kentucky, Med Ctr, Dept Pharmacol, Atherosclerosis Res Grp,Linda & Jack Gill Heart I, MS305, Lexington, KY 40536 USA.		Daugherty, Alan/C-8282-2009	Daugherty, Alan/0000-0003-2093-3775; Post, Steven/0000-0002-4711-1723	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055487] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55487] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; CLINTON SK, 1992, AM J PATHOL, V140, P301; CORRE I, 1995, BLOOD, V86, P1776, DOI 10.1182/blood.V86.5.1776.bloodjournal8651776; de Villiers WJS, 1998, ARTERIOSCL THROM VAS, V18, P631, DOI 10.1161/01.ATV.18.4.631; DEVILLIERS WJS, 1994, IMMUNOL LETT, V43, P73, DOI 10.1016/0165-2478(94)00148-0; DEVILLIERS WJS, 1994, J EXP MED, V180, P705, DOI 10.1084/jem.180.2.705; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; HALLET MM, 1991, BLOOD, V77, P780; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HE YX, 1988, BLOOD, V71, P1187; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HUME DA, 1989, IMMUNOL CELL BIOL, V67, P243, DOI 10.1038/icb.1989.37; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; IMAMURA K, 1990, EMBO J, V9, P2423, DOI 10.1002/j.1460-2075.1990.tb07418.x; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; INABA T, 1992, J BIOL CHEM, V267, P5693; INOUE I, 1992, ATHEROSCLEROSIS, V93, P245, DOI 10.1016/0021-9150(92)90261-E; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; ISHII I, 1994, BBA-LIPID LIPID MET, V1212, P278, DOI 10.1016/0005-2760(94)90201-1; Jessup W, 1997, ARTERIOSCL THROM VAS, V17, P18, DOI 10.1161/01.ATV.17.1.18; KATADA T, 1982, J BIOL CHEM, V257, P7210; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Qiao JH, 1997, AM J PATHOL, V150, P1687; RACOOSIN EL, 1992, J CELL SCI, V102, P867; RACOOSIN EL, 1989, J EXP MED, V170, P1635, DOI 10.1084/jem.170.5.1635; Rajavashisth T, 1998, J CLIN INVEST, V101, P2702, DOI 10.1172/JCI119891; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; RAMBALDI A, 1987, BLOOD, V69, P1409; ROSENFELD ME, 1992, AM J PATHOL, V140, P291; SACCA R, 1986, P NATL ACAD SCI USA, V83, P3331, DOI 10.1073/pnas.83.10.3331; Sano H, 1998, J BIOL CHEM, V273, P8630, DOI 10.1074/jbc.273.15.8630; SHERR CJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P225, DOI 10.1016/0304-419X(88)90011-X; SHERR CJ, 1988, COLD SPRING HARB SYM, V53, P521, DOI 10.1101/SQB.1988.053.01.060; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SIEFF CA, 1988, BLOOD, V72, P1316; SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669, DOI 10.1146/annurev.bi.46.070177.003321; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P89, DOI 10.1016/S0962-8924(00)88956-4; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; Whitman SC, 2000, J LIPID RES, V41, P807; XIE Y, 1993, BRIT J HAEMATOL, V84, P392, DOI 10.1111/j.1365-2141.1993.tb03092.x; YANO H, 1995, BIOCHEM J, V312, P145, DOI 10.1042/bj3120145	51	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35807	35813		10.1074/jbc.M001797200	http://dx.doi.org/10.1074/jbc.M001797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964909	hybrid			2022-12-27	WOS:000165382000025
J	Brabetz, W; Muller-Loennies, S; Brade, H				Brabetz, W; Muller-Loennies, S; Brade, H			3-Deoxy-D-manno-oct-2-ulosonic acid (Kdo) transferase (WaaA) and Kdo kinase (KdkA) of Haemophilus influenzae are both required to complement a waaA knockout mutation of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE; GENE; STRAIN; BIOSYNTHESIS; CHLAMYDIA; EPITOPE; KDTA; PHOSPHORYLATION; IDENTIFICATION; ANTIBODIES	The lipopolysaccharide (LPS) of the deep rough mutant Haemophilus influenzae I69 consists of lipid A and a single 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo) residue substituted with one phosphate at position 4 or 5 (Helander, I. M,, Lindner, B,, Brade, H., Altmann, K,, Lindberg, A. A., Rietschel, E, T,, and Zahringer, U, (1988) fur. J, Biochem, 177, 483-492), The waaA gene encoding the essential LPS-specific Kdo transferase was cloned from this strain, and its nucleotide sequence was identical to H, influenzae DSM11121, The gene was expressed in the Gram-positive host Corynebacterium glutamicum: and characterized in vitro to encode a monofunctional Kdo transferase. waaA of H, influenzae could not complement a knockout mutation in the corresponding gene of an Re-type Escherichia coli strain. However, complementation was possible by coexpressing the recombinant waaA together with the LPS-specific Kdo kinase gene (kdkA) of H, influenzae DSM11121 or I69, respectively. The sequences of both kdkA genes were determined and differed in 25 nucleotides, giving rise to six amino acid exchanges between the deduced proteins. Both E, coli strains which expressed waaA and kdkA from H, influenzae synthesized an LPS containing a single Kdo residue that was exclusively phosphorylated: at position 4, The structure was determined by nuclear magnetic resonance spectroscopy of deacylated LPS, Therefore, the reaction products of both cloned Kdo kinases represent only one of the two chemical structures synthesized by H, influenzae I69.	Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, D-23845 Borstel, Germany	Forschungszentrum Borstel	Brabetz, W (corresponding author), Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, Parkallee 22, D-23845 Borstel, Germany.	wbrabetz@fz-borstel.de						AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BELUNIS CJ, 1995, J BIOL CHEM, V270, P27646, DOI 10.1074/jbc.270.46.27646; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; Bode CE, 1998, EUR J BIOCHEM, V254, P404, DOI 10.1046/j.1432-1327.1998.2540404.x; Brabetz W, 2000, EUR J BIOCHEM, V267, P5458, DOI 10.1046/j.1432-1327.2000.01619.x; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HELANDER IM, 1988, EUR J BIOCHEM, V177, P483, DOI 10.1111/j.1432-1033.1988.tb14398.x; HOISETH SK, 1992, PROKARYOTES, P3312; Holst O, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P115; HOLST O, 1994, EUR J BIOCHEM, V222, P183, DOI 10.1111/j.1432-1033.1994.tb18856.x; Hood DW, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P39; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; IMOTO M, 1985, TETRAHEDRON LETT, V26, P1545, DOI 10.1016/S0040-4039(00)98548-4; Isobe T, 1999, J BACTERIOL, V181, P2648, DOI 10.1128/JB.181.8.2648-2651.1999; KACA W, 1988, CARBOHYD RES, V179, P289, DOI 10.1016/0008-6215(88)84125-9; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KUSHNER SR, 1972, P NATL ACAD SCI USA, V69, P1366, DOI 10.1073/pnas.69.6.1366; LIEBL W, 1990, DECHEMA BIOTECHNOLOG, V4, P323; LOBAU S, 1995, MOL MICROBIOL, V18, P391, DOI 10.1111/j.1365-2958.1995.mmi_18030391.x; MAMAT U, 1993, MOL MICROBIOL, V10, P935, DOI 10.1111/j.1365-2958.1993.tb00965.x; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MOXON ER, 1992, J INFECT DIS, V165, pS77, DOI 10.1093/infdis/165-Supplement_1-S77; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Preston A, 1996, J BACTERIOL, V178, P396, DOI 10.1128/jb.178.2.396-402.1996; Rick PD, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P283; ROZALSKI A, 1989, INFECT IMMUN, V57, P2645, DOI 10.1128/IAI.57.9.2645-2652.1989; Rozalski A, 1997, MOL MICROBIOL, V23, P569, DOI 10.1046/j.1365-2958.1997.d01-1877.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; White KA, 1997, J BIOL CHEM, V272, P16555, DOI 10.1074/jbc.272.26.16555; White KA, 1999, J BIOL CHEM, V274, P31391, DOI 10.1074/jbc.274.44.31391; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; Zahradka D, 1999, J BACTERIOL, V181, P6179, DOI 10.1128/JB.181.19.6179-6183.1999; ZAMZE SE, 1987, BIOCHEM J, V245, P583, DOI 10.1042/bj2450583; ZWAHLEN A, 1985, J INFECT DIS, V152, P485, DOI 10.1093/infdis/152.3.485	43	28	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34954	34962		10.1074/jbc.M005204200	http://dx.doi.org/10.1074/jbc.M005204200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952982	hybrid			2022-12-27	WOS:000165422800019
J	Zhang, DJ; Tang, W; Yao, PM; Yang, CW; Xie, BX; Jackowski, S; Tabas, I				Zhang, DJ; Tang, W; Yao, PM; Yang, CW; Xie, BX; Jackowski, S; Tabas, I			Macrophages deficient in CTP : phosphocholine cytidylyltransferase-alpha are viable under normal culture conditions but are highly susceptible to free cholesterol-induced death - Molecular genetic evidence that the induction of phosphatidylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; FOAM CELL NECROSIS; ACYL-COENZYME-A; LOADED MACROPHAGES; MEMBRANE-FUNCTION; APOPTOTIC CELLS; UP-REGULATION; FED RABBITS; BIOSYNTHESIS; PROLIFERATION	Macrophages in atherosclerotic lesions accumulate excess free cholesterol (FC) and phospholipid. Because excess FC is toxic to macrophages, these observations may have relevance to macrophage death and necrosis in atheromata. Previous work by us showed that at early stages of FC loading, when macrophages are still healthy,there is activation of the phosphatidylcholine (PC) biosynthetic enzyme, CTP:phosphocholine cytidylyltransferase (CT), and accumulation of PC mass, We hypothesized that this is an adaptive response, albeit transient, that prevents the FC:PC ratio from reaching a toxic level; To test this hypothesis directly, we created mice With macrophage-targeted disruption of the major CT gene, CT alpha, using the Cre-lox system. Surprisingly, the number of peritoneal macrophages harvested from CT alpha ;deficient mice and their overall health under normal culture conditions appeared normal, Moreover, CT activity-and PC biosynthesis and in vitro CT activity were decreased by 70-90% but were not absent. As a likely explanation of this residual activity, we showed that CT beta2, a form of CT that arises from another gene, is induced in CT alpha -deficient macrophages. To test our hypothesis that increased PC biosynthesis is an adaptive response to FC loading, the viability of wild-type versus CT alpha -deficient macrophages under control and FC-loading conditions was compared. After 5 h of FC loading, death increased from 0.7% to only 2.0% in wild-type macrophages but from 0.9% to 29.5% in CT alpha -deficient macrophages, These data offer the first molecular genetic evidence that activation of CT alpha and induction of PC biosynthesis in FC-loaded macrophages is an adaptive response. Furthermore, the data reveal that CT beta2 in macrophages is induced in the absence of CT alpha and that a low: level of residual CT activity, presumably due to CT beta2, is enough to keep the cells viable in the peritoneum in vivo and under normal culture conditions.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Rockefeller Univ, Gene Targeting Lab, New York, NY 10021 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	Columbia University; Columbia University; Rockefeller University; St Jude Children's Research Hospital	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	iat1@columbia.edu	Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NHLBI NIH HHS [HL-54591] Funding Source: Medline; NIGMS NIH HHS [GM45737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthony ML, 1999, J BIOL CHEM, V274, P19686, DOI 10.1074/jbc.274.28.19686; BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; BAURIEDEL G, 1999, CIRCULATION, V96, P190; BERBERIAN PA, 1990, AM J PATHOL, V136, P71; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COHN ZA, 1975, FED PROC, V34, P1725; Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; Fazio S, 1999, CIRCULATION, V100, P613; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; HAMILTON DL, 1984, J MOL BIOL, V178, P481, DOI 10.1016/0022-2836(84)90154-2; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Newby AC, 1999, CARDIOVASC RES, V41, P321; PAPAHADJOPOULOS D, 1974, J THEOR BIOL, V43, P329, DOI 10.1016/S0022-5193(74)80064-0; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; RAPP JH, 1983, J LIPID RES, V24, P1329; REKHTER MD, 1995, AM J PATHOL, V147, P668; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Schwartz BR, 1999, J IMMUNOL, V162, P4842; SHIO H, 1979, LAB INVEST, V41, P160; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; SHIRATORI Y, 1995, J BIOL CHEM, V270, P29894; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; Tabas I, 1997, CURR OPIN LIPIDOL, V8, P263, DOI 10.1097/00041433-199710000-00004; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; Tabas I, 1997, TRENDS CARDIOVAS MED, V7, P256, DOI 10.1016/S1050-1738(97)00086-8; Tang W, 1999, BBA-MOL CELL BIOL L, V1437, P301, DOI 10.1016/S1388-1981(99)00023-2; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; Xiong Y, 2000, NEUROSCI LETT, V283, P129, DOI 10.1016/S0304-3940(00)00929-0; Yao PM, 2000, J BIOL CHEM, V275, P23807, DOI 10.1074/jbc.M002087200; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G	44	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35368	35376		10.1074/jbc.M007099200	http://dx.doi.org/10.1074/jbc.M007099200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10944538	hybrid			2022-12-27	WOS:000165422800072
J	Takahashi, M; Mukai, H; Oishi, K; Isagawa, T; Ono, Y				Takahashi, M; Mukai, H; Oishi, K; Isagawa, T; Ono, Y			Association of immature hypophosphorylated protein kinase C epsilon with an anchoring protein CG-NAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; PHOSPHORYLATION; PDK1; DOMAIN; ACTIVATION; FAMILY; GOLGI; ZETA; PKN	Protein kinase C (PKC) family requires phosphorylation of itself to become competent for responding to second messengers. Much attention has been focused on elucidating the role of phosphorylation in PKC activity; however, it remains unknown where this modification takes place in the cells. This study examines whether anchoring protein is involved in the regulation of PKC phosphorylation. A certain population of PKC epsilon in rat brain extracts as well as that expressed in COS7 cells was associated with an endogenous anchoring protein CG-NAP (centrosome and Golgi localized PKN-associated protein). Pulse chase experiments revealed that the associated PKC epsilon was an immature species at the hypophosphorylated state. In vitro binding studies confirmed that non- or hypophosphorylated PKC epsilon directly bound to CG-NAP via its catalytic domain, whereas sufficiently phosphorylated PKC epsilon did not. PKC epsilon mutant at a potential phosphorylation site of Thr-566 or Ser-729 to Ala, possessing almost no catalytic activity, was associated and co-localized with CG-NAP at Golgi/centrosome area. On the other hand, wild type and a phosphorylation-mimicking mutant at Thr-566 were mainly distributed in cytosol and represented second messenger-dependent catalytic activation. These results suggest that CG-NAP anchors hypophosphorylated PKC epsilon at the Golgi/centrosome area during maturation and serves as a scaffold for the phosphorylation reaction.	Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan; Kobe Univ, Grad Sch Sci & Technol, Kobe, Hyogo 6578501, Japan	Kobe University; Kobe University	Ono, Y (corresponding author), Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan.			Mukai, Hideyuki/0000-0002-0167-8695				Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Dong LQ, 2000, P NATL ACAD SCI USA, V97, P5089, DOI 10.1073/pnas.090491897; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; Li WQ, 1997, J BIOL CHEM, V272, P24550, DOI 10.1074/jbc.272.39.24550; Mochly-Rosen D, 1998, FASEB J, V12, P35; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1988, J BIOL CHEM, V263, P6927; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; Yoshinaga C, 1999, J BIOCHEM, V126, P475, DOI 10.1093/oxfordjournals.jbchem.a022476	27	74	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34592	34596		10.1074/jbc.M005285200	http://dx.doi.org/10.1074/jbc.M005285200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10945988	hybrid			2022-12-27	WOS:000165095300081
J	Tepper, AD; Diks, SH; van Blitterswijk, WJ; Borst, J				Tepper, AD; Diks, SH; van Blitterswijk, WJ; Borst, J			Glucosylceramide synthase does not attenuate the ceramide pool accumulating during apoptosis induced by CD95 or anti-cancer regimens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAUNORUBICIN-INDUCED APOPTOSIS; GLYCOSPHINGOLIPID SYNTHESIS; ACID SPHINGOMYELINASE; CELLS; RESISTANCE; GLYCOSYLATION; CYTOTOXICITY; PROPAGATION; EXPRESSION; GENERATION	Ceramide (Cer) accumulating during the execution phase of apoptosis is generated from plasma membrane sphingomyelin (SM), which gains access to a sphingomyelinase due to phospholipid scrambling (Tepper, A. D., Ruurs, P., Wiedmer T., Sims, P., Borst, J., and van Blitterswijk W. J. (2000) J. Cell. Biol; 150, 155-164), To evaluate the functional significance of this Cer pool, we aimed to convert it to glucosylceramide (GlcCer), by constitutive overexpression of glucosylceramide synthase (GCS). Jurkat cells, retrovirally transduced with GCS cDNA, showed a 10-12-fold increase in GCS activity in vitro and a 7-fold elevated basal GlcCer level in vivo. However, Cer accumulating during apoptosis induced by ligation of the death receptor CD95, treatment with the anti-cancer drug etoposide, or exposure to gamma -radiation was not glycosylated by GCS. Likewise, Cer liberated at the plasma membrane by bacterial SMase was not concerted by the enzyme. Thus, GCS, located at the Golgi, is topologically segregated from Cer produced in the plasma membrane. In contrast, de novo synthesized Cer as well as an exogenously supplied cell-permeable Cer analog were efficiently glycosylated, apparently due to different. Cer topology and distinct physicochemical behavior of the synthetic Cer species, respectively. Exogenous cell-permeable Cer species, despite their conversion by GCS, effectively induced apoptosis. We also observed that GCS activity is down-regulated in cells undergoing apoptosis. In conclusion, GCS can convert de novo synthesized Cer but not SM-derived Cer, and, therefore, the ability of GCS overexpression to protect cells ii om possible detrimental effects of Cer accumulation is limited.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Borst, J (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	jborst@nki.nl		Borst, Jannie/0000-0002-8043-5009				Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bourteele S, 1998, J BIOL CHEM, V273, P31245, DOI 10.1074/jbc.273.47.31245; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; DHAIBO GS, 1997, J EXP MED, V185, P481; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Ichikawa S, 1998, TRENDS CELL BIOL, V8, P198, DOI 10.1016/S0962-8924(98)01249-5; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Liu YY, 2000, J BIOL CHEM, V275, P7138, DOI 10.1074/jbc.275.10.7138; Liu YY, 1999, EXP CELL RES, V252, P464, DOI 10.1006/excr.1999.4649; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; MANDON EC, 1992, J BIOL CHEM, V267, P11144; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PAGANO RE, 1998, BIOCHEMISTRY-US, V27, P4439; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; RIDGWAY ND, 1995, BBA-LIPID LIPID MET, V1256, P57, DOI 10.1016/0005-2760(95)00010-A; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Simon CG, 1999, BIOCHEMISTRY-US, V38, P14676, DOI 10.1021/bi991537w; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Veldman RJ, 1998, BIOCHEM J, V331, P563, DOI 10.1042/bj3310563; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2	37	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34810	34817		10.1074/jbc.M005142200	http://dx.doi.org/10.1074/jbc.M005142200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10945987	hybrid			2022-12-27	WOS:000165095300108
J	Boland, MP; Fitzgerald, KA; O'Neill, LAJ				Boland, MP; Fitzgerald, KA; O'Neill, LAJ			Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HL-60 LEUKEMIA-CELLS; CATALYTIC ACTIVITY; MAMMALIAN-CELLS; KINASE COMPLEX; FAS-LIGAND; SACCHAROMYCES-CEREVISIAE; ANTINEOPLASTIC AGENTS; LIPID-PEROXIDATION; IONIZING-RADIATION; INDUCED APOPTOSIS	Topoisomerase II is a target for a number of chemotherapeutic agents used in the treatment of cancer. Its essential physiological role in modifying the topology of DNA involves the generation of transient double-strand breaks. Anti-cancer drugs, such as mitoxantrone, that target this enzyme interrupt its catalytic cycle and give rise to persistent double strand breaks, which may be lethal to a cell. We investigated the role of such lesions in signaling the activation of the transcription factor nuclear factor kappa B (NF kappa B) by this drug. Mitoxantrone activated NF kappa B and stimulated I kappa B alpha degradation in the promyelocytic leukemia cell line HL60 but not in the variant cells, HL60/MX2 cells, which lack the beta isoform of topoisomerase II and express a truncated alpha isoform that results in an altered subcellular distribution. Treatment of sensitive HL60 cells with mitoxantrone led to a depletion of both isoforms, suggesting the stabilization of transient DNA-topoisomerase II complexes. This depletion was absent in the variant cells, HL60/MX2. Activation of caspase 3 by mitoxantrone was also impaired in the HL60/MX2 cells. NF kappa B activation in response to tumor necrosis factor and bleomycin, the latter causing topoisomerase II-independent DNA damage, was intact in both cell lines. An inhibitor rather than a poison of topoisomerase II, Imperial Cancer Research Fund 187 (ICRF 187) the mechanism of which does not involve the generation of double strand breaks, did not activate NF kappa B, nor did it induce apoptosis in parental HL60 cells. However, ICRF 187 protected against I kappa B degradation in parental HL60 cells in response to mitoxantrone. This protection was also shown with another topoisomerase II inhibitor, merbarone, which is structurally and functionally distinct from ICRF 187. Their effects were specific, as neither protected against tumor necrosis factor-stimulated I kappa B degradation. The poisoning of topoisomerase II with resultant DNA damage is therefore a critical signal for NF kappa B activation.	Trinity Coll Dublin, Dept Biochem, Dublin 2, Ireland; Trinity Coll Dublin, Inst Biotechnol, Dublin 2, Ireland	Trinity College Dublin; Trinity College Dublin	O'Neill, LAJ (corresponding author), Trinity Coll Dublin, Dept Biochem, Dublin 2, Ireland.	laoneill@tcd.ie	Fitzgerald, Katherine/ABE-6317-2020	Fitzgerald, Kate/0000-0003-3175-609X; O'Neill, Luke/0000-0002-4333-2748				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; Boland MP, 1998, J BIOL CHEM, V273, P15494, DOI 10.1074/jbc.273.25.15494; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BROWN GA, 1995, CANCER RES, V55, P78; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Capranico G, 1998, BBA-GENE STRUCT EXPR, V1400, P185, DOI 10.1016/S0167-4781(98)00135-3; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Consoli U, 1997, LEUKEMIA, V11, P2066, DOI 10.1038/sj.leu.2400511; Cowell IG, 1998, EXP CELL RES, V243, P232, DOI 10.1006/excr.1998.4150; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; DAVIES SM, 1988, J BIOL CHEM, V263, P17724; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; Errington F, 1999, MOL PHARMACOL, V56, P1309, DOI 10.1124/mol.56.6.1309; FISHER GR, 1992, CANCER CHEMOTH PHARM, V30, P451, DOI 10.1007/BF00685596; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Fortune JM, 1998, J BIOL CHEM, V273, P17643, DOI 10.1074/jbc.273.28.17643; FRY AM, 1991, CANCER RES, V51, P6592; Furuke K, 1999, J IMMUNOL, V162, P1988; GERWITZ DA, 1999, BIOCHEM PHARMACOL, V57, P724; Gieseler F, 1996, LEUKEMIA, V10, pS46; Gilmore TD, 1996, ONCOGENE, V13, P1367; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; HARKER WG, 1989, CANCER RES, V49, P4542; HARKER WG, 1991, BIOCHEMISTRY-US, V30, P9953, DOI 10.1021/bi00105a020; HARKER WG, 1995, CANCER RES, V55, P4962; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; Jensen PB, 1997, BIOCHEM PHARMACOL, V54, P755; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; Liu BQ, 1996, J IMMUNOL, V157, P160; McPherson JP, 1997, ANTICANCER RES, V17, P4243; Meczes EL, 1997, CANCER CHEMOTH PHARM, V39, P367, DOI 10.1007/s002800050585; Mo YY, 1999, EXP CELL RES, V252, P50, DOI 10.1006/excr.1999.4616; Mo YY, 1999, MOL PHARMACOL, V55, P216, DOI 10.1124/mol.55.2.216; Redwood C, 1998, J BIOL CHEM, V273, P3635, DOI 10.1074/jbc.273.6.3635; ROBSON CN, 1987, CANCER RES, V47, P1560; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SEHESTED M, 1993, BIOCHEM PHARMACOL, V46, P389, DOI 10.1016/0006-2952(93)90514-W; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SIKIC BI, 1986, CANCER SURV, V5, P81; Son YS, 1998, CANCER CHEMOTH PHARM, V41, P353, DOI 10.1007/s002800050751; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VILE GF, 1989, CANCER CHEMOTH PHARM, V24, P105; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Weiss G, 1999, GEN PHARMACOL, V32, P155, DOI 10.1016/S0306-3623(98)00100-1; WELLS NJ, 1995, EUR J BIOCHEM, V231, P491, DOI 10.1111/j.1432-1033.1995.tb20723.x; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; WILSON RE, 1993, ONCOGENE, V8, P3229; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	63	64	66	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25231	25238		10.1074/jbc.275.33.25231	http://dx.doi.org/10.1074/jbc.275.33.25231			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10940316	hybrid			2022-12-27	WOS:000088849400027
J	Bridges, JP; Davis, HW; Damodarasamy, M; Kuroki, Y; Howles, G; Hui, DY; McCormack, FX				Bridges, JP; Davis, HW; Damodarasamy, M; Kuroki, Y; Howles, G; Hui, DY; McCormack, FX			Pulmonary surfactant proteins A and D are potent endogenous inhibitors of lipid peroxidation and oxidative cellular injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID AGGREGATION; CALCIUM; DOMAINS; BINDING; ANTIOXIDANTS; HOMEOSTASIS; ROLES; CELLS; A(2)	The lung is composed of a series of branching conducting airways that terminate in grape-like clusters of delicate gas-exchanging airspaces called pulmonary alveoli. Maintenance of alveolar patency at end expiration requires pulmonary surfactant, a mixture of phospholipids and proteins that coats the epithelial surface and reduces surface tension. The surfactant lining is exposed to the highest ambient oxygen tension of any internal interface and encounters a variety of oxidizing toxicants including ozone and trace metals contained within the 10 kl of air that is respired daily. The pathophysiological consequences of surfactant oxidation in humans and experimental animals include airspace collapse, reduced lung compliance, and impaired gas exchange. me now report that the hydrophilic surfactant proteins A (SP-A) and D (SP-D) directly protect surfactant phospholipids and macrophages from oxidative damage. Both proteins block accumulation of thiobarbituric acid-reactive substances and conjugated dienes during copper-induced oxidation of surfactant lipids or low density lipoprotein particles by a mechanism that does not involve metal chelation or oxidative modification of the proteins. Low density lipoprotein oxidation is instantaneously arrested upon SP-A or SP-D addition, suggesting direct interference with free radical formation or propagation. The antioxidant activity of SP-A maps to the carboxyl-terminal domain of the protein, which, like SP-D, contains a C-type lectin carbohydrate recognition domain. These results indicate that SP-A and SP-D, which are ubiquitous among air breathing organisms, could contribute to the protection of the lung from oxidative stresses due to atmospheric or supplemental oxygen, air pollutants, and lung inflammation.	Univ Cincinnati, Dept Med, Div Pulm & Crit Care, Cincinnati, OH 45267 USA; Univ Cincinnati, Dept Pathobiol & Mol Med, Cincinnati, OH 45267 USA; Sapporo Med Univ, Sch Med, Dept Biochem, Sapporo, Hokkaido 0608556, Japan	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Sapporo Medical University	McCormack, FX (corresponding author), POB 670564, Cincinnati, OH 45267 USA.	frank.mccormack@uc.edu	McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464; Bridges, James P./0000-0002-4815-117X	PHS HHS [06096, 61332, 61612] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; COCKSHUTT AM, 1990, BIOCHEMISTRY-US, V29, P8424, DOI 10.1021/bi00488a032; CROUCH E, 1994, J BIOL CHEM, V269, P15808; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; EFRATI H, 1987, BIOCHEMISTRY-US, V26, P7986, DOI 10.1021/bi00398a066; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FISHER AB, 1994, AM J PHYSIOL, V267, pL335, DOI 10.1152/ajplung.1994.267.3.L335; GELVAN D, 1990, BIOCHIM BIOPHYS ACTA, V1035, P353, DOI 10.1016/0304-4165(90)90100-B; Goerke J, 1998, BBA-MOL BASIS DIS, V1408, P79, DOI 10.1016/S0925-4439(98)00060-X; Gutteridge JMC, 1996, BIOCHEM BIOPH RES CO, V220, P1024, DOI 10.1006/bbrc.1996.0518; HAAGSMAN HP, 1990, BIOCHEMISTRY-US, V29, P8894, DOI 10.1021/bi00490a003; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V201, P1567, DOI 10.1006/bbrc.1994.1883; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; Lawson PR, 2000, IMMUNOL REV, V173, P66, DOI 10.1034/j.1600-065X.2000.917308.x; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; MacNee W, 1999, AM J RESP CRIT CARE, V160, pS58, DOI 10.1164/ajrccm.160.supplement_1.15; MATALON S, 1987, J APPL PHYSIOL, V62, P756, DOI 10.1152/jappl.1987.62.2.756; McCormack FX, 1997, J BIOL CHEM, V272, P27971, DOI 10.1074/jbc.272.44.27971; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P13963, DOI 10.1021/bi970745q; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; McCormack FX, 1999, J BIOL CHEM, V274, P3173, DOI 10.1074/jbc.274.5.3173; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; Patel RP, 1997, BIOCHEM J, V322, P425, DOI 10.1042/bj3220425; Postle AD, 1999, AM J RESP CELL MOL, V20, P90, DOI 10.1165/ajrcmb.20.1.3253; Qin XF, 1998, AM J PHYSIOL-HEART C, V274, pH1836, DOI 10.1152/ajpheart.1998.274.5.H1836; Sestili P, 1999, FEBS LETT, V457, P139, DOI 10.1016/S0014-5793(99)01027-3; Sullivan LC, 1998, J MOL EVOL, V46, P131, DOI 10.1007/PL00006287; Suwabe A, 1996, ARCH BIOCHEM BIOPHYS, V327, P285, DOI 10.1006/abbi.1996.0123; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; Touqui L, 1999, MOL MED TODAY, V5, P244, DOI 10.1016/S1357-4310(99)01470-7; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931	42	124	131	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38848	38855		10.1074/jbc.M005322200	http://dx.doi.org/10.1074/jbc.M005322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10969075	hybrid			2022-12-27	WOS:000165739800096
J	Fukada, M; Watakabe, I; Yuasa-Kawada, J; Kawachi, H; Kuroiwa, A; Matsuda, Y; Noda, M				Fukada, M; Watakabe, I; Yuasa-Kawada, J; Kawachi, H; Kuroiwa, A; Matsuda, Y; Noda, M			Molecular characterization of CRMP5, a novel member of the collapsin response mediator protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-NERVE PROJECTION; NEURAL-SPECIFIC PROTEIN; GROWTH CONE COLLAPSE; SEMAPHORIN-III; HUMAN DIHYDROPYRIMIDINASE; AXON GUIDANCE; SPINAL-CORD; GENE; NEUROPILIN; UNC-33	The CRMP (collapsin response mediator protein) family is thought to play key roles in growth cone guidance during neural development. The four members (CRMP1-4) identified to date have been demonstrated to form hetero-multimeric structures through mutual associations. In this study, we cloned a novel member of this family, which we call CRMP5, by the yeast two-hybrid method. This protein shares relatively low amino acid identity with the other CRMP members (49-50%) and also with dihydropyrimidinase (51%), whereas CRMP1-4 exhibit higher identity with each other (68-75%), suggesting that CRMP5 might be categorized into a third subfamily. The mouse CRMP5 gene was located at chromosome 5 B1, Northern blot and in situ hybridization analyses indicated that CRMP5 is expressed throughout the nervous system similarly to the other members (especially CRMP1 and CRMP4) with the expression peak in the first postnatal week. Association experiments using the yeast two-hybrid method and coimmunoprecipitation showed that CRMP5 interacts with dihydropyrimidinase and all the CRMPs including itself, except for CRMP1, although the expression profile almost overlaps with that of CRMP1 during development. These results suggest that CRMP complexes in the developing nervous system are classifiable into two populations that contain either CRMP1 or CRMP5. This indicates that different complexes may have distinct functions in shaping the neural networks.	Natl Inst Basic Biol, Div Mol Neurobiol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan; Hokkaido Univ, Grad Sch Environm Earth Sci, Div Biosci, Lab Cytogenet,Kita Ku, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Fac Sci, Chromosome Res Unit, Sapporo, Hokkaido 0600810, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan; Hokkaido University; Hokkaido University	Noda, M (corresponding author), Natl Inst Basic Biol, Div Mol Neurobiol, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.		Noda, Masaharu/D-7146-2016	Noda, Masaharu/0000-0002-3796-524X; KAWACHI, HIROYUKI/0000-0002-7508-5569; Kuroiwa, Asato/0000-0002-3942-3372; Yuasa-Kawada, Junichi/0000-0002-1382-3159				Byk T, 1998, EUR J BIOCHEM, V254, P14, DOI 10.1046/j.1432-1327.1998.2540014.x; Byk T, 1996, J NEUROSCI, V16, P688; Carninci P, 1998, P NATL ACAD SCI USA, V95, P520, DOI 10.1073/pnas.95.2.520; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; EVANS EP, 1996, GENETIC VARIANTS STR, P1446; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gaetano C, 1997, J BIOL CHEM, V272, P12195, DOI 10.1074/jbc.272.18.12195; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Goshima Y, 1997, J NEUROBIOL, V33, P316, DOI 10.1002/(SICI)1097-4695(199709)33:3<316::AID-NEU9>3.0.CO;2-4; Hamajima N, 1998, AM J HUM GENET, V63, P717, DOI 10.1086/302022; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; Honnorat J, 1999, EUR J NEUROSCI, V11, P4226, DOI 10.1046/j.1460-9568.1999.00864.x; Kamata T, 1998, MOL BRAIN RES, V57, P201, DOI 10.1016/S0169-328X(98)00082-5; Kamata T, 1998, MOL BRAIN RES, V54, P219, DOI 10.1016/S0169-328X(97)00332-X; Kato Y, 1998, MOL REPROD DEV, V51, P105, DOI 10.1002/(SICI)1098-2795(199809)51:1&lt;105::AID-MRD13&gt;3.0.CO;2-6; Kawachi H, 1999, MOL BRAIN RES, V72, P47, DOI 10.1016/S0169-328X(99)00204-1; KIKUGAWA M, 1994, EUR J BIOCHEM, V219, P393, DOI 10.1111/j.1432-1033.1994.tb19951.x; Kitamura K, 1999, DNA Res, V6, P291, DOI 10.1093/dnares/6.5.291; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; MATSUDA Y, 1995, ELECTROPHORESIS, V16, P261, DOI 10.1002/elps.1150160142; MATSUDA Y, 1992, CYTOGENET CELL GENET, V61, P282, DOI 10.1159/000133423; Matsuo T, 2000, J BIOL CHEM, V275, P16560, DOI 10.1074/jbc.M001312200; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; MINTURN JE, 1995, J COMP NEUROL, V355, P369, DOI 10.1002/cne.903550304; MINTURN JE, 1995, J NEUROSCI, V15, P6757; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Quach TT, 2000, GENE, V242, P175, DOI 10.1016/S0378-1119(99)00528-4; Quinn CC, 1999, J NEUROBIOL, V41, P158, DOI 10.1002/(SICI)1097-4695(199910)41:1<158::AID-NEU19>3.0.CO;2-0; Shepherd IT, 1997, DEVELOPMENT, V124, P1377; Shirvan A, 1999, J NEUROCHEM, V73, P961, DOI 10.1046/j.1471-4159.1999.0730961.x; SOMSSICH IE, 1996, GENETIC VARIANTS STR, P1450; Suzuki H, 1996, NUCLEIC ACIDS RES, V24, P289, DOI 10.1093/nar/24.2.289; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Taniguchi M, 1997, NEURON, V19, P519, DOI 10.1016/S0896-6273(00)80368-2; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Torres R, 1998, DNA Res, V5, P393, DOI 10.1093/dnares/5.6.393; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; Yoshida H, 1998, J BIOL CHEM, V273, P9761, DOI 10.1074/jbc.273.16.9761; Yuasa J, 1996, NATURE, V382, P632, DOI 10.1038/382632a0	45	109	121	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37957	37965		10.1074/jbc.M003277200	http://dx.doi.org/10.1074/jbc.M003277200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10956643	Green Submitted, hybrid			2022-12-27	WOS:000165618700088
J	Harvey, TJ; Hooper, JD; Myers, SA; Stephenson, SA; Ashworth, LK; Clements, JA				Harvey, TJ; Hooper, JD; Myers, SA; Stephenson, SA; Ashworth, LK; Clements, JA			Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; SERINE-PROTEASE GENE; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; FAMILY; RAT; CDNA; ANDROGEN; BREAST; CANCER	The tissue or glandular kallikreins (KLK) are members of a highly conserved multigene family encoding serine proteases that are central to many biological processes. The rodent KLK families are large, highly conserved and clustered at one locus. The human KLK gene family is clustered on chromosome 19q13.3-13.4, and until recently consisted of just three members. However, recent studies have identified up to II new members of the KLK family that are less conserved than their rodent counterparts. Using a Southern blot and sequence analysis of 10 BACs and cosmids spanning approximately 400 kilobases (kb) either side of the original KLK 60-kb locus, we demonstrated that these genes also lie adjacent to this. We have also clarified the position of several microsatellite markers in relation to the extended KLK locus. Moreover, from Southern blot analysis of the cosmids and BACs with a degenerate oligonucleotide probe to the histidine-encoding region of serine proteases, we have shown that there are no other serine protease genes approximately 400 kb centromeric and 220 kb telomeric of the extended locus. We performed an extensive analysis of the expression patterns of these genes by poly(A)' RNA dot blot and reverse transcriptase-polymerase chain reaction analysis, and demonstrated a diverse pattern of expression. Of interest are clusters of genes with high prostate (KLK2-4) and pancreatic (KLK6-13) expression suggesting evolutionary conservation of elements conferring tissue specificity. From these findings, it is likely that the human KLK gene family consists of just 14 clustered genes within 300 kb and thus is of a comparable size to the rodent families (13-24 genes within 310 and 480 kb, respectively). In contrast to the rodent families, the newest members of the human KLK family are much less conserved in sequence (23-44% at the protein level) and appear to consist of at least four subfamilies. In addition, like the rat, these genes are expressed at varying levels in a diverse range of tissues although they exhibit quite distinct patterns of expression.	Queensland Univ Technol, Sch Life Sci, Ctr Mol Biotechnol, Brisbane, Qld 4001, Australia; Lawrence Livermore Natl Lab, Livermore, CA 94551 USA	Queensland University of Technology (QUT); United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Clements, JA (corresponding author), Queensland Univ Technol, Sch Life Sci, Ctr Mol Biotechnol, GPO Box 2434, Brisbane, Qld 4001, Australia.	j.clements@qut.edu.au	Hooper, John/C-1481-2016; Stephenson, Sally-Anne/I-9801-2012; Harvey, Tracey/P-4305-2016	Hooper, John/0000-0003-1054-8486; Harvey, Tracey/0000-0001-5388-0337; Stephenson, Sally-Anne/0000-0003-3227-2476; Clements, Judith/0000-0001-6026-1964; Myers, Stephen/0000-0003-4793-3820				Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646; Berg T, 1992, Agents Actions Suppl, V38 ( Pt 1), P19; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BOULET AM, 1986, P NATL ACAD SCI USA, V83, P3599, DOI 10.1073/pnas.83.11.3599; Carroll VA, 1999, SEMIN THROMB HEMOST, V25, P183, DOI 10.1055/s-2007-994920; CHAPDELAINE P, 1988, FEBS LETT, V236, P205, DOI 10.1016/0014-5793(88)80315-6; CHEN ZL, 1995, J NEUROSCI, V15, P5088; CLEMENTS J, 1997, KININ SYSTEM, P71; CLEMENTS JA, 1989, ENDOCR REV, V10, P393, DOI 10.1210/edrv-10-4-393; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; DeClerck YA, 1997, ADV EXP MED BIOL, V425, P89; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; DIAMANDIS EP, 2000, IN PRESS CLIN CHEM; DRINKWATER CC, 1988, TRENDS BIOCHEM SCI, V13, P169, DOI 10.1016/0968-0004(88)90144-2; EVANS BA, 1987, J BIOL CHEM, V262, P8027; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; Frenette G, 1997, INT J CANCER, V71, P897, DOI 10.1002/(SICI)1097-0215(19970529)71:5<897::AID-IJC31>3.0.CO;2-2; FUKUSHIMA D, 1985, BIOCHEMISTRY-US, V24, P8037, DOI 10.1021/bi00348a030; Goyal J, 1998, CANCER RES, V58, P4782; GRIESBACHER T, 1977, KININ SYSTEM, P197; KURTZ TW, 1992, J AM SOC NEPHROL, V3, P28; LIN FK, 1993, BIOCHIM BIOPHYS ACTA, V1173, P325, DOI 10.1016/0167-4781(93)90131-V; Little SP, 1997, J BIOL CHEM, V272, P25135, DOI 10.1074/jbc.272.40.25135; Liu XL, 1996, CANCER RES, V56, P3371; LUNDSTROM A, 1991, ACTA DERM-VENEREOL, V71, P471; MacDonald RJ, 1996, J BIOL CHEM, V271, P13684, DOI 10.1074/jbc.271.23.13684; MURRAY SR, 1990, J CARDIOVASC PHARM, V15, pS7, DOI 10.1097/00005344-199000156-00003; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; REIGMAN PHJ, 1989, BIOCHEM BIOPH RES CO, V159, P95, DOI 10.1016/0006-291X(89)92409-1; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; RIEGMAN PHJ, 1992, GENOMICS, V14, P6, DOI 10.1016/S0888-7543(05)80275-7; Rittenhouse HG, 1998, CRIT REV CL LAB SCI, V35, P275, DOI 10.1080/10408369891234219; SCHEDLICH LJ, 1987, DNA-J MOLEC CELL BIO, V6, P429, DOI 10.1089/dna.1987.6.429; SOUTHARDSMITH M, 1994, GENOMICS, V22, P404, DOI 10.1006/geno.1994.1402; Stephenson SA, 1999, J BIOL CHEM, V274, P23210, DOI 10.1074/jbc.274.33.23210; SWIFT GH, 1984, J BIOL CHEM, V259, P4271; Underwood LJ, 1999, CANCER RES, V59, P4435; WINES DR, 1989, J BIOL CHEM, V264, P7653; WINES DR, 1991, J MOL EVOL, V32, P476, DOI 10.1007/BF02102650; WOLF DA, 1992, MOL ENDOCRINOL, V6, P753, DOI 10.1210/me.6.5.753; Yamashiro K, 1997, BBA-GENE STRUCT EXPR, V1350, P11, DOI 10.1016/S0167-4781(96)00187-X; Yoshida S, 1998, BBA-GENE STRUCT EXPR, V1399, P225, DOI 10.1016/S0167-4781(98)00116-X; Yoshida S, 1998, GENE, V213, P9, DOI 10.1016/S0378-1119(98)00232-7; Yousef GM, 2000, GENOMICS, V65, P184, DOI 10.1006/geno.2000.6159; Yousef GM, 2000, J BIOL CHEM, V275, P11891, DOI 10.1074/jbc.275.16.11891; Yousef GM, 1999, CANCER RES, V59, P4252; Yousef GM, 1999, GENOMICS, V62, P251, DOI 10.1006/geno.1999.6012; Yousef GM, 1999, J BIOL CHEM, V274, P37511, DOI 10.1074/jbc.274.53.37511; Yousef GM, 1999, ANTICANCER RES, V19, P2843	49	137	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37397	37406		10.1074/jbc.M004525200	http://dx.doi.org/10.1074/jbc.M004525200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10969073	Green Published, hybrid			2022-12-27	WOS:000165618700014
J	Wisniewski, M; Balakrishnan, M; Palaniappan, C; Fay, PJ; Bambara, RA				Wisniewski, M; Balakrishnan, M; Palaniappan, C; Fay, PJ; Bambara, RA			The sequential mechanism of HIV reverse transcriptase RNase H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MURINE LEUKEMIA-VIRUS; DNA STRAND TRANSFER; POLYPURINE TRACT PRIMER; AVIAN-MYELOBLASTOSIS; CLEAVAGE SPECIFICITY; ANGSTROM RESOLUTION; FEATURES IMPORTANT; CRYSTAL-STRUCTURE; TYPE-1	Synthesis of the minus strand of viral DNA by human immunodeficiency virus, type 1 (HIV-1) reverse transcriptase is accompanied by RNase H degradation of the viral RNA genome. RNA fragments remain after synthesis and are degraded by the polymerase-independent mode of RNase H cleavage, Recently, we showed that this mode of cleavage occurs by a specific ordered mechanism in which primary cuts are first, secondary and 5-nucleotide cuts are next, and second primary cuts oc cur last (Wisniewski, Ri,, Balakrishnan, M., Palaniappan, C., Fay, P., J., and Bambara, R., A. (2000) Proc. Natl. Acad. Sci. U.S.A. 97, 11978-11983), Ultimately the RNAs are cleaved into small fragments that can dissociate from the DNA template. Because the cleavage mechanism is an ordered series of events, we determined in this study whether any earlier cut is required for a later cut, By precisely inhibiting cleavage at each site, we examined the dependence of later cuts on cleavage at that site, We found that each cut is independent of the other cuts, demonstrating that the order of this stepwise mechanism is based on the rates of each cut. A mechanism for unlinked ordered cleavage consistent with these results is presented.	Univ Rochester, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Dept Biochem & Biophys, Box 712,601 Elmwood Ave, Rochester, NY 14642 USA.				NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER; NCI NIH HHS [CA11198] Funding Source: Medline; NIDCR NIH HHS [T32DE07207-09] Funding Source: Medline; NIGMS NIH HHS [GM49573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAIN SW, 1995, J VIROL, V69, P5113, DOI 10.1128/JVI.69.8.5113-5116.1995; Blain SW, 1996, J BIOL CHEM, V271, P1448, DOI 10.1074/jbc.271.3.1448; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; DESTEFANO JJ, 1993, BIOCHEMISTRY-US, V32, P6908, DOI 10.1021/bi00078a014; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1995, NUCLEIC ACIDS RES, V23, P3901, DOI 10.1093/nar/23.19.3901; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; Fuentes GM, 1996, NUCLEIC ACIDS RES, V24, P1719, DOI 10.1093/nar/24.9.1719; FURFINE ES, 1991, J BIOL CHEM, V266, P406; Gabbara S, 1999, BIOCHEMISTRY-US, V38, P13070, DOI 10.1021/bi991085n; Gao HQ, 1999, J MOL BIOL, V294, P1097, DOI 10.1006/jmbi.1999.3325; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; GHOSH M, 1995, J BIOL CHEM, V270, P7068, DOI 10.1074/jbc.270.13.7068; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; Gotte M, 1998, J BIOL CHEM, V273, P10139, DOI 10.1074/jbc.273.17.10139; GUO JH, 1995, BIOCHEMISTRY-US, V34, P5018, DOI 10.1021/bi00015a013; JACOBOMOLINA A, 1991, P NATL ACAD SCI USA, V88, P10895, DOI 10.1073/pnas.88.23.10895; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kelleher CD, 1998, J BIOL CHEM, V273, P9976, DOI 10.1074/jbc.273.16.9976; Kelleher CD, 2000, J BIOL CHEM, V275, P13061, DOI 10.1074/jbc.275.17.13061; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; OYAMA F, 1989, J BIOL CHEM, V264, P18808; Palaniappan C, 1997, J BIOL CHEM, V272, P11157, DOI 10.1074/jbc.272.17.11157; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Powell MD, 1999, J BIOL CHEM, V274, P19885, DOI 10.1074/jbc.274.28.19885; Powell MD, 1997, J BIOL CHEM, V272, P13262, DOI 10.1074/jbc.272.20.13262; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; PULLEN KA, 1990, J VIROL, V64, P6274, DOI 10.1128/JVI.64.12.6274-6277.1990; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; SCHULTZ SJ, 1995, J BIOL CHEM, V270, P24135, DOI 10.1074/jbc.270.41.24135; Schultz SJ, 2000, J BIOL CHEM, V275, P32299, DOI 10.1074/jbc.M000021200; Schultz SJ, 1999, J BIOL CHEM, V274, P34547, DOI 10.1074/jbc.274.49.34547; Smith CM, 1998, J VIROL, V72, P6805, DOI 10.1128/JVI.72.8.6805-6812.1998; SMITH JS, 1994, J VIROL, V68, P5721, DOI 10.1128/JVI.68.9.5721-5729.1994; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; TELESNITSKY A, 1993, EMBO J, V12, P4433, DOI 10.1002/j.1460-2075.1993.tb06128.x; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; WOHRL BM, 1991, BEHRING I MITT, V89, P100	51	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37664	37671		10.1074/jbc.M007381200	http://dx.doi.org/10.1074/jbc.M007381200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10956669	hybrid			2022-12-27	WOS:000165618700050
J	Maestri-El Kouhen, O; Wang, GL; Solberg, J; Erickson, LJ; Law, PY; Loh, HH				Maestri-El Kouhen, O; Wang, GL; Solberg, J; Erickson, LJ; Law, PY; Loh, HH			Hierarchical phosphorylation of delta-opioid receptor regulates agonist-induced receptor desensitization and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-DEPENDENT ENDOCYTOSIS; G-PROTEIN; BETA(2)-ADRENERGIC RECEPTOR; CARBOXYL-TERMINUS; OPIATE RECEPTOR; DOWN-REGULATION; C-TERMINUS; KINASE; INVOLVEMENT; CELLS	Treatment of HEK293 cells expressing the delta -opioid re ceptor with agonist [D-Pen(2,5)]enkephalin (DPDPE) resulted in the rapid phosphorylation of the receptor, We constructed several mutants of the potential phosphorylation sites (Ser/Thr) at the carboxyl tail of the receptor in order to delineate the receptor phosphorylation sites and the agonist-induced desensitization and internalization. The Ser and Thr were substituted to alanine, and the corresponding mutants were transiently and stably expressed in HEK293 cells. We found that only two residues, i.e. Thr(358) and Ser(363), were phosphorylated, with Ser(363) being critical for the DPDPE-induced phosphorylation of the receptor. Furthermore, using alanine and aspartic acid substitutions, we found that the phosphorylation of the receptor is hierarchical, with Ser(363) as the primary phosphorylation site. Here, we demonstrated that DPDPE-induced rapid receptor desensitization, as measured by adenylyl cyclase activity, and receptor internalization are intimately related to phosphorylation of Thr(358) and Ser(363), with Thr(358) being involved in the receptor internalization.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Maestri-El Kouhen, O (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	elkou002@tc.umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NATIONAL INSTITUTE ON DRUG ABUSE [R56DA000564, R37DA001583, R01DA007339, R01DA001583, R01DA000564, P50DA011806] Funding Source: NIH RePORTER; NIDA NIH HHS [P50 DA011806, DA07339, R01 DA007339, R56 DA000564, DA00564, DA01583, R01 DA000564, R01 DA001583] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Appleyard SM, 1997, J NEUROCHEM, V69, P2405; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Burd AL, 1998, J BIOL CHEM, V273, P34488, DOI 10.1074/jbc.273.51.34488; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Cvejic S, 1996, J BIOL CHEM, V271, P4073; El Kouhen R, 1999, J BIOL CHEM, V274, P9207, DOI 10.1074/jbc.274.14.9207; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FANTOZZI R, 1981, MOL PHARMACOL, V20, P8; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Hasbi A, 1998, J NEUROCHEM, V70, P2129; HASHI A, 2000, J PHARMACOL EXP THER, V293, P237; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; Ko JL, 1999, MOL BRAIN RES, V69, P171, DOI 10.1016/S0169-328X(99)00094-7; Koch T, 1997, J NEUROCHEM, V69, P1767; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Law PY, 2000, J BIOL CHEM, V275, P32057, DOI 10.1074/jbc.M002395200; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; Pak Y, 1996, MOL PHARMACOL, V50, P1214; PEI G, 1995, MOL PHARMACOL, V48, P173; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Wang CH, 1998, BIOCHEM BIOPH RES CO, V249, P321, DOI 10.1006/bbrc.1998.9080; YANG J, 1995, MOL PHARMACOL, V48, P477; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; Zhao J, 1997, BIOCHEM BIOPH RES CO, V238, P71, DOI 10.1006/bbrc.1997.7242	37	68	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36659	36664		10.1074/jbc.M006788200	http://dx.doi.org/10.1074/jbc.M006788200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973976	hybrid, Green Accepted			2022-12-27	WOS:000165577700030
J	Scherle, PA; Ma, WG; Lim, H; Dey, SK; Trzaskos, JM				Scherle, PA; Ma, WG; Lim, H; Dey, SK; Trzaskos, JM			Regulation of cyclooxygenase-2 induction in the mouse uterus during decidualization - An event of early pregnancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; GRANULOSA-CELLS; GENE DISRUPTION; GROWTH-FACTOR; KINASE; INHIBITOR; IMPLANTATION; BINDING; MICE; IDENTIFICATION	The infertility phenotype of cyclooxygenase-2 (Cox-2)deficient female mice establishes the important role of Cox-8 in pregnancy. Cox-2 deficiency results in defective ovulation, fertilization, implantation, and decidualization; the latter of which can be restored in part by the prostacyclin analog carbaprostacyclin. Uterine Cox-g expression during early pregnancy shows distinct focalization and kinetics in the uterine luminal epithelium and underlying stromal cells, suggesting that expression is tightly regulated. Several intracellular signaling cascades including ERK, p38, and JNK are implicated in vitro as critical components of regulated Cox-8 expression in response to mitogens, growth factors, and cytokines. We investigated the involvement of these signaling pathways during Cox-2 induction in vivo by monitoring uterine kinase activity after intraluminal application of a deciduogenic stimulus. Our results show that the ERK and p38 pathways are activated in uterine preparations as early as 5-min post-stimulation, ERK activation was sustained for several hours with a return to baseline levels by 4 h. p38 activation was rapid with a peak at 5-min post-stimulation and returned to near baseline levels after 45 min. Systemic administration of a MEK inhibitor completely inhibited ERK activation, but did not affect early (2 h) luminal epithelial or late (24 h) stromal Cox-2 expression and only modestly affected decidualization. In contrast, administration of a p38 inhibitor modestly inhibited early Cox-2 expression in the luminal epithelium, while dramatically diminishing late stromal expression. In parallel, induced stromal peroxisomal proliferator activated receptor-delta (PPAR delta) expression is blunted by p38 inhibition. p38 inhibition also significantly inhibited decidualization. These results suggest that p38, but not ERK activation is required for induced Cox-2 and PPAR delta expression during decidualization. In addition, inhibition of p38 led to decreased decidualization suggesting that an intracrine prostanoid pathway consisting of Cox-a, prostacyclin, and PPAR delta is required for maintenance of early pregnancy.	DuPont Pharmaceut Co, Res Lab, Wilmington, DE 19880 USA; Univ Kansas, Med Ctr, Ralph L Smith Res Ctr, Dept Mol & INtegrat Physiol, Kansas City, KS 66160 USA	DuPont; University of Kansas; University of Kansas Medical Center	Trzaskos, JM (corresponding author), DuPont Pharmaceut Co, Res Lab, POB 80400, Wilmington, DE 19880 USA.		Lim, Hyunjung J/D-5343-2011	Lim, Hyunjung J/0000-0003-2191-666X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012304, U01HD022968, R01HD012304] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 12304, HD 22968, HD 33994] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CHAKRABORTY I, 1995, J ENDOCRINOL, V147, P339, DOI 10.1677/joe.0.1470339; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAS SK, 1994, DEVELOPMENT, V120, P1071; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Frantz B, 1998, BIOCHEMISTRY-US, V37, P13846, DOI 10.1021/bi980832y; GALLIN JI, 1992, INFLAMMATION BASIC P, P11227; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; HUETHUDSON YM, 1989, ENDOCRINOLOGY, V125, P1638; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; OGRADY JP, 1972, PROSTAGL, V1, P97, DOI 10.1016/0090-6980(72)90072-X; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; PSYCHOYOS A, 1973, HDB PHYSL, P187; Scherle PA, 1998, J IMMUNOL, V161, P5681; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259	26	86	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37086	37092		10.1074/jbc.M006168200	http://dx.doi.org/10.1074/jbc.M006168200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10969080	hybrid			2022-12-27	WOS:000165577700088
J	Houvras, Y; Benezra, M; Zhang, HB; Manfredi, JJ; Weber, BL; Licht, JD				Houvras, Y; Benezra, M; Zhang, HB; Manfredi, JJ; Weber, BL; Licht, JD			BRCA1 physically and functionally interacts with ATF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE RESPONSE; FACTOR-ALPHA PROMOTER; TRANSCRIPTIONAL ACTIVATION; MALIGNANT-MELANOMA; NUCLEAR PROTEINS; RING FINGER; CDNA-CLONES; SOFT PARTS; CELL-CYCLE; IN-VIVO	BRCA1, a breast and ovarian cancer susceptibility gene, encodes a 220-kDa protein whose precise biochemical function::remains unclear. BRCA1 contains an N-terminal- RING finger that mediates protein-protein interaction. The C-terminal domain of BRCA1 (BRCT) can activate transcription and interacts with RNA polymerase holoenzyme. Using the yeast two-hybrid system, we identified an interaction between the BRCA1 RING finger and ATF1, a member of the cAMP response element-binding protein/activating transcription factor (CREB/ATF) family. We demonstrate that BRCA1 and ATF1 can physically associate in vitro, in yeast, and in human cells. BRCA1 stimulated transcription from a cAMP response-element reporter gene in transient transfections. BRCA1 also stimulated transcription from a natural promoter, that of tumor necrosis factor-alpha, in a manner dependent on the integrity of the cAMP response element. These results implicate BRCA1 in transcriptional activation of ATF1 target genes, some of which are involved in the transcriptional response to DNA damage.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Hematol, Boston, MA 02115 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Pennsylvania; University of Pennsylvania	Licht, JD (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, 1 Gustave L Levy Pl,POB 1130, New York, NY 10029 USA.	jonathan.licht@mssm.edu	Licht, Jonathan/L-4239-2019	Licht, Jonathan/0000-0002-3942-1369; Houvras, Yariv/0000-0003-0751-3215	NATIONAL CANCER INSTITUTE [P01CA080058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007280] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA80058, CA75417] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07280-19] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cui JQ, 1998, ONCOL REP, V5, P591; ENGLANDER EW, 1992, DNA CELL BIOL, V11, P61, DOI 10.1089/dna.1992.11.61; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Fujimura Y, 1996, ONCOGENE, V12, P159; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; Hayes F, 2000, CANCER RES, V60, P2411; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Kibitel J, 1998, PHOTOCHEM PHOTOBIOL, V67, P541, DOI 10.1111/j.1751-1097.1998.tb09452.x; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; LIU F, 1993, J BIOL CHEM, V268, P6714; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Narayan S, 1996, J BIOL CHEM, V271, P18508, DOI 10.1074/jbc.271.31.18508; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Speleman F, 1997, MODERN PATHOL, V10, P496; Taylor CT, 1999, J BIOL CHEM, V274, P19447, DOI 10.1074/jbc.274.27.19447; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Vispe S, 1997, BIOCHIMIE, V79, P587, DOI 10.1016/S0300-9084(97)82007-X; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	62	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36230	36237		10.1074/jbc.M002539200	http://dx.doi.org/10.1074/jbc.M002539200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10945975	hybrid			2022-12-27	WOS:000165382000083
J	Kapahi, P; Takahashi, T; Natoli, G; Adams, SR; Chen, Y; Tsien, RY; Karin, M				Kapahi, P; Takahashi, T; Natoli, G; Adams, SR; Chen, Y; Tsien, RY; Karin, M			Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of I kappa B kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IKK-BETA SUBUNIT; TRANSCRIPTION FACTOR; PHOSPHORYLATION; COMPLEX; ALPHA; AP-1; JNK	Arsenite is a potent environmental toxin that causes various pathologies including cancers and skin disorders. Arsenite is believed to exert its biological effects through reaction with exposed sulfhydryl groups, especially pairs of adjacent thiols. Here, we describe the mechanism by which arsenite affects the NF-kappaB signaling pathway. Activation of transcription factor NF-kappaB depends on the integrity of the I kappaB kinase (IKK) complex. We found that arsenite potently inhibits NF-kappaB and IKK activation by binding to Cys-179 in the activation loop of the IKK catalytic subunits, IKK alpha/beta. The affinity of IKK beta for trivalent arsenic was verified in vitro by the ability of IKK beta to enhance the fluorescence of an arsenic-substituted fluorescein dye. The addition of 1,2-dithiol antidotes or replacement of Cys-179 with an alanine residue abolished dye binding to and arsenite inhibition of IKK beta. Overexpression of IKK beta (C179A) protects NF-kappaB from inhibition by arsenite, indicating that despite the involvement of a large number of distinct gene products in this activation pathway, the critical target for inhibition by arsenite is on the IKK catalytic subunits.	Univ Calif San Diego, Dept Pharmacol 0636, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst 0647, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol 0636, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Natoli, gioacchino/J-2100-2018; Natoli, gioacchino/ABB-8679-2020	Natoli, Gioacchino/0000-0003-0711-2411	NIEHS NIH HHS [ES 04151] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES004151, R01ES004151] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abernathy CO, 1999, ENVIRON HEALTH PERSP, V107, P593, DOI 10.2307/3434403; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; CUZICK J, 1982, BRIT J CANCER, V45, P904, DOI 10.1038/bjc.1982.143; DAS D, 1995, ANALYST, V120, P917, DOI 10.1039/an9952000917; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FARBER EM, 1992, J AM ACAD DERMATOL, V27, P640, DOI 10.1016/0190-9622(92)70232-5; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GRIFFIN B, 2000, IN PRESS METHODS ENZ; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; NEVENS F, 1990, J HEPATOL, V11, P80, DOI 10.1016/0168-8278(90)90276-W; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; PIONTEK M, 1989, DEUT MED WOCHENSCHR, V114, P1653, DOI 10.1055/s-2008-1066810; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; ROTHWARF DM, 1999, SCIENCE; Rudolph D, 2000, GENE DEV, V14, P854; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	29	296	313	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36062	36066		10.1074/jbc.M007204200	http://dx.doi.org/10.1074/jbc.M007204200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967126	hybrid			2022-12-27	WOS:000165382000060
J	Li, XH; Shimada, K; Showalter, LA; Weinman, SA				Li, XH; Shimada, K; Showalter, LA; Weinman, SA			Biophysical properties of ClC-3 differentiate it from swelling-activated chloride channels in Chinese hamster ovary-K1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY VOLUME DECREASE; P-GLYCOPROTEIN; CL CHANNEL; EXPRESSION; IDENTIFICATION; CURRENTS	ClC-3 is a highly conserved voltage-gated chloride channel, which together with ClC-4 and ClC-5 belongs to one subfamily of the larger group of ClC chloride channels, Whereas ClC-5 is localized intracellularly, ClC-3 has:been reported to be a swelling-activated plasma membrane channel, However, recent studies have shown that native ClC-3 in hepatocytes is primarily intracellular, Therefore, we reexamined the properties of ClC-3 in a mammalian cell expression system and compared them with the properties of endogenous swelling-activated channels. Chinese hamster ovary (CHO)-K1 cells;were transiently transfected with rat ClC-3, The resulting chloride currents were Cl- > I- selective, showed extreme outward rectification, and lacked inactivation at positive voltages, In addition, they were insensitive to the chloride channel blockers, 5-nitro-2-(3-phenylpropylamino)-benzoic acid (NPPB) and 4,4'diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) and were not inhibited by phorbol esters or activated by osmotic swelling. These properties are identical to those of ClC-5 but differ from those previously attributed to ClC-3, In contrast, nontransfected CHO-K1 cells displayed an endogenous swelling-activated chloride current, which was weakly outward rectifying, inactivated at positive voltages, sensitive to NPPB and DIDS, and inhibited by phorbol esters, These properties are identical to those previously attributed to ClC-3, Therefore, we conclude that when expressed in CHO-K1 cells, ClC-3 is an extremely outward rectifying channel with similar properties to ClC-5 and is neither activated by cell swelling nor identical to the endogenous swelling-activated channel. These data suggest that ClC-3 cannot be responsible for the swelling-activated chloride channel under all circumstances.	Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Weinman, SA (corresponding author), Univ Texas, Med Branch, Dept Physiol & Biophys, 301 Univ Blvd, Galveston, TX 77555 USA.		Weinman, Steven/E-7012-2011		NIDDK NIH HHS [DK42917] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042917, R01DK042917] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Begenisich T, 1998, J MEMBRANE BIOL, V163, P77, DOI 10.1007/s002329900372; Bond TD, 1998, J PHYSIOL-LONDON, V508, P333, DOI 10.1111/j.1469-7793.1998.333bq.x; Buyse G, 1997, J BIOL CHEM, V272, P3615, DOI 10.1074/jbc.272.6.3615; Duan D, 1999, J GEN PHYSIOL, V113, P57, DOI 10.1085/jgp.113.1.57; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; GSCHWENTNER M, 1995, PFLUG ARCH EUR J PHY, V430, P464, DOI 10.1007/BF00373882; HIGGINS CF, 1995, J BIOENERG BIOMEMBR, V27, P63, DOI 10.1007/BF02110332; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; KAWASAKI M, 1995, NEURON, V14, P1285, DOI 10.1016/0896-6273(95)90275-9; KAWASAKI M, 1994, NEURON, V12, P597, DOI 10.1016/0896-6273(94)90215-1; Laich A, 1997, KIDNEY INT, V51, P477, DOI 10.1038/ki.1997.65; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Meng XJ, 1996, AM J PHYSIOL-CELL PH, V271, pC112, DOI 10.1152/ajpcell.1996.271.1.C112; Sakamoto H, 1996, J BIOL CHEM, V271, P10210, DOI 10.1074/jbc.271.17.10210; Shimada K, 2000, AM J PHYSIOL-GASTR L, V279, pG268, DOI 10.1152/ajpgi.2000.279.2.G268; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; Strange K, 1998, J GEN PHYSIOL, V111, P617, DOI 10.1085/jgp.111.5.617; Vanoye CG, 1997, J PHYSIOL-LONDON, V502, P249, DOI 10.1111/j.1469-7793.1997.249bk.x; Waldegger S, 2000, J AM SOC NEPHROL, V11, P1331, DOI 10.1681/ASN.V1171331; Wang LW, 2000, J PHYSIOL-LONDON, V524, P63, DOI 10.1111/j.1469-7793.2000.t01-1-00063.x; Weinman SA, 1998, J BIOL CHEM, V273, P34691, DOI 10.1074/jbc.273.52.34691; Xiong H, 1999, J MEMBRANE BIOL, V167, P215, DOI 10.1007/s002329900485	23	115	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35994	35998		10.1074/jbc.M002712200	http://dx.doi.org/10.1074/jbc.M002712200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10973952	hybrid			2022-12-27	WOS:000165382000050
J	Mahmmoud, YA; Vorum, H; Cornelius, F				Mahmmoud, YA; Vorum, H; Cornelius, F			Identification of a phospholemman-like protein from shark rectal glands - Evidence for indirect regulation of Na,K-ATPase by protein kinase C via a novel member of the FXYDY family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; NA+/K+-ATPASE; ALPHA-1 SUBUNIT; INTACT-CELLS; SIDED ACTION; PHOSPHORYLATION; PHOSPHOLAMBAN; K+; NA+,K+-ATPASE; INHIBITION	The Na,K-ATPase provides the driving force for many ion transport processes through control of Na+ and K+ concentration gradients across the plasma membranes of animal cells. It is composed of two subunits, cu and beta, In many tissues, predominantly in kidney, it is associated with a small ancillary component, the gamma -subunit that plays a modulatory role. A novel 15-kDa protein, sharing considerable homology to the gamma -subunit and to phospholemman (PLM) was identified in purified Na,K-ATPase preparations from rectal glands of the shark Squalus acanthias, but was absent in pig kidney preparations. This PLM-like protein from shark (PLMS) was found to be a substrate for both PKA and PKC, Antibodies to the Na,K-ATPase or subunit coimmunoprecipitated PLMS, Purified PLMS also coimmunoprecipitated with the ol-subunit of pig kidney Na,K-ATPase, indicating specific association with different alpha -isoforms. Finally, PLMS and the alpha -subunit were expressed in stoichiometric amounts in rectal gland membrane preparations. Incubation of membrane bound Na,K-ATPase with non-solubilizing concentrations of C12E8 resulted in functional dissociation of PLMS from Na,K-ATPase and increased the hydrolytic activity. The same effects were observed after PKC phosphorylation of Na,K-ATPase membrane preparations. Thus, PLMS may function as a modulator of shark Na,K-ATPase in a way resembling the phospholamban regulation of the Ca-ATPase.	Aarhus Univ, Dept Biophys, DK-8000 Aarhus C, Denmark	Aarhus University	Cornelius, F (corresponding author), Aarhus Univ, Dept Biophys, Ole Worms Alle 185, DK-8000 Aarhus C, Denmark.	fc@biophys.au.dk	Cornelius, Flemming/C-1912-2019	Cornelius, Flemming/0000-0003-1566-0020				Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; Beggah AT, 1999, J BIOL CHEM, V274, P8217, DOI 10.1074/jbc.274.12.8217; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Celis JE, 1998, CELL BIOLOGY - A LABOARATORY HANDBOOK, 2ND EDITION, VOL 4, P404; CELIS JE, 1994, CELL BIOL LABORATORY, V3, P222; Chen LSK, 1997, GENOMICS, V41, P435, DOI 10.1006/geno.1997.4665; Chen ZH, 1998, CIRC RES, V82, P367, DOI 10.1161/01.RES.82.3.367; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P188; CORNELIUS F, 1987, BIOCHIM BIOPHYS ACTA, V904, P353, DOI 10.1016/0005-2736(87)90385-3; CORNELIUS F, 1988, BIOCHIM BIOPHYS ACTA, V944, P223, DOI 10.1016/0005-2736(88)90435-X; Cornelius F, 1996, FEBS LETT, V380, P277, DOI 10.1016/0014-5793(96)00032-4; CORNELIUS F, 2000, IN PRESS INT C SER; Feschenko MS, 1997, J BIOL CHEM, V272, P17726, DOI 10.1074/jbc.272.28.17726; FESCHENKO MS, 1995, J BIOL CHEM, V270, P14072, DOI 10.1074/jbc.270.23.14072; FISONE G, 1994, J BIOL CHEM, V269, P9368; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; Hansen O, 1999, PFLUG ARCH EUR J PHY, V437, P517, DOI 10.1007/s004240050812; HARDWICKE PMD, 1981, BIOCHEM BIOPH RES CO, V102, P250, DOI 10.1016/0006-291X(81)91514-X; HUANG WH, 1985, J BIOL CHEM, V260, P7356; JONES LR, 1979, J BIOL CHEM, V254, P530; KOVACS RJ, 1988, J BIOL CHEM, V263, P18364; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG O, 1956, METHODS BIOCHEMICAL, V3, P1; Logvinenko NS, 1996, P NATL ACAD SCI USA, V93, P9132, DOI 10.1073/pnas.93.17.9132; LU YZ, 1994, BIOCHEMISTRY-US, V33, P5056, DOI 10.1021/bi00183a008; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; Middleton JP, 1996, MINER ELECTROL METAB, V22, P293; MIDDLETON JP, 1993, J BIOL CHEM, V268, P15958; Minor NT, 1998, P NATL ACAD SCI USA, V95, P6521, DOI 10.1073/pnas.95.11.6521; MOORMAN JR, 1995, NATURE, V377, P737, DOI 10.1038/377737a0; Moorman JR, 1998, ADV EXP MED BIOL, V442, P219; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; MORRISON BW, 1995, J BIOL CHEM, V270, P2176, DOI 10.1074/jbc.270.5.2176; NAKADATE T, 1987, J BIOL CHEM, V262, P11507; Nishi A, 1999, J NEUROCHEM, V73, P1492, DOI 10.1046/j.1471-4159.1999.0731492.x; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PLESNER IW, 1986, BIOCHEM J, V239, P175, DOI 10.1042/bj2390175; Ramjeesingh M, 1999, BIOCHEM J, V342, P119, DOI 10.1042/0264-6021:3420119; Shi YL, 1996, BIOCHEMISTRY-US, V35, P13393, DOI 10.1021/bi9614085; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; TUNON P, 1984, J BIOCHEM BIOPH METH, V9, P171, DOI 10.1016/0165-022X(84)90008-3; TURI A, 1988, BIOCHIM BIOPHYS ACTA, V940, P77, DOI 10.1016/0005-2736(88)90010-7; TURI A, 1985, BIOCHIM BIOPHYS ACTA, V818, P123, DOI 10.1016/0005-2736(85)90555-3; Vasilets LA, 1999, FEBS LETT, V455, P8, DOI 10.1016/S0014-5793(99)00851-0; VASILETS LA, 1992, J MEMBRANE BIOL, V125, P119; WALAAS SI, 1988, BIOCHIM BIOPHYS ACTA, V968, P127, DOI 10.1016/0167-4889(88)90052-3; Yang L, 1996, BIOCHEMISTRY-US, V35, P13966, DOI 10.1021/bi9610008; Zhai J, 2000, J BIOL CHEM, V275, P10538, DOI 10.1074/jbc.275.14.10538	54	106	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35969	35977		10.1074/jbc.M005168200	http://dx.doi.org/10.1074/jbc.M005168200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10961995	hybrid			2022-12-27	WOS:000165382000047
J	Mazurek, N; Conklin, J; Byrd, JC; Raz, A; Bresalier, RS				Mazurek, N; Conklin, J; Byrd, JC; Raz, A; Bresalier, RS			Phosphorylation of the beta-galactoside-binding protein galectin-3 modulates binding to its ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANIMAL LECTIN; HUMAN NEUTROPHILS; MESSENGER-RNA; CELL-ADHESION; COLON-CANCER; EPSILON-BP; EXPRESSION; IGE; METASTASIS; SEQUENCE	The beta -galactoside-binding protein galectin-3 has pleiotropic biological functions and has been implicated in cell growth, differentiation, adhesion, RNA processing, apoptosis, and malignant transformation. Galectin-3 may be phosphorylated at N-terminal Ser(6), but the role of phosphorylation in determining interactions of this endogenous lectin with its ligands remains to be elucidated. We therefore studied the effect of phosphorylation on binding of galectin-3 to two of its reported ligands, laminin and purified colon cancer mucin, Human recombinant galectin-3 was phosphorylated in vitro by casein kinase I, and separated from the native species by isoelectric focusing for use in solid phase binding assays. Non-phosphorylated galectin-3 bound to laminin and asialomucin in a dose-dependent manner with half-maximal binding at 1.5 mug/ml. Phosphorylation reduced saturation binding to each ligand by >85%. Ligand binding could be fully restored by dephosphorylation with protein phosphatase type 1. Mutation of galectin-3 at Ser(6) (Ser to Glu) did not alter galectin ligand binding. Metabolic labeling or separation by isoelectric focusing confirmed the presence of phosphorylated galectin-8 species in vivo in the cytosol of human colon cancer cells from which ligand mucin was purified. Phosphorylation significantly reduces the interaction of galectin-3 with its ligands. The process by which phosphorylation modulates protein-carbohydrate interactions has important implications for understanding the biological functions of this protein, and may serve as an "on/off" switch for its sugar binding capabilities.	Henry Ford Hlth Sci Ctr K7, Gastrointestinal Canc Res Lab, Detroit, MI 48202 USA; Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48109 USA; Wayne State Univ, Sch Med, Karmanos Canc Inst, Metastasis Res Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	University of Michigan System; University of Michigan; Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University	Bresalier, RS (corresponding author), Henry Ford Hlth Sci Ctr K7, Gastrointestinal Canc Res Lab, 2799 W Grand Blvd, Detroit, MI 48202 USA.			Bresalier, Robert/0000-0002-9740-281X	NATIONAL CANCER INSTITUTE [R01CA046120, R01CA069480] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA 46120, R01CA 69480] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akahani S, 1997, CANCER RES, V57, P5272; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; BAO Q, 1995, J CELL SCI, V108, P2791; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Bresalier RS, 1996, CANCER RES, V56, P4354; Bresalier RS, 1998, GASTROENTEROLOGY, V115, P287, DOI 10.1016/S0016-5085(98)70195-7; Bresalier RS, 1997, CANCER, V80, P776; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; COWLES EA, 1990, J BIOL CHEM, V265, P17706; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Dudas SP, 2000, GASTROENTEROLOGY, V118, pA273, DOI 10.1016/S0016-5085(00)83173-X; Dyer KD, 1997, GENOMICS, V40, P217, DOI 10.1006/geno.1996.4590; FRIGERI LG, 1993, BIOCHEMISTRY-US, V32, P7644, DOI 10.1021/bi00081a007; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; Gong HC, 1999, CANCER RES, V59, P6239; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HAMANN KK, 1991, EXP CELL RES, V196, P82, DOI 10.1016/0014-4827(91)90458-7; HERRMANN J, 1993, J BIOL CHEM, V268, P26704; HSU DK, 1992, J BIOL CHEM, V267, P14167; HUFLEJT ME, 1993, J BIOL CHEM, V268, P26712; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; INOHARA H, 1994, BIOCHEM BIOPH RES CO, V201, P1366, DOI 10.1006/bbrc.1994.1854; INOHARA H, 1995, CANCER RES, V55, P3267; IRIMURA T, 1991, CANCER RES, V51, P387; JIA SH, 1988, J BIOL CHEM, V263, P6009; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; Kuwabara I, 1996, J IMMUNOL, V156, P3939; LIU FT, 1995, AM J PATHOL, V147, P1016; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; MEHUL B, 1994, J BIOL CHEM, V269, P18250; MORSA SM, 1993, BIOCHEMISTRY-US, V32, P260; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; Nakamura M, 1999, INT J ONCOL, V15, P143; NANGIAMAKKER P, 1995, INT J ONCOL, V7, P1079; OCHIENG J, 1992, BIOCHEM BIOPH RES CO, V186, P1674, DOI 10.1016/S0006-291X(05)81601-8; OCHIENG J, 1993, BIOCHEMISTRY-US, V32, P4455, DOI 10.1021/bi00067a038; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; RAZ A, 1991, CANCER RES, V51, P2173; RAZ A, 1986, CANCER RES, V46, P3367; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; SCHOEPPNER HL, 1995, CANCER, V75, P2818, DOI 10.1002/1097-0142(19950615)75:12<2818::AID-CNCR2820751206>3.0.CO;2-#; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TRUONG MJ, 1993, J EXP MED, V177, P243, DOI 10.1084/jem.177.1.243; VASS PG, 1994, GLYCOCONJ J, V11, P353; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; YAMAOKA A, 1995, J IMMUNOL, V154, P3479; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yoshida M, 1998, J IMMUNOL, V161, P933; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; ZUBERI RI, 1994, CELL IMMUNOL, V156, P1, DOI 10.1006/cimm.1994.1148	55	98	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36311	36315		10.1074/jbc.M003831200	http://dx.doi.org/10.1074/jbc.M003831200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10961987	hybrid			2022-12-27	WOS:000165382000094
J	Xavier, GD; Varadi, A; Ainscow, EK; Rutter, GA				Xavier, GD; Varadi, A; Ainscow, EK; Rutter, GA			Regulation of gene expression by glucose in pancreatic beta-cells (MIN6) via insulin secretion and activation of phosphatidylinositol 3 '-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; UPSTREAM STIMULATORY FACTOR; ACETYL-COA CARBOXYLASE; PROTEIN-KINASE; METABOLIC-REGULATION; CA2+ CONCENTRATION; RESPONSE ELEMENT; TRANSCRIPTIONAL REGULATION; CARBOHYDRATE REGULATION; TRANSPORTER ISOFORMS	Increases in glucose concentration control the transcription of the preproinsulin (PPI) gene and several other genes in the pancreatic islet beta -cell. Although recent data have demonstrated that secreted insulin may regulate the PPT gene (Leibiger, I. B., Leibiger, B., Moede, T,, and Berggren, P, O, (1998) Mel. Cell 1, 933-938), the role of insulin in the control of other beta -cell genes is unexplored. To study the importance of insulin secretion in the regulation of the PPI and liver-type pyruvate kinase (L-PK) genes by glucose, we have used intranuclear microinjection of promoter-luciferase constructs into MING beta -cells and photon-counting imaging. The activity of each promoter was increased either by 30 (versus 3) mM glucose or by 1-20 nM insulin. These effects of insulin were not due to enhanced glucose metabolism since culture with the hormone had no impact on the stimulation of increases in intracellular ATP concentration caused by 30 mM glucose. Furthermore, the islet-specific glucokinase promoter and cellular glucokinase immunoreactivity were unaffected by 30 mM glucose or 20 nM insulin. Inhibition of insulin secretion with the Ca2+ channel blocker verapamil, the ATP-sensitive K+ channel opener diazoxide, or the alpha (2)-adrenergic agonist clonidine blocked the effects of glucose on L-PK gene transcription. Similarly, 30 mM glucose failed to induce the promoter after inhibition of phosphatidylinositol 3'-kinase activity with LY294002 and the expression of dominant negative-acting phosphatidylinositol 3'-kinase (Delta p85) or the phosphoinositide 3'-phosphatase PTEN (phosphatase and tensin homologue), LY294002 also diminished the activation of the L-PK gene caused by inhibition of 5'-AMP-activated protein kinase with anti-5'-AMP-activated protein kinase alpha2 antibodies. Conversely, stimulation of insulin secretion with 13 mM KCI or 10 muM tolbutamide strongly activated the PPI and L-PK promoters. These data indicate that, in MING beta -cells, stimulation of insulin secretion is important for the activation by glucose of L-PK as well as the PPI promoter, but does not cause increases in glucokinase gene expression or glucose metabolism.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Rutter, GA (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	g.a.rutter@bris.ac.uk		da Silva Xavier, Gabriela/0000-0002-0678-012X; Rutter, Guy/0000-0001-6360-0343	Diabetes UK [13/0004672] Funding Source: Medline	Diabetes UK(Diabetes UK)		Ainscow EK, 2000, DIABETES, V49, P1149, DOI 10.2337/diabetes.49.7.1149; Aspinwall CA, 2000, J BIOL CHEM, V275, P22331, DOI 10.1074/jbc.M909647199; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Berman HK, 1998, BIOCHEMISTRY-US, V37, P4543, DOI 10.1021/bi9726133; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUN T, 1993, J BIOL CHEM, V268, P18905; Bryan J, 1997, CURR OPIN CELL BIOL, V9, P553, DOI 10.1016/S0955-0674(97)80033-6; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Cuif MH, 1997, FEBS LETT, V417, P81, DOI 10.1016/S0014-5793(97)01260-X; CUIF MH, 1993, J BIOL CHEM, V268, P13769; deVargas LM, 1997, J BIOL CHEM, V272, P26573, DOI 10.1074/jbc.272.42.26573; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; EFRAT S, 1991, J BIOL CHEM, V266, P11141; Emmanouilidou E, 1999, CURR BIOL, V9, P915, DOI 10.1016/S0960-9822(99)80398-4; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GILON P, 1992, J BIOL CHEM, V267, P20713; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Harvey J, 2000, J BIOL CHEM, V275, P4660, DOI 10.1074/jbc.275.7.4660; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; Kahn A, 1997, BIOCHIMIE, V79, P113, DOI 10.1016/S0300-9084(97)81501-5; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; Kennedy HJ, 1999, BIOCHEM J, V342, P275, DOI 10.1042/0264-6021:3420275; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; KILO C, 1967, DIABETES, V16, P377, DOI 10.2337/diab.16.6.377; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Leclerc I, 1998, FEBS LETT, V431, P180, DOI 10.1016/S0014-5793(98)00745-5; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; LIANG Y, 1990, J BIOL CHEM, V265, P16863; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; LUO XC, 1990, NUCLEIC ACIDS RES, V18, P3249, DOI 10.1093/nar/18.11.3249; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MARIE S, 1993, J BIOL CHEM, V268, P23881; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Moriizumi S, 1998, GENE EXPRESSION, V7, P103; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Pauli-Magnus C, 2000, J PHARMACOL EXP THER, V293, P376; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; Qian J, 1999, BIOCHEM J, V341, P315, DOI 10.1042/0264-6021:3410315; Rafiq I, 2000, J BIOL CHEM, V275, P15977, DOI 10.1074/jbc.275.21.15977; Rafiq I, 1998, J BIOL CHEM, V273, P23241, DOI 10.1074/jbc.273.36.23241; Rutter CA, 2000, NEWS PHYSIOL SCI, V15, P149; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; Rutter GA, 1998, CHEM BIOL, V5, pR285, DOI 10.1016/S1074-5521(98)90287-3; Rutter GA, 1999, CURR BIOL, V9, pR443, DOI 10.1016/S0960-9822(99)80277-2; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; SHIH HM, 1994, J BIOL CHEM, V269, P9380; Su HS, 2000, J NUTR, V130, p315S, DOI 10.1093/jn/130.2.315S; Thornton C, 1998, J BIOL CHEM, V273, P12443, DOI 10.1074/jbc.273.20.12443; Tiedge M, 1999, DIABETES, V48, P514, DOI 10.2337/diabetes.48.3.514; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Webb GC, 2000, P NATL ACAD SCI USA, V97, P5773, DOI 10.1073/pnas.100126597; WELSH M, 1985, J BIOL CHEM, V260, P3590; Wu H, 1999, BIOCHEM J, V344, P813, DOI 10.1042/0264-6021:3440813; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Yamada K, 1999, BIOCHEM J, V337, P1, DOI 10.1042/0264-6021:3370001; YASUDA K, 1992, DIABETES, V41, P76, DOI 10.2337/diabetes.41.1.76; ZHANG S, 1995, J ENDOCRINOL, V147, P33, DOI 10.1677/joe.0.1470033	76	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36269	36277		10.1074/jbc.M006597200	http://dx.doi.org/10.1074/jbc.M006597200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967119	hybrid, Green Published			2022-12-27	WOS:000165382000089
J	Kim, WJ; Lee, S; Park, MS; Jang, YK; Kim, JB; Park, SD				Kim, WJ; Lee, S; Park, MS; Jang, YK; Kim, JB; Park, SD			Rad22 protein, a Rad52 homologue in Schizosaccharomyces pombe, binds to DNA double-strand breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST; RECOMBINATION; REPAIR; PATHWAYS	DNA double-strand breaks can be introduced by exogenous agents or during normal cellular processes. Genes belonging to the RAD52 epistasis group are known to repair these breaks in budding yeast. Among these genes, RAD52 plays a central role in homologous recombination and DNA double-strand break repair. Despite its importance, its mechanism of action is not yet clear. It is known, however, that the human homologue of Rad52 is capable of binding to DNA ends in vitro. Herein, we show that Rad22 protein, a Rad52 homologue in the fission yeast Schizosaccharomyces pombe, can similarly bind to DNA ends at double-strand breaks. This end-binding ability was demonstrated in vitro by electron microscopy and by protection from exonuclease attack. We also showed that Rad22 specifically binds near double-strand break associated with mating type switching in vivo by chromatin immunoprecipitation analysis. This is the first evidence that a recombinational protein directly binds to DNA double-strand breaks in vivo.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; CHA Gen Hosp, Pochon CHA Med Sch, Genet Lab, Tokyo 135081, Japan; Los Alamos Natl Lab, Div Biosci, Los Alamos, NM 87545 USA	Seoul National University (SNU); United States Department of Energy (DOE); Los Alamos National Laboratory	Park, SD (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.	sdpark@plaza.snu.ac.kr	Park, Min Sung/HCH-2207-2022; Song, Minsun/I-5701-2015	KIM, Jae Bum/0000-0003-2337-6935				Ayoub N, 1999, GENETICS, V152, P495; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Fortunato EA, 1996, MUTAT RES-DNA REPAIR, V364, P147, DOI 10.1016/S0921-8777(96)00022-5; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; Haber JE, 1999, NATURE, V398, P665, DOI 10.1038/19423; Hecht A, 1999, METHOD ENZYMOL, V304, P399; HEIM L, 1990, CURR GENET, V17, P13, DOI 10.1007/BF00313243; Kanaar R, 1998, NATURE, V391, P335, DOI 10.1038/34790; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Muris DFR, 1997, CURR GENET, V31, P248, DOI 10.1007/s002940050202; Nasim A., 1989, MOL BIOL FISSION YEA; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OSTERMANN K, 1993, NUCLEIC ACIDS RES, V21, P5940, DOI 10.1093/nar/21.25.5940; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; SCHLAKE C, 1993, MUTAT RES, V294, P59, DOI 10.1016/0921-8777(93)90058-O; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Suto K, 1999, MOL BIOL CELL, V10, P3331, DOI 10.1091/mbc.10.10.3331; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; Wilson S, 1999, NUCLEIC ACIDS RES, V27, P2655, DOI 10.1093/nar/27.13.2655; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430	28	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35607	35611		10.1074/jbc.M007060200	http://dx.doi.org/10.1074/jbc.M007060200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956666	hybrid			2022-12-27	WOS:000165422800102
J	Laser, M; Willey, CD; Jiang, WJ; Cooper, G; Menick, DR; Zile, MR; Kuppuswamy, D				Laser, M; Willey, CD; Jiang, WJ; Cooper, G; Menick, DR; Zile, MR; Kuppuswamy, D			Integrin activation and focal complex formation in cardiac hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; CELL-CYCLE PROGRESSION; ADHESION KINASE FAK; SRC FAMILY KINASES; MYOCYTES IN-VITRO; PROTEIN-KINASE; C-SRC; FIBRONECTIN RECEPTOR; TYROSINE PHOSPHORYLATION; CONTRACTILE DYSFUNCTION	Cardiac hypertrophy is characterized by both remodeling of the extracellular matrix (ECM) and hypertrophic growth of the cardiocytes. Here we show increased expression and cytoskeletal association of the ECM: proteins fibronectin and vitronectin in pressure-overloaded feline myocardium. These changes are accompanied by cytoskeletal binding and phosphorylation of focal adhesion kinase (FAK) at Tyr-397 and Tyr-925, c-Src at Tyr-416, recruitment of the adapter proteins p130(Cas), Shc, and Nck, and activation of the extracellular-regulated: kinases ERK1/2. A synthetic peptide containing the Arg-Gly-Asp (RGD) motif of fibronectin and vitronectin was used to stimulate adult feline cardiomyocytes cultured on laminin or within a type-1 collagen matrix. Whereas cardiocytes under both conditions showed RGD-stimulated ERK1/2 activation, only collagen-embedded cells exhibited cytoskeletal assembly of FAK, c-Src, Nck, and Shc. In ROD-stimulated collagen-embedded cells, FAK was phosphorylated only at Tyr-397 and; c-Src association occurred without Tyr-416 phosphorylation and p130(Cas) association. Therefore, c-Src activation is not required for its cytoskeletal binding:but may be important for additional phosphorylation of:FAK. Overall, our study suggests that multiple signaling pathways originate in pressure-overloaded heart following integrin engagement with ECM proteins, including focal complex formation and ERK1/2 activation, and many of these pathways can be activated in cardiomyocytes via RGD-stimulated integrin activation.	Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Cell Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Physiol, Charleston, SC 29425 USA; Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA; Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Kuppuswamy, D (corresponding author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Cell Biol, 114 Doughty St, Charleston, SC 29425 USA.	kuppusd@musc.edu		Willey, Christopher/0000-0001-9953-0279; Zile, Michael/0000-0001-7076-221X	NHLBI NIH HHS [HL-48788] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BLATTI SP, 1988, P NATL ACAD SCI USA, V85, P1119, DOI 10.1073/pnas.85.4.1119; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Cary LA, 1999, HISTOL HISTOPATHOL, V14, P1001, DOI 10.14670/HH-14.1001; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; COOPER G, 1973, CIRC RES, V33, P213, DOI 10.1161/01.RES.33.2.213; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Farhadian F, 1996, CARDIOVASC RES, V32, P433, DOI 10.1016/S0008-6363(96)00119-8; Fassler R, 1996, J CELL SCI, V109, P2989; FRANCIS GS, 1994, CURR OPIN CARDIOL, V9, P280, DOI 10.1097/00001573-199405000-00004; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Green LJ, 1998, INT J BIOCHEM CELL B, V30, P179, DOI 10.1016/S1357-2725(97)00107-6; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Hefti MA, 1997, J MOL CELL CARDIOL, V29, P2873, DOI 10.1006/jmcc.1997.0523; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Jaffe R, 1997, ADV EXP MED BIOL, V430, P257; Kasi VS, 1999, MOL CELL BIOL, V19, P6858; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; Laser M, 1998, J BIOL CHEM, V273, P24610, DOI 10.1074/jbc.273.38.24610; LASER M, 2000, HYPERTROPHIED HEART, P143; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; MANN DL, 1991, CIRC RES, V68, P402, DOI 10.1161/01.RES.68.2.402; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MULLER JG, 1998, SCIENCE, V282, pA1007; Nagai T, 1999, AM J CARDIOL, V83, p38H; Ogawa E, 2000, J MOL CELL CARDIOL, V32, P765, DOI 10.1006/jmcc.2000.1119; Page C, 1996, MOL CELL BIOCHEM, V157, P49; Pasqualini R, 1996, BRAZ J MED BIOL RES, V29, P1151; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Ross RS, 1998, CIRC RES, V82, P1160, DOI 10.1161/01.RES.82.11.1160; ROZICH JD, 1995, J MOL CELL CARDIOL, V27, P485, DOI 10.1016/S0022-2828(08)80044-2; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYSECK RP, 1989, EXP CELL RES, V180, P537, DOI 10.1016/0014-4827(89)90080-3; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SAMUEL JL, 1991, J CLIN INVEST, V88, P1737, DOI 10.1172/JCI115492; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; Sieg DJ, 1999, J CELL SCI, V112, P2677; Smilenov LB, 1999, SCIENCE, V286, P1172, DOI 10.1126/science.286.5442.1172; TSUTSUI H, 1993, SCIENCE, V260, P682, DOI 10.1126/science.8097594; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yang JT, 1996, MOL BIOL CELL, V7, P1737, DOI 10.1091/mbc.7.11.1737; YAZAKI Y, 1992, BASIC RES CARDIOL, V87, P11; Zou YZ, 1998, CIRC RES, V82, P337, DOI 10.1161/01.RES.82.3.337	59	101	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35624	35630		10.1074/jbc.M006124200	http://dx.doi.org/10.1074/jbc.M006124200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10958798	hybrid			2022-12-27	WOS:000165422800105
J	Santra, M; Eichstetter, I; Iozzo, RV				Santra, M; Eichstetter, I; Iozzo, RV			An anti-oncogenic role for decorin - Down-regulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH PROTEOGLYCANS; DROSOPHILA EGF RECEPTOR; HUMAN-BREAST-CANCER; GENE-EXPRESSION; SULFATE PROTEOGLYCAN; NEU PROTOONCOGENE; SIGNALING NETWORK; FAMILY; ACTIVATION; LIGAND	The leucine-rich proteoglycan decorin interacts with the epidermal growth factor receptor and triggers a signaling pathway that leads to growth suppression. We find that decorin causes a functional inactivation of the oncogenic ErbB2 protein in breast carcinoma cells. Upon de novo expression of decorin, the ErbB2 protein is reduced by similar to 40%, whereas its degree of tyrosyl phosphorylation is almost completely abrogated. Both co-culture experiments or experiments with recombinant decorin demonstrate an initial induction of ErbB2 tyrosine kinase, followed by a profound and long-lasting downregulation of its activity. This leads to growth inhibition and cytodifferentiation of mammary tumor cells and a concurrent suppression of their tumorigenic potential in vivo. These decorin-mediated effects appear to involve the activation of ErbB4, which in turn would block the phosphorylation of heterodimers containing either ErbB2 or ErbB3. These results provide an explanation for the heightened decorin levels around invasive carcinomas and suggest that decorin may function as a natural antagonist of neoplastic cells enriched in ErbB2.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Cellular Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Signaling Program, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Kimmel Canc Ctr, Rm 249,JAH,1020 Locust St, Philadelphia, PA 19107 USA.	iozzo@lac.jci.tju.edu	Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [CA39481, CA47282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADANY R, 1990, J BIOL CHEM, V265, P11389; ALIMANDI M, 1995, ONCOGENE, V10, P1813; ASUNDI VK, 1992, EUR J CELL BIOL, V59, P314; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Cohen BM, 1996, J BIOL CHEM, V271, P4813; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; KAHARI VM, 1995, J INVEST DERMATOL, V104, P503, DOI 10.1111/1523-1747.ep12605969; KIBBEY MC, 1992, J NATL CANCER I, V84, P1633, DOI 10.1093/jnci/84.21.1633; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Komurasaki T, 1997, ONCOGENE, V15, P2841, DOI 10.1038/sj.onc.1201458; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KRESSE H, 1993, EXPERIENTIA, V49, P403, DOI 10.1007/BF01923585; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Leevers SJ, 1999, NAT CELL BIOL, V1, pE10, DOI 10.1038/8969; MANN DM, 1990, J BIOL CHEM, V265, P5317; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; Musacchio M, 1996, DEV BIOL, V178, P63, DOI 10.1006/dbio.1996.0198; Nash MA, 1999, CANCER RES, V59, P6192; Neame P. J., 2000, PROTEOGLYCANS STRUCT, P201; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Stander M, 1999, CELL TISSUE RES, V296, P221, DOI 10.1007/s004410051283; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; Zhang K, 1996, J BIOL CHEM, V271, P3884	67	167	182	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35153	35161		10.1074/jbc.M006821200	http://dx.doi.org/10.1074/jbc.M006821200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10942781	hybrid			2022-12-27	WOS:000165422800045
J	Thompson, JE; Fahnestock, S; Farrall, L; Liao, DI; Valent, B; Jordan, DB				Thompson, JE; Fahnestock, S; Farrall, L; Liao, DI; Valent, B; Jordan, DB			The second naphthol reductase of fungal melanin biosynthesis in Magnaporthe grisea - Tetrahydroxynaphthalene reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCYTALONE DEHYDRATASE INHIBITORS; RICE BLAST FUNGICIDES; ACTIVE-SITE; 1,3,8-TRIHYDROXYNAPHTHALENE REDUCTASE; CRYSTAL-STRUCTURE; COMPLEX; DESIGN; MUTAGENESIS; PENETRATION; RESOLUTION	Mutants of Magnaporthe grisea harboring a defective gene for 1,3,8-trihydroxynaphthalene reductase retain the capability to produce scytalone, thus suggesting the existence of a second naphthol reductase that can catalyze the reduction of 1,3,6,8-tetrahydroxynaphthalene to scytalone within the fungal melanin biosynthetic pathway. The second naphthol reductase gene was cloned from M. grisea by identification of cDNA fragments with weak homology to the cDNA of trihydroxynaphthalene reductase. The amino acid sequence for the second naphthol reductase is 46% identical to that of trihydroxynaphthalene reductase. The second naphthol reductase was produced in Esherichia coli and purified to homogeneity. Substrate competition experiments indicate that the second reductase prefers tetrahydroxynaphthalene over trihydroxynaphthalene by a factor of 310; trihydroxynaphthalene reductase prefers trihydroxynaphthalene over tetrahydroxynaphthalene by a factor of 4.2. On the basis of the 1300-fold difference in substrate specificities between the two reductases, the second reductase is designated tetrahydroxynaphthalene reductase, Tetrahydroxynaphthalene reductase has a 200-fold larger K-i for the fungicide tricyclazole than that of trihydroxynaphthalene reductase, and this accounts for the latter enzyme being the primary physiological target of the fungicide. M. grisea mutants lacking activities for both trihydroxynaphthalene and tetrahydroxynaphthalene reductases do not produce scytalone, indicating that there are no other metabolic routes to scytalone.	Dupont Merck Pharmaceut Co, Expt Stn, Wilmington, DE 19880 USA; DuPont Agr Prod, Wilmington, DE 19880 USA; Dupont Co, Cent Res & Dev, Wilmington, DE 19880 USA; DuPont Agr Prod, Stine Haskell Res Ctr, Newark, DE 19714 USA	DuPont; DuPont; DuPont; DuPont	Jordan, DB (corresponding author), Dupont Merck Pharmaceut Co, Expt Stn, Rt 141 & Henry Clay Rd, Wilmington, DE 19880 USA.			Valent, Barbara/0000-0002-5088-3345				Andersson A, 1996, PROTEINS, V24, P525, DOI 10.1002/(SICI)1097-0134(199604)24:4<525::AID-PROT14>3.0.CO;2-N; Andersson A, 1997, FEBS LETT, V400, P173, DOI 10.1016/S0014-5793(96)01382-8; Andersson A, 1996, STRUCTURE, V4, P1161, DOI 10.1016/S0969-2126(96)00124-4; Basarab GS, 1999, BIOORG MED CHEM LETT, V9, P1613, DOI 10.1016/S0960-894X(99)00247-4; Basarab GS, 1999, BIOCHEMISTRY-US, V38, P6012, DOI 10.1021/bi982952b; Bechinger C, 1999, SCIENCE, V285, P1896, DOI 10.1126/science.285.5435.1896; BELL AA, 1986, ANNU REV PHYTOPATHOL, V24, P411, DOI 10.1146/annurev.py.24.090186.002211; Chen JM, 1998, BIOCHEMISTRY-US, V37, P17735, DOI 10.1021/bi981848r; CHUMLEY FG, 1990, MOL PLANT MICROBE IN, V3, P135, DOI 10.1094/MPMI-3-135; FERSHT A, 1984, ENZYME STRUCTURE MEC, P109; Guncar G, 1998, STRUCTURE, V6, P51; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOWARD RJ, 1989, EXP MYCOL, V13, P403, DOI 10.1016/0147-5975(89)90036-4; Howard RJ, 1996, ANNU REV MICROBIOL, V50, P491, DOI 10.1146/annurev.micro.50.1.491; ISHIDA M, 1975, NOYAKU KAGAKU, V3, P10; Jennings LD, 1999, BIOORG MED CHEM LETT, V9, P2509, DOI 10.1016/S0960-894X(99)00424-2; Jordan DB, 2000, BIOCHEMISTRY-US, V39, P8593, DOI 10.1021/bi000467m; Jordan DB, 2000, BIOCHEMISTRY-US, V39, P2276, DOI 10.1021/bi991839y; Jordan DB, 1999, BIOORG MED CHEM LETT, V9, P1607, DOI 10.1016/S0960-894X(99)00246-2; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Jornvall H, 1999, FEBS LETT, V445, P261, DOI 10.1016/S0014-5793(99)00130-1; Kurahashi Y, 1997, J PESTIC SCI, V22, P108; Liao DI, 2000, BIOORG MED CHEM LETT, V10, P491, DOI 10.1016/S0960-894X(00)00037-8; MINOR W, 1993, BIOCHEMISTRY-US, V32, P6320, DOI 10.1021/bi00076a003; Nakasako M, 1998, BIOCHEMISTRY-US, V37, P9931, DOI 10.1021/bi980321b; PERRY KM, 1993, BIOCHEMISTRY-US, V32, P7116, DOI 10.1021/bi00079a007; SAMBROOK J, 1989, MOL CLONGING LAB MAN; SCHONER BE, 1990, METHOD ENZYMOL, V185, P94; Sweigard JA, 1998, MOL PLANT MICROBE IN, V11, P404, DOI 10.1094/MPMI.1998.11.5.404; Thompson JE, 1998, ANAL BIOCHEM, V256, P7, DOI 10.1006/abio.1997.2490; Thompson JE, 1997, BIOCHEMISTRY-US, V36, P1852, DOI 10.1021/bi962355u; Thompson JE, 1998, ANAL BIOCHEM, V256, P1, DOI 10.1006/abio.1997.2489; TOKOUSBALIDES MC, 1978, PESTIC BIOCHEM PHYS, V8, P26, DOI 10.1016/0048-3575(78)90089-5; Tsuji G, 1997, PESTIC BIOCHEM PHYS, V57, P211, DOI 10.1006/pest.1997.2272; VIDALCROS A, 1994, EUR J BIOCHEM, V219, P985, DOI 10.1111/j.1432-1033.1994.tb18581.x; VIVIANI F, 1992, NEW J CHEM, V16, P81; VIVIANI F, 1993, B SOC CHIM FR, V136, P395; VOET D, 1995, BIOCHEMISTRY-US, P617; Ward WHJ, 1999, BIOCHEMISTRY-US, V38, P12514, DOI 10.1021/bi9907779; Wawrzak Z, 1999, PROTEINS, V35, P425, DOI 10.1002/(SICI)1097-0134(19990601)35:4<425::AID-PROT6>3.3.CO;2-T; WOLOSHUK CP, 1981, PESTIC SCI, V12, P86, DOI 10.1002/ps.2780120113; YASUEDA H, 1991, APPL MICROBIOL BIOT, V36, P211, DOI 10.1007/BF00164422	42	113	124	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34867	34872		10.1074/jbc.M006659200	http://dx.doi.org/10.1074/jbc.M006659200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956664	hybrid			2022-12-27	WOS:000165422800008
J	Wu, YM; Bressette, D; Carrell, JA; Kaufman, T; Feng, P; Taylor, K; Gan, YX; Cho, YH; Garcia, AD; Gollatz, E; Dimke, D; LaFleur, D; Migone, TS; Nardelli, B; Wei, P; Ruben, SM; Ullrich, SJ; Olsen, HS; Kanakaraj, P; Moore, PA; Baker, KP				Wu, YM; Bressette, D; Carrell, JA; Kaufman, T; Feng, P; Taylor, K; Gan, YX; Cho, YH; Garcia, AD; Gollatz, E; Dimke, D; LaFleur, D; Migone, TS; Nardelli, B; Wei, P; Ruben, SM; Ullrich, SJ; Olsen, HS; Kanakaraj, P; Moore, PA; Baker, KP			Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPESVIRUS ENTRY MEDIATOR; CELL-GROWTH; KAPPA-B; LIGAND; IDENTIFICATION; ACTIVATION; DOMAIN; BAFF	An expression cloning approach was employed to identify the receptor for B-lymphocyte stimulator (BLyS) and identified the tumor necrosis factor receptor superfamily member TACI as a BLyS-binding protein. Expression of TACI in HEK293T cells confers on the cells the ability to bind BLyS with subnanomolar affinity. Furthermore, a TACI-Fc fusion protein recognizes both the cleaved, soluble form of BLyS as well as the membrane BLyS present on the cell surface of a recombinant cell line. TACI mRNA is found predominantly in B-cells and correlates with BLyS binding in a panel of B-cell lines. We: also demonstrate that TACI interacts with nanomolar affinity with the BLyS-related tumor necrosis factor homologue APRIL for which no clear in vivo role has been described. BLyS and APRIL are capable of signaling through TACI to mediate NF-KB responses in HEK293 cells. We conclude that TACI is a receptor for BLS S and APRIL and discuss the implications for B-cell biology.	Human Genome Sci Inc, Dept Mol Biol, Rockville, MD 20850 USA; Human Genome Sci Inc, Dept Cell Biol, Rockville, MD 20850 USA; Human Genome Sci Inc, Dept Gene Discovery, Rockville, MD 20850 USA; Human Genome Sci Inc, Dept Prot Dev, Rockville, MD 20850 USA	GlaxoSmithKline; Human Genome Sciences Inc; GlaxoSmithKline; Human Genome Sciences Inc; GlaxoSmithKline; Human Genome Sciences Inc; GlaxoSmithKline; Human Genome Sciences Inc	Baker, KP (corresponding author), Human Genome Sci Inc, Dept Mol Biol, Rockville, MD 20850 USA.	kevin_baker@hgsi.com						Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Gross JA, 2000, NATURE, V404, P995, DOI 10.1038/35010115; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; Harrop JA, 1998, J BIOL CHEM, V273, P27548, DOI 10.1074/jbc.273.42.27548; KANAKARAJ P, 2000, IN PRESS CYTOKINE; Kelly K, 2000, CANCER RES, V60, P1021; Khare SD, 2000, P NATL ACAD SCI USA, V97, P3370, DOI 10.1073/pnas.050580697; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; Madry C, 1998, INT IMMUNOL, V10, P1693, DOI 10.1093/intimm/10.11.1693; Marsters SA, 2000, CURR BIOL, V10, P785, DOI 10.1016/S0960-9822(00)00566-2; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Moore PA, 1999, SCIENCE, V285, P260, DOI 10.1126/science.285.5425.260; Mukhopadhyay A, 1999, J BIOL CHEM, V274, P15978, DOI 10.1074/jbc.274.23.15978; PACHOLCZYK T, 1990, BIOTECHNIQUES, V9, P556; Pan GH, 1998, FEBS LETT, V431, P351, DOI 10.1016/S0014-5793(98)00791-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Shu HB, 2000, P NATL ACAD SCI USA, V97, P9156, DOI 10.1073/pnas.160213497; Shu HB, 1999, J LEUKOCYTE BIOL, V65, P680, DOI 10.1002/jlb.65.5.680; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; Tribouley C, 1999, BIOL CHEM, V380, P1443, DOI 10.1515/BC.1999.186; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; WALLACH D, 1999, CYTOKINE NETWORK IMM, P51; Ware Carl F., 1998, P549; Ware CF, 2000, NATURE, V404, P949, DOI 10.1038/35010263; Xia XZ, 2000, J EXP MED, V192, P137, DOI 10.1084/jem.192.1.137; Yan MH, 2000, NAT IMMUNOL, V1, P37, DOI 10.1038/76889	31	196	243	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35478	35485		10.1074/jbc.M005224200	http://dx.doi.org/10.1074/jbc.M005224200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956646	hybrid			2022-12-27	WOS:000165422800085
J	Foster, W; Helm, A; Turnbull, I; Gulati, H; Yang, BX; Verkman, AS; Skach, WR				Foster, W; Helm, A; Turnbull, I; Gulati, H; Yang, BX; Verkman, AS; Skach, WR			Identification of sequence determinants that direct different intracellular folding pathways for aquaporin-1 and aquaporin-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; TRANSMEMBRANE CONDUCTANCE REGULATOR; STOP-TRANSFER SEQUENCE; CHIP28 WATER CHANNELS; HUMAN P-GLYCOPROTEIN; PROTEIN TRANSLOCATION; SIGNAL SEQUENCE; ER MEMBRANE; STRUCTURAL REQUIREMENTS; SECRETORY PROTEINS	Homologous aquaporin water channels utilize different folding pathways to acquire their transmembrane (TM) topology in the endoplasmic reticulum (ER), AQP4 acquires each of its six TM segments via cotranslational translocation events, whereas AQP1 is initially synthesized with four TM segments and subsequently converted into a six membrane-spanning topology, To identify sequence determinants responsible for these pathways, peptide segments from AQP1 and AQP4 were systematically exchanged, Chimeric proteins were then truncated, fused to a C-terminal translocation reporter, and topology was analyzed by protease accessibility. In each chimeric context, TM1 initiated ER targeting and translocation, However, AQP4-TM2 cotranslationally terminated translocation, while AQP1-TM2 failed to terminate translocation and passed into the ER lumen, This difference in stop transfer activity was due to two residues that altered both the length and hydrophobicity of TM2 (Asn(49) and Lys(51) in AQP1 versus Met(48) and Leu(50) in AQP4), A second peptide region was identified within the TM3-4 peptide loop that enabled AQP4-TM3 but not AQP1-TM3 to reinitiate translocation and cotranslationally span the membrane. Based on these findings, it was possible to convert AQP1 into a cotranslational biogenesis mode similar to that of AQP4 by substituting just two peptide regions at the N terminus of TM2 and the C terminus of TM3, Interestingly, each of these substitutions disrupted water channel activity. These data thus establish the structural basis for different AQP folding pathways and provide evidence that variations in cotranslational folding enable polytopic proteins to acquire and/or maintain primary sequence determinants necessary for function.	Oregon Hlth Sci Univ, Div Mol Med, Portland, OR 97201 USA; Univ Calif San Francisco, Cardiovasc Res Unit, San Francisco, CA 94143 USA	Oregon Health & Science University; University of California System; University of California San Francisco	Skach, WR (corresponding author), Oregon Hlth Sci Univ, Div Mol Med, 3181 SW San Jackson Pk Rd, Portland, OR 97201 USA.			Foster, William/0000-0002-5594-0791	NIDDK NIH HHS [DK51818] Funding Source: Medline; NIGMS NIH HHS [GM53457] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051818] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; Bayle D, 1997, J BIOL CHEM, V272, P19697, DOI 10.1074/jbc.272.32.19697; Beguin P, 2000, MOL BIOL CELL, V11, P1657, DOI 10.1091/mbc.11.5.1657; BIBI E, 1992, P NATL ACAD SCI USA, V89, P3180, DOI 10.1073/pnas.89.8.3180; Bibi E, 1998, TRENDS BIOCHEM SCI, V23, P51, DOI 10.1016/S0968-0004(97)01134-1; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BROWN D, 1995, HISTOCHEM CELL BIOL, V104, P1, DOI 10.1007/BF01464780; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Frokiaer J, 1998, AM J MED SCI, V316, P291; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hegde RS, 1999, TRENDS CELL BIOL, V9, P132, DOI 10.1016/S0962-8924(99)01504-4; Hegde RS, 1998, CELL, V92, P621, DOI 10.1016/S0092-8674(00)81130-7; HO NS, 1989, GENE, V77, P51; Johnson AE, 1997, TRENDS CELL BIOL, V7, P90, DOI 10.1016/S0962-8924(97)01029-5; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; Kuroiwa T, 1996, J BIOL CHEM, V271, P6423, DOI 10.1074/jbc.271.11.6423; KUROIWA T, 1990, J BIOCHEM, V108, P829, DOI 10.1093/oxfordjournals.jbchem.a123288; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; Lu Y, 2000, MOL BIOL CELL, V11, P2973, DOI 10.1091/mbc.11.9.2973; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Moss K, 1998, MOL BIOL CELL, V9, P2681, DOI 10.1091/mbc.9.9.2681; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Murphy EC, 1997, J CELL BIOL, V136, P1213, DOI 10.1083/jcb.136.6.1213; Nielsen S, 1999, J AM SOC NEPHROL, V10, P647; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; SHI LB, 1995, BIOCHEMISTRY-US, V34, P8250, DOI 10.1021/bi00026a006; SHI LB, 1994, J BIOL CHEM, V269, P10417; Skach WR, 1998, METHOD ENZYMOL, V292, P265; SKACH WR, 1994, CANCER RES, V54, P3202; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SMITH BL, 1991, J BIOL CHEM, V266, P6407; Tector M, 1999, EMBO J, V18, P6290, DOI 10.1093/emboj/18.22.6290; Verbavatz JM, 1997, J CELL SCI, V110, P2855; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; Verkman AS, 1996, AM J PHYSIOL-CELL PH, V270, pC12, DOI 10.1152/ajpcell.1996.270.1.C12; Verkman AS, 1998, AM J MED SCI, V316, P310, DOI 10.1097/00000441-199811000-00004; WALTER P, 1983, METHOD ENZYMOL, V96, P4; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563; Xiong XM, 1997, J CLIN INVEST, V100, P1079, DOI 10.1172/JCI119618; Yang BX, 1996, J BIOL CHEM, V271, P4577; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; Zhang JT, 1996, MOL BIOL CELL, V7, P1709, DOI 10.1091/mbc.7.11.1709; Zhang JT, 1998, MOL BIOL CELL, V9, P853, DOI 10.1091/mbc.9.4.853; Zhang JT, 1996, MOL BIOL CELL, V7, P471, DOI 10.1091/mbc.7.3.471; ZHANG R, 1991, AM J PHYSIOL, V260, P26	70	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34157	34165		10.1074/jbc.M000165200	http://dx.doi.org/10.1074/jbc.M000165200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944517	hybrid			2022-12-27	WOS:000165095300024
J	Hua, XX; Miller, ZA; Benchabane, H; Wrana, JL; Lodish, HF				Hua, XX; Miller, ZA; Benchabane, H; Wrana, JL; Lodish, HF			Synergism between transcription factors TFE3 and Smad3 in transforming growth factor-beta-induced transcription of the Smad7 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR-1 GENE; TGF-BETA; PROTEINS; COOPERATION; PROMOTER; COACTIVATOR; ANTAGONIST; RESPONSES; RECEPTOR; FAST-1	Activation of transforming growth factor-beta (TGF-beta) receptors triggers phosphorylation of Smad2 and Smad3. After binding to Smad4, the complex enters the nucleus and interacts with other transcription factors to activate gene transcription. Unlike other Smads, Smad7 inhibits phosphorylation of Smad2 and Smad3, and its transcription is induced by TGF-beta, suggesting a negative feedback loop. Here, we show that TFE3 and Smad3 synergistically mediate TGF-beta -induced transcription from the Smad7 promoter by binding to an E-box and two adjacent Smad binding elements (SBEs ), respectively. A precise 3-base pair spacer between one SEE and the E-box is essential. Previously, me showed that a similar arrangement between a SEE and an E-box of an element is essential for TGF-beta -dependent transcription of the plasminogen activator inhibitor-1 gene (PAI-1) and that TGF-beta -induced phosphorylation of Smad3 triggers its association with TFE3. Thus, TFE3-Smad3 response elements may represent a common target for TGF-beta -induced gene expression.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lodish@wi.mit.edu	Wrana, Jeffrey/F-8857-2013		NATIONAL CANCER INSTITUTE [R01CA063260, K01CA078592] Funding Source: NIH RePORTER; NCI NIH HHS [CA78592-02, CA63260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Sambrook J, 1989, MOL CLONING; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Stopa M, 2000, MAMM GENOME, V11, P169, DOI 10.1007/s003350010032; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Wong C, 1999, MOL CELL BIOL, V19, P1821; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	31	57	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33205	33208		10.1074/jbc.C000568200	http://dx.doi.org/10.1074/jbc.C000568200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10973944	hybrid			2022-12-27	WOS:000090104600006
J	Barberis, L; Wary, KK; Fiucci, G; Liu, F; Hirsch, E; Brancaccio, M; Altruda, F; Tarone, G; Giancotti, FG				Barberis, L; Wary, KK; Fiucci, G; Liu, F; Hirsch, E; Brancaccio, M; Altruda, F; Tarone, G; Giancotti, FG			Distinct roles of the adaptor protein Shc and focal adhesion kinase in integrin signaling to ERK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CELL-ADHESION; JUN NH2-TERMINAL KINASE; MAP KINASE; TYROSINE PHOSPHORYLATION; C-SRC; B-RAF; GROWTH-FACTOR; ACTIVATION; FIBRONECTIN; PATHWAYS	It has been proposed that integrins activate ERK through the adaptor protein She independently of focal adhesion kinase (FAK) or through FAK acting on multiple target effecters, including She. We show that disrupt ion of the actin cytoskeleton by cytochalasin D causes a complete inhibition of FAK. but does not inhibit She signaling and activation of ERK. We have then generated primary fibroblasts carrying a targeted deletion of the segment of beta (1) subunit cytoplasmic domain required for activation of FAK Analysis of these cells indicates that FAK is not necessary for efficient tyrosine phosphorylation of She, association of She with Grb2, and activation of ERK in response to matrix adhesion. In addition, integrin-mediated activation of FAK does not appear to be required for signaling to ERK following growth factor stimulation. To examine if FAK could contribute to the activation of ERK in a cell type-specific manner through the Rap1/B-Raf pathway, we have used Swiss-3T3 cells, which in contrast to primary fibroblasts express B-Raf. Dominant negative studies indicate that She mediates the early phase and peak, whereas FAK, p130(CAS), Crk, and Rap1 contribute to the late phase of integrin-dependent activation of ERK in these cells. In addition, introduction of B-Raf enhances and sustains integrin-mediated activation of ERK in wild-type primary fibroblasts but not in those carrying the targeted deletion of the beta (1) cytoplasmic domain. Thus, the She and FAK pathways are activated independently and function in a parallel fashion. Although not necessary for signaling to ERK in primary fibroblasts, FAH may enhance and prolong integrin-mediated activation of ERK through p130(CAS), Crk, and Rap1 in cells expressing B-Raf.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Turin, Dipartimento Genet Biol & Chim Med, I-10100 Turin, Italy	Memorial Sloan Kettering Cancer Center; University of Turin	Giancotti, FG (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave,Box 216, New York, NY 10021 USA.	F-Giancotti@ski.mskcc.org	Hirsch, Emilio/F-4848-2013	Hirsch, Emilio/0000-0002-9073-6024; Tarone, Guido/0000-0003-4805-086X; Wary, Kishore/0000-0001-8851-8565	NCI NIH HHS [P30 CA08748, R01 CA78901] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078901, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; Buensuceso CS, 2000, J BIOL CHEM, V275, P13118, DOI 10.1074/jbc.275.17.13118; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Clark EA, 1997, BBA-REV CANCER, V1333, pR9, DOI 10.1016/S0304-419X(97)00028-0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; de Jong R, 1998, ONCOGENE, V17, P2805, DOI 10.1038/sj.onc.1202207; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Igishi T, 1999, J BIOL CHEM, V274, P30738, DOI 10.1074/jbc.274.43.30738; ILLC D, 1995, NATURE, V377, P539; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lai KMV, 2000, GENE DEV, V14, P1132; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lock P, 1998, EMBO J, V17, P4346, DOI 10.1093/emboj/17.15.4346; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Pozzi M, 1998, J CELL BIOL, V142, P587; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Retta SF, 1999, METH MOL B, V96, P119; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; Syu LJ, 1997, J CELL BIOCHEM, V67, P367, DOI 10.1002/(SICI)1097-4644(19971201)67:3<367::AID-JCB8>3.3.CO;2-N; Tomatis D, 1999, EXP CELL RES, V246, P421, DOI 10.1006/excr.1998.4315; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	64	148	151	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36532	36540		10.1074/jbc.M002487200	http://dx.doi.org/10.1074/jbc.M002487200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10976102	hybrid			2022-12-27	WOS:000165577700012
J	Stewart, RJ; Fredenburgh, JC; Rischke, JA; Bajzar, L; Weitz, JI				Stewart, RJ; Fredenburgh, JC; Rischke, JA; Bajzar, L; Weitz, JI			Thrombin-activable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator - A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA CARBOXYPEPTIDASE; LYS-PLASMINOGEN; FACTOR-VA; ONE-CHAIN; COMPLEX; TAFI; KINETICS; BINDING; THROMBOMODULIN; PURIFICATION	A complex of D-dimer noncovalently associated with fragment E ((DD)E), a degradation product of crosslinked fibrin that binds tissue plasminogen activator (t-PA) and plasminogen (Pg) with affinities similar to those of fibrin, compromises the fibrin specificity of t-PA by stimulating systemic Pg activation. In this study, we examined the effect of thrombin-activable fibrinolysis inhibitor (TAFI), a latent carboxypeptidase B (CPB)-like enzyme, on the stimulatory activity of (DD)E. Incubation of (DD)E with activated TAFI (TAFIa) or CPB (a) produces a 96% reduction in the capacity of (DD)E to stimulate t-PA-mediated activation of Glu- or Lys-Pg by reducing k(cat) and increasing K-m for the reaction; (b) induces the release of 8 mol of lysine/mol of (DD)E, although most of the stimulatory activity is lost after release of only 4 mol of lysine/mol (DD)E; and (c) reduces the affinity of (DD)E for Glu-Pg, Lys-Pg, and t-PA. by 2-, 4-, and 160-fold, respectively. Because TAFIa- or CPB-exposed (DD)E produces little stimulation of Glu-Pg activation by t-PA, (DD)E is not degraded into fragment E and D-dimer, the latter of which has been reported to impair fibrin polymerization. These data suggest a novel role for TAFIa. By attenuating systemic Pg activation by (DD)E, TAFIa renders t-PA more fibrin-specific.	Hamilton Civ Hosp Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Hamilton, ON L8V 1C3, Canada	McMaster University; McMaster University	Weitz, JI (corresponding author), Hamilton Civ Hosp Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.		Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Blanchoin L, 1996, J BIOL CHEM, V271, P12380, DOI 10.1074/jbc.271.21.12380; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; Boffa MB, 2000, J BIOL CHEM, V275, P12868, DOI 10.1074/jbc.275.17.12868; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BRINGMANN P, 1995, J BIOL CHEM, V270, P25596, DOI 10.1074/jbc.270.43.25596; BUDZYNSKI AZ, 1979, BIOCHIM BIOPHYS ACTA, V584, P284, DOI 10.1016/0304-4165(79)90273-3; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; COLLEN D, 1986, HAEMOSTASIS, V16, P25; DELLENBACK RJ, 1970, P SOC EXP BIOL MED, V134, P353; DEVRIES C, 1989, J BIOL CHEM, V264, P12604; EATON DL, 1991, J BIOL CHEM, V266, P21833; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; FREDENBURGH JC, 1992, J BIOL CHEM, V267, P26150; GAEDE G, 1974, ANAL BIOCHEM, V66, P393; GAFFNEY PJ, 1979, THROMB RES, V15, P673, DOI 10.1016/0049-3848(79)90177-4; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HIGGINS DL, 1986, ARCH BIOCHEM BIOPHYS, V249, P418, DOI 10.1016/0003-9861(86)90018-4; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2183; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; HUSAIN SS, 1989, J BIOL CHEM, V264, P11414; Marx PF, 2000, J BIOL CHEM, V275, P12410, DOI 10.1074/jbc.275.17.12410; Mosesson MW, 1998, THROMB HAEMOSTASIS, V79, P796; MOSKOWITZ KA, 1994, BIOCHEMISTRY-US, V33, P12937, DOI 10.1021/bi00248a001; NAKATANI Y, 1972, ANAL BIOCHEM, V49, P225, DOI 10.1016/0003-2697(72)90261-8; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; Nesheim ME, 1999, FIBRINOLYSIS PROTEOL, V13, P72, DOI 10.1016/S0268-9499(99)90082-6; NIEUWENHUIZEN W, 1988, EUR J BIOCHEM, V174, P163, DOI 10.1111/j.1432-1033.1988.tb14077.x; OLEXA SA, 1979, BIOCHEMISTRY-US, V18, P991, DOI 10.1021/bi00573a009; OLEXA SA, 1979, J BIOL CHEM, V254, P4925; OLEXA SA, 1981, BIOCHEMISTRY-US, V20, P6139, DOI 10.1021/bi00524a035; OLEXA SA, 1980, P NATL ACAD SCI-BIOL, V77, P1374, DOI 10.1073/pnas.77.3.1374; RYAN CA, 1974, J BIOL CHEM, V249, P5495; Sakharov DV, 1997, J BIOL CHEM, V272, P14477, DOI 10.1074/jbc.272.22.14477; Stewart R. J., 1998, Blood Coagulation and Fibrinolysis, V9, P691, DOI 10.1097/00001721-199810000-00065; Stewart RJ, 2000, J BIOL CHEM, V275, P10112, DOI 10.1074/jbc.275.14.10112; Stewart RJ, 1998, J BIOL CHEM, V273, P18292, DOI 10.1074/jbc.273.29.18292; Walker JB, 1999, J BIOL CHEM, V274, P5201, DOI 10.1074/jbc.274.8.5201; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WANG W, 1994, J BIOL CHEM, V269, P15937; Weitz JI, 1999, THROMB HAEMOSTASIS, V82, P974; WEITZ JI, 1991, J CLIN INVEST, V87, P1082, DOI 10.1172/JCI115069	44	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36612	36620		10.1074/jbc.M005483200	http://dx.doi.org/10.1074/jbc.M005483200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10970891	hybrid			2022-12-27	WOS:000165577700023
J	Yin, L; Hubbard, AK; Giardina, C				Yin, L; Hubbard, AK; Giardina, C			NF-kappa B regulates transcription of the mouse telomerase catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE; C-MYC; GENE; PROMOTER; CANCER; CELLS; PROLIFERATION; EXPRESSION; PROTEINS; RECEPTOR	Expression of the telomerase catalytic subunit (TERT) is the rate-limiting determinant of telomerase activity in most cells. Analysis of the mouse TERT promoter revealed a potential NF-kappaB binding site 350 base pairs upstream from the translational start site. An oligonucleotide from this region of the TERT promoter bound to proteins in a nuclear extract prepared from a mouse hepatoma cell line. These proteins were identified as NF-kappaB by a number of criteria: 1) the protein complex formed on the TERT oligonucleotide had an electrophoretic mobility similar to that formed on an NF-kappaB consensus oligonucleotide; 2) protein binding to this site was enhanced by NF-kappaB activators tumor necrosis factor-alpha, phorbol 12-myristate 13-acetate, and interleukin-1 beta; and 3) the complex was specific and could be supershifted with antibodies against the p50 or p65 NF-kappaB subunits. The NF-kappaB binding site from the mouse TERT promoter activated transcription when fused to a basal SV40 promoter and enhanced the activity of the native TERT promoter in mouse hepatoma cells stimulated with phorbol 12-myristate 13-acetate. Transcriptional activation by the TERT NF-kappaB site could also be enhanced by co-transfection with an NF-kappa B1 expression vector. NF-kappaB may therefore contribute to the activation of TERT expression observed in mouse tissue.	Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA; Univ Connecticut, Dept Pharmaceut Sci, Storrs, CT 06269 USA	University of Connecticut; University of Connecticut	Giardina, C (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, 75 N Eagleville Rd,U-125, Storrs, CT 06269 USA.							Avilion AA, 1996, CANCER RES, V56, P645; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Cerni C, 2000, MUTAT RES-REV MUTAT, V462, P31, DOI 10.1016/S1383-5742(99)00091-5; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; GRILLI M, 1993, INT REV CYTOL, V143, P1; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Holt SE, 1999, J CELL PHYSIOL, V180, P10, DOI 10.1002/(SICI)1097-4652(199907)180:1<10::AID-JCP2>3.0.CO;2-D; Horikawa I, 1999, CANCER RES, V59, P826; Igarashi H, 1997, BLOOD, V89, P1299, DOI 10.1182/blood.V89.4.1299; Inan MS, 2000, GASTROENTEROLOGY, V118, P724, DOI 10.1016/S0016-5085(00)70142-9; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1999, CANCER RES, V59, P5917; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Schauer SL, 1996, J IMMUNOL, V157, P81; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Ueda M, 1997, CANCER RES, V57, P370; Ulaner GA, 1998, CANCER RES, V58, P4168; Ulaner GA, 2000, INT J CANCER, V85, P330, DOI 10.1002/(SICI)1097-0215(20000201)85:3<330::AID-IJC6>3.0.CO;2-U; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Yuan XM, 1999, GENES CELLS, V4, P563, DOI 10.1046/j.1365-2443.1999.00284.x	29	100	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36671	36675		10.1074/jbc.M007378200	http://dx.doi.org/10.1074/jbc.M007378200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10970902	hybrid			2022-12-27	WOS:000165577700032
J	Berjanskii, MV; Riley, MI; Xie, AY; Semenchenko, V; Folk, WR; Van Doren, SR				Berjanskii, MV; Riley, MI; Xie, AY; Semenchenko, V; Folk, WR; Van Doren, SR			NMR structure of the N-terminal J domain of murine polyomavirus T antigens - Implications for DnaJ-like domains and for mutations of T antigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-RESONANCE NMR; PROTEIN PHOSPHATASE 2A; ESCHERICHIA-COLI DNAJ; SIMIAN-VIRUS-40 LARGE-T; SV40 LARGE T; MIDDLE-T; SIDE-CHAIN; MOLECULAR CHAPERONES; COUPLING-CONSTANTS; CHEMICAL-SHIFTS	The NMR structure of the N-terminal, DnaJ-like domain of murine polyomavirus tumor antigens (PyJ) has been determined to high precision, with root mean square -deviations to the mean structure of 0.38 Angstrom for backbone atoms and 0.94 Angstrom for all heavy atoms of ordered residues 5-41 and 50-69, PyJ possesses a three-helix fold, in which anti-parallel helices II and III are bridged by helix I, similar to the four-helix fold of the J domains of DnaJ and human DnaJ-1. PyJ differs significantly in the lengths of N terminus, helix I, and helix III. The universally conserved HPD motif appears to form a His-Pro C-cap of helix II. Helix I features a stabilizing Schellman C-cap that is probably conserved universally among J domains. On the helix II surface where positive charges of other J domains have been implicated in binding of hsp70s, PyJ contains glutamine residues. Nonetheless, chimeras that replace the J domain of DnaJ with PyJ function like wild-type DnaJ in promoting growth of Escherichia coli. This activity can be modulated by mutations of at least one of these glutamines. T antigen mutations reported to impair cellular transformation by the virus, presumably via interactions with PP2A, cluster in the hydrophobic folding core and at the extreme N terminus, remote from the HPD loop.	Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Van Doren, SR (corresponding author), Univ Missouri, Dept Biochem, 117 Schweitzer Hall, Columbia, MO 65211 USA.		Berjanskii, Mark/AAA-1352-2022	Van Doren, Steven/0000-0003-2838-4598; Folk, William/0000-0003-2216-3233	NATIONAL CANCER INSTITUTE [R01CA038538] Funding Source: NIH RePORTER; NCI NIH HHS [CA38538] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON SGE, 1990, MICROBIOL REV, V54, P198, DOI 10.1128/MMBR.54.2.198-210.1990; Apeler H, 1997, EUR J BIOCHEM, V247, P890, DOI 10.1111/j.1432-1033.1997.t01-1-00890.x; ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; Auger I, 1997, J CLIN INVEST, V99, P1818, DOI 10.1172/JCI119348; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BOUCHER W, 1992, J AM CHEM SOC, V114, P2262, DOI 10.1021/ja00032a053; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CLOWES RT, 1993, J BIOMOL NMR, V3, P349, DOI 10.1007/BF00212520; CLUBB RT, 1992, J BIOMOL NMR, V2, P203, DOI 10.1007/BF01875531; COOK DN, 1990, J VIROL, V64, P1879, DOI 10.1128/JVI.64.5.1879-1887.1990; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; DOTSCH V, 1995, J MAGN RESON SER B, V108, P285, DOI 10.1006/jmrb.1995.1135; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; Fletcher CM, 1996, J BIOMOL NMR, V8, P292, DOI 10.1007/BF00410328; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; GRONENBORN AM, 1994, J BIOMOL NMR, V4, P455; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1995, J AM CHEM SOC, V117, P5312, DOI 10.1021/ja00124a014; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Huang K, 1999, PROTEIN SCI, V8, P203; Ivanov IG, 1997, INT J BIOCHEM CELL B, V29, P659, DOI 10.1016/S1357-2725(96)00161-6; KAY LE, 1990, J AM CHEM SOC, V112, P888, DOI 10.1021/ja00158a070; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; KELLEY WL, 1994, TRENDS BIOCHEM SCI, V19, P277, DOI 10.1016/0968-0004(94)90003-5; KIM KS, 1993, BIOCHEMISTRY-US, V32, P9600, DOI 10.1021/bi00088a012; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lemieux B, 2000, VIROLOGY, V269, P370, DOI 10.1006/viro.2000.0231; Li RH, 1999, PROTEIN SCI, V8, P1571, DOI 10.1110/ps.8.8.1571; MADSEN JC, 1993, J BIOMOL NMR, V3, P239; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; MONTELIONE GT, 1989, J AM CHEM SOC, V111, P5474, DOI 10.1021/ja00196a068; Mullane KP, 1998, MOL CELL BIOL, V18, P7556, DOI 10.1128/MCB.18.12.7556; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OLEJNICZAK ET, 1992, J MAGN RESON, V100, P444, DOI 10.1016/0022-2364(92)90280-K; PALLAS DC, 1989, J VIROL, V63, P4533, DOI 10.1128/JVI.63.11.4533-4539.1989; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PEDEN KWC, 1992, VIRUS GENES, V6, P107, DOI 10.1007/BF01703060; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; Porras A, 1996, J VIROL, V70, P6902; Prieto J, 1997, J MOL BIOL, V274, P276, DOI 10.1006/jmbi.1997.1322; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; Riley MI, 1997, J VIROL, V71, P6068, DOI 10.1128/JVI.71.8.6068-6074.1997; SAWAI ET, 1989, J VIROL, V63, P3961, DOI 10.1128/JVI.63.9.3961-3973.1989; Schuchner S, 1999, J VIROL, V73, P9266; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P79; Sheng Q, 2000, J VIROL, V74, P5280, DOI 10.1128/JVI.74.11.5280-5290.2000; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; VANDOREN SR, 1994, J MAGN RESON SER B, V104, P193, DOI 10.1006/jmrb.1994.1076; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xia XH, 1998, GENETICS, V149, P37; ZAVILDE J, 1998, MOL CELL BIOL, V18, P1408	73	31	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36094	36103		10.1074/jbc.M006572200	http://dx.doi.org/10.1074/jbc.M006572200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10950962	hybrid			2022-12-27	WOS:000165382000065
J	Jelacic, TM; Kennedy, ME; Wickman, K; Clapham, DE				Jelacic, TM; Kennedy, ME; Wickman, K; Clapham, DE			Functional and biochemical evidence for G-protein-gated inwardly rectifying K+ (GIRK) channels composed of GIRK2 and GIRK3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; RECTIFIER POTASSIUM CHANNELS; SODIUM-DEPENDENT ACTIVATION; MESSENGER-RNAS; ACH CHANNEL; RAT-BRAIN; EXPRESSION; IDENTIFICATION; LOCALIZATION; REGIONS	G-protein-gated inwardly rectifying K+ (GIRK) channels are widely expressed in the brain and are activated by at least eight different neurotransmitters. As Kt channels, they drive the transmembrane potential toward E-K when open and thus dampen neuronal excitability. There are four mammalian GIRK subunits (GIRK1-4 or Kir 3.1-4), with GIRK1 being the most unique of the four by possessing a long carboxyl-terminal tail. Early studies suggested that GIRK1 was an integral component of native GIRK channels. However, more recent data indicate that native channels can be either homo- or heterotetrameric complexes composed of several GIRK subunit combinations. The functional implications of subunit composition are poorly understood at present. The purpose of this study was to examine the functional and biochemical properties of GIRK channels formed by the co-assembly of GIRK2 and GIRK3, the most abundant GIRK subunits found in the mammalian brain. To examine the properties of a channel composed of these two subunits, we co-transfected GIRK2 and GIRK3 in CHO-K1 cells and assayed the cells for channel activity by patch clamp. The most significant difference between the putative GIRK2/GIRK3 heteromultimeric channel and GIRK1/GIRKx channels at the single channel level was an similar to5-fold lower sensitivity to activation by G beta gamma. Complexes containing only GIRK2 and GIRK3 could be immunoprecipitated from transfected cells and could be purified from native brain tissue. These data indicate that functional GIRK channels composed of GIRK2 and GIRK3 subunits exist in brain.	Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Mayo Clinic	Clapham, DE (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Enders 1309,320 Longwood Ave, Boston, MA 02115 USA.		Clapham, David/R-5974-2019; Jelacic, Tanya/S-3173-2019; Clapham, David/S-1123-2019	Jelacic, Tanya/0000-0002-1584-5300; Clapham, David/0000-0002-4459-9428; Wickman, Kevin/0000-0002-5179-9540				Chan KW, 1997, J BIOL CHEM, V272, P6548, DOI 10.1074/jbc.272.10.6548; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Chen SC, 1997, BRAIN RES, V778, P251, DOI 10.1016/S0006-8993(97)00896-2; Corey S, 1998, J BIOL CHEM, V273, P27499, DOI 10.1074/jbc.273.42.27499; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; Dissmann E, 1996, BIOCHEM BIOPH RES CO, V223, P474, DOI 10.1006/bbrc.1996.0918; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x; Ho IHM, 1999, J BIOL CHEM, V274, P8639, DOI 10.1074/jbc.274.13.8639; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Isomoto S, 1996, BIOCHEM BIOPH RES CO, V218, P286, DOI 10.1006/bbrc.1996.0050; Jelacic TM, 1999, J MEMBRANE BIOL, V169, P123, DOI 10.1007/s002329900524; Karschin C, 1996, J NEUROSCI, V16, P3559; Kennedy ME, 1996, NEUROPHARMACOLOGY, V35, P831, DOI 10.1016/0028-3908(96)00132-3; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; KOBAYASHI T, 1995, BIOCHEM BIOPH RES CO, V208, P1166, DOI 10.1006/bbrc.1995.1456; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P28777, DOI 10.1074/jbc.270.48.28777; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; Petit-Jacques J, 1999, J GEN PHYSIOL, V114, P673, DOI 10.1085/jgp.114.5.673; Schoots O, 1999, CELL SIGNAL, V11, P871, DOI 10.1016/S0898-6568(99)00059-5; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Spauschus A, 1996, J NEUROSCI, V16, P930; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; VELIMIROVIC BM, 1996, FEBS LETT, V379, P91; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Wei JJ, 1998, GENOMICS, V51, P379, DOI 10.1006/geno.1998.5369; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Wischmeyer E, 1997, MOL CELL NEUROSCI, V9, P194, DOI 10.1006/mcne.1997.0614	35	85	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36211	36216		10.1074/jbc.M007087200	http://dx.doi.org/10.1074/jbc.M007087200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10956667	hybrid			2022-12-27	WOS:000165382000080
J	Lee, KB; Ptasienski, JA; Bunemann, M; Hosey, MM				Lee, KB; Ptasienski, JA; Bunemann, M; Hosey, MM			Acidic amino acids flanking phosphorylation sites in the M-2 muscarinic receptor regulate receptor phosphorylation, internalization, and interaction with arrestins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ADRENERGIC-RECEPTOR; VISUAL ARRESTIN; BETA-ARRESTIN; ACETYLCHOLINE-RECEPTOR; CHOLINERGIC RECEPTORS; KINASE ACTIVATION; RHODOPSIN KINASE; CHICK HEART; DESENSITIZATION	The studies reported here address the molecular events underlying the interactions of arrestins with the M-2 muscarinic acetylcholine receptor (mAChR), In particular, we focused on the role of receptor phosphorylation in this process. Agonist-dependent phosphorylation of the M-2 mAChR can occur at clusters of serines and threonines at positions 286-290 (site pi) or 307-311 (site P2) in the third intracellular loop (Pals-Rylaarsdam, R,, and Hosey, M, M. (1997) J, Biol, Chem, 272, 14152-14158). Phosphorylation at either P1 or P2 can support agonist-dependent internalization. However, phosphorylation at P2 is required for receptor interaction with arrestins (Pals-Rylaarsdam, R,, Gurevich, V, V,, Lee, K. B,, Ptasienski, J, A., Benovic, J, L,, and Hosey, M, M, (1997) J, Biol, Chem. 272, 23682-26389), The present study investigated the role of acidic amino acids between P1 and P2 in regulating receptor phosphorylation, internalization, and receptor/arrestin interactions. Mutation of the acidic amino acids at positions 298-300 (site Al) and/or 304-305 (site A2) to alanines had significant effects on agonist-dependent phosphorylation, P2 was identified as the preferred site of agonist-dependent phosphorylation, and full phosphorylation at P2 required the acidic amino acids at Al or their neutral counterparts. In contrast, phosphorylation at site P1 was dependent on site A2, In addition, sites Al and A2 significantly affected the ability of the wild type and P1 and P2 mutant receptors to internalization and to interact with arrestina. Substitution of asparagine and glutamine for the aspartates and glutamates at sites Al or A2 did not influence receptor phosphorylation but did influence arrestin interaction with the receptor. We propose that the amino acids at sites Al and A2 play important roles in agonist-dependent phosphorylation at sites P2 and Fl, respectively, and also play an important role in arrestin interactions with the M-2 mAChR.	Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Evanston, IL 60208 USA; Northwestern Univ, Sch Med, Inst Neurosci, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Lee, KB (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Hogan Hall 2-100,2153 N Sheridan Rd, Evanston, IL 60208 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50121] Funding Source: Medline; NIGMS NIH HHS [T32GM08061] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; CRAFT CM, 1995, FEBS LETT, V362, P247, DOI 10.1016/0014-5793(95)00213-S; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; JEWELLMOTZ EA, 1995, BIOCHEMISTRY-US, V34, P11946, DOI 10.1021/bi00037a036; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUHN H, 1982, METHOD ENZYMOL, V81, P489; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; Lee KB, 2000, J BIOL CHEM, V275, P9284, DOI 10.1074/jbc.275.13.9284; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; McDowell JH, 1999, BIOCHEMISTRY-US, V38, P6119, DOI 10.1021/bi990175p; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; RANGANATHAN R, 1995, CELL, V81, P841, DOI 10.1016/0092-8674(95)90004-7; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; Tsuga H, 1998, J BIOL CHEM, V273, P5323, DOI 10.1074/jbc.273.9.5323; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zhang LR, 1997, J BIOL CHEM, V272, P14762, DOI 10.1074/jbc.272.23.14762	45	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35767	35777		10.1074/jbc.M002225200	http://dx.doi.org/10.1074/jbc.M002225200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10952973	hybrid			2022-12-27	WOS:000165382000020
J	Prigent, M; Barlat, I; Langen, H; Dargemont, C				Prigent, M; Barlat, I; Langen, H; Dargemont, C			I kappa B alpha and I kappa B alpha/NF-kappa B complexes are retained in the cytoplasm through interaction with a novel partner, RasGAP SH3-binding protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; DNA-BINDING SUBUNIT; TRANSCRIPTION FACTOR; KINASE COMPLEX; PORE COMPLEX; TYROSINE PHOSPHORYLATION; INDUCED DEGRADATION; P50 PRECURSOR; P62 COMPLEX; ACTIVATION	I kappaB alpha inhibits the transcriptional activity of NF-kappaB both in the cytoplasm by preventing the nuclear translocation of NF-kappaB and in the nucleus where it dissociates NF-kappaB from DNA and transports it back to the cytoplasm, Cytoplasmic localization of inactive NF-kappaB/I kappaB alpha complexes is controlled by mutual masking of nuclear import sequences of NF-kappaB p65 and I kappaB alpha and active CRM1-mediated nuclear export. Here, we describe an additional mechanism accounting for the cytoplasmic anchoring of I kappaB alpha or NF-kappaB/I kappaB alpha complexes. The N-terminal domain of I kappaB alpha contains a sequence responsible for the cytoplasmic retention of I kappaB alpha that is specifically recognized by G3BP2, a cytoplasmic protein that interacts with both IKB alpha and I kappaB alpha /NF-kappaB complexes. G3BP2 is composed of an N-terminal domain homologous to the NTF2 protein, followed by an acidic domain sufficient for the interaction with the I kappaB alpha cytoplasmic retention sequence, a region containing five PXXP motifs and a C-terminal domain containing RNA-binding motifs. Overexpression of G3BP2 directly promotes retention of I kappaB alpha in the cytoplasm, indicating that subcellular distribution of I kappaB alpha and NF-kappaB/I kappaB alpha complexes likely results from a equilibrium between nuclear import, nuclear export, and cytoplasmic retention. The molecular organization of G3BP2 suggests that this putative scaffold protein might connect the NF-kappaB signal transduction cascade with cellular functions such as nuclear transport or RNA metabolism.	Inst Curie, CNRS UMR144, Lab Transport Nucleoytoplasm, F-75248 Paris 05, France; Avantis Pharma, F-94403 Vitry, France; Hoffmann La Roche Ag, PRPN G, CH-4070 Basel, Switzerland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Roche Holding	Dargemont, C (corresponding author), Inst Jacques Monod, CNRS UMR 7592, Lab Transport Nucleoytoplasm, Tour 43,2 Pl Jussieu, F-75251 Paris 05, France.							ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Bachelerie F, 1997, J CELL SCI, V110, P2883; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bauerle PA, 1996, CELL, V87, P13; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Cheng JD, 1998, J EXP MED, V188, P1055, DOI 10.1084/jem.188.6.1055; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; de Lera TL, 1999, ONCOGENE, V18, P1581, DOI 10.1038/sj.onc.1202455; DeFranco DB, 1995, VITAM HORM, V51, P315, DOI 10.1016/S0083-6729(08)61043-2; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GUAN TL, 1995, MOL BIOL CELL, V6, P1591, DOI 10.1091/mbc.6.11.1591; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Hirano F, 1998, MOL CELL BIOL, V18, P2596, DOI 10.1128/MCB.18.5.2596; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Kennedy D, 1996, Biomed Pept Proteins Nucleic Acids, V2, P93; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOONG AC, 1994, CANCER RES, V54, P5278; LABAIL O, 1993, EMBO J, V12, P5043; Latimer M, 1998, MOL CELL BIOL, V18, P2640, DOI 10.1128/MCB.18.5.2640; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; Love DC, 1998, P NATL ACAD SCI USA, V95, P10608, DOI 10.1073/pnas.95.18.10608; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Ossareh-Nazari B, 1999, EXP CELL RES, V252, P236, DOI 10.1006/excr.1999.4599; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Parker F, 1996, MOL CELL BIOL, V16, P2561; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; RODRIGUEZ MS, 1996, ONCOGENE, V12, P369; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; Weil R, 1997, J BIOL CHEM, V272, P9942; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	84	87	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36441	36449		10.1074/jbc.M004751200	http://dx.doi.org/10.1074/jbc.M004751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10969074	hybrid			2022-12-27	WOS:000165382000111
J	Qiu, L; Joazeiro, C; Fang, N; Wang, HY; Elly, C; Altman, Y; Fang, DY; Hunter, T; Liu, YC				Qiu, L; Joazeiro, C; Fang, N; Wang, HY; Elly, C; Altman, Y; Fang, DY; Hunter, T; Liu, YC			Recognition and ubiquitination of notch by Itch, a hect-type E3 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME PATHWAY; PROTEIN LIGASE; DOMAIN; DEGRADATION; EXPRESSION; REGULATOR; LOCUS; CELLS; MICE; CBL	Genetic studies identified Itch, which is a homologous to the EG-associated protein carboxyl terminus (Hect) domain-containing E3 ubiquitin-protein ligase that is disrupted in non-agouti lethal mice or Itchy mice. Itch-deficiency results in abnormal immune responses and constant itching in the skin. Here, Itch was shown to associate with Notch, a protein involved in cell fate decision in many mammalian cell types, including cells in the immune System. Itch binds to the N-terminal portion of the Notch intracellular domain via its WW domains and promotes ubiquitination of Notch through its Hect ubiquitin ligase domain. Thus, Itch may participate in the-regulation of immune responses by modifying Notch-mediated signaling.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA; Salk Inst, La Jolla, CA 92037 USA	La Jolla Institute for Immunology; Salk Institute	Liu, YC (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA.		Fang, Deyu/I-7245-2013	Fang, Deyu/0000-0002-4211-2751; LIU, YUN-CAI/0000-0002-0996-7109	NIDDK NIH HHS [DK56558] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056558] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Cornell M, 1999, GENETICS, V152, P567; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Deftos ML, 2000, CURR OPIN IMMUNOL, V12, P166, DOI 10.1016/S0952-7915(99)00067-9; Haas AL, 1997, FASEB J, V11, P1257; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; HUSTAD CM, 1995, GENETICS, V140, P255; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9	25	253	259	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35734	35737		10.1074/jbc.M007300200	http://dx.doi.org/10.1074/jbc.M007300200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10940313	hybrid			2022-12-27	WOS:000165382000015
J	Guschin, D; Geiman, TM; Kikyo, N; Tremethick, DJ; Wolffe, AP; Wade, PA				Guschin, D; Geiman, TM; Kikyo, N; Tremethick, DJ; Wolffe, AP; Wade, PA			Multiple ISWI ATPase complexes from Xenopus laevis - Functional conservation of an ACF/CHRAC homolog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-REMODELING FACTORS; MAJOR DEVELOPMENTAL TRANSITION; GENE-EXPRESSION; DNA-REPAIR; IN-VITRO; SWI-SNF; TRANSCRIPTION; NUCLEOSOME; FAMILY; TOPOISOMERASE	The nucleosomal ATPase ISWI is the catalytic subunit of several protein complexes that either organize or perturb chromatin structure in vitro. This work reports the cloning and biochemical characterization of a Xenopus ISWI homolog. Surprisingly, whereas we find four complex forms of ISWI in egg extracts, we find no functional homolog of NURF. One of these complexes, xACF, consists of ISWI, Acf1, and a previously uncharacterized protein of 175 kDa. Like both ACF and CHRAC, this complex organizes randomly deposited histones into a regularly spaced array. The remaining three forms include two novel ISWI complexes distinct from known ISWI complexes plus a histone-dependent ATPase complex. This comprehensive biochemical characterization of ISWI underscores the evolutionary conservation of the ACF/CHRAC family.	NICHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Australian National University; John Curtin School of Medical Research	Wade, PA (corresponding author), Emory Univ, Dept Pathol, Woodruff Mem Res Bldg,Rm 7105-B,1639 Pierce Dr, Atlanta, GA 30322 USA.	pwade@emory.edu	Guschin, Dmitry/O-7594-2018; Wade, Paul A/D-2374-2019; Guschin, Dmitry/U-3731-2019	Guschin, Dmitry/0000-0002-4184-0001; Wade, Paul A/0000-0002-6042-357X; Guschin, Dmitry/0000-0002-4184-0001; Tremethick, David/0000-0001-5274-8078				Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Aihara T, 1998, CYTOGENET CELL GENET, V81, P191, DOI 10.1159/000015027; ALMOUZNI G, 1988, EMBO J, V7, P665, DOI 10.1002/j.1460-2075.1988.tb02861.x; ALMOUZNI G, 1993, EXP CELL RES, V205, P1, DOI 10.1006/excr.1993.1051; ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; BURNS LG, 1997, BIOCHIM BIOPHYS ACTA, V1330, P159; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; Corona DFV, 2000, EMBO J, V19, P3049, DOI 10.1093/emboj/19.12.3049; DePamphilis ML, 1999, BIOESSAYS, V21, P5, DOI 10.1002/(SICI)1521-1878(199901)21:1<5::AID-BIES2>3.0.CO;2-6; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; Gelius B, 1999, EUR J BIOCHEM, V262, P426, DOI 10.1046/j.1432-1327.1999.00379.x; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; Guschin D, 1999, CURR BIOL, V9, pR742, DOI 10.1016/S0960-9822(99)80473-4; Guschin D, 2000, BIOCHEMISTRY-US, V39, P5238, DOI 10.1021/bi000421t; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; Henikoff S, 1997, CURR OPIN CELL BIOL, V9, P388, DOI 10.1016/S0955-0674(97)80012-9; Imbalzano AN, 1998, CRIT REV EUKAR GENE, V8, P225, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.10; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Jones MH, 2000, GENOMICS, V63, P40, DOI 10.1006/geno.1999.6071; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kornberg RD, 1999, CURR OPIN GENET DEV, V9, P148, DOI 10.1016/S0959-437X(99)80022-7; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LeRoy G, 2000, J BIOL CHEM, V275, P14787, DOI 10.1074/jbc.C000093200; LUKE M, 1989, DEV BIOL, V136, P459, DOI 10.1016/0012-1606(89)90271-6; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; Moggs JG, 1999, BIOCHIMIE, V81, P45, DOI 10.1016/S0300-9084(99)80037-6; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Peterson CL, 1998, COLD SPRING HARB SYM, V63, P545, DOI 10.1101/sqb.1998.63.545; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; RANJAN M, 1994, J BIOL CHEM, V269, P24699; Schlissel MS, 2000, SCIENCE, V287, P438, DOI 10.1126/science.287.5452.438; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; Trachtulcova P, 2000, YEAST, V16, P35, DOI 10.1002/(SICI)1097-0061(20000115)16:1<35::AID-YEA504>3.0.CO;2-0; TREMETHICK D, 1990, J BIOL CHEM, V265, P5014; TREMETHICK DJ, 1992, J BIOL CHEM, V267, P15041; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171	61	59	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35248	35255		10.1074/jbc.M006041200	http://dx.doi.org/10.1074/jbc.M006041200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10942776	hybrid			2022-12-27	WOS:000165422800057
J	Jansen, MS; Cook, GA; Song, S; Park, EA				Jansen, MS; Cook, GA; Song, S; Park, EA			Thyroid hormone regulates carnitine palmitoyltransferase I alpha gene expression through elements in the promoter and first intron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA ABUNDANCE; BROWN ADIPOSE-TISSUE; RESPONSE ELEMENT; CPT-I; CHROMOSOMAL LOCALIZATION; BINDING PROTEIN; RECEPTOR GENE; FATTY-ACIDS; MALONYL-COA; RAT	Carnitine palmitoyltransferase I (CPT-I) catalyzes the transfer of long chain fatty acyl groups from CoA to carnitine for translocation across the mitochondrial inner membrane. CPT-I alpha is a key regulatory enzyme in the oxidation of fatty acids in the liver, CPT-I alpha is expressed in all tissues except skeletal muscle and adipose tissue, which express CPT-I beta. Expression of CPT-I alpha mRNA and enzyme activity are elevated in the liver in hyperthyroidism, fasting, and diabetes. CPT-I alpha mRNA abundance is increased 40-fold in the liver of hyperthyroid compared with hypothyroid rats, Here, we examine the mechanisms by which thyroid hormone (T3) stimulates CPT-I alpha gene expression. Four potential T3 response elements (TRE), which contain direct repeats separated by four nucleotides, are located 3000-4000 base pairs 5' to the start site of transcription in the CPT-I alpha gene. However, only one of these elements functions as a TRE. This TRE binds the T3 receptor as well as other nuclear proteins. Surprisingly, the first intron of the CPT-I alpha gene is required for the T3 induction of CPT-I alpha expression, but this region of the gene does not contain a TRE. In addition, we show that CPT-I alpha is induced by T3 in cell lines of hepatic origin but not in nonhepatic cell lines.	Univ Tennessee, Sch Med, Dept Pharmacol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Park, EA (corresponding author), Univ Tennessee, Sch Med, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.	epark@utmem.edu						Bahouth SW, 1997, J MOL CELL CARDIOL, V29, P3223, DOI 10.1006/jmcc.1997.0549; BAHOUTH SW, 1991, J BIOL CHEM, V266, P15863; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRITTON CH, 1995, P NATL ACAD SCI USA, V92, P1984, DOI 10.1073/pnas.92.6.1984; Chatelain F, 1996, EUR J BIOCHEM, V235, P789, DOI 10.1111/j.1432-1033.1996.00789.x; de Arrieta CM, 1999, ENDOCRINOLOGY, V140, P335, DOI 10.1210/en.140.1.335; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; ESSER V, 1993, J BIOL CHEM, V268, P5817; Gaunitz F, 1997, BIOL CHEM, V378, P11, DOI 10.1515/bchm.1997.378.1.11; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HEIMBERG M, 1985, ENDOCR REV, V6, P590, DOI 10.1210/edrv-6-4-590; Indiveri C, 1997, BIOCHEM J, V321, P713, DOI 10.1042/bj3210713; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; Jump DB, 1997, J BIOL CHEM, V272, P27778, DOI 10.1074/jbc.272.44.27778; KATZ RW, 1995, J BIOL CHEM, V270, P5238, DOI 10.1074/jbc.270.10.5238; KATZ RW, 1993, J BIOL CHEM, V268, P19392; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LIU HC, 1994, MOL ENDOCRINOL, V8, P1021, DOI 10.1210/me.8.8.1021; Madden TJ, 1997, NUCLEIC ACIDS RES, V25, P3930, DOI 10.1093/nar/25.19.3930; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MYNATT RL, 1994, BIOCHEM BIOPH RES CO, V201, P932, DOI 10.1006/bbrc.1994.1791; Olson DP, 1997, J BIOL CHEM, V272, P9907; Olson DP, 1998, J BIOL CHEM, V273, P3375, DOI 10.1074/jbc.273.6.3375; PARK EA, 1995, BIOCHEM J, V310, P853, DOI 10.1042/bj3100853; Park EA, 1998, BIOCHEM J, V330, P217; PARK EA, 1993, J BIOL CHEM, V268, P613; Park EA, 1997, BIOCHEM J, V322, P343, DOI 10.1042/bj3220343; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; Shuler FD, 1998, DNA CELL BIOL, V17, P689, DOI 10.1089/dna.1998.17.689; Steffen ML, 1999, BIOCHEM J, V340, P425, DOI 10.1042/0264-6021:3400425; THUMELIN S, 1994, BIOCHEM J, V300, P583, DOI 10.1042/bj3000583; VOZ ML, 1992, MOL CELL BIOL, V12, P3991, DOI 10.1128/MCB.12.9.3991; Weiss RE, 1998, ENDOCRINOLOGY, V139, P4945, DOI 10.1210/en.139.12.4945; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	44	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34989	34997		10.1074/jbc.M001752200	http://dx.doi.org/10.1074/jbc.M001752200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956641	hybrid			2022-12-27	WOS:000165422800024
J	Lee, KJ; Huang, JR; Takeda, Y; Dynan, WS				Lee, KJ; Huang, JR; Takeda, Y; Dynan, WS			DNA ligase IV and XRCC4 form a stable mixed tetramer that functions synergistically with other repair factors in a cell-free end-joining system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; V(D)J RECOMBINATION; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; KU; COMPLEX; MICE; REQUIREMENT; EXTRACTS	Repair of DNA double-strand breaks in mammalian cells occurs via a direct nonhomologous end-joining pathway. Although this pathway can be studied in vivo and in crude cell-free systems, a deeper understanding of the mechanism requires reconstitution with purified enzymes. We have expressed and purified a complex of two proteins that are critical for double-strand break repair, DNA ligase IV (DNL IV) and XRCC4. The complex is homogeneous, with a molecular mass of about 300,000 Da, suggestive of a mixed tetramer containing two copies of each polypeptide. The presence of multiple copies of DNL TV was confirmed in an experiment where different epitope-tagged forms of DNL TV were recovered simultaneously in the same complex. Cross-linking suggests that an XRCC4 XRCC4 dimer interface forms the core of the tetramer, and that the DNL TV polypeptides are in contact with XRCC4 but not with one another. Purified DNL IV.XRCC4 complex functioned synergistically with Ku protein, the DNA-dependent protein kinase catalytic subunit, and other repair factors in a cell-free end-joining assay. We suggest that a dyad-symmetric DNL IV.XRCC4 tetramer bridges the two ends of the broken DNA and catalyzes the coordinate ligation of the two DNA strands.	Med Coll Georgia, Inst Mol Med & Genet, Gene Regulat Program, Augusta, GA 30912 USA; Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Dynan, WS (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Gene Regulat Program, Rm CB-2803,1120 15th St, Augusta, GA 30912 USA.	wdynan@mail.mcg.edu		Dynan, William/0000-0002-4045-5662	NIGMS NIH HHS [GM 35886] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailin T, 1999, MOL CELL BIOL, V19, P4664; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; Bogue MA, 1997, IMMUNITY, V7, P37, DOI 10.1016/S1074-7613(00)80508-7; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; CHRAMBACH A, 1971, SCIENCE, V172, P440, DOI 10.1126/science.172.3982.440; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; GANGULY T, 1995, INT J RADIAT BIOL, V68, P447, DOI 10.1080/09553009514551411; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Goedecke W, 1999, NAT GENET, V23, P194, DOI 10.1038/13821; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, J BIOL CHEM, V273, P24708, DOI 10.1074/jbc.273.38.24708; Grawunder U, 1998, CURR BIOL, V8, P873, DOI 10.1016/S0960-9822(07)00349-1; Gu XY, 1996, J BIOL CHEM, V271, P19660, DOI 10.1074/jbc.271.33.19660; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; Koh SS, 1997, BIOTECHNIQUES, V23, P622, DOI 10.2144/97234bm14; Labhart P, 1999, MOL CELL BIOL, V19, P2585; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Mizuta R, 1997, INT IMMUNOL, V9, P1607, DOI 10.1093/intimm/9.10.1607; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; PANG D, 1997, CANCER RES, V57, P112; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; PFEIFFER P, 1988, NUCLEIC ACIDS RES, V16, P907, DOI 10.1093/nar/16.3.907; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Takeda Y, 1999, J IMMUNOL, V163, P6269; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; Tsukamoto Y, 1998, GENES CELLS, V3, P135, DOI 10.1046/j.1365-2443.1998.00180.x; Wachsberger PR, 1999, RADIAT RES, V151, P398, DOI 10.2307/3579826; WEI YF, 1995, MOL CELL BIOL, V15, P3206; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Yoo S, 1999, J BIOL CHEM, V274, P20034, DOI 10.1074/jbc.274.28.20034	63	69	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34787	34796		10.1074/jbc.M004011200	http://dx.doi.org/10.1074/jbc.M004011200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10945980	hybrid			2022-12-27	WOS:000165095300105
J	Brinkman, AB; Dahlke, I; Tuininga, JE; Lammers, T; Dumay, V; de Heus, E; Lebbink, JHG; Thomm, M; de Vos, WM; van der Oost, J				Brinkman, AB; Dahlke, I; Tuininga, JE; Lammers, T; Dumay, V; de Heus, E; Lebbink, JHG; Thomm, M; de Vos, WM; van der Oost, J			An Lrp-like transcriptional regulator from the archaeon Pyrococcus furiosus is negatively autoregulated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE TRANSCRIPTION; INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; TATA-BOX; CRYSTAL-STRUCTURE; SULFOLOBUS-SOLFATARICUS; METHANOCOCCUS-VANNIELII; REPRESSOR BINDING; GLOBAL REGULATOR; DNA INTERACTIONS	The archaeal transcriptional initiation machinery closely resembles core elements of the eukaryal polymerase II system. However, apart from the established basal archaeal transcription system, little is known about the modulation of gene expression in archaea, At present, no obvious eukaryal-like transcriptional regulators have been identified in archaea. Instead, we have previously isolated an archaeal gene, the Pyrococcus furiosus lrpA, that potentially encodes a bacterial-like transcriptional regulator, In the present study, we have for the first time addressed the actual involvement of an archaeal Lrp homologue in transcription modulation, For that purpose, we have produced LrpA in Escherichia coli, In a cell-free P. furiosus transcription system we used wild-type and mutated lrpA promoter fragments to demonstrate that the purified LrpA negatively regulates its own transcription. In addition, gel retardation analyses revealed a single protein-DNA complex, in which LrpA appeared to be present in (at least) a tetrameric conformation. The location of the LrpA binding site was further identified by DNaseI and hydroxyl radical footprinting, indicating that LrpA binds to a 46-base pair sequence that overlaps the transcriptional start site of its own promoter. The molecular basis of the transcription inhibition by LrpA is discussed.	Univ Wageningen & Res Ctr, Microbiol Lab, Dept Agrotechnol & Food Sci, NL-6703 CT Wageningen, Netherlands; Univ Kiel, Inst Allgemeine Mikrobiol, D-24118 Kiel, Germany	Wageningen University & Research; University of Kiel	Brinkman, AB (corresponding author), Univ Wageningen & Res Ctr, Microbiol Lab, Dept Agrotechnol & Food Sci, Hesselink van Suchtelenweg 4, NL-6703 CT Wageningen, Netherlands.		van+der+Oost, John/Y-2548-2019; Brinkman, Arie/V-1533-2018; Lammers, Twan/U-2794-2018	Brinkman, Arie/0000-0002-9875-1835; Lammers, Twan/0000-0002-1090-6805				Bell SD, 1999, MOL CELL, V4, P971, DOI 10.1016/S1097-2765(00)80226-9; Bell SD, 1998, TRENDS MICROBIOL, V6, P222, DOI 10.1016/S0966-842X(98)01281-5; Bell SD, 1999, P NATL ACAD SCI USA, V96, P13662, DOI 10.1073/pnas.96.24.13662; Bernues J, 1996, NUCLEIC ACIDS RES, V24, P2950, DOI 10.1093/nar/24.15.2950; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHAPON C, 1983, J BACTERIOL, V156, P1135, DOI 10.1128/JB.156.3.1135-1143.1983; Charlier D, 1997, GENE, V201, P63, DOI 10.1016/S0378-1119(97)00428-9; Cohen-Kupiec R, 1999, J BACTERIOL, V181, P256, DOI 10.1128/JB.181.1.256-261.1999; CohenKupiec R, 1997, P NATL ACAD SCI USA, V94, P1316, DOI 10.1073/pnas.94.4.1316; Cui YH, 1996, J BIOL CHEM, V271, P6611, DOI 10.1074/jbc.271.12.6611; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DEWIND N, 1985, NUCLEIC ACIDS RES, V13, P8797, DOI 10.1093/nar/13.24.8797; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; EGGEN RIL, 1993, GENE, V132, P143, DOI 10.1016/0378-1119(93)90527-A; FERRARIO M, 1995, J BACTERIOL, V177, P103, DOI 10.1128/jb.177.1.103-113.1995; FREY G, 1990, NUCLEIC ACIDS RES, V18, P1361, DOI 10.1093/nar/18.6.1361; Galasinski SK, 2000, MOL CELL BIOL, V20, P1923, DOI 10.1128/MCB.20.6.1923-1930.2000; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GASTON K, 1992, NUCLEIC ACIDS RES, V20, P3391, DOI 10.1093/nar/20.13.3391; GAZEAU M, 1994, J MOL BIOL, V241, P378, DOI 10.1006/jmbi.1994.1514; HAUSNER W, 1991, J MOL BIOL, V222, P495, DOI 10.1016/0022-2836(91)90492-O; Hausner W, 1996, J BIOL CHEM, V271, P30144, DOI 10.1074/jbc.271.47.30144; Hethke C, 1996, NUCLEIC ACIDS RES, V24, P2369, DOI 10.1093/nar/24.12.2369; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hochheimer A, 1999, MOL MICROBIOL, V31, P641, DOI 10.1046/j.1365-2958.1999.01204.x; HOCHSEHILD A, 1991, METHOD ENZYMOL, V208, P434; Huang N, 1996, BIOCHEM BIOPH RES CO, V223, P315, DOI 10.1006/bbrc.1996.0891; Jafri S, 1999, J MOL BIOL, V288, P811, DOI 10.1006/jmbi.1999.2715; Kawarabayasi Y, 1998, DNA Res, V5, P147, DOI 10.1093/dnares/5.2.147; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; KELLEY WL, 1991, J BIOL CHEM, V266, P15924; KEUNTJE B, 1995, J BACTERIOL, V177, P6432, DOI 10.1128/jb.177.22.6432-6439.1995; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOLLING R, 1985, J BACTERIOL, V164, P310; Kruger K, 1998, J MOL BIOL, V279, P761, DOI 10.1006/jmbi.1998.1795; KYRPIDES NC, 1995, TRENDS BIOCHEM SCI, V20, P140, DOI 10.1016/S0968-0004(00)88988-4; Kyrpides NC, 1999, P NATL ACAD SCI USA, V96, P8545, DOI 10.1073/pnas.96.15.8545; LILJELUND P, 1993, MOL GEN GENET, V241, P694, DOI 10.1007/BF00279913; Littlefield O, 1999, P NATL ACAD SCI USA, V96, P13668, DOI 10.1073/pnas.96.24.13668; MADHUSUDHAN KT, 1995, J BACTERIOL, V177, P636, DOI 10.1128/jb.177.3.636-641.1995; Mathew E, 1996, J BACTERIOL, V178, P7234, DOI 10.1128/jb.178.24.7234-7240.1996; Morgan RM, 1997, J BACTERIOL, V179, P889, DOI 10.1128/jb.179.3.889-898.1997; Napoli A, 1999, J BACTERIOL, V181, P1474, DOI 10.1128/JB.181.5.1474-1480.1999; NEWMAN EB, 1995, ANNU REV MICROBIOL, V49, P747, DOI 10.1146/annurev.mi.49.100195.003531; Nolling J, 1997, J BACTERIOL, V179, P899; NOU XW, 1995, EMBO J, V14, P5785, DOI 10.1002/j.1460-2075.1995.tb00267.x; PLUMBRIDGE J, 1991, J MOL BIOL, V217, P661, DOI 10.1016/0022-2836(91)90524-A; Rhee KY, 1996, J BIOL CHEM, V271, P26499, DOI 10.1074/jbc.271.43.26499; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Rink R, 1997, J BIOL CHEM, V272, P14650, DOI 10.1074/jbc.272.23.14650; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SIRKO A, 1993, J BACTERIOL, V175, P5769, DOI 10.1128/JB.175.18.5769-5777.1993; Soppa J, 1999, MOL MICROBIOL, V31, P1589, DOI 10.1046/j.1365-2958.1999.01274.x; Soppa J, 1999, MOL MICROBIOL, V31, P1295, DOI 10.1046/j.1365-2958.1999.01273.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Thomm M, 1996, FEMS MICROBIOL REV, V18, P159; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TSAI MM, 1990, J BACTERIOL, V172, P4603, DOI 10.1128/jb.172.8.4603-4609.1990; Voorhorst WGB, 1999, J BACTERIOL, V181, P3777, DOI 10.1128/JB.181.12.3777-3783.1999; WANG Q, 1993, J MOL BIOL, V229, P306, DOI 10.1006/jmbi.1993.1036; WANG Q, 1993, EMBO J, V12, P2495, DOI 10.1002/j.1460-2075.1993.tb05904.x; WANG Q, 1994, J BACTERIOL, V176, P1831, DOI 10.1128/jb.176.7.1831-1839.1994; Ward DE, 2000, J BACTERIOL, V182, P2559, DOI 10.1128/JB.182.9.2559-2566.2000; WEBSTER C, 1988, GENE, V68, P297, DOI 10.1016/0378-1119(88)90032-7; Wiese DE, 1997, J MOL BIOL, V270, P152, DOI 10.1006/jmbi.1997.1057; WILLINS DA, 1991, J BIOL CHEM, V266, P10768	69	72	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38160	38169		10.1074/jbc.M005916200	http://dx.doi.org/10.1074/jbc.M005916200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10973967	hybrid			2022-12-27	WOS:000165739800006
J	Graversen, JH; Jacobsen, C; Sigurskjold, BW; Lorentsen, RH; Moestrup, SK; Thogersen, HC; Etzerodt, M				Graversen, JH; Jacobsen, C; Sigurskjold, BW; Lorentsen, RH; Moestrup, SK; Thogersen, HC; Etzerodt, M			Mutational analysis of affinity and selectivity of kringle-tetranectin interaction - Grafting novel kringle affinity onto the tetranectin lectin scaffold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; CARBOHYDRATE-RECOGNITION DOMAIN; HUMAN-PLASMINOGEN; BINDING-SITE; PLASMA-TETRANECTIN; HOMOLOGOUS DOMAINS; CRYSTAL-STRUCTURE; GENE-EXPRESSION; PROTEIN; ANGIOSTATIN	C-type lectin-like domains are found in many proteins, where they mediate binding to a wide diversity of compounds, including carbohydrates, lipids, and proteins. The binding of a C-type lectin-like domain to a ligand is often influenced by calcium. Recently, we have identified a site in the C-type lectin-like domain of tetranectin, involving Lys-148, Glu-150, and Asp-165, which mediates calcium-sensitive binding to plasminogen kringle 4. Here, we investigate the effect of conservative substitutions of these and a neighboring amino acid residue. Substitution of Thr-149 in tetranectin with a tyrosine residue considerably increases the affinity for plasminogen kringle 4, and, in addition, confers affinity for plasminogen kringle 2. As shown by isothermal titration calorimetry analysis, this new interaction is stronger than the binding of wild-type tetranectin to plasminogen kringle 4. This study provides further insight into molecular determinants of importance for binding selectivity and affinity of C-type lectin kringle interactions.	Aarhus Univ, Dept Biol Mol & Struct, Lab Gene Express, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Biochem Med, DK-8000 Aarhus, Denmark; Univ Copenhagen, August Krogh Inst, DK-2100 Copenhagen O, Denmark	Aarhus University; Aarhus University; University of Copenhagen	Etzerodt, M (corresponding author), Sci Pk Aarhus,Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.		Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019	Moestrup, Søren Kragh/0000-0003-3862-2107; Graversen, Jonas Heilskov/0000-0002-2411-9933; Graversen, Jonas Heilskov/0000-0001-7119-2108				Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; CHRISTENSEN L, 1991, HISTOCHEMISTRY, V95, P427, DOI 10.1007/BF00315737; CHRISTENSEN L, 1989, HISTOCHEMISTRY, V92, P29, DOI 10.1007/BF00495012; CLEMMENSEN I, 1989, SCAND J CLIN LAB INV, V49, P719, DOI 10.3109/00365518909091550; CLEMMENSEN I, 1986, EUR J BIOCHEM, V156, P327, DOI 10.1111/j.1432-1033.1986.tb09586.x; deVries TJ, 1996, J PATHOL, V179, P260, DOI 10.1002/(SICI)1096-9896(199607)179:3<260::AID-PATH586>3.0.CO;2-T; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Ellgaard L, 1997, EUR J BIOCHEM, V244, P544, DOI 10.1111/j.1432-1033.1997.00544.x; Ewart KV, 1998, BIOCHEMISTRY-US, V37, P4080, DOI 10.1021/bi972503w; FUHLENDORFF J, 1987, BIOCHEMISTRY-US, V26, P6757, DOI 10.1021/bi00395a027; Graversen JH, 1998, J BIOL CHEM, V273, P29241, DOI 10.1074/jbc.273.44.29241; Graversen JH, 2000, BIOCHEMISTRY-US, V39, P7414, DOI 10.1021/bi000155j; Hogdall C K, 1998, APMIS Suppl, V86, P1; Holtet TL, 1997, PROTEIN SCI, V6, P1511, DOI 10.1002/pro.5560060715; JENSEN BA, 1988, CANCER, V62, P869, DOI 10.1002/1097-0142(19880901)62:5<869::AID-CNCR2820620503>3.0.CO;2-6; Ji WDR, 1998, FASEB J, V12, P1731, DOI 10.1096/fasebj.12.15.1731; Kastrup JS, 1998, ACTA CRYSTALLOGR D, V54, P757, DOI 10.1107/S0907444997016806; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; LORENTSEN RH, 2000, BIOCHEM J, V347, P33; MacDonald NJ, 1999, BIOCHEM BIOPH RES CO, V264, P469, DOI 10.1006/bbrc.1999.1486; MARTI D, 1994, EUR J BIOCHEM, V219, P455, DOI 10.1111/j.1432-1033.1994.tb19959.x; Marti DN, 1999, BIOCHEMISTRY-US, V38, P15741, DOI 10.1021/bi9917378; Marti DN, 1997, BIOCHEMISTRY-US, V36, P11591, DOI 10.1021/bi971316v; Natarajan K, 1999, IMMUNITY, V11, P591, DOI 10.1016/S1074-7613(00)80134-X; Nielsen BB, 1997, FEBS LETT, V412, P388, DOI 10.1016/S0014-5793(97)00664-9; OREILLY MS, 1994, COLD SPRING HARB SYM, V59, P471, DOI 10.1101/SQB.1994.059.01.052; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; Sohndel S, 1996, BIOCHEMISTRY-US, V35, P2357, DOI 10.1021/bi9520949; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; Tormo J, 1999, NATURE, V402, P623, DOI 10.1038/45170; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; Wewer UM, 1998, DEV BIOL, V200, P247, DOI 10.1006/dbio.1998.8962; WEWER UM, 1994, J CELL BIOL, V127, P1767, DOI 10.1083/jcb.127.6.1767; WEWER UM, 1992, LAB INVEST, V67, P253; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WU TP, 1991, BIOCHEMISTRY-US, V30, P10589, DOI 10.1021/bi00107a030	40	10	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37390	37396		10.1074/jbc.M004873200	http://dx.doi.org/10.1074/jbc.M004873200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10964919	hybrid			2022-12-27	WOS:000165618700013
J	Lijnen, HR; Arza, B; Van Hoef, B; Collen, D; Declerck, PJ				Lijnen, HR; Arza, B; Van Hoef, B; Collen, D; Declerck, PJ			Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROKINASE RECEPTOR; HUMAN-PLASMA; ALPHA-1-PROTEINASE INHIBITOR; CONFORMATIONAL-CHANGES; BINDING-PROTEIN; GENE-EXPRESSION; CELL-MIGRATION; U-PA; VITRONECTIN; TYPE-1	Matrix metalloproteinase-3 (MMP-3 or stromelysin-1) specifically hydrolyzes the Ser(337)-Ser(338) (P10-P9) and Val(341)-Ile(342) (P6-P5) peptide bonds in human plasminogen activator inhibitor-1 (PAI-1). Cleavage is completely abolished in the presence of the metal chelators EDTA or 1,10-phenanthroline. A stabilized active PAI-1 variant was also cleaved by MMP-3. At an enzyme/substrate ratio of 1/10 at 37 degreesC, PAI-1 protein cleavage occurred with half-lives of 27 or 14 min for active or stable PAI-1 and was associated with rapid loss of inhibitory activity toward tissue-type plasminogen activator with half-lives of 15 or 13 min, respectively. A substrate-like variant of PAI-1, lacking inhibitory activity but with exposed reactive site loop, was cleaved with a half-life of 23 min, whereas latent PAI-1 in which a major part of the reactive site loop is inserted into the molecule, was resistant to cleavage, Biospecific interaction analysis indicated comparable binding of active, stable, and substrate PAI-1 to both proMMP-3 and MMP-3 (K-A of 12-22 x 10(6) M-1), whereas binding of latent PAI-1 occurred with lower affinity (1.7-2.3 x 10(6) M-1). Stable PAI-1 bound to vitronectin was cleaved and inactivated by MMP-3 in a manner comparable with that of free PAI-1; however, the cleaved protein did not bind to vitronectin. Cleavage and inactivation of PAI-1 by MMP-3 may thus constitute a mechanism decreasing the antiproteolytic activity of PAI-1 and impairing the potential inhibitory effect of vitronectin-bound PAI-1 on cell adhesion and/or migration.	Katholieke Univ Leuven, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Lijnen, HR (corresponding author), Katholieke Univ Leuven, Ctr Mol & Vasc Biol, Campus Gasthuisberg O&N,Herestr 49, B-3000 Louvain, Belgium.	roger.lijnen@med.kuleuven.ac.be	Declerck, Paul J/A-2330-2017; Lijnen, Roger/AAA-4085-2020	Declerck, Paul J/0000-0003-1259-9105; 				AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; AUDENAERT AM, 1994, J BIOL CHEM, V269, P19559; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Bini A, 1996, BIOCHEMISTRY-US, V35, P13056, DOI 10.1021/bi960730c; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; COLUCCI M, 1985, J CLIN INVEST, V75, P818, DOI 10.1172/JCI111777; DECLERCK PJ, 1995, THROMB HAEMOSTASIS, V74, P1305; DECLERCK PJ, 1988, BLOOD, V71, P220; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; Ehnebom J, 2000, FIBRINOLYSIS PROTEOL, V14, P47, DOI 10.1054/fipr.2000.0052; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; FEINBERG RF, 1989, LAB INVEST, V61, P20; Gibson A, 1997, J BIOL CHEM, V272, P5112, DOI 10.1074/jbc.272.8.5112; Gils A, 1997, J BIOL CHEM, V272, P12662, DOI 10.1074/jbc.272.19.12662; Gils A, 1998, THROMB HAEMOSTASIS, V80, P531; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JuhanVague I, 1997, THROMB HAEMOSTASIS, V78, P656; JUHANVAGUE I, 1995, BAILLIERE CLIN HAEM, V8, P329, DOI 10.1016/S0950-3536(05)80271-9; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; KNAUPER V, 1990, FEBS LETT, V263, P355, DOI 10.1016/0014-5793(90)81412-H; Kuhn W, 1999, BRIT J CANCER, V79, P1746, DOI 10.1038/sj.bjc.6690278; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LI XK, 1992, BLOOD, V79, P417; Lijnen HR, 1999, THROMB HAEMOSTASIS, V82, P837; LIJNEN HR, 1994, EUR J BIOCHEM, V224, P567, DOI 10.1111/j.1432-1033.1994.00567.x; LIJNEN HR, 1995, BAILLIERE CLIN HAEM, V8, P277, DOI 10.1016/S0950-3536(05)80268-9; Lijnen HR, 1998, BIOCHEMISTRY-US, V37, P4699, DOI 10.1021/bi9731798; LINDAHL TL, 1990, BIOCHEM J, V265, P109, DOI 10.1042/bj2650109; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; MAREY MI, 1991, BIOCHEMISTRY-US, V30, P6476; MARSHALL CJ, 1993, PHILOS T ROY SOC B, V342, P101, DOI 10.1098/rstb.1993.0141; MAST AE, 1991, J BIOL CHEM, V266, P15810; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Murphy G, 1995, ACTA ORTHOP SCAND, V66, P55, DOI 10.3109/17453679509157648; Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604; NASKI MC, 1993, J BIOL CHEM, V268, P12367; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PEI DQ, 1994, J BIOL CHEM, V269, P25849; SALOMAA V, 1995, CIRCULATION, V91, P284, DOI 10.1161/01.CIR.91.2.284; Samad F, 1999, THROMB HAEMOSTASIS, V82, P742, DOI 10.1055/s-0037-1615906; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHNEIDERMAN J, 1992, P NATL ACAD SCI USA, V89, P6998, DOI 10.1073/pnas.89.15.6998; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 1998, TRENDS CARDIOVAS MED, V8, P175, DOI 10.1016/S1050-1738(98)00003-6; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Ugwu F, 1998, BIOCHEMISTRY-US, V37, P7231, DOI 10.1021/bi9728708; Vleugels N, 1998, FIBRINOLYSIS PROTEOL, V12, P277, DOI 10.1016/S0268-9499(98)80020-9; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Wiman B, 1999, SCAND J CLIN LAB INV, V59, P23; WINYARD PG, 1991, FEBS LETT, V279, P91, DOI 10.1016/0014-5793(91)80258-5	62	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37645	37650		10.1074/jbc.M006475200	http://dx.doi.org/10.1074/jbc.M006475200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10967118	hybrid			2022-12-27	WOS:000165618700047
J	Smith, SB; Watada, H; Scheel, DW; Mrejen, C; German, MS				Smith, SB; Watada, H; Scheel, DW; Mrejen, C; German, MS			Autoregulation and maturity onset diabetes of the young transcription factors control the human PAX4 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC TRANSCRIPTION; PANCREATIC BETA-CELLS; DOMAIN-DNA COMPLEX; INSULIN GENE; PAIRED DOMAIN; CRYSTAL-STRUCTURE; BINDING PROTEINS; MICE LACKING; FACTOR HNF-4; FACTOR STF-1	Duping pancreatic development, the paired homeodomain transcription factor PAX4 is required for the differentiation of the insulin-producing beta cells and somatostatin-producing delta cells. To establish the position of PAX4 in the hierarchy of factors controlling islet cell development, we examined the control of the humanPAX4 gene promoter. In both cell Lines and transgenic animals, a 4.9-kilobase pair region directly upstream of the human PAX4 gene transcriptional start site acts as a potent pancreas-specific promoter. Deletion mapping experiments demonstrate that a 118-base pair region lying approximately 1.9 kilobase pairs upstream of the transcription start site is both necessary and sufficient to direct pancreas-specific expression. Serial deletions through this region reveal the presence of positive elements that bind several pancreatic transcription factors as follows: the POU homeodomain factor HNF1 alpha, the orphan nuclear receptor HNF4 alpha, the homeodomain factor PDX1, and a heterodimer composed of two basic helix-loop-helix factors. Interestingly, mutations in the genes encoding four of these factors cause a dominantly inherited form of human diabetes called Maturity Onset Diabetes of the Young. In addition, PAX4 itself has at least two high affinity binding sites within the promoter through which it exerts a strong negative autoregulatory effect. Together, these results suggest a model in which PAX4 expression is activated during pancreatic development by a combination of pancreas-specific factors but is then switched off once PAX4 protein reaches sufficient levels.	Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	German, MS (corresponding author), Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA.			Watada, Hirotaka/0000-0001-5961-1816	NIDDK NIH HHS [DK55340, DK21344, R01 DK021344] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055340, R01DK021344, R37DK021344, R56DK021344] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; Campbell SC, 1999, FEBS LETT, V463, P53, DOI 10.1016/S0014-5793(99)01584-7; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; Danilov V, 1998, J BIOL CHEM, V273, P627, DOI 10.1074/jbc.273.1.627; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dukes ID, 1998, J BIOL CHEM, V273, P24457, DOI 10.1074/jbc.273.38.24457; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; Fujitani Y, 1999, MOL CELL BIOL, V19, P8281; GERMAN MS, 1994, GENOMICS, V24, P403, DOI 10.1006/geno.1994.1639; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Harrison KA, 1999, NAT GENET, V23, P71, DOI 10.1038/12674; Huang HP, 2000, MOL CELL BIOL, V20, P3292, DOI 10.1128/MCB.20.9.3292-3307.2000; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1989, MOL CELL BIOL, V9, P823, DOI 10.1128/MCB.9.2.823; Li H, 1999, NAT GENET, V23, P67; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Offield MF, 1996, DEVELOPMENT, V122, P983; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; PEYTON M, 1994, J BIOL CHEM, V269, P25936; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; Sharma S, 1997, MOL CELL BIOL, V17, P2598, DOI 10.1128/MCB.17.5.2598; SHEIH S, 1991, J BIOL CHEM, V266, P16708; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; Smith KM, 1997, INT IMMUNOL, V9, P1355, DOI 10.1093/intimm/9.9.1355; Smith SB, 1999, MOL CELL BIOL, V19, P8272; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; Tao M, 1998, DIABETES, V47, P1650, DOI 10.2337/diabetes.47.10.1650; Tokuyama Y, 1998, BIOCHEM BIOPH RES CO, V248, P153, DOI 10.1006/bbrc.1998.8925; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	53	63	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36910	36919		10.1074/jbc.M005202200	http://dx.doi.org/10.1074/jbc.M005202200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967107	hybrid			2022-12-27	WOS:000165577700066
J	Bell, DR; Poland, A				Bell, DR; Poland, A			Binding of aryl hydrocarbon receptor (AhR) to AhR-interacting protein - The role of hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; PROGESTERONE-RECEPTOR; DIOXIN RECEPTOR; CORE COMPLEX; IN-VIVO; DOMAIN; IDENTIFICATION; GELDANAMYCIN; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; HEAT-SHOCK-PROTEIN-90	The aryl hydrocarbon receptor (AhR) has been shown to interact with an immunophilin-like molecule known as AhR-interacting protein (AIP) and to enhance AhR function. We show here that AIP associates with AhR homologues from mouse and fish, which can bind ligands such as dioxin, but nonligand binding homologues from Caenorhabditis elegans or Drosophila do not bind to AIP. However, a minimal ligand-binding domain of the AhR is incapable of binding AIP. The binding of AIP to AhR in reticulocyte lysate shows several of the characteristics of an hsp90-dependent process, including sensitivity to geldanamycin and temperature and a requirement for ATP or nonhydrolyzable analogues. Purified AIP binds to the C terminus of hsp90, and mutation of a conserved basic residue in the tetratricopeptide repeats of AIP (K266A, analogous to K97A in protein phosphatase 5) abolishes binding to hsp90. Mutation of K266A in AIP reduces binding to AhR by 75-80%; the geldanamycin sensitivity of this complex shows that AhR stabilizes the AIP-hsp90-AhR complex. The alpha -helical C terminus of AIP, which is outside the tetratricopeptide repeat domain, is absolutely required for binding to AhR as shown by deletions of the C-terminal 5 amino acids or alanine-scanning mutagenesis, but it is not required for binding of AIP to hsp90. The data support a model where 1) AIP binds to both hsp90 and AhR; 2) hsp90 is required for AhR-AIP binding; and 3) the binding of AhR to AIP stabilizes the AIP-hsp90-AhR complex.	NIOSH, Hlth Effects Lab Div, Ctr Dis Control, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Bell, DR (corresponding author), Univ Nottingham, Sch Biol Sci, Nottingham NG7 2RD, England.	david.bell@nottingham.ac.uk						Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chen HS, 1997, ARCH BIOCHEM BIOPHYS, V348, P190, DOI 10.1006/abbi.1997.0398; COUMAILLEAU P, 1995, J BIOL CHEM, V270, P25291, DOI 10.1074/jbc.270.42.25291; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Duncan DM, 1998, GENE DEV, V12, P1290, DOI 10.1101/gad.12.9.1290; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Giannone JV, 1998, BIOCHEM PHARMACOL, V55, P489, DOI 10.1016/S0006-2952(97)00493-0; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; Karchner SI, 1999, J BIOL CHEM, V274, P33814, DOI 10.1074/jbc.274.47.33814; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432; Ma Q, 1997, J BIOL CHEM, V272, P8878; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1994, MOL PHARMACOL, V46, P915; Powell-Coffman JA, 1998, P NATL ACAD SCI USA, V95, P2844, DOI 10.1073/pnas.95.6.2844; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P10879, DOI 10.1021/bi00159a031; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; SMITH DF, 1992, J BIOL CHEM, V267, P1350; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	36	130	132	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36407	36414		10.1074/jbc.M004236200	http://dx.doi.org/10.1074/jbc.M004236200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10961990	hybrid			2022-12-27	WOS:000165382000106
J	Huang, THJ; Yang, DS; Fraser, PE; Chakrabartty, A				Huang, THJ; Yang, DS; Fraser, PE; Chakrabartty, A			Alternate aggregation pathways of the Alzheimer beta-amyloid peptide - An in vitro model of preamyloid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN FIBRILLOGENESIS; FIBRIL FORMATION; DOWNS-SYNDROME; DISEASE; PRECURSOR; REQUIRES; PLAQUES	Deposition of amyloid-beta (A beta) aggregates in the brain is a defining characteristic of Alzheimer's disease (AD), Fibrillar amyloid, found in the cores of senile plaques, is surrounded by dystrophic neurites, In contrast, the amorphous A beta (also called preamyloid) in diffuse plaques: is ndt associated with neurodegeneration. Depending on the conditions, A beta will also form fibrillar or amorphous aggregates in vitro, In this present study, we sought to characterize the properties of the amorphous aggregate and determine whether we could establish an in vitro model for amorphous A beta, CD data indicated that A beta 40 assembled to form either a beta -structured aggregate or an unfolded aggregate with the structured aggregate forming at high peptide concentrations and the unstructured aggregate forming at low A beta 40 levels. The critical concentration separating these two pathways was 10 muM. Fluorescence emission and polarization showed the structured aggregate was tightly packed containing peptides that were not accessible to water. Peptides in the unstructured aggregate were loosely packed, mobile, and accessible to water. When examined by electron microscopy, the structured aggregate appeared as protofibrillar structures and formed classic amyloid fibrils over a period of several weeks. The unstructured aggregate was not visible by electron microscopy and did not generate fibrils, These findings suggest that the unstructured aggregate shares many properties with the amorphous A beta of AD and that conditions can be established to form amorphous A beta in vitro. This would allow for investigations to better understand the relationship between fibrillar and amorphous A beta and could have significant impact upon efforts to find therapies for AD.	Univ Toronto, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Chakrabartty, A (corresponding author), Univ Toronto, Ontario Canc Inst, Div Mol & Struct Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Chakrabartty, Avi/0000-0001-7002-8381				CHANTLER PD, 1978, BIOCHEMISTRY-US, V17, P5440, DOI 10.1021/bi00618a018; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MANN DMA, 1989, NEUROBIOL AGING, V10, P397, DOI 10.1016/0197-4580(89)90073-0; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; WISNIEWSKI KE, 1985, NEUROLOGY, V35, P957, DOI 10.1212/WNL.35.7.957; YAMAGUCHI H, 1989, AM J PATHOL, V135, P593; Yang DS, 1999, J BIOL CHEM, V274, P32970, DOI 10.1074/jbc.274.46.32970	20	64	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36436	36440		10.1074/jbc.M005698200	http://dx.doi.org/10.1074/jbc.M005698200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10961999	hybrid			2022-12-27	WOS:000165382000110
J	Petersen, DN; Tkalcevic, GT; Mansolf, AL; Rivera-Gonzalez, R; Brown, TA				Petersen, DN; Tkalcevic, GT; Mansolf, AL; Rivera-Gonzalez, R; Brown, TA			Identification of osteoblast/osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMAL CELL-CULTURES; IMPERFECTA TYPE-II; MATRIX ACIDIC PHOSPHOPROTEIN; OSTEOCALCIN-DEFICIENT MICE; ADULT HUMAN BONE; PROGRESSIVE DEVELOPMENT; EXTRACELLULAR-MATRIX; MESSENGER-RNA; IN-VITRO; MARROW	We describe the cloning and characterization of a novel bone-specific cDNA predicted to encode an extracellular matrix protein. This cDNA was identified by subtractive hybridization based upon its high expression in bone marrow-derived osteoblasts. By Northern blot analysis, we detected a single a-kilobase mRNA transcript in bone, whereas no expression was detected in Other tissues. Immunohistochemistry revealed that the protein was expressed highly in osteocytes within trabecular and cortical bone. RNA and protein expression analysis using in vivo marrow ablation as a model of bone remodeling demonstrated that this gene was expressed only in cells that were embedded within bone matrix in contrast to the earlier expression of known osteoblast markers. The cDNA was predicted to encode a serine/glycine-rich secreted peptide containing numerous potential phosphorylation sites and one RGD sequence motif. The interaction of RGD domain-containing peptides with integrins has been shown previously to regulate bone remodeling by promoting recruitment, attachment, and differentiation of osteoblasts and osteoclasts,: Secretion of this RGD-containing protein from osteocytes has the potential to regulate cellular activities within-the bone environment and thereby may impact bone homeostasis. We propose the name OF45 (osteoblast/osteocyte factor of 45 kDa) for this novel cDNA.	Pfizer Inc, Global Res & Dev, Dept Cardiovasc & Metab Dis, Groton, CT 06340 USA	Pfizer	Brown, TA (corresponding author), Pfizer Inc, Global Res & Dev, Dept Cardiovasc & Metab Dis, Box 8118W-215,Eastern Point Rd, Groton, CT 06340 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APLIN HM, 1995, GENOMICS, V30, P347, DOI 10.1006/geno.1995.9867; Aubin JE, 1999, J CELL BIOCHEM, V72, P396, DOI 10.1002/(SICI)1097-4644(19990301)72:3<396::AID-JCB9>3.3.CO;2-Y; BAB IA, 1995, BONE, V17, pA437; BERESFORD JN, 1992, J CELL SCI, V102, P341; Bodine PVN, 1999, BONE, V25, P535, DOI 10.1016/S8756-3282(99)00213-6; Boskey AL, 1998, BONE, V23, P187, DOI 10.1016/S8756-3282(98)00092-1; Boskey AL, 1996, CONNECT TISSUE RES, V35, P357, DOI 10.3109/03008209609029212; Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101; Butler W T, 1995, Connect Tissue Res, V33, P59, DOI 10.3109/03008209509016983; Butler WT, 1997, CIBA F SYMP, V205, P107; BUTLER WT, 1995, INT J DEV BIOL, V39, P169; CHEN TL, 1983, ENDOCRINOLOGY, V112, P1739, DOI 10.1210/endo-112-5-1739; CHOMCZYNSKI P, 1995, BIOTECHNIQUES, V19, P942; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Erdmann J, 1999, MECH AGEING DEV, V110, P73, DOI 10.1016/S0047-6374(99)00043-3; FROHMAN MA, 1994, PCR METH APPL, V4, P540; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; George A, 1995, Connect Tissue Res, V33, P67, DOI 10.3109/03008209509016984; GEORGE A, 1993, J BIOL CHEM, V268, P12624; Harlow E., 1988, ANTIBODIES LAB MANUA; Herbertson A, 1997, BONE, V21, P491, DOI 10.1016/S8756-3282(97)00197-X; Hirst KL, 1997, GENOMICS, V42, P38, DOI 10.1006/geno.1997.4700; INGRAM RT, 1993, J BONE MINER RES, V8, P1019; Katzburg S, 1999, BONE, V25, P667, DOI 10.1016/S8756-3282(99)00225-2; Lanyon L.E., 1993, CALCIFIED TISSUE INT, V53, P102; LEBOY PS, 1991, J CELL PHYSIOL, V146, P370, DOI 10.1002/jcp.1041460306; Lozupone E, 1996, CLIN RHEUMATOL, V15, P563, DOI 10.1007/BF02238545; MacDougall M, 1998, J BONE MINER RES, V13, P422, DOI 10.1359/jbmr.1998.13.3.422; MacDougall M, 1998, EUR J ORAL SCI, V106, P227, DOI 10.1111/j.1600-0722.1998.tb02180.x; MacDougall M, 1996, CYTOGENET CELL GENET, V74, P189, DOI 10.1159/000134410; Malaval L, 1999, J CELL BIOCHEM, V74, P616; MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PALUMBO C, 1990, ACTA ANAT, V137, P350; PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303; RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022; Rickard DJ, 1996, J BONE MINER RES, V11, P312; Rivera-Gonzalez R, 1998, J STEROID BIOCHEM, V64, P13, DOI 10.1016/S0960-0760(97)00142-8; Robey PG, 1996, CONNECT TISSUE RES, V35, P131, DOI 10.3109/03008209609029183; Rodriguez JP, 1999, J CELL BIOCHEM, V75, P414, DOI 10.1002/(SICI)1097-4644(19991201)75:3<414::AID-JCB7>3.0.CO;2-C; ROHOLL PJM, 1994, J BONE MINER RES, V9, P355; Sambrook J., 2002, MOL CLONING LAB MANU; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; SUVA LJ, 1993, J BONE MINER RES, V8, P379; THIEDE MA, 1994, ENDOCRINOLOGY, V135, P929, DOI 10.1210/en.135.3.929; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WLODARSKI KH, 1990, CLIN ORTHOP RELAT R, P276; YAO KL, 1994, J BONE MINER RES, V9, P231	53	94	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36172	36180		10.1074/jbc.M003622200	http://dx.doi.org/10.1074/jbc.M003622200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967096	hybrid			2022-12-27	WOS:000165382000075
J	Srinivasula, SM; Datta, P; Fan, XJ; Fernandes-Alnemri, T; Huang, ZW; Alnemri, ES				Srinivasula, SM; Datta, P; Fan, XJ; Fernandes-Alnemri, T; Huang, ZW; Alnemri, ES			Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CELL-SURVIVAL; APOPTOSIS; ACTIVATION; INHIBITOR; PROTEIN; OLIGOMERIZATION; MITOCHONDRIA; PROCASPASE-9; CLEAVAGE	Smac/DLABLO is a mitochondrial protein that is released along with cytochrome c during apoptosis and promotes cytochrome c-dependent caspase activation by neutralizing inhibitor of apoptosis proteins (IAPs). We provide evidence that Smac/DIABLO functions at the levels: of both :the Apaf-1-caspase-9 apoptosome and effector caspases. The N terminus of Smac/DIABLO is absolutely required for its ability to interact with the baculovirus IAP repeat (BIR3) of XIAP and to promote cytochrome c dependent caspase activation. However, it is less critical for its ability to interact with BIR1/BIR2 of XIAP and to promote the activity of the effector caspases. Consistent with the ability of Smac/DIABLO to function at the level of the effector caspases, expression of a cytosolic Smac/DIABLO in Type II cells allowed TRAIL to bypass Bcl-xL inhibition of death receptor-induced apoptosis. Combined, these data suggest that Smac/DIABLO plays a critical role in neutralizing IAP inhibition of the effector caspases in the death receptor pathway of Type II cells.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg,904,233 S 10th St, Philadelphia, PA 19107 USA.		Alnemri, Emad S/B-4526-2010		NCI NIH HHS [CA78890] Funding Source: Medline; NIA NIH HHS [AG14357, AG13487] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013487, R01AG014357] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	33	288	323	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36152	36157		10.1074/jbc.C000533200	http://dx.doi.org/10.1074/jbc.C000533200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10950947	hybrid			2022-12-27	WOS:000165382000072
J	Turner, FB; Taylor, SM; Moran, RG				Turner, FB; Taylor, SM; Moran, RG			Expression patterns of the multiple transcripts from the folylpolyglutamate synthetase gene in human leukemias and normal differentiated tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMATE SYNTHETASE; ORGANIZATION; CELLS	Folylpoly-gamma -glutamate synthetase (FPGS) catalyzes the activation of folate antimetabolites in mammalian tissues and tumors. We have determined the sequence, abundance, and function of human FPGS transcripts and found some striking differences to transcription of the mouse gene that allow production of FPGS isoforms in mouse liver and dividing tissues. Multiple human transcripts were identified, including the homolog of the mouse transcripts that initiate at two upstream exons. However, the human FPGS upstream promoter is infrequently used, and transcripts from this promoter include sequences homologous with only one of the upstream exons found in the mouse, The downstream promoter generates an array of transcripts, some of which do not produce active enzyme, a phenomenon not seen in the mouse, Hence, the dual promoter mechanism directing expression of FPGS isozymes in mouse tissues is not conserved in humans, and, unlike the mouse downstream promoter, the human downstream promoter is active in both dividing and differentiated tissues. This study raises questions about the differences in function served by the two mouse FPGS isozymes and how, or if, human tissues fulfill these functions. How humans and mice-produce FPGS in only a subset of tissues using such different promoter structures also becomes a central issue.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Immunol & Microbiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Moran, RG (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA.	rmoran@hsc.vcu.edu			NATIONAL CANCER INSTITUTE [R01CA039687] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39687] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen J, 2000, GENE, V242, P257, DOI 10.1016/S0378-1119(99)00507-7; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; Freemantle SJ, 1997, J BIOL CHEM, V272, P25373, DOI 10.1074/jbc.272.40.25373; FREEMANTLE SJ, 1995, J BIOL CHEM, V270, P9579, DOI 10.1074/jbc.270.16.9579; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Longo GSA, 1997, BLOOD, V90, P1241, DOI 10.1182/blood.V90.3.1241.1241_1241_1245; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCGUIRE JJ, 1986, BIOCHEM PHARMACOL, V35, P2607, DOI 10.1016/0006-2952(86)90060-2; MORAN RG, 1984, ANAL BIOCHEM, V140, P326, DOI 10.1016/0003-2697(84)90174-X; Roy K, 1997, J BIOL CHEM, V272, P5587, DOI 10.1074/jbc.272.9.5587; Roy K, 1996, J BIOL CHEM, V271, P23820, DOI 10.1074/jbc.271.39.23820; SHANE B, 1989, VITAM HORM, V45, P263; SIROTNAK FM, 1988, BIOCHEM PHARMACOL, V37, P4239, DOI 10.1016/0006-2952(88)90122-0; TAYLOR SM, 1995, CANCER RES, V55, P6030; Turner FB, 1999, CANCER RES, V59, P6074	15	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35960	35968		10.1074/jbc.M005228200	http://dx.doi.org/10.1074/jbc.M005228200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964921	hybrid			2022-12-27	WOS:000165382000046
J	Ozaki, M; Deshpande, SS; Angkeow, P; Suzuki, S; Irani, K				Ozaki, M; Deshpande, SS; Angkeow, P; Suzuki, S; Irani, K			Rac1 regulates stress-induced, redox-dependent heat shock factor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; JUN NH2-TERMINAL KINASE; NECROSIS-FACTOR-ALPHA; DNA-BINDING ACTIVITY; C-JUN; TRANSCRIPTION FACTOR; HEME OXYGENASE-1; GENE-EXPRESSION; PROTEIN-KINASES; FACTOR-I	The signaling pathway by which environmental stresses activate heat shock factors (HSFs) is not completely understood. We show that the small GTPase rad, and Rad-regulated reactive oxygen species (ROS) play an important role in stress-stimulated heat shock response. A dominant-negative allele of Rad (Rac1N17) inhibits the hypoxia/reoxygenation and sodium arsenite-induced transcriptional activity of HSF-1 and the transcription of heat shock protein 70. Rac1N17 also suppresses the production of intracellular ROS induced by hypoxia/reoxygenation or sodium arsenite. Moreover, direct suppression of intracellular ROS levels by antioxidants decreases stress-stimulated HSF activity. However, expression of a constitutively active mutant of Rad (Rac1V12) in the absence of extracellular stresses does not increase intracellular ROS levels or induce the heat shock response. These results show that Rad is a necessary but insufficient component of the stress-induced signaling pathway that leads to ROS production, activation of HSFs, and transcription of heat shock proteins.	Johns Hopkins Univ, Sch Med, Div Cardiol, Dept Med, Baltimore, MD 21205 USA; Natl Childrens Med Res Ctr, Div Expt Surg, Tokyo 1548509, Japan	Johns Hopkins University; National Center for Child Health & Development - Japan	Irani, K (corresponding author), Johns Hopkins Univ, Sch Med, Div Cardiol, Dept Med, Ross 1023,720 Rutland Ave, Baltimore, MD 21205 USA.		Ozaki, Michitaka/A-4549-2012	Irani, Kaikobad/0000-0001-9194-7387				AUCOIN MM, 1995, AM J PHYSIOL-HEART C, V268, pH1651, DOI 10.1152/ajpheart.1995.268.4.H1651; BAUMAN JW, 1993, FUND APPL TOXICOL, V21, P15, DOI 10.1006/faat.1993.1066; BENJAMIN IJ, 1990, P NATL ACAD SCI USA, V87, P6263, DOI 10.1073/pnas.87.16.6263; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Cool RH, 1998, BIOCHEM J, V332, P5, DOI 10.1042/bj3320005; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; DAS DK, 1993, CARDIOVASC RES, V27, P578, DOI 10.1093/cvr/27.4.578; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P1217, DOI 10.1091/mbc.4.11.1217; HUANG LE, 1994, J BIOL CHEM, V269, P30718; Hutter JJ, 1996, CIRCULATION, V94, P1408, DOI 10.1161/01.CIR.94.6.1408; IRANI K, 1994, BIOCHEM BIOPH RES CO, V202, P1252, DOI 10.1006/bbrc.1994.2065; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JacquierSarlin MR, 1996, BIOCHEM J, V318, P187, DOI 10.1042/bj3180187; JACQUIERSARLIN MR, 1995, J BIOL CHEM, V270, P14094, DOI 10.1074/jbc.270.23.14094; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; Kim SH, 1999, BIOCHEM BIOPH RES CO, V262, P516, DOI 10.1006/bbrc.1999.1229; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; KUKREJA RC, 1994, AM J PHYSIOL-HEART C, V267, pH2213, DOI 10.1152/ajpheart.1994.267.6.H2213; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Lee YJ, 1998, J BIOL CHEM, V273, P29857, DOI 10.1074/jbc.273.45.29857; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; MIVECHI NF, 1994, INT J HYPERTHER, V10, P371, DOI 10.3109/02656739409010281; MIVECHI NF, 1995, CANCER RES, V55, P5512; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; POMBO CM, 1994, J BIOL CHEM, V269, P26546; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; REDDY MV, 1992, INFECT IMMUN, V60, P2386, DOI 10.1128/IAI.60.6.2386-2390.1992; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SAUNDERS EL, 1991, ARCH BIOCHEM BIOPHYS, V288, P368, DOI 10.1016/0003-9861(91)90208-Z; SCHOENIGER LO, 1994, GASTROENTEROLOGY, V106, P177, DOI 10.1016/S0016-5085(94)95209-4; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441	45	74	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35377	35383		10.1074/jbc.M005287200	http://dx.doi.org/10.1074/jbc.M005287200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952983	hybrid			2022-12-27	WOS:000165422800073
J	Yoo, BC; Aoki, K; Xiang, Y; Campbell, LR; Hull, RJ; Xoconostle-Cazares, B; Monzer, J; Lee, JY; Ullman, DE; Lucas, WJ				Yoo, BC; Aoki, K; Xiang, Y; Campbell, LR; Hull, RJ; Xoconostle-Cazares, B; Monzer, J; Lee, JY; Ullman, DE; Lucas, WJ			Characterization of Cucurbita maxima phloem serpin-1 (CmPS-1) - A developmentally regulated elastase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-TO-CELL; PROTEINASE-INHIBITORS; PROTEASE INHIBITORS; RICINUS-COMMUNIS; MESSENGER-RNA; ACYRTHOSIPHON-PISUM; PLANT DEFENSE; MANDUCA-SEXTA; INSECTS; EXUDATE	We report on the molecular, biochemical, and functional characterization of Cucurbita maxima phloem serpin-1 (CmPS-1), a novel 42-kDa serine proteinase inhibitor,that is developmentally regulated and has anti-elastase properties. CmPS-1 was purified to near homogeneity from C. maxima (pumpkin) phloem exudate and, based on microsequence analysis, the cDNA encoding CmPS-1 was cloned. The association rate constant (k(a)) of phloem-purified and recombinant His(6)-tagged CmPS-1 for elastase was 3.5 +/- 1.6 x 10(5) and 2.7 +/- 0.4 x 10(5) M-1 s(-1), respectively. The fraction of complex-forming CmPS-1 X-inh, was estimated at 79%. CmPS-1 displayed no detectable inhibitory properties against chymotrypsin, trypsin, or thrombin. The elastase cleavage sites within the reactive center loop of CmPS-1 were determined to be Val(347)-Gly(348) and Val(350)-Ser(351) With a 3:2 molar ratio. In vivo feeding assays conducted with the piercing-sucking aphid, Myzus persicae, established a close correlation between the developmentally regulated increase in CmPS-1 within the phloem sap and the reduced ability of these insects to survive and reproduce on C. maxima. However, in vitro feeding experiments, using purified phloem CmPS-1, failed to demonstrate a direct effect on aphid survival. Likely roles of this novel phloem serpin in defense against insects/pathogens are discussed.	Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Coll Agr & Environm Sci, Davis, CA 95616 USA; Univ Calif Davis, Dept Entomol, Coll Agr & Environm Sci, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Lucas, WJ (corresponding author), Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Coll Agr & Environm Sci, 1 Shields Ave, Davis, CA 95616 USA.			Lee, Jinkee/0000-0001-5590-0549; Lee, Jung-Youn/0000-0003-4604-7974				Balachandran S, 1997, P NATL ACAD SCI USA, V94, P14150, DOI 10.1073/pnas.94.25.14150; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; BORKOVEC V, 1994, PLANT GROWTH REGUL, V15, P137, DOI 10.1007/BF00024103; BRANDT A, 1990, EUR J BIOCHEM, V194, P499, DOI 10.1111/j.1432-1033.1990.tb15644.x; BROADWAY RM, 1986, ENTOMOL EXP APPL, V41, P33, DOI 10.1007/BF00343486; Caillaud CM, 1996, EXPERIENTIA, V52, P927, DOI 10.1007/BF01938882; Carrell RW, 1996, BIOL CHEM H-S, V377, P1; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; Chino M, 1991, RECENT ADV PHLOEM TR, P64; Christeller JT, 1998, EUR J BIOCHEM, V254, P160, DOI 10.1046/j.1432-1327.1998.2540160.x; CHRISTELLER JT, 1992, INSECT BIOCHEM MOLEC, V22, P735, DOI 10.1016/0965-1748(92)90052-G; Dahl SW, 1996, FEBS LETT, V394, P165, DOI 10.1016/0014-5793(96)00940-4; Dahl SW, 1996, J BIOL CHEM, V271, P25083, DOI 10.1074/jbc.271.41.25083; Duffey SS, 1996, ARCH INSECT BIOCHEM, V32, P3, DOI 10.1002/(SICI)1520-6327(1996)32:1&lt;3::AID-ARCH2&gt;3.0.CO;2-1; FISHER DB, 1992, PLANT PHYSIOL, V100, P1433, DOI 10.1104/pp.100.3.1433; Golecki B, 1999, PLANT CELL, V11, P127, DOI 10.1105/tpc.11.1.127; Habu Y, 1996, PLANT MOL BIOL, V32, P1209, DOI 10.1007/BF00041408; Ishiwatari Y, 1998, PLANTA, V205, P12, DOI 10.1007/s004250050291; Jiang HB, 1997, J BIOL CHEM, V272, P1082, DOI 10.1074/jbc.272.2.1082; Jongsma MA, 1997, J INSECT PHYSIOL, V43, P885, DOI 10.1016/S0022-1910(97)00040-1; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Kamboj JS, 1998, PLANT GROWTH REGUL, V25, P123, DOI 10.1023/A:1006016023707; KANOST MR, 1989, J BIOL CHEM, V264, P965; Khadhair AH, 2000, MICROBIOL RES, V155, P53, DOI 10.1016/S0944-5013(00)80023-3; Klingler J, 1998, ENTOMOL EXP APPL, V86, P79, DOI 10.1023/A:1003153410049; Koiwa H, 1997, TRENDS PLANT SCI, V2, P379, DOI 10.1016/S1360-1385(97)90052-2; Kuhn C, 1997, SCIENCE, V275, P1298, DOI 10.1126/science.275.5304.1298; Lherminier J, 1999, MOL CELL PROBE, V13, P41, DOI 10.1006/mcpr.1998.0213; MACGIBBON DB, 1986, J SCI FOOD AGR, V37, P515, DOI 10.1002/jsfa.2740370602; MURRAY C, 1995, BIOL CHEM H-S, V376, P281, DOI 10.1515/bchm3.1995.376.5.281; RAHBE Y, 1993, ENTOMOL EXP APPL, V67, P149, DOI 10.1007/BF02386520; RAHBE Y, 1995, ENTOMOL EXP APPL, V76, P143, DOI 10.1007/BF02383212; RASMUSSEN SK, 1993, BIOCHIM BIOPHYS ACTA, V1172, P151, DOI 10.1016/0167-4781(93)90282-I; Rasmussen SK, 1996, PLANT MOL BIOL, V30, P673, DOI 10.1007/BF00049343; Ruiz-Medrano R, 1999, DEVELOPMENT, V126, P4405; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; Ryan CA, 1998, ANNU REV CELL DEV BI, V14, P1, DOI 10.1146/annurev.cellbio.14.1.1; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; Sasaki T, 1998, PLANT CELL PHYSIOL, V39, P895, DOI 10.1093/oxfordjournals.pcp.a029451; Schaller A, 1996, BIOESSAYS, V18, P27, DOI 10.1002/bies.950180108; Simpson AJ, 1999, FEBS LETT, V452, P309, DOI 10.1016/S0014-5793(99)00670-5; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TIEDEMANN R, 1994, J PLANT PHYSIOL, V143, P189, DOI 10.1016/S0176-1617(11)81685-8; WIECZOREK M, 1985, BIOCHEM BIOPH RES CO, V126, P646, DOI 10.1016/0006-291X(85)90233-5; Xoconostle-Cazares B, 1999, SCIENCE, V283, P94, DOI 10.1126/science.283.5398.94; ZIMMERMANN HM, 1975, ENCY PLANT PHYSL NEW, V1	48	66	70	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35122	35128		10.1074/jbc.M006060200	http://dx.doi.org/10.1074/jbc.M006060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10960478	hybrid			2022-12-27	WOS:000165422800041
J	Escargueil, AE; Plisov, SY; Filhol, O; Cochet, C; Larsen, AK				Escargueil, AE; Plisov, SY; Filhol, O; Cochet, C; Larsen, AK			Mitotic phosphorylation of DNA topoisomerase II alpha by protein kinase CK2 creates the MPM-2 phosphoepitope on Ser-1469	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-PHASE PHOSPHOPROTEINS; CELL-CYCLE; CASEIN KINASE-2; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; SPECIFICITY DETERMINANTS; MONOCLONAL-ANTIBODIES; SUBSTRATE-SPECIFICITY; MOLECULAR-CLONING; IN-VITRO	DNA. topoisomerase II alpha is required for chromatin condensation during prophase, This process is temporally linked with the appearance of mitosis-specific phosphorylation sites on topoisomerase II alpha including one recognized by the MPM-2 monoclonal antibody. We now report that the ability of mitotic extracts to create the MPM-2 epitope on human topoisomerase II alpha is abolished by immunodepletion of protein kinase CK2. Furthermore, the MPM-2 phosphoepitope on topoisomerase II alpha can be generated by purified CR2. Phosphorylation of C-truncated topoisomerase II alpha mutant proteins conclusively shows, that the MPM-2 epitope is present in the last 163 amino acids. Use of peptides containing all conserved CK2 consensus sites in this region indicates that only the peptide containing Arg-1466 to Ala-1485 is able to compete with topoisomerase II alpha for binding of the MPM-2 antibody. Replacement of Ser-1469 with Ala abolishes the ability of the phosphorylated peptide to bind to the MPM-2 antibody while a peptide containing phosphorylated Ser-1469 binds tightly. Surprisingly, the MPM-2 phosphoepitope influences neither the catalytic activity of topoisomerase II alpha nor its, ability to form molecular complexes with CR2 in vitro. In conclusion, we have identified protein kinase CR2 as a new MPM-2 kinase able to phosphorylate an important mitotic protein, topoisomerase II alpha; on Ser-1469.	Inst Gustave Roussy PR2, CNRS UMR 8532, Lab Biol & Pharmacol Tumeurs, F-94805 Villejuif, France; CEA, INSERM, U244, Lab Biochim Regulat Cellulaires Endocrine, F-38054 Grenoble 9, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Larsen, AK (corresponding author), Inst Gustave Roussy PR2, CNRS UMR 8532, Lab Biol & Pharmacol Tumeurs, F-94805 Villejuif, France.	aklarsen@igr.fr	Escargueil, Alexandre/K-5192-2019; Filhol-Cochet, Odile/I-3962-2016	Escargueil, Alexandre/0000-0002-7419-7518; Filhol, Odile/0000-0003-1964-7958; Cochet, Claude/0000-0002-1772-4270				ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; Che SL, 1997, FEBS LETT, V413, P417, DOI 10.1016/S0014-5793(97)00948-4; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DAVIS FM, 1989, CELL STRUCT FUNCT, V14, P271, DOI 10.1247/csf.14.271; Ding M, 1997, EXP CELL RES, V231, P3, DOI 10.1006/excr.1996.3439; ENGLE DB, 1988, CELL MOTIL CYTOSKEL, V10, P432, DOI 10.1002/cm.970100310; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FILHOL O, 1994, BIOCHEM BIOPH RES CO, V198, P660, DOI 10.1006/bbrc.1994.1096; FILHOLCOCHET O, 1994, CELL MOL BIOL RES, V40, P529; Gulli MP, 1997, CHROMOSOMA, V105, P532, DOI 10.1007/s004120050215; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; Ishida R, 1996, J BIOL CHEM, V271, P30077, DOI 10.1074/jbc.271.47.30077; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; Kimura K, 1996, J BIOL CHEM, V271, P10990, DOI 10.1074/jbc.271.18.10990; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KUANG J, 1993, J CELL BIOL, V123, P859, DOI 10.1083/jcb.123.4.859; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Larsen A K, 1996, Prog Cell Cycle Res, V2, P229; Li DX, 1996, J BIOL CHEM, V271, P15662, DOI 10.1074/jbc.271.26.15662; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; Logarinho E, 1998, J CELL SCI, V111, P2897; Lu KP, 1996, NATURE, V380, P544; MARCHIORI F, 1988, BIOCHIM BIOPHYS ACTA, V971, P332; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; MEGGIO F, 1995, EUR J BIOCHEM, V230, P1025, DOI 10.1111/j.1432-1033.1995.tb20651.x; MEGGIO F, 1988, BIOCHIM BIOPHYS ACTA, V971, P227, DOI 10.1016/S0005-2728(88)80111-7; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; Mirski SEL, 1997, EXP CELL RES, V237, P452, DOI 10.1006/excr.1997.3805; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Rattner JB, 1996, J CELL BIOL, V134, P1097, DOI 10.1083/jcb.134.5.1097; Redwood C, 1998, J BIOL CHEM, V273, P3635, DOI 10.1074/jbc.273.6.3635; Renzi L, 1997, J CELL SCI, V110, P2013; Rethinaswamy A, 1998, J BIOL CHEM, V273, P5869, DOI 10.1074/jbc.273.10.5869; Rieder CL, 1998, J CELL BIOL, V142, P1013, DOI 10.1083/jcb.142.4.1013; Schwab MS, 1997, EUR J CELL BIOL, V73, P287; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Suganuma M, 1999, CANCER RES, V59, P5887; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TAAGEPERA S, 1994, MOL BIOL CELL, V5, P1243, DOI 10.1091/mbc.5.11.1243; TOMBES RM, 1991, CELL REGUL, V2, P861, DOI 10.1091/mbc.2.11.861; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VANDRE DD, 1991, J CELL SCI, V98, P577; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WELLS NJ, 1995, EUR J BIOCHEM, V231, P491, DOI 10.1111/j.1432-1033.1995.tb20723.x; WELLS NJ, 1994, J BIOL CHEM, V269, P29746; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x	74	70	75	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34710	34718		10.1074/jbc.M005179200	http://dx.doi.org/10.1074/jbc.M005179200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942766	hybrid			2022-12-27	WOS:000165095300095
J	Pei, DQ; Kang, TB; Qi, HX				Pei, DQ; Kang, TB; Qi, HX			Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN STROMELYSIN-3; BREAST-CARCINOMA; MEMBRANE-PROTEIN; DOMAIN; FAMILY; SURFACE; CLONING; CELLS; ALPHA; IDENTIFICATION	Matrix metalloproteinases characterized so far are either secreted or membrane anchored via a type I transmembrane domain or a glycosylphosphatidylinositol linkage. Lacking either membrane-anchoring mechanism, the newly discovered CA-MMP/MMP-23 was reported to be expressed as a cell-associated protein. In this report, we present evidence that CA-MMP is expressed as an integral membrane zymogen with an N-terminal signal anchor, and secreted as a fully processed mature enzyme. We further demonstrate that L(20)GAALSGLCLLSALALL(36) is required for this unique membrane localization as a signal anchor and its secretion is regulated by a proprotein convertase motif RRRR79 sandwiched between its pro- and catalytic domains. Thus, CA-MMP is a type II transmembrane MMP that can be regulated by a single proteolytic cleavage for both activation and secretion, establishing a novel paradigm for protein trafficking and processing within the secretory pathway.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Pei, DQ (corresponding author), Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA.	peixx003@tc.umn.edu			NATIONAL CANCER INSTITUTE [R01CA076308, R29CA076308] Funding Source: NIH RePORTER; NCI NIH HHS [CA76308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belien ATJ, 1999, J CELL BIOL, V144, P373, DOI 10.1083/jcb.144.2.373; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Kirschner M, 1999, TRENDS CELL BIOL, V9, pM42, DOI 10.1016/S0962-8924(99)01666-9; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; McLaughlin RE, 1999, BBA-MOL CELL RES, V1451, P82, DOI 10.1016/S0167-4889(99)00074-9; Mody N, 1999, NEUROPHARMACOLOGY, V38, P1485, DOI 10.1016/S0028-3908(99)00099-4; Nagase H, 1997, BIOL CHEM, V378, P151; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Pei DQ, 1998, PROTEIN EXPRES PURIF, V13, P277, DOI 10.1006/prep.1998.0894; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1999, FEBS LETT, V457, P262, DOI 10.1016/S0014-5793(99)01046-7; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Puente XS, 1996, CANCER RES, V56, P944; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Rolls MM, 1999, J CELL BIOL, V146, P29, DOI 10.1083/jcb.146.1.29; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Shapiro SD, 1999, THROMB HAEMOSTASIS, V82, P846; SPIESS M, 1987, EMBO J, V6, P2683, DOI 10.1002/j.1460-2075.1987.tb02560.x; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Velasco G, 1999, J BIOL CHEM, V274, P4570, DOI 10.1074/jbc.274.8.4570; Villadangos JA, 1999, IMMUNOL REV, V172, P109, DOI 10.1111/j.1600-065X.1999.tb01360.x; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	51	98	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33988	33997		10.1074/jbc.M006493200	http://dx.doi.org/10.1074/jbc.M006493200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10945999	hybrid			2022-12-27	WOS:000090104600112
J	Zeng, HW; Phang, T; Song, YS; Ji, I; Ji, TH				Zeng, HW; Phang, T; Song, YS; Ji, I; Ji, TH			The role of the hinge region of the luteinizing hormone receptor in hormone interaction and signal generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; AMINO-TERMINAL REGION; LEUCINE-RICH REPEATS; EXTRACELLULAR DOMAIN; HIGH-AFFINITY; SECONDARY-STRUCTURE; BINDING; PROTEIN; ACTIVATION	Luteinizing hormone receptor, a G protein-coupled receptor, consists of two halves, the N-terminal extracellular hormone binding domain (exodomain) and the C-terminal membrane-associated, signal-generating domain (endodomain). The exodomain has seven to nine Leu-rich repeats, which are generally thought to form a 1/3 donut-like structure and interact with human choriogonadotropin (hCG), The resulting hCG-exodomain complex adjusts the structure and its association with the endodomain, which results in signal generation in the endodomain. It is unclear whether the rigid 1/3 donut structure could provide the agility and versatility of this dynamic action. In addition, there is no clue as to where the endodomain contact point (the signal modulator) in the exodomain is. To address these issues, the exodomain was examined by Ala scan and multiple substitutions, while receptor peptides were used for photoaffinity labeling and affinity cross-linking. Our results show that the C-flanking sequence (hinge region), Thr(250)-Gln(268), Of the Leu-rich repeats (LRRs) specifically interacts with hCG, preferentially hCG alpha. This interaction is inhibited by exoloop 2 of the endodomain but not by exoloops 1 and 3, suggesting an intimate relationship between Thg(250)-Gln(268), exoloop a, and hCG, Taken together, our observations in this article suggest a new paradigm that the LRRs contact the front of hCG, while both flanking regions of the LRRs interact with the sides of hCG. This would trap hCG in the 1/3 donut structure of the LRRs and enhance the binding affinity. In addition, mutations of conserved Ser(255) in the sequence can constitutively activate the receptor. This provides a clue for the signal modulator in the exodomain. In contrast, a phenyl or phenolic group is necessary at conserved Tyr(253) for targeting the receptor to the surface.	Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul 110744, South Korea	University of Kentucky; Seoul National University (SNU)	Ji, TH (corresponding author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.		Song, Yong Sang/E-7824-2012	SONG, YONGSANG/0000-0001-7115-4021	NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abell A, 1996, J BIOL CHEM, V271, P4518; Angelova K, 2000, MOL ENDOCRINOL, V14, P459, DOI 10.1210/me.14.4.459; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Bhowmick N, 1999, ENDOCRINOLOGY, V140, P4558, DOI 10.1210/en.140.10.4558; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; Dias JA, 1998, BIOL REPROD, V58, P1331, DOI 10.1095/biolreprod58.6.1331; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Hong SH, 1998, J BIOL CHEM, V273, P13835, DOI 10.1074/jbc.273.22.13835; Huhtaniemi I, 1999, MOL CELL ENDOCRINOL, V151, P89, DOI 10.1016/S0303-7207(99)00015-5; JANIN J, 1990, J BIOL CHEM, V265, P16027; Jeoung MK, 2001, J BIOL CHEM, V276, P3443, DOI 10.1074/jbc.M003774200; JI I, 1993, J BIOL CHEM, V268, P20851; JI I, 1991, J BIOL CHEM, V266, P13076; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; Ji IH, 1995, ENDOCRINE, V3, P907, DOI 10.1007/BF02738896; JI IH, 1995, J BIOL CHEM, V270, P15970, DOI 10.1074/jbc.270.27.15970; JI L, 1980, P NATL ACAD SCI USA, V77, P7167; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Lobel LI, 1997, ENDOCRINOLOGY, V138, P1232, DOI 10.1210/en.138.3.1232; Lustbader JW, 1998, RECENT PROG HORM RES, V53, P395; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; Nakabayashi K, 2000, J BIOL CHEM, V275, P30264, DOI 10.1074/jbc.M005568200; Osuga Y, 1997, MOL ENDOCRINOL, V11, P1659, DOI 10.1210/me.11.11.1659; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; Phang T, 1998, J BIOL CHEM, V273, P13841, DOI 10.1074/jbc.273.22.13841; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; ROCHE PC, 1985, LUTEINIZING HORMONE, P17; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Ryu K, 1998, J BIOL CHEM, V273, P28953, DOI 10.1074/jbc.273.44.28953; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; Song YS, 2001, J BIOL CHEM, V276, P3426, DOI 10.1074/jbc.M003772200; Song YS, 2001, J BIOL CHEM, V276, P3436, DOI 10.1074/jbc.M003773200; Struthers MD, 1996, SCIENCE, V271, P342, DOI 10.1126/science.271.5247.342; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; XIE YB, 1990, J BIOL CHEM, V265, P21411; Zhang R, 1996, J BIOL CHEM, V271, P5755, DOI 10.1074/jbc.271.10.5755	55	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3451	3458		10.1074/jbc.M007488200	http://dx.doi.org/10.1074/jbc.M007488200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	10964934	hybrid			2022-12-27	WOS:000166784900061
J	Voit, R; Feldmaier-Fuchs, G; Schweikardt, T; Decker, H; Burmester, T				Voit, R; Feldmaier-Fuchs, G; Schweikardt, T; Decker, H; Burmester, T			Complete sequence of the 24-mer hemocyanin of the tarantula Eurypelma californicum - Structure and intramolecular evolution of the subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ARTHROPOD HEMOCYANINS; CRYSTAL-STRUCTURE; QUATERNARY STRUCTURE; MOLECULAR-CLONING; SPIDERS; HETEROGENEITY; HEXAMERINS; RESOLUTION	Hemocyanins are large oligomeric respiratory proteins found in many arthropods and molluscs. The hemocyanin of the tarantula Eurypelma californicum is a 24-mer protein complex with molecular mass of 1,726,459 Da that consists of seven different polypeptides (a-g); each occupying a distinct position within the native molecule, Here we report the complete molecular structure of the E. californicum hemocyanin as deduced from the corresponding cDNAs, This represents the first complex arthropod hemocyanin to be completely sequenced. The different subunits display 52-66% amino acid sequence identity. Within the subunits, the central domain, which bears the active center with the copper-binding sites A and B, displays the highest degree of identity. Using a homology modeling approach, the putative three-dimensional structure of individual subunits was deduced and compared. Phylogenetic analyses suggest that differentiation of the individual subunits occurred 400-550 million years ago. The hemocyanin of the stemline Chelicerata was probably a hexamer built up of six distinct subunit types a, b/c, d, e, f, and g, whereas that of the early Arachnida was originally a 24-mer that emerged after the differentiation of subunits b and c.	German Canc Res Ctr, Div Mol Biol Cell 2, D-69120 Heidelberg, Germany; Univ Munich, Inst Zool, D-80333 Munich, Germany; Johannes Gutenberg Univ Mainz, Inst Biophys, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Zool, D-55099 Mainz, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Voit, R (corresponding author), German Canc Res Ctr, Div Mol Biol Cell 2, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	R.Voit@dkfz-heidelberg.de	Burmester, Thorsten/I-7225-2013	Burmester, Thorsten/0000-0002-5772-7863; Schweikardt, Thorsten/0000-0002-1304-7970				BASYONY M, 1991, THESIS MUNCHEN GERMA; BEINTEMA JJ, 1994, MOL BIOL EVOL, V11, P493; Burmester T, 1998, J MOL EVOL, V47, P93, DOI 10.1007/PL00006366; Burmester T, 1996, J MOL EVOL, V42, P713, DOI 10.1007/BF02338804; Burmester T, 1999, J BIOL CHEM, V274, P13217, DOI 10.1074/jbc.274.19.13217; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; DAYHOFF MO, 1979, ATLAS PROTEIN SEQ S3, V5; DECKER H, 1979, H-S Z PHYSIOL CHEM, V360, P1505; Decker H, 1998, J BIOL CHEM, V273, P25889, DOI 10.1074/jbc.273.40.25889; Decker H, 2000, ANGEW CHEM INT EDIT, V39, P1591, DOI 10.1002/(SICI)1521-3773(20000502)39:9<1591::AID-ANIE1591>3.0.CO;2-H; Decker H, 1996, FEBS LETT, V393, P226, DOI 10.1016/0014-5793(96)00887-3; Dunlop J.A., 1998, Systematics Association Special Volume Series, V55, P221; Felsenstein J., 1985, EVOLUTION 1985, V39, P783; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; HAZES B, 1993, PROTEIN SCI, V2, P597; KEMPTER B, 1985, BIOL CHEM H-S, V366, P77, DOI 10.1515/bchm3.1985.366.1.77; KEMPTER B, 1983, NATURWISSENSCHAFTEN, V70, P255, DOI 10.1007/BF00405449; LAMY J, 1979, H-S Z PHYSIOL CHEM, V360, P889, DOI 10.1515/bchm2.1979.360.2.889; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LINZEN B, 1985, SCIENCE, V229, P519, DOI 10.1126/science.4023698; LOEWE R, 1973, HOPPESEYLERS Z PHYSL, V324, P182; MARKL J, 1981, H-S Z PHYSIOL CHEM, V362, P1631, DOI 10.1515/bchm2.1981.362.2.1631; MARKL J, 1979, J COMP PHYSIOL, V130, P283, DOI 10.1007/BF00689845; MARKL J, 1981, H-S Z PHYSIOL CHEM, V362, P185; Markl J., 1992, Advances in Comparative and Environmental Physiology, V13, P325; MARKL J, 1986, BIOL BULL, V171, P90, DOI 10.2307/1541909; MARKL J, 1980, H-S Z PHYSIOL CHEM, V361, P649, DOI 10.1515/bchm2.1980.361.1.649; MARKL J, 1981, H-S Z PHYSIOL CHEM, V362, P429, DOI 10.1515/bchm2.1981.362.1.429; MARKL J, 1982, H-S Z PHYSIOL CHEM, V363, P73, DOI 10.1515/bchm2.1982.363.1.73; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALVATO B, 1990, LIFE CHEM REPORTS, V8, P1; SCHARTAU W, 1983, H-S Z PHYSIOL CHEM, V364, P1383, DOI 10.1515/bchm2.1983.364.2.1383; Schartau W., 1986, P177; SCHARTAU W, 1990, BIOL CHEM H-S, V371, P557, DOI 10.1515/bchm3.1990.371.2.557; SCHNEIDER HJ, 1983, H-S Z PHYSIOL CHEM, V364, P1357, DOI 10.1515/bchm2.1983.364.2.1357; SCHNEIDER HJ, 1977, H-S Z PHYSIOL CHEM, V358, P1133, DOI 10.1515/bchm2.1977.358.2.1133; SONNER P, 1990, THESIS MUNCHEN GERMA; Valentine JW, 1999, DEVELOPMENT, V126, P851; VANHEEL M, 1994, MICRON, V25, P387, DOI 10.1016/0968-4328(94)90007-8; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; VOIT R, 1990, J BIOL CHEM, V265, P19447; VOIT R, 1986, EUR J BIOCHEM, V159, P23, DOI 10.1111/j.1432-1033.1986.tb09828.x; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; VOLL W, 1990, P NATL ACAD SCI USA, V87, P5312, DOI 10.1073/pnas.87.14.5312; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	47	57	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39339	39344		10.1074/jbc.M005442200	http://dx.doi.org/10.1074/jbc.M005442200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10961996	hybrid			2022-12-27	WOS:000165953100056
J	Iwamoto, T; Uehara, A; Imanaga, I; Shigekawa, M				Iwamoto, T; Uehara, A; Imanaga, I; Shigekawa, M			The Na+/Ca2+ exchanger NCX1 has oppositely oriented reentrant loop domains that contain conserved aspartic acids whose mutation alters its apparent Ca2+ affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOLEMMAL NA+-CA2+ EXCHANGER; PROTEIN-KINASE-C; FUNCTIONAL EXPRESSION; TRANSMEMBRANE SEGMENTS; DEPENDENT REGULATION; MOLECULAR-CLONING; POTASSIUM CHANNEL; GATED CHANNEL; PHOSPHORYLATION; SELECTIVITY	We examined the membrane topology and functional importance of residues in regions of the Na+/Ca2+ exchanger NCX1 encompassing the conserved internal a repeats by substituted cysteine scanning analysis and kinetic analysis of site directed mutants. The results suggest that both the alpha -1 repeat and a region encompassing the a-a repeat and its immediately C-terminal segment contain reentrant loop domains, each oriented in an opposite direction with respect to the membrane, We found that single or multiple mutations of six residues including Asn-125 and conserved aspartates Asp-130, Asp-825, and Asp-829 in the a repeat reentrant domains reduce the apparent affinity of the exchanger for extracellular Ca2+ by up to g-fold, In contrast, the triple cysteine mutation D130C/D825C/D829C did not influence the current-voltage (I-V) relationship of the exchange current. Cysteine accessibility scanning with different thiol modifiers suggested that N125C, D130C, and D825C may be located in a restricted aqueous space in the membrane accessible only to ions when examined with external probes, although N125C and D825C were previously shown to be internally accessible during exchange reaction. The results suggest that these reentrant domains in the a repeats may participate in the formation of the ion transport pathway in the exchanger with some of the aspartates possibly lining it or located close to it.	Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Suita, Osaka 5658565, Japan; Fukuoka Univ, Sch Med, Dept Physiol, Fukuoka 8140180, Japan	National Cerebral & Cardiovascular Center - Japan; Fukuoka University	Shigekawa, M (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Fujishiro Dai 5, Suita, Osaka 5658565, Japan.	shigekaw@ri.ncvc.go.jp						Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; Dingledine R, 1999, PHARMACOL REV, V51, P7; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1999, BIOPHYS J, V77, P775, DOI 10.1016/S0006-3495(99)76931-6; EISMANN E, 1994, P NATL ACAD SCI USA, V91, P1109, DOI 10.1073/pnas.91.3.1109; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Iwamoto T, 1999, J BIOL CHEM, V274, P23094, DOI 10.1074/jbc.274.33.23094; Iwamoto T, 1998, EUR J CELL BIOL, V76, P228, DOI 10.1016/S0171-9335(98)80038-1; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; Iwamoto T, 1998, AM J PHYSIOL-CELL PH, V275, pC423, DOI 10.1152/ajpcell.1998.275.2.C423; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; LI ZP, 1994, J BIOL CHEM, V269, P17434; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; ROOT MJ, 1993, NEURON, V11, P459, DOI 10.1016/0896-6273(93)90150-P; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Shaul O, 1999, EMBO J, V18, P3973, DOI 10.1093/emboj/18.14.3973; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Uehara A, 1997, PFLUG ARCH EUR J PHY, V434, P335, DOI 10.1007/s004240050405; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882	36	84	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38571	38580		10.1074/jbc.M003788200	http://dx.doi.org/10.1074/jbc.M003788200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10967097	hybrid			2022-12-27	WOS:000165739800059
J	Small, KM; Forbes, SL; Brown, KM; Liggett, SB				Small, KM; Forbes, SL; Brown, KM; Liggett, SB			An Asn to Lys polymorphism in the third intracellular loop of the human alpha(2A)-adrenergic receptor imparts enhanced agonist-promoted G(i) coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(2)-ADRENERGIC RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; ESSENTIAL-HYPERTENSION; SIGNAL-TRANSDUCTION; DOWN-REGULATION; SUBTYPE; DESENSITIZATION; PHOSPHORYLATION; ASSOCIATION; EXPRESSION	alpha (2A)-Adrenergic receptors (alpha (2A)AR) are presynaptic autoinhibitory receptors of noradrenergic neurons in the central and peripheral sympathetic nervous systems, which act to dynamically regulate neurotransmitter release. Signaling through the G(i)/G(o) family of G-proteins, the receptor subserves numerous homeostatic and central nervous system functions. A single nucleotide polymorphism of this receptor, which results in an Asn to Lys substitution at amino acid 251 of the third intracellular loop, was identified in the human population. The frequency of Lys-251 was 10-fold greater in African-Americans than in Caucasians, but was not associated with essential hypertension. To determine the consequences of this substitution, wild-type and Lys-251 receptors were expressed in CHO and COS-7 cells. Expression, ligand binding, and basal receptor function were unaffected by the substitution. However, agonist-promoted [S-35]GTP gammaS binding was similar to 40% greater with the Lys-251 receptor. This enhanced agonist function was observed with catecholamines, azepines, and imidazolines albeit to different degrees. In studies of agonist-promoted functional coupling to G(i), the polymorphic receptor displayed enhanced inhibition of adenylyl cyclase (60 +/- 4.4 versus 46 +/- 4.1% inhibition) and markedly enhanced stimulation of MAP kinase (57 +/- versus 15- +/- a-fold increase over basal) compared with wild-type alpha (2A)AR. The potency of epinephrine in stimulating inositol phosphate accumulation was increased similar to4 fold with the Lys-251 receptor. Unlike previously described variants of G-protein-coupled receptors, where the minor species causes either a loss of function or increased non-agonist function, Lys-251 alpha (2A)AR represents a new class of polymorphism whose phenotype is a gain of agonist-promoted function.	Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Liggett, SB (corresponding author), 231 Bethesda Ave,Rm 7511, Cincinnati, OH 45267 USA.		liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41496] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Altman JD, 1999, MOL PHARMACOL, V56, P154, DOI 10.1124/mol.56.1.154; Dao TT, 1998, J HYPERTENS, V16, P779, DOI 10.1097/00004872-199816060-00009; DECHASSEVAL R, 1992, NUCLEIC ACIDS RES, V20, P245, DOI 10.1093/nar/20.2.245; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; EASON MG, 1992, J BIOL CHEM, V267, P25473; Eason MG, 1996, J BIOL CHEM, V271, P12826, DOI 10.1074/jbc.271.22.12826; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; GOLDSTEIN DS, 1991, HYPERTENSION S3, V18, P40; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GUYER CA, 1990, J BIOL CHEM, V265, P17307; Hein L, 1999, NATURE, V402, P181, DOI 10.1038/46040; HOLMES B, 1983, DRUGS, V26, P212, DOI 10.2165/00003495-198326030-00003; Jewell-Motz EA, 1998, BIOCHEMISTRY-US, V37, P15720, DOI 10.1021/bi980999r; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; Kotanko P, 1997, HYPERTENSION, V30, P773, DOI 10.1161/01.HYP.30.4.773; Lakhlani PP, 1997, P NATL ACAD SCI USA, V94, P9950, DOI 10.1073/pnas.94.18.9950; Liggett SB, 1998, J CLIN INVEST, V102, P1534, DOI 10.1172/JCI4059; Liggett SB, 1998, CLIN EXP ALLERGY, V28, P77; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; LOCKETTE W, 1995, AM J HYPERTENS, V8, P390, DOI 10.1016/0895-7061(95)00024-J; LUTTRELL LM, 1998, CATECHOLAMINES BRIDG, P466; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; MacMillan LB, 1998, RECENT PROG HORM RES, V53, P25; Makaritsis KP, 1999, HYPERTENSION, V34, P403, DOI 10.1161/01.HYP.34.3.403; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; Onions KL, 1998, HYPERTENSION, V31, P1230, DOI 10.1161/01.HYP.31.6.1230; RUFFOLO RR, 1993, ANN REV PHARM TOXICO, V32, P243; SCHWINN DA, 1991, MOL PHARMACOL, V40, P619; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Svetkey LP, 1996, HYPERTENSION, V27, P1210, DOI 10.1161/01.HYP.27.6.1210; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X	34	60	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38518	38523		10.1074/jbc.M004550200	http://dx.doi.org/10.1074/jbc.M004550200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10948191	hybrid			2022-12-27	WOS:000165739800052
J	Goto, T; Kato, N; Ono-Nita, SK; Yoshida, H; Otsuka, M; Shiratori, Y; Omata, M				Goto, T; Kato, N; Ono-Nita, SK; Yoshida, H; Otsuka, M; Shiratori, Y; Omata, M			Large isoform of hepatitis delta antigen activates serum response factor-associated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-X-PROTEIN; TERNARY COMPLEX FACTORS; IMMEDIATE-EARLY GENES; RNA-POLYMERASE-II; C-FOS PROMOTER; B VIRUS; ABERRANT INDUCTION; NUCLEAR TRANSPORT; BINDING-ACTIVITY; GROWTH-FACTORS	Hepatitis delta virus infection sometimes causes severe and fulminant hepatitis as a coinfection or superinfection along with the hepatitis B virus. To elucidate the underlying mechanism of injury caused by hepatitis delta virus, we examined whether two isoforms of the hepatitis delta antigen (HDAg) had any effect on five well defined intracellular signal transduction pathways: serum response factor (SRF)-, serum response element (SRE)-, nuclear factor kappaB-, activator protein 1-, and cyclic AMP response element-dependent pathways. Reporter assays revealed that large HDAg (LIDDAg) activated the SRF- and SRE-dependent pathways. In contrast, small HDAg (LHDAg) did not activate any of five pathways. LHDAg enhanced the transcriptional ability of SRF without changing its DNA binding affinity in an electrophoretic mobility shift assay. In addition, LHDAg activated a rat SM22 alpha promoter containing SRF binding site and a human c-fos promoter containing SRE. In conclusion, LHDAg, but not SHDAg, enhances SRF-associated transcriptions. Despite structural similarities be tween the two HDAgs, there are significant differences in their effects on intracellular signal transduction pathways. These results may provide clues that will aid in the clarification of functional differences between LHDAg and SHDAg and the pathogenesis of delta hepatitis.	Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Kato, N (corresponding author), Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Ono, Suzane K/I-3107-2012; Otsuka, Motoyuki/H-9067-2019	Otsuka, Motoyuki/0000-0003-2869-2881				AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BERGMANN KF, 1986, J INFECT DIS, V154, P702, DOI 10.1093/infdis/154.4.702; Bichko V, 1997, J VIROL, V71, P512, DOI 10.1128/JVI.71.1.512-518.1997; Brazas R, 1996, SCIENCE, V274, P90, DOI 10.1126/science.274.5284.90; CHANG FL, 1991, P NATL ACAD SCI USA, V88, P8490, DOI 10.1073/pnas.88.19.8490; CHANG MF, 1988, J VIROL, V62, P2403, DOI 10.1128/JVI.62.7.2403-2410.1988; CHANG MF, 1992, J VIROL, V66, P6019, DOI 10.1128/JVI.66.10.6019-6027.1992; CHAO M, 1990, J VIROL, V64, P5066, DOI 10.1128/JVI.64.10.5066-5069.1990; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; Chou HC, 1998, J VIROL, V72, P3684, DOI 10.1128/JVI.72.5.3684-3690.1998; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FU TB, 1993, J VIROL, V67, P6965, DOI 10.1128/JVI.67.12.6965-6972.1993; FUJII M, 1995, ONCOGENE, V11, P7; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GAUTHIERROUVIERE C, 1995, MOL CELL BIOL, V15, P433, DOI 10.1128/MCB.15.1.433; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Ginisty H, 1999, J CELL SCI, V112, P761; GLENN JS, 1992, SCIENCE, V256, P1331, DOI 10.1126/science.1598578; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOOFNAGLE JH, 1989, JAMA-J AM MED ASSOC, V261, P1321, DOI 10.1001/jama.261.9.1321; IMAZEKI F, 1990, J VIROL, V64, P5594, DOI 10.1128/JVI.64.11.5594-5599.1990; Ishikawa T, 1999, BIOCHEM BIOPH RES CO, V254, P566, DOI 10.1006/bbrc.1998.9979; KEMP PR, 1995, BIOCHEM J, V310, P1037, DOI 10.1042/bj3101037; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KUO MYP, 1989, J VIROL, V63, P1945, DOI 10.1128/JVI.63.5.1945-1950.1989; KUO MYP, 1988, J VIROL, V62, P1855, DOI 10.1128/JVI.62.6.1855-1861.1988; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; Lee CH, 1998, J BIOL CHEM, V273, P7650, DOI 10.1074/jbc.273.13.7650; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; LIN JH, 1990, J VIROL, V64, P4051, DOI 10.1128/JVI.64.9.4051-4058.1990; Lin Y, 1997, CANCER RES, V57, P5137; Lin Y, 1998, J BIOL CHEM, V273, P27097, DOI 10.1074/jbc.273.42.27097; Lo K, 1998, VIROLOGY, V247, P178, DOI 10.1006/viro.1998.9253; MACNAUGHTON TB, 1991, VIROLOGY, V184, P387, DOI 10.1016/0042-6822(91)90855-6; MACNAUGHTON TB, 1990, VIROLOGY, V177, P692, DOI 10.1016/0042-6822(90)90535-Y; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MIN BH, 1990, J BIOL CHEM, V265, P16667; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OLIVERI F, 1991, PROG CLIN BIOL RES, V364, P217; RIZZETTO M, 1977, GUT, V18, P997, DOI 10.1136/gut.18.12.997; RIZZETTO M, 1983, HEPATOLOGY, V3, P906; Sambrook J., 1989, MOL CLONING, pA1; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Taylor J, 1993, Prog Clin Biol Res, V382, P1; Togo G, 1996, CANCER RES, V56, P5620; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WANG JG, 1993, J VIROL, V67, P446, DOI 10.1128/JVI.67.1.446-454.1993; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; Wei Y, 1998, J VIROL, V72, P2089, DOI 10.1128/JVI.72.3.2089-2096.1998; WU JC, 1991, J VIROL, V65, P1099, DOI 10.1128/JVI.65.3.1099-1104.1991; XIA YP, 1992, J VIROL, V66, P914, DOI 10.1128/JVI.66.2.914-921.1992; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20	63	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37311	37316		10.1074/jbc.M002947200	http://dx.doi.org/10.1074/jbc.M002947200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10961986	hybrid			2022-12-27	WOS:000165618700003
J	Heaton, D; Nittis, T; Srinivasan, C; Winge, DR				Heaton, D; Nittis, T; Srinivasan, C; Winge, DR			Mutational analysis of the mitochondrial copper metallochaperone Cox17	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; TARGETING SIGNAL; YEAST; PROTEIN; SCO1; GENE; COMPLEMENTATION; LOCALIZATION	The copper metallochaperone Cox17 is proposed to shuttle Cu(I) ions to the mitochondrion for the assembly of cytochrome c oxidase, The Cu(I) ions are liganded by cysteinyl thiolates, Mutational analysis on the yeast Cox17 reveals three of the seven cysteinyl residues to be critical for Cox17 function, and these three residues are present in a Cys-Cys-Xaa-Cys sequence motif. Single substitution of any of these three cysteines with serines results in a nonfunctional cytochrome oxidase complex. Cells harboring such a mutation fail to grow on nonfermentable carbon sources and have no cytochrome c oxidase activity in isolated mitochondria, Wild-type Cox17 purified as untagged protein binds three Cu(I) ions/molecule. Mutant proteins lacking only one of these critical Cys residues retain the ability to bind three Cu(I) ions and are imported within the mitochondria, In contrast, Cox17 molecules with a double Cys --> Ser mutation exhibit no Cu(I) binding but are still localized to the mitochondria, Thus, mitochondrial uptake of Cox17 is not restricted to the Cu(I) conformer of Cox17, COX17 was originally cloned by virtue of complementation of a mutant containing a nonfunctional Cys --> Tyr substitution at codon 57, The mutant C57Y Cox17 fails to accumulate within the mitochondria but retains the ability to bind three Cu(I) ions. A C57S Cox17 variant is functional, and a quadruple Cox17 mutant with C16S/C36S/C47S/C57S substitutions binds three Cu(I) ions. Thus, only three cysteinyl residues are important for the ligation of three Cu(I) ions. A novel mode of Cu(I) binding is predicted.	Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, 50 N Med Dr, Salt Lake City, UT 84132 USA.		Winge, Dennis/G-3611-2010		NCI NIH HHS [5P30CA42014] Funding Source: Medline; NIEHS NIH HHS [ES03817] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSSON SGE, 1990, MICROBIOL REV, V54, P198, DOI 10.1128/MMBR.54.2.198-210.1990; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; GLERUM DM, 1994, P NATL ACAD SCI USA, V91, P8452, DOI 10.1073/pnas.91.18.8452; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Lee CM, 1999, J BIOL CHEM, V274, P20937, DOI 10.1074/jbc.274.30.20937; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Papadopoulou LC, 1999, NAT GENET, V23, P333; Paret C, 1999, FEBS LETT, V447, P65, DOI 10.1016/S0014-5793(99)00266-5; Poyton RO, 1995, METHOD ENZYMOL, V260, P97, DOI 10.1016/0076-6879(95)60133-3; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; SCHULZE M, 1988, MOL GEN GENET, V211, P492, DOI 10.1007/BF00425706; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990	28	82	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37582	37587		10.1074/jbc.M006639200	http://dx.doi.org/10.1074/jbc.M006639200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10970896	hybrid			2022-12-27	WOS:000165618700039
J	Sadasivan, C; Yee, VC				Sadasivan, C; Yee, VC			Interaction of the factor XIII activation peptide with alpha-thrombin - Crystal structure of its enzyme-substrate analog complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XIII; PRO-ARG CHLOROMETHYLKETONE; MYOCARDIAL-INFARCTION; COMMON POLYMORPHISM; VENOUS THROMBOSIS; TRYPSIN COMPLEX; BOVINE THROMBIN; BINDING-SITE; A-SUBUNIT; ASSOCIATION	The serine protease thrombin proteolytically activates blood coagulation factor XIII by cleavage at residue Arg(37); factor XIII in turn cross-links fibrin molecules and gives mechanical stability to the blood clot. The 2.0-Angstrom resolution x-ray crystal structure of human cy-thrombin bound to the factor XII-(28-37) decapeptide has been determined. This structure reveals the detailed atomic level interactions between the factor XIII activation peptide and thrombin and provides the first high resolution view of this functionally important part of the factor XIII molecule. A comparison of this structure with the crystal structure of fibrinopeptide A complexed with thrombin highlights several important determinants of thrombin substrate interaction. First, the P1 and P2 residues must be compatible with the geometry and chemistry of the SI and S2 specificity sites in thrombin. Second, a glycine in the P5 position is necessary for the conserved substrate conformation seen in both factor XIII-(28-37) and fibrinopeptide A. Finally, the hydrophobic residues, which occupy the aryl binding site of thrombin determine the substrate conformation further away from the catalytic residues. In the case of factor XII-(28-37), the aryl binding site is shared by hydrophobic residues P4 (Val(34)) and P9 (Val(29)). A bulkier residue in either of these sites may alter the substrate peptide conformation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Med Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Struct Biol Ctr, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Yee, VC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Med Cardiol, 9500 Euclid Ave,NB 20, Cleveland, OH 44195 USA.	yee@pierre.lerner.ccf.org	Chittalakkottu, Sadasivan/AAR-1786-2020					Ariens RAS, 2000, BLOOD, V96, P988, DOI 10.1182/blood.V96.3.988.015k57_988_995; Balogh I, 2000, BLOOD, V96, P2479; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1990, EUR J BIOCHEM, V193, P175, DOI 10.1111/j.1432-1033.1990.tb19320.x; BODE W, 1992, PROTEIN SCI, V1, P426; BRUNGER AT, 1992, XPLOR VERSION 3 1; Catto AJ, 1998, STROKE, V29, P813, DOI 10.1161/01.STR.29.4.813; Catto AJ, 1999, BLOOD, V93, P906, DOI 10.1182/blood.V93.3.906.403k24_906_908; CHEN ZG, 1995, ARCH BIOCHEM BIOPHYS, V322, P198, DOI 10.1006/abbi.1995.1452; Chirgadze NY, 1997, PROTEIN SCI, V6, P1412, DOI 10.1002/pro.5560060705; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Elbaz A, 2000, BLOOD, V95, P586, DOI 10.1182/blood.V95.2.586; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FENTON JW, 1986, SEMIN THROMB HEMOST, V12, P200, DOI 10.1055/s-2007-1003551; FOLK JE, 1973, ADV ENZYMOL RAMB, V38, P109; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; Fox BA, 1999, J BIOL CHEM, V274, P4917, DOI 10.1074/jbc.274.8.4917; Franco RF, 2000, HAEMATOLOGICA, V85, P67; Franco RF, 1999, THROMB HAEMOSTASIS, V81, P676; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HORNYAK TJ, 1989, BIOCHEMISTRY-US, V28, P7326, DOI 10.1021/bi00444a027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kangsadalampai S, 1998, BLOOD, V92, P2766, DOI 10.1182/blood.V92.8.2766.420k26_2766_2770; Kohler HP, 1998, THROMB HAEMOSTASIS, V79, P8, DOI 10.1055/s-0037-1614250; Kohler HP, 1998, THROMB HAEMOSTASIS, V80, P704; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krishnan R, 1998, BIOCHEMISTRY-US, V37, P12094, DOI 10.1021/bi980840e; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LORAND L, 1986, ANN NY ACAD SCI, V485, P144, DOI 10.1111/j.1749-6632.1986.tb34577.x; Malkowski MG, 1997, BIOCHEM J, V326, P815, DOI 10.1042/bj3260815; MARTIN PD, 1992, J BIOL CHEM, V267, P7911; MATSUZAKI T, 1989, J BIOCHEM-TOKYO, V105, P949, DOI 10.1093/oxfordjournals.jbchem.a122785; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Muszbek L, 1996, CRIT REV CL LAB SCI, V33, P357, DOI 10.3109/10408369609084691; Muszbek L, 1999, THROMB RES, V94, P271, DOI 10.1016/S0049-3848(99)00023-7; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REHSE PH, 1995, BIOCHEMISTRY-US, V34, P11537, DOI 10.1021/bi00036a029; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TOLLEFSEN DM, 1974, J BIOL CHEM, V249, P2646; Trumbo TA, 2000, J BIOL CHEM, V275, P20627, DOI 10.1074/jbc.M000209200; TURK D, 1991, FEBS LETT, V287, P133, DOI 10.1016/0014-5793(91)80033-Y; van den Akker F, 1999, ACTA CRYSTALLOGR D, V55, P206, DOI 10.1107/S0907444998007161; Wartiovaara U, 1999, ATHEROSCLEROSIS, V142, P295, DOI 10.1016/S0021-9150(98)00241-X; Weir MP, 1998, BIOCHEMISTRY-US, V37, P6645, DOI 10.1021/bi972499o; YEE VC, 1995, THROMB RES, V78, P389, DOI 10.1016/0049-3848(95)00072-Y; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	56	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36942	36948		10.1074/jbc.M006076200	http://dx.doi.org/10.1074/jbc.M006076200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10956659	hybrid			2022-12-27	WOS:000165577700070
J	Frit, P; Li, RY; Arzel, D; Salles, B; Calsou, P				Frit, P; Li, RY; Arzel, D; Salles, B; Calsou, P			Ku entry into DNA inhibits inward DNA transactions in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; NUCLEOTIDE EXCISION-REPAIR; CELL-FREE-EXTRACTS; RNA-POLYMERASE-II; V(D)J RECOMBINATION; CATALYTIC SUBUNIT; IN-VITRO; TRANSCRIPTION; BINDING	Association of the DNA end-binding Ku70/Ku80 heterodimer with the 460-kDa serine/threonine kinase catalytic subunit forms the DNA-dependent protein kinase (DNA-PK) that is required for double-strand break repair by non-homologous recombination in mammalian cells. Recently, we have proposed a model in which the kinase activity is required for translocation of the DNA end-binding subunit Ku along the DNA helix when DNA-PK assembles on DNA ends. Here, we have questioned the consequences of Ku entry into DNA on local DNA processes by using human nuclear cell extracts incubated in the presence of linearized plasmid DNA, As two model processes, we have chosen nucleotide excision repair (NER) of UVC DNA lesions and transcription from viral promoters. We show that although NER efficiency is strongly reduced on linear DNA, it can be fully restored in the presence of DNA-PK inhibitors. Simultaneously, the amount of NER proteins bound to the UVC-damaged linear DNA is increased and the amount of Ku bound to the same DNA molecules is decreased. Similarly, the poor transcription efficiency exhibited by viral promoters on linear DNA is enhanced in the presence of DNA-PK inhibitor concentrations that prevent Ku entry into the DNA substrate molecule, The present results show that DNA-PK catalytic activity can regulate DNA transactions including transcription in the vicinity of double-strand breaks by controlling Ku entry into DNA.	Inst Pharmacol & Biol Struct, CNRS UMR 5089, F-31077 Toulouse 4, France; Soc Francaise Rech & Investissements, F-33127 Berganton, St Jean Illac, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Salles, B (corresponding author), Inst Pharmacol & Biol Struct, CNRS UMR 5089, 205 Route Narbonne, F-31077 Toulouse 4, France.		salles, bernard/B-8531-2008; calsou, patrick/AAB-5123-2020	Calsou, Patrick/0000-0001-7951-9806				Batty DP, 2000, GENE, V241, P193, DOI 10.1016/S0378-1119(99)00489-8; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Calsou P, 1996, J BIOL CHEM, V271, P27601, DOI 10.1074/jbc.271.44.27601; Calsou P, 1999, J BIOL CHEM, V274, P7848, DOI 10.1074/jbc.274.12.7848; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FALZON M, 1993, J BIOL CHEM, V268, P10546; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Finnie NJ, 1996, PHILOS T ROY SOC B, V351, P173, DOI 10.1098/rstb.1996.0014; Frit P, 1998, J MOL BIOL, V284, P963, DOI 10.1006/jmbi.1998.2257; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Haber JE, 1999, CELL, V97, P829, DOI 10.1016/S0092-8674(00)80795-3; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Izzard RA, 1999, CANCER RES, V59, P2581; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jin SF, 1997, CANCER SURV, V29, P221; Jin SF, 1998, CARCINOGENESIS, V19, P965, DOI 10.1093/carcin/19.6.965; Johnson AP, 1996, MUTAT RES-DNA REPAIR, V364, P103, DOI 10.1016/0921-8777(96)00028-6; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Li RY, 1998, J MOL BIOL, V281, P211, DOI 10.1006/jmbi.1998.1949; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Mason RM, 1996, NUCLEIC ACIDS RES, V24, P4946, DOI 10.1093/nar/24.24.4946; McAinsh AD, 1999, CURR BIOL, V9, P963, DOI 10.1016/S0960-9822(99)80424-2; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; MIMORI T, 1986, J BIOL CHEM, V261, P375; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; Pastink A, 1999, MUTAT RES-FUND MOL M, V428, P141, DOI 10.1016/S1383-5742(99)00042-3; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; Polotnianka RM, 1998, CURR BIOL, V8, P831, DOI 10.1016/S0960-9822(98)70325-2; SALLES B, 1995, ANAL BIOCHEM, V232, P37, DOI 10.1006/abio.1995.9964; Satoh MS, 1996, NUCLEIC ACIDS RES, V24, P3576, DOI 10.1093/nar/24.18.3576; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Woodard RL, 1999, J BIOL CHEM, V274, P478, DOI 10.1074/jbc.274.1.478; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2; Zhu C, 1996, CANCER SURV, V28, P295	61	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35684	35691		10.1074/jbc.M004315200	http://dx.doi.org/10.1074/jbc.M004315200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10945984	hybrid			2022-12-27	WOS:000165382000008
J	Jones, EA; Conover, J; Symes, AJ				Jones, EA; Conover, J; Symes, AJ			Identification of a novel gp130-responsive site in the vasoactive intestinal peptide cytokine response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; LEUKEMIA INHIBITORY FACTOR; TYROSINE-PHOSPHATASE SHP-2; ACTIVATED PROTEIN-KINASE; CENTRAL-NERVOUS-SYSTEM; SIGNALING PATHWAYS; GENE-EXPRESSION; CHOLINERGIC DIFFERENTIATION; SYMPATHETIC NEURONS; STAT PROTEINS	The neuropoietic cytokine ciliary neurotrophic factor (CNTF) potently induces transcription of the vasoactive intestinal peptide (VIP) gene through a 180-base pair (bp) cytokine response element (CyRE) in the VIP promoter. We have previously shown that CNTF induction of STAT and AP-1 protein binding within the CyRE is necessary to mediate CNTF induction of VIP gene transcription. We now show that a third, previously uncharacterized site at the S'-end of the CyRE is also critical to CNTF induction of CyRE transcription. A 4-bp mutation in this 3'-region reduced CNTF-mediated induction of transcription similar to 80%. Whereas mutations in both the STAT and AP-1 sites substantially reduced CNTF induction of transcription, mutations in these sites together with the novel 3'-site completely abolished the ability of CNTF to induce CyRE-mediated transcription. Gel shift analysis indicated that a complex in neuroblastoma cells bound specifically to this 3'-site. This complex was not altered by CNTF treatment. Mutations in an 8-bp sequence (TTACTGGA) eliminated binding of this protein complex and markedly reduced transcriptional activation of the CyRE by CNTF. Thus, we have identified a protein complex binding to a novel DNA sequence that is necessary for full CNTF induction of VIP gene transcription.	Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Symes, AJ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	Asymes@usuhs.mil	Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035839] Funding Source: NIH RePORTER; NINDS NIH HHS [R29 NS035839, R29 NS-35839] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Bousquet C, 1999, J CLIN INVEST, V104, P1277, DOI 10.1172/JCI7924; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Carpenter LR, 1999, ADV PROTEIN CHEM, V52, P109; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Choi I, 1998, IMMUNOL LETT, V61, P103, DOI 10.1016/S0165-2478(98)00005-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DESERIO A, 1995, J MOL BIOL, V254, P795, DOI 10.1006/jmbi.1995.0655; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; FAN GP, 1993, DEVELOPMENT, V118, P83; Frank DA, 1996, PERSPECT DEV NEUROBI, V4, P3; Giordano V, 1997, J IMMUNOL, V158, P4097; GOZES I, 1988, NEUROENDOCRINOLOGY, V47, P27, DOI 10.1159/000124886; GOZES I, 1987, MOL BRAIN RES, V2, P137, DOI 10.1016/0169-328X(87)90007-6; Hahm SH, 1998, J BIOL CHEM, V273, P17086, DOI 10.1074/jbc.273.27.17086; Hahm SH, 1996, J NEUROCHEM, V67, P1872; Hahm SH, 1999, J BIOL CHEM, V274, P25588, DOI 10.1074/jbc.274.36.25588; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOHNSON JA, 1994, J BIOL CHEM, V269, P18856; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEWIS SE, 1994, J NEUROCHEM, V63, P429; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Nakashima K, 1999, J NEUROSCI, V19, P5429; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; RAO MS, 1992, DEV BIOL, V150, P281, DOI 10.1016/0012-1606(92)90242-9; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; SCHWARZSCHILD MA, 1994, J NEUROCHEM, V63, P1246; SENA M, 1994, DNA SEQUENCE, V5, P25, DOI 10.3109/10425179409039701; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; Symes A, 1997, J BIOL CHEM, V272, P9648; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; SYMES AJ, 1993, P NATL ACAD SCI USA, V90, P572, DOI 10.1073/pnas.90.2.572; SYMES AJ, 1995, J BIOL CHEM, V270, P8068, DOI 10.1074/jbc.270.14.8068; SYMES AJ, 1995, J NEUROCHEM, V65, P1926; SYMES AJ, 1998, LUNG BIOL HEALTH DIS, V112, P293; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; WINTER CG, 1995, P NATL ACAD SCI USA, V92, P5865, DOI 10.1073/pnas.92.13.5865; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; YOSHIDA T, 1993, DEV BRAIN RES, V76, P147, DOI 10.1016/0165-3806(93)90132-T	65	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36013	36020		10.1074/jbc.M007373200	http://dx.doi.org/10.1074/jbc.M007373200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964933	hybrid			2022-12-27	WOS:000165382000053
J	Bullesbach, EE; Schwabe, C				Bullesbach, EE; Schwabe, C			The relaxin receptor-binding site geometry suggests a novel gripping mode of interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE PEPTIDE-SYNTHESIS; PORCINE RELAXIN; AMINO-ACIDS; INSULIN; CHAIN; HOMOLOGY	Relaxin has a unique, clearly identifiable, mixed function receptor-binding region comprising amino acid residues that evolve sequentially from the central portion of the B chain alpha -helix. Two arginine residues in positions B13 and B17 that project like forefinger and middle finger from the helix provide the electrostatic element-opposed by the hydrophobic (thumb) element isoleucine (B20), offset from the arginines by about 40 degrees. The binding:intensity of relaxin to its receptor decreases by 3 orders of magnitude if alanine is substituted for the newly discovered binding component isoleucine in position B20. The arginine residues cannot be replaced by other positive charges, nor can the guanidinium group be presented on a longer or shorter hydrocarbon chain. In contrast, the hydrophobic interaction is incremental in nature, and the contribution to the total binding energy is roughly proportional to the number of hydrocarbon units in the side chain. It appears that a hydrophobic surface exists on the receptor that-offers optimal van der Waals' interaction with beta -branched hydrophobic amino acids. The binding energy increases roughly 10-fold with each methylene group whereby beta -branching is more effective per surface unit than chain elongation. Aromatic side chains appear-to demarcate the extent of the binding region in so far as residues larger than phenylalanine decrease receptor binding. The exceptional clarity of binding site geometry in relaxin makes for an excellent opportunity to design peptido-mimetics.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Schwabe, C (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.				NIGMS NIH HHS [GM 48893] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler A J, 1973, Methods Enzymol, V27, P675; ATHERTON E, 1988, J CHEM SOC PERK T 1, P2887, DOI 10.1039/p19880002887; BEDARKAR S, 1977, NATURE, V270, P449, DOI 10.1038/270449a0; BULLESBACH EE, 1992, J BIOL CHEM, V267, P22957; Bullesbach EE, 1996, BIOCHEMISTRY-US, V35, P9754, DOI 10.1021/bi960082x; BULLESBACH EE, 1991, J BIOL CHEM, V266, P10754; Bullesbach EE, 1999, J BIOL CHEM, V274, P22354, DOI 10.1074/jbc.274.32.22354; BULLESBACH EE, 1988, INT J PEPT PROT RES, V32, P361; CONNOLLY ML, 1986, J MOL GRAPHICS, V4, P3; DALEAN A, 1978, AM J PHYSIOL, V235, pE97; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Hisaw FL, 1926, P SOC EXP BIOL MED, V23, P661; JAMES R, 1977, NATURE, V267, P544, DOI 10.1038/267544a0; KING DS, 1990, INT J PEPT PROT RES, V36, P255; MCCASLIN RB, 1995, BIOL REPROD, V53, P454, DOI 10.1095/biolreprod53.2.454; SCHWABE C, 1977, BIOCHEM BIOPH RES CO, V75, P503, DOI 10.1016/0006-291X(77)91070-1; SCHWABE C, 1976, BIOCHEM BIOPH RES CO, V70, P397, DOI 10.1016/0006-291X(76)91059-7; SCHWABE C, 1994, FASEB J, V8, P1152, DOI 10.1096/fasebj.8.14.7958621; SCHWABE C, 1977, SCIENCE, V197, P914, DOI 10.1126/science.887933; Seibold JR, 2000, ANN INTERN MED, V132, P871, DOI 10.7326/0003-4819-132-11-200006060-00004; Seibold JR, 1998, J RHEUMATOL, V25, P302; SHERWOOD OD, 1994, PHYSL REPRODUCTION, V1, P861; STEINETZ BG, 1960, ENDOCRINOLOGY, V67, P102, DOI 10.1210/endo-67-1-102; YANG S, 1992, ENDOCRINOLOGY, V130, P179, DOI 10.1210/en.130.1.179	25	84	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35276	35280		10.1074/jbc.M005728200	http://dx.doi.org/10.1074/jbc.M005728200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956652	hybrid			2022-12-27	WOS:000165422800060
J	Creuzenet, C; Schur, MJ; Lin, JJ; Wakarchuk, WW; Lam, JS				Creuzenet, C; Schur, MJ; Lin, JJ; Wakarchuk, WW; Lam, JS			FlaA1, a new bifunctional UDP-GlcNAc C-6 dehydratase C-4 reductase from Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSE 4,6-DEHYDRATASE; GDP-L-FUCOSE; ESCHERICHIA-COLI; LIPOPOLYSACCHARIDE BIOSYNTHESIS; PSEUDOMONAS-AERUGINOSA; STAPHYLOCOCCUS-AUREUS; MOLECULAR-CLONING; GENE-CLUSTER; ACTIVE-SITE; KEY ENZYME	FlaA1 is a small soluble protein of unknown function in Helicobacter pylori, It has homologues that are essential for the virulence of numerous medically relevant bacteria. FlaA1 was overexpressed as a histidine-tagged protein and purified to homogeneity by nickel chelation and cation exchange chromatography, Spectrophotometric assays, capillary electrophoresis, and mass spectrometry analyses showed that FlaA1 is a novel bifunctional C-6 dehydratase/C-4 reductase specific for UDP-GlcNAc. It converts UDP-GlcNAc into a UDP-4-keto-6-methyl-GlcNAc intermediate, which is stereospecifically reduced into UDP-QuiNAc. Substrate conversions as high as 80% were obtained at equilibrium. The K-m and V-max for UDP-GlcNAc were 159 muM and 65 pmol/min, respectively. No exogenous cofactor was required to obtain full activity of FlaA1, Additional NADH was only used with poor efficiency for the reduction step. The biochemical characterization of FlaA1 is important for the elucidation of biosynthetic pathways that lead to the formation of 2,6-deoxysugars in medically relevant bacteria. It establishes unambiguously the first step of the pathway and provides the means of preparing the substrate UDP-QuiNAc, which is necessary for the study of downstream enzymes.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Lam, JS (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.		Wakarchuk, Warren/Q-9514-2017; Wakarchuk, Warren/AAO-2774-2020	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679; Schur, Melissa/0000-0002-6047-1416				Allard STM, 2000, ACTA CRYSTALLOGR D, V56, P222, DOI 10.1107/S0907444999016200; Allen A, 1996, MOL MICROBIOL, V19, P37, DOI 10.1046/j.1365-2958.1996.354877.x; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; Burrows LL, 1996, MOL MICROBIOL, V22, P481, DOI 10.1046/j.1365-2958.1996.1351503.x; Burrows LL, 2000, INFECT IMMUN, V68, P931, DOI 10.1128/IAI.68.2.931-936.2000; Creuzenet C, 2000, J BIOL CHEM, V275, P19060, DOI 10.1074/jbc.M001171200; Doig P, 1996, MOL MICROBIOL, V19, P379, DOI 10.1046/j.1365-2958.1996.370890.x; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; EATON KA, 1992, J MED MICROBIOL, V37, P123, DOI 10.1099/00222615-37-2-123; FOURNIER JM, 1984, INFECT IMMUN, V45, P87, DOI 10.1128/IAI.45.1.87-93.1984; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; GINSBURG V, 1961, J BIOL CHEM, V236, P2389; He XM, 1996, BIOCHEMISTRY-US, V35, P4721, DOI 10.1021/bi952706p; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; JOSENHANS C, 1995, J BACTERIOL, V177, P3010, DOI 10.1128/jb.177.11.3010-3020.1995; Knirel' Iu A, 1994, Biokhimiia, V59, P1784; Labigne A, 1996, INFECT AGENT DIS, V5, P191; Leclerc G, 1998, J BACTERIOL, V180, P5010, DOI 10.1128/JB.180.19.5010-5019.1998; LIU HW, 1994, ANNU REV MICROBIOL, V48, P223, DOI 10.1146/annurev.micro.48.1.223; MAROLDA CL, 1995, J BACTERIOL, V177, P5539, DOI 10.1128/jb.177.19.5539-5546.1995; Monteiro MA, 2000, EUR J BIOCHEM, V267, P305, DOI 10.1046/j.1432-1327.2000.01007.x; MORENO F, 1981, CELL MOL BIOL, V27, P589; MUOTIALA A, 1992, INFECT IMMUN, V60, P1714, DOI 10.1128/IAI.60.4.1714-1716.1992; Newton DT, 1999, BIOCHEM J, V339, P63, DOI 10.1042/0264-6021:3390063; Ohyama C, 1998, J BIOL CHEM, V273, P14582, DOI 10.1074/jbc.273.23.14582; PETERSON WL, 1991, NEW ENGL J MED, V324, P1043, DOI 10.1056/NEJM199104113241507; REISSIG JL, 1955, J BIOL CHEM, V217, P959; Rizzi M, 1998, STRUCTURE, V6, P1453, DOI 10.1016/S0969-2126(98)00144-0; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; Sau S, 1996, J BACTERIOL, V178, P2118, DOI 10.1128/jb.178.7.2118-2126.1996; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SKURNIK M, 1995, MOL MICROBIOL, V17, P575, DOI 10.1111/j.1365-2958.1995.mmi_17030575.x; SMOOT DT, 1990, INFECT IMMUN, V58, P1992, DOI 10.1128/IAI.58.6.1992-1994.1990; SNIPES CE, 1977, J BIOL CHEM, V252, P8113; Somers WS, 1998, STRUCTURE, V6, P1601, DOI 10.1016/S0969-2126(98)00157-9; Stern RJ, 1999, MICROBIOL-UK, V145, P663, DOI 10.1099/13500872-145-3-663; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; Szymanski CM, 1999, MOL MICROBIOL, V32, P1022, DOI 10.1046/j.1365-2958.1999.01415.x; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; THOMPSON MW, 1992, J GEN MICROBIOL, V138, P779, DOI 10.1099/00221287-138-4-779; THORSON JS, 1993, J AM CHEM SOC, V115, P5827, DOI 10.1021/ja00066a062; THORSON JS, 1993, J AM CHEM SOC, V115, P6993, DOI 10.1021/ja00068a075; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tonetti M, 1998, BIOCHIMIE, V80, P923, DOI 10.1016/S0300-9084(00)88889-6; VARA JA, 1988, J BIOL CHEM, V263, P14992; WEST SEH, 1994, GENE, V148, P81, DOI 10.1016/0378-1119(94)90237-2; YAMAMOTO K, 1993, ARCH BIOCHEM BIOPHYS, V300, P694, DOI 10.1006/abbi.1993.1096; Yoshida Y, 1999, J BIOL CHEM, V274, P16933, DOI 10.1074/jbc.274.24.16933; YU Y, 1992, J BIOL CHEM, V267, P5868	51	53	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34873	34880		10.1074/jbc.M006369200	http://dx.doi.org/10.1074/jbc.M006369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954725	hybrid			2022-12-27	WOS:000165422800009
J	Zhong, XT; Malhotra, R; Guidotti, G				Zhong, XT; Malhotra, R; Guidotti, G			Regulation of yeast ectoapyrase Ynd1p activity by activator subunit Vma13p of vacuolar H+ -ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; PREPRO-ALPHA-FACTOR; BRAIN ECTO-APYRASE; SACCHAROMYCES-CEREVISIAE; GOLGI-APPARATUS; NUCLEOSIDE-DIPHOSPHATASE; GUANOSINE DIPHOSPHATASE; NUCLEOTIDE SULFATE; GENE ENCODES; MEMBRANE	CD39-like ectoapyrases are involved in protein and lipid glycosylation in the Golgi lumen of Saccharomyces cerevisiae, By using a two-hybrid screen, we found that air activator subunit (Vma13p) of yeast vacuolar HC ATPase:CV-ATPase) binds to the cytoplasmic domain of Ynd1p, a yeast ectoapyrase. Interaction of Ynd1p with Vma13p was demonstrated by direct binding and coimmunoprecipitation, Surprisingly, the membrane-bound ADPase activity of Ynd1p in a vma13 Delta mutant was drastically increased compared with that of Ynd1p in VMA13 cells. A similar increase in the apyrase activity of Ynd1p was found in a vma1 Delta mutant, in which the catalytic subunit A of V-ATPase is missing, and the membrane peripheral subunits including Vma13p are dissociated from the membranes. However, the E286Q mutant of VMA1, which assembles inactive V-ATPase complex including Vma13p in the membrane, retained wild type levels' of Ynd1p activity, demonstrating that the presence of Vmal13p rather than the function of V-ATPase in the membrane represses Ynd1p activity. These results suggest that association of Vma13p with the cytoplasmic domain of Ynd1p regulates its apyrase activity in the Golgi lumen.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Guidotti, G (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.			Malhotra, Rajeev/0000-0003-0120-4630	NHLBI NIH HHS [HL08893] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; Biederbick A, 1999, J CELL SCI, V112, P2473; BRANDAN E, 1982, BIOCHEMISTRY-US, V21, P4640, DOI 10.1021/bi00262a019; Chadwick BP, 1998, GENOMICS, V50, P357, DOI 10.1006/geno.1998.5317; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Forgac M, 1999, J BIOENERG BIOMEMBR, V31, P57, DOI 10.1023/A:1005496530380; Forgac M, 2000, J EXP BIOL, V203, P71; Forgac M, 1998, FEBS LETT, V440, P258, DOI 10.1016/S0014-5793(98)01425-2; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Gao XD, 1999, J BIOL CHEM, V274, P21450, DOI 10.1074/jbc.274.30.21450; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Graham LA, 1999, J BIOENERG BIOMEMBR, V31, P39, DOI 10.1023/A:1005492429471; Graham LA, 2000, J EXP BIOL, V203, P61; GRAHAM TR, 1995, MOL BIOL CELL, V6, P809, DOI 10.1091/mbc.6.7.809; GRAHAM TR, 1994, J CELL BIOL, V127, P667, DOI 10.1083/jcb.127.3.667; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; HO MN, 1993, J BIOL CHEM, V268, P18286; HURT EC, 1988, EUR J CELL BIOL, V46, P554; James P, 1996, GENETICS, V144, P1425; Johnson CH, 1999, YEAST, V15, P799, DOI 10.1002/(SICI)1097-0061(19990630)15:9&lt;799::AID-YEA419&gt;3.0.CO;2-N; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Kane PM, 1999, J BIOENERG BIOMEMBR, V31, P49, DOI 10.1023/A:1005444513542; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KHATRA BS, 1974, EUR J BIOCHEM, V44, P537, DOI 10.1111/j.1432-1033.1974.tb03513.x; Kirley TL, 1997, J BIOL CHEM, V272, P1076, DOI 10.1074/jbc.272.2.1076; KUHN NJ, 1977, BIOCHEM J, V168, P423, DOI 10.1042/bj1680423; Liu Q, 1997, J BIOL CHEM, V272, P11750, DOI 10.1074/jbc.272.18.11750; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Makita K, 1998, INT J HEMATOL, V68, P297; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; MELLMAN I, 1992, J EXP BIOL, V172, P39; MILLER JH, 1992, SHORT COURSE BACTERI, P439; Nagy AK, 1998, J BIOL CHEM, V273, P16043, DOI 10.1074/jbc.273.26.16043; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; PLESNER L, 1995, INT REV CYTOL, V158, P141; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; Sambrook J., 2002, MOL CLONING LAB MANU; SHERMAN F, 1986, METHODS YEAST GENETI, P160; Smith TM, 1998, BBA-PROTEIN STRUCT M, V1386, P65, DOI 10.1016/S0167-4838(98)00063-6; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Todorov LD, 1997, NATURE, V387, P76, DOI 10.1038/387076a0; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WADA Y, 1994, J BIOENERG BIOMEMBR, V26, P631, DOI 10.1007/BF00831538; Wang TF, 1997, MOL BRAIN RES, V47, P295, DOI 10.1016/S0169-328X(97)00066-1; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392; Wang TF, 1998, J BIOL CHEM, V273, P24814, DOI 10.1074/jbc.273.38.24814; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; Zhong XT, 1999, J BIOL CHEM, V274, P32704, DOI 10.1074/jbc.274.46.32704; Zhong XT, 1998, J BACTERIOL, V180, P1347, DOI 10.1128/JB.180.6.1347-1353.1998; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7	65	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35592	35599		10.1074/jbc.M006932200	http://dx.doi.org/10.1074/jbc.M006932200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954728	hybrid, Green Published			2022-12-27	WOS:000165422800100
J	Cornillon, S; Pech, E; Benghezal, M; Ravanel, K; Gaynor, E; Letourneur, F; Bruckert, F; Cosson, P				Cornillon, S; Pech, E; Benghezal, M; Ravanel, K; Gaynor, E; Letourneur, F; Bruckert, F; Cosson, P			Phg1p is a nine-transmembrane protein superfamily member involved in Dictyostelium adhesion and phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-MEDIATED INTEGRATION; CELL-DEATH; DISCOIDEUM; MUTANTS; CYTOKINESIS	To identify the molecular mechanisms involved in phagocytosis, we generated random insertion mutants of Dictyostelium discoideum and selected two mutants defective for phagocytosis. Both represented insertions in the same gene, named PHG1. This gene encodes a polytopic membrane protein with an N-terminal lumenal domain and nine potential transmembrane segments. Homologous genes can be identified in many species; however, their function is yet to be elucidated. Disruption of PHG1 caused a selective defect in phagocytosis of latex beads and Escherichia coli, but not Klebsiella aerogenes bacteria. This defect in phagocytosis was caused by a decrease in the adhesion of mutant cells to phagocytosed particles. These results indicate that the Phg1 protein is involved in the adhesion of Dictyostelium to various substrates, a crucial event of phagocytosis and demonstrate the usefulness of a genetic approach to dissect the molecular events involved in the phagocytic process.	Univ Geneva, Ctr Med, Dept Morphol, CH-1211 Geneva 4, Switzerland; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; CNRS, UPR 412, Inst Biol & Chim Prot, F-69367 Lyon, France; CEA, CNRS, UMR 314, Lab Biochim & Biophys Syst Integres, F-38054 Grenoble, France	University of Geneva; Stanford University; Centre National de la Recherche Scientifique (CNRS); CEA; Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Cosson, P (corresponding author), Univ Geneva, Ctr Med, Dept Morphol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	pierre.cosson@medecine.unige.ch		Letourneur, Francois/0000-0003-2232-6127				ADACHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1808, DOI 10.1006/bbrc.1994.2880; BROWN EJ, 1995, BIOESSAYS, V17, P109, DOI 10.1002/bies.950170206; Chang WT, 1995, PLASMID, V34, P175, DOI 10.1006/plas.1995.0003; Chluba-de Tapia J, 1997, GENE, V197, P195, DOI 10.1016/S0378-1119(97)00263-1; COHEN CJ, 1994, J CELL BIOL, V126, P955, DOI 10.1083/jcb.126.4.955; CORNILLON S, 1994, J CELL SCI, V107, P2691; Cornillon S, 1998, CELL DEATH DIFFER, V5, P416, DOI 10.1038/sj.cdd.4400361; COZENSROBERTS C, 1990, BIOPHYS J, V58, P107, DOI 10.1016/S0006-3495(90)82357-2; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Favre-Bonte S, 1999, INFECT IMMUN, V67, P554, DOI 10.1128/IAI.67.2.554-561.1999; Hacker U, 1997, J CELL SCI, V110, P105; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; LYDAN MA, 1991, BIOCHEM BIOPH RES CO, V174, P990, DOI 10.1016/0006-291X(91)91516-F; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; Monnat J, 1997, FEBS LETT, V418, P357, DOI 10.1016/S0014-5793(97)01415-4; Morio T, 1998, DNA Res, V5, P335, DOI 10.1093/dnares/5.6.335; Niewohner J, 1997, J CELL BIOL, V138, P349, DOI 10.1083/jcb.138.2.349; Rivero F, 1999, MOL BIOL CELL, V10, P1205, DOI 10.1091/mbc.10.4.1205; Schimmoller F, 1998, GENE, V216, P311, DOI 10.1016/S0378-1119(98)00349-7; SINGERKRUGER B, 1993, J BIOL CHEM, V268, P14376; Titus MA, 1999, CURR BIOL, V9, P1297, DOI 10.1016/S0960-9822(00)80051-2; VOGEL G, 1980, J CELL BIOL, V86, P456	25	158	164	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34287	34292		10.1074/jbc.M006725200	http://dx.doi.org/10.1074/jbc.M006725200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944536	hybrid			2022-12-27	WOS:000165095300041
J	Lee, WY; Loflin, P; Clancey, CJ; Peng, H; Lever, JE				Lee, WY; Loflin, P; Clancey, CJ; Peng, H; Lever, JE			Cyclic nucleotide regulation of Na+/glucose cotransporter (SGLT1) mRNA stability - Interaction of a nucleocytoplasmic protein with a regulatory domain in the 3 '-untranslated region critical for stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; AU-RICH ELEMENT; 3' UNTRANSLATED REGION; LLC-PK1 CELLS; BINDING-PROTEIN; C-FOS; GLUCOSE TRANSPORTERS; GENE-EXPRESSION; AMP ELEVATION; HIGH-AFFINITY	Expression of the Nac-coupled glucose cotransporter SGLT1 is regulated post-transcriptionally at the level of mRNA stability. We have previously demonstrated that cAMP-dependent stabilization of the SGLT1 message was correlated with the protein phosphorylation-dependent binding of cytoplasmic proteins to a uridine-rich sequence (URE) in the 3'-untranslated region (UTR). In the present study, the regulatory role of the URE was demonstrated by inserting it into the 3'-UTR of a beta -globin reporter minigene under the control of the tetracycline-regulated promoter. The resultant chimeric globin/SGLT1 mRNA expressed after transfection into LLC-PK1 cells exhibited a decreased half-life compared with the beta -globin control, indicating that the URE serves a destabilizing function, Activation of protein kinase A stabilized the chimeric message but not the beta -globin control, indicating the presence of a regulatory stabilizing sequence within the URE. A 38-kDa nucleocytoplasmic protein was identified that recognized a 12-nucleotide binding site within the URE, A mutation in this binding site that prevented protein binding assayed in vitro by UV cross-linking also prevented protein kinase A-dependent stabilization of the chimeric message assayed in vivo, These findings identify the interaction between a 38-kDa nucleocytoplasmic protein and a regulatory uridine-rich sequence in the 3'-UTR as critical for cAMP-mediated SGLT1 message stabilization.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA	University of Texas System	Lever, JE (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.	Julia.E.Lever@uth.tmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027400, R37DK027400] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27400] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AbdulManan N, 1996, NUCLEIC ACIDS RES, V24, P4063, DOI 10.1093/nar/24.20.4063; Afonina E, 1998, J BIOL CHEM, V273, P13015, DOI 10.1074/jbc.273.21.13015; AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; AMSLER K, 1982, AM J PHYSIOL, V242, pC94, DOI 10.1152/ajpcell.1982.242.1.C94; Blaxall BC, 2000, J BIOL CHEM, V275, P4290, DOI 10.1074/jbc.275.6.4290; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHEN M, 1993, J BIOL CHEM, V268, P24138; Danner S, 1998, J BIOL CHEM, V273, P3223, DOI 10.1074/jbc.273.6.3223; DAYHUFF TJ, 1992, BIOTECHNIQUES, V13, P499; DOMINGUEZ JH, 1994, J AM SOC NEPHROL, V5, pS29; Duret L, 1997, CURR OPIN STRUC BIOL, V7, P399, DOI 10.1016/S0959-440X(97)80058-9; FAN XC, 1999, P NATL ACAD SCI USA, V96, P5; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; HUANG DL, 1995, MOL ENDOCRINOL, V9, P994, DOI 10.1210/me.9.8.994; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KAESTNER KH, 1991, P NATL ACAD SCI USA, V88, P1933, DOI 10.1073/pnas.88.5.1933; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; LEE WS, 1994, J BIOL CHEM, V269, P12032; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; OHTA T, 1990, MOL CELL BIOL, V10, P6491, DOI 10.1128/MCB.10.12.6491; PENG H, 1993, J CELL PHYSIOL, V154, P238, DOI 10.1002/jcp.1041540205; PENG H, 1995, J BIOL CHEM, V270, P20536, DOI 10.1074/jbc.270.35.20536; PENG H, 1995, J BIOL CHEM, V270, P23996, DOI 10.1074/jbc.270.41.23996; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIODA T, 1994, P NATL ACAD SCI USA, V91, P11919, DOI 10.1073/pnas.91.25.11919; Short S, 2000, J BIOL CHEM, V275, P12963, DOI 10.1074/jbc.275.17.12963; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SILVERMAN M, 1991, ANNU REV BIOCHEM, V60, P757, DOI 10.1146/annurev.bi.60.070191.003545; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; Tian D, 1998, J BIOL CHEM, V273, P24861, DOI 10.1074/jbc.273.38.24861; Tillmann-Bogush M, 1999, J BIOL CHEM, V274, P1172, DOI 10.1074/jbc.274.2.1172; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; WRIGHT E M, 1992, Current Opinion in Cell Biology, V4, P696, DOI 10.1016/0955-0674(92)90091-P; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558; Yang Q, 1997, J BIOL CHEM, V272, P15466, DOI 10.1074/jbc.272.24.15466; YET SF, 1994, J CELL PHYSIOL, V158, P506, DOI 10.1002/jcp.1041580315; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	49	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33998	34008		10.1074/jbc.M005040200	http://dx.doi.org/10.1074/jbc.M005040200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10950955	hybrid			2022-12-27	WOS:000090104600113
J	Mothe-Satney, I; Brunn, GJ; McMahon, LP; Capaldo, CT; Abrahams, RT; Lawrence, JC				Mothe-Satney, I; Brunn, GJ; McMahon, LP; Capaldo, CT; Abrahams, RT; Lawrence, JC			Mammalian target of rapamycin-dependent phosphorylation of PHAS-I in four (S/T)P sites detected by phospho-specific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; P70 S6 KINASE; TRANSLATIONAL REGULATOR; CELL-PROLIFERATION; 3T3-L1 ADIPOCYTES; RAT ADIPOCYTES; GROWTH-FACTORS; INSULIN; INITIATION; PATHWAY	The role and control of the four rapamycin-sensitive phosphorylation sites that govern the association of PHAS-I with the mRNA cap-binding protein, eukaryotic initiation factor 4E (eIF4E), were investigated by using newly developed phospho-specific antibodies. Thr(P)-36/45 antibodies reacted with all three forms of PHAS-I that were resolved when cell extracts were subjected to SDS-polyacrylamide gel electrophoresis. Thr(P)-69 antibodies bound the forms of intermediate and lowest mobility, and Ser(P)-64 antibodies reacted only with the lowest mobility form. A portion of PHAS-I that copurified with eIF4E reacted with Thr(P)-36/45 and Thr(P)-69 antibodies but not with Ser(P)-64 antibodies. Insulin and/or amino acids increased, and rapamycin decreased, the reactivity of all three antibodies with PHAS-I in both HEK293 cells and 3T3-L1 adipocytes, Immunoprecipitated epitope-tagged mammalian target of rapamycin (mTOR) phosphorylated Thr-36/45. mTOR also phosphorylated Thr-69 and Ser-64 but only when purified immune complexes were incubated with the activating antibody, mTAb1, interestingly, the phosphorylation of Thr-69 and Ser-64 was much more sensitive to inhibition by rapamycin-FKBP12 than the phosphorylation of Thr-36/45, and the phosphorylation of Ser-64 by mTOR was facilitated by phosphorylation of Thr-SG, Thr-45, and Thr-69. In these respects the phosphorylation of PHAS-I by mTOR in vitro resembles the ordered phosphorylation of PHAS-I in cells.	Univ Virginia, Hlth Syst, Dept Pharmacol, Sch Med, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	University of Virginia; University of Virginia; Duke University	Lawrence, JC (corresponding author), Univ Virginia, Hlth Syst, Dept Pharmacol, Sch Med, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.		MOTHE-SATNEY, ISABELLE/Q-6377-2016; Capaldo, Chris/B-4143-2010	MOTHE-SATNEY, ISABELLE/0000-0002-2693-8385; 	NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312, DK52753] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312, R01DK052753] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Fadden P, 1997, J BIOL CHEM, V272, P10240; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Heesom KJ, 1999, FEBS LETT, V457, P489, DOI 10.1016/S0014-5793(99)01094-7; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JC, 1997, ADV ENZYME REGUL, V37, P239, DOI 10.1016/S0065-2571(96)00016-7; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, BIOCHIMIE, V77, P40, DOI 10.1016/0300-9084(96)88102-8; MADER S, 1995, MOL CELL BIOL, V15, P4990; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Yang DQ, 1999, FEBS LETT, V453, P387, DOI 10.1016/S0014-5793(99)00762-0	33	111	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33836	33843		10.1074/jbc.M006005200	http://dx.doi.org/10.1074/jbc.M006005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10942774	hybrid			2022-12-27	WOS:000090104600091
J	Cardinale, F; Jonak, C; Ligterink, W; Niehaus, K; Boller, T; Hirt, H				Cardinale, F; Jonak, C; Ligterink, W; Niehaus, K; Boller, T; Hirt, H			Differential activation of four specific MAPK pathways by distinct elicitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE AMMONIA-LYASE; PROTEIN-KINASE-ACTIVITY; TOMATO CELLS; TRANSIENT ACTIVATION; TOBACCO CELLS; EXTRACELLULAR ALKALINIZATION; SUBNANOMOLAR CONCENTRATIONS; GLYCOPEPTIDE ELICITOR; CHITIN FRAGMENTS; RESISTANCE GENE	Plant cells respond to elicitors by inducing a variety of defense responses. Some of these reactions are dependent on the activity of protein kinases. Recently, mitogen-activated protein kinases (MAPKs) have been identified to be activated by fungal and bacterial elicitors as well as by pathogen infection. In gel kinase assays of alfalfa cells treated with yeast cell wall-derived elicitor (YE) revealed that 44- and 46-kDa MAPKs are rapidly and transiently activated. Immunokinase assays with specific MAPK antibodies revealed that YE mainly activated the 46-kDa SIMK and the 44-kDa MMK3 and to a lesser extent the 44-kDa MMK2 and SAMK. When cells mere treated with chemically defined elicitors potentially contained in the YE (chitin and N-acetylglucosamine oligomers, beta -glucan, and ergosterol), the four MAPKs were found to be activated to different levels and with different kinetics, Whereas SIMK and SAMK have been found to be activated by a number of diverse stimuli, MMK3 is activated during mitosis and was therefore assumed to participate in cell division (22). No physiological, process could be associated with MMK2 activity so far. This is the first report that MMK2 and MMK3 can be activated by external stimuli. Overall, our findings indicate that plant cells can sense different cues of a given microorganism through the activation of multiple MAPKs.	Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria; Univ Bielefeld, D-33501 Bielefeld, Germany; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	University of Vienna; Vienna Biocenter (VBC); University of Bielefeld; Friedrich Miescher Institute for Biomedical Research	Hirt, H (corresponding author), Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, Dr Bohrgasse 9, A-1030 Vienna, Austria.	hehi@gem.univie.ac.at	Niehaus, Karsten/A-3966-2010; Ligterink, Wilco/C-8103-2009; Jonak, Claudia/G-1362-2016; Cardinale, Francesca/B-9758-2013; Hirt, Heribert/A-2061-2013; Boller, Thomas/G-3500-2012	Ligterink, Wilco/0000-0002-0228-169X; Boller, Thomas/0000-0001-6768-7503; Cardinale, Francesca/0000-0001-9892-9325; Jonak, Claudia/0000-0001-9605-6751				Adam AL, 1997, PLANT PHYSIOL, V115, P853, DOI 10.1104/pp.115.2.853; Baier R, 1999, PLANTA, V210, P157, DOI 10.1007/s004250050665; BASSE CW, 1992, J BIOL CHEM, V267, P10258; BASSE CW, 1993, J BIOL CHEM, V268, P14724; Bogre L, 1999, PLANT CELL, V11, P101, DOI 10.1105/tpc.11.1.101; Bogre L, 1997, PLANT CELL, V9, P75, DOI 10.1105/tpc.9.1.75; Bogre L, 1996, NATURE, V383, P489, DOI 10.1038/383489a0; Desikan R, 1999, PLANTA, V210, P97, DOI 10.1007/s004250050658; DIETRICH A, 1990, J BIOL CHEM, V265, P6360; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; Felix G, 1998, PLANT PHYSIOL, V117, P643, DOI 10.1104/pp.117.2.643; FELIX G, 1993, PLANT J, V4, P307, DOI 10.1046/j.1365-313X.1993.04020307.x; GRANADO J, 1995, PLANT PHYSIOL, V107, P485, DOI 10.1104/pp.107.2.485; GROSS P, 1993, EMBO J, V12, P1735, DOI 10.1002/j.1460-2075.1993.tb05821.x; GROSSKOPF DG, 1991, J PLANT PHYSIOL, V138, P741, DOI 10.1016/S0176-1617(11)81325-8; GROSSKOPF DG, 1990, FEBS LETT, V275, P177, DOI 10.1016/0014-5793(90)81466-2; He CZ, 1999, MOL PLANT MICROBE IN, V12, P1064, DOI 10.1094/MPMI.1999.12.12.1064; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hirt H, 2000, RES PRO CEL, V27, P85; Hirt H, 2000, RES PRO CEL, V27, P1; Inui H, 1997, BIOSCI BIOTECH BIOCH, V61, P975, DOI 10.1271/bbb.61.975; Jonak C, 1999, CELL MOL LIFE SCI, V55, P204, DOI 10.1007/s000180050285; Jonak C, 1996, P NATL ACAD SCI USA, V93, P11274, DOI 10.1073/pnas.93.20.11274; JONAK C, 1995, MOL GEN GENET, V248, P686, DOI 10.1007/BF02191708; Lebrun-Garcia A, 1998, PLANT J, V15, P773, DOI 10.1046/j.1365-313X.1998.00269.x; Ligterink W, 1997, SCIENCE, V276, P2054, DOI 10.1126/science.276.5321.2054; Mizoguchi T, 1996, P NATL ACAD SCI USA, V93, P765, DOI 10.1073/pnas.93.2.765; Munnik T, 1999, PLANT J, V20, P381, DOI 10.1046/j.1365-313x.1999.00610.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Nuhse TS, 2000, J BIOL CHEM, V275, P7521, DOI 10.1074/jbc.275.11.7521; Romeis T, 1999, PLANT CELL, V11, P273, DOI 10.1105/tpc.11.2.273; Seo S, 1999, PLANT CELL, V11, P289, DOI 10.1105/tpc.11.2.289; Stratmann JW, 1997, P NATL ACAD SCI USA, V94, P11085, DOI 10.1073/pnas.94.20.11085; SUZUKI K, 1995, PLANT CELL PHYSIOL, V36, P281, DOI 10.1093/oxfordjournals.pcp.a078760; SUZUKI K, 1995, PLANT CELL, V7, P639, DOI 10.1105/tpc.7.5.639; USAMI S, 1995, P NATL ACAD SCI USA, V92, P8660, DOI 10.1073/pnas.92.19.8660; VIARD MP, 1994, PLANT PHYSIOL, V104, P1245, DOI 10.1104/pp.104.4.1245; Zhang SQ, 2000, RES PRO CEL, V27, P65; Zhang SQ, 1998, PLANT CELL, V10, P435, DOI 10.1105/tpc.10.3.435; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7433, DOI 10.1073/pnas.95.13.7433; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7225, DOI 10.1073/pnas.95.12.7225; Zhang SQ, 1997, PLANT CELL, V9, P809, DOI 10.1105/tpc.9.5.809	42	119	130	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36734	36740		10.1074/jbc.M007418200	http://dx.doi.org/10.1074/jbc.M007418200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973984	hybrid			2022-12-27	WOS:000165577700042
J	Cowan, KJ; Law, DA; Phillips, DR				Cowan, KJ; Law, DA; Phillips, DR			Identification of Shc as the primary protein binding to the tyrosine-phosphorylated beta(3) subunit of alpha(IIb)beta(3) during outside-in integrin platelet signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; ALPHA(6)BETA(4) INTEGRIN; PHOSPHOLIPASE A(2); THROMBIN RECEPTOR; CELL-ADHESION; MAP KINASE; ACTIVATION; GROWTH; TRANSDUCTION; ASSOCIATION	Outside-in signaling mediated by the integrin alpha (IIb)beta (3) (GPIIbIIIa) is critical to platelet function and has been shown to involve the phosphorylation of tyrosine residues on the cytoplasmic tail of beta (3). To identify proteins that bind directly to phosphorylated beta (3), we utilized an affinity column consisting of a peptide modeled on the tyrosine-phosphorylated cytoplasmic domain of beta (3). Tandem mass spectrometric sequencing and immunoblotting demonstrated that She was the primary protein binding to phosphorylated beta (3). To determine the involvement of Shc in outside-in alpha (IIb)beta (3) signaling, the phosphorylation of Shc during platelet aggregation was examined; transient She phosphorylation was observed when thrombin-stimulated platelets were allowed to aggregate or when aggregation was induced by an LIBS (ligand-induced binding site) antibody, D3. Moreover, She was co-immunoprecipitated with tyrosine-phosphorylated beta (3) in detergent lysates of aggregated platelets. Using purified, recombinant protein, it was found that the binding of Shc to monophosphorylated (C-terminal tyrosine) and diphosphorylated beta (3) peptides was direct, demonstrating She recognition motifs on phospho-beta (3). Aggregation-induced She phosphorylation was also observed to be robust in platelets from wild-type mice, but not in those from mice expressing (Y747F,Y759F) beta (3), which are defective in outside-in alpha (IIb)beta (3) signaling. Thus, Shc is the primary downstream signaling partner of beta (3) in its tyrosine phosphorylation outside-in signaling pathway.	COR Therapeut Inc, San Francisco, CA 94080 USA		Phillips, DR (corresponding author), COR Therapeut Inc, 256 E Grand Ave, San Francisco, CA 94080 USA.	dphillips@corr.com						Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, J BIOL CHEM, V269, P28859; Clements JL, 1999, J CLIN INVEST, V103, P925, DOI 10.1172/JCI6562; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; Eigenthaler R, 1997, J BIOL CHEM, V272, P7693, DOI 10.1074/jbc.272.12.7693; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FOX JEB, 1982, J BIOL CHEM, V257, P4120; FRACKELTON AR, 1984, J BIOL CHEM, V259, P7909; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Law DA, 1999, BLOOD, V93, P2645, DOI 10.1182/blood.V93.8.2645.408k13_2645_2652; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; LINDBERG FP, 1994, J BIOL CHEM, V269, P1567; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROSS AH, 1981, NATURE, V294, P654, DOI 10.1038/294654a0; Sato T, 1999, J BIOCHEM, V125, P96, DOI 10.1093/oxfordjournals.jbchem.a022275; SAXTON TM, 1994, J IMMUNOL, V153, P623; Shattil SJ, 1999, THROMB HAEMOSTASIS, V82, P318; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Shock DD, 1997, BIOCHEM J, V321, P525, DOI 10.1042/bj3210525; Shock DD, 1999, BIOCHEM J, V342, P729, DOI 10.1042/0264-6021:3420729; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; Tridandapani S, 1999, J IMMUNOL, V162, P1408; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILLIAMS LT, 1991, COLD SH Q B, V56, P243; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265	51	82	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36423	36429		10.1074/jbc.M004068200	http://dx.doi.org/10.1074/jbc.M004068200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964917	hybrid			2022-12-27	WOS:000165382000108
J	Kong, M; Mounier, C; Wu, J; Posner, BI				Kong, M; Mounier, C; Wu, J; Posner, BI			Epidermal growth factor-induced phosphatidylinositol 3-kinase activation and DNA synthesis - Identification of Grb2-associated binder 2 as the major mediator in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATED 100-KDA PROTEIN; INSULIN-RECEPTOR SUBSTRATE-1; PLECKSTRIN HOMOLOGY DOMAIN; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; ADAPTER PROTEIN; HEMATOPOIETIC-CELLS; P85 SUBUNIT; SH2 DOMAIN; S6 KINASE	In previous work we showed that the phosphatidylinositol S-kinase (PI3-kinase), not the mitogen-activated protein kinase, pathway is necessary and sufficient to account for insulin- and epidermal growth factor (EGF)induced DNA synthesis in rat hepatocytes. Here, using a dominant-negative p85, we confirmed the key role of EGF-induced PI3-kinase activation and sought to identify the mechanism by which this is effected. Our results show that EGF activates PI3-kinase with a time course similar to that of the association of p85 with three principal phosphotyrosine proteins (i.e. PY180, PY105, and PY52), We demonstrated that each formed a distinct p85-associated complex. PY180 and PY52 each constituted about 10% of EGF-activated PI3-kinase, whereas PY105 was responsible for 80%. PY105 associated with Grb2 and SHP-2, and although it behaved like Gab1, none of the latter was detected in rat liver. We therefore cloned a cDNA from rat liver, which was found to be 95% homologous to the mouse Grb2-associated binder 2 (Gab2) cDNA sequence. Using a specific Gab2 antibody, we demonstrated its expression in and association with p85, SHP-2, and Grb2 upon EGF treatment of rat hepatocytes, Gab2 accounted for most if not all of the PY105 species, since immunoprecipitation of Gab2 with specific antibodies demonstrated parallel immunodepletion of Gab2 and PY105 from the residual supernatants, We also found that the PI3-kinase activity associated with Gaba was totally abolished by dominant negative p85. Thus, Gab2 appears to be the principal EGF-induced PY protein recruiting and activating PI3-kinase and mitogenesis.	McGill Univ, Fac Med, Polypeptide Hormone Lab, Montreal, PQ H3A 2B2, Canada	McGill University	Posner, BI (corresponding author), McGill Univ, Fac Med, Polypeptide Hormone Lab, Strathocona Anat Bldg 3640 Univ St, Montreal, PQ H3A 2B2, Canada.		Posner, Barry/B-6733-2008; Mounier, Catherine/D-3690-2011	Mounier, Catherine/0000-0003-3608-4229				ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Band CJ, 1999, ENDOCRINOLOGY, V140, P5626, DOI 10.1210/en.140.12.5626; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Carver RS, 1996, J BIOL CHEM, V271, P13491, DOI 10.1074/jbc.271.23.13491; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Derossi D, 1998, BIOCHEM BIOPH RES CO, V251, P148, DOI 10.1006/bbrc.1998.9444; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eder AM, 1998, J BIOL CHEM, V273, P28025, DOI 10.1074/jbc.273.43.28025; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Gadina M, 1999, J IMMUNOL, V162, P2081; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HADARI YR, 1992, J BIOL CHEM, V267, P17483; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOLGADOMADRUGA M, 1996, NATURE, V379, P8560; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Kanagasundaram V, 1996, BIOCHEM J, V320, P69, DOI 10.1042/bj3200069; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KIM HH, 1994, J BIOL CHEM, V269, P24747; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; LEE CC, 1995, J BIOL CHEM, V270, P507, DOI 10.1074/jbc.270.2.507; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Takahashi Y, 1999, J CELL PHYSIOL, V178, P69, DOI 10.1002/(SICI)1097-4652(199901)178:1<69::AID-JCP9>3.0.CO;2-Z; THOMPSON DM, 1985, J BIOL CHEM, V260, P8824; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Wong L, 1996, J BIOL CHEM, V271, P20981, DOI 10.1074/jbc.271.35.20981; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Zhang SL, 1999, BIOCHEM BIOPH RES CO, V254, P440, DOI 10.1006/bbrc.1998.9959; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	53	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36035	36042		10.1074/jbc.M005621200	http://dx.doi.org/10.1074/jbc.M005621200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10973965	hybrid			2022-12-27	WOS:000165382000056
J	Arora, PD; Manolson, MF; Downey, GP; Sodek, J; McCulloch, CAG				Arora, PD; Manolson, MF; Downey, GP; Sodek, J; McCulloch, CAG			A novel model system for characterization of phagosomal maturation, acidification, and intracellular collagen degradation in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR MEDIATED PHAGOCYTOSIS; NATIVE COLLAGEN; LATE ENDOSOMES; MACROPHAGES; TRANSPORT; DIGESTION; MEMBRANE; SUSCEPTIBILITY; CATHEPSIN-B1; LOCALIZATION	Intracellular collagen degradation by fibroblasts is an important but poorly understood pathway for the physiological remodeling of mature connective tissues. The objective of this study was to determine whether gingival-fibroblasts that express endogenous alpha (2)beta (1) integrin, the collagen:receptor, would exhibit the cellular machinery required for phagosomal maturation and collagen degradation. There was a time-dependent increase of collagen bead internalization and a time-dependent decrease of bead-associated alpha (2)beta (1) integrin after initial bead; binding. beta -Actin and gelsolin associated transiently with beads (0-30 min) followed by LAMP-1 (60-240 min) and cathepsin B (30-240 min). Cytochalasin D prevented phagosome formation and also prevented the sequential fusion of early endosomes with lysosomes, Collagen bead-associated pH was progressively reduced from: 7.25 to 5.4, which was contemporaneous with progressive increases in degradation of bead-associated collagen (30-120 min). Concanamycin blocked acidification of phagolysosomes and collagen degradation but not phagosome maturation, Phagosomal acidification was partly dependent on elevated intracellular calcium. These studies demonstrate that the cellular machinery required for intracellular collagen degradation in fibroblasts closely resembles the vacuolar system in macrophages.	Univ Toronto, MRC, Grp Periodontal Physiol, Toronto, ON M5S 3E8, Canada; Univ Toronto, Fac Dent, Toronto, ON M5S 3E8, Canada; Univ Toronto, Fac Med, Div Respirol, Toronto, ON M5S 3E8, Canada; Univ Hlth Network, Inst Res, Toronto, ON M5G 2C4, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	McCulloch, CAG (corresponding author), Univ Toronto, MRC, Grp Periodontal Physiol, Rm 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E8, Canada.			Manolson, Morris/0000-0001-8755-5460; Downey, Gregory P/0000-0003-3253-5862				ARORA PD, 1994, J CELL PHYSIOL, V159, P161, DOI 10.1002/jcp.1041590120; BERG RA, 1980, P NATL ACAD SCI-BIOL, V77, P4746, DOI 10.1073/pnas.77.8.4746; BIENKOWSKI RS, 1978, J BIOL CHEM, V253, P4356; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BURLEIGH MC, 1974, BIOCHEM J, V137, P387, DOI 10.1042/bj1370387; Chou DHI, 1996, J IMMUNOL, V156, P4354; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; DePina AS, 1999, MICROSC RES TECHNIQ, V47, P93, DOI 10.1002/(SICI)1097-0029(19991015)47:2<93::AID-JEMT2>3.0.CO;2-P; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; DSOUZA MP, 1986, ARCH BIOCHEM BIOPHYS, V249, P522, DOI 10.1016/0003-9861(86)90030-5; EISSENBERG LG, 1993, J EXP MED, V177, P1605, DOI 10.1084/jem.177.6.1605; ETHERINGTON DJ, 1976, BIOCHEM J, V153, P199, DOI 10.1042/bj1530199; Everts V, 1996, HISTOCHEM J, V28, P229, DOI 10.1007/BF02409011; EVERTS V, 1985, COLLAGEN REL RES, V5, P315; EVERTS V, 1994, MATRIX BIOL, V14, P665; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HASSELL TM, 1983, AM J PATHOL, V112, P218; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; JACONI MEE, 1991, J CELL BIOL, V112, P1249, DOI 10.1083/jcb.112.6.1249; Jahraus A, 1998, J BIOL CHEM, V273, P30379, DOI 10.1074/jbc.273.46.30379; KIELTY CM, 1993, BIOCHEM BIOPH RES CO, V191, P1230, DOI 10.1006/bbrc.1993.1349; KNOWLES GC, 1991, J CELL SCI, V98, P551; Kwiatkowska K, 1999, BIOESSAYS, V21, P422, DOI 10.1002/(SICI)1521-1878(199905)21:5<422::AID-BIES9>3.0.CO;2-#; LANG T, 1988, EUR J CELL BIOL, V46, P39; Lee W, 1996, J CELL PHYSIOL, V168, P695, DOI 10.1002/(SICI)1097-4652(199609)168:3<695::AID-JCP22>3.0.CO;2-X; LUTZ DA, 1993, ANAL BIOCHEM, V214, P205, DOI 10.1006/abio.1993.1478; MUROI M, 1993, BIOCHEM BIOPH RES CO, V193, P999, DOI 10.1006/bbrc.1993.1724; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; PITT A, 1992, J BIOL CHEM, V267, P126; RABINOVITCH M, 1995, TRENDS CELL BIOL, V5, P85, DOI 10.1016/S0962-8924(00)88955-2; Ripley CR, 1997, EXP CELL RES, V236, P147, DOI 10.1006/excr.1997.3707; SODEK J, 1988, BIOL MECHANISMS TOOT, P303; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; TENCATE AR, 1972, J ANAT, V112, P401; VANDERZEE E, 1995, J CELL SCI, V108, P3307; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Zimmerli S, 1996, J CELL BIOL, V132, P49, DOI 10.1083/jcb.132.1.49	42	89	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35432	35441		10.1074/jbc.M003221200	http://dx.doi.org/10.1074/jbc.M003221200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10945978	hybrid			2022-12-27	WOS:000165422800080
J	Chambers, RC; Leoni, P; Blanc-Brude, OP; Wembridge, DE; Laurent, GJ				Chambers, RC; Leoni, P; Blanc-Brude, OP; Wembridge, DE; Laurent, GJ			Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG FIBROBLAST PROLIFERATION; FACTOR GENE-EXPRESSION; IMMEDIATE-EARLY GENE; FACTOR-BETA; ENDOTHELIAL-CELLS; PROCOLLAGEN SYNTHESIS; PULMONARY-FIBROSIS; INDUCIBLE GENE; MESSENGER-RNA; SMOOTH-MUSCLE	The coagulation protease thrombin plays a critical role in hemostasis and exerts pro-inflammatory and profibrotic: effects via proteolytic activation of the major thrombin receptor, protease-activated receptor-1 (PAR-1), Connective tissue growth factor (CTGF) is a novel fibroblast mitogen and also promotes extracellular matrix protein production. It is selectively induced by transforming growth factor beta (TGF-beta) and is thought to be the autocrine agent responsible for mediating its pro-fibrotic effects. CTGF is up-regulated during tissue repair and in fibrotic conditions associated with activation of the coagulation cascade. We therefore hypothesized that coagulation proteases promote the production of CTGF by cells at sites of tissue injury, To begin to address this hypothesis, we assessed the effect of coagulation proteases on fibroblast CTGF expression in vitro, and we show that thrombin, at physiological concentrations, up-regulated CTGF mRNA levels 5-fold relative to base line (p < 0.01) in fetal fibroblasts and 7-fold in primary adult fibroblasts (p < 0.01), These effects were cycloheximide-insensitive and were not blocked with a pan-specific TGF-beta -neutralizing antibody. They were further paralleled by a concomitant increase in CTGF protein production and could be mimicked with selective PAR-1 agonists, In addition, fibroblasts derived from PAR-1 knockout mice were unresponsive to thrombin but responded normally to TGF-beta (1) Finally, factor Xa, which is responsible for activating prothrombin during blood coagulation, exerted similar stimulatory effects. We propose that coagulation proteases and PAR-1 may play a role in promoting connective tissue formation during normal tissue repair and the development of fibrosis by up-regulating fibroblast CTGF expression.	UCL, Royal Free & Univ Coll Med Sch, Rayne Inst, Ctr Cardiopulm Biochem & Resp Med, London WC1E 6JJ, England	University of London; King's College London; University College London	Chambers, RC (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Rayne Inst, Ctr Cardiopulm Biochem & Resp Med, 5 Univ St, London WC1E 6JJ, England.	R.Chambers@ucl.ac.uk	BLANC-BRUDE, Olivier/O-8629-2017	BLANC-BRUDE, Olivier/0000-0002-4015-0615; Chambers, Rachel/0000-0003-1370-9417				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Akers IA, 2000, AM J PHYSIOL-LUNG C, V278, pL193, DOI 10.1152/ajplung.2000.278.1.L193; Allen JT, 1999, AM J RESP CELL MOL, V21, P693, DOI 10.1165/ajrcmb.21.6.3719; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; CARNEY DH, 1992, J CLIN INVEST, V89, P1469, DOI 10.1172/JCI115737; Chambers RC, 1998, BIOCHEM J, V333, P121, DOI 10.1042/bj3330121; Cirino G, 1996, J EXP MED, V183, P821, DOI 10.1084/jem.183.3.821; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Cunningham MA, 2000, J EXP MED, V191, P455, DOI 10.1084/jem.191.3.455; Dabbagh K, 1998, THROMB HAEMOSTASIS, V79, P405; Dammeier J, 1998, INT J BIOCHEM CELL B, V30, P909, DOI 10.1016/S1357-2725(98)00046-6; DAWES KE, 1993, EUR J CELL BIOL, V61, P126; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; DuhamelClerin E, 1997, ARTERIOSCL THROM VAS, V17, P1931, DOI 10.1161/01.ATV.17.10.1931; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; GOLDSACK NR, 1999, AM J CRIT CARE MED, V159, P73; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hollenberg MD, 1997, CAN J PHYSIOL PHARM, V75, P832, DOI 10.1139/cjpp-75-7-832; Hong HH, 1999, LAB INVEST, V79, P1655; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KANG YH, 1991, J HISTOCHEM CYTOCHEM, V39, P413, DOI 10.1177/39.4.2005371; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCANULTY RJ, 1991, BIOCHIM BIOPHYS ACTA, V1091, P231, DOI 10.1016/0167-4889(91)90066-7; NELKEN NA, 1992, J CLIN INVEST, V90, P1614, DOI 10.1172/JCI116031; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Oemar BS, 1997, CIRCULATION, V95, P831; OHBA T, 1994, AM J RESP CELL MOL, V10, P405, DOI 10.1165/ajrcmb.10.4.7510986; Papadimitriou E, 1997, AM J PHYSIOL-CELL PH, V272, pC1112, DOI 10.1152/ajpcell.1997.272.4.C1112; Rade JJ, 1996, NAT MED, V2, P293, DOI 10.1038/nm0396-293; Ragosta M, 1996, CIRCULATION, V93, P1194, DOI 10.1161/01.CIR.93.6.1194; Ricupero DA, 1999, AM J PHYSIOL-LUNG C, V277, pL1165, DOI 10.1152/ajplung.1999.277.6.L1165; RODRIGUEZ NAH, 1995, LANCET, V346, P1071; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; STOUFFER GA, 1994, J CLIN INVEST, V93, P2048, DOI 10.1172/JCI117199; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; TANI K, 1991, AM J RESP CELL MOL, V5, P34, DOI 10.1165/ajrcmb/5.1.34; Trejo J, 1996, J BIOL CHEM, V271, P21536, DOI 10.1074/jbc.271.35.21536; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALZ DA, 1985, P SOC EXP BIOL MED, V180, P518; Yamabe H, 1997, NEPHROL DIAL TRANSPL, V12, P438, DOI 10.1093/ndt/12.3.438	51	208	219	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35584	35591		10.1074/jbc.M003188200	http://dx.doi.org/10.1074/jbc.M003188200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952976	hybrid			2022-12-27	WOS:000165422800099
J	Moll, JR; Olive, M; Vinson, C				Moll, JR; Olive, M; Vinson, C			Attractive interhelical electrostatic interactions in the proline- and acidic-rich region (PAR) leucine zipper subfamily preclude heterodimerization with other basic leucine zipper subfamilies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL; TRANSCRIPTION FACTOR; DNA-BINDING; CRYSTAL-STRUCTURE; C-FOS; EXPRESSION; SPECIFICITY; LEUKEMIA; GENE; PROTEIN	Basic region-leucine zipper (B-ZIP) proteins homo- or heterodimerize to bind sequence-specific double-stranded DNA. We present circular dichroism (CD) thermal denaturation data on vitellogenin promoter-binding protein (VBP), a member of the PAR subfamily of E-ZIP proteins that also includes thyroid embryonic factor, hepatocyte leukemia factor, and albumin site D-binding protein. VBP does not heterodimerize with B-ZIP domains from C/EBP alpha, JUND, or FOS, We describe a dominant negative protein, A-VEP, that contains the VBP leucine zipper and an acidic amphipathic protein sequence that replaces the basic region critical for DNA binding. The acidic extension forms a coiled coil structure with the VEP basic region in the VBP A-VBP heterodimer, This new alpha -helical structure extends the leucine zipper N-terminally, stabilizing the complex by 2.0 kcal/mol, A-VBP abolishes DNA binding of VBP in an equimolar competition assay, but does not affect DNA binding even at 100-fold excess of CREB, C/EBP alpha, or FOS/JUND, Likewise, proteins containing the acidic extension appended to seven other leucine zippers do not inhibit VBP DNA binding. We show that conserved g <-> e' or i, i' + 5 salt bridges are sufficient to confer specificity to VBP by mutating the C/EBP alpha leucine zipper to contain the g <-> e' salt bridges that characterize VBP, A-VBP heterodimerizes with this mutant C/EBP, preventing it from binding to DNA These conserved g <-> e' electrostatic interactions define the specificity of the PAR subfamily of B-ZIP proteins and preclude interaction with other B-ZIP subfamilies.	NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; INSERM, U441, F-33600 Pessac, France	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Institut National de la Sante et de la Recherche Medicale (Inserm)	Vinson, C (corresponding author), NCI, Lab Metab, NIH, Bldg 37,Rm 4D06, Bethesda, MD 20892 USA.	vinsonc@dc37a.nci.nih.gov						Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; Blau J, 1999, CELL, V99, P661, DOI 10.1016/S0092-8674(00)81554-8; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Hitzler JK, 1999, BRAIN RES, V820, P1, DOI 10.1016/S0006-8993(98)00999-8; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Inukai T, 1997, MOL CELL BIOL, V17, P1417, DOI 10.1128/MCB.17.3.1417; IYER SV, 1991, MOL CELL BIOL, V11, P4863, DOI 10.1128/MCB.11.10.4863; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; Krylov D, 1998, J MOL BIOL, V279, P959, DOI 10.1006/jmbi.1998.1762; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WUARIN J, 1992, J CELL SCI, P123; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365	29	34	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34826	34832		10.1074/jbc.M004545200	http://dx.doi.org/10.1074/jbc.M004545200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942764	hybrid			2022-12-27	WOS:000165095300110
J	Delehedde, M; Seve, M; Sergeant, N; Wartelle, I; Lyon, M; Rudland, PS; Fernig, DG				Delehedde, M; Seve, M; Sergeant, N; Wartelle, I; Lyon, M; Rudland, PS; Fernig, DG			Fibroblast growth factor-2 stimulation of p42/44(MAPK) phosphorylation and I kappa B degradation is regulated by heparan sulfate/heparin in rat mammary fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RIBOSOMAL S6 KINASE; BASIC FGF; SULFATE PROTEOGLYCAN; CELL-PROLIFERATION; XENOPUS EGGS; RECEPTOR; BINDING; ALPHA; INHIBITOR	Fibroblast growth factor-2 (FGF-2) interacts with a dual receptor system consisting of tyrosine kinase receptors and heparan sulfate proteoglycans (HSPGs). In rat mammary fibroblasts, FGF-2 stimulated DNA synthesis and induced a sustained phosphorylation of p42/44(MAPK) and of its downstream target, p90(RSK). Moreover, FGF-S also stimulated the transient degradation of I kappaB alpha and I kappaB beta. PD098059, a specific inhibitor of p42/44(MAPK) phosphorylation, inhibited FGF-2-stimulated DNA synthesis, phosphorylation of p42/44(MAPK) and p90(RSK) and degradation of I kappaB beta. In contrast, in chlorate-treated and hence sulfated glycosaminoglycan-deficient cells, FGF-2 was unable to stimulate DNA synthesis. However, FGF-2 was able to trigger a transient phosphorylation of both p42/44(MAPK) and p90(RSK), which peaked at 15 min and returned to control levels at 30 min. In these sulfated glycosaminoglycan-deficient cells, no degradation of I kappaB alpha and I kappaB beta was observed after FGF-2 addition. However, in chlorate-treated cells, the addition of heparin or purified HSPGs simultaneously with FGF-2 restored DNA synthesis, the sustained phosphorylation of p42/44(MAPK) and p90(RSK), and the degradation of I kappaB alpha and I kappaB beta. These results suggest that the HSPG receptor for FGF-2 not only influences the outcome of FGF-2 signaling, e.g. cell proliferation, but importantly regulates the immediate-early signals generated by this growth factor.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Manchester, Christie Hosp NHS Trust, Dept Med Oncol, Canc Res Campaign, Manchester M20 4BX, Lancs, England	University of Liverpool; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Fernig, DG (corresponding author), Univ Liverpool, Sch Biol Sci, Life Sci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.		Fernig, David G/A-3590-2008; Seve, Michel/M-2786-2013; Sergeant, Nicolas/O-5467-2017	Fernig, David G/0000-0003-4875-4293; Sergeant, Nicolas/0000-0003-1448-124X; Lyon, Malcolm/0000-0001-9575-6879; DELEHEDDE, Maryse/0000-0003-2724-143X; SEVE, Michel/0000-0001-5503-9488				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P13, DOI 10.1002/jcp.1041240104; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Deakin JA, 1999, J CELL SCI, V112, P1999; Delehedde M, 1996, EXP CELL RES, V229, P398, DOI 10.1006/excr.1996.0385; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1991, J BIOL CHEM, V266, P5249; Fannon M, 2000, BIOCHEMISTRY-US, V39, P1434, DOI 10.1021/bi991895z; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FERNIG DG, 1990, J CELL PHYSIOL, V142, P108, DOI 10.1002/jcp.1041420114; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GREVE H, 1988, J BIOL CHEM, V263, P12886; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Heilker R, 1999, EUR J BIOCHEM, V259, P253, DOI 10.1046/j.1432-1327.1999.00028.x; Hoshi S, 2000, J BIOL CHEM, V275, P883, DOI 10.1074/jbc.275.2.883; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; Lyon M, 1998, MATRIX BIOL, V17, P485, DOI 10.1016/S0945-053X(98)90096-8; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REILAND J, 1993, J CELL SCI, V105, P1085; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUDLAND PS, 1984, J CELL PHYSIOL, V120, P364, DOI 10.1002/jcp.1041200315; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Safaiyan F, 1999, J BIOL CHEM, V274, P36267, DOI 10.1074/jbc.274.51.36267; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Sellers LA, 1999, J BIOL CHEM, V274, P16423, DOI 10.1074/jbc.274.23.16423; Sergeant N, 2000, J BIOL CHEM, V275, P17094, DOI 10.1074/jbc.M000237200; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sperinde GV, 2000, BIOCHEMISTRY-US, V39, P3788, DOI 10.1021/bi992243d; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; WALKER A, 1994, J BIOL CHEM, V269, P931; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	55	59	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33905	33910		10.1074/jbc.M005949200	http://dx.doi.org/10.1074/jbc.M005949200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10944532	hybrid			2022-12-27	WOS:000090104600100
J	Bender, AT; Nakatsuka, M; Osawa, Y				Bender, AT; Nakatsuka, M; Osawa, Y			Heme insertion, assembly, and activation of apo-neuronal nitric-oxide synthase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE NO SYNTHASE; TETRAHYDROBIOPTERIN INTERACTION; SUBUNIT DIMERIZATION; ESCHERICHIA-COLI; DIMERIC ENZYME; L-ARGININE; BINDING; DOMAIN; INACTIVATION; BRAIN	It has been established that in the case of inducible NO synthase (NOS), a functionally active homodimer is assembled from the heme deficient monomeric apo-NOS in vitro by the addition of heme, whereas the heme-deficient neuronal isoform (apo-nNOS) is at best only partially activated. In the current study we have discovered that reactive oxygen species, which can be removed by the addition of superoxide dismutase and catalase, destroy the heme and limit the activation of apon-NOS in vitro. With the use of these improved conditions, we show for the first time that heme insertion is a rapid process that results in formation of a heme-bound monomeric nNOS that is able to form the ferrous-CO P450 complex but is unable to synthesize NO. A slow process requiring more than 90 min is required for dimerization and activation of this P450 intermediate to give an enzyme with a specific activity of approximately 1100 nmol of NO formed/min/mg of protein, similar to that of the native enzyme. Interestingly, the dimer is not SDS-resistant and is not the same dimer that forms in vivo. These studies indicate at least two intermediates in the assembly of nNOS and advance our understanding of the regulation of nNOS.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Osawa, Y (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES08365] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; [Anonymous], [No title captured]; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bender AT, 2000, J BIOL CHEM, V275, P17407, DOI 10.1074/jbc.M000155200; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Brunner K, 1998, BIOCHEMISTRY-US, V37, P17545, DOI 10.1021/bi981138l; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Cubberley RR, 1997, BIOCHEM J, V323, P141, DOI 10.1042/bj3230141; Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; Ghosh DK, 1999, EMBO J, V18, P6260, DOI 10.1093/emboj/18.22.6260; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Hemmens B, 1998, BIOCHEM J, V332, P337, DOI 10.1042/bj3320337; Iwasaki T, 1999, J BIOL CHEM, V274, P7705, DOI 10.1074/jbc.274.12.7705; Jianmongkol S, 2000, J BIOL CHEM, V275, P13370, DOI 10.1074/jbc.275.18.13370; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; McMillan K, 2000, P NATL ACAD SCI USA, V97, P1506, DOI 10.1073/pnas.97.4.1506; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; Nakatsuka M, 1998, DRUG METAB DISPOS, V26, P497; Noguchi S, 2000, J BIOL CHEM, V275, P2376, DOI 10.1074/jbc.275.4.2376; OLKEN NM, 1994, BIOCHEMISTRY-US, V33, P14784, DOI 10.1021/bi00253a017; POU S, 1992, J BIOL CHEM, V267, P24173; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SCHAEFER WH, 1985, BIOCHEMISTRY-US, V24, P3254, DOI 10.1021/bi00334a027; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Vuletich JL, 1998, ANAL BIOCHEM, V265, P375, DOI 10.1006/abio.1998.2926; Watanabe Y, 1998, BBA-PROTEIN STRUCT M, V1388, P199, DOI 10.1016/S0167-4838(98)00191-5; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; Wolff DJ, 1997, ARCH BIOCHEM BIOPHYS, V338, P73, DOI 10.1006/abbi.1996.9811	38	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26018	26023		10.1074/jbc.275.34.26018	http://dx.doi.org/10.1074/jbc.275.34.26018			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10950965	hybrid			2022-12-27	WOS:000088999700020
J	Bhattacharya, AA; Curry, S; Franks, NP				Bhattacharya, AA; Curry, S; Franks, NP			Binding of the general anesthetics propofol and halothane to human serum albumin - High resolution crystal structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLATILE ANESTHETICS; LIGAND-BINDING; SITES; ACID; ENFLURANE; PROTEINS; ISOFLURANE; STABILITY; DYNAMICS; F-19-NMR	Human serum albumin (HSA) is one of the most abundant proteins in the circulatory system and plays a key role in the transport of fatty acids, metabolites, and drugs. For many drugs, binding to serum albumin is a critical determinant of their distribution and pharmacokinetics; however, there have as yet been no high resolution crystal structures published of drug-albumin complexes. Here we describe high resolution crystal structures of HSA with two of the most widely used general anesthetics, propofol and halothane. In addition, we describe a crystal structure of HSA complexed with both halothane and the fatty acid, myristate. We show that the intravenous anesthetic propofol binds at two discrete sites on HSA in preformed pockets that have been shown to accommodate fatty acids. Similarly we show that the inhalational agent halothane binds (at concentrations in the pharmacologically relevant range) at three sites that are also fatty acid binding loci. At much higher halothane concentrations, we have identified additional sites that are occupied, All of the higher affinity anesthetic binding sites are amphiphilic in nature, with both polar and apolar parts, and anesthetic binding causes only minor changes in local structure.	Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, London SW7 2BW, England	Imperial College London	Curry, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, Prince Consort Rd, London SW7 2BW, England.			Curry, Stephen/0000-0002-0552-8870; Franks, Nicholas/0000-0003-4874-4212				ABRAHAM MH, 1991, J PHARM SCI-US, V80, P719, DOI 10.1002/jps.2600800802; ALTMAYER P, 1995, ARZNEIMITTEL-FORSCH, V45-2, P1053; ALTMAYER P, 1987, ACTA ANAESTH SCAND, V31, P756, DOI 10.1111/j.1399-6576.1987.tb02659.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Carter D. C., 1994, ADV PROTEIN CHEM, V45, P152; Curry S, 1999, BBA-MOL CELL BIOL L, V1441, P131, DOI 10.1016/S1388-1981(99)00148-1; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; DALE O, 1986, BIOCHEM PHARMACOL, V35, P557, DOI 10.1016/0006-2952(86)90347-3; DALE O, 1986, BRIT J ANAESTH, V58, P1022, DOI 10.1093/bja/58.9.1022; DALE O, 1984, BRIT J ANAESTH, V56, P535, DOI 10.1093/bja/56.5.535; DIPAOLO T, 1974, NATURE, V252, P471, DOI 10.1038/252471a0; DUBOIS BW, 1993, P NATL ACAD SCI USA, V90, P6478, DOI 10.1073/pnas.90.14.6478; DUBOIS BW, 1992, BIOCHEMISTRY-US, V31, P7069, DOI 10.1021/bi00146a007; ECKENHOFF RG, 1993, ANESTHESIOLOGY, V79, P96, DOI 10.1097/00000542-199307000-00015; Eckenhoff RG, 1996, J BIOL CHEM, V271, P15521, DOI 10.1074/jbc.271.26.15521; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; Fletcher DA, 1996, J CHEM INF COMP SCI, V36, P746, DOI 10.1021/ci960015+; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Franks NP, 1998, BIOPHYS J, V75, P2205, DOI 10.1016/S0006-3495(98)77664-7; FRANKS NP, 1985, CHEM BRIT, V21, P919; FRANKS NP, 1978, NATURE, V274, P339, DOI 10.1038/274339a0; GURSKY O, 1994, P NATL ACAD SCI USA, V91, P12388, DOI 10.1073/pnas.91.26.12388; HANSCH C, 1975, J MED CHEM, V18, P546, DOI 10.1021/jm00240a002; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; Johansson JS, 1999, ANESTHESIOLOGY, V90, P235, DOI 10.1097/00000542-199901000-00030; JOHANSSON JS, 1995, ANESTHESIOLOGY, V83, P316, DOI 10.1097/00000542-199508000-00012; KATZ Y, 1977, BIOCHIM BIOPHYS ACTA, V471, P1, DOI 10.1016/0005-2736(77)90387-X; KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57; Krasowski MD, 1999, CELL MOL LIFE SCI, V55, P1278, DOI 10.1007/s000180050371; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Mazoit JX, 1999, BRIT J CLIN PHARMACO, V47, P35, DOI 10.1046/j.1365-2125.1999.00860.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Peters T., 1996, ALL ALBUMIN BIOCH GE; REED RG, 1975, BIOCHEMISTRY-US, V14, P4578, DOI 10.1021/bi00692a004; SAIFER A, 1961, J LIPID RES, V2, P268; SOGAMI M, 1968, BIOCHEMISTRY-US, V7, P2172, DOI 10.1021/bi00846a020; SUDLOW G, 1976, MOL PHARMACOL, V12, P1052; SUDLOW G, 1975, MOL PHARMACOL, V11, P824; Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439; Tanner JW, 1999, BBA-PROTEIN STRUCT M, V1430, P46, DOI 10.1016/S0167-4838(98)00258-1	41	468	489	2	57	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38731	38738		10.1074/jbc.M005460200	http://dx.doi.org/10.1074/jbc.M005460200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10940303	hybrid			2022-12-27	WOS:000165739800082
J	Pons, S; Torres-Aleman, I				Pons, S; Torres-Aleman, I			Insulin-like growth factor-I stimulates dephosphorylation of I kappa B through the serine phosphatase calcineurin (protein phosphatase 2B)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TNF-ALPHA; ACTIVATION; KINASE; RECEPTOR; SURVIVAL; ASTROCYTES; PATHWAY; AKT; NEURODEGENERATION	Astrocytes represent the most abundant cell type of the adult nervous system. Under normal conditions, astrocytes participate in neuronal feeding and detoxification. However, following brain injury, local increases in inflammatory cytokines trigger a reactive phenotype in astrocytes during which these cells produce their own inflammatory cytokines and neurotoxic free radicals. Indeed, progression of this inflammatory reaction is responsible for most neurological damage associated with brain trauma. Insulin-Like growth factor-I (IGF-I) protects neurons against a variety of brain pathologies associated with glial overproduction of proinflammatory cytokines. Here, we demonstrate that in astrocyte cultures IGF-I regulates NF kappaB, a transcription factor known to play a key role in the inflammatory reaction. IGF-I induces a site-specific dephosphorylation of I kappaB alpha (phospho-Ser(32)) in astrocytes. Moreover, IGF-I-mediated dephosphorylation of I kappaB alpha protects this molecule from tumor necrosis factor cu (TNF alpha)-stimulated degradation; therefore, IGF-I also inhibits the nuclear translocation of NF kappaB (p65) induced by TNF alpha exposure. Finally, we show that dephosphorylation of I kappaB alpha by IGF-I pathways requires activation of calcineurin. Activation of this phosphatase is independent of phosphatidylinositol 3-kinase and mitogen-activated protein kinase. Thus, these data suggest that the therapeutic benefits associated with IGF-I treatment of brain injury are derived from both its positive effects on neuronal survival and inhibition of the glial inflammatory reaction.	CSIC, Inst Cajal Neurobiol, Cellular & Mol Neuroendocrinol Lab, E-28002 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	Pons, S (corresponding author), CSIC, Inst Cajal Neurobiol, Cellular & Mol Neuroendocrinol Lab, Av Doctor Arce 37, E-28002 Madrid, Spain.	pons@cajal.csic.es	Torres-Aleman, Ignacio/A-1613-2008; Pons, Sebastian/K-7794-2014	Torres-Aleman, Ignacio/0000-0001-8107-7947; Pons, Sebastian/0000-0003-1027-0621				Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bence-Hanulec KK, 2000, NEURON, V27, P121, DOI 10.1016/S0896-6273(00)00014-3; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Dore S, 1997, TRENDS NEUROSCI, V20, P326; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Feldman EL, 1997, NEUROBIOL DIS, V4, P201, DOI 10.1006/nbdi.1997.0156; Fernandez AM, 1999, EUR J NEUROSCI, V11, P2019, DOI 10.1046/j.1460-9568.1999.00623.x; Fernandez AM, 1997, NEUROSCIENCE, V76, P117; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Le Roith D, 1998, INT CONGR SER, V1151, P285; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; MOYNAGH PN, 1993, BIOCHEM J, V294, P343, DOI 10.1042/bj2940343; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Ozes ON, 1999, NATURE, V401, P82; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; Perry SW, 1998, J BIOL CHEM, V273, P17660, DOI 10.1074/jbc.273.28.17660; PONS S, 1992, ENDOCRINOLOGY, V131, P2271, DOI 10.1210/en.131.5.2271; PONS S, 1995, MOL CELL BIOL, V15, P4453; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L; Venters HD, 1999, P NATL ACAD SCI USA, V96, P9879, DOI 10.1073/pnas.96.17.9879; Venters HD, 2000, TRENDS NEUROSCI, V23, P175, DOI 10.1016/S0166-2236(99)01533-7; White MF, 1998, RECENT PROG HORM RES, V53, P119; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	33	78	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38620	38625		10.1074/jbc.M004531200	http://dx.doi.org/10.1074/jbc.M004531200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10973957	hybrid			2022-12-27	WOS:000165739800065
J	Angenieux, C; Salamero, J; Fricker, D; Cazenave, JP; Goud, B; Hanau, D; de la Salle, H				Angenieux, C; Salamero, J; Fricker, D; Cazenave, JP; Goud, B; Hanau, D; de la Salle, H			Characterization of CD1e, a third type of CD1 molecule expressed in dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MOLECULES; T-CELLS; HELA-CELLS; ANTIGENS; GLYCOLIPIDS; DISTINCT; BINDING; MOUSE; BETA(2)-MICROGLOBULIN; PROTEINS	Dendritic cells express several alternatively spliced CD1e mRNAs. These molecules encode proteins characterized by the presence of either one, two, or three cu domains and either a 51- or 63-amino acid cytoplasmic domain. Moreover, mRNAs encoding isoforms lacking the transmembrane domain are observed. Several of these CD1e isoforms were expressed in transfected cells, and two of them, with three a domains, displayed a particular processing pathway. These latter isoforms slowly leave the endoplasmic reticulum due to the presence of atypical dilysine motifs in the cytoplasmic tail. These molecules are associated with the beta (2)-microglobulin and accumulate in late Golgi and late endosomal compartments. In the latter compartments, they are cleaved into soluble forms that appear to be stable, In dendritic cells, these isoforms are mainly located in the Golgi apparatus, and upon maturation they are redistributed to late endosomal compartments. This work demonstrates the existence of CD1e molecules. As compared with other CD1 molecules, CD1e displays fundamentally different properties and therefore may represent a third type of CD1 molecules.	Etab Francais Sang Alsace, Equipe Propre INSERM 99 08, F-67065 Strasbourg, France; Etab Francais Sang Alsace, Unite INSERM 311, F-67065 Strasbourg, France; Inst Curie, UMR CNRS 144, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	de la Salle, H (corresponding author), Etab Francais Sang Alsace, Equipe Propre INSERM 99 08, F-67065 Strasbourg, France.		Goud, Bruno/GWC-4807-2022; De La Salle, Henri/H-9353-2016; Cazenave, Jean-Pierre/AAE-2935-2019	De La Salle, Henri/0000-0001-5136-0776; salamero, jean/0000-0002-2610-5826				BALK SP, 1994, SCIENCE, V265, P259, DOI 10.1126/science.7517575; Bauer A, 1997, EUR J IMMUNOL, V27, P1366, DOI 10.1002/eji.1830270611; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; Chiu YH, 1999, J EXP MED, V189, P103, DOI 10.1084/jem.189.1.103; Dascher CC, 1999, J IMMUNOL, V163, P5478; HANAU D, 1987, P NATL ACAD SCI USA, V84, P2901, DOI 10.1073/pnas.84.9.2901; Joyce S, 1998, SCIENCE, V279, P1541, DOI 10.1126/science.279.5356.1541; Karlsson K, 1998, J BIOL CHEM, V273, P18966, DOI 10.1074/jbc.273.30.18966; Kim HS, 1999, J BIOL CHEM, V274, P9289, DOI 10.1074/jbc.274.14.9289; Mandal M, 1998, MOL IMMUNOL, V35, P525, DOI 10.1016/S0161-5890(98)00055-8; MARTIN LH, 1986, P NATL ACAD SCI USA, V83, P9154, DOI 10.1073/pnas.83.23.9154; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Murakami M, 1998, J IMMUNOL, V160, P2649; Naidenko OV, 1999, J EXP MED, V190, P1069, DOI 10.1084/jem.190.8.1069; Porcelli SA, 1999, ANNU REV IMMUNOL, V17, P297, DOI 10.1146/annurev.immunol.17.1.297; Prescott AR, 1997, EUR J CELL BIOL, V72, P238; Rodionov DG, 1999, J IMMUNOL, V162, P1488; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Saudrais C, 1998, J IMMUNOL, V160, P2597; Shamshiev A, 1999, EUR J IMMUNOL, V29, P1667, DOI 10.1002/(SICI)1521-4141(199905)29:05<1667::AID-IMMU1667>3.0.CO;2-U; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Somnay-Wadgaonkar K, 1999, INT IMMUNOL, V11, P383, DOI 10.1093/intimm/11.3.383; Sonoda KH, 1999, J EXP MED, V190, P1215, DOI 10.1084/jem.190.9.1215; Sugita M, 1999, IMMUNITY, V11, P743, DOI 10.1016/S1074-7613(00)80148-X; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; WOOLFSON A, 1994, P NATL ACAD SCI USA, V91, P6683, DOI 10.1073/pnas.91.14.6683	26	76	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37757	37764		10.1074/jbc.M007082200	http://dx.doi.org/10.1074/jbc.M007082200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10948205	hybrid			2022-12-27	WOS:000165618700062
J	Matsushita, T; Fujii-Taira, I; Tanaka, Y; Homma, KJ; Natori, S				Matsushita, T; Fujii-Taira, I; Tanaka, Y; Homma, KJ; Natori, S			Male-specific IDGF, a novel gene encoding a membrane-bound extracellular signaling molecule expressed exclusively in testis of Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEREGRINA FLESH FLY; CDC25 HOMOLOG TWINE; MEIOTIC CELL-CYCLE; SPERMATID DIFFERENTIATION; PROTEIN; SPERMATOGENESIS; PROLIFERATION; MEIOSIS; COORDINATE; LINE	We identified a novel gene of Drosophila melanogaster, Male-specific IDGF (MSI), encoding a transmembrane signaling molecule with exclusive expression in the testis. This molecule (MSI) contains a single transmembrane domain and has 35% amino acid identity with insect-derived growth factor (IDGF), a soluble growth factor for embryonic cells of the flesh fly, Sarcophaga peregrina. When MSI was exogenously expressed in Schneiders's line 2 cells, it was shown to be localized on the cell surface and exhibits growth factor activity, suggesting that MSI is a membrane-bound extracellular signaling molecule. Gene expression studies revealed that MSI mRNA was restricted to mature primary spermatocytes, whereas MSI was detected in the cells at the later developmental stages. Analysis using four meiotic arrest mutants, aly, can, mia, and sa suggested that MSI is involved in spermiogenesis, the final differentiation step of spermatogenesis. These results suggest that MSI is an extracellular signaling molecule participating in spermatogenesis and is a new member of the IDGF family.	Inst Phys & Chem Res, Natori Special Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; University of Tokyo	Natori, S (corresponding author), Inst Phys & Chem Res, Natori Special Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.							ALPHEY L, 1992, EUR J CELL BIOL, V56, P151; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; Cooper K. W, 1965, BIOL DROSOPHILA, P1; COURTOT C, 1992, DEVELOPMENT, V116, P405; Eberhart CG, 1996, NATURE, V381, P783, DOI 10.1038/381783a0; ENDO K, 1996, CELL, V90, P121; Fuller Margaret T., 1993, P71; Gonczy P, 1996, DEVELOPMENT, V122, P2437; GOULDSOMERO M, 1974, ROUX ARCH DEV BIOL, V174, P133, DOI 10.1007/BF00573626; HACKSTEIN JHP, 1991, EUR J CELL BIOL, V56, P151; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; HARDY RW, 1979, J ULTRA MOL STRUCT R, V69, P180, DOI 10.1016/S0022-5320(79)90108-4; Hisahara S, 1998, J CELL SCI, V111, P667; Homma K, 1996, J BIOL CHEM, V271, P13770, DOI 10.1074/jbc.271.23.13770; Hori S, 1997, BIOCHEM BIOPH RES CO, V236, P497, DOI 10.1006/bbrc.1997.6918; KEMPHUES KJ, 1982, CELL, V31, P655, DOI 10.1016/0092-8674(82)90321-X; KOMANO H, 1991, FEBS LETT, V289, P167, DOI 10.1016/0014-5793(91)81061-C; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIFSCHYTZ E, 1987, INT REV CYTOL, V109, P211, DOI 10.1016/S0074-7696(08)61723-4; Lin TY, 1996, DEVELOPMENT, V122, P1331; Lindsley D.L., 1980, Genetics and Biology of Drosophila, V2d, P225; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; OLIVIERI G, 1965, MUTAT RES, V2, P366, DOI 10.1016/0027-5107(65)90072-2; Santel A, 1997, MECH DEVELOP, V64, P19, DOI 10.1016/S0925-4773(97)00031-2; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SOSSIN WS, 1989, J BIOL CHEM, V264, P16933; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; White-Cooper H, 1998, DEVELOPMENT, V125, P125; WHITECOOPER H, 1993, J CELL SCI, V106, P1035	33	21	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36934	36941		10.1074/jbc.M003455200	http://dx.doi.org/10.1074/jbc.M003455200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967093	hybrid			2022-12-27	WOS:000165577700069
J	Oda, T; Morikawa, N; Saito, Y; Masuho, Y; Matsumoto, S				Oda, T; Morikawa, N; Saito, Y; Masuho, Y; Matsumoto, S			Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-3 RECEPTOR; COUPLED RECEPTORS; CELLS; CLOZAPINE; IDENTIFICATION; RESPONSES; AFFINITY; RELEASE	Recently cDNA encoding the histamine H3 receptor was isolated after 15 years of considerable research. However, several studies have proposed heterogeneity of the H3 receptor. We report here the molecular cloning and characterization of a novel type of histamine receptor. A novel orphan G-protein-coupled receptor named GPRv53 was obtained through a search of the human genomic DNA data base and analyzed by rapid amplification of cDNA ends (RACE), GPRv53 possessed the features of biologic amine receptors and had the highest homology with H3 receptor among known G-protein-coupled receptors. Mammalian cells expressing GPRv53 were demonstrated to bind and respond to histamine in a concentration-dependent manner. In functional assays, not only an H3 receptor agonist, R-(alpha)-methylhistamine, but also a H3 receptor antagonist, clobenpropit, and a neuroleptic, clozapine, activated GPRv53-expressing cells. Tissue distribution analysis revealed that expression of GPRv53 is localized in the peripheral blood leukocytes, spleen, thymus, and colon, which was totally different from the H3 receptor, whose expression was restricted to the brain. The discovery of the GPRv53 receptor will open a new phase of research on the physiological role of histamine.	Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Lab, Tsukuba, Ibaraki 3058585, Japan; Helix Res Inst Inc, Chiba 2920812, Japan; Fujisawa Pharmaceut Co Ltd, Adv Technol Platform Res Lab, Tsukuba, Ibaraki 3002698, Japan	Astellas Pharmaceuticals; Astellas Pharmaceuticals	Matsumoto, S (corresponding author), Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Lab, 21 Miyukigaoka, Tsukuba, Ibaraki 3058585, Japan.	matsumot@yamanouchi.co.jp	Beldar, Sagar V/C-8542-2011					Alphs LD, 1999, J CLIN PSYCHIAT, V60, P39; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ARRANG JM, 1983, NATURE, V302, P832, DOI 10.1038/302832a0; CASTANON MJ, 1994, BIOCHEM BIOPH RES CO, V198, P626, DOI 10.1006/bbrc.1994.1091; CLARK MA, 1993, AGENTS ACTIONS, V40, P129, DOI 10.1007/BF01984051; ENDOU M, 1994, J PHARMACOL EXP THER, V269, P221; Fitzgerald LR, 1999, ANAL BIOCHEM, V275, P54, DOI 10.1006/abio.1999.4295; FUKUI H, 1994, BIOCHEM BIOPH RES CO, V201, P894, DOI 10.1006/bbrc.1994.1786; George SE, 1997, J NEUROCHEM, V69, P1278; GESPACH C, 1982, FEBS LETT, V149, P85, DOI 10.1016/0014-5793(82)81077-6; Hill SJ, 1997, PHARMACOL REV, V49, P253; HILL SJ, 1990, PHARMACOL REV, V42, P45; HIMMLER A, 1993, J RECEPTOR RES, V13, P79, DOI 10.3109/10799899309073647; JOHNSON CL, 1979, MOL PHARMACOL, V16, P417; KATHMANN M, 1994, PSYCHOPHARMACOLOGY, V116, P464, DOI 10.1007/BF02247479; KRUPP P, 1992, BRIT J PSYCHIAT, V160, P38, DOI 10.1192/S0007125000296906; Laitinen JT, 1998, J NEUROCHEM, V71, P808; LEURS R, 1995, PHARMACOL THERAPEUT, V66, P413, DOI 10.1016/0163-7258(95)00006-3; Leurs R, 1996, J PHARMACOL EXP THER, V276, P1009; Leurs R, 2000, TRENDS PHARMACOL SCI, V21, P11, DOI 10.1016/S0165-6147(99)01411-X; Lovenberg TW, 1999, MOL PHARMACOL, V55, P1101, DOI 10.1124/mol.55.6.1101; Matsumoto SI, 1997, BBA-GENE STRUCT EXPR, V1354, P159, DOI 10.1016/S0167-4781(97)00120-6; Minneman KP, 2000, J NEUROCHEM, V74, P2392, DOI 10.1046/j.1471-4159.2000.0742392.x; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; RAIBLE DG, 1994, AM J RESP CRIT CARE, V149, P1506, DOI 10.1164/ajrccm.149.6.8004306; RODRIGUES AA, 1995, BRIT J PHARMACOL, V114, P1523, DOI 10.1111/j.1476-5381.1995.tb14934.x; Schlicker E, 1996, N-S ARCH PHARMACOL, V353, P482; SCHWORER H, 1994, N-S ARCH PHARMACOL, V350, P375; SOLL AH, 1979, ANNU REV PHYSIOL, V41, P35, DOI 10.1146/annurev.ph.41.030179.000343; TRAIFFORT E, 1995, BIOCHEM BIOPH RES CO, V211, P570, DOI 10.1006/bbrc.1995.1851; WEST RE, 1990, MOL PHARMACOL, V38, P610; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049	34	512	581	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36781	36786		10.1074/jbc.M006480200	http://dx.doi.org/10.1074/jbc.M006480200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973974	hybrid			2022-12-27	WOS:000165577700049
J	Wakimoto, K; Kobayashi, K; Kuro-o, M; Yao, A; Iwamoto, T; Yanaka, N; Kita, S; Nishida, A; Azuma, S; Toyoda, Y; Omori, K; Imahie, H; Oka, T; Kudoh, S; Kohmoto, O; Yazaki, Y; Shigekawa, M; Imai, Y; Nabeshima, Y; Komuro, I				Wakimoto, K; Kobayashi, K; Kuro-o, M; Yao, A; Iwamoto, T; Yanaka, N; Kita, S; Nishida, A; Azuma, S; Toyoda, Y; Omori, K; Imahie, H; Oka, T; Kudoh, S; Kohmoto, O; Yazaki, Y; Shigekawa, M; Imai, Y; Nabeshima, Y; Komuro, I			Targeted disruption of Na+/Ca2+ exchanger gene leads to cardiomyocyte apoptosis and defects in heartbeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC NA+-CA2+ EXCHANGER; SODIUM-CALCIUM EXCHANGER; PROTEIN-KINASE-C; DEPENDENT REGULATION; CA2+-BINDING DOMAIN; MOLECULAR-CLONING; GUINEA-PIG; PHOSPHORYLATION; MYOCYTES; MUSCLE	Ca2+, which enters cardiac myocytes through voltage dependent Ca2+ channels during excitation, is extruded from myocytes primarily by the Na+/Ca2+ exchanger (NCX1) during relaxation. The increase in intracellular Ca2+ concentration in myocytes by digitalis treatment and after ischemia/reperfusion is also thought to result from the reverse mode of the Na+/Ca2+ exchange mechanism. However, the precise roles of the NCX1 are still unclear because of the lack of its specific inhibitors. We generated Ncx1-deficient mice by gene targeting to determine the in vivo function of the exchanger. Homozygous Ncx1-deficient mice died between embryonic days 9 and 10. Their hearts did not beat, and cardiac myocytes showed apoptosis. No forward mode or reverse mode of the Na+/Ca2+ exchange activity was detected in null mutant hearts. The Na+-dependent Ca2+ exchange activity as well as protein content of NCX1 were decreased by similar to 50% in the heart, kidney, aorta, and smooth muscle cells of the heterozygous mice, and tension development of the aortic ring in Na+-free solution was markedly impaired in heterozygous mice. These findings suggest that NCX1 is required for heartbeats and survival of cardiac myocytes in embryos and plays critical roles in Na+-dependent Ca2+ handling in the heart and aorta.	Tanabe Seiyaku Co Ltd, Adv Med Res Dept, Yodogawa Ku, Osaka 5328505, Japan; Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, Osaka 5328505, Japan; Natl Inst Neurosci, Div Mol Genet, Kodaira, Tokyo 1870000, Japan; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Suita, Osaka 5658565, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan; Obihiro Univ Agr & Vet Med, Res Ctr Protozoan Mol Immunol, Obihiro, Hokkaido 0808555, Japan; Saitama Med Sch, Dept Med 2, Moroyama, Saitama 3500495, Japan; Kyoto Univ, Fac Med, Grad Sch Med, Dept Pathol & Tumor Biol,Sakyo Ku, Kyoto 6068501, Japan	Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation; National Center for Neurology & Psychiatry - Japan; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Tokyo; National Cerebral & Cardiovascular Center - Japan; Obihiro University of Agriculture & Veterinary Medicine; Saitama Medical University; Kyoto University	Nabeshima, Y (corresponding author), Tanabe Seiyaku Co Ltd, Adv Med Res Dept, Yodogawa Ku, 3-16-89 Kashima, Osaka 5328505, Japan.		Andoh, Akira/AAB-9303-2022; Yanaka, Noriyuki/P-9096-2016					Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; BERS DM, 1993, CARDIOVASC RES, V27, P1772, DOI 10.1093/cvr/27.10.1772; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CALLEWAERT G, 1989, AM J PHYSIOL, V257, P147; CHAPMAN RA, 1976, J PHYSIOL-LONDON, V258, P1; CONDRESCU M, 1995, J BIOL CHEM, V270, P9137, DOI 10.1074/jbc.270.16.9137; DOERING AE, 1994, J PHYSIOL-LONDON, V480, P9, DOI 10.1113/jphysiol.1994.sp020336; GADSBY DC, 1991, ANN NY ACAD SCI, V639, P140, DOI 10.1111/j.1749-6632.1991.tb17297.x; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; IWAMOTO T, 1995, J BIOL CHEM, V270, P8996, DOI 10.1074/jbc.270.15.8996; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KIMURA J, 1986, NATURE, V319, P596, DOI 10.1038/319596a0; KLEBER AG, 1983, CIRC RES, V52, P442, DOI 10.1161/01.RES.52.4.442; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; Kraev A, 1996, GENOMICS, V37, P105, DOI 10.1006/geno.1996.0526; Ladilov Y, 1999, AM J PHYSIOL-HEART C, V276, pH1868, DOI 10.1152/ajpheart.1999.276.6.H1868; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI ZP, 1994, J BIOL CHEM, V269, P17434; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MOTLEY ED, 1993, AM J PHYSIOL, V264, pH1028, DOI 10.1152/ajpheart.1993.264.4.H1028; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; REEVES JP, 1984, J BIOL CHEM, V259, P7733; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; RUGH R, 1994, MOUSE ITS REPROD DEV; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULZE D, 1993, CARDIOVASC RES, V27, P1726, DOI 10.1093/cvr/27.10.1726; Tsuda M, 1997, J NEUROSCI, V17, P6678; Yao AS, 1998, CIRC RES, V82, P657, DOI 10.1161/01.RES.82.6.657	33	173	180	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36991	36998		10.1074/jbc.M004035200	http://dx.doi.org/10.1074/jbc.M004035200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967099	hybrid			2022-12-27	WOS:000165577700076
J	Okazaki, Y; Ohno, H; Takase, K; Ochiai, T; Saito, T				Okazaki, Y; Ohno, H; Takase, K; Ochiai, T; Saito, T			Cell surface expression of calnexin, a molecular chaperone in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; UNFOLDED-PROTEIN RESPONSE; IMMATURE THYMOCYTES; SIGNALING PATHWAY; BINDING PROTEIN; CALRETICULIN; RETENTION; MEMBRANE; IDENTIFICATION; GLYCOPROTEIN	The folding and assembly of nascent proteins in the endoplasmic reticulum are assisted by the molecular chaperone calnexin, which is itself retained within the endoplasmic reticulum, It was up to now assumed that calnexin was selectively expressed on the surface of immature thymocytes because of a particular characteristic of the protein sorting machinery in these cells. We now report that a small fraction of calnexin is normally expressed on the surface of various cells such as mastocytoma cells, murine splenocytes, fibroblast cells, and human HeLa cells. Surface biotinylation followed by chase culture of living cells revealed that calnexin is continuously delivered to the cell surface and then internalized for lysosomal degradation. These results suggest that there is continuous exocytosis and endocytosis of calnexin, and the amount of calnexin on the plasma membrane results from the balance of the rates of these two events, To study the structural requirement of calnexin for surface expression, we created deletion mutants of calnexin and found that the luminal domain, particularly the glycoprotein binding domain, is necessary. These findings suggest that the surface expression of calnexin depends on the association with glycoproteins and that calnexin may play a certain role as a chaperone on the plasma membrane as well.	Chiba Univ, Grad Sch Med, Dept Mol Genet, Chuo Ku, Chiba 2608670, Japan; Kanazawa Univ, Inst Canc Res, Div Mol Membrane Biol, Kanazawa, Ishikawa 9200934, Japan; Chiba Univ, Sch Med, Dept Surg 2, Chuo Ku, Chiba 2608670, Japan	Chiba University; Kanazawa University; Chiba University	Saito, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Genet, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.		Ohno, Hiroshi/L-7899-2014; Saito, Takashi/C-9684-2009	Ohno, Hiroshi/0000-0001-8776-9661; Saito, Takashi/0000-0001-9495-3547				Altmeyer A, 1996, INT J CANCER, V69, P340, DOI 10.1002/(SICI)1097-0215(19960822)69:4<340::AID-IJC18>3.0.CO;2-9; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; ARASE H, 1993, J IMMUNOL, V151, P546; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; Coppolino MG, 1999, BIOCHEM J, V340, P41, DOI 10.1042/0264-6021:3400041; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; ESSEX DW, 1995, BLOOD, V86, P2168, DOI 10.1182/blood.V86.6.2168.bloodjournal8662168; FEBBRAIO M, 1990, J BIOL CHEM, V265, P18531; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HORN M, 1994, BIOCHEM J, V301, P69, DOI 10.1042/bj3010069; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nagata K, 1997, IMMUNITY, V7, P559, DOI 10.1016/S1074-7613(00)80377-5; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; Roquemore EP, 1998, MOL BIOL CELL, V9, P2125, DOI 10.1091/mbc.9.8.2125; Sarafian V, 1998, INT J CANCER, V75, P105, DOI 10.1002/(SICI)1097-0215(19980105)75:1<105::AID-IJC16>3.3.CO;2-L; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Takase K, 1997, J IMMUNOL, V159, P741; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; VANBUSKIRK AM, 1991, J IMMUNOL, V146, P500; WADA I, 1991, J BIOL CHEM, V266, P19599; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; WHITNEY JA, 1995, CELL, V83, P703; Wiest DL, 1997, P NATL ACAD SCI USA, V94, P1884, DOI 10.1073/pnas.94.5.1884; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x; Xiao GQ, 1999, MOL BRAIN RES, V72, P121, DOI 10.1016/S0169-328X(99)00188-6; Yeates LC, 1997, BIOCHEM BIOPH RES CO, V238, P66, DOI 10.1006/bbrc.1997.7238	38	101	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35751	35758		10.1074/jbc.M007476200	http://dx.doi.org/10.1074/jbc.M007476200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10956670	hybrid			2022-12-27	WOS:000165382000018
J	Wagner, PD; Vu, ND				Wagner, PD; Vu, ND			Phosphorylation of geranyl and farnesyl pyrophosphates by Nm23 proteins/nucleoside diphosphate kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; ENZYMATIC-ACTIVITY; TUMOR-METASTASIS; MELANOMA-CELLS; PC12 CELLS; MUTATION; GENE; TRANSFECTION; MOTILITY; OVEREXPRESSION	The biochemical mechanism(s) by which Nm23 proteins/nucleoside diphosphate kinases suppress tumor metastasis, inhibit cell motility, and affect cellular differentiation are not known. Here we report that Nm23 proteins can phosphorylate geranyl and farnesyl pyrophosphates to give triphosphates. Wild type Nm23-H1 had higher geranyl and farnesyl pyrophosphate kinase activities than did mutants of Nm23-H1 that do not inhibit-cell motility. The phosphorylation of farnesyl pyrophosphate appears to occur in vivo as cells with an elevated level of Nm23-H1 contained more farnesyl triphosphate than did control cells. To our knowledge, this is the first report that farnesyl triphosphate exists in cells, The phosphorylation of farnesyl pyrophosphate by Nm23 proteins could alter isoprenoid metabolism, and cells with an elevated level of Nm23 proteins were found to contain more farnesylated 46- and 24-kDa proteins than did control cells. The phosphorylation of geranyl and farnesyl pyrophosphates by Nm23 proteins provides a novel mechanism by which these proteins might-exert their biological effects.	NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wagner, PD (corresponding author), NCI, Biochem Lab, NIH, Bldg 37,Rm 4C24, Bethesda, MD 20892 USA.							BABA H, 1995, CANCER RES, V55, P1977; BEYER P, 1985, METHOD ENZYMOL, V111, P248; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; DANESI R, 1995, BIOCHEM BIOPH RES CO, V206, P637, DOI 10.1006/bbrc.1995.1090; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; FARNSWORTH CC, 1990, METHODS COMPANION ME, P231; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; Fukuda M, 1996, INT J CANCER, V65, P531, DOI 10.1002/(SICI)1097-0215(19960208)65:4<531::AID-IJC23>3.0.CO;2-B; Gervasi F, 1996, CELL GROWTH DIFFER, V7, P1689; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; HOWLETT AR, 1994, J NATL CANCER I, V86, P1838, DOI 10.1093/jnci/86.24.1838; KANTOR JD, 1993, CANCER RES, V53, P1971; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; Lascu I, 1997, J BIOL CHEM, V272, P15599, DOI 10.1074/jbc.272.25.15599; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1993, ONCOGENE, V8, P855; Lu Q, 1996, J BIOL CHEM, V271, P32886, DOI 10.1074/jbc.271.51.32886; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; PARHAR RS, 1995, INT J CANCER, V60, P204; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Ren ZB, 1997, BIOCHEM PHARMACOL, V54, P113, DOI 10.1016/S0006-2952(97)00151-2; SHECHTER I, 1973, BIOCHIM BIOPHYS ACTA, V316, P222, DOI 10.1016/0005-2760(73)90012-X; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1997, ADV ONCOL, V13, P3; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; VU ND, 1993, BIOCHEM J, V296, P169, DOI 10.1042/bj2960169; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; Wagner PD, 2000, BIOCHEM J, V346, P623, DOI 10.1042/0264-6021:3460623; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; WATSON JA, 1985, J BIOL CHEM, V260, P4083; Xu J, 1996, DEV BIOL, V177, P544, DOI 10.1006/dbio.1996.0184; ZHANG DL, 1993, ANAL BIOCHEM, V213, P356, DOI 10.1006/abio.1993.1432; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	38	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35570	35576		10.1074/jbc.M006106200	http://dx.doi.org/10.1074/jbc.M006106200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952986	hybrid			2022-12-27	WOS:000165422800097
J	Zhu, WD; Shiojima, I; Hiroi, Y; Zou, YZ; Akazawa, H; Mizukami, M; Toko, H; Yazaki, Y; Nagai, R; Komuro, I				Zhu, WD; Shiojima, I; Hiroi, Y; Zou, YZ; Akazawa, H; Mizukami, M; Toko, H; Yazaki, Y; Nagai, R; Komuro, I			Functional analyses of three Csx/Nkx-2.5 mutations that cause human congenital heart disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN-DNA COMPLEX; TRANSCRIPTION FACTOR; BINDING TARGETS; GATA-4; TINMAN; APOPTOSIS; GENES	A homeodomain-containing transcription factor Csx/Nkx-2.5 is an important regulator of cardiogenesis in mammals. Three different mutants, Gln170ter (designated A) and Thr178Met (designated B) in the helix 2 of the homeodomain and Gln198ter mutation (designated C) just after homeodomain, have been reported to cause atrial septal defect with atrial ventricular block. We here examined the functions of these three mutants of Csx/Nkx-2.5. The atrial natriuretic peptide (ANP) promoter was activated by wild type Csx/Nkx-2.5 (WT, similar to8-fold), B (similar to2-fold), and C (similar to6-fold) but not by A. When A, B, or C was cotransfected into COS-7 cells with the same amount of WT, WT-induced activation of the ANP promoter was attenuated by A and B (A > B), whereas C further enhanced the activation. Immunocytochemical analysis using anti-Myc tag antibody indicated that transfected Myc-tagged WT, B, and C were localized in the nucleus of both COS-7 cells and cardiomyocytes of neonatal rats, whereas A was distributed diffusely in the cytoplasm and nucleus in COS-7 cells. Electrophoretic mobility shift assay showed that Csx/Nkx-2.5-binding sequences were bound strongly by WT and C, weakly by B, but not by A Immunoprecipitation and GST pull-down assay revealed that WT and all mutants interacted with GATA-4, The synergistic activation of the ANP promoter by WT and GATA-4 was further enhanced by C but was inhibited by A and B, In the cultured cardiomyocytes, overexpression of C but not WT, A, or B, induced apoptosis, These results suggest that although the three mutants induce the same cardiac phenotype, transactivation ability and DNA binding ability are different among the three mutants and that apoptosis may be a cause for C-induced cardiac defect.	Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Komuro, I (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	komuro-tky@umin.ac.jp		Akazawa, Hiroshi/0000-0002-3574-9607				BODMER R, 1993, DEVELOPMENT, V118, P719; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Gajewski K, 1997, EMBO J, V16, P515, DOI 10.1093/emboj/16.3.515; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Monzen K, 1999, MOL CELL BIOL, V19, P7096; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; Pehlivan T, 1999, AM J MED GENET, V83, P201, DOI 10.1002/(SICI)1096-8628(19990319)83:3<201::AID-AJMG11>3.0.CO;2-V; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; Rivkees SA, 1999, J BIOL CHEM, V274, P14204, DOI 10.1074/jbc.274.20.14204; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shiojima I, 1996, CIRC RES, V79, P920, DOI 10.1161/01.RES.79.5.920; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; Takimoto E, 2000, BIOCHEM BIOPH RES CO, V270, P1074, DOI 10.1006/bbrc.2000.2561; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Wu CF, 1997, J BIOL CHEM, V272, P14860, DOI 10.1074/jbc.272.23.14860; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790	25	53	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35291	35296		10.1074/jbc.M000525200	http://dx.doi.org/10.1074/jbc.M000525200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10948187	hybrid			2022-12-27	WOS:000165422800062
J	Rhee, SH; Hwang, D				Rhee, SH; Hwang, D			Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL WALL COMPONENTS; HUMAN COLON-CANCER; GENETIC-CONTROL; BACTERIAL LIPOPOLYSACCHARIDE; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; DROSOPHILA TOLL; CUTTING EDGE; MICE; RECOGNITION	Genetic evidence indicating that TOLL-like receptor 4 (Tlr4) is the lipopolysaccharide (LPS) receptor in mice was reported. However, biochemical evidence that murine Tlr4 confers LPS responsiveness has not been convincingly demonstrated. Inducible cyclooxygenase (COX-2) is selectively expressed in LPS-stimulated macrophages in part mediated through the activation of NF kappaB. Thus, we determined whether murine Tlr4 confers LPS responsiveness as evaluated by the activation of NF kappaB and COX-2 expression. Transfection of a murine macrophage-like cell line (RAW264.7) with the constitutively active form (Delta Tlr4) of Tlr4 is sufficient to activate NF kappaB and COX-2 expression. However, the truncated form (Delta Tlr4(P712H)) of the missense mutant Tlr4(P712H) found in LPS-hyporesponsive mouse strain (C3H/HeJ) inhibits LPS-induced NF kappaB activation and COX-2 expression. The inability of Delta Tlr4(P712H) to activate NF kappaB and induce COX-2 expression is rescued by a constitutively active adapter protein myeloid differentiation factor 88 (MyD88), which interacts directly with the cytoplasmic domain of Tlr proteins. Furthermore, MyD88 is co-immunoprecipitated with the wild-type Delta Tlr4 but not with the Delta Tlr4(P712H) mutant. Together, these results indicate that Tlr4 confers LPS responsiveness in RAW264.7 cells and suggest that hyporesponsiveness of C3H/HeJ mice to LPS is attributed to the disruption of Tlr4-mediated signaling pathways that results from the inability of the mutant Tlr4(P712H) to interact with MyD88.	Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Hwang, D (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.				NATIONAL CANCER INSTITUTE [R01CA075613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041868] Funding Source: NIH RePORTER; NCI NIH HHS [CA-75613] Funding Source: Medline; NIDDK NIH HHS [DK-41868] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; Ingalls RR, 1999, INFECT DIS CLIN N AM, V13, P341, DOI 10.1016/S0891-5520(05)70078-7; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1992, J BIOL CHEM, V267, P25934; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; MORRISON DC, 1978, AM J PATHOL, V93, P526; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; OBRIEN AD, 1980, J IMMUNOL, V124, P20; Paik JH, 2000, J BIOL CHEM, V275, P28173; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, TRENDS GENET, V15, P291, DOI 10.1016/S0168-9525(99)01782-5; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ROSENSTREICH DL, 1982, CRC CR REV IMMUNOL, V3, P263; SANO H, 1995, CANCER RES, V55, P3785; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tracey K J, 1990, Adv Surg, V23, P21; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Vogel SN, 1999, J IMMUNOL, V162, P5666; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; WINANS KA, 1995, MOL BIOL CELL, V6, P587, DOI 10.1091/mbc.6.5.587; Yang RB, 1999, J IMMUNOL, V163, P639; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yoshimura A, 1999, J IMMUNOL, V163, P1; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	41	227	241	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34035	34040		10.1074/jbc.M007386200	http://dx.doi.org/10.1074/jbc.M007386200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10952994	hybrid			2022-12-27	WOS:000165095300007
J	Guzey, M; Takayama, S; Reed, JC				Guzey, M; Takayama, S; Reed, JC			BAG1L enhances trans-activation function of the vitamin D receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC PROTEIN BAG-1; PROSTATE-CANCER CELLS; HEAT-SHOCK PROTEINS; RETINOIC ACID; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; GLUCOCORTICOID RECEPTOR; ANDROGEN RECEPTOR; DNA; GROWTH; LINES	The vitamin D receptor (VDR) is a member of the steroid/retinoid receptor superfamily of nuclear receptors that has potential tumor-suppressive functions. We show here that VDR interacts with and is regulated by BAG1L, a nuclear protein that binds heat shock 70-kDa (Hsp70) family molecular chaperones. Endogenous BAG1L can be eo-immunoprecipitated with VDR from prostate cancer cells (ALVA31; LNCaP) in a ligand-dependent manner. BAG1L, but not shorter non-nuclear isoforms of this protein (BAG1; BAG1M/Rap46), markedly enhanced, in a ligand-dependent manner, the ability of VDR to trans-activate reporter gene plasmids containing a vitamin D response element in transient transfection assays. Mutant BAG1L lacking the C-terminal Hsc70-binding domain suppressed tin a concentration-dependent fashion) VDR-mediated trans-activation of vitamin D response element-containing reporter gene plasmids, without altering levels of VDR or endogenous BAG1L protein, suggesting that it operates as a trans-dominant inhibitor of BAG1L. Gene transfer-mediated elevations in BAG1L protein levels in a prostate cancer cell line (PC3), which is moderately responsive to VDR ligands, increased the ability of natural (1 alpha ,25(OH)(2) vitamin D-3) and synthetic (1 alpha ,25-dihydroxy19-nor-22(E)-vitamin D-3) VDR ligands to induce expression of the VDR target gene, p21(Waf1), and suppress DNA synthesis. Thus, BAG1L is a direct regulator of VDR, which enhances its trans-activation function and improves tumor cell responses to growth-suppressive VDR ligands.	Burnham Inst, La Jolla, CA 92037 USA; RIGEB, MAM TUBITAK, TR-41470 Kocaeli, Turkey	Sanford Burnham Prebys Medical Discovery Institute; Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		güzey, meral/AAW-4124-2020					Agadir A, 1999, CARCINOGENESIS, V20, P577, DOI 10.1093/carcin/20.4.577; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Cohen Michael B., 2000, American Journal of Pathology, V156, P355, DOI 10.1016/S0002-9440(10)64737-2; DAME MC, 1986, BIOCHEMISTRY-US, V25, P4523, DOI 10.1021/bi00364a011; Darwish HM, 1996, PROG NUCLEIC ACID RE, V53, P321, DOI 10.1016/S0079-6603(08)60149-X; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Feldman D, 1997, VITAMIN D, P3; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GLASS CK, 2000, INTRO MOL CELLULAR R, P83; Graumann K, 2000, BIOCHEM J, V345, P627, DOI 10.1042/0264-6021:3450627; Gross C., 1997, Vitamin D., P1125; Guzey M, 1997, RES COMMUN MOL PATH, V98, P3; Hedlund TE, 1999, PROSTATE, V41, P154; KOSHIYAMA M, 1995, J CLIN ENDOCR METAB, V80, P1106, DOI 10.1210/jc.80.4.1106; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; LANDEL CC, 1994, MOL ENDOCRINOL, V8, P1407, DOI 10.1210/me.8.10.1407; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Leeuwen J. P. T. M. van, 1997, Vitamin D., P1089; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Ly LH, 1999, ENDOCRINOLOGY, V140, P2071, DOI 10.1210/en.140.5.2071; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; PERLMAN KL, 1990, TETRAHEDRON LETT, V31, P1823, DOI 10.1016/S0040-4039(00)98795-1; Prost S, 1998, FEBS LETT, V425, P499, DOI 10.1016/S0014-5793(98)00296-8; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SRINIVASAN G, 1994, MOL ENDOCRINOL, V8, P189, DOI 10.1210/me.8.2.189; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Takayama S, 1996, GENOMICS, V35, P494, DOI 10.1006/geno.1996.0389; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 1998, CANCER RES, V58, P3116; WU Q, 1997, EMBO J, V16, P1658; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; Zhao XY, 1999, ENDOCRINOLOGY, V140, P1205, DOI 10.1210/en.140.3.1205	38	44	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40749	40756		10.1074/jbc.M004977200	http://dx.doi.org/10.1074/jbc.M004977200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10967105	hybrid			2022-12-27	WOS:000166114600014
J	Hsu, HY; Twu, YC				Hsu, HY; Twu, YC			Tumor necrosis factor-alpha-mediated protein kinases in regulation of scavenger receptor and foam cell formation on macrophage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SIGNAL-TRANSDUCTION PATHWAYS; SMOOTH-MUSCLE CELLS; FACTOR-KAPPA-B; TNF-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; ATHEROSCLEROTIC LESIONS; OXIDATIVE STRESS; JNK ACTIVATION; IN-VITRO	We previously reported tumor necrosis factor-cr (TNF) modulates transcriptional and post-transcriptional down-regulation of macrophage scavenger receptor (MSR) (Hsu, H. Y., Nicholson, A. C., and Hajjar, D. P. (1996) J. Biol. Chem. 271, 7767-7773); however, TNF-mediated signaling mechanisms are unknown. Here, we demonstrate that ligation of TNF receptor stimulates activity of pal-activated protein kinase (PAK and mitogen-activated protein kinases (MAPK) as follows: ERK, JNK, and p38 in murine macrophage J774A.1 cells. Upon activation of protein kinases (PK), TNF rapidly increases MSR message and protein; later it markedly reduces MSR expression. Studies using PK inhibitors and dominant negative constructs demonstrate phosphatidylinositol 3-kinase/Rac1/PAK/JNK and phosphatidylinositol 3-kinase/Rac1/PAK/p38 pathways contribute to important roles in the late stage of TNF down-regulation of MSR expression and taking up of OxLDL. Alternatively, the PKC/MEK1/ERK pathway in the early stage plays a significant role in up-regulation of the MSR gene. By using anti-TNF-R1 agonist antibody, we further confirm TNF-R1-mediated MAPK in regulation of MSR. Furthermore, in MSR gene promoter-driven luciferase reporter assays with TNF, PKC activator increases, but antioxidant N-acetylcysteine, PK inhibitors, and dominant negative constructs decrease luciferase activity in MSR gene promoter-transfected cells. Our current results show the first evidence of crucial roles for TMF-mediated MAPK pathways in the transcriptional regulation of MSR gene and increase MSR expression; in contrast, with TNF longer treatment the pathways down-regulate MSR and foam cell formation probably via post-transcriptional process.	Natl Yang Ming Univ, Inst Biotechnol Med, Fac Med Technol, Taipei 112, Taiwan; Mackay Mem Hosp, Dept Med Res, Transfus Med Lab, Taipei 251, Taiwan	National Yang Ming Chiao Tung University; Mackay Memorial Hospital	Hsu, HY (corresponding author), Natl Yang Ming Univ, Inst Biotechnol Med, Fac Med Technol, 115 Li Nong St, Taipei 112, Taiwan.	hyhsu@ym.edu.tw						AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BASU SK, 1977, J CELL BIOL, V74, P119, DOI 10.1083/jcb.74.1.119; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Benigni F, 1996, J IMMUNOL, V157, P5563; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Chan ED, 1999, J IMMUNOL, V162, P415; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; Fitzgerald ML, 2000, J IMMUNOL, V164, P2692, DOI 10.4049/jimmunol.164.5.2692; GENG YJ, 1995, ARTERIOSCL THROM VAS, V15, P1995, DOI 10.1161/01.ATV.15.11.1995; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GONG QQ, 1995, J BIOL CHEM, V270, P21672, DOI 10.1074/jbc.270.37.21672; GOWN AM, 1986, AM J PATHOL, V125, P191; Han JH, 1998, AM J PATHOL, V152, P1647; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hsu HY, 1998, J BIOL CHEM, V273, P1240, DOI 10.1074/jbc.273.2.1240; Hsu HY, 1996, J BIOL CHEM, V271, P7767, DOI 10.1074/jbc.271.13.7767; HSU HY, 1994, J BIOL CHEM, V269, P9213; Huh HY, 1996, BLOOD, V87, P2020; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; Jovinge S, 1996, ARTERIOSCL THROM VAS, V16, P1573, DOI 10.1161/01.ATV.16.12.1573; KAKAR SS, 1994, CANCER LETT, V87, P85, DOI 10.1016/0304-3835(94)90413-8; Kanaly ST, 1999, J IMMUNOL, V163, P3883; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRONKE M, 1990, CELL SIGNAL, V2, P1, DOI 10.1016/0898-6568(90)90027-8; KULL FC, 1985, P NATL ACAD SCI USA, V82, P5756, DOI 10.1073/pnas.82.17.5756; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LI HM, 1995, J CLIN INVEST, V95, P122, DOI 10.1172/JCI117628; Li YS, 1996, MOL CELL BIOL, V16, P5947; Lin JK, 1997, J CELL BIOCHEM, P39; Liu RY, 1999, J BIOL CHEM, V274, P13877, DOI 10.1074/jbc.274.20.13877; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; Mietus-Snyder M, 1998, ARTERIOSCL THROM VAS, V18, P1440, DOI 10.1161/01.ATV.18.9.1440; MietusSnyder M, 1997, ARTERIOSCL THROM VAS, V17, P969, DOI 10.1161/01.ATV.17.5.969; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; MOULTON KS, 1992, P NATL ACAD SCI USA, V89, P8102, DOI 10.1073/pnas.89.17.8102; MUNRO JM, 1988, LAB INVEST, V58, P249; NAITO M, 1992, AM J PATHOL, V141, P591; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Nishimura N, 1998, J BIOL CHEM, V273, P1562, DOI 10.1074/jbc.273.3.1562; NUNNARI JJ, 1989, EXP MOL PATHOL, V51, P1, DOI 10.1016/0014-4800(89)90002-6; OKADA T, 1994, J BIOL CHEM, V269, P3563; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Peppelenbosch M, 1999, J IMMUNOL, V162, P837; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; Peschon JJ, 1998, J IMMUNOL, V160, P943; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sakaguchi H, 1998, LAB INVEST, V78, P423; Schreyer SA, 1996, J BIOL CHEM, V271, P26174, DOI 10.1074/jbc.271.42.26174; SHINOHARA C, 1993, BIOCHIM BIOPHYS ACTA, V1167, P303, DOI 10.1016/0005-2760(93)90233-Y; Steinberg D, 1999, JAMA-J AM MED ASSOC, V282, P2043, DOI 10.1001/jama.282.21.2043; STEINBERG D, 1989, CIRCULATION, V80, P719, DOI 10.1161/01.CIR.80.3.719; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; Teupser D, 1999, ATHEROSCLEROSIS, V144, P109, DOI 10.1016/S0021-9150(99)00040-4; TIPPING PG, 1993, AM J PATHOL, V142, P1721; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANLENTEN BJ, 1985, J IMMUNOL, V134, P3718; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	75	52	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41035	41048		10.1074/jbc.M003464200	http://dx.doi.org/10.1074/jbc.M003464200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10969071	hybrid			2022-12-27	WOS:000166114600052
J	Loo, DDF; Eskandari, S; Boorer, KJ; Sarkar, HK; Wright, EM				Loo, DDF; Eskandari, S; Boorer, KJ; Sarkar, HK; Wright, EM			Role of Cl- in electrogenic Na+-coupled cotransporters GAT1 and SGLT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; GLUCOSE COTRANSPORTER; RAT-BRAIN; TRANSPORT; SODIUM; NA+/GLUCOSE; STOICHIOMETRY; CURRENTS; STATE; BIOENERGETICS	We have investigated the functional role of Cl- in the human Na+/Cl-/gamma -aminobutyric acid (GABA) and Na+/glucose cotransporters (GAT1 and SGLT1, respectively) expressed in Xenopus laevis oocytes, Substrate-evoked steady-state inward currents were examined in the presence and absence of external Cl-. Replacement of Cl- by gluconate or 2-(N-morpholino)ethanesulfonic acid decreased the apparent affinity of GAT1 and SGLT1 for Na+ and the organic substrate. In the absence of substrate, GAT1 and SGLT1 exhibited charge movements that manifested as pre-steady-state current transients. Removal of Cl- shifted the voltage dependence of charge movements to more negative potentials, with apparent affinity constants (K-0.5) for Cl- of 21 and 115 mM for SGLT1 and GAT1, respectively. The maximum charge moved and the apparent valence were not altered. GAT1 stoichiometry was determined by measuring GABA-evoked currents and the unidirectional influx of Cl-36(-), Na-22(+), or [H-3]GABA. Uptake of each GABA molecule was accompanied by inward movement of 2 positive charges, which was entirely accounted for by the influx of Naf in the presence or absence of Cl-. Thus, the GAT1 stoichiometry was 2Na(+):1GABA, However, Cl- was transported by GAT1 because the inward movement of 2 positive charges was accompanied by the influx of one Cl- ion, suggesting unidirectional influx of 2Na(+):1Cl(-):1GABA per transport cycle. Activation of forward Na+/Cl-/GABA transport evoked Cl-36(-) efflux and was blocked by the inhibitor SKF 89976A. These data suggest a Cl-/Cl- exchange mechanism during the GAT1 transport cycle. In contrast, Cl- was not transported by SGLT1. Thus, in both GAT1 and SGLT1, Cl- modulates the kinetics of cotransport by altering Na+ affinity, but does not contribute to net charge transported per transport cycle, We conclude that Cl- dependence per se is not a useful criterion to classify Na+ cotransporters.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Baylor College of Medicine	Loo, DDF (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, 10833 Le Conte Ave,53-317 CHS, Los Angeles, CA 90095 USA.	dloo@mednet.ucla.edu			NIDDK NIH HHS [DK19567] Funding Source: Medline; NIGMS NIH HHS [GM99004] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019567] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORDEN LA, 1992, J BIOL CHEM, V267, P21098; CAMMACK JN, 1994, NEURON, V13, P949, DOI 10.1016/0896-6273(94)90260-7; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; Fairman WA, 1999, AM J PHYSIOL-RENAL, V277, pF481, DOI 10.1152/ajprenal.1999.277.4.F481; Forster I, 1998, J GEN PHYSIOL, V112, P1, DOI 10.1085/jgp.112.1.1; Forster IC, 1999, AM J PHYSIOL-RENAL, V276, pF644, DOI 10.1152/ajprenal.1999.276.4.F644; Forster IC, 1997, J MEMBRANE BIOL, V160, P9, DOI 10.1007/s002329900291; Hazama A, 1997, J MEMBRANE BIOL, V155, P175, DOI 10.1007/s002329900169; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; Hilgemann DW, 1999, J GEN PHYSIOL, V114, P459, DOI 10.1085/jgp.114.3.459; KANNER BI, 1983, BIOCHIM BIOPHYS ACTA, V726, P293, DOI 10.1016/0304-4173(83)90013-7; KATAYAMA Y, 1991, J PHYSIOL-LONDON, V443, P587, DOI 10.1113/jphysiol.1991.sp018853; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; LAM DMK, 1993, MOL BRAIN RES, V19, P227, DOI 10.1016/0169-328X(93)90032-K; LESTER HA, 1994, ANNU REV PHARMACOL, V34, P219; Li M, 2000, J GEN PHYSIOL, V115, P491, DOI 10.1085/jgp.115.4.491; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Loo DDF, 1999, J PHYSIOL-LONDON, V518, P195, DOI 10.1111/j.1469-7793.1999.0195r.x; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; Lu CC, 1999, J GEN PHYSIOL, V114, P445, DOI 10.1085/jgp.114.3.445; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Nelson N, 1998, J NEUROCHEM, V71, P1785; OHRUI T, 1994, AM J PHYSIOL, V266, pC1586; Okuda T, 2000, NAT NEUROSCI, V3, P120, DOI 10.1038/72059; Pajor AM, 1999, ANNU REV PHYSIOL, V61, P663, DOI 10.1146/annurev.physiol.61.1.663; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PASTUSZKO A, 1982, J BIOL CHEM, V257, P7514; RADIAN R, 1983, BIOCHEMISTRY-US, V22, P1236, DOI 10.1021/bi00274a038; Risso S, 1996, J PHYSIOL-LONDON, V490, P691, DOI 10.1113/jphysiol.1996.sp021178; Rudnick G, 1998, J BIOENERG BIOMEMBR, V30, P173, DOI 10.1023/A:1020573325823; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	43	100	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37414	37422		10.1074/jbc.M007241200	http://dx.doi.org/10.1074/jbc.M007241200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973981	hybrid			2022-12-27	WOS:000165618700016
J	Leffers, G; Rao, VB				Leffers, G; Rao, VB			Biochemical characterization of an ATPase activity associated with the large packaging subunit gp17 from bacteriophage T4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED DNA; DEFINED SYSTEM; TERMINASE; PROTEINS; INVITRO; LAMBDA; PHAGE-T4; PROHEAD; ENDONUCLEASE; MOLECULES	Double-stranded DNA-packaging in icosahedral bacteriophages is believed to be driven by a packaging "machine" constituted by the portal protein and the two packaging/terminase proteins assembled at the unique portal vertex of the empty prohead shell. Although ATP hydrolysis is evidently the principal driving force, which component of the packaging machinery functions as the translocating ATPase has not been elucidated. Evidence suggests that the large packaging subunit is a strong candidate for the translocating ATPase. We have constructed new phage T4 terminase recombinants under the control of phage T7 promoter and overexpressed the packaging/terminase proteins gp16 and gp17 in various configurations. The hexahistidine-tagged-packaging proteins were purified to near homogeneity by Ni2+-agarose chromatography and were shown to be highly active for packaging DNA in, vitro. The large packaging subunit gp17 but not the small subunit gp16 exhibited an ATPase activity. Although gp16 lacked ATPase activity, it enhanced the gp17-associated ATPase activity by >50-fold, The gp16 enhancement was specific and was due to an increased catalytic rate for ATP hydrolysis. A phosphorylated gp17 was demonstrated under conditions of low catalytic rates but not under high catalytic rates in the presence of gp16. The data are consistent with the hypothesis that a weak ATPase is transformed into a translocating ATPase of high catalytic capacity after assembly of the packaging machine.	Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA	Catholic University of America	Rao, VB (corresponding author), Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA.			Rao, Venigalla/0000-0002-0777-6587				Andrew SM, 1997, CURRENT PROTOCOLS IM; BHATTACHARYYA SP, 1993, VIROLOGY, V196, P34, DOI 10.1006/viro.1993.1452; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLACK LW, 1981, VIROLOGY, V113, P336, DOI 10.1016/0042-6822(81)90160-4; BLACK LW, 1978, J VIROL, V28, P643, DOI 10.1128/JVI.28.2.643-655.1978; BLACK LW, 1995, BIOESSAYS, V17, P1052; BLACK LW, 1988, BACTERIOPHAGES, V2, P321; CATALANO CE, 1995, MOL MICROBIOL, V16, P1075, DOI 10.1111/j.1365-2958.1995.tb02333.x; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; EARNSHAW WC, 1980, CELL, V21, P319, DOI 10.1016/0092-8674(80)90468-7; FEISS M, 1986, TRENDS GENET, V2, P100, DOI 10.1016/0168-9525(86)90193-9; Franklin JL, 1998, J MOL BIOL, V277, P541, DOI 10.1006/jmbi.1998.1619; Fujisawa H, 1997, GENES CELLS, V2, P537, DOI 10.1046/j.1365-2443.1997.1450343.x; Golz S, 1999, J MOL BIOL, V285, P1131, DOI 10.1006/jmbi.1998.2399; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; Hwang Y, 1996, BIOCHEMISTRY-US, V35, P2796, DOI 10.1021/bi952322z; HWANG Y, 1995, VIROLOGY, V211, P367, DOI 10.1006/viro.1995.1419; Kuebler D, 1998, J MOL BIOL, V281, P803, DOI 10.1006/jmbi.1998.1952; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leffers G, 1996, J MOL BIOL, V258, P839, DOI 10.1006/jmbi.1996.0291; LEFFERS G, 1997, THESIS CATHOLIC U AM; Lin H, 1997, J BIOL CHEM, V272, P3495, DOI 10.1074/jbc.272.6.3495; Lin HC, 1998, VIROLOGY, V242, P118, DOI 10.1006/viro.1997.9019; Maniatis T., 1982, MOL CLONING LAB MANU; MANNE V, 1982, J BIOL CHEM, V257, P13223; MOORE JT, 1993, PROTEIN EXPRES PURIF, V4, P160, DOI 10.1006/prep.1993.1022; MORITA M, 1994, J MOL BIOL, V235, P248, DOI 10.1016/S0022-2836(05)80031-2; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; POWELL D, 1990, NUCLEIC ACIDS RES, V18, P4005, DOI 10.1093/nar/18.13.4005; RAO VB, 1994, ANAL BIOCHEM, V216, P1, DOI 10.1006/abio.1994.1001; RAO VB, 1988, J MOL BIOL, V200, P475, DOI 10.1016/0022-2836(88)90537-2; RAO VB, 1985, J MOL BIOL, V185, P565, DOI 10.1016/0022-2836(85)90072-5; RAO VB, 1992, GENE, V113, P25, DOI 10.1016/0378-1119(92)90666-D; SERWER P, 1988, BIOPOLYMERS, V27, P165, DOI 10.1002/bip.360270113; SHIBATA H, 1987, J MOL BIOL, V196, P845, DOI 10.1016/0022-2836(87)90409-8; Soultanas P, 1999, J MOL BIOL, V290, P137, DOI 10.1006/jmbi.1999.2873; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P61; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNQUIST S, 1992, P NATL ACAD SCI USA, V89, P10479, DOI 10.1073/pnas.89.21.10479; VALPUESTA JM, 1994, Q REV BIOPHYS, V27, P107, DOI 10.1017/S0033583500004510; Yap NL, 1996, J MOL BIOL, V263, P539, DOI 10.1006/jmbi.1996.0597	43	81	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37127	37136		10.1074/jbc.M003357200	http://dx.doi.org/10.1074/jbc.M003357200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967092	hybrid			2022-12-27	WOS:000165577700093
J	Werner, F; Jain, MK; Feinberg, MW; Sibinga, NES; Pellacani, A; Wiesel, P; Chin, MT; Topper, JN; Perrella, MA; Lee, ME				Werner, F; Jain, MK; Feinberg, MW; Sibinga, NES; Pellacani, A; Wiesel, P; Chin, MT; Topper, JN; Perrella, MA; Lee, ME			Transforming growth factor-beta 1 inhibition of macrophage activation is mediated via Smad3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; TGF-BETA SUPERFAMILY; DNA-BINDING PROTEIN; SMOOTH-MUSCLE CELLS; TRANSCRIPTIONAL ACTIVATION; TARGETED DISRUPTION; INFLAMMATORY RESPONSE; RHEUMATOID-ARTHRITIS; PULMONARY FIBROSIS	Activated macrophages are critical cellular participants in inflammatory disease states. Transforming growth factor (TGF)-beta1 is a growth factor with pleiotropic effects including inhibition of immune cell activation. Although the pathway of gene activation by TGF-beta1 via Smad proteins has recently been elucidated, suppression of gene expression by TGF-beta1 remains poorly understood. We found that of Smad1-Smad7, Smad3 alone was able to inhibit expression of markers of macrophage activation (inducible nitric-oxide synthase and matrix metalloproteinase-12 following lipopolysaccharide treatment in gene reporter assays. Transient and constitutive overexpression of a dominant negative Smad3 opposed the inhibitory effect of TGF-beta1. Domain swapping experiments suggest that both the Smad MH-1 and MH-2 domains are required for inhibition. Mutation of a critical amino acid residue required for DNA binding in the MH-1 of Smad3 (R74A) resulted in the loss of inhibition. Transient overexpression of p300, an interactor of the Smad MH-2 domain, partially alleviated the inhibition by TGF-beta1/Smad3, suggesting that inhibition of gene expression may be due to increased competition for limiting amounts of this coactivator. Our results have implications for the understanding of gene suppression by TGF-beta1 and for the regulation of activated macrophages by TGF-beta1.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Program Dev Cardiovasc Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Stanford Univ, Sch Med, Dept Med, Div Cardiovasc, Stanford, CA 94305 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Stanford University	Jain, MK (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St,Thorn 11, Boston, MA 02115 USA.		Sibinga, Nicholas/GOJ-8544-2022	Sibinga, Nicholas/0000-0003-4838-910X; Feinberg, Mark/0000-0001-9523-3859	NHLBI NIH HHS [HL03747, HL03194, HL03274] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; AUSUBEL FM, 1993, SHORT PROTOCOLS MOL; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; Biggs JR, 1999, J BIOL CHEM, V274, P36987, DOI 10.1074/jbc.274.52.36987; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BOTTALICO LA, 1991, J BIOL CHEM, V266, P22866; BRODY AR, 1981, EXP LUNG RES, V2, P207, DOI 10.3109/01902148109052316; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Curci JA, 1998, J CLIN INVEST, V102, P1900, DOI 10.1172/JCI2182; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; ESPEVIK T, 1987, J EXP MED, V166, P571, DOI 10.1084/jem.166.2.571; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; FORSTERMANN U, 1992, EUR J PHARM-MOLEC PH, V225, P161, DOI 10.1016/0922-4106(92)90096-E; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; HAMILTON JA, 1993, CELL IMMUNOL, V152, P7, DOI 10.1006/cimm.1993.1263; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBBY P, 1991, LAB INVEST, V64, P5; Lukacs NW, 1996, ADV IMMUNOL, V62, P257, DOI 10.1016/S0065-2776(08)60432-0; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; Rich JN, 1999, J BIOL CHEM, V274, P35053, DOI 10.1074/jbc.274.49.35053; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J., 2002, MOL CLONING LAB MANU; SARLES H, 1989, ANNU REV MED, V40, P453; SATO K, 1995, J LEUKOCYTE BIOL, V57, P36, DOI 10.1002/jlb.57.1.36; SEWELL KL, 1993, LANCET, V341, P283, DOI 10.1016/0140-6736(93)92627-6; SHAPIRO SD, 1994, AM J RESP CRIT CARE, V150, pS160, DOI 10.1164/ajrccm/150.6_Pt_2.S160; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	62	140	155	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36653	36658		10.1074/jbc.M004536200	http://dx.doi.org/10.1074/jbc.M004536200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973958	hybrid			2022-12-27	WOS:000165577700029
J	Obata, T; Yaffe, MB; Leparc, GG; Piro, ET; Maegawa, H; Kashiwagi, A; Kikkawa, R; Cantley, LC				Obata, T; Yaffe, MB; Leparc, GG; Piro, ET; Maegawa, H; Kashiwagi, A; Kikkawa, R; Cantley, LC			Peptide and protein library screening defines optimal substrate motifs for AKT/PKB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; NF-KAPPA-B; MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL 3-KINASE; STRUCTURAL BASIS; GROWTH-FACTOR; SWISS-MODEL; AKT; ACTIVATION; PHOSPHORYLATION	AKT was originally identified as a proto-oncogene with a pleckstrin homology and Ser/Thr protein kinase domains. Recent studies revealed that AKT regulates a variety of cellular functions including cell survival, cell growth, cell differentiation, cell cycle progression, transcription, translation, and cellular metabolism. To clarify:the substrate specificity of AKT, we have used an oriented peptide library approach to determine optimal amino acids at positions N-terminal and C-terminal to the site of phosphorylation. The predicted optimal peptide substrate (Arg-Lys-Arg-Xaa-Arg-Thr-Tyr-Ser*-Phe-Gly where Ser* is the phosphorylation site) has similarities to but is distinct from optimal substrates that we previously defined for related basophilic protein kinases such: as protein kinase A, Ser/Arg-rich kinases, and protein kinase C family members. The positions most important for high V-max/K-m ratio were Arg-3>Arg-5>Arg-7. The substrate specificity of AKT was further investigated by screening a lambda GEX phage HeLa cell cDNA expression library. All of the substrates identified by this procedure contained Arg-Xaa-Arg-Xaa-Xaa-(Ser/Thr) motifs and were in close agreement with the motif identified by peptide library screening. The results of this study should help in prediction of likely AKT substrates from Primary sequences.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; Shiga Univ Med Sci, Dept Med 3, Otsu, Shiga 5202192, Japan	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Shiga University of Medical Science	Cantley, LC (corresponding author), Harvard Inst Med, Div Signal Transduct, 10th Floor,330 Brookline Ave, Boston, MA 02215 USA.	cantley@helix.mgh.harvard.edu	Kashiwagi, Atsunori/H-8712-2019; Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Maegawa, Hiroshi/0000-0002-4611-8149	NIGMS NIH HHS [R01 GM041890, GM56203, R01 GM056203] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203, R01GM041890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alberti S, 1998, PROTEINS, V31, P1, DOI 10.1002/(SICI)1097-0134(19980401)31:1<1::AID-PROT1>3.0.CO;2-R; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; DEL PL, 1997, SCIENCE, V278, P687; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KEMP BE, 1991, METHOD ENZYMOL, V201, P287; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kobayashi T, 1999, BIOCHEM J, P319; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Ozes ON, 1999, NATURE, V401, P82; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Reif K, 1997, CURR BIOL, V7, P285, DOI 10.1016/S0960-9822(06)00151-5; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yaffe MB, 1999, NATURE, V402, P30; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zhou SY, 1998, METH MOL B, V87, P87; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	62	320	333	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36108	36115		10.1074/jbc.M005497200	http://dx.doi.org/10.1074/jbc.M005497200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10945990	hybrid			2022-12-27	WOS:000165382000067
J	Matter, N; Marx, M; Weg-Remers, S; Ponta, H; Herrlich, P; Konig, H				Matter, N; Marx, M; Weg-Remers, S; Ponta, H; Herrlich, P; Konig, H			Heterogeneous ribonucleoprotein A1 is part of an exon-specific splice-silencing complex controlled by oncogenic signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; CD44 VARIANT ISOFORMS; HNRNP A/B PROTEINS; IN-VIVO; NUCLEAR RIBONUCLEOPROTEINS; PREMESSENGER RNA; SITE SELECTION; EXPRESSION; CDC42; CELL	Regulation of alternative pre-mRNA splicing, recognized as increasingly important in causing human disease, was studied using the CD44 gene, whose splice variants have been implicated in tumor progression. We identified heterogeneous ribonucleoprotein (hnRNP) Al as a protein interacting in vitro and in vivo with regulatory splice elements in CD44 variant exon v5, Transient overexpression of hnRNP Al prevented v5 exon inclusion, dependent on the exonic elements. HnRNP Al-dependent repression was exon-specific and could be relieved by coexpression of oncogenic forms of Ras and Cdc42, The results define hnRNP Al as a decisive part of an oncogene-regulated splice-silencing complex, which can select between multiple alternatively spliced exons.	Forschungszentrum Karlsruhe, Inst Toxikol & Genet, D-76021 Karlsruhe, Germany; Univ Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Karlsruhe Institute of Technology	Konig, H (corresponding author), Forschungszentrum Karlsruhe, Inst Toxikol & Genet, Postfach 3640, D-76021 Karlsruhe, Germany.			Konig, Harald/0000-0002-0117-0939				Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; Bai YD, 1999, NUCLEIC ACIDS RES, V27, P1126, DOI 10.1093/nar/27.4.1126; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; COOPER DL, 1995, NAT MED, V1, P635, DOI 10.1038/nm0795-635; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FU XD, 1995, RNA, V1, P663; Ghigna C, 1998, CANCER RES, V58, P5818; Hanamura A, 1998, RNA, V4, P430; Herrlich P, 1998, CELL ADHES COMMUN, V6, P141, DOI 10.3109/15419069809004470; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Konig H, 1996, EMBO J, V15, P4030, DOI 10.1002/j.1460-2075.1996.tb00776.x; Konig H, 1998, EMBO J, V17, P2904, DOI 10.1093/emboj/17.10.2904; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; KRAWCZAK M, 1992, HUM GENET, V90, P41; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moore M., 1993, RNA WORLD, P303; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; RIO DC, 1993, CURR OPIN GENET DEV, V3, P574, DOI 10.1016/0959-437X(93)90093-5; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Sherman L, 1996, CURR TOP MICROBIOL, V213, P249; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; Weiss JM, 1997, J CELL BIOL, V137, P1137, DOI 10.1083/jcb.137.5.1137; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924	56	84	87	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35353	35360		10.1074/jbc.M004692200	http://dx.doi.org/10.1074/jbc.M004692200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10958793	hybrid			2022-12-27	WOS:000165422800070
J	Koch, SE; Bodi, I; Schwartz, A; Varadi, G				Koch, SE; Bodi, I; Schwartz, A; Varadi, G			Architecture of Ca2+ channel pore-lining segments revealed by covalent modification of substituted cysteines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING SEGMENT; BINDING-SITE CREVICE; TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDENT CALCIUM-CHANNEL; DOPAMINE D2 RECEPTOR; RAT PHEOCHROMOCYTOMA CELLS; NORMAL HUMAN HEART; ION PERMEATION; SODIUM-CHANNEL; BETA-SUBUNIT	The cysteine accessibility method was used to explore calcium channel pore topology. Cysteine mutations were introduced into the SS1-SS2 segments of Motifs I-TV of the human cardiac L-type calcium channel, expressed in Xenopus oocytes and the current block by methanethiosulfonate compounds was measured. Our studies revealed that several consecutive mutants of motifs ZI and III are accessible to methanethiosulfonates, suggesting that these segments exist as random coils. Motif I cysteine mutants exhibited an intermittent sensitivity to these compounds, providing evidence for a beta -sheet secondary structure. Motif IV showed a periodic sensitivity, suggesting the presence of an cr-helix. These studies reveal that the SS1-SS2 segment repeat in each motif have non-uniform secondary structures. Thus, the channel architecture evolves as a highly distorted 4-fold pore symmetry.	Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA	University of Cincinnati	Varadi, G (corresponding author), Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, 231 Bethesda Ave, Cincinnati, OH 45267 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07382, HL22619] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; ARMSTRONG CM, 1992, ANN NY ACAD SCI, V635, P18; Benitah JP, 1996, P NATL ACAD SCI USA, V93, P7392, DOI 10.1073/pnas.93.14.7392; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; COLLIN T, 1993, CIRC RES, V72, P1337, DOI 10.1161/01.RES.72.6.1337; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Dang TX, 1998, J GEN PHYSIOL, V111, P185, DOI 10.1085/jgp.111.2.185; Doughty SW, 1995, J MOL GRAPHICS, V13, P342, DOI 10.1016/0263-7855(95)00074-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; GUY HR, 1995, SOC GEN PHY, V50, P1; HEINEMANN SH, 1994, BRAZ J MED BIOL RES, V27, P2781; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; ILES DE, 1994, HUM MOL GENET, V3, P969, DOI 10.1093/hmg/3.6.969; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Javitch JA, 1995, BIOCHEMISTRY-US, V34, P16433, DOI 10.1021/bi00050a026; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P10355, DOI 10.1073/pnas.91.22.10355; Javitch JA, 1996, MOL PHARMACOL, V49, P692; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; Klockner U, 1996, J BIOL CHEM, V271, P22293; KUO CC, 1992, NEURON, V9, P515, DOI 10.1016/0896-6273(92)90189-K; KUO CC, 1993, J PHYSIOL-LONDON, V466, P629; KUO CC, 1993, J PHYSIOL-LONDON, V466, P657; KURZ LL, 1995, BIOPHYS J, V68, P900, DOI 10.1016/S0006-3495(95)80266-3; Lee JH, 1999, J NEUROSCI, V19, P1912; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; MIKALA G, 1993, FEBS LETT, V335, P265, DOI 10.1016/0014-5793(93)80743-E; Parent L, 1995, BIOPHYS J, V69, P1801, DOI 10.1016/S0006-3495(95)80050-0; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; Quinn KE, 1997, J GEN PHYSIOL, V109, P255, DOI 10.1085/jgp.109.2.255; ROSENBERG RL, 1991, J GEN PHYSIOL, V97, P1207, DOI 10.1085/jgp.97.6.1207; SCHETZ JA, 1993, BIOL BULL, V185, P462, DOI 10.2307/1542486; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; Stuhmer W., 1995, SINGLE CHANNEL RECOR, P341, DOI DOI 10.1007/978-1-4419-1229-9_15; Sun ZP, 1996, NEURON, V16, P141, DOI 10.1016/S0896-6273(00)80031-8; TANG SQ, 1993, J BIOL CHEM, V268, P13026; Tsushima RG, 1997, J GEN PHYSIOL, V109, P463, DOI 10.1085/jgp.109.4.463; XU M, 1993, J BIOL CHEM, V268, P21505; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; Yamagishi T, 1997, BIOPHYS J, V73, P195, DOI 10.1016/S0006-3495(97)78060-3; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; YATANI A, 1994, CIRC RES, V75, P315, DOI 10.1161/01.RES.75.2.315	59	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34493	34500		10.1074/jbc.M005569200	http://dx.doi.org/10.1074/jbc.M005569200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10950957	hybrid			2022-12-27	WOS:000165095300067
J	Bartoli, M; Gu, XL; Tsai, NT; Venema, RC; Brooks, SE; Marrero, MB; Caldwell, RB				Bartoli, M; Gu, XL; Tsai, NT; Venema, RC; Brooks, SE; Marrero, MB; Caldwell, RB			Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; SMOOTH-MUSCLE CELLS; II AT(1) RECEPTOR; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTOR; NUCLEAR TRANSLOCATION; NITRIC-OXIDE; FACTOR VEGF; PATHWAY; PHOSPHORYLATION	Vascular endothelial growth factor (VEGF) intracellular signaling in endothelial cells is initiated by the activation of distinct tyrosine kinase receptors, VEGFR1 (Flt-1) and VEGFR2 (Flk-1/KDR). Because the tyrosine kinase-dependent transcription factors known as STAT (signal transducers and activators of transcription) proteins are important modulators of cell growth responses induced by other growth factor receptors, we have determined the effects VEGF of on STAT activation in BAEC (bovine aortic endothelial cells). Here, we show that VEGF induces tyrosine phosphorylation and nuclear translocation of STAT1 and STAT6. VEGF also stimulates STAT3 tyrosine phosphorylation, but nuclear translocation does not occur. We found that placenta growth factor, which selectively activates VEGFR1, has no effect on the STATs. However, upon VEGF stimulation, STAT1 associates with the VEGFR2 in a tyrosine kinase-dependent manner, indicating that VEGF-induced STAT1 activation is mediated primarily by VEGFR2. Thus, our study shows for the first time that VEGF activates the STAT pathway through VEGFR2. Because the growth-promoting activity of VEGF depends upon VEGFR2 activation, these findings suggest a role for the STATs in the regulation of gene expression associated with the angiogenic effects of VEGF.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Anat & Cellular Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Caldwell, RB (corresponding author), Med Coll Georgia, Vasc Biol Ctr, 1120 15 St, Augusta, GA 30912 USA.			Caldwell, Ruth/0000-0003-0168-0354	NEI NIH HHS [EY11766, EY04618] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011766, R01EY004618] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Behzadian MA, 1995, GLIA, V15, P480, DOI 10.1002/glia.440150411; Decker T, 1999, CELL MOL LIFE SCI, V55, P1535, DOI 10.1007/s000180050393; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dumler I, 1999, ARTERIOSCL THROM VAS, V19, P290, DOI 10.1161/01.ATV.19.2.290; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Frank DA, 1999, NAT MED, V5, P444, DOI 10.1038/7445; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; LAWRENCE M, 1997, SCIENCE, V276, P1418; Levy DE, 1999, CELL MOL LIFE SCI, V55, P1559, DOI 10.1007/s000180050395; Liang HY, 1999, J BIOL CHEM, V274, P19846, DOI 10.1074/jbc.274.28.19846; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; Mui ALF, 1999, CELL MOL LIFE SCI, V55, P1547, DOI 10.1007/s000180050394; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Ortega Nathalie, 1999, Frontiers in Bioscience, V4, pD141, DOI 10.2741/Ortega; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; Paukku K, 2000, BIOCHEM J, V345, P759, DOI 10.1042/0264-6021:3450759; Schindler C, 1999, CELL MOL LIFE SCI, V55, P1509, DOI 10.1007/s000180050391; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEETHARAM L, 1995, ONCOGENE, V10, P135; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Struman I, 1999, P NATL ACAD SCI USA, V96, P1246, DOI 10.1073/pnas.96.4.1246; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Yamamoto H, 1996, EXP CELL RES, V222, P125, DOI 10.1006/excr.1996.0016; Yeh TC, 1999, CELL MOL LIFE SCI, V55, P1523, DOI 10.1007/s000180050392	41	121	126	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33189	33192		10.1074/jbc.C000318200	http://dx.doi.org/10.1074/jbc.C000318200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10961983	hybrid			2022-12-27	WOS:000090104600002
J	Lonart, G; Sudhof, TC				Lonart, G; Sudhof, TC			Assembly of SNARE core complexes prior to neurotransmitter release sets the readily releasable pool of synaptic vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; METABOTROPIC GLUTAMATE RECEPTORS; MEMBRANE-FUSION; HIPPOCAMPAL SYNAPSES; IN-VITRO; TRANSMISSION; EXOCYTOSIS; DOCKING; SIZE; PHOSPHORYLATION	Precise regulation of neurotransmitter release is essential for the normal function of neural networks, but the mechanisms involved are largely unclear. Using superfused synaptosomes, we have studied the readily releasable pool of synaptic vesicles, measured as the amount of release triggered by hypertonic sucrose, We show that activation of presynaptic metabotropic glutamate receptors by dihydroxyphenylglycine and stimulation of protein kinase C by phorbol esters enhance the readily releasable pool of glutamate, Although the molecular nature of the readily releasable pool is unknown, one possibility is that during its generation, SNARE proteins form full core complexes, and that core complex formation occurs prior to neurotransmitter release. To test this possibility, we employed N-ethylmaleimide (NEM), an inhibitor of the ATPase N-ethylmaleimide-sensitive factor that dissociates core complexes, to study the relation of the readily releasable pool to core complex assembly in synaptosomes. NEM induced a dose-dependent increase in the readily releasable pool of neurotransmitters but by itself did not trigger release. Direct measurements of core complexes confirmed that NEM caused an increase in the levels of SNARE core complexes under these conditions. Our data suggest that in the readily releasable pool of synaptic vesicles, SNARE proteins are fully assembled into core complexes, and that SNARE complex assembly is a target of presynaptic regulation.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Ctr Basic Neurosci, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	Tsudho@mednet.swmed.edu			NIMH NIH HHS [5K01-MH02505-02] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002505] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BIT RA, 1993, J MED CHEM, V36, P21, DOI 10.1021/jm00053a003; Calakos N, 1996, PHYSIOL REV, V76, P1; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; de Vries KJ, 2000, EUR J NEUROSCI, V12, P385, DOI 10.1046/j.1460-9568.2000.00931.x; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Dobrunz LE, 1999, NEURON, V22, P157, DOI 10.1016/S0896-6273(00)80687-X; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; Goda Y, 1998, P NATL ACAD SCI USA, V95, P1283, DOI 10.1073/pnas.95.3.1283; HAJOS F, 1975, J NEUROCHEM, V24, P1277, DOI 10.1111/j.1471-4159.1975.tb03913.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Herrero I, 1998, J BIOL CHEM, V273, P1951, DOI 10.1074/jbc.273.4.1951; LIU GS, 1995, NATURE, V375, P404, DOI 10.1038/375404a0; Lonart G, 1998, J NEUROSCI, V18, P634; Lonart G, 1998, NEURON, V21, P1141, DOI 10.1016/S0896-6273(00)80631-5; Montecucco C, 1995, Q REV BIOPHYS, V28, P423, DOI 10.1017/S0033583500003292; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; NAGY A, 1984, J NEUROCHEM, V43, P1114, DOI 10.1111/j.1471-4159.1984.tb12851.x; Robinson LJ, 1998, CURR OPIN CELL BIOL, V10, P483, DOI 10.1016/S0955-0674(98)80063-X; Rodriguez-Moreno A, 1998, NEURON, V21, P1477, DOI 10.1016/S0896-6273(00)80665-0; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Scanziani M, 1998, P NATL ACAD SCI USA, V95, P12004, DOI 10.1073/pnas.95.20.12004; Schneggenburger R, 1999, NEURON, V23, P399, DOI 10.1016/S0896-6273(00)80789-8; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Stevens CF, 1998, NEURON, V21, P885, DOI 10.1016/S0896-6273(00)80603-0; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1993, CELL, V75, P1; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TERRIAN DM, 1988, BRAIN RES BULL, V21, P343, DOI 10.1016/0361-9230(88)90146-3; Turner JP, 1999, J PHYSIOL-LONDON, V519, P481, DOI 10.1111/j.1469-7793.1999.0481m.x; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; vonGersdorff H, 1997, J NEUROSCI, V17, P1919; Wang LY, 1998, NATURE, V394, P384, DOI 10.1038/28645; Whittaker VP, 1969, HDB NEUROCHEMISTRY, VII, P327, DOI DOI 10.1007/978-1-4899-7321-4_14; Wu LG, 1999, NEURON, V23, P821, DOI 10.1016/S0896-6273(01)80039-8; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Zhang L, 1996, NEURON, V17, P287, DOI 10.1016/S0896-6273(00)80160-9	39	101	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27703	27707						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10970903				2022-12-27	WOS:000089197100025
J	Shakur, Y; Takeda, K; Kenan, Y; Yu, ZX; Rena, G; Brandt, D; Houslay, MD; Degerman, E; Ferrans, VJ; Manganiello, VC				Shakur, Y; Takeda, K; Kenan, Y; Yu, ZX; Rena, G; Brandt, D; Houslay, MD; Degerman, E; Ferrans, VJ; Manganiello, VC			Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDES) - Two N-terminal, domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-SPECIFIC PHOSPHODIESTERASE; INHIBITED CAMP-PHOSPHODIESTERASE; PROTEIN-KINASE B; MICROSOMAL ALDEHYDE DEHYDROGENASE; SARCOPLASMIC-RETICULUM; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 3-KINASE; SELECTIVE INHIBITOR; MOLECULAR-CLONING; RAT ADIPOCYTES	Subcellular localization of cyclic nucleotide phosphodiesterases (PDEs) may be important in compartmentalization of cAMP/cGMP signaling responses. In 3T3-L1 adipocytes, mouse (M) PDE3B was associated with the endoplasmic reticulum (ER) as indicated by its immunofluorescent colocalization with the ER protein BiP and subcellular fractionation studies. In transfected NIH 3006 or COS-7 cells, recombinant wild-type PDE3A and PDE3B isoforms were both found almost exclusively in the ER. The N-terminal portion of PDE3 can be arbitrarily divided into region 1 (aa 1-300), which contains a large hydrophobic domain with six predicted transmembrane helices, followed by region 2 (aa 301-500) containing a smaller hydrophobic domain (of similar to 50 aa). To investigate the role of regions 1 and 2 in membrane association, we examined the subcellular localization of a series of catalytically active, Flag-tagged N-terminal-truncated human (H) PDE3A and MPDE3B recombinants, as well as a series of fragments from regions 1 and 2 of MPDESB synthesized as enhanced green fluorescent (EGFP) fusion proteins in COS-7 cells. In COS-7 cells, the localization of a mutant HPDE3A, lacking the first 189 amino acids (aa) and therefore four of the six predicted transmembrane helices (H3A-Delta 189), was virtually identical to that of the wild type. R3B-Delta 302 (lacking region 1) and H3A-Delta 397 (lacking region 1 as well as part of region 2) retained, to different degrees, the ability to associate with membranes, albeit less efficiently than H3A-Delta 189. Proteins that lacked both regions I and 2, H3A-Delta 510 and M3B-Delta 604, did not associate with membranes. Consistent with these findings, region I EGFP-MPDE3B fusion proteins colocalized with the ER, whereas region 2 EGFP fusion proteins were diffusely distributed. Thus, some portion of the N-terminal hydrophobic domain in region 1 plus a second domain in region 2 are important for efficient membrane association/targeting of PDES.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Pathol Sect, NIH, Bethesda, MD 20892 USA; Otsuka Amer Pharmaceut Inc, Rockville, MD 20850 USA; Univ Glasgow, Mol Pharmacol Grp, Div Biochem & Mol Biol, Glasgow G12 8Q0, Lanark, Scotland; Lund Univ, Dept Cell & Mol Biol, Sect Mol Signaling, S-22100 Lund, Sweden	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Glasgow; Lund University	Manganiello, VC (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10,Rm 5N307,9000 Rockville Pike, Bethesda, MD 20892 USA.	manganiv@nhlbi.nih.gov	Rena, Graham/AAV-7985-2021; Houslay, Miles/AAM-5281-2020; Houslay, Miles D/A-6825-2011	Houslay, Miles/0000-0002-3826-8091; Rena, Graham/0000-0002-9121-1350	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000654, Z01HL002540, ZIAHL002540] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad F, 2000, J IMMUNOL, V164, P4678, DOI 10.4049/jimmunol.164.9.4678; Andersen CB, 1998, J BIOL CHEM, V273, P18705, DOI 10.1074/jbc.273.30.18705; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Bochkareva E, 1996, J BIOL CHEM, V271, P22256, DOI 10.1074/jbc.271.36.22256; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Chini CCS, 1997, J BIOL CHEM, V272, P9854; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; DALLNER G, 1966, J CELL BIOL, V30, P97, DOI 10.1083/jcb.30.1.97; DEGERMAN E, 1994, BBA-PROTEIN STRUCT M, V1205, P189, DOI 10.1016/0167-4838(94)90233-X; DEGERMAN E, 1987, J BIOL CHEM, V262, P5797; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; DOENST T, 1998, ENDOCRINOL METAB, V275, pE558; ERIKSSON H, 1995, BBA-MOL CELL RES, V1266, P101, DOI 10.1016/0167-4889(94)00237-9; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Fawcett L, 2000, P NATL ACAD SCI USA, V97, P3702, DOI 10.1073/pnas.050585197; FLEISCHER B, 1969, J CELL BIOL, V43, P59, DOI 10.1083/jcb.43.1.59; FOLETTI D, 1995, FASEB J, V9, P670, DOI 10.1096/fasebj.9.8.7768360; Goransson O, 1998, BIOCHEM BIOPH RES CO, V246, P249, DOI 10.1006/bbrc.1998.8602; HEYWORTH CM, 1983, BIOCHEM J, V214, P99, DOI 10.1042/bj2140099; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; KASUYA J, 1995, J BIOL CHEM, V270, P14305, DOI 10.1074/jbc.270.24.14305; KAUFFMAN RF, 1986, MOL PHARMACOL, V30, P609; KAWANO S, 1992, CIRC RES, V71, P585, DOI 10.1161/01.RES.71.3.585; Kenan Y, 2000, J BIOL CHEM, V275, P12331, DOI 10.1074/jbc.275.16.12331; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Komas N., 1996, PHOSPHODIESTERASE IN, P89, DOI [10.1016/b978-012210720-7/50008-3, DOI 10.1016/B978-012210720-7/50008-3]; KONO T, 1975, J BIOL CHEM, V250, P7826; Kurtz A, 1998, P NATL ACAD SCI USA, V95, P4743, DOI 10.1073/pnas.95.8.4743; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Landstrom TR, 2000, BIOCHEM J, V346, P337, DOI 10.1042/bj3460337; Leroy MJ, 1996, BIOCHEMISTRY-US, V35, P10194, DOI 10.1021/bi952711t; Liu H, 1998, BRIT J PHARMACOL, V125, P1501, DOI 10.1038/sj.bjp.0702227; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; MANGANIELLO V, 1973, J BIOL CHEM, V248, P7164; Manganiello V.C., 1990, CYCLIC NUCLEOTIDE PH, P61; Masaki R, 1996, J BIOL CHEM, V271, P16939, DOI 10.1074/jbc.271.28.16939; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; MCCARTNEY S, 1995, J BIOL CHEM, V270, P9327, DOI 10.1074/jbc.270.16.9327; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; Obeyesekere VR, 1997, MOL CELL ENDOCRINOL, V131, P173, DOI 10.1016/S0303-7207(97)00106-8; OConnell JC, 1996, BIOCHEM J, V318, P255, DOI 10.1042/bj3180255; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; Rosman GJ, 1997, GENE, V191, P89, DOI 10.1016/S0378-1119(97)00046-2; Sayers LG, 1997, BIOCHEM J, V323, P273, DOI 10.1042/bj3230273; Shakur Y, 2001, PROG NUCLEIC ACID RE, V66, P241; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; SICHEL F, 1990, CLIN CHIM ACTA, V188, P49, DOI 10.1016/0009-8981(90)90145-I; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V190, P516, DOI 10.1006/bbrc.1993.1078; Smith KJ, 1996, J BIOL CHEM, V271, P16703, DOI 10.1074/jbc.271.28.16703; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; SONNENBURG WK, 1991, J BIOL CHEM, V266, P17655; TANAKA T, 1991, SEC MESS PHOSPHOPROT, V13, P87; VILLA A, 1993, J CELL BIOL, V121, P1041, DOI 10.1083/jcb.121.5.1041; VOLPE P, 1994, BIOCHEM J, V301, P465, DOI 10.1042/bj3010465; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; WEISHAAR RE, 1987, CIRC RES, V61, P539, DOI 10.1161/01.RES.61.4.539; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; YANG Q, 1994, BIOCHEM BIOPH RES CO, V205, P1850, DOI 10.1006/bbrc.1994.2886; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920	70	90	93	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38749	38761		10.1074/jbc.M001734200	http://dx.doi.org/10.1074/jbc.M001734200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10952971	hybrid			2022-12-27	WOS:000165739800084
J	Lee, M; Goodall, J; Verastegui, C; Ballotti, R; Goding, CR				Lee, M; Goodall, J; Verastegui, C; Ballotti, R; Goding, CR			Direct regulation of the Microphthalmia promoter by Sox10 links Waardenburg-Shah syndrome (WS4)-associated hypopigmentation and deafness to WS2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER TRANSCRIPTION FACTOR; ENDOTHELIN-B RECEPTOR; HIRSCHSPRUNG-DISEASE; BETA-CATENIN; SYNDROME TYPE-2; MELANOMA-CELLS; FACTOR LEF-1; MOUSE MODEL; IN-VIVO; GENE	The transcription factor Sox10 is genetically linked with Waardenburg syndrome 4 (WS4) in humans and the Dominant megacolon (Dom) mouse model for this disease. The pigmentary defects observed in the Dom mouse and WS4 are reminiscent of those associated with mutations in the microphthalmia (Mitf) gene, which encodes a transcription factor essential for the development of the melanocyte lineage. We demonstrate here that wild type Sox10 directly binds and activates transcription of the MITF promoter, whereas a mutant form of the Sox10 protein genetically linked with WS4 acts as a dominant-negative repressor of MITF expression and can reduce endogenous MITF protein levels. The ability of Sox10 to activate transcription of the MITF promoter implicates Sox10 in the regulation of melanocyte development and provides a molecular basis for the hypopigmentation and deafness associated with WS4.	Marie Curie Res Inst, Eukaryot Transcript Lab, Oxted RH8 0TL, Surrey, England; Fac Med Nice, INSERM, U385, F-06107 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Goding, CR (corresponding author), Marie Curie Res Inst, Eukaryot Transcript Lab, The Chart, Oxted RH8 0TL, Surrey, England.		BALLOTTI, Robert/F-8825-2013	BALLOTTI, Robert/0000-0002-7322-4908; Goding, Colin/0000-0002-1614-3909				Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; ATTIE T, 1995, HUM MOL GENET, V4, P2407, DOI 10.1093/hmg/4.12.2407; BALDWIN CT, 1994, HUM MUTAT, V3, P205, DOI 10.1002/humu.1380030306; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BENNETT DC, 1983, CELL, V34, P445, DOI 10.1016/0092-8674(83)90378-1; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Carreira S, 1998, MOL CELL BIOL, V18, P5099, DOI 10.1128/MCB.18.9.5099; Dorsky RI, 2000, GENE DEV, V14, P158; Edery P, 1996, NAT GENET, V12, P442, DOI 10.1038/ng0496-442; Fuse N, 1996, BIOCHEM BIOPH RES CO, V219, P702, DOI 10.1006/bbrc.1996.0298; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Herbarth B, 1998, P NATL ACAD SCI USA, V95, P5161, DOI 10.1073/pnas.95.9.5161; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hofstra RMW, 1996, NAT GENET, V12, P445, DOI 10.1038/ng0496-445; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P23033, DOI 10.1074/jbc.273.36.23033; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; LEVENSON R, 1981, CELL, V25, P5, DOI 10.1016/0092-8674(81)90225-7; Lister JA, 1999, DEVELOPMENT, V126, P3757; Liu Q, 1999, J NEUROSCI, V19, P9747; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; Opdecamp K, 1997, DEVELOPMENT, V124, P2377; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; Planque N, 1999, CELL GROWTH DIFFER, V10, P525; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; Takeda K, 2000, J BIOL CHEM, V275, P14013, DOI 10.1074/jbc.C000113200; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	39	141	144	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37978	37983		10.1074/jbc.M003816200	http://dx.doi.org/10.1074/jbc.M003816200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973953	hybrid			2022-12-27	WOS:000165618700090
J	Zhou, B; Weigel, JA; Fauss, LA; Weigel, PH				Zhou, B; Weigel, JA; Fauss, LA; Weigel, PH			Identification of the hyaluronan receptor for endocytosis (HARE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ENDOTHELIAL-CELLS; ISOLATED RAT HEPATOCYTES; BINDING PROTEINS; ACID; DISEASE; CD44; METABOLISM; OLIGOSACCHARIDES; INTERNALIZATION; MORPHOGENESIS	Rat liver sinusoidal endothelial cells (LECs) express two hyaluronan (HA) receptors, of 175 and 300 kDa, responsible for the endocytic clearance of HA. We have characterized eight monoclonal antibodies (mAbs) raised against the 175-kDa HA receptor partially purified from rat LECs. These mAbs also cross-react with the 300-kDa HA receptor. The 175-kDa HA receptor is a single protein, whereas the 300-kDa species contains three subunits, alpha, beta, and gamma at 260, 230, and 97 kDa, respectively (Zhou, B., Oka, J. A., and Weigel, P. H. (1999) J. Biol. Chem. 274, 35831-53834). The 97-kDa subunit was not recognized by any of the mAbs in Western blots. Based on their cross-reactivity with these mAbs, the 175-, 230-, and 260-kDa proteins appear to be related. Two of the mAbs inhibit I-125-HA binding and endocytosis by LECs at 37 degreesC. All of these results confirm that the mAbs recognize the bone fide LEC HA receptor. Indirect immunofluoresence shows high protein expression in liver sinusoids, the venous sinuses of the red pulp in spleen, and the medullary sinuses of lymph nodes. Because the tissue distribution for this endocytic HA receptor is not unique to liver, we propose the name HARE (HA receptor for endocytosis).	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35978] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguiar DJ, 1999, EXP CELL RES, V252, P292, DOI 10.1006/excr.1999.4641; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUMETTE WN, 1981, ANAL BIOCHEM, V112, P195; BURD DAR, 1991, BRIT J PLAST SURG, V44, P579, DOI 10.1016/0007-1226(91)90093-Y; Cantor JO, 1998, P SOC EXP BIOL MED, V217, P471; Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J; EVERED D, 1989, CIBA F SYMP, V143, P1; FORSBERG N, 1991, BIOCHIM BIOPHYS ACTA, V1078, P12, DOI 10.1016/0167-4838(91)90085-E; FRASER JRE, 1983, CELL TISSUE RES, V233, P285; FRASER JRE, 1981, BIOCHEM J, V200, P415, DOI 10.1042/bj2000415; FROST SJ, 1990, BIOCHEMISTRY-US, V29, P10425, DOI 10.1021/bi00497a019; Fuxe K, 1996, BRAIN RES, V736, P329, DOI 10.1016/S0006-8993(96)00720-2; Gakunga P, 1997, DEVELOPMENT, V124, P3987; GHOSH P, 1994, CLIN EXP RHEUMATOL, V12, P75; GOA KL, 1994, DRUGS, V47, P536, DOI 10.2165/00003495-199447030-00009; GUSTAFSON S, 1995, GLYCOCONJUGATE J, V12, P350, DOI 10.1007/BF00731337; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; Harlow E., 1988, ANTIBODIES LAB MANUA; Hayflick JS, 1998, IMMUNOL RES, V17, P313, DOI 10.1007/BF02786454; Hofmann M, 1998, J CELL SCI, V111, P1673; Horton MR, 1998, J BIOL CHEM, V273, P35088, DOI 10.1074/jbc.273.52.35088; HUA Q, 1993, J CELL SCI, V106, P365; ILLUM L, 1994, J CONTROL RELEASE, V29, P133, DOI 10.1016/0168-3659(94)90129-5; Iocono JA, 1998, J SURG RES, V76, P111, DOI 10.1006/jsre.1998.5305; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai KN, 1998, J LAB CLIN MED, V131, P354, DOI 10.1016/S0022-2143(98)90186-X; LAURENT C, 1988, ARCH OTOLARYNGOL, V114, P1435; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; McCourt PAG, 1997, INT J BIOCHEM CELL B, V29, P1179, DOI 10.1016/S1357-2725(97)00058-7; MCCOURT PAG, 1994, J BIOL CHEM, V269, P30081; McCourt PAG, 1999, HEPATOLOGY, V30, P1276, DOI 10.1002/hep.510300521; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Meyer K, 1934, J BIOL CHEM, V107, P629; MORALES TI, 1989, ARTHRITIS RHEUM-US, V32, P1197, DOI 10.1002/anr.1780321003; OKA JA, 1987, J CELL PHYSIOL, V133, P243, DOI 10.1002/jcp.1041330207; PELLETIER JP, 1993, J RHEUMATOL, V20, P19; Rahmanian M, 1997, EXP CELL RES, V237, P223, DOI 10.1006/excr.1997.3792; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; RAJA RH, 1988, J BIOL CHEM, V263, P16661; Rockey DC, 1998, HEPATOLOGY, V27, P86, DOI 10.1002/hep.510270115; SMEDSROD B, 1994, GUT, V35, P1509, DOI 10.1136/gut.35.11.1509; TAMMI R, 1994, PROG HISTOCHEM CYTOC, V29, P1; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x; TURLEY EA, 1993, BLOOD, V81, P446; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; VERTEL BM, 1994, BIOCHEM J, V301, P211, DOI 10.1042/bj3010211; WEIGEL PH, 1986, J THEOR BIOL, V119, P219, DOI 10.1016/S0022-5193(86)80076-5; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Yamada M, 1998, ACTA HAEMATOL-BASEL, V99, P212, DOI 10.1159/000040841; YannarielloBrown J, 1997, GLYCOBIOLOGY, V7, P15, DOI 10.1093/glycob/7.1.15; YannarielloBrown J, 1996, BIOCHEM BIOPH RES CO, V218, P314, DOI 10.1006/bbrc.1996.0055; YANNARIELLOBROWN J, 1992, BIOCHEMISTRY-US, V31, P576, DOI 10.1021/bi00117a039; YANNARIELLOBROWN J, 1992, J BIOL CHEM, V267, P20451; Yaron I, 1997, J RHEUMATOL, V24, P2221; Zhou B, 1999, J BIOL CHEM, V274, P33831, DOI 10.1074/jbc.274.48.33831	62	213	218	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37733	37741		10.1074/jbc.M003030200	http://dx.doi.org/10.1074/jbc.M003030200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10952975	hybrid			2022-12-27	WOS:000165618700059
J	Lee, SL; Dickson, RB; Lin, CY				Lee, SL; Dickson, RB; Lin, CY			Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-DEGRADING PROTEASE; BREAST-CANCER CELLS; PLASMINOGEN-ACTIVATOR; SCATTER FACTOR; PRO-UROKINASE; RECEPTOR; TISSUE; FORM; IDENTIFICATION; PROUROKINASE	Matriptase is an epithelial-derived, integral membrane serine protease. The enzyme was initially isolated from human breast cancer cells and has been implicated in breast cancer invasion and metastasis. In the current study, using active matriptase isolated from human milk we demonstrate that matriptase is able to cleave various synthetic substrates with arginine or lysine as their P1 sites and prefers small side chain amino acids, such as Ala and Gly, at P2 sites. For the most reactive substrates, N-tert-butoxycarbonyl (N-t-Boc)-gamma -benzyl-Glu-Ala-Arg-7-amino-4-methylcoumarin (AMC) and N-t-Boc-Gln-Ala-Arg-AMC, the K-m values were determined to be 3.81 and 4.89 muM respectively. We further demonstrated that matriptase can convert hepatocyte growth factor/scattering factor to its active form, which can induce scatter of Madin-Darby canine kidney epithelial cells and can activate c-Met tyrosine phosphorylation in A549 human lung carcinoma cells. In addition, we noted that matriptase can activate urokinase plasminogen activator but has no affect on plasminogen. These results suggest that matriptase could act as an epithelial, upstream membrane activator to recruit and activate stromal-derived downstream effecters important for extracellular matrix degradation and epithelial migration, two major events of tissue remodeling, cancer invasion, and metastasis.	Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA	Georgetown University	Lin, CY (corresponding author), Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Dept Oncol, 3970 Reservoir Rd NW, Washington, DC 20007 USA.				NCI NIH HHS [R21-CA80897, 1P50CA58158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R44CA058158, R21CA080897, R43CA058158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUNNER G, 1992, BLOOD, V79, P2099; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; GORETZKI L, 1992, FEBS LETT, V297, P112, DOI 10.1016/0014-5793(92)80339-I; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; Kim MG, 1999, IMMUNOGENETICS, V49, P420, DOI 10.1007/s002510050515; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; KOIVUNEN E, 1989, J BIOL CHEM, V264, P14095; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; NAKA D, 1992, J BIOL CHEM, V267, P20114; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; SHI YE, 1993, CANCER RES, V53, P1409; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; STACK MS, 1994, J BIOL CHEM, V269, P9416; Stewart F, 1996, Rev Reprod, V1, P144, DOI 10.1530/ror.0.0010144; STOKER M, 1985, J CELL SCI, V77, P209; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WOLF BB, 1993, J BIOL CHEM, V268, P16327; Yoshida E, 1995, INT J CANCER, V63, P863, DOI 10.1002/ijc.2910630618	28	347	376	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36720	36725		10.1074/jbc.M007802200	http://dx.doi.org/10.1074/jbc.M007802200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10962009	hybrid			2022-12-27	WOS:000165577700040
J	Maya-Monteiro, CM; Daffre, S; Logullo, C; Lara, FA; Alves, EW; Capurro, ML; Zingali, R; Almeida, IC; Oliveira, PL				Maya-Monteiro, CM; Daffre, S; Logullo, C; Lara, FA; Alves, EW; Capurro, ML; Zingali, R; Almeida, IC; Oliveira, PL			HeLp, a heme lipoprotein from the hemolymph of the cattle tick, Boophilus microplus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; DENSITY LIPOPROTEINS; POLYACRYLAMIDE GELS; LIPID TRANSPORT; INSECT EGG; APOLIPOPROTEIN; PROTECTION; MECHANISMS; LIPOPHORIN; HEMOGLOBIN	The main protein of the hemolymph of the cattle tick Boophilus microplus has been isolated and shown to be a heme lipoprotein (HeLp). HeLp has an apparent molecular mass of 354,000 and contains two apoproteins (103 and 92 kDa) found in equal amounts. HeLp presents a pi of 5.8 and a density of 1.28 g/ml and contains 33% Lipids, containing both neutral lipids and phospholipids, and 3% of sugars. A remarkable feature of Help is the abundance of cholesterol ester (35% of total lipids), a lipid not previously reported in invertebrate lipoproteins. Western blot analysis showed Help in hemolymph from adult females and males, but not in eggs. Although Help contains 2 heme molecules, it is capable of binding 6 additional molecules of heme. Boophilus feeds large amount of blood, and we recently showed that this tick is unable to perform de novo synthesis of heme (Braz, G, R. C., Coelho, H. S. L., Masuda, H., and Oliveira, P. L. (1999) Curr. Biol. 9, 703-706). Injection of tick females with Fe-55-labeled heme-HeLp indicated that this protein transports heme from hemolymph to tissues. Help is suggested to be an essential adaptation to the loss of the heme synthesis pathway.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, BR-05508900 Sao Paulo, Brazil; Univ Fed Fluminense, Inst Biol, Dept Cellular & Mol Biol, BR-24001970 Niteroi, RJ, Brazil; Univ Estadual Norte Fluminense, Ctr Biociencias & Biotecnol, BR-28015620 Rio De Janeiro, Brazil; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	Universidade Federal do Rio de Janeiro; Universidade de Sao Paulo; Universidade Federal Fluminense; Universidade Estadual do Norte Fluminense; University of California System; University of California Irvine	Maya-Monteiro, CM (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.		maya-monteiro, clarissa/A-9091-2010; Logullo de Oliveira, Carlos Jorge/G-3436-2013; Capurro, Margareth L/F-8679-2012; Lara, Flavio Alves/L-1861-2013; Almeida, Igor C./AAF-9409-2019; Daffre, Sirlei/M-4233-2013; Capurro, Margareth/M-5286-2019; Zingali, Russolina/G-4862-2012; L. Oliveira, Pedro/A-9438-2010	Capurro, Margareth L/0000-0002-7480-2116; Almeida, Igor C./0000-0002-2443-8213; Daffre, Sirlei/0000-0002-9966-0433; Zingali, Russolina/0000-0003-3156-6923; L. Oliveira, Pedro/0000-0003-0307-354X				[Anonymous], 1991, BIOL BLOOD SUCKING I; BEAVEN GH, 1974, EUR J BIOCHEM, V41, P530; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Braz GRC, 1999, CURR BIOL, V9, P703, DOI 10.1016/S0960-9822(99)80312-1; CANNON JB, 1984, BIOCHEMISTRY-US, V23, P3715, DOI 10.1021/bi00311a022; CHAPMAN MJ, 1986, METHOD ENZYMOL, V128, P70; DANSAPETRETSKI M, 1995, J BIOL CHEM, V270, P10893, DOI 10.1074/jbc.270.18.10893; Doolittle R. F., 1986, URFS ORFS PRIMER ANA; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; DUBOIS M, 1956, ANAL CHEM, V28, P356; Duffin K, 2000, ANAL BIOCHEM, V279, P179, DOI 10.1006/abio.1999.4452; El Hafidi M, 1999, CHEM PHYS LIPIDS, V100, P127, DOI 10.1016/S0009-3084(99)00049-3; Eskew JD, 1999, J BIOL CHEM, V274, P638, DOI 10.1074/jbc.274.2.638; FALK JE, 1964, PORPHYRINS METALLOPO; GALBRAITH RA, 1985, J BIOL CHEM, V260, P2198; GEORGE R, 1987, J BIOL CHEM, V262, P16838; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; HALLIWELL B, 1990, ARCH BIOCHEM BIOPHYS, V280, P1, DOI 10.1016/0003-9861(90)90510-6; HORWITZ J, 1987, METHOD ENZYMOL, V141, P169; IWAHARA S, 1995, BIOCHEMISTRY-US, V34, P13398, DOI 10.1021/bi00041a017; JONAS A, 1993, J BIOL CHEM, V268, P1596; Kanost M.R., 1990, Advances in Insect Physiology, V22, P299, DOI 10.1016/S0065-2806(08)60008-9; KAWOOYA JK, 1988, J BIOL CHEM, V263, P8748; KAWOOYA JK, 1988, J BIOL CHEM, V263, P8740; KAWOOYA JK, 1989, BIOCHEMISTRY-US, V28, P6658, DOI 10.1021/bi00442a019; KERWIN JL, 1994, J LIPID RES, V35, P1102; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BC, 1995, MOL MICROBIOL, V18, P383, DOI 10.1111/j.1365-2958.1995.mmi_18030383.x; Lovry O.H., 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILLER YI, 1995, BBA-MOL BASIS DIS, V1272, P119, DOI 10.1016/0925-4439(95)00075-F; MONTEIRO CM, 1997, BIOCHEMISTRY-US, V36, P11216; Morris K., 1972, TECHNIQUES LIPIDOLOG; MOURAO PAS, 1995, J BIOL CHEM, V270, P3132, DOI 10.1074/jbc.270.7.3132; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Noyer CM, 1998, HEPATOLOGY, V28, P150, DOI 10.1002/hep.510280120; OLIVEIRA PL, 1995, J BIOL CHEM, V270, P10897, DOI 10.1074/jbc.270.18.10897; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004; Ponka P, 1997, BLOOD, V89, P1; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; SHIPMAN BA, 1986, BIOCHEMISTRY-US, V26, P1885; SOLAR I, 1989, BIOCHIM BIOPHYS ACTA, V983, P199, DOI 10.1016/0005-2736(89)90234-4; Sonenshine D. E., 1993, ECOLOGY NIDICOLOUS T, V2; SOULAGES JL, 1994, ADV PROTEIN CHEM, V45, P371; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; TIPPING E, 1976, BIOCHEM J, V157, P461, DOI 10.1042/bj1570461; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VINCENT SH, 1988, ARCH BIOCHEM BIOPHYS, V265, P539, DOI 10.1016/0003-9861(88)90159-2; VINCENT SH, 1989, SEMIN HEMATOL, V26, P105	52	80	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36584	36589		10.1074/jbc.M007344200	http://dx.doi.org/10.1074/jbc.M007344200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10964932	hybrid			2022-12-27	WOS:000165577700019
J	Ovide-Bordeaux, S; Ventura-Clapier, R; Veksler, V				Ovide-Bordeaux, S; Ventura-Clapier, R; Veksler, V			Do modulators of the mitochondrial K-ATP channel change the mitochondria in situ?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ACTION-POTENTIAL DURATION; POTASSIUM CHANNEL; LIVER-MITOCHONDRIA; RAT-LIVER; CARDIOPROTECTION; OPENER; ACTIVATION; DIAZOXIDE; MEMBRANE	Pharmacological opening of mitochondrial cardiac ATP-sensitive potassium (K-ATP) channels has the chance to be a promising but still controversial cardioprotective mechanism. Physiological roles of mitochondrial K-ATP, channels in the myocardium remain unclear. We studied the effects of diazoxide, a specific opener of these channels, on the function of rat mitochondria in. situ in saponin-permeabilized fibers using an ionic medium that mimics the cytosol, In the presence of NADH-producing substrates (malate + glutamate), neither 100 muM diazoxide nor 100 muM glibenclamide (a K-ATP channel blocker) changed the mitochondrial respiration in the absence or presence of ADP, Because the K-ATP channel function could be modified by changes in adenine nucleotide concentrations near the mitochondria, we studied the effects of diazoxide and glibenclamide on the functional activity of mitochondrial kinases, Both diazoxide and glibenclamide did not change the in situ ADP sensitivity in the presence or absence of creatine (apparent IE,values for ADP were, respectively, 59 +/- 9 and 379 +/- 45 muM) Similarly, stimulation of the mitochondrial respiration with AMP in the presence of ATP due to adenylate kinase activity was not affected by the modulators of K-ATP channels, However, when succinate was used as substrate, diazoxide significantly inhibited basal respiration by 22% and maximal respiration by 24%. Thus, at a cardioprotective dose, the main functional effect of diazoxide depends on respiratory substrates and seems not to be related to K-ATP channel activity.	Univ Paris Sud, Fac Pharm, INSERM U446, Lab Cardiol Cellulaire & Mol, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Veksler, V (corresponding author), Univ Paris Sud, Fac Pharm, INSERM U446, Lab Cardiol Cellulaire & Mol, F-92296 Chatenay Malabry, France.			Ventura-Clapier, Renee/0000-0002-7488-4123; Veksler, Vladimir/0000-0002-8869-9594				Baines CP, 1999, J CARDIOVASC ELECTR, V10, P741, DOI 10.1111/j.1540-8167.1999.tb00251.x; Baines CP, 1999, AM J PHYSIOL-HEART C, V276, pH1361, DOI 10.1152/ajpheart.1999.276.4.H1361; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; Garlid KD, 1997, CIRC RES, V81, P1072; Garlid KD, 1996, BBA-BIOENERGETICS, V1275, P123, DOI 10.1016/0005-2728(96)00061-8; Garlid KD, 1996, J BIOL CHEM, V271, P8796, DOI 10.1074/jbc.271.15.8796; Grigoriev SM, 1999, BBA-BIOENERGETICS, V1410, P91, DOI 10.1016/S0005-2728(98)00179-0; Grimmsmann T, 1998, BRIT J PHARMACOL, V123, P781, DOI 10.1038/sj.bjp.0701663; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; GROVER GJ, 1995, J CARDIOVASC PHARM, V26, P145, DOI 10.1097/00005344-199507000-00023; Han J, 1996, J MOL CELL CARDIOL, V28, P2043, DOI 10.1006/jmcc.1996.0197; Holmuhamedov EL, 1999, J PHYSIOL-LONDON, V519, P347, DOI 10.1111/j.1469-7793.1999.0347m.x; Holmuhamedov EL, 1998, AM J PHYSIOL-HEART C, V275, pH1567, DOI 10.1152/ajpheart.1998.275.5.H1567; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; Jaburek M, 1998, J BIOL CHEM, V273, P13578; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; MCDONALD MJ, 1984, BIOCH INT, V8, P771; MOORE PF, 1968, ANN NY ACAD SCI, V150, P256, DOI 10.1111/j.1749-6632.1968.tb19050.x; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; Ribalet B, 1996, J GEN PHYSIOL, V107, P231, DOI 10.1085/jgp.107.2.231; Sato T, 1998, CIRC RES, V83, P110, DOI 10.1161/01.RES.83.1.110; SCHAFER G, 1971, BIOCHEM PHARMACOL, V20, P1271, DOI 10.1016/0006-2952(71)90358-3; SELLERS EM, 1974, BIOCHEM PHARMACOL, V23, P553, DOI 10.1016/0006-2952(74)90620-0; SZEWCZYK A, 1995, BIOCHEM BIOPH RES CO, V207, P126, DOI 10.1006/bbrc.1995.1162; Takashi E, 1999, CIRC RES, V85, P1146; VEKSLER VI, 1995, J BIOL CHEM, V270, P19921, DOI 10.1074/jbc.270.34.19921; VEKSLER VI, 1987, BIOCHIM BIOPHYS ACTA, V892, P191, DOI 10.1016/0005-2728(87)90174-5; Wang YG, 1999, CIRC RES, V85, P731, DOI 10.1161/01.RES.85.8.731; YAO ZH, 1994, CIRCULATION, V89, P1769, DOI 10.1161/01.CIR.89.4.1769	31	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37291	37295		10.1074/jbc.M005772200	http://dx.doi.org/10.1074/jbc.M005772200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10970894	hybrid			2022-12-27	WOS:000165577700115
J	Segerman, B; Larsson, N; Holmfeldt, P; Gullberg, M				Segerman, B; Larsson, N; Holmfeldt, P; Gullberg, M			Mutational analysis of Op18/stathmin-tubulin-interacting surfaces - Binding cooperativity controls tubulin GTP hydrolysis in the ternary complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE DYNAMICS; PROTEIN-KINASE; ONCOPROTEIN-18; PHOSPHORYLATION; STATHMIN; TARGET	Oncoprotein 18 (Op18) is a microtubule regulator that forms a ternary complex with two tubulin heterodimers. Dispersed regions of Op18 are involved in two-site cooperative binding and subsequent modulation of tubulin GTPase activity. Here we have analyzed specific determinants of Op18 that govern both stoichiometry and positive cooperativity in tubulin binding and consequent stimulatory and inhibitory effects on tubulin GTPase activity. The data revealed that the central and C-terminal regions of Op18 contain overlapping binding-motifs contacting both tubulin heterodimers, suggesting that these regions of Op18 are wedged into the previously noted l-nm gap between the two longitudinally arranged tubulin heterodimers. Both the N- and C-terminal flanks adjacent to the central region are involved in stabilizing the ternary complex, but only the C-terminal flank does so by imposing positive binding cooperativity, Within the C-terminal flank, deletion of a 7-amino acid region attenuated positive binding cooperativity and resulted in a switch from stimulation to inhibition of tubulin GTP hydrolysis, This switch can be explained by attenuated binding cooperativity, because Op18 under these conditions may block longitudinal contact surfaces of single tubulins with consequent interference of tubulin-tubulin interaction-dependent GTP hydrolysis. Together, our results suggest that Op18 links two tubulin heterodimers via longitudinal contact surfaces to form a ternary GTPase productive complex.	Umea Univ, Dept Cell & Mol Biol, S-90187 Umea, Sweden	Umea University	Gullberg, M (corresponding author), Umea Univ, Dept Cell & Mol Biol, S-90187 Umea, Sweden.		Holmfeldt, Per/AAF-7940-2021	Gullberg, Martin/0000-0002-3984-4572				Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Arnal I, 2000, J CELL BIOL, V149, P767, DOI 10.1083/jcb.149.4.767; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Carlier MF, 1997, BIOPHYS J, V73, P418, DOI 10.1016/S0006-3495(97)78081-0; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; Gradin HM, 1997, MOL CELL BIOL, V17, P3459, DOI 10.1128/MCB.17.6.3459; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; Larsson NL, 1999, MOL CELL BIOL, V19, P2242; Lawler S, 1998, CURR BIOL, V8, pR212, DOI 10.1016/S0960-9822(98)70128-9; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; McNally FJ, 1999, CURR BIOL, V9, pR274, DOI 10.1016/S0960-9822(99)80177-8; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Redeker V, 2000, J BIOL CHEM, V275, P6841, DOI 10.1074/jbc.275.10.6841; Steinmetz MO, 2000, EMBO J, V19, P572, DOI 10.1093/emboj/19.4.572; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; Wallon G, 2000, EMBO J, V19, P213, DOI 10.1093/emboj/19.2.213	27	16	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35759	35766		10.1074/jbc.M005875200	http://dx.doi.org/10.1074/jbc.M005875200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10954719	hybrid			2022-12-27	WOS:000165382000019
J	Dhar, SK; Dutta, A				Dhar, SK; Dutta, A			Identification and characterization of the human ORC6 homolog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; DROSOPHILA HOMOLOG; S-PHASE; XENOPUS; PROTEINS; CDC6P; PROLIFERATION; INITIATION	A new protein was cloned and identified as the sixth member of the human origin recognition complex (ORC). The newly identified 30-kDa protein hsORC6 is 28% identical and 49% similar to ORC6p from Drosophila melanogaster, which is consistent with the identities and similarities found among the other ORC members reported in the two species. The human ORC6 gene is located on chromosome 16q12. ORC6 protein level did not change through the cell cycle. Like ORC1, ORC6 did not co-immunoprecipitate with other ORC subunits but was localized in the nucleus along with the other ORC subunits. Several cellular proteins co-immunoprecipitated with ORC6, including a 65-kDa protein that was hyperphosphorylated in G(1) and dephosphorylated in mitosis, Therefore, unlike the tight stoichiometric association of six yeast ORC subunits in one hole-complex, only a small fraction of human ORC1 and ORC6 is likely to be associated with a subcomplex of ORC2, 3, 4, and 5, suggesting differences in the architecture and regulation of human ORC.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Div Mol Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dutta, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Div Mol Oncol, Boston, MA 02115 USA.		Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073	NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER; NCI NIH HHS [CA60499] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Chesnokov I, 1999, GENE DEV, V13, P1289, DOI 10.1101/gad.13.10.1289; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Ishiai M, 1997, GENOMICS, V46, P294, DOI 10.1006/geno.1997.5003; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL CELL BIOL, V16, P741; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; Moon KY, 1999, P NATL ACAD SCI USA, V96, P12367, DOI 10.1073/pnas.96.22.12367; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tatsumi Y, 2000, J BIOL CHEM, V275, P5904, DOI 10.1074/jbc.275.8.5904; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421	28	60	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34983	34988		10.1074/jbc.M006069200	http://dx.doi.org/10.1074/jbc.M006069200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10945994	hybrid			2022-12-27	WOS:000165422800023
J	Kirsch, T; Harrison, G; Golub, EE; Nah, HD				Kirsch, T; Harrison, G; Golub, EE; Nah, HD			The roles of annexins and types II and X collagen in matrix vesicle-mediated mineralization of growth plate cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE UNILAMELLAR VESICLES; CALCIUM-CHANNEL ACTIVITY; ANCHORIN-CII; CRYSTAL-STRUCTURE; BINDING-PROTEINS; MEMBRANE-PROTEIN; CALCIFICATION; CHONDROCYTES; RECOMBINANT; FAMILY	Annexins II, V, and VI are major components of matrix vesicles (MV), i.e. particles that have the critical role of initiating the mineralization process in skeletal tissues. Furthermore, types II and X collagen are associated with MV, and these interactions mediated by annexin V stimulate Ca2+ uptake and mineralization of MV. However, the exact roles of annexin II, V, and VI and the interaction between annexin V and types II and X collagen in MV function and initiation of mineralization are not well understood. In this study, we demonstrate that annexin II, V, or VI mediate Ca2+ influx into phosphatidylserine (PS)-enriched liposomes, liposomes containing lipids extracted from authentic MV, and intact authentic MV. The annexin Ca2+ channel blocker, K-201, not only inhibited Ca2+ influx into fura-2-loaded PS-enriched liposomes mediated by annexin II, V, or VI, but also inhibited Ca2+ uptake by authentic MV. Types II and X collagen only bound to liposomes in the presence of annexin V but not in the presence of annexin II or VI. Binding of these collagens to annexin V stimulated its Ca2+ channel activities, leading to an increased Ca2+ influx into the liposomes. These findings indicate that the formation of annexin II, V, and VI Ca2+ channels in MV together with stimulation of annexin V channel activity by collagen (types II and X) binding can explain how MV are able to rapidly take up Ca2+ and initiate the formation of the first crystal phase.	Univ Penn, Sch Dent Med, Dept Anat, Philadelphia, PA 19104 USA; Univ Penn, Sch Dent Med, Dept Histol, Philadelphia, PA 19104 USA; Univ Penn, Sch Dent Med, Dept Biochem, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Kirsch, T (corresponding author), Penn State Coll Med, Hershey Med Ctr, Dept Orthopaed Rehabil, H089,500 Univ Dr, Hershey, PA 17033 USA.				NIAMS NIH HHS [AR-43732, AR-46245] Funding Source: Medline; NIDCR NIH HHS [DE-06533] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043732, R01AR046245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE006533] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALI S Y, 1985, Scanning Electron Microscopy, P1555; ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266; Arias JL, 1997, CONNECT TISSUE RES, V36, P21, DOI 10.3109/03008209709160211; Arispe N, 1996, BIOPHYS J, V71, P1764, DOI 10.1016/S0006-3495(96)79377-3; Benz J, 1996, J MOL BIOL, V260, P638, DOI 10.1006/jmbi.1996.0426; BERENDES R, 1993, SCIENCE, V262, P427, DOI 10.1126/science.7692599; BERENDES R, 1993, FEBS LETT, V317, P131, DOI 10.1016/0014-5793(93)81507-V; Burger A, 1996, J MOL BIOL, V257, P839, DOI 10.1006/jmbi.1996.0205; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CROMPTON MR, 1988, EMBO J, V7, P21, DOI 10.1002/j.1460-2075.1988.tb02779.x; Derfus B, 1998, CALCIFIED TISSUE INT, V63, P258, DOI 10.1007/s002239900523; DOYLE DV, 1982, J PATHOL, V136, P199, DOI 10.1002/path.1711360304; Geisow MJ, 1988, MOL MECH SECRETION, P598; GENGE BR, 1992, J BONE MINER RES, V7, P807, DOI 10.1002/jbmr.5650070710; GENGE BR, 1989, J BIOL CHEM, V264, P10917; GERKE V, 1990, NUCLEIC ACIDS RES, V18, P4246, DOI 10.1093/nar/18.14.4246; HOHIMADAHL R, 1986, ARTHRITIS RHEUM, V29, P400; Hsu HHT, 1999, ATHEROSCLEROSIS, V143, P353, DOI 10.1016/S0021-9150(98)00322-0; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; Kaneko N, 1997, BBA-BIOMEMBRANES, V1330, P1, DOI 10.1016/S0005-2736(97)00132-6; Kaneko N, 1997, J MOL BIOL, V274, P16, DOI 10.1006/jmbi.1997.1375; KANEKO N, 1994, DRUG DEVELOP RES, V33, P429, DOI 10.1002/ddr.430330406; KIRSCH T, 1990, BIOCHEM J, V265, P453, DOI 10.1042/bj2650453; KIRSCH T, 1992, BONE MINER, V18, P107, DOI 10.1016/0169-6009(92)90851-4; KIRSCH T, 1994, J BIOL CHEM, V269, P11462; KIRSCH T, 1991, FEBS LETT, V294, P149, DOI 10.1016/0014-5793(91)81363-D; Kirsch T, 1997, BIOCHEMISTRY-US, V36, P3359, DOI 10.1021/bi9626867; KIRSCH T, 1992, FEBS LETT, V310, P143, DOI 10.1016/0014-5793(92)81316-E; Kirsch T, 2000, OSTEOARTHR CARTILAGE, V8, P294, DOI 10.1053/joca.1999.0304; Kirsch T, 2000, J BONE MINER RES, V15, P261, DOI 10.1359/jbmr.2000.15.2.261; Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; Matsuda R, 1997, BIOCHEM BIOPH RES CO, V237, P499, DOI 10.1006/bbrc.1997.7177; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MOLLENHAUER J, 1984, J CELL BIOL, V98, P1572, DOI 10.1083/jcb.98.4.1572; Nah HD, 2000, J BONE MINER RES, V15, P522, DOI 10.1359/jbmr.2000.15.3.522; PACIFICI M, 1991, EXP CELL RES, V192, P266, DOI 10.1016/0014-4827(91)90185-W; Paschalis EP, 1996, BONE, V19, P151, DOI 10.1016/8756-3282(96)00164-0; POOLE AR, 1989, J CELL BIOL, V109, P2547, DOI 10.1083/jcb.109.5.2547; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; SAUER GR, 1989, BONE MINER, V7, P233, DOI 10.1016/0169-6009(89)90080-9; SCHMID TM, 1990, DEV BIOL, V138, P53, DOI 10.1016/0012-1606(90)90176-J; Stehbens WE, 2000, CELL MOL BIOL, V46, P99; TURNAY J, 1995, J CELL BIOCHEM, V58, P208, DOI 10.1002/jcb.240580210; Worch KP, 1998, J DENT RES, V77, P927; WU LNY, 1991, J BIOL CHEM, V266, P1195; WUTHIER RE, 1982, CLIN ORTHOP RELAT R, P219	49	155	166	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35577	35583		10.1074/jbc.M005648200	http://dx.doi.org/10.1074/jbc.M005648200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956650	hybrid			2022-12-27	WOS:000165422800098
J	Leonard, BJN; Clarke, BJ; Sridhara, S; Kelley, R; Ofosu, FA; Blajchman, MA				Leonard, BJN; Clarke, BJ; Sridhara, S; Kelley, R; Ofosu, FA; Blajchman, MA			Activation and active site occupation alter conformation in the region of the first epidermal growth factor-like domain of human factor VII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-VIIA; TISSUE FACTOR-BINDING; BLOOD-COAGULATION; PROTEASE DOMAIN; CA2+ BINDING; MONOCLONAL-ANTIBODY; CATALYTIC FUNCTION; CRYSTAL-STRUCTURE; FACTOR-XA; AFFINITY	The first epidermal growth factor-like domain (EGF-1) of factor VII (FVII) provides the region of greatest contact during the interaction of FVIIa with tissue factor. To understand this interaction better, the conformation-sensitive FVII EGF-l-specific monoclonal antibody (mAb) 231-7 was used to investigate the conformational effects occurring in this region upon both FVII activation and active site occupation. The binding affinity of mAb 231-7 was approximately 3-fold greater for the zymogen state than for the active state; a result affected by the presence of both calcium and the adjacent Gla domain. Once activated, active site inhibition of FVIIa with:a variety of chloromethyl ketone inhibitors resulted in a 10-fold range of affinities of FVIIai molecules to mAb 231-7. Gla domain removal eliminated this variation in affinity, suggesting the involvement of a Gla/EGF-I interaction in this conformational effect. In addition, the binding of mAb 231-7 to FVIIa EGF-1 stimulated the amidolytic activity of free FVIIa. Taken together, these results imply an allosteric interaction between the FVIIa active site and the EGF-1 domain that is sensitive to variation in active site occupant structure. Thus, these present studies indicate that the conformational change associated with FVII activation and active site occupation involves the EGF-1 domain and suggest potential functional consequences of these changes.	McMaster Univ, Med Ctr, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada; Genentech Inc, San Francisco, CA 94080 USA	McMaster University; Roche Holding; Genentech	Blajchman, MA (corresponding author), McMaster Univ, Med Ctr, Dept Pathol & Mol Med, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							Ambrosini G, 1997, J BIOL CHEM, V272, P8340, DOI 10.1074/jbc.272.13.8340; BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; CERSKUS AL, 1985, BRIT J HAEMATOL, V61, P467, DOI 10.1111/j.1365-2141.1985.tb02850.x; CHANG JY, 1995, BIOCHEMISTRY-US, V34, P12227, DOI 10.1021/bi00038a017; CLARKE BJ, 1992, FEBS LETT, V298, P206, DOI 10.1016/0014-5793(92)80058-O; Colwell NS, 1998, BIOCHEMISTRY-US, V37, P15057, DOI 10.1021/bi980925f; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; Dickinson CD, 1997, J BIOL CHEM, V272, P19875, DOI 10.1074/jbc.272.32.19875; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Dickinson CD, 1998, J MOL BIOL, V277, P959, DOI 10.1006/jmbi.1998.1639; Freskgard PO, 1998, BIOCHEMISTRY-US, V37, P7203, DOI 10.1021/bi972847m; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HIGASHI S, 1994, J BIOL CHEM, V269, P18891; Kemball-Cook G, 1999, J STRUCT BIOL, V127, P213, DOI 10.1006/jsbi.1999.4158; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; Leonard BJN, 1998, BLOOD, V91, P142, DOI 10.1182/blood.V91.1.142.142_142_148; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NICHOLAISEN EM, 1992, FEBS LETT, V306, P157; Persson E, 1997, J BIOL CHEM, V272, P19919, DOI 10.1074/jbc.272.32.19919; PERSSON E, 1995, EUR J BIOCHEM, V234, P293, DOI 10.1111/j.1432-1033.1995.293_c.x; Pike ACW, 1999, P NATL ACAD SCI USA, V96, P8925, DOI 10.1073/pnas.96.16.8925; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAO LVM, 1986, BLOOD, V68, P685; Rezaie AR, 1997, BIOCHEMISTRY-US, V36, P7437, DOI 10.1021/bi962965u; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; Rezaie AR, 1996, J BIOL CHEM, V271, P23807, DOI 10.1074/jbc.271.39.23807; Ruiz SM, 2000, THROMB RES, V98, P203, DOI 10.1016/S0049-3848(99)00227-3; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHIODT J, 1992, FEBS LETT, V306, P265, DOI 10.1016/0014-5793(92)81014-D; Shobe J, 1999, BIOCHEMISTRY-US, V38, P2745, DOI 10.1021/bi981951g; Sorensen BB, 1997, J BIOL CHEM, V272, P11863, DOI 10.1074/jbc.272.18.11863; Sridhara S, 1996, AM J HEMATOL, V53, P66; Sunnerhagen M, 1996, BIOCHEMISTRY-US, V35, P11547, DOI 10.1021/bi960633j; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	44	21	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34894	34900		10.1074/jbc.M001166200	http://dx.doi.org/10.1074/jbc.M001166200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952970	hybrid			2022-12-27	WOS:000165422800012
J	Polesskaya, A; Duquet, A; Naguibneva, I; Weise, C; Vervisch, A; Bengal, E; Hucho, F; Robin, P; Harel-Bellan, A				Polesskaya, A; Duquet, A; Naguibneva, I; Weise, C; Vervisch, A; Bengal, E; Hucho, F; Robin, P; Harel-Bellan, A			CREB-binding protein/p300 activates MyoD by acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; HISTONE ACETYLTRANSFERASES; TRANSCRIPTIONAL ACTIVATION; COACTIVATORS P300; DNA-BINDING; ONCOPROTEIN E1A; MUSCLE; CBP; DIFFERENTIATION; DOMAIN	The myogenic protein MyoD requires two nuclear histone acetyltransferases, CREB-binding protein (CBP)/p300 and PCAF, to transactivate muscle promoters. MyoD is acetylated by PCAF in vitro, which seems to increase its affinity for DNA We here show that MyoD is constitutively acetylated in muscle cells. In vitro, MyoD is acetylated both by CBP/p300 and by PCAF on two lysines located at the boundary of the DNA binding domain. MyoD acetylation by CBP/p300 (as well as by PCAF) increases its activity on a muscle-specific promoter, as assessed by microinjection experiments. MyoD mutants that cannot be acetylated in vitro are not activated in the functional assay, Our results provide direct evidence that MyoD acetylation functionally activates the protein and show that both PCAF and CBP/p300 are candidate enzymes for MyoD acetylation in vivo.	Inst Federat Andre Lwoff, CNRS UPR 9079, Lab Oncogenese Differenciat & Transduct Signal, Villejuif, France; Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany; Inst Federat Andre Lwoff, Serv Commun Cytofluorometrie, Villejuif, France; Technion Israel Inst Technol, Dept Biochem, IL-31096 Haifa, Israel	Centre National de la Recherche Scientifique (CNRS); Free University of Berlin; Technion Israel Institute of Technology	Harel-Bellan, A (corresponding author), Inst Federat Andre Lwoff, CNRS UPR 9079, Lab Oncogenese Differenciat & Transduct Signal, 7 Rue Guy Moquet, Villejuif, France.		Harel-Bellan, Annick/M-9795-2015	Harel-Bellan, Annick/0000-0002-2339-153X; Naguibneva, Irina/0000-0001-9566-6152				Ait-Si-Ali S, 1998, NUCLEIC ACIDS RES, V26, P3869, DOI 10.1093/nar/26.16.3869; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; BUCKINGHAM M, 1994, CURR BIOL, V4, P61, DOI 10.1016/S0960-9822(00)00014-2; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; Chaurand P, 1999, J AM SOC MASS SPECTR, V10, P91, DOI 10.1016/S1044-0305(98)00145-7; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WOLFFE AP, 1994, CURR BIOL, V4, P525, DOI 10.1016/S0960-9822(00)00114-7; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	38	105	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34359	34364		10.1074/jbc.M003815200	http://dx.doi.org/10.1074/jbc.M003815200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944526	hybrid			2022-12-27	WOS:000165095300050
J	Ray, K; Hauschild, BC				Ray, K; Hauschild, BC			Cys-140 is critical for metabotropic glutamate receptor-1 dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE PHEROMONE RECEPTORS; HUMAN CALCIUM RECEPTOR; TERMINAL EXTRACELLULAR DOMAIN; CELL-SURFACE EXPRESSION; LIGAND-BINDING; SIGNAL-TRANSDUCTION; MULTIGENE FAMILY; CLONING; IDENTIFICATION; PURIFICATION	Metabotropic glutamate receptor 1 (mGluR1) expresses at the cell surface as disulfide-linked dimers and can be reduced to monomers with sulfhydryl reagents. To identify the dimerization domain, we transiently expressed in HEK-293 cells a truncated version of mGluR1 (RhodC-R1) devoid of the extracellular domain (ECD), RhodC-R1 was a monomer in the absence or presence of the reducing agents, suggesting that dimerization occurs via the ECD, To identify cysteine residues involved in dimerization within the ECD, cysteine to serine point mutations were made at three cysteines within the amino-terminal half of the ECD, A mutation at positions Cys-67, Cys-109, and Cys-140 all resulted in significant amounts of monomers in the absence of reducing agents. The monomeric C67S and C109S mutants were not properly glycosylated, failed to reach the cell surface, and showed no glutamate response, indicating that these mutant receptors were improperly folded and/or processed and thus retained intracellularly, In contrast, the monomeric C140S mutant was properly glycosylated, processed, and expressed at the cell surface. Phosphoinositide hydrolysis assay showed that the glutamate response of the C140S mutant receptor was similar to the wild type receptor. Substitution of a cysteine for Ser-129, Lys-134, Asp-143, and Thr-146 on the C140S mutant background restored receptor dimerization. Taken together, the results suggest that Cys-140 contributes to intermolecular disulfide linked dimerization of mGluR1.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Ray, K (corresponding author), Natl Inst Deafness & Other Commun Disorders, Lab Signal Transduct, 5 Res Ct, Rockville, MD 20850 USA.							Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BARSOMIAN GD, 1990, J BIOL CHEM, V265, P6967; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Copani A, 2000, BRAIN RES, V867, P165, DOI 10.1016/S0006-8993(00)02293-9; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Goldsmith PK, 1999, J BIOL CHEM, V274, P11303, DOI 10.1074/jbc.274.16.11303; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Mary S, 1997, EUR J PHARMACOL, V335, P65, DOI 10.1016/S0014-2999(97)01155-2; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Robbins MJ, 1999, J NEUROCHEM, V72, P2539, DOI 10.1046/j.1471-4159.1999.0722539.x; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535	31	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34245	34251		10.1074/jbc.M005581200	http://dx.doi.org/10.1074/jbc.M005581200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10945991	hybrid			2022-12-27	WOS:000165095300035
J	Davies, C; White, SW; Nicholas, RA				Davies, C; White, SW; Nicholas, RA			Crystal structure of a deacylation-defective mutant of penicillin-binding protein 5 at 2.3-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANINE CARBOXYPEPTIDASE IA; SITE-DIRECTED MUTAGENESIS; ACYL-ENZYME INTERMEDIATE; A BETA-LACTAMASE; ESCHERICHIA-COLI; STREPTOMYCES R61; TRANSPEPTIDASE; PURIFICATION; MECHANISM; FORM	Penicillin-binding protein 5 (PBP 5) of Escherichia coli functions as a D-alanine carboxypeptidase, cleaving the C-terminal D-alanine residue from cell wall peptides, Like all PBPs, PBP 5 forms a covalent acyl-enzyme complex with p-lactam antibiotics; however, PBP 5 is distinguished by its high rate of deacylation of the acyl-enzyme complex (t(1/2) similar to 9 min). A Gly-105 --> Asp mutation in PBP 5 markedly impairs this beta -lactamase activity (deacylation), with only minor effects on acylation, and promotes accumulation of a covalent complex with peptide substrates, To gain further insight into the catalytic mechanism of PBP 5, we determined the three-dimensional structure of the G105D mutant form of soluble PBP 5 (termed sPBP 5') at 2.3 Angstrom resolution. The structure is composed of two domains, a penicillin binding domain with a striking similarity to Class A beta -lactamases (TEM-1-like) and a domain of unknown function. In addition, the penicillin-binding domain contains an active site loop spatially equivalent to the Omega loop of beta -lactamases. In beta -lactamases, the Omega loop contains two amino acids involved in catalyzing deacylation, This similarity may explain the high beta -lactamase activity of wild-type PBP 5. Because of the low rate of deacylation of the G105D mutant, visualization of peptide substrates bound to the active site may be possible.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England	University of North Carolina; University of North Carolina Chapel Hill; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; University of Sussex	Nicholas, RA (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	nicholas@med.unc.edu	White, Stephen W/N-8164-2018					Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ADACHI H, 1991, J BIOL CHEM, V266, P3186; AMANUMA H, 1980, J BIOL CHEM, V255, P1173; AMANUMA H, 1984, J BIOL CHEM, V259, P1294; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRANNIGAN J, 1991, BIOCHEM J, V278, P673, DOI 10.1042/bj2780673; BUSH K, 1984, ANTIMICROBIAL DRUG R, P1; CURTIS SJ, 1978, J BIOL CHEM, V253, P2584; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; ELLERBY LM, 1990, BIOCHEMISTRY-US, V29, P5797, DOI 10.1021/bi00476a022; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P406; Fonze E, 1999, J BIOL CHEM, V274, P21853, DOI 10.1074/jbc.274.31.21853; FRERE JM, 1975, EUR J BIOCHEM, V57, P353, DOI 10.1111/j.1432-1033.1975.tb02308.x; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; GHUYSEN JM, 1988, REV INFECT DIS, V10, P726; GHUYSEN JM, 1994, BACTERIAL CELL WALL, P103; Guillaume G, 1997, J BIOL CHEM, V272, P5438, DOI 10.1074/jbc.272.9.5438; HERZBERG O, 1987, SCIENCE, V236, P694, DOI 10.1126/science.3107125; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORIS B, 1988, BIOCHEM J, V250, P313, DOI 10.1042/bj2500313; KELLY JA, 1986, SCIENCE, V231, P1429, DOI 10.1126/science.3082007; KELLY JA, 1985, J BIOL CHEM, V260, P6449; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSTU SG, 1974, J BIOL CHEM, V249, P6976; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MALHOTRA KT, 1992, J BIOL CHEM, V267, P11386; MARTIN MT, 1988, BIOCHEM J, V254, P923, DOI 10.1042/bj2540923; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; Matagne A, 1998, BIOCHEM J, V330, P581, DOI 10.1042/bj3300581; MATSUHASHI M, 1979, J BACTERIOL, V137, P644, DOI 10.1128/JB.137.1.644-647.1979; Nelson DE, 2000, J BACTERIOL, V182, P1714, DOI 10.1128/JB.182.6.1714-1721.2000; NICHOLAS RA, 1988, REV INFECT DIS, V10, P733; NICHOLAS RA, 1988, J BIOL CHEM, V263, P2034; NICHOLAS RA, 1985, J BIOL CHEM, V260, P6394; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pares S, 1996, NAT STRUCT BIOL, V3, P284, DOI 10.1038/nsb0396-284; PRATT JM, 1986, EMBO J, V5, P2399, DOI 10.1002/j.1460-2075.1986.tb04510.x; PRATT RF, 1984, P NATL ACAD SCI-BIOL, V81, P1302, DOI 10.1073/pnas.81.5.1302; Rhazi N, 1999, BIOCHEM J, V341, P409, DOI 10.1042/0264-6021:3410409; SAMRAOUI B, 1986, NATURE, V320, P378, DOI 10.1038/320378a0; SPRATT BG, 1975, P NATL ACAD SCI USA, V72, P2999, DOI 10.1073/pnas.72.8.2999; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; VANDERLINDEN MPG, 1994, BIOCHEM J, V303, P357, DOI 10.1042/bj3030357; VANDERLINDEN MPG, 1993, BIOCHEM J, V289, P593, DOI 10.1042/bj2890593; VANDERLINDEN MPG, 1992, EUR J BIOCHEM, V204, P197	49	78	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					616	623		10.1074/jbc.M004471200	http://dx.doi.org/10.1074/jbc.M004471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	10967102	hybrid, Green Published			2022-12-27	WOS:000166280700083
J	Borges, E; Jan, YW; Ruoslahti, E				Borges, E; Jan, YW; Ruoslahti, E			Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta(3) integrin through its extracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; ALPHA(V)BETA(3) INTEGRIN; GLYCOPROTEIN-IIB; ACTIVATION; ADHESION; PROTEIN; PDGF; VITRONECTIN; APOPTOSIS; INSULIN	Integrin-mediated cell attachment and growth factor stimulation often act synergistically on cell proliferation, differentiation, migration, and survival. Some of these synergistic effects depend on the physical interaction of integrins with growth factor receptors, Here we examine the nature of the physical interaction between the alpha (v)beta (3) integrin and two receptor tyrosine kinases (RTKs), the platelet-derived growth factor receptor beta (PDGF-R beta) and the vascular endothelial growth factor receptor 2 (VEGF-R2, also known as KDR and flk-1). Both of these RTKs associate with the alpha (v)beta (3), integrin but do not associate with beta (1) integrins, Furthermore, growth factor stimulation of these RTKs promotes increased cell proliferation and migration when cells are attached to the alpha (v)beta (3) ligand, vitronectin. We show that alpha (v)beta (3) in which the beta (3) cytoplasmic domain is deleted or replaced with the beta (1) cytoplasmic domain coimmunoprecipitates with PDGF-R beta and VEGF-R2, The beta (3) extracellular domain alone was sufficient for the PDGF-R beta association whereas the VEGF-R2 association required the presence of the cu, subunit, Activation of the RTKs by their ligands was not required for them to associate with the integrin, Cell migration to PDGF was enhanced in the cells transfected with the chimeric subunit containing the beta (3) extracellular domain but not when that domain came from the beta (1) subunit, These results show that the interactions that lead to the association of the alpha (v)beta (3) integrin with PDGF-R beta and VEGF-R2 and enhancement of RTK activity take place outside the cell.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Ruoslahti, E (corresponding author), Burnham Inst, Ctr Canc Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA67224, CA30199] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA030199, R01CA067224] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAJT ML, 1992, J BIOL CHEM, V267, P22211; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CLARK EA, 1995, SCIENCE, V268, P223; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; KOVALENKO M, 1994, CANCER RES, V54, P6106; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Woodard AS, 1998, J CELL SCI, V111, P469; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9	23	231	238	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39867	39873		10.1074/jbc.M007040200	http://dx.doi.org/10.1074/jbc.M007040200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10964931	hybrid			2022-12-27	WOS:000166039500013
J	Karandikar, M; Xu, SC; Cobb, MH				Karandikar, M; Xu, SC; Cobb, MH			MEKK1 binds Raf-1 and the ERK2 cascade components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGEN-ACTIVATED PROTEIN; PHEROMONE RESPONSE PATHWAY; MAP KINASE CASCADE; BETA-GAMMA COMPLEX; SIGNAL-TRANSDUCTION; SACCHAROMYCES-CEREVISIAE; XENOPUS OOCYTES; YEAST; PHOSPHORYLATION; SCAFFOLD	Mitogen-activated protein (MAP) kinase cascades are involved in transmitting signals that are generated at the cell surface into the cytosol and nucleus and consist of three sequentially acting enzymes: a MAP kinase, an upstream MAP/extracellular signal-regulated protein kinase (ERK) kinase (MEK), and a MEK kinase (MEKK), Protein-protein interactions within these cascades provide a mechanism to control the localization and function of the proteins. MEKK1 is implicated in activation of the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and ERK1/2 MAP kinase pathways. We showed previously that MEKK1 binds directly to JNR/SAPK. In this study we demonstrate that endogenous MEKK1 binds to endogenous ERK2, MEK1, and another MEKK level kinase, Raf-1, suggesting that it can assemble all three proteins of the ERK2 MAP kinase module.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75216 USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056498] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34128] Funding Source: Medline; NIGMS NIH HHS [GM56498] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akada R, 1996, GENETICS, V143, P103; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; CHOI KY, 1994, CELL, V78, P499; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; ERREDE B, 1995, MOL REPROD DEV, V42, P477, DOI 10.1002/mrd.1080420416; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mochly-Rosen D, 2000, SEMIN IMMUNOL, V12, P55, DOI 10.1006/smim.2000.0207; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Nishina H, 1999, DEVELOPMENT, V126, P505; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; PRINTEN JA, 1994, GENETICS, V138, P609; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SPRAGUE GF, 1993, MOL BIOL YEAST SACCH; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; YASHAR B, 1995, MOL CELL BIOL, V15, P6545; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876	69	93	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40120	40127		10.1074/jbc.M005926200	http://dx.doi.org/10.1074/jbc.M005926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10969079	hybrid			2022-12-27	WOS:000166039500045
J	Sandoval, IV; Martinez-Arca, S; Valdueza, J; Palacios, S; Holman, GD				Sandoval, IV; Martinez-Arca, S; Valdueza, J; Palacios, S; Holman, GD			Distinct reading of different structural determinants modulates the dileucine-mediated transport steps of the lysosomal membrane protein LIMPII and the insulin-sensitive glucose transporter GLUT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DI-LEUCINE MOTIF; MANNOSE 6-PHOSPHATE RECEPTOR; FACTOR-II RECEPTOR; LEU-LEU SEQUENCE; DOWN-REGULATION; CARBOXYL-TERMINUS; CYTOPLASMIC DOMAIN; TRAFFICKING KINETICS; SORTING SIGNALS; HIV-1 NEF	Leucine-based motifs mediate the sorting of membrane proteins at such cellular sites as the trans-Golgi network, endosomes, and plasma membrane. A Leu paired with a second Leu, He, or Met, while itself lacking the ability to mediate transport, is the key structural feature in these motifs, Here we have studied the structural differences between the leucine-based motifs contained in the COOH tails of LIMPII and GLUT4, two membrane proteins that are transported through the secretory pathway and are targeted to lysosomes (1-3) and to a perinuclear compartment adjacent to the Golgi complex (4), respectively. LIMPII and GLUT4 display negatively (Asp(470)/Glu(471)) and positively (Arg(484)/Ar-485) charged residues, respectively, at positions -4 and -5 upstream from the critical Leu residue. The change in the charge sign of residues -4 and -5 results in missorting of LIMPII and GLUT4. We note that the acidic Glu residue at position -4 is critical for efficient intracellular sorting of LIMPII to lysosomes, but is dispensable for its surface internalization by endocytosis. Efficient intracellular sorting and endocytosis of GLUT4 require an Arg pair between positions -4 and -7. These results are consistent with the existence of distinct leucine-based motifs and provide evidence of their different readings at different cellular sites.	Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Univ Bath, Dept Biochem, Bath BA2 7AY, Avon, England	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); University of Bath	Sandoval, IV (corresponding author), Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, Cantoblanco, E-28049 Madrid, Spain.	isandoval@cbm.uam.es		Holman, Geoffrey/0000-0001-7045-1358				Abe H, 1998, J VET MED SCI, V60, P769, DOI 10.1292/jvms.60.769; Araki S, 1996, BIOCHEM J, V315, P153, DOI 10.1042/bj3150153; BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Bresnahan PA, 1998, CURR BIOL, V8, P1235, DOI 10.1016/S0960-9822(07)00517-9; Brodsky FM, 1997, TRENDS CELL BIOL, V7, P175, DOI 10.1016/S0962-8924(97)01038-6; CAMPS M, 1994, ENDOCRINOLOGY, V134, P924, DOI 10.1210/en.134.2.924; CARLSSON SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P630, DOI 10.1016/0003-9861(92)90619-8; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Geisler C, 1998, J BIOL CHEM, V273, P21316, DOI 10.1074/jbc.273.33.21316; Gillingham AK, 1999, J CELL SCI, V112, P4793; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Haft CR, 1998, ENDOCRINOLOGY, V139, P1618, DOI 10.1210/en.139.4.1618; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Hein C, 1997, MOL MICROBIOL, V24, P607, DOI 10.1046/j.1365-2958.1997.3771735.x; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; Johnson AO, 1998, J BIOL CHEM, V273, P17968, DOI 10.1074/jbc.273.28.17968; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Karlsson K, 1998, J BIOL CHEM, V273, P18966, DOI 10.1074/jbc.273.30.18966; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Koumanov F, 1998, BIOCHEM J, V330, P1209, DOI 10.1042/bj3301209; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWON BS, 1995, NUCLEIC ACIDS RES, V23, P154, DOI 10.1093/nar/23.1.154; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Martinez-Arca S, 2000, J CELL SCI, V113, P1705; Melvin DR, 1999, BIOCHEMISTRY-US, V38, P1456, DOI 10.1021/bi980988y; OGATA S, 1994, J BIOL CHEM, V269, P5210; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Petris MJ, 1998, HUM MOL GENET, V7, P2063, DOI 10.1093/hmg/7.13.2063; PIPER RC, 1991, AM J PHYSIOL, V247, pE726; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Ralston E, 1996, J CELL SCI, V109, P2967; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Ross SA, 1997, BIOCHEM BIOPH RES CO, V239, P247, DOI 10.1006/bbrc.1997.7459; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Sheikh H, 1996, J BIOL CHEM, V271, P12185, DOI 10.1074/jbc.271.21.12185; SHIN JY, 1991, J BIOL CHEM, V266, P10658; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Sumitani S, 1997, ENDOCRINOLOGY, V138, P1029, DOI 10.1210/en.138.3.1029; Tan PK, 1998, J BIOL CHEM, V273, P17351, DOI 10.1074/jbc.273.28.17351; Traub LM, 1997, TRENDS CELL BIOL, V7, P43, DOI 10.1016/S0962-8924(96)20042-X; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; VIJAYASARADHI S, 1995, J CELL BIOL, V130, P807, DOI 10.1083/jcb.130.4.807; Vowels JJ, 1998, EMBO J, V17, P2482, DOI 10.1093/emboj/17.9.2482	71	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39874	39885		10.1074/jbc.M006261200	http://dx.doi.org/10.1074/jbc.M006261200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10973972	hybrid			2022-12-27	WOS:000166039500014
J	Bagheri-Yarmand, R; Vadlamudi, RK; Wang, RA; Mendelsohn, J; Kumar, R				Bagheri-Yarmand, R; Vadlamudi, RK; Wang, RA; Mendelsohn, J; Kumar, R			Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta 1-mediated angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; RECEPTOR TYROSINE KINASES; DIFFERENTIATION FACTOR; ERBB RECEPTORS; TUMOR-CELLS; EXPRESSION; MICE; GLYCOPROTEIN; ACTIVATION; INDUCTION	Heregulin-beta1 promotes the activation of p21-activated kinase 1 (Pak1) and the motility and invasiveness of breast cancer cells. In this study, we identified vascular endothelial growth factor (VEGF) as a gene product induced by heregulin-beta1, The stimulation by heregulin-beta1 of breast cancer epithelial cells induced the expression of the VEGF mRNA and protein and its promoter activity. Heregulin-beta1 also stimulated angiogenesis in a VEGF-dependent manner. Herceptin, an anti-HER2 antibody inhibited heregulin-beta1-mediated stimulation of both VEGF expression in epithelial cells and angiogenesis in endothelial cells. Because the activation of Pak1 and VEGF expression are positively regulated by heregulin-beta1, we hypothesized that Pak1 regulates VEGF expression, and hence explored the role of Pak1 in angiogenesis,We provide new evidence to implicate Pak1 signaling in VEGF expression. Overexpression of a kinase-dead K299R Pak1 leads to suppression of VEGF promoter activity, as well as VEGF mRNA expression and secretion of VEGF protein. Conversely, kinase-active T423E Pak1 promotes the expression and secretion of VEGF. Furthermore, expression of the heregulin-beta1 transgene, HRG, in harderian tumors in mice enhances the activation of Pak1 as well as expression of VEGF and angiogenic marker CD34 antigen. These results suggest that heregulin-beta1 regulates angiogenesis via up-regulation of VEGF expression and that Pak1 plays an important role in controlling VEGF expression and, consequently, VEGF secretion and function.	Univ Texas, MD Anderson Canc Ctr 108, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr 108, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Wang, Brian/HGA-9535-2022	Bagheri-Yarmand, Rozita/0000-0001-5139-6381	NCI NIH HHS [CA80066, CA65746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA065746, R01CA065746, R01CA080066] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Bagheri-Yarmand R, 1999, CANCER RES, V59, P507; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FIDLER IJ, 1995, J NATL CANCER I, V87, P1588, DOI 10.1093/jnci/87.21.1588; FINA L, 1990, BLOOD, V75, P2417; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; ITO A, 1995, LAB INVEST, V72, P532; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; Krane IM, 1996, ONCOGENE, V12, P1781; Kumar R, 1996, CLIN CANCER RES, V2, P1215; KUMAR R, 2000, IN PRESS SEMIN ONCOL; KUMAR R, 1995, J CELL BIOCHEM, V62, P102; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Petit AMV, 1997, AM J PATHOL, V151, P1523; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; RAK J, 1995, CANCER RES, V55, P4575; Russell KS, 1999, AM J PHYSIOL-HEART C, V277, pH2205, DOI 10.1152/ajpheart.1999.277.6.H2205; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tang CK, 1996, CANCER RES, V56, P3350; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Wang DG, 1999, CANCER RES, V59, P1464; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	35	99	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39451	39457		10.1074/jbc.M006150200	http://dx.doi.org/10.1074/jbc.M006150200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10967114	hybrid			2022-12-27	WOS:000165953100070
J	Charsky, CMH; Schumann, NJ; Kane, PM				Charsky, CMH; Schumann, NJ; Kane, PM			Mutational analysis of subunit G (Vma10p) of the yeast vacuolar H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; V-TYPE ATPASE; ESCHERICHIA-COLI; B-SUBUNIT; ADENOSINE-TRIPHOSPHATASES; SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; SYNTHASE; F1-ATPASE; ROTATION	The G subunit of V-ATPases is a soluble subunit that shows homology with the b subunit of F-ATPases and may be part of the "stator'' stalk connecting the peripheral V-1 and membrane V-0 sectors. When the N-terminal half of the G subunit is modeled as an or helix, most of the conserved residues fall on one face of the helix (Hunt, I. E., and Bowman, B. J. (1997) J. Bioenerg. Biomembr. 29, 533-540). We probed the function of this region by site-directed mutagenesis of the yeast VMA10 gene. Stable Gr subunits were produced in the presence of Y46A and K55A mutations, but subunit E was destabilized, resulting in loss of the V-ATPase assembly. Mutations E14A and K50A allowed wild-type growth and assembly of V-ATPase complexes, but the complexes formed were unstable. Mutations R25A and R25L stabilized V-ATPase complexes relative to wild-type and partially inhibited disassembly of V, from V, in response to glucose deprivation even though the mutant enzymes were fully active. A 2-amino acid deletion in the middle of the predicted N-terminal helix (Delta Q29D30) allowed assembly of a functional V-ATPase. The results indicate that, although the N-terminal half of the G subunit is essential for V-ATPase activity, either this region is not a rigid helix or the presence of a continuous, conserved face of the helix is not essential.	SUNY, Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; SUNY Maritime College	Kane, PM (corresponding author), SUNY, Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.	kanepm@mail.upstate.edu			NIGMS NIH HHS [R01 GM050322, R01-GM50322] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boekema EJ, 1999, NATURE, V401, P37, DOI 10.1038/43369; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Bottcher B, 2000, J MOL BIOL, V296, P449, DOI 10.1006/jmbi.1999.3435; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1992, J BIOL CHEM, V267, P7630; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; HALLBERG EM, 1993, MOL CELL BIOL, V13, P3050, DOI 10.1128/MCB.13.5.3050; HO MN, 1993, J BIOL CHEM, V268, P221; Hunt IE, 1997, J BIOENERG BIOMEMBR, V29, P533, DOI 10.1023/A:1022474816665; Kane PM, 2000, FEBS LETT, V469, P137, DOI 10.1016/S0014-5793(00)01265-5; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Margolles-Clark E, 1999, J BIOENERG BIOMEMBR, V31, P29, DOI 10.1023/A:1005440412633; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SHERMAN F, 1982, METHODS YEAST GENETI, P177; SIKORSKI RS, 1989, GENETICS, V122, P19; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; Sorgen PL, 1999, J BIOL CHEM, V274, P36261, DOI 10.1074/jbc.274.51.36261; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Supekova L, 1996, J EXP BIOL, V199, P1147; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 1998, BBA-BIOENERGETICS, V1365, P93, DOI 10.1016/S0005-2728(98)00048-6; Xie XS, 1996, J BIOL CHEM, V271, P30980; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909	49	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37232	37239		10.1074/jbc.M006640200	http://dx.doi.org/10.1074/jbc.M006640200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10969085	hybrid			2022-12-27	WOS:000165577700106
J	Wu, HJ; Xu, H; Miraglia, LJ; Crooke, ST				Wu, HJ; Xu, H; Miraglia, LJ; Crooke, ST			Human RNase III is a 160-kDa protein involved in preribosomal RNA processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNAS; COLI RIBONUCLEASE-III; PRE-RIBOSOMAL-RNA; ESCHERICHIA-COLI; STRANDED-RNA; S-POMBE; GENE; SEQUENCE; SPLICEOSOME; SNRNA	A human RNase III gene encodes a protein of 160 kDa with multiple domains, a proline-rich, a serine- and arginine-rich, and an RNase III domain. The expressed purified RNase III domain cleaves double-strand RNA and does not cleave single-strand RNA. The gene is ubiquitously expressed in human tissues and cell lines, and the protein is localized in the nucleus of the cell, The levels of transcription and translation of the protein do not change during different phases of the cell cycle. However, a significant fraction of the protein in the nucleus is translocated to the nucleolus during the S phase of the cell cycle, That this human RNase III is involved in processing of pre-rRNA, but might cleave at sites different from those described for yeast RNase III, is shown by antisense inhibition of RNase III expression. Inhibition of human RNase III expression causes cell death, suggesting an essential role for human RNase III in the cell. The antisense inhibition technique used in this study provides an effective method for functional analysis of newly identified human genes.	ISIS Pharmaceut, Dept Biol Struct, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Crooke, ST (corresponding author), ISIS Pharmaceut, Dept Biol Struct, 2292 Faraday Ave, Carlsbad, CA 92008 USA.	scrooke@isisph.com						AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; ANASTASSOVAKRISTEVA M, 1977, J CELL SCI, V25, P103; ARES M, 1995, PROG NUCLEIC ACID RE, V50, P131, DOI 10.1016/S0079-6603(08)60813-2; ARRAIANO CM, 1993, WORLD J MICROB BIOT, V9, P421, DOI 10.1007/BF00328030; BRAM RJ, 1980, CELL, V19, P393, DOI 10.1016/0092-8674(80)90513-9; Chanfreau C, 2000, P NATL ACAD SCI USA, V97, P3142, DOI 10.1073/pnas.070043997; Chanfreau G, 1997, GENE DEV, V11, P2741, DOI 10.1101/gad.11.20.2741; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; Court D. L., 1993, CONTROL MESSENGER RN, P71; CROOKE ST, 1998, ANTISENSE RES APPL; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUNN JJ, 1976, J BIOL CHEM, V251, P3807; Elela SA, 1998, EMBO J, V17, P3738, DOI 10.1093/emboj/17.13.3738; Filippov V, 2000, GENE, V245, P213, DOI 10.1016/S0378-1119(99)00571-5; FU XD, 1995, RNA, V1, P663; GEGENHEIMER P, 1977, J BIOL CHEM, V252, P3064; GONZALEZ IL, 1990, J MOL BIOL, V212, P27, DOI 10.1016/0022-2836(90)90302-3; HADJIOLOVA KV, 1993, EUR J BIOCHEM, V212, P211, DOI 10.1111/j.1432-1033.1993.tb17652.x; Harlow E., 1988, ANTIBODIES LAB MANUA; IINO Y, 1991, EMBO J, V10, P221, DOI 10.1002/j.1460-2075.1991.tb07939.x; Johnson R. T., 1993, CELL CYCLE PRACTICAL, P1; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KINGSTON R, 1997, CURRENT PROTOCOLS MO, V1; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kufel J, 1999, RNA, V5, P909, DOI 10.1017/S135583829999026X; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MARCH PE, 1985, NUCLEIC ACIDS RES, V13, P4677, DOI 10.1093/nar/13.13.4677; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; NASHIMOTO H, 1985, MOL GEN GENET, V201, P25, DOI 10.1007/BF00397981; NAZAR RN, 1976, BIOCHEMISTRY-US, V15, P505, DOI 10.1021/bi00648a008; Nicholson AW, 1996, PROG NUCLEIC ACID RE, V52, P1, DOI 10.1016/S0079-6603(08)60963-0; Qu LH, 1999, MOL CELL BIOL, V19, P1144; ROBERTSON HD, 1990, METHOD ENZYMOL, V181, P189; ROBERTSON HD, 1968, J BIOL CHEM, V243, P82; Santos JM, 1997, FEMS MICROBIOL LETT, V157, P31, DOI 10.1111/j.1574-6968.1997.tb12749.x; Seipelt RL, 1999, NUCLEIC ACIDS RES, V27, P587, DOI 10.1093/nar/27.2.587; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Tollervey D, 1996, SCIENCE, V273, P1056, DOI 10.1126/science.273.5278.1056; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; Wang W, 1997, J BACTERIOL, V179, P7379, DOI 10.1128/jb.179.23.7379-7385.1997; WATSON N, 1985, P NATL ACAD SCI USA, V82, P849, DOI 10.1073/pnas.82.3.849; XU HP, 1990, NUCLEIC ACIDS RES, V18, P5304, DOI 10.1093/nar/18.17.5304; Zhang KJ, 1997, P NATL ACAD SCI USA, V94, P13437, DOI 10.1073/pnas.94.25.13437	45	139	161	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36957	36965		10.1074/jbc.M005494200	http://dx.doi.org/10.1074/jbc.M005494200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10948199	hybrid			2022-12-27	WOS:000165577700072
J	Hemmens, B; Goessler, W; Schmidt, K; Mayer, B				Hemmens, B; Goessler, W; Schmidt, K; Mayer, B			Role of bound zinc in dimer stabilization but not enzyme activity of neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAHYDROBIOPTERIN BINDING; SUBUNIT DIMERIZATION; PTERIN-BINDING; HEME DOMAIN; BRAIN; SUBSTRATE; REQUIREMENT; CATALYSIS; REVEALS; OXYGEN	Nitric-oxide synthases (NOS) are homodimeric proteins and dan form an intersubunit Zn(4S) cluster. We have measured zinc bound to NOS purified from pig brain (0.6 mol/mol of NOS) and baculovirus-expressed rat neuronal NOS (nNOS) (0.49 +/- 0.13 mol/mol of NOS), by on-line gel-filtration/inductively coupled plasma mass spectrometry, Cobalt, manganese, molybdenum, nickel, and vanadium were all undetectable, Baculovirus-expressed nNOS also bound up to 2.00 +/- 0.58 mel of copper/mol of NOS. Diethylenetriaminepentaacetic acid (DTPA) reduced the bound zinc to 0.28 +/- 0.07 and the copper to 0.97 +/- 0.24 mol/mol of NOS. Desalting of samples into thiol-free buffer did not affect the zinc content but completely eliminated the bound copper (less than or equal to0.02 mol/mol of NOS). Most (greater than or equal to 75%) of the bound zinc was released from baculovirus-expressed rat nNOS by p-chloromercuriphenylsulfonic acid (PMPS), PMPS-treated nNOS was strongly (90 +/- 5%) inactivated. To isolate functional effects of zinc release from other effects of PMPS, PMPS-substituted thiols were unblocked by excess reduced thiol in the presence of DTPA, which hindered reincorporation of zinc. The resulting enzyme contained 0.12 +/- 0.05 mel of zinc but had a specific activity of 426 +/- 46 nmol of citrulline.mg(-1).min(-1), corresponding to 93 +/- 10% of non-PMPS-treated controls. PMPS also caused dissociation of nNOS dimers under native conditions, an effect that was blocked by the pteridine cofactor tetrahydrobiopterin (H-4 biopterin). H(4)biopterin did not affect zinc release. Even in the presence of H(4)biopterin, PMPS prevented conversion of NOS dimers to an SDS-resistant form. We conclude that zinc binding is a prerequisite for formation of SDS-resistant NOS dimers but is not essential for catalysis.	Graz Univ, Inst Pharmacol & Toxicol, A-8010 Graz, Austria; Graz Univ, Inst Chem, A-8010 Graz, Austria	University of Graz; University of Graz	Mayer, B (corresponding author), Graz Univ, Inst Pharmacol & Toxicol, Univ Pl 2, A-8010 Graz, Austria.	mayer@kfunigraz.ac.at	Mayer, Bernd/B-9391-2008; Goessler, Walter/A-1084-2016	Goessler, Walter/0000-0002-0142-9373; Mayer, Bernd/0000-0002-2921-3494				ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; CHENG KL, 1982, CRC HDB ORGANIC ANAL, P213; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Ghosh DK, 1999, EMBO J, V18, P6260, DOI 10.1093/emboj/18.22.6260; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Gorren ACF, 1997, BIOCHEMISTRY-US, V36, P4360, DOI 10.1021/bi962381s; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; Griep MA, 1996, BIOCHEMISTRY-US, V35, P8260, DOI 10.1021/bi952948p; Hemmens B, 1998, BIOCHEM J, V332, P337, DOI 10.1042/bj3320337; HOFMANN H, 1995, BIOCHEMISTRY-US, V34, P13443, DOI 10.1021/bi00041a023; HUNT JB, 1984, J BIOL CHEM, V259, P4793; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leber A, 1999, J BIOL CHEM, V274, P37658, DOI 10.1074/jbc.274.53.37658; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; List BM, 1996, BIOCHEM J, V315, P57, DOI 10.1042/bj3150057; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; Martasek P, 1998, J BIOL CHEM, V273, P34799, DOI 10.1074/jbc.273.52.34799; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1994, NEUROPHARMACOLOGY, V33, P1253, DOI 10.1016/0028-3908(94)90024-8; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Miller RT, 1999, J BIOL CHEM, V274, P14537, DOI 10.1074/jbc.274.21.14537; Perry JM, 1998, P NATL ACAD SCI USA, V95, P11101, DOI 10.1073/pnas.95.19.11101; Pfeiffer S, 1997, BIOCHEM J, V328, P349, DOI 10.1042/bj3280349; Pfeiffer S, 1999, ANGEW CHEM INT EDIT, V38, P1715, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1714::AID-ANIE1714>3.0.CO;2-3; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; QIU HW, 1994, J BIOL CHEM, V269, P2773; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Riethmuller C, 1999, J BIOL CHEM, V274, P16047, DOI 10.1074/jbc.274.23.16047; Rodriguez-Crespo I, 1999, J BIOL CHEM, V274, P21617, DOI 10.1074/jbc.274.31.21617; Sono M, 1999, BIOCHEMISTRY-US, V38, P15853, DOI 10.1021/bi991580j; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771	42	81	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35786	35791		10.1074/jbc.M005976200	http://dx.doi.org/10.1074/jbc.M005976200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10954720	hybrid			2022-12-27	WOS:000165382000022
J	Picard, V; Govoni, G; Jabado, N; Gros, P				Picard, V; Govoni, G; Jabado, N; Gros, P			Nramp 2 (DCT1/DMT1) expressed at the plasma membrane transports iron and other divalent cations into a calcein-accessible cytoplasmic pool	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; NATURAL-RESISTANCE; TRANSMEMBRANE ORGANIZATION; FUNCTIONAL COMPLEMENTATION; EPITOPE INSERTION; P-GLYCOPROTEIN; PROTEIN; FAMILY; CELLS; GENE	Nrampa, also known as DMT1 and DCT1, is a la-transmembrane (TM) domain protein responsible for dietary iron uptake in the duodenum and iron acquisition from transferrin:in peripheral tissues. Nramp2/DMT1 produces by alternative splicing two isoforms differing at their C terminus (isoforms I and II). The subcellular localization, mechanism of action, and destination of divalent cations transported by the two Nrampa isoforms are not completely understood. Stable CHO transfectants expressing Nramp2 isoform II modified by addition of a hemaglutinin epitope in the loop defined by the TM7-TM8 interval were generated. Immunofluorescence with permeabilized and intact cells established that Nrampa isoform II is expressed at the plasma membrane and demonstrated the predicted extracytoplasmic location of the TM7-TR18 loop. Using the fluorescent, metal-sensitive dye calcein, and a combination of membrane-permeant and -impermeant iron chelators, Nrampa transport was measured and quantitated with respect to kinetic parameters and at steady state. Iron transport at the plasma membrane was time- and pH-dependent, saturable, and proportional to the amount of Nrampa expression. Iron uptake by Nrampa at the plasma membrane was into the nonferritin-bound, calcein-accessible so-called "labile iron pool." Ion selectivity experiments show that Nrampa isoform II can also transport Co2+ and Cd2+ but not Mg2+ into the calcein-accessible pool. Parallel experiments with transfectants expressing the lysosomal Nramp1 homolog do not show any divalent cation transport activity, establishing major functional differences between Nramp1 and Nramp2. Monitoring the effect of Nramp2 on the calcein-sensisitve labile iron pool allows a simple, rapid, and nonisotopic approach to the functional study of this protein.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Gros, P (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond,Rm 907, Montreal, PQ H3G 1Y6, Canada.		Jabado, Nada/AAN-4026-2020	Govoni, Gregory/0000-0002-4664-0834	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035237] Funding Source: NIH RePORTER; NIAID NIH HHS [1 RO1 AI35237-08] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agranoff D, 1999, J EXP MED, V190, P717, DOI 10.1084/jem.190.5.717; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; BREUER W, 1995, AM J PHYSIOL-CELL PH, V268, pC1354, DOI 10.1152/ajpcell.1995.268.6.C1354; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; Canonne-Hergaux F, 1999, BLOOD, V93, P4406, DOI 10.1182/blood.V93.12.4406.412k21_4406_4417; CELLIER M, 1995, P NATL ACAD SCI USA, V92, P10089, DOI 10.1073/pnas.92.22.10089; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chen XZ, 1999, J BIOL CHEM, V274, P35089, DOI 10.1074/jbc.274.49.35089; Curie C, 2000, BIOCHEM J, V347, P479; D'Souza J, 1999, J EXP BIOL, V202, P1909; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; EDWARDS JA, 1972, P SOC EXP BIOL MED, V141, P81; Epsztejn S, 1997, ANAL BIOCHEM, V248, P31, DOI 10.1006/abio.1997.2126; Erdahl WL, 1996, BIOCHEMISTRY-US, V35, P13817, DOI 10.1021/bi961391q; Essodaigui M, 1998, BIOCHEMISTRY-US, V37, P2243, DOI 10.1021/bi9718043; FARCICH EA, 1992, AM J PHYSIOL, V262, pR220, DOI 10.1152/ajpregu.1992.262.2.R220; FARCICH EA, 1992, AM J HEMATOL, V39, P9, DOI 10.1002/ajh.2830390104; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Fleming RE, 1999, P NATL ACAD SCI USA, V96, P3143, DOI 10.1073/pnas.96.6.3143; Govoni G, 1999, INFECT IMMUN, V67, P2225, DOI 10.1128/IAI.67.5.2225-2232.1999; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; GRUENHEID S, 1995, GENOMICS, V25, P514, DOI 10.1016/0888-7543(95)80053-O; Gruenheid S, 1997, J EXP MED, V185, P717, DOI 10.1084/jem.185.4.717; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; Kast C, 1998, BIOCHEMISTRY-US, V37, P2305, DOI 10.1021/bi972332v; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lee PL, 1998, BLOOD CELL MOL DIS, V24, P199, DOI 10.1006/bcmd.1998.0186; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Makui H, 2000, MOL MICROBIOL, V35, P1065, DOI 10.1046/j.1365-2958.2000.01774.x; Moffett P, 1996, GENOMICS, V35, P144, DOI 10.1006/geno.1996.0333; Orgad S, 1998, J EXP BIOL, V201, P115; Picard V, 1998, J BIOL CHEM, V273, P15382, DOI 10.1074/jbc.273.25.15382; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; Ponka P, 1999, KIDNEY INT, V55, pS2, DOI 10.1046/j.1523-1755.1999.055Suppl.69002.x; RUSSELL ES, 1970, BLOOD-J HEMATOL, V35, P838, DOI 10.1182/blood.V35.6.838.838; Su MA, 1998, BLOOD, V92, P2157, DOI 10.1182/blood.V92.6.2157.418k16_2157_2163; Tabuchi M, 1999, BIOCHEM J, V344, P211, DOI 10.1042/0264-6021:3440211; Tabuchi M, 2000, J BIOL CHEM, V275, P22220, DOI 10.1074/jbc.M001478200; Tandy S, 2000, J BIOL CHEM, V275, P1023, DOI 10.1074/jbc.275.2.1023; van Geest M, 2000, MICROBIOL MOL BIOL R, V64, P13, DOI 10.1128/MMBR.64.1.13-33.2000	43	146	151	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35738	35745		10.1074/jbc.M005387200	http://dx.doi.org/10.1074/jbc.M005387200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10942769	hybrid			2022-12-27	WOS:000165382000016
J	Neaud, V; Hisaka, T; Monvoisin, A; Bedin, C; Balabaud, C; Foster, DC; Desmouliere, A; Kisiel, W; Rosenbaum, J				Neaud, V; Hisaka, T; Monvoisin, A; Bedin, C; Balabaud, C; Foster, DC; Desmouliere, A; Kisiel, W; Rosenbaum, J			Paradoxical pro-invasive effect of the serine proteinase inhibitor tissue factor pathway inhibitor-2 on human hepatocellular carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; EXTRACELLULAR-MATRIX; PROTEASE INHIBITOR; STROMAL CELLS; MYOFIBROBLASTS; DEGRADATION; EXPRESSION; CULTURE; CLONING; LIVER	We have previously shown that human liver myofibroblasts promote in vitro invasion of human hepatocellular carcinoma (HCC) cells through a hepatocyte growth factor (HGF)/urokinase/plasmin-dependent mechanism. In this study, we demonstrate that myofibroblasts synthesize the serine proteinase inhibitor tissue factor pathway inhibitor-2 (TFPI-8). Despite the fact that recombinant TFPI-2 readily inhibits plasmin, we show that it potentiates HGF-induced invasion of HCC cells and is capable of inducing invasion on its own. Furthermore, HCC cells stably transfected with a TFPI-2 expression vector became spontaneously invasive. HCC cells express tissue factor and specifically factor VII, Addition of an antibody to factor VII abolished the pro-invasive effect of TFPI-2. We suggest that TFPI-2 induces invasion following binding to a tissue factor-factor VIIa complex preformed on HCC cells. Our data thus demonstrate an original mechanism of cell invasion that may be specific for liver tumor cells.	Univ Bordeaux 2, INSERM E9917, Grp Rech Etud Foie, F-33076 Bordeaux, France; Zymogenet Inc, Seattle, WA 98105 USA; Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Zymogenet Inc.; University of New Mexico	Rosenbaum, J (corresponding author), Univ Bordeaux 2, INSERM E9917, Grp Rech Etud Foie, F-33076 Bordeaux, France.	jean.rosenbaum@gref.u-bordeaux2.fr	Rosenbaum, Jean/F-5547-2013	Rosenbaum, Jean/0000-0001-8585-5152; Monvoisin, Arnaud/0000-0002-9915-4872	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035246] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-35246] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BAROUKI R, 1984, J BIOL CHEM, V259, P7970; Blazejewski S, 1997, AM J PATHOL, V151, P651; BLAZEJEWSKI S, 1995, HEPATOLOGY, V22, P788, DOI 10.1016/0270-9139(95)90298-8; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; ENZAN H, 1994, HEPATOLOGY, V19, P895, DOI 10.1016/0270-9139(94)90289-5; Faouzi S, 1999, J HEPATOL, V30, P275, DOI 10.1016/S0168-8278(99)80074-9; Fischer EG, 1999, J CLIN INVEST, V104, P1213, DOI 10.1172/JCI7750; Iino M, 1998, ARTERIOSCL THROM VAS, V18, P40, DOI 10.1161/01.ATV.18.1.40; Monvoisin A, 1999, J HEPATOL, V30, P511, DOI 10.1016/S0168-8278(99)80113-5; Neaud V, 1997, HEPATOLOGY, V26, P1458, DOI 10.1002/hep.510260612; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; Rao CN, 1996, ARCH BIOCHEM BIOPHYS, V335, P82, DOI 10.1006/abbi.1996.0484; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V317, P311, DOI 10.1006/abbi.1995.1168; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Shinoda E, 1999, J BIOL CHEM, V274, P5379, DOI 10.1074/jbc.274.9.5379; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Terada T, 1996, J HEPATOL, V24, P706; Toi M, 1998, BREAST CANCER RES TR, V52, P113, DOI 10.1023/A:1006167202856; WILDGOOSE P, 1989, BLOOD, V73, P1888; WIN KM, 1993, HEPATOLOGY, V18, P137, DOI 10.1002/hep.1840180121	25	44	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35565	35569		10.1074/jbc.M006101200	http://dx.doi.org/10.1074/jbc.M006101200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10954721	hybrid			2022-12-27	WOS:000165422800096
J	Schumacher, MA; Goodman, RH; Brennan, RG				Schumacher, MA; Goodman, RH; Brennan, RG			The structure of a CREB bZIP center dot somatostatin CRE complex reveals the basis for selective dimerization and divalent cation-enhanced DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGION LEUCINE-ZIPPER; X-RAY-STRUCTURE; CRYSTAL-STRUCTURE; PROTEIN; TRANSCRIPTION; RECOGNITION; REPLACEMENT; REPRESSOR; MAGNESIUM; ANGSTROM	The cAMP responsive element-binding protein (CREB) is central to second messenger regulated transcription. To elucidate the structural mechanisms of DNA binding and selective dimerization of CREB, we determined to 3.0 Angstrom resolution, the structure of the CREB bZIP, (residues 283-341) bound to a 21-base pair deoxynucleotide that encompasses the canonical 8-base pair somatostatin cAMP response element (SSCRE), The CREB dimer is stabilized in part by ionic interactions from -Arg(314) to Glu(319') and Glu(328) to, Lys(333') as,,well as a hydrogen bond network that links the carboxamide side chains of Gln(322') -Asn(321)-Asn(321')-Gln(322). Critical to family selective dimerization are intersubunit hydrogen bonds between basic-region residue Tyr(307) and leucine zipper residue: Glu(312), which are conserved in all CREB/CREM/ ATF-1: family members. Strikingly, the structure reveals a hexahydrated Mg2+ ion bound in the cavity between the basic region and SSCRE that makes a water-mediated:DNA contact. DNA binding studies demonstrate that Mg2+ ions enhance CREB bZIP:SSCRE binding by more than 25-fold and suggest a possible physiological role for this ion in somatostatin cAMP response element and potentially other CRE-mediated gene expression.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Brennan, RG (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	brennanr@ohsu.edu		Brennan, Richard/0000-0001-7647-485X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bock CW, 1999, J AM CHEM SOC, V121, P7360, DOI 10.1021/ja9906960; BROCARD JB, 1993, NEURON, V11, P751, DOI 10.1016/0896-6273(93)90084-5; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; De Cesare D, 1999, TRENDS BIOCHEM SCI, V24, P281, DOI 10.1016/S0968-0004(99)01414-0; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P1011, DOI 10.1038/nsb1296-1011; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kato H, 1998, BRAIN RES, V779, P329, DOI 10.1016/S0006-8993(97)01232-8; KELLER W, 1995, J MOL BIOL, V254, P657, DOI 10.1006/jmbi.1995.0645; KERPPOLA T, 1995, NATURE, V373, P199, DOI 10.1038/373199a0; KIM J, 1993, P NATL ACAD SCI USA, V90, P4513, DOI 10.1073/pnas.90.10.4513; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; Oakley MG, 1998, BIOCHEMISTRY-US, V37, P12603, DOI 10.1021/bi981269m; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Parraga A, 1998, STRUCT FOLD DES, V6, P661, DOI 10.1016/S0969-2126(98)00067-7; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SLITANI A, 1998, P NATL ACAD SCI USA, V95, P1404; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647	33	126	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35242	35247		10.1074/jbc.M007293200	http://dx.doi.org/10.1074/jbc.M007293200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10952992	hybrid			2022-12-27	WOS:000165422800056
J	Chen, LY; Lin, BC; Pan, CJ; Hiraiwa, H; Chou, JY				Chen, LY; Lin, BC; Pan, CJ; Hiraiwa, H; Chou, JY			Structural requirements for the stability and microsomal transport activity of the human glucose 6-phosphate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE-DISEASE; PUTATIVE GLUCOSE-6-PHOSPHATE TRANSLOCASE; TRANSMEMBRANE TOPOLOGY; CHROMOSOME 11Q23; GENE; IB; 1B; MUTATION; PROTEIN	Deficiencies in glucose 6-phosphate (G6P) transporter (G6PT), a 10-helical endoplasmic reticulum transmembrane protein of 429 amino acids, cause glycogen storage disease type Ib. To date, only three missense mutations in G6PT have been shown to abolish microsomal G6P transport activity. Here, we report the results of structure-function studies on human G6PT and demonstrate that 15 missense mutations and a codon deletion (Delta F93) mutation abolish microsomal G6P uptake activity and that two splicing mutations cause exon skipping. While most missense mutants support the synthesis of G6PT protein similar to that of the wild-type transporter, immunoblot analysis shows that G20D, Delta F93, and I278N mutations, located in helix 1, 2, and 6, respectively, destabilize the G6PT. Further, we demonstrate that G6PT mutants lacking an intact helix 10 are misfolded and undergo degradation within cells. Moreover, amino acids 415-417 in the cytoplasmic tail of the carboxyl-domain, extending from helix 10, also play a critical role in the correct folding of the transporter. However, the last 12 amino acids of the cytoplasmic tail play no essential role(s) in functional integrity of the G6PT. Our results, for the first time, elucidate the structural requirements for the stability and transport activity of the G6PT protein.	NICHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Chou, JY (corresponding author), NICHD, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S241, Bethesda, MD 20892 USA.	chou@helix.nih.gov	Lin, Baochuan/A-8390-2009	Lin, Baochuan/0000-0002-9484-0785	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000912] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000912] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Annabi B, 1998, AM J HUM GENET, V62, P400, DOI 10.1086/301727; ARION WJ, 1980, J BIOL CHEM, V255, P396; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BEAUDET AL, 1980, J PEDIATR-US, V97, P906, DOI 10.1016/S0022-3476(80)80418-5; Chen Y-T, 1995, METABOLIC MOL BASES, P935; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chou JY, 1999, TRENDS ENDOCRIN MET, V10, P104; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; Galli L, 1999, FEBS LETT, V459, P255, DOI 10.1016/S0014-5793(99)01248-X; Gerin I, 1999, GENE, V227, P189, DOI 10.1016/S0378-1119(98)00614-3; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; GITZELMANN R, 1993, EUR J PEDIATR, V152, pS33; Hardesty Boyd, 1999, Current Opinion in Structural Biology, V9, P111, DOI 10.1016/S0959-440X(99)80014-1; Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532; Hou DC, 1999, AM J MED GENET, V86, P253, DOI 10.1002/(SICI)1096-8628(19990917)86:3<253::AID-AJMG11>3.0.CO;2-7; Ihara K, 1998, HUM GENET, V103, P493, DOI 10.1007/s004390050856; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; Kure S, 1998, BIOCHEM BIOPH RES CO, V248, P426, DOI 10.1006/bbrc.1998.8985; Lam C W, 2000, Hum Mutat, V16, P94, DOI 10.1002/1098-1004(200007)16:1<94::AID-HUMU26>3.0.CO;2-Q; LEI KJ, 1995, J BIOL CHEM, V270, P11882, DOI 10.1074/jbc.270.20.11882; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; Marcolongo P, 1998, FEBS LETT, V436, P247, DOI 10.1016/S0014-5793(98)01129-6; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Pan CJ, 1999, J BIOL CHEM, V274, P13865, DOI 10.1074/jbc.274.20.13865; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Veiga-Da-Cunha M, 1999, EUR J HUM GENET, V7, P717, DOI 10.1038/sj.ejhg.5200366; Veiga-da-Cunha M, 1998, AM J HUM GENET, V63, P976, DOI 10.1086/302068; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888	30	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34280	34286		10.1074/jbc.M006439200	http://dx.doi.org/10.1074/jbc.M006439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10940311	hybrid			2022-12-27	WOS:000165095300040
J	MacDonald, MJ; Fahien, LA				MacDonald, MJ; Fahien, LA			Glutamate is not a messenger in insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLETS; AMINO-ACID; METHYL SUCCINATE; L-LEUCINE; RELEASE; METABOLISM; DEHYDROGENASE; GLUCOSE; PYRUVATE; SECRETAGOGUES	Experiments do not support a recent claim that glutamate formed from the amination of citric acid cycle-derived alpha -ketoglutarate is a messenger in glucose-induced insulin secretion (Maechler, P., and Wollheim, C. (1999) Nature 402, 685-689), Glucose, leucine, succinic acid methyl ester, and alpha -ketoisocaproic acid all markedly stimulate insulin release but do not increase glutamate levels in pancreatic islets, Increasing the intracellular glutamate levels to 10-fold higher than basal levels by adding glutamine to islets does not stimulate insulin release. When leucine, in addition to glutamine, is applied to islets, insulin release is almost as high as with glucose alone. This is consistent with the known ability of leucine to allosterically activate glutamate deamination by glutamate dehydrogenase, which can supply alpha -ketoglutarate to the citric acid cycle. Experiments with mitochondria from pancreatic islets suggest that flux through the glutamate dehydrogenase reaction is quiescent during glucose-induced insulin secretion. These experiments support the traditional idea that when insulin release is associated with flux through glutamate dehydrogenase, the flux is in the direction of alpha -ketoglutarate.	Univ Wisconsin, Sch Med, Childrens Diabet Ctr, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	MacDonald, MJ (corresponding author), Med Sci Ctr, Rm 3459,1300 Univ Ave, Madison, WI 53706 USA.				NIDDK NIH HHS [DK28438] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DANIELSSON B, 1970, HORM METAB RES, V2, P28; FAHIEN LA, 1990, MOL PHARMACOL, V37, P943; FAHIEN LA, 1992, J BIOL CHEM, V267, P10411; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; Frieden C., 1963, ENZYMES 7, P3; Gao Z, 1999, DIABETES, V48, P1535, DOI 10.2337/diabetes.48.8.1535; GYLFE E, 1976, ACTA DIABETOL LAT, V13, P20, DOI 10.1007/BF02591577; Khan A, 1996, J BIOL CHEM, V271, P2539, DOI 10.1074/jbc.271.5.2539; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD MJ, 1991, J BIOL CHEM, V266, P1335; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P201, DOI 10.1006/abbi.1993.1028; MACDONALD MJ, 1990, AM J PHYSIOL, V259, pE548, DOI 10.1152/ajpendo.1990.259.4.E548; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P205, DOI 10.1006/abbi.1993.1413; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; MALAISSE WJ, 1984, BIOCHIM BIOPHYS ACTA, V797, P194, DOI 10.1016/0304-4165(84)90122-3; MALAISSE WJ, 1982, J BIOL CHEM, V257, P8731; PACE CS, 1975, DIABETES, V24, P476, DOI 10.2337/diabetes.24.5.476; PANTEN U, 1984, BIOCHEM J, V219, P189, DOI 10.1042/bj2190189; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; SENER A, 1981, P NATL ACAD SCI-BIOL, V78, P5460, DOI 10.1073/pnas.78.9.5460; Stanley CA, 2000, DIABETES, V49, P667, DOI 10.2337/diabetes.49.4.667; TRUS M, 1980, DIABETES, V29, P1, DOI 10.2337/diabetes.29.1.1; Williamson D. H., 1974, METHODS ENZYMATIC AN, P2266, DOI [10.1016/B978-0-12-091304-6.50093-8, DOI 10.1016/B978-0-12-091304-6.50093-8]; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514	26	122	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34025	34027		10.1074/jbc.C000411200	http://dx.doi.org/10.1074/jbc.C000411200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10967090	hybrid			2022-12-27	WOS:000165095300005
J	Pedersen, LC; Tsuchida, K; Kitagawa, H; Sugahara, K; Darden, TA; Negishi, M				Pedersen, LC; Tsuchida, K; Kitagawa, H; Sugahara, K; Darden, TA; Negishi, M			Heparan/chondroitin sulfate biosynthesis - Structure and mechanism of human glucuronyltransferase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE-REGION; HEPARAN-SULFATE; N-ACETYLGALACTOSAMINE; MAST-CELLS; GLYCOSYLTRANSFERASES; DROSOPHILA; ENZYME; DOMAIN; PROTEOGLYCANS; ENCODES	Human beta1,3-glucuronyltransferase I (GlcAT-I) is a central enzyme in the initial steps of proteoglycan synthesis. GlcAT-I transfers a glucuronic acid moiety from the uridine diphosphate-glucuronic acid (UDP-GlcUA) to the common linkage region trisaccharide Gal beta1-3Gal beta1-4Xyl covalently bound to a Ser residue at the glycosaminylglycan attachment site of proteoglycans, We have now determined the crystal structure of GlcAT-I at 2.3 Angstrom in the presence of the donor substrate product UDP, the catalytic Mn2+ ion, and the acceptor substrate analog Gal beta1-3Gal beta1-4Xyl, The enzyme is a alpha/beta protein with two subdomains that constitute the donor and acceptor substrate binding site. The active site residues lie in a cleft extending across both subdomains in which the trisaccharide molecule is oriented perpendicular to the UDP. Residues Glu(227), Asp(252), and Glu(281) dictate the binding orientation of the terminal Gal-2 moiety. Residue Glu(281) is in position to function as a catalytic base by deprotonating the incoming 3-hydroxyl group of the acceptor. The conserved DXD motif (Asp(191), Asp(195), Asp(196)) has direct interaction with the ribose of the UDP molecule as well as with the Mn2+ ion. The key residues involved in substrate binding and catalysis are conserved in the glucuronyltransferase family as well as of her glycosyltransferases.	NIEHS, Reprod & Dev Toxicol Lab, Pharmacogenet Sect, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6858858, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Kobe Pharmaceutical University	Negishi, M (corresponding author), NIEHS, Reprod & Dev Toxicol Lab, Pharmacogenet Sect, NIH, Res Triangle Pk, NC 27709 USA.	negishi@niehs.nih.gov	Kitagawa, Hiroshi/AAJ-1344-2020; Pedersen, Lars/C-6173-2019; Negishi, Masahiko/F-7805-2019	Kitagawa, Hiroshi/0000-0002-9307-7079; Pedersen, Lars/0000-0002-4488-4077; Negishi, Masahiko/0000-0002-2076-8928	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071005] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; *CCP4 SUIT, 1994, COMPUTATIONAL PROJ D, V50, P760; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; DEANGELIS PL, 2000, IN PRESS J BIOL CHEM; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murray BW, 1996, BIOCHEMISTRY-US, V35, P11183, DOI 10.1021/bi961065a; Nadanaka S, 1999, BIOCHEM J, V340, P353, DOI 10.1042/0264-6021:3400353; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OUZZINE M, 2000, IN PRESS J BIOL CHEM; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; Tone Y, 1999, FEBS LETT, V459, P415, DOI 10.1016/S0014-5793(99)01287-9; Tsuchida K, 1999, EUR J BIOCHEM, V264, P461, DOI 10.1046/j.1432-1327.1999.00635.x; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170	32	164	170	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34580	34585		10.1074/jbc.M007399200	http://dx.doi.org/10.1074/jbc.M007399200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10946001	hybrid			2022-12-27	WOS:000165095300079
J	Yu, XF; Weissman, SM				Yu, XF; Weissman, SM			Characterization of the promoter of human leukocyte-specific transcript 1 - A small gene with a complex pattern of alternative transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; FACTOR PU.1; TNF REGION; ETS FAMILY; EXPRESSION; PROTEIN; BINDING; MEMBER; POLYMORPHISM; NF-IL6	The gene for the human leukocyte-specific transcript 1 (LST1) encodes a small protein that modulates immune responses and cellular morphogenesis. The LST1 transcripts are expressed at high levels in dendritic cells. Because of the complex splicing pattern, use of alternative 5'-untranslated exons, and a biologically interesting pattern of expression of LST1 mRNA, we studied the human LST1 gene promoter and regulatory elements. We identified an additional upstream 5'-untranslated exon in U937 monocytic cells. Transient transfection studies demonstrated that the combination of regions from -1363 to -621 with -112 to -54, relative to the translation start codon, produced the highest level of transcripts from among the various constructs tested, but the pattern of transcripts produced was only a subset of those produced from the endogenous gene. DNase I footprinting analysis and electrophoretic mobility shift assays showed that oligonucleotide probes corresponding to three regions, -1171 to -1142 (BI), -1136 to -1111 (BII), and -783 to -751 (BTV), bound proteins in U937 nuclear extracts. Competition and supershift electrophoretic mobility shift assay did not identify any known transcription factors responsible for BII probe binding. These studies suggest that a novel DNA-binding site and interaction of multiple regulatory elements may be involved in mediating the expression of the various forms of LST1 mRNA.	Yale Univ, Sch Med, Dept Genet, Boyer Ctr Mol Med, New Haven, CT 06510 USA	Yale University	Weissman, SM (corresponding author), Yale Univ, Sch Med, Dept Genet, Boyer Ctr Mol Med, 295 Congress Ave, New Haven, CT 06510 USA.				NHLBI NIH HHS [HL63357-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL063357] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Asano H, 1997, TISSUE ANTIGENS, V50, P484, DOI 10.1111/j.1399-0039.1997.tb02903.x; BORRAS FE, 1995, J BIOL CHEM, V270, P24385, DOI 10.1074/jbc.270.41.24385; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1994, J BIOL CHEM, V269, P10341; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; CAMPBELL RD, 1997, IMMUNOL TODAY, V18, P43; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; De Baey A., 1996, Human Immunology, V47, P65, DOI 10.1016/0198-8859(96)85042-7; DEBAEY A, 1995, HUM IMMUNOL, V42, P9, DOI 10.1016/0198-8859(94)00070-7; deBaey A, 1997, GENOMICS, V45, P591, DOI 10.1006/geno.1997.4963; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gruen JR, 1997, BLOOD, V90, P4252; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLZINGER I, 1995, IMMUNOGENETICS, V42, P315, DOI 10.1007/BF00179392; HOLZINGER IR, 2000, J IMMUNOL, V164, P3169; IRIS FJM, 1993, NAT GENET, V3, P137, DOI 10.1038/ng0293-137; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUSTERSVANSOMEREN M, 1995, BIOCHEMISTRY-US, V34, P10620, DOI 10.1021/bi00033a037; LEE KAW, 1994, CELL BIOL LAB HDB, P668; Matsui K, 2000, J IMMUNOL, V164, P3002, DOI 10.4049/jimmunol.164.6.3002; McKercher SR, 1999, J LEUKOCYTE BIOL, V66, P727, DOI 10.1002/jlb.66.5.727; Middleton PG, 1998, BLOOD, V92, P3943, DOI 10.1182/blood.V92.10.3943.422k35_3943_3948; Nalabolu SR, 1996, GENOMICS, V31, P215, DOI 10.1006/geno.1996.0034; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; TSUGE I, 1987, IMMUNOGENETICS, V26, P378, DOI 10.1007/BF00343709; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P2; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	31	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34597	34608		10.1074/jbc.M004700200	http://dx.doi.org/10.1074/jbc.M004700200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944527	hybrid			2022-12-27	WOS:000165095300082
J	Ingram-Smith, C; Barber, RD; Ferry, JG				Ingram-Smith, C; Barber, RD; Ferry, JG			The role of histidines in the acetate kinase from Methanosarcina thermophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; PROTEINS; SYSTEM; GENES	The role of histidine in the catalytic mechanism of acetate kinase from Methanosarcina thermophila was investigated by diethylpyrocarbonate inactivation and site-directed mutagenesis, Inactivation was accompanied by an increase in absorbance at 240 nm with no change in absorbance at 280 nm, and treatment of the inactivated enzyme with hydroxylamine restored 95% activity, results that indicated diethylpyrocarbonate inactivates the enzyme by the specific modification of histidine, The substrates ATP, ADP, acetate, and acetyl phosphate protected against inactivation suggesting at least one active site where histidine is modified. Correlation of residual activity with the number of histidines modified, as determined by absorbance at 240 nm, indicated that a maximum of three histidines are modified per subunit, two of which are essential for full inactivation. Comparison of the M, thermophila acetate kinase sequence with 56 putative acetate kinase sequences revealed eight highly conserved histidines, three of which (His-123, His-180, and His-208) are perfectly conserved. Diethylpyrocarbonate inactivation of the eight histidine --> alanine variants indicated that His-180 and His-123 are in the active site and that the modification of both is necessary for full inactivation. Kinetic analyses of the eight variants showed that no other histidines are important for activity. Analysis of additional His-180 variants indicated that phosphorylation of His-180 is not essential for catalysis, Possible functions of His-180 are discussed.	Penn State Univ, Eberly Coll Sci, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ferry, JG (corresponding author), Penn State Univ, Eberly Coll Sci, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.			Ingram-Smith, Cheryl/0000-0002-6752-6678	NIGMS NIH HHS [GM19720] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACETI DJ, 1988, J BIOL CHEM, V263, P15444; ALLEN SHG, 1964, J BACTERIOL, V87, P171, DOI 10.1128/JB.87.1.171-187.1964; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; ANTHONY RS, 1972, J BIOL CHEM, V247, P2120; ANTHONY RS, 1971, J BIOL CHEM, V246, P6129; ANTHONY RS, 1970, J BIOL CHEM, V245, P6739; BLATTLER WA, 1979, BIOCHEMISTRY-US, V18, P3927, DOI 10.1021/bi00585a013; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Ferry JG, 1997, BIOFACTORS, V6, P25, DOI 10.1002/biof.5520060104; FOX DK, 1986, J BIOL CHEM, V261, P3487; KAHANE I, 1979, J BACTERIOL, V137, P764, DOI 10.1128/JB.137.2.764-772.1979; KIM YS, 1988, BIOCHIM BIOPHYS ACTA, V956, P103, DOI 10.1016/0167-4838(88)90255-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATIMER MT, 1993, J BACTERIOL, V175, P6822, DOI 10.1128/jb.175.21.6822-6829.1993; LIPMANN F, 1945, J BIOL CHEM, V159, P21; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, P101; LUNDBLAD RL, 1995, TECHNIQUES PROTEIN M, P105; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; NAKAJIMA H, 1978, J BIOCHEM, V84, P193, DOI 10.1093/oxfordjournals.jbchem.a132108; NISHIMURA JS, 1981, METHOD ENZYMOL, V71, P311; ROMANIUK PJ, 1981, J BIOL CHEM, V256, P7322; ROSE IA, 1954, J BIOL CHEM, V211, P737; Rosenthal A, 1992, DNA Seq, V3, P61, DOI 10.3109/10425179209039697; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUPP A, 1974, ARCH MICROBIOL, V100, P121, DOI 10.1007/BF00446312; Singh-Wissmann K, 2000, BIOCHEMISTRY-US, V39, P3671, DOI 10.1021/bi991998h; SPECTOR LB, 1980, P NATL ACAD SCI-BIOL, V77, P2626, DOI 10.1073/pnas.77.5.2626; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TODHUNTER JA, 1974, BIOCHEM BIOPH RES CO, V60, P273, DOI 10.1016/0006-291X(74)90201-0; TSOU C, 1962, SCI SINICA, V11, P1535; VIGENSCHOW H, 1986, BIOL CHEM H-S, V367, P951, DOI 10.1515/bchm3.1986.367.2.951; WEBB BC, 1976, ARCH BIOCHEM BIOPHYS, V173, P282, DOI 10.1016/0003-9861(76)90261-7	37	22	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33765	33770		10.1074/jbc.M005303200	http://dx.doi.org/10.1074/jbc.M005303200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10958794	hybrid			2022-12-27	WOS:000090104600081
J	Majone, F; Jeang, KT				Majone, F; Jeang, KT			Clastogenic effect of the human T-cell leukemia virus type I tax oncoprotein correlates with unstabilized DNA breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICRONUCLEI; PROTEIN; REPAIR; GENE; IDENTIFICATION; CHROMOSOMES; INDUCTION	Expression of the human T-cell leukemia virus type I (HTLV-I) Tax oncoprotein rapidly engenders DNA damage as reflected in a significant increase of micronuclei (MN) in cells, To understand better this phenomenon, we have investigated the DNA content of MN induced by Tax. Using an approach that we termed FISHI, fluorescent in situ hybridization and incorporation, we attempted to characterize MN with centric or acentric DNA fragments for the presence or absence of free 3'-OH ends. Free 3'-OH ends were defined as those ends accessible to in situ addition of digoxigenin-dUTP using terminal deoxynucleotidyl transferase. MN were also assessed for centromeric sequences using standard fluorescent in situ hybridization (FISH). Combining these results, we determined that Tax oncoprotein increased the frequency of MN containing centric DNA with free 3'-OH and decreased the frequency of MN containing DNA fragments that had incorporation-inaccessible 3'-ends. Recently, it has been suggested that intracellular DNA breaks without detectable 3'-OH ends are stabilized by the protective addition of telomeric caps, while breaks with freely detectable 3'-OH are uncapped and are labile to degradation, incomplete replication, and loss during cell division. Accordingly, based on increased detection of free 3'-OH-containing DNA fragments, we concluded that HTLV-I Tax interferes with protective cellular mechanism(s) used normally for stabilizing DNA breaks.	Univ Padua, Dept Biol, I-35131 Padua, Italy; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	University of Padua; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Majone, F (corresponding author), Univ Padua, Dept Biol, Viale G Colombo 3, I-35131 Padua, Italy.	majone@civ.bio.unipd.it	Jeang, Kuan-Teh/A-2424-2008					Driller L, 2000, J BIOL CHEM, V275, P24921, DOI 10.1074/jbc.M002588200; Fiumicino S, 2000, INT J CANCER, V85, P590, DOI 10.1002/(SICI)1097-0215(20000215)85:4<590::AID-IJC23>3.0.CO;2-O; GILLEY D, 1988, MOL CELL BIOL, V8, P4765, DOI 10.1128/MCB.8.11.4765; Jeang KT, 1997, J VIROL, V71, P6277, DOI 10.1128/JVI.71.9.6277-6278.1997; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KAMPER J, 1989, MOL CELL BIOL, V9, P3931; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Kibler KV, 1999, JNCI-J NATL CANCER I, V91, P903, DOI 10.1093/jnci/91.11.903; Li RH, 2000, P NATL ACAD SCI USA, V97, P3236, DOI 10.1073/pnas.040529797; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; MAJONE F, 1992, TERATOGEN CARCIN MUT, V12, P155, DOI 10.1002/tcm.1770120402; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MAJONE F, 1990, MUTAT RES, V244, P147, DOI 10.1016/0165-7992(90)90064-Q; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; MATERA AG, 1992, HUM MOL GENET, V1, P535, DOI 10.1093/hmg/1.7.535; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; MILLER BM, 1993, MUTAGENESIS, V8, P35, DOI 10.1093/mutage/8.1.35; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Perucho M, 1996, BIOL CHEM, V377, P675; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; SOKAL P, 1991, BIOMETRY; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C	25	65	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32906	32910		10.1074/jbc.C000538200	http://dx.doi.org/10.1074/jbc.C000538200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10969065	hybrid			2022-12-27	WOS:000090003800073
J	Robertson, JD; Gogvadze, V; Zhivotovsky, B; Orrenius, S				Robertson, JD; Gogvadze, V; Zhivotovsky, B; Orrenius, S			Distinct pathways for stimulation of cytochrome c release by etoposide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE; INDUCED APOPTOSIS; CELL-DEATH; MITOCHONDRIA; ACTIVATION; BCL-2; CASPASE-2; HOMOLOGY; SEQUENCE; REGIONS	Induction of apoptosis by DNA-damaging agents, such as etoposide, is known to involve the release of mitochondrial cytochrome c, although the mechanism responsible for this event is unclear. In the present study, using Jurkat T-lymphocytes, a reconstituted cell-free system, or isolated liver mitochondria, we demonstrate the ability of etoposide to induce cytochrome c release via two distinct pathways. Caspase inhibition by either benzyloxycarbonyl-val-Alwa-Asp-fluoromethyl ketone (z-VAD-fmk) or benzyloxycarbonyl-val-Asp-Val-Ala-Asp-fluoromethyl ketone (z-VDVAD-fmk) attenuates cytochrome c release triggered by a low dose of etoposide via an apparent inhibition of nuclear events involving the release of protein factor(s) that is (are) able to interact with mitochondria. In contrast, caspase inhibition has no effect on cytochrome c release induced by a higher dose of etoposide. Moreover, the higher dose of etoposide heightens the sensitivity of Ca2+-loaded isolated mitochondria to mitochondrial permeability transition, an effect that is completely abolished by cyclosporin A. Interestingly, cyclosporin A is ineffective at preventing similar mitochondrial damage in Jurkat cells treated with etoposide. We propose that lower doses of etoposide predominantly target the nucleus and stimulate the release of caspase-sensitive protein factor(s) that interact with mitochondria to trigger cytochrome c release, whereas higher doses of the drug impart a more direct effect on mitochondria and thus are not mitigated by caspase inhibition.	Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden	Karolinska Institutet	Robertson, JD (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, Box 210, SE-17177 Stockholm, Sweden.	john.robertson@imm.ki.se	Gogvadze, Vladimir/A-4392-2014; Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482				BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Crabtree HG, 1929, BIOCHEM J, V23, P536, DOI 10.1042/bj0230536; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; HSIEH TS, 1980, CELL, V21, P115, DOI 10.1016/0092-8674(80)90119-1; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Mesner PW, 1999, J BIOL CHEM, V274, P22635, DOI 10.1074/jbc.274.32.22635; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Robertson JD, 2000, CRIT REV TOXICOL, V30, P609, DOI 10.1080/10408440008951122; SANDER M, 1987, J MOL BIOL, V194, P219, DOI 10.1016/0022-2836(87)90370-6; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zhuang JG, 1998, TOXICOL LETT, V103, P121, DOI 10.1016/S0378-4274(98)00296-3; Zhuang JG, 1998, CELL DEATH DIFFER, V5, P953, DOI 10.1038/sj.cdd.4400440; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	30	133	137	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32438	32443		10.1074/jbc.C000518200	http://dx.doi.org/10.1074/jbc.C000518200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10961984	hybrid			2022-12-27	WOS:000090003800010
J	Fajloun, Z; Mosbah, A; Carlier, E; Mansuelle, P; Sandoz, G; Fathallah, M; di Luccio, E; Devaux, C; Rochat, H; Darbon, H; De Waard, M; Sabatier, JM				Fajloun, Z; Mosbah, A; Carlier, E; Mansuelle, P; Sandoz, G; Fathallah, M; di Luccio, E; Devaux, C; Rochat, H; Darbon, H; De Waard, M; Sabatier, JM			Maurotoxin versus Pi1/HsTx1 scorpion toxins - Toward new insights in the understanding of their distinct disulfide bridge patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL BLOCKING TOXIN; PANDINUS-IMPERATOR; CHEMICAL-SYNTHESIS; HIGH-AFFINITY; PEPTIDES; MAURUS; FRAGMENTS	Maurotoxin (MTX) is a scorpion toxin acting on several K+ channel subtypes. It is a 34-residue peptide cross-linked by four disulfide bridges that are in an "uncommon" arrangement of the type C1-C5, C2-C6, C3-C4, and C7-C8 (versus C1-C5, C2-C6, C3-C7, and C4-C8 for Pi1 or HsTx1, two MTX-related scorpion toxins). We report here that a single mutation in MTX in either position 15 or 33, resulted in a shift from the MTX toward the Pi1/HsTx1 disulfide bridge pattern. This shift is accompanied by structural and pharmacological changes of the peptide without altering the general alpha/beta scaffold of scorpion toxins.	CNRS UMR 6560, F-13916 Marseille 20, France; CNRS UPR 9039, F-13402 Marseille, France; INSERM U464, F-13916 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Sabatier, JM (corresponding author), CNRS UMR 6560, Blvd Pierre Dramard, F-13916 Marseille 20, France.	sabatier.jm@jean-roche.univ-mrs.fr	Fajloun, Ziad/AAO-8595-2021; di Luccio, Eric/Z-5388-2019; sandoz, guillaume/AAI-9236-2020; De Waard, Michel/G-7406-2014	sandoz, guillaume/0000-0003-1251-0852; De Waard, Michel/0000-0002-2782-9615; SABATIER, Jean-Marc/0000-0002-9040-5647; mansuelle, pascal/0000-0002-4504-6809; di Luccio, Eric/0000-0002-2256-2157				ALBERICIO F, 1991, INT J PEPT PROT RES, V37, P402; Avdonin V, 2000, BIOPHYS J, V79, P776, DOI 10.1016/S0006-3495(00)76335-1; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Blanc E, 1997, PROTEINS, V29, P321, DOI 10.1002/(SICI)1097-0134(199711)29:3&lt;321::AID-PROT6&gt;3.0.CO;2-D; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlier E, 2000, J PEPT RES, V55, P419, DOI 10.1034/j.1399-3011.2000.00715.x; Darbon H, 1999, PERSPECT DRUG DISCOV, V16, P41; Delepierre M, 1997, BIOCHEMISTRY-US, V36, P2649, DOI 10.1021/bi9617116; EPPIG JJ, 1976, IN VITRO CELL DEV B, V12, P418; Fajloun Z, 2000, J BIOL CHEM, V275, P13605, DOI 10.1074/jbc.275.18.13605; Fajloun Z, 2000, EUR J BIOCHEM, V267, P5149, DOI 10.1046/j.1432-1327.2000.01577.x; FROIMOWITZ M, 1989, INT J PEPT PROT RES, V34, P88; GRAY EG, 1962, J ANAT, V96, P79; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; Kharrat R, 1997, FEBS LETT, V406, P284, DOI 10.1016/S0014-5793(97)00285-8; Kharrat R, 1996, EUR J BIOCHEM, V242, P491, DOI 10.1111/j.1432-1033.1996.0491r.x; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lebrun B, 1997, BIOCHEM J, V328, P321, DOI 10.1042/bj3280321; Lecomte C, 2000, J PEPT RES, V55, P246, DOI 10.1034/j.1399-3011.2000.00170.x; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MENEZ A, 1992, P ROY SOC EDINB B, V99, P83, DOI 10.1017/S0269727000013075; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; OlamendiPortugal T, 1996, BIOCHEM J, V315, P977, DOI 10.1042/bj3150977; PAGE MGP, 1986, BIOCHIM BIOPHYS ACTA, V858, P67, DOI 10.1016/0005-2736(86)90292-0; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Savarin P, 1999, PROTEIN SCI, V8, P2672; SIEDLER F, 1994, BIOPOLYMERS, V34, P1563, DOI 10.1002/bip.360341114; SIEDLER F, 1993, BIOCHEMISTRY-US, V32, P7488, DOI 10.1021/bi00080a021; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117	34	38	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39394	39402		10.1074/jbc.M006810200	http://dx.doi.org/10.1074/jbc.M006810200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10970898	hybrid			2022-12-27	WOS:000165953100063
J	Lee, C; Miura, K; Liu, XP; Zweier, JL				Lee, C; Miura, K; Liu, XP; Zweier, JL			Biphasic regulation of leukocyte superoxide generation by nitric oxide and peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FREE-RADICAL GENERATION; HUMAN-NEUTROPHILS; NADPH OXIDASE; TYROSINE PHOSPHORYLATION; POLYMORPHONUCLEAR LEUKOCYTES; COMPONENT P47(PHOX); SIGNAL-TRANSDUCTION; POSTISCHEMIC HEART; SUBUNIT P47(PHOX)	Activation of the NADPH oxidase-derived oxidant burst of polymorphonuclear leukocytes (PMNs) is of critical importance in inflammatory disease, PMN-derived superoxide (O-2(.-)) can be scavenged by nitric oxide (NO.) with the formation of peroxynitrite (ONOO-); however, questions remain regarding the effects and mechanisms by which NO. and ONOO- modulate the PMN oxidative burst. Therefore, we directly measured the dose-dependent effects of NO. and ONOO- on O-2(.-) generation from human PMNs stimulated with phorbol 12-myristate 13-acetate using EPR spin trapping. Pretreatment with low physiological (muM) concentrations of NO. from NO. gas had no effect on PMN O-2(.-) generation, whereas high levels (greater than or equal to 50 muM) exerted inhibition. With ONOO- pretreatment, however, a biphasic modulation of O-2(.-) generation was seen with stimulation by muM levels, but inhibition at higher levels. With the NO. donor NOR-1, which provides more sustained release of NO. persisting at the time of O(2)(.-)generation, a similar biphasic modulation of O-2(.-) generation was seen, and this was inhibited by ONOO- scavengers. The enhancement of O-2(.-) generation by low concentrations of ONOO- or NOR-1 was associated with activation of the ERR MAPKs and was blocked by their inhibition, Thus, low physiological levels of NO. present following PMN activation are converted to ONOO-, which enhances O-2(.-) generation through activation of the ERK MAPK pathway, whereas higher levels of NO. or ONOO- feed back and inhibit O-2(.-) generation. This biphasic concentration-dependent regulation of the PMN oxidant burst by NO.-derived ONOO- may be of critical importance in regulating the process of inflammation.	Johns Hopkins Med Inst, Dept Med, Div Cardiol, Mol & Cellular Biophys Labs, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Elect Paramagnet Resonance Ctr, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Dept Med, Div Clin Immunol, Baltimore, MD 21224 USA; Kanagawa Dent Coll, Dept Pharmacol, Yokosuka, Kanagawa 2380003, Japan; Kanagawa Dent Coll, Electron Spin Resonance Ctr, Yokosuka, Kanagawa 2380003, Japan	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Kanagawa Dental College; Kanagawa Dental College	Zweier, JL (corresponding author), Johns Hopkins Asthma & Allergy Ctr, EPR Ctr, 5501 Johns Hopkins Bayview Circle, Baltimore, MD 21224 USA.	jzweier@welch.jhu.edu	Liu, Xiaoping/A-4516-2008		NHLBI NIH HHS [R01 HL063744, HL-38324, HL-63744, R01 HL038324] Funding Source: Medline; NIBIB NIH HHS [R01 EB004900] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063744, R29HL038324, R01HL038324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB004900] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Babior B M, 1995, Curr Opin Hematol, V2, P55; BABIOR BM, 1981, J BIOL CHEM, V256, P2321; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CURNUTTE JT, 1994, J BIOL CHEM, V269, P10813; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Downey GP, 1996, J BIOL CHEM, V271, P21005, DOI 10.1074/jbc.271.35.21005; Downey GP, 1998, J IMMUNOL, V160, P434; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; Fujii H, 1997, J BIOL CHEM, V272, P32773, DOI 10.1074/jbc.272.52.32773; GRINSTEIN S, 1990, J BIOL CHEM, V265, P318; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Inanami O, 1998, ARCH BIOCHEM BIOPHYS, V350, P36, DOI 10.1006/abbi.1997.0484; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; KELM M, 1990, CIRC RES, V66, P1561, DOI 10.1161/01.RES.66.6.1561; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; MATHEIS G, 1992, AM J PHYSIOL, V262, pH616, DOI 10.1152/ajpheart.1992.262.2.H616; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; MCPHAIL LC, 1984, J BIOL CHEM, V259, P5768; Miura K, 1999, J IMMUNOL, V162, P4198; Nick JA, 1996, J IMMUNOL, V156, P4867; RADI R, 1991, J BIOL CHEM, V266, P4244; Rohn TT, 1999, J LEUKOCYTE BIOL, V65, P59, DOI 10.1002/jlb.65.1.59; Roubaud V, 1997, ANAL BIOCHEM, V247, P404, DOI 10.1006/abio.1997.2067; ROWE GT, 1984, J MOL CELL CARDIOL, V16, P1075, DOI 10.1016/S0022-2828(84)80020-6; Schieke SM, 1999, FEBS LETT, V448, P301, DOI 10.1016/S0014-5793(99)00372-5; SCHLEIMER RP, 1986, J IMMUNOL, V136, P649; SCHULZ R, 1995, CARDIOVASC RES, V30, P432; SHANDELYA SML, 1993, CIRCULATION, V88, P2812, DOI 10.1161/01.CIR.88.6.2812; SHANDELYA SML, 1993, CIRCULATION, V87, P536, DOI 10.1161/01.CIR.87.2.536; SZABO C, 1995, FEBS LETT, V372, P229, DOI 10.1016/0014-5793(95)00984-H; TARPEY MM, 1995, FEBS LETT, V364, P314, DOI 10.1016/0014-5793(95)00413-4; TORRES M, 1993, J IMMUNOL, V150, P1563; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; Zu YL, 1996, BLOOD, V87, P5287, DOI 10.1182/blood.V87.12.5287.bloodjournal87125287; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	56	106	114	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38965	38972		10.1074/jbc.M006341200	http://dx.doi.org/10.1074/jbc.M006341200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10976106	hybrid			2022-12-27	WOS:000165953100005
J	Seisenberger, C; Specht, V; Welling, A; Platzer, J; Pfeifer, A; Kuhbandner, S; Striessnig, J; Klugbauer, N; Feil, R; Hofmann, F				Seisenberger, C; Specht, V; Welling, A; Platzer, J; Pfeifer, A; Kuhbandner, S; Striessnig, J; Klugbauer, N; Feil, R; Hofmann, F			Functional embryonic cardiomyocytes after disruption of the L-type alpha(1C) (Ca(v)1.2) calcium channel gene in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATIONARY NIGHT BLINDNESS; BETA-ADRENERGIC MODULATION; CA2+ CHANNEL; ION CHANNELS; MICE LACKING; DEVELOPMENTAL-CHANGES; DRUG-BINDING; SUBUNIT; HEART; EXPRESSION	The L-type alpha (1c) (Ca(V)1.2) calcium channel is the major calcium entry pathway in cardiac and smooth muscle. We inactivated the Ca(nu)1.2 gene in two independent mouse lines that had indistinguishable phenotypes. Homozygous knockout embryos (Ca(V)1.2-/-) died before day 14.5 postcoitum (p.c.), At day 12.5 p.c., the embryonic heart contracted with identical frequency in wild type (+/+), heterozygous (+/-), and homozygous (-/-) Ca(V)1.2 embryos. Beating of isolated embryonic cardiomyocytes depended on extracellular calcium and was blocked by 1 muM nisoldipine, In (+/+), (+/-), and (-/-) cardiomyocytes, an L-type Ba2+ inward current (I-Ba) was present that was stimulated by Bay K 8644 in all genotypes. At a holding potential of -80 mV, nisoldipine blocked I-Ba of day 12.5 p.c. (+/+) and (+/-) cells with two IC50 values of approximate to0.1 and approximate to1 muM. Inhibition of I-Ba of (-/-) camdiomyocytes was monophasic with an IC50 of approximate to1 mum. The low affinity I-Ba was also present in cardiomyocytes of homozygous alpha (1D) (Ca(V)1.3) knockout embryos at day 12.5 p.c. These results indicate that, up to day 14 p.c., contraction of murine embryonic hearts requires an unidentified, low affinity L-type like calcium channel.	Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany; Univ Innsbruck, Inst Biochem Pharmacol, A-6020 Innsbruck, Austria	Technical University of Munich; University of Innsbruck	Hofmann, F (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.	pharma@ipt.med.tu-muenchen.de	Feil, Susanne/AAF-7032-2019; Feil, Robert/B-8918-2014; Striessnig, Joerg/S-9334-2017; Welling, Andrea/K-6674-2017	Feil, Robert/0000-0002-7335-4841; Striessnig, Joerg/0000-0002-9406-7120; Welling, Andrea/0000-0002-5364-4980				An RH, 1996, CIRC RES, V78, P371, DOI 10.1161/01.RES.78.3.371; BEAM KG, 1986, NATURE, V320, P168, DOI 10.1038/320168a0; Bech-Hansen NT, 1998, NAT GENET, V19, P264, DOI 10.1038/947; Davies MP, 1996, CIRC RES, V78, P15, DOI 10.1161/01.RES.78.1.15; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; HAASE H, 1994, RECEPTOR CHANNEL, V2, P41; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Jun K, 1999, P NATL ACAD SCI USA, V96, P15245, DOI 10.1073/pnas.96.26.15245; KATZ AM, 1993, NEW ENGL J MED, V328, P1244; Klugbauer N, 1999, PFLUG ARCH EUR J PHY, V437, P710, DOI 10.1007/s004240050836; Lacinova L, 2000, PFLUG ARCH EUR J PHY, V440, P50, DOI 10.1007/s004240051021; LACINOVA L, 1995, FEBS LETT, V373, P103, DOI 10.1016/0014-5793(95)01013-5; LACINOVA L, 2000, NEUROPHARMACOLOGY, V12, P1217; Littleton JT, 2000, NEURON, V26, P35, DOI 10.1016/S0896-6273(00)81135-6; Liu W, 1999, AM J PHYSIOL-HEART C, V276, pH608, DOI 10.1152/ajpheart.1999.276.2.H608; MA WJ, 1992, J BIOL CHEM, V267, P22728; MEJIAALVAREZ R, 1994, J PHYSIOL-LONDON, V478, P315, DOI 10.1113/jphysiol.1994.sp020252; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Morel N, 1998, BRIT J PHARMACOL, V125, P1005, DOI 10.1038/sj.bjp.0702162; Perchenet L, 2000, N-S ARCH PHARMACOL, V361, P590, DOI 10.1007/s002100000238; Platzer J, 2000, CELL, V102, P89, DOI 10.1016/S0092-8674(00)00013-1; REUTER H, 1984, ANNU REV PHYSIOL, V46, P473; Saegusa H, 2000, P NATL ACAD SCI USA, V97, P6132, DOI 10.1073/pnas.100124197; Santana LF, 1998, SCIENCE, V279, P1027, DOI 10.1126/science.279.5353.1027; Satin J, 2000, CIRC RES, V86, P636, DOI 10.1161/01.RES.86.6.636; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; Strom TM, 1998, NAT GENET, V19, P260, DOI 10.1038/940; Takimoto K, 1997, J MOL CELL CARDIOL, V29, P3035, DOI 10.1006/jmcc.1997.0532; VASSORT G, 1994, J CARDIOVASC ELECTR, V5, P376, DOI 10.1111/j.1540-8167.1994.tb01175.x; Viatchenko-Karpinski S, 1999, P NATL ACAD SCI USA, V96, P8259, DOI 10.1073/pnas.96.14.8259; Welling A, 1997, CIRC RES, V81, P526, DOI 10.1161/01.RES.81.4.526; WELLING A, 1993, CIRC RES, V73, P974, DOI 10.1161/01.RES.73.5.974; Wyatt CN, 1997, J PHYSIOL-LONDON, V502, P307, DOI 10.1111/j.1469-7793.1997.307bk.x; YANEY GC, 1992, MOL ENDOCRINOL, V6, P2143, DOI 10.1210/me.6.12.2143; Zuhlke RD, 1998, FEBS LETT, V427, P220, DOI 10.1016/S0014-5793(98)00425-6	40	208	216	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39193	39199		10.1074/jbc.M006467200	http://dx.doi.org/10.1074/jbc.M006467200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10973973	hybrid			2022-12-27	WOS:000165953100035
J	Shimono, Y; Murakami, H; Hasegawa, Y; Takahashi, M				Shimono, Y; Murakami, H; Hasegawa, Y; Takahashi, M			RET finger protein is a transcriptional repressor and interacts with enhancer of polycomb that has dual transcriptional functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION-EFFECT VARIEGATION; NUCLEAR-BODIES; DROSOPHILA-MELANOGASTER; TRANSFORMING GENE; BINDING-PROTEIN; RAR-ALPHA; ENCODES; PML; RING; COMPLEXES	RET finger protein (RFP) belongs to the large B-box RING; finger protein family and is known to become oncogenic by fusion with RET tyrosine kinase. Although RFP is reported to be a nuclear protein that is present in the nuclear matrix, its function is largely unknown. Here we show that REP interacts with Enhancer of Polycomb (EPC) and strongly represses the gene transcription. Yeast two-hybrid assays revealed that the coiled-coil domain of RFP was associated with the EPcA domain and the carboxyl-terminal region of EPC. In addition, both proteins were co-precipitated from the lysates of human cells and mostly colocalized in the nucleus. Using the luciferase reporter-gene assay, we found that they repress the gene transcription activity independent of the differences of enhancers and promoters used, although the repressive activity of RFP was much stronger than that of EPC. The coiled-coil domain of RFP and the carboxyl-terminal region of EPC were most important for the repressive activity of each protein, whereas the EPcA domain had the transcription activating ability that is unique as the Polycomb group protein function. These results suggested that RFP may be involved in the epigenetic gene silencing mechanism cooperating with Polycomb group proteins and that EPC is a unique molecule with both repressive and transactivating activities.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Takahashi, Masahide/AAN-4770-2020; Hasegawa, Yoshinori/I-1277-2012; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; Shimono, Yohei/0000-0002-6256-4704				ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Bardos JI, 2000, J BIOL CHEM, V275, P28785, DOI 10.1074/jbc.M001835200; BERG JM, 1990, J BIOL CHEM, V265, P6513; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; CAMPBELL RB, 1995, MOL GEN GENET, V246, P291, DOI 10.1007/BF00288601; Cao TY, 1998, J CELL SCI, V111, P1319; Cao TY, 1997, J CELL SCI, V110, P1563; Carrington EA, 1996, DEVELOPMENT, V122, P4073; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; CHENG NSN, 1994, GENETICS, V138, P1151; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Grande MA, 1996, J CELL BIOCHEM, V63, P280, DOI 10.1002/(SICI)1097-4644(19961201)63:3<280::AID-JCB3>3.0.CO;2-T; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; GUTJAHR T, 1995, EMBO J, V14, P4296, DOI 10.1002/j.1460-2075.1995.tb00104.x; Hasegawa N, 1996, BIOCHEM BIOPH RES CO, V225, P627, DOI 10.1006/bbrc.1996.1221; Henry J, 1998, MOL BIOL EVOL, V15, P1696, DOI 10.1093/oxfordjournals.molbev.a025896; ISOMURA T, 1992, NUCLEIC ACIDS RES, V20, P5305, DOI 10.1093/nar/20.20.5305; Iwata Y, 1999, BIOCHEM BIOPH RES CO, V261, P381, DOI 10.1006/bbrc.1999.1037; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219; LaJeunesse D, 1996, DEVELOPMENT, V122, P2189; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X; Satijn DPE, 1999, MOL CELL BIOL, V19, P57; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SHEARN A, 1989, GENETICS, V121, P517; Sinclair DAR, 1998, GENETICS, V148, P211; Stankunas K, 1998, DEVELOPMENT, V125, P4055; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; STUURMAN N, 1992, J CELL SCI, V101, P773; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Tetsu O, 1998, IMMUNITY, V9, P439, DOI 10.1016/S1074-7613(00)80627-5; Tezel G, 1999, PATHOL INT, V49, P881, DOI 10.1046/j.1440-1827.1999.00957.x; Topcu Z, 1999, ONCOGENE, V18, P7091, DOI 10.1038/sj.onc.1203201; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602	53	83	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39411	39419		10.1074/jbc.M006585200	http://dx.doi.org/10.1074/jbc.M006585200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10976108	hybrid			2022-12-27	WOS:000165953100065
J	Guilherme, A; Emoto, M; Buxton, JM; Bose, S; Sabini, R; Theurkauf, WE; Leszyk, J; Czech, MP				Guilherme, A; Emoto, M; Buxton, JM; Bose, S; Sabini, R; Theurkauf, WE; Leszyk, J; Czech, MP			Perinuclear localization and insulin responsiveness of GLUT4 requires cytoskeletal integrity in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; ISOLATED RAT ADIPOCYTES; PLASMA-MEMBRANE; GLUT4-CONTAINING VESICLES; GOLGI-COMPLEX; CELL-SURFACE; INTERMEDIATE FILAMENTS; DEPENDENT TRAFFICKING; INTRACELLULAR GLUT4; ADIPOSE CONVERSION	The GLUT4 glucose transporter resides mostly in perinuclear membranes in unstimulated 3T3-L1 adipocytes and is acutely translocated to the cell surface in response to insulin. Using a novel method to purify intracellular GLUT4-enriched membranes, we identified by mass spectrometry the intermediate filament protein vimentin and the microtubule protein alpha -tubulin as components of these membranes. Immunoelectron microscopy of the GLUT4-containing membranes also revealed their association with these cytoskeletal proteins, Disruption of intermediate filaments and microtubules in 3T3-L1 adipocytes by microinjection of a vimentin-derived peptide of the helix initiation 1A domain caused marked dispersion of perinuclear GLUT4 to peripheral regions of the cells. Inhibition of the microtubule-based motor dynein by brief cytoplasmic acidification of cultured adipocytes also dispersed perinuclear GLUT4 and inhibited insulin-stimulated GLUT4 translocation to the cell surface. Insulin sensitivity was restored as GLUT4 was again concentrated near the nucleus upon recovery of cells in physiological buffer. These data suggest that GLUT4 trafficking to perinuclear membranes of cultured adipocytes is directed by dynein and is required for optimal GLUT4 regulation by insulin.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.			Sabini, Rosanna/0000-0002-9273-3855; Theurkauf, William/0000-0001-7342-1912	NIDDK NIH HHS [DK30898, DK32520] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030898, R37DK030898, P30DK032520] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Burkhardt JK, 1998, BBA-MOL CELL RES, V1404, P113, DOI 10.1016/S0167-4889(98)00052-4; CAIN CC, 1992, J BIOL CHEM, V267, P11681; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Fischer Y, 1997, J BIOL CHEM, V272, P7085, DOI 10.1074/jbc.272.11.7085; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; GYOEVA FK, 1991, NATURE, V353, P445, DOI 10.1038/353445a0; Harada A, 1998, J CELL BIOL, V141, P51, DOI 10.1083/jcb.141.1.51; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kandror KV, 1998, BIOCHEM J, V331, P829, DOI 10.1042/bj3310829; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; Lee W, 1999, J BIOL CHEM, V274, P37755, DOI 10.1074/jbc.274.53.37755; Lieber JG, 1996, J CELL SCI, V109, P3047; Lin BZ, 1997, J BIOL CHEM, V272, P24145, DOI 10.1074/jbc.272.39.24145; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; MAISON C, 1993, J CELL BIOL, V123, P1491, DOI 10.1083/jcb.123.6.1491; MARETTE A, 1992, DIABETES, V41, P1562, DOI 10.2337/diabetes.41.12.1562; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; MARTIN S, 1994, BIOCHEM J, V300, P743, DOI 10.1042/bj3000743; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; Millar CA, 1999, MOL BIOL CELL, V10, P3675, DOI 10.1091/mbc.10.11.3675; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Morris NJ, 1997, J BIOL CHEM, V272, P9388; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROGERS SL, 2000, P NATL ACAD SCI USA, V12, P57; Sin WC, 1998, MOL CELL BIOL, V18, P6325, DOI 10.1128/MCB.18.11.6325; Sleeman MW, 1998, J BIOL CHEM, V273, P3132, DOI 10.1074/jbc.273.6.3132; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; St-Denis Jean-Francois, 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P153; St-Denis JF, 1999, BIOCHEM J, V338, P709, DOI 10.1042/0264-6021:3380709; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; Vaughan KT, 1999, J CELL SCI, V112, P1437; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; YANG J, 1993, J BIOL CHEM, V268, P4600; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	66	101	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38151	38159		10.1074/jbc.M003432200	http://dx.doi.org/10.1074/jbc.M003432200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10950952	hybrid			2022-12-27	WOS:000165739800005
J	Meetei, AR; Ullas, KS; Rao, MRS				Meetei, AR; Ullas, KS; Rao, MRS			Identification of two novel zinc finger modules and nuclear localization signal in rat spermatidal protein TP2 by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOLAR LOCALIZATION; TRANSITION PROTEIN-2; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; SPERM CHROMATIN; GENE-EXPRESSION; DNA RECOGNITION; SEQUENCE; COMPLEX; CDNA	Spermatidal protein TP2, which appears transiently during stages 12-16 of mammalian spermiogenesis, is a DNA condensing zinc metalloprotein with a preference to GC-rich DNA. We have carried out a detailed site-directed mutagenesis analysis of rat spermatidal protein TP2 to delineate the amino acid residues involved in coordination with two atoms of zinc. Two zinc fingers modules have been identified involving 4 histidine and 4 cysteine residues, respectively. The modular structure of the two zinc fingers identified in TP2 define a new class of zinc finger proteins that do not fall into any of the known classes of zinc fingers. Transfection experiments with COS-7 cells using wild type and the two zinc finger pocket mutants have shown that TP2 preferentially localizes to nucleolus. The nuclear localization signal in TP2 was identified to be (87)GKVSKRKAV(95) present in the C-terminal third of TP2 as a part of an extended NoLS sequence.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Rao, MRS (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.							Akama K, 1999, FEBS LETT, V442, P189, DOI 10.1016/S0014-5793(98)01649-4; Akama K, 1997, BIOCHEM MOL BIOL INT, V42, P865; Annilo T, 1998, BIOCHEM BIOPH RES CO, V249, P759, DOI 10.1006/bbrc.1998.9187; BASKARAN R, 1990, J BIOL CHEM, V265, P21039; BASKARAN R, 1991, BIOCHEM BIOPH RES CO, V179, P1491, DOI 10.1016/0006-291X(91)91741-T; BUSCH H, 1970, NUCLEUS, P161; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Donaldson IM, 2000, J BIOL CHEM, V275, P13780, DOI 10.1074/jbc.275.18.13780; FALKNER FG, 1988, VIROLOGY, V164, P450, DOI 10.1016/0042-6822(88)90559-4; GATEWOOD JM, 1987, SCIENCE, V236, P962, DOI 10.1126/science.3576213; KEIME S, 1992, ANIM GENET, V23, P373, DOI 10.1111/j.1365-2052.1992.tb00161.x; KLEENE KC, 1987, J BIOL CHEM, V262, P17272; Klug A, 1999, J MOL BIOL, V293, P215, DOI 10.1006/jmbi.1999.3007; KUNDU TK, 1994, FEBS LETT, V351, P6, DOI 10.1016/0014-5793(94)00799-3; KUNDU TK, 1995, BIOCHEMISTRY-US, V34, P5143, DOI 10.1021/bi00015a027; Kundu TK, 1999, J BIOCHEM, V125, P217, DOI 10.1093/oxfordjournals.jbchem.a022276; Kundu TK, 1996, BIOCHEMISTRY-US, V35, P15626, DOI 10.1021/bi961271i; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JL, 1997, J VIROL, V71, P3188, DOI 10.1128/JVI.71.4.3188-3196.1997; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MEARS WE, 1995, J VIROL, V69, P935, DOI 10.1128/JVI.69.2.935-947.1995; Meetei AR, 1996, PROTEIN EXPRES PURIF, V8, P409, DOI 10.1006/prep.1996.0118; Meetei AR, 1998, PROTEIN EXPRES PURIF, V13, P184, DOI 10.1006/prep.1998.0887; Meetei AR, 1998, ANAL BIOCHEM, V264, P288; Meistrich M., 1989, HISTONES OTHER BASIC, P165; NELSON JE, 1993, J BIOL CHEM, V268, P2932; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Pittoggi C, 1999, J CELL SCI, V112, P3537; RIKKONEN M, 1992, VIROLOGY, V189, P462, DOI 10.1016/0042-6822(92)90570-F; Sato H, 1999, PROTEIN EXPRES PURIF, V16, P454, DOI 10.1006/prep.1999.1095; SINGH J, 1987, J BIOL CHEM, V262, P734; SINGH J, 1988, BIOCHEM INT, V17, P701; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; Wolfe SA, 1999, J MOL BIOL, V285, P1917, DOI 10.1006/jmbi.1998.2421; Yu YE, 2000, P NATL ACAD SCI USA, V97, P4683, DOI 10.1073/pnas.97.9.4683	38	25	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38500	38507		10.1074/jbc.M002734200	http://dx.doi.org/10.1074/jbc.M002734200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10961985	hybrid			2022-12-27	WOS:000165739800050
J	Howorka, S; Sara, M; Wang, YJ; Kuen, B; Sleytr, UB; Lubitz, W; Bayley, H				Howorka, S; Sara, M; Wang, YJ; Kuen, B; Sleytr, UB; Lubitz, W; Bayley, H			Surface-accessible residues in the monomeric and assembled forms of a bacterial surface layer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCAL ALPHA-HEMOLYSIN; BACILLUS-STEAROTHERMOPHILUS STRAINS; CYSTEINE SCANNING MUTAGENESIS; CELL-WALL POLYMER; N-TERMINAL PART; S-LAYER; ESCHERICHIA-COLI; OUTER-MEMBRANE; CAULOBACTER-CRESCENTUS; AEROMONAS-SALMONICIDA	The S-layer protein SbsB of the thermophilic, Grampositive organism Bacillus stearothermophilus PV72/p2 forms a crystalline, porous array constituting the outermost component of the cell envelope. SbsB has a molecular mass of 98 kDa, and the corresponding S-layer exhibits an oblique lattice symmetry. To investigate the molecular structure and assembly of SbsB, we replaced 75 residues (mainly serine, threonine, and alanine), located throughout the primary sequence, with cysteine, which is not found in the wild-type protein. As determined by electron microscopy, 72 out of 75 mutants formed regularly-structured self-assembly products identical to wild-type, thereby proving that the replacement of most of the selected amino acids by cysteine does not dramatically alter the structure of the protein. The three defective mutants, which showed a greatly reduced ability to self-assemble, were, however, successfully incorporated into S-layers of wild-type protein. Monomeric SbsB mutants and SbsB mutants assembled into S-layers were subjected to a surface accessibility screen by targeted chemical modification with a 5-kDa hydrophilic cysteine-reactive polyethylene glycol conjugate. In the monomeric form of SbsB, 34 of the examined residues were not surface accessible, while 23 were classified as very accessible, and 18 were of intermediate surface accessibility. By contrast, in the assembled Slayers, 57 of the mutated residues were not accessible, six were very accessible, and 12 of intermediate accessibility. Together with other structural information, the results suggest a model for SbsB in which functional domains are segregated along the length of the polypeptide chain.	Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Univ Agr Sci, Ctr Ultrastruct Res, A-1180 Vienna, Austria; Univ Agr Sci, Ludwig Boltzmann Inst Mol Nanotechnol, A-1180 Vienna, Austria; Univ Vienna, Inst Genet & Microbiol, A-1030 Vienna, Austria; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Natural Resources & Life Sciences, Vienna; Ludwig Boltzmann Institute; University of Natural Resources & Life Sciences, Vienna; University of Vienna; Texas A&M University System; Texas A&M University College Station	Howorka, S (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Biochem & Genet, 440 Reynolds Med Bldg, College Stn, TX 77843 USA.			Howorka, Stefan/0000-0002-6527-2846; Bayley, Hagan/0000-0003-2499-6116				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; BEVERIDGE TJ, 1994, CURR OPIN STRUC BIOL, V4, P204, DOI 10.1016/S0959-440X(94)90309-3; Bingle WH, 1997, MOL MICROBIOL, V26, P277, DOI 10.1046/j.1365-2958.1997.5711932.x; Bingle WH, 1997, J BACTERIOL, V179, P601, DOI 10.1128/jb.179.3.601-611.1997; Boot HJ, 1996, MOL MICROBIOL, V21, P1117, DOI 10.1046/j.1365-2958.1996.711442.x; Chami M, 1997, MOL MICROBIOL, V23, P483, DOI 10.1046/j.1365-2958.1997.d01-1868.x; Cheley S, 1997, PROTEIN ENG, V10, P1433, DOI 10.1093/protein/10.12.1433; CHU S, 1991, J BIOL CHEM, V266, P15258; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Demchick P, 1996, J BACTERIOL, V178, P768, DOI 10.1128/jb.178.3.768-773.1996; DOIG P, 1993, J MOL BIOL, V233, P753, DOI 10.1006/jmbi.1993.1550; DWORKIN J, 1995, J BACTERIOL, V177, P1734, DOI 10.1128/jb.177.7.1734-1741.1995; Engelhardt H, 1998, J STRUCT BIOL, V124, P276, DOI 10.1006/jsbi.1998.4070; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Howorka S, 1998, BIOTECHNIQUES, V25, P764, DOI 10.2144/98255bm03; HUFF JP, 1990, BIOTECHNIQUES, V9, P570; Jones Douglas H., 1995, P591; Kleinschmidt JH, 1999, PROTEIN SCI, V8, P2065, DOI 10.1110/ps.8.10.2065; KLOSE M, 1988, J BIOL CHEM, V263, P13291; KRISHNASASTRY M, 1994, FEBS LETT, V356, P66, DOI 10.1016/0014-5793(94)01240-7; Kuen B, 1997, J BACTERIOL, V179, P1664, DOI 10.1128/jb.179.5.1664-1670.1997; KURFURST MM, 1992, ANAL BIOCHEM, V200, P244, DOI 10.1016/0003-2697(92)90460-O; LUPAS A, 1994, J BACTERIOL, V176, P1224, DOI 10.1128/jb.176.5.1224-1233.1994; Mesnage S, 1999, MOL MICROBIOL, V31, P927, DOI 10.1046/j.1365-2958.1999.01232.x; MESSNER P, 1984, INT J SYST BACTERIOL, V34, P202, DOI 10.1099/00207713-34-2-202; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; NAKAMURA K, 1976, J BIOCHEM, V80, P1411, DOI 10.1093/oxfordjournals.jbchem.a131414; NEUBAUER A, 2000, P 4 SEM QUANT MICR Q, P118; Olabarria G, 1996, J BACTERIOL, V178, P4765, DOI 10.1128/jb.178.16.4765-4772.1996; PUM D, 1989, J BACTERIOL, V171, P5296, DOI 10.1128/jb.171.10.5296-5303.1989; REST B, 1994, PROTEINS, V20, P216; Ries W, 1997, J BACTERIOL, V179, P3892, DOI 10.1128/jb.179.12.3892-3898.1997; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Sambrook J., 2002, MOL CLONING LAB MANU; Sara M, 1996, J BACTERIOL, V178, P2108, DOI 10.1128/jb.178.7.2108-2117.1996; Sara M, 1998, J BACTERIOL, V180, P6780; SARA M, 1994, J BACTERIOL, V176, P7182; Sara M, 2000, J BACTERIOL, V182, P859, DOI 10.1128/JB.182.4.859-868.2000; SCHERRER R, 1971, J BACTERIOL, V107, P718, DOI 10.1128/JB.107.3.718-735.1971; Sleytr U.B., 1996, CRYSTALLINE BACTERIA; Sleytr UB, 1999, TRENDS MICROBIOL, V7, P253, DOI 10.1016/S0966-842X(99)01513-9; THOMAS S, 1992, J MOL BIOL, V228, P652, DOI 10.1016/0022-2836(92)90847-D; Tsai CJ, 1997, PROTEIN SCI, V6, P53; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065; WEI J, 1995, BIOCHEMISTRY-US, V34, P6408, DOI 10.1021/bi00019a021; WIEDER KJ, 1979, J BIOL CHEM, V254, P2579	47	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37876	37886		10.1074/jbc.M003838200	http://dx.doi.org/10.1074/jbc.M003838200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10969072	hybrid			2022-12-27	WOS:000165618700077
J	Ji, Y; Lalli, MJ; Babu, GJ; Xu, YF; Kirkpatrick, DL; Liu, LH; Chiamvimonvat, N; Walsh, RA; Shull, GE; Periasamy, M				Ji, Y; Lalli, MJ; Babu, GJ; Xu, YF; Kirkpatrick, DL; Liu, LH; Chiamvimonvat, N; Walsh, RA; Shull, GE; Periasamy, M			Disruption of a single copy of the SERCA2 gene results in altered Ca2+ homeostasis and cardiomyocyte function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; ENHANCED MYOCARDIAL-CONTRACTILITY; CARDIAC NA+-CA2+ EXCHANGER; SODIUM-CALCIUM EXCHANGE; VENTRICULAR MYOCYTES; TRANSGENIC MICE; PROTEIN-LEVELS; HEART-FAILURE; PHOSPHOLAMBAN; PHOSPHORYLATION	A mouse model carrying a null mutation in one copy of the sarcoplasmic reticulum (SR) Ca2+-ATPase isoform 2 (SERCA2) gene, in which SERCA2 protein levels are reduced by similar to 35%, was used to investigate the effects of decreased SERCA2 level on intracellular Ca2+ homeostasis and contractile properties in isolated cardiomyocytes, When compared with wild-type controls, SR Ca2+ stores and Ca2+ release in myocytes of SERCA2 heterozygous mice were decreased by similar to 40-60% and similar to 30-40%, respectively, and the rate of myocyte shortening and relengthening were each decreased by similar to 40%. However, the rate of Ca2+ transient decline (tau) was not altered significantly, suggesting that compensation was occurring in the removal of Ca2+ from the cytosol, Phospholamban, which inhibits SERCA2, was decreased by similar to 40% in heterozygous hearts, and basal phosphorylation of Ser-16 and Thr-17, which relieves the inhibition, was increased similar to2- and 2.1-fold. These results indicate that reduced expression and increased phosphorylation of phospholamban provides compensation for decreased SERCA2 protein levels in heterozygous heart. Furthermore, both expression and current density of the sarcolemmal Na+-Ca2+ exchanger were up-regulated, These results demonstrate that a decrease in SERCA2 levels can directly modify intracellular Ca2+ homeostasis and myocyte contractility. However, the resulting deficit is partially compensated by alterations in phospholamban/SERCA2 interactions and by up-regulation of the Na+-Ca2+ exchanger.	Univ Cincinnati, Coll Med, Div Cardiol, Dept Internal Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Case Western Reserve University; University Hospitals of Cleveland	Periasamy, M (corresponding author), Univ Cincinnati, Coll Med, Div Cardiol, Dept Internal Med, 231 Bethesda Ave,ML 0542, Cincinnati, OH 45267 USA.	muthu.periasamy@UC.edu	Babu, Gopal/AAB-7787-2021	Babu, Gopal/0000-0001-7833-5300; Periasamy, Muthu/0000-0001-8834-5975	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061974, P50HL052318, R01HL068507, R01HL064140] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL64140-01, HL52318, R01 HL068507, HL61974] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AdachiAkahane S, 1997, J GEN PHYSIOL, V109, P717, DOI 10.1085/jgp.109.6.717; ARAI M, 1994, CIRC RES, V74, P555, DOI 10.1161/01.RES.74.4.555; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; Baker DL, 1998, CIRC RES, V83, P1205, DOI 10.1161/01.RES.83.12.1205; BARRY WH, 1993, CIRCULATION, V87, P1806, DOI 10.1161/01.CIR.87.6.1806; BASSANI JWM, 1994, J PHYSIOL-LONDON, V476, P279, DOI 10.1113/jphysiol.1994.sp020130; BERS DM, 1991, EXCITATION CONTRACTI; BEUCKELMANN DJ, 1989, J PHYSIOL-LONDON, V414, P499, DOI 10.1113/jphysiol.1989.sp017700; Bhogal MS, 1998, P NATL ACAD SCI USA, V95, P1484, DOI 10.1073/pnas.95.4.1484; Cernohorsky J, 1998, AM J PHYSIOL-HEART C, V275, pH264, DOI 10.1152/ajpheart.1998.275.1.H264; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; Dipla K, 1999, CIRC RES, V84, P435, DOI 10.1161/01.RES.84.4.435; DRAGO GA, 1994, BIOCHEM J, V269, P20573; EGGERMONT JA, 1990, BIOCHEM J, V271, P649, DOI 10.1042/bj2710649; GIAS AU, 2000, CIRC RES, V86, P558; Greene AL, 2000, J BIOL CHEM, V275, P24722, DOI 10.1074/jbc.M001783200; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; HARRER JM, 1995, BIOTECHNIQUES, V18, P995; Hasenfuss G, 1999, CIRCULATION, V99, P641, DOI 10.1161/01.CIR.99.5.641; Ji Y, 1999, AM J PHYSIOL-HEART C, V276, pH89, DOI 10.1152/ajpheart.1999.276.1.H89; Ji Y, 1999, ANAL BIOCHEM, V269, P236, DOI 10.1006/abio.1999.4059; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Li L, 1998, AM J PHYSIOL-HEART C, V274, pH1335, DOI 10.1152/ajpheart.1998.274.4.H1335; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; Litwin S, 1996, ANN NY ACAD SCI, V779, P451, DOI 10.1111/j.1749-6632.1996.tb44820.x; Loukianov E, 1998, CIRC RES, V83, P889; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Mattiello JA, 1998, CARDIOVASC RES, V37, P424, DOI 10.1016/S0008-6363(97)00271-X; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NEGRETTI N, 1993, CARDIOVASC RES, V27, P1826, DOI 10.1093/cvr/27.10.1826; Pawloski-Dahm CM, 1998, CIRCULATION, V97, P1508; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Reddy LG, 1999, BIOCHEMISTRY-US, V38, P3954, DOI 10.1021/bi981795d; Reed TD, 2000, J MOL CELL CARDIOL, V32, P453, DOI 10.1006/jmcc.1999.1095; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; Sato Y, 1998, J BIOL CHEM, V273, P28470, DOI 10.1074/jbc.273.43.28470; SCHWARTZ K, 1981, J MOL CELL CARDIOL, V13, P1071, DOI 10.1016/0022-2828(81)90297-2; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SMITH GL, 1988, J GEN PHYSIOL, V92, P351, DOI 10.1085/jgp.92.3.351; STUDER R, 1994, CIRC RES, V75, P443, DOI 10.1161/01.RES.75.3.443; TADA M, 1974, J BIOL CHEM, V249, P6174; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; Vikstrom KL, 1998, CIRC RES, V82, P773, DOI 10.1161/01.RES.82.7.773; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; Yao AS, 1998, CIRC RES, V82, P657, DOI 10.1161/01.RES.82.6.657; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	50	104	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38073	38080		10.1074/jbc.M004804200	http://dx.doi.org/10.1074/jbc.M004804200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10970890	hybrid			2022-12-27	WOS:000165618700102
J	Bennett, RG; Duckworth, WC; Hamel, FG				Bennett, RG; Duckworth, WC; Hamel, FG			Degradation of amylin by insulin-degrading enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-AMYLOID POLYPEPTIDE; TRANSGENIC MICE; DIABETES-MELLITUS; OVERPRODUCTION; HYPERGLYCEMIA; PURIFICATION; EXPRESSION; SUBSTRATE; PROTEIN	A pathological feature of Type 2 diabetes is deposits in the pancreatic islets primarily composed of amylin (islet amyloid polypeptide). Although much attention has been paid to the expression and secretion of amylin, little is known about the enzymes involved in amylin turnover. Recent reports suggest that insulin-degrading enzyme (IDE) may have specificity for amyloidogenic proteins, and therefore we sought to determine whether amylin is an IDE substrate. Amylin-degrading activity co-purified with IDE from rat muscle through several chromatographic steps. Metalloproteinase inhibitors inactivated amylin-degrading activity with a pattern consistent with the enzymatic properties of IDE, whereas inhibitors of acid and serine proteases, calpains, and the proteasome were ineffective. Amylin degradation was inhibited by insulin in a dose-dependent manner, whereas insulin degradation was inhibited by amylin. Other substrates of IDE such as atrial natriuretic peptide and glucagon also competitively inhibited amylin degradation. Radiolabeled amylin and insulin were both covalently cross-linked to a protein of 110 kDa, and the binding was competitively inhibited by either unlabeled insulin or amylin. Finally, a monoclonal anti-IDE antibody immunoprecipitated both insulin- and amylin-degrading activities. The data strongly suggest that IDE is an amylin-degrading enzyme and plays an important role in the clearance of amylin and the prevention of islet amyloid formation.	Vet Affairs Med Ctr, Med Res Serv 151, Omaha, NE 68105 USA; Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68105 USA; Carl T Hayden Vet Affairs Med Ctr, Endocrinol Sect, Phoenix, AZ 85012 USA; Arizona State Univ, Dept Mol & Cellular Biol, Tempe, AZ 85287 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Nebraska System; University of Nebraska Medical Center; Arizona State University; Arizona State University-Tempe	Bennett, RG (corresponding author), Vet Affairs Med Ctr, Med Res Serv 151, 4101 Woolworth Ave, Omaha, NE 68105 USA.		chene, genevieve/H-8665-2014	chene, genevieve/0000-0002-8368-6460				BENNETT RG, 2000, END SOC 82 ANN M END, P89; BHATHENA SJ, 1985, DIABETES, V34, P121, DOI 10.2337/diabetes.34.2.121; DALESSIO DA, 1994, DIABETES, V43, P1457, DOI 10.2337/diabetes.43.12.1457; DUCKWORT.WC, 1972, P NATL ACAD SCI USA, V69, P3698, DOI 10.1073/pnas.69.12.3698; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; DUCKWORTH WC, 1974, DIABETES, V23, P536, DOI 10.2337/diab.23.6.536; FOX N, 1993, FEBS LETT, V323, P40, DOI 10.1016/0014-5793(93)81444-5; HOPPENER JWM, 1993, DIABETOLOGIA, V36, P1258, DOI 10.1007/BF00400803; Janson J, 1996, P NATL ACAD SCI USA, V93, P7283, DOI 10.1073/pnas.93.14.7283; JOHNSON KH, 1989, NEW ENGL J MED, V321, P513; Kahn SE, 1999, DIABETES, V48, P241, DOI 10.2337/diabetes.48.2.241; Kurochkin IV, 1998, FEBS LETT, V427, P153, DOI 10.1016/S0014-5793(98)00422-0; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; MULLER D, 1991, EUR J BIOCHEM, V202, P285, DOI 10.1111/j.1432-1033.1991.tb16374.x; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; ROTH RA, 1984, ENDOCR RES, V10, P101, DOI 10.3109/07435808409035411; SHII K, 1986, DIABETES, V35, P675, DOI 10.2337/diabetes.35.6.675; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; Vekrellis K, 2000, J NEUROSCI, V20, P1657; Verchere CB, 1996, P NATL ACAD SCI USA, V93, P3492, DOI 10.1073/pnas.93.8.3492; Verchere CB, 1997, HORM METAB RES, V29, P311, DOI 10.1055/s-2007-979042; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; YAGUI K, 1995, EUR J ENDOCRINOL, V132, P487, DOI 10.1530/eje.0.1320487	24	133	141	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36621	36625		10.1074/jbc.M006170200	http://dx.doi.org/10.1074/jbc.M006170200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973971	hybrid			2022-12-27	WOS:000165577700024
J	Kadoya, T; Kishida, S; Fukui, A; Hinoi, T; Michiue, T; Asashima, M; Kikuchi, A				Kadoya, T; Kishida, S; Fukui, A; Hinoi, T; Michiue, T; Asashima, M; Kikuchi, A			Inhibition of Wnt signaling pathway by a novel axin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; MOUSE FUSED LOCUS; F-BOX PROTEIN; BETA-CATENIN; NEGATIVE REGULATOR; DIRECTLY INTERACTS; GENE-EXPRESSION; MAMMALIAN-CELLS; XENOPUS EMBRYOS; PHOSPHATASE 2A	Axin forms a complex with adenomatous polyposis coli gene product, glycogen synthase kinase-3 beta (GSK-3 beta), beta -catenin, DvI, and protein phosphatase 2A and functions as a scaffold protein in the Wnt signaling pathway. In the Axin complex, GSK-3 beta efficiently phosphorylates beta -catenin, which is then ubiquitinated and degraded by proteasome. We isolated a novel protein that binds to Axin and named it Axam (for Axin associating molecule). Axam formed a complex with Axin in intact cells and bound directly to Axin. Axam inhibited the complex formation of DvI with Axin and the activity of DvI to suppress GSK-3 beta -dependent phosphorylation of Axin. Furthermore, Axam induced the degradation of beta -catenin in SW480 cells and inhibited Wnt-dependent axis duplication in Xenopus embryos. These results suggest that Axam regulates the Wnt signaling pathway negatively by inhibiting the binding of DvI to Axin.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Japan Sci & Technol Corp, PRESTO, Hiroshima 7348551, Japan; Univ Tokyo, Dept Life Sci Biol, Meguro Ku, Tokyo 1538902, Japan; Univ Tokyo, CREST Project, Meguro Ku, Tokyo 1538902, Japan	Hiroshima University; Japan Science & Technology Agency (JST); University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.		Hinoi, Takao/AAI-1443-2020; Fukui, Akimasa/F-5284-2011	Hinoi, Takao/0000-0003-0462-6177; kishida, shosei/0000-0003-0405-851X				Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Dale TC, 1998, BIOCHEM J, V329, P209; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Itoh K, 2000, MOL CELL BIOL, V20, P2228, DOI 10.1128/MCB.20.6.2228-2238.2000; Jho EH, 1999, BIOCHEM BIOPH RES CO, V266, P28, DOI 10.1006/bbrc.1999.1760; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kodama S, 1999, J BIOL CHEM, V274, P27682, DOI 10.1074/jbc.274.39.27682; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Maniatis T., 1982, MOL CLONING LAB MANU; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; PERRY WL, 1995, GENETICS, V141, P321; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Ruel L, 1999, J BIOL CHEM, V274, P21790, DOI 10.1074/jbc.274.31.21790; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; Wagner U, 1997, FEBS LETT, V411, P369, DOI 10.1016/S0014-5793(97)00733-3; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yanagawa SI, 1997, J BIOL CHEM, V272, P25243, DOI 10.1074/jbc.272.40.25243; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247	50	48	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37030	37037		10.1074/jbc.M005984200	http://dx.doi.org/10.1074/jbc.M005984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10944533	hybrid			2022-12-27	WOS:000165577700081
J	Sakurai, H; Fukasawa, T				Sakurai, H; Fukasawa, T			Functional connections between mediator components and general transcription factors of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; FACTOR TF IIE; CTD KINASE; IN-VIVO; FINGER PROTEIN; LARGE SUBUNIT; YEAST GAL11; HOLOENZYME; PROMOTER	The yeast Gal11 protein is an important component of the Mediator complex in RNA polymerase II-directed transcription. Gal11 and the general transcription factor (TF) IIE are involved in regulation of the protein kinase activity of TFIIH that phosphorylates the carboxyl-terminal domain of RNA polymerase II. We have previously shown that Gal11 binds the small and large subunits of TFIIE at two Gal11 domains, A and B, respectively, which are important for normal function of Gal11 in vivo. Here we demonstrate that Gal11 binds directly to TFIIH through domain A in vitro. A null mutation in GAL11 caused lethality of cells when combined with temperature-sensitive mutations in the genes encoding TFIIE or the carboxyl-terminal domain kinase, indicating the presence of genetic interactions between Gal11 and these proteins. Mutational depletion of Gal11 or TFIIE caused inefficient opening of the transcription initiation region, but had no significant effect on TATA-binding protein occupancy of the TATA sequence in vivo. These results suggest that the functions of Gal11 and TFIIE are necessary after recruitment of TATA-binding protein to the TATA box presumably at the step of stable preinitiation complex formation and/or promoter melting. We illustrate genetic interactions between Gal11 and other Mediator components such as Med2 and Pgd1/Hrs1/Med3.	Kanazawa Univ, Fac Med, Sch Hlth Sci, Kanazawa, Ishikawa 9200942, Japan; Keio Univ, Sch Med, Dept Microbiol, Shinjyuku Ku, Tokyo 1608582, Japan	Kanazawa University; Keio University	Sakurai, H (corresponding author), Kanazawa Univ, Fac Med, Sch Hlth Sci, 5-11-80 Kodatsuno, Kanazawa, Ishikawa 9200942, Japan.							Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; Bjorklund S, 1999, CELL, V96, P759, DOI 10.1016/S0092-8674(00)80586-3; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; BROHL S, 1994, YEAST, V10, P719, DOI 10.1002/yea.320100604; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; CHEN S, 1993, GENETICS, V134, P701; CHEN SM, 1993, MOL CELL BIOL, V13, P831, DOI 10.1128/MCB.13.2.831; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Faye G, 1997, MOL GEN GENET, V255, P460, DOI 10.1007/s004380050518; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Guzman E, 1999, MOL CELL BIOL, V19, P5652; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; JIANG YW, 1995, GENETICS, V140, P47; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kuldell NH, 1997, MOL CELL BIOL, V17, P5288, DOI 10.1128/MCB.17.9.5288; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Lee YC, 1999, MOL CELL BIOL, V19, P2967; Lee YC, 1998, MOL CELL BIOL, V18, P5364, DOI 10.1128/MCB.18.9.5364; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Parvin JD, 1998, CURR OPIN GENET DEV, V8, P565, DOI 10.1016/S0959-437X(98)80012-9; Piruat JI, 1997, GENETICS, V147, P1585; Roberts SM, 1997, GENETICS, V147, P451; Sakurai H, 1997, J BIOL CHEM, V272, P15936, DOI 10.1074/jbc.272.25.15936; Sakurai H, 1996, P NATL ACAD SCI USA, V93, P9488, DOI 10.1073/pnas.93.18.9488; Sakurai H, 1998, J BIOL CHEM, V273, P9534, DOI 10.1074/jbc.273.16.9534; Sakurai H, 1997, J BIOL CHEM, V272, P32663, DOI 10.1074/jbc.272.51.32663; SERIZAWA H, 1994, J BIOL CHEM, V269, P20750; Song WJ, 1996, MOL CELL BIOL, V16, P115; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; VALLIER LG, 1991, GENETICS, V129, P675	48	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37251	37256		10.1074/jbc.M004364200	http://dx.doi.org/10.1074/jbc.M004364200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973956	hybrid			2022-12-27	WOS:000165577700109
J	Barton, VA; Hall, MA; Hudson, KR; Heath, JK				Barton, VA; Hall, MA; Hudson, KR; Heath, JK			Interleukin-11 signals through the formation of a hexameric receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; CRYSTAL-STRUCTURE; MOLECULAR-CLONING; BINDING SITES; ONCOSTATIN-M; ALPHA-CHAIN; 2 DISTINCT; GP130; IL-6	Interleukin-11 (IL-11) is a member of the gp130 family of cytokines. These cytokines drive the assembly of multisubunit receptor complexes, all of which contain at least one molecule of the transmembrane signaling receptor gp130. IL-11 has been shown to induce gp130-dependent signaling through the formation of a high affinity complex with the IL-11 receptor (IL-11R) and gp130. Site-directed mutagenesis studies have identified three distinct receptor binding sites of IL-11, which enable it to form this high affinity receptor complex. Here we present data from immunoprecipitation experiments, using differentially tagged forms of ligand and soluble receptor components, which show that multiple copies of IL-11, IL-11R, and gp130 are present in the receptor complex. Furthermore, it is demonstrated that sites II and III of IL-11 are independent gp130 binding epitopes and that both are essential for gp130 dimerization. We also show that a stable high affinity complex of IL-11, IL-11R, and gp130 can be resolved by nondenaturing polyacrylamide gel electrophoresis, and its composition verified by second dimension denaturing polyacrylamide gel electrophoresis. Results indicate that the three receptor binding sites of IL-11 and the Ig-like domain of gp130 are all essential for this stable receptor complex to be formed. We therefore propose that IL-11 forms a hexameric receptor complex composed of two molecules each of IL-11, IL-11R, and gp130.	Univ Birmingham, Sch Biosci, Canc Res Campaign Growth Factor Grp, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Heath, JK (corresponding author), Univ Birmingham, Sch Biosci, Canc Res Campaign Growth Factor Grp, Birmingham B15 2TT, W Midlands, England.	j.k.heath@bham.ac.uk						ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; BANK S, 1997, SHOCK, V7, P520; Barton VA, 1999, J BIOL CHEM, V274, P5755, DOI 10.1074/jbc.274.9.5755; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bilinski P, 1998, GENE DEV, V12, P2234, DOI 10.1101/gad.12.14.2234; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; Ciapponi L, 1995, J BIOL CHEM, V270, P31249, DOI 10.1074/jbc.270.52.31249; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; Dahmen H, 1998, BIOCHEM J, V331, P695, DOI 10.1042/bj3310695; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DiMarco A, 1996, P NATL ACAD SCI USA, V93, P9247, DOI 10.1073/pnas.93.17.9247; Du XX, 1997, BLOOD, V89, P3897, DOI 10.1182/blood.V89.11.3897; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Fuhrer DK, 1996, EXP HEMATOL, V24, P195; Gordon MS, 1996, BLOOD, V87, P3615, DOI 10.1182/blood.V87.9.3615.bloodjournal8793615; Grotzinger J, 1999, BIOL CHEM, V380, P803, DOI 10.1515/BC.1999.100; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; Harlow E., 1988, ANTIBODIES LAB MANUA; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hermann JA, 1998, ARTHRITIS RHEUM, V41, P1388, DOI 10.1002/1529-0131(199808)41:8<1388::AID-ART7>3.0.CO;2-F; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; Horsten U, 1997, J BIOL CHEM, V272, P23748, DOI 10.1074/jbc.272.38.23748; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; Karow J, 1996, BIOCHEM J, V318, P489, DOI 10.1042/bj3180489; Kurth I, 1999, J IMMUNOL, V162, P1480; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; Nandurkar HH, 1996, ONCOGENE, V12, P585; Neddermann P, 1996, J BIOL CHEM, V271, P30986, DOI 10.1074/jbc.271.48.30986; Olivier C, 2000, J BIOL CHEM, V275, P5648, DOI 10.1074/jbc.275.8.5648; Owczarek CM, 1997, J BIOL CHEM, V272, P23976, DOI 10.1074/jbc.272.38.23976; PANAYOTATOS N, 1995, J BIOL CHEM, V270, P14007, DOI 10.1074/jbc.270.23.14007; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Robb L, 1998, NAT MED, V4, P303, DOI 10.1038/nm0398-303; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; Schwertschlag US, 1999, LEUKEMIA, V13, P1307, DOI 10.1038/sj.leu.2401514; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989; SONIS S, 1995, ORAL ONCOL, V31B, P261, DOI 10.1016/0964-1955(95)00015-A; Staunton D, 1998, PROTEIN ENG, V11, P1093, DOI 10.1093/protein/11.11.1093; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Timmermann A, 2000, FEBS LETT, V468, P120, DOI 10.1016/S0014-5793(00)01205-9; WALKER PA, 1994, BIO-TECHNOL, V12, P601, DOI 10.1038/nbt0694-601; WANG XY, 1995, J BIOL CHEM, V270, P27999; WARD LD, 1994, J BIOL CHEM, V269, P23286; Warren AJ, 2000, EMBO J, V19, P3004, DOI 10.1093/emboj/19.12.3004; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YIN TG, 1994, J BIOL CHEM, V269, P3731	50	67	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36197	36203		10.1074/jbc.M004648200	http://dx.doi.org/10.1074/jbc.M004648200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10948192	hybrid			2022-12-27	WOS:000165382000078
J	Kashiwagi, K; Kuraishi, A; Tomitori, H; Igarashi, A; Nishimura, K; Shirahata, A; Igarashi, K				Kashiwagi, K; Kuraishi, A; Tomitori, H; Igarashi, A; Nishimura, K; Shirahata, A; Igarashi, K			Identification of the putrescine recognition site on polyamine transport protein PotE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; ORNITHINE DECARBOXYLASE; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; LACTOSE PERMEASE; SYSTEM; SPERMIDINE; BINDING; MECHANISM; GENE	The PotE protein can catalyze both uptake and excretion of putrescine. The K-m, values of putrescine for uptake and excretion are 1.8 and 73 muM respectively. Uptake of putrescine is dependent on the membrane potential, whereas excretion involves putrescine-ornithine antiporter activity. Amino acids involved in both activities were identified using mutated PotE proteins. It was found that Cys(62), Trp(201), Trp(292),,d Tyr(425) were strongly involved in both activities, and that Tyr(92), Cys(210) Cys(285), and Cys(286) were moderately involved in the activities. Mutations of Tyr(78), Trp(90), and Trp(422) mainly affected uptake activity, and the K-m, values for putrescine uptake by these PotE mutants increased greatly, indicating that these amino acids are involved in the high affinity uptake of putrescine by PotE. Mutations of Lys(301) and Tyr(308) mainly affected excretion activity (putrescine-ornithine antiporter activity), and excretion by these mutants was not stimulated by ornithine, indicating that these amino acids are involved in the recognition of ornithine. It was found that the putrescine and ornithine recognition site on PotE is located at the cytoplasmic surface and the vestibule of the pore consisting of 12 transmembrane segments. Based on the results of competition experiments with various putrescine analogues and the disulfide cross-linking of PotE between cytoplasmic loops and the COOH terminus, a model of the putrescine recognition site on PotE consisting of the identified amino acids is presented.	Chiba Univ, Fac Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan; Niigata Univ, Sch Dent, Niigata 9518514, Japan; Josai Univ, Fac Pharmaceut Sci, Sakado, Saitama 3500295, Japan	Chiba University; Niigata University; Josai University	Igarashi, K (corresponding author), Chiba Univ, Fac Pharmaceut Sci, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan.			Nishimura, Kazuhiro/0000-0002-6209-5522; Igarashi, Kazuei/0000-0003-3751-3187				AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; CUNNINGHAMRUNDLES S, 1975, J BACTERIOL, V124, P791, DOI 10.1128/JB.124.2.791-799.1975; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Hu LA, 1998, J BIOL CHEM, V273, P20162, DOI 10.1074/jbc.273.32.20162; Igarashi K, 1999, BIOCHEM J, V344, P633, DOI 10.1042/0264-6021:3440633; KABACK HR, 1987, BIOCHEMISTRY-US, V26, P2071, DOI 10.1021/bi00382a001; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KASHIWAGI K, 1994, BIOCHEM BIOPH RES CO, V200, P591, DOI 10.1006/bbrc.1994.1489; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KASHIWAGI K, 1991, J BIOL CHEM, V266, P20922; Kashiwagi K, 1997, J BIOL CHEM, V272, P6318, DOI 10.1074/jbc.272.10.6318; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; Kashiwagi K, 1996, J BIOL CHEM, V271, P12205, DOI 10.1074/jbc.271.21.12205; KASHIWAGI K, 1988, J BACTERIOL, V170, P3131, DOI 10.1128/jb.170.7.3131-3135.1988; Kubo Y, 2000, J BIOL CHEM, V275, P5270, DOI 10.1074/jbc.275.8.5270; LEE JI, 1992, J BIOL CHEM, V267, P20758; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NIELSEN PJ, 1982, J BIOL CHEM, V257, P2316; PEGG AE, 1988, CANCER RES, V48, P759; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; POOLMAN B, 1992, J BIOL CHEM, V267, P9150; SAHINTOTH M, 1994, P NATL ACAD SCI USA, V91, P5421, DOI 10.1073/pnas.91.12.5421; Sambrook J., 1989, MOL CLONING LAB MANU, pA9; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; SHIRAHATA A, 1991, BIOCHEM PHARMACOL, V41, P205, DOI 10.1016/0006-2952(91)90478-N; Sugiyama S, 1996, J BIOL CHEM, V271, P9519, DOI 10.1074/jbc.271.16.9519; Sugiyama S, 1996, PROTEIN SCI, V5, P1984, DOI 10.1002/pro.5560051004; Sun JZ, 1997, BIOCHEMISTRY-US, V36, P11959, DOI 10.1021/bi971172k; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Tomitori H, 1999, J BIOL CHEM, V274, P3265, DOI 10.1074/jbc.274.6.3265; Vassylyev DG, 1998, J BIOL CHEM, V273, P17604, DOI 10.1074/jbc.273.28.17604; Wu JH, 1997, J MOL BIOL, V270, P285, DOI 10.1006/jmbi.1997.1099; YAMAGUCHI A, 1992, BIOCHEMISTRY-US, V31, P8344, DOI 10.1021/bi00150a031	36	53	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36007	36012		10.1074/jbc.M006083200	http://dx.doi.org/10.1074/jbc.M006083200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964926	hybrid			2022-12-27	WOS:000165382000052
J	Sakamoto, Y; Taguchi, T; Honke, K; Korekane, H; Watanabe, H; Tano, Y; Dohmae, N; Takio, K; Horii, A; Taniguchi, N				Sakamoto, Y; Taguchi, T; Honke, K; Korekane, H; Watanabe, H; Tano, Y; Dohmae, N; Takio, K; Horii, A; Taniguchi, N			Molecular cloning and expression of cDNA encoding chicken UDP-N-acetyl-D-glucosamine (GlcNAc): GlcNAc beta 1-6(GlcNAc beta 1-2)-Man alpha 1-R[GlcNAc to Man]beta 1,4N-acetylglucosaminyltransferase VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN UDP-N-ACETYLGLUCOSAMINE-ALPHA-1,3-D-MANNOSIDE BETA-1,4-N-ACETYLGLUCOSAMINY; ACETYLGLUCOSAMINYLTRANSFERASE-V; GLYCOPROTEIN-SYNTHESIS; ORYZIAS-LATIPES; SUGAR CHAINS; RAT-KIDNEY; PURIFICATION; IV; ENZYME; LIVER	A cDNA that encodes UDP-N-acetyl-D-glucosamine (GlcNAc):GlcNAc beta1-6(GlcNAc beta1-2)Man alpha1-R[GlcNAc to Man]beta1,4N-acetylglucosaminyltransferase VI (GnT VI), which is responsible for the formation of pentaantennary asparagine-linked oligosaccharides (N-glycans), has been cloned from a hen oviduct cDNA library based on the partial amino acid sequences of the purified enzyme. The isolated cDNA clone contained an open reading frame encoding 464 amino acids, including all of the peptides that were sequenced. The deduced amino acid sequence predicts a type II transmembrane topology and contains two potential N-glycosylation sites. The primary structure was found to be significantly similar to human GnT IV-homologue, the gene for which was cloned from the deleted region in pancreatic cancer, and to human and bovine GnT IVs, Chicken GnT VI-transfected COS-1 cells showed a high GnT VI activity (26.8 pmol/h/mg protein), whereas nontransfected, mock-transfected, or human GnT IV-homologue-transfected COS-l cells had no activity. Northern blot analysis using poly(A)(+) RNA from hen oviduct indicated that the size of GnT VT mRNA is 2.1 kilobases, Reverse transcription-polymerase chain reaction analysis showed that GnT VI mRNA was relatively highly expressed in oviduct, spleen, lung, and colon.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan; RIKEN, Inst Phys & Chem Res, Synthet Cellular Chem Lab, Wako, Saitama 3510198, Japan; RIKEN, Inst Phys & Chem Res, Div Biomol Characterizat, Wako, Saitama 3510198, Japan; Tohoku Univ, Sch Med, Dept Mol Pathol, Aoba Ku, Sendai, Miyagi 9808575, Japan	Osaka University; Osaka University; RIKEN; RIKEN; Tohoku University	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Horii, Akira/AAW-2839-2021; Taniguchi, Naoyuki/A-7086-2016; Taguchi, Tomohiko/I-5014-2019; Taniguchi, Naoyuki/I-4182-2014; Dohmae, Naoshi/C-2040-2011	Horii, Akira/0000-0002-3967-3291; Taguchi, Tomohiko/0000-0003-0464-6370; Taniguchi, Naoyuki/0000-0001-5889-5968; Dohmae, Naoshi/0000-0002-5242-9410				BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BROCKHAUSEN I, 1989, J BIOL CHEM, V264, P11211; Buckhaults P, 1997, J BIOL CHEM, V272, P19575, DOI 10.1074/jbc.272.31.19575; DAGOSTARO GAF, 1995, J BIOL CHEM, V270, P15211, DOI 10.1074/jbc.270.25.15211; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Furukawa T, 1999, J HUM GENET, V44, P397, DOI 10.1007/s100380050186; GU J, J BIOCH TOKYO, V113, P614; Ihara Y, 1997, J BIOL CHEM, V272, P9629; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; KITAJIMA K, 1989, DEV BIOL, V132, P544, DOI 10.1016/0012-1606(89)90249-2; KOBATA A, 1988, J CELL BIOCHEM, V37, P79, DOI 10.1002/jcb.240370108; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; Minowa MT, 1998, J BIOL CHEM, V273, P11556, DOI 10.1074/jbc.273.19.11556; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; Oguri S, 1997, J BIOL CHEM, V272, P22721, DOI 10.1074/jbc.272.36.22721; OPPENHEIMER CL, 1981, J BIOL CHEM, V256, P799; PARENTE JP, 1982, J BIOL CHEM, V257, P13173; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; Taguchi T, 1997, BIOCHEM BIOPH RES CO, V230, P533, DOI 10.1006/bbrc.1996.6013; Taguchi T, 1998, ANAL BIOCHEM, V255, P155, DOI 10.1006/abio.1997.2465; Taguchi T, 2000, J BIOL CHEM, V275, P32598, DOI 10.1074/jbc.M004673200; TAGUCHI T, 1995, GLYCOBIOLOGY, V5, P611, DOI 10.1093/glycob/5.6.611; Xu NX, 1997, J AM SOC MASS SPECTR, V8, P116, DOI 10.1016/S1044-0305(96)00233-4; YAMASHITA K, 1982, J BIOL CHEM, V257, P2809; Yoshida A, 1998, GLYCOCONJUGATE J, V15, P1115, DOI 10.1023/A:1006951519522; Yoshida A, 1999, GLYCOBIOLOGY, V9, P303, DOI 10.1093/glycob/9.3.303	34	9	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36029	36034		10.1074/jbc.M005860200	http://dx.doi.org/10.1074/jbc.M005860200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10962001	hybrid			2022-12-27	WOS:000165382000055
J	Silva, AM; Reis, LFL				Silva, AM; Reis, LFL			Sodium salicylate induces the expression of the immunophilin FKBP51 and Biglycan genes and inhibits p34(cdc2) mRNA both in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACETYLSALICYLIC-ACID; C-KROX; TRANSCRIPTIONAL ACTIVATION; ALPHA PHOSPHORYLATION; ALZHEIMERS-DISEASE; ENDOTHELIAL-CELLS; PROTEIN-KINASE; ASPIRIN	One of the mechanisms proposed to explain the antiinflammatory, activity of sodium salicylate (NaSal) is based, at least in part, on its ability to inhibit nuclear factor-kappaB activation and inhibition of nuclear factor-kappaB-dependent gene expression. On the other hand, little is known about the ability of NaSal to activate gene expression. By differential display reverse transcription polymerase chain reaction, we identified several genes that are modulated upon treatment of mouse fibroblasts with NaSal. From the various cDNA fragments recovered from autoradiograms, we found that NaSal can increase the levels of mRNA for biglycan, the mouse homologue of the human eIF-3 p47 unit, and immunophilin FRBP51. NaSal-induced expression of these genes was time- and dose-dependent. Moreover, FKBP51 gene expression was augmented in vivo, in mice treated orally or intraperitoneally with NaSal, We also found that treating,cells with NaSal can inhibit the expression of the p34(cdc2) kinase. The impact this inhibition on cell cycle was evaluated by measuring the content of DNA during the cell cycle. Treatment of cells with NaSal led to a G(2)/M arrest. By investigating the signaling events that regulate the expression of these genes and their biological activities, we can contribute to the understanding of the mechanism of NaSal.	Ludwig Inst Canc Res, Lab Inflammat, BR-01509010 Sao Paulo, SP, Brazil; Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil	Ludwig Institute for Cancer Research; Universidade Federal de Minas Gerais	Reis, LFL (corresponding author), Ludwig Inst Canc Res, Lab Inflammat, Rua Prof Antonio Prudente 109-4th Floor Liberdade, BR-01509010 Sao Paulo, SP, Brazil.		Reis, Luiz F. L./C-4556-2013; Silva, Aristóbolo/AAA-2239-2021; Silva, Aristobolo/CAF-4874-2022; Silva, Aristobolo AMS/F-7326-2016	Silva, Aristóbolo/0000-0001-7473-7433; Reis, Luiz/0000-0002-4040-2456				ABRAMSON S, 1989, CLIN EXP RHEUMATOL, V7, pS163; ALTMEYER A, 1995, J BIOL CHEM, V270, P25584, DOI 10.1074/jbc.270.43.25584; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BAUGHMAN G, 1995, MOL CELL BIOL, V15, P4395; BAUGHMAN G, 1991, MOL ENDOCRINOL, V5, P637, DOI 10.1210/mend-5-5-637; Bitko V, 1997, VIROLOGY, V232, P369, DOI 10.1006/viro.1997.8582; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRONSTEIN BN, 1994, INFLAMMATION, V18, P323, DOI 10.1007/BF01534273; Damme B, 1996, TOXICOLOGY, V106, P99, DOI 10.1016/0300-483X(95)03168-F; Elder DJE, 1996, CANCER RES, V56, P2273; Farivar RS, 1996, CIRC RES, V78, P759; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; Galera P, 1996, J BIOL CHEM, V271, P21331, DOI 10.1074/jbc.271.35.21331; GAUTAM SC, 1995, BLOOD, V86, P2541; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Heegaard AM, 1997, J BONE MINER RES, V12, P2050, DOI 10.1359/jbmr.1997.12.12.2050; Housby JN, 1999, CYTOKINE, V11, P347, DOI 10.1006/cyto.1998.0437; JURIVICH DA, 1995, J BIOL CHEM, V270, P24489, DOI 10.1074/jbc.270.41.24489; Kagawa A, 1999, J BIOL CHEM, V274, P34111, DOI 10.1074/jbc.274.48.34111; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIU RY, 1994, J CELL SCI, V107, P2209; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; OETH P, 1995, BLOOD, V86, P4144, DOI 10.1182/blood.V86.11.4144.bloodjournal86114144; OHMORI Y, 1995, J IMMUNOL, V155, P3593; PANKOW D, 1994, ARCH TOXICOL, V68, P261, DOI 10.1007/s002040050066; Perugini RA, 2000, J GASTROINTEST SURG, V4, P24, DOI 10.1016/S1091-255X(00)80029-3; Pierce JW, 1996, J IMMUNOL, V156, P3961; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; ROSENKRANZ B, 1986, BRIT J CLIN PHARMACO, V21, P309, DOI 10.1111/j.1365-2125.1986.tb05195.x; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023; SPURR NK, 1990, J DNA SEQUENCING MAP, V1, P49; Stevenson MA, 1999, J IMMUNOL, V163, P5608; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Ungefroren H, 1998, J BIOL CHEM, V273, P29230, DOI 10.1074/jbc.273.44.29230; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WEGROWSKI Y, 1995, GENOMICS, V30, P8, DOI 10.1006/geno.1995.0002; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; WU KK, 1991, P NATL ACAD SCI USA, V88, P2384, DOI 10.1073/pnas.88.6.2384; Xia LJ, 1998, BLOOD, V91, P1625, DOI 10.1182/blood.V91.5.1625.1625_1625_1632; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11081, DOI 10.1073/pnas.92.24.11081; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	46	8	8	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36388	36393		10.1074/jbc.M005887200	http://dx.doi.org/10.1074/jbc.M005887200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10962002	hybrid			2022-12-27	WOS:000165382000103
J	Biere, AL; Wood, SJ; Wypych, J; Steavenson, S; Jiang, YJ; Anafi, D; Jacobsen, FW; Jarosinski, MA; Wu, GM; Louis, JC; Martin, F; Narhi, LO; Citron, M				Biere, AL; Wood, SJ; Wypych, J; Steavenson, S; Jiang, YJ; Anafi, D; Jacobsen, FW; Jarosinski, MA; Wu, GM; Louis, JC; Martin, F; Narhi, LO; Citron, M			Parkinson's disease-associated alpha-sylnuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; LEWY-BODY-DISEASE; NO PATHOGENIC MUTATIONS; NACP/ALPHA-SYNUCLEIN; IN-VITRO; CYTOPLASMIC INCLUSIONS; GENE; AGGREGATION; DEMENTIA; BODIES	Parkinson's disease (PD) is a neurodegenerative disorder that is pathologically characterized by the presence of intracytoplasmic Lewy bodies. Recently, two point mutations in alpha -synuclein were found to be associated with familial PD, but as of yet no mutations have been described in the homologous genes beta- and gamma -synuclein. alpha -Synuclein forms the major fibrillar component of Lewy bodies, but these do not stain for beta- or gamma -synuclein. This result is very surprising, given the extent of sequence conservation and the high similarity in expression and subcellular localization, in particular between alpha- and beta -synuclein, Here we compare in vitro fibrillogenesis of all three purified synucleins, We show that fresh solutions of alpha-, beta-, and gamma- synuclein show the same natively unfolded structure. While over time alpha -synuclein forms the previously described fibrils, no fibrils could be defected for beta- and gamma -synuclein under the same conditions. Most importantly, beta- and gamma -synuclein could not be cross-seeded with alpha -synuclein fibrils. How ever, under conditions that drastically accelerate aggregation, gamma -synuclein can form fibrils with a lag phase roughly three times longer than alpha -synuclein. These results indicate that beta- and gamma -synuclein are intrinsically less fibrillogenic than alpha -synuclein and cannot form mixed fibrils with alpha -synuclein, which mag explain why they do not appear in the pathological hallmarks of PD, although they are closely related to alpha -synuclein and are also abundant in brain.	Amgen Inc, Thousand Oaks, CA 91320 USA	Amgen	Biere, AL (corresponding author), Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.							ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; Arai T, 1999, NEUROSCI LETT, V259, P83, DOI 10.1016/S0304-3940(98)00890-8; Arima K, 1998, ACTA NEUROPATHOL, V96, P439, DOI 10.1007/s004010050917; Baba M, 1998, AM J PATHOL, V152, P879; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DONG AC, 1995, J PHARM SCI-US, V84, P415, DOI 10.1002/jps.2600840407; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Ji HJ, 1997, CANCER RES, V57, P759; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lavedan C, 1998, GENOMICS, V54, P173, DOI 10.1006/geno.1998.5556; Lewy F.H., 2017, HDB NEUROLOGIE, V3, P920; Lincoln S, 1999, NEUROSCI LETT, V259, P65, DOI 10.1016/S0304-3940(98)00901-X; Lincoln S, 1999, NEUROSCI LETT, V269, P107, DOI 10.1016/S0304-3940(99)00420-6; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509	36	142	149	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34574	34579		10.1074/jbc.M005514200	http://dx.doi.org/10.1074/jbc.M005514200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942772	hybrid			2022-12-27	WOS:000165095300078
J	Hicks-Berger, CA; Chadwick, BP; Frischauf, AM; Kirley, TL				Hicks-Berger, CA; Chadwick, BP; Frischauf, AM; Kirley, TL			Expression and characterization of soluble and membrane-bound human nucleoside triphosphate diphosphohydrolase 6 (CH39L2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN ECTO-APYRASE; SACCHAROMYCES-CEREVISIAE; GUANOSINE DIPHOSPHATASE; FUNCTIONAL EXPRESSION; TRANSVERSE TUBULE; SKELETAL-MUSCLE; PURIFICATION; PROTEINS; GLYCOSYLATION; ATPASES	Ecto-nucleoside-triphosphate diphosphohydrolase-6 (eNTPDase6(1), also known as CD39L2) cDNA was expressed in mammalian COS-1 cells and characterized using nucleotidase assays as well as size exclusion, anion exchange, and cation exchange chromatography. The deduced amino acid sequence of eNTPDase6 is more homologous with the soluble E-type ATPase, eNTPDase5, than other E-type ATPases, suggesting it may also be soluble. To test this possibility, both the cell membranes and the growth media from eNTPDase6-transfected COS-1 cells were assayed for nucleotidase activities. Activity was found in both the membranes and the media. Soluble eNTPDase6 preferentially exhibits nucleoside diphosphatase activity, which is dependent on the presence of divalent cations. Western blot analysis of eNTPDase6 treated with PNGase-F indicated both soluble and membrane-bound forms are glycosylated. However, unlike some membrane-bound ecto-nucleotidases, the eNTPDase6 activity was not specifically inhibited by deglycosylation with peptide N-glycosidase F. Soluble eNTPDase6 hydrolyzed nucleoside triphosphates poorly and nucleoside monophosphates not at all. Analysis of the relative rates of hydrolysis of nucleoside diphosphates (GDP = IDP > UDP > CDP much greater than ADP) suggests that soluble eNTPDase6 is a diphosphatase most likely not involved in regulation of ADP levels important for circulatory hemostasis.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Salzburg Univ, Inst Genet & Allgemeine Biol, A-5020 Salzburg, Austria	University System of Ohio; University of Cincinnati; Case Western Reserve University; Salzburg University	Kirley, TL (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA.			Kirley, Terence/0000-0002-6211-1414; Chadwick, Brian/0000-0001-5272-8384	NHLBI NIH HHS [HL59915] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059915] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; AMESCH S, 1999, BIOCHEMISTRY-US, V38, P2248; Arca B, 1999, P NATL ACAD SCI USA, V96, P1516, DOI 10.1073/pnas.96.4.1516; Chadwick BP, 1998, GENOMICS, V50, P357, DOI 10.1006/geno.1998.5317; CORITRAVERSO A, 1970, ARCH BIOCH BIPHYS, V137, P133; Dzhandzhugazyan KN, 2000, BBA-BIOMEMBRANES, V1466, P267, DOI 10.1016/S0005-2736(00)00169-3; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gao XD, 1999, J BIOL CHEM, V274, P21450, DOI 10.1074/jbc.274.30.21450; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; Hicks-Berger CA, 2000, IUBMB LIFE, V50, P43; KIRLEY TL, 1988, J BIOL CHEM, V263, P12682; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LewisCarl S, 1997, J BIOL CHEM, V272, P23645, DOI 10.1074/jbc.272.38.23645; Mateo J, 1999, BRIT J PHARMACOL, V128, P396, DOI 10.1038/sj.bjp.0702805; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Miles E W, 1977, Methods Enzymol, V47, P431; Mulero JJ, 1999, J BIOL CHEM, V274, P20064, DOI 10.1074/jbc.274.29.20064; PLESNER L, 1995, INT REV CYTOL, V158, P141; SABORIDO A, 1991, J BIOL CHEM, V266, P23490; SARKIS J, 1986, BIOCHEM J, V223, P885; Smith TM, 1999, BIOCHEMISTRY-US, V38, P1509, DOI 10.1021/bi9821768; Smith TM, 1997, ARCH BIOCHEM BIOPHYS, V337, P351, DOI 10.1006/abbi.1996.9779; Smith TM, 1998, BBA-PROTEIN STRUCT M, V1386, P65, DOI 10.1016/S0167-4838(98)00063-6; Smith TM, 1999, BIOCHEMISTRY-US, V38, P321, DOI 10.1021/bi9820457; Smith TM, 1997, ECTO-ATPASES, P135; STOSCHECK CM, 1990, ANAL BIOCHEM, V184, P111, DOI 10.1016/0003-2697(90)90021-Z; Trombetta ES, 1999, EMBO J, V18, P3282, DOI 10.1093/emboj/18.12.3282; Wang TF, 1998, J BIOL CHEM, V273, P24814, DOI 10.1074/jbc.273.38.24814; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351	29	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34041	34045		10.1074/jbc.M004723200	http://dx.doi.org/10.1074/jbc.M004723200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10948193	hybrid			2022-12-27	WOS:000165095300008
J	Homma, K; Saito, J; Ikebe, R; Ikebe, M				Homma, K; Saito, J; Ikebe, R; Ikebe, M			Ca2+-dependent regulation of the motor activity of myosin V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PHOSPHORYLATION-DEPENDENT REGULATION; UNCONVENTIONAL MYOSINS; CALMODULIN-BINDING; 2-HEADED STRUCTURE; PEPTIDE COMPLEX; I-BETA; CLEAVAGE; KINETICS; BRAIN	Mouse myosin V constructs were produced that consisted of the myosin motor domain plus either one IQ motif (M5IQ1), two IQ motifs (M5IQ2), a complete set of six IQ motifs (SHM5), or the complete IQ motifs plus the coiled-coil domain (thus permitting formation of a double-headed structure,DHM5) and expressed in Sf9 cells. The actin-activated ATPase activity of all constructs except M5IQ1 was inhibited above pCa 5, but: this inhibition was completely reversed by addition of exogenous calmodulin, At the same Ca2+ concentration, 2 mol of calmodulin from SHM5 and DHM5 or 1 mol of calmodulin from M5IQ2 were dissociated, suggesting that the inhibition of the ATPase activity is due to dissociation of calmodulin from the heavy chain. However, the motility activity of DRM5 and M5IQ2 was completely inhibited at pCa 6, where no dissociation of calmodulin was detected. inhibition of the motility activity was not reversed by the addition of exogenous calmodulin. These results indicate that inhibition of the motility is due to conformational changes of calmodulin upon the Ca2+ binding to the high affinity site but is not due to dissociation of calmodulin from the heavy chain.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60381] Funding Source: Medline; NIAMS NIH HHS [AR 41653] Funding Source: Medline; NIGMS NIH HHS [GM 55834] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; ESPINDOLA FS, 1992, J CELL BIOL, V118, P359, DOI 10.1083/jcb.118.2.359; ESPINDOLA FS, 1996, MOL BIOL CELL, V7, P372; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; Houdusse A, 1996, STRUCTURE, V4, P1475, DOI 10.1016/S0969-2126(96)00154-2; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XD, 2000, BIOCHEMISTRY-US, V39, P2254, DOI 10.1021/bi9924617; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Titus MA, 1997, TRENDS CELL BIOL, V7, P119, DOI 10.1016/S0962-8924(97)01019-2; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; WHITE HD, 1993, J BIOL CHEM, V268, P10039; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; WOLENSKI JS, 1993, J CELL BIOL, V122, P613, DOI 10.1083/jcb.122.3.613; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; Zhu T, 1998, J BIOL CHEM, V273, P20481, DOI 10.1074/jbc.273.32.20481; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c	35	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34766	34771		10.1074/jbc.M003132200	http://dx.doi.org/10.1074/jbc.M003132200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10945977	hybrid			2022-12-27	WOS:000165095300102
J	Nagao, Y; Kitada, S; Kojima, K; Toh, H; Kuhara, S; Ogishima, T; Ito, A				Nagao, Y; Kitada, S; Kojima, K; Toh, H; Kuhara, S; Ogishima, T; Ito, A			Glycine-rich region of mitochondrial processing peptidase alpha-subunit is essential for binding and cleavage of the precursor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; BOVINE HEART-MITOCHONDRIA; RAT-LIVER; BETA-SUBUNIT; YEAST MITOCHONDRIA; SUBSTRATE RECOGNITION; SYNTHETIC PEPTIDE; PROTEASE; MATRIX; RESIDUES	Mitochondrial processing peptidase, a metalloendopeptidase consisting of alpha- and B -subunits, specifically recognizes a large variety of mitochondrial precursor proteins and cleaves off amino-terminal extension peptides. The alpha -subunit has a characteristic glycine-rich segment in the middle portion. To elucidate the role of the region in processing functions of the enzyme, deletion or site-directed mutations were introduced, and effects on kinetic parameters and substrate binding of the enzyme were analyzed. Deletion of three residues of the region, Phe(289) to Ala(291), led to a dramatic reduction in processing activity to practically zero. Mutation of Phe(289), Lys(296), and Met(298) to alanine resulted in a decrease in the activity, but these mutations had no apparent effect on interactions between the two subunits, indicating that reduction in processing activity is not due to structural disruption at the interface interacting with the beta -subunit, Although the mutant enzymes, Phe289Ala, Lys296Ala, and Met298Ala, had an approximate 10-fold less affinity for substrate peptides than did that of the wild type, the deletion mutant, Delta 289-291, showed an extremely low affinity. Thus, shortening of the glycine-rich stretch led to a dramatic reduction of interaction between the enzyme and substrate peptides and cleavage reaction, whereas mutation of each amino acid in this region seemed to affect primarily the cleavage reaction.	Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan; Kyushu Univ, Grad Sch Genet Resources Technol, Fukuoka 8128581, Japan	Kyushu University; Kyushu University	Ito, A (corresponding author), Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan.	a.itoscc@mbox.nc.kyushu-u.ac.jp						ARRETZ M, 1991, BIOMED BIOCHIM ACTA, V50, P403; ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; Brumme S, 1998, J BIOL CHEM, V273, P13143, DOI 10.1074/jbc.273.21.13143; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; Deng KP, 1998, J BIOL CHEM, V273, P20752, DOI 10.1074/jbc.273.33.20752; ERIKSSON AC, 1992, BIOCHIM BIOPHYS ACTA, V1140, P208, DOI 10.1016/0005-2728(92)90010-Y; GELI V, 1993, P NATL ACAD SCI USA, V90, P6247, DOI 10.1073/pnas.90.13.6247; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; KITADA S, 1995, J BIOCHEM-TOKYO, V117, P1148, DOI 10.1093/oxfordjournals.jbchem.a124836; Kitada S, 1998, J BIOL CHEM, V273, P32547, DOI 10.1074/jbc.273.49.32547; KITADA S, 1993, BIOCHEM BIOPH RES CO, V190, P289, DOI 10.1006/bbrc.1993.1044; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; Kojima K, 1998, J BIOL CHEM, V273, P32542, DOI 10.1074/jbc.273.49.32542; Luciano P, 1997, J MOL BIOL, V272, P213, DOI 10.1006/jmbi.1997.1231; MIURA S, 1986, BIOCHEM BIOPH RES CO, V134, P1151, DOI 10.1016/0006-291X(86)90371-2; NIIDOME T, 1994, J BIOL CHEM, V269, P24719; Ogishima T, 1995, J BIOL CHEM, V270, P30322, DOI 10.1074/jbc.270.51.30322; OU WJ, 1994, J BIOL CHEM, V269, P24673; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; ROHLEN DA, 1991, FEBS LETT, V278, P75, DOI 10.1016/0014-5793(91)80087-J; SAAVEDRAALANIS VM, 1994, J BIOL CHEM, V269, P9284; SAGARA Y, 1984, J BIOCHEM-TOKYO, V96, P1743, DOI 10.1093/oxfordjournals.jbchem.a135007; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SCHULTE U, 1989, NATURE, V339, P147, DOI 10.1038/339147a0; Shimokata K, 1998, J BIOL CHEM, V273, P25158, DOI 10.1074/jbc.273.39.25158; Shimokata K, 1997, J BIOCHEM-TOKYO, V122, P1019; Song MC, 1996, J BIOCHEM-TOKYO, V120, P1163; Song MC, 1998, J BIOCHEM, V124, P1045, DOI 10.1093/oxfordjournals.jbchem.a022198; Striebel HM, 1996, ARCH BIOCHEM BIOPHYS, V335, P211, DOI 10.1006/abbi.1996.0500; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG M, 1991, J BIOL CHEM, V266, P6416; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	43	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34552	34556		10.1074/jbc.M003110200	http://dx.doi.org/10.1074/jbc.M003110200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10942759	hybrid			2022-12-27	WOS:000165095300075
J	Oppegard, LM; Kabb, AL; Connell, GJ				Oppegard, LM; Kabb, AL; Connell, GJ			Activation of guide RNA-directed editing of a cytochrome b mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI MITOCHONDRIA; LEISHMANIA-TARENTOLAE; URIDINE INSERTION; MESSENGER-RNAS; IN-VITRO; TRANSCRIPTS; COMPLEXES; MECHANISM	The coding sequence of several mitochondrial mRNAs of the kinetoplastid protozoa is created only after the addition or deletion of specific uridines. Although in vitro systems have been valuable in characterizing the editing mechanism, only a limited number of mRNAs are accurately edited in vitro. We demonstrate here that in vitro editing of cytochrome b mRNA is inhibited by an A-U sequence present on both the 5'-untranslated sequence and on a cytochrome b guide RNA. Mutation of the sequence on the guide RNA stimulates directed editing and results in the loss of binding to at least one component within the editing extract. Mutation of the sequence on the mRNA increases the accuracy of the editing. Evidence is provided that suggests the A-U sequence interacts with the editing machinery both in vitro and in vivo.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Connell, GJ (corresponding author), Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA.	gconnell@lenti.med.umn.edu			NIAID NIH HHS [R29-AI41138] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI041138] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; Brown LM, 1999, J BIOL CHEM, V274, P6295, DOI 10.1074/jbc.274.10.6295; Byrne EM, 1996, EMBO J, V15, P6758, DOI 10.1002/j.1460-2075.1996.tb01065.x; Connell GJ, 1997, J BIOL CHEM, V272, P4212, DOI 10.1074/jbc.272.7.4212; Cruz-Reyes J, 1998, NUCLEIC ACIDS RES, V26, P3634, DOI 10.1093/nar/26.16.3634; Estevez AM, 1999, GENE, V240, P247, DOI 10.1016/S0378-1119(99)00437-0; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KOSLOWSKY DJ, 1992, MOL CELL BIOL, V12, P2043, DOI 10.1128/MCB.12.5.2043; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Piller KJ, 1997, RNA, V3, P279; RILEY GR, 1995, NUCLEIC ACIDS RES, V23, P708, DOI 10.1093/nar/23.4.708; Rusche LN, 1997, EMBO J, V16, P4069, DOI 10.1093/emboj/16.13.4069; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; SIMPSON AM, 1985, NUCLEIC ACIDS RES, V13, P5977, DOI 10.1093/nar/13.16.5977; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8	23	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33911	33919		10.1074/jbc.M003002200	http://dx.doi.org/10.1074/jbc.M003002200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10940300	hybrid			2022-12-27	WOS:000090104600101
J	Piatigorsky, J; Kozmik, Z; Horwitz, J; Ding, LL; Carosa, E; Robison, WG; Steinbach, PJ; Tamm, ER				Piatigorsky, J; Kozmik, Z; Horwitz, J; Ding, LL; Carosa, E; Robison, WG; Steinbach, PJ; Tamm, ER			Omega-crystallin of the scallop lens - A dimeric aldehyde dehydrogenase class 1/2 enzyme-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; MULTIPLE-SEQUENCE ALIGNMENT; MAJOR SOLUBLE-PROTEIN; CORNEAL EPITHELIUM; EYE LENS; BINDING-PROTEIN; ACTIVE-SITE; GENE; RECRUITMENT; EXPRESSION	While many of the diverse crystallins of the transparent lens of vertebrates are related or identical to metabolic enzymes, much less is known about the lens crystallins of invertebrates. Here we investigate the complex eye of scallops. Electron microscopic inspection revealed that the anterior, single layered corneal epithelium overlying the cellular lens contains a regular array of microvilli that we propose might contribute to its optical properties. The sole crystallin of the scallop eye lens was found to be homologous to Omega -crystallin, a minor crystallin in cephalopods related to aldehyde dehydrogenase (ALDH) class 1/2. Scallop Omega -crystallin (officially designated ALDH1A9) is 55-56% identical to its cephalopod homologues, while it is 67 and 64% identical to human ALDH 2 and 1, respectively, and 61% identical to retinaldehyde dehydrogenase/eta -crystallin of elephant shrews.:like other enzyme-crystallins, scallop Omega -crystallin appears to be present in low amounts in nonocular tissues. Within the scallop eye, immunofluorescence tests indicated that Omega -crystallin expression is confined to the lens and cornea, Although it has conserved the critical residues required for activity in other ALDHs and appears by homology modeling to have a structure very similar to human ALDH2, scallop Omega -crystallin was enzymatically inactive with diverse substrates and did not bind NAD or NADP, In contrast to mammalian ALDH1 and -2 and other cephalopod Omega -crystallins, which are tetrameric proteins, scallop Omega -crystallin is a dimeric protein. Thus, ALDH is the most diverse lens enzyme-crystallin identified so far, having been used as-a lens crystallin in at least two classes of molluscs as well as elephant shrews.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; NEI, Lab Mechanisms Ocular Dis, NIH, Bethesda, MD 20892 USA; NIH, Ctr Mol Modeling, Ctr Informat Technol, Bethesda, MD 20892 USA; Acad Sci Czech Republ, Inst Mol Genet, Lab Transcript Regulat, Prague 6, Czech Republic; Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Piatigorsky, J (corresponding author), NEI, Mol & Dev Biol Lab, NIH, Bldg 6,Rm 201, Bethesda, MD 20892 USA.	joramp@intra.nei.nih.gov	Tamm, Ernst/AAB-9772-2019; Kozmik, Zbynek/G-3581-2014; Kozmik, Zbynek/I-8807-2014	Tamm, Ernst/0000-0002-6679-8743; CAROSA, Eleonora/0000-0002-6593-6833; Kozmik, Zbynek/0000-0002-5850-2105	CENTER FOR INFORMATION TECHNOLOGY [Z01CT000265, ZIACT000265] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [Z01EY000126, Z01EY000149] Funding Source: NIH RePORTER	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; ALEXANDER RJ, 1981, EXP EYE RES, V32, P205, DOI 10.1016/0014-4835(81)90009-9; BARBER VC, 1967, Z ZELLFORSCH MIK ANA, V76, P295, DOI 10.1007/BF00339290; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BOSTIAN KA, 1978, BIOCHEM J, V173, P787, DOI 10.1042/bj1730787; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHIOU SH, 1988, FEBS LETT, V241, P261, DOI 10.1016/0014-5793(88)81073-1; COOPER DL, 1991, GENE, V98, P201, DOI 10.1016/0378-1119(91)90174-A; CUTHBERTSON RA, 1992, P NATL ACAD SCI USA, V89, P4004, DOI 10.1073/pnas.89.9.4004; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DEJONG WW, 1994, PROG RETIN EYE RES, V13, P391, DOI 10.1016/1350-9462(94)90018-3; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DOHLMAN CH, 1971, INVEST OPHTH VISUAL, V10, P383; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; FARRES J, 1995, BIOCHEMISTRY-US, V34, P2592, DOI 10.1021/bi00008a025; FARRES J, 1994, J BIOL CHEM, V269, P13854; Felsentein J, 1993, PHYLIP PHYLOGENY INF; GORMAN ALF, 1969, SCIENCE, V165, P309, DOI 10.1126/science.165.3890.309; Graham C, 1996, J BIOL CHEM, V271, P15623, DOI 10.1074/jbc.271.26.15623; HAZLETT LD, 1984, SCAN ELECTRON MICROS, P1379; HAZLETT LD, 1981, EXP EYE RES, V32, P97, DOI 10.1016/S0014-4835(81)80043-7; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; Hickson RE, 2000, MOL BIOL EVOL, V17, P530, DOI 10.1093/oxfordjournals.molbev.a026333; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HURLEY TD, 1999, ENZYMOLOGY MOL BIOL, V7, P15; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; INOUE J, 1995, J BACTERIOL, V177, P1196, DOI 10.1128/jb.177.5.1196-1201.1995; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; Jester JV, 1999, J CELL SCI, V112, P613; Johnsen S, 1999, J THEOR BIOL, V199, P181, DOI 10.1006/jtbi.1999.0948; Johnsen S, 2000, SCI AM, V282, P80, DOI 10.1038/scientificamerican0200-80; KIM RY, 1992, P NATL ACAD SCI USA, V89, P9292, DOI 10.1073/pnas.89.19.9292; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krupenko SA, 1997, J BIOL CHEM, V272, P10266; KUZAK JR, 1994, PRINCIPLES PRACTICE, P82; LAND MF, 1965, J PHYSIOL-LONDON, V179, P138, DOI 10.1113/jphysiol.1965.sp007653; LAND MF, 1988, CONTEMP PHYS, V29, P435, DOI 10.1080/00107518808222601; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; LUBSEN NH, 1988, PROG BIOPHYS MOL BIO, V51, P47, DOI 10.1016/0079-6107(88)90010-7; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MONTGOMERY MK, 1992, J BIOL CHEM, V267, P20999; NICHOLS B, 1983, INVEST OPHTH VIS SCI, V24, P570; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEREIRA F, 1991, BIOCHEM BIOPH RES CO, V175, P831, DOI 10.1016/0006-291X(91)91640-X; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; PFISTER RR, 1973, INVEST OPHTH VISUAL, V12, P654; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; PIATIGORSKY J, 1989, J COMP PHYSIOL A, V164, P577, DOI 10.1007/BF00614500; Sax CM, 1996, J BIOL CHEM, V271, P33568, DOI 10.1074/jbc.271.52.33568; SAX CM, 1993, ADV ENZYMOL RAMB, V69, P155; SILVERMAN B, 1981, EXP EYE RES, V33, P19, DOI 10.1016/S0014-4835(81)80078-4; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sun LJ, 1999, J BIOL CHEM, V274, P17334, DOI 10.1074/jbc.274.24.17334; TAKAHASHI K, 1980, J BIOL CHEM, V255, P8206; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMAREV SI, 1992, J BIOL CHEM, V267, P8604; TOMAREV SI, 1988, NATURE, V336, P86, DOI 10.1038/336086a0; Tomarev SI, 1996, EUR J BIOCHEM, V235, P449, DOI 10.1111/j.1432-1033.1996.00449.x; Vasiliou V, 1999, PHARMACOGENETICS, V9, P421, DOI 10.1097/00008571-199910000-00004; VERHAGEN C, 1991, EXP EYE RES, V53, P283, DOI 10.1016/0014-4835(91)90085-S; Vie MP, 1997, MOL ENDOCRINOL, V11, P1728, DOI 10.1210/me.11.11.1728; WANG XP, 1995, BIOCHEMISTRY-US, V34, P237, DOI 10.1021/bi00001a028; Werten PJL, 2000, P NATL ACAD SCI USA, V97, P3282, DOI 10.1073/pnas.050500597; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1991, J MOL EVOL, V32, P262, DOI 10.1007/BF02342749; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; XIAO Q, 1995, J CLIN INVEST, V96, P2180, DOI 10.1172/JCI118272; Xu YS, 2000, J BIOL CHEM, V275, P24645, DOI 10.1074/jbc.M001159200; Yamauchi K, 1999, J BIOL CHEM, V274, P8460, DOI 10.1074/jbc.274.13.8460; Yoshida A, 1998, EUR J BIOCHEM, V251, P549, DOI 10.1046/j.1432-1327.1998.2510549.x; Zhou JZ, 1997, EUR J BIOCHEM, V245, P123, DOI 10.1111/j.1432-1033.1997.00123.x; ZINOVIEVA RD, 1993, J BIOL CHEM, V268, P11449	79	39	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41064	41073		10.1074/jbc.M005625200	http://dx.doi.org/10.1074/jbc.M005625200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10961997	hybrid			2022-12-27	WOS:000166114600055
J	Li, M; Kondo, T; Zhao, QL; Li, FJ; Tanabe, K; Arai, Y; Zhou, ZC; Kasuya, M				Li, M; Kondo, T; Zhao, QL; Li, FJ; Tanabe, K; Arai, Y; Zhou, ZC; Kasuya, M			Apoptosis induced by cadmium in human lymphoma U937 cells through Ca2+-calpain and caspase-mitochondria dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CYTOCHROME-C RELEASE; DNA FRAGMENTATION; T-CELLS; BCL-X; CALCIUM; DEATH; ACTIVATION; INDUCTION; PROTEIN	Apoptosis induced by cadmium has been shown in many tissues in vivo and in cultured cells in vitro. However, its molecular mechanism is not fully understood. When the human histiocytic lymphoma cell line U937 was treated with cadmium for 12 h, evidence of apoptotic features, including change in nuclear morphology, DNA fragmentation, formation of DNA ladder in agarose gel electrophoresis, and phosphatidylserine externalization, were obtained. Moreover, loss of the mitochondrial membrane potential (Delta psi (m)) was observed in the cadmium-treated cells and was inhibited by a broad caspase inhibitor (Z-VAD-FMK). Caspase inhibitors suppressed the DNA fragmentation in the order of Z-VAD-FMK > caspase-8 inhibitor > caspase-3 inhibitor. Expression of Bcl-x(L) and Bid decreased significantly in the cadmium-treated cells, although no apparent change in Bcl-2 and Bax expression was found. Tetrakis-(2-pyridylmethyl) ethylendiamine, a cell-permeable heavy metal chelator, partially reversed the increase of fluorescence of Fura-a in the cadmium-treated cells. In addition, verapamil (70 muM), a voltage-dependent Ca2+ channel blocker, inhibited the DNA fragmentation induced by cadmium less than 100 muM and decreased the fluorescence of Fura-8. Cadmium up-regulated the expression of type 1 inositol 1,4,5-trisphosphate receptor (IP3R) but not type 2 or type 3 IP3R Calpain inhibitors I and II partially prevented DNA fragmentation. No effects of Z-VAD-FMK on the expression of type 1 IP3R or of calpain inhibitors on the loss of Delta psi (m) were observed. These results suggest that cadmium possibly induced apoptosis in U937 cells through two independent pathways, the Ca2+-calpain-dependent pathway and the caspase-mitochondria-dependent pathway.	Toyama Med & Pharmaceut Univ, Fac Med, Dept Radiol Sci, Sugitani, Toyama 9300197, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Publ Hlth, Sugitani, Toyama 9300197, Japan; Beijing Med Univ, Sch Publ Hlth, Dept Toxicol, Beijing 100083, Peoples R China; China Med Univ, Sch Publ Hlth, Dept Ind Hyg & Occupat Dis, Shenyang 110001, Peoples R China	University of Toyama; University of Toyama; Peking University; China Medical University	Kondo, T (corresponding author), Toyama Med & Pharmaceut Univ, Fac Med, Dept Radiol Sci, Sugitani, Toyama 9300197, Japan.							Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bossy-Wetzel E, 1999, MUTAT RES-DNA REPAIR, V434, P243, DOI 10.1016/S0921-8777(99)00032-4; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Caricchio R, 1998, J IMMUNOL, V161, P241; Denecker G, 2000, FEBS LETT, V465, P47, DOI 10.1016/S0014-5793(99)01702-0; ELAZZOUZI B, 1994, TOXICOLOGY, V88, P127; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P699, DOI 10.1006/bbrc.1999.1888; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 1997, CANCER RES, V57, P3823; Habeebu SSM, 1998, TOXICOL APPL PHARM, V149, P203, DOI 10.1006/taap.1997.8334; Hamada T, 1996, BIOCHEM BIOPH RES CO, V219, P829, DOI 10.1006/bbrc.1996.0318; HARNICK DJ, 1995, J BIOL CHEM, V270, P2833, DOI 10.1074/jbc.270.6.2833; Hart BA, 1999, TOXICOLOGY, V133, P43, DOI 10.1016/S0300-483X(99)00013-X; Harwood FG, 2000, J BIOL CHEM, V275, P10023, DOI 10.1074/jbc.275.14.10023; Haugland R., 1996, HDB FLUORESCENT PROB; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Jones MM, 1997, TOXICOLOGY, V116, P169, DOI 10.1016/S0300-483X(96)03541-X; Kato M, 2000, J BIOCHEM, V127, P297, DOI 10.1093/oxfordjournals.jbchem.a022607; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Khodarev NN, 1998, INT J RADIAT BIOL, V73, P455; Kimura C, 1998, EXP CELL RES, V239, P411, DOI 10.1006/excr.1997.3912; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KONDO T, 1993, CELL CALCIUM, V14, P621, DOI 10.1016/0143-4160(93)90087-M; KOSTRZEWSKA A, 1990, FEBS LETT, V263, P381, DOI 10.1016/0014-5793(90)81419-O; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Long GJ, 1997, TOXICOL LETT, V91, P91, DOI 10.1016/S0378-4274(97)03880-0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; MORSELT AFW, 1991, TOXICOLOGY, V70, P1; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; OTLVAI ZN, 1993, CELL, V74, P609; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; RICKAN LE, 2000, J BIOCHEM MOL TOXIC, V14, P110; SELLINS KS, 1987, J IMMUNOL, V139, P3199; Somji S, 1999, ENVIRON HEALTH PERSP, V107, P545, DOI 10.2307/3434396; Squier MKT, 1997, J IMMUNOL, V158, P3690; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; SWANDULLA D, 1989, P NATL ACAD SCI USA, V86, P1736, DOI 10.1073/pnas.86.5.1736; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsangaris GT, 1998, TOXICOLOGY, V128, P143, DOI 10.1016/S0300-483X(98)00032-8; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; VERBOST PM, 1987, BIOCHIM BIOPHYS ACTA, V902, P247, DOI 10.1016/0005-2736(87)90302-6; VISSER GJ, 1993, BIOCHIM BIOPHYS ACTA, V1152, P26, DOI 10.1016/0005-2736(93)90227-Q; Wang Z, 1998, J BIOL CHEM, V273, P73, DOI 10.1074/jbc.273.1.73; WHO, 1992, ENV HLTH CRIT, V134; Xu CY, 1996, TOXICOLOGY, V107, P1, DOI 10.1016/0300-483X(95)03195-L; Yang CF, 1997, ENVIRON HEALTH PERSP, V105, P712, DOI 10.1289/ehp.97105712; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZHANG GH, 1990, J BIOL CHEM, V265, P2184; Zhao QL, 1999, INT J RADIAT BIOL, V75, P493, DOI 10.1080/095530099140429; Zhou T, 1999, TOXICOLOGY, V142, P1, DOI 10.1016/S0300-483X(99)00115-8	64	207	220	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39702	39709		10.1074/jbc.M007369200	http://dx.doi.org/10.1074/jbc.M007369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10970901	hybrid			2022-12-27	WOS:000165953100099
J	Brunet, A; Samaan, A; Deshaies, F; Kindt, TJ; Thibodeau, J				Brunet, A; Samaan, A; Deshaies, F; Kindt, TJ; Thibodeau, J			Functional characterization of a lysosomal sorting motif in the cytoplasmic tail of HLA-DO beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MOLECULES; INVARIANT CHAIN EXPRESSION; INTRACELLULAR-TRANSPORT; MICE LACKING; DR MOLECULES; HISTOCOMPATIBILITY ANTIGENS; CELL-SURFACE; MONOCLONAL-ANTIBODIES; ENDOCYTIC PATHWAY; TARGETING SIGNALS	HLA-DO is an intracellular non-classical class II major histocompatibility complex molecule expressed in the endocytic pathway of B lymphocytes, which regulates the loading of antigenic peptides onto classical class II molecules such as HLA-DR. The activity of HLA-DO is mediated through its interaction with the peptide editor HLA-DM. Here, our results demonstrate that although HLA-DO is absolutely dependent on its association with DM: to egress the endoplasmic reticulum, the cytoplasmic portion of its beta chain encodes a functional lysosomal sorting signal, By confocal microscopy and flow cytometry analysis, we show that reporter transmembrane molecules fused to the cytoplasmic tail of HLA-DO beta accumulated in Lamp-1(+) vesicles of transfected HeLa cells. Mutagenesis of a leucine-leucine motif abrogated lysosomal accumulation and resulted in cell surface redistribution of reporter molecules. Finally, we show that mutation of the di-leucine sequence in DO beta did not alter its lysosomal sorting when associated with DM molecules. Taken together, these results demonstrate that lysosomal expression of the DO-DM complex is mediated primarily by the tyrosine-based motif of HLA-DM and suggest that the DO beta -encoded motif is involved in the fine-tuning of the intracellular sorting.	Univ Montreal, Dept Microbiol & Immunol, Lab Immunol Mol, Montreal, PQ H3C 3J7, Canada; NIAID, Immunogenet Lab, NIH, Bethesda, MD 20892 USA	Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Thibodeau, J (corresponding author), Univ Montreal, Dept Microbiol & Immunol, Lab Immunol Mol, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000180] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; Busch R, 1996, EMBO J, V15, P418, DOI 10.1002/j.1460-2075.1996.tb00372.x; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; CHOUCHANE L, 1993, IMMUNOGENETICS, V38, P64, DOI 10.1007/BF00216394; Copier J, 1998, IMMUNOLOGY, V93, P505; Copier J, 1996, J IMMUNOL, V157, P1017; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Denzin LK, 1997, SCIENCE, V278, P106, DOI 10.1126/science.278.5335.106; Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; Douek DC, 1997, INT IMMUNOL, V9, P355, DOI 10.1093/intimm/9.3.355; ERICSON ML, 1994, J BIOL CHEM, V269, P26531; GORVEL JP, 1995, J BIOL CHEM, V270, P2741, DOI 10.1074/jbc.270.6.2741; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; Hammond C, 1998, J IMMUNOL, V161, P3282; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; Jensen PE, 1999, IMMUNOL REV, V172, P229, DOI 10.1111/j.1600-065X.1999.tb01368.x; KARLSSON L, 1991, NATURE, V351, P485, DOI 10.1038/351485a0; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; Kropshofer H, 1996, EMBO J, V15, P6144, DOI 10.1002/j.1460-2075.1996.tb01002.x; Kropshofer H, 1998, EMBO J, V17, P2971, DOI 10.1093/emboj/17.11.2971; Kropshofer H, 1997, IMMUNITY, V6, P293, DOI 10.1016/S1074-7613(00)80332-5; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LARHAMMAR D, 1985, J BIOL CHEM, V260, P4111; Lavoie PM, 1997, P NATL ACAD SCI USA, V94, P6892, DOI 10.1073/pnas.94.13.6892; Liljedahl M, 1996, EMBO J, V15, P4817, DOI 10.1002/j.1460-2075.1996.tb00862.x; Liljedahl M, 1998, IMMUNITY, V8, P233, DOI 10.1016/S1074-7613(00)80475-6; LINDSTEDT R, 1995, IMMUNITY, V3, P561, DOI 10.1016/1074-7613(95)90127-2; LOSS GE, 1993, J IMMUNOL, V150, P3187; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; Nakagawa TY, 1999, IMMUNOL REV, V172, P121, DOI 10.1111/j.1600-065X.1999.tb01361.x; Neefjes J, 1999, EUR J IMMUNOL, V29, P1421, DOI 10.1002/(SICI)1521-4141(199905)29:05<1421::AID-IMMU1421>3.3.CO;2-3; Nordeng TW, 1999, J BIOL CHEM, V274, P21139, DOI 10.1074/jbc.274.30.21139; Nordeng TW, 1998, CURR TOP MICROBIOL, V232, P179; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; PANINABORDIGNON P, 1992, J EXP MED, V176, P1779, DOI 10.1084/jem.176.6.1779; PIETERS J, 1993, J CELL SCI, V106, P831; Pinet VM, 1998, EUR J IMMUNOL, V28, P799, DOI 10.1002/(SICI)1521-4141(199803)28:03<799::AID-IMMU799>3.0.CO;2-5; Potter PK, 1999, EUR J IMMUNOL, V29, P3936, DOI 10.1002/(SICI)1521-4141(199912)29:12<3936::AID-IMMU3936>3.3.CO;2-B; RADKA SF, 1984, HUM IMMUNOL, V10, P177, DOI 10.1016/0198-8859(84)90038-7; Robadey C, 1997, J IMMUNOL, V159, P3238; ROBBINS AR, 1987, METHOD ENZYMOL, V138, P458; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROMAGNOLI P, 1994, J EXP MED, V180, P1107, DOI 10.1084/jem.180.3.1107; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; ROSENBRONSON S, 1991, IMMUNOGENETICS, V33, P124; Rovere P, 1997, ADV EXP MED BIOL, V417, P195; Runnels HA, 1997, MOL IMMUNOL, V34, P471, DOI 10.1016/S0161-5890(97)00043-6; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Samaan A, 1999, INT IMMUNOL, V11, P99, DOI 10.1093/intimm/11.1.99; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SEKALY RP, 1986, J EXP MED, V164, P1490, DOI 10.1084/jem.164.5.1490; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; Stumptner P, 1997, EMBO J, V16, P5807, DOI 10.1038/sj.emboj.7590555; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Thibodeau J, 1998, MOL IMMUNOL, V35, P885, DOI 10.1016/S0161-5890(98)00061-3; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; van Ham M, 2000, J EXP MED, V191, P1127, DOI 10.1084/jem.191.7.1127; vanHam SM, 1997, CURR BIOL, V7, P950, DOI 10.1016/S0960-9822(06)00414-3; vanHam SM, 1996, J EXP MED, V184, P2019, DOI 10.1084/jem.184.5.2019; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; Wang K, 1997, J BIOL CHEM, V272, P17055, DOI 10.1074/jbc.272.27.17055; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; Wubbolts R, 1996, J CELL BIOL, V135, P611, DOI 10.1083/jcb.135.3.611; Zhong GM, 1997, J EXP MED, V185, P429, DOI 10.1084/jem.185.3.429; Zhong GM, 1996, J EXP MED, V184, P2061, DOI 10.1084/jem.184.5.2061	81	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37062	37071		10.1074/jbc.M005112200	http://dx.doi.org/10.1074/jbc.M005112200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10964920	hybrid			2022-12-27	WOS:000165577700085
J	Muimo, R; Hornickova, Z; Riemen, CE; Gerke, V; Matthews, H; Mehta, A				Muimo, R; Hornickova, Z; Riemen, CE; Gerke, V; Matthews, H; Mehta, A			Histidine phosphorylation of annexin I in airway epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; LIPOCORTIN-I; PHOSPHOLIPID-BINDING; CALCIUM-BINDING; CROSS-LINKING; PROTEIN; AGGREGATION; ACTIVATION; CELLS; ENHANCEMENT	Although [C1(-)](i) regulates many cellular functions including cell secretion, the mechanisms governing these actions are not known. me have previously shown that the apical membrane of airway epithelium contains a 37-kDa phosphoprotein (p37) whose phosphorylation is regulated by chloride concentration. Using metal affinity (chelating Fe3+-Sepharose) and anion exchange (POROS HQ 20) chromatography, we have purified p37 from ovine tracheal epithelia to electrophoretic homogeneity. Sequence analysis and immunoprecipitation using monoclonal and specific polyclonal antibodies identified p37 as annexin I, a member of a family of Ca2+-dependent phospholipid-binding proteins. Phosphate on [P-32]annexin I, phosphorylated using both [gamma-P-32]ATP and [gamma-P-32]GTP, was labile under acidic but not alkaline conditions. Phosphoamino acid analysis showed the presence of phosphohistidine. The site of phosphorylation was localized to a carboxyl-terminal fragment of annexin I. Our data suggest that cAMP andAMP (but not cGMP) may regulate annexin I histidine phosphorylation. me propose a role for annexin I in an intracellular signaling system involving histidine phosphorylation.	Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland; Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA; Univ Munster, Inst Med Biochem, D-48149 Munster, Germany	University of Dundee; University of California System; University of California Davis; University of Munster	Muimo, R (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland.	r.muimo@dundee.ac.uk						AmsterChoder O, 1997, J BACTERIOL, V179, P5621, DOI 10.1128/jb.179.17.5621-5624.1997; ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; ANDO Y, 1989, BIOCHEM BIOPH RES CO, V163, P944, DOI 10.1016/0006-291X(89)92313-9; ANDO Y, 1991, J BIOL CHEM, V266, P1101; ANDO Y, 1989, J BIOL CHEM, V264, P6948; Brown JM, 1998, CURR BIOL, V8, pR662, DOI 10.1016/S0960-9822(07)00417-4; BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9; CHAN HC, 1994, J BIOL CHEM, V269, P32464; CHAP H, 1991, M S-MED SCI, V7, P8, DOI 10.4267/10608/4270; CHUAH SY, 1989, J BIOL CHEM, V264, P21160; Cohen BE, 1995, FEBS LETT, V377, P444, DOI 10.1016/0014-5793(95)01395-4; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; CORBIN JD, 1985, J BIOL CHEM, V260, P8731; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CROVELLO CS, 1995, CELL, V82, P279, DOI 10.1016/0092-8674(95)90315-1; DINUDOM A, 1993, J MEMBRANE BIOL, V135, P289; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Donnelly SR, 1997, CELL MOL LIFE SCI, V53, P533, DOI 10.1007/s000180050068; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Fuhrmann M, 1999, AM J RESP CELL MOL, V20, P292, DOI 10.1165/ajrcmb.20.2.3140; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; HAYES JD, 1989, BIOCHEM J, V264, P437, DOI 10.1042/bj2640437; JOHNSTONE SA, 1993, BIOCHEM J, V294, P801, DOI 10.1042/bj2940801; Jorgensen AJ, 1997, PFLUG ARCH EUR J PHY, V434, P261; Jost M, 1996, BBA-MOL CELL RES, V1313, P283, DOI 10.1016/0167-4889(96)00101-2; KAETZEL MA, 1994, J BIOL CHEM, V269, P5297; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Marshall LJ, 1999, AM J PHYSIOL-CELL PH, V276, pC109, DOI 10.1152/ajpcell.1999.276.1.C109; Mizuno T, 1998, J BIOCHEM, V123, P555; Muimo R, 1998, AM J RESP CELL MOL, V18, P270, DOI 10.1165/ajrcmb.18.2.2850; Nilius B, 1996, J BIOL CHEM, V271, P30631, DOI 10.1074/jbc.271.48.30631; PEPINSKY RB, 1991, METHOD ENZYMOL, V198, P260; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; REGNOUF F, 1995, J BIOL CHEM, V270, P27143, DOI 10.1074/jbc.270.45.27143; Rothhut B, 1997, CELL MOL LIFE SCI, V53, P522, DOI 10.1007/s000180050066; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; Seemann J, 1997, FEBS LETT, V413, P185, DOI 10.1016/S0014-5793(97)00911-3; Seemann J, 1996, MOL BIOL CELL, V7, P1359, DOI 10.1091/mbc.7.9.1359; VARTICOVSKI L, 1988, BIOCHEMISTRY-US, V27, P3682, DOI 10.1021/bi00410a024; WEI W, 1992, BIOCHEMISTRY-US, V31, P9934, DOI 10.1021/bi00156a011; WEI YF, 1991, METHOD ENZYMOL, V200, P388; WENG XW, 1993, PROTEIN SCI, V2, P448; WIELAND T, 1993, J BIOL CHEM, V268, P18111	47	74	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36632	36636		10.1074/jbc.M000829200	http://dx.doi.org/10.1074/jbc.M000829200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10956639	hybrid			2022-12-27	WOS:000165577700026
J	Zobel-Thropp, P; Yang, MC; Machado, L; Clarke, S				Zobel-Thropp, P; Yang, MC; Machado, L; Clarke, S			A novel post-translational modification of yeast elongation factor 1A - Methylesterification at the C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLATION; AMINOACYL-TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE; FACTOR 1-ALPHA; STE14 GENE; NUCLEOTIDE-SEQUENCE; BOVINE BRAIN; FACTOR-I; A-FACTOR; METHYLTRANSFERASE	Protein methylation reactions can play important roles in cell physiology. After labeling intact Saccharomyces cerevisiae cells with S-adenosyl-L-[methyl-H-3]methionine, we identified a major methylated 49-kDa polypeptide containing [H-3]methyl groups in two distinct types of linkages. Peptide sequence analysis of the purified methylated protein revealed that it is eukaryotic elongation factor 1A (eEF1A, formerly EF-1 alpha), the protein that forms a complex with GTP and aminoacyl-tRNAs for binding to the ribosomal A site during protein translation, Previous studies have shown that eEF1A is methylated on several internal lysine residues to give mono-, di-, and tri-N-epsilon -methyl-lysine derivatives. We confirm this finding but also detect methylation that is released as volatile methyl groups after base hydrolysis, characteristic of ester linkages. In cycloheximide-treated cells, methyl esterified eEF1A was detected largely in the ribosome and polysome fractions; little or no methylated protein was found in the soluble fraction. Because the base-labile, volatile [methyl-H-3]radioactivity of eEF1A could be released by trypsin treatment but not by carboxypeptidase Y or chymotrypsin treatment, we suggest that the methyl ester is present on the alpha -carboxyl group of its C-terminal lysine residue, From the results of pulse-chase experiments using radiolabeled intact yeast cells, we find that the N-methylated lysine residues of eEF1A. are stable over 4 h, whereas the eEF1A carboxyl methyl ester has a half-life of less than 10 min. The rapid turnover of the methyl ester suggests that the methylation/demethylation of eEF1A at the C-terminal carboxyl group may represent a novel mode of regulation of the activity of this protein in yeast.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, S (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.				NIGMS NIH HHS [GM26020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GFL, 1979, J BIOL CHEM, V254, P9947; AMONS R, 1983, FEBS LETT, V153, P37, DOI 10.1016/0014-5793(83)80115-X; BAI Y, 1975, J BIOCHEM-TOKYO, V78, P617, DOI 10.1093/oxfordjournals.jbchem.a130948; BERNHARD SA, 1955, BIOCHEM J, V59, P506, DOI 10.1042/bj0590506; Carr-Schmid A, 1999, J BIOL CHEM, V274, P30297, DOI 10.1074/jbc.274.42.30297; Cavallius J, 1997, BBA-GENE STRUCT EXPR, V1350, P345, DOI 10.1016/S0167-4781(96)00181-9; CAVALLIUS J, 1993, BIOCHIM BIOPHYS ACTA, V1163, P75, DOI 10.1016/0167-4838(93)90281-U; Cavallius J, 1998, J BIOL CHEM, V273, P28752, DOI 10.1074/jbc.273.44.28752; CLARKE S, 1984, METHOD ENZYMOL, V106, P330; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; COTTRELLE P, 1985, J BIOL CHEM, V260, P3090; DEVER TE, 1989, J BIOL CHEM, V264, P20518; FAVRE B, 1994, J BIOL CHEM, V269, P16311; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Graves JD, 1999, PHARMACOL THERAPEUT, V82, P111, DOI 10.1016/S0163-7258(98)00056-4; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GRUNWALD SK, 1995, J BACTERIOL, V177, P628, DOI 10.1128/jb.177.3.628-635.1995; HAN KK, 1993, INT J BIOCHEM, V25, P957, DOI 10.1016/0020-711X(93)90108-Q; HIATT WR, 1982, P NATL ACAD SCI-BIOL, V79, P3433, DOI 10.1073/pnas.79.11.3433; HRYCYNA CA, 1990, MOL CELL BIOL, V10, P5071, DOI 10.1128/MCB.10.10.5071; HRYCYNA CA, 1994, BIOCHEMISTRY-US, V33, P9806, DOI 10.1021/bi00198a053; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; JANSSEN GMC, 1994, J BIOL CHEM, V269, P31410; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITALIEN JJ, 1979, FEBS LETT, V107, P359, DOI 10.1016/0014-5793(79)80407-X; Liu G, 1996, TRENDS CELL BIOL, V6, P168, DOI 10.1016/0962-8924(96)20013-3; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MURPHY JT, 1972, J BACTERIOL, V109, P499, DOI 10.1128/JB.109.2.499-504.1972; Negrutskii BS, 1998, PROG NUCLEIC ACID RE, V60, P47, DOI 10.1016/S0079-6603(08)60889-2; Pintard L, 2000, MOL CELL BIOL, V20, P1370, DOI 10.1128/MCB.20.4.1370-1381.2000; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; SAHA SK, 1986, J BIOL CHEM, V261, P2599; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; Savitz AJ, 1997, J BIOL CHEM, V272, P13140, DOI 10.1074/jbc.272.20.13140; SCHIRMAIER F, 1984, EMBO J, V3, P3311, DOI 10.1002/j.1460-2075.1984.tb02295.x; SCHWERT GW, 1949, J BIOL CHEM, V179, P665; SHERMAN M, 1989, ARCH BIOCHEM BIOPHYS, V275, P371, DOI 10.1016/0003-9861(89)90384-6; THIELE D, 1985, J BIOL CHEM, V260, P3084; TOLEDO H, 1990, FEMS MICROBIOL LETT, V71, P241, DOI 10.1016/0378-1097(90)90227-H; VANDAMME HTF, 1992, EUR J BIOCHEM, V207, P1025; XIE HY, 1993, J BIOL CHEM, V268, P13364; XIE HY, 1994, J BIOL CHEM, V269, P1981; YOUNG SG, 2000, PROTEIN LIPIDATION E, V21, P155	44	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37150	37158		10.1074/jbc.M001005200	http://dx.doi.org/10.1074/jbc.M001005200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973948	hybrid			2022-12-27	WOS:000165577700095
J	Cavalcante, MCM; Allodi, S; Valente, AP; Straus, AH; Takahashi, HK; Mourao, PAS; Pavao, MSG				Cavalcante, MCM; Allodi, S; Valente, AP; Straus, AH; Takahashi, HK; Mourao, PAS; Pavao, MSG			Occurrence of heparin in the invertebrate Styela plicata (Tunicata) is restricted to cell layers facing the outside environment - An ancient role in defense?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATED L-GALACTANS; ANTICOAGULANT ACTIVITY; DERMATAN SULFATE; MAST-CELLS; ANTIBODY ST-1; ASCIDIANS; GLYCOSAMINOGLYCANS; PROTEOGLYCANS; MECHANISM	Heparin is an intracellular product of vertebrate mast cell currently used as exogenous anticoagulant. Despite of the potent biological activities of exogenous heparin, its physiological function has not been clearly established yet. Here, a heparin with similar structure and anticoagulant properties to the mammalian counterpart was shown to occur as the intracellular product of test cells, a cell monolayer that surrounds egg of the invertebrate Styela plicata (Chordata-Tunicata). As in the case of mammalian mast cells, heparin from the ascidian test cells is removed from the intracellular granules after incubation with compound 48/80, Following fertilization, the test cells surrounding the developing larva still retain heparin as metachromatic granulation. In the adult invertebrate, heparin occurs as intracellular granules at the apical tip of epithelial cells surrounding the lumen of both intestine and pharynx, in close contact with the external environment. This is the first description of the presence of heparin in cytoplasmic granules of epithelial-like cells around the lumen of sites exposed to external agents. This arrangement may reflect the participation of heparin in defense mechanisms in this invertebrate.	Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, HOsp Clementino Fraga Filho, Lab Tecido Conjuntivo, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Histol & Embriol, Inst Ciencias Biomed, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Ctr Nacl Ressonancia Magnet Nucl Macromol, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Dept Bioquim, BR-04023900 Sao Paulo, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal de Sao Paulo (UNIFESP)	Pavao, MSG (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Dept Bioquim Med, Caixa Postal 68041, BR-21941590 Rio De Janeiro, Brazil.		Mourao, Paulo/AAA-5386-2020; Pavao, Mauro Sergio Goncalves/B-1979-2010; Straus, Anita H/K-7629-2013; Allodi, Silvana/G-1781-2012; Valente, Ana Paula/J-3010-2017; S, Allodi/AAR-7968-2020; Takahashi, Helio/J-1725-2012	Pavao, Mauro Sergio Goncalves/0000-0002-1336-4271; Allodi, Silvana/0000-0002-3053-3866; Valente, Ana Paula/0000-0001-7219-1123; 				BARWIG B, 1985, J COMP PHYSIOL B, V155, P135, DOI 10.1007/BF00685206; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; Cavalcante MCM, 1999, BBA-GEN SUBJECTS, V1428, P77, DOI 10.1016/S0304-4165(99)00046-X; Chahdi A, 2000, J PHARMACOL EXP THER, V292, P122; CLONEY RA, 1990, ACTA ZOOL-STOCKHOLM, V71, P151, DOI 10.1111/j.1463-6395.1990.tb01190.x; Conrad H. E., 1998, HEPARIN BINDING PROT; DIETRICH CP, 1985, BIOCHIM BIOPHYS ACTA, V843, P1, DOI 10.1016/0304-4165(85)90041-8; DIETRICH CP, 1976, ANAL BIOCHEM, V70, P645, DOI 10.1016/0003-2697(76)90496-6; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; LANE DL, 1989, HEPARIN CHEM BIOL PR; LINDAHL U, 1979, P NATL ACAD SCI USA, V76, P3198, DOI 10.1073/pnas.76.7.3198; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; Mourao PAS, 1997, CARBOHYD RES, V300, P315, DOI 10.1016/S0008-6215(97)00061-X; MULLOY B, 1994, CARBOHYD RES, V255, P1, DOI 10.1016/S0008-6215(00)90968-6; OFUSO FA, 1989, HEPARIN RELATED POLY; Oliani SM, 1997, J HISTOCHEM CYTOCHEM, V45, P231, DOI 10.1177/002215549704500208; Pavao MSG, 1995, J BIOL CHEM, V270, P31027, DOI 10.1074/jbc.270.52.31027; PAVAO MSG, 1989, J BIOL CHEM, V264, P9972; PAVAO MSG, 1994, BBA-GEN SUBJECTS, V1199, P229, DOI 10.1016/0304-4165(94)90001-9; Pavao MSG, 1998, J BIOL CHEM, V273, P27848, DOI 10.1074/jbc.273.43.27848; PAVAO MSG, 1990, CARBOHYD RES, V208, P153, DOI 10.1016/0008-6215(90)80095-K; RATCLIFFE NA, 1985, INT REV CYTOL, V97, P183, DOI 10.1016/S0074-7696(08)62351-7; Rowley AF., 1981, INVERTEBRATE BLOOD C; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; STRAUS AH, 1982, BIOCHIM BIOPHYS ACTA, V717, P478, DOI 10.1016/0304-4165(82)90291-4; STRAUS AH, 1992, ANAL BIOCHEM, V201, P1, DOI 10.1016/0003-2697(92)90167-6; TAKAHASHI H, 1995, EUR J BIOCHEM, V233, P778, DOI 10.1111/j.1432-1033.1995.778_3.x; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; Wright R.K., 1981, INVERTEBR BLOOD CELL, V2, P565; YOUNG NS, 1972, J CLIN INVEST, V51, P1790, DOI 10.1172/JCI106980	37	53	55	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36189	36196		10.1074/jbc.M005830200	http://dx.doi.org/10.1074/jbc.M005830200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10956656	hybrid			2022-12-27	WOS:000165382000077
J	Miyahara, T; Schrum, L; Rippe, R; Xiong, SG; Yee, HF; Motomura, K; Anania, FA; Willson, TM; Tsukamoto, H				Miyahara, T; Schrum, L; Rippe, R; Xiong, SG; Yee, HF; Motomura, K; Anania, FA; Willson, TM; Tsukamoto, H			Peroxisome proliferator-activated receptors and hepatic stellate cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GENE-EXPRESSION; SMOOTH-MUSCLE CELLS; 9-CIS RETINOIC ACID; RAT-LIVER FIBROSIS; IN-VIVO; ENDOTHELIAL-CELLS; ALL-TRANS; ITO CELL; LIPOCYTES; BINDING	The present study examined the roles of peroxisome proliferator-activated receptors (PPAR) in activation of hepatic stellate cells (HSC), a pivotal event in liver fibrogenesis. RNase protection assay detected mRNA for PPAR gamma1 but not that for the adipocyte-specific gamma (2) isoform in HSC isolated from sham-operated rats, whereas the transcripts for neither isoforms were detectable in HSC from cholestatic liver fibrosis induced by bile duct ligation (BDL), Semi-quantitative reverse transcriptase-polymerase chain reaction confirmed a 70% reduction in PPAR gamma mRNA level in HSC from BDL, Nuclear extracts from BDL cells showed an expected diminution of binding to PPAR-responsive element, whereas NF-kappaB and AP-I binding were increased. Treatment of cultured-activated HSC with ligands for PPAR gamma (10 muM 15-deoxy-Delta (12,14)-PGJ(2) (15dPGJ(2)); 0.1 similar to 10 muM BRL49653) inhibited DNA and collagen synthesis without affecting the cell viability. Suppression of HSC collagen by 15dPGJ(2), was abrogated 70% by the concomitant treatment with a PPAR gamma antagonist (GW9662). HSC DNA and collagen synthesis were inhibited by WY14643 at the concentrations known to activate both PPAR alpha and gamma (>100 muM) but not at those that only activate PPARa (<10 <mu>M) Or by a synthetic PPAR alpha -selective agonist (GW9578). 15dPGJ(2), reduced Phi1(I) procollagen, smooth muscle alpha -actin, and monocyte chemotactic protein-1 mRNA levels while inducing matrix metalloproteinase-3 and CD36, 15dPGJ(2), and BRL49653 inhibited alpha1(I) procollagen promoter activity. Tumor necrosis factor or (10 ng/ml) reduced PPAR gamma mRNA, and this effect was prevented by the treatment with 15dPGJ(2),, These results demonstrate that HSC activation is associated with the reductions in PPAR gamma expression and PPAR-responsive element binding in vivo and is reversed by the treatment with PPAR gamma ligands in vitro. These findings implicate diminished PPAR gamma signaling in molecular mechanisms underlying activation of HSC in liver fibrogenesis and the potential therapeutic value of PPAR gamma ligands for liver fibrosis.	Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Dept Vet Affairs Greater Los Angeles Healthcare S, Sepulveda, CA 91343 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA; Univ Maryland, Dept Med, College Pk, MD 21201 USA; Glaxo Wellcome Res & Dev Ltd, Dept Med Chem, Res Triangle Pk, NC 27709 USA	University of Southern California; University of Southern California; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University System of Maryland; University of Maryland College Park; GlaxoSmithKline	Miyahara, T (corresponding author), Univ So Calif, Keck Sch Med, Dept Med, 1333 San Pablo St,MMR-412, Los Angeles, CA 90033 USA.		feinstein, doug/M-9414-2019		NIAAA NIH HHS [AA10459, R37-AA06603] Funding Source: Medline; NIDDK NIH HHS [DK02450] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006603, R01AA010459, R29AA010459] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; BACHEM MG, 1992, J CLIN INVEST, V89, P19, DOI 10.1172/JCI115561; BISSELL DM, 1990, SEMIN LIVER DIS, V10, P3; Camp HS, 1997, J BIOL CHEM, V272, P10811; Carloni V, 1997, GASTROENTEROLOGY, V112, P522, DOI 10.1053/gast.1997.v112.pm9024306; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS BH, 1990, J CLIN INVEST, V86, P2062, DOI 10.1172/JCI114943; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DEVEHAND PR, 1996, NATURE, V384, P39; Fadok VA, 1998, J IMMUNOL, V161, P6250; FRIEDMAN SL, 1993, AM J PHYSIOL, V264, pG947, DOI 10.1152/ajpgi.1993.264.5.G947; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; Graf K, 1997, FEBS LETT, V400, P119, DOI 10.1016/S0014-5793(96)01371-3; Hautekeete ML, 1997, VIRCHOWS ARCH, V430, P195, DOI 10.1007/BF01324802; Hellemans K, 1999, GUT, V45, P134, DOI 10.1136/gut.45.1.134; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Imai S, 1997, FEBS LETT, V411, P102, DOI 10.1016/S0014-5793(97)00673-X; IREDALE JP, 1995, CLIN SCI, V89, P75, DOI 10.1042/cs0890075; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Lin M, 1997, AM J PHYSIOL-GASTR L, V272, pG1355; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; Mangelsdorf David J., 1994, P319; MATSUOKA M, 1990, HEPATOLOGY, V11, P173, DOI 10.1002/hep.1840110204; NAKATSUKASA H, 1990, J CLIN INVEST, V85, P1833, DOI 10.1172/JCI114643; Ohata M, 1997, AM J PHYSIOL-GASTR L, V272, pG589, DOI 10.1152/ajpgi.1997.272.3.G589; Okuno M, 1997, HEPATOLOGY, V26, P913, DOI 10.1002/hep.510260417; PAN LY, 1995, J CELL BIOCHEM, V57, P575, DOI 10.1002/jcb.240570402; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; PEKTOVICH M, 1987, NATURE, V330, P444; Potter JJ, 1998, BIOCHEM BIOPH RES CO, V244, P178, DOI 10.1006/bbrc.1997.8193; Poulos JE, 1997, AM J PHYSIOL-GASTR L, V273, pG804, DOI 10.1152/ajpgi.1997.273.4.G804; Qi Z, 1999, P NATL ACAD SCI USA, V96, P2345, DOI 10.1073/pnas.96.5.2345; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RIPPE RA, 1995, HEPATOLOGY, V22, P241, DOI 10.1016/0270-9139(95)90378-X; Rockey DC, 1996, J CLIN INVEST, V98, P1381, DOI 10.1172/JCI118925; ROCKEY DC, 1992, J SUBMICR CYTOL PATH, V24, P193; ROCKEY DC, 1993, J CLIN INVEST, V92, P1795, DOI 10.1172/JCI116769; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tsukamoto H, 1999, ALCOHOL CLIN EXP RES, V23, P911, DOI 10.1111/j.1530-0277.1999.tb04202.x; Tsukamoto H, 1996, AM J PHYSIOL-GASTR L, V270, pG581, DOI 10.1152/ajpgi.1996.270.4.G581; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Wang SC, 1998, J BIOL CHEM, V273, P302, DOI 10.1074/jbc.273.1.302; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; WONG L, 1994, J CLIN INVEST, V94, P1563, DOI 10.1172/JCI117497; Yee HF, 1998, HEPATOLOGY, V28, P843, DOI 10.1002/hep.510280336; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457	55	396	423	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35715	35722		10.1074/jbc.M006577200	http://dx.doi.org/10.1074/jbc.M006577200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10969082	hybrid, Green Published			2022-12-27	WOS:000165382000012
J	Kihara, M; Nakai, W; Asano, S; Suzuki, A; Kitada, K; Kawasaki, Y; Johnston, LH; Sugino, A				Kihara, M; Nakai, W; Asano, S; Suzuki, A; Kitada, K; Kawasaki, Y; Johnston, LH; Sugino, A			Characterization of the yeast Cdc7p/Dbf4p complex purified from insect cells - Its protein kinase activity is regulated by Rad53p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE CDC7; S-PHASE; DNA-REPLICATION; BUDDING YEAST; MCM PROTEINS; FISSION YEAST; CHROMOSOMAL REPLICATION; CDC7-RELATED KINASE; CHECKPOINT PATHWAY; G(1)/S TRANSITION	The yeast Saccharomyces cerevisiae Cdc7p/Dbf4p protein kinase complex was purified to near homogeneity from insect cells. The complex efficiently phosphorylated yeast Mcm2p and less efficiently the remaining Mcm proteins or other replication proteins. Significantly, when pretreated with alkaline phosphatase, Mcm2p became completely inactive as a substrate, suggesting that it must be phosphorylated by other protein kinase(s) to be a substrate for the Cdc7p/Dbf4p complex. Mutant Cdc7p/Dbf4p complexes containing either Cdc7-1p or Dbf4-1 similar to 5p were also partially purified from insect cells and characterized in vitro. Furthermore, the autonomously replicating sequence binding activity of various dbf4 mutants was also analyzed. These studies suggest that the autonomously replicating sequence-binding and Cdc7p protein kinase activation domains of Dbf4p collaborate to form an active Cdc7p/Dbf4p complex and function during S phase in S. cerevisiae, It is shown that Rad53p phosphorylates the Cdc7p/Dbf4p complex in vitro and that this phosphorylation greatly inhibits the kinase activity of Cdc7p/Dbf4p, This result suggests that Rad53p controls the initiation of chromosomal DNA replication by regulating the protein kinase activity associated with the Cdc7p/Dbf4p complex.	Osaka Univ, Dept Biochem & Mol Biol, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; Nippon Roche Res Ctr, Kanagawa 2470063, Japan; Natl Inst Med Res, Div Yeast Genet, London NW7 1AA, England	Osaka University; Roche Holding; MRC National Institute for Medical Research	Sugino, A (corresponding author), Osaka Univ, Dept Biochem & Mol Biol, Microbial Dis Res Inst, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.							Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; CHAPMAN JW, 1989, EXP CELL RES, V180, P419, DOI 10.1016/0014-4827(89)90068-2; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Detweiler CS, 1997, J CELL SCI, V110, P753; Dohrmann PR, 1999, GENETICS, V151, P965; Donaldson AD, 1998, MOL CELL, V2, P173, DOI 10.1016/S1097-2765(00)80127-6; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; Feng L, 1998, J BIOL CHEM, V273, P1298, DOI 10.1074/jbc.273.3.1298; Fujita M, 1997, J BIOL CHEM, V272, P10928; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; Hardy CFJ, 1996, MOL CELL BIOL, V16, P6775; HARTWELL LH, 1973, J BACTERIOL, V115, P966, DOI 10.1128/JB.115.3.966-974.1973; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; Hashimoto K, 1998, NUCLEIC ACIDS RES, V26, P477, DOI 10.1093/nar/26.2.477; Hess GF, 1998, GENE, V211, P133, DOI 10.1016/S0378-1119(98)00094-8; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; Jiang W, 1997, P NATL ACAD SCI USA, V94, P14320, DOI 10.1073/pnas.94.26.14320; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; JOHNSTON LH, 1982, MOL GEN GENET, V186, P445, DOI 10.1007/BF00729467; Kamimura Y, 1998, MOL CELL BIOL, V18, P6102, DOI 10.1128/MCB.18.10.6102; Kim JM, 1998, J BIOL CHEM, V273, P23248, DOI 10.1074/jbc.273.36.23248; KITADA K, 1992, GENETICS, V131, P21; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; Oshiro G, 1999, MOL CELL BIOL, V19, P4888; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Sambrook J., 2002, MOL CLONING LAB MANU; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Sugimoto K, 1997, MOL CELL BIOL, V17, P5905, DOI 10.1128/MCB.17.10.5905; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tye BK, 2000, P NATL ACAD SCI USA, V97, P2399, DOI 10.1073/pnas.97.6.2399; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	51	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35051	35062		10.1074/jbc.M003491200	http://dx.doi.org/10.1074/jbc.M003491200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10964916	hybrid			2022-12-27	WOS:000165422800032
J	Skiba, NP; Hopp, JA; Arshavsky, VY				Skiba, NP; Hopp, JA; Arshavsky, VY			The effector enzyme regulates the duration of G protein signaling in vertebrate photoreceptors by increasing the affinity between transducin and RGS protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE ACCELERATING PROTEIN; CGMP PHOSPHODIESTERASE; INHIBITORY SUBUNIT; ROD PHOTORECEPTORS; TRANSITION-STATE; TARGET ENZYME; GAMMA-SUBUNIT; IN-VIVO; HYDROLYSIS; BINDING	The photoreceptor-specific G protein transducin acts as a molecular switch, stimulating the activity of its downstream effector in its GTP-bound form and inactivating the effector upon GTP hydrolysis, This activity makes the rate of transducin GTPase an essential factor in determining the duration of photoresponse in vertebrate rods and cones. In photoreceptors, the slow intrinsic rate of transducin GTPase is accelerated by the complex of the ninth member of the regulators of G protein signaling family with the long splice variant of type 5 G protein beta subunit (RGS9-G beta 5L). However, physiologically rapid GTPase is observed only when transducin forms a complex with its effector, the gamma subunit of cGMP phosphodiesterase (PDE gamma), In this study, we addressed the mechanism by which PDE gamma regulates the rate of transducin GTPase, We found that RGS9-G beta 5L alone has a significant ability to activate transducin GTPase, but its affinity for transducin is low. PDEy acts by enhancing the affinity between activated transducin and RGS9-G beta 5L by more than 15-fold, which is evident both from kinetic measurements of transducin GTPase rate and from protein binding assays with immobilized transducin. Furthermore, our data indicate that a single RGS9-G beta 5L molecule is capable of accelerating the GTPase activity of similar to 100 transducin molecules/s. This rate is faster than the rates reported previously for any RGS protein and is sufficient for timely photoreceptor recovery in both rod and cone photoreceptors.	Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Howe Lab Ophthalmol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Arshavsky, VY (corresponding author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Howe Lab Ophthalmol, 243 Charles St, Boston, MA 02114 USA.	vadim_arshavsky@meei.harvard.edu			NATIONAL EYE INSTITUTE [R01EY012859] Funding Source: NIH RePORTER; NEI NIH HHS [EY-12859] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANANT JS, 1992, J BIOL CHEM, V267, P687; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; Artemyev NO, 1997, BIOCHEMISTRY-US, V36, P4188, DOI 10.1021/bi963002y; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BOWNDS MD, 1995, BEHAV BRAIN SCI, V18, P415, DOI 10.1017/S0140525X00039170; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; Cowan CW, 2000, METHOD ENZYMOL, V315, P524; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lyubarsky AL, 1996, J NEUROSCI, V16, P563, DOI 10.1523/jneurosci.16-02-00563.1996; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; McEntaffer RL, 1999, BIOCHEMISTRY-US, V38, P4931, DOI 10.1021/bi982636x; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; Nekrasova ER, 1997, BIOCHEMISTRY-US, V36, P7638, DOI 10.1021/bi970427r; PEPPERBERG DR, 1992, VISUAL NEUROSCI, V8, P9, DOI 10.1017/S0952523800006441; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; RIPPS H, 1976, EYE A, V2, P185; Skiba NP, 1999, J BIOL CHEM, V274, P8770, DOI 10.1074/jbc.274.13.8770; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TING TD, 1993, METH NEUROSCI, V15, P180; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; YAMAZAKI A, 1993, J BIOL CHEM, V268, P8899	37	58	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32716	32720		10.1074/jbc.C000413200	http://dx.doi.org/10.1074/jbc.C000413200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10973941	hybrid			2022-12-27	WOS:000090003800048
J	Jakob, U; Eser, M; Bardwell, JCA				Jakob, U; Eser, M; Bardwell, JCA			Redox switch of Hsp33 has a novel zinc-binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; ESCHERICHIA-COLI; PROTEIN; THIOLATE; LIGANDS; FINGER; METALLOTHIONEIN; IDENTIFICATION; SPECTROSCOPY; RUBREDOXIN	The chaperone activity of the heat shock protein Hsp33 is regulated by reversible disulfide bond formation. Oxidized Hsp33 is active, and reduced Hsp33 is inactive. We show that zinc binding is essential for the function of this redox switch. Our results reveal that Hps33 contains a new, high affinity (K-alpha > 10(17) M-1), zinc-binding motif in the form Cys-X-Cys-X27-32-Cys-X-X-Cys. All four conserved cysteines within this moth act to coordinate a single zinc atom. Experiments where reduced wild type Hsp33 is reconstituted with cobalt or cadmium demonstrate that the metal-coordinating cysteines are present as highly reactive thiolate anions. This ionization may allow for the fast and successful activation of the chaperone function of Hsp33 upon incubation in oxidizing agents.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Jakob, U (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.							ANDEREGG G, 1967, HELV CHIM ACTA, V50, P2330, DOI 10.1002/hlca.19670500817; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; Barbirz S, 2000, J BIOL CHEM, V275, P18759, DOI 10.1074/jbc.M001089200; Berendji D, 1997, FEBS LETT, V405, P37, DOI 10.1016/S0014-5793(97)00150-6; Berkovits HJ, 1999, BIOCHEMISTRY-US, V38, P16826, DOI 10.1021/bi991433l; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bertini I, 1984, Adv Inorg Biochem, V6, P71; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Casadevall M, 1998, J INORG BIOCHEM, V71, P147, DOI 10.1016/S0162-0134(98)10046-6; CHEVION M, 1988, FREE RADICAL BIO MED, V5, P27, DOI 10.1016/0891-5849(88)90059-7; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P155; Hasler DW, 1998, BIOCHEMISTRY-US, V37, P14966, DOI 10.1021/bi9813734; HENEHAN CJ, 1993, PROTEIN SCI, V2, P1756, DOI 10.1002/pro.5560021019; Huang CC, 1997, J BIOL CHEM, V272, P20; Hunt JA, 1997, J BIOL CHEM, V272, P20364, DOI 10.1074/jbc.272.33.20364; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; HUNT JB, 1977, ANAL BIOCHEM, V64, P297; Jacob C, 1998, P NATL ACAD SCI USA, V95, P3489, DOI 10.1073/pnas.95.7.3489; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; KAIM W, 1995, BIOANORGANISCHE CHEM, P248; Kang JG, 1999, EMBO J, V18, P4292, DOI 10.1093/emboj/18.15.4292; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; MARET W, 1993, METHOD ENZYMOL, V226, P52; MAY SW, 1978, BIOCHEMISTRY-US, V17, P3333, DOI 10.1021/bi00609a025; Park JS, 1999, J BIOL CHEM, V274, P29075, DOI 10.1074/jbc.274.41.29075; Park OK, 1999, J BACTERIOL, V181, P1636, DOI 10.1128/JB.181.5.1636-1642.1999; Richardson A, 1998, TRENDS BIOCHEM SCI, V23, P138, DOI 10.1016/S0968-0004(98)01193-1; Ruddock LW, 1999, CURR BIOL, V9, pR400, DOI 10.1016/S0960-9822(99)80253-X; Ruediger Stefan, 1997, Nature Structural Biology, V4, P342; SUTTON HC, 1989, FREE RADICAL BIO MED, V6, P53, DOI 10.1016/0891-5849(89)90160-3; Swaroop M, 1999, FREE RADICAL BIO MED, V27, P193, DOI 10.1016/S0891-5849(99)00078-7; Wong C, 2000, BIOTECHNIQUES, V28, P426, DOI 10.2144/00283bm07; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zhou ZHS, 1999, BIOCHEMISTRY-US, V38, P15915, DOI 10.1021/bi992062b	36	155	156	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38302	38310		10.1074/jbc.M005957200	http://dx.doi.org/10.1074/jbc.M005957200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10976105	hybrid			2022-12-27	WOS:000165739800025
J	Jin, TC; Gu, YP; Zanusso, G; Sy, MS; Kumar, A; Cohen, M; Gambetti, P; Singh, N				Jin, TC; Gu, YP; Zanusso, G; Sy, MS; Kumar, A; Cohen, M; Gambetti, P; Singh, N			The chaperone protein BiP binds to a mutant prion protein and mediates its degradation by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; MOLECULAR CHAPERONES; APOLIPOPROTEIN-B; RETENTION; PRECURSOR; PATHWAY; TRANSPORT; DISEASES; CELLS	Familial prion diseases are thought to result from a change in structure of the mutant prion protein (PrP), which takes a pathogenic conformation. We have examined the role of molecular chaperones in the folding of normal and mutant PrP Q217R (PrP217) in transfected neuroblastoma cells. In a previous report we showed that, although most of the PrP217 forms escape the endoplasmic reticulum quality control system and aggregate in post-Golgi compartments, a significant proportion of PrP217 retains the C-terminal glycosylphos-phatidyl inositol signal peptide (PrP32), and does not exit the endoplasmic reticulum (Singh, N., Zanusso, G., Chen, S, G., Fujioka, H., Richardson, S., Gambetti, P., and Petersen, R, B, (1997) J. Biol Chem. 272, 28461-28470), We have now studied the folding and turnover of PrP32 to understand the mechanism by which abnormal PrP forms cause cellular toxicity in our cell culture model and in the human brain carrying the Gerstmann-Straussler-Scheinker disease Q217R mutation. In this report, we show that PrP32 remains associated with the chaperone BiP for an abnormally prolonged period of time and is degraded by the proteasomal pathway. This study is the first demonstration that BiP is chaperoning the folding of PrP and plays a role in maintaining the quality control in the PrP maturation pathway. Our data provide new insight into the diverse pathways of mutant PrP metabolism and neurotoxicity.	Case Western Reserve Univ, Inst Pathol, Div Neuropathol, Cleveland, OH 44106 USA	Case Western Reserve University	Singh, N (corresponding author), Case Western Reserve Univ, Inst Pathol, Div Neuropathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.		Zanusso, Gianluigi/K-2823-2018; Kumar, Anil/B-6909-2008	Zanusso, Gianluigi/0000-0001-5199-6264; 				Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Chesebro B, 1999, NEURON, V24, P503, DOI 10.1016/S0896-6273(00)81105-8; Clark HB, 2000, J NEUROPATH EXP NEUR, V59, P265, DOI 10.1093/jnen/59.4.265; COTNER T, 1995, J BIOL CHEM, V270, P2379, DOI 10.1074/jbc.270.5.2379; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FIELD MC, 1994, J BIOL CHEM, V269, P10830; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Gambetti P., 1999, PRION BIOL DIS; Hellman R, 1999, J CELL BIOL, V144, P21, DOI 10.1083/jcb.144.1.21; Imamura T, 1998, J BIOL CHEM, V273, P11183, DOI 10.1074/jbc.273.18.11183; Kaytor MD, 1999, J BIOL CHEM, V274, P37507, DOI 10.1074/jbc.274.53.37507; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Meerovitch K, 1998, J BIOL CHEM, V273, P21025, DOI 10.1074/jbc.273.33.21025; Newnam GP, 1999, MOL CELL BIOL, V19, P1325; Oda K, 1996, BIOCHEM J, V316, P623, DOI 10.1042/bj3160623; Oda K, 1996, BIOCHEM BIOPH RES CO, V219, P800, DOI 10.1006/bbrc.1996.0314; PAULY PC, 1995, BIOCHEM J, V306, P643, DOI 10.1042/bj3060643; Perlmutter DH, 1999, LAB INVEST, V79, P623; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; Sakata N, 1999, J BIOL CHEM, V274, P17068, DOI 10.1074/jbc.274.24.17068; Schirmer EC, 1997, P NATL ACAD SCI USA, V94, P13932, DOI 10.1073/pnas.94.25.13932; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Singh N, 1997, J BIOL CHEM, V272, P28461, DOI 10.1074/jbc.272.45.28461; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; Welch WJ, 1998, NATURE, V392, P23, DOI 10.1038/32049; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wilbourn B, 1998, BIOCHEM J, V332, P111, DOI 10.1042/bj3320111; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396	43	136	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38699	38704		10.1074/jbc.M005543200	http://dx.doi.org/10.1074/jbc.M005543200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10970892	hybrid			2022-12-27	WOS:000165739800077
J	Yi, JZ; Arthur, JW; Dunbrack, RL; Skalka, AM				Yi, JZ; Arthur, JW; Dunbrack, RL; Skalka, AM			An inhibitory monoclonal antibody binds at the turn of the helix-turn-helix motif in the N-terminal domain of HIV-1 integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DEPENDENT ROTAMER LIBRARY; TYPE-1 INTEGRASE; CATALYTIC DOMAIN; ACTIVE-SITE; DNA-BINDING; RETROVIRAL INTEGRASE; DIVALENT-CATIONS; IN-VITRO; PROTEIN	With the increase in our understanding of its structure and enzymatic mechanism, HIV-1 integrase (IN) ha, become a promising target for designing drugs to treat patients with AIDS, To investigate the structure and function of IN, a panel of monoclonal antibodies (mAbs) directed against HIV-1 IN was raised and characterized previously in this laboratory, Among them, mAbs17, -4, and -33 were found to inhibit IN activity in vitro. In this study, we investigated the interaction of N-terminal-specific mAb17 and its isolated Fab fragment with full-length HIV-1 IN(1-288) and its isolated N-terminal, Zn2+ binding domain IN(1-49). Our results show that binding of Zn2+ to IN(1-49) stabilizes the mAb17-IN complex and that dimer dissociation is not required for binding of the Fab. To identify the epitope recognized by mAb17, we developed a protein footprinting technique based on controlled proteolysis and matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Binding was mapped to a region within amino acids Asp(25)-Glu(35). This peptide corresponds to the end of a helix-turn-helix motif in the IN(1-55) NMR structure and contributes to the dimerization of the N-terminal domain. Antibody binding also appears to destabilize the N-terminal helix in this domain. A molecular model of the [IN(1-49)](2).(Fab)(1) complex shows Fab binding across the dimer protein and suggests a potential target for drug design. These data also suggest that mAb17 inhibits integrase activity by blocking critical protein-protein interactions and/or by distorting the orientation of the N-terminal alpha -helix, The relevance of our results to an understanding of IN function is discussed.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Skalka, AM (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Dunbrack, Roland/ABG-7141-2020; Arthur, Jonathan/A-5367-2009	Arthur, Jonathan/0000-0003-3615-7352; Dunbrack, Roland/0000-0001-7674-6667	NATIONAL CANCER INSTITUTE [P30CA006927, R01CA071515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040385] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA71515] Funding Source: Medline; NIAID NIH HHS [AI40385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; Asante-Appiah E, 1998, J BIOL CHEM, V273, P35078, DOI 10.1074/jbc.273.52.35078; Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; AsanteAppiah E, 1997, J BIOL CHEM, V272, P16196, DOI 10.1074/jbc.272.26.16196; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BIZUBBENDER D, 1994, AIDS RES HUM RETROV, V10, P1105, DOI 10.1089/aid.1994.10.1105; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Buchbinder JL, 1998, J MOL BIOL, V282, P1033, DOI 10.1006/jmbi.1998.2025; Bujacz G, 1997, J BIOL CHEM, V272, P18161, DOI 10.1074/jbc.272.29.18161; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; BUSHMAN FD, 1994, J VIROL, V68, P2215, DOI 10.1128/JVI.68.4.2215-2223.1994; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; Chen ZG, 2000, J MOL BIOL, V296, P521, DOI 10.1006/jmbi.1999.3451; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; Dunbrack RL, 1997, PROTEIN SCI, V6, P1661, DOI 10.1002/pro.5560060807; Dunbrack RL, 1999, PROTEINS, P81; EIJKELENBOOM AP, 1997, CURR BIOL, V7, P7398; Eijkelenboom APAM, 1999, PROTEINS, V36, P556, DOI 10.1002/(SICI)1097-0134(19990901)36:4<556::AID-PROT18>3.0.CO;2-6; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; ELLISON V, 1995, J BIOL CHEM, V270, P3320, DOI 10.1074/jbc.270.7.3320; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836, DOI 10.1128/MMBR.63.4.836-843.1999; JEFFREY PD, 1995, J MOL BIOL, V248, P344, DOI 10.1016/S0022-2836(95)80055-7; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; Kaminski MJ, 1999, J BIOL CHEM, V274, P5597, DOI 10.1074/jbc.274.9.5597; Katz RA, 1996, VIROLOGY, V217, P178, DOI 10.1006/viro.1996.0105; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; Koehl Patrice, 1999, Nature Structural Biology, V6, P108, DOI 10.1038/5794; Lee SP, 1996, BIOCHEMISTRY-US, V35, P3837, DOI 10.1021/bi952056p; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; LevyMintz P, 1996, J VIROL, V70, P8821, DOI 10.1128/JVI.70.12.8821-8832.1996; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; Lubkowski J, 1998, P NATL ACAD SCI USA, V95, P4831, DOI 10.1073/pnas.95.9.4831; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; Mazumder A, 1996, BIOCHEMISTRY-US, V35, P13762, DOI 10.1021/bi960541u; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3; Ritchie DW, 2000, PROTEINS, V39, P178, DOI 10.1002/(SICI)1097-0134(20000501)39:2<178::AID-PROT8>3.3.CO;2-Y; STEVENSON M, 1990, J VIROL, V64, P2421, DOI 10.1128/JVI.64.5.2421-2425.1990; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; Yang ZN, 2000, J MOL BIOL, V296, P535, DOI 10.1006/jmbi.1999.3463; Yi JZ, 1999, BIOCHEMISTRY-US, V38, P8458, DOI 10.1021/bi982870n; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659	53	22	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38739	38748		10.1074/jbc.M005499200	http://dx.doi.org/10.1074/jbc.M005499200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10969077	hybrid			2022-12-27	WOS:000165739800083
J	Halaszovich, CR; Zitt, C; Jungling, E; Luckhoff, A				Halaszovich, CR; Zitt, C; Jungling, E; Luckhoff, A			Inhibition of TRP3 channels by lanthanides - Block from the cytosolic side of the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; OPERATED HTRP3 CHANNELS; ENDOTHELIAL-CELLS; MAST-CELLS; CA2+ ENTRY; EXPRESSION; GADOLINIUM; DEPLETION; PROTEINS; RECEPTOR	The lanthanide ions La3+ and Gd3+ block Ca2+-permeable cation channels and have been used as important tools to characterize channels of the transient receptor potential (TRP) family, However, widely different concentrations of La3+ and Gd3+ have reportedly been required for block of TRP3 channels in Various expression systems. The present study provides a possible explanation for this discrepancy. After overexpression of TRP3 in Chinese hamster ovary cells, whole-cell currents through TRP3 were reversibly inhibited by La3+ with an EC50 of 4 mum. For comparison, the organic blocker SKF96365 required an EC50 of 8 mum. Gd3+ blocked with an EC50 of 0.1 mum, but this block was slow in onset and was not reversible after wash-out. When the two lanthanides were added to the cytosolic side of inside-out patches, block was achieved with considerably lower concentrations (EC50 for La3+, 0.02 mum; EC50 for Gd3+, 0.02 mum). Uptake of La3+ into the cytosol of Chinese hamster ovary cells was demonstrated with intracellular fura a. We conclude that lanthanides block TRP3 more potently from the cytosolic than from the extracellular side of the plasma membrane and that uptake of lanthanides will largely affect the apparent EC50 values after extracellular application.	Univ Klinikum Aachen, Rhein Westfal TH Aachen, Inst Physiol, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Luckhoff, A (corresponding author), Univ Klinikum Aachen, Rhein Westfal TH Aachen, Inst Physiol, Pauwelsstr 30, D-52074 Aachen, Germany.		Halaszovich, Christian/I-7231-2012					Aussel C, 1996, BIOCHEM J, V313, P909, DOI 10.1042/bj3130909; Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Caldwell RA, 1998, AM J PHYSIOL-CELL PH, V275, pC619, DOI 10.1152/ajpcell.1998.275.2.C619; Cheng Y, 1999, J BIOL INORG CHEM, V4, P447, DOI 10.1007/s007750050331; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; EVANS CH, 1990, BIOCHEMISTRY LANTHAN; FRANZIUS D, 1994, PFLUG ARCH EUR J PHY, V428, P433, DOI 10.1007/BF00374562; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSEN DE, 1991, CIRC RES, V69, P820, DOI 10.1161/01.RES.69.3.820; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hongo K, 1997, EXP PHYSIOL, V82, P647, DOI 10.1113/expphysiol.1997.sp004053; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; KWAN CY, 1990, J BIOL CHEM, V265, P678; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; MARTELL AE, 1976, CRITICAL STABILITY C; PEETERS GA, 1989, AM J PHYSIOL, V256, pC351, DOI 10.1152/ajpcell.1989.256.2.C351; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Preuss KD, 1997, BIOCHEM BIOPH RES CO, V240, P167, DOI 10.1006/bbrc.1997.7528; Putney JW, 1999, BIOESSAYS, V21, P38; STACY GP, 1992, AM J PHYSIOL, V263, pH613, DOI 10.1152/ajpheart.1992.263.2.H613; TAKANO H, 1995, CIRCULATION, V91, P1575, DOI 10.1161/01.CIR.91.5.1575; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	34	111	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37423	37428		10.1074/jbc.M007010200	http://dx.doi.org/10.1074/jbc.M007010200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10970899	hybrid			2022-12-27	WOS:000165618700017
J	Liu, L; Sazonova, IY; Turner, RB; Chowdhry, SA; Tsai, J; Houng, AK; Reed, GL				Liu, L; Sazonova, IY; Turner, RB; Chowdhry, SA; Tsai, J; Houng, AK; Reed, GL			Leucine 42 in the fibronectin motif of streptokinase plays a critical role in fibrin-independent plasminogen activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOLYTIC THERAPY; BINDING REGION; COMPLEX; MECHANISM; CONVERSION; DOMAINS; ACID	The NH2 terminus (residues 1-59) of streptokinase (SK) is a molecular switch that permits fibrin-independent plasminogen activation. Targeted mutations were made in recombinant (r) SK1-59 to identify structural interactions required for this process. Mutagenesis established the functional roles of Phe-37and Glu-39, which were projected to interact with microplasmin in the activator complex. Mutation of Leu-42 (rSK1-59(L42A)), a conserved residue in the SK fibronectin motif that lacks interactions with microplasmin, strongly reduced plasminogen activation (k(cat) decreased 50-fold) but not amidolysis (k(cat) decreased 1.5-fold). Otherwise rSK1-59(L42A) and native rSK1-59 were indistinguishable in several parameters. Both displayed saturable and specific binding to Glu-plasminogen or the remaining SK fragment (rSK Delta 59), Similarly rSK1-59 and rSK1-59(L42A) bound simultaneously to two different plasminogen molecules, indicating that both plasminogen binding sites were intact. However, when bound to SK1-59, rSK1-59(L42A) was less effective than rSK1-59 in restructuring the native conformation of the SK A domain, as detected by conformation-dependent monoclonal antibodies. In the light of previous studies, these data provide evidence that SK1-59 contributes to fibrin-independent plasminogen activation through 1) intermolecular interactions with the plasmin in the activator complex, 2) binding interactions with the plasminogen substrate, and 3) intramolecular interactions that structure the A domain of SK for Pg substrate processing.	Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital	Reed, GL (corresponding author), Cardiovasc Biol Lab, HSHP 2-127,677 Huntington Ave, Boston, MA 02115 USA.	reed@cvlab.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057314] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57314] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROCKWAY WJ, 1974, BIOCHEMISTRY-US, V13, P2063, DOI 10.1021/bi00707a010; Caballero RR, 1999, INFECT IMMUN, V67, P6478; CAMIOLO SM, 1971, P SOC EXP BIOL MED, V138, P277; Conejero-Lara F, 1998, PROTEIN SCI, V7, P2190, DOI 10.1002/pro.5560071017; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GONZALEZGRONOW M, 1993, BIOCHIM BIOPHYS ACTA, V1180, P283, DOI 10.1016/0925-4439(93)90051-2; Hirst JD, 1996, PROTEIN ENG, V9, P657, DOI 10.1093/protein/9.8.657; Lin LF, 1996, BIOCHEMISTRY-US, V35, P16879, DOI 10.1021/bi961531w; Lin LF, 2000, BIOCHEMISTRY-US, V39, P4740, DOI 10.1021/bi992028x; LUKACOVA D, 1991, BIOCHEMISTRY-US, V30, P10164, DOI 10.1021/bi00106a013; MARDER VJ, 1988, NEW ENGL J MED, V318, P1585, DOI 10.1056/NEJM198806163182406; MARDER VJ, 1988, NEW ENGL J MED, V318, P1512, DOI 10.1056/NEJM198806093182306; MARKUS G, 1976, J BIOL CHEM, V251, P6495; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; Moitra J, 1997, BIOCHEMISTRY-US, V36, P12567, DOI 10.1021/bi971424h; Nihalani D, 1997, PROTEIN SCI, V6, P1284, DOI 10.1002/pro.5560060616; Nihalani D, 1998, PROTEIN SCI, V7, P637, DOI 10.1002/pro.5560070313; Pace CN, 1996, FASEB J, V10, P75, DOI 10.1096/fasebj.10.1.8566551; ParhamiSeren B, 1997, J MOL BIOL, V271, P333, DOI 10.1006/jmbi.1997.1174; Parrado J, 1996, PROTEIN SCI, V5, P693; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REED GL, 1995, BIOCHEMISTRY-US, V34, P10266, DOI 10.1021/bi00032a021; Reed GL, 1999, P NATL ACAD SCI USA, V96, P8879, DOI 10.1073/pnas.96.16.8879; REED GL, 1993, J IMMUNOL, V150, P4407; RODRIGUEZ P, 1995, EUR J BIOCHEM, V229, P83, DOI 10.1111/j.1432-1033.1995.0083l.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Serrano RL, 1996, BIOCHEM J, V313, P171, DOI 10.1042/bj3130171; SIEFRING GE, 1976, J BIOL CHEM, V251, P3913; SUMMARIA L, 1967, J BIOL CHEM, V242, P4279; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; WOHL RC, 1980, J BIOL CHEM, V255, P2005; WULF RJ, 1969, CAN J BIOCHEM CELL B, V47, P927, DOI 10.1139/o69-145	35	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37686	37691		10.1074/jbc.M003963200	http://dx.doi.org/10.1074/jbc.M003963200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10961989	hybrid			2022-12-27	WOS:000165618700053
J	Schulz, A; Bruns, K; Henklein, P; Krause, G; Schubert, M; Gudermann, T; Wray, V; Schultz, G; Schoneberg, T				Schulz, A; Bruns, K; Henklein, P; Krause, G; Schubert, M; Gudermann, T; Wray, V; Schultz, G; Schoneberg, T			Requirement of specific intrahelical interactions for stabilizing the inactive conformation of glycoprotein hormone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD INTRACELLULAR LOOP; HUMAN LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; HUMAN THYROTROPIN RECEPTOR; CARBOXYL-TERMINAL REGION; G-PROTEIN RECEPTOR; CYTOPLASMIC LOOP; ALPHA-HELIX; CONSTITUTIVE ACTIVATION; SECONDARY STRUCTURE; CIRCULAR-DICHROISM	Systematic analysis of structural changes induced by activating mutations has been frequently utilized to study activation mechanisms of G-protein-coupled receptors (GPCRs). In the thyrotropin receptor and the lutropin receptor (LHR), a large number of naturally occurring mutations leading to constitutive receptor activation were identified. Saturating mutagenesis studies of a highly conserved Asp in the junction of the third intracellular loop and transmembrane domain 6 suggested a participation of this anionic residue in a salt bridge stabilizing the inactive receptor conformation. However, substitution of all conserved cationic residues at the cytoplasmic receptor surface did not support this hypothesis. Asp/Glu residues are a common motif at the N-terminal ends of alpha -helices terminating and stabilizing the helical structure (helix capping). Since Asp/Glu residues in the third intracellular loop/transmembrane domain 6 junction are not only preserved in glycoprotein hormone receptors but also in other GPCRs we speculated that this residue probably participates in an N-terminal helix-capping structure. Poly-Ala stretches are known to form and stabilize alpha -helices. Herein, we show that the function of the highly conserved Asp can be mimicked by poly-Ala substitutions in the LHR and thyrotropin receptor. CD and NMR studies of peptides derived from the juxtamembrane portion of the LHR confirmed the helix extension by the poly-Ala substitution and provided further evidence for an involvement of Asp in a helix-capping structure. Our data implicate that in addition to well established interhelical interactions the inactive conformation of GPCRs is also stabilized by specific intrahelical structures.	Free Univ Berlin, Inst Pharmakol, Klinikum Benjamin Franklin, D-14195 Berlin, Germany; Gesell Biotechnol Forsch GmbH, Dept Mol Struct Res, D-38124 Braunschweig, Germany; Humboldt Univ, Charite, Fak Med, Inst Biochem, D-10098 Berlin, Germany; Inst Mol Pharmakol, D-10315 Berlin, Germany; Univ Marburg, Fachberiech Humanmed, Inst Pharmakol & Toxikol, D-35033 Marburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Gesellschaft fur Biotechnologische Forschung mbH; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Philipps University Marburg	Schoneberg, T (corresponding author), Free Univ Berlin, Inst Pharmakol, Klinikum Benjamin Franklin, Thielallee 69-73, D-14195 Berlin, Germany.		Schubert, Mario/B-3972-2008	Schubert, Mario/0000-0003-0278-4091				Abell AN, 1997, J BIOL CHEM, V272, P14586, DOI 10.1074/jbc.272.23.14586; Abell AN, 1998, MOL ENDOCRINOL, V12, P1857, DOI 10.1210/me.12.12.1857; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Arshava B, 1998, BIOPOLYMERS, V46, P343, DOI 10.1002/(SICI)1097-0282(199811)46:6<343::AID-BIP1>3.0.CO;2-L; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Biebermann H, 1998, FASEB J, V12, P1461, DOI 10.1096/fasebj.12.14.1461; Blondelle SE, 1997, BIOCHEMISTRY-US, V36, P8393, DOI 10.1021/bi963015b; Boice JA, 1997, J BIOL CHEM, V272, P24825, DOI 10.1074/jbc.272.40.24825; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; CHAZENBALK GD, 1991, MOL ENDOCRINOL, V5, P1523, DOI 10.1210/mend-5-10-1523; Chopra A, 2000, BBA-BIOMEMBRANES, V1463, P1, DOI 10.1016/S0005-2736(99)00212-6; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; ELMASRY NF, 1994, PROTEIN ENG, V7, P777, DOI 10.1093/protein/7.6.777; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FOROOD B, 1993, P NATL ACAD SCI USA, V90, P838, DOI 10.1073/pnas.90.3.838; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HEINZ DW, 1992, P NATL ACAD SCI USA, V89, P3751, DOI 10.1073/pnas.89.9.3751; HENKLEIN P, 1993, PEPTIDE RES, V6, P79; HENRY GD, 1994, METHOD ENZYMOL, V239, P515; Higuchi R., 1989, PCR TECHNOLOGY, P61; HITT M, 1995, VIRAL GENE TECHNIQUE, P13; HOGGER P, 1995, J BIOL CHEM, V270, P7405; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JUNG H, 1995, FEBS LETT, V358, P133, DOI 10.1016/0014-5793(94)01409-T; Jung H, 1996, BIOCHEMISTRY-US, V35, P6399, DOI 10.1021/bi952575s; KILLIAN JA, 1994, FEBS LETT, V348, P161, DOI 10.1016/0014-5793(94)00594-X; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Kosugi S, 1998, MOL PHARMACOL, V53, P894; Kosugi S, 1996, J BIOL CHEM, V271, P31813, DOI 10.1074/jbc.271.50.31813; Krause G, 2000, MOL PHARMACOL, V57, P232; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Rigby AC, 1998, BBA-BIOMEMBRANES, V1371, P241, DOI 10.1016/S0005-2736(98)00020-0; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; Soulie S, 1999, BIOCHEMISTRY-US, V38, P5813, DOI 10.1021/bi983039d; Thapar R, 1996, BIOCHEMISTRY-US, V35, P11268, DOI 10.1021/bi960349s; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; Wan WY, 1999, J MOL BIOL, V286, P1633, DOI 10.1006/jmbi.1999.2552; WANG HY, 1993, MOL ENDOCRINOL, V7, P1437, DOI 10.1210/me.7.11.1437; Wang Z, 1996, MOL ENDOCRINOL, V10, P748, DOI 10.1210/me.10.6.748; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wonerow P, 1998, J BIOL CHEM, V273, P7900, DOI 10.1074/jbc.273.14.7900; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P9649, DOI 10.1021/bi970908a; YEAGLE PL, 1995, BIOCHEMISTRY-US, V34, P14621, DOI 10.1021/bi00045a002; YEAGLE PL, 1995, NAT STRUCT BIOL, V2, P832, DOI 10.1038/nsb1095-832; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P3864, DOI 10.1021/bi962403a; ZHANG XJ, 1991, BIOCHEMISTRY-US, V30, P2012, DOI 10.1021/bi00222a001; ZHU X, 1993, J BIOL CHEM, V268, P1723	63	28	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37860	37869		10.1074/jbc.M006709200	http://dx.doi.org/10.1074/jbc.M006709200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10967122	hybrid			2022-12-27	WOS:000165618700075
J	Carter, C; Thornburg, RW				Carter, C; Thornburg, RW			Tobacco nectarin I - Purification and characterization as a germin-like, manganese superoxide dismutase implicated in the defense of floral reproductive tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARLEY OXALATE OXIDASE; OXIDATIVE BURST; PROTEIN; EXPRESSION; ENZYMES; GLYCOPROTEIN; AFFINITY; EMBRYOS; CLONING; CDNA	Nectarin I, a protein that accumulates in the nectar of Nicotiana sp., was determined to contain superoxide dismutase activity by colorimetric and in-gel assays. This activity was found to be remarkably thermostable. Extended incubations at temperatures up to 90 degreesC did not diminish the superoxide dismutase activity of nectarin I. This attribute allowed nectarin I to be purified to homogeneity by heat denaturation of the other nectar proteins. By SDS-polyacrylamide gel electrophoresis, nectarin I appeared as a 29-kDa monomer. If the protein sample was not boiled prior to loading the gel, then nectarin I migrated as 165-kDa oligomeric protein. By matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, the protomer subunit was found to be a 22.5-kDa protein. Purified nectarin I contained 0.5 atoms of manganese/monomer, and the superoxide dismutase activity of nectarin I was not inhibited by either H2O2 or NaCN. Following denaturation, the superoxide dismutase activity was restored after Mn2+ addition. Addition of Fe2+, Cu2+, Zn2+ and Cu2+/Zn2+ did not restore superoxide dismutase activity. The quaternary structure of the reconstituted enzyme was examined, and only tetrameric and pentameric aggregates were enzymatically active, The reconstituted enzyme was also shown to generate H2O2,. Putative nectarin I homologues mere found in the nectars of several other plant species.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Thornburg, RW (corresponding author), Iowa State Univ, Dept Biochem & Biophys, 2212 Mol Biol Bldg, Ames, IA 50011 USA.	thorn@iastate.edu						AHMAD S, 1988, FREE RADICAL RES COM, V4, P403, DOI 10.3109/10715768809066908; Baker H.G., 1983, P126; BEARD ME, 1987, P NATL ACAD SCI USA, V84, P7433, DOI 10.1073/pnas.84.21.7433; BRYANT J, 1976, BIOCHEMISTRY-US, V15, P3418, DOI 10.1021/bi00661a004; Carter C, 1999, PLANT MOL BIOL, V41, P207, DOI 10.1023/A:1006363508648; Carter C, 1998, PLANT MOL BIOL, V38, P929, DOI 10.1023/A:1006038117130; Carter Clay, 1999, Journal of Plant Biology, V42, P97; COLLEN J, 1994, PHYSIOL PLANTARUM, V92, P417; de Azeredo-Oliveira MTV, 1998, CYTOBIOS, V93, P83; DOMON JM, 1995, PLANT PHYSIOL, V108, P141, DOI 10.1104/pp.108.1.141; DUMAS B, 1995, PLANT PHYSIOL, V107, P1091, DOI 10.1104/pp.107.4.1091; DUMAS B, 1993, CR ACAD SCI III-VIE, V316, P793; FELTON GW, 1995, ARCH INSECT BIOCHEM, V29, P187, DOI 10.1002/arch.940290208; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; Gane PJ, 1998, J MOL EVOL, V46, P488, DOI 10.1007/PL00006329; GELLER BL, 1983, ANAL BIOCHEM, V128, P86, DOI 10.1016/0003-2697(83)90348-2; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HESLOPHARRISON Y, 1971, PLANTA, V96, P183, DOI 10.1007/BF00387439; HURKMAN WJ, 1991, PLANT PHYSIOL, V97, P366, DOI 10.1104/pp.97.1.366; Hurkman WJ, 1996, PLANT PHYSIOL, V111, P735, DOI 10.1104/pp.111.3.735; JAIKARAN ASI, 1990, J BIOL CHEM, V265, P12503; KEELE BB, 1970, J BIOL CHEM, V245, P6176; KOSTER JF, 1980, BIOL CLIN ASPECTS SU; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE BG, 1992, EUR J BIOCHEM, V209, P961, DOI 10.1111/j.1432-1033.1992.tb17369.x; LANE BG, 1993, J BIOL CHEM, V268, P12239; LANE BG, 1991, FASEB J, V5, P2893, DOI 10.1096/fasebj.5.14.1752357; LINDNER WA, 1988, PHYTOCHEMISTRY, V27, P2501, DOI 10.1016/0031-9422(88)87017-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCUBBIN WC, 1987, BIOCHEM CELL BIOL, V65, P1039, DOI 10.1139/o87-136; McManaman JL, 1996, ARCH BIOCHEM BIOPHYS, V332, P135, DOI 10.1006/abbi.1996.0325; Neutelings G, 1998, PLANT MOL BIOL, V38, P1179, DOI 10.1023/A:1006033622928; Ohmiya A, 1998, PLANT CELL PHYSIOL, V39, P492, DOI 10.1093/oxfordjournals.pcp.a029396; Peumans WJ, 1997, PLANTA, V201, P298, DOI 10.1007/s004250050070; RAHMAN S, 1988, BIOCHEM CELL BIOL, V66, P100, DOI 10.1139/o88-013; Requena L, 1999, BIOCHEM J, V343, P185, DOI 10.1042/0264-6021:3430185; SCALA J, 1969, PLANT PHYSIOL, V44, P367, DOI 10.1104/pp.44.3.367; Sommer U, 1999, GLYCOCONJUGATE J, V16, P425, DOI 10.1023/A:1007030627948; STEINMAN HM, 1974, J BIOL CHEM, V249, P7326; SUGIURA M, 1979, CHEM PHARM BULL, V27, P2003; TIMMONS TM, 1990, METHOD ENZYMOL, V182, P679; Vallelian-Bindschedler L, 1998, PLANT MOL BIOL, V37, P297, DOI 10.1023/A:1005982715972; Wei YD, 1998, PLANT MOL BIOL, V36, P101, DOI 10.1023/A:1005955119326; Wojtaszek P, 1997, BIOCHEM J, V322, P681, DOI 10.1042/bj3220681; Woo EJ, 1998, FEBS LETT, V437, P87, DOI 10.1016/S0014-5793(98)01203-4; Yamahara T, 1999, J BIOL CHEM, V274, P33274, DOI 10.1074/jbc.274.47.33274; YOST FJ, 1973, J BIOL CHEM, V248, P4905; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2; ZHANG ZG, 1995, PLANT J, V8, P139, DOI 10.1046/j.1365-313X.1995.08010139.x; Zhou L, 1999, INDUCIBLE GENE EXPRESSION IN PLANTS, P127	50	150	167	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36726	36733		10.1074/jbc.M006461200	http://dx.doi.org/10.1074/jbc.M006461200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10952990	hybrid			2022-12-27	WOS:000165577700041
J	Chen, FS; Yang, DS; Petanceska, S; Yang, A; Tandon, A; Yu, G; Rozmahel, R; Ghiso, J; Nishimura, M; Zhang, DM; Kawara, T; Levesque, G; Mills, J; Levesque, L; Song, YQ; Rogaeva, E; Westaway, D; Mount, H; Gandy, S; St George-Hyslop, P; Fraser, PE				Chen, FS; Yang, DS; Petanceska, S; Yang, A; Tandon, A; Yu, G; Rozmahel, R; Ghiso, J; Nishimura, M; Zhang, DM; Kawara, T; Levesque, G; Mills, J; Levesque, L; Song, YQ; Rogaeva, E; Westaway, D; Mount, H; Gandy, S; St George-Hyslop, P; Fraser, PE			Carboxyl-terminal fragments of Alzheimer beta-amyloid precursor protein accumulate in restricted and unpredicted intracellular compartments in presenilin 1-deficient cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; ENDOPLASMIC-RETICULUM; SECRETASE CLEAVAGE; MUTANT PRESENILIN-1; MISSENSE MUTATIONS; PEPTIDE VARIANTS; PRE-GOLGI; DISEASE; MEMBRANE; PHOSPHORYLATION	Absence of functional presenilin 1 (PS1) protein leads to loss of gamma -secretase cleavage of the amyloid precursor protein (beta APP), resulting in a dramatic reduction in amyloid beta peptide (A beta) production and accumulation of alpha- or beta -secretase-cleaved COOH-terminal fragments of PAPP (alpha- or beta -CTFs). The major COOH-terminal fragment (CTF) in brain was identified as PAPP-CTF-(11-98), which is consistent with the observation that cultured neurons generate primarily A beta-(11-40). In PS1(-/-) murine neurons and fibroblasts expressing the loss-of-function PS1(D385A) mutant, CTFs accumulated in the endoplasmic reticulum, Golgi, and lysosomes, but not late endosomes. There were some subtle differences in the subcellular distribution of CTFs in PS1(-/-) neurons as compared with PS1(D385A) mutant fibroblasts. However, there was no obvious redistribution of full-length beta APP or of markers of other organelles in either mutant. Blockade of endoplasmic reticulum-to-Golgi trafficking indicated that in PS1-/- neurons las in normal cells) trafficking of beta APP to the Golgi compartment is necessary before alpha- and beta -secretase cleavages occur. Thus, although we cannot exclude a specific role for PS1 in trafficking of CTFs, these data argue against a major role in general protein trafficking. These results are more compatible with a role for PS1 either as the actual gamma -secretase catalytic activity or in other functions indirectly related to gamma -secretase catalysis (e,g. an activator of gamma -secretase, a substrate adaptor for gamma -secretase, or delivery of gamma -secretase to beta APP-containing compartments).	Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med, Toronto, ON M5S 3H2, Canada; Toronto Hosp, Dept Med Neurol, Toronto, ON M5S 3H2, Canada; NYU, Sch Med, Nathan S Kline Inst Psychiat Res, Dept Psychiat, Orangeburg, NY 10962 USA; NYU, Sch Med, Nathan S Kline Inst Psychiat Res, Dept Pathol, Orangeburg, NY 10962 USA; Hosp Sick Children, Res Inst, Dept Pharmacol, Toronto, ON M5S 3H2, Canada; Hosp Sick Children, Res Inst, Dept Genet, Toronto, ON M5S 3H2, Canada; Hosp Sick Children, Dept Genet, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Nathan Kline Institute for Psychiatric Research; New York University; Nathan Kline Institute for Psychiatric Research; New York University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	St George-Hyslop, P (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Lab Med & Pathobiol, 6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	p.hyslop@utoronto.ca	Song, You-qiang/C-4401-2009; Song, You-Qiang/E-5207-2011; Mount, Howard/B-4097-2013	Song, You-Qiang/0000-0001-9407-2256	Canadian Institutes of Health Research [37920] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; GARDELLA JE, 1993, BIOCHEM J, V294, P667, DOI 10.1042/bj2940667; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Gouras GK, 1998, J NEUROCHEM, V71, P1920; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; JIN MJ, 1993, J BIOL CHEM, V268, P18390; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; Levesque L, 1999, MOL MED, V5, P542, DOI 10.1007/BF03401981; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Parkin ET, 1997, J NEUROCHEM, V69, P2179; Peraus GC, 1997, J NEUROSCI, V17, P7714; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Petanceska SS, 2000, J NEUROCHEM, V74, P1878, DOI 10.1046/j.1471-4159.2000.0741878.x; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; REFOLO LM, 1995, J NEUROSCI RES, V40, P694, DOI 10.1002/jnr.490400515; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; Storrie B, 1998, BBA-MOL CELL RES, V1404, P127, DOI 10.1016/S0167-4889(98)00053-6; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Tjelle TE, 1996, J CELL SCI, V109, P2905; Tjernberg LO, 1997, J BIOL CHEM, V272, P1870, DOI 10.1074/jbc.272.3.1870; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WATT CB, 1985, J NEUROSCI, V5, P857; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	75	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36794	36802		10.1074/jbc.M006986200	http://dx.doi.org/10.1074/jbc.M006986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10962005	hybrid			2022-12-27	WOS:000165577700051
J	De Gois, S; Houhou, L; Oda, Y; Corbex, M; Pajak, F; Thevenot, E; Vodjdani, G; Mallet, J; Berrard, S				De Gois, S; Houhou, L; Oda, Y; Corbex, M; Pajak, F; Thevenot, E; Vodjdani, G; Mallet, J; Berrard, S			Is RE1/NRSE a common cis-regulatory sequence for ChAT and VAChT genes?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR ACETYLCHOLINE TRANSPORTER; CHOLINE-ACETYLTRANSFERASE GENE; RESTRICTIVE SILENCER ELEMENT; NEURON-SPECIFIC EXPRESSION; SODIUM-CHANNEL GENE; TISSUE-SPECIFIC EXPRESSION; CELL-ADHESION MOLECULE; ZINC-FINGER PROTEIN; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE	Choline acetyltransferase (ChAT), the biosynthetic enzyme of acetylcholine, and the vesicular acetylcholine transporter (VAChT) are both required for cholinergic neurotransmission. These proteins are encoded by two embedded genes, the VAChT gene lying within the first intron of the ChAT gene. In the nervous system, both ChAT and VAChT are synthesized only in cholinergic neurons, and it is therefore likely that the cell type-specific expression of their genes is coordinately regulated. It has been suggested that a. 2336-base pair genomic region upstream from the ChAT and VAChT coding sequences drives ChAT gene expression in cholinergic structures. We investigated whether this region also regulates VAChT gene transcription. Transfection assays showed that this region strongly represses the activity of the native VAChT promoters in non-neuronal cells, but has no major effect in neuronal cells whether or not they express the endogenous ChAT and VAChT genes. The silencer activity of this region is mediated solely by a repressor element 1 or neuron-restrictive silencer element (RE1/NRSE). Moreover, several proteins, including RE1-silencing transcription factor or neuron-restrictive silencer factor, are recruited by this regulatory sequence. These data suggest that this upstream region and RE1/NRSE co-regulate the expression of the ChAT and VAChT genes.	Hop La Pitie Salpetriere, CNRS, UMRC 9935, Lab Genet Mol Neurotransmiss & Proc, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Mallet, J (corresponding author), Hop La Pitie Salpetriere, CNRS, UMRC 9935, Lab Genet Mol Neurotransmiss & Proc, Batiment CERVI,83 Blvd Hop, F-75013 Paris, France.	mallet@infobiogen.fr	VODJDANI, Guilan/GSN-1174-2022	CORBEX, Marilys/0000-0001-5755-7326; Thevenot, Etienne A./0000-0003-1019-4577				ALFONSO A, 1994, J MOL BIOL, V241, P627, DOI 10.1006/jmbi.1994.1538; Arvidsson U, 1997, J COMP NEUROL, V378, P454; BEJANIN S, 1992, J NEUROCHEM, V58, P1580, DOI 10.1111/j.1471-4159.1992.tb11383.x; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; BERRARD S, 1995, J NEUROCHEM, V65, P939; Berse B, 1997, FEBS LETT, V410, P175, DOI 10.1016/S0014-5793(97)00568-1; BERSE B, 1995, J BIOL CHEM, V270, P22101, DOI 10.1074/jbc.270.38.22101; Bessis A, 1997, P NATL ACAD SCI USA, V94, P5906, DOI 10.1073/pnas.94.11.5906; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; CERVINI R, 1995, J BIOL CHEM, V270, P24654, DOI 10.1074/jbc.270.42.24654; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; HIGASHIDA H, 1991, ANN NY ACAD SCI, V635, P153, DOI 10.1111/j.1749-6632.1991.tb36489.x; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; IBANEZ CF, 1991, EUR J NEUROSCI, V3, P1309, DOI 10.1111/j.1460-9568.1991.tb00063.x; Ichikawa T, 1997, J CHEM NEUROANAT, V13, P23, DOI 10.1016/S0891-0618(97)00021-5; Kallunki P, 1998, P NATL ACAD SCI USA, V95, P3233, DOI 10.1073/pnas.95.6.3233; Kallunki P, 1997, J CELL BIOL, V138, P1343, DOI 10.1083/jcb.138.6.1343; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; KENGAKU M, 1993, MOL BRAIN RES, V18, P71, DOI 10.1016/0169-328X(93)90174-N; Kitamoto T, 1998, J BIOL CHEM, V273, P2706, DOI 10.1074/jbc.273.5.2706; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; Leichter M, 1999, EUR J NEUROSCI, V11, P1937, DOI 10.1046/j.1460-9568.1999.00617.x; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LI YP, 1993, J NEUROCHEM, V61, P748; LI YP, 1995, MOL BRAIN RES, V30, P106, DOI 10.1016/0169-328X(94)00285-M; LONNERBERG P, 1995, P NATL ACAD SCI USA, V92, P4046, DOI 10.1073/pnas.92.9.4046; Lonnerberg P, 1996, J BIOL CHEM, V271, P33358, DOI 10.1074/jbc.271.52.33358; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; Millecamps S, 1999, NAT BIOTECHNOL, V17, P865, DOI 10.1038/12849; MISAWA H, 1993, J NEUROCHEM, V60, P1383, DOI 10.1111/j.1471-4159.1993.tb03299.x; MISAWA H, 1992, J BIOL CHEM, V267, P20392; MISAWA H, 1995, NEUROREPORT, V6, P965, DOI 10.1097/00001756-199505090-00004; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Naciff JM, 1999, J NEUROCHEM, V72, P17, DOI 10.1046/j.1471-4159.1999.0720017.x; Naciff JM, 1997, NEUROREPORT, V8, P3467, DOI 10.1097/00001756-199711100-00011; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Oosawa H, 1999, J NEUROSCI RES, V57, P381, DOI 10.1002/(SICI)1097-4547(19990801)57:3<381::AID-JNR10>3.3.CO;2-3; Palm K, 1998, J NEUROSCI, V18, P1280; PATHAK BG, 1994, NUCLEIC ACIDS RES, V22, P4748, DOI 10.1093/nar/22.22.4748; PU HF, 1993, MOL CELL NEUROSCI, V4, P131, DOI 10.1006/mcne.1993.1017; RAND JB, 1984, GENETICS, V106, P227; SCHAFER MKH, 1994, J MOL NEUROSCI, V5, P1, DOI 10.1007/BF02736691; Schafer MKH, 1995, J MOL NEUROSCI, V6, P225, DOI 10.1007/BF02736782; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Scholl T, 1996, J IMMUNOL, V156, P1448; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shimojo M, 1998, J NEUROCHEM, V71, P1118; Tanaka H, 1998, J NEUROCHEM, V70, P1799; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; Thiel G, 1998, J BIOL CHEM, V273, P26891, DOI 10.1074/jbc.273.41.26891; Tian XT, 1996, NEUROSCI LETT, V209, P134, DOI 10.1016/0304-3940(96)12629-X; Timmusk T, 1999, J BIOL CHEM, V274, P1078	54	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36683	36690		10.1074/jbc.M006895200	http://dx.doi.org/10.1074/jbc.M006895200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973977	Green Published, hybrid			2022-12-27	WOS:000165577700034
J	Li, HH; Lyles, DS; Thomas, MJ; Pan, W; Sorci-Thomas, MG				Li, HH; Lyles, DS; Thomas, MJ; Pan, W; Sorci-Thomas, MG			Structural determination of lipid-bound ApoA-I using fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HIGH-DENSITY-LIPOPROTEIN; BINDING CASSETTE TRANSPORTER-1; TANGIER-DISEASE; TRANSGENIC MICE; BELT MODEL; DEFICIENCY; CONFORMATION; PARTICLES; ATHEROSCLEROSIS	Based on the x-ray crystal structure of lipid-free Delta 43 apoA-1, two monomers of apoA-1 were suggested to bind to a phospholipid bilayer in an antiparallel paired dimer, or "belt orientation." This hypothesis challenges the currently held model in which each of the two apoA-I monomers fold as antiparallel alpha -helices or "pick-et fence orientation" When apoA-I is bound to a phospholipid disc, the first model predicts that the glutamine at position 132 on one apoA-I molecule lies within 16 Angstrom of glutamine 132 in the second monomer, whereas, the second model predicts glutamines at position 132 to be 104 Angstrom apart. To distinguish between these models, glutamine at position 132 was mutated to cysteine in wild-type apoA-I to produce Q132C apoA-I, which were labeled with thiol-reactive fluorescent probes. Q132C apoA-I was labeled with either fluorescein (donor probe) or tetramethylrhodamine (acceptor probe) and then used to make recombinant phospholipid discs (recombinant high density lipoprotein (rHDL)). The rHDL containing donor- and acceptor-labeled Q132C apoA-I were of similar size, composition, and lecithin:cholesterol acyltransferase reactivity when compared to rHDL- containing human plasma apoA-I. Analysis of donor probe fluorescence showed highly efficient quenching in rHDL containing one donor- and one acceptor-labeled Q132C apoA-I. rHDL containing only acceptor probe-labeled Q132C apoA-I showed rhodamine selfquenching. Both of these observations demonstrate that position 132 in two lipid-bound apoA-I monomers were in close proximity, supporting the ''belt conformation" hypothesis for apoA-I on rHDL.	Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Sorci-Thomas, MG (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Med Ctr Blvd, Winston Salem, NC 27157 USA.			Sorci-Thomas, Mary/0000-0002-6464-5006; Lyles, Douglas/0000-0002-8401-3073	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373, R01HL060079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015892, R55AI015892] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49373, HL-60079] Funding Source: Medline; NIAID NIH HHS [AI15892] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AJTAI K, 1992, BIOCHEMISTRY-US, V31, P12431, DOI 10.1021/bi00164a019; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BRASSEUR R, 1991, J BIOL CHEM, V266, P16120; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROUILLETTE CG, 2000, IN PRESS BIOCH BIOPH; Frank PG, 2000, J LIPID RES, V41, P853; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Hughes SD, 1997, ARTERIOSCL THROM VAS, V17, P1725, DOI 10.1161/01.ATV.17.9.1725; Jonas A, 1998, PROG LIPID RES, V37, P209, DOI 10.1016/S0163-7827(98)00007-1; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; LI WH, 1988, J LIPID RES, V29, P245; LYLES DS, 1990, BIOCHEMISTRY-US, V29, P2442, DOI 10.1021/bi00462a002; LYLES DS, 1985, BIOCHEMISTRY-US, V24, P8121, DOI 10.1021/bi00348a043; Maiorano JN, 2000, J BIOL CHEM, V275, P17374, DOI 10.1074/jbc.M000044200; McManus DC, 2000, J BIOL CHEM, V275, P5043, DOI 10.1074/jbc.275.7.5043; MILLER NE, 1975, LANCET, V1, P1033, DOI 10.1016/S0140-6736(75)91977-7; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; Packard BZ, 1996, P NATL ACAD SCI USA, V93, P11640, DOI 10.1073/pnas.93.21.11640; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; Phillips JC, 1997, BIOPHYS J, V73, P2337, DOI 10.1016/S0006-3495(97)78264-X; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SEGREST JP, 1977, CHEM PHYS LIPIDS, V18, P7, DOI 10.1016/0009-3084(77)90023-8; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; Segrest JP, 2000, CURR OPIN LIPIDOL, V11, P105, DOI 10.1097/00041433-200004000-00002; Sorci-Thomas MG, 2000, J BIOL CHEM, V275, P12156, DOI 10.1074/jbc.275.16.12156; Sorci-Thomas MG, 1998, J BIOL CHEM, V273, P11776, DOI 10.1074/jbc.273.19.11776; SorciThomas MG, 1996, J LIPID RES, V37, P673; SorciThomas MG, 1997, J BIOL CHEM, V272, P7278, DOI 10.1074/jbc.272.11.7278; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; STANTON SG, 1984, BIOCHIM BIOPHYS ACTA, V776, P228, DOI 10.1016/0005-2736(84)90212-8; SWANEY JB, 1986, METHOD ENZYMOL, V128, P613; TALL AR, 1977, J BIOL CHEM, V252, P4701; TALUSSOT C, 1994, J THEOR BIOL, V169, P143, DOI 10.1006/jtbi.1994.1136; Voyiaziakis E, 1998, J LIPID RES, V39, P313; WALD JH, 1990, J BIOL CHEM, V265, P20037; WALD JH, 1990, J BIOL CHEM, V265, P20044; WolffLong VL, 1995, J BIOL CHEM, V270, P31111, DOI 10.1074/jbc.270.52.31111	41	78	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37048	37054		10.1074/jbc.M005336200	http://dx.doi.org/10.1074/jbc.M005336200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10956648	hybrid			2022-12-27	WOS:000165577700083
J	Zhang, ZY; Baron, R; Horne, WC				Zhang, ZY; Baron, R; Horne, WC			Integrin engagement, the actin cytoskeleton, and c-Src are required for the calcitonin-induced tyrosine phosphorylation of paxillin and HEF1, but not for calcitonin-induced Erk1/2 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ACTIVATED PROTEIN-KINASE; SWISS 3T3 CELLS; CRK-ASSOCIATED SUBSTRATE; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; SIGNALING PATHWAYS; COUPLED RECEPTORS; EXTRACELLULAR-MATRIX	We have previously shown that in a HEK-293 cell line that overexpresses the Cia isoform of the calcitonin receptor (C1a-HEK), calcitonin induces the tyrosine phosphorylation of the focal adhesion-associated proteins HEF1 (a p130(CAS)-like docking protein), paxillin, and focal adhesion kinase and that it also stimulates the phosphorylation and activation of Erk1 and Erk2, We report here that cell attachment to the extracellular matrix, an intact actin cytoskeleton, and c-Src are absolutely required for the calcitonin-induced phosphorylation of focal adhesion-associated proteins, In contrast to the phosphorylation of paxillin and HEF1 in cells attached to fibronectin-coated dishes, calcitonin failed to stimulate the phosphorylation of paxillin and HEF1 in suspended cells, in cells attached to poly-D-lysine-coated dishes, and in attached cells pretreated with the RGD-containing peptide GRGDS, Overexpression of wild-type c-Src increased calcitonin-induced paxillin and HEF1 phosphorylation, whereas overexpression of kinase-dead Src or Src lacking a functional SH2 domain inhibited the calcitonin-stimulated tyrosine phosphorylation of these proteins, Overexpression of Src lacking the SH3 domain did not affect the calcitonin-induced phosphorylation of paxillin and HEF1. In contrast to the regulation of paxillin and HEF1 phosphorylation, the calcitonin-induced phosphorylation of Erk1 and Erk2 did not appear to involve c-Src and was only partially dependent on cell adhesion to the extracellular matrix and an intact actin cytoskeleton. Furthermore, inhibition of Erk1 and Erk2 phosphorylation had no effect on the calcitonin-induced phosphorylation of paxillin and HEF1, Thus, in C1a-HEK cells, the calcitonin receptor is coupled to the tyrosine phosphorylation of focal adhesion-associated proteins and to Erk1/2 phosphorylation by mechanisms that are in large part independent.	Yale Univ, Sch Med, Dept Orthopaed, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Horne, WC (corresponding author), Yale Univ, Sch Med, Dept Orthopaed, POB 208044, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042927, P30AR046032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE004724, R01DE004724] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-46032, AR-42927] Funding Source: Medline; NIDCR NIH HHS [DE-04724] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; BOCKHOLT SM, 1995, CELL ADHES COMMUN, V3, P91, DOI 10.3109/15419069509081279; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen Y, 1998, J BIOL CHEM, V273, P19809, DOI 10.1074/jbc.273.31.19809; CLARK EA, 1994, J BIOL CHEM, V269, P28859; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; deCurtis I, 1997, EXP CELL RES, V230, P233, DOI 10.1006/excr.1996.3423; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; Grant RL, 1996, IN VITRO CELL DEV-AN, V32, P38, DOI 10.1007/BF02722992; Guo C, 1998, EUR J BIOCHEM, V257, P403, DOI 10.1046/j.1432-1327.1998.2570403.x; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ishida T, 1999, J CLIN INVEST, V103, P789, DOI 10.1172/JCI4189; Kanda H, 1999, IMMUNOLOGY, V97, P56; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Mehta D, 1999, J PHYSIOL-LONDON, V519, P829, DOI 10.1111/j.1469-7793.1999.0829n.x; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDELY AJ, 1992, CELL, V70, P389; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Sayeski PP, 1998, CIRC RES, V82, P1279, DOI 10.1161/01.RES.82.12.1279; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; Slack BE, 1998, P NATL ACAD SCI USA, V95, P7281, DOI 10.1073/pnas.95.13.7281; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TURNER CE, 1995, J CELL SCI, V108, P333; VAN BT, 1995, NATURE, V376, P781; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; ZAIDI M, 1990, J ENDOCRINOL, V126, P473, DOI 10.1677/joe.0.1260473; Zhang ZY, 1999, J BIOL CHEM, V274, P25093, DOI 10.1074/jbc.274.35.25093; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	54	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37219	37223		10.1074/jbc.M001818200	http://dx.doi.org/10.1074/jbc.M001818200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10954702	hybrid			2022-12-27	WOS:000165577700104
J	Chen, J; Mitcheson, JS; Lin, M; Sanguinetti, MC				Chen, J; Mitcheson, JS; Lin, M; Sanguinetti, MC			Functional roles of charged residues in the putative voltage sensor of the HCN2 pacemaker channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER K+ CHANNEL; POTASSIUM CHANNEL; XENOPUS-OOCYTES; ELECTROSTATIC INTERACTIONS; TRANSMEMBRANE SEGMENTS; SENSING RESIDUES; CATION CHANNELS; FAMILY; IDENTIFICATION; EXPRESSION	Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels contribute to pacemaking activity in specialized neurons and cardiac myocytes, HCN channels have a structure similar to voltage-gated K+ channels but have a much larger putative S4 transmembrane domain and open in response to membrane hyperpolarization instead of depolarization. As an initial attempt to define the structural basis of HCN channel gating, we have characterized the functional roles of the charged residues in the S2, S3, and S4 transmembrane domains. The nine basic residues and a single Ser in S4 were mutated individually to Gin, and the function of mutant channels was analyzed in Xenopus oocytes using two-microelectrode voltage clamp techniques, Surface membrane expression of hemagglutinin-epitope-tagged channel proteins was examined by chemiluminescence. Our results suggest that 1) Lys-291, Arg-294, Arg-297, and Arg-300 contribute to the voltage dependence of gating but not to channel folding or trafficking to the surface membrane; 2) Lys-303 and Ser-306 are essential for gating, but not for channel folding/trafficking; 3) Arg-312 is important for folding but not gating; and 4) Arg-309, Arg-315, and Arg-318 are crucial for normal protein folding/trafficking and may charge-pair with Asp residues located in the S2 and S3 domains.	Univ Utah, Eccles Inst Human Genet, Dept Med, Div Cardiol, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Sanguinetti, MC (corresponding author), Univ Utah, Eccles Inst Human Genet, Dept Med, Div Cardiol, 15 N 2030 E,Rm 4220, Salt Lake City, UT 84112 USA.		Sanguinetti, Michael/AAN-2615-2020	Mitcheson, John/0000-0002-2683-2839	NHLBI NIH HHS [HL65299] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065299] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Biel M, 1999, REV PHYSIOL BIOCH P, V136, P165, DOI 10.1007/BFb0032324; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Clapham DE, 1998, NEURON, V21, P5, DOI 10.1016/S0896-6273(00)80508-5; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; GOLDIN AL, 1991, METHOD CELL BIOL, V36, P487; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; Li-Smerin YY, 2000, J GEN PHYSIOL, V115, P33, DOI 10.1085/jgp.115.1.33; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Marten I, 1998, BIOPHYS J, V74, P2953, DOI 10.1016/S0006-3495(98)78002-6; Marten I, 1997, P NATL ACAD SCI USA, V94, P3448, DOI 10.1073/pnas.94.7.3448; Miller AG, 1996, NEURON, V16, P853, DOI 10.1016/S0896-6273(00)80105-1; Mitcheson JS, 2000, J GEN PHYSIOL, V115, P229, DOI 10.1085/jgp.115.3.229; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PLANELLSCASES R, 1995, P NATL ACAD SCI USA, V92, P9422, DOI 10.1073/pnas.92.20.9422; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; SIGWORTH FJ, 1993, Q REV BIOPHYS, V27, P1; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Tiwari-Woodruff SK, 2000, J GEN PHYSIOL, V115, P123, DOI 10.1085/jgp.115.2.123; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; Zei PC, 1998, J GEN PHYSIOL, V112, P679, DOI 10.1085/jgp.112.6.679; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	31	62	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36465	36471		10.1074/jbc.M007034200	http://dx.doi.org/10.1074/jbc.M007034200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10962006	hybrid			2022-12-27	WOS:000165382000114
J	Morelli, S; Buitrago, C; Vazquez, G; De Boland, AR; Boland, R				Morelli, S; Buitrago, C; Vazquez, G; De Boland, AR; Boland, R			Involvement of tyrosine kinase activity in 1 alpha,25(OH)(2)-vitamin D-3 signal transduction in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; VITAMIN-D; C-ALPHA; PHOSPHOLIPASE-C; CALCIUM FLUXES; HERBIMYCIN-A; CA2+ INFLUX; PHOSPHORYLATION; D-3; STIMULATION	In cultured chick skeletal muscle cells loaded with Fura-a, the tyrosine kinase inhibitors herbimycin A and genistein abolished both the fast inositol 1,4,5-trisphosphatedependent Ca2+ release from internal stores and extracellular Ca2+ influx induced by 1 alpha ,25(OH)(2)-vitamin D-3 (1 alpha ,25(OH)(2)D-3). Daidzein, an inactive analog of genistein, was without effects. Tyrosine phosphatase inhibition by orthovanadate increased cytosolic Ca2+. Antiphosphotyrosine immunoblot analysis revealed that 1 alpha ,2S(OH)(2)D-3 rapidly (0.5-10 min) stimulates in a concentrationdependent fashion (0.1-10 nM) tyrosine phosphorylation of several myoblast proteins, among which the major targets of the hormone could be immunochemically identified as phospholipase C gamma (127 kDa), which mediates intracellular store Ca2+ mobilization and external Ca2+ influx, and the growth-related proteins mitogen-activated protein (MAP) kinase (42/44 kDa) and c-myc (65 kDa), Genistein suppressed the increase in phosphorylation and concomitant elevation of MAPK activity elicited by the sterol, Both genistein and the MAPK kinase (MEK) inhibitor PD98059 abolished stimulation of DNA synthesis by 1 alpha ,25(OH)(2)D-3. The sterol-induced increase in tyrosine phosphorylation of c-myc, a finding not reported before for cell growth regulators, was totally suppressed by the specific Src inhibitor PP1, These results demonstrate that tyrosine phosphorylation is a previously unrecognized mechanism involved in 1 alpha ,25(OH)(2)D-3 regulation of Ca2+ homeostasis in hormone target cells. In addition, the data involve tyrosine kinase cascades in the mitogenic effects of 1 alpha ,25(OH)(2)D-3 on skeletal muscle cells.	Univ Nacl Sur, Dept Biol Bioquim & Farm, RA-8000 Bahia Blanca, Buenos Aires, Argentina	National University of the South	Boland, R (corresponding author), Univ Nacl Sur, Dept Biol Bioquim & Farm, San Juan 670, RA-8000 Bahia Blanca, Buenos Aires, Argentina.	rboland@criba.edu.ar						AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BELLIDO T, 1993, MOL CELL ENDOCRINOL, V90, P231, DOI 10.1016/0303-7207(93)90156-E; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BERS D, 1996, METHOD CELL BIOL, P21; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BOLAND R, 1995, MOL CELL ENDOCRINOL, V114, P1, DOI 10.1016/0303-7207(95)03650-V; BOLAND R, 1986, ENDOCR REV, V7, P434, DOI 10.1210/edrv-7-4-434; BOLAND R, 1997, VITAMIN D CHEM BIOL, P361; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Buitrago C, 2000, J CELL BIOCHEM, V79, P274, DOI 10.1002/1097-4644(20001101)79:2<274::AID-JCB100>3.0.CO;2-R; Capiati DA, 1999, MOL CELL ENDOCRINOL, V153, P39, DOI 10.1016/S0303-7207(99)00093-3; Capiati DA, 1999, J CELL BIOCHEM, V74, P292, DOI 10.1002/(SICI)1097-4644(19990801)74:2<292::AID-JCB13>3.0.CO;2-M; Cataldi M, 1996, J BIOL CHEM, V271, P9441, DOI 10.1074/jbc.271.16.9441; Dang CV, 1999, MOL CELL BIOL, V19, P1; de Boland AR, 1998, J CELL BIOCHEM, V69, P470, DOI 10.1002/(SICI)1097-4644(19980615)69:4<470::AID-JCB8>3.0.CO;2-K; DEBOLAND AR, 1994, CELL SIGNAL, V6, P717, DOI 10.1016/0898-6568(94)00042-5; DEBOLAND AR, 1994, J BIOL CHEM, V269, P8675; DEBOLAND AR, 1995, BBA-LIPID LIPID MET, V1257, P274, DOI 10.1016/0005-2760(95)00083-O; DEBOLAND AR, 1998, 1 INT M RAP RESP STE, P90; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; DISALVO J, 1988, BIOCHEM BIOPH RES CO, V153, P388, DOI 10.1016/S0006-291X(88)81236-1; DRITTANTI L, 1989, BIOCHIM BIOPHYS ACTA, V1014, P112, DOI 10.1016/0167-4889(89)90022-0; EKBOM K, 1964, ACTA MED SCAND, V176, P493; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GIULIANI DL, 1984, CALCIFIED TISSUE INT, V36, P200, DOI 10.1007/BF02405318; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hatakeyama N, 1996, AM J PHYSIOL-CELL PH, V270, pC1780, DOI 10.1152/ajpcell.1996.270.6.C1780; HAUSSLER MR, 1986, ANNU REV NUTR, V6, P527, DOI 10.1146/annurev.nu.06.070186.002523; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Katsube Y, 1998, EUR J PHARMACOL, V345, P309, DOI 10.1016/S0014-2999(98)00010-7; Khare S, 1997, J CLIN INVEST, V99, P1831, DOI 10.1172/JCI119350; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE KM, 1993, J BIOL CHEM, V268, P9945; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; LIEBERHERR M, 1989, J BIOL CHEM, V264, P20403; Liu HY, 1997, CAN J PHYSIOL PHARM, V75, P1063, DOI 10.1139/cjpp-75-9-1063; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOLAGAS SC, 1990, KIDNEY INT, V38, pS9; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; MORELLI S, 1993, BIOCHEM J, V289, P675, DOI 10.1042/bj2890675; Morelli S, 1996, MOL CELL ENDOCRINOL, V122, P207, DOI 10.1016/0303-7207(96)03886-5; Morelli S, 1999, J BONE MINER RES, V14, pS423; Neary JT, 1997, NEWS PHYSIOL SCI, V12, P286; Nemere I, 1998, BIOCHEM BIOPH RES CO, V248, P443, DOI 10.1006/bbrc.1998.8492; NORMAN AW, 1982, ENDOCR REV, V3, P331, DOI 10.1210/edrv-3-4-331; NORMAN AW, 1992, J STEROID BIOCHEM, V41, P231, DOI 10.1016/0960-0760(92)90349-N; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; REICHEL H, 1989, ANNU REV MED, V40, P71; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; Selbie LA, 1998, TRENDS PHARMACOL SCI, V19, P87, DOI 10.1016/S0165-6147(97)01166-8; SETH A, 1991, J BIOL CHEM, V266, P23521; Sharma NR, 1996, AM J PHYSIOL-HEART C, V270, pH267, DOI 10.1152/ajpheart.1996.270.1.H267; SMITH R, 1969, J NEUROL SCI, V8, P511, DOI 10.1016/0022-510X(69)90010-0; SMITH R, 1967, BRAIN, V90, P593, DOI 10.1093/brain/90.3.593; Snedecor G.W., 1967, STAT METHODS; Song XD, 1998, ENDOCRINOLOGY, V139, P457, DOI 10.1210/en.139.2.457; Takahashi R, 1997, JPN CIRC J, V61, P1030, DOI 10.1253/jcj.61.1030; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VAZQUEZ G, 1993, BIOCHEM MOL BIOL INT, V31, P677; Vazquez G, 1997, BIOCHEM BIOPH RES CO, V234, P125, DOI 10.1006/bbrc.1997.6590; Vazquez G, 1996, BBA-MOL CELL RES, V1310, P157, DOI 10.1016/0167-4889(95)00158-1; Vazquez G, 1998, J BIOL CHEM, V273, P33954, DOI 10.1074/jbc.273.51.33954; Vazquez G, 1997, BIOCHEM BIOPH RES CO, V239, P562, DOI 10.1006/bbrc.1997.7501; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365	74	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36021	36028		10.1074/jbc.M002025200	http://dx.doi.org/10.1074/jbc.M002025200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964910	hybrid			2022-12-27	WOS:000165382000054
J	Routledge, EJ; White, R; Parker, MG; Sumpter, JP				Routledge, EJ; White, R; Parker, MG; Sumpter, JP			Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ER beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION FUNCTIONS; NUCLEAR HORMONE-RECEPTOR; RAT PITUITARY; MESSENGER-RNA; BINDING; LIGAND; PHYTOESTROGENS; IDENTIFICATION; ANTIESTROGENS; HETERODIMERS	It has been proposed that tissue-specific estrogenic and/or antiestrogenic actions of certain xenoestrogens may be associated with alterations in the tertiary structure of estrogen receptor (ER) alpha and/or ER beta following ligand binding; changes which are sensed by cellular factors (coactivators) required for normal gene expression. However, it is still unclear whether xenoestrogens affect the normal behavior of ER alpha and/or ER beta subsequent to receptor binding. In view of the wide range of structural forms now recognized to mimic the actions of the natural estrogens, we have assessed the ability of ER alpha and ER beta to recruit TIF2 and SRC-1a in the presence of 17 beta -estradiol, genistein, diethylstilbestrol, 4-tert-oc-tylphenol, 2',3',4',5' -tetrachlorobiphenyl-1, and bisphenol A. We show that ligand-dependent differences exist in the ability of ER alpha and ER beta to bind coactivator proteins in vitro, despite the similarity in binding affinity of the various ligands for both ER subtypes, The enhanced ability of ER beta (over ER alpha) to recruit coactivators in the presence of xenoestrogens was consistent with a greater ability of ERP to potentiate reporter gene activity in transiently transfected HeLa cells expressing SRC-1e and TIFS. We conclude that ligand-dependent differences in the ability of ER alpha and ER beta to recruit coactivator proteins may contribute to the complex tissue-dependent agonistic/antagonistic responses observed with certain xenoestrogens.	Brunel Univ, Dept Biol Sci, Uxbridge UB8 3PH, Middx, England; Imperial Canc Res Fund, Mol Endocrinol Lab, London WC2A 3PX, England	Brunel University; Cancer Research UK; University of London; Queen Mary University London	Routledge, EJ (corresponding author), Brunel Univ, Dept Biol Sci, Uxbridge UB8 3PH, Middx, England.	edwin.routledge@brunel.ac.uk	sumpter, john/HGB-7584-2022; Routledge, Edwin John/V-2336-2019; Routledge, Edwin/AGI-0283-2022	Routledge, Edwin/0000-0001-7695-364X				ADLERCREUTZ H, 1993, LANCET, V342, P1209, DOI 10.1016/0140-6736(93)92188-Y; ADLERCREUTZ H, 1995, ENVIRON HEALTH PERSP, V103, P103, DOI 10.2307/3432518; BROUWER A, 1995, EUR J PHARM-ENVIRON, V293, P1; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Collins BM, 1997, STEROIDS, V62, P365, DOI 10.1016/S0039-128X(96)00246-2; Connor K, 1997, TOXICOL APPL PHARM, V145, P111, DOI 10.1006/taap.1997.8169; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; JANSEN HT, 1993, REPROD TOXICOL, V7, P237, DOI 10.1016/0890-6238(93)90230-5; JOBLING S, 1995, ENVIRON HEALTH PERSP, V103, P582, DOI 10.2307/3432434; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KALDAS RS, 1989, REPROD TOXICOL, V3, P81, DOI 10.1016/0890-6238(89)90042-7; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Klinge CM, 1996, STEROIDS, V61, P278, DOI 10.1016/0039-128X(95)00219-G; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Le Bail JC, 1998, CANCER LETT, V130, P209, DOI 10.1016/S0304-3835(98)00141-4; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; MADHABANANDA S, 1999, ENDOCRINOLOGY, V140, P963; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; MIKSICEK RJ, 1993, MOL PHARMACOL, V44, P37; Mitchner NA, 1998, ENDOCRINOLOGY, V139, P3976, DOI 10.1210/en.139.9.3976; Nishikawa J, 1999, TOXICOL APPL PHARM, V154, P76, DOI 10.1006/taap.1998.8557; ONATE SA, 1995, SCIENCE, V270, P1354; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Pennie WD, 1998, J ENDOCRINOL, V158, pR11, DOI 10.1677/joe.0.158R011; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; RUH MF, 1995, BIOCHEM PHARMACOL, V50, P1485, DOI 10.1016/0006-2952(95)02061-6; SEIELSTAD DA, 1995, BIOCHEMISTRY-US, V34, P12605, DOI 10.1021/bi00039a016; Shughrue PJ, 1996, STEROIDS, V61, P678, DOI 10.1016/S0039-128X(96)00222-X; Shughure PJ, 1998, STEROIDS, V63, P498, DOI 10.1016/S0039-128X(98)00054-3; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Sun J, 1999, ENDOCRINOLOGY, V140, P800, DOI 10.1210/en.140.2.800; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; VONBAUR E, 1996, EMBO J, V15, P110	49	271	278	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35986	35993		10.1074/jbc.M006777200	http://dx.doi.org/10.1074/jbc.M006777200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964929	hybrid			2022-12-27	WOS:000165382000049
J	Boeke, J; Ammerpohl, O; Kegel, S; Moehren, U; Renkawitz, R				Boeke, J; Ammerpohl, O; Kegel, S; Moehren, U; Renkawitz, R			The minimal repression domain of MBD2b overlaps with the methyl-CpG-binding domain and binds directly to Sin3A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; LYSOZYME DOWNSTREAM ENHANCER; RETINOIC ACID RECEPTOR; TRANSCRIPTIONAL REPRESSOR; HISTONE DEACETYLASE; DNA METHYLATION; PROTEIN; DEMETHYLATION; CHROMATIN; COMPLEX	Different mechanisms mediating methylation-dependent repression have been demonstrated. Two of these mechanisms play a role in the context of the granulocyte/macrophage-specific lysozyme gene: direct interference with DNA binding of the transcription factor GA-binding protein and deacetylation of histones. Besides enhancement in the unmethylated state, and transcriptional repression upon DNA methylation, the lysozyme downstream enhancer confers tissue-specific demethylation, Because both demethylation activity and repression ability have been attributed to the methyl-CpG-binding domain-containing protein MBD2, we analyzed this protein. The short form MBD2b binds to the methylated lysozyme enhancer and mediates transcriptional repression. MBD2b is capable of binding to the transcriptional repressor Sin3A The interaction domain of Sin3A required for binding to MBD2b contains the paired amphipathic helix 3, We identified a minimal functional domain that confers both transcriptional repression as well as the interaction to Sin3A in contrast to the functionally related proteins MeCP2 and MBD1, the repression domain of MBD2b overlaps with the methyl-CpG-binding domain.	Univ Giessen, Genet Inst, D-35392 Giessen, Germany	Justus Liebig University Giessen	Renkawitz, R (corresponding author), Univ Giessen, Genet Inst, Heinrich Buff Ring 58, D-35392 Giessen, Germany.	Rainer.Renkawitz@gen.bio.uni-giessen.de	Ammerpohl, Ole/G-2691-2010					Ammerpohl O, 1998, NUCLEIC ACIDS RES, V26, P5256, DOI 10.1093/nar/26.23.5256; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; Baniahmad A, 1997, MOL CELL BIOL, V17, P4259, DOI 10.1128/MCB.17.8.4259; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; Bergman Y, 1998, BIOL CHEM, V379, P401; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Eng C, 2000, NAT GENET, V24, P101, DOI 10.1038/72730; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; KLAGES S, 1992, NUCLEIC ACIDS RES, V20, P1925, DOI 10.1093/nar/20.8.1925; Lutz M, 2000, NUCLEIC ACIDS RES, V28, P1707, DOI 10.1093/nar/28.8.1707; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, CIBA F SYMP, V214, P6; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nickel J, 1995, NUCLEIC ACIDS RES, V23, P4785, DOI 10.1093/nar/23.23.4785; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Schmitz A, 1997, J BIOL CHEM, V272, P20850, DOI 10.1074/jbc.272.33.20850; Short ML, 1996, CELL GROWTH DIFFER, V7, P1545; SIMPSON VJ, 1986, NUCLEIC ACIDS RES, V14, P6711, DOI 10.1093/nar/14.16.6711; URIELISHOVAL S, 1982, FEBS LETT, V146, P148, DOI 10.1016/0014-5793(82)80723-0; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; YU F, 1908, NUCLEIC ACIDS RES, V28, P2201; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	38	83	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34963	34967		10.1074/jbc.M005929200	http://dx.doi.org/10.1074/jbc.M005929200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10950960	hybrid			2022-12-27	WOS:000165422800020
J	Uchiumi, T; Nomura, T; Shimizu, T; Katakai, Y; Mita, K; Koike, Y; Nakagaki, M; Taira, H; Hachimori, A				Uchiumi, T; Nomura, T; Shimizu, T; Katakai, Y; Mita, K; Koike, Y; Nakagaki, M; Taira, H; Hachimori, A			A covariant change of the two highly conserved bases in the GTPase-associated center of 28 S rRNA in silkworms and other moths	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							23-S RIBOSOMAL-RNA; FACTOR EF-G; ESCHERICHIA-COLI; FACTOR-II; THIOSTREPTON; BINDING; SITE; PROTEINS; AUTOANTIBODY; COMPLEX		Shinshu Univ, Fac Text Sci & Technol, Inst High Polymer Res, Ueda, Nagano 3868567, Japan; Shinshu Univ, Fac Text Sci & Technol, Dept Appl Biol Sci, Ueda, Nagano 3868567, Japan; Natl Inst Radiol Sci, Genome Res Grp, Chiba 2638555, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Agr & Environm Biol, Tokyo 1138657, Japan; Iwate Univ, Fac Agr, Dept Biosci & Technol, Morioka, Iwate 0208550, Japan	Shinshu University; Shinshu University; National Institutes for Quantum Science & Technology; University of Tokyo; Iwate University	Uchiumi, T (corresponding author), Shinshu Univ, Fac Text Sci & Technol, Inst High Polymer Res, Ueda, Nagano 3868567, Japan.							BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390; Conn GL, 1998, BIOCHEMISTRY-US, V37, P11980, DOI 10.1021/bi980825+; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; CUNDLIFFE E, 1986, STRUCTURE FUNCTION G; EGEBJERG J, 1989, EMBO J, V8, P607, DOI 10.1002/j.1460-2075.1989.tb03415.x; ELBARADI TTAL, 1987, J MOL BIOL, V195, P909, DOI 10.1016/0022-2836(87)90494-3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJIWARA H, 1986, NUCLEIC ACIDS RES, V14, P6393, DOI 10.1093/nar/14.16.6393; GUTELL RR, 1993, NUCLEIC ACIDS RES, V21, P3055, DOI 10.1093/nar/21.13.3055; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Huang SG, 1996, J MOL BIOL, V258, P308, DOI 10.1006/jmbi.1996.0252; Iwasaki K, 1979, Methods Enzymol, V60, P657; KJER KM, 1994, BBA-GENE STRUCT EXPR, V1217, P147, DOI 10.1016/0167-4781(94)90028-0; MADJAR JJ, 1981, MOL GEN GENET, V182, P273, DOI 10.1007/BF00269670; MANKIN AS, 1994, J MOL BIOL, V244, P151, DOI 10.1006/jmbi.1994.1715; McKnight S L, 1976, Prog Nucleic Acid Res Mol Biol, V19, P313; MITA K, 1994, J MOL EVOL, V38, P583; MITA K, 1999, RIKEN REV, V22, P63; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; Munishkin A, 1997, P NATL ACAD SCI USA, V94, P12280, DOI 10.1073/pnas.94.23.12280; MUSTERS W, 1991, P NATL ACAD SCI USA, V88, P1469, DOI 10.1073/pnas.88.4.1469; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; Rodnina MV, 1999, P NATL ACAD SCI USA, V96, P9586, DOI 10.1073/pnas.96.17.9586; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; RYAN PC, 1991, P NATL ACAD SCI USA, V88, P6308, DOI 10.1073/pnas.88.14.6308; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT FJ, 1981, J BIOL CHEM, V256, P2301; Schnare MN, 1996, J MOL BIOL, V256, P701, DOI 10.1006/jmbi.1996.0119; TAUTZ D, 1988, MOL BIOL EVOL, V5, P366; THOMPSON J, 1982, J BIOL CHEM, V257, P7915; THOMPSON J, 1993, EMBO J, V12, P1499, DOI 10.1002/j.1460-2075.1993.tb05793.x; UCHIUMI T, 1995, J BIOL CHEM, V270, P29889; UCHIUMI T, 1990, J BIOL CHEM, V265, P89; UCHIUMI T, 1986, EUR J BIOCHEM, V156, P37, DOI 10.1111/j.1432-1033.1986.tb09545.x; UCHIUMI T, 1994, EMBO J, V13, P3389, DOI 10.1002/j.1460-2075.1994.tb06641.x; UCHIUMI T, 1992, J BIOL CHEM, V267, P19179; UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580; UCHIUMI T, 1991, J BIOL CHEM, V266, P2054; Uchiumi T, 1997, J BIOL CHEM, V272, P3302, DOI 10.1074/jbc.272.6.3302; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; XING YY, 1995, J MOL BIOL, V249, P319, DOI 10.1006/jmbi.1995.0299	43	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35116	35121		10.1074/jbc.M004596200	http://dx.doi.org/10.1074/jbc.M004596200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10960474	hybrid			2022-12-27	WOS:000165422800040
J	Yan, ZJ; Jetten, AM				Yan, ZJ; Jetten, AM			Characterization of the repressor function of the nuclear orphan receptor retinoid receptor-related testis-associated receptor/germ cell nuclear factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RELATED RECEPTOR; DNA-BINDING; RESPONSE ELEMENT; TRANSCRIPTIONAL ACTIVATION; CHROMOSOMAL LOCALIZATION; DIFFERENTIAL EXPRESSION; SILENCING MEDIATOR; N-COR; GENE; COACTIVATOR	Retinoid receptor-related testis-associated receptor (RTR)/germ cell nuclear factor is a nuclear orphan receptor that plays an important role in the control of gene expression during early embryonic development and gametogenesis. It has been shown to repress transcriptional activation, In this study, we further characterize this repressor function. We demonstrate that RTR can suppress the transcriptional activation induced by the estrogen receptor related-receptor alpha1 through its response element. The latter is at least in part due to competition for binding to the same response element. In addition, RTR inhibits basal transcriptional activation, indicating that it functions as an active repressor. Mammalian two-hybrid analyses showed that RTR interacts with the co-repressor nuclear co-repressor (N-CoR) but is unable to interact with the co-repressor SMRT or RIP140. Pull-down analyses with glutathione S-transferase-RTR fusion protein demonstrated that RTR physically interacts with N-CoR in vitro, suggesting a potential role for N-CoR in the transcriptional repression by RTR. To identify the regions in RTR essential for the binding of RTR to N-CoR, the effect of various deletion and point mutations on this interaction was examined. This analysis revealed that this interaction requires the hinge domain, helix 3 as well as the helix 12 region of RTR. The residues Ser(246)-Tyr(247) in the hinge domain, Lys(318) in helix 3, and Lys(489)-Thr(490) in helix 12 are identified as being critical in this interaction. Our results demonstrate that RTR can function as an active transcriptional repressor and that this repression can be mediated through interactions with the corepressor N-CoR. We show that this interaction exhibits several characteristics unique to RTR. Through its repressor function, RTR can suppress the induction of transcriptional activation by other nuclear receptors. These repressor activities may provide important mechanisms by which RTR regulates gene expression during development and gametogenesis.	NIEHS, Pulm Pathobiol Lab, Cell Biol Sect, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Jetten, AM (corresponding author), NIEHS, Pulm Pathobiol Lab, Cell Biol Sect, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	jetten@niehs.nih.gov	Jetten, Anton/C-3736-2019	Jetten, Anton/0000-0003-0954-4445	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025042] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agoulnik IY, 1998, FEBS LETT, V424, P73, DOI 10.1016/S0014-5793(98)00142-2; Bailey PJ, 1997, J STEROID BIOCHEM, V63, P165, DOI 10.1016/S0960-0760(97)00079-4; Bauer UM, 1997, EUR J BIOCHEM, V249, P826, DOI 10.1111/j.1432-1033.1997.t01-1-00826.x; Bonnelye E, 1997, MECH DEVELOP, V65, P71, DOI 10.1016/S0925-4773(97)00059-2; Borgmeyer U, 1997, EUR J BIOCHEM, V244, P120, DOI 10.1111/j.1432-1033.1997.00120.x; Braat AK, 1999, MOL REPROD DEV, V53, P369, DOI 10.1002/(SICI)1098-2795(199908)53:4&lt;369::AID-MRD1&gt;3.0.CO;2-U; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHEN F, 1994, MOL ENDOCRINOL, V8, P1434, DOI 10.1210/me.8.10.1434; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cooney AJ, 1999, AM ZOOL, V39, P796; Cooney AJ, 1998, BIOCHEM BIOPH RES CO, V245, P94, DOI 10.1006/bbrc.1998.8391; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Glass CK, 2000, GENE DEV, V14, P121; Greschik H, 1998, J MOL MED-JMM, V76, P800, DOI 10.1007/s001090050284; Greschik H, 1999, MOL CELL BIOL, V19, P690; Heinzer C, 1998, BIOL CHEM, V379, P349, DOI 10.1515/bchm.1998.379.3.349; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; HIROSE T, 1995, GENE, V152, P247, DOI 10.1016/0378-1119(94)00656-D; Hong SH, 1998, MOL ENDOCRINOL, V12, P1161, DOI 10.1210/me.12.8.1161; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Hummelke GC, 1998, MOL REPROD DEV, V50, P396, DOI 10.1002/(SICI)1098-2795(199808)50:4<396::AID-MRD3>3.0.CO;2-D; Joos TO, 1996, MECH DEVELOP, V60, P45, DOI 10.1016/S0925-4773(96)00599-0; Kapelle M, 1997, BBA-GENE STRUCT EXPR, V1352, P13, DOI 10.1016/S0167-4781(97)00043-2; Katz D, 1997, ENDOCRINOLOGY, V138, P4364, DOI 10.1210/en.138.10.4364; KATZ D, 1998, KEYST S NUCL REC GEN; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; Laudet V, 1997, J MOL ENDOCRINOL, V19, P207, DOI 10.1677/jme.0.0190207; Lei W, 1997, J MOL ENDOCRINOL, V18, P167, DOI 10.1677/jme.0.0180167; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Morasso MI, 1999, P NATL ACAD SCI USA, V96, P162, DOI 10.1073/pnas.96.1.162; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Pettersson K, 1996, MECH DEVELOP, V54, P211, DOI 10.1016/0925-4773(95)00479-3; Schmitz TP, 1999, BBA-GENE STRUCT EXPR, V1446, P173, DOI 10.1016/S0167-4781(99)00079-2; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Shi HP, 1997, GENOMICS, V44, P52, DOI 10.1006/geno.1997.4850; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Susens U, 1996, BBA-GENE STRUCT EXPR, V1309, P179, DOI 10.1016/S0167-4781(96)00157-1; Susens U, 1997, DEV NEUROSCI-BASEL, V19, P410, DOI 10.1159/000111238; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; WILLY PJ, 1998, HORMONES SIGNALING, V1, P308; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yan ZH, 1998, J BIOL CHEM, V273, P10948, DOI 10.1074/jbc.273.18.10948; Yan ZH, 1997, J BIOL CHEM, V272, P10565; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795; Zhang JS, 1999, MOL CELL BIOL, V19, P6448; Zhang YL, 1998, MOL REPROD DEV, V50, P93, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;93::AID-MRD12&gt;3.0.CO;2-Z	56	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35077	35085		10.1074/jbc.M005566200	http://dx.doi.org/10.1074/jbc.M005566200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10940306	hybrid			2022-12-27	WOS:000165422800035
J	Zhang, QM; Miyabe, I; Matsumoto, Y; Kino, K; Sugiyama, H; Yonei, S				Zhang, QM; Miyabe, I; Matsumoto, Y; Kino, K; Sugiyama, H; Yonei, S			Identification of repair enzymes for 5-formyluracil in DNA - Nth, Nei, and MutM proteins of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; BASE-EXCISION-REPAIR; ENDONUCLEASE-III NTH; IONIZING-RADIATION; FPG PROTEIN; IN-VITRO; GLYCOSYLASE ACTIVITIES; IRRADIATED DNA; DAMAGE; THYMINE	5-Formyluracil (5-foU) is a potentially mutagenic lesion of thymine produced in DNA by ionizing radiation and various chemical oxidants. Although 5-foU has been reported to be removed from DNA by Escherichia coli AlkA protein in vitro, its repair mechanisms are not fully understood. In this study, we used the borohydride trapping assay to detect and characterize repair activities for 5-foU in E. cold extracts with site-specifically designed oligonucleotides containing a 5-foU at defined sites. The trapping assay revealed that there are three kinds of proteins that form covalent complexes with the 5-foU-containing oligonucleotides. Extracts from strains defective in the nth, nei, or mutM gene lacked one of the proteins. All of the trapped complexes were completely lost in extracts from the nth nei mutM triple mutant. The introduction of a plasmid carrying the nth, nei, or mutM gene into the E. coli triple mutant restored the formation of the corresponding protein-DNA complex. Purified Nth, Nei, and MutM proteins were trapped by the 5-foU-containing oligonucleotide to form the complex in the presence of NaBH4. Furthermore, the purified Nth, Nei, and MutM proteins efficiently cleaved the oligonucleotide at the 5-foU site. In addition, 5-foU was site-specifically incorporated into plasmid pSVK3, and the resulting plasmid was replicated in E. cold. The mutation frequency of the plasmid was significantly increased in the E. coli nth nei mutM alkA mutant, compared with the wild-type and alkA strains. From these results it is concluded that the Nth, Nei, and MutM proteins are involved in the repair pathways for 5-foU that serve to avoid mutations in E. coli.	Kyoto Univ, Grad Sch Sci, Radiat Biol Lab, Sakyo Ku, Kyoto 6068502, Japan; Tokyo Med & Dent Univ, Inst Biomat & Bioengn, Chiyoda Ku, Tokyo 1010062, Japan	Kyoto University; Tokyo Medical & Dental University (TMDU)	Yonei, S (corresponding author), Kyoto Univ, Grad Sch Sci, Radiat Biol Lab, Sakyo Ku, Kyoto 6068502, Japan.	yonei@kingyo.zool.kyoto-u.ac.jp	Miyabe, Izumi/K-7536-2017; Matsumoto, Yoichiro/M-4093-2014; Sugiyama, Hiroshi/C-7687-2011	Miyabe, Izumi/0000-0002-4546-2837; Sugiyama, Hiroshi/0000-0001-8923-5946				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ARMEL PR, 1978, NUCLEIC ACIDS RES, V5, P3347, DOI 10.1093/nar/5.9.3347; Asagoshi K, 2000, J BIOL CHEM, V275, P4956, DOI 10.1074/jbc.275.7.4956; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BJELLAND S, 1995, BIOCHEMISTRY-US, V34, P14758, DOI 10.1021/bi00045a017; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; Blaisdell JO, 1999, J BACTERIOL, V181, P6396, DOI 10.1128/JB.181.20.6396-6402.1999; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; BREIMER LH, 1984, J BIOL CHEM, V259, P5543; Bruner SD, 1998, CURR BIOL, V8, P393, DOI 10.1016/S0960-9822(98)70158-7; Cadet J, 1999, MUTAT RES-FUND MOL M, V424, P9, DOI 10.1016/S0027-5107(99)00004-4; CUNNINGHAM RP, 1985, P NATL ACAD SCI USA, V82, P474, DOI 10.1073/pnas.82.2.474; D'Ham C, 1999, BIOCHEMISTRY-US, V38, P3335, DOI 10.1021/bi981982b; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Dizdaroglu M, 2000, BIOCHEMISTRY-US, V39, P5586, DOI 10.1021/bi9927787; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Eisen JA, 1999, MUTAT RES-DNA REPAIR, V435, P171, DOI 10.1016/S0921-8777(99)00050-6; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Fujikawa K, 1998, NUCLEIC ACIDS RES, V26, P4582, DOI 10.1093/nar/26.20.4582; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Hazra TK, 2000, J BIOL CHEM, V275, P27762; HAZRA TK, 1998, NUCLEIC ACIDS RES, V226, P5116; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; KASAI H, 1990, MUTAT RES, V243, P249, DOI 10.1016/0165-7992(90)90139-B; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; Masaoka A, 1999, J BIOL CHEM, V274, P25136, DOI 10.1074/jbc.274.35.25136; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; Miller JH, 1972, EXPT MOL GENETICS, P201; Mol CD, 1999, ANNU REV BIOPH BIOM, V28, P101, DOI 10.1146/annurev.biophys.28.1.101; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; Purmal AA, 1998, J BIOL CHEM, V273, P10026, DOI 10.1074/jbc.273.16.10026; PURMAL AA, 1994, NUCLEIC ACIDS RES, V22, P72, DOI 10.1093/nar/22.1.72; Rabow LE, 1997, BIOCHEMISTRY-US, V36, P5084, DOI 10.1021/bi963005a; RADMAN M, 1976, J BIOL CHEM, V251, P1438; Saito Y, 1997, J BACTERIOL, V179, P3783, DOI 10.1128/jb.179.11.3783-3785.1997; Sambrook J., 1989, MOL CLONING, pA1; Sarker AH, 1998, J MOL BIOL, V282, P761, DOI 10.1006/jmbi.1998.2042; Sidorkina OM, 1998, NUCLEIC ACIDS RES, V26, P5351, DOI 10.1093/nar/26.23.5351; Sugiyama H, 1996, TETRAHEDRON LETT, V37, P9067, DOI 10.1016/S0040-4039(96)02130-2; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TEEBOR GW, 1988, INT J RADIAT BIOL, V54, P131, DOI 10.1080/09553008814551591; TOFIGH S, 1989, FREE RADICAL BIO MED, V7, P131, DOI 10.1016/0891-5849(89)90004-X; VONSONNTAG C, 1994, INT J RADIAT BIOL, V66, P485, DOI 10.1080/09553009414551501; Wagner JR, 1996, ANAL BIOCHEM, V233, P76, DOI 10.1006/abio.1996.0010; WALLACE SS, 1997, OXIDATIVE STRESS MOL, P49; WARNER HR, 1994, FREE RADICAL BIO MED, V17, P249, DOI 10.1016/0891-5849(94)90080-9; Yoshida M, 1997, NUCLEIC ACIDS RES, V25, P1570, DOI 10.1093/nar/25.8.1570; Zhang QM, 1995, INT J RADIAT BIOL, V68, P603, DOI 10.1080/09553009514551601; Zhang QM, 1997, NUCLEIC ACIDS RES, V25, P3969, DOI 10.1093/nar/25.20.3969; Zhang QM, 1999, INT J RADIAT BIOL, V75, P59, DOI 10.1080/095530099140816	62	42	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35471	35477		10.1074/jbc.M006125200	http://dx.doi.org/10.1074/jbc.M006125200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956660	hybrid			2022-12-27	WOS:000165422800084
J	Schmidt, PJ; Kunst, C; Culotta, VC				Schmidt, PJ; Kunst, C; Culotta, VC			Copper activation of superoxide dismutase 1 (SOD1) in vivo - Role for protein-protein interactions with the copper chaperone for SOD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CEREVISIAE LYS7 GENE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ATX1 GENE; IN-VIVO; METAL; COX17; HSP70; HOMEOSTASIS	Insertion of copper into superoxide dismutase 1 (SOD1) in vivo requires the copper chaperone for SOD1 (CCS). CCS encompasses three protein domains: copper binding Domains I and III at the amino and carboxyl termini, and a central Domain II homologous to SOD1, Using a yeast interaction mating system, yeast CCS was seen to physically interact with SOD1, and this interaction required sequences at the predicted dimer interface of CCS Domain II. Interactions with SOD1 also required sequences of Domain III, but not Domain I. Mutations were introduced at the dimer interface of yeast SOD1, and the corresponding mutant failed to interact with CCS. When loaded with copper independent of CCS, this mutant SOD1 exhibited superoxide scavenging activity, but was normally inactive in vivo because CCS failed to recognize the enzyme. Activation of SOD1 by CCS was also examined using an in vivo assay for copper incorporation into SOD1. Yeast CCS was observed to insert copper into a pre-existing pool of apoSOD1 without the need for new SOD1 synthesis or for protein unfolding by the major SSA cytosolic heat shock proteins. Our data are consistent with a model in which prefolded dimers of apoSOD1 serve as substrate for the CCS copper chaperone.	Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Eleanor Roosevelt Inst Canc Res, Denver, CO 80206 USA	Johns Hopkins University	Culotta, VC (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Rm 7032, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050016, R37GM050016] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES-07141] Funding Source: Medline; NIGMS NIH HHS [GM50016] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; Becker J, 1996, MOL CELL BIOL, V16, P4378; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BERTINI I, 1994, EUR BIOPHYS J BIOPHY, V23, P167, DOI 10.1007/BF01007608; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BORCHELT DR, 1995, J BIOL CHEM, V270, P3234, DOI 10.1074/jbc.270.7.3234; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P82292; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Corson LB, 1998, P NATL ACAD SCI USA, V95, P6361, DOI 10.1073/pnas.95.11.6361; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Falconi M, 1999, STRUCT FOLD DES, V7, P903, DOI 10.1016/S0969-2126(99)80117-8; Ferraroni M, 1999, J MOL BIOL, V288, P413, DOI 10.1006/jmbi.1999.2681; FINLEY RL, 1995, DNA CLONING, V2, P169; Gamonet F, 1998, EUR J BIOCHEM, V251, P716, DOI 10.1046/j.1432-1327.1998.2510716.x; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Hall LT, 2000, BIOCHEMISTRY-US, V39, P3611, DOI 10.1021/bi992716g; HORECKA J, 1995, GENE, V162, P87, DOI 10.1016/0378-1119(95)00325-Z; Kim S, 1998, P NATL ACAD SCI USA, V95, P12860, DOI 10.1073/pnas.95.22.12860; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P1589, DOI 10.1021/bi992822i; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Lippard SJ, 1999, SCIENCE, V284, P748, DOI 10.1126/science.284.5415.748; Liu XF, 1999, J MOL BIOL, V289, P885, DOI 10.1006/jmbi.1999.2815; LIU XF, 1992, J BIOL CHEM, V267, P18298; Lyons TJ, 1998, J BIOL INORG CHEM, V3, P650, DOI 10.1007/s007750050279; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; Sherman F., 1978, METHODS YEAST GENETI; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; Valentine J.S., 1981, COPPER PROTEINS, P291; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; Zhu HN, 2000, BIOCHEMISTRY-US, V39, P5413, DOI 10.1021/bi992727+	42	100	105	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33771	33776		10.1074/jbc.M006254200	http://dx.doi.org/10.1074/jbc.M006254200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10944535	hybrid			2022-12-27	WOS:000090104600082
J	Knodler, LA; Noiva, R; Mehta, K; McCaffery, JM; Aley, SB; Svard, SG; Nystul, TG; Reiner, DS; Silberman, JD; Gillin, FD				Knodler, LA; Noiva, R; Mehta, K; McCaffery, JM; Aley, SB; Svard, SG; Nystul, TG; Reiner, DS; Silberman, JD; Gillin, FD			Novel protein-disulfide isomerases from the early-diverging protist Giardia lanblia (vol 274, pg 29805, 1999)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction													Reiner, David S./F-6106-2012; Silberman, Jeffrey D/AAK-8220-2020	Reiner, David S./0000-0002-8289-7311; Silberman, Jeffrey D/0000-0002-2965-9197; Svard, Staffan/0000-0002-7392-1746				Knodler LA, 1999, J BIOL CHEM, V274, P29805, DOI 10.1074/jbc.274.42.29805	1	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28339	28339						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10970904				2022-12-27	WOS:000089197100107
J	Bennett, BD; Denis, P; Haniu, M; Teplow, DB; Kahn, S; Louis, JC; Citron, M; Vassar, R				Bennett, BD; Denis, P; Haniu, M; Teplow, DB; Kahn, S; Louis, JC; Citron, M; Vassar, R			A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's beta-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; PROCESSING ENZYME; HUMAN PRORENIN; DISEASE; ENDOPROTEOLYSIS; IDENTIFICATION; PURIFICATION; LOCALIZATION; CONVERSION; RECEPTOR	The novel transmembrane aspartic protease BACE (for Beta-site APP Cleaving Enzyme) is the beta -secretase that cleaves amyloid precursor protein to initiate beta -amyloid formation. As such, RACE is a prime therapeutic target for the treatment of Alzheimer's disease. BACE, like other aspartic proteases, has a propeptide domain that is removed to form the mature enzyme. RACE propeptide cleavage occurs at the sequence RLPR down arrow E, a potential furin recognition motif. Here, we explore the role of furin in BACE propeptide domain processing. BACE propeptide cleavage in cells does not appear to be autocatalytic, since an inactive D93A mutant of BACE is still cleaved appropriately. BACE and furin co-localize within the Golgis apparatus, and propeptide cleavage is inhibited by brefeldin A and monensin, drugs that disrupt trafficking through the Golgi. Treatment of cells with the calcium ionophore A23187, leading to inhibition of calcium-dependent proteases including furin, or transfection with the alpha (1)-antitrypsin variant alpha (1)-PDX, a potent furin inhibitor, dramatically reduces cleavage of the RACE propeptide. Moreover, the BACE propeptide is not processed in the furin-deficient LoVo cell line; however, processing is restored upon furin transfection. Finally, in vitro digestion of recombinant soluble RACE with recombinant furin results in complete cleavage only at the established E46 site. Taken together, our results strongly suggest that furin, or a furin-like proprotein convertase, is responsible for cleaving the RACE propeptide domain to form the mature enzyme.	Amgen Inc, Thousand Oaks, CA 91320 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA	Amgen; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Vassar, R (corresponding author), Amgen Inc, 1 Amgen Ctr Dr,M-S 29-2-B, Thousand Oaks, CA 91320 USA.							ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Khan AR, 1998, PROTEIN SCI, V7, P815; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Mercure C, 1996, HYPERTENSION, V28, P840, DOI 10.1161/01.HYP.28.5.840; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; TAKEDAEZAKI M, 1993, ARCH BIOCHEM BIOPHYS, V304, P352, DOI 10.1006/abbi.1993.1361; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WANG PH, 1991, J BIOL CHEM, V266, P12633; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1	32	225	241	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37712	37717		10.1074/jbc.M005339200	http://dx.doi.org/10.1074/jbc.M005339200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10956649	hybrid			2022-12-27	WOS:000165618700056
J	Stoeckelhuber, M; Dobner, P; Baumgartner, P; Ehlert, J; Brandt, E; Mentele, R; Adam, D; Engelmann, B				Stoeckelhuber, M; Dobner, P; Baumgartner, P; Ehlert, J; Brandt, E; Mentele, R; Adam, D; Engelmann, B			Stimulation of cellular sphingomyelin import by the chemokine connective tissue-activating peptide III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET BASIC-PROTEIN; LIPID TRANSFER PROTEINS; NECROSIS-FACTOR-ALPHA; NEUTRAL SPHINGOMYELINASE; BETA-THROMBOGLOBULIN; CRYSTAL-STRUCTURE; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL	The selective import of phospholipids into cells could be mediated by proteins secreted from the cells into the extracellular compartment. We observed that the supernatants obtained from suspensions of thrombin-activated platelets stimulated the exchange of pyrene (py)labeled sphingomyelin between lipid vesicles in vitro. The proteins with sphingomyelin transfer activity were purified and identified as the chemokine connective tissue-activating peptide III (CTAP-III) and platelet basic protein. Isolated CTAP-III stimulated the exchange of py-sphingomyelin between lipid vesicles but did not affect the translocations of py-labeled phosphatidylcholine and phosphatidylethanolamine. CTAP-III rapidly increased the transfer of py-sphingomyelin from low density lipoproteins into peripheral blood lymphocytes, other immune cells, and fibroblasts, In the presence of heparin, CTAP-III was unable to insert sphingomyelin into the peripheral blood lymphocytes. The activation energy of the py sphingomyelin transfer suggested that the translocation proceeded entirely in a hydrophobic environment, [H-3]Sphingomyelin transferred to the cells by CTAP-III was hydrolyzed to [H-3]ceramide and [H-3]sphingosine after activation with tumor necrosis factor a. The generation of the [H-3]sphingolipid messengers was catalyzed by acid sphingomyelinase. Our results identify CTAP-III as the first mediator of the selective (endocytosis-independent) cellular import of sphingomyelin allowing the paracrine modulation of the sphingolipid signaling.	Univ Munich, Inst Physiol, D-80336 Munich, Germany; Forschungszentrum, Abt Immunol & Zellbiol, D-23845 Borstel, Germany; Univ Munich, Chirurg Klin, Abt Klin Chem & Biochem, D-80336 Munich, Germany; Univ Kiel, Inst Immunol, D-24105 Kiel, Germany	University of Munich; University of Munich; University of Kiel	Engelmann, B (corresponding author), Univ Munich, Inst Physiol, Schillerstr 44, D-80336 Munich, Germany.		Adam, Dieter/E-9763-2010	Adam, Dieter/0000-0002-5668-5032				Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; ALBERS JJ, 1984, ARTERIOSCLEROSIS, V4, P49, DOI 10.1161/01.ATV.4.1.49; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Andrieu-Abadie N, 1998, BIOCHEM J, V333, P91, DOI 10.1042/bj3330091; Bligh E.G., 1959, CAN J BIOCHEM PHYSIO, V37, P912; BRANDT E, 1992, J IMMUNOL, V149, P1356; BRANDT E, 1991, CYTOKINE, V3, P311, DOI 10.1016/1043-4666(91)90499-4; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN RE, 1991, SUBCELLULAR BIOCH, V16, P333; BRUCKDORFER KR, 1976, BIOLOGICAL MEMBRANES, V3, P103; CASTOR CW, 1983, P NATL ACAD SCI-BIOL, V80, P765, DOI 10.1073/pnas.80.3.765; CASTOR CW, 1977, ARTHRITIS RHEUM-US, V20, P859, DOI 10.1002/art.1780200316; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; Diaz C, 1996, J MEMBRANE BIOL, V151, P1, DOI 10.1007/s002329900051; Ehlert JE, 1998, J IMMUNOL, V161, P4975; Engelmann B, 1998, J BIOL CHEM, V273, P27800, DOI 10.1074/jbc.273.43.27800; Engelmann B, 1996, BIOCHEM J, V315, P781, DOI 10.1042/bj3150781; FADOK VA, 1992, J IMMUNOL, V148, P2207; FOGELMAN AM, 1988, J LIPID RES, V29, P1243; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELMKAMP GM, 1974, J BIOL CHEM, V249, P6382; HOLT JC, 1986, BIOCHEMISTRY-US, V25, P1988, DOI 10.1021/bi00356a023; HOLT JC, 1988, EXP HEMATOL, V16, P303; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Ludwig A, 1997, BLOOD, V90, P4588; Malkowski MG, 1997, J MOL BIOL, V266, P367, DOI 10.1006/jmbi.1996.0796; MALKOWSKI MG, 1995, J BIOL CHEM, V270, P7077, DOI 10.1074/jbc.270.13.7077; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MATHIAS S, 1968, BIOCHEM J, V335, P3596; Petersen F, 1996, J IMMUNOL, V156, P1954; Petersen F, 1998, J IMMUNOL, V161, P4347; Rajarathnam K, 1997, METHOD ENZYMOL, V287, P89; Ridgway ND, 1998, J BIOL CHEM, V273, P31621, DOI 10.1074/jbc.273.47.31621; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; WALTZ A, 1990, J EXP MED, V171, P449; WALZ A, 1989, J EXP MED, V170, P1745, DOI 10.1084/jem.170.5.1745; Wang PY, 1999, J BIOL CHEM, V274, P23235, DOI 10.1074/jbc.274.33.23235; WENGER RH, 1989, BLOOD, V73, P1498; WIRTZ KWA, 1968, J BIOL CHEM, V243, P3596; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353; YANG YQ, 1994, J BIOL CHEM, V269, P20110	48	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37365	37372		10.1074/jbc.M003709200	http://dx.doi.org/10.1074/jbc.M003709200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10956644	hybrid			2022-12-27	WOS:000165618700010
J	Takahara, T; Kanazu, S; Yanagisawa, S; Akanuma, H				Takahara, T; Kanazu, S; Yanagisawa, S; Akanuma, H			Heterogeneous Sp1 mRNAs in human HepG2 cells include a product of homotypic trans-splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; MESSENGER-RNA PRECURSORS; MAMMALIAN-CELLS; DNA-BINDING; RAT-LIVER; ACTIVATION; GENE; EXON; SEQUENCES; PROMOTER	Spl is one of the well documented transcription factors, but the whole structure of human Spl has not been determined yet. In the present study, we isolated several cDNAs representing two forms of human Spl mRNA with different 5'-terminal structures in HepG2 cells. Isolation of a genomic clone established that one of the cDNAs represents the mRNA having consecutive alignment of exons, which allowed deducing the complete amino acid sequence for human Spl. Another cDNA clone had a surprising structure that possessed an alignment of exons 3-2-3. Both reverse transcriptase-polymerase chain reaction and RNase protection assays confirmed accumulation of the two forms of Spl mRNA in HepG2 cells. Because Southern blot analysis suggested that exon 3 is of a single copy in the genome, the cDNA clone having the duplicated sequences for exon 3 appeared to reflect the trans-splicing between pre-mRNAs of human Sp1.	Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci Chem, Meguro Ku, Tokyo 1538902, Japan	University of Tokyo	Yanagisawa, S (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci Chem, Meguro Ku, Tokyo 1538902, Japan.							Akopian AN, 1999, FEBS LETT, V445, P177, DOI 10.1016/S0014-5793(99)00126-X; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; BRUZIK JP, 1992, NATURE, V360, P692, DOI 10.1038/360692a0; BRUZIK JP, 1995, P NATL ACAD SCI USA, V92, P7056, DOI 10.1073/pnas.92.15.7056; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; CHAPDELAINE Y, 1991, CELL, V65, P465, DOI 10.1016/0092-8674(91)90464-A; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DIRKSEN WP, 1994, J BIOL CHEM, V269, P6431; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; EUL J, 1995, EMBO J, V14, P3226, DOI 10.1002/j.1460-2075.1995.tb07325.x; Frantz SA, 1999, P NATL ACAD SCI USA, V96, P5400, DOI 10.1073/pnas.96.10.5400; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KITADAI Y, 1992, BIOCHEM BIOPH RES CO, V189, P1342, DOI 10.1016/0006-291X(92)90221-6; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Persengiev SP, 1996, ENDOCRINOLOGY, V137, P638, DOI 10.1210/en.137.2.638; Pink JJ, 1996, NUCLEIC ACIDS RES, V24, P962, DOI 10.1093/nar/24.5.962; SAMBROOK J, 1989, MOL CLONING, V2, P9; SHIMIZU A, 1993, FASEB J, V7, P149, DOI 10.1096/fasebj.7.1.7916698; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; SULLIVAN PM, 1991, J BIOL CHEM, V266, P143; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; WISSINGER B, 1991, CELL, V65, P473, DOI 10.1016/0092-8674(91)90465-B; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660	38	49	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38067	38072		10.1074/jbc.M002010200	http://dx.doi.org/10.1074/jbc.M002010200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973950	hybrid			2022-12-27	WOS:000165618700101
J	Detrich, HW; Parker, SK; Williams, RC; Nogales, E; Downing, KH				Detrich, HW; Parker, SK; Williams, RC; Nogales, E; Downing, KH			Cold adaptation of microtubule assembly and dynamics - Structural interpretation of primary sequence changes present in the alpha- and beta-tubulins of antarctic fishes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOL-CHLOROFORM EXTRACTION; SINGLE-STEP METHOD; LOW-TEMPERATURES; IN-VITRO; NOTOTHENIA-CORIICEPS; BRAIN TUBULIN; RNA ISOLATION; PROTEIN; EVOLUTION; ISOTYPES	The microtubules of Antarctic fishes, unlike those of homeotherms, assemble at very low temperatures (-1.8 degreesC). The adaptations that enhance assembly of these microtubules are intrinsic to the tubulin dimer and reduce its critical concentration for polymerization at 0 degreesC to similar to0.9 mg/ml (Williams, R, C., Jr., Correia, J. J., and DeVries, A. L. (1985) Biochemistry 24, 2790-2798). Here we demonstrate that microtubules formed by pure brain tubulins of Antarctic fishes exhibit slow dynamics at both low (5 degreesC) and high (25 degreesC) temperatures; the rates of polymer growth and shortening and the frequencies of interconversion between these states are small relative to those observed for mammalian microtubules (37 degreesC). To investigate the contribution of tubulin primary sequence variation to the functional properties of the microtubules of Antarctic fishes, we have sequenced brain cDNAs that encode 9 alpha -tubulins and 4 beta -tubulins from the yellowbelly rockcod Notothenia coriiceps and 4 alpha -tubulins and 2 beta -tubulins from the ocellated icefish Chionodraco rastrospinosus. The tubulins of these fishes mere found to contain small sets of unique or rare residue substitutions that mapped to the lateral, interprotofilament surfaces or to the interiors of the alpha- and beta -polypeptides; longitudinal interaction surfaces are not altered in the fish tubulins. Four changes (A278T and S287T in alpha; S280G and A285S in beta) were present in the S7-H9 interprotofilament ''M'' loops of some monomers and would be expected to increase the flexibility of these regions. A fifth lateral substitution specific to the alpha -chain (M302L or M302F) may increase the hydrophobicity of the interprotofilament interaction. Two hydrophobic substitutions (alpha :S187A in helix H5 and beta :Y202F in sheet S6) may act to stabilize the monomers in conformations favorable to polymerization. We propose that cold adaptation of microtubule assembly in Antarctic fishes has occurred in part by evolutionary restructuring of the lateral surfaces and the cores of the tubulin monomers.	Northeastern Univ, Dept Biol, Boston, MA 02115 USA; Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Northeastern University; Vanderbilt University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Detrich, HW (corresponding author), Northeastern Univ, Dept Biol, 414 Mugar Hall,360 Huntington Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025638] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46033, GM25638] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amos LA, 1999, CHEM BIOL, V6, pR65, DOI 10.1016/S1074-5521(99)89002-4; BANERJEE A, 1990, J BIOL CHEM, V265, P1794; BARGELLONI L, 1994, MOL BIOL EVOL, V11, P854; BILLGER M, 1994, CELL MOTIL CYTOSKEL, V28, P327, DOI 10.1002/cm.970280406; BINDER LI, 1975, P NATL ACAD SCI USA, V72, P1122, DOI 10.1073/pnas.72.3.1122; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLARKE A, 1989, GEOLOGICAL SOC SPECI, V47, P253; DAVIS A, 1994, SCIENCE, V264, P839, DOI 10.1126/science.8171338; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DETRICH HW, 1992, J BIOL CHEM, V267, P18766; Detrich HW, 1997, COMP BIOCHEM PHYS A, V118, P501, DOI 10.1016/S0300-9629(97)00012-1; DETRICH HW, 1986, J BIOL CHEM, V261, P922; DETRICH HW, 1987, J BIOL CHEM, V262, P8360; DETRICH HW, 1993, CELL MOTIL CYTOSKEL, V24, P156, DOI 10.1002/cm.970240303; DETRICH HW, 1989, BIOCHEMISTRY-US, V28, P10085, DOI 10.1021/bi00452a031; DEWITT HH, 1971, ANTARCTIC MAP FOLIO, P1; Eastman J. T, 1993, ANTARCTIC FISH BIOL; EASTMAN JT, 1989, GEOL SOC SPECIAL PUB, V47, P241; Fields PA, 1998, P NATL ACAD SCI USA, V95, P11476, DOI 10.1073/pnas.95.19.11476; GAMBLIN TC, 1995, ANAL BIOCHEM, V232, P43; GILDERSLEEVE RF, 1992, J BIOL CHEM, V267, P7995; Greenwood P. H., 1966, Bulletin of the American Museum of Natural History, V131, P339; HERZOG W, 1977, P NATL ACAD SCI USA, V74, P1860, DOI 10.1073/pnas.74.5.1860; HIMES RH, 1989, BIOCHEMISTRY-US, V28, P5089, DOI 10.1021/bi00438a028; KENNETT JP, 1976, NATURE, V260, P513, DOI 10.1038/260513a0; KENNETT JP, 1977, J GEOPHYS RES-OC ATM, V82, P3843, DOI 10.1029/JC082i027p03843; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Luduena RF, 1998, INT REV CYTOL, V178, P207; LUDUENA RF, 1993, MOL BIOL CELL, V4, P445, DOI 10.1091/mbc.4.5.445; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MARTIN SR, 1993, BIOPHYS J, V65, P578, DOI 10.1016/S0006-3495(93)81091-9; Modig C, 1999, CELL MOTIL CYTOSKEL, V42, P315, DOI 10.1002/(SICI)1097-0169(1999)42:4<315::AID-CM5>3.0.CO;2-C; Modig C, 2000, BIOCHEM BIOPH RES CO, V269, P787, DOI 10.1006/bbrc.2000.2362; NICHOLLS A, 1993, GRASP GRAPHICAL REPR; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358; Parker SK, 1998, J BIOL CHEM, V273, P34358, DOI 10.1074/jbc.273.51.34358; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; REIJO RA, 1994, MOL BIOL CELL, V5, P29, DOI 10.1091/mbc.5.1.29; Richards KL, 2000, MOL BIOL CELL, V11, P1887, DOI 10.1091/mbc.11.5.1887; SAGE CR, 1995, CELL MOTIL CYTOSKEL, V30, P285, DOI 10.1002/cm.970300406; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shackleton N.J., 1975, INITIAL REPORTS DEEP, V29, P743, DOI [DOI 10.2973/DSDP.PROC.29.117.1975, 10.2973/DSDP.PROC.29.117.1975]; SHACKLETON NJ, 1984, NATURE, V307, P620, DOI 10.1038/307620a0; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; Tran PT, 1997, J STRUCT BIOL, V118, P107, DOI 10.1006/jsbi.1997.3844; TRINCZEK B, 1993, MOL BIOL CELL, V4, P323, DOI 10.1091/mbc.4.3.323; Wallin M, 1997, CELL MOTIL CYTOSKEL, V38, P297, DOI 10.1002/(SICI)1097-0169(1997)38:3<297::AID-CM8>3.0.CO;2-2; Willem S, 1999, EXTREMOPHILES, V3, P221, DOI 10.1007/s007920050119; WILLIAMS RC, 1985, BIOCHEMISTRY-US, V24, P2790, DOI 10.1021/bi00332a029	54	116	120	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37038	37047		10.1074/jbc.M005699200	http://dx.doi.org/10.1074/jbc.M005699200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10956651	hybrid			2022-12-27	WOS:000165577700082
J	Giannoukakis, N; Rudert, WA; Trucco, M; Robbins, PD				Giannoukakis, N; Rudert, WA; Trucco, M; Robbins, PD			Protection of human islets from the effects of interleukin-1 beta by adenoviral gene transfer of an I kappa B repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE PRODUCTION; NECROSIS-FACTOR-ALPHA; DEPENDENT DIABETES-MELLITUS; RECEPTOR ANTAGONIST PROTEIN; BETA-CELL DESTRUCTION; PANCREATIC-ISLETS; INSULIN-SECRETION; DEATH PATHWAYS; NOD MICE; EXPRESSION	Interleukin-1 beta (IL-1 beta) is a pro-inflammatory cytokine that inhibits beta cell function and promotes Fas-triggered apoptosis. IL-IP is thought to act early in the initiation of the autoimmune destruction of pancreatic beta cells in type I diabetes. IL-1 beta promotes beta cell impairment, in part, by activating NF-KB transcription factor-dependent signaling pathways. We have examined whether beta cells could be protected from the effects of IL-1 beta by overexpressing an inhibitor of NF-kappaB activity, I kappaB alpha by adenoviral gene transfer to intact human islets in culture. Infection of islets with an adenoviral vector encoding a non-phosphorylatable, non-degradable variant of I kappaB alpha resulted in normal insulin responses to glucose in the presence of IL-1 beta. Furthermore, nitric oxide production was prevented and, more importantly, Fas-triggered apoptosis was inhibited following I kappaB alpha gene transfer. These results suggest that blocking the NF-KB pathway might prevent cytokine-induced beta cell impairment as a means of facilitating islet transplantation.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Robbins, PD (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, W1246 BST, Pittsburgh, PA 15261 USA.							Arnush M, 1998, J IMMUNOL, V160, P2684; Arnush M, 1998, J CLIN INVEST, V102, P516, DOI 10.1172/JCI844; BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; Beckman JS, 1997, AM J RESP CELL MOL, V16, P495, DOI 10.1165/ajrcmb.16.5.9160830; Burcin MM, 1999, P NATL ACAD SCI USA, V96, P355, DOI 10.1073/pnas.96.2.355; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Clesham GJ, 1998, GENE THER, V5, P174, DOI 10.1038/sj.gt.3300576; CORBETT JA, 1993, AUTOIMMUNITY, V15, P145, DOI 10.3109/08916939309043889; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; CSETE ME, 1994, TRANSPLANT P, V26, P756; CSETE ME, 1995, TRANSPLANTATION, V59, P263, DOI 10.1097/00007890-199501270-00019; Darville MI, 1998, DIABETOLOGIA, V41, P1101, DOI 10.1007/s001250051036; De Vera ME, 1997, AM J PHYSIOL-GASTR L, V273, pG1290, DOI 10.1152/ajpgi.1997.273.6.G1290; DECRAEN MV, 1999, CELL DEATH DIFFER, V6, P1117; EIZIRIK DL, 1991, DIABETOLOGIA, V34, P445, DOI 10.1007/BF00403185; EIZIRIK DL, 1994, J CLIN INVEST, V93, P1968, DOI 10.1172/JCI117188; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Flodstrom M, 1997, ENDOCRINOLOGY, V138, P2747, DOI 10.1210/en.138.7.2747; Foo SY, 1999, TRENDS GENET, V15, P229; Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211; Freundlieb S, 1999, J GENE MED, V1, P4, DOI 10.1002/(SICI)1521-2254(199901/02)1:1<4::AID-JGM4>3.0.CO;2-Y; Freundlieb S, 1997, METHOD ENZYMOL, V283, P159; Giannoukakis N, 1999, DIABETES, V48, P1730, DOI 10.2337/diabetes.48.9.1730; Giannoukakis N, 1999, GENE THER, V6, P1545, DOI 10.1038/sj.gt.3300996; Haddad IY, 1997, AM J RESP CELL MOL, V16, P501, DOI 10.1165/ajrcmb.16.5.9160832; HANENBERG H, 1989, DIABETOLOGIA, V32, P126, DOI 10.1007/BF00505185; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hellerbrand C, 1998, AM J PHYSIOL-GASTR L, V275, pG269, DOI 10.1152/ajpgi.1998.275.2.G269; Hostens K, 1999, J CLIN INVEST, V104, P67, DOI 10.1172/JCI6438; Hsu SC, 1999, EUR J IMMUNOL, V29, P2948, DOI 10.1002/(SICI)1521-4141(199909)29:09<2948::AID-IMMU2948>3.0.CO;2-0; Jobin C, 1998, J IMMUNOL, V160, P410; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KASUGA A, 1993, DIABETOLOGIA, V36, P1252, DOI 10.1007/BF00400802; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; LACY PE, 1991, AM J PATHOL, V138, P1183; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Linetsky E, 1997, DIABETES, V46, P1120, DOI 10.2337/diabetes.46.7.1120; McDaniel ML, 1996, P SOC EXP BIOL MED, V211, P24; McIlroy D, 1999, ONCOGENE, V18, P4401, DOI 10.1038/sj.onc.1202868; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; Oligino T, 1998, GENE THER, V5, P491, DOI 10.1038/sj.gt.3300612; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; RABINOVITCH A, 1994, J CLIN ENDOCR METAB, V79, P1058, DOI 10.1210/jc.79.4.1058; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; REDDY S, 1993, PANCREAS, V8, P602, DOI 10.1097/00006676-199309000-00012; Reddy S, 1997, HISTOCHEM J, V29, P53, DOI 10.1023/A:1026416918339; Renard P, 1999, CELL BIOL TOXICOL, V15, P341, DOI 10.1023/A:1007652414175; Renard P, 1997, BIOCHEM PHARMACOL, V53, P149, DOI 10.1016/S0006-2952(96)00645-4; Roebuck KA, 1999, J LEUKOCYTE BIOL, V66, P876, DOI 10.1002/jlb.66.6.876; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Sorli CH, 1998, P NATL ACAD SCI USA, V95, P1788, DOI 10.1073/pnas.95.4.1788; SOUTHERN C, 1990, FEBS LETT, V276, P42, DOI 10.1016/0014-5793(90)80502-A; Stephens LA, 1999, ENDOCRINOLOGY, V140, P3219, DOI 10.1210/en.140.7.3219; SuarezPinzon WL, 1997, DIABETES, V46, P907, DOI 10.2337/diabetes.46.5.907; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Weber M, 1997, J SURG RES, V69, P23, DOI 10.1006/jsre.1997.4995; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Yamada K, 1996, DIABETOLOGIA, V39, P1306, DOI 10.1007/s001250050574	62	186	192	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36509	36513		10.1074/jbc.M005943200	http://dx.doi.org/10.1074/jbc.M005943200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967112	hybrid			2022-12-27	WOS:000165577700009
J	Kast, P; Grisostomi, C; Chen, IA; Li, SL; Krengel, U; Xue, YF; Hilvert, D				Kast, P; Grisostomi, C; Chen, IA; Li, SL; Krengel, U; Xue, YF; Hilvert, D			A strategically positioned cation is crucial for efficient catalysis by chorismate mutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; SITE-DIRECTED MUTAGENESIS; ELECTRON-DENSITY MAPS; BACILLUS-SUBTILIS; CLAISEN REARRANGEMENT; ACTIVE-SITE; CRYSTAL-STRUCTURES; ENZYME; PREPHENATE; MECHANISM	Combinatorial mutagenesis and in vivo selection experiments previously afforded functional variants of the AroH class Bacillus subtilis chorismate mutase lacking the otherwise highly conserved active site residue Arg(90). Here, we present a detailed kinetic and crystallographic study of several such variants. Removing the arginine side chain (R90G and R90A) reduced catalytic efficiency by more than 5 orders of magnitude. Reintroducing a positive charge to the active site through lysine substitutions restored more than a factor of a thousand in k(cat) Remarkably, the lysine could be placed at position 90 or at the more remote position 88 provided a sterically suitable residue was present at the partner site. Crystal structures of the double mutants C88S/R90K and C88K/R90S show that the lysine adopts an extended conformation that would place its E-ammonium group within hydrogen-bonding distance of the ether oxygen of bound chorismate in the transition state. These results provide support for the hypothesis that developing negative charge in the highly polarized transition state is stabilized electrostatically by a strategically placed cation. The implications of this finding for the mechanism of all natural chorismate mutases and for the design of artificial catalysts are discussed.	ETH Zurich, Swiss Fed Inst Technol, Organ Chem Lab, CH-8092 Zurich, Switzerland; Scripps Res Inst, Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Gothenburg, Dept Biochem & Biophys, SE-90530 Gothenburg, Sweden; Univ Gothenburg, Dept Mol Biotechnol, SE-90530 Gothenburg, Sweden; Chalmers Univ Technol, SE-90530 Gothenburg, Sweden	Swiss Federal Institutes of Technology Domain; ETH Zurich; Scripps Research Institute; Scripps Research Institute; University of Gothenburg; University of Gothenburg; Chalmers University of Technology	Hilvert, D (corresponding author), ETH Zurich, Swiss Fed Inst Technol, Organ Chem Lab, Univ Str 16, CH-8092 Zurich, Switzerland.			Chen, Irene/0000-0001-6040-7927; Xue, Yafeng/0000-0002-7526-8672; Krengel, Ute/0000-0001-6688-8151	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038273, R29GM038273] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38273] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDADI L, 1983, BIOCHEMISTRY-US, V22, P4494, DOI 10.1021/bi00288a022; ANDREWS PR, 1973, BIOCHEMISTRY-US, V12, P3492, DOI 10.1021/bi00742a022; BARTLETT PA, 1985, J AM CHEM SOC, V107, P7792, DOI 10.1021/ja00311a111; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1993, XPLOR SYSTEM CRYSTAL; CHOOK YM, 1993, P NATL ACAD SCI USA, V90, P8600, DOI 10.1073/pnas.90.18.8600; CHOOK YM, 1994, J MOL BIOL, V240, P476, DOI 10.1006/jmbi.1994.1462; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; Cload ST, 1996, J AM CHEM SOC, V118, P1787, DOI 10.1021/ja953152g; COPLEY SD, 1985, J AM CHEM SOC, V107, P5306, DOI 10.1021/ja00304a064; DAVIDSON MM, 1996, J CHEM SOC P1, V2, P525; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fersht A, 1985, ENZYME STRUCTURE MEC, V2, P107; GAJEWSKI JJ, 1987, J AM CHEM SOC, V109, P1170, DOI 10.1021/ja00238a029; Galopin CC, 1996, TETRAHEDRON LETT, V37, P8675, DOI 10.1016/S0040-4039(96)02007-2; Ganem B., 1996, ANGEW CHEM INT EDIT, V35, P936, DOI [10.1002/anie.19960936, DOI 10.1002/ANIE.199609361]; GORISCH H, 1978, BIOCHEMISTRY-US, V17, P3700, DOI 10.1021/bi00611a004; GRAY JV, 1990, BIOCHEMISTRY-US, V29, P8872, DOI 10.1021/bi00489a051; Grisostomi C, 1997, BIOORG CHEM, V25, P297, DOI 10.1006/bioo.1997.1073; Gu W, 1997, Microb Comp Genomics, V2, P141, DOI 10.1089/omi.1.1997.2.141; Gustin DJ, 1999, J AM CHEM SOC, V121, P1756, DOI 10.1021/ja9841759; Haslam E., 1993, SHIKIMIC ACID METABO; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; HILVERT D, 1988, J AM CHEM SOC, V110, P5593, DOI 10.1021/ja00224a066; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kast P, 1996, TETRAHEDRON LETT, V37, P2691, DOI 10.1016/0040-4039(96)00338-3; Kast P, 1996, J AM CHEM SOC, V118, P3069, DOI 10.1021/ja953701i; Kast P, 1996, P NATL ACAD SCI USA, V93, P5043, DOI 10.1073/pnas.93.10.5043; Kast P, 1997, J PHYS CHEM B, V101, P10976, DOI 10.1021/jp972501l; Khanjin NA, 1999, J AM CHEM SOC, V121, P11831, DOI 10.1021/ja992453d; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE AY, 1995, CHEM BIOL, V2, P195, DOI 10.1016/1074-5521(95)90269-4; LEE AY, 1995, J AM CHEM SOC, V117, P3627, DOI 10.1021/ja00117a038; Liu DR, 1996, J AM CHEM SOC, V118, P1789, DOI 10.1021/ja953151o; LYNE PD, 1995, J AM CHEM SOC, V117, P11345, DOI 10.1021/ja00150a037; MacBeath G, 1998, BIOTECHNIQUES, V24, P789, DOI 10.2144/98245st02; MacBeath G, 1998, BIOCHEMISTRY-US, V37, P10062, DOI 10.1021/bi980449t; Mattei P, 1999, EUR J BIOCHEM, V261, P25, DOI 10.1046/j.1432-1327.1999.00169.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1993, DENZO OSCILLATION DA; PHILLIPS MA, 1990, J BIOL CHEM, V265, P20692; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; SCHIMMEL P, 1989, ACCOUNTS CHEM RES, V22, P232, DOI 10.1021/ar00163a001; SMITH WW, 1993, J ORG CHEM, V58, P7308, DOI 10.1021/jo00077a070; Strater N, 1997, STRUCTURE, V5, P1437, DOI 10.1016/S0969-2126(97)00294-3; TANG Y, 1991, P NATL ACAD SCI USA, V88, P8784, DOI 10.1073/pnas.88.19.8784; WIEST O, 1995, J AM CHEM SOC, V117, P11628, DOI 10.1021/ja00152a002; XUE YF, 1995, P NATL ACAD SCI USA, V92, P10595, DOI 10.1073/pnas.92.23.10595; XUE YF, 1994, P NATL ACAD SCI USA, V91, P10814, DOI 10.1073/pnas.91.23.10814; Zhang S, 1996, BIOORGAN MED CHEM, V4, P1015, DOI 10.1016/0968-0896(96)00099-5	57	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36832	36838		10.1074/jbc.M006351200	http://dx.doi.org/10.1074/jbc.M006351200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10960481	hybrid			2022-12-27	WOS:000165577700056
J	Christiansen, J; Seefeldt, LC; Dean, DR				Christiansen, J; Seefeldt, LC; Dean, DR			Competitive substrate and inhibitor interactions at the physiologically relevant active site of nitrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM-IRON PROTEIN; AZOTOBACTER-VINELANDII NITROGENASE; Q-BAND ENDOR; FEMO-COFACTOR; MOFE PROTEIN; STATE NITROGENASE; BINDING; PROGRAM	Nitrogenase catalyzes the MgATP-dependent reduction of dinitrogen gas to ammonia. In addition to the physiological substrate, nitrogenase catalyzes reduction: of a variety of other multiply bonded substrates, such as acetylene, nitrous oxide, and azide, Although Carbon monoxide (CO) is not reduced by nitrogenase, it is a potent inhibitor of all nitrogenase catalyzed substrate: reductions except proton reduction. Here, we present kinetic parameters for an altered Azotobacter vinelandii MoFe protein for which the alpha Gly(69) residue was substituted by serine (Christiansen, J., Cash, V. L., Seefeldt, L. C., and Dean, D. R. (2000) J. Biol. Chem. 275, 11459-11464), For the wild type enzyme, CO and acetylene:are: both noncompetitive inhibitors of dinitrogen reduction. However, for the (alpha Ser(69) MoFe protein both CO and acetylene have become competitive inhibitors of dinitrogen reduction. CO is also converted from a noncompetitive inhibitor to a competitive inhibitor of acetylene, nitrous oxide, and azide reduction. These results are interpreted in terms of a two-site model. Site 1 is a high affinity acetylene-binding site to which CO also binds) but dinitrogen, azide, and nitrous oxide do not bind. This site is the one primarily accessed during typical:acetylene reduction assays. Site 2 is a low affinity acetylene-binding site to which CO, dinitrogen, azide, and nitrous oxide also bind. Site 1 and site 2 are proposed to be located in close proximity within a specific 4Fe-4S face of FeMo cofactor.	Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA; Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA	Utah System of Higher Education; Utah State University; Virginia Polytechnic Institute & State University	Seefeldt, LC (corresponding author), Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA.			Seefeldt, Lance/0000-0002-6457-9504	NIGMS NIH HHS [R01-GM59087] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059087] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Burgess B. K., 1985, MOLYBDENUM ENZYMES, P161; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; Burris R. H., 1979, A treatise on dinitrogen fixation. Inorganic and physical chemistry and biochemistry, P569; Christiansen J, 2000, PROKARYOTIC NITROGEN FIXATION, P101; Christiansen J, 2000, J BIOL CHEM, V275, P11459, DOI 10.1074/jbc.275.15.11459; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; DAVIS LC, 1979, BIOCHEMISTRY-US, V18, P4860, DOI 10.1021/bi00589a014; DILWORTH MJ, 1992, ANAL BIOCHEM, V207, P6, DOI 10.1016/0003-2697(92)90491-O; DILWORTH MJ, 1981, BIOCHEM J, V193, P371; ENNOR AH, 1957, METHOD ENZYMOL, V3, P850, DOI 10.1016/S0076-6879(57)03460-6; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; KIM CH, 1995, BIOCHEMISTRY-US, V34, P2798, DOI 10.1021/bi00009a008; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee HI, 1997, J AM CHEM SOC, V119, P11395, DOI 10.1021/ja971508d; Lee HI, 1997, J AM CHEM SOC, V119, P10121, DOI 10.1021/ja9715096; LIANG JH, 1988, BIOCHEMISTRY-US, V27, P6726, DOI 10.1021/bi00418a013; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Segel IH, 1976, BIOCH CALCULATIONS; Shen J, 1997, BIOCHEMISTRY-US, V36, P4884, DOI 10.1021/bi9628578; Thorneley R. N. F., 1985, MOLYBDENUM ENZYMES, P221; YATES MG, 1991, BIOL NITROGEN FIXATI, P685	25	55	55	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36104	36107		10.1074/jbc.M004889200	http://dx.doi.org/10.1074/jbc.M004889200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10948195	hybrid			2022-12-27	WOS:000165382000066
J	Imai, Y; Soda, M; Takahashi, R				Imai, Y; Soda, M; Takahashi, R			Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE JUVENILE PARKINSONISM; C-CBL; RING; APOPTOSIS; UBCH7	Autosomal recessive juvenile parkinsonism (AR-JP) is caused by mutations in the parkin gene. Parkin protein is characterized by a ubiquitin-like domain at its NH,terminus and two RING finger motifs and an IBR (in between RING: fingers) at its COOH terminus (RING-IBR-RING). Here, we show that Parkin is a RING-type E3 ubiquitin-protein ligase which binds to E2 ubiquitin-conjugating enzymes, including UbcH7 and UbcH8, through its RING-IBR-RING motif, Moreover, we found that unfolded protein stress induces up-regulation of both the mRNA and protein level of Parkin, Furthermore, overexpression of Parkin, but not a set of mutants without the E3 activity, specifically suppressed unfolded protein stress-induced cell death. These findings demonstrate that Parkin is an E3 enzyme and suggest that it is involved in the ubiquitination pathway for misfolded proteins derived from endoplasmic reticulum and contributes to protection from neurotoxicity induced by unfolded protein stresses.	RIKEN, BSI, Lab Motor Syst Neurodegenerat, Wako, Saitama 3510198, Japan	RIKEN	Takahashi, R (corresponding author), RIKEN, BSI, Lab Motor Syst Neurodegenerat, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Imai, Yuzuru/AAA-6472-2019	Imai, Yuzuru/0000-0003-2924-5231				ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Dawson TM, 2000, CELL, V101, P115, DOI 10.1016/S0092-8674(00)80629-7; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Moynihan TP, 1999, J BIOL CHEM, V274, P30963, DOI 10.1074/jbc.274.43.30963; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; YAMAMURA Y, 1973, NEUROLOGY, V23, P239, DOI 10.1212/WNL.23.3.239; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707	24	618	636	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35661	35664		10.1074/jbc.C000447200	http://dx.doi.org/10.1074/jbc.C000447200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10973942	hybrid			2022-12-27	WOS:000165382000002
J	Kato-Yamada, Y; Yoshida, M; Hisabori, T				Kato-Yamada, Y; Yoshida, M; Hisabori, T			Movement of the helical domain of the epsilon subunit is required for the activation of thermophilic F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ATP SYNTHASE; ALPHA(3)BETA(3)GAMMA COMPLEX; ENDOGENOUS INHIBITOR; GAMMA-SUBUNIT; BETA-SUBUNITS; CROSS-LINKING; H+-ATPASE; IN-SITU; ROTATION	The inhibitory effect of epsilon subunit in F-1-ATPase from thermophilic Bacillus PS3 was examined focusing on the structure-function relationship. For this purpose, we designed: a mutant for epsilon subunit similar to the one constructed by Schulenberg and Capaldi (Schulenberg, B,, and Capaldi, R, A. (1999) J, Biol, Chem. 274, 28351-28355), We introduced two cysteine residues at the interface of N-terminal beta -sandwich domain (S48C) and C-terminal cu-helical domain (N125C) of epsilon subunit, The alpha (3)beta (3)gamma epsilon complex containing the reduced form of this mutant epsilon subunit showed suppressed ATPase activity and gradual activation during the measurement. This activation pattern was similar to the complex with the wild type epsilon subunit, The conformation of the mutant epsilon subunit must be fixed and similar to the reported three-dimensional structure of the isolated epsilon subunit, when the intramolecular disulfide bridge was formed on this subunit by oxidation. This oxidized mutant epsilon subunit could form the alpha (3)beta (3)gamma epsilon complex but did not show any inhibitory effect. The complex was converted to the activated state, and the cross-link in the mutant epsilon subunit in the complex was efficiently formed in the presence of ATP-Mg, whereas no cross-link was observed without ATP-Mg, suggesting the conformation of the oxidized mutant epsilon subunit must be similar to that in the activated state complex. A non-hydrolyzable analog of ATP, 5'-adenylyl-beta,gamma -imidodiphosphate, could stimulate the formation of the cross-link on the epsilon subunit, Furthermore, the cross-link formation was stimulated by nucleotides even when this mutant epsilon subunit was assembled with a mutant alpha (3)beta (3)gamma complex lacking non-catalytic sites. These results indicate that binding of ATP to the catalytic sites induces a conformational change in the epsilon subunit and triggers transition of the complex from the suppressed state to the activated state.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Hisabori, T (corresponding author), Tokyo Inst Technol, Chem Resources Lab, R-1,4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	thisabor@res.titech.ac.jp	Hisabori, Toru/E-5205-2014	Hisabori, Toru/0000-0003-2046-0277				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; Capaldi RA, 2000, BBA-BIOENERGETICS, V1458, P263, DOI 10.1016/S0005-2728(00)00078-5; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; HASHIMOTO T, 1990, J BIOENERG BIOMEMBR, V22, P27, DOI 10.1007/BF00762843; HASHIMOTO T, 1996, SEIKAGAKU, V68, P775; Hisabori T, 1999, FEBS LETT, V463, P35, DOI 10.1016/S0014-5793(99)01602-6; Hisabori T, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1711; Hisabori T, 1997, EUR J BIOCHEM, V247, P1158, DOI 10.1111/j.1432-1033.1997.01158.x; Jones PC, 2000, J BIOL CHEM, V275, P31340, DOI 10.1074/jbc.M003687200; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; Kato Y, 1997, J BIOL CHEM, V272, P24906, DOI 10.1074/jbc.272.40.24906; Kato-Yamada Y, 1999, J BIOL CHEM, V274, P33991, DOI 10.1074/jbc.274.48.33991; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; KUKI M, 1988, J BIOL CHEM, V263, P17437; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGET PP, 1979, ARCH BIOCHEM BIOPHYS, V197, P83, DOI 10.1016/0003-9861(79)90222-4; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; ORT DR, 1992, ANNU REV PLANT PHYS, V43, P269, DOI 10.1146/annurev.pp.43.060192.001413; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schulenberg B, 1999, J BIOL CHEM, V274, P28351, DOI 10.1074/jbc.274.40.28351; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; Stiggall D L, 1979, Methods Enzymol, V55, P308; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Wilkens S, 1998, J BIOL CHEM, V273, P26645, DOI 10.1074/jbc.273.41.26645; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837	46	43	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35746	35750		10.1074/jbc.M006575200	http://dx.doi.org/10.1074/jbc.M006575200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10958801	hybrid			2022-12-27	WOS:000165382000017
J	Zilkha-Falb, R; Barzilai, A; Djaldeti, R; Ziv, I; Melamed, E; Shirvan, A				Zilkha-Falb, R; Barzilai, A; Djaldeti, R; Ziv, I; Melamed, E; Shirvan, A			Involvement of T-complex protein-1 delta in dopamine triggered apoptosis in chick embryo sympathetic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; CELL-DEATH; MOLECULAR CHAPERONE; EUKARYOTIC CYTOSOL; MESSENGER-RNA; IDENTIFICATION; PROTEIN; SUBUNITS; DISEASE; HSP60	The neurotransmitter dopamine (DA) is capable of inducing: apoptosis in post-mitotic sympathetic neurons via its oxidative metabolites. The differential display method was applied to cultured sympathetic neurons in an effort to detect genes whose expression is transcriptionally regulated during the early stages of DA-triggered apoptosis. One of the up-regulated genes was identified as the chick homologue to T-complex polypeptida-1 delta (TCP-1 delta), a member of the molecular chaperone family of proteins. Each chaperone protein is a complex of seven to nine different subunits. A full-length clone of 1.9 kilobases-was isolated containing an open reading frame of 586 amino acids with a predicted molecular weight of 57,736, Comparison with the mouse TCP-1 delta revealed 78 and 91% homology on the DNA and protein levels, respectively. Northern blot analysis disclosed a steady and Significant increase in mRNA levels of TCP-1 delta after DA administration, reaching a peak between 4 and 9 h and declining thereafter. Induction of the TCP-1 delta protein levels was also observed as a function Of DA treatment, Overexpression of TCP-1 delta in sympathetic neurons accelerated DA-induced apoptosis; inhibition of TCP-1 delta expression in these neurons using antisense technology significantly reduced DA-induced neuronal death. These findings suggest a functional role fdr TCP-1 delta as a positive mediator of DA-induced neuronal apoptosis.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Rabin Med Ctr, Dept Neurol, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Felsenstein Med Res Ctr, IL-49100 Petah Tiqwa, Israel	Tel Aviv University; Rabin Medical Center; Rabin Medical Center; Tel Aviv University	Barzilai, A (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.							BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; BENSON D, 1993, NUCLEIC ACIDS RES, V21, P2963, DOI 10.1093/nar/21.13.2963; BINDOLI A, 1992, FREE RADICAL BIO MED, V13, P391, DOI 10.1016/0891-5849(92)90182-G; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Chuang DM, 1996, NAT MED, V2, P609, DOI 10.1038/nm0696-609; Creagh EM, 1999, IMMUNOLOGY, V97, P36; Freyaldenhoven TE, 1996, BRAIN RES, V735, P42; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GaleaLauri J, 1996, J IMMUNOL, V157, P4109; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; GREENE LA, 1977, DEV BIOL, V58, P96, DOI 10.1016/0012-1606(77)90076-8; GUPTA RS, 1995, MOL MICROBIOL, V15, P1, DOI 10.1111/j.1365-2958.1995.tb02216.x; HARLOW E, 1988, LAB MANUAL, P490; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; JONSSON G, 1971, PROGR HISTOCHEM CYTO, V2, P299; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; KOPIN IJ, 1985, PHARMACOL REV, V37, P333; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; Kuo YP, 1997, J BACTERIOL, V179, P6318, DOI 10.1128/jb.179.20.6318-6324.1997; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liang P, 1997, J CELL SCI, V110, P1431; LICHTENSTEIGER RM, 1970, PROG HISTOCHEM CYTOC, V1, P185; Lu KP, 1998, BIOCHEM BIOPH RES CO, V253, P828, DOI 10.1006/bbrc.1998.9866; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; MICHEL PP, 1990, J NEUROSCI RES, V26, P428, DOI 10.1002/jnr.490260405; OFFEN D, 1995, BBA-MOL CELL RES, V1268, P171, DOI 10.1016/0167-4889(95)00075-4; Offen D, 1997, CELL MOL NEUROBIOL, V17, P289, DOI 10.1023/A:1026390201168; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; Punyiczki M, 1998, ANN NY ACAD SCI, V851, P67, DOI 10.1111/j.1749-6632.1998.tb08978.x; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Roobol A, 1999, J BIOL CHEM, V274, P2408, DOI 10.1074/jbc.274.4.2408; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Sambrook J, 1989, MOL CLONING LAB MANU, VII; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Shirvan A, 1999, J NEUROCHEM, V73, P961, DOI 10.1046/j.1471-4159.1999.0730961.x; Shirvan A, 1997, J NEUROCHEM, V69, P539; Shirvan A, 1997, J NEURAL TRANSM-SUPP, P67; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; SPINA MB, 1989, P NATL ACAD SCI USA, V86, P1398, DOI 10.1073/pnas.86.4.1398; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wu-Baer Foon, 1996, Journal of Biological Chemistry, V271, P4201, DOI 10.1074/jbc.271.8.4201; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Yoda T, 1995, GENE, V166, P249, DOI 10.1016/0378-1119(95)00604-4; Zhang J, 1998, BIOCHEM BIOPH RES CO, V248, P812, DOI 10.1006/bbrc.1998.9044; ZilkhaFalb R, 1997, CELL MOL NEUROBIOL, V17, P101, DOI 10.1023/A:1026333222008; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	55	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36380	36387		10.1074/jbc.M001692200	http://dx.doi.org/10.1074/jbc.M001692200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10954701	hybrid			2022-12-27	WOS:000165382000102
J	Dukuzumuremyi, JM; Rosqvist, R; Hallberg, B; Akerstrom, B; Wolf-Watz, H; Schesser, K				Dukuzumuremyi, JM; Rosqvist, R; Hallberg, B; Akerstrom, B; Wolf-Watz, H; Schesser, K			The Yersinia protein kinase A is a host factor inducible RhoA/Rac-binding virulence factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SECRETED PROTEIN; MAMMALIAN-CELLS; FOCAL ADHESIONS; RHO-GTPASES; PSEUDOTUBERCULOSIS; INHIBITION; MEMBRANE; EFFECTOR; PHOSPHORYLATION	The pathogenic yersiniae inject proteins directly into eukaryotic cells that interfere with a number of cellular processes including phagocytosis and inflammatory-associated host responses. One of these injected proteins, the Yersinia protein kinase A (YpktA), has previously been shown to affect the morphology of cultured eukaryotic cells as well as to localize to the plasma membrane following its injection into HeLa cells. Here it is shown that these activities are mediated by separable domains of YpkA. The amino terminus, which contains the kinase domain, is sufficient to localize YpkA to the plasma membrane while the carboxyl terminus of YpkA is required for YpkAs morphological effects. YpkAs carboxyl-terminal region was found to affect the levels of actin-Containing stress fibers as well as block the activation of the GTPase RhoA in Yersinia-infected cells. We show that the carboxyl-terminal region of YpkA, which contains sequences that bear similarity to the RhoA-binding domains of several eukaryotic RhoA-binding kinases, directly interacts with RhoA as well as Rac (but not Cdc42) and displays a slight but measurable binding preference for the GDP-bound form of RhoA, Surprisingly, YpkA binding to RhoA(GDP) affected neither the intrinsic nor guanine nucleotide exchange factor-mediated GDP/GTP exchange reaction suggesting that YpkA controls activated RhoA levels by a mechanism other than by simply blocking guanine nucleotide exchange factor activity. We go on to show that YpkAs kinase activity is neither dependent on nor promoted by its interaction with RhoA and Rac but is, however, entirely dependent on heat-sensitive eukaryotic factors present in HeLa cell extracts and fetal calf serum. Collectively, our data show that YpkA possesses both similarities and differences with the eukaryotic RhoA/Rac-binding kinases and suggest that the yersiniae utilize the Rho GTPases for unique activities during their interaction with eukaryotic cells.	Univ Lund, CMB, Immunol Sect, Dept Cell & Mol Biol, S-22362 Lund, Sweden; Umea Univ, Dept Cell & Mol Biol, SE-90187 Umea, Sweden; Univ Lund, Mol Signalling Sect, Dept Cell & Mol Biol, SE-22100 Lund, Sweden	Lund University; Umea University; Lund University	Schesser, K (corresponding author), Univ Lund, CMB, Immunol Sect, Dept Cell & Mol Biol, Solvegatan 21, S-22362 Lund, Sweden.							AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BEUSCHER HU, 1995, INFECT IMMUN, V63, P1270, DOI 10.1128/IAI.63.4.1270-1277.1995; Black DS, 2000, MOL MICROBIOL, V37, P515, DOI 10.1046/j.1365-2958.2000.02021.x; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Boland A, 1998, INFECT IMMUN, V66, P1878, DOI 10.1128/IAI.66.5.1878-1884.1998; BOLIN I, 1984, INFECT IMMUN, V43, P72; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; GALYOV EE, 1993, NATURE, V361, P730, DOI 10.1038/361730a0; GALYOV EE, 1994, J BACTERIOL, V176, P4543, DOI 10.1128/JB.176.15.4543-4548.1994; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Hakansson S, 1996, MOL MICROBIOL, V20, P593, DOI 10.1046/j.1365-2958.1996.5251051.x; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Henriksson ML, 2000, BIOCHEM J, V349, P697, DOI 10.1042/bj3490697; Horiguchi Y, 1997, P NATL ACAD SCI USA, V94, P11623, DOI 10.1073/pnas.94.21.11623; Houssa B, 1999, J BIOL CHEM, V274, P6820, DOI 10.1074/jbc.274.11.6820; Iriarte M, 1998, MOL MICROBIOL, V29, P915, DOI 10.1046/j.1365-2958.1998.00992.x; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; James P, 1996, GENETICS, V144, P1425; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Palmer LE, 1998, MOL MICROBIOL, V27, P953, DOI 10.1046/j.1365-2958.1998.00740.x; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; ROSQVIST R, 1991, INFECT IMMUN, V59, P4562, DOI 10.1128/IAI.59.12.4562-4569.1991; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; SALMOND GPC, 1993, TRENDS BIOCHEM SCI, V18, P7, DOI 10.1016/0968-0004(93)90080-7; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Schulte R, 1996, INFECT IMMUN, V64, P2106, DOI 10.1128/IAI.64.6.2106-2113.1996; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Viprey V, 1998, MOL MICROBIOL, V28, P1381, DOI 10.1046/j.1365-2958.1998.00920.x; von Pawel-Rammingen U, 2000, MOL MICROBIOL, V36, P737, DOI 10.1046/j.1365-2958.2000.01898.x; Wood MW, 1996, MOL MICROBIOL, V22, P327, DOI 10.1046/j.1365-2958.1996.00116.x; YANG Y, 1997, SCIENCE, V284, P1322; Zumbihl R, 1999, J BIOL CHEM, V274, P29289, DOI 10.1074/jbc.274.41.29289	49	86	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35281	35290		10.1074/jbc.M003009200	http://dx.doi.org/10.1074/jbc.M003009200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10950948	hybrid			2022-12-27	WOS:000165422800061
J	Perrier, AL; Cousin, X; Boschetti, N; Haas, R; Chatel, JM; Bon, S; Roberts, WL; Pickett, SR; Massoulie, J; Rosenberry, TL; Krejci, E				Perrier, AL; Cousin, X; Boschetti, N; Haas, R; Chatel, JM; Bon, S; Roberts, WL; Pickett, SR; Massoulie, J; Rosenberry, TL; Krejci, E			Two distinct proteins are associated with tetrameric acetylcholinesterase on the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; CAUDATE-NUCLEUS; QUATERNARY ASSOCIATIONS; ATTACHMENT DOMAIN; COLLAGEN TAIL; SUBUNIT; BRAIN; IDENTIFICATION; FORMS; TORPEDO	In mammalian brain, acetylcholinesterase (AChE) exists mostly as a tetramer of 70-kDa catalytic subunits that are linked through disulfide bonds to a hydrophobic subunit P of approximately 20 kDa. To characterize P, we reduced the disulfide bonds in purified bovine brain AChE and sequenced tryptic fragments from bands in the 80-kDa region. We obtained sequences belonging to at least two distinct proteins: the P protein and another protein that was not disulfide-linked to catalytic subunits. Both proteins were recognized in Western blots by antisera raised against specific peptides. We cloned cDNA encoding the second protein in a cDNA-library from bovine substantia nigra and obtained rat and human homologs. We call this protein mCutA because of its homology to a bacterial protein (CutA). We could not demonstrate a direct interaction between mCutA and AChE in vitro in transfected cells. However, in a mouse neuroblastoma cell line that produced membrane-bound AChE as an amphiphilic tetramer, the expression of mCutA antisense mRNA eliminated cell surface AChE and decreased the level of amphiphilic tetramer in cell extracts. mCutA therefore appears necessary for the localization of AChE at the cell surface; it may be part of a multicomponent complex that anchors AChE in membranes, together with the hydrophobic P protein.	Ecole Normale Super, CNRS, UMR 8544, Neurobiol Cellulaire & Mol Lab, F-75230 Paris 05, France; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Mayo Clin & Mayo Grad Sch Med, Dept Pharmacol, Jacksonville, FL 32224 USA; Mayo Clin & Mayo Grad Sch Med, Mol Neurosci Program, Jacksonville, FL 32224 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Case Western Reserve University; Mayo Clinic; Mayo Clinic	Krejci, E (corresponding author), Ecole Normale Super, CNRS, UMR 8544, Neurobiol Cellulaire & Mol Lab, 46 Rue Ulm, F-75230 Paris 05, France.		Chatel, Jean-marc/ABB-9837-2020; Cousin, Xavier/E-2542-2013; Perrier, Anselme L/B-2272-2019; Chatel, Jean-Marc/F-9450-2013; Perrier, Anselme/E-3764-2010	Cousin, Xavier/0000-0002-8520-3610; Perrier, Anselme L/0000-0001-7915-1968; 	NINDS NIH HHS [NS-16577] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016577] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bon S, 1997, J BIOL CHEM, V272, P3007, DOI 10.1074/jbc.272.5.3007; Bon S, 1997, J BIOL CHEM, V272, P3016, DOI 10.1074/jbc.272.5.3016; Boschetti N, 1996, FEBS LETT, V380, P133, DOI 10.1016/0014-5793(96)00041-5; CHAN SL, 1972, J NEUROCHEM, V19, P2747, DOI 10.1111/j.1471-4159.1972.tb03812.x; DUVAL N, 1992, J CELL BIOL, V118, P641, DOI 10.1083/jcb.118.3.641; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Feng GP, 1999, J CELL BIOL, V144, P1349, DOI 10.1083/jcb.144.6.1349; Fernandez HL, 1996, J NEUROCHEM, V66, P1335; FONG ST, 1995, MOL MICROBIOL, V15, P1127, DOI 10.1111/j.1365-2958.1995.tb02286.x; GENNARI K, 1987, J NEUROCHEM, V49, P12, DOI 10.1111/j.1471-4159.1987.tb03386.x; HAAS R, 1995, ANAL BIOCHEM, V224, P425, DOI 10.1006/abio.1995.1061; HAAS R, 1985, ANAL BIOCHEM, V148, P154, DOI 10.1016/0003-2697(85)90640-2; Hanner M, 1998, J BIOL CHEM, V273, P16289, DOI 10.1074/jbc.273.26.16289; INESTROSA NC, 1987, J BIOL CHEM, V262, P4441; Krejci E, 1997, J BIOL CHEM, V272, P22840, DOI 10.1074/jbc.272.36.22840; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; LAZAR M, 1980, J NEUROCHEM, V35, P1067, DOI 10.1111/j.1471-4159.1980.tb07860.x; LIAO J, 1993, J NEUROCHEM, V61, P1127, DOI 10.1111/j.1471-4159.1993.tb03629.x; MARSH D, 1984, J NEUROCHEM, V43, P204, DOI 10.1111/j.1471-4159.1984.tb06698.x; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; Navaratnam DS, 2000, J NEUROCHEM, V74, P2146, DOI 10.1046/j.1471-4159.2000.0742146.x; ROBERTS WL, 1991, J BIOL CHEM, V266, P7481; ROSENBERRY TL, 1977, BIOCHEMISTRY-US, V16, P3550, DOI 10.1021/bi00635a008; ROSENBERRY TL, 1984, J BIOL CHEM, V259, P5643; ROTUNDO RL, 1987, P NATL ACAD SCI USA, V84, P2063, DOI 10.1073/pnas.84.7.2063; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Simon S, 1998, EMBO J, V17, P6178, DOI 10.1093/emboj/17.21.6178; SORENSEN K, 1982, J NEUROCHEM, V39, P1050, DOI 10.1111/j.1471-4159.1982.tb11496.x; TAKAYUKI N, 1994, Patent No. 1994056895; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WENTHOLD RJ, 1974, J NEUROCHEM, V22, P945, DOI 10.1111/j.1471-4159.1974.tb04320.x	35	38	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34260	34265		10.1074/jbc.M004289200	http://dx.doi.org/10.1074/jbc.M004289200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10954708	hybrid, Green Published			2022-12-27	WOS:000165095300037
J	Xie, X; Rivier, AS; Zakrzewicz, A; Bernimoulin, M; Zeng, XL; Wessel, HP; Schapira, M; Spertini, O				Xie, X; Rivier, AS; Zakrzewicz, A; Bernimoulin, M; Zeng, XL; Wessel, HP; Schapira, M; Spertini, O			Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides - Studies with carboxyl-reduced and sulfated heparin and with trestatin A sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; ROLLING IN-VIVO; SIALYL-LEWIS-X; P-SELECTIN; GLYCOPROTEIN LIGAND-1; DEFICIENT MICE; MONOCLONAL-ANTIBODY; LEUKOCYTE ADHESION; ENDOTHELIAL-CELLS; MOLECULAR-CLONING	Selectins play a major role in the inflammatory reaction by initiating neutrophil attachment to activated vascular endothelium, Some heparin preparations can interact with L- and P-selectin; however, the determinants required for inhibiting selectin-mediated cell adhesion have not yet been characterized. We now report that carboxyl-reduced and sulfated heparin (prepared by chemical modifications of porcine intestinal mucosal heparin leading to the replacement of carboxylates by O-sulfate groups) and trestatin A sulfate (obtained by sulfation of trestatin A, a non-uronic pseudo-nonasaccharide extracted from Streptomyces dimorphogenes) exhibit strong anti-P-selectin and anti-L-selectin activity while lacking antithrombin-mediated anticoagulant activity. In vitro experiments revealed that both compounds inhibited P-selectin- and L-selectin-mediated cell adhesion under laminar flow conditions. Moreover, carboxyl-reduced and sulfated heparin and trestatin A sulfate were also active in vivo, as assessed by experiments showing 1) that microinfusion of trestatin A sulfate reduced by 96% leukocyte rolling along rat mesenteric postcapillary venules and 2) that both compounds inhibited (by 58-81%) neutrophil migration into thioglycollate-inflamed peritoneum of BALB/c mice. These results indicate that nonanticoagulant sulfated saccharides targeted at P-selectin and L-selectin may have therapeutic potential in inflammatory disorders.	Univ Lausanne, Div Hematol, CHU Vaudois, CH-1011 Lausanne, Switzerland; Univ Lausanne, Cent Lab Hematol, CHU Vaudois, CH-1011 Lausanne, Switzerland; Free Univ Berlin, Inst Physiol, D-14195 Berlin, Germany; Hoffmann La Roche Ltd, Dept Pharmaceut Res, CH-4002 Basel, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Free University of Berlin; Roche Holding	Spertini, O (corresponding author), Univ Lausanne, Div Hematol, CHU Vaudois, BH 18-543,Bugnon 46, CH-1011 Lausanne, Switzerland.	olivier.spertini@chuv.hospvd.ch	Wessel, Hans Peter/E-9701-2015	Wessel, Hans Peter/0000-0002-2608-0657				ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Bullard DC, 1996, J EXP MED, V183, P2329, DOI 10.1084/jem.183.5.2329; CASTELLOT JJ, 1984, J CELL PHYSIOL, V120, P315, DOI 10.1002/jcp.1041200309; Davenpeck KL, 1997, J IMMUNOL, V159, P1977; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; Giuffre L, 1997, J CELL BIOL, V136, P945, DOI 10.1083/jcb.136.4.945; HANNINEN A, 1993, J CLIN INVEST, V92, P2509, DOI 10.1172/JCI116859; HARENBERG J, 1983, J CHROMATOGR, V261, P287, DOI 10.1016/S0021-9673(01)87952-8; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Jung U, 1996, AM J PHYSIOL-HEART C, V271, pH2740, DOI 10.1152/ajpheart.1996.271.6.H2740; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kirschfink M, 1997, J IMMUNOL, V158, P1324; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Kouretas PC, 1998, ANN THORAC SURG, V66, P1210, DOI 10.1016/S0003-4975(98)00811-X; Kouretas PC, 1999, CIRCULATION, V99, P1062, DOI 10.1161/01.CIR.99.8.1062; Kumar A, 1999, CIRCULATION, V99, P1363, DOI 10.1161/01.CIR.99.10.1363; Kunkel EJ, 1998, CIRC RES, V82, P30; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEFER AM, 1994, CARDIOVASC RES, V28, P289, DOI 10.1093/cvr/28.3.289; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; LEY K, 1991, AM J PHYSIOL, V260, pH1667, DOI 10.1152/ajpheart.1991.260.5.H1667; LEY K, 1995, BLOOD, V85, P3727, DOI 10.1182/blood.V85.12.3727.bloodjournal85123727; LEY K, 1993, BLOOD, V82, P1632; LEY K, 1993, BLOOD, V81, P177; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; MA XL, 1993, CIRCULATION, V88, P649, DOI 10.1161/01.CIR.88.2.649; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MIHELCIC D, 1994, BLOOD, V84, P2322; MOORE KL, 1994, J BIOL CHEM, V269, P23318; Nagashima M, 1998, CIRCULATION, V98, pII391; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NELSON RM, 1993, BLOOD, V82, P3253; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; Ouyang YB, 1998, J BIOL CHEM, V273, P24770, DOI 10.1074/jbc.273.38.24770; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; Palazzo AJ, 1998, AM J PHYSIOL-HEART C, V275, pH1865, DOI 10.1152/ajpheart.1998.275.5.H1865; Park JL, 1999, PHARMACOLOGY, V58, P120, DOI 10.1159/000028274; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Ramos CL, 1997, BLOOD, V89, P3009, DOI 10.1182/blood.V89.8.3009; RAZI N, 1995, J BIOL CHEM, V270, P11267, DOI 10.1074/jbc.270.19.11267; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; Scalia R, 1999, J EXP MED, V189, P931, DOI 10.1084/jem.189.6.931; SPERTINI O, 1991, J IMMUNOL, V147, P942; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Suzuki H, 1999, NEUROL RES, V21, P269, DOI 10.1080/01616412.1999.11740930; Tang MLK, 1997, J IMMUNOL, V158, P5191; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; Toppila S, 1999, AM J PATHOL, V155, P1303, DOI 10.1016/S0002-9440(10)65232-7; Tu L, 1999, J EXP MED, V189, P241, DOI 10.1084/jem.189.2.241; Tu LL, 1996, J IMMUNOL, V157, P3995; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Watanabe N, 1999, J BIOCHEM-TOKYO, V125, P826, DOI 10.1093/oxfordjournals.jbchem.a022355; WEILER JM, 1992, J IMMUNOL, V148, P3210; WESSEL HP, 1990, CARBOHYD RES, V204, P131, DOI 10.1016/0008-6215(90)84028-S; WESSEL HP, 1995, BIOORG MED CHEM LETT, V5, P437, DOI 10.1016/0960-894X(95)00051-T; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Yadav SS, 1999, HEPATOLOGY, V29, P1494, DOI 10.1002/hep.510290505; Yanaka K, 1996, J NEUROSURG, V85, P1108, DOI 10.3171/jns.1996.85.6.1108; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; Zakrzewicz A, 1997, BLOOD, V89, P3228, DOI 10.1182/blood.V89.9.3228	84	72	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34818	34825		10.1074/jbc.M001257200	http://dx.doi.org/10.1074/jbc.M001257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10944519	hybrid			2022-12-27	WOS:000165095300109
J	Lee, SK; Lee, B; Lee, JW				Lee, SK; Lee, B; Lee, JW			Mutations in retinoid X receptor that impair heterodimerization with specific nuclear hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; THYROID-HORMONE; DIRECT REPEATS; CO-REPRESSOR; GENE; RXR; TRANSACTIVATION; DETERMINANTS; RESISTANCE; BETA	Retinoid X receptor (RXR) serves as a promiscuous heterodimerization partner for many nuclear receptors through the identity box, a 40-amino acid subregion within the ligand binding domain. In this study, we randomly mutated two specific residues within the human RXR alpha identity box region previously identified as important determinants in heterodimerization (i.e. Ala(416) and Arg(421)). interestingly, most of these mutants still retained wild type interactions with thyroid hormone receptor (TR), retinoic acid receptor, peroxisome proliferator-activated receptor alpha, small heterodimer partner, and constitutive androstane receptor. However, RXR-A416D and R421L were specifically impaired for interactions with TR, whereas RXR-A416K lost both TR and retinoic acid receptor interactions. Accordingly, RXR-A416D did not support T3 transactivation in mammalian cells, whereas RXR-A416K was not supportive of transactivation by retinoids or T3. These results provide a basis upon which to further design mutant RXRs highly selective in heterodimerization, potentially useful tools to probe nuclear receptor function in vivo.	Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea	Chonnam National University; Chonnam National University; Chonnam National University	Lee, JW (corresponding author), Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea.	jlee@chonnam.chonnam.ac.kr						Apriletti JW, 1998, CLIN EXP PHARMACOL P, V25, pS2, DOI 10.1111/j.1440-1681.1998.tb02293.x; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Collingwood TN, 1997, J BIOL CHEM, V272, P13060, DOI 10.1074/jbc.272.20.13060; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; Kakizawa T, 1997, J BIOL CHEM, V272, P23799, DOI 10.1074/jbc.272.38.23799; LEE JW, 1994, MOL ENDOCRINOL, V8, P1245, DOI 10.1210/me.8.9.1245; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lee SK, 1998, MOL ENDOCRINOL, V12, P325, DOI 10.1210/me.12.3.325; Lee SK, 1998, MOL ENDOCRINOL, V12, P1184, DOI 10.1210/me.12.8.1184; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; Pohlenz J, 1999, J CLIN ENDOCR METAB, V84, P3919, DOI 10.1210/jc.84.11.3919; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; QI JS, 1995, MOL CELL BIOL, V15, P1817; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; REFETOFF S, 1994, THYROID, V4, P345, DOI 10.1089/thy.1994.4.345; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; Weiss RE, 1996, J CLIN ENDOCR METAB, V81, P4196, DOI 10.1210/jc.81.12.4196; Weiss RE, 1999, EMBO J, V18, P1900, DOI 10.1093/emboj/18.7.1900; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x	32	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33522	33526		10.1074/jbc.M006418200	http://dx.doi.org/10.1074/jbc.M006418200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10948200	hybrid			2022-12-27	WOS:000090104600049
J	Li, YH; Marzolo, MP; van Kerkhof, P; Strous, GJ; Bu, GJ				Li, YH; Marzolo, MP; van Kerkhof, P; Strous, GJ; Bu, GJ			The YXXL motif, but not the two NPXY motifs, serves as the dominant endocytosis signal for low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; MEDIATED INTERNALIZATION; SORTING SIGNALS; BINDING-PROTEIN; VLDL RECEPTOR; APOE RECEPTOR; CELL-LINE; IN-VIVO; SYSTEM; LRP	All members of the low density lipoprotein (LDL) receptor family contain at least one copy of the NPXY sequence within their cytoplasmic tails. For the LDL receptor, it has been demonstrated that the NPXY motif serves as a signal for rapid endocytosis through coated pits. Thus, it is generally believed that the NPXY sequences function as endocytosis signals for an the LDL receptor family members. The primary aim of this study is to define the endocytosis signal(s) within the cytoplasmic tail of LDL receptor-related protein (LRP). By using LRP minireceptors, which mimic the function and trafficking of full-length endogenous LRP, we demonstrate that the YXXL motif, but not the two NPXY motifs, serves as the dominant signal for LRP endocytosis. We also found that the distal di-leucine motif within the LRP tail contributes to its endocytosis, and its function is independent of the YXXL motif. Although the proximal NPXY motif and the proximal di-leucine motif each play a limited role in LRP endocytosis in the context of the full-length tail, these motifs were functional within the truncated receptor tail. In addition, we show that LRP minireceptor mutants defective in endocytosis signal(s) accumulate at the cell surface and are less efficient in delivery of ligand for degradation.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA; Univ Chile, Dept Biol, Santiago, Chile; Univ Utrecht, Dept Cell Biol, Utrecht, Netherlands	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Universidad de Chile; Utrecht University	Bu, GJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, Box 8116,1 Childrens Pl, St Louis, MO 63110 USA.		Eckhardt, Erik/G-1567-2010	van Kerkhof, Peter/0000-0002-8954-2230	NHLBI NIH HHS [R01 HL52753-07] Funding Source: Medline; NHLBI NIH HHS [HL59150] Funding Source: Medline; NINDS NIH HHS [NS37525] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1994, J BIOL CHEM, V269, P18521; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BU GJ, 1994, J BIOL CHEM, V269, P29874; BU GJ, 1993, J BIOL CHEM, V268, P13002; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; Govers P, 1998, J BIOL CHEM, V273, P16426, DOI 10.1074/jbc.273.26.16426; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li YH, 1997, BIOCHEM BIOPH RES CO, V240, P122, DOI 10.1006/bbrc.1997.7619; MORTON PA, 1990, J BIOL CHEM, V265, P14093; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; Strous GJ, 1999, J CELL SCI, V112, P1417; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; Vilhardt F, 1999, MOL BIOL CELL, V10, P179, DOI 10.1091/mbc.10.1.179; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Webb DJ, 2000, J CELL SCI, V113, P123; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761; York SJ, 1999, J BIOL CHEM, V274, P1164, DOI 10.1074/jbc.274.2.1164; ZAGURSKY RJ, 1995, BIOTECHNIQUES, V18, P504; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	51	236	242	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17187	17194		10.1074/jbc.M000490200	http://dx.doi.org/10.1074/jbc.M000490200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747918	hybrid			2022-12-27	WOS:000087392200111
J	Li, YS; Liu, JL; Zhan, X				Li, YS; Liu, JL; Zhan, X			Tyrosine phosphorylation of cortactin is required for H2O2-mediated injury of human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; OXIDANT INJURY; CROSS-LINKING; STRESS; SRC; RECEPTOR; H2O2; IDENTIFICATION; CYTOSKELETON; LOCOMOTION	Injury of endothelial cells induced by reactive oxygen species plays an important role in the development of early stages of vascular diseases such as hypertension and atherosclerosis. Exposure of human umbilical vein endothelial cells to hydrogen peroxide (H2O2), a common form of reaction oxygen species, triggers a series of intracellular events, including actin cytoskeletal reorganization, cytoplasm shrinkage, membrane blebbing and protein-tyrosine phosphorylation. The effect of H2O2 on endothelial cells is dramatically enhanced when a survival pathway involving extracellular signal-regulated kinase is blocked by PD098059. In contrast, the injury of endothelial cells mediated by H2O2, is inhibited by PP2, a selective specific inhibitor for protein-tyrosine kinase Src. Cortactin, a filamentous actin (F-actin)-associated protein, becomes phosphorylated at tyrosine residues upon stimulation by H2O2 in a manner dependent on the activity of Src. The level of tyrosine phosphorylation of cortactin is correlated with the formation of membrane blebs, Overexpression of wild-type cortactin tagged with green fluorescent protein in endothelial cells via a retroviral vector substantiates the H2O2,-induced morphological changes, whereas overexpression of a green fluorescent protein-cortactin mutant deficient in tyrosine phosphorylation renders endothelial cells resistant to H2O2. The functional role of cortactin in H2O2-mediated shape changes was also evaluated in NIH 3T3 cells. Stable 3T3 transfectants expressing wild-type cortactin in the presence of either H2O2/ PD098059 or H2O2 alone at 200 muM exhibited a dramatic shape change characterized by rounding up or aggregation, However, the similar changes were not detected with cells overexpressing a cortactin mutant deficient in tyrosine phosphorylation. These data demonstrate an important role of the Src/cortactin-dependent actin reorganization in the injury of endothelial cells mediated by reactive oxygen species.	Amer Red Cross, Jerome H Holland Lab, Dept Expt Pathol, Rockville, MD 20855 USA	American Red Cross	Zhan, X (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Expt Pathol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	zhanx@usa.redcross.org	Eckhardt, Erik/G-1567-2010	van Kerkhof, Peter/0000-0002-8954-2230	NHLBI NIH HHS [R01 HL52753-07] Funding Source: Medline; NHLBI NIH HHS [HL59150] Funding Source: Medline; NINDS NIH HHS [NS37525] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barchowsky A, 1995, AM J PHYSIOL-LUNG C, V269, pL829, DOI 10.1152/ajplung.1995.269.6.L829; Berk BC, 1999, THROMB HAEMOSTASIS, V82, P810; Carbajal JM, 1998, BIOCHEM BIOPH RES CO, V249, P461, DOI 10.1006/bbrc.1998.9172; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hagmann J, 1999, J CELL BIOCHEM, V73, P488, DOI 10.1002/(SICI)1097-4644(19990615)73:4<488::AID-JCB7>3.0.CO;2-P; Hastie LE, 1998, J CELL BIOCHEM, V68, P511, DOI 10.1002/(SICI)1097-4644(19980315)68:4<511::AID-JCB10>3.0.CO;2-C; HINSHAW DB, 1986, AM J PATHOL, V123, P454; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; HULL DS, 1984, INVEST OPHTH VIS SCI, V25, P1246; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; KURODA K, 1995, J IMMUNOL, V155, P4427; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LEVYTOLEDANO S, 1995, THROMB HAEMOSTASIS, V73, P857; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Natarajan V, 1998, ENVIRON HEALTH PERSP, V106, P1205, DOI 10.2307/3433987; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Peus D, 1998, J INVEST DERMATOL, V110, P966, DOI 10.1046/j.1523-1747.1998.00210.x; SACKS T, 1978, J CLIN INVEST, V61, P1161, DOI 10.1172/JCI109031; SCHROR K, 1988, N-S ARCH PHARMACOL, V338, P268; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; ZHAN X, 1993, J BIOL CHEM, V268, P24427; Zhan X, 1997, BLOOD, V89, P457, DOI 10.1182/blood.V89.2.457	33	236	242	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37187	37193		10.1074/jbc.M000490200	http://dx.doi.org/10.1074/jbc.M000490200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10747918	hybrid			2022-12-27	WOS:000165577700100
